Risk Factors Comparison 2025-03-06 to 2024-02-01 Form: 10-K

Legend: **New Text** ~~Removed Text~~ Unchanged Text Moved Text Section

~~An investment~~ **We are subject to a number of risks that could harm our business, financial condition, results of operations and / or growth prospects or cause our actual results to differ materially from those contained** in **forward- looking statements we have made in this Form 10- K and those we may make from time to time. The success of** our ~~securities involves~~ **product candidates will depend on a variety of factors. We do not have complete control over many of these factors, including** certain **aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any current or future collaborator. In addition, some of the factors, events and contingencies discussed below may have occurred in the past, but the disclosures below are not representations as to whether or not the factors, events or contingencies have occurred in the past and instead reflect our beliefs and opinions as to the factors, events, or contingencies that could materially and adversely affect us in the future. The following summary is not exhaustive and is qualified by reference to the full set of** ~~risks~~ - **risk factors** ~~, including those~~ set forth ~~below and elsewhere~~ in **Item 1A** ~~this report. In addition to the risks set forth below and elsewhere in this report, other risks and uncertainties not known to us, that are beyond our control or that we deem to be immaterial may also materially adversely affect our business operations. You should carefully consider the risks described below as well as other information and data included in this report. Summary of Risk Factors Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading~~ “ Risk Factors ” ~~and should be~~ **of this Form 10- K. Please** carefully ~~considered~~ -- **consider all** ~~, together with other~~ -- **the** information in this Form 10- K **, including the full set of risks set forth in the “ Risk Factors ” section** and **in** our other filings with the **U. S. Securities and Exchange Commission (“** SEC **”)** , before making an investment decision regarding **Oruka. Risks Related to Drug Development and Regulatory Approval • Drug development and obtaining and maintaining regulatory approval for drug products is costly, time- consuming, and highly uncertain. • We are substantially dependent on the success of** our ~~common stock~~ **two most advanced programs, ORKA- 001 and ORKA- 002** . ~~• there is~~ **Our projected development goals, including our clinical trials, may** ~~no~~ **not be successful or** ~~guarantee that even if~~ we ~~do engage~~ **may fail to achieve our projected development goals** in **the time frames** ~~a strategic transaction that such strategic transaction will increase stockholder value; • if~~ we **announce** ~~engage in an~~ **and expect. • We may** ~~acquisition, reorganization or business combination, we will incur a variety of risks potentially adversely affecting our business operations or our stockholders; • if we are~~ not **be** able to **meet requirements** ~~successfully develop, obtain FDA approval for, and provide~~ for the ~~commercialization~~ **chemistry, manufacturing and control** of ~~Gencaro or~~ **our** ~~rNAPc2 in a~~ **programs. • The U. S. Food and Drug Administration (“ FDA ”) and comparable foreign regulatory approval processes are lengthy and** ~~timely~~ -- **time** ~~manner,~~ **consuming and** we may not be able to ~~continue~~ **obtain or may be delayed in obtaining regulatory approvals for our product candidates. Moreover, even if we obtain regulatory approval, we will be subject to ongoing regulatory obligations. • We face competition from entities that have developed or may develop programs for the diseases addressed by product candidates developed by us. Risks Related to Our Financial Condition and Capital Requirements • We are a clinical stage biopharmaceutical company with a limited operating history on which to assess** our business **; we have not completed any clinical trials, and have no products approved for commercial sale. • We have historically incurred losses and we anticipate that we will continue to incur losses for the foreseeable future. • We have never generated revenue from product sales and may never be profitable. • We may not be able to raise the capital that we need to support our business plans. • Raising additional capital may cause dilution to our stockholders, restrict our** operations ~~; •~~ **or require us to relinquish rights to our technologies or product candidates. Risks Related to Our Intellectual Property • Our ability to obtain and protect our patents and other proprietary rights is uncertain and we may fail in obtaining or maintaining necessary rights to our programs. • We may become subject to claims challenging the inventorship or ownership of our intellectual property and may be subject to patent infringement claims or may need to file such claims. • Our patents and our ability to protect our products may be impaired by changes to patent laws, and our patent protection could be reduced or eliminated for non- compliance with legal requirements. • We may fail to identify or interpret relevant third- party patents. • Patent terms may be inadequate to protect our competitive position of our programs. • Our technology licensed from third parties may be subject to retained rights. Risks Related to Our Reliance on Third Parties • We currently rely on agreements with third parties to develop our product candidates. If we are unable to maintain collaborations or licensing arrangements, or if our collaborations or licensing arrangements are not successful, our business could be negatively impacted. • Third parties we rely on for the execution of nonclinical studies and clinical trials may fail to carry out their contractual duties. • We may be unable to use third- party manufacturing sites, our third- party manufacturers may encounter difficulties in production or we may need to switch or create third- party manufacturer redundancies. Other Risk Factors- Risks Related to Employee Matters, Managing Growth, Other Risks Related to Our Business, and Owning Our Common Stock • Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all. • Our business is dependent on key personnel, and we will be harmed** if we ~~encounter~~ **cannot recruit and retain highly qualified personnel to successfully implement our business strategy. • In order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience** difficulties ~~enrolling patients~~ in **managing this growth. • Significant disruptions of information technology systems or breaches of data security could adversely affect our business. • Changes in and failures to comply with United States and foreign privacy and data protection laws, regulations and standards may adversely affect our business, operations and consolidated financial performance. • We may become exposed to costly and damaging liability claims and our insurance may not cover all damages from such claims. • Our business could be adversely affected by macroeconomic or geopolitical conditions. • We do not anticipate paying any dividends in the foreseeable future. • Future sales of shares by existing stockholders could cause our stock price to decline. • Future sales and issuances of equity and debt could result in additional dilution to our stockholders and could cause our stock price to decline. We are a clinical stage biopharmaceutical company with a limited operating history on which to assess our business; we have not completed any clinical trials, have no products approved for commercial sale, have historically incurred losses, and we anticipate that we will continue to incur significant losses for the foreseeable future. Moreover, we have never generated revenue from product sales and may never be profitable. We are a clinical stage biopharmaceutical company with a limited operating history. We will need to raise substantial additional capital to continue to fund our operations in the future. We have based our estimates on assumptions that may prove to be wrong, and could exhaust our available financial resources sooner than we currently anticipate. We have devoted substantially all of our financial resources to identify, acquire, and develop our product candidates, organizing and staffing our company, and providing general and administrative support for our operations. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We expect our losses to increase as our product candidates enter advanced clinical trials. It may be several years, if ever, before we complete pivotal clinical trials or have a product candidate approved for commercialization. We expect to invest significant funds into the research and development of our programs to determine the potential to advance product candidates to regulatory approval. If we obtain regulatory approval to market a product candidate,** our future **revenue will depend upon the size of any markets in which our product candidates may receive approval, and our ability to achieve sufficient market acceptance, pricing, coverage and adequate reimbursement from third- party payors, and adequate market share for our product candidates in those markets. Even if we obtain adequate market share for our product candidates, we may never become profitable despite obtaining such market share and acceptance of our products. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future and our expenses will increase substantially if and as we: • continue the clinical development of our product candidates, including advancing our product candidates into larger, more expensive trials; • continue efforts to discover and develop new product candidates, including initiating preclinical studies or** clinical trials **; • progress our chemistry** , **manufacturing and control development, registration, and validation, including the manufacture of our product candidates by third parties, including increasing volumes manufactured by third parties; • seek regulatory and marketing approvals and reimbursement for our product candidates; • establish a sales, marketing, and distribution infrastructure to commercialize** any ~~potential enrollment~~ **products for which we may obtain marketing approval and market for ourselves; • make** ~~milestones~~ - **milestone, royalty,** or **other payments under third- party license agreements; • seek to maintain, protect, and expand our intellectual property portfolio; and • experience any delays or encounter issues with the development and** potential regulatory ~~approvals~~ - **approval of our product candidates such as safety issues, manufacturing delays, clinical trial delays, longer follow- up for planned studies or trials, additional major studies or trials, or supportive trials necessary to support marketing approval. If we are unable to raise additional capital when required or on acceptable terms, we may be required to curtail our product development activities and other activities commensurate with the magnitude of the shortfall and our product development activities may cease altogether, which could materially harm our business, financial condition, and results of operations. To the extent that the costs of our activities exceed our current estimates and we are unable to raise sufficient additional capital to cover such costs, we will need to reduce operating expenses, sell assets, enter into strategic transactions, or effect a combination of the above. No assurance can be given that we will be able to enter into any of such transactions on acceptable terms, if at all. Any of the following events could have a material adverse effect on our business, operating results, and prospects: • a delay, scaling back, or discontinuation of the development or commercialization of our product candidates; • seeking strategic partnerships, or amending existing partnerships, for research and development programs at an earlier stage than otherwise would be desirable or that we otherwise would have sought to develop independently, or on terms that are less favorable than might otherwise be available in the future; • disposal of technology assets, or the relinquishing or licensing of assets on unfavorable terms, of our rights to technologies or any of our product candidates that we otherwise would seek to develop or commercialize ourselves; • pursuing the sale of the company to a third party at a price that may result in a loss on investment for our stockholders; or • filing for bankruptcy or cease operations altogether. Even if we are successful in raising new capital, we** could be ~~delayed~~ **limited in the amount of capital we raise due to investor demand restrictions placed on the amount of capital we raise,** or ~~otherwise~~ **other reasons. Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights. To the extent that we raise additional capital through the sale of equity securities or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that** adversely ~~affected~~ -- **affect** ~~; •~~ **the rights of holders of** our **common stock. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. For example, in September 2024, we entered into a Securities Purchase Agreement with certain new institutional and accredited investors, whereby the investors purchased an aggregate of 5, 600, 000 shares of common stock, 2, 439 shares of Series A Preferred Stock and pre- funded warrants to purchase an aggregate of 680, 000 shares of common stock for an aggregate purchase price of approximately $ 200. 5 million. Each share of Series A Preferred Stock is convertible into 1, 000 shares of common stock. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our research programs or product candidates or grant licenses on terms that may not be favorable to us. Debt financing, if available, would likely involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, making additional product acquisitions, or declaring dividends. Risks Related to Clinical Development, Regulatory Approval and Commercialization We face competition from entities that have developed or may develop programs for the diseases addressed by our product candidates. The development and commercialization of drugs is highly competitive. Product candidates developed by us, if approved, will face significant competition and our failure to effectively compete may prevent us from achieving significant market penetration. We compete with a variety of biopharmaceutical companies as well as academic institutions, governmental agencies, and public and private research institutions, among others. Many of the companies with which we are currently competing or will compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, clinical trials, regulatory approvals, and marketing than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early- stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in establishing clinical trial sites, recruiting participants for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our product candidates. Our competitors have developed, are developing or will develop programs and processes competitive with our programs and processes. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments. Our success will depend partially on our ability to develop and commercialize products that have a competitive safety, efficacy, dosing and / or presentation profile. Our commercial opportunity and success will be reduced or eliminated if competing products are safer, more effective, have a more attractive dosing profile or presentation or are less expensive than the products we develop, or if biosimilars enter the market and are able to gain market acceptance more quickly than we do or at wider scale. Our product candidates may fail in development or suffer delays. We depend on the successful initiation and completion of** clinical trials for our product candidates **to advance our product development plans. We have no products on the market, and all of our programs are in preclinical or clinical stages of development. As a result, we expect it will be many years before we can obtain regulatory approval for and commercialize any product candidate, if ever. Clinical testing is expensive, difficult to design and implement, and can take years to complete and is uncertain as to outcome. A failure of one or more of our clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials** may not ~~yield~~ **be predictive of the success of later clinical trials, and interim** results **of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies** that ~~will~~

~~enable~~ have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for their products. It may be difficult for us to raise additional capital if we experience any issues that delay or prevent the regulatory approval or the ability to commercialize our product candidates. We may experience a number of unforeseen events affecting our product development timeline, including the following: ● our clinical trials may fail to show safety or efficacy, produce negative or inconclusive results, or our product candidates may have undesirable side effects or unexpected characteristics, and we may decide, or regulators may require that we conduct additional preclinical studies or clinical trials or we may decide to abandon product development programs; ● the supply or quality of our clinical trial materials or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; ● regulators or IRBs, the FDA, or ethics committees may not authorize us or our investigators to commence or conduct a clinical trial at one or more prospective trial sites; or may require that we or our investigators materially modify, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants in our trials are being exposed to unacceptable health risks; ● our failure to establish an appropriate safety profile for a product candidate based on clinical or preclinical data as well as data emerging from other therapies in the same class as our product candidates; ● the number of subjects required for clinical trials of any product candidates may be larger than we anticipate, especially if regulatory bodies require completion of non- inferiority or superiority trials; enrollment in these clinical trials may be slower than we anticipate or subjects may drop out of these clinical trials or fail to return for post- treatment follow- up at a higher rate than we anticipate; ● trial conduct or data analysis errors may occur, including, but not limited to, failure by investigators or participants to adhere to the study protocol or data entry and / or labeling errors; ● we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and / or contract research organizations (" CROs "); ● our third- party contractors or clinical trial sites may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators and could potentially complicate the analysis of data; ● the cost of clinical trials of any of our programs may be greater than we anticipate; ● reports from clinical testing of other therapies may raise safety or efficacy concerns about our programs; and ● the FDA or other regulatory authorities may require us to submit additional data or impose other requirements and our product development timeline may be adversely affected. If our clinical trials do not produce favorable results, our ability to obtain regulatory approval for our product candidates will be adversely impacted. Moreover, the combined data from our trials may be inconclusive or may not be sufficient to ultimately gain marketing approval from the FDA or other regulatory authorities. There are equivalent processes and risks applicable to clinical trial applications in other countries outside of the United States. In addition, because of the competitive landscape for immunology and inflammation (commonly referred to as " I & I ") indications, we may also face competition for clinical trial enrollment. Clinical trial enrollment will depend on many factors, including if potential clinical trial participants choose to undergo treatment with approved products or enroll in competitors' ongoing clinical trials for programs that are under development for the same indications as our programs. An increase in the number of approved products for the indications we are targeting with our programs may further exacerbate this competition. Our inability to enroll a sufficient number of participants could, among other things, delay our development timeline, which may further harm our competitive position and have an adverse effect on our business and operations. We are substantially dependent on the success of our two most advanced programs, ORKA- 001 and ORKA- 002, and our clinical trials of such programs may not be successful. Our future success is substantially dependent on our ability to develop and timely obtain marketing approval for, and then successfully commercialize, our two most advanced programs, ORKA- 001 and ORKA- 002. We are investing a majority of our efforts and financial resources into the research and development of these programs. We have initiated a Phase 1 clinical trial of ORKA- 001 in healthy volunteers and anticipate initiating a Phase 1 clinical trial of ORKA- 002 in healthy volunteers in the second half of 2025, subject to the filing of an IND or foreign equivalent and regulatory approval. Currently, we believe that the success of our programs is dependent on observing a longer half- life of our ~~products -~~ product candidates in humans than monoclonal antibodies (" mAbs ") currently marketed and in development as we believe this longer half- life has the potential to result in a more favorable dosing schedule for our product candidates, assuming they successfully complete clinical development and obtain ~~regulatory~~ marketing ~~approvals -~~ approval ~~necessary to sell~~. This is based in part on ~~them -~~ the ~~; •~~ assumption that the longer half- life we ~~may~~ have observed in NHPs will translate into an extended half- life of our product candidates in humans. To the extent we do not observe this extended half- life in humans, it would significantly and adversely affect the clinical and commercial potential of our product candidates. If we do not achieve our projected development goals in the time frames we announce and expect ~~; •~~, the development and potential commercialization of our product candidates may be delayed and our expenses may increase and, as a result, our business may be materially harmed and our stock price may decline. From time to time, we estimate the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials, such as the expected timing of our clinical trials in our target indications, anticipated data analysis and results from our clinical trials, as well as the submission of regulatory filings. From time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones are and will be based on numerous assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our control. If we do not meet these milestones as publicly announced, or at all, the development and potential commercialization of our product candidates may be delayed or never achieved and, as a result, our business may be materially harmed and our stock price may decline. Additionally, delays relative to our projected timelines are likely to cause overall expenses to increase, which may require us to raise additional capital sooner than expected and prior to achieving targeted development milestones. Any drug delivery device that we may use to deliver our product candidates may have its own regulatory, development, supply and other risks. We expect to deliver our product candidates via a drug delivery device, such as an injector or other delivery system. There may be unforeseen technical complications related to the development activities required to bring such a product to market, including primary container compatibility and / or dose volume requirements. If our product candidates are intended to be used with drug delivery devices, we expect to utilize drug delivery devices authorized for marketing under clearances of approvals held by third parties. Our product candidates may not be approved or may be substantially delayed in receiving approval if the devices that we choose to develop do not gain and / or maintain their own regulatory approvals or clearances. Where approval of the drug product and device is sought under a ~~Phase 3 PRECISION~~ single application, the increased complexity of the review process may delay approval. In addition, some drug delivery devices are provided by single - ~~AF clinical trial will~~ source third- party companies. We may be dependent on the sustained cooperation and effort of those third- party companies both to supply the devices and, in some cases, to conduct the studies ~~require~~ required ~~substantially more capital~~ for approval or other regulatory clearance of the devices. Even if approval is obtained for our products, we may also be dependent on those third- party companies continuing to maintain such approvals or clearances, if required, for their drug delivery devices once they have been received. Failure of third- party companies to supply the devices on time and in accordance with the agreed- upon specifications, to successfully complete studies on the devices in a timely manner, or to obtain or maintain required approvals or clearances of the devices could result in increased development costs, delays in or failure to obtain regulatory approval and delays in product candidates reaching patients. Our approach to the discovery and development of our programs is unproven , and we may not ~~cannot guarantee when or if we will~~ be ~~able~~ successful in our efforts to ~~secure such additional financing; • we will need~~ build a pipeline of programs with commercial value. Our approach to the discovery ~~raise substantial additional funds through public or private equity or debt transactions~~ and ~~/ or complete one or more strategic transactions or partnerships, to continue~~ development of ~~Gencaro~~ the research programs with respect to which we have signed a license agreement , ~~rNAPc2~~ exercised the Option to acquire intellectual property license rights to or ~~any~~ have the Option to acquire intellectual property license rights to pursuant to the Option Agreements, leverages clinically validated mechanisms of action and incorporates advanced antibody engineering to optimize half- life and other properties designed to overcome limitations of existing therapies. Our programs are purposefully designed to improve upon existing product candidates and products while maintaining the same, well- established mechanisms of action. However, the scientific research that forms the basis of our ~~other~~ efforts to develop programs using half- life extension technologies is ongoing and may not result in viable programs. There is limited clinical data available on product candidates utilizing half- life extension technologies, especially in I & I indications, demonstrating whether they are safe or effective for long- term treatment in humans. The long- term safety and efficacy of these technologies and the extended half-lives and exposure profiles of our programs compared to currently approved products are unknown. We may ultimately discover that utilizing half- life extension technologies for our specific targets and indications and any programs resulting therefrom does not possess certain properties required for therapeutic effectiveness. In addition, programs using half- life extension technologies may demonstrate different chemical and pharmacological properties in human participants than they do in laboratory studies or preclinical studies. This technology and any programs resulting therefrom may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways. In addition, we may in the future seek to discover and develop programs that are based on novel targets and technologies that are unproven . If ~~we are unable~~ our discovery activities fail to ~~raise~~ identify novel targets or technologies for drug discovery, or such ~~financing~~ targets prove to be unsuitable ~~or~~ for treating human disease ~~complete such a transaction~~, we may not be able to develop viable additional programs. We and our existing or future collaborators may never receive approval to market and commercialize any product candidate. Even if we or an existing or future collaborator obtains regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. If the products resulting from the research programs with respect to which we have signed license agreements with Paragon, exercised the Option to acquire intellectual property license rights to or have the Option to acquire intellectual property license rights to pursuant to the Option Agreements prove to be ineffective, unsafe or commercially unviable, such programs would have little, if any, value, which would have a material and adverse effect on our business, financial condition, results of operations and prospects. Preclinical and clinical development involves a lengthy and expensive process that is subject to delays and uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results. If our preclinical studies and clinical trials are not sufficient to support regulatory approval of any of our product candidates, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such product candidate. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of such product candidate in humans. Our clinical trials may not be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process. Furthermore, a failure of one or more clinical trials can occur at any stage of testing. Clinical data is often susceptible to varying interpretations and analyses, and in addition, we expect to rely on participants to provide feedback on measures such as measures of quality of life, which are subjective and inherently difficult to evaluate. These measures can be influenced by factors outside of our control, and can vary widely from day- to- day for a particular participant, and from participant to participant and from site to site within a clinical trial. We cannot be sure that the FDA, or comparable foreign regulatory authority, as applicable, will agree with our clinical development plan. We plan to use the data from our Phase 1 trials of our ORKA- 001 and ORKA- 002 programs in healthy volunteers to support Phase 2 trials in PsO and potentially other I & I indications. If the FDA and / or comparable foreign regulatory authority requires us to materially modify our proposed trial designs, conduct additional trials or enroll additional participants, our development timelines may be delayed. We cannot be sure that submission of an IND, Clinical Trial Application or similar application will result in the FDA or comparable foreign regulatory authorities, as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could suspend or terminate such clinical trials. Events that may prevent successful or timely initiation or completion of clinical trials include: inability to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation or continuation of clinical trials; delays in reaching a consensus with regulatory authorities on study design or implementation of the clinical trials; delays or failure in obtaining regulatory authorization to commence a trial; delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites; recruiting and training suitable clinical investigators; delays in obtaining required IRB approval at each clinical trial site; delays in manufacturing, testing, releasing, validating or importing / exporting sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing; failure by our CROs, other third parties or us to adhere to clinical trial protocols; failure to perform in accordance with the FDA' s or any other regulatory authority' s current GCP requirements or applicable regulatory guidelines in other countries; changes to the clinical trial protocols; clinical sites deviating from trial protocol or dropping out of a trial; delays or failure by our third party vendors or us in the manufacturing, packaging, labeling and proper delivery of clinical trial materials; and third parties being unwilling or unable to satisfy their contractual obligations to us. We could also encounter delays if a clinical trial is required to be materially modified or suspended or terminated by us, the IRBs, by the Data Safety Monitoring Board, if any, or by the FDA or comparable foreign regulatory authorities. Such authorities may suspend, put on clinical hold or terminate a clinical trial due to a number of factors, including not aligning with or supporting our clinical trial designs or our failure to conduct the clinical trial in accordance with regulatory requirements or our clinical trial protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from the programs, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates, if the results of these trials are not positive or are only moderately positive or if there are safety concerns, our business and results of operations ~~; •~~ may be adversely affected and we may need to ~~partner rNAPc2 to continue~~ adjust or abandon our business plans and we may incur significant additional costs. If we encounter difficulties enrolling participants in our current and future clinical trials, our clinical development ~~and commercialization~~ activities could be delayed or ~~expansion into~~ otherwise adversely affected. We depend on the successful completion of clinical trials for our product candidates. We may experience difficulties in patient participant enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other ~~disease~~ things, on our ability to enroll a sufficient number of participants who remain in the trial until conclusion. The enrollment of participants in future trials for any of our programs will depend on many factors, including if participants choose to enroll in clinical trials, rather than using approved products, or if our competitors have ongoing clinical trials for programs that are under development for the same indications as our programs, and participants instead enroll in such clinical trials . ~~If~~ Even if we are ~~unable~~ -- able to ~~find~~ enroll a ~~partner~~ sufficient number of participants for our clinical trials, it may have difficulty maintaining participants in our clinical trials. Our inability to enroll or maintain a sufficient number of participants would result in significant delays in completing clinical trials and increased development costs or may require us to abandon one or more clinical trials altogether. Preliminary, “ topline ” or interim data from our clinical trials may change as more participant data becomes available and are subject to audit and verification procedures, and should be viewed with caution until the final data are available. From time to time , we may publicly disclose preliminary or topline data from our preclinical studies and clinical trials, which are based on a preliminary analysis of then- available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data. We also make assumptions, estimations, calculations and conclusions as part of our analyses of these data without the opportunity to fully and carefully evaluate complete data. As a result, the preliminary or topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated or subsequently made subject to audit and verification procedures. From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data are subject to the risk that one or more of the clinical outcomes may materially change as participant enrollment continues and more participant data become available or as participants from our clinical trials continue other treatments. Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular product candidate, the approvability or commercialization of the particular product candidate and our company in general. In addition, the information we choose to publicly disclose regarding a particular preclinical study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the preliminary, topline or interim data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition. Our clinical trials may reveal significant adverse events, undesirable side effects or patient intolerance not seen in our preclinical studies or earlier clinical trials, and may result in a safety profile that could halt clinical development, inhibit regulatory approval or limit commercial potential or market acceptance of any of our product candidates. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or patient intolerance, adverse events or unexpected characteristics, and any of these occurrences could harm our business, financial condition, results of operations and prospects significantly. If significant adverse events or other side effects are observed in any of our clinical trials, we may have difficulty recruiting participants to such trials, participants may drop out of the trials, or we may have to suspend, materially modify or abandon the trials or our development efforts of one or more programs altogether. We, the FDA or other applicable regulatory authorities, or an IRB, may suspend or require the material modification of any clinical trials of any program at any time for various reasons, including a belief that participants in such trials are being exposed to unacceptable health risks or adverse side effects. Moreover, negative or inconclusive results could cause the FDA or other regulatory agencies to require that we repeat or conduct additional clinical trials. If our clinical trials do not produce favorable results, our ability to obtain regulatory approval for our product candidates may be adversely impacted. Even if side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to their tolerability versus other therapies. In addition, an extended half- life could prolong the duration of undesirable side effects, which could also affect our clinical trials or inhibit market acceptance. Potential side effects associated with our product candidates may not be ~~able to continue operations; •~~ appropriately recognized or managed by the treating medical staff, as toxicities resulting from our product candidates may not be normally encountered in the general patient population and by medical personnel. In addition, even if we successfully advance our product candidates through clinical trials, such trials will only include a limited number of participants and limited duration of exposure to our product candidates. As a result, we cannot be assured that adverse effects of our product candidates will not be uncovered when a significantly larger number of participants are exposed to the product candidate after approval. Further, any clinical trials may not ~~able~~ be sufficient to ~~maintain~~ determine the ~~requirements~~ effect and safety consequences of using our product candidates over a multi- year period. If any of the foregoing events occur or if one or more of the research programs with respect to which we have signed a licensed agreement for ~~listing on~~ or exercised the ~~Nasdaq Capital Market~~ Option to acquire intellectual property license rights to or have the Option to acquire intellectual property license rights to pursuant to the Option Agreements prove to be unsafe , ~~we~~ our pipeline could be ~~delisted~~ affected , which ~~could~~ would have a material adverse effect on our business, financial condition, results of operations and prospects. We may expend our limited resources to pursue a particular program and fail to capitalize on programs that may be more profitable or for which there is a greater likelihood of success. We are initially focused on our most advanced programs, ORKA- 001 and ORKA- 002, and as a result, we may forgo or delay pursuit of opportunities with other programs that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may be in a position where we may have to relinquish valuable rights to that product candidate through collaboration, licensing or other arrangements in cases in which we would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Any approved products resulting from our programs may not achieve adequate market acceptance among clinicians, patients, healthcare third- party payors and others in the medical community necessary for commercial success and we may not generate any future revenue from the sale or licensing of such products. Even if regulatory approval is obtained for a product candidate resulting from one of our current or future programs, it may not gain market acceptance among physicians, patients, healthcare payors or the medical community. Market acceptance of our product candidates will depend on many factors, including factors that are not within our control. While there are several approved products and product candidates in later stages of development for the treatment of PsO, our programs incorporate advanced antibody engineering to optimize the half- life and formulation of antibodies, and to date, no such antibody has been approved by the FDA for the treatment of PsO. Market participants with influence over acceptance of new treatments, such as clinicians and third- party payors, may not adopt a biologic that incorporates half- life extension for our targeted indications, and we may not be able to convince the medical community and third- party payors to accept and use, or to provide favorable reimbursement for, any programs developed by us or our existing or future collaborators. Moreover, an extended half- life may make it more difficult for patients to change treatments and there may be a perception that half- life extension could exacerbate side effects, each of which may adversely affect our ability to ~~raise~~ gain market acceptance. Sales of medical products also depend on the willingness of healthcare providers to prescribe the treatment, and if any of our product candidates is approved but does not achieve an adequate level of acceptance, we may not generate or derive sufficient revenue from that product candidate and may not become or remain profitable. Certain of our programs may compete with our other programs, which could negatively impact our business and reduce our future revenue. We are developing product candidates for the same indication, PsO, and may in the future develop our programs for other I & I indications. Each such program targets a different mechanism of action. However, developing multiple programs for a single indication may negatively impact our business if the programs compete with each other. For example, if multiple programs are conducting clinical trials at the same time, they could compete for the enrollment of participants. In addition, if multiple product candidates are approved for the same indication, they may compete for market share, which could limit our future revenue. We may conduct clinical trials for programs at sites outside the United States, and the FDA may not accept data from trials conducted in such locations. Moreover, conducting clinical trials outside of the U. S. presents additional ~~funds~~ risks that may delay our clinical trials. We may choose to conduct one or more of our future clinical trials outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to conditions imposed by the FDA. If the FDA does not accept the data from any trial that we conduct outside the United States, it would likely result in the need for additional trials, which would be costly and time- consuming and would delay or permanently halt our development of the applicable product candidates. Even if the FDA accepted such data, it could impose additional conditions, such as requiring us to modify our planned clinical trials to receive clearance to initiate such trials in the United States or to continue such trials once initiated. Further, conducting clinical trials outside of the U. S. presents additional risks that may delay completion of our clinical trials. These risks include the failure of investigators or enrolled participants in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs that could restrict or limit our ability to conduct our clinical trials, the administrative burdens of conducting clinical trials under multiple sets of foreign regulations, potential restrictions, such as local privacy restrictions, on data generated from the clinical trial, diminished protection of intellectual property in some countries, as well as political and economic risks relevant to foreign countries. Risks Related to Government Regulation The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time- consuming and unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we may not be able to commercialize, or may be delayed in commercializing, our product candidates, and our ability to generate revenue may be materially impaired. The lengthy regulatory approval process as well as the ~~price~~ unpredictability of clinical trial results may result in our failing to obtain or be delayed in obtaining approval to market our product candidates, which would significantly harm our business, results of operations and ~~liquidity~~ prospects. Of the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The process of obtaining regulatory approvals, both in the United States and abroad, is unpredictable, expensive and typically takes many years following commencement of clinical trials. Approval may never be obtained and the approval process can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Before obtaining regulatory approvals for the commercial sale of our ~~common stock~~ product candidates, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for each targeted indication. Securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Further, our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval. The FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other data. Our product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including: the failure to demonstrate that a product candidate’ s benefits outweigh safety risks ; ~~•~~ regulatory authorities may disagree with our interpretation of clinical data or the data collected may not be acceptable or sufficient to support submission; or the results may not meet the level of statistical significance required for approval by the relevant regulatory authorities or otherwise considered insufficient by the FDA or comparable foreign regulatory authorities. Regulatory authorities may require the addition of labeling statements, such as black box or other warnings or contraindications that could diminish the usage of the product or otherwise limit the commercial success of the affected product. Moreover, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, including failing to approve the most commercially promising indications, may grant approval contingent on the performance of costly post- marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates and our ability to generate revenue will be materially impaired. We may not be able to meet requirements for the chemistry, manufacturing and control of our programs. In order to receive approval of our products by the FDA and comparable foreign regulatory authorities, we must show that we and our CMO partners are able to characterize, control and manufacture our drug products safely and in accordance with regulatory requirements. This includes manufacturing the active ingredient, developing an acceptable formulation, manufacturing the drug product, performing tests to adequately characterize the formulated product, documenting a repeatable manufacturing process, and demonstrating that our drug products meet stability requirements. As noted above, we may deliver our product candidates via a drug delivery device, which also requires us to meet certain chemistry, manufacturing and control requirements set forth by the FDA and other foreign regulatory authorities. Meeting these chemistry, manufacturing and control requirements is a complex task that requires specialized expertise. If we are not able to meet the chemistry, manufacturing and control requirements, we may not be successful in getting our products approved. Our product candidates for which we intend to seek approval as biologics may face competition sooner than anticipated. The Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Reconciliation Act (the “ ACA ”), includes a subtitle called the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA- licensed reference biological product. Under the BPCIA, an application for a highly similar or “ biosimilar ” product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first approved. During this 12- year period of exclusivity, another company may still market ~~conditions~~ a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor’ s own preclinical data and ~~changing circumstances~~ data from adequate and well- controlled clinical trials to demonstrate the safety, purity and potency of their product. We believe that any of our product candidates approved as biologics under a BLA should qualify for the 12- year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. Other aspects of the BPCIA , some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be ~~beyond our control, could impair our ability~~ substituted for any reference products in a way that is similar to ~~access our existing cash~~ traditional generic substitution for non- biological products is not yet clear , ~~cash equivalents~~ and will ~~investments and to timely pay key vendors and~~

~~others; • our business could be adversely affected by the effects of health epidemics, including the ongoing COVID- 19 global pandemic, in regions where we or third parties on which we rely may have clinical trial sites or other business operations. • we depend or may~~ depend on **a number of marketplace** ~~third parties to conduct clinical trials~~ and **regulatory factors that are still** ~~provide diagnostic information, as well as to develop~~ **developing** ~~, commercialize and / or manufacture~~ **. Even if we receive regulatory approval of** our product candidates ~~; • unless we are able to generate sufficient product revenue~~ , we will ~~continue~~ **be subject** to ~~incur losses from operations~~ **extensive ongoing regulatory obligations** and ~~will not achieve~~ **continued regulatory review and may result in restrictions on the use of the product, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements** or **experience unanticipated problems with** ~~maintain profitability. We are years away from commercializing a product and generating product revenue; •~~ our product candidates **. Any** ~~are subject to extensive regulation, which can be costly and time- consuming, and unsuccessful or delayed~~ regulatory approvals ~~could increase~~ **that we may receive for** our ~~future development costs~~ **product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions** or ~~impair~~ **contraindications, and may include burdensome post- approval study or risk management requirements. For example, the FDA may require a REMS in order to approve** our ~~future revenue; •~~ **product candidates. In addition, even** if our product candidates receive ~~regulatory~~ approval, ~~we would~~ **our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export will** be subject to ~~ongoing~~ **comprehensive regulation by the FDA and other** regulatory ~~obligations~~ **agencies in the United States** and **by comparable foreign regulatory authorities. These requirements include submissions of safety and other post- marketing information and reports, registration, as well as on- going compliance with current CGMPs and GCPs for any clinical trials that we conduct following approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with CGMPs. If we or a regulatory authority discover previously unknown problems with a product or problems with the facilities where the product is manufactured, a regulatory authority may impose** restrictions **on that product** , ~~which may result in significant expenses and limit~~ **the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing, restrictions on** our ability to ~~develop~~ **conduct clinical trials, including full or partial clinical holds on ongoing or planned trials, restrictions on the manufacturing process, warning or untitled letters, civil** and ~~commercialize other potential~~ **criminal penalties, injunctions,** ~~products~~ - **product** ~~; • transitioning from a clinical development stage company will require successful completion~~ **seizures, detentions or import bans, voluntary or mandatory publicity requirements and imposition** of **restrictions on operations** ~~a number of steps~~ , **including costly new manufacturing requirements. Disruptions at** ~~many of which are outside of our control and, consequently, we can provide no assurance of our successful and timely transition from a clinical development stage company; • if approved by~~ the FDA, ~~Genecaro~~ **the SEC and other government agencies and regulatory authorities caused by funding shortages** or ~~rNAPc2 will be entering a competitive marketplace~~ **global health concerns could hinder their ability to hire** and **retain key leadership** ~~may not succeed; • if we fail to identify~~ and ~~license or acquire~~ other **personnel** ~~products or product candidates~~ , **prevent new** ~~then we may be unable to expand our business, and the acquisition or licensing of other products or product candidates may put a strain on our operations and will likely require us to seek additional financing; • the loss of any rights to market key products would significantly impair our operating results; • third parties may own or control patents or patent applications that we may be required to license to commercialize our product candidates or that could result in litigation that would be costly and time consuming; • our intellectual property rights may not preclude competitors from developing competing~~ products and **services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of** our business may ~~suffer~~ **rely, which could negatively impact our business** . ~~Risks Related~~ **The ability of the FDA** to ~~Our Strategic Evaluation Process There~~ **review regulatory filings and our ability to commence human clinical trials can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC, and other government agencies on which our operations may rely, including those that fund research and development activities** is **subject to** ~~no guarantee that even if we do engage in a strategic transaction that such strategic transaction will increase stockholder value. In April 2022,~~ the **political process, which is inherently fluid** ~~Board of Directors established a Special Committee (Special Committee)~~ and **unpredictable** ~~, in May 2022, retained Ladenburg Thalmann & Co~~ . **Disruptions at the FDA and other agencies** ~~Inc. (Ladenburg) to evaluate strategic options, including transactions involving a merger, sale of all~~ or ~~part of our assets~~ **comparable foreign regulatory authorities** , **may also slow** ~~or other alternatives with~~ the **time necessary** ~~goal of maximizing stockholder value (Strategic Review). We and Ladenburg have reviewed several potential strategic transactions and continue to evaluate further potential development of our existing assets, in order to maximize stockholder value. We do not have a defined timeline~~ for the ~~strategic~~ review ~~process~~ and **approval of applications for clinical trial** ~~the review may not result in any specific action~~ or **marketing authorization** ~~transaction. We may never complete a strategic transaction~~ , **which would** ~~and in the event that we do complete a strategic transaction, implementation of such transactions may impair stockholder value or otherwise~~ adversely affect our business. ~~Any~~ **For example, in recent years, including in 2018 and 2019, the U. S. government shut down several times and certain regulatory agencies,** such ~~transaction~~ **as the FDA and the SEC, had to furlough critical employees and stop critical activities. Additionally, action by the new Trump Administration to limit federal agency budgets or personnel** may ~~require us~~ **result in reductions** to ~~incur non- recurring or other~~ -- **the** ~~charges~~ **FDA' s budget, employees,** and **operations, which** may ~~pose significant integration challenges~~ **lead to slower response times** and **longer review periods** ~~/ or management and business disruptions~~ , ~~any of which could harm our results of operation and business prospects and impair the value of any such strategic transaction to our stockholders. If we engage in an acquisition, reorganization or business combination, we will incur a variety of risks~~ potentially ~~adversely~~ affecting our **ability** ~~business operations or our stockholders. In connection with our strategic transaction process, we are considering strategic business initiatives, which may include exploration and evaluation of strategic options such as a merger, reverse merger, other business combination, sale of assets, licensing, or other strategic transactions. If we pursue such a strategic transaction, we could, among other things: • issue equity securities dilutive~~ to ~~our current stockholders' percentage ownership; • incur substantial debt straining our operations; • spend substantial operational, financial, and management resources to integrate new businesses, technologies, and products; • assume substantial actual or contingent liabilities; • reprioritize our development programs~~ **progress** ~~and even cease~~ development of our product candidates ~~;~~ or **obtain regulatory approval** ~~• merge with, or~~ **for** ~~otherwise enter into~~ **our product candidates. If** a ~~business combination with~~ **prolonged government shutdown occurs** , **it** ~~another company in which our stockholders would~~ **could significantly impact the ability** ~~receive cash and / or shares~~ of the ~~other company on terms certain of~~ **FDA to timely review and process** our **regulatory submissions** ~~stockholders may not deem desirable. There is no guarantee we will be able to complete the strategic transaction process in a timely or successful manner~~ , which could have a material adverse effect on our business. **Further** ~~Risks Related to Our Business and Financial Condition If we are not able to successfully develop~~ , **future government shutdowns** ~~obtain FDA approval for, and provide for the commercialization of Gencaro or rNAPc2 in a timely manner, we may not be able to continue our business operations. We currently have no products that have received regulatory approval for commercial sale. The process to develop, obtain regulatory approval for and commercialize potential product candidates is long, complex and costly. Failure to demonstrate that a product candidate, including Gencaro or rNAPc2, is safe and effective, or significant delays in demonstrating such safety and efficacy, would adversely affect our business. Failure to obtain marketing approval of Gencaro or rNAPc2 from appropriate regulatory authorities, or significant delays in obtaining such approval, would also adversely affect our business and~~ could ~~, among other things, preclude us from completing a strategic transaction or obtaining additional financing necessary to continue as a going concern. Even if approved for sale, a product candidate must be successfully commercialized to generate value. We do not currently have the capital resources or management expertise to commercialize Gencaro, rNAPc2 or any of our other product candidates and, as a result, will need to complete a strategic transaction, or, alternatively, raise substantial additional funds to enable commercialization of Gencaro, rNAPc2 or any of our other product candidates, if approved. Failure to successfully provide for the commercialization of Gencaro, rNAPc2 or any other product candidate, if approved, would damage our business. If we encounter difficulties enrolling patients in our future clinical trial of Gencaro, any potential enrollment milestones or potential regulatory approvals could be delayed or otherwise adversely affected. We may encounter difficulty enrolling a sufficient number of patients in our clinical trials, due to circumstances which are outside our control, including other clinical trials that may limit the availability of study participants. As a result, we may need to delay or terminate our trial, which would have a negative~~ impact ~~on our business. Delays in enrolling patients in the clinical trial would also adversely affect~~ our ability to **access** ~~meet projected enrollment milestones or timelines for completing~~ the **public markets** ~~study and obtaining regulatory approval. Our clinical trials from our product candidates may not yield results that will enable us to further develop our products as a therapy~~ and obtain ~~regulatory approvals~~ necessary **capital in order** to ~~be used as~~ **properly capitalize and continue our operations. If** a **prolonged government shutdown occurs,** ~~drug. We will receive regulatory approval for~~ - **or** ~~our product candidates only~~ if **global** ~~we can demonstrate, in carefully designed and conducted clinical trials, that the product candidate is safe and effective. We do not know whether any future clinical trials for Gencaro, rNAPc2 or any other product candidate will demonstrate sufficient safety and efficacy to obtain the requisite regulatory approvals or will result in marketable products. The results from preclinical testing and early clinical trials may not be predictive of results from later studies. We may suffer significant setbacks in advanced clinical trials, even after seeing promising results in earlier studies. Based on results at any stage of clinical trials, we may decide to repeat or redesign a trial or discontinue development of one or more of our product candidates. If we fail to adequately demonstrate the safety and efficacy of our product candidates, we will not be able to obtain the required regulatory approvals to commercialize it and our business, results of operations and financial condition would be materially adversely affected. In addition, administering our product candidates to humans may produce undesirable side effects. These side effects could interrupt, delay or halt~~ **health concerns prevent** ~~clinical trials of our product candidates, and could result in~~ the FDA or other regulatory authorities ~~denying approval~~ **from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability** of **the FDA or other regulatory authorities to timely review and process** our ~~product candidates, for any or all targeted indications. We may not achieve our projected development goals in the time frames we announce and expect. We set goals for, and make public statements regarding, the timing of certain accomplishments, such as the initiation of our clinical trials, the steps for commencing and continuing our clinical trials, the disclosure of trial results, the obtainment of regulatory approval and the sale of drug products, which we sometimes refer to as milestones. These milestones may not be achieved, and the actual timing of these events can vary dramatically due to a number of factors such as delays or failures in our clinical trials, disagreements with any collaborative partners, the uncertainties inherent in the regulatory approval process and manufacturing scale- up, delays in achieving manufacturing or marketing arrangements sufficient to commercialize our products or our inability to obtain sufficient financing in a timely manner. There can be no assurance that we will make~~ regulatory submissions ~~or receive regulatory approvals as planned. If we fail to achieve one or more of these milestones as planned, our business will be materially adversely affected. We expect a Phase 3 PRECISION- AF clinical trial will require substantially more capital, and we cannot guarantee when or if we will be able to secure such additional financing. We will need to secure additional financing in order to initiate enrollment of our Phase 3 PRECISION- AF clinical trial. Even if we can begin enrolling patients, we expect to have to raise significant additional capital to continue enrollment. If we are not able to obtain financing in the future or on acceptable terms, we may have to terminate the clinical trial early, which could adversely affect our business. We will need to raise substantial additional funds through public or private equity or debt transactions and / or complete one or more strategic transactions or partnerships, to continue development of Gencaro, rNAPc2 or any of our other product candidates. If we are unable to raise such financing or complete such a transaction, we may not be able to continue operations. As a result of the expected development timeline to potentially obtain FDA approval for Gencaro or rNAPc2, if at all, the substantial additional costs associated with the development of our product candidates, including the costs associated with clinical trials related thereto, and the substantial cost of commercializing Gencaro or rNAPc2, if approved, we will need to raise substantial additional funding through public or private equity or debt transactions or a strategic combination or partnership. If we are delayed in obtaining funding or are unable to complete a strategic transaction, we may discontinue our development activities on Gencaro, rNAPc2 and our other product candidates or discontinue our operations. Even if we are able to fund continued development of Gencaro, rNAPc2 or any of our other product candidates is approved, we expect that we will need to complete a strategic transaction or raise substantial additional funding through public or private equity or debt securities or partnership to successfully commercialize Gencaro, rNAPc2 or any other product candidate. We believe our cash and cash equivalents as of December 31, 2023 will be sufficient to fund our operations through the middle of fiscal year 2025. Our review of our strategic options may impact this projection. Conducting a Phase 3 PRECISION- AF trial would likely require additional financing. However, changing circumstances may cause us to consume capital significantly faster or slower than currently anticipated. We have based these estimates on assumptions that may prove to be wrong, and we could exhaust our available financial resources sooner than we currently anticipate; therefore, we may have to raise additional capital for other clinical trials. Initiating any Phase 3 clinical trial of Gencaro will require additional financing. On July 22, 2020, we entered into a new sales agreement with a placement agent to sell, from time to time, our common stock having an aggregate offering price of up to $ 54. 0 million, in an " at the market offering. " As of December 31, 2022, we sold an aggregate of 9, 928, 272 shares of our common stock pursuant to the terms of such sales agreement for aggregate gross proceeds of approximately $ 54. 0 million. Net proceeds received in this offering were approximately $ 52. 2 million, after deducting expenses for executing the " at the market offering " and commissions paid to the placement agent. In April 2021, we amended the new sales agreement and the amount available for the offering under our prospectus to our registration statement on Form S- 3 (No. 333- 254585). As of January 31, 2024, the amount available for the offering under the prospectus supplement is subject to the limitation of not selling a total value amount of shares exceeding more than one- third of our public float in any 12- month period, which as of January 31, 2024 would have been approximately $ 6. 3 million. Sales of our common stock dilute the ownership interest of our stockholders and may cause the price per share of our common stock to decrease. Changing circumstances may cause us to consume capital significantly faster or slower than we currently anticipate. We have based these estimates on assumptions that may prove to be wrong, and we could exhaust our available financial resources sooner than we currently anticipate. Additionally, in March 2020, the World Health Organization declared the outbreak of COVID- 19 a global pandemic. This outbreak is causing major disruptions to businesses and markets worldwide as the virus spreads. The economic uncertainty surrounding the COVID- 19 pandemic may dramatically reduce our ability to secure equity or debt financing necessary to support our operations. We are unable to currently estimate the financial effect of the pandemic. If the pandemic continues to be a severe worldwide crisis, economic conditions may cause capital not to be available to us, or not be available on acceptable terms, regardless of our business efforts. Our liquidity, and our ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following: • the costs and timing for potential additional clinical trials in order to gain possible regulatory approval~~

~~for Genearo, rNAPc2 and our other product candidates; • the market price of our stock and the availability and cost of additional equity capital from existing and potential new investors; • our ability to retain the listing of our common stock on the Nasdaq Capital Market; • general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas' attack against Israel and the ensuing conflict; • our ability to control costs associated with our operations; • the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and • the terms and conditions of our existing collaborative and licensing agreements. The sale of additional equity or convertible debt securities would likely result in substantial dilution to our stockholders. If we raise additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of our capital stock and could contain covenants that would restrict our operations. We also cannot predict what consideration might be available, if any, to us or our stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to us, or not be available on acceptable terms, we may be unable to realize value from our assets and discharge our liabilities in the normal course of business which may, among other alternatives, cause us to further delay, substantially reduce or discontinue operational activities to conserve our cash resources. We have received an SPA agreement from the FDA relating to our planned Phase 3 program for Genearo. This SPA agreement does not guarantee approval of Genearo or any other particular outcome from regulatory review. In 2019, we received an SPA agreement from the FDA for our planned Phase 3 clinical trial of Genearo. The FDA' s SPA process is designed to facilitate the FDA' s review and approval of drugs by allowing the FDA to evaluate the proposed design and size of certain clinical trials that are intended to form the primary basis for determining a drug product' s efficacy. Upon specific request by a clinical trial sponsor, the FDA will evaluate the protocol and respond to a sponsor' s questions regarding, among other things, primary efficacy endpoints, trial conduct and data analysis, within 45 days of receipt of the request. The FDA ultimately assesses whether the protocol design and planned analysis of the trial are acceptable to support regulatory approval of the product candidate with respect to the effectiveness of the indication studied. All agreements and disagreements between the FDA and the sponsor regarding a SPA must be clearly documented in a SPA letter or the minutes of a meeting between the sponsor and the FDA. However, an SPA agreement does not guarantee approval of a product candidate, even if the trial is conducted in accordance with the protocol. Moreover, the FDA may revoke or alter our SPA agreement in certain circumstances. In particular, a SPA agreement is not binding on the FDA if public health concerns emerge that were unrecognized at the time of the SPA agreement, other new scientific concerns regarding product safety or efficacy arise, we fail to comply with the agreed upon trial protocols, or the relevant data, assumptions or information provided by us in our request for the SPA change or are found to be false or omit relevant facts. In addition, even after an SPA agreement is finalized, the SPA agreement may be modified, and such modification will be deemed binding on the FDA review division, except under the circumstances described above, if the FDA and the sponsor agree in writing to modify the protocol and such modification is intended to improve the study. The FDA retains significant latitude and discretion in interpreting the terms of the SPA agreement and the data and results from any study that is the subject of the SPA agreement. Even though we obtained an agreement on our SPA, we cannot assure you that our planned Phase 3 clinical trial will succeed, will be deemed binding by the FDA under our SPA agreement, or will result in any FDA approval for Genearo. We may also alter the design of the trial to focus on endpoints that are not covered by the SPA. Moreover, if the FDA revokes or alters its agreement under our SPA, or interprets the data collected from the clinical trial differently than we do, the FDA may not deem the data sufficient to support an application for regulatory approval, which could materially adversely affect our business, financial condition and results of operations. If we are not able to maintain the requirements for listing on the Nasdaq Capital Market, we could be delisted~~ , which could have a material adverse effect on our ~~ability~~ **business. We may face difficulties from legislative or regulatory reform measures. We may be faced with additional or changing regulatory and governmental regulations that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, the Trump Administration has discussed several changes** to ~~raise additional funds~~ **the reach and oversight of the FDA, which could affect its relationship with the pharmaceutical industry, transparency in decision making and ultimately the cost and availability of prescription drugs. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. The price of pharmaceuticals** ~~as~~ **has** ~~well~~ **been a topic of considerable public discussion that could lead to price controls or other price- limiting strategies by payors that have the effect of lowering payment and reimbursement rates for drugs or otherwise making the commercialization of pharmaceuticals less profitable. Many federal and state legislatures have considered, and adopted, healthcare policies intended to curb rising healthcare costs, such** as the **IRA. These cost- containment measures may include, among other measures: requirements for pharmaceutical companies to negotiate prescription drug** ~~price~~ **prices** ~~and liquidity of~~ **with government healthcare programs; controls on government- funded reimbursement for drugs; new** ~~our~~ - **or** ~~common stock. Our common stock is currently listed~~ **increased requirements to pay prescription drug rebates to government healthcare programs, including if drug prices increase at a higher rate than inflation; controls on healthcare providers; challenges to or limits** on the ~~Nasdaq Capital Market~~ **pricing of drugs, including pricing controls or limits or prohibitions on reimbursement for specific products through other means; requirements to try less expensive products or generics before a more expensive branded product; and public funding for cost effectiveness research, which may be used by government and private third- party payors to make coverage and payment decisions** . ~~To maintain~~ **Political, economic and regulatory developments may further complicate developments in healthcare systems and pharmaceutical drug pricing. These developments could, for example, impact our potential licensing agreements as commercial and collaborative partners may also consider** the ~~listing~~ **impact** of **these pressures** ~~our common stock~~ on **their licensing strategies. Any new laws or regulations that have** the ~~Nasdaq Capital Market we are required to meet certain listing requirements, including, among others, (i) a minimum closing bid price of $ 1. 00 per share, (ii) a market value of publicly held shares (excluding shares held by our executive officers, directors and 10 % or more stockholders) of at least $ 1 million and (iii) either: (x) stockholders' equity of at least $ 2. 5 million; or (y) a total market value of listed securities of at least $ 35 million. We have received three potential delisting notices from Nasdaq since 2012. In each of 2012, 2015 and 2018, we received notification from Nasdaq of potential delisting of our shares from the Nasdaq Capital Market because the closing bid price of our common stock had not met the minimum closing bid price of $ 1. 00 per share during the preceding 30 business days. We subsequently regained compliance with Nasdaq' s minimum closing bid price requirements related to the 2012, 2015 and 2018 notices, by effecting a 1 - for - 6 reverse split of our common stock in March 2013, a 1 - for - 7 reverse split of our common stock in September 2015 and a 1- for- 18 reverse split of our common stock in April 2019. Despite effecting a 1- for- 18 reverse split of our common stock in April 2019, there can be no assurance that the market price per share of our common stock will remain in excess of the $ 1. 00 minimum bid price for a sustained period of time. The continuing~~ effect of **imposing additional costs** ~~our~~ - **or regulatory burden** ~~reverse stock split~~ on **pharmaceutical manufacturers, or otherwise negatively affect** the **industry** ~~market price of our common stock cannot be predicted with any certainty~~ , ~~and the history of similar stock split combinations for companies in like circumstances is varied. It is possible that the per share price of our common stock after the reverse stock split will not rise in proportion to the reduction in the number of shares of common stock outstanding resulting from the reverse stock split, effectively reducing our market capitalization, and there can be no assurance that the market price per post- reverse split share will either exceed or remain in excess of the $ 1. 00 minimum bid price for a sustained period of time. The market price of our common stock may vary based on other factors that are unrelated to the number of shares outstanding, including our future performance. The delisting of our common stock from a national exchange could impair the liquidity and market price of the common stock. It could also materially, adversely affect our access to the capital markets, and any limitation on market liquidity or reduction in the price of the common stock as a result of that delisting~~ could adversely affect our ability to ~~raise capital~~ **successfully commercialize our product candidates. The implementation of any price controls, caps** on ~~terms acceptable~~ **prescription drugs or price transparency requirements could adversely affect our business, operating results and financial condition. Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third- party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, including conflicts of interest rules, which could expose us to penalties. Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third- party payors, patient organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Principal investigators for our clinical trials may serve as scientific advisors or consultants** to us ~~,~~ or **may be affiliated with our other service providers, including CROs or site management organizations, and from time to time may receive cash compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, the integrity of the data generated** at ~~all~~ **the applicable clinical trial site or in the applicable trial may be questioned or jeopardized. Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve costs and management attention. If our operations are found to be in violation of any of these laws or any other governmental laws and regulations that may apply to it, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government- funded healthcare programs, integrity oversight and reporting obligations to resolve allegations of non- compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. Further, defending against any such actions can be costly and time- consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Even if we are able to commercialize any product candidates, due to unfavorable pricing regulations and / or third- party coverage and reimbursement policies, we may not be able to offer such product candidates at competitive prices, which would seriously harm our business. We intend to seek approval to market our product candidates in the United States and in selected foreign jurisdictions, and we will be subject to rules and regulations in those jurisdictions where we obtain approval. Our ability to successfully commercialize any product candidates that we may develop will depend in part on the extent to which reimbursement for these product candidates and related treatments will be available from government health administration authorities, private health insurers and other organizations** . In ~~future periods~~ **some jurisdictions** , **government authorities and other third- party payors decide which medications they will pay for and establish reimbursement levels, and have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. These entities may create preferential access policies for a competitor' s product, including a branded or generic / biosimilar product, over our products in an attempt to reduce their costs, which may reduce our commercial opportunity. Additionally, if any of our product candidates are approved and we are found to have improperly promoted off- label uses of those product candidates, we may become subject to significant liability, which would materially adversely affect our business and financial condition. We are subject to U. S. and certain foreign export and import controls, sanctions, embargoes, anti- corruption laws, and anti- money laundering laws and regulations. We can face criminal liability and other serious consequences for violations, which can harm our business. We are subject to export control and import laws and regulations, including the U. S. Export Administration Regulations, U. S. Customs regulations, various economic and trade sanctions regulations administered by the U. S. Treasury Department' s Office of Foreign Assets Controls, the U. S. Foreign Corrupt Practices Act of 1977, as amended, the U. S. domestic bribery statute contained in 18 U. S. C. § 201, the U. S. Travel Act, the USA PATRIOT Act, the U. S. Physician Payments Sunshine Act and other state and national anti- bribery and anti- money laundering laws in the countries in which we conduct activities. Anti- corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to or from recipients in the public or private sector. We may engage third parties to sell our products outside the United States, to conduct clinical trials, and / or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government- affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even** if we do not ~~meet~~ **explicitly authorize or have actual knowledge of such activities. Any violations of** the ~~minimum stockholders' equity~~ **laws and regulations described above may result in substantial civil and criminal fines and penalties** , ~~minimum closing bid~~ **imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. Governments outside the United States tend to impose strict** price ~~requirements~~ **controls** , **which may adversely affect** ~~or~~ **our revenue, if** any **. In some countries, particularly member states of** ~~other~~ -- **the** ~~listing requirements~~ **EU (" EU Member States ")** , ~~we would be~~ **the pricing of prescription drugs is** subject to ~~delisting from~~ **governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a therapeutic. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States and parallel distribution, or arbitrage between low- priced and high- priced EU Member States, can further reduce prices. To obtain coverage and reimbursement or pricing approvals in some countries, we or current or future collaborators may be required to conduct a clinical trial or other studies that compare** the **cost- effectiveness** ~~Nasdaq Capital Market. As of January 31, 2024, the closing price~~ of our ~~common stock was $ 1~~ **product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval** . ~~59 per share~~ **Publication of discounts by third- party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or amount** , **or if pricing is set at unsatisfactory levels, our business, financial condition, results of operations or prospects could be materially and adversely affected. If the UK or EU Member States were to significantly alter their regulations affecting the pricing of prescription pharmaceuticals, we could face significant new costs. Our ability to obtain and protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage. We rely upon a combination of patents, trademarks, trade secret protection, confidentiality agreements** and the **Option and License Agreements to protect** ~~total market value of our listed securities was approximately $ 23. 1 million. As of December 31, 2023, we had stockholders' equity of $ 37. 0 million. Our audited financial statements for~~ the **intellectual property related** ~~fiscal year ended December 31, 2023 were prepared assuming that we will continue as a going concern. Our management has concluded that due~~ to our **programs** ~~need for additional capital,~~ and ~~the uncertainties surrounding~~ **technologies and to prevent third parties from competing unfairly**

with it. Our success depends in large part on our ability to ~~raise such funding,~~ **obtain and maintain patent protection for our programs and our product candidates and** ~~there~~ - **their** ~~may be uncertainty about~~ **uses, as well as** our ability to **operate without infringing on** ~~continue as a going concern in future years. Our audited financial statements for~~ - **or violating** the ~~fiscal year ended December 31~~ **proprietary rights of others. Paragon has filed** , ~~2023 were prepared assuming~~ **on our behalf, provisional patent applications and we have filed non- provisional patent applications directed to antibodies** that **target IL- 23, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including ORKA- 001. In addition, Paragon has filed, on our behalf, provisional patent applications and** we ~~will continue as a going concern. The going concern basis~~ **intend to file one or more additional provisional patent applications directed to antibodies that target IL- 17, including applications covering composition** of ~~presentation assumes that~~ **matter, pharmaceutical formulations, and methods of using such antibodies, including ORKA- 002. However,** we **may not** ~~will continue in operation for the foreseeable future and will~~ be able to ~~realize~~ **protect** our ~~assets~~ **intellectual property rights throughout the world** and ~~discharge~~ **the legal systems in certain countries may not favor enforcement or protection of patents, trade secrets and other intellectual property. Filing, prosecuting and defending patents on programs worldwide is expensive and** our ~~liabilities and commitments~~ **intellectual property rights in some foreign jurisdictions can be less extensive than those** in the **United States;** ~~normal course of business and do not include any adjustments to reflect~~ the **reverse** ~~possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that~~ may **also** ~~result from our~~ **occur** ~~inability to continue as a going concern~~ . As ~~of December 31, 2019, our management and our independent registered public accounting firm concluded that, due to our need for additional capital and the uncertainties surrounding our ability to raise~~ such ~~funding, substantial doubt existed as to our ability to continue as a going concern for a period from one year after our annual financial statements had been issued. We believe our cash and cash equivalents as of December 31, 2023 will be sufficient to fund our operations through the middle of fiscal year 2025. Our review of our strategic options may impact this projection. Conducting a Phase 3 PRECISION- AF trial would likely require additional financing. However, changing circumstances may cause us to consume capital significantly faster or slower than currently anticipated. We have based these estimates on assumptions that may prove to be wrong, and we could exhaust our available financial resources sooner than we currently anticipate; therefore~~ , we may **not** have **patents** ~~to raise additional capital for other clinical trials. Initiating any Phase 3 clinical trial of Gencaro will require additional financing. We cannot be certain that we will be able to make any other sale of our common stock~~ in **all countries** ~~any future offering to cover our future capital needs,~~ or ~~at~~ all ~~. Changing circumstances~~ **major markets and** may ~~cause us to consume capital significantly faster or slower than we currently anticipate. If we are delayed in completing or are unable to complete additional funding and / or a strategic transaction, we may discontinue our development activities or operations, but there are no~~ **not** ~~assurances that these reductions would be sufficient to allow us to continue to operate as a going concern. Therefore, even if we resolve this uncertainty, our independent registered public accountants and / or management could conclude that uncertainty as to our ability to continue as a going concern could exist at a future date. We have based these estimates on assumptions that may prove to be wrong, and we could exhaust our available financial resources sooner than we currently anticipate. We may be forced to reduce our operating expenses and raise additional funds to meet our working capital needs, principally through the additional sales of our securities or debt financings. However, we cannot guarantee that we will~~ be able to obtain **patents in all jurisdictions even if we apply for them. Our competitors may operate in countries where we do not have patent protection and can freely use our technologies and discoveries in such countries to the extent such technologies and discoveries are publicly known or disclosed in countries where we do have patent protection or pending patent applications. Our pending and future patent applications may not result in patents being issued. Any issued patents may not afford** sufficient ~~additional funds when needed~~ **protection of our programs** or **their intended uses against competitors, nor can there be any assurance** that **the patents issued will not be infringed, designed around, invalidated by third parties, or effectively prevent others from commercializing competitive technologies, products or programs. Even if these patents are granted, they may be difficult to enforce. Further, any issued patents that we may license or own covering our programs could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad, including the United States Patent and Trademark Office (“ USPTO ”). Further, if we encounter delays in our clinical trials or delays in obtaining regulatory approval, the period of time during which we could market our product candidates under patent protection would be reduced. Thus, the patents that we may own and license may not afford us any meaningful competitive advantage. In addition to seeking patents for some of our technology and programs, we may also rely on trade secrets, including unpatented know- how, technology and other proprietary information, to maintain our competitive position. Any disclosure, either intentional or unintentional, by our employees, the personnel of third parties with whom we share our facilities or third- party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (** such ~~funds~~ **as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. In order to protect our proprietary technology and processes, we rely in part on agreements, such as confidentiality agreements, with our vendors, collaborators, employees, consultants, outside scientific collaborators and sponsored researchers and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. We may need to share our proprietary information, including trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or state actors and those affiliated with or controlled by state actors. In addition, while we undertake efforts to protect our trade secrets and other confidential information from disclosure, others may independently discover trade secrets and proprietary information, and in such cases, we may not be able to assert any trade secret rights against such party. Enforcing a claim that a party illegally obtained and is using our trade secrets is challenging and the outcome is unpredictable. In addition, courts outside of the U. S. may be less willing to protect trade secrets. Costly and time- consuming litigation could be necessary to enforce and determine the scope of our proprietary rights and failure to obtain or maintain trade secret protection could adversely affect our competitive business position. Lastly** , if ~~available~~ **our trademarks and trade names are not registered or adequately protected** , ~~will~~ **then we may not** be **able to build name recognition in our markets of interest and our business may be adversely affected. We may not be successful in obtaining or maintaining necessary rights to our programs through acquisitions and in- licenses. Because our development programs currently do and may in the future require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in- license, or use these third- party proprietary rights. It is possible that we may be unable to** ~~obtainable~~ ---- **obtain licenses at a reasonable cost or on reasonable terms, if at all. Even if we are able to obtain a license, it may be non- exclusive, thereby giving our competitors access to the same technologies licensed to us. We may be unable to acquire or in- license any compositions, methods of use, processes or other third- party intellectual property rights from third parties that we identify as necessary for our programs. The licensing and acquisition of third- party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third- party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third- party intellectual property rights** on terms ~~satisfactory~~ **that would allow us** to ~~us~~ **make an appropriate return on our investment or at all** . If we are unable to ~~raise sufficient additional capital~~ **successfully obtain rights to required third- party intellectual property rights** or ~~complete a strategic transaction,~~ **maintain the existing intellectual property rights** we **do obtain** ~~may be unable to continue to fund our operations, develop Gencaro, rNAPc2 or our other product candidates, or realize value from our assets and discharge our liabilities in the normal course of business. If we cannot raise sufficient funds~~ , we may have to **abandon development** ~~liquidate our assets, and might realize significantly less than the values at which they are carried on our financial statements, and stockholders may lose all or part of their investment in our securities. Market conditions and changing circumstances, some of which may be beyond our control, could impair our ability to access our existing cash, cash equivalents and investments and to timely pay key vendors and others. Market conditions and changing circumstances, some of which may be beyond our control, could impair our ability to access our existing cash, cash equivalents and investments and to timely pay key vendors and others. For example, on March 10, 2023, Silicon Valley Bank (SVB), where we maintain certain accounts, was placed into receivership with the Federal Deposit Insurance Corporation (FDIC), which resulted in all funds held at SVB being temporarily inaccessible by SVB' s customers. If other banks and financial institutions with whom we have banking relationships enter receivership or become insolvent in the future, we may be unable to access, and we may lose, some or all of our existing cash, cash equivalents and investments to the extent those funds are not insured or otherwise protected by the FDIC. In addition, in such circumstances we might not be able to timely pay key vendors and others. We regularly maintain cash balances that are not insured or are in excess~~ of the **relevant program** ~~FDIC' s insurance limit. Any delay in our ability to access our cash~~ , **which** ~~cash equivalents and investments (or the loss of some or all of such funds) or to timely pay key vendors and others~~ could have a material adverse effect on our **business, financial condition, results of** operations **,** and ~~cause us~~ **prospects. While we plan** to ~~need~~ **obtain the right** to ~~seek additional capital sooner than planned. Our business could~~ **control prosecution, maintenance and enforcement of the patents relating to our programs, there may** be ~~adversely affected~~ **times when the filing and prosecution activities for patents and patent applications relating to our programs are controlled** by **our current and future licensors** ~~the effects of health epidemics, including the ongoing COVID- 19 global pandemic, in regions where we~~ or ~~third~~ **collaboration** ~~parties~~ **partners** ~~on which we rely may have clinical trial sites or other business operations~~ . **If any** ~~We anticipate having clinical trial sites in countries that have been directly affected by COVID- 19 and depend on third party manufacturing operations for various stages~~ of our **current and future licensors or collaboration partners fail to prosecute** ~~supply chain. Our business could be adversely affected by health epidemics~~ , ~~including~~ **maintain and enforce such patents and patent applications in a manner consistent with** the **best interests** ~~ongoing COVID- 19 pandemic, in regions where we may have concentrations of future clinical trial sites or other business operations. If the recent COVID- 19 outbreak continues to spread, we may need to further limit operations or implement limitations, including work- from- home policies. There is a risk that other countries or regions may be less effective at containing COVID- 19, or it may be more difficult to contain if the outbreak reaches a larger population or broader geography, in which case the risks described herein could be elevated significantly. In addition, third party manufacturing~~ of our ~~drug product candidates~~ **business, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, our ability to develop** and **commercialize** ~~suppliers of the~~ **those** ~~materials used in the production of our drug~~ product candidates may be ~~impacted by significant delays or restrictions resulting from the COVID- 19 outbreak which may disrupt our supply chain or limit our ability to manufacture drug product candidates for our clinical trials. The ultimate impact of the COVID- 19 outbreak or a similar future health epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. However, these effects could have a material impact on our operations, and we will continue to monitor the COVID- 19 situation closely. If we encounter difficulties enrolling patients in any future clinical trials, our future trials could be delayed or otherwise~~ adversely affected ~~. If we have difficulty enrolling a sufficient number of patients in any future clinical trial, we may need to delay or terminate our trial, which would have a negative impact on our business. Delays in enrolling patients in any future clinical trials would also adversely affect our ability to generate any product, milestone~~ and ~~royalty revenues under collaboration agreements, if any, and could impose significant additional costs on us or on any future collaborators. For example, the development of vaccines for the SARS- CoV- 2 virus and the development of other therapies for COVID- 19 disease impacted our ability to enroll patients in our rNAPc2 (AB201) Phase 2b clinical trial and such enrollment was slower than expected. The GENETIC- AF clinical trial required that we identify and enroll a large number of patients with the condition under investigation and the trial enrolled only those patients having a specific genotype, and certain patients who have or are willing to have a Medtronic device implanted for monitoring and recording AFB data. As a result, enrollment for GENETIC- AF was slower than expected, with our first patient enrolled in June 2014 and enrollment completed in August 2017. Because of the rigorous enrollment criteria, our clinical trial timelines were delayed from our original projections. We anticipate that any future Phase 3 clinical trial of Gencaro, including PRECISION- AF, may have similar enrollment criteria, and we cannot guarantee that we will not have similar enrollment issues in any future clinical trials. We may also encounter difficulty enrolling a sufficient number of patients in any future clinical trial, due to circumstances which are outside our control, including as a result of the ongoing COVID- 19 global pandemic, continued hostilities between Russia and Ukraine and Hamas' attack against Israel and the ensuing conflict. See “ Our business could be adversely affected by the effects of health epidemics, including the ongoing COVID- 19 global pandemic, in regions where we or third parties on which we rely have clinical trial sites or other business operations. We anticipate having clinical trial sites in countries that have been directly affected by COVID- 19 and depend on third party manufacturing operations for various stages of our supply chain ” for a discussion of the risks that the COVID- 19 pandemic poses to, among other things, our anticipated clinical trials. We will rely on contract research organizations to conduct substantial portions of our clinical trials, including any future clinical trial of Gencaro, rNAPc2, and as a result, we will be unable to directly control the timing, conduct and expense of all aspects of our clinical trials. We do not currently have sufficient staff with the requisite experience to conduct our clinical trials and therefore will rely on third parties to conduct certain aspects of any future clinical trials. We previously contracted with a CRO to conduct components of our GENETIC- AF clinical trial and anticipate contracting with a CRO to conduct components of any future clinical trial for Gencaro and components of the clinical study of rNAPc2 or any future clinical trials for our other product candidates. As a result, we will have less control over many details and steps of any clinical trial, the timing and completion of any clinical trial, the required reporting of adverse events and the management of data developed through any clinical trial than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties, such as CROs, may have staffing difficulties, may undergo changes in priorities or may become financially distressed, adversely affecting their willingness or ability to conduct our clinical trial. We may experience unexpected cost increases that are beyond our control. Problems with the timeliness or quality of the work of a CRO may lead us to seek to terminate the relationship and use an alternative service provider. However, making any change may be costly and may delay ongoing trials, if any, and contractual restrictions may make such a change difficult or impossible. Additionally, it may be impossible to find a replacement organization that can conduct clinical trials in an acceptable manner and at an acceptable cost. Even though we anticipate relying on CROs in the future, we will likely have to devote substantial resources and rely on the expertise of our employees to manage the work being done by the CROs. Due to our limited experience in managing clinical trials, we cannot guarantee our employees will do so effectively. We expect to depend on existing and future collaborations with third parties for the development of some of our product candidates. If those collaborations are not successful,~~ we may not be able to **prevent competitors from making, using and selling competing products. In addition, even where we have the right to control patent prosecution of patents and patent applications we have licensed to and from third parties, we may still be adversely affected**

or prejudiced by actions or inactions of our licensees, our future licensors and our counsel that took place prior to the date upon which we assumed control over patent prosecution. Moreover, if other third parties have ownership rights to our future in- licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. Failure to obtain licenses at a reasonable cost or terms may require us to expend significant time and resources to redesign our technology, programs, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates. This could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects. Disputes may arise between us and our future licensors regarding intellectual property subject to a license agreement, including: the scope of rights granted under the license agreement and other interpretation- related issues; whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; our right to sublicense patents and other rights to third parties; our right to transfer or assign the license; the inventorship and ownership of inventions and know- how resulting from the joint creation or use of intellectual property by our future licensors and us and our partners; and the priority of invention of patented technology. We may be subject to patent infringement claims or may need to file claims to protect our intellectual property, which could result in substantial costs and liability and prevent us from commercializing our potential products. Because the intellectual property landscape in the biopharmaceutical industry is rapidly evolving and interdisciplinary, it is difficult to conclusively assess our freedom to operate and guarantee that we can operate without infringing on or violating third- party rights. Third party patent rights, if found to be valid and enforceable, could be alleged to render one or more of our product candidates infringing. If a third party successfully brings a claim against us, we may be required to pay substantial damages, be forced to abandon any affected product candidate and / or seek a license from the patent holder. Any intellectual property claims brought against us, whether or not successful, may cause us to incur significant legal expenses and divert the attention of our management and key personnel from other business concerns. We cannot be certain that patents owned or licensed by us will not be challenged by others in the course of litigation. Some of our competitors may be able to sustain the costs of ~~complete~~ complex intellectual property litigation more effectively than we can because they have substantially greater resources. In addition, any litigation could have a material adverse effect on our business and operations, including our ability to raise funds. Competitors may infringe or otherwise violate our patents, trademarks, copyrights or other intellectual property. To counter infringement or other violations, we may be required to file claims, which can be expensive and time- consuming, and any such claims could provoke these parties to assert counterclaims against us. In addition, in a patent infringement proceeding, a court or administrative body may decide that one or more of the patents we assert is invalid or unenforceable, in whole or in part, construe the patent' s claims narrowly or refuse to prevent the other party from using the technology at issue on the grounds that our patents do not cover the technology. Similarly, if we assert trademark infringement claims, a court or administrative body may determine that the marks we have asserted are invalid or unenforceable or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In such a case, we could ultimately be forced to cease use of such marks. In any intellectual property litigation, even if we are successful, any award of monetary damages or other remedy we receive may not be commercially valuable. Further, we may be required to protect our patents through procedures created to attack the validity of a patent at the USPTO. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U. S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. In addition, if our programs are found to infringe the intellectual property rights of third parties, these third parties may assert infringement claims against our future licensees and other parties with whom we have business relationships and we may be required to indemnify those parties for any damages they suffer as a result of these claims, which may require us to initiate or defend protracted and costly litigation on behalf of licensees and other parties regardless of the merits of such claims. If any of these claims succeed, we may be forced to pay damages on behalf of those parties or may be required to obtain licenses for the products they use. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings. We may be subject to claims that we have wrongfully hired an employee from a competitor or that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties. As is common in the biopharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development of our programs. Many of these ~~product candidates~~ consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology or pharmaceutical companies including our competitors or potential competitors . We ~~collaborated with one~~ could in the future be subject to claims that we, our employees or ~~more clinical trial networks~~ our consultants have inadvertently or otherwise used or disclosed alleged intellectual property, such as trade secrets, or other confidential information of former employers or competitors. Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information, know- how or trade secrets of others in their work for us, we may become subject to claims that we caused an individual to breach the terms of his or her non- competition or non- solicitation agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor. While we may litigate to defend ourselves against these claims, even if we are successful, litigation could result in substantial costs and could be a distraction to management. If our ~~development program for rNAPc2. As~~ defenses to these claims fail, in addition to requiring us to pay monetary damages, a ~~result~~ court could prohibit us from using technologies or features that are essential to our programs , ~~we lacked direct control over certain aspects~~ if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the ~~development program~~ former employers. Moreover, any such litigation or the threat thereof may adversely affect our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results of operations and financial condition. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products. Changes in either the patent laws or interpretation of patent laws in the United States and foreign jurisdictions could increase the uncertainties and costs surrounding the prosecution of our owned and in-licensed patent applications and the ~~amount~~ maintenance, enforcement or defense of our owned and ~~timing of resources that~~ in- licensed issued patents. Additionally, ~~these~~ there ~~collaborators devote~~ have been proposals for additional changes to the patent laws of the United States and other countries that, if adopted, could impact our ability to enforce our proprietary technology. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U. S. Congress, the federal courts, the USPTO and the relevant law- making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to ~~project~~ protect , defend and enforce our patent rights in the future. In addition, geopolitical instability could increase the uncertainties and costs surrounding the prosecution or maintenance of patent applications and the maintenance, enforcement or defense of issued patents. The patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. U. S. Supreme Court and U. S. Court of Appeals for the Federal Circuit rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations, including in the antibody arts. For example, the United States Supreme Court in Amgen, Inc. v. Sanofi (Amgen) stated that if patent claims are directed to an entire class of compositions of matter, then the patent specification must enable a person skilled in the art to make and use the entire class of compositions. This decision makes it unlikely that we will be granted U. S. patents with composition of matter claims directed to antibodies functionally defined by their ability to bind a particular antigen. Even if we are granted claims directed to functionally defined antibodies, it is possible that a third party may challenge our patents, when issued, relying on the reasoning in Amgen or other recent precedential court decisions. In addition, a European Unified Patent Court (" UPC ") entered into force on June 1, 2023. The UPC is a common patent court that hears patent infringement and revocation proceedings effective for EU Member States. This could enable third parties to seek revocation of a European patent in a single proceeding at the UPC rather than through multiple proceedings in each of the jurisdictions in which the European patent is validated. Although we do not currently own any European patents or applications, if we obtain such patents and applications in the future, any such revocation and loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and products. Moreover, the controlling laws and regulations of the UPC will develop over time, and may adversely affect our ability to enforce or defend the validity of any European patents we may obtain . We ~~had~~ may decide to opt out from the UPC any future European patent applications that we may file and any patents we may obtain. If certain formalities and requirements are not met, however, such European patents and patent applications could be challenged for non- compliance and brought under the jurisdiction of the UPC. We cannot be certain that future European patents and patent applications will avoid falling under the jurisdiction of the UPC, if we decide to opt out of the UPC. Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non- compliance with these requirements. Periodic maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and / or patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and / or patent application. The USPTO and various foreign governmental patent agencies also require compliance with a ~~collaboration agreement~~ number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with ~~Medtronic~~ the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non- compliance events that ~~supported~~ could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non- payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our programs, ~~GENETIC- AF clinical trial. If~~ our ~~arrangement with Medtronic, as amended, is continued as~~ competitive position would be adversely affected. We may not identify relevant third- ~~part~~ party patents or may incorrectly interpret the relevance, scope or expiration of a third- party patent, which might adversely affect our ability to develop and market our products. We cannot guarantee that any of our ~~future development~~ patent searches or analyses, including the identification of ~~Gencaro~~ relevant patents , the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we ~~will~~ be certain that we have ~~limited control over~~ identified each and every third- party patent and pending application in the ~~amount~~ United States and abroad ~~timing of resources~~ that ~~they dedicate~~ is relevant to or necessary ~~the development of Gencaro. This is also likely to be true in any future collaboration with third parties and we may seek additional third party collaborators~~ for the ~~development of Gencaro, rNAPc2 or any other product candidates. Our ability to benefit from these arrangements will depend on our collaborators' abilities to successfully perform the functions assigned to them in these arrangements. Collaborations involving our product candidates pose the following risks to us: • collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; • collaborators may not pursue development and~~ commercialization of our product candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent' s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, we may incorrectly determine that our products are not covered by a third- party patent or may ~~elect not to continue or renew development or commercialization programs based on clinical trial results, changes~~ incorrectly predict whether a third- party' s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States ~~collaborator' s strategic focus~~ or ~~available funding~~ abroad that we consider relevant may be incorrect. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products. In addition , because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our issued patents or ~~external factors~~ our pending applications, or that we were the first to invent the technology. Our competitors may have filed, and may in the future file, patent applications covering products or technology similar to ours. Any such patent application may have priority over our patent applications or patents, which could require us to obtain rights to issued patents covering such technologies. We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property. We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co- inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our programs or as a result of questions regarding co- ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and / or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an ~~acquisition~~ outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Patent terms may be inadequate to protect the competitive position of our product candidates for an adequate amount of time. Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest United States non- provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has

expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. Our technology licensed from various third parties may be subject to retained rights. Our future licensors may retain certain rights under the relevant agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse. In addition, our future licensors may rely on third- party consultants or collaborators or on funds from third parties, such as the U. S. government, such that ~~diverts resources~~ **our licensors would not be the sole and exclusive owners of any patents we in- license. If other third parties have ownership rights** or ~~creates~~ **other rights to our in- licensed patents, they may be able to license such patents to our competitors, and our competitors could market** competing ~~priorities; •~~ **products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. We currently rely on licensing arrangements with Paragon through the License Agreements. If we are unable to maintain** ~~collaborators~~ **collaborations or licensing arrangements** ~~may delay clinical trials~~ , ~~provide insufficient funding~~ **or if our collaborations or licensing arrangements are not successful, our business could be negatively impacted. We currently rely on our licensing arrangements with Paragon through the License Agreements** for a ~~clinical trial program, stop a clinical trial~~ **substantial portion of our in- licenses. Collaborations** or ~~abandon a~~ **licensing arrangements that we enter into may not be successful, and any success will depend heavily on the efforts and activities of such collaborators or licensors. If any of our current or future collaborators or licensors experience delays in performance of, or fails to perform our obligations under their agreement with us, disagrees with our interpretation of the terms of such agreement or terminates their agreement with us, the research programs with respect to which we have the option to acquire intellectual property license rights to pursuant to the Option Agreements, the licensing agreements we have pursuant to the License Agreements and our development timeline could be adversely affected. If we fail to comply with any of the obligations under our collaborations or license agreements, including payment terms and diligence terms, our collaborators or licensors may have the right to terminate such agreements, in which event we may lose intellectual property rights and may not be able to develop, manufacture, market or sell the products covered by our agreements or may face other penalties under our agreements. Our collaborators and licensors may also fail to properly maintain or defend the intellectual property we have licensed from them, if required by our agreement with them, or even infringe upon, our intellectual property rights, leading to the potential invalidation of our intellectual property or subjecting us to litigation or arbitration, any of which would be time- consuming and expensive and could harm our ability to commercialize our** product ~~candidate~~ **candidates . In addition** , ~~repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; •~~ collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our **programs and** ~~product~~ **products** ~~candidates~~ if the collaborators believe that **the** competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours ~~; • collaborators may not properly maintain~~ **. As part of our strategy, we plan to evaluate additional opportunities to enhance our capabilities and expand our development pipeline** or **provide** ~~defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation; • disputes may arise between the collaborators and us that result in the delay or termination of the research,~~ development or commercialization **capabilities that complement ours. We may not realize the benefits** of **such collaborations, alliances or licensing arrangements. Any of these relationships may require us to incur non- recurring and other charges, increase** our ~~product candidates or~~ **near and long- term expenditures, issue securities** that ~~result in costly litigation or arbitration that diverts management attention and resources; • collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates; • collaborators may elect to take over manufacturing rather than retain us as manufacturers and may encounter problems in starting up or gaining approval for their manufacturing facility and so be unable to continue development of product candidates; • we may be required to undertake the expenditure of substantial operational, financial and management resources in connection with any collaboration; • we may be required to issue equity securities to collaborators that would~~ dilute our existing stockholders ~~' percentage ownership; •~~ **or disrupt our management and business. We may face significant competition in attracting appropriate collaborators, and more established companies may also be pursuing strategies to license or acquire third- party intellectual property rights that** we **consider attractive. These companies may have a competitive advantage over us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor** may be ~~required~~ **unwilling** to **assign** ~~assume substantial actual~~ or **license rights** ~~contingent liabilities; • collaborators may not commit adequate resources~~ to **us** ~~the marketing and distribution of our product candidates, limiting our potential revenues from these products; and • collaborators may experience financial difficulties~~ . ~~We face a number of challenges in seeking additional collaborations. Collaborations are complex and any potential discussions may not result in a definitive agreement for many reasons. For example, whether~~ **Whether** we reach a definitive agreement for a collaboration will depend **upon** , among other things, ~~upon~~ our assessment of the collaborator' s resources and expertise, the terms and conditions of the proposed collaboration ~~,~~ and the proposed collaborator' s evaluation of a number of factors **. Collaborations are complex** ~~, such as the design or results of our clinical trials, the potential market for our product candidates, the costs~~ and ~~complexities of manufacturing~~ **time- consuming to negotiate, document** and **execute** ~~delivering our product candidates to patients, the potential of competing products, the existence of uncertainty with respect to ownership or the coverage of our intellectual property, and industry and market conditions generally. If we were to determine that additional collaborations for our Gencaro development is necessary and were unable to enter into such collaborations on acceptable terms, we might elect to delay or scale back the development or commercialization of Gencaro in order to preserve our financial resources or to allow us adequate time to develop the required physical resources and systems and expertise ourselves. Collaboration agreements may not lead to development or commercialization of our product candidates in the most efficient manner, or at all~~ . In addition, **consolidation** ~~there have been a significant number of recent business combinations~~ among large pharmaceutical **and biotechnology** companies **has** ~~that have resulted in a~~ reduced **the** number of potential future collaborators. ~~If a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated. Any future clinical trial for Gencaro will require the use of a third- party diagnostic services provider to administer a genetic test needed to identify the patient receptor genotypes of clinical trial participants, and as a result, we will be unable to directly control the timing, conduct and expense of the genetic test.~~ We ~~anticipate that any future clinical trial of Gencaro, if any, will require a companion diagnostic test that identifies the patient' s receptor genotype. The trial would only enroll those patients with the receptor that has the potential for enhanced efficacy, the beta- 1 389 Arg receptor as detected by a beta- 1 389 Arg / Arg genotype. Accordingly, we anticipate that any future clinical trial for Gencaro will require the use of a third- party diagnostic service to perform the genetic testing. There has been limited experience in our industry in prospective development of companion diagnostics required to perform the required molecular profiling. We entered into an agreement with LabCorp to provide the diagnostic services of the genetic test needed to support our GENETIC- AF clinical trial. To provide those services, LabCorp obtained from the FDA an investigational device exemption, or IDE, for the companion diagnostic test being used in our GENETIC- AF clinical trial. We would expect a similar agreement and approval would be necessary for any companion diagnostic used in any future clinical trials for Gencaro. The FDA and similar regulatory authorities outside the United States regulate companion diagnostics. Companion diagnostics require separate or coordinated regulatory approval prior to commercialization. Changes to regulatory advice could delay our development programs or delay or prevent eventual marketing approval for our product candidates that may otherwise be approvable. In July 2011, the FDA issued draft guidance that stated that if safe and effective use of a therapeutic depends on an in vitro diagnostic, the FDA generally will not approve the therapeutic unless the FDA approves or clears this " in vitro companion diagnostic device " at the same time that the FDA approves the therapeutic. The approval or clearance of the companion diagnostic would occur through the FDA' s Center for Devices and Radiological Health. In 2014, the FDA issued guidance on in vitro companion diagnostic devices. The guidance allows for flexibility by the FDA in the case of therapeutic products to treat serious conditions for which no alternative treatment exists and the benefits of using the companion diagnostic outweigh the risk, but it is unclear how this discretion may be applied by the agency with respect to the companion diagnostic test related to any Gencaro clinical trials. The FDA' s evolving position on the topic of companion diagnostics could affect our clinical development programs that utilize companion diagnostics. In particular, the FDA may limit our ability to use retrospective data, otherwise disagree with our approaches to trial design, biomarker qualification, clinical and analytical validity, and clinical utility, or make us repeat aspects of a trial or initiate new trials. Given our limited experience in developing diagnostics, we expect to rely primarily on third parties for the design and manufacture of the companion diagnostics for our product candidates. If we, or any third parties that we engage to assist us, are unable to successfully develop companion diagnostics for our product candidates that require such diagnostics, or experience delays in doing so, the development of our product candidates may be adversely affected, our product candidates may not receive marketing approval and we may not realize the full commercial potential of any products that receive marketing approval. As a result, our business could be materially harmed. We will need to establish a collaborative arrangement with a third- party diagnostics services provider to obtain marketing clearance or approval of the companion genetic test for Gencaro. There is no guarantee that the FDA will grant timely clearance or approval of the genetic test, if at all, and failure to obtain such timely clearance or approval would adversely affect our ability to market Gencaro. The drug label we intend to seek for Gencaro would identify the patient receptor genotype for which the drug is approved. Accordingly, we believe developing a genetic test that is simple to administer and widely available will be critical to the successful commercialization of Gencaro. The genetic test will be subject to regulation by the FDA and by comparable agencies in various foreign countries. The process of complying with the requirements of the FDA and comparable agencies is costly, time consuming and burdensome. Despite the time and expense expended, regulatory clearance or approval is never guaranteed. If regulatory clearance or approval is delayed, or if one or more third- party diagnostic services providers are unable to obtain FDA approval of the genetic test at all or in parallel with the approval of Gencaro, or are unable to commercialize the test successfully and in a manner that effectively supports the commercial efforts for Gencaro, or if the information concerning the differential response to Gencaro resulting from certain genetic variation is not included in the approval label for Gencaro, the commercial launch of Gencaro may be significantly and adversely affected. Regulatory approval is required for the genetic test to be used in our Gencaro clinical trials and to support the commercialization of the test, if approved. Delays or failures in obtaining such regulatory approval, including any required validation analyses may prevent a third- party diagnostics provider from commercializing such genetic test and will adversely affect our business, operating results and prospects. Before a genetic test can be used commercially, including in conjunction with Gencaro, if it is approved for marketing, the third- party diagnostics provider must obtain FDA Premarket Approval, or PMA, for such test. The FDA may require additional validation of the genetic test we used in GENETIC- AF prior to any approval of Gencaro or the genetic test or prior to the use of such test in any future clinical trials for Gencaro. We anticipate the genetic test will be required as a condition to prescribing Gencaro. There is no guarantee the FDA will approve the anticipated PMA submission for the genetic test. Even if the genetic test is eventually approved, performing additional validation work necessary to support the PMA, if required, for current or future genetic test products, including one associated with Gencaro, would require additional time and expense and the outcome would be uncertain. Moreover, such delays or increased costs or failures could adversely affect our business, operating results and prospects for commercializing the genetic test. If a third- party diagnostics provider responsible for the genetic test associated with Gencaro or certain of its third- party suppliers fails to comply with ongoing FDA or other foreign regulatory authority requirements, or if there are unanticipated problems with the genetic test, these products could be subject to restrictions or withdrawal from use in a trial or from the market. Any diagnostic for which a third- party diagnostics provider obtains clearance or approval, and the manufacturing processes, reporting requirements, post- approval clinical data and promotional activities for such product, will be subject to continued regulatory review, oversight and periodic inspections by the FDA and other domestic and foreign regulatory bodies. With respect to the genetic test, to the extent applicable, any third- party diagnostics provider and certain of its suppliers will be required to comply with the FDA' s Quality System Regulation, or QSR, and International Standards Organization, or ISO, requirements which cover the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of any product for which clearance or approval is obtained. Regulatory bodies, such as the FDA, enforce the QSR and other regulations through periodic inspections. The failure by a third- party diagnostics provider, or certain of its third- party manufacturers or suppliers, as the case may be, to comply with applicable statutes and regulations administered by the FDA and other regulatory bodies, or the failure to timely and adequately respond to any adverse inspectional observations or product safety issues, could result in, among other things, enforcement actions. If any of these actions were to occur, it could harm our reputation and cause product sales and profitability of Gencaro, if approved, to suffer and may prevent us from generating revenue or utilizing the genetic test further in any clinical trial. Even if regulatory clearance or approval is granted, such clearance or approval may be subject to limitations on the intended uses for which the product may be marketed and reduce our potential to successfully commercialize the product and generate revenue from the product. Future sales of Gencaro may suffer if its marketplace acceptance is negatively affected by the genetic test. The genetic test is an important component of the commercial strategy for Gencaro in addition to being required for our clinical trials. We believe that the genetic test helps predict patient response to Gencaro, and that this aspect of the drug is important to its ability to compete effectively with current therapies. The genetic test adds an additional step in the prescribing process, an additional cost for the patient and payors, the risk that the test results may not be rapidly available and the possibility that it may not be available at all to hospitals and medical centers. Although we anticipate that Gencaro, if approved in a timely manner, would be the first genetically- targeted cardiovascular drug, Gencaro will be one of a number of successful drugs in the beta- blocker class currently on the market. Prescribers may be more familiar with these other beta- blockers, and may be resistant to prescribing Gencaro as an AF therapy in patients with HF. For instance, the top- line results of our Phase 2B GENETIC- AF clinical trial indicated that Gencaro demonstrated a similar treatment benefit compared to the active comparator, metoprolol succinate (TOPROL- XL). If our future clinical trials in Gencaro do not show that Gencaro has a clear therapeutic benefit as compared to other drugs in the beta- blocker class currently on the market, then prescribers may be unlikely to prescribe Gencaro to patients, even if approved. Any one of these factors could affect prescriber behavior, which in turn may substantially impede market acceptance of the genetic test, which could cause significant harm to Gencaro' s ability to compete, and in turn harm our business. Unless we are able to generate sufficient product revenue, we will continue to incur losses from operations and will not achieve or maintain profitability. We are years away from commercializing a product and generating product revenue. Our historical losses have had and will continue to have an adverse effect on our stockholders' equity and working capital, among other things. We are years away from commercializing a product and generating any product revenue. As a result, we expect to continue to incur significant operating~~

~~losses for the foreseeable future. Even if we ultimately receive regulatory approval for Gencaro, rNAPc2 or our other product candidates, sales of such products may not generate sufficient revenue for it to achieve or maintain profitability. Because of the numerous risks and uncertainties associated with developing therapeutic drugs, we may experience larger than expected future losses and may never reach profitability. Our product candidates are subject to extensive regulation, which can be costly and time- consuming, and unsuccessful or delayed regulatory approvals could increase our future development costs or impair our future revenue. The preclinical and clinical development, testing, manufacture, safety, efficacy, labeling, storage, recordkeeping, and subsequent advertising, promotion, sale, marketing, and distribution, if approved, of our product candidates are subject to extensive regulation by the FDA and other regulatory authorities in the United States and elsewhere. These regulations also vary in important, meaningful ways from country to country. We are not permitted to market a potential drug in the United States until we receive approval of an NDA from the FDA for such drug. We have not received an NDA approval from the FDA for Gencaro, rNAPc2 or any of our other product candidates. There can be no guarantees with respect to our product candidates that clinical studies will adequately support an NDA, that the products will receive necessary regulatory approvals, or that they will prove to be commercially successful. To receive regulatory approval for the commercial sale of any product candidates, we must demonstrate safety and efficacy in humans to the satisfaction of regulatory authorities through preclinical studies and adequate and well- controlled clinical trials of the product candidates. This process is expensive and can take many years, and failure can occur at any stage of the testing. Our failure to adequately demonstrate the safety and efficacy of our product candidates will prevent regulatory approval and commercialization of such products. In 2008, we submitted and the FDA accepted our NDA filing for Gencaro for the treatment of chronic HF. In 2009, the FDA issued a Complete Response Letter, or CRL, in which the FDA stated that it could not approve the Gencaro NDA in its current form and specified actions required for approval of the NDA, including conducting an additional Phase 3 clinical trial of Gencaro in patients with HF. We completed a Phase 2B clinical study of Gencaro in HF patients to assess its efficacy in reducing or preventing AF. We enrolled 267 HF patients with AF in the Phase 2B clinical trial. We reported top- line Phase 2B data in February 2018. In the third quarter of 2018, we submitted a SPA to the FDA for a Phase 3 clinical trial. In 2019, the FDA approved our SPA request for a Phase 3 clinical trial of Gencaro. Even though the FDA approved our SPA, this product candidate will require years of additional clinical development. Even if we conduct additional studies in accordance with our SPA agreement or further FDA guidance and submit or file a new or amended NDA, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. In the event that we or our collaborators conduct preclinical studies that do not comply with Good Laboratory Practices, or GLP, or incorrectly design or carry out human clinical trials in accordance with Good Clinical Practices, or GCP, or those clinical trials fail to demonstrate clinical significance, it is unlikely that we will be able to obtain FDA approval for product development candidates. Our inability to successfully initiate and effectively complete clinical trials for any product candidate on schedule, or at all, will severely harm our business. Significant delays in clinical development could materially increase product development costs or allow our competitors to bring products to market before we do, impairing our ability to effectively commercialize any future product candidate. We do not know whether planned clinical trials will begin on time, will need to be redesigned or will be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including: • delays or failures in obtaining regulatory authorization to commence a trial because of safety concerns of regulators relating to our product candidates or similar product candidates of our competitors or failure to follow regulatory guidelines; • delays or failures in obtaining clinical materials and manufacturing sufficient quantities of the product candidates for use in trials; • failure of clinical materials to meet pre- established specifications at product release or during ongoing stability studies; • delays or failures in reaching agreement on acceptable terms with prospective study sites; • delays or failures in obtaining approval of our clinical trial protocol from an institutional review board to conduct a clinical trial at a prospective study site; • delays in recruiting patients to participate in a clinical trial, which may be due to the size of the patient population, eligibility criteria, protocol design, perceived risks and benefits of the drug, availability of other approved and standard of care therapies or, availability of clinical trial sites; • other clinical trials seeking to enroll subjects with similar profile; • failure of our clinical trials and clinical investigators to be in compliance with GCP; • unforeseen safety issues, including negative results from ongoing preclinical studies; • inability to monitor patients adequately during or after treatment; • difficulty recruiting and monitoring multiple study sites; • failure of our third-party contract research organizations, clinical site organizations and other clinical trial managers, to satisfy their contractual duties, comply with regulations or meet expected deadlines; and • an insufficient number of patients who have, or are willing to have, a Medtronic device implanted for monitoring and recording AF burden data. In addition, any approvals we may obtain may not cover all of the clinical indications for which we seek approval or permit us to make claims of superiority over currently marketed competitive products. Also, an approval might contain significant limitations in the form of narrow indications, warnings, precautions or contraindications with respect to conditions of use. If the FDA determines that a risk evaluation and mitigation strategy, or REMS, is necessary to ensure that the benefits of the drug outweigh the risks, we may be required to include as part of the NDA a proposed REMS that may include a package insert directed to patients, a plan for communication with healthcare providers, restrictions on a drug’ s distribution, or a Medication Guide, to provide better information to consumers about the drug’ s risks and benefits. Finally, an approval could be conditioned on our commitment to conduct further clinical trials, which we may not have the resources to conduct or which may negatively impact our financial situation. The manufacture and analytical testing of Gencaro and rNAPc2 is performed by third party suppliers, who must also meet cGMP requirements and pass a pre- approval inspection of their facilities before we can obtain marketing approval. All of our product candidates are prone to the risks of failure inherent in drug development. The results from preclinical animal testing and early human clinical trials may not be predictive of results obtained in later human clinical trials. Further, although a new product may show promising results in preclinical or early human clinical trials, it may subsequently prove unfeasible or impossible to generate sufficient safety and efficacy data to obtain necessary regulatory approvals. The data obtained from preclinical and clinical studies are susceptible to varying interpretations that may delay, limit or prevent regulatory approval, and the FDA and other regulatory authorities in the United States and elsewhere exercise substantial discretion in the drug approval process. The numbers, size and design of preclinical studies and clinical trials that will be required for FDA or other regulatory approval will vary depending on the product candidate, the disease or condition for which the product candidate is intended to be used and the regulations and guidance documents applicable to any particular product candidate. The FDA or other regulators can delay, limit or deny approval of any product candidate for many reasons, including, but not limited to: • side effects; • safety and efficacy; • defects in the design of clinical trials; • the fact that the FDA or other regulatory officials may not approve our or our third party manufacturer’ s processes or facilities; or • the fact that new regulations may be enacted by the FDA or other regulators may change their approval policies or adopt new regulations requiring new or different evidence of safety and efficacy for the intended use of a product candidate. In light of widely publicized events concerning the safety of certain drug products, regulatory authorities, members of Congress, the Government Accountability Office, medical professionals and the general public have raised concerns about potential drug safety issues. These events have resulted in the withdrawal of certain drug products, revisions to certain drug labeling that further limit use of the drug products and establishment of risk management programs that may, for instance, restrict distribution of drug products. The increased attention to drug safety issues may result in a more cautious approach by the FDA to clinical trials and approval. Data from clinical trials may receive greater scrutiny with respect to safety and the product’ s risk / benefit profile, which may make the FDA or other regulatory authorities more likely to terminate clinical trials before completion, or require longer or additional clinical trials that may result in substantial additional expense, and a delay or failure in obtaining approval or approval for a more limited indication than originally sought. Aside from issues concerning the quality and sufficiency of submitted preclinical and clinical data, the FDA may be constrained by limited resources from reviewing and determining the approvability of the Gencaro NDA in a timely manner. In pursuing clinical development of Gencaro for an AF indication, we will be required to amend the Gencaro HF NDA or prepare a new NDA. The FDA could approve Gencaro, but without including some or all of the prescribing information that we have requested. For instance, the FDA could approve Gencaro for AF in a more limited patient population or include additional warnings in the drug’ s label. This, in turn, could substantially and detrimentally impact our ability to successfully commercialize Gencaro and effectively protect our intellectual property rights in Gencaro. If our product candidates receive regulatory approval, we would be subject to ongoing regulatory obligations and restrictions, which may result in significant expenses and limit our ability to develop and commercialize other potential products. If a product candidate of ours is approved by the FDA or by another regulatory authority, we would be held to extensive regulatory requirements over product manufacturing, testing, distribution, labeling, packaging, adverse event reporting and other reporting to regulatory authorities, storage, advertising, marketing, promotion, distribution, and record keeping. Regulatory approvals may also be subject to significant limitations on the indicated uses or marketing of the product candidates. Potentially costly follow- up or post- marketing clinical studies may be required as a condition of approval to further substantiate safety or efficacy, or to investigate specific issues of interest to the regulatory authority. Previously unknown problems with the product candidate, including adverse events of unanticipated severity or frequency, may result in additional regulatory controls or restrictions on the marketing or use of the product or the need for post marketing studies, and could include suspension or withdrawal of the products from the market. Furthermore, our third- party manufacturers and the manufacturing facilities that they use to make our product candidates are regulated by the FDA. Quality control and manufacturing procedures must continue to conform to cGMP after approval. Drug manufacturers and their subcontractors are required to register their facilities and products manufactured annually with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA, state and / or other foreign authorities. Any subsequent discovery of problems with a product, or a manufacturing or laboratory facility used by us or our collaborators, may result in restrictions on the product, or on the manufacturing or laboratory facility, including a withdrawal of the drug from the market or suspension of manufacturing. Any changes to an approved product, including the way it is manufactured or promoted, often require FDA approval before the product, as modified, can be marketed. We and our third- party manufacturers will also be subject to ongoing FDA requirements for submission of safety and other post- market information. The marketing and advertising of our drug products by our collaborators or us will be regulated by the FDA, certain state agencies or foreign regulatory authorities. Violations of these laws and regulations, including promotion of our products for unapproved uses or failing to disclose risk information, are punishable by criminal and civil sanctions and may result in the issuance of enforcement letters or other enforcement action by the FDA, U. S. Department of Justice, state agencies, or foreign regulatory authorities that could jeopardize our ability to market the product. In addition to the FDA, state or foreign regulations, the marketing of our drug products by us or our collaborators will be regulated by federal, state or foreign laws pertaining to health care “ fraud and abuse, ” such as the federal anti- kickback law prohibiting bribes, kickbacks or other remuneration for the order or recommendation of items or services reimbursed by federal health care programs. Many states have similar laws applicable to items or services reimbursed by commercial insurers. Violations of these laws are punishable by criminal and civil sanctions, including, in some instances, imprisonment and exclusion from participation in federal and state health care programs, including the Medicare, Medicaid and Veterans Affairs healthcare programs. Because of the far- reaching nature of these laws, we may be required to discontinue one or more of our practices to be in compliance with these laws. Healthcare fraud and abuse regulations are complex, and even minor irregularities can potentially give rise to claims that a statute or prohibition has been violated. Any violations of these laws, or any action against us for violations of these laws, even if we successfully defend against it, could have a material adverse effect on our business, financial condition and results of operations. We could also become subject to false claims litigation under federal statutes, which can lead to civil money penalties, restitution, criminal fines and imprisonment, and exclusion from participation in Medicare, Medicaid and other federal and state health care programs. These false claims statutes include the False Claims Act, which allows any person to bring a suit on behalf of the federal government alleging submission of false or fraudulent claims, or causing to present such false or fraudulent claims, under federal programs or contracts claims or other violations of the statute and to share in any amounts paid by the entity to the government in fines or settlement. These suits against pharmaceutical companies have increased significantly in volume and breadth in recent years. Some of these suits have been brought on the basis of certain sales practices promoting drug products for unapproved uses. This new growth in litigation has increased the risk that a pharmaceutical company will have to defend a false claim action, pay fines or restitution, or be excluded from the Medicare, Medicaid, Veterans Affairs and other federal and state healthcare programs as a result of an investigation arising out of such action. We may become subject to such litigation and, if we are not successful in defending against such actions, those actions may have a material adverse effect on our business, financial condition and results of operations. We could also become subject to false claims litigation and consumer protection claims under state statutes, which also could lead to civil monetary penalties, restitution, criminal fines and imprisonment, and exclusion from participation in state health care programs. Of note, over the past few years there has been an increased focus on the sales and marketing practices of the pharmaceutical industry at both the federal and state level. Additionally, the law or regulatory policies governing pharmaceuticals may change. New statutory requirements may be enacted or additional regulations may be adopted that could prevent or delay regulatory approval of our product candidates or limit our ability to commercialize our products. We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative action, either in the United States or elsewhere. If we, our collaborators or our third- party manufacturers fail to comply with applicable continuing regulatory requirements, our business could be seriously harmed because a regulatory agency may: • issue untitled or warning letters; • suspend or withdraw our regulatory approval for approved products; • seize or detain products or recommend a product recall of a drug or medical device, or issue a mandatory recall of a medical device; • refuse to approve pending applications or supplements to approved applications filed by us; • suspend our ongoing clinical trials; • restrict our operations, including costly new manufacturing requirements, or restrict the sale, marketing and / or distribution of our products; • seek an injunction; • pursue criminal prosecutions; • close the facilities of our contract manufacturers; or • impose civil or criminal penalties. Reliance on third parties to commercialize Gencaro, rNAPc2 or our other product candidates could negatively impact our business. If we are required to establish a direct sales force in the United States and are unable to do so, our business may be harmed. Commercialization of Gencaro, rNAPc2 or any other product candidate, if approved, particularly the establishment of a sales organization, will require substantial additional capital resources. We currently intend to pursue a strategic partnership alternative for the commercialization of Gencaro or rNAPc2, if it is approved, and we have suspended our efforts to build internal sales, marketing and distribution capabilities. If we elect to rely on third parties to sell Gencaro, rNAPc2 and any other products, then we may receive less revenue than if we sold such products directly. In addition, we may have little or no control over the sales efforts of those third parties. If we are unable to complete a strategic transaction, we would be unable to commercialize Gencaro, rNAPc2 or any other product candidate without substantial additional capital. Even if such capital were secured, we would be required to build internal sales, marketing and distribution capabilities to market Gencaro or rNAPc2 in the United States. None of our current employees have experience in establishing and managing a sales force. In the event we are unable to sell Gencaro, rNAPc2 and other selected product candidates, either directly or through third parties via a strategic transaction, the commercialization of Gencaro or rNAPc2, if approved, may be delayed indefinitely. We are dependent on our key personnel. The success of our business is highly dependent on the principal members of our board of directors and executive management, including our President and Chief Executive Officer, Michael R. Bristow. The loss of the services of any such individual might seriously harm our product development, partnering and financing efforts. Recruiting and training personnel with the requisite skills is challenging and we compete for talent with companies that are larger and have more financial resources. We have~~

~~no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. We do not currently operate manufacturing facilities for clinical or commercial production of our product candidates, including their drug substance or active pharmaceutical ingredients, or API. We have no experience in drug formulation or manufacturing, and we lack the resources and the capabilities to manufacture any of our product candidates on a clinical or commercial scale. We do not intend to develop facilities for the manufacture of product candidates for clinical trials or commercial purposes in the foreseeable future. We have contracted with several third- party manufacturing organizations for production and analytical testing of our product candidates. These contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to successfully produce, store and distribute our products. In addition, these manufacturers may have staffing difficulties, may experience delays due to key material or component availability,~~ may not be able to **negotiate collaborations** ~~manufacture our products~~ on a timely basis **, on acceptable terms** or **at all** ~~may become financially distressed~~ . **If** ~~In the event of errors in forecasting production quantities required to meet demand, natural disaster, equipment malfunctions or failures, technology malfunctions, strikes, lock- outs or work stoppages, regional power outages, product tampering, war or terrorist activities, actions of regulatory authorities, business failure, strike or other difficulty,~~ we ~~may be unable to find an alternative third- party manufacturer in a timely manner and the production of our product candidates would be interrupted, resulting in delays and additional costs, which could impact our ability to commercialize and sell our product candidates. We or our contract manufacturers may also~~ fail to ~~achieve~~ **enter into collaborations** and **do not have sufficient funds** ~~maintain required manufacturing standards, which could result in patient injury~~ or **expertise** ~~death, product recalls or withdrawals, an order by governmental authorities~~ to **undertake** ~~halt production, delays or failures in product testing or delivery, stability testing failures, cost overruns or other~~ -- **the necessary development** ~~problems that could seriously hurt our business. Contract manufacturers also often encounter difficulties involving production yields, quality control~~ and **commercialization activities** ~~quality assurance, as well as shortages of qualified personnel. In addition, our contract manufacturers are subject to ongoing inspections and regulation by the FDA, the U. S. Drug Enforcement Agency and corresponding foreign and state agencies and they may fail to meet these agencies' acceptable standards of compliance. If our contract manufacturers fail to comply with applicable governmental regulations, such as quality control, quality assurance and the maintenance of records and documentation~~ , we may not be able to **further develop our product candidates or bring them to market. We currently rely, and plan to rely in the future, on third parties to conduct and support our preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates. We have utilized and plan to** continue **to utilize and depend upon independent investigators and collaborators, such as medical institutions, CROs, contract testing labs, CMOs and strategic partners, to supply, conduct and support our preclinical studies and clinical trials under agreements with us. We will rely heavily on these third parties over the course of our preclinical studies and clinical trials, and we control only certain aspects of their activities. As a result, we will have less direct control over the conduct, timing and completion of these preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third- party contractors and CROs are required to comply with GCP regulations, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our programs in clinical development. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications or refuse to approve our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violate federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. Any third parties conducting our clinical trials will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether they devote sufficient time and resources to our programs. These third parties may have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other** ~~production~~ --- **product development activities, which could negatively affect their performance on our behalf and the timing thereof and could lead to products that compete directly or indirectly with our product candidates. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy** of the **clinical data** ~~API or finished product. If the~~ **they obtain** ~~safety of any API or product supplied~~ is compromised due to **the** failure to adhere to ~~applicable laws~~ **our clinical protocols or regulatory requirements** or for other reasons, ~~this may jeopardize~~ our **clinical trials** ~~regulatory approval for Gencaro, rNAPc2 and other product candidates, and we~~ may be ~~held liable~~ **extended, delayed** ~~for~~ - **or terminated** ~~any injuries sustained as a result. Upon the occurrence of one of the aforementioned events, the ability to switch manufacturers may be difficult for a number of reasons, including: • the number of potential manufacturers is limited~~ and we may not be able to ~~negotiate agreements with alternative manufacturers~~ **complete development of, obtain regulatory approval of or successfully commercialize our product candidates. We currently rely and expect to rely in the future** on **the use of manufacturing suites in third- party facilities or on third parties** ~~commercially reasonable terms, if at all; • long lead times are often needed~~ to manufacture ~~drugs; •~~ **our product candidates, and we may rely on third parties to produce and process our products, if approved. Our business could be adversely affected if we are unable to use third- party manufacturing suites or if the third- party manufacturers encounter difficulties in production. We do not currently own any facility that may be used as our clinical or commercial manufacturing and processing facility and must currently rely on CMOs to manufacture our product candidates. We have not yet caused any product candidates to be manufactured on a commercial scale and may not be able to do so for any of our product candidates, if approved. We currently have a sole source relationship for our supply of the ORKA- 001 and ORKA- 002 programs. If there should be any disruption in such supply arrangement, including any adverse events affecting our sole supplier, it could have a negative effect on the clinical development of our programs and other operations while we work to identify and qualify an alternate supply source. We may not control** the manufacturing process ~~is complex~~ **of,** and may ~~require a significant learning curve;~~ **be completely dependent on, our contract manufacturing partners for compliance with cGMP requirements** and ~~•~~ **any other regulatory requirements of** the FDA ~~must~~ **or comparable foreign regulatory authorities for the manufacture of our product candidates. Beyond periodic audits, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not** approve **these facilities for the manufacture of our product candidates or if it withdraws** any ~~replacement prior~~ **approval in the future, we may need** to **find alternative** manufacturing **facilities** , which **would** ~~requires~~ - **require** ~~new testing~~ **the incurrence of significant additional costs, delays,** and ~~compliance inspections~~ **materially adversely affect our ability to develop, obtain regulatory approval for or market our product candidates, if approved** . ~~Transitioning from~~ **Similarly, our failure, or the failure of our CMOs, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or drugs and harm our business and results of operations. Moreover, our CMOs may experience manufacturing difficulties due to resource constraints, supply chain issues, proposed or actual legislative changes or requirements, or as** a ~~clinical development stage company~~ **result of labor disputes or unstable political environments. If any CMOs on which we** will ~~require successful~~ **rely fail to manufacture quantities of our product candidates at quality levels necessary to meet regulatory requirements and at a scale sufficient to meet anticipated demand at a cost that allows us to achieve profitability, our business, financial condition and prospects could be materially and adversely affected. In addition, our CMOs are responsible for transporting temperature- controlled materials that can be inadvertently degraded during transport due to several factors, rendering certain batches unsuitable for trial use for failure to meet, among others, our integrity and purity specifications. We and any of our CMOs may also face product seizure or detention or refusal to permit the import or export of products. Our business could be materially adversely affected by business disruptions to our third- party providers that could materially adversely affect our anticipated timelines, potential future revenue and financial condition and increase our costs and expenses. Each of these risks could delay or prevent the** completion of ~~a number~~ **our preclinical studies and clinical trials or the approval** of ~~steps, many~~ - **any** ~~of which are outside~~ of our ~~control and~~ **product candidates by the FDA** , ~~consequently, we can provide no assurance~~ **result in higher costs or adversely impact commercialization** of our ~~successful~~ **product candidates. Foreign CMOs may be subject to U. S. legislation, including the proposed BIOSECURE bill, trade restrictions** and ~~timely transition from a clinical development stage company. We are a clinical development stage biopharmaceutical company with a limited operating history. To date we~~ **other foreign regulatory requirements, which could increase the cost or reduce the supply of material available to us, delay the procurement or supply of such material or** have ~~not generated any~~ - **an adverse effect** ~~product revenue and have historically funded our operations through investment capital. Our future growth depends~~ on our ability to ~~emerge~~ **secure significant commitments from governments to purchase our potential therapies. We currently rely on foreign CROs and CMOs, including WuXi Biologics (Hong Kong) Limited and its affiliates (" WuXi Biologics ") and will likely continue to rely on foreign CROs and CMOs in the future. WuXi Biologics is identified in the U. S. legislation known as the BIOSECURE Act, which was proposed in the 118th Congress, as a " biotechnology company of concern. " The version of the BIOSECURE Act introduced in the U. S. House of Representatives during the 118th Congress would prohibit federal agencies from entering into procurement contracts with, as well as providing grants and loans to, an entity that uses biotechnology equipment or services from a biotechnology company of concern, and includes a grandfathering provision allowing biotechnology equipment and services provided or produced by named " biotechnology companies of concern " under a contract or agreement entered into before the effective date until January 1, 2032. The pathway and timing for the BIOSECURE Act or its provisions to become law are uncertain. Depending on whether the BIOSECURE Act becomes law, what the final language of the BIOSECURE Act includes, and how the law is interpreted by U. S. federal agencies, we could be potentially restricted from pursuing U. S. federal government business or grants in the future if we continue to use WuXi or other parties identified as " biotechnology companies of concern " beyond the grandfathering period. Furthermore, our operations and financial condition may be negatively impacted as a result of any delays or increased costs arising** from the **trade restrictions and other foreign regulatory requirements affecting such collaborators. In addition, while we have established relationships with CROs and CMOs outside of China, moving to those suppliers in the event of geopolitical instability affecting our collaborators in China could introduce delays into the development program. Risks Related to Employee Matters, Managing Growth and Other Risks Related to Our Business In order to successfully implement our plans and strategies, we will need to grow the size of our organization and we may experience difficulties in managing this growth. We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of preclinical and** clinical **drug** development ~~stage~~ **, technical operations, clinical operations, regulatory affairs** and ~~successfully commercialize~~ **, potentially, sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial personnel and systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team working together in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations** or **recruit** ~~provide for the commercialization of Gencaro, rNAPc2~~ and **train additional qualified personnel. We are highly** ~~our other product candidates which in turn, will depend~~ **dependent** ~~, among other things,~~ on our **key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. Our** ability to ~~: • conduct additional~~ **pursue our growth strategy will be limited if we are unable to continue to attract and retain high quality personnel. We have been and will continue to be highly dependent on the research and development,** clinical ~~trials~~ and **business** ~~develop~~ **development expertise of our executive officers, as well as the other principal members of our management, scientific** and ~~obtain regulatory approval~~ **clinical team. Any of our management team members may terminate their employment with us at any time. We do not maintain " key person " insurance** for ~~Gencaro, rNAPc2~~ **any of our executives** or other ~~product candidates; • successfully partner a companion genetic test~~ **employees. Attracting and retaining qualified personnel will also be critical to our success, including** with **respect to any** ~~the commercial launch of Gencaro or rNAPc2; • enter into a~~ strategic transaction ~~enabling~~ **that we may pursue. The loss of our executive officers or other key employees could impede** the ~~continued~~ **achievement of our research,** development and commercialization **objectives** ~~of Gencaro or rNAPc2, or alternatively, raise significant additional capital to enable these activities; • pursue additional indications for Gencaro or rNAPc2~~ and **seriously harm** ~~develop other product candidates, including other cardiovascular therapies; and • obtain commercial quantities of Gencaro, rNAPc2 or other product candidates at acceptable cost levels. Any one of these factors or other factors discussed in this report could affect~~ our ability to successfully **implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, facilitate regulatory approval of and** commercialize ~~Gencaro and other~~ product candidates **. Competition** ~~, which could impact our ability~~ to **hire** ~~earn sufficient revenues to transition~~ from ~~a clinical development stage company~~ **this limited pool is intense,** and ~~continue our business. If approved by the FDA, Gencaro or rNAPc2 will be entering a competitive marketplace and may not succeed. Gencaro is a new type of beta- blocker and vasodilator being developed for AF. While we anticipate that this drug, if approved, would be the first genetically- targeted cardiovascular drug, and potentially the only beta- blocker approved for AF, Gencaro will be one of a number of accepted treatments for AF. In addition, our proposed prescribing information for Gencaro is expected to include a requirement for genetic testing of the patient to ascertain if they have the genotype that we believe responds best to Gencaro. This additional step will add incremental cost and procedures to prescribing Gencaro, which could make it more difficult to compete against existing therapies. We do not yet know what the commercial opportunity will be, if any, for rNAPc2 if it is approved for treating COVID- 19 disease. We do not know how and to whom rNAPc2 would be marketed and what the commercial arrangements would be for its sales and reimbursement. While we anticipate that rNAPc2, if approved, could potentially be used in combination with antiviral drugs and other therapies, there are other vaccines and therapies under development. Our commercial opportunity may be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer side effects, are more convenient or are less expensive than Gencaro. If products with any of these properties are developed, or any of the existing products are better marketed, then prescriptions of Gencaro by physicians and patient use of Gencaro could be significantly reduced or rendered obsolete and noncompetitive. Further, public~~

~~announcements regarding the development of any such competing drugs could adversely affect the market price of our common stock and the value of our assets. Future sales of our products may suffer if they are not accepted in the marketplace by physicians, patients and the medical community. Gencaro, rNAPc2 or our other product candidates may not gain market acceptance among physicians, patients and the medical community. The degree of market acceptance of Gencaro, rNAPc2 or our other product candidates will depend on a number of factors, such as its effectiveness and tolerability, as compared with competitive drugs. For instance, if rNAPc2 is approved, by that time there may be superior alternatives in terms of vaccines and / or therapeutics that may significantly impact the relative medical benefits offered by rNAPc2. If our future clinical trials for rNAPc2 do not show that rNAPc2 has a clear therapeutic benefit as compared to other therapies or vaccines that are approved in the interim, then there may be a limited or no commercial market for rNAPc2. Also, prevalence and severity of side- effects could negatively affect market acceptance of rNAPc2. Failure to achieve market acceptance of Gencaro or rNAPc2 would significantly harm our business. If we are unable to obtain acceptable prices or adequate reimbursement from third- party payors for Gencaro, rNAPc2, or any other product candidates that we may seek to commercialize, then our revenues and prospects for profitability will suffer. Our or any strategic partner' s ability to commercialize Gencaro, rNAPc2, or any other product candidates that we may seek to commercialize, is highly dependent on the extent to which coverage and reimbursement for these product candidates will be available from: • governmental payors, such as Medicare and Medicaid; • private health insurers, including managed- care organizations; and • other third- party payors. Many patients will not be capable of paying for our potential products themselves and will rely on third- party payors to pay for their medical needs. A primary current trend in the U. S. health care industry is toward cost containment. Large private payors, managed- care organizations, group purchasing organizations and similar organizations are exerting increasing influence on decisions regarding the use of, and reimbursement levels for, particular treatments. Such third- party payors, including Medicare, are challenging the prices charged for medical products and services, and many third- party payors limit reimbursement for newly approved health care products. Cost- control initiatives could decrease the price we might establish for products, which could result in product revenues lower than anticipated. If the prices for our product candidates decrease, or if governmental and other third- party payors do not provide adequate coverage and reimbursement levels, then our revenue and prospects for profitability will suffer. Health care reform measures could materially and adversely affect our business. The business and financial condition of pharmaceutical and biotechnology companies are affected by the efforts of governmental and third- party payors to contain or reduce the costs of health care. The U. S. Congress has enacted legislation to reform the health care system. While we anticipate that this legislation may, over time, increase the number of patients who have insurance coverage for pharmaceutical products, it also imposes cost containment measures that may adversely affect the amount of reimbursement for pharmaceutical products. These measures include increasing the minimum rebates for products covered by Medicaid programs and extending such rebates to drugs dispensed to Medicaid beneficiaries enrolled in Medicaid managed care organizations as well as expansion of the 340 (B) Public Health Services drug discount program. In addition, such legislation contains a number of provisions designed to generate the revenues necessary to fund the coverage expansion, including new fees or taxes on certain health- related industries, including medical device manufacturers. Each medical device manufacturer has to pay an excise tax (or sales tax) in an amount equal to 2. 3 % of the price for which such manufacturer sells its medical devices. Such excise taxes may impact any potential sales of the genetic test if it is approved for marketing. On January 22, 2018, legislation was enacted suspending the medical device tax in 2018 and 2019. In December 2019, a permanent repeal of the medical device tax was enacted. The Gencaro Test is likely to be subject to this tax if this tax is reinstated in the future. In foreign jurisdictions there have been, and we expect that there will continue to be, a number of legislative and regulatory proposals aimed at changing the health care system. For example, in some countries other than the United States, pricing of prescription drugs is subject to government control and we expect to see continued efforts to reduce healthcare costs in international markets. Some states are also considering legislation that would control the prices of drugs, and state Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Managed care organizations continue to seek price discounts and, in some cases, to impose restrictions on the coverage of particular drugs. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding constraint on prices and reimbursement for drugs. It is likely that federal and state legislatures and health agencies will continue to focus on additional health care reform in the future although we are unable to predict what additional legislation or regulation, if any, relating to the health care industry or third- party coverage and reimbursement may be enacted in the future or what effect such legislation or regulation would have on our business. We or any strategic partner' s ability to commercialize Gencaro, rNAPc2, or any other product candidates that we may seek to commercialize, is highly dependent on the extent to which coverage and reimbursement for these product candidates will be available from government payors, such as Medicare and Medicaid, private health insurers, including managed care organizations, and other third- party payors, and any change in reimbursement levels could materially and adversely affect our business. Further, the pendency or approval of future proposals or reforms could result in a decrease in our stock price or limit our ability to raise capital or to obtain strategic partnerships or licenses. Our competitors may be better positioned in the marketplace and thereby may be more successful than us at developing, manufacturing and marketing approved products. Many of our competitors currently have significantly greater financial resources and expertise in conducting clinical trials, obtaining regulatory approvals, managing manufacturing and marketing approved products than us. Other early- stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. In addition, these third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring therapies and therapy licenses complementary to our programs or advantageous to our business. We expect that our ability to compete effectively will depend upon our ability to: • successfully and rapidly complete clinical trials for any product candidates and obtain all requisite regulatory approvals in a cost- effective manner; • build an adequate sales and marketing infrastructure, raise additional funding, or enter into strategic transactions enabling the commercialization of our products; • develop competitive formulations of our product candidates; • attract and retain key personnel; and • identify and obtain other product candidates on commercially reasonable terms. If we fail to identify and license or acquire other products or product candidates, then~~ we may be unable to ~~expand~~ **hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel, as well as from universities and research institutions. In addition, we rely on consultants and advisors to assist us in formulating** our **discovery** ~~business,~~ and **nonclinical and clinical development and commercialization strategy. Our consultants and advisors may be employed by employers** ~~the~~ **other** ~~acquisition~~ **than us and may have commitments under consulting** or ~~licensing of~~ **advisory contracts with** other **entities that** ~~products or product candidates~~ may ~~put a strain~~ **limit their availability to us. Our future growth may depend, in part,** on our **ability** ~~operations and will likely require us~~ to **operate in foreign** ~~seek additional financing. One of our strategies is to license or acquire clinical- stage products or product candidates and further develop them for commercialization. The market~~ **markets , where** ~~for licensing and acquiring products and product candidates is intensely competitive and many of our competitors may have greater resources than~~ we ~~do. If we undertake any additional acquisitions, whether of product candidates or other biopharmaceutical companies, the process of integrating an acquired product candidate or complementary company into our business may put a strain on our operations, divert personnel, financial resources and management' s attention. In 2020, our research and development activities were dedicated to initiating the clinical trial of rNAPc2. If we are not able to substantially expand our research and development efforts, or identify, or license or acquire other products or product candidates or complete future acquisitions, then we will likely be unable expand our pipeline of product candidates. In addition, any future acquisition would give rise to additional operating costs and will likely require us to seek additional financing. Future acquisitions could result in additional issuances of equity securities that would dilute the ownership of existing stockholders. Future acquisitions could also result in the incurrence of debt, contingent liabilities or the amortization of expenses related to other intangible assets, any of which could adversely affect our operating results. We~~ would be subject to ~~applicable~~ **additional** regulatory **burdens and** ~~approval requirements of the~~ **other risks and uncertainties. Our future growth may depend, in part, on our ability to develop and commercialize our product candidates in** foreign ~~countries in~~ **markets for** which we ~~market our products, which are costly and~~ may **rely on collaboration with third parties** ~~prevent or delay us from marketing our products in those countries~~ . ~~In addition~~ **If we fail** to **comply with the** regulatory requirements in **foreign markets and receive applicable marketing approvals, our target market will be reduced and our ability to realize** the ~~United States~~ **full market potential of our product candidates will be harmed and our business will be adversely affected. Moreover, even if we obtain approval of our product candidates and ultimately commercialize our product candidates in foreign markets** , we would be subject to the **risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and reduced protection of intellectual property rights in some foreign countries. Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all. Our market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate. Even if the markets in which we compete meet our size estimates and growth forecasts, our business may not grow at similar rates, or at all. Our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain** regulatory approval **, the accepted price for the product, the ability to obtain coverage and reimbursement and whether we own the commercial rights for that territory. If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and** requirements **. We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors acting for or on our behalf may engage** in **misconduct** ~~each foreign country where we market our~~ - **or** ~~products~~ **other improper activities** . ~~In addition~~ **We have adopted a code of conduct and ethics** , ~~we might be required~~ **but it is not always possible** to identify ~~one~~ **and deter misconduct by these parties and the precautions we take to detect and prevent this activity may not be effective in controlling unknown** or ~~more~~ **unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Our internal information technology systems, or those of any of our third- party service providers, or potential future** collaborators **, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data or personal data, which could result** in ~~these foreign countries~~ **additional costs, loss of revenue, significant liabilities, harm** to **our brand** ~~develop, seek approval for~~ and ~~manufacture~~ **material disruption of** our ~~products~~ **operations. In the ordinary course of our business, we** and ~~any companion genetic test for Gencaro~~ **the third parties upon which we rely collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) proprietary, confidential, and sensitive data, including personal data, intellectual property, trade secrets, and other sensitive data (collectively, sensitive information)** . If we ~~decide~~ **(or a third party upon whom we rely) experience a security incident or are perceived** to ~~pursue~~ **have experienced a security incident, we may experience adverse consequences. While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. Further, cybersecurity breaches or other cybersecurity incidents may allow hackers access to our preclinical compounds, strategies, discoveries, trade secrets, and / or other confidential information. Additionally, sensitive data could be leaked, disclosed, or revealed as a result of or in connection with our employees', personnel' s, vendors' or partners' use of generative AI technologies. Our ability to monitor third parties' information security practices is limited, and these third parties may not have adequate security measures in place. We may be unable in the future to detect vulnerabilities in our information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. Applicable data privacy and security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. Moreover, while we may be entitled to damages if our third- party service providers fail to satisfy their privacy or security- related obligations to us, any award may be insufficient or we may be unable to recover such award. Security incidents and attendant consequences may negatively impact our ability to grow and operate our business. The risk of a cybersecurity incident or other informational technology disruption, particularly through cyber- attacks, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. To the extent that any disruption or security breach were to result in loss, destruction, unavailability, alteration or dissemination of, or damage to, our data (including clinical trial data) or applications, or for it to be believed or reported that any of these occurred, we could incur liability, including under laws and** ~~regulatory~~ **regulations** ~~approvals~~ **governing the protection of protected health information and other personal data, and reputational damage and the development** and commercialization of our product candidates ~~internationally~~ **could be delayed. Further** , ~~we~~ **our insurance policies** may not be ~~able~~ **adequate** to ~~obtain~~ **compensate us for** the ~~required foreign regulatory approvals on a timely basis~~ **potential losses arising from any such disruption in** , ~~if at all~~ **or failure or security breach of** , **our systems or third- party systems where information important to our business operations or commercial development is stored. Despite the implementation of security measures in an effort to protect systems that store our information, given their size** and **complexity and the increasing amounts of information maintained** ~~any failure to do so may cause us to incur additional costs or prevent us from marketing our products in foreign countries, which may have a material adverse effect~~ on our ~~business, financial condition~~ **internal information technology systems** and ~~results of operations. If our internal control over financial reporting is not considered effective, our business and stock price could be adversely affected. Section 404 of the~~ **those** ~~Sarbanes- Oxley Act of 2002 requires us to evaluate the effectiveness~~ of our **third- party CROs** ~~internal control over financial reporting as of the end of each fiscal year~~ , **contractors (including sites performing our clinical trials), third- party service providers** and **supply chain companies, and consultants, these systems are potentially vulnerable** to **breakdown** ~~include a management report assessing the effectiveness of our internal control over financial reporting in our annual report on Form 10- K for that fiscal year. Our management, including our principal executive officer and principal financial officer, does not expect that our internal control over financial reporting will prevent all error and all fraud. We continue to operate with a small staff for financial reporting. Though the process and design of our internal controls over financial reporting have not been altered, the small number of staff involved in financial reporting may limit our ability to properly segregate internal control procedures which could result in deficiencies or material weaknesses in our internal controls in the future. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system' s objectives will be met. Further, the design of a control system must reflect~~

~~the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud involving a company have been, or will be, detected. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and we cannot assure you that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become ineffective because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in a cost- effective control system, misstatements due to error or fraud may occur and not be detected. We cannot assure you that we or our independent registered public accounting firm will not identify a material weakness in our internal control over financial reporting in the future. A material weakness in our internal control over financial reporting would require management to consider our internal control over financial reporting as ineffective. If our internal control over financial reporting is not considered effective, we may experience a loss of public confidence, which could have an adverse effect on our business and on the market price of our common stock. Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations. New income, sales, use~~ or other **damage** ~~tax laws, statutes, rules, regulations~~ or ~~ordinances could be enacted at any time~~ **interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions or from cyber- attacks by malicious third parties, or ransomware attacks** , which ~~could affect the tax treatment of~~ **, in each case, may compromise** our **system infrastructure** ~~domestic and foreign earnings. Any new taxes could adversely affect our domestic and international business operations, and our business and financial performance. Further, existing tax laws, statutes, rules, regulations~~ or **lead** ~~ordinances could be interpreted, changed, modified or applied adversely to us. For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, significantly revised the Internal Revenue Code of 1986, as amended, or the Code. Future guidance from the Internal Revenue Service and other tax authorities with respect~~ to the ~~Tax Cuts and Jobs Act~~ **loss, destruction, alteration or dissemination of, or damage to, our data. Our hybrid- remote workforce** may **create** ~~affect us, and certain aspects of the Tax Cuts and Jobs Act could be repealed or modified in future legislation. In addition~~ **additional** ~~, it is uncertain if and to what extent various states will conform to the Tax Cuts and Jobs Act or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Cuts and Jobs Act or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one- time charges, and could increase our future U. S. tax expense. Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations. As of December 31, 2023, we had net operating loss, or NOL, carryforwards of approximately $ 208. 1 million, and approximately $ 2. 4 million of research and development credits that may be used to offset future taxable income. Our net operating loss carryforwards generated prior to 2018 will expire beginning in 2025 if not utilized. Under the Tax Cuts and Jobs Act, U. S. federal NOLs incurred in tax years ending after December 31, 2017, may be carried forward indefinitely, but the deductibility of federal NOLs generated in tax years beginning after December 31, 2017, may be limited. In general, under Section 382 of the Code, a corporation that undergoes an " ownership change " (as defined under Section 382 of the Code and applicable Treasury Regulations) is subject to limitations on its ability to utilize its pre- change NOLs to offset future taxable income. We have not determined whether we have experienced an ownership change in the past, and we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. There is also a risk~~ **risks** ~~that due to regulatory changes, such as suspensions on the use of NOLs or other unforeseen reasons, our existing NOLs could expire or otherwise be unavailable to reduce future income tax liabilities, including~~ for ~~state tax purposes. For these reasons, we may not be able to utilize a material portion of the NOLs reflected on our balance sheet, even if we attain profitability, which could potentially result in increased future tax liability to us and could adversely affect our operating results and financial condition. Security breaches, cyber- attacks, or other disruptions or incidents could expose us to liability and affect our business and reputation. We are increasingly dependent on~~ our information technology systems and ~~infrastructure for~~ **data because** our ~~business. We~~ **employees work remotely and utilize network connections** , **computers, and devices working at home, while in transit and in public locations. Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in** our ~~collaborators and~~ **contracts are sufficient to protect us from liabilities, damages,** ~~our~~ - **or claims related** ~~service providers collect, store, and transmit sensitive information including intellectual property, proprietary business information, clinical trial data and personal information in connection with our business operations. The secure maintenance of this information is critical~~ to our ~~operations~~ **data privacy** and ~~business strategy~~ **security obligations** . **We cannot** ~~Some of this information could~~ be **sure that** ~~an attractive target of criminal attack by third parties with a wide range of motives and expertise, including organized criminal groups, " hacktivists, " patient groups, disgruntled current or former employees, nation- state and nation- state supported actors, and others. Cyber- attacks are of ever- increasing levels of sophistication, and despite~~ our **insurance coverage** ~~security measures, our information technology and infrastructure may be vulnerable to such attacks or may be breached, including due to employee error or malfeasance. We have implemented information security measures to protect our systems, proprietary information and sensitive data against the risk of inappropriate and unauthorized external use and disclosure and other types of compromise. However, despite these measures, and due to the ever changing information cyber- threat landscape, we cannot guarantee that these measures~~ will be adequate **or sufficient** to ~~detect, prevent~~ **protect us from** or **to** mitigate **liabilities arising out of** ~~security breaches and other incidents and we may be subject to data breaches through cyber- attacks, malicious code (such as viruses and worms), phishing attacks, social engineering schemes, and insider theft or misuse. Any such breach could compromise~~ our ~~networks and the information stored there could be accessed, modified, destroyed, publicly disclosed, lost or stolen. If our systems become compromised, we may not promptly discover the intrusion. Any security breach of other incident, whether real or perceived, could cause us to suffer reputational damage. Such incidents could result in costs to respond to, investigate and remedy such incidents, notification obligations to affected individuals, government agencies, credit reporting agencies and other third parties, legal claims or proceedings, and liability under our contracts with other parties and federal and state laws that protect the~~ privacy and security **practices, that such coverage will continue** ~~of personal information. Any one of these events could cause our business~~ to be ~~materially harmed~~ **available on commercially reasonable terms or at all, or that such coverage will pay future claims. We are subject to stringent** and **changing laws, regulations and standards, and contractual obligations relating to privacy, data protection, and data security. The actual** ~~our~~ - **or perceived** ~~results of operations would be adversely impacted. Failure~~ **failure** to comply with **such obligations** ~~data protection laws and regulations~~ could lead to government enforcement actions (which could include civil or criminal penalties), **fines and sanctions,** private litigation ~~,~~ and / or adverse publicity and could negatively affect our operating results and business. We and **third parties who we work with are or may become subject to numerous domestic and foreign laws, regulations, and standards relating to privacy, data protection, data transfer, and data security, the scope of which is changing, subject to differing applications and interpretations, and may be inconsistent among countries, or conflict with other rules. We are or may become subject to the terms of contractual obligations related to privacy, data protection and data security. Our obligations may also change or expand as** our **business grows. The actual or perceived failure by us or third** ~~partners~~ - **parties related to us to comply with such laws, regulations and obligations could increase our compliance and operational costs, expose us to regulatory scrutiny, actions, fines and penalties, result in reputational harm, lead to a loss of customers, result in litigation and liability, and otherwise cause a material adverse effect on our business, financial condition, and results of operations. If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations may involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. We** may be subject to **adverse legislative or regulatory tax changes that could negatively impact our financial condition. The rules dealing with U. S.** federal, state ~~,~~ and ~~foreign data protection~~ **local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U. S. Treasury Department. Changes to tax** laws **(which may have retroactive application) could adversely affect our stockholders or us. We continue to assess the impact of various tax reform proposals** and ~~regulations (i. e., laws~~ **modifications to existing tax treaties in all jurisdictions where we have operations or employees to determine the potential effect on our business** and ~~regulations~~ **any assumptions we make about our future taxable income. We cannot predict whether any specific proposals will be enacted, the terms of any such proposals or** ~~that~~ **what** ~~address privacy and data security)~~ **effect, if any, such proposals would have on our business if they were to be enacted** . ~~In~~ **For example,** the United States **enacted** ~~, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations (e. g., Section 5 of~~ the **IRA** ~~FTC Act)~~ , **which implements** ~~that govern the collection~~ , **among** ~~use, disclosure, and protection of health- related and~~ other **changes, a 1 % excise tax on certain stock buybacks** ~~personal information could apply to our operations or the operations of our partners~~ . In addition, ~~we may obtain health information from third parties (including~~ **beginning in 2022, the Tax Cuts and Jobs Act eliminated the previously available option to deduct** research **and development expenditures and requires taxpayers** ~~institutions from which we obtain clinical trial data) that are subject~~ to **amortize** ~~privacy and security requirements under the~~ **them generally over five years** ~~Health Insurance Portability and Accountability Act of 1996, as amended, or~~ **for research activities conducted** ~~HIPAA. Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA- covered entity~~ in ~~a manner that is not authorized or permitted by HIPAA. In addition, the California Consumer Privacy Act, or the CCPA, became effective on January 1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt- out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Although there are limited exemptions for clinical trial data and the CCPA' s implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, the CCPA may increase our compliance costs and potential liability. Many similar privacy laws have been proposed at the federal level and in other states. Foreign data protection laws, including, without limitation, the European Union Directive 95 / 46 / EC, or the Directive, and the European Union' s General Data Protection Regulation, or the GDPR, that became effective in May 2018, and member state data protection legislation, may also apply to health- related and other personal information obtained outside of~~ the United States ~~. These laws impose strict obligations on the ability to process health- related~~ and **over 15 years** ~~other personal information of data subjects in the European Union and the United Kingdom, including in relation to use, collection, analysis, and transfer (including cross- border transfer) of such personal information. These laws include several requirements relating to the consent of the individuals to whom the personal data relates, limitations on data processing, establishing a legal basis~~ for **research activities conducted** ~~processing, notification of data processing obligations or security incidents to appropriate data protection authorities or data subjects, the security and confidentiality of the personal data and various rights that data subjects may exercise. The Directive and the GDPR prohibit, without an appropriate legal basis, the transfer of personal data to countries~~ outside ~~of the European Economic Area, or EEA, such as~~ the United States **. Such changes** , ~~which are~~ **among others, may adversely affect our effective tax rate, results of operation and general business condition. We may acquire businesses or products, or form strategic alliances, in the future, and may** not **realize** ~~considered by~~ the **benefits** ~~European Commission to provide an adequate level~~ of ~~data protection~~ **such acquisitions** . **We may acquire additional businesses or products,** ~~Switzerland has adopted similar restrictions. Although there are legal mechanisms to allow for~~ **form strategic alliances** ~~the transfer of personal data from the EEA and Switzerland to the United States~~ , ~~uncertainty about compliance~~ **or create joint ventures** with ~~European Union data protection laws remains. For example, ongoing legal challenges in Europe to the mechanisms allowing companies to transfer personal data from the EEA to the United States could result in further limitations on the ability to transfer personal data across borders, particularly if governments are unable or unwilling to reach new or maintain existing agreements that support cross- border data transfers, such as the European Union- U. S. and Swiss- U. S. Privacy Shield framework. Additionally, other countries have passed or are considering passing laws requiring local data residency. Under the GDPR, regulators may impose substantial fines and penalties for non- compliance. Companies that violate the GDPR can face fines of up to the greater of 20 million Euros or 4 % of their~~ - **third parties** ~~worldwide annual turnover (revenue). The GDPR increases our responsibility and potential liability in relation to personal data~~ that we **believe will complement or augment** ~~process, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR and other EU and international data protection rules. Compliance with U. S. and foreign privacy and security laws, rules and regulations could require us to take on more onerous obligations in~~ our **existing** ~~contracts, require us to engage in costly compliance exercises, restrict our ability to collect, use and disclose data, or in some cases, impact our or our partners' or suppliers' ability to operate in certain jurisdictions. Each of these constantly evolving laws can be subject to varying interpretations. Failure to comply with U. S. and foreign data protection laws and regulations could result in government investigations and enforcement actions (which could include civil or criminal penalties), fines, private litigation, and / or adverse publicity and could negatively affect our operating results and~~ business ~~. Moreover, patients about whom we or our partners obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals' privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time- consuming to defend and could result in adverse publicity that could harm our business. Risks Related to Intellectual Property and Other Legal Matters If product liability lawsuits are successfully brought against us, then we will incur substantial liabilities and may be required to limit commercialization of Gencaro, rNAPc2 or other product candidates. We face product liability exposure related to the testing of our product candidates in human clinical trials, and may face exposure to claims by an even greater number of persons once we begin marketing and distributing our products commercially~~ . If we ~~cannot successfully defend against product liability claims~~ **acquire businesses with promising markets or technologies** , ~~then~~ we ~~will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: • decreased demand for our products and product candidates; • injury to our reputation; • withdrawal of clinical trial participants; • costs of related litigation; • substantial monetary awards to patients and others; • loss of revenues; and • the inability to commercialize our products and product candidates. We have obtained limited product liability insurance coverage. Such coverage, however, may not be adequate or may not continue to be available to us in sufficient amounts or at an acceptable cost, or at all. We~~ may not be able to ~~obtain commercially reasonable product liability insurance for~~ **realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing** any **new** ~~product candidate. Defending against claims relating to~~

~~improper handling, storage or disposal of hazardous chemicals, radioactive or biological materials could be time consuming and expensive. Our research and development of~~ product candidates ~~may involve~~ **or products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. There is no assurance that, following any such acquisition, we will achieve** the ~~controlled use~~ **synergies expected in order to justify the transaction, which could result in a material adverse effect on our business and prospects. We maintain our cash at financial institutions, often in balances that exceed federally- insured limits. The failure** of ~~hazardous materials, including chemicals, radioactive~~ **financial institutions could adversely affect our ability to pay our operational expenses or make other payments. Our cash held in non- interest- bearing** and **interest- bearing accounts exceeds** ~~biological materials. We cannot eliminate~~ the ~~risk~~ **Federal Deposit Insurance Corporation insurance limits. If such banking institutions were to fail, we could lose all or a portion** of ~~accidental contamination or discharge~~ **those amounts held in excess of such insurance limitations. In addition, even if account holders are ultimately made whole with respect to a future bank failure, account holders' access to their accounts** and **assets held in** ~~any resultant injury from the~~ **their accounts** ~~materials. Various laws and regulations govern the use, manufacture, storage, handling and disposal of hazardous materials. We~~ may be ~~sued~~ **substantially delayed. Any material loss that we may experience in the future** or ~~be required~~ **inability for a material time period to access our cash and cash equivalents could have an adverse effect on our ability** to pay **our operational expenses** ~~fines for any injury~~ or ~~contamination that results from~~ **make other payments, which could adversely affect** our ~~use~~ **business. General Risk Factors Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates,** or **at all** ~~the use by third parties of these materials~~ . ~~Compliance with environmental laws~~ **Our market opportunity estimates** and **growth forecasts** ~~regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts. The loss of any rights to market key products would significantly impair our operating results. Our patent portfolios relating to Gencaro, including a patent that issued in 2021, are either owned by us or~~ are subject to ~~licenses~~ **significant uncertainty and are based on assumptions and estimates** that ~~impose~~ **may** ~~no~~ **not** ~~royalty obligations~~ **prove to be accurate. Even if the markets in which we compete meet our size estimates and growth forecasts, our business may not grow at similar rates,** or ~~milestone payments relating~~ **at all. Our growth is subject** to **many factors, including our success in implementing our business strategy, which is subject to many risks and uncertainties. We may become exposed to costly and damaging liability claims, either when testing a product candidate in** the ~~further~~ **clinical or at the commercial stage, and our insurance may not cover all damages from such claims. We are exposed to potential product liability and professional indemnity risks that are inherent in the research,** development, ~~approval~~ **manufacturing, marketing,** and ~~commercialization~~ **use** of ~~Gencaro~~ **pharmaceutical products** . ~~Termination~~ **The use of a product candidate in clinical trials and the sale of any approved products in the future may expose us to liability claims. An individual or group of individuals may bring a liability claim against us if one** of our ~~license agreements~~ **product candidates causes, or merely appears to have caused, an injury. Any claims against us, regardless of their merit,** could **be difficult and costly** ~~result in the loss of our further rights~~ to ~~develop~~ **defend** and ~~commercialize Gencaro for any indication. The termination of any such license, or of any other agreement which enables us to market a key product or product candidate,~~ could ~~significantly~~ **materially** and adversely affect our business. **While** ~~Certain intellectual property licensed by us is the subject of additional licensing arrangements to which the party that has licensed rights to us is subject. If such parties were to breach the terms of such licenses or such licenses were otherwise to terminate, our and our partners' rights to use such technology and develop and commercialize their products such as the genetic test may terminate and our business would be materially harmed. Third parties may own or control patents or patent applications that~~ we **carry** ~~may be required to license to commercialize our~~ product ~~candidates or that could result in litigation that would be costly and time consuming. Our or any strategic partner' s ability~~ **liability insurance** ~~to commercialize Gencaro, rNAPc2 and other product candidates depends upon our ability to develop, manufacture, market and sell these drugs without infringing the proprietary rights of third parties. A number of pharmaceutical and biotechnology companies, universities and research institutions have or may be granted patents that cover technologies similar to the technologies owned by or licensed to us. We may choose to seek, or be required to seek, licenses under third party patents, which would likely require the payment of license fees or royalties or both. We may also be unaware of existing patents that may be infringed by Gencaro or rNAPc2, the genetic testing we intend to use in connection with Gencaro or our other product candidates. Because patent applications can take many years to issue, there may be other currently pending applications that may later result in issued patents that are infringed by Gencaro, rNAPc2 or our other product candidates. Moreover, a license may not be available to us on commercially reasonable terms, or at all. There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and biopharmaceutical industries generally. If a third party claims that we are infringing on its technology, then our business and results of operations could be harmed by a number of factors, including: • infringement and other intellectual property claims, even if without merit, are expensive and time- consuming to litigate and can divert management' s attention from our core business; • monetary damage awards for past infringement can be substantial; • a court may prohibit us from selling or licensing product candidates unless the patent holder chooses to license the patent to us; and • if a license is available from a patent holder, we may have to pay substantial royalties. We may also be forced to bring an infringement action if we believe that a competitor is infringing our protected intellectual property. Any such litigation will be costly, time- consuming and divert management' s attention, and the outcome of any such litigation may not be favorable to us. Our intellectual property rights may not preclude competitors from developing competing products and our business may suffer. Our competitive success will depend, in part, on our ability to obtain and maintain patent protection~~ for our ~~inventions, technologies and discoveries, including intellectual property that we license. The patent positions of biotechnology companies involve complex legal and factual questions, and we cannot be certain that our patents and licenses will successfully preclude others from using our technology. Consequently, we cannot be certain that any of our patents will provide significant market protection or will not be circumvented or challenged and found to be unenforceable or invalid. In some cases, patent applications in the United States and certain other jurisdictions are maintained in secrecy until patents issue, and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain of the priority of inventions covered by pending patent applications. Moreover, we may have to participate in interference proceedings declared by the U. S. Patent and Trademark Office to determine priority of invention, in opposition proceedings in a foreign patent office, or in a post- grant challenge proceeding such as an ex parte reexamination or inter partes review at the U. S. Patent and Trademark Office, any of which could result in substantial cost to us, even if the eventual outcome is favorable. There can be no assurance that a court of competent jurisdiction would hold any claims in any issued patent to be valid and enforceable. An adverse outcome could subject us to significant liabilities to third parties, require disputed rights to be licensed from third parties or require us to cease using such technology. We own the clinical development program of rNAPc2, including Phase 2b~~ clinical trials ~~. If rNAPc2 is successfully developed~~ , ~~we believe it will have intellectual property protection for a specific use, including 12 years of market exclusivity as an innovative biologic product under FDA law in the United States, 10 years data protection exclusivity in the EU, and potentially patent protection in addition to this. However, another competitor could develop a compound with similar biological properties to rNAPc2 that may not be barred by our exclusivity. We have also filed a patent application for rNAPc2 and its use for COVID- 19 disease, but there is no assurance that this application will ultimately result in an issued patent. Regardless of merit, the listing of patents in the FDA Orange Book for Gencaro may be challenged as being improperly listed. We may have to defend against such claims and possible associated antitrust issues. We could also incur substantial costs in seeking to enforce our proprietary rights against infringement. While the composition of matter patents on the compound that comprises Gencaro have expired, we hold intellectual property concerning the interaction of Gencaro with the polymorphisms of the beta- 1 and alpha- 2C receptors. We have obtained patents that claim methods involving Gencaro after a patient' s receptor genotype has been determined. We anticipate that any NDA for Gencaro will request a label including a claim that efficacy varies based on receptor genotype and a recommendation in the prescribing information that prospective patients be tested for their receptor genotype. We believe that under applicable law, a generic bucindolol label would likely be required to include this recommendation as it pertains directly to the safe or efficacious use of the drug. Such a label may be considered as inducing infringement, carrying the same liability as direct infringement. If the label with the genotype information for Gencaro is not approved or it is approved after the relevant patents expire, or if generic labels are not required to copy the approved label, competitors could have an easier path to introduce competing products and our business may suffer. The approved label may not contain language covered by these patents, or we may be unsuccessful in enforcing them. We also have obtained intellectual property related to the use of Gencaro for various cardiovascular indications in the genetic population we plan to study in Phase 3. The approved label may not contain language covered by our patents and~~ it is possible **that any liabilities could exceed our insurance coverage or that in** the **future** ~~intellectual property may not preclude others from commercializing a generic version of Gencaro, which could cause our business to suffer. Additionally, the patents may be invalidated and / or or~~ we ~~may be unsuccessful in enforcing them We~~ may not be able to ~~effectively protect~~ **maintain insurance coverage at a reasonable cost** ~~our~~ - **or obtain insurance coverage that will be adequate** ~~intellectual property rights in some foreign countries, as our patents are limited by jurisdiction and many countries do not offer the same level of legal protection for intellectual property as the United States. We require our employees, consultants, business partners and members of our scientific advisory board~~ to **satisfy any liability** ~~execute confidentiality agreements upon the commencement of employment, consulting or business relationships with us. These agreements provide that all confidential information developed or made known during the course of the relationship with us be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions resulting from work performed for us, utilizing the property or relating to our business and conceived or completed by the individual during employment shall be our exclusive property to the extent permitted by applicable law. Third parties may breach these and other agreements with us regarding our intellectual property and we may not have adequate remedies for the breach. Third parties could also fail to take necessary steps to protect our licensed intellectual property, which could seriously harm our intellectual property position. If we are not able to protect our proprietary technology, trade secrets and know- how, then our competitors may develop competing products. Any issued patent may not be sufficient to prevent others from competing with us. Further, we have trade secrets relating to rNAPc2 and Gencaro, and such trade secrets may become known or independently discovered. Our issued patents and those~~ that may ~~issue~~ **arise. On occasion, large judgments have been awarded** in **class action** ~~the future,~~ or **individual lawsuits. A successful product liability claim** ~~those licensed to us, may be challenged, opposed, invalidated~~ or **series** ~~circumvented, which could allow competitors to market similar products or limit the patent protection term~~ of ~~our product candidates. All of these factors may affect our competitive position. If the manufacture, use or sale of our products infringe on the intellectual property rights of others, we could face costly litigation, which could cause us to pay substantial damages or licensing fees and limit our ability to sell some or all of our products. Extensive litigation regarding patents and other intellectual property rights has been common in the biopharmaceutical industry. Litigation may be necessary to assert infringement~~ claims **brought** ~~, enforce patent rights, protect trade secrets or know- how and determine the enforceability, scope and validity of certain proprietary rights. Litigation may even be necessary to defend disputes of inventorship or ownership of proprietary rights. The defense and prosecution of intellectual property lawsuits, U. S. Patent and Trademark Office interference proceedings, and related legal and administrative proceedings (e. g., a reexamination, inter partes review, or post- grant review) in the United States and internationally involve complex legal and factual questions. As a result, such proceedings are costly and time- consuming to pursue, and their outcome is uncertain. Regardless of merit or outcome, our involvement in any litigation, interference or other administrative proceedings could cause us to incur substantial expense and could significantly divert the efforts of our technical and management personnel. Any public announcements related to litigation or interference proceedings initiated or threatened~~ against us could cause our stock price to decline **and, if judgments exceed our insurance coverage, could decrease our cash and our business operations could be impaired** . ~~Adverse~~ **Litigation costs and the** ~~outcomes~~ - **outcome of litigation could have a material adverse effect on our business. From time to time we may be subject to litigation claims through the ordinary course of our business operations regarding, but not limited to, employment matters, security of patient and employee personal information, contractual relations with collaborators and intellectual property rights. Litigation to defend ourselves against claims by third parties, or to enforce any rights that we may have against third parties, may continue to be necessary, which could result** in ~~patent litigation~~ **substantial costs and diversion of our resources, causing a material adverse effect on our business, financial condition, results of operations or cash flows. Our business could be adversely affected by economic downturns, inflation, fluctuation in interest rates, natural disasters, public health crises, political crises, geopolitical events or other macroeconomic conditions, which could have a material and adverse effect on our results of operations and financial condition. The global economy, including credit and financial markets, has experienced and** may ~~potentially subject us~~ **experience in the future extreme volatility and disruptions, including, among other things, diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, supply chain shortages, new or increased tariffs and other barriers** to **trade** ~~antitrust litigation which~~ , ~~regardless~~ **trade and other international disputes, increases in inflation rates, fluctuation in interest rates, slower growth or recession, tighter credit, volatility in financial markets, high unemployment, labor availability constraints, public health crises, significant natural disasters, including as a result of climate change, changes to fiscal and monetary policy or government budget dynamics (particularly in the pharmaceutical and biotech areas), particularly in the pharmaceutical and biotech areas, political and military conflict, and uncertainty about economic stability. Fluctuation in interest rates, coupled with reduced government spending and volatility in financial markets, may increase economic uncertainty and affect consumer spending. Similarly, the ongoing military conflict between Russia and Ukraine and in the Middle East and rising tensions with China have created extreme volatility in the global capital markets and may have further global economic consequences, including disruptions** of the ~~outcome, would~~ **global supply chain. Any such volatility and disruptions may** adversely affect our business **or** ~~. An adverse determination may subject us to~~ the ~~loss of our proprietary position or to significant liabilities, or require us to seek licenses that may include substantial cost and ongoing royalties. Licenses may not be available from~~ third parties **on whom we rely. If the equity and credit markets deteriorate** , **including as a result of political unrest** or **war, it** may ~~not be~~ **make any necessary debt or equity financing more costly, more dilutive, or more difficult to** ~~obtainable~~ ---- **obtain in a timely manner or** on ~~satisfactory~~ **favorable** terms **, if at all** . ~~An~~ **Increased inflation rates can** ~~adverse~~ **adversely** ~~determination~~ **affect us by increasing our costs, including materials, operational, labor and employee benefit costs. We may in the future experience disruptions as a result of such macroeconomic conditions, including delays or difficulties in initiating or expanding clinical trials and manufacturing sufficient quantities of materials. Any one** or a **combination of these** ~~failure to obtain necessary licenses may restrict or prevent~~ -- **events** ~~us from manufacturing~~ **could have a material** and ~~selling~~ **adverse effect on** our ~~products, if any. These outcomes could materially harm our business, financial condition and~~ results of operations **and financial condition. Geopolitical events and global economic conditions may also affect the ability of the FDA and other regulatory authorities to perform routine functions. If such concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business** . Risks Related to ~~Ownership~~ **Owning Our Stock The market price** of our ~~Common~~ **common** ~~Stock~~ **stock has been,** and ~~Stock~~ **may continue to be volatile. The market** ~~Price~~ **price** ~~Volatility Our~~ **of our common** stock ~~price~~ has been and is ~~expected~~ **likely** to be **highly** volatile ~~. Our common stock has in the past been~~ and **is** ~~in the future could be~~ subject to significant fluctuations ~~. Market prices for securities of early- stage pharmaceutical, biotechnology and other life sciences companies have historically been particularly volatile~~ . Some of the factors that may cause the market price of our common stock to fluctuate include: **● timing** ~~• the regulatory status of Genecaro, rNAPc2~~ and ~~the genetic test, and whether and when they are approved for sale, if at all, and the labeling or other conditions of use imposed by the FDA; • our ability to secure additional funding or complete a strategic transaction or to complete development of and commercialize Genecaro or rNAPc2; • progress of any future clinical trials for Genecaro, rNAPc2 or our other product candidate, including enrollment and any data that may become available; • the~~ results of ~~our future~~ clinical trials and **preclinical studies** ~~any future NDAs~~ of our ~~current and future~~ product candidates **, or those of our competitors or our existing or future collaborators** ; ~~•~~ **● failure to meet or exceed financial and development projections that we may provide to** the ~~entry into,~~ **public; ● announcements of significant** or **potential equity or debt sales by us** ~~termination of, key agreements, including key strategic alliance agreements~~ ; **● actions taken by** ~~• the results and timing of~~ regulatory ~~reviews relating~~ **agencies with respect** to our product candidates **, clinical studies, manufacturing process or sales and marketing terms** ; ~~•~~ **●** failure **to meet or exceed the financial and development projections** of **the investment community or if securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading opinions regarding our business and stock; ● announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors; ● general market, macroeconomic or geopolitical conditions or market conditions in the pharmaceutical and biotechnology sectors; ● disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies; ● additions or departures of key personnel, including scientific or management personnel; ● significant lawsuits, including patent or stockholder litigation; ● changes in the market valuations of similar companies; ● sales of securities by us or our securityholders in the future; ● if we fail to raise** ~~any~~ **an adequate amount of capital to fund our operations or continued development** of our product candidates ~~, if approved, to achieve commercial success~~ ; **● trading volume** ~~• general and industry- specific economic conditions that may affect our research and development expenditures; • the results of clinical trials conducted by others on drugs that would compete with our product candidates; • issues in manufacturing or testing our product candidates or any approved products; • the initiation of or material developments in or the conclusion of litigation to enforce or defend any~~ of our **common stock** ~~intellectual property rights~~ ; ~~• the loss~~ **● announcements by competitors** of ~~key employees~~ **new products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments** ; ~~•~~ **●** the introduction of technological innovations or new ~~commercial~~ **therapies that compete with our** products ~~by our competitors~~ ; **and ●** ~~• changes in estimates or recommendations by securities analysts, if any, who cover our common stock; • future sales of our common stock; • changes in the structure of health care payment systems; •~~ period- to- period fluctuations in our financial results ~~; and • our ability to retain the listing of our common stock on the Nasdaq Capital Market~~ . Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies ~~, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas' attack against Israel and the ensuing conflict~~ . These broad market fluctuations may also adversely affect the trading price of our common stock. In **addition, a recession, depression or other sustained adverse market event could materially and adversely affect our business and the value of our common stock. In** the past, following periods of volatility in the market price of a company' s securities, stockholders have often instituted class action securities litigation against ~~those~~ **such** companies. ~~Such~~ **Furthermore, market volatility may lead to securities** litigation ~~,~~ **or increased stockholder activism** if ~~instituted,~~ **we experience a market valuation that activists believe is not reflective of our intrinsic value. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors** could **have an adverse effect on our operating** ~~result~~ **results , financial condition and cash flows. Our certificate of incorporation and bylaws, as well as provisions under Delaware law, could make an acquisition of the company more difficult and may prevent attempts by our stockholders to replace or remove management. Provisions** in ~~substantial costs~~ **our certificate of incorporation** and ~~diversion~~ **bylaws may discourage, delay or prevent a merger, acquisition or other change in control** of ~~management attention and resources~~ **the company that stockholders may consider favorable** , **including transactions in** which **our common stockholders might otherwise receive a premium price for their shares. These provisions** could **also limit** ~~significantly harm our profitability and reputation. Future sales or~~ the ~~possibility of~~ **price that investors might be willing to pay in the** future ~~sales~~ **for shares** of our common stock ~~may~~ **, thereby** ~~depress~~ **depressing** the market price of our common stock. ~~Sales in the public market of substantial amounts of our common stock could depress prevailing market prices of our common stock. As of December 31, 2023, approximately 14. 5 million shares of common stock were outstanding, and all of these shares are freely transferable without restriction or further registration under the Securities Act of 1933, as amended, or the Securities Act, except for shares held by our directors, officers and other affiliates and unregistered shares held by non- affiliates. The sale of these additional shares, or the perception that such sales may occur, could depress the market price of our common stock. As of December 31, 2023, there were approximately 617, 000 shares of our common stock which may be issued upon the exercise of outstanding stock options, and we anticipate that we will continue to issue stock option and restricted stock unit awards to our employees and consultants in the fiscal year ended December 31, 2023 and thereafter. If and when these options are exercised, such shares will be available for sale in the open market without further registration under the Securities Act. The existence of these outstanding options may negatively affect our ability to complete future equity financings at acceptable prices and on acceptable terms. The exercise of those options, and the prompt resale of shares of our common stock received, may also result in downward pressure on the price of our common stock.~~ In ~~the absence of a significant strategic transaction, we will need to raise significant additional~~ -- **addition** ~~capital to finance the research~~ , **because** ~~development and commercialization of Genecaro, rNAPc2 and our other product candidate. If future securities offerings occur, they would dilute our current stockholders' equity interests and could reduce the market price of our common stock. We do not expect to pay cash dividends, and accordingly, stockholders must rely on stock appreciation for any return on their investment. We anticipate that we will retain our earnings, if any, for future growth and therefore do not anticipate paying cash dividends in the future. As a result, only appreciation of the price of our common stock will provide a return to stockholders. Investors seeking cash dividends should not invest in our common stock. Our business could be negatively affected as a result of actions of activist shareholders. Responding to actions by activist shareholders could be costly and time- consuming, disrupt our operations and divert the attention of management and our employees. For example, in connection with the negotiation and entry into a cooperation agreement in June 2022 with Cable Car Capital LLC, The Funicular Fund, LP, Funicular Funds, LP and Jacob Ma- Weaver, collectively, Cable Car, one of our stockholders, we appointed two new directors in 2022. Activist shareholders may advocate for certain governance and strategic changes at our company. In the event of stockholder activism, particularly with respect to matters which~~ our board of directors ~~, in exercising~~ **is responsible for appointing** ~~their~~ -- **the** ~~fiduciary duties~~ **members of our management team** , ~~disagree with~~ **these provisions may frustrate** or ~~have determined not~~ **prevent any attempts by our stockholders** to **replace** ~~pursue, our~~ - **or remove current management** ~~business could be adversely affected because responding to actions~~ by **making** ~~activist stockholders can be costly and time- consuming, disrupting our operations and diverting the attention of management, and perceived uncertainties as to our future direction may result in the loss of potential business opportunities and may make~~ it more difficult **for stockholders** to **replace members of** ~~attract and retain qualified personnel, business partners, and customers. Additionally, if faced with a consent solicitation or proxy contest, we may not be able to respond successfully to the contest or dispute, which would be disruptive to our business. If individuals are elected to~~ our board of directors ~~with a differing agenda, our ability to effectively and timely implement our strategic plan and create additional value for our stockholders may be adversely affected~~ . ~~In addition~~ **Among other things** , **these** ~~our share price could experience periods of increased volatility as a result of shareholder activism. We have implemented anti- takeover~~ provisions ~~that could discourage, prevent or delay a takeover, even if the acquisition would be beneficial to our stockholders. Provisions of our certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us, even if doing so would benefit our stockholders. These provisions~~ : ~~•~~ **●** establish a classified board of directors ~~so~~ **such** that ~~not~~ all members of ~~our~~ **the** board ~~may be~~ **are not** elected at one time; ~~• authorize~~ **● allow** the ~~issuance~~ **authorized number** of ~~up~~ **our directors** to ~~approximately 5 million additional shares~~ **be changed only by resolution** of ~~preferred stock that could be issued by~~ our board of directors ~~to increase~~ **; ● limit** the **manner in which** ~~number of outstanding shares and hinder a takeover attempt; • limit who may call a special meeting of~~ stockholders **can remove directors from the board** ; **●** ~~• prohibit stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders; and •~~ establish advance notice requirements for nominations for election to ~~our~~ **the** board of directors or for proposing matters that can be acted ~~upon~~ **on** at ~~a~~ stockholder ~~meeting~~ **meetings ; ● require** ~~. Specifically, our certificate of incorporation provides~~ that ~~all~~ stockholder ~~action~~ **actions** must be effected at a duly called **stockholder** meeting and ~~not~~ **prohibit actions** by ~~a~~ **our stockholders by** written consent **; ● limit who** ~~. The bylaws provide, however, that our stockholders~~ may call a special meeting of stockholders ~~only upon~~ **; ● authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute** a ~~request~~ **" poison pill " that would work to dilute the stock ownership** of **a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and ● require the approval of the holders of at least 66 2 / 3 % of the votes that all stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws. Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law (" DGCL "), which prohibits** stockholders owning ~~at least 50~~ **more than 15** % **of our outstanding voting stock from merging or combining with us. Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirors to negotiate with our board of directors, they would apply even if the offer may be considered beneficial by some stockholders. Our governing documents provide that, unless we consent in writing to the selection of an alternative forum, certain designated courts will be the sole and exclusive forum for certain legal actions between us and our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents. Our governing documents provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for state law claims for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of or based on a breach of a fiduciary duty owed by any of our current or former directors, officers, or other employees or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL, the certificate of incorporation or the bylaws, (iv) any action to interpret, apply, enforce or determine the validity of the certificate of incorporation or bylaws, or (v) any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein, which for purposes of this risk factor refers to herein as the " Delaware Forum Provision. " Our governing documents further provide that, unless we consent in writing to an alternative forum, the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, which for purposes of this risk factor refers to herein as the " Federal Forum Provision. " Neither the Delaware Forum Provision nor the Federal Forum Provision will apply to any causes of action arising under the Exchange Act. In addition, any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and consented to the foregoing Delaware Forum Provision and Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the U. S. federal securities laws and the rules and regulations thereunder. The Delaware Forum Provision and the Federal Forum Provision may impose additional litigation costs on our stockholders in pursuing any such claims, particularly if such stockholders do not reside in or near the State of Delaware. Additionally, these forum selection clauses may limit our stockholders' ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. Future sales of shares by existing stockholders could cause our stock price to decline. If our stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after legal restrictions on resale lapse, the trading price of our common stock could decline. In addition, shares of our common stock that are subject to our outstanding options will become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements and Rules 144 and 701 under the Securities Act. We do not anticipate that we will pay any cash dividends in the foreseeable future. We do not anticipate that we will pay any cash dividends in the foreseeable future. The current expectation is that we will retain our future earnings, if any, to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain, if any, for the foreseeable future. Our executive officers, directors and principal stockholders have the ability to control or significantly influence all matters submitted to our stockholders for approval. Our executive officers, directors and principal stockholders beneficially own a significant percentage** of our outstanding common stock. **As a result, if** ~~These~~ **these** ~~provisions~~ **stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these stockholders, if they choose to act together, would control or significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all** of our ~~certificate~~ **assets. This concentration** of **voting power** ~~incorporation and bylaws could discourage potential acquisition proposals and~~ could delay or prevent ~~a change in control. We designed these provisions to reduce~~ our ~~vulnerability to unsolicited~~ acquisition ~~proposals~~ **on terms that other stockholders may desire. If equity research analysts do not publish research or reports, or publish unfavorable research or reports about us, our business or our market, our stock price** and **trading volume** ~~to discourage certain tactics that may be used in proxy fights. These provisions, however,~~ could **decline. The trading market** ~~also have the effect of discouraging others from making tender offers~~ for our ~~shares. As a consequence,~~ **common stock will be influenced by** ~~they~~ - **the** ~~also~~ **research and reports that equity research analysts publish about us and our business. Equity research analysts** may ~~inhibit fluctuations in~~ **elect to not provide research coverage of our common stock, and such lack of research coverage may adversely affect** the market price of our **common stock. If we do have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our common stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of us or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause our stock price or trading volume to decline. Item 1B. Unresolved Staff Comments. None. Item 1C. Cybersecurity. We collect, use, store, and transmit confidential, sensitive, proprietary, personal, and health- related information in the ordinary course of our business. As such, we leverage third-party information technology service providers who have implemented and maintain various information security processes designed to identify, assess, and manage material risks from cybersecurity threats to our information technology systems, including critical computer networks, third party hosted services, communications systems, hardware and software, and our data** residing on these systems. Our Senior Vice President, Finance is responsible for overseeing these third- party service providers and processes. Cybersecurity risks are identified by monitoring and evaluating our threat environment, and then assessed by various methods, for example, by manual and automated tools designed to identify and combat cybersecurity threats, analyzing reports of threats, conducting scans and assessments of the threat environment and to identify vulnerabilities, the use of detection and response services and conducting reviews of third- party service providers, among other things. Depending on the threat environment, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our information systems and data, including, for example, physical security and access controls, asset management, systems monitoring, incident detection and response, risk assessment, the implementation of security standards and certifications, encryption of data, network security controls, and a recovery / business continuity plan, among other mitigation tactics. Our recovery / business continuity plan is designed to mitigate and remediate identified cybersecurity incidents and escalate certain incidents as appropriate to management and the Audit Committee. We plan to conduct due diligence on and audits of key technology vendors, contract research organizations, and other third-party contractors and suppliers. Additionally, we conduct periodic employee training that covers cyber and information security, among other topics. Our assessment and management of material risks from cybersecurity threats are integrated into the Company' s overall risk management process. Our Senior Vice President, Finance, who reports directly to the Chief Executive Officer, together with our senior management, is responsible for assessing and managing cybersecurity risks with support from our third- party information technology service providers that employ information technology consultants with over 20 years of experience managing cybersecurity programs. Our cybersecurity program aligns to the National Institute of Standards and Technology (NIST) Cybersecurity Framework (CSF) and is consistently updated as NIST recommendations change year over year. Our Senior Vice President, Finance, together with our senior management and other employees works closely with our information technology service providers to evaluate material cybersecurity threats against our overall business objectives as part of our cybersecurity incident response. The Board of Directors, as a whole and at the committee level, has oversight for the most significant risks facing us and for our processes to identify, prioritize, assess, manage and mitigate those risks. The Audit Committee has been designated by our Board to oversee cybersecurity risks. The Audit Committee receives regular updates on cybersecurity and information technology matters and related risk exposures from our Senior Vice President, Finance. The Board also receives updates from management and the Audit Committee on cybersecurity risks on a regular basis. In the last fiscal year, we have not identified any risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us, but we face certain ongoing cybersecurity risks or threats that, if realized, are reasonably likely to materially affect us. For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our " Risk Factors " under Part 1 Item 1A. Risk Factors, in this Annual Report on Form 10- K. Item 2. Properties. Our corporate headquarters are in Menlo Park, California and we have an additional office in Waltham, Massachusetts. Our lease for our Menlo Park headquarters expires on September 30, 2027 and our lease for our Waltham office expires in 2029. We believe our current facilities are sufficient for our needs for the foreseeable future. Item 3. Legal Proceedings. From time to time, we may become involved in legal proceedings relating to claims arising from the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could reasonably be expected to have a material adverse effect on our results of operations, financial condition or cash flows. Item 4. Mine Safety Disclosures. Not applicable. PART II Item 5. Market for Registrant' s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. Market Information Our common stock is traded on the Nasdaq Global Market under the symbol " ORKA. " Holders of Record As of February 28, 2025, there were approximately 20 stockholders of record of our common stock based on information provided by our transfer agent. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities. Dividends We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. We do not intend to pay cash dividends on our common stock for the foreseeable future. Recent Sales of Unregistered Securities Purchases of Equity Securities by the Issuer and Affiliated Purchasers Performance Graph As a " smaller reporting company, " as defined by Rule 12b- 2 of the Exchange Act, and pursuant to Instruction 6 to Item 201 (e) of Regulation S- K, we are not required to provide the stock performance graph. Item 6. [Reserved] Item 7. Management' s Discussion and Analysis of Financial Condition and Results of Operations. You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes included elsewhere in this Annual Report on Form 10- K for the year ended December 31, 2024 (this " Annual Report "). This discussion contains forward-looking statements that involve risks and uncertainties, such as statements regarding our plans, objectives, expectations, intentions, hopes, beliefs, strategies or projections regarding the future of its pipeline and business and words such as " may, " " will, ", " should, " " could, " " would, " " expect, " " plan, " " anticipate, " " believe, " " estimate, " " project, " " potential, " " seek, " " target, " " goal, " " intend " and variations of such words and any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, and similar expressions are intended to identify forward- looking statements. You should not place undue reliance on these forward- looking statements. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting us will be those that have been anticipated. These forward- looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward- looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this Annual Report entitled " Risk Factors " and elsewhere in this Annual Report. These and many other factors could affect our future financial and operating results. We undertake no obligation to update any forward- looking statement to reflect events after the date of this Annual Report. As used in this Annual Report, unless the context suggests otherwise, " we, " " us, " " our, " " the Company, " " Oruka Therapeutics, Inc., " " Oruka, " " ARCA biopharma, Inc., " " ARCA, " refers to Oruka Therapeutics, Inc. and its consolidated subsidiaries, including Oruka Therapeutics Operating Company LLC, taken as a whole. Overview We are a clinical- stage biotechnology company focused on developing novel monoclonal antibody therapeutics for psoriasis (" PsO ") and other inflammatory and immunology (" I & I ") indications. Our name is derived from or, for " skin, " and arukah, for " restoration, " and reflects our mission to deliver therapies for chronic skin diseases that provide patients the most possible freedom from their condition. Our strategy is to apply antibody engineering and format innovations to validated modes of action, which we believe will enable us to improve meaningfully upon the efficacy and dosing regimens of standard- of- care medicines while significantly reducing technical and biological risk. Our programs aim to treat and potentially modify disease by targeting mechanisms with proven efficacy and safety involved in disease pathology and the activity of pathogenic tissue- resident memory T cells (" TRMs "). Our lead program, ORKA- 001, is designed to target the p19 subunit of interleukin- 23 (" IL- 23p19 ") for the treatment of PsO. Our co- lead program, ORKA- 002, is designed to target interleukin- 17A and interleukin- 17F (" IL- 17A / F ") for the treatment of PsO, psoriatic arthritis (" PsA "), and other conditions. These programs each bind their respective targets at high affinity and incorporate half- life extension technology with the aim to increase exposure and decrease dosing frequency. We believe that our focused strategy, differentiated portfolio, and deep expertise position us to set a new treatment standard in large I & I markets with continued unmet need. Since our inception in February 2024, we have devoted substantially all of our resources to raising capital, organizing and staffing the company, business and scientific planning, conducting discovery and research activities, establishing arrangements with third parties for the manufacture of our programs and component materials, and providing general and administrative support for these operations. We do not have any programs approved for sale and have not generated any revenue from product sales. To date, we have funded our operations primarily with proceeds from the issuance of convertible preferred stock, common stock, a convertible note, pre- funded warrants, and the proceeds from the reverse recapitalization and merger with ARCA biopharma, Inc., our Pre- Closing Financing and subsequent PIPE Financing (as defined and further described in " Recent developments " below). Since our inception, we have incurred significant losses and negative cash flows from our operations. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of any programs we may develop. We generated net losses of $ 83. 7 million for the period from February 6, 2024 (inception) to December 31, 2024. For the period from February 6 (inception) to December 31, 2024, we have used net cash of $ 57. 8 million for our operating activities. We had cash, cash equivalents, and marketable securities of $ 393. 7 million as of December 31, 2024. We expect that our existing cash, cash equivalents, and marketable securities will be sufficient to fund our operating plans for at least twelve months from the date of filing of this Annual Report. We expect to continue to incur substantial losses for the foreseeable future, and our transition to profitability will depend upon successful development, approval and commercialization of our product candidates and upon achievement of sufficient revenues to support our cost structure. ORKA- 001 is a high affinity, extended half- life monoclonal antibody (" mAb ") designed to target IL- 23p19. IL- 23 is a pro- inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (" Th17 ") cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL- 23 is composed of two subunits: a p40 subunit that is shared with IL- 12 and a p19 subunit that is specific to IL- 23. First- generation IL- 23 antibodies bound p40 and inhibited both IL- 12 and IL- 23 signaling, while more recent IL- 23 antibodies targeting the p19 subunit have shown improved efficacy and safety. Based on preclinical evidence, we believe that ORKA- 001 could achieve higher response rates than established therapies in PsO while requiring less frequent dosing and maintaining the favorable safety profile of therapies targeting IL-23p19. ORKA- 001 is engineered with YTE half- life extension technology, a specific three amino acid change in the fragment crystallizable (" Fc ") domain to modify the pH- dependent binding to the neonatal Fc receptor. As a result , it has a pharmacokinetic profile designed to support a subcutaneous (" SQ ") injection as infrequently as once or twice a year. In addition, emerging evidence suggests that IL- 23 blockade can modify the disease biology of PsO, possibly leading to durable remissions and preventing the development of PsA. We believe that the expected characteristics of ORKA- 001 increase its potential to deliver these disease- modifying benefits. We initiated the dosing of healthy volunteers in a Phase 1 trial of ORKA- 001 in the fourth quarter of 2024. We expect to share interim data from ~~actual~~ the first- in- human trial in healthy volunteers, including initial pharmacokinetic data, in the second half of 2025 and initial efficacy data in PsO patients in the second half of 2026. Based on recent precedent for PsO, we anticipate that the entire development program from first- in- human to biologics license application (" BLA ") filing could take as little as six to seven years based on the averages for recently approved medicines. However, we have no control over the length of time needed for United States Food and Drug Administration (" FDA ") review, and this timeline could vary. ORKA- 002 is a high affinity, extended half- life mAb designed to target IL- 17A and IL- 17F (" IL- 17A / F "). IL- 17 inhibition has become central to the treatment of psoriatic diseases, including PsO and PsA, and has also shown efficacy in other I & I indications, such as hidradenitis suppurativa and axial spondyloarthritis. More recently, the importance of inhibiting the IL- 17F isoform along with IL- 17A has become appreciated, and dual blockade with the recently approved therapy Bimzelx (bimekizumab) has led to higher response rates in patients than blockade of IL- 17A alone. ORKA- 002 is designed to bind IL- 17A / F at similar epitopes, or ~~rumored takeover attempts~~ binding sites, and affinity ranges as bimekizumab, but incorporates half- life extension technology that could enable more convenient dosing intervals . We plan to initiate the dosing of healthy volunteers in a Phase 1 trial of ORKA-002 in the third quarter of 2025. We expect to share interim data from the first- in- human trial in healthy volunteers, including initial pharmacokinetic data, in the first half of 2026. We view ORKA- 002 and ORKA- 001 as highly complementary. Patients with moderate- to- severe PsO that have purely skin manifestations are most often treated with IL- 23 inhibitors due to the high efficacy and tolerability of this mechanism. However, for patients who also have joint involvement, or signs and symptoms of PsA, an IL- 17 inhibitor is typically used due to its efficacy in addressing both skin and joint symptoms. In addition, IL- 17 inhibitors are often used in patients with highly resistant skin symptoms that do not adequately resolve through treatment with an IL- 23 inhibitor. Furthermore, we have the potential opportunity to administer ORKA- 002 and ORKA- 001 sequentially, called ORKA- 021, to combine two features of each program: the rapid response of an IL- 17 inhibitor with the ideal maintenance profile of an IL- 23 inhibitor. We believe that ORKA- 001 and ORKA- 002 provide the potential to offer a highly compelling product profile for most patients with PsO and / or PsA, as well as the opportunity to address additional I & I indications. Additional Pipeline Program We have a third mAb program, ORKA- 003, designed to target an undisclosed pathway. Our strategy as a company is to remain highly focused on I & I diseases, and specifically on inflammatory dermatology conditions. Our third program provides the potential for indication expansion beyond PsO and may create combination opportunities with our more advanced programs. Recent Developments Acquisition of Pre- Merger Oruka On August 29, 2024 (the " Merger Closing "), we completed our acquisition (the " Merger ") of Oruka Therapeutics, Inc. (" Pre- Merger Oruka ") pursuant to an Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024 (the " Merger Agreement "). Following the transactions contemplated by the Merger Agreement, Pre- Merger Oruka merged with and into Atlas Merger Sub Corp., a wholly owned subsidiary of ARCA biopharma, Inc. (" ARCA ") and following that, Pre- Merger Oruka then merged with and into Atlas Merger Sub II, LLC (" Second Merger Sub "), with Second Merger Sub being the surviving entity. Second Merger Sub changed its corporate name to " Oruka Therapeutics Operating Company, LLC. " Pre- Merger Oruka was a pre- clinical stage biotechnology company that was incorporated on February 6, 2024 under the direction of Peter Harwin, a Managing Member of Fairmount Funds Management LLC (" Fairmount "), for the purposes of holding rights to certain intellectual property being developed by Paragon Therapeutics, Inc. (" Paragon "). On August 29, 2024, we changed our name from " ARCA biopharma, Inc. " (" ARCA ") to " Oruka Therapeutics, Inc. " and our Nasdaq ticker symbol from " ABIO " to " ORKA ". Pre- Closing Financing Immediately prior to the execution and delivery of the Merger Agreement on April 3, 2024, certain new and existing investors of Pre- Merger Oruka entered into a subscription agreement with Pre- Merger Oruka (the " Subscription Agreement "), pursuant to which, and on the terms and subject to the conditions of which, immediately prior to the Closing, those investors purchased shares of common stock of Pre- Merger Oruka (" Pre- Merger Oruka Common Stock ") and Pre- Merger Oruka pre- funded warrants for gross proceeds of approximately $ 275. 0 million (which includes $ 25. 0 million of proceeds previously received from the issuance of the Convertible Note (refer to Note 7 in our consolidated financial statements included in Part II – Item 8 of this Annual Report for additional details) and accrued interest on ~~Such~~ such note which converted to shares of Pre- Merger Oruka Common Stock) (the " Pre- Closing Financing "). We incurred transaction costs of $ 20. 5 million, which was recorded as a reduction to additional paid- in capital in the consolidated financial statements. At the Closing, the shares of Pre- Merger Oruka Common Stock and Pre- Merger Oruka pre- funded warrants issued pursuant to the Subscription Agreement were converted into shares of Company Common Stock and pre- funded warrants of Company Common Stock in accordance with the Exchange Ratio (defined below). In accordance with an Exchange Ratio determined by terms of the Merger Agreement and upon the effective time of the First Merger (the " First Effective Time "), (i) each then- issued and outstanding share of Pre- Merger Oruka Common Stock including outstanding and unvested Pre- Merger Oruka restricted stock and shares of Pre- Merger Oruka Common Stock issued in connection with the Subscription Agreement, were converted into the right to receive a number of shares of Company Common Stock, equal to the exchange ratio of 6. 8569 shares of Company Common Stock (the " Exchange Ratio "), which were subject to the same vesting provisions ~~also may~~ as those immediately prior to the Merger, (ii) each share of Pre- Merger Oruka Series A convertible preferred stock, par value $ 0. 0001 (" Pre- Merger Oruka Series A Preferred Stock "), outstanding immediately prior to the First Effective Time was converted into the right to receive a number of shares of ARCA Series B non- voting convertible preferred stock, par value $ 0. 001 per share, which are convertible into shares of Company Common Stock at a conversion ratio of approximately 83. 3332: 1 after the reverse stock split discussed below, (iii) each outstanding option to purchase Pre- Merger Oruka Common Stock was converted into an option to purchase shares of Company Common Stock, (iv) each outstanding warrant to purchase shares of Pre- Merger Oruka Common Stock was converted into a warrant to purchase shares of Company Common Stock, and (v) each share of Company Common Stock issued and outstanding at the First Effective Time remain issued and outstanding in accordance with its terms and such shares. Subsequent to the close of the merger, the common stock shares were then, subject to a reverse stock split of 1- for- 12 effected on September 3, 2024 (" Reverse Stock Split "). As part of the Pre- Closing Financing and the Closing, the investors in the Pre- Closing Financing received 22, 784, 139 shares of Company Common Stock in exchange for 39, 873, 706 shares of Pre- Merger Oruka Common Stock (which includes the issuance of 2, 722, 207 shares of Company Common Stock in exchange for 4, 764, 032 shares of Pre- Merger Oruka Common Stock on the conversion of Convertible Note along with the accrued interest through the conversion date) and 5, 522, 207 Company pre- funded warrants in exchange for 9, 664, 208 Pre- Merger pre- funded warrants. The Merger was accounted for as a reverse recapitalization in accordance with U. S. GAAP. Under this method of accounting, Pre- Merger Oruka was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the fact that, immediately following the Merger: (i) Pre- Merger Oruka stockholders own a substantial majority of the voting rights in the combined company; (ii) Pre- Merger Oruka' s largest stockholders retain the largest interest in the combined company; (iii) Pre- Merger Oruka designated a majority of the initial members of the board of directors of the combined company; and (iv) Pre- Merger Oruka' s executive management team became the management team of the combined company. Accordingly, for accounting purposes: (i) the Merger was treated as the equivalent of Pre- Merger Oruka issuing stock to acquire the net assets of ARCA; (ii) the reported historical operating results of the combined company prior to the Merger are those of Pre- Merger Oruka; and (iii) Pre- Merger Oruka was not a variable interest entity as it had sufficient equity at risk in order to fund its next development milestones at the time of the reverse recapitalization. Additional information regarding the Merger is included in Note 3 to the consolidated financial statements included in Part II – Item 8 of this Annual Report. Reverse Stock Split On September 3, 2024, we effected the Reverse Stock Split, a 1- for- 12 reverse stock split of Company Common Stock. The par value per share and the number of authorized shares were not adjusted as a result of the Reverse Stock Split. The shares of Company Common Stock underlying outstanding stock options, common stock warrants and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. All references to common stock, options to purchase common stock, outstanding common stock warrants, common stock share data, per share data, and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect of ~~preventing~~ the Reverse Stock Split for all periods presented, unless otherwise specifically indicated or the context otherwise requires. PIPE Financing On September 11, 2024, we entered into a Securities Purchase Agreement for a private placement (the " PIPE Financing ") with certain institutional and accredited investors. The closing of the PIPE Financing occurred on September 13, 2024. Pursuant to the Securities Purchase Agreement, the investors purchased an aggregate of 5, 600, 000 shares of Company Common Stock at a purchase price of $ 23. 00 per share, an aggregate of 2, 439 shares of the Company' s Series A non- voting convertible preferred stock, par value $ 0. 001 per share (" Company Series A Preferred Stock "), at a purchase price of $ 23, 000. 00 per share (each Company Series A Preferred Stock is convertible into 1, 000 shares of Company Common Stock), and pre- funded warrants to purchase an aggregate of 680, 000 shares of Company Common Stock at a purchase price of $ 22. 999 per pre- funded warrant, for aggregate net proceeds of approximately $ 188. 7 million (net of issuance costs of $ 11. 9 million). Components of Results of Operations To date, we have not generated revenue from any sources, including product sales, and do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, we may generate revenue in the future from product sales or payments from future collaboration or license agreements that we may enter into with third parties, or any combination thereof. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates. Operating Expenses Research and Development Research and development expenses consist primarily of costs incurred in connection with the development and research of our programs. These expenses include: ● costs of funding research performed by third parties, including Paragon, that conduct research and development activities on our behalf; ● costs incurred, and milestone payments under license and option agreements; ● expenses incurred in connection with continuing our current research programs and discovery- phase development of any programs we may identify, including under future agreements with third parties, such as consultants and contractors; ● expenses incurred under agreements with contract research organizations (" CROs "), contract manufacturing organizations (" CMOs "), and with clinical trial sites that conduct research and development activities on our behalf; ● the cost of development and validating our manufacturing process for use in our preclinical studies and current and future clinical trials; ● personnel- related expenses, including salaries, bonuses, employee benefits, travel, and stock- based compensation expense, including stock- based compensation related to the Paruka warrant; and ● allocated human resource costs, information technology costs, and facility- related costs, including rent, maintenance, utilities, and depreciation for our leased office space. We expense research and development costs as incurred. Non- refundable advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered or the services rendered. Our primary focus since inception has been the identification and development of our pipeline programs. Our research and development expenses primarily consist of external costs, such as fees paid to Paragon under the Option Agreements. See " — Contractual Obligations and Commitments " below for further details on the Option Agreements. We expect our research and development expenses will increase substantially for the foreseeable future as we continue to invest in research and development activities related to the continued development of our programs, developing any future programs, including investments in manufacturing, as we advance any program we may identify and continue to conduct clinical trials. The success of programs we may identify and develop will depend on many factors, including the following: ● timely and successful completion of preclinical studies; ● effective investigational new drug (" IND ") or comparable foreign applications that allow commencement of our planned clinical trials or future clinical trials for any programs we may develop; ● successful enrollment and completion of clinical trials; ● positive results from our future clinical trials that support a finding of safety and effectiveness, acceptable pharmacokinetics profile, and an acceptable risk- benefit profile in the intended populations; ● receipt of marketing approvals from applicable regulatory authorities; ● establishment of arrangements through our own facilities or with third- party manufacturers for clinical supply and, where applicable, commercial manufacturing capabilities; and ● maintenance of a continued acceptable safety, tolerability, and efficacy profile of any programs we may develop following approval. Any changes in the outcome of any of these variables with respect to the development of programs that we may identify could mean a significant change in the costs and possible delays in timing associated with the development of such programs. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development of a program, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development. We may never obtain regulatory approval for any of our programs. General and Administrative General and administrative expenses consist primarily of personnel- related expenses, including salaries, bonuses, employee benefits, travel, and stock- based compensation, for our executive and other administrative personnel. Other significant general and administrative expenses include legal services, including intellectual property and corporate matters; professional fees for accounting, auditing, tax, insurance, and allocated human resource costs, information technology costs, and facility- related costs, including rent, utilities, maintenance, and depreciation for our leased office space. We expect our general and administrative expenses will increase substantially for the foreseeable future as we anticipate an increase in our personnel headcount to support the expansion of research and development activities, as well as to support our operations generally. We also expect to continue to incur significant expenses associated with being a public company, including costs related to accounting, audit, legal, regulatory, and tax- related services associated with maintaining compliance with applicable Nasdaq and SEC requirements; director and officer insurance costs; and investor and public relations costs. We also expect to incur additional intellectual property- related expenses as we file patent applications to protect innovations arising from our research and development activities. Other Income, Net Other income, net consists of interest earned on our cash, cash equivalents, and marketable securities; interest expense on the convertible note from a related party (see discussion herein); and foreign currency transactions gains and losses. Interest expense relates to a convertible note (the " Convertible Note ") issued to Fairmount Healthcare Fund II, L. P. (" Fairmount "), a related party, in March 2024. At the effective time of the Merger, the Convertible Note, along with the accrued interest, was automatically converted into Company Common Stock. Income Taxes No provision for income taxes was recorded for the period from February 6, 2024 (inception) through December 31, 2024. Deferred tax assets generated from our net operating losses have been fully offset by the valuation allowance as we believe it is not more likely than not that the benefit will be realized due to our cumulative losses generated to date. Results of Operations for the Period from February 6, 2024 (inception) to December 31, 2024 The following table summarizes our results of operations for the period presented (in thousands): Period from February 6, 2024 (Inception) to December 31, 2024 Operating expenses Research and development (1) $ 75, 060 General and administrative (2) 13, 063 Total operating expenses 88, 123 Loss from operations (88, 123) Other income (expense) Interest income 5, 863 Interest expense (3) (1, 468) Other income, net 4 Total other income, net 4, 399 Net loss $ (83, 724) (1) Includes related party amount of $ 42, 640 for the period from February 6, 2024 (inception) to December 31, 2024 (2) Includes related party amount of $ 1, 364 for the period from February 6, 2024 (inception) to December 31, 2024 (3) Includes related party amount of $ 1, 468 for the period from February 6, 2024 (inception) to December 31, 2024Research and Development Expenses The following table summarizes our research and development expenses for the period presented (in thousands): Period from February 6, 2024 (Inception) to December 31, 2024 External research and development expenses (1) $ 57, 680 Other research and development expenses: Personnel- related (excluding stock- based compensation) 3, 959 Stock- based compensation (2) 11, 992 Other 1, 429 Total research and development expenses $ 75, 060 (1) Includes related party amount of $ 32, 283 for the period from February 6, 2024 (inception) to December 31, 2024 (2) Includes related party amount of $ 10, 357 for the period from February 6, 2024 (inception) to December 31, 2024Research and development expenses were $ 75. 1 million for the period from February 6, 2024 (inception) to December 31, 2024 and consisted primarily of the following: ● $ 57. 7 million of research and development expense primarily includes: $ 18. 3 million related to Paragon services rendered under the Option Agreements for ORKA- 001, including $ 4. 8 million for milestones achieved under the Option and License Agreements upon exercise of the option to enter into a license agreement and achievement of development candidate for IL- 23 and dosing of the first subject in a Phase 1 clinical trial; $ 13. 3 million of research and development expense primarily related to Paragon services rendered under the Option Agreements for ORKA- 002, including $ 2. 3 million for milestones achieved under the Option and License Agreements upon exercise of the option to enter into a license agreement and achievement of development candidate for IL- 17; $ 0. 7 million of other research and development expense due to Paragon; $ 16. 5 million of research and development expense on chemistry, manufacturing, and development costs; $ 5. 7 million in toxicology testing with a third- party contract research organization; and $ 3. 2 million of other external research and development costs; ● $ 4. 0 million of personnel- related costs related to salaries, benefits, and other compensation- related costs; ● $ 12. 0 million of stock- based compensation expense, including $ 10. 4 million of stock- based compensation related to the Paruka warrant; and ● $ 1. 4 million of other expense and allocated human resource costs, information technology costs, and facility- related costs, including rent, maintenance, utilities, and depreciation for our leased office space. General and Administrative Expenses The following table summarizes our general and administrative expenses for the period presented (in thousands): Period from February 6, 2024 (Inception) to December 31, 2024 Personnel- related (including stock- based compensation) (1) $ 7, 981 Professional and consulting fees (2) 4, 606 Other (3) 476 Total general and administrative expenses $ 13, 063 (1) Includes related party amount of $ 609 for the period from February 6, 2024 (inception) to December 31, 2024 (2) Includes related party amount of $ 575 for the period from February 6, 2024 (inception) to December 31, 2024 (3) Includes related party amount of $ 180 for the period from February 6, 2024 (inception) to December 31, 2024General and administrative expenses were $ 13. 1 million for the period from February 6, 2024 (inception) to December 31, 2024 and consisted primarily of the following: ● $ 8. 0 million of personnel- related costs related to salaries, benefits, other compensation- related costs, recruiting costs, including stock- based compensation of $ 2. 9 million, and $ 0. 6 million of personnel- related costs are recruiting costs reimbursed to Paragon for hiring of our executive team, legal, and finance and accounting functions; ● $ 4. 6 million of professional and consulting fees associated with accounting, audit, and legal fees associated with becoming a public company, including $ 0. 6 million of legal fees due to Paragon associated with patent- related activities; and ● $ 0. 5 million of other business expenses and net of allocated human resource costs, information technology costs, and facility- related costs, including rent, maintenance, utilities, and depreciation for our leased office space to research and development expenses, including $ 0. 2 million of other business expenses due to Paragon. Total Other Income, Net Interest income from cash equivalents and marketable securities was $ 5. 9 million for the period from February 6, 2024 (inception) to December 31, 2024. Interest expense was $ 1. 5 million for the period from February 6, 2024 (inception) to December 31, 2024 relating to the Convertible Note from Fairmount. Liquidity and Capital Resources As of December 31, 2024, we had $ 393. 7 million of cash, cash equivalents, and marketable securities. Since our inception, we have incurred significant operating losses and negative cash flow from operations. We expect to incur significant expenses and operating losses for the foreseeable future as we continue the pre- clinical and clinical development of our programs and our early- stage research activities. We have not yet commercialized any products, and we do not expect to generate revenue from sales of products for several years, if at all. Through December 31, 2024, we had funded our operations primarily with proceeds from issuances of convertible preferred stock, common stock, a convertible note, and pre- funded warrants. In March 2024, we received $ 2. 9 million in net proceeds from the issuance of Pre- Merger Oruka Series A Preferred Stock and $ 25. 0 million in gross proceeds from the issuance of the Convertible Note, both of which were related party transactions. In August 2024, we raised approximately $ 228. 0 million in net proceeds from Pre- Closing Financing and received $ 4. 9 million in cash from ARCA upon consummation of the Merger. In September 2024, we received approximately $ 188. 7 million in net proceeds from the issuance of common stock, Company Series A Preferred Stock, and pre- funded warrants in connection with the PIPE Financing. Our primary use of cash is to fund the development of our product candidates and advance our pipeline. This includes both the research and development costs and the general and administrative expenses required to support those operations. Since we are a clinical stage biotechnology company, we have incurred significant operating losses since our inception and we anticipate such losses, in absolute dollar terms, to increase as we continue to pursue clinical development of our product candidates, prepare for the potential commercialization of our product candidates, and expand our development efforts in our pipeline of nonclinical candidates. We expect that our existing cash, cash equivalents, and marketable securities will be sufficient to fund our operating plans for at least twelve months from the date of filing of this Annual Report. We will need to secure additional financing in the future to fund additional research and development, and before a commercial drug can be produced, marketed, and sold. If we are unable to obtain additional financing or generate license or product revenue, the lack of liquidity could have a material adverse effect on our company. Cash Flows The following table summarizes our cash flows for the period presented (in thousands): Period from February 6, 2024 (Inception) to December 31, 2024 Net cash used in operating activities $ (57, 837) Net cash used in investing activities (330, 127) Net cash provided by financing activities 449, 539 Net increase in cash and cash equivalents $ 61, 575 Operating Activities From February 6, 2024 (inception) to December 31, 2024, net cash used in operating activities was $ 57. 8 million, which was primarily attributable to a net loss of $ 83. 7 million, offset by net non- cash charges of $ 14. 3 million and net changes in operating activities of $ 11. 6 million. Non- cash charges primarily consisted of $ 14. 9 million in stock- based compensation expense (including $ 10. 4 million related to the Paruka warrant) and $ 1. 5 million of non- cash interest expense, partially offset by net accretion of premiums and discounts on marketable securities of $ 2. 2 million. Net changes in our ~~management~~ operating activities primarily consisted of a $ 3. 5 million increase in accounts payable, a $ 3. 3 million increase in accrued expenses and other current liabilities, a $ 6. 0 million increase in related parties accounts payable and other current liabilities, partially offset by a $ 1. 1 million increase in prepaid expenses and other current assets. The increase in amounts due to related parties, accounts payable, and accrued expenses and other current liabilities was primarily due to an increase in our business activity, as well as vendor invoicing and payments. The increase in prepaid expenses and other current assets was primarily due to prepaid research and development expenses with our contract research organization. Investing Activities From February 6, 2024 (inception) to December 31, 2024, net cash used in investing activities was $ 330. 1 million, which was primarily attributable to purchases of marketable securities. Financing Activities From February 6, 2024 (inception) to December 31, 2024, net cash provided by financing activities was $ 449. 5 million, consisting of $ 228. 0 million of net proceeds from the Pre- Closing Financing, $ 188. 7 million of net proceeds from the PIPE Financing, $ 25. 0 million of net proceeds from the issuance of notes payable to related parties, $ 4. 9 million of cash acquired in connection with the reverse recapitalization and $ 2. 9 million of net proceeds from issuance of the Pre- Merger Oruka Series A Preferred Stock. We enter into contracts in the normal course of business with CROs, CMOs and with other vendors for preclinical research studies, clinical trials, manufacturing, and other services and products for operating purposes. These contracts generally provide for termination on notice or may have a potential termination fee if a purchase order is cancelled within a specified time, and therefore, are cancelable contracts. We do not expect any such contract terminations and did not have any non- cancellable obligations under these agreements as of December 31, 2024. Paragon Therapeutics- Option Agreements In March 2024, we entered into two antibody discovery and option agreements (“ Option Agreements ”) with Paragon and Paruka Holding, LLC (“ Paruka ”). Under the terms of each agreement, Paragon identifies, evaluates, and develops antibodies directed against certain mutually agreed therapeutic targets of interest to us. From time to time, we can choose to add additional targets to the collaboration upon agreement with Paragon and Paruka. Under the Option Agreements, we have the exclusive option to, on a research program- by- research program basis, be granted an exclusive, worldwide license to all of Paragon’ s right, title, and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture, and commercialize the antibodies and products directed to the selected target (s) (each, an “ Option ”). We have initiated certain research programs with Paragon that generally focus on discovering, generating, identifying and / or characterizing antibodies directed to a particular target (each, a “ Research Program ”), including for IL- 23 and IL- 17A / F for ORKA- 001 and ORKA- 002, respectively. Our exclusive option with respect to each Research Program is exercisable at our sole discretion at such time as specified in the Option Agreements (the “ Option Period ”). There is no payment due upon exercise of an Option pursuant to the Option Agreements. For each of these agreements, once we enter into the corresponding license agreements, we will be required to make non- refundable milestone payments to Paragon of up to $ 12. 0 million under each respective agreement upon the achievement of certain clinical development milestones, up to $ 10. 0 million under each respective agreement upon the achievement of certain regulatory milestones, as well as a low single- digit percentage royalty for antibody products beginning on the first commercial sale in each program. We may terminate any Option Agreement or any Research Program at any time for any or no reason upon 30 days’ prior written notice to Paragon, provided that we must pay certain unpaid fees due to Paragon upon such termination, as well as any non- cancellable obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate any Option Agreement or a Research Program immediately upon written notice to us if, as a result of any action or failure to act by us or our affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed for a certain consecutive number of months. Each party has the right to terminate the Option Agreements or any Research Program upon material breach that remains uncured or the other party’ s bankruptcy. Additionally, as part of the Option Agreements, on December 31, 2024 and December 31, 2025, we granted and will grant, respectively, Paruka a warrant to purchase a number of shares equal to 1. 00 % of outstanding shares as of the date of the grant on a fully- diluted basis, with an exercise price equal to the fair market value of the underlying shares on the grant date. The warrant is liability- classified and after the initial recognition, the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the consolidated statement of operations and comprehensive loss as stock- based compensation expenses under research and development expenses. On issuance of the December 31, 2024 warrant to Paruka, the change in fair value of the warrant immediately prior to issuance was recorded in the consolidated statement of operations and comprehensive loss and the resultant carrying value of the liability was reclassified to equity on the consolidated balance sheet as of December 31, 2024. Pursuant to the Option Agreements, on a research program- by- research program basis following the finalization of the research plan for each respective research program, we were required to pay Paragon a one- time, nonrefundable research initiation fee of $ 0. 8 million related to the ORKA- 001 program. This amount was recognized as a research and development expense during the period from February 6, 2024 (inception) to December 31, 2024. In June 2024, pursuant to the Option Agreements with Paragon, we completed the selection process of our development candidate for IL- 23 antibody for ORKA- 001 program. We were responsible for 50 % of the development costs incurred through the completion of the IL- 23 selection process. We received the rights to at least one selected IL- 23 antibody in June 2024. During the period from February 6, 2024 (inception) to December 31, 2024, we exercised our option for ORKA- 001 and recorded a $ 1. 5 million milestone payment related to the achievement of development candidate as research and development expense in our consolidated statement of operations and comprehensive loss. In addition, during the period from February 6, 2024 (inception) to December 31, 2024, we recorded a $ 2. 5 million milestone payment related to the first dosing of a human subject in a Phase 1 trial of ORKA- 001 in December 2024 as research and development expense in our consolidated statement of operations and comprehensive loss. Our share of development costs incurred for the period from February 6, 2024 (inception) to December 31, 2024 was $ 13. 5 million, which was recorded as research and development expenses. An amount of $ 2. 8 million related to ORKA- 001 is included in related party accounts payable and other current liabilities as of December 31, 2024. We were also required to reimburse Paragon $ 3. 3 million for development costs related to ORKA- 002 incurred by Paragon through December 31, 2023 and certain other development costs incurred by Paragon between January 1, 2024 and March 6, 2024 as stipulated by the Option Agreements. This amount was recognized as a research and development expense during the period from February 6, 2024 (inception) to December 31, 2024 . We are also responsible for the development costs incurred by Paragon from January 1, 2024 through the completion of the IL- 17 selection process. We recognized an amount of $ 0. 8 million payable to Paragon for the research initiation fee related to ORKA- 002 following the finalization of the ORKA- 002 research plan. This was recognized as research and development expenses in the period from February 6, 2024 (inception) to December 31, 2024. During the period from February 6, 2024 (inception) to December 31, 2024, we exercised our option for ORKA- 002 and recorded a $ 1. 5 million milestone payment related to the achievement of development candidate as research and development expense in our consolidated statement of operations and comprehensive loss. We accounted for development costs of $ 7. 8 million for the period from February 6, 2024 (inception) to December 31, 2024 as research and development expenses. An amount of $ 2. 7 million related to ORKA- 002 is included in related party accounts payable and other current liabilities as of December 31, 2024. We expense the service fees as the associated costs are incurred when the underlying services are rendered. Such amounts are classified within research and development expenses in the accompanying consolidated statement of operations and comprehensive loss. We concluded that the rights obtained under the Option Agreements represent an asset acquisition whereby the underlying assets comprise in- process research and development assets with no alternative future use. The Option Agreements did not qualify as a business combination because substantially all of the fair value of the assets acquired was concentrated in the exclusive license options, which represent a group of similar identifiable assets. The research initiation fee represents a one- time cost on a research program- by- research program basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of on- going development cost, monthly development cost fee and additional development expenses incurred by Paragon due to work completed for selected targets prior to the effective date of the Option Agreements that is associated with services being rendered under the related Research Programs are recognized as research and development expense when incurred. For the period from February 6, 2024 (inception) to December 31, 2024, we recognized $ 42. 0 million of expenses in connection with services provided by Paragon and Paruka under the Option Agreements. Paragon Therapeutics – License Agreements In September 2024, we exercised the Option to acquire certain rights to ORKA- 001, and in December 2024, we entered into the corresponding license agreement with Paragon (the “ ORKA- 001 License Agreement ”), pursuant to which Paragon granted us a royalty- bearing, world- wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting IL- 23 in all fields other than the field of inflammatory bowel disease (“ ORKA- 001 Field ”). In December 2024, we exercised the Option with respect to ORKA- 002 for the IL- 17A / F program, and in February 2025, we entered into the corresponding license agreement with Paragon (the “ ORKA- 002 License Agreement ” and together with the ORKA- 001 License Agreement, the “ License Agreements ”), pursuant to which Paragon granted us a royalty- bearing, world- wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting IL- 17A / F in all fields (“ ORKA- 002 Field ” and together with the ORKA- 001 Field, the “ Fields ”). The License Agreements provide us with exclusive licenses in the Fields to Paragon’ s patent applications covering the related antibodies, their method of use and their method of manufacture and Paragon has agreed not to conduct any new campaigns that generate anti- IL- 23 monospecific antibodies or anti- IL- 17A / F monospecific antibodies for the ORKA- 001 Field or the ORKA- 002 Field, respectively, for at least five years. Each of the ORKA- 001 and ORKA- 002 License Agreements may be terminated on 60 days’ notice to Paragon, on material breach without cure, and on a party’ s insolvency or bankruptcy to the extent permitted by law. Pursuant to the terms of each of the ORKA- 001 and ORKA- 002 License Agreements, we are obligated to pay Paragon non- refundable milestone payments of up to $ 12. 0 million under each respective agreement upon the achievement of certain clinical development milestones and up to $ 10. 0 million under each respective agreement upon the achievement of certain regulatory milestones, including a $ 1. 5 million fee for nomination of a development candidate (or initiation of an IND- enabling toxicology study) and a further milestone payment of $ 2. 5 million upon the first dosing of a human patient in a Phase 1 trial for each of ORKA- 001 and ORKA- 002. In addition, we are obligated to pay Paragon a low single- digit percentage royalty for antibody products for each of ORKA- 001 and ORKA- 002. For each of the License Agreements, the royalty term ends on the later of (i) the last- to- expire licensed patent or our patent directed to the manufacture, use or sale of a licensed antibody in the country at issue or (ii) 12 years from the date of first sale of a Company product. There is also a royalty step- down if there is no Paragon patent in effect during the royalty term for each program. Cell Line License Agreement In March 2024, we entered into the Cell Line License Agreement (the “ Cell Line License Agreement ”) with WuXi Biologics Ireland Limited (“ WuXi Biologics ”). Under the Cell Line License Agreement, we received a non- exclusive, worldwide, sublicensable license to certain of WuXi Biologics’ know- how, cell line, biological materials (the “ WuXi Biologics Licensed Technology ”) and media and feeds to make, have made, use, sell and import certain therapeutic products produced through the use of the cell line licensed by WuXi Biologics under the Cell Line License Agreement (the “ WuXi Biologics Licensed Products ”). Specifically, the WuXi Biologics Licensed Technology is used in certain manufacturing activities in support of the ORKA- 001 and ORKA- 002 programs. In consideration for the license, we agreed to pay WuXi Biologics a non- refundable license fee of $ 150, 000, which was recognized as a research and development expense during the period from February 6, 2024 (inception) to December 31, 2024. Additionally, to the extent that we manufacture our commercial supplies of bulk drug product with a manufacturer other than WuXi Biologics or its affiliates, we are required to make royalty payments to WuXi Biologics at a rate of less than one percent of net sales of WuXi Biologics Licensed Products manufactured by the third- party manufacturer. Pursuant to an amendment to the Cell Line License Agreement effective in November 2024, a provision was added that permits the royalties owed under the agreement to be bought out on a product- by- product basis for a lump- sum payment. The Cell Line License Agreement will continue indefinitely unless terminated (i) by us upon six months’ prior written notice and our payment of all undisputed amounts due to WuXi Biologics through the effective date of termination, (ii) by WuXi Biologics for a material breach by us that remains uncured for 60 days after written notice, (iii) by WuXi Biologics if we fail to make a payment and such failure continues for 30 days after receiving notice of such failure, or (iv) by either party upon the other party' s bankruptcy. Note Payable with Related Party In March 2024, we entered into a Series A Preferred Stock and Convertible Note Purchase Agreement (the " Purchase Agreement ") with Fairmount, whereby we issued the Convertible Note, with an initial principal amount of $ 25. 0 million that, at the time of issuance, could be converted into Pre- Merger Oruka Series A Preferred Stock (or a series of preferred shares that is identical in respect to the shares of preferred shares issued in its next equity financing) or shares of Pre- Merger Oruka Common Stock in exchange for aggregate proceeds of $ 25. 0 million. The Convertible Note accrued interest at a rate of 12. 0 % per annum. At issuance, the Convertible Note required all unpaid interest and principal to mature on December 31, 2025 (the " Maturity Date ") and prepayment was not permitted without prior written consent of Fairmount. At issuance, the principal payment along with the accrued interest on the Convertible Note was due in full on the Maturity Date. Pursuant to the Purchase Agreement, we had the right to sell and issue additional convertible notes up to an aggregate principal amount equal to $ 30. 0 million, in addition to the $ 25. 0 million initial principal amount of the Convertible Note. Immediately prior to the completion of the Merger, the Convertible Note was converted into shares of Pre- Merger Oruka Common Stock based on the aggregate principal amount of $ 25. 0 million, plus unpaid accrued interest of $ 1. 5 million divided by the conversion price, which was determined based upon the Company' s fully- diluted capitalization immediately prior to the Merger. At the effective time of the Merger, the Pre- Merger Oruka Common Stock issued upon the conversion of the Convertible Note (including accrued interest) automatically converted into shares of Company Common Stock. 2, 722, 207 shares of Company Common Stock were issued on conversion of the Convertible Note and accrued interest. As of December 31, 2024, there is no note payable to a related party. Lease Agreement Our contractual obligations include minimum lease payments under our ~~preferred~~ operating lease obligation for our headquarters in Menlo Park, California. See Note 13 to the consolidated financial statements elsewhere in this report for additional information. Critical Accounting Policies and Significant Judgments and Estimates Our management' s discussion and analysis of its financial condition and results of operations is based on its financial statements, which have been prepared in accordance with U. S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues recognized and expenses incurred during the reporting periods. Our estimates are based on its historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. While our significant accounting policies are described in more detail in Note 2 to our consolidated financial statements appearing elsewhere in this Annual Report, we believe the following accounting policies used in the preparation of our financial statements require the most significant judgments and estimates. Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, overhead costs, contract services and other related costs. The value of goods and services received from contract research organizations and contract manufacturing organizations in the reporting period are estimated based on the level of services performed, and progress in the period in cases when we have not received an invoice from the supplier. In circumstances where amounts have been paid in excess of costs incurred, we record a prepaid expense. When billing terms under these contracts do not coincide with the timing of when the work is performed, we are required to make estimates of outstanding obligations to those third parties as of period end. Any accrual estimates are based on a number of factors, including our knowledge of the progress towards completion of the specific tasks to be performed, invoicing to date under the contracts, communication from the vendors of any actual costs incurred during the period that have not yet been invoiced and the costs included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by us. Stock- Based Compensation We measure stock ~~without stockholder approval upon~~ options granted to employees and non- employees based on the estimated fair values of the awards as of the grant date using the Black- Scholes option- pricing model. The model requires management to make a number of assumptions, including common stock fair value, expected volatility, expected term, risk- free interest rate and expected dividend yield. For restricted stock awards and restricted stock units, the estimated fair value is the fair market value of the underlying stock on the grant date. We expense the fair value of our equity- based compensation awards on a straight- line basis over the requisite service period, which is the period in which the related services are received. We account for award forfeitures as they occur. The expense for stock- based awards with performance conditions is recognized when it is probable that a performance condition is met during the vesting period. Determination of Fair Value of Common Stock A public trading market for Company Common Stock has been established in connection with the completion of the Merger. As such ~~terms as~~, it is no longer necessary for our board of directors to estimate the fair value of our stock- based awards in connection with its accounting for granted stock- based awards or other such awards we may grant, as the fair value of Company Common Stock and share- based awards is determined based on the quoted market price of Company Common Stock. Prior to the merger, Pre- Merger Oruka' s common stock valuations were prepared using a hybrid method, including an option pricing method (" OPM "). The OPM treats common stock and preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company' s securities changes. Under this method, the common stock has value only if the funds available for distribution to stockholders exceed the value of the preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. The hybrid method is a probability- weighted expected return method (" PWERM "), where the equity value in one or more of the scenarios is calculated using an OPM. The PWERM is a scenario- based methodology that estimates the fair value of common stock based upon an analysis of future values for the Company, assuming various outcomes. The common stock value is based on the probability- weighted present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class of stock. The future value of the common stock under each outcome is discounted back to the valuation date at an appropriate risk- adjusted discount rate and probability weighted to arrive at an indication of value for the common stock. A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for the common stock. The assumptions underlying these valuations represented management' s best estimate, which involved inherent uncertainties and the application of management' s judgment. As a result, if Pre- Merger Oruka had used significantly different assumptions or estimates, the fair value of Pre- Merger Oruka' s incentive shares and its stock- based compensation expense could have been materially different. Recently Issued Accounting Pronouncements See Note 2 to the consolidated financial statements included in Part II- Item 8 of this Annual Report for more information regarding recently issued accounting pronouncements. Off- Balance Sheet Arrangements As of December 31, 2024, we did not have any off- balance sheet arrangements, as defined in the rules and regulations of the SEC. Item 7A. Quantitative and Qualitative Disclosures About Market Risk. We are a smaller reporting company, as defined by Rule 12b- 2 under the Securities Exchange Act of 1934, as amended (the " Exchange Act "), and in Item 10 (f) (1) of Regulation S- K, and are not required to provide the information under this item. Item 8. Financial Statements and Supplementary Data. ORUKA THERAPEUTICS, INC. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page Audited Financial Statements: Report of Independent Registered Public Accounting Firm (PCAOB ID 238) F- 2 Consolidated Balance Sheets F- 3 Consolidated Statement of Operations and Comprehensive Loss F- 4 Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity F- 5 Consolidated Statement of Cash Flows F- 6 Notes to Consolidated Financial Statements F- 7 F- 1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Stockholders of Oruka Therapeutics, Inc. Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Oruka Therapeutics, Inc. and its subsidiaries (the " Company ") as of December 31, 2024 and February 6, 2024, and the related consolidated statements of operations and comprehensive loss, of convertible preferred stock and stockholders' equity and of cash flows for the period from February 6, 2024 (inception) to December 31, 2024, including the related notes (collectively referred to as the " consolidated financial statements "). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and February 6, 2024, and the results of its operations and its cash flows for the period from February 6, 2024 (inception) to December 31, 2024 in conformity with accounting principles generally accepted in the United States of America. Basis for Opinion These consolidated financial statements are the responsibility of the Company' s management. Our responsibility is to express an opinion on the Company' s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U. S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company' s internal control over financial reporting. Accordingly, we express no such opinion. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. Critical Audit Matters The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. External Research and Development Costs As described in Note 2 to the consolidated financial statements, research and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock- based compensation, employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities, as well as allocated human resource costs, information technology costs, and facility- related costs, including rent, maintenance, utilities, and depreciation. As disclosed by management, the Company' s research and development expense for the period from February 6, 2024 (inception) to December 31, 2024 was $ 75. 1 million, $ 57. 7 million of which relates to external research and development costs. The principal consideration for our determination that performing procedures relating to external research and development costs is a critical audit matter is a high degree of auditor effort in performing procedures related to the Company' s external research and development costs. Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included, among others, testing external research and development costs, on a sample basis, by obtaining and agreeing the contractual terms of the agreement, amounts incurred to date, and estimates of work performed to date to the (i) underlying agreements with vendors engaged to conduct research and development; (ii) purchase orders; (iii) invoices received; (iv) underlying payments made for expenses incurred on the contracts; and (v) external confirmations or communications obtained by management from vendors. / s / PricewaterhouseCoopers LLP Boston, Massachusetts March 6, 2025 We have served as the Company' s auditor since 2024. CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share data) December 31, February 6, 2024 2024 Assets Current assets: Cash and cash equivalents $ 61, 575 $ — Marketable securities, current 314, 073 — Subscription receivable — 1 Prepaid expenses and other current assets 1, 221 — Total current assets 376, 869 1 Marketable securities, long- term 18, 069 — Property and equipment, net 162 — Operating lease right- of- use assets 876 — Other non- current assets 43 — Total assets $ 396, 019 $ 1 Liabilities, Convertible Preferred Stock and Stockholders' Equity Current liabilities: Accounts payable $ 3, 462 $ — Accrued expenses and other current liabilities 3, 346 — Operating lease liability, current 213 — Related party accounts payable and other current liabilities 6, 022 — Total current liabilities 13, 043 — Operating lease liability, non- current 755 — Total liabilities 13, 798 — Commitments and contingencies (Note 13) Series A convertible preferred stock, $ 0. 0001 par value; no shares and 20, 000, 000 shares authorized as of December 31, 2024 and February 6, 2024, respectively; none issued and outstanding as of December 31, 2024 and February 6, 2024 — — Series A non- voting convertible preferred stock, $ 0. 001 par value; none authorized as of December 31, 2024 and February 6, 2024; none issued and outstanding as of December 31, 2024 and February 6, 2024 — — Stockholders' equity: Series B non- voting convertible preferred stock, $ 0. 001 par value; 251, 504 and no shares authorized as of December 31, 2024 and February 6, 2024, respectively; 137, 138 and no shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively 2, 931 — Common stock, $ 0. 001 and $ 0. 001 par value as of December 31, 2024 and February 6, 2024, respectively; 545, 000, 000 and 65, 000, 000 shares authorized, 37, 440, 510 and 3, 197, 975 shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively 37 — Additional paid- in capital 463, 018 1 Accumulated other comprehensive loss (41) — Accumulated deficit (83, 724) — Total stockholders' equity 382, 221 1 Total liabilities, convertible preferred stock and stockholders' equity $ 396, 019 $ 1 The accompanying notes are an integral part of these consolidated financial statements. CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS Period from February 6, 2024 (Inception) to December 31, 2024 Operating expenses Research and development (1) $ 75, 060 General and administrative (2) 13, 063 Total operating expenses 88, 123 Loss from operations (88, 123) Other income (expense) Interest income 5, 863 Interest expense (3) (1, 468) Other income, net 4 Total other income, net 4, 399 Net loss (83, 724) Unrealized loss on marketable securities (41) Comprehensive loss $ (83, 765) Net loss per share attributable to common stockholders, basic and diluted $ (3. 87) Net loss per share attributable to Series A non- voting convertible preferred stockholders, basic and diluted $ (3, 873. 25) Net loss per share attributable to Series B non- voting convertible preferred stockholders, basic and diluted $ (322. 81) Weighted- average shares used in computing net loss per share attributable to common stockholders, basic and diluted 16, 789, 362 Weighted- average shares used in computing net loss per share attributable to Series A non- voting convertible preferred stockholders, basic and diluted 495 Weighted- average shares used in computing net loss per share attributable to Series B non- voting convertible preferred stockholders, basic and diluted 51, 946 (1) Includes related party amount of $ 42, 640 for the period from February 6, 2024 (inception) to December 31, 2024 (2) Includes related party amount of $ 1, 364 for the period from February 6, 2024 (inception) to December 31, 2024 (3) Includes related party amount of $ 1, 468 for the period from February 6, 2024 (inception) to December 31, 2024 CONSOLIDATED STATEMENT OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (In thousands, except share data) Series A Convertible Preferred Stock Series A Non- Voting Convertible Preferred Stock Series B Non- Voting Convertible Preferred Stock Common Stock Additional Paid- In Accumulated Other Comprehensive Accumulated Total Stockholders’ Shares Amount Shares Amount Shares Amount Shares Amount Capital Gain (Loss) Deficit Equity Balances as of February 6, 2024 (inception) — $ — — $ — — $ — 3, 197, 975 $ 3 $ (2) $ — $ — $ 1 Issuance of common stock — — — — — — 2, 207, 553 2 (2) — — — Issuance of Series A convertible preferred stock, net of issuance costs of $ 69 20, 000, 000 2, 931 — — — — — — — — — — Exchange of Series A convertible preferred stock for Series B non- voting convertible preferred stock upon the closing of the reverse capitalization (20, 000, 000) (2, 931) — — 137, 138 2, 931 — — — — — 2, 931 Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization — — — — — — 2, 722, 207 3 26, 445 — — 26, 448 Issuance of common stock and pre- funded warrants in the Pre- Closing Financing — — — — — — 20, 061, 932 20 248, 437 — — 248, 457 Issuance costs of Pre- Closing Financing and reverse recapitalization — — — — — — — — (20, 504) — — (20, 504) Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization — — — — — — 1, 208, 883 1 4, 999 — — 5, 000 Issuance of common stock, Series A non- voting convertible preferred stock, and pre- funded warrants in connection with the PIPE Financing — — 2, 439 56, 097 — — 5, 600, 000 6 144, 433 — — 144, 439 Issuance costs of PIPE Financing — — — (3, 263) — — — — (8, 592) — — (8, 592) Conversion of Series A non- voting convertible preferred stock to common stock — — (2, 439) (52, 834) — — 2, 439, 000 2 52, 832 — — 52, 834 Issuance of common stock under employee stock purchase plan — — — — — — 2, 960 — 53 — — 53 Reclassification of the Paruka warrant from liability to equity — — — — — — — — 10, 357 — — 10, 357 Stock- based compensation expense — — — — — — — — 4, 562 — — 4, 562 Unrealized loss on marketable securities — — — — — — — — — (41) — (41) Net loss — — — — — — — — — — (83, 724) (83, 724) Balances as of December 31, 2024 — $ — — $ — 137, 138 $ 2, 931 37, 440, 510 $ 37 $ 463, 018 $ (41) $ (83, 724) $ 382, 221 CONSOLIDATED STATEMENT OF CASH FLOWS (In thousands) Period from February 6, 2024 (Inception) to December 31, 2024 Cash flows from operating activities: Net loss $ (83, 724) Adjustments to reconcile net loss to net cash used in operating activities: Stock- based compensation expense 14, 919 Net accretion of premiums and discounts on marketable securities (2, 245) Non- cash interest expense 1, 468 Non- cash lease expense 127 Depreciation expense 27 Changes in operating assets and liabilities: Prepaid expenses and other current assets (1, 128) Other non- current assets (43) Accounts payable 3, 462 Accrued expenses and other current liabilities 3, 292 Operating lease liability (14) Related party accounts payable and other current liabilities 6, 022 Net cash used in operating activities (57, 837) Cash flows from investing activities: Purchases of property and equipment (189) Purchases of marketable securities (329, 938) Net cash used in investing activities (330, 127) Cash flows from financing activities: Proceeds from issuance of Pre- Merger Oruka Series A Preferred Stock, net of issuance costs paid 2, 931 Proceeds from issuance of notes payable to related party, net of issuance costs paid 24, 980 Proceeds from the Pre- Closing Financing, net 227, 953 Proceeds from the PIPE Financing, net 188, 681 Cash acquired in connection with the reverse recapitalization 4, 940 Proceeds from issuance of common stock 54 Net cash provided by financing activities 449, 539 Net increase in cash and cash equivalents 61, 575 Cash at beginning of period — Cash and cash equivalents at end of period $ 61, 575 Supplemental disclosures of non- cash operating and financing activities: Operating lease liability arising from obtaining operating right- of- use asset $ 982 Assets acquired in connection with the reverse capitalization $ 114 Other liabilities assumed in connection with the reverse recapitalization $ (54) Non- cash accrued interest on convertible note converted to common stock $ 1, 468 Non- cash exchange of Pre- Merger Oruka Series A preferred stock for Series B convertible preferred stock $ 2, 931 Conversion of Series A non- voting convertible preferred stock to common stock $ 52, 834 Reclassification of the Paruka warrant from liability to equity $ 10, 357 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 1. Nature of the Business and Basis of Presentation Background and Basis of Presentation Oruka Therapeutics, Inc., together with its subsidiaries (collectively, the “ Company ”), formerly known as ARCA biopharma, Inc. (“ ARCA ”), is a clinical- stage biotechnology company that is the result of the reverse recapitalization discussed below. Prior to the reverse recapitalization, the private company Oruka Therapeutics, Inc. (“ Pre- Merger Oruka ”) was established and incorporated under the laws of the state of Delaware on February 6, 2024 (referred to in the Notes as the inception of the Company). The Company is headquartered in Menlo Park, California. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (“ PsO ”) and other inflammatory and immunology (“ I & I ”) indications. The accompanying consolidated financial statements reflect the operations of the Company and its wholly- owned subsidiaries. Intercompany balances and transactions have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared in conformity with United States (“ U. S. ”) generally accepted accounting principles (“ GAAP ”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ ASC ”) and Accounting Standards Updates (“ ASU ”) of the Financial Accounting Standards Board (“ FASB ”). Reverse Recapitalization and Pre- Closing Financing On August 29, 2024 (the “ Merger Closing ”), the Company completed the acquisition (the “ Merger ”) of Pre- Merger Oruka pursuant to an Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024 (the “ Merger Agreement ”). Following the transactions contemplated by the Merger Agreement, Pre- Merger Oruka merged with and into Atlas Merger Sub Corp., a wholly owned subsidiary of ARCA and following that, Pre- Merger Oruka then merged with and into Atlas Merger Sub II, LLC (“ Second Merger Sub ”), with Second Merger Sub being the surviving entity. Second Merger Sub changed its corporate name to “ Oruka Therapeutics Operating Company, LLC. ” On August 29, 2024, the Company changed its name from “ ARCA biopharma, Inc. ” to “ Oruka Therapeutics, Inc. ” and its Nasdaq ticker symbol from “ ABIO ” to “ ORKA ”. Following consummation of the Merger, the Company effected a 1- for- 12 reverse stock split (the “ Reverse Stock Split ”) of the common stock, par value $ 0. 001 per share, of the Company (“ Company Common Stock ”), which became effective on September 3, 2024. The Company Common Stock commenced trading on a post- Reverse Stock Split, post- Merger basis at the opening of trading on September 3, 2024. The Company is led by the Pre- Merger Oruka management team and remains focused on developing biologics to optimize the treatment of inflammatory skin diseases. Immediately prior to the execution and delivery of the Merger Agreement on April 3, 2024, certain new and existing investors of Pre- Merger Oruka entered into a subscription agreement with Pre- Merger Oruka (the “ Subscription Agreement ”), pursuant to which, and on the terms and subject to the conditions of which, immediately prior to the Closing, those investors purchased shares of common stock of Pre- Merger Oruka (“ Pre- Merger Oruka Common Stock ”) and Pre- Merger Oruka pre- funded warrants for gross proceeds of approximately $ 275. 0 million (which includes $ 25. 0 million of proceeds previously received from the issuance of the Convertible Note (as defined in Note 7) and accrued interest on such note which converted to shares of Pre- Merger Oruka Common Stock) (the “ Pre- Closing Financing ”). The Company incurred transaction costs of $ 20. 5 million which was recorded as a reduction to additional paid- in capital in the consolidated financial statements. At the Merger Closing, the shares of Pre- Merger Oruka Common Stock and Pre- Merger Oruka pre- funded warrants issued pursuant to the Subscription Agreement were converted into shares of Company Common Stock and pre- funded warrants of Company Common Stock in accordance with the Exchange Ratio (defined below). In accordance with an Exchange Ratio determined by terms of the Merger Agreement and upon the effective time of the First Merger (the “ First Effective Time ”), (i) each then- issued and outstanding share of Pre- Merger Oruka Common Stock including outstanding and unvested Pre- Merger Oruka restricted stock and shares of Pre- Merger Oruka Common Stock issued in connection with the Subscription Agreement, were converted into the right to receive a number of shares of Company Common Stock, equal to the Exchange Ratio of 6. 8569 shares of Company Common Stock, which were subject to the same vesting provisions as those immediately prior to the Merger, (ii) each share of Pre- Merger Oruka Series A convertible preferred stock, par value $ 0. 0001 (“ Pre- Merger Oruka Series A Preferred Stock ”), outstanding immediately prior to the First Effective Time was converted into the right to receive a number of shares of ARCA Series B non- voting convertible preferred stock, par value $ 0. 001 per share (“ Company Series B Preferred Stock ”), which are convertible into shares of Company Common Stock, at a conversion ratio of approximately 83: 3332: 1 (iii) each outstanding option to purchase Pre- Merger Oruka Common Stock was converted into an option to purchase shares of Company Common Stock, (iv) each outstanding warrant to purchase shares of Pre- Merger Oruka Common Stock was converted into a warrant to purchase shares of Company Common Stock, and (v) each share of Company Common Stock issued and outstanding at the First Effective Time remain issued and outstanding in accordance with its terms and such shares. Subsequent to the close of the merger, the common stock shares were then subject to the reverse stock split of 1- for- 12 effected on September 3, 2024. As part of the Pre- Closing Financing and the Merger Closing, investors in the Pre- Closing Financing received 22, 784, 139 shares of Company Common Stock in exchange for 39, 873, 706 shares of Pre- Merger Oruka Common Stock (which includes the issuance of 2, 722, 207 shares of Company Common Stock in exchange for 4, 764, 032 shares of Pre- Merger Oruka Common Stock on the conversion of Convertible Note along with the accrued interest through the conversion date) and 5, 522, 207 Company pre- funded warrants in exchange for 9, 664, 208 Pre- Merger pre- funded warrants. The Merger was accounted for as a reverse recapitalization in accordance with U. S. GAAP. Under this method of accounting, Pre- Merger Oruka was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the fact that, immediately following the Merger: (i) Pre- Merger Oruka stockholders own a substantial majority of the voting rights in the combined company; (ii) Pre- Merger Oruka’ s largest stockholders retain the largest interest in the combined company; (iii) Pre- Merger Oruka designated a majority of the initial members of the board of directors of the combined company; and (iv) Pre- Merger Oruka’ s executive management team became the management team of the combined company. Accordingly, for accounting purposes: (i) the Merger was treated as the equivalent of Pre- Merger Oruka issuing stock to acquire the net assets of ARCA, and (ii) the reported historical operating results of the combined company prior to the Merger are those of Pre- Merger Oruka. Additional information regarding the Merger is included in Note 3. On September 3, 2024, the Company effected the Reverse Stock Split, a 1- for- 12 reverse stock split of Company Common Stock. The par value per share and the number of authorized shares were not adjusted as a result of the Reverse Stock Split. The shares of Company Common Stock underlying outstanding stock options, common stock warrants and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. All references to common stock, options to purchase common stock, outstanding common stock warrants, common stock share data, per share data, and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented, unless otherwise specifically indicated or the context otherwise requires. On September 11, 2024, the Company entered into a Securities Purchase Agreement for a private placement (the “ PIPE Financing ”) with certain institutional and accredited investors. The closing of the PIPE Financing occurred on September 13, 2024. Pursuant to the Securities Purchase Agreement, the investors purchased an aggregate of 5, 600, 000 shares of Company Common Stock at a purchase price of $ 23. 00 per share, an aggregate of 2, 439 shares of the Company’ s Series A non- voting convertible preferred stock, par value $ 0. 001 per share (“ Company Series A Preferred Stock ”), at a purchase price of $ 23, 000. 00 per share (each Company Series A Preferred Stock is convertible into 1, 000 shares of Company Common Stock), and pre- funded warrants to purchase an aggregate of 680, 000 shares of Company Common Stock at a purchase price of $ 22. 999 per pre- funded warrant, for aggregate net proceeds of approximately $ 188. 7 million (net of issuance costs of $ 11. 9 million). F- 8 Liquidity and Going Concern Since its inception, the Company has devoted substantially all of its resources to advancing the development of its portfolio of programs, organizing and staffing the Company, business planning, raising capital, and providing general and administrative support for these operations. Current and future programs will require significant research and development efforts, including preclinical and clinical trials, and regulatory approvals to commercialization. Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination of equity offerings and debt financings. The Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception. For the period from February 6, 2024 (inception) to December 31, 2024, the Company has incurred a net loss of $ 83. 7 million and used net cash of $ 57. 8 million for its operating activities. As of December 31, 2024, the Company had cash, cash equivalents, and marketable securities of $ 393. 7 million. The Company’ s management expects that the existing cash, cash equivalents, and marketable securities will be sufficient to fund the Company’ s operating plans for at least twelve months from the date these consolidated financial statements were issued. The Company expects that its research and development and general and administrative costs will continue to increase significantly, including in connection with conducting future pre- clinical activities and clinical trials and manufacturing for its existing product candidates and any future product candidates to support commercialization and providing general and administrative support for its operations, including the costs associated with operating as a public company. The Company’ s ability to access capital when needed is not assured and, if capital is not available to the Company when, and in the amounts needed, the Company may be required to significantly curtail, delay, or discontinue one or more of its research or development programs or the commercialization of any product candidate, or be unable to expand its operations or otherwise capitalize on the Company’ s business opportunities, as desired, which could materially harm the Company’ s business, financial condition and results of operations. 2. Summary of Significant Accounting Policies Use of Estimates The preparation of the Company’ s consolidated financial statements in conformity with U. S. GAAP requires management to make estimates, assumptions, and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected within these consolidated financial statements include but are not limited to research and development expenses and related prepaid or accrued costs and the valuation of stock- based compensation awards and related expenses. The Company bases its estimates on known trends and other market- specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Actual results could differ materially from those estimates or assumptions. Concentrations of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities. The Company’ s investment policy limits investments to high credit quality securities issued by the U. S. government, U. S. government- sponsored agencies, highly rated banks, and corporate issuers, subject to certain concentration limits and restrictions on maturities. The Company’ s cash, cash equivalents and marketable securities are held by financial institutions that management believes are of high credit quality. The financial instruments that potentially

subject the Company to a concentration of credit risk consist principally of cash deposits. Accounts at the Company' s U. S. banking institution are insured by the Federal Deposit Insurance Corporation (" FDIC ") up to $ 250, 000 per depositor. As of December 31, 2024, the balance at the Company' s U. S. banking institution exceeded the FDIC limits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its accounts are monitored by management to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents, and bond issuers. F- 9 The Company is dependent on third- party organizations to research, develop, manufacture, and process its product candidates for its development programs, including its two most advanced programs, ORKA- 001 and ORKA- 002. The Company expects to continue to be dependent on a small number of manufacturers to supply it with its requirements for all products. The Company' s research and development programs could be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Company' s research and development activities are performed under its agreements with Paragon Therapeutics, Inc. (" Paragon ") (see Note 12). Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to be cash equivalents. The cash equivalents were comprised of investments in money market funds, U. S. treasury securities, U. S. government agency securities, and debt securities and are stated at fair value. Marketable Securities The Company invests in marketable securities, primarily securities issued by the U. S. government and its agencies, commercial paper and corporate debt securities. The Company' s marketable securities are classified as available- for- sale and reported at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive loss. For available- for- sale debt securities in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security' s amortized cost basis is written down to fair value and recognized in other income (expense) in the results of operations. For available- for- sale debt securities that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, an allowance is recorded for the difference between the present value of cash flows expected to be collected and the amortized cost basis of the security. Impairment losses attributable to credit loss factors are charged against the allowance when management believes an available- for- sale security is uncollectible or when either of the criteria regarding intent or requirement to sell is met. Any unrealized losses from declines in fair value below the amortized cost basis as a result of non- credit loss factors are recognized as a component of accumulated other comprehensive loss, net of unrealized gains. Realized gains and losses and declines in fair value, if any, on available- for- sale securities are included in other income, net, in the results of operations. Marketable securities with stated maturities of greater than three months from the date of purchase but less than one year from the consolidated balance sheet date are classified as current, while marketable securities with maturities in one year or beyond one year from the consolidated balance sheet date are classified as long- term. The cost of securities sold is determined using the specific- identification method. Interest earned and adjustments for the amortization of premiums and discounts on investments are included in interest income on the consolidated statements of operations and comprehensive loss. Debt Issuance Costs Debt issuance costs incurred in connection with the Convertible Note (see Note 7) are recorded as a reduction of the carrying value of the notes payable liability on the Company' s balance sheet and are amortized to interest expense over the term of the loan using the effective interest method. At the effective time of the Merger the Converted Note was converted to common stock and is no longer on the balance sheet as of December 31, 2024. Subscription Receivable The Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable is paid prior to the date the financial statement is available to be issued. F- 10 Fair Value Measurements Certain assets and liabilities are carried at fair value under U. S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: ● Level 1 — Quoted prices in active markets that are identical assets or liabilities. ● Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. ● Level 3 — Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies, and similar techniques. The Company' s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy described above (see Note 4). The carrying values of the Company' s prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to their relatively short maturity period. Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight- line method over the estimated useful life of each asset as follows: Estimated Useful Life Furniture and fixtures 3- 5 years Computer and office equipment 3- 5 yearsClassification of Convertible Preferred Stock Prior to the reverse recapitalization, the Company had classified its Pre- Merger Oruka Series A Preferred Stock outside of stockholders' equity on the Company' s consolidated balance sheet because the holders of such stock have certain liquidation rights in the event of a deemed liquidation event that, in certain situations, is not solely within the control of the Company and would require the redemption of the then- outstanding convertible preferred stock. Upon the closing of the Merger, the Company converted its Pre- Merger Oruka Series A Preferred Stock to Company Series B Preferred Stock and has classified the Company Series B Preferred Stock within stockholders' equity on its consolidated balance sheet because the Company Series B Preferred Stock is not redeemable or puttable to the Company by the holder under any circumstances. In connection with the PIPE Financing (see Note 1) the Company issued Company Series A Preferred Stock, and has classified the Company Series A Preferred Stock outside of stockholders' equity on the Company' s consolidated balance sheet because the holders of such stock have certain rights (see Note 8) that, in certain situations, is not solely within the control of the Company and would require the redemption of the then- outstanding convertible preferred stock. In November 2024, the Company Series A Preferred Stock shares were converted to common stock, and as of December 31, 2024, there were no shares of Company Series A Preferred Stock outstanding. F- 11 Note Payable to Related Party The Company accounted for the Convertible Note (as defined in Note 7) at amortized cost. The Company considered if optional conversion features are required to be bifurcated and separately accounted for as a derivative. Costs related to the issuance of the Convertible Note were recorded as a debt discount, amortized over the term of the Convertible Note (see Note 7) and were accounted for as interest expense in other income (expenses) within the consolidated statement of operations and comprehensive loss using the effective interest method. At the effective time of the Merger, shares of Pre- Merger Oruka Common Stock issued pursuant to the conversion of the Convertible Note (including accrued interest) automatically converted into shares of Company Common Stock (see Note 1). Research and Development Contract Costs Accruals The Company records the costs associated with research studies and manufacturing development as incurred. These costs are a significant component of the Company' s research and development expenses, with a substantial portion of the Company' s ongoing research and development activities conducted by third- party service providers, including contract research organizations (" CROs ") and contract manufacturing organizations (" CMOs "), and the Company' s related- party Paragon (see Note 12). The Company accrues for expenses resulting from obligations under its two antibody discovery and option agreements (the " Option Agreements ") (see Note 12), by and among Paragon, Paruka Holding LLC (" Paruka "), an entity formed by Paragon as a vehicle to hold equity in the Company, and the Company as well as agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrual balance in each reporting period. If advance payments are made to Paragon, a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be expensed as the contracted services are performed. Changes in these estimates that result in material changes to the Company' s accruals could materially affect the Company' s results of operations. As of December 31, 2024, the Company has not experienced any material deviations between accrued and actual research and development expenses. Leases At the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies a lease as either an operating or finance lease and recognizes a right- of- use (" ROU ") asset and a current and non- current lease liability, as applicable, in the balance sheet if the lease has a term greater than one year. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise its option. At the lease commencement date, operating lease liabilities and their corresponding ROU assets are recorded at the present value of future minimum lease payments over the expected remaining lease term. The Company determines **the present value of lease payments using the implicit rate, if it is readily determinable, or the risk- free discount rate for a period comparable with that of the lease term. For operating leases, lease expense for lease payments is recognized on a straight- line basis over the lease term. For finance leases, lease expense includes amortization expense of the ROU asset recognized on a straight- line basis over the lease term and interest expense recognized on the finance lease liability. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments, incentives received or initial direct costs. As of December 31, 2024, the Company has one operating lease and no finance leases. The Company accounts for lease and non- lease components related to operating leases as a single lease component. The Company has elected that costs associated with leases having an initial term of 12 months or less are recognized in the consolidated statement of operations and comprehensive loss on a straight- line basis over the lease term and are not recorded on its consolidated balance sheets. Variable lease expense is recognized as incurred and consists primarily of real estate taxes, utilities, and other office space related expenses. F- 12 Segment Reporting The Company operates as a single reportable and operating segment. Its Chief Executive Officer, serving as the Chief Operating Decision Maker (" CODM "), oversees operations on an aggregated basis to allocate resources effectively. In assessing the Company' s financial performance, the CODM regularly reviews total operating expenses and consolidated net loss. Research and Development Costs Research and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock- based compensation, employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities, as well as allocated human resource costs, information technology costs, and facility- related costs, including rent, maintenance, utilities, and depreciation. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses on the accompanying consolidated balance sheet. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable advance payments represent a one- time cost for obtaining goods or services, with anticipated benefits to be utilized within a year of period end, the payment is expensed immediately. General and administrative expenses consist primarily of salaries and bonuses, stock- based compensation, employee benefits, finance and administration costs, patent and intellectual property costs, professional fees, as well as allocated human resource costs, information technology costs, and facility- related costs, including rent, maintenance, utilities and depreciation. Commitments and Contingencies The Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities. The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but not probable; however, it discloses the range of reasonably possible losses. As of December 31, 2024, no liabilities were recorded for loss contingencies (see Note 13). The Company estimates the fair value of its stock awards using the Black- Scholes option pricing model, which uses as inputs the fair value of the Company' s common stock, and certain management estimates, including the expected stock price volatility, the expected term of the award, the risk- free interest rate, and expected dividends. Expected volatility is calculated based on reported volatility data for a representative group of publicly traded companies for which historical information is available. The Company selects companies with comparable characteristics with historical share price information that approximates the expected term of the equity- based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies' shares during the equivalent period that approximates the calculated expected term of the stock options. The Company will continue to apply this method until a sufficient amount of historical information regarding the volatility of its stock price becomes available. The risk- free interest rate is based on the U. S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. For employee and non- employee awards (except the Paruka warrant) the Company uses the simplified method, under which the expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to lack of historical exercise data. For the Paruka warrant, the contractual term is used for the expected term. The expected dividend yield is assumed to be zero as the Company has no current plans to pay any dividends on common stock. The Company measures restricted common stock awards (" RSAs ") using the difference, if any, between the purchase price per share of the award and the fair value of the Company' s common stock at the date of grant. F- 13 The Company grants stock options, restricted stock awards, and warrants that are subject to service or performance- based vesting conditions. Compensation expense for awards to employees and directors with service- based vesting conditions is recognized using the straight- line method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards to non- employees with service- based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. As of each reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation expense until it is probable that the performance- based vesting condition will be achieved. The Company has issued stock options, warrants, and RSAs with service- based and performance- based vesting conditions. The Company recognizes the compensation expense for the option to purchase common**

stock under the Employee Stock Purchase Plan (“ ESPP ”), based on the fair value of the common stock estimated using the closing price of the Company’ s common stock as reported on the date of offering, less the purchase discount percentage provided for in the plan. The Company classifies stock- based compensation expense in its consolidated statement of operations and comprehensive loss in the same manner in which the award recipient’ s payroll costs are classified or in which the award recipient’ s service payments are classified, as applicable. Comprehensive Loss Comprehensive loss includes net loss as well as other changes in stockholders’ equity that result from transactions and events other than those with stockholders. The Company’ s unrealized gains and losses on marketable securities represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the consolidated statement of comprehensive loss. Net Loss per Share Attributable to Stockholders Basic and diluted net loss attributable to stockholders per share is presented in conformity with the two- class method required for participating securities (Pre- Merger Oruka Series A Preferred Stock). Basic earnings per share is computed by dividing net income available to each class of shares by the weighted- average number of shares of common stock and participating securities outstanding during the period. Pre- funded warrants were included as the exercise price is negligible and these warrants are fully vested and exercisable. Company Series A Preferred Stock and Company Series B Preferred Stock share the same characteristics as Common Stock and have no substantive preference attributed to them and, accordingly, have been considered as classes of Common Stock in the computation of net loss per share regardless of their legal form. Net loss is allocated to common stock based on its proportional ownership on an as- converted basis. Net loss is not allocated to participating securities as they do not have an obligation to fund losses. The weighted- average number of shares outstanding of common stock reflects changes in ownership over the periods presented. See Note 8 — Convertible Preferred Stock and Stockholders’ Equity. Diluted net loss per share is computed by dividing the net loss attributable to stockholders adjusted for income (expenses), net of tax, related to any diluted securities, by the weighted- average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of this calculation, stock options to purchase common stock, employee warrants to purchase common stock, and unvested RSAs are considered potential dilutive common shares. The Company generated a net loss for the periods presented. Accordingly, basic and diluted net loss per share is the same because the inclusion of the potentially dilutive securities would be anti- dilutive. Other income, net, consists of interest earned on the Company’ s cash, cash equivalents, and marketable securities; interest expense on the convertible note from a related party and foreign currency transactions gains and losses. F- 14 The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company’ s tax returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis of assets and liabilities using enacted tax rates in effect for the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two- step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50 % likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or penalties related to uncertain tax positions as of December 31, 2024. Recently Adopted Accounting Pronouncements In November 2023, the FASB issued ASU 2023- 07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ ASU 2023- 07 ”), which enhances the segment disclosure requirements for public entities on an annual and interim basis. Under this standard, public entities will be required to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss. Additionally, current annual disclosures about a reportable segment’ s profit or loss and assets will be required on an interim basis. Entities will also be required to disclose information about the CODM’ s title and position at the Company along with an explanation of how the CODM uses the reported measures of segment profit or loss in their assessment of segment performance and deciding how to allocate resources. Finally, ASU 2023- 07 requires all segment disclosures for public entities that have only a single reportable segment. The amendments in ASU 2023- 07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company adopted ASU 2023- 07 in 2024 and additional required disclosures have been included in Note 10. In December 2023, the FASB issued ASU 2023- 09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU expands disclosures in an entity’ s income tax rate reconciliation table and disclosures regarding taxes paid both in the U. S. and foreign jurisdictions. This update is effective beginning with the Company’ s 2025 fiscal year annual reporting period. The Company is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements. In November 2024, the FASB issued ASU 2024- 03, Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures (Subtopic 220- 40): Disaggregation of Income Statement Expenses. This ASU requires more detailed disclosures, on an annual and interim basis, about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. This ASU may be applied either prospectively or retrospectively. The Company is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements. F- 15 3. Reverse Recapitalization and Pre- Closing Financing As described within the Reverse Recapitalization and Pre- Closing Financing section in Note 1, on August 29, 2024, the reverse recapitalization between Pre- Merger Oruka and ARCA was consummated. The Merger was accounted for as a reverse recapitalization in accordance with U. S. GAAP. At the effective time of the Merger, substantially all of the assets of ARCA consisted of cash and cash equivalents and other nominal non- operating assets and liabilities. No goodwill or intangible assets were recognized. As part of the recapitalization, the Company acquired the assets and liabilities listed below (in thousands): August 29, 2024 Cash and cash equivalents $ 4, 940 Other current assets 114 Accrued liabilities (54) Net assets acquired $ 5, 000 4. Fair Value Measurements The following tables present the Company’ s fair value hierarchy for financial assets measured as of December 31, 2024 (in thousands): December 31, 2024 Level 1 Level 2 Level 3 Total Cash equivalents Money market funds $ 6, 350 $ — $ — $ 6, 350 U. S. treasury securities — 19, 660 — 19, 660 U. S. government agency securities — 3, 988 — 3, 988 Commercial papers — 22, 177 — 22, 177 Total cash equivalents 6, 350 45, 825 — 52, 175 Marketable securities Marketable securities, current U. S. treasury securities — 190, 792 — 190, 792 U. S. government agency securities — 12, 966 — 12, 966 Commercial papers — 34, 811 — 34, 811 Corporate debt securities — 75, 504 — 75, 504 Total marketable securities, current — 314, 073 — 314, 073 Marketable securities, long- term U. S. treasury securities — 13, 607 — 13, 607 U. S. government agency securities — 4, 462 — 4, 462 Total marketable securities, long- term — 18, 069 — 18, 069 Total cash equivalents and marketable securities $ 6, 350 $ 377, 967 $ — $ 384, 317 There were no transfers in or out of Level 3 during the period from February 6, 2024 (inception) to December 31, 2024. F- 16 5. Cash equivalents and marketable Securities Cash equivalents and marketable securities, which are classified as available- for- sale, consisted of the following as of December 31, 2024 (in thousands): December 31, 2024 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash equivalents Money market funds $ 6, 350 $ — $ — $ 6, 350 U. S. treasury securities 19, 656 4 — 19, 660 U. S. government agency securities 3, 988 — — 3, 988 Commercial papers 22, 180 — (3) 22, 177 Total cash equivalents 52, 174 4 (3) 52, 175 Marketable securities Marketable securities, current U. S. treasury securities 190, 748 55 (11) 190, 792 U. S. government agency securities 12, 967 1 (2) 12, 966 Commercial papers 34, 808 3 — 34, 811 Corporate debt securities 75, 537 7 (40) 75, 504 Total marketable securities, current 314, 060 66 (53) 314, 073 Marketable securities, long- term U. S. treasury securities 13, 639 — (32) 13, 607 U. S. government agency securities 4, 485 — (23) 4, 462 Total marketable securities, long- term 18, 124 — (55) 18, 069 Total cash equivalents and marketable securities $ 384, 358 $ 70 $ (111) $ 384, 317 The following table summarizes the available- for- sale securities in an unrealized loss position, aggregated by major security type and length of time in a continuous unrealized loss position, for which an allowance for credit losses was not recorded as of December 31, 2024, (in thousands): December 31, 2024 Less than 12 months months or longer Total Fair Value Unrealized Losses Fair Value Unrealized Losses Fair Value Unrealized Losses Cash equivalents Commercial papers $ 18, 199 $ (3) $ — $ — $ 18, 199 $ (3) Marketable securities Marketable securities, current U. S. treasury securities 49, 904 (11) — — 49, 904 (11) U. S. government agency securities 4, 713 (2) — — 4, 713 (2) Corporate debt securities 39, 468 (40) — — 39, 468 (40) Marketable securities, long- term — — U. S. treasury securities 13, 607 (32) — — 13, 607 (32) U. S. government agency securities 4, 462 (23) — — 4, 462 (23) Total $ 130, 353 $ (111) $ — $ — $ 130, 353 $ (111) The Company evaluated its securities for credit losses and considered the decline in market value to be primarily attributable to current economic and market conditions and not to a credit loss or other factors. Additionally, the Company does not intend to sell the securities in an unrealized loss position and it is not more likely than not that the Company will be required to sell the securities before recovery of the unamortized cost basis, which may be at maturity. There were no material realized gains or realized losses on marketable securities for the period presented. Given the Company’ s intent and ability to hold such securities until recovery, and the lack of significant change in credit risk of these investments, the Company does not consider these marketable securities to be impaired as of December 31, 2024. As of December 31, 2024, the Company did not record an allowance for credit losses. F- 17 The following table summarizes the contractual maturities of the Company’ s marketable securities at estimated fair value (in thousands): December 31, 2024 Due in one year or less $ 314, 073 Due in 1- 2 years 18, 069 Total $ 332, 142 6. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands): December 31, 2024 Accrued employee compensation and benefits $ 2, 041 Accrued professional and consulting 221 Accrued research and development 1, 084 Total $ 3, 346 7. Note Payable with Related Party In March 2024, Pre- Merger Oruka entered into a Series A Preferred Stock and Convertible Note Purchase Agreement (the “ Purchase Agreement ”) with Fairmount Healthcare Fund II, L. P. (“ Fairmount ”), whereby Pre- Merger Oruka issued a convertible note (the “ Convertible Note ”), with an initial principal amount of $ 25. 0 million that, at the time of issuance, could be converted into Pre- Merger Oruka Series A Preferred Stock (or a series of preferred shares that is identical in respect to the shares of preferred shares issued in its next equity financing) or shares of Pre- Merger Oruka Common Stock in exchange for aggregate proceeds of $ 25. 0 million. The Convertible Note accrued interest at a rate of 12. 0 % per annum. At issuance, the Convertible Note required all unpaid interest and principal to mature on December 31, 2025 (the “ Maturity Date ”) and prepayment was not permitted without prior written consent of Fairmount. The Company assessed all terms and features of the Convertible Note in order to identify any potential embedded features that would require bifurcation. As part of this analysis, the Company assessed the economic characteristics and risks of the embedded features. The Company determined that the share settled redemption feature was clearly and closely related to the debt host and did not require separate accounting. The Company determined that the conversion options of the Convertible Note were not clearly and closely associated with a debt host. However, these features did not meet the definition of a derivative under ASC 815, Derivatives and Hedging, and as a result, did not require separate accounting as a derivative liability. The Company paid debt issuance costs of less than $ 0. 1 million in relation to the Convertible Note. The debt issuance costs were reflected as a reduction of the carrying value of Convertible Note on the consolidated balance sheet and were being amortized as interest expense over the term of the Convertible Note using the effective interest method. For the period from February 6, 2024 (inception) to December 31, 2024, the Company recognized interest expenses related to the Convertible Note of $ 1. 5 million, which includes non- cash interest expense related to the amortization of debt issuance. F- 18 Immediately prior to the completion of the Merger (see Note 1), the Convertible Note was converted into shares of Pre- Merger Oruka Common Stock based on the aggregate principal amount of $ 25. 0 million, plus unpaid accrued interest of $ 1. 5 million divided by the conversion price which was determined based upon the Company’ s fully- diluted capitalization immediately prior to the Merger. At the effective time of the Merger, the Pre- Merger Oruka Common Stock issued upon the conversion of the Convertible Note (including accrued interest) automatically converted into 2, 722, 207 shares of Company Common Stock. As of December 31, 2024, the Convertible Note is not outstanding. 8. Convertible Preferred Stock and Stockholders’ Equity Pre- Funded Warrants In August 2024, pursuant to the Subscription Agreement and immediately prior to the Closing, certain new and current investors purchased pre- funded warrants, which, at the effective time of the Merger, were exercisable for 5, 522, 207 shares of Company Common Stock at a purchase price of approximately $ 9. 70 per warrant. After the Merger, there are 5, 522, 207 pre- funded warrants outstanding and are exercisable for 5, 522, 207 shares of the Company Common Stock at an exercise price of $ 0. 01 per share. In September 2024, in connection with the PIPE Financing, the Company issued and sold 680, 000 pre- funded warrants, at a purchase price of $ 22. 999 per warrant, exercisable for 680, 000 shares of Company Common Stock at an exercise price of $ 0. 001 per share. The pre- funded warrants were recorded as a component of stockholders’ equity within additional paid- in- capital and have no expiration date. As of December 31, 2024, none of the pre- funded warrants have been exercised and 6, 202, 207 pre- funded warrants remain outstanding. Employee Warrants In July 2024, Pre- Merger Oruka entered into a Subscription Agreement that provided for, among other things, the issuance of warrants to certain of Pre- Merger Oruka’ s employees and directors immediately prior to the closing of the Merger. During the period from February 6, 2024 (inception) to December 31, 2024, 3, 054, 358 employee warrants were issued at an exercise price of $ 7. 80 per warrant. These warrants vest over a period of four years. Per the terms of the Employee Warrant Agreement, the holders of the Company’ s warrants shall not have any of the rights or privileges of a stockholder of the Company in respect of any shares purchasable upon the exercise of the warrant or any portion thereof unless and until a certificate or certificates representing such shares have been issued or a book entry representing such shares has been made and such shares have been deposited with the appropriate registered book- entry custodian. The Company recognizes compensation cost related to warrants on a straight- line basis over the requisite service period, which is the period in which the related services are received. As of December 31, 2024, none of the warrants have been exercised and 3, 054, 358 warrants remain outstanding. Convertible Preferred Stock In March 2024, Pre- Merger Oruka issued and sold an aggregate of 20, 000, 000 shares of Pre- Merger Oruka Series A Preferred Stock to Fairmount (see Note 15), at a purchase price of approximately $ 0. 15 per share, for aggregate gross proceeds of $ 3. 0 million. Pre- Merger Oruka incurred less than $ 0. 1 million of issuance costs in connection with this transaction. Upon the issuance of the Pre- Merger Oruka Series A Preferred Stock, the Company assessed the embedded conversion and liquidation features of the securities as described below and determined that such features did not require the Company to separately account for these features. In August 2024, upon the closing of the Merger, the Company converted the Pre- Merger Oruka Series A Preferred Stock to 137, 138 shares of Company Series B Preferred Stock. In September 2024, in connection with the PIPE Financing, the Company issued and sold an aggregate of 2, 439 shares of the Company Series A Preferred Stock at a purchase price of $ 23, 000. 00 per share. In November 2024, the 2, 439 shares of the Company Series A Preferred Stock were converted to 2, 439, 000 shares of Company Common Stock. As of December 31, 2024, there are no outstanding shares of Company Series A Preferred Stock. F- 19 As of December 31, 2024, convertible preferred stock consisted of the following (in thousands, except share data): December 31, 2024 Preferred Stock Authorized Preferred Stock Issued and Outstanding Carrying Value Common Stock Issuable Upon Conversion Series B convertible preferred stock 251, 504 137, 138 2, 931 11, 428, 149 Pursuant to the Certificate of Designation of Preferences, Rights and Limitations of the Series A Non- Voting Convertible Preferred Stock (the " Series A Certificate of Designation ") filed in connection with the PIPE Financing, holders of Company Series A Preferred Stock were entitled to receive dividends on shares of Company Series A Preferred Stock equal to, on an as- if- converted- to- Company Common Stock basis, and in the same form as, dividends actually paid on shares of Company Common Stock. Except as provided in the Series A Certificate of Designation or as otherwise required by law, the Company Series A Preferred Stock did not have voting rights. The Company Series A Preferred Stock shall rank on parity with the Company Common Stock and Company Series B Preferred Stock upon any liquidation, dissolution or winding- up of the Company. Subject to the terms and limitations contained in the Series A Certificate of Designation, the Company Series A Preferred Stock issued in the PIPE Financing will not become convertible until the Company' s stockholders approve the conversion of the Company Series A Preferred Stock into shares of Company Common Stock in accordance with the listing rules of the Nasdaq Stock Market (the " Stockholder Approval "), which, on issuance, resulted in the Company Series A Preferred Stock being classified outside of stockholders' equity on the Company' s consolidated balance sheet. Following the Stockholder Approval in November 2024, each share of Company Series A Preferred Stock was automatically converted into 1, 000 shares of Company Common Stock. Pursuant to the Certificate of Designation of Preferences, Rights and Limitations of the Series B Non- Voting Convertible Preferred Stock (the " Series B Certificate of Designation ") filed in connection with the Merger, holders of Company Series B Preferred Stock are entitled to receive dividends on shares of Company Series B Preferred Stock equal to, on an as- if- converted- to- Company Common Stock basis, and in the same form as, dividends actually paid on shares of Company Common Stock. Except as provided in the Series B Certificate of Designation or as otherwise required by law, the Company Series B Preferred Stock does not have voting rights. The Company Series B Preferred Stock shall rank on parity with the Company Common Stock as to the distribution of assets upon any liquidation, dissolution, or winding- up of the Company. Each share of Company Series B Preferred Stock is convertible at the option of the holder, at any time, and without the payment of additional consideration by the holder. As of December 31, 2024, each outstanding share of Company Series B Preferred Stock was convertible into common stock at a ratio of approximately 83. 3332: 1. Paruka Warrant On December 31, 2024, the Company settled its 2024 obligations under the Paruka Warrant Obligation (defined below) by issuing Paruka a warrant to purchase 596, 930 shares of Company Common Stock at an exercise price of $ 19. 39 per share. The warrant has a term of 10 years, is fully vested, and is exercisable in part or full at any time during the term of the warrant. As of December 31, 2024, the warrant issued under the Paruka Warrant Obligation is outstanding and unexercised. See Note 9 for additional information on the Paruka Warrant Obligation. As of December 31, 2024, the Certificate of Incorporation provides for 545, 000, 000 authorized shares of Company Common Stock. As of December 31, 2024, 37, 440, 510 shares of Company Common Stock were issued and outstanding, including 2, 207, 553 shares of RSAs issued and outstanding. F- 20 As of December 31, 2024, the Company had common stock reserved for future issuance as follows: December 31, 2024 Shares issuable on conversion of Company Series B Preferred Stock 11, 428, 149 Shares issuable upon exercise of pre- funded warrants 6, 202, 207 Shares issuable upon exercise of warrant under the Paruka Warrant Obligation 596, 930 Outstanding and issued stock options 1, 567, 760 Outstanding and issued employee warrants 3, 054, 358 Shares available for grant under 2024 Stock Incentive Plan 4, 246, 324 Shares available for grant under 2024 Employee Stock Purchase Plan 460, 529 Total shares of common stock reserved 27, 556, 257 9. Stock- Based Compensation Equity Incentive Plan The 2024 Equity Incentive Plan (" 2024 Plan ") was adopted by the board of directors of Pre- Merger Oruka on February 6, 2024. The 2024 Plan provided for Pre- Merger Oruka to grant stock options, restricted stock awards, restricted stock units, and other stock- based awards to employees, officers, directors, consultants, and advisors. Equity Incentive Stock options granted under the 2024 Plan generally vest over four years, subject to the participant' s continued service, and expire after ten years, although two non- employee stock options were granted with vesting terms less than four years. As of December 31, 2024, there are no shares of common stock available for issuance. Stock Incentive Plan On August 22, 2024, the 2024 Stock Incentive Plan (" 2024 Stock Plan ") was approved by the Company' s stockholders and on August 29, 2024, the board of directors of the Company (the " Board ") ratified the 2024 Stock Plan. The 2024 Stock Plan allows for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock units, other stockholder- based awards and incentive bonuses. The 2024 Stock Plan is administered by the Compensation Committee of the Board (the " Compensation Committee ") or another committee designated by the Board to administer the Plan. The initial share pool under the 2024 Stock Plan is 4, 634, 891 shares of Company Common Stock. During the period from February 6, 2024 (inception) to December 31, 2024, 388, 567 shares were subject to outstanding stock options, and as of December 31, 2024, there were 4, 246, 324 shares available in the pool. The shares that may be issued under the 2024 Stock Plan will be automatically increased on January 1 of each year beginning in 2025 and ending with a final increase on January 1, 2034 in an amount equal to 5 % of the diluted stock (including Company Common Stock, preferred stock and unexercised pre- funded warrants) on the preceding December 31, unless a lower, or no, increase is determined by the Compensation Committee. Current or prospective employees, officers, non- employee directors, and other independent service providers of the Company and its subsidiaries are eligible to participate in the 2024 Stock Plan. Employee Stock Purchase Plan The 2024 Employee Stock Purchase Plan (the " ESPP ") became effective on August 29, 2024, at which time 463, 489 shares of Company Common Stock were reserved for issuance. Eligible employees may purchase shares of Company Common Stock under the ESPP at 85 % of the lower of the fair market value of the Company Common Stock as of the first or the last day of each offering period. Employees are limited to contributing 15 % of the employee' s eligible compensation and may not purchase more than $ 25, 000 of stock during any calendar year. The ESPP will terminate ten years from the first purchase date under the plan, unless terminated earlier by the board of directors. The shares that may be issued under the ESPP will be automatically increased on January 1 of each year beginning in 2025 and ending with a final increase on January 1, 2034 in an amount equal to 1 % of the diluted stock (including Company Common Stock, preferred stock and unexercised pre- funded warrants) on the preceding December 31, unless a lower, or no increase is determined by the Compensation Committee. During the period from February 6, 2024 (inception) to December 31, 2024, 2, 960 shares of Company Common Stock were issued out of the ESPP and as of December 31, 2024, there were 460, 529 shares of Company Common Stock available in the pool. For the period February 6, 2024 (inception) to December 31, 2024, stock- based compensation expense related to the ESPP was less than $ 0. 1 million. F- 21 Stock Option Valuation The following table summarizes the weighted- average assumptions used in calculating the fair value of the awards for the period from February 6, 2024 (inception) to December 31, 2024: Period from February 6, 2024 (Inception) to December 31, 2024 Expected term (in years) 6. 1 Expected volatility 100. 21 % Risk- free interest rate 4. 26 % Expected dividend yield — Stock Options The following table summarizes the stock option activities under the 2024 Plan and 2024 Stock Plan for the period of February 6, 2024 (inception) through December 31, 2024: Number of Stock Options Outstanding Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (in Years) Aggregate Intrinsic Value (in Thousands) Balance as of February 6, 2024 (inception) — $ — — $ — Granted 1, 567, 760 $ 11. 39 Exercised — $ — Forfeited — $ — Balance as of December 31, 2024 1, 567, 760 $ 11. 39 9. 4 $ 15, 470 Vested and expected to vest, December 31, 2024 1, 567, 760 $ 11. 39 9. 4 $ 15, 470 Exercisable, December 31, 2024 — $ — — $ — The weighted average grant- date fair value per share of stock options granted during the period from February 6, 2024 (inception) to December 31, 2024 was $ 9. 12 per share. Aggregate intrinsic value represents the difference between the estimated fair value of the underlying Company Common Stock and the exercise price of outstanding, in- the- money employee stock options. Restricted Stock Awards In February 2024 and March 2024, the Company issued 2, 207, 553 shares of RSAs to certain employees, directors, and consultants at a price of $ 0. 0001 per share, the then par value of Pre- Merger Oruka Common Stock. Such RSAs have service- based vesting conditions only and vest over a four- year period, during which time all unvested shares are subject to forfeiture in the event the holder' s service with the Company voluntarily or involuntarily terminates. As of December 31, 2024, none of the RSAs had vested. For the period February 6, 2024 (inception) to December 31, 2024, stock- based compensation expense related to RSAs was less than $ 0. 1 million. F- 22 The following table summarizes the RSA activity for the period from February 6, 2024 (inception) through December 31, 2024: Number of RSAs Weighted Average Grant Date Fair Value Unvested balance as of February 6, 2024 (inception) — $ — Granted 2, 207, 553 $ — Unvested balance as of December 31, 2024 2, 207, 553 $ — Option Agreements and the Paruka Warrant Obligation As part of the Option Agreements, on December 31, 2024 the Company granted and on December 31, 2025, will grant Paruka a warrant to purchase a number of shares equal to 1. 00 % of outstanding shares as of the date of the grant on a fully- diluted basis, with an exercise price equal to the fair market value of the underlying shares on the grant date (the " Paruka Warrant Obligation "). The grant dates for the issuance of warrants were expected to be December 31, 2024 and December 31, 2025 as all terms of the award, including number of shares and exercise price, will be known by all parties. The Company determined that the 2024 and 2025 grants are two separate grants, as there would be no obligation for the 2025 grant had the Company exercised or terminated all of the options under the Option Agreements prior to December 31, 2024. The service inception period for the grant precedes the grant date, with the full award being vested as of the grant date with no post- grant date service requirement. Accordingly, the warrant expected to be granted to Paruka was accounted for as a liability on the balance sheet on the service inception date and, after the initial recognition, the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the consolidated statement of operations and comprehensive loss as stock- based compensation expenses under research and development expenses. Accordingly, the Company measured the grant date fair value of the warrant granted on December 31, 2024 at $ 10. 4 million. For the period from February 6, 2024 (inception) to December 31, 2024, $ 10. 4 million was recognized as stock- based compensation expense related to the Paruka Warrant Obligation in the consolidated statement of operations and comprehensive loss. As of December 31, 2024, there was no unamortized expense related to the December 31, 2024 Paruka Warrant Obligation. On issuance of the warrant to Paruka, the fair value of the warrant was reclassified from liability to equity on the consolidated balance sheet as of December 31, 2024. As stated above, on July 3, 2024, the Subscription Agreement was amended and restated, among other things, for employee warrants to be issued to certain Pre- Merger Oruka employees and directors immediately prior to the closing of the Merger. Pursuant to this amendment, during the period from February 6, 2024 (inception) to December 31, 2024, the Company issued 3, 054, 358 warrants at an exercise price of $ 7. 80 per warrant, which are accounted as equity in the consolidated financial statements. The employee warrants were subject to performance and service based vesting requirements and upon completion of the Merger the performance- based requirements had been achieved. The following table summarizes the warrant activity for the period from February 6, 2024 (inception) through December 31, 2024: Number of Employee Warrants Outstanding Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (in Years) Aggregate Intrinsic Value (in Thousands) Balance as of February 6, 2024 (inception) — $ — — $ — Granted 3, 054, 358 $ 7. 80 Exercised — $ — Forfeited — $ — Balance as of December 31, 2024 3, 054, 358 $ 7. 80 9. 5 $ 35, 400 Vested and expected to vest, December 31, 2024 3, 054, 358 $ 7. 80 9. 5 $ 35, 400 Exercisable, December 31, 2024 — $ — — $ — The weighted average grant- date fair value per share of warrants granted during the period from February 6, 2024 (inception) to December 31, 2024 was $ 6. 27 per share. Aggregate intrinsic value represents the difference between the estimated fair value of the underlying Company Common Stock and the exercise price of outstanding, in- the- money warrants. F- 23 The following table summarizes the weighted- average assumptions used in calculating the fair value of the warrants for the period from February 6, 2024 (inception) to December 31, 2024: Period from February 6, 2024 (Inception) to December 31, 2024 Expected term (in years) 6. 1 Expected volatility 99. 02 % Risk- free interest rate 4. 15 % Expected dividend yield — Stock- Based Compensation Expense The following table summarizes the classification of the Company' s stock- based compensation expense in the consolidated statement of operations and comprehensive loss (in thousands): Period from February 6, 2024 (Inception) to December 31, 2024 Research and development $ 11, 992 General and administrative 2, 927 Total $ 14, 919 As of December 31, 2024, total unrecognized compensation cost related to the unvested stock options was $ 12. 7 million, which is expected to be recognized over a weighted average period of approximately 3. 2 years. As of December 31, 2024, total unrecognized compensation cost related to the unvested RSAs was less than $ 0. 1 million, which is expected to be recognized over a weighted average period of 3. 1 years. As of December 31, 2024, the unrecognized compensation cost related to the employee warrants was $ 16. 3 million, which is expected to be recognized over a weighted average period of 3. 3 years. The following table summarizes the award types of the Company' s stock- based compensation expense in the consolidated statement of operations and comprehensive loss (in thousands): Period from February 6, 2024 (Inception) to December 31, 2024 Paruka Warrant Obligation $ 10, 357 Employee warrants 2, 899 Stock options 1, 626 Employee stock purchase plan 37 Total $ 14, 919 F- 24 10. Segment disclosures The Company operates and manages its business activities on a consolidated basis and operates in one reportable segment. The Company operates as a single reportable and operating segment. Its Chief Executive Officer, serving as the Chief Operating Decision Maker (" CODM "), oversees operations on an aggregated basis to allocate resources effectively. In assessing the Company' s financial performance, the CODM regularly reviews total operating expenses and consolidated net loss. The measure of segment assets is reported on the balance sheet as total consolidated assets. The Company' s long- lived assets consist primarily of property and equipment, net. As of December 31, 2024 all of long- lived assets were in the U. S. The table below is a summary of the segment loss from operations, including significant segment expenses (in thousands): Period from February 6, 2024 (Inception) to December 31, 2024 Research and development personnel- related (excluding stock- based compensation) $ 3, 959 General and administrative personnel- related (excluding stock- based compensation) 5, 054 Research and development stock- based compensation 11, 992 General and administrative stock- based compensation 2, 927 External research and development 57, 680 Other research and development 1, 429 General and administrative, excluding personnel- related and stock- based compensation 5, 082 Total operating expenses 88, 123 Loss from operations $ (88, 123) 11. Income Taxes No provision for income taxes was recorded for the period from February 6, 2024 (inception) to December 31, 2024. The following table summarizes the loss before income tax expense by

jurisdiction for the periods indicated: Period from February 6, 2024 (Inception) to December 31, 2024 Domestic $ (83, 724) Foreign — Loss before income tax expense $ (83, 724) For the period from February 6, 2024 (inception) to December 31, 2024, the Company recognized no provision or benefit from income taxes. The difference between the Company' s provision for income taxes and the amounts computed by applying the statutory federal income tax rate to income before income taxes is as follows: Period from February 6, 2024 (Inception) to December 31, 2024 Tax benefit derived by applying the federal statutory rate to income before income taxes (21. 00) % Permanent differences (0. 18) Research and development credits (3. 41) Other (0. 87) Change in the valuation allowance 25. 46 Income tax (benefit) expense 0. 00 % F- 25 The components of the deferred tax assets and liabilities consist of the following (in thousands): December 31, 2024 Deferred tax assets Net operating loss carryforwards $ 2, 260 Research and development credits 3, 080 Stock- based compensation 3, 063 Accruals and other 424 Lease liability 203 Intangibles 1, 477 Capitalized R & D expenses 10, 994 Total deferred tax assets 21, 501 Deferred tax liabilities Right- of- use asset (184) Total deferred tax liabilities (184) Less valuation allowance (21, 317) Deferred tax assets, net $ — The Company has established a full federal and state valuation allowance equal to the net deferred tax assets due to uncertainties regarding the realization of the deferred tax asset based on the Company' s lack of earnings history. The valuation allowance increased by $ 21. 3 million primarily due to continuing loss from operations. December 31, 2024 Beginning balance as of February 6, 2024 $ — Change in valuation allowance 21, 317 Ending balance as of December 31, 2024 $ 21, 317 As of December 31, 2024, the Company had U. S. net operating loss carryforwards (" NOL ") of $ 10. 8 million. The federal NOL carryforwards do not expire and can be utilized to offset up to 80 % of the taxable income in any tax year. For the period from February 6, 2024 (inception) to December 31, 2024 the Company had federal tax credit carryforwards and state tax credit carryforwards of $ 3. 8 million and $ 0. 4 million, respectively. The federal credits will expire starting in 2044 if not utilized, and the state research credit can be carried forward indefinitely. The Tax Reform Act of 1986 limits the use of net operating loss carryforwards in certain situations where changes occur in the stock ownership of a company. The annual limitation may result in the expiration of net operating losses and credits before utilization. The Company has not performed a Section 382 analysis through December 31, 2024. To the extent that an assessment is completed in the future, the Company' s ability to utilize tax attributes could be restricted on a year- by- year basis and certain attributes could expire before they are utilized. The Company will examine the impact of any potential ownership changes in the future. A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands): Period from February 6, 2024 (Inception) to December 31, 2024 Beginning balance as of February 6, 2024 $ — Changes related to tax positions taken in the current year 1, 047 Ending balance as of December 31, 2024 $ 1, 047 F- 26 The Company includes penalties and interest expense related to income taxes as a component of income tax expense, as necessary. As of December 31, 2024, the Company had no accrued interest or penalties related to uncertain tax positions. The Company will be filing initial year income tax returns in the United States federal jurisdiction and state jurisdictions. Due to net operating loss carryforwards, the statute of limitations will remain open for income tax examination. 12. Option Agreements and License Agreements In March 2024, the Company entered into two antibody discovery and option agreements (" Option Agreements ") with Paragon and Paruka. Under the terms of each agreement, Paragon identifies, evaluates, and develops antibodies directed against certain mutually agreed therapeutic targets of interest to the Company. From time to time, the Company can choose to add additional targets to the collaboration upon agreement with Paragon and Paruka. Under the Option Agreements, the Company has the exclusive option to, on a research program- by- research program basis, be granted an exclusive, worldwide license to all of Paragon' s right, title, and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture, and commercialize the antibodies and products directed to the selected target (s) (each, an " Option "). The Company has initiated certain research programs with Paragon that generally focus on discovering, generating, identifying and / or characterizing antibodies directed to a particular target (each, a " Research Program "), including for IL- 23 and IL- 17A / F for ORKA- 001 and ORKA- 002, respectively. The exclusive option with respect to each Research Program is exercisable at the Company' s sole discretion at such time as specified in the Option Agreements (the " Option Period "). There is no payment due upon exercise of an Option pursuant to the Option Agreements. For each of these agreements, once the Company enters into the corresponding license agreements, it will be required to make non- refundable milestone payments to Paragon of up to $ 12. 0 million under each respective agreement upon the achievement of certain clinical development milestones, up to $ 10. 0 million under each respective agreement upon the achievement of certain regulatory milestones, as well as a low single- digit percentage royalty for antibody products beginning on the first commercial sale in each program. The Company may terminate any Option Agreement or any Research Program at any time for any or no reason upon 30 days' prior written notice to Paragon, provided that it must pay certain unpaid fees due to Paragon upon such termination, as well as any non- cancellable obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate any Option Agreement or a Research Program immediately upon written notice to the Company if, as a result of any action or failure to act by the Company or its affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed for a certain consecutive number of months. Each party has the right to terminate the Option Agreements or any Research Program upon material breach that remains uncured or the other party' s bankruptcy. In September 2024, the Company exercised the Option to acquire certain rights to ORKA- 001, and in December 2024, it entered into the corresponding license agreement with Paragon (the " ORKA- 001 License Agreement "), pursuant to which Paragon granted the Company a royalty- bearing, world- wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting IL- 23 in all fields other than the field of inflammatory bowel disease (" ORKA- 001 Field "). In December 2024, the Company exercised the Option with respect to ORKA- 002 for the IL- 17A / F program, and in February 2025, it entered into the corresponding license agreement with Paragon (the " ORKA- 002 License Agreement " and together with the ORKA- 001 License Agreement, the " License Agreements "), pursuant to which Paragon granted the Company a royalty- bearing, world- wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting IL- 17A / F in all fields (" ORKA- 002 Field " and together with the ORKA- 001 Field, the " Fields "). The License Agreements provide the Company with exclusive licenses in the Fields to Paragon' s patent applications covering the related antibodies, their method of use and their method of manufacture and Paragon has agreed not to conduct any new campaigns that generate anti- IL- 23 monospecific antibodies or anti- IL- 17A / F monospecific antibodies for the ORKA- 001 Field or the ORKA- 002 Field, respectively, for at least five years. Each of the ORKA- 001 and ORKA- 002 License Agreements may be terminated on 60 days' notice to Paragon, on material breach without cure, and on a party' s insolvency or bankruptcy to the extent permitted by law. Pursuant to the terms of each of the ORKA- 001 and ORKA- 002 License Agreements, the Company is obligated to pay Paragon non- refundable milestone payments of up to $ 12. 0 million under each respective agreement upon the achievement of certain clinical development milestones and up to $ 10. 0 million under each respective agreement upon the achievement of certain regulatory milestones, including a $ 1. 5 million fee for nomination of a development candidate (or initiation of an IND- enabling toxicology study) and a further milestone payment of $ 2. 5 million upon the first dosing of a human patient in a Phase 1 trial for each of ORKA- 001 and ORKA- 002. In addition, the Company is obligated to pay Paragon a low single- digit percentage royalty for antibody products for each of ORKA- 001 and ORKA- 002. For each of the License Agreements, the royalty term ends on the later of (i) the last- to- expire licensed patent or our patent directed to the manufacture, use or sale of a licensed antibody in the country at issue or (ii) 12 years from the date of first sale of a Company product. There is also a royalty step- down if there is no Paragon patent in effect during the royalty term for each program. F- 27 Additionally, as part of the Option Agreements, on December 31, 2024 the Company granted and on December 31, 2025, will grant Paruka a warrant to purchase a number of shares equal to 1. 00 % of outstanding shares as of the date of the grant on a fully- diluted basis, with an exercise price equal to the fair market value of the underlying shares on the grant date. Pursuant to the Option Agreements, on a research program- by- research program basis following the finalization of the research plan for each respective research program, the Company was required to pay Paragon a one- time, nonrefundable research initiation fee of $ 0. 8 million related to the ORKA- 001 program. This amount was recognized as a research and development expense during the period from February 6, 2024 (inception) to December 31, 2024. In June 2024, pursuant to the Option Agreements with Paragon, the Company completed the selection process of its development candidate for IL- 23 antibody for ORKA- 001 program. The Company was responsible for 50 % of the development costs incurred through the completion of the IL- 23 selection process. The Company received the rights to at least one selected IL- 23 antibody in June 2024. During the period from February 6, 2024 (inception) to December 31, 2024, the Company exercised its option for ORKA- 001 and recorded a $ 1. 5 million milestone payment related to the achievement of development candidate as research and development expense in the Company' s consolidated statement of operations and comprehensive loss. In addition, during the period from February 6, 2024 (inception) to December 31, 2024, the Company recorded a $ 2. 5 million milestone payment related to the first dosing of a human subject in a Phase 1 trial of ORKA- 001 in December 2024 as research and development expense in its consolidated statement of operations and comprehensive loss. The Company' s share of development costs incurred for the period from February 6, 2024 (inception) to December 31, 2024 was $ 13. 5 million (excluding research initiation fee and milestones), which were recorded as research and development expenses. An amount of $ 2. 8 million related to ORKA- 001 is included in related party accounts payable and other current liabilities as of December 31, 2024. The Company was also required to reimburse Paragon $ 3. 3 million for development costs related to ORKA- 002 incurred by Paragon through December 31, 2023 and certain other development costs incurred by Paragon between January 1, 2024 and March 6, 2024 as stipulated by the Option Agreements. This amount was recognized as a research and development expense during the period from February 6, 2024 (inception) to December 31, 2024. The Company is also responsible for the development costs incurred by Paragon from January 1, 2024 through the completion of the IL- 17 selection process. The Company recognized an amount of $ 0. 8 million payable to Paragon for the research initiation fee related to ORKA- 002 following the finalization of the ORKA- 002 research plan. This was recognized as research and development expenses in the period from February 6, 2024 (inception) to December 31, 2024. During the period from February 6, 2024 (inception) to December 31, 2024, the Company exercised its option for ORKA- 002 and recorded a $ 1. 5 million milestone payment related to the achievement of development candidate as research and development expense in its consolidated statement of operations and comprehensive loss. The Company accounted for development costs of $ 7. 8 million (excluding research initiation fee, milestone, and reimbursements of development costs through December 31, 2023) for the period from February 6, 2024 (inception) to December 31, 2024 as research and development expenses. An amount of $ 2. 7 million related to ORKA- 002 is included in related party accounts payable and other current liabilities as of December 31, 2024. The Company expenses the service fees as the associated costs are incurred when the underlying services are rendered. Such amounts are classified within research and development expenses in the accompanying consolidated statement of operations and comprehensive loss. The Company concluded that the rights obtained under the Option Agreements represent an asset acquisition whereby the underlying assets comprise in- process research and development assets with no alternative future use. The Option Agreements did not qualify as a business combination because substantially all of the fair value of the assets acquired was concentrated in the exclusive license options, which represent a group of similar identifiable assets. The research initiation fee represents a one- time cost on a research program- by- research program basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of ongoing development cost, monthly development cost fee and additional development expenses incurred by Paragon due to work completed for selected targets prior to the effective date of the Option Agreements that is associated with services being rendered under the related Research Programs are recognized as research and development expense when incurred. For the period from February 6, 2024 (inception) to December 31, 2024, the Company recognized $ 42. 0 million of expenses in connection with services provided by Paragon and Paruka under the Option Agreements. F- 28 13. Commitment and Contingencies In April 2024, the Company entered into an operating lease agreement for the Company' s headquarters in Menlo Park, California, which commenced on June 15, 2024 with an initial term of 39. 5 months. The Company leases office space under this noncancelable operating lease agreement. Lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate when measuring operating lease liabilities as discount rates were not implicit or readily determinable. As of December 31, 2024, the Company had $ 0. 9 million of operating lease right- of- use assets, operating lease liability, current of $ 0. 2 million, and operating lease liability, noncurrent of $ 0. 8 million on its consolidated balance sheet. As of December 31, 2024, the operating lease arrangement had a remaining lease term of 33 months and a discount rate of 17. 95 %. For the period from February 6, 2024 (inception) to December 31, 2024, the Company recorded operating and variable lease expense of $ 0. 3 million in general and administrative expenses in its consolidated statement of operations and comprehensive loss. The following table presents the Company' s supplemental cash flow information related to leases (in thousands): Period from February 6, 2024 (Inception) to December 31, 2024 Cash paid for amounts included in the measurement of lease liabilities $ 116 The following table summarizes a maturity analysis of the Company' s operating lease liabilities showing the aggregate lease payments as of December 31, 2024 (in thousands): Year ending December 31, Amount $ Total undiscounted lease payments 1, 243 Less: imputed interest (275) Total discounted lease payments Less: current portion of lease liability (213) Non- current portion of lease liability $ In March 2024, the Company entered into the Cell Line License Agreement (the " Cell Line License Agreement ") with WuXi Biologics Ireland Limited (" WuXi Biologics "). Under the Cell Line License Agreement, the Company received a non- exclusive, worldwide, sublicensable license to certain of WuXi Biologics' know- how, cell line, biological materials (the " WuXi Biologics Licensed Technology ") and media and feeds to make, have made, use, sell and import certain therapeutic products produced through the use of the cell line licensed by WuXi Biologics under the Cell Line License Agreement (the " WuXi Biologics Licensed Products "). Specifically, the WuXi Biologics Licensed Technology is used in certain manufacturing activities in support of the ORKA- 001 and ORKA- 002 programs. In consideration for the license, the Company agreed to pay WuXi Biologics a non- refundable license fee of $ 150, 000, which was recognized as a research and development expense during the period from February 6, 2024 (inception) to December 31, 2024. Additionally, to the extent that the Company manufactures its commercial supplies of bulk drug product with a manufacturer other than WuXi Biologics or its affiliates, the Company is required to make royalty payments to WuXi Biologics at a rate of less than one percent of net sales of WuXi Biologics Licensed Products manufactured by the third- party manufacturer. Pursuant to an amendment to the Cell Line License Agreement effective in November 2024, a provision was added that permits the royalties owed under the agreement to be bought out on a product- by- product basis for a lump- sum payment. The Cell Line License Agreement will continue indefinitely

unless terminated (i) by the Company upon six months' prior written notice and its payment of all undisputed amounts due to WuXi Biologics through the effective date of termination, (ii) by WuXi Biologics for a material breach by the Company that remains uncured for 60 days after written notice, (iii) by WuXi Biologics if the Company fails to make a payment and such failure continues for 30 days after receiving notice of such failure, or (iv) by either party upon the other party' s bankruptcy. F- 29 14. Net Loss per Share Basic and diluted net loss per share attributable to stockholders were calculated as follows (in thousands, except share and per share data): Period from February 6, 2024 (Inception) to December 31, 2024 Loss Allocation Weighted Average Shares Outstanding Loss Per Share, Basic and Diluted Common Stock $ (65, 037) 16, 789, 362 $ (3. 87) Company Series A Preferred Stock (1) (1, 918) 495 $ (3, 873. 25) Company Series B Preferred Stock (2) (16, 769) 51, 946 $ (322. 81) Net loss $ (83, 724) (1) The weighted- average number of shares of as- converted Company Series A Preferred Stock used in the loss allocation was 495, 191 for the period from February 6, 2024 (inception) to December 31, 2024. (2) The weighted- average number of shares of as- converted Company Series B Preferred Stock used in the loss allocation was 4, 328, 844 for the period from February 6, 2024 (inception) to December 31, 2024. For the computation of basic net loss per share attributable to stockholders, the amount of weighted- average shares outstanding excludes all shares of unvested restricted common stock as such shares are not considered outstanding for accounting purposes until vested. The amount of weighted- average shares outstanding includes the pre- funded warrants as the exercise price is negligible and these warrants are fully vested and exercisable. The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to stockholders for the periods presented because including them would have had an anti- dilutive effect were as follows: December 31, 2024 Outstanding employee warrants to purchase common stock 3, 054, 358 Outstanding unvested restricted stock awards 2, 207, 553 Outstanding and issued common stock options 1, 567, 760 Outstanding and issued warrant to Paruka 596, 930 Total 7, 426, 601 15. Related Party Transactions Paragon and Paruka each beneficially own less than 5 % of the Company' s capital stock through their respective holdings of Company Common Stock. Fairmount beneficially owns more than 5 % of the Company' s capital, currently has one representative appointed to the Board, and beneficially owns more than 5 % of Paragon. Fairmount appointed Paragon' s board of directors and has the contractual right to approve the appointment of any executive officers of Paragon. The following is a summary of related party accounts payable and other current liabilities (in thousands): December 31, 2024 Paragon reimbursable Option Agreements' fees $ 1, 482 Paragon milestone payments for Option Agreement 4, 000 Paragon reimbursable other research expenses 515 Paragon reimbursable patent expenses 25 Total $ 6, 022 16. Subsequent Events In February 2025, the Company entered into a lease agreement for an office space located in Waltham, Massachusetts. The lease is for an initial period of 54 months. The Company expects to pay approximately $ 1. 6 million over the lease term. F- 30 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure. Item 9A. Controls and Procedures. Management' s Evaluation of Disclosure Controls and Procedures Our management, with the participation of our Principal Executive Officer and our Principal Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2024. Based on the foregoing evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of December 31, 2024. The term " disclosure controls and procedures, " as defined in Rules 13a- 15 (e) and 15d- 15 (e) under the Exchange Act means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC' s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our Principal Executive Officer and Principal Financial Officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and our management necessarily applies its judgment in evaluating the cost- benefit relationship of possible controls and procedures. Management' s Report on Internal Control over Financial Reporting Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rules 13a- 15 (f) and 15d- 15 (f) promulgated under the Exchange Act as a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by our board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U. S. GAAP. Our internal control over financial reporting includes those policies and procedures that: ● pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of our assets; ● provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U. S. GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and ● provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Our management, with the participation of our principal executive officer and principal financial officer, assessed the effectiveness of our internal control over financial reporting as of December 31, 2024. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in its 2013 Internal Control – Integrated Framework. Based on our assessment, our management has concluded that, as of December 31, 2024, our internal control over financial reporting was effective based on those criteria. This Annual Report on Form 10- K does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. For as long as we remain a " smaller reporting company " as defined by Rule 12b- 2 of the Exchange Act and report less than $ 100 million of annual revenues in our most recent fiscal year, we intend to take advantage of the exemption permitting us not to comply with the requirement that our independent registered public accounting firm provide an attestation on the effectiveness of our internal control over financial reporting. Changes in Internal Control over Financial Reporting There were no changes in our internal control over financial reporting during the quarter ended December 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Item 9B. Other Information. During the quarter ended December 31, 2024, no director or Section 16 officer (as defined in Section 16 of the Securities Exchange Act of 1934, as amended) adopted or terminated any Rule 10b5- 1 trading arrangements or non- Rule 10b5- 1 trading arrangements (in each case, as defined in Item 408 (a) of Regulation S- K). Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. PART III Item 10. Directors, Executive Officers and Corporate Governance. Executive Officers and Directors The following table sets forth the names, ages as of March 6, 2025, and positions of the individuals who currently serve as executive officers and directors of the Company. Name Age Position Executive Officers and Employee Director Lawrence Klein, Ph. D. President, Chief Executive Officer and Director Arjun Agarwal Senior Vice President, Finance and Treasurer Joana Goncalves, MBChB Chief Medical Officer Paul Quinlan General Counsel and Corporate Secretary Non- Employee Directors Samarth Kulkarni, Ph. D. (2) (3) Chair and Director Kristine Ball (1) (3) Director Carl Dambkowski, M. D. (1) Director Peter Harwin (2) (3) Director Cameron Turtle, D. Phil. (1) (2) Director (1) Member of the Audit Committee. (2) Member of the Compensation Committee. (3) Member of the Nominating and Governance Committee (the " Governance Committee "). Our business affairs are managed under the direction of our Board, which currently consists of six members. Our Board is divided into three classes, with members of each class holding office for staggered three- year terms. There are currently two Class I directors, who are up for election at the 2025 Annual Meeting of Stockholders for a term expiring at the 2028 Annual Meeting of Stockholders; two Class II directors, whose terms expire at the 2026 Annual Meeting of Stockholders; and two Class III directors, whose terms expire at the 2027 Annual Meeting of Stockholders. Each executive officer serves at the discretion of the of the Board and holds office until their successor is duly appointed and qualified or until their earlier resignation or removal. Biographical and other information regarding our executive officers and directors is set forth below. There are no family relationships among any of our executive officers or directors. Executive Officers and Employee Director Lawrence Klein, Ph. D. Dr. Klein has served as Chief Executive Officer and as a member of the board of directors of the Company since the Merger Closing and of Pre- Merger Oruka from February 2024 through the Merger Closing. Prior to joining Pre- Merger Oruka, Dr. Klein was a Partner at Versant Venture Management, LLC, a healthcare and biotechnology venture capital firm, from January 2023 to February 2024, where he invested in and helped to grow early- stage biotechnology companies. Prior to Versant, Dr. Klein served in various positions at CRISPR Therapeutics AG (Nasdaq: CRSP), a biopharmaceutical company, including Chief Operating Officer from January 2020 to October 2022, Chief Business Officer from January 2019 to January 2020, Senior Vice President, Business Development and Strategy from November 2017 to December 2018 and as Vice President, Strategy from February 2016 to November 2017, where he helped to initiate and execute on several transformative partnerships, establish the strategic direction of the company, oversee important pipeline programs and led several functions, including program and portfolio management. Before joining CRISPR, Dr. Klein was an Associate Partner at McKinsey & Company, a global management consulting firm, from October 2014 to February 2016. Dr. Klein served as a member of the board of directors of Dyne Therapeutics, Inc. (Nasdaq: DYN) from September 2019 to May 2023 and of Jasper Therapeutics, Inc. (Nasdaq: JSPR) from September 2021 to June 2023. Dr. Klein received his B. S. in biochemistry and physics from the University of Wisconsin- Madison and his Ph. D. in biophysics from Stanford University. We believe Dr. Klein is qualified to serve as a member of the Board because of his business development, operational and senior management experience in the biotechnology industry and his academic expertise and accomplishments. Joana Goncalves, MBChB. Dr. Goncalves has served as the Chief Medical Officer of the Company since the Merger Closing and of Pre- Merger Oruka from April 2024 through the Merger Closing. Prior to joining Pre- Merger Oruka, Dr. Goncalves served as Chief Medical Officer of Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company, from October 2018 to April 2024, where she was responsible for representing Cara Therapeutics in interactions with regulatory agencies, the investor and scientific communities and the board of directors, building multifunctional terms and developing the clinical development strategy in dermatological conditions. Prior to Cara, Dr. Goncalves held various positions at Celgene Corporation, a pharmaceutical company, which was later acquired by Bristol- Myers Squibb Company, from April 2014 to October 2018, where she most recently served as Vice President, Medical Affairs for Dermatology and Neurology and was instrumental in planning and executing medical support activities for a number of programs, including OTEZLA ® for psoriasis. Prior to Celgene, Dr. Goncalves served as Vice President, Medical Strategy and Scientific Affairs at LEO Pharma Inc., the U. S. subsidiary of LEO Pharma A / S, a global healthcare company specializing in dermatology and critical care, from February 2012 to April 2014. She began her pharmaceutical career at Novartis Pharmaceuticals, working on a range of products across various therapeutic areas from 2001 to 2012. Dr. Goncalves received her MBChB from the University of Cape Town, South Africa. Paul Quinlan. Mr. Quinlan has served as General Counsel and Corporate Secretary of the Company since the Merger Closing and of Pre- Merger Oruka since April 2024 through the Merger Closing. Prior to joining Pre- Merger Oruka, Mr. Quinlan served as General Counsel, Chief Compliance Officer and Corporate Secretary of CymaBay Therapeutics, Inc., a biopharmaceutical company, from October 2020 to March 2024, where he was responsible for the general supervision of the company' s legal affairs. From December 2017 to February 2020, he served as General Counsel and Corporate Secretary of CymaBay, where he was responsible for the general supervision of the company' s legal affairs. Prior to CymaBay, Mr. Quinlan served as General Counsel and Secretary, from 2010 to January 2018, and Chief Legal Officer from 2016 to January 2018, of TerraVia Holdings, Inc., a biotechnology company, where he was responsible for the general supervision of the company' s legal affairs. Prior to joining TerraVia, Mr. Quinlan served as General Counsel of Metabolex, Inc., a biopharmaceutical company, from 2005 to 2010. Prior to joining Metabolex, Mr. Quinlan held various positions at Maxygen, Inc., a biopharmaceutical company, from 2000 to 2005. Prior to Maxygen, Mr. Quinlan practiced law at Cooley LLP and Cravath, Swaine, & Moore LLP. Mr. Quinlan received a law degree from Columbia Law School and an M. Sc. in Medical Biophysics from the University of Toronto. Arjun Agarwal. Mr. Agarwal has served as the Senior Vice President of Finance of the Company since the Merger Closing and of Pre- Merger Oruka from March 2024 through the Merger Closing, where he is responsible for overseeing the company' s finance and accounting functions. Prior to joining Pre- Merger Oruka, Mr. Agarwal served as VP of Finance at Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company, from June 2021 to March 2024, including through multiple financings and the company' s successful transition to become a publicly traded entity. Before joining Jasper, Mr. Agarwal served as Vice President, Corporate Controller at Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a biotechnology company, from August 2019 to June 2021, where he was responsible for overseeing the company' s finance and accounting functions. Prior to joining Protagonist, Mr. Agarwal served in various roles of increasing responsibility at McKesson Corporation (NYSE: MCK), an international healthcare services company, from 2009 to 2019. Prior to McKesson, Mr. Agarwal worked at PricewaterhouseCoopers LLP, where he managed a portfolio of audit clients. He is a graduate of Sydenham College of Commerce and Economics at Mumbai University, India. He is a Certified Public Accountant (CPA) and a Chartered Accountant accredited by the Institute of Chartered Accountants of India. Non- Employee Directors Samarth Kulkarni, Ph. D. Dr. Kulkarni has served as Chair and a member of the board of directors of the Company since the Merger Closing and as a member of the board of directors of Pre- Merger Oruka from February 2024 through the Merger Closing. Dr. Kulkarni has served as the Chief Executive Officer of CRISPR Therapeutics AG (Nasdaq: CRSP), a biopharmaceutical company, since December 2017, where he has also served as a member and chair of the board of directors since June 2018 and September 2023, respectively. Previously, Dr. Kulkarni served as CRISPR' s President and Chief Business Officer from May 2017 to November 2017 and as Chief Business Officer from August 2015. Prior to joining CRISPR, Dr. Kulkarni was at McKinsey & Company, a global management consulting firm, from 2006 to 2015, with various titles, his most recent being Partner within the Pharmaceuticals and Biotechnology practice. Dr. Kulkarni has also served as a member of the boards of directors of Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), Repare Therapeutics Inc. (Nasdaq: RPTX), and Centessa Pharmaceuticals plc (Nasdaq: CNTA). Dr. Kulkarni received a Ph. D. in Bioengineering and Nanotechnology from the University of Washington and a B. Tech. from the Indian Institute of Technology. Dr. Kulkarni has authored several publications in leading scientific and business journals. We believe that Dr. Kulkarni is qualified to serve as a member of the Board because of his experience as a consultant and an executive in the biopharmaceutical industry and his academic expertise and accomplishments. Kristine Ball. Ms. Ball has served as a member of the board of directors of the Company since the Merger Closing and of Pre- Merger Oruka since May 2024 through the

Merger Closing. Ms. Ball has served as President and Chief Executive Officer of Antiva Biosciences, Inc., a private biopharmaceutical company, since April 2023. Prior to Antiva, Ms. Ball served as Chief Executive Officer of Soteria Biotherapeutics, Inc., a private biotechnology company, from September 2020 to August 2022. Prior to joining Soteria, Ms. Ball served as Senior Vice President, Corporate Strategy and Chief Financial Officer of Menlo Therapeutics, Inc., a Nasdaq- listed biopharmaceutical company, which later became VYNE Therapeutics Inc. (Nasdaq: VYNE), from September 2017 to March 2020, where she was responsible for leading all non- R & D functions, including strategic planning, corporate development, commercial, human resources, legal, finance and information technology. Prior to joining Menlo, Ms. Ball served as Chief Financial Officer and Senior Vice President of Relypsa, Inc., a Nasdaq- listed pharmaceutical company, which was later acquired by Galenica Group, from November 2012 to October 2016. Prior to Relypsa, Ms. Ball held various other finance roles in the life sciences industry, including Senior Vice President of Finance & Administration and Chief Financial Officer of KAI Pharmaceuticals, Inc., a biopharmaceutical company, and Vice President of Finance at Exelixis, Inc. (Nasdaq: EXEL), a biotechnology company. Prior to that, Ms. Ball served as a senior manager in the life sciences audit practice of Ernst & Young LLP. Ms. Ball has previously served on the boards of directors of Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company, from 2020 to 2024, Soteria from 2020 to 2022 and Forty Seven, Inc. (Nasdaq: FTSV), a Nasdaq- listed biotechnology company, which was acquired by Gilead Sciences, Inc., from 2018 to 2020. Ms. Ball received a B. S. from Babson College. We believe Ms. Ball is qualified to serve as a member of the Board because of her experience as an executive officer and director of life sciences companies and her background in finance, corporate development and strategic planning. Carl Dambkowski, M. D. Dr. Dambkowski has served as a member of the board of directors of the Company since the Merger Closing and of Pre- Merger Oruka from February 2024 through the Merger Closing. Dr. Dambkowski has served as the Chief Medical Officer of Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company, since September 2022. Prior to joining Apogee, Dr. Dambkowski served as a strategic and clinical leader for a variety of companies, including as Chief Medical Officer of QED Therapeutics, Inc., a private biotechnology company, from July 2021 to September 2022; Chief Strategy Officer and EVP of Operations of Origin Biosciences, Inc., a private bioecology company, from March 2018 to June 2021; and Chief Medical Officer of Navire Pharma, Inc., a private biotechnology company, from January 2020 to September 2022, where he served as the clinical lead starting prior to IND for BBP- 398 through the out licensing of the compound to Bristol- Myers Squibb based on initial clinical data and for low- dose infigratinib in achondroplasia through initial proof- of- concept data. He was part of the core team that brought TRUSELTIQ ® (infigratinib) and NULIBRY ® (fosdenopterin) through regulatory review and FDA approval at QED Therapeutics and Origin Biosciences, respectively. From July 2016 to March 2018, Dr. Dambkowski was an associate at McKinsey & Company, a global management consulting firm, where he advised biotech and pharmaceutical companies across the world on a range of research and development activities. Dr. Dambkowski co- founded Novonate, Inc., a private medical device company focused on building life- saving devices for neonates, in January 2015. Dr. Dambkowski has coauthored numerous peer- reviewed publications and scientific abstracts and is a named inventor on multiple published and granted patents. Dr. Dambkowski was trained as a physician at Stanford University, where he also received his M. D. with a concentration in bioengineering. He also received a B. A. (with honors) from Stanford University and an M. A. from Columbia University. We believe Dr. Dambkowski is qualified to serve as a member of the Board because of his significant experience and innovations in the biotechnology industry and his academic expertise and accomplishments. Peter Harwin. Mr. Harwin has served as a member of the board of directors of the Company since the Merger Closing and of Pre- Merger Oruka from February 2024 through the Merger Closing. Mr. Harwin is a Managing Member at Fairmount Funds Management, a healthcare investment firm he co- founded in April 2016. Prior to Fairmount Funds Management, Mr. Harwin was a member of the investment team at Boxer Capital, LLC, an investment fund that was part of the Tavistock Group, based in San Diego. Mr. Harwin also serves as chairman of the board of directors of Cogent Biosciences, Inc. (Nasdaq: COGT) and is a member of the board of directors of Apogee Therapeutics, Inc. (Nasdaq: APGE), Viridian Therapeutics, Inc. (Nasdaq: VRDN) and Spyre Therapeutics, Inc. (formerly Aeglea BioTherapeutics, Inc.) (Nasdaq: SYRE). Mr. Harwin received a B. B. A. from Emory University. We believe Mr. Harwin is qualified to serve as a member of the Board because of his experience serving as a director of biotechnology companies and as a manager of funds specializing in the area of life sciences. Cameron Turtle, D. Phil. Dr. Turtle has served as a member of the board of directors of the Company since the Merger Closing and of Pre- Merger Oruka from February 2024 through the Merger Closing. Dr. Turtle has served as Chief Executive Officer and a member of the board of directors of Spyre Therapeutics, Inc. (formerly Aeglea BioTherapeutics, Inc.) (Nasdaq: SYRE), a biotechnology company, since November 2023 and, before that, as Chief Operating Officer from June 2023 to November 2023. Prior to joining Spyre, Dr. Turtle was an advisor to Spyre Therapeutics, Inc., a private biotechnology company, from May 2023 to June 2023. Previously, he served as Venture Partner at Foresite Labs, a life sciences investment firm, from July 2022 to May 2023; Chief Strategy Officer of BridgeBio Pharma (Nasdaq: BBIO), a biotechnology company, from January 2021 to April 2022; and Chief Business Officer of Eidos Therapeutics (Nasdaq: EIDX), a biopharmaceutical company, from November 2018 to January 2021, where he led business development, investor relations, and multiple operational functions as the company advanced an investigational medicine for a form of heart failure. Prior to joining BridgeBio and Eidos, he was a consultant at McKinsey & Company, a global management consulting firm, where he worked with pharmaceutical and medical device companies on topics including M & A, growth strategy, clinical trial strategy, and sales force optimization. Dr. Turtle received his B. S. with honors in Bioengineering from the University of Washington and his D. Phil. in Cardiovascular Medicine from the University of Oxford, St. John' s College. He is the recipient of several awards, including a Rhodes Scholarship, Goldwater Scholarship, Forbes 30 Under 30, San Francisco Business Times 40 Under 40, and the Biocom Life Sciences Catalyst Award. We believe Dr. Turtle is qualified to serve as a member of the Board because of his experience as a leader in building, financing, and shaping biopharmaceutical organizations from preclinical development to late- stage clinical trials and commercialization. Code of Business Conduct and Ethics We have adopted a Code of Business Conduct and Ethics that establishes the standards of ethical conduct applicable to all our directors, officers and employees, including our principal executive officer, principal financial officer and principal accounting officer, or persons performing similar functions. It addresses, among other matters, compliance with laws and policies, conflicts of interest, corporate opportunities, regulatory reporting, external communications, confidentiality requirements, insider trading, proper use of assets and how to report compliance concerns. A copy of the code is available on our website located at https: / / ir. oruka. com / corporate- governance under " Governance Documents. " We intend to disclose any amendments to the code, or any waivers of its requirements, on our website to the extent required by applicable rules. The Audit Committee is responsible for applying and interpreting the code in situations where questions are presented to it. Information contained on, or that can be accessed through, the Company' s website is not incorporated by reference into this report, and you should not consider information on the Company' s website to be part of this report. Insider Trading Policy We have adopted insider trading policies and procedures governing the purchase, sale and other transactions in Company securities by our directors, officers and employees, and other covered persons, as well as the Company itself, that we believe are reasonably designed to promote compliance with insider trading laws, rules and regulations, and Nasdaq Stock Market (" Nasdaq ") listing rules, as applicable. As part of these policies and procedures, we prohibit any employee, director or other covered person from engaging in short sales, transactions involving publicly traded options or other derivative securities based on the Company' s securities, hedging transactions, margin accounts, pledges, or other inherently speculative transactions with respect to the Company' s securities at any time. Audit Committee and Audit Committee Financial Expert We have a separately designated standing Audit Committee. The members of our Audit Committee are Ms. Ball, Dr. Dambkowski, and Dr. Turtle, each of whom qualifies as an " independent " director for audit committee purposes as defined under Nasdaq listing rules and the rules and regulations established by the SEC. Ms. Ball chairs the Audit Committee and qualifies as an " audit committee financial expert " as that term is defined under the rules and regulations established by the SEC, and all members of the Audit Committee are financially literate under Nasdaq listing rules. Delinquent Section 16 (a) Reports Section 16 (a) of the Exchange Act requires our directors, officers and persons who beneficially own more than 10 % of a registered class of our equity securities to file with the SEC initial reports of ownership and reports of changes in ownership of our common stock and other equity securities. To our knowledge, based solely on our review of Forms 3, 4 and 5 filed with the SEC or written representations that no Form 5 was required, during the year ended December 31, 2024, we believe that all of our directors, officers and persons who beneficially own more than 10 % of a registered class of our equity securities timely filed all reports required under Section 16 (a) of the Exchange Act. Stockholder Proposals and Director Nominations for 2025 Annual Meeting of Stockholders We will hold our 2025 Annual Meeting of Stockholders (the " Annual Meeting ") on Monday, June 2, 2025. Pursuant to Rule 14a- 8 of the Exchange Act, stockholders who wish to submit proposals for inclusion in the proxy statement for the Annual Meeting must send such proposals to our Corporate Secretary at the address 855 Oak Grove Avenue, Suite 100, Menlo Park, CA 94025. Such proposals must be received by us a reasonable time before we begin to print and mail our proxy materials and must comply with Rule 14a- 8 of the Exchange Act. The submission of a stockholder proposal does not guarantee that it will be included in the proxy statement. On August 29, 2024, in connection with the Merger Closing, the Board adopted an amendment and restatement of our Bylaws, effective as of such date, as described in our Current Report on Form 8- K filed on September 5, 2024. As set forth in our Bylaws, if a stockholder intends to make a nomination for director election or present a proposal for other business (other than pursuant to Rule 14a- 8 of the Exchange Act) at the Annual Meeting, the stockholder' s notice must be received by our Corporate Secretary at the address 855 Oak Grove Avenue, Suite 100, Menlo Park, CA 94025 no earlier than the 120th day and no later than the close of business on the 90th day before the anniversary of the last annual meeting; provided, however, that if the date of the annual meeting is more than 30 days before or more than 60 days after such anniversary date, the stockholder' s notice must be delivered not earlier than the close of business on the 120th day prior to such annual meeting and not later than the close of business on the later of the 90th day prior to such annual meeting or the 10th day following the date on which the first public announcement of the date of such annual meeting is made by the Company . Therefore, notice of proposed nominations or proposals (other than pursuant to Rule 14a- 8 of the Exchange Act) must be received by our Corporate Secretary no later than the close of business on March 16, 2025. Any such director nomination or stockholder proposal must be a proper matter for stockholder action and must comply with the terms and conditions set forth in our Bylaws (which includes the timing and information required under Rule 14a- 19 of the Exchange Act). If a stockholder fails to meet these deadlines or fails to satisfy the requirements of Rule 14a- 4 of the Exchange Act, we may exercise discretionary voting authority under proxies we solicit to vote on any such proposal as we determine appropriate. We reserve the right to reject, rule out of order or take other appropriate action with respect to any nomination or proposal that does not comply with these and other applicable requirements. Item 11. Executive Compensation. This section provides information regarding the compensation of our principal executive officer (Dr. Klein), and our two other highest paid executive officers who were serving as executive officers on December 31, 2024 (Dr. Goncalves and Mr. Quinlan). This section also includes compensation information for certain former executives of the Company (then known as ARCA). The individuals listed below are collectively referred to herein as the " NEOs " or " Named Executive Officers. " Name Title Lawrence Klein, Ph. D. Chief Executive Officer (1) Joana Goncalves, MBChB Chief Medical Officer (1) Paul Quinlan General Counsel and Corporate Secretary (1) Michael Bristow, M. D. Former President and Chief Executive Officer (2) Thomas A. Keuer Former President and Chief Operating Officer (3) C. Jeffrey Dekker Former Chief Financial Officer (3) (1) Drs. Klein and Goncalves and Mr. Quinlan were appointed to these positions in connection with the consummation of the Merger. Prior to the Merger, they each served in these positions at Pre- Merger Oruka. (2) Dr. Bristow' s employment with the Company terminated on April 3, 2024. Following his termination, Dr. Bristow provided transition services as a consultant. (3) Mr. Keuer' s and Mr. Dekker' s employment with the Company terminated in connection with the Merger. Following the Merger, Mr. Dekker provided transition services as a consultant. A Year of Transition was a year of transition for the Company as we completed the Merger, shifted our drug candidate pipeline to focus on novel biologics designed to set a new standard for the treatment of chronic skin diseases and transformed our management team. Our mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice per year. The compensation described below reflects both compensatory decisions necessary to engage a new leadership team that is critical to lead the advancement of the Company' s pipeline of novel biologics and improve the standard of care for the treatment of chronic skin diseases and compensatory decisions made by ARCA prior to the consummation of the Merger with respect to the former executive officers. Summary Compensation Table The following table shows information regarding the compensation earned by the NEOs during the fiscal years ending December 31, 2024 and 2023, by our named executive officers. Name and Principal Position (1) Year Salary ($) (2) Bonus ($) (3) Option Awards ($) (4) Non- Equity Incentive Plan Compensation ($) (5) All Other Compensation ($) Total ($) Lawrence Klein, Ph. D. 2024 203, 288 — — 317, 623 — 520, 911 Chief Executive Officer Joana Goncalves, MBChB 2024 155, 854 — — 162, 132 — 317, 986 Chief Medical Officer Paul Quinlan 2024 155, 854 — — 154, 591 — 310, 445 General Counsel Michael Bristow, M. D. 2024 96, 865 — 39, 676 — 373, 875 (6) 510, 416 Former President and Chief Executive Officer 2023 345, 000 — — — 13, 800 358, 800 Thomas A. Keuer 2024 235, 385 165, 000 22, 484 — 430, 651 (7) 853, 520 Former President and Chief Operating Officer 2023 340, 000 — — — 60, 802 400, 802 C. Jeffrey Dekker 2024 206, 923 165, 000 24, 947 — 359, 734 (8) 756, 604 Former Chief Financial Officer 2023 270, 000 — — — 53, 072 323, 072 (1) The amounts reflected herein for Drs. Klein and Goncalves and Mr. Quinlan do not include any compensation they received from Pre- Merger Oruka prior to the Merger. (2) Includes $ 157, 595 of consulting fees for Dr. Bristow and $ 20, 000 of consulting fees for Mr. Keuer, in each case, pursuant to their respective consulting agreements as described in more detail under " Narrative Disclosure to Summary Compensation Table — ARCA Arrangements " below. (3) Amounts reported in this column represent retention bonuses, as described in more detail under " Narrative Disclosure to Summary Compensation Table — ARCA Arrangements " below. (4) Amounts reported in this column represent the incremental fair value under Accounting Standards Codification Topic 718 (" ASC 718 ") resulting from the acceleration of the Named Executive Officer' s stock options in the Merger, as described in more detail under " Narrative to Summary Compensation Table — ARCA Arrangements " below. (5) Amounts reported in this column represent the annual bonuses earned under the 2024 annual bonus program, as described in more detail under " Narrative to Summary Compensation Table — Elements of Compensation — Annual Bonus Program " below. (6) Includes $ 3, 875 of Company contributions under the ARCA 401 (k) plan and $ 370, 000 of severance payments and benefits, as described in more detail under " Narrative Disclosure to Summary Compensation Table — ARCA Arrangements " below. (7) Includes $ 16, 800 of Company contributions under the ARCA 401 (k) plan, $ 340, 000 of severance payments and $ 69, 715 in COBRA continuation premiums, as described in more detail under " Narrative Disclosure to

Summary Compensation Table — ARCA Arrangements ” below, and $ 4, 136 for group term life insurance premiums. (8) Includes $ 14, 687 of Company contributions under the ARCA 401 (k) plan, $ 270, 000 of severance payments and $ 69, 715 in COBRA continuation premiums, as described in more detail under “ Narrative Disclosure to Summary Compensation Table — ARCA Arrangements ” below, $ 2, 692 for group term life insurance premiums and $ 2, 640 for healthcare reimbursements. Narrative Disclosure to Summary Compensation Table In December 2024, our Compensation Committee adopted a compensation philosophy to frame future compensation decisions for the Company. Under this philosophy, compensation positioning is used to attract and retain key employees for the Company’ s continued success and growth. While market data is helpful to the Compensation Committee in setting compensation framework and guiding decisions, other factors such as Company strategy, stockholder feedback, tenure, performance and criticality are also considered. The compensation philosophy serves as the foundation to reinforce the Company’ s business strategy and desired culture, while balancing internal and external alignment. Peer Group In July 2024, Pre- Merger Oruka, in consultation with Alpine, the Compensation Committee’ s independent compensation consultant, established a peer group that focuses on U. S.- based, pre- clinical or early clinical biopharma companies (with priority placed on companies with a similar therapeutic focus) with a market capitalization ranging from $ 250 million to $ 2 billion and less than 100 employees. The peer group, which was used in making compensation decisions in connection with establishing post- Merger executive compensation for 2024, includes the following companies (the “ Peer Group ”): Apogee Therapeutics Astria Therapeutics Cabaletta Bio CARGO Therapeutics Celldex Therapeutics Contineum Therapeutics Entrada Therapeutics Janux Therapeutics Kymera Therapeutics Kyverna Therapeutics Lexeo Therapeutics Longboard Pharmaceuticals Lyell Immunopharma Pliant Therapeutics Prime Medicine Spyre Therapeutics Structure Therapeutics Third Harmonic BioElements of Compensation Base Salaries Our Compensation Committee recognizes the importance of base salary as an element of compensation to provide our executive officers with steady cash flow during the year that is not contingent on short- term variations in our corporate performance. The setting of base salaries also includes an evaluation of each individual’ s job duties, responsibilities, performance and experience, as well as internal pay equity among the executive officer team. The Compensation Committee reviews base salaries at least annually and may recommend adjustment from time to time based on the results of that review. The Compensation Committee determines salary increases using a combination of relevant competitive market data, scope of responsibilities and assessment of individual performance. For 2024, the annual base salaries of Drs. Klein and Goncalves and Mr. Quinlan were established in connection with the consummation of their employment with Pre- Merger Oruka as a result of negotiations in the context of a competitive recruitment process. The annual base salaries as of December 31, 2024 for each of our continuing NEOs were as follows: $ 600, 000 for Dr. Klein and $ 460, 000 for each of Dr. Goncalves and Mr. Quinlan. Annual Bonus Program We have an annual cash incentive plan under which cash incentives may be paid to each of our employees, including our executive officers, after the end of each calendar year. The Compensation Committee generally determines target bonuses based on Peer Group practices and each individual’ s job duties. For 2024, the target bonuses for each NEO (excluding the former ARCA executive officers), which were established by Pre- Merger Oruka in connection with the consummation of their employment with Pre- Merger Oruka, were as follows: 50 % of base salary for Dr. Klein and 40 % of base salary for each of Dr. Goncalves and Mr. Quinlan, in each case, pro- rated based on their respective start dates with Pre- Merger Oruka. Pre- Merger Oruka established the corporate goals and targets for the 2024 bonus program, which were heavily weighted towards the preclinical development of ORKA- 001 and ORKA- 002, progress towards the commencement of their respective Phase 1 clinical studies and regulatory progress. In addition, the corporate goals included measures designed to ensure adequate funding for the Company. The Board, upon the recommendation of the Compensation Committee, reviewed our achievement against our 2024 corporate goals and determined the achievement to have been 125 % of target, based on the achievement of substantially all the goals, with overperformance on several of the goals. Based on our corporate performance, the 2024 annual bonuses awarded to our continuing NEOs were as follows: $ 317, 623 for Dr. Klein, $ 162, 132 for Dr. Goncalves and $ 154, 591 for Mr. Quinlan. Long- Term Incentives We intend our equity incentive program to reward longer- term performance and to align the interests of our executive officers with those of our stockholders. We also believe that our equity incentive program, which currently consists predominantly of time- based stock options (or, for certain grants by Pre- Merger Oruka, time- based compensatory warrants), is an important retention tool for our employees, including our NEOs. The Compensation Committee believes that stock options, which require increased stock price performance for value realization, create a key connection between the interests of the NEOs and stockholders. Each of the grants described below are presented after giving effect to the share conversion completed in the Merger and the subsequent 1- for- 12 reverse stock split. In connection with his appointment as Chief Executive Officer of Pre- Merger Oruka, Dr. Klein purchased 852, 338 shares of restricted stock at fair market value, which vests as to 25 % on February 26, 2025 and in equal monthly installments thereafter through February 26, 2028. In accordance with the anti- dilution provisions of his offer letter, as described in more detail below, on July 15, 2024, Dr. Klein received a compensatory warrant to purchase 1, 628, 513 shares of our common stock, which vests as to 25 % on April 3, 2025 and in equal monthly installments thereafter through April 3, 2028. In connection with her appointment as Chief Medical Officer of Pre- Merger Oruka, Dr. Goncalves was granted stock options to purchase 228, 563 shares of our common stock, which vests as to 25 % on April 18, 2025 and in equal monthly installments thereafter through April 18, 2028. On July 15, 2024, Dr. Goncalves was granted a compensatory warrant to purchase 199, 992 shares of our common stock, which vests on the same schedule as her initial stock option grant. In connection with his appointment as General Counsel of Pre- Merger Oruka, Mr. Quinlan was granted stock options to purchase 228, 563 shares of our common stock, which vests as to 25 % on April 30, 2025 and in equal monthly installments thereafter through April 30, 2028. On July 15, 2024, Mr. Quinlan was granted a compensatory warrant to purchase 99, 996 shares of our common stock, which vests on the same schedule as his initial stock option grant. None of the former ARCA executive officers received grants of equity incentive awards during 2024. Offer Letters In connection with their appointments, we entered into offer letters with each of Dr. Klein, Dr. Goncalves and Mr. Quinlan, each of which was amended and restated as of October 3, 2024 (for Dr. Klein) or October 1, 2024 (for Dr. Goncalves and Mr. Quinlan) following the Merger (collectively, the “ Offer Letters ”). The Offer Letters provided for each NEO’ s initial base salary, target annual bonus and initial equity incentive award. The Offer Letter with Dr. Klein also provided for periodic grants of stock options sufficient to maintain Dr. Klein’ s ownership at approximately 5 % on a fully- diluted basis until Oruka raised an aggregate of $ 200 million in financing, which obligations were fully satisfied prior to the consummation of the Merger through the warrant issued on July 15, 2024. The Offer Letter with Dr. Goncalves also provided for a sign- on bonus of $ 100, 000, which is subject to repayment in the event of a termination for cause or resignation without good reason prior to April 18, 2025. Under the Offer Letters, the NEOs are eligible for certain payments or benefits upon certain terminations of employment, as described under “ Additional Narrative Disclosure — Potential Payments Upon Termination or Change in Control ” below. Each of Dr. Klein, Dr. Goncalves and Mr. Quinlan is also party to our standard employee invention assignment, confidentiality and non- competition agreement, which, among other things, provides standard protections regarding our ownership of intellectual property, the confidentiality of our proprietary information, non- competition and non- solicitation. ARCA Arrangements Michael Bristow, M. D. Dr. Bristow served as the Company’ s President and Chief Executive Officer through April 3, 2024. In connection with his separation, the Company (then known as ARCA) and Dr. Bristow entered into a separation agreement pursuant to which Dr. Bristow provided a release of claims in favor of the Company and the Company paid Dr. Bristow a lump sum severance payment of $ 370, 000. The Company and Dr. Bristow also entered into a consulting agreement, effective April 3, 2024, pursuant to which Dr. Bristow provided certain consulting services to the Company through the Merger. Under the consulting agreement, Dr. Bristow continued to vest in his outstanding equity awards during the consulting term. Thomas A. Keuer and C. Jeffrey Dekker. Mr. Keuer served as the Company’ s President and Chief Operating Officer and Mr. Dekker served as the Company’ s Chief Financial Officer, in each case, through the consummation of the Merger. Pursuant to retention bonus letters approved by the ARCA Compensation Committee prior to the Merger, each of Messrs. Keuer and Dekker were paid a retention bonus upon consummation of the Merger of $ 165, 000. As a result of the Merger and the accompanying termination of their employment, the Company and each of Mr. Keuer and Mr. Dekker entered into a separation agreement, pursuant to which Mr. Keuer and Mr. Dekker each provided a release of claims in favor of the Company and the Company provided the following severance payments and benefits, in accordance with the terms of their employment agreement: (i) a lump sum cash severance payment equal to 12 months of their respective annual base salary ($ 340, 000 and $ 270, 000, respectively) and (ii) a lump sum cash payment of $ 69, 715 in lieu of 12 months of group health plan continuation premiums. Treatment of ARCA Equity Awards. In connection with the Merger, all outstanding ARCA stock options held by the NEOs were accelerated and cashed out for an amount equal to the difference between $ 3. 9489 and the applicable per share exercise price; however, any ARCA stock options having an exercise price in excess of $ 3. 9489 were cancelled for no consideration. Outstanding Equity Awards at Fiscal Year End The following table presents information regarding outstanding stock options, compensatory warrants and restricted stock held by each NEO as of December 31, 2024. The equity awards reflected below give effect to the share conversion completed in the Merger and the subsequent 1- for- 12 reverse stock split. None of the former ARCA executive officers held any outstanding equity awards as of December 31, 2024. Option Awards Stock Awards Name Number of Securities Underlying Unexercised Options (#) Exercisable Number of Securities Underlying Unexercised Options (#) Unexercisable Option Exercise Price ($) Option Expiration Date Number of Shares or Units of Stock That Have Not Vested (#) Market Value of Shares or Units of Stock That Have Not Vested ($) (1) Lawrence Klein, Ph. D. — 1, 628, 513 (2) 7. 80 7 / 14 / 2034 852, 338 (3) 16, 526, 834 Joana Goncalves, MBChB — 228, 563 (4) 6. 84 10 / 30 / 2034 — 199, 992 (4) 7. 80 7 / 14 / 2034 Paul Quinlan — 228, 563 (5) 6. 84 10 / 30 / 2034 — 99, 996 (5) 7. 80 7 / 14 / 2034 Michael Bristow, M. D. — — — — — — Thomas A. Keuer — — — — — — C. Jeffrey Dekker — — — — — — (1) The market value was determined by multiplying the numbers of shares by $ 19. 39, the closing price of our common stock on December 31, 2024. (2) These compensatory warrants vest as to 25 % on April 3, 2025 and in equal monthly installments thereafter through April 3, 2028, subject to Dr. Klein’ s continued services to us. (3) These restricted shares vest as to 25 % on February 26, 2025 and in equal monthly installments thereafter through February 26, 2028, subject to Dr. Klein’ s continued services to us. (4) These stock options and compensatory warrants vest as to 25 % on April 18, 2025 and in equal monthly installments thereafter through April 18, 2028, subject to Dr. Goncalves’ continued services to us. (5) These stock options and compensatory warrants vest as to 25 % on April 30, 2025 and in equal monthly installments thereafter through April 30, 2028, subject to Mr. Quinlan’ s continued services to us. Additional Narrative Disclosures Employee Benefits and Perquisites Our NEOs are eligible to participate in our employee benefit plans, including our health and welfare plans, term life insurance, disability insurance and a 401 (k) plan, in each case on the same basis as all our other employees. During 2024, following the Merger, we did not provide any Company contributions under the 401 (k) plan; however, in 2025, the Company will make matching contributions of 100 % of the first 3 % of eligible compensation deferred by participants, subject to legal maximum contributions. Following the Merger, we generally do not provide perquisites or personal benefits to our NEOs, except in limited circumstances. Potential Payments Upon Termination or Change in Control Pursuant to the terms of the Offer Letters, in the event each NEO that is a current executive officer is terminated by the Company without “ cause ” or as a result of a resignation for “ good reason ” (collectively, an “ Involuntary Termination ”), such NEO will, subject to the execution of a release in favor of the Company, receive: (i) severance payments equal to 12 months of base salary; (ii) Company- paid continuation coverage under the Company’ s group health plans for up to 12 months; and (iii) in the case of Dr. Klein, accelerated vesting of 30 % of any outstanding time- based equity. However, if the Involuntary Termination is within three months before or 12 months after a change in control of the Company, the NEO will instead receive: (A) severance payments equal to 1. 0 times (or, for Dr. Klein, 1. 5x times) the sum of the NEO’ s base salary and target bonus; (B) Company- paid continuation coverage under the Company’ s group health plans for up to 12 months (or, for Dr. Klein, up to 18 months); and (C) full acceleration of all equity awards. In addition, upon severance due to the death or disability of the named executive officer, the officer’ s equity awards shall accelerate in full. As used in the Offer Letters: “ Cause ” generally means the NEO’ s (i) dishonest statements or acts with respect to the Company or any affiliate of the Company, or any current or prospective customers, suppliers, vendors or other third parties with which such entity does business that results in or is reasonably anticipated to result in material harm to the Company; (ii) conviction or plea of no contest to a felony or misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) failure to perform his or her duties or responsibilities, subject to a 30- day cure period; (iv) gross negligence, willful misconduct that results in or is reasonably anticipated to result in material harm to the Company; or (v) violation of any material provision of any agreement with the Company or any written Company policies. “ Good reason ” generally means (i) a material diminution in the named executive officer’ s base salary or target bonus (excluding across- the- board reductions of less than 10 %); (ii) a material geographic relocation or requirement to change the named executive officer’ s remote work location; (iii) a material reduction in the named executive officer’ s duties, authority or responsibilities; (iv) the failure of the Company to obtain the assumption of the Offer Letter by a successor; or (v) the material breach of any agreement between the NEO and the Company, in each case, subject to standard notice and cure periods. Clawback Policy We maintain a Compensation Recoupment (Clawback) Policy, which is intended to comply with the requirements of Nasdaq Listing Standard 5608 implementing Rule 10D- 1 under the Exchange Act. In the event the Company is required to prepare an accounting restatement of the Company’ s financial statements due to material non- compliance with any financial reporting requirement under the federal securities laws, the Company will recover, on a reasonably prompt basis, the excess incentive- based compensation received by any covered executive, including the NEOs, during the prior three fiscal years that exceeds the amount that the executive otherwise would have received had the incentive- based compensation been determined based on the restated financial statements. Equity Grant Practices Following the Merger, we generally grant annual equity awards, including stock options, in January of each year. We also grant stock options as new hire awards as of their date of employment commencement. Employees, including the NEOs, may enroll to purchase shares under the terms of our 2024 Employee Stock Purchase Plan, as amended (the “ ESPP ”), with purchase dates generally occurring during open trading windows in June and December of each year using payroll deductions accumulated during the prior six- month period. During 2024, the Compensation Committee did not take material nonpublic information into account when determining the timing and terms of stock options, and the Company did not time the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation. Director Compensation The following table provides information for the year ended December 31, 2024 regarding all compensation awarded to, earned by or paid to each person who served as a non- employee director for some portion of 2024. Employees who served on our Board during 2024 did not receive additional compensation for such service: Name (1) (2) Fees Earned or Paid in Cash ($) Option Awards ($) (3) Total ($) Kristine Ball 20, 548- 20, 548 Carl Dambkowski, M. D. 16, 267- 16, 267 Peter Harwin 19, 178- 19, 178 Samarth Kulkarni, Ph. D. 27, 740- 27, 740 Cameron Turtle, D. Phil. (4) 20, 377- 20, 377 Dan Mitchell 30, 810- 30, 810 Raymond Woosley 27, 500- 27, 500 Robert Conway 197, 916 2, 739 200, 655 James Flynn 71, 042 12, 620 83, 662 Linda Grais 168, 124 2, 739 170, 863 Anders Hove 159, 583 2, 739 162, 322 Jacob Ma- Weaver 119, 167 8, 215 127, 382 (1) The amounts reflected herein for directors who served on the Pre- Merger Oruka board of directors do not include any compensation they received from Pre- Merger Oruka prior to the Merger. (2) Messrs. Woosley and Mitchell resigned from our Board effective as of February 2, 2024. In connection with the Merger on August 29, 2024, Drs. Hove and Grais as well as Messrs. Conway, Ma- Weaver and Flynn resigned from our Board and Drs. Turtle, Dambkowski and Kulkarni as well as Ms. Ball and Mr. Harwin were appointed to our Board. (3) In connection with the Merger, all outstanding ARCA stock options held by Drs. Hove and Grais and Messrs. Conway, Ma- Weaver and Flynn were accelerated and cashed out for an amount equal to the difference between $ 3. 9489 and the applicable per share exercise price; however, any ARCA stock options having an exercise price in excess of $ 3. 9489 were cancelled for no consideration. Amounts reported in this column represent the incremental fair value under ASC Topic 718 resulting from the acceleration of the stock options in the Merger. As of December 31, 2024, each of Drs. Turtle and Dambkowski and Ms. Ball held outstanding options or compensatory warrants to purchase 94, 282 shares of our common stock (which were assumed by the Company in connection with the Merger), Dr. Kulkarni held outstanding options or compensatory warrants to purchase 199, 992 shares of our common stock (which were assumed by the Company in connection with the Merger), and no other non- employee directors held any outstanding options or compensatory warrants. (4) Prior to the Merger, Dr. Turtle purchased 85, 233 shares (after giving effect to the share conversion completed in the Merger and the subsequent 1- for- 12 reverse stock split) of restricted common stock that vest as to 25 % on March 1, 2025 and in and in equal monthly installments thereafter through March 1, 2028. All of such restricted shares were outstanding as of December 31, 2024. Non- Employee Director Compensation Program Non- employee members of the Board are eligible to receive cash and equity compensation in accordance with our non- employee director compensation program. This program provides for the following annual cash retainers: Pre- Merger Post- Merger Annual Cash Retainer $ 40, 000 $ 40, 000 Annual Board Chair Retainer $ 30, 000 $ 30, 000 Audit Committee Retainers: Chair $ 15, 000 $ 15, 000 Non- Chair Member $ 7, 500 $ 7, 500 Compensation Committee Retainers: Chair $ 10, 000 $ 12, 000 Non- Chair Member $ 5, 000 $ 6, 000 Nominating and Corporate Governance Committee Retainers Chair $ 10, 000 $ 10, 000 Non- Chair Member $ 5, 000 $ 5, 000 In connection with the Company' s annual meeting of stockholders, each member of the Board will receive an annual grant of stock options to purchase 17, 500 shares of common stock, which will vest in equal monthly installments over 12 months so long as such director joined the Board prior to January 1 of the year in which such annual meeting occurs. Prior to the Merger, the annual grant of stock options was for 6, 000 shares of common stock. In addition, in connection with a non- employee director' s initial appointment to the Board, they will receive an initial grant of stock options to purchase 35, 000 shares of common stock, which will vest in equal monthly installments over 36 months. Prior to the Merger, the initial grant of stock options was for 12, 000 shares of common stock. All members of the Board are also reimbursed for reasonable and documented out- of- pocket travel and lodging expenses incurred in connection with attending meetings and activities of the Board and its committees. Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. Security Ownership of Certain Beneficial Owners and Management The following table sets forth information, to the extent known by us or ascertainable from public filings, with respect to the beneficial ownership of our Common Stock as of February 15, 2025. ● each person or group of affiliated persons, who is known by us to be the beneficial owner of more than 5 % of Common Stock; ● each of our directors; ● each of our named executive officers; and ● all of our current directors and executive officers as a group. The column entitled " Percentage of Shares Outstanding Beneficially Owned " is based on a total of 37, 440, 510 shares of our Common Stock outstanding as of February 15, 2025. Beneficial ownership is determined in accordance with the rules and regulations of the SEC and includes voting or investment power with respect to the Common Stock. Shares of Common Stock subject to options that are currently exercisable or exercisable within 60 days of the date of this table are considered outstanding and beneficially owned by the person holding the options for the purpose of calculating the percentage ownership of that person but not for the purpose of calculating the percentage ownership of any other person. Except as otherwise noted, the persons and entities in this table have sole voting and investing power with respect to all the shares of Common Stock beneficially owned by them, subject to community property laws, where applicable. Except as otherwise indicated in the table below, addresses of named beneficial owners are in care of Oruka Therapeutics, Inc., 855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025. Name of Beneficial Owner Number of Shares Beneficially Owned Percentage of Shares Outstanding Beneficially Owned 5 % Stockholders: Entities affiliated with Fairmount Funds Management LLC (1) 8, 511, 824 19. 99 % FMR LLC (2) 5, 561, 808 14. 86 % Entities affiliated with Venrock Healthcare Capital Partners (3) 4, 148, 428 11. 08 % Entities affiliated with RTW Investments, LP (4) 2, 058, 147 5. 50 % Named Executive Officers and Directors: Lawrence Klein (5) 1, 522, 440 4. 02 % Arjun Agarwal (6) 61, 068 * Joana Goncalves (7) 10, 347 * Paul Quinlan (8) 10, 156 * Michael R. Bristow (9) 399 * Thomas A. Keuer (10) 3, 394 * C. Jeffrey Dekker (11) 3, 333 * Cameron Turtle (12) 110, 579 * Samarth Kulkarni (13) 35, 713 * Peter Harwin (1) 8, 511, 824 19. 99 % Carl Dambkowski (14) 25, 058 * Kristine Ball — * All current executive officers and directors as a group (9 persons) (15) 10, 287, 185 24. 69 % * Less than 1 %. (1) Consists of (i) (A) 798, 614 shares of common stock, (B) 409, 326 shares of common stock issuable upon the exercise of pre- funded warrants and (C) 4, 730, 576 shares of common stock issuable upon conversion of 56, 767 shares of Series B Preferred Stock held by Fairmount Healthcare Fund II L. P. (" Fairmount Fund II ") and (ii) 2, 573, 308 shares of common stock held by Fairmount Healthcare Co- Invest III L. P. (" Fairmount Fund III "). Excludes (i) 4, 888, 338 shares of common stock issuable upon the exercise of the pre- funded warrants and (ii) 6, 697, 573 shares of common stock issuable upon the conversion of 80, 371 shares of Series B Preferred Stock. The pre- funded warrants are subject to a beneficial ownership limitation of 9. 99 % and the shares of Series B Preferred Stock are subject to a beneficial ownership limitation of 19. 99 %, which such limitations restrict Fairmount Funds Management LLC (" Fairmount ") and its affiliates from exercising that portion of the warrants and converting those shares of preferred stock that would result in Fairmount and its affiliates owning, after exercise or conversion, a number of shares of common stock in excess of the applicable ownership limitation. At such time as Fairmount and its affiliates beneficially own 9. 0 % or less of the shares of common stock, the beneficial ownership limitation applicable to the shares of Series B Preferred Stock will automatically reduce to 9. 99 %. Fairmount serves as investment manager for Fairmount Fund II and Fairmount Fund III. Fairmount Fund II and Fairmount Fund III have delegated to Fairmount the sole power to vote and the sole power to dispose of all securities held in Fairmount Fund II and Fairmount Fund III' s portfolios. Because Fairmount Fund II and Fairmount Fund III have divested themselves of voting and investment power over the securities they hold and may not revoke that delegation on less than 61 days' notice, Fairmount Fund II and Fairmount Fund III disclaim beneficial ownership of the securities they hold. As managers of Fairmount, Peter Harwin and Tomas Kiselak may be deemed to have voting and investment power over the shares held by Fairmount Fund II and Fairmount Fund III. Fairmount, Peter Harwin and Tomas Kiselak disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The address of the entities and individuals listed is 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA 19428. (2) All of the shares listed in the table above are owned by funds or accounts managed by direct or indirect subsidiaries of FMR LLC, all of which shares are beneficially owned, or may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49 % of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of FMR LLC is 245 Summer Street, Boston, MA 02210. (3) Consists of (i) 3, 205, 865 shares of common stock held by Venrock Healthcare Capital Partners EG, L. P. (" VHCPEG "), (ii) 856, 747 shares of common stock held by Venrock Healthcare Capital Partners III, L. P. (" VHCP3 "), and (iii) 85, 816 shares of common stock held by VHCP Co- Investment Holdings III, LLC (" VHCPCo3 "). Excludes 405, 980, 107, 788 and 10, 775 shares of common stock issuable upon the exercise of the pre- funded warrants held by VHCPEG, VHCP3 and VHCPCo3, respectively. The pre- funded warrants are subject to a beneficial ownership limitation of 9. 99 %, which such limitations restrict Venrock Healthcare Capital Partners and its affiliates from exercising that portion of the warrants that would result in Venrock Healthcare Capital Partners and its affiliates owning, after exercise, a number of shares of common stock in excess of the applicable ownership limitation. VHCP Management III, LLC (" VHCPM3 ") is the sole general partner of VHCP3 and the sole manager of VHCPCo3. VHCP Management EG, LLC (" VHCPM EG ") is the sole general partner of VHCPEG. As voting members of VHCPM3 and VHCPM EG, Dr. Bong Koh and Nimish Shah may be deemed beneficial owners of any securities beneficially owned by VHCPM3 and VHCPM EG. The principal business address of each of these persons and entities is 7 Bryant Park, 23rd Floor, New York, NY 10018. (4) Consists of 2, 058, 147 shares of common stock held in the aggregate by RTW Master Fund, Ltd. (" RTW Master Fund "), RTW Innovation Master Fund, Ltd. (" RTW Innovation Master Fund "), and RTW Biotech Opportunities Operating Ltd. (" RTW Biotech " and together with RTW Master Fund and RTW Innovation Fund, the " RTW Funds "). RTW Investments, LP (" RTW "), in its capacity as the investment manager of the RTW Funds, has the power to vote and the power to direct the disposition of the shares held by the RTW Funds. Accordingly, RTW may be deemed to be the beneficial owner of such securities. Roderick Wong, M. D., as the Managing Partner of RTW, has the power to direct the vote and disposition of the securities held by RTW. Dr. Wong disclaims beneficial ownership of the shares held by the RTW Funds, except to the extent of his pecuniary interest therein. The principal business address of RTW Investments, LP is 40 10th Avenue, Floor 7, New York, NY 10014, and the address of Dr. Wong and each of the RTW Funds is c / o RTW Investments, LP, 40 10th Avenue, Floor 7, New York, NY 10014. (5) Includes (i) 852, 338 shares of common stock, (ii) 421, 503 shares of common stock issuable upon the exercise of options that will vest within 60 days of the date of this table and (iii) 248, 599 shares of common stock issuable upon the vesting of restricted stock awards that will vest within 60 days of the date of this table. (6) Includes 61, 068 shares of common stock issuable upon the exercise of options that will vest within 60 days of the date of this table. (7) Includes (i) 191 shares of common stock and (ii) 10, 156 shares of common stock issuable upon the exercise of options that will vest within 60 days of the date of this table (8) Includes 10, 156 shares of common stock issuable upon the exercise of options that will vest within 60 days of the date of this table (9) Includes (i) 92 shares owned by Investocor Trust, of which Dr. Bristow is the sole trustee and (ii) 117 shares owned by NFS as Custodian for Michael Bristow' s IRA. Dr. Bristow and ARCA mutually agreed to conclude Dr. Bristow' s employment effective April 3, 2024. (10) Mr. Keuer resigned as named executive officer at the Merger Closing and his last day of employment was September 1, 2024, which termination was considered to be without " cause " related to a change in control for purposes of his employment agreement with ARCA. (11) Mr. Dekker resigned as named executive officer at the Merger Closing and his last day of employment was September 1, 2024, which termination was considered to be without " cause " related to a change in control for purposes of his employment agreement with ARCA. (12) Includes (i) 85, 233 shares of common stock held by the Turtle Family Trust, for which Mr. Turtle serves as Trustee, (ii) 2, 262 shares of common stock issuable upon the exercise of options that will vest within 60 days of the date of this table and (iii) 23, 084 shares of common stock issuable upon the vesting of restricted stock awards that will vest within 60 days of the date of this table. (13) Includes 35, 713 shares of common stock issuable upon the exercise of options that will vest within 60 days of the date of this table (14) Includes 25, 058 shares of common stock issuable upon the exercise of options that will vest within 60 days of the date of this table (15) See notes (1), (5), (6), (7), (8), (12), (13) and (14) above. Securities Authorized for Issuance Under Equity Compensation Plans The following table provides information with respect to all our equity compensation plans in effect as of December 31, 2024. Number of Securities to be Issued upon Exercise of Outstanding Options Weighted Average Exercise Price of Outstanding Options Number of Securities Remaining Available for Future Issuances under Equity Compensation Plans (excluding securities reflected in column (a)) Plan Category (a) (b) (c) Equity Compensation Plans Approved by Security Holders: Stock Incentive Plan 388, 567 $ 26. 91 4, 246, 324 (1) Employee Stock Purchase Plan — — 460, 529 (2) Equity Incentive Plan (3) 1, 179, 193 $ 6. 27 — Equity Compensation Plans Not Approved by Security Holders: Non- Plan Compensatory Warrants (4) 3, 054, 358 $ 7. 80 — Total 4, 622, 118 $ 9. 02 4, 706, 853 (1) The 2024 Stock Incentive Plan (the " 2024 SIP ") provides for an automatic increase in the number of shares reserved for issuance thereunder on January 1 of each year through and including January 1, 2034 equal to (a) 5 % of number of issued and outstanding shares of common stock plus outstanding preferred stock and shares underlying unexercised pre- funded warrants on an as- converted basis) (collectively, " Shares Outstanding ") on December 31 of the immediately preceding year, or (b) a lesser amount as approved by the Board each year. Pursuant to this provision, the number of shares available for issuance under the 2024 SIP increased by 2, 753, 543 shares on January 1, 2025. (2) The ESPP provides for an automatic annual increase in the number of shares reserved for issuance thereunder on January 1 of each year through and including January 1, 2034 equal to (a) 1 % of the number of Shares Outstanding on December 31 of the immediately preceding year, or (2) a lesser amount as approved by the Board each year. Pursuant to this provision, the number of shares available for issuance under the ESPP increased by 550, 709 shares on January 1, 2025. (3) Stock options granted by Pre- Merger Oruka under the 2024 Equity Incentive Plan were assumed by the Company in connection with the Merger. No further awards may be made under the 2024 Equity Incentive Plan. (4) Non- plan compensatory warrants granted by Pre- Merger Oruka were assumed by the Company in connection with the Merger. No further non- plan compensatory warrants are expected to be granted following the Merger. Item 13. Certain Relationships and Related Transactions, and Director Independence. Certain Relationships and Related Transactions Other than the compensation agreements and other arrangements disclosed above under " Executive Compensation, " below we describe the transactions to which we or Pre- Merger Oruka were or are a party since January 1, 2023, in which the amount involved exceeds the lesser of $ 120, 000 or one percent of the average of our or Pre- Merger Oruka' s total assets at year- end for the last two completed fiscal years and in which our or Pre- Merger Oruka directors, executive officers, holders of more than 5 % of our common stock, or members of their immediate family had a direct or indirect material interest. ARCA Transactions Transactions With ARCA' s Former President and Chief Executive Officer ARCA previously entered into unrestricted research grants with its former President and Chief Executive Officer' s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants was contingent upon ARCA' s financial condition, and could be deferred or terminated at ARCA' s discretion. There was no expense under these arrangements for the year ended December 31, 2024. Total expense under these arrangements for the year ended December 31, 2023 was $ (91, 000). In December 2023, ARCA made a payment of $ 125, 000 for the grant period July 2022 through December 2023 under these arrangements. In April 2024, the

President and Chief Executive Officer resigned. Pre- Merger Oruka Transactions Private Placements of Securities Pre- Merger Oruka Series A Preferred Stock and Convertible Note Financing On March 6, 2024, Oruka entered into a Convertible Note Purchase Agreement with Fairmount Healthcare Fund II, L. P. (“ Fairmount Fund II ”), whereby Oruka issued and sold to Fairmount Fund II (i) an aggregate of 20, 000, 000 shares of Pre- Merger Oruka Series A Preferred Stock at a purchase price of $ 0. 15 per share and (ii) a convertible note (the “ Convertible Note ”) with an initial principal amount of $ 25. 0 million at an interest rate of 12 % per annum, for aggregate gross proceeds of $ 28 million. Fairmount Fund II contributed the aggregate principal amount of $ 25. 0 million and all accrued interest under the Convertible Note (unpaid accrued interest of $ 1. 5 million divided by the conversion price of $ 66. 62 ($ 5. 55 prior to the impact of the Reverse Stock Split) per share) in exchange for Pre- Merger Oruka Common Stock and Pre- Merger Oruka pre- funded warrants in connection with the Pre- Merger Closing Financing (as defined below), immediately prior to the completion of the Merger. Fairmount Funds Management (“ Fairmount ”) is the investment manager of Fairmount Fund II. Peter Harwin, one of our directors, is a managing member of Fairmount. Pre- Merger Oruka Pre- Merger Closing Financing On April 3, 2024, in connection with the execution of the Merger Agreement, Pre- Merger Oruka entered into the Subscription Agreement to consummate the Pre- Merger Closing Financing. Pursuant to the Subscription Agreement, the Financing Investors purchased 39, 873, 706 shares of Pre- Merger Oruka common stock and 9, 664, 208 Pre- Merger Oruka pre- funded warrants for gross proceeds of approximately $ 275. 0 million (which includes $ 25. 0 million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note, which converted to 4, 764, 032 shares of Pre- Merger Oruka common stock), immediately prior to the Merger Closing and before the effect of the Reverse Stock Split. Three of the investors or their affiliates were beneficial holders of more than 5 % of Pre- Merger Oruka’ s capital stock, and the table below sets forth the number of shares of Pre- Merger Oruka common stock and Pre- Merger Oruka pre- funded warrants purchased by such holders at the closing of the Pre- Merger Closing Financing. Participant Shares of Pre- Merger Oruka Common Stock Pre- funded Warrants of Pre- Merger Oruka Total Purchase Price Entities affiliated with Fairmount 5, 139, 797 9, 271, 241 $ 79, 907, 282 (1) Entities affiliated with Venrock Healthcare Capital Partners 5, 011, 172 392, 967 $ 29, 996, 067 Entities affiliated with FMR LLC 4, 503, 445 — $ 24, 999, 974 (1) Includes $ 25. 0 million of proceeds previously received by Pre- Merger Oruka from the issuance of the Convertible Note and accrued interest on such note, with the remainder of the purchase price paid in cash. Company Transactions September 2024 Private Placement On September 11, 2024, the Company entered into a Securities Purchase Agreement (the “ SPA ”) with certain selling stockholders to consummate a private placement (the “ Private Placement ”). Pursuant to the SPA, the selling stockholders purchased (i) an aggregate of 5, 600, 000 shares of Common Stock, at a price per share of $ 23. 00, (ii) an aggregate of 2, 439 shares of Series A Preferred Stock, at a price per share of $ 23, 000. 00, and (iii) pre- funded warrants to purchase an aggregate of 680, 000 shares of Common Stock at a purchase price of $ 22. 999 per pre- funded warrant, which represents the per share purchase price of the Private Placement Common Shares less the $ 0. 001 per share exercise price for each pre- funded warrant, for an aggregate purchase price of approximately $ 200. 5 million. Three of the selling stockholders or their affiliates were beneficial holders of more than 5 % of the Company’ s capital stock, and the table below sets forth the number of shares of Common Stock, Series A Preferred Stock and pre- funded warrants purchased by such holders at the closing of the Private Placement. Participant Shares of Common Stock Series A Preferred Stock Pre- Funded Warrants Total Purchase Price Entities affiliated with FMR LLC 2, 105, 000 830 — $ 67, 505, 000 Entities affiliated with Venrock Healthcare Capital Partners 150, 000 200 300, 000 $ 14, 949, 700 Entities affiliated with Fairmount 275, 000 160 — $ 10, 005, 000 Our Relationship with Paragon and Paruka We are party to a number of agreements with Paragon and Paruka. Paragon and Paruka do not beneficially own more than 5 % of our capital stock through their joint holdings of our Common Stock. Fairmount beneficially owns more than 5 % of our capital, one of Fairmount’ s employees serves on our Board, and Fairmount beneficially owns more than 5 % of Paragon. Fairmount appointed Paragon’ s board of directors and has the contractual right to approve the appointment of any executive officers of Paragon, but is not the beneficial owner of Paragon’ s securities. Paruka is an entity formed by Paragon as a vehicle to hold equity in our Company in order to share profits with certain employees of Paragon. In March 2024, Pre- Merger Oruka entered into the Option Agreements with Paragon and Paruka. Under the terms of the Option Agreements, Paragon identifies, evaluates and develops antibodies directed against certain mutually agreed therapeutic targets of interest to us. The Option Agreements include two selected targets, IL- 23 (ORKA- 001) and IL- 17A / F (ORKA- 002). Under each of the Option Agreements, we have the exclusive option to, on a research program- by- research program basis, be granted an exclusive, worldwide license to all of Paragon’ s right, title and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture, and commercialize the antibodies and potential products directed to the selected targets (each, an “ Option ”), with the exception of pursuing ORKA- 001 for the treatment of inflammatory bowel disease. In September 2024, we exercised our Option to acquire the rights to ORKA- 001 and executed the corresponding license agreement (the “ IL- 23 License Agreement ”) on December 17, 2024. In December 2024 we exercised our Option to acquire the rights to ORKA- 002 and executed the corresponding license agreement (the IL- 17A / F License Agreement) on February 4, 2025. Under each license agreement we are required to make non-refundable milestone payments to Paragon of up to $ 12. 0 million under each respective agreement upon the achievement of certain clinical development milestones, up to $ 10. 0 million under each respective agreement upon the achievement of certain regulatory milestones, as well as a low single- digit percentage royalty for antibody products beginning on the first commercial sale in each program. From time to time, we can choose to add additional targets to the collaboration by mutual agreement with Paragon. During 2024, we accrued two $ 1. 5 million milestone payments related to the achievement of development candidates as research and development expense in our consolidated statements of operations and comprehensive loss for the year ended December 31, 2024. As of December 31, 2024, this amount is included under related party accounts payable and other current liabilities on the consolidated balance sheet. Pursuant to the terms of the Option Agreements, the parties initiated certain Research Programs. Each Research Program is aimed at discovering, generating, identifying and / or characterizing antibodies directed to the respective target. For each Research Program, the parties established a Research Plan (each, a “ Research Plan ”) that sets forth the activities that will be conducted, and the associated research budget. We and Paragon agreed on initial Research Plans that outlined the services that were performed commencing at inception of the arrangement related to IL- 17 and IL- 23. Our exclusive option with respect to each Research Program was exercisable at our sole discretion at any time during the period beginning on the initiation of activities under the associated Research Program and ending a specified number of days following the delivery of the data package from Paragon related to the results of the Research Plan activities. There is no payment due upon exercise of an Option pursuant to the Option Agreements. Pursuant to the Option Agreements, on a research program- by- research program basis following the finalization of the Research Plan for each respective research program, the Company was required to pay Paragon a one- time nonrefundable research initiation fee of $ 0. 8 million related to the ORKA- 001 program. This amount was recognized as a research and development expense during the period from February 6 (inception) to December 31, 2024. In June 2024, pursuant to the Option Agreements with Paragon, the Company completed the selection process of its development candidate for IL- 23 antibodies for the ORKA- 001 program. The Company was responsible for 50 % of the development costs incurred through the completion of the IL- 23 selection process. The Company received the rights to at least one selected IL- 23 antibody in June 2024. During 2024, the Company exercised its option for ORKA-001 and recorded a $ 1. 5 million milestone payment related to the achievement of development candidate as research and development expense in the Company’ s consolidated statement of operations and comprehensive loss. In addition, during the period from February 6, 2024 (inception) to December 31, 2024, the Company recorded a $ 2. 5 million milestone payment related to the first dosing of a human subject in a Phase 1 trial of ORKA- 001 in December 2024 as research and development expense in its consolidated statement of operations and comprehensive loss. The Company’ s share of development costs incurred during the period from February 6, 2024 (inception) to December 31, 2024 was $ 13. 5 million, which was recorded as research and development expenses. An amount of $ 2. 8 million related to ORKA- 001 is included in related party accounts payable and other current liabilities as of December 31, 2024. The Company is also required to reimburse Paragon $ 3. 3 million for development costs related to ORKA- 002 incurred by Paragon through December 31, 2023 and certain other development costs incurred by Paragon between January 1, 2024 and March 6, 2024 as stipulated by the Option Agreements. This amount was recognized as a research and development expense during the period from February 6 (inception) to December 31, 2024. The Company is also responsible for development costs incurred by Paragon from January 1, 2024 through the completion of the IL- 17 selection process. The Company recognized an amount of $ 0. 8 million payable to Paragon for the research initiation fee related to ORKA- 002 following the finalization of the ORKA- 002 research plan. This was recognized as research and development expenses in the period from February 6 (inception) to December 31, 2024. During the period from February 6, 2024 (inception) to December 31, 2024, the Company exercised its option for ORKA- 002 and recorded a $ 1. 5 million milestone payment related to the achievement of development candidate as research and development expense in its consolidated statement of operations and comprehensive loss. The Company accounted for development costs of $ 7. 8 million during the period from February 6, 2024 (inception) to December 31, 2024 as research and development expenses. An amount of $ 2. 7 million related to ORKA- 002 is included in related party accounts payable and other current liabilities as of December 31, 2024. Furthermore, the Option Agreements provide for an annual equity grant of warrants to purchase a number of shares equal to 1. 00 % of the then outstanding shares of our stock, on a fully diluted basis, on each of December 31, 2024 and December 31, 2025, during the term of the Option Agreements, at the fair market value determined by our Board. Indemnification Agreements and Insurance We have entered into an indemnification agreement with each of our directors and senior officers and purchased directors’ and officers’ liability insurance. The indemnification agreements require us to indemnify our directors and officers to the fullest extent permitted under Delaware law. Review, Approval or Ratification of Transactions with Related Parties Prior to the Merger Closing, Pre- Merger Oruka did not have a formal policy regarding approval of transactions with related parties. All disclosable transactions with related parties that occurred prior to the Merger Closing were approved by the directors not interested in such transactions, pursuant to Section 144 (a) (1) of the DGCL. Our Board has adopted a written related person transactions policy. Under this policy, our executive officers, directors, nominees for election as a director, beneficial owners of more than 5 % of our Common Stock, and any members of the immediate family of and any entity affiliated with any of the foregoing persons, are not permitted to enter into a material related person transaction with us without the review and approval of our Audit Committee, or a committee composed solely of independent directors in the event it is inappropriate for our Audit Committee to review such transaction due to a conflict of interest. The policy provides that, subject to limited exceptions, any transaction, arrangement or relationship or series of similar transactions, arrangements or relationships in which (1) the aggregate amount involved since the beginning of the Company’ s last completed fiscal year exceeds or is expected to exceed $ 120, 000, (2) the Company or any of our subsidiaries is a participant, and (3) any related person has or will have a direct or indirect interest, will be presented to our Audit Committee for review, consideration and approval. In approving or rejecting any such proposal, our Audit Committee will consider the material facts and other factors it deems appropriate, including, but not limited to, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related person’ s interest in the transaction. Director Independence Our Board has reviewed the independence of all directors in light of each director’ s (or any family member’ s, if applicable) affiliations with the Company and members of management, as well as significant holdings of our securities and all other facts and circumstances that the Board has deemed relevant in determining the independence of each director. The Board has determined that each of the directors other than Lawrence Klein, our current President and Chief Executive Officer, including Kristine Ball, Carl Dambkowski, Peter Harwin, Samarth Kulkarni and Cameron Turtle, qualify as “ independent directors ” as defined by the Nasdaq listing rules. Nasdaq listing rules have objective tests and a subjective test for determining who is an “ independent director. ” The subjective test states that an independent director must be a person who lacks a relationship that, in the opinion of the Board, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. The Board has not established categorical standards or guidelines to make these subjective determinations but considers all relevant facts and circumstances. In addition, ARCA’ s board of directors determined that former directors Drs. Linda Grais, Anders Hove and Raymond Woosley, and Messrs. Robert Conway, Daniel Mitchell and James Flynn were independent during the period each served on the Board in 2024. ARCA’ s board of directors determined Dr. Michael R. Bristow, ARCA’ s former President and Chief Executive Officer, was not an independent director in 2024 by virtue of his employment relationship with ARCA. Item 14. Principal Accountant Fees and Services. Principal Accountant Fees and Services The following is a summary of the audit fees billed and expected to be billed for the indicated fiscal year to Oruka by PricewaterhouseCoopers LLP (“ PwC ”), Pre- Merger Oruka’ s independent registered public accounting firm and Oruka’ s independent registered public accounting firm on and after August 30, 2024, and the fees billed by PwC for all other services rendered during the indicated fiscal year. All services associated with such fees on and after August 30, 2024 were pre- approved by our Audit Committee in accordance with the “ Pre- Approval Policies and Procedures ” described below. Fiscal Year ended December 31, 2024 Audit Fees (1) $ 1, 928, 000 Audit- Related Fees — Tax Fees — All Other Fees (2) 2, 000 Total $ 1, 930, 000 (1) Audit Fees consisted of fees and expenses covering the audit of our consolidated financial statements, reviews of our interim quarterly reports, accounting and financial reporting consultations, and the issuance of consents and comfort letters in connection with registration statement filings with the Securities and Exchange Commission (the “ SEC ”). (2) All Other Fees consist of all other services and fees billed for an annual subscription to PwC’ s online resource library. Pre- Approval Policies and Procedures In connection with the Merger Closing, our Board and Audit Committee adopted a policy and procedures for the pre- approval of audit and non- audit services performed by our independent registered public accounting firm. These procedures generally approve the performance of specific services subject to a cost limit for all such services. This general approval is reviewed, and if necessary modified, at least annually. Management must obtain the specific prior approval of the Audit Committee for each engagement of our independent registered public accounting firm to perform other audit- related or non-audit services. The Audit Committee does not delegate its responsibility to pre- approve services performed by our independent registered public accounting firm to any member of management. The Audit Committee has delegated authority to the Audit Committee chair to pre- approve audit and non- audit services to be provided to us by our independent registered public accounting firm provided that the fees for such services do not exceed $ 100, 000. Any pre- approval of services by the Audit Committee chair pursuant to this delegated authority must be reported to the Audit Committee at its next regularly scheduled meeting. PART IV Item 15. Exhibits, Financial Statement Schedules. (a) The following documents are filed as part of this Annual Report: (1) Financial Statements See Index to Financial Statements included in Part II, Item 8 of this Annual Report. (2) Financial Statement Schedules All schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes thereto. (3) List of Exhibits required by Item 601 of Regulation S- K Incorporation By Reference Exhibit Number Description Form Exhibit No. Filing Date 2. 1 † Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024, by and among ARCA biopharma, Inc., Atlas Merger Sub Corp., Atlas Merger Sub II, LLC and Oruka Therapeutics, Inc. 8- K 2. 1 4 / 3 / 2024 3. 1 Second Amended and Restated Certificate of Incorporation 8- K 3. 5 9 / 5 / 2024 3. 2 Amended and Restated Bylaws 8- K 3. 6 9 / 5 / 2024 3. 3 Form of Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock S- 1 / A 3. 1 (b) 5 / 24 / 2013 3. 4 Certificate of Elimination of Series A Convertible Preferred Stock, dated August 29, 2024 8- K 3. 8 9 / 5 / 2024 3. 5 Certificate of Designation of Preferences, Rights and Limitations of Series B Non- Voting Convertible Preferred Stock 8- K 3. 9 9 / 5 / 2024 3. 6 Certificate of Designation of Preferences, Rights and Limitations of Series A Non- Voting Convertible Preferred Stock 8- K 3. 1 9 / 13 / 2024 4. 1 Description of Securities Filed herewith 4. 2 Investors’ Rights Agreement by and among Oruka Therapeutics, Inc. and certain investors, dated March 6, 2024 S- 4 4. 3 5 / 14 / 2024 4. 3 Form of Pre- Funded Warrant, dated August 29, 2024 Filed herewith 4. 4 Form of Pre- Funded Warrant, dated September 13, 2024 8- K 4. 1 9 / 13 / 2024 10. 1 # Oruka Therapeutics, Inc. 2024 Stock Incentive Plan 8- K 10. 10 9 / 5 / 2024 10. 2 # Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan 8- K 10. 11 9 / 5 / 2024 10. 3 # Amended and Restated 2024 Equity Incentive Plan S- 4 10. 40 5 / 14 / 2024 10. 4 # Second Amendment to the Oruka Therapeutics, Inc. Amended and Restated 2024 Equity Incentive Plan 8- K 10. 13 9 / 5 / 2024 10. 5 # Form of Employee Warrant Agreement 8- K 10. 16 9 / 5 / 2024 10. 6 # Form of Grant Notice for Nonqualified Stock Option and Standard Terms and Conditions for Stock Options (Directors) S- 8 99. 2 11 / 14 / 2024 10. 7 # Form of Grant Notice for Stock Option and Standard Terms and Conditions for Stock Options (Employees) S- 8 99. 3 11 / 14 / 2024 10. 8 # Form of Stock Option Agreement under the Oruka Therapeutics, Inc. Amended and Restated 2024 Equity Incentive Plan S- 4 10. 42 5 / 14 / 2024 10. 9 # Separation Agreement and Release by and between Michael Bristow and ARCA biopharma, Inc., dated April 3, 2024 8- K 10. 1 4 / 4 / 2024 10. 10 # Second Amendment to Retention Bonus Letter by and between ARCA biopharma, Inc. and Thomas A. Keuer, dated April 22, 2024 8- K 10. 1 4 / 23 / 2024 10. 11 # Second Amendment to Retention Bonus Letter by and between ARCA biopharma, Inc. and C. Jeffrey Dekker 8- K 10. 2 4 / 23 / 2024 10. 12 † # Consulting Agreement, effective as of August 30, 2024, by and between the Company and Jeff Dekker 8- K 10. 25 9 / 5 / 202410. 13 # Amended and Restated Director Offer Letter, dated March 22, 2024, by and between Oruka Therapeutics, Inc. and Samarth Kulkarni S- 4 10. 43 5 / 14 / 2024 10. 14 # Director Offer Letter, dated April 24, 2024, by and between Oruka Therapeutics, Inc. and Kristine Ball S- 4 10. 44 5 / 14 / 2024 10. 15 # Amended and Restated Employment Letter Agreement by and between Oruka Therapeutics, Inc. and Lawrence Klein, dated October 3, 2024 8- K 10. 1 10 / 4 / 2024 10. 16 # Amended and Restated Employment Letter Agreement by and between Oruka Therapeutics, Inc. and Arjun Agarwal, dated October 3, 2024 8- K 10. 2 10 / 4 / 2024 10. 17 * # Amended and Restated Employment Letter Agreement by and between Oruka Therapeutics, Inc. and Paul Quinlan, dated October 1, 2024 Filed herewith 10. 18 * # Amended and Restated Employment Letter Agreement by and between Oruka Therapeutics, Inc. and Joana Goncalves, dated October 1, 2024 Filed herewith 10. 19 * # Form of Indemnification Agreement Filed herewith 10. 20 * Non- Employee Directors Compensation Program Filed herewith 10. 21 Form of Lock- Up Agreement 8- K 10. 4 4 / 3 / 2024 10. 22 Form of Amendment to Subscription Agreement 8- K 10. 1 7 / 9 / 2024 10. 23 Form of Amended & Restated Subscription Agreement 8- K 10. 2 7 / 9 / 2024 10. 24 Form of Registration Rights Agreement, dated August 29, 2024 10- Q 10. 4 11 / 13 / 2024 10. 25 † Securities Purchase Agreement by and between Oruka Therapeutics, Inc. and each of the entities listed on Exhibit A thereto, dated September 11, 2024 8- K 10. 1 9 / 13 / 2024 10. 26 Form of Registration Rights Agreement, dated as of September 13, 2024 8- K 10. 2 9 / 13 / 2024 10. 27 Asset Purchase Agreement, dated August 14, 2024, by and between ARCA biopharma, Inc. and Genvara Biopharma, Inc. 8- K 10. 1 8 / 15 / 2024 10. 28 † Amended and Restated Antibody Discovery and Option Agreement (IL- 17) by and among Paragon Therapeutics, Inc., Paruka Holding, LLC, and Oruka Therapeutics, Inc. dated March 28, 2024 S- 4 / A 10. 50 6 / 18 / 2024 10. 29 * † IL- 17 License Agreement by and between Paragon Therapeutics, Inc. and Oruka Therapeutics, Inc., dated February 4, 2025 Filed herewith 10. 30 † Amended and Restated Antibody Discovery and Option Agreement (IL- 23) by and among Paragon Therapeutics, Inc., Paruka Holding, LLC, and Oruka Therapeutics, Inc. dated March 28, 2024 S- 4 / A 10. 51 6 / 18 / 2024 10. 31 * † IL- 23 License Agreement by and between Paragon Therapeutics, Inc. and Oruka Therapeutics, Inc., dated December 17, 2024 Filed herewith 10. 32 * † Cell Line License Agreement by and between WuXi Biologics Ireland Limited and Oruka Therapeutics, Inc., dated March 4, 2024 Filed herewith 10. 33 * † Amendment No. 1 to the Cell Line License Agreement by and between WuXi Biologics Ireland Limited and Oruka Therapeutics, Inc., dated November 20, 2024 Filed herewith 14. 1 Code of Business Conduct and Ethics 8- K 14. 1 9 / 5 / 2024 16. 1 Letter from KPMG LLP, dated September 5, 2024 8- K 16. 1 9 / 5 / 2024 19. 1 * Insider Trading Policy Filed herewith 21. 1 * List of subsidiaries of the Registrant Filed herewith 23. 1 * Consent of Independent Registered Public Accounting Firm Filed herewith 24. 1 * Power of Attorney (Incorporated by reference to the signature page of this Annual Report on Form 10- K) Filed herewith31. 1 * Certification of the Principal Executive Officer pursuant to Rule 13a- 14 (a) or 15d- 14 (a) promulgated under the Securities Exchange Act of 1934 Filed herewith 31. 2 * Certification of the Principal Financial Officer pursuant to Rule 13a- 14 (a) or 15d- 14 (a) promulgated under the Securities Exchange Act of 1934 Filed herewith 32. 1 * * Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U. S. C. Section 1350 and Rule 13a- 14 (B) promulgated under the Securities Exchange Act of 1934 Furnished herewith 97. 1 * Incentive Compensation Clawback Policy Filed herewith 101. INS * Inline XBRL Instance Document Filed herewith 101. SCH * Inline XBRL Taxonomy Extension Schema with Embedded Linkbases Document Filed herewith 101. CAL * Inline XBRL Taxonomy Extension Calculation Linkbase Document. Filed herewith 101. DEF * Inline XBRL Taxonomy Extension Definition Linkbase Document. Filed herewith 101. LAB * Inline XBRL Taxonomy Extension Label Linkbase Document. Filed herewith 101. PRE * Inline XBRL Taxonomy Extension Presentation Linkbase Document. Filed herewith Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith. * * Furnished herewith. The certifications on Exhibit 32. 1 hereto are deemed not “ filed ” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act. # Indicates management contract or compensatory plan. † Exhibits and / or schedules have been omitted pursuant to Item 601 (a) (5) of Regulation S- K. The Company hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however, that the Company may request confidential treatment pursuant to Rule 24b- 2 under the Exchange Act for any exhibits or schedules so furnished. Certain portions of this exhibit (indicated by “ [* * *] ”) have been omitted because they are both (i) not material and (ii) is the type of information that the registrant both customarily and actually treats as private and confidential. Item 16. Form 10- K Summary SIGNATURES Pursuant to the requirements of Section 13 or 15 (d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized. Oruka Therapeutics, Inc. Date: March 6, 2025 By: / s / Lawrence Klein Lawrence Klein President and Chief Executive Officer (Principal Executive Officer) POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Dr. Lawrence Klein and Mr. Arjun Agarwal, jointly and severally, his or her attorneys- in- fact, each with the power of substitution, for him or her in any and all capacities, to sign any amendments to this Report on Form 10- K and to file same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys- in- fact, or his substitutes, may do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated. Signature Title Date / s / Lawrence Klein Chief Executive Officer & Director March 6, 2025 Lawrence Klein (Principal Executive Officer) / s / Arjun Agarwal Senior Vice President, Finance and Treasurer March 6, 2025 Arjun Agarwal (Principal Financial Officer and Principal Accounting Officer) / s / Samarth Kulkarni Chairman of the Board March 6, 2025 Samarth Kulkarni / s / Kristine Ball Director March 6, 2025 Kristine Ball / s / Carl Dambkowski Director March 6, 2025 Carl Dambkowski / s / Peter Harwin Director March 6, 2025 Peter Harwin / s / Cameron Turtle Director March 6, 2025 Cameron Turtle false FY2024- 02- 06 2024- 12- 312024- 06- 302025- 02- 282024- 12- 312024- 02- 06us- gaap: RelatedPartyMember2024- 12- 31us- gaap: RelatedPartyMember2024- 02- 06orka: SeriesAConvertiblePreferredStockMember2024- 12- 31orka: SeriesAConvertiblePreferredStockMember2024- 02- 06orka: SeriesANonVotingConvertiblePreferredStockMember2024- 12- 31orka: SeriesANonVotingConvertiblePreferredStockMember2024- 02- 06orka: SeriesBNonVotingConvertiblePreferredStockAmountMember2024- 12- 31orka: SeriesBNonVotingConvertiblePreferredStockAmountMember2024- 02- 06us- gaap: ResearchAndDevelopmentExpenseMember2024- 02- 06 2024- 12- 31us- gaap: GeneralAndAdministrativeExpenseMember2024- 02- 06 2024- 12- 31us- gaap: InterestExpenseMember2024- 02- 06 2024- 12- 31orka: SeriesANonVotingConvertiblePreferredStockholdersMember2024- 02- 06 2024- 12- 31orka: SeriesBNonVotingConvertiblePreferredStockholdersMember2024- 02- 06 2024- 12- 31us- gaap: SeriesAPreferredStockMember us- gaap: PreferredStockMember2024- 02- 05orka: SeriesANonVotingConvertiblePreferredStockMember us- gaap: PreferredStockMember2024- 02- 05orka: SeriesBNonVotingConvertiblePreferredStockAmountMember us- gaap: PreferredStockMember2024- 02- 05us- gaap: CommonStockMember2024- 02- 05us- gaap: AdditionalPaidInCapitalMember2024- 02- 05us- gaap: AccumulatedOtherComprehensiveIncomeMember2024- 02- 05us- gaap: RetainedEarningsMember2024- 02- 052024- 02- 05us- gaap: SeriesAPreferredStockMember us- gaap: PreferredStockMember2024- 02- 06 2024- 12- 31orka: SeriesANonVotingConvertiblePreferredStockMember us- gaap: PreferredStockMember2024- 02- 06 2024- 12- 31orka: SeriesBNonVotingConvertiblePreferredStockAmountMember us- gaap: PreferredStockMember2024- 02- 06 2024- 12- 31us- gaap: CommonStockMember2024- 02- 06 2024- 12- 31us- gaap: AdditionalPaidInCapitalMember2024- 02- 06 2024- 12- 31us- gaap: AccumulatedOtherComprehensiveIncomeMember2024- 02- 06 2024- 12- 31us- gaap: RetainedEarningsMember2024- 02- 06 2024- 12- 31us- gaap: SeriesAPreferredStockMember us- gaap: PreferredStockMember2024- 12- 31orka: SeriesANonVotingConvertiblePreferredStockMember us- gaap: PreferredStockMember2024- 12- 31orka: SeriesBNonVotingConvertiblePreferredStockAmountMember us- gaap: PreferredStockMember2024- 12- 31us- gaap: CommonStockMember2024- 12- 31us- gaap: AdditionalPaidInCapitalMember2024- 12- 31us- gaap: AccumulatedOtherComprehensiveIncomeMember2024- 12- 31us- gaap: RetainedEarningsMember2024- 12- 31orka: OrukaCommonStockMember2024- 09- 03 2024- 09- 03orka: OrukaCommonStockMember2024- 09- 03orka: PrefundedWarrantsMember orka: PreMergerOrukaMember2024- 04- 03 2024- 04- 032024- 04- 03 2024- 04- 03orka: ARCACommonStockMember2024- 02- 06 2024- 12- 31orka: OrukaSeriesAConvertiblePreferredStockMember2024- 12- 31orka: SeriesANonVotingConvertiblePreferredStockMember2024- 12- 31us- gaap: SeriesBPreferredStockMember2024- 02- 06 2024- 12- 31us- gaap: CommonStockMember2024- 02- 06 2024- 12- 31us- gaap: CommonStockMember orka: PreMergerOrukaMember2024- 02- 06 2024- 12- 31us- gaap: CommonStockMember orka: PIPEFinancingMember2024- 12- 31orka: SeriesANonVotingConvertiblePreferredStockMember orka: PIPEFinancingMember2024- 02- 06 2024- 12- 31orka: SeriesANonVotingConvertiblePreferredStockMember orka: PIPEFinancingMember2024- 12- 31us- gaap: SeriesAPreferredStockMember us- gaap: CommonStockMember2024- 02- 06 2024- 12- 31orka: PrefundedWarrantsMember2024- 12- 31orka: PrefundedWarrantsMember2024- 02- 06 2024- 12- 31srt: MinimumMember us- gaap: FurnitureAndFixturesMember2024- 12- 31srt: MaximumMember us- gaap: FurnitureAndFixturesMember2024- 12- 31srt: MinimumMember us- gaap: ComputerEquipmentMember2024- 12- 31srt: MaximumMember us- gaap: ComputerEquipmentMember2024- 12- 312024- 08- 29us- gaap: MoneyMarketFundsMember us- gaap: FairValueInputsLevel1Member2024- 12- 31us- gaap: MoneyMarketFundsMember us- gaap: FairValueInputsLevel2Member2024- 12- 31us- gaap: MoneyMarketFundsMember us- gaap: FairValueInputsLevel3Member2024- 12- 31us- gaap: MoneyMarketFundsMember2024- 12- 31us- gaap: USTreasurySecuritiesMember us- gaap: FairValueInputsLevel2Member2024- 12- 31us- gaap: USTreasurySecuritiesMember us- gaap: FairValueInputsLevel3Member2024- 12- 31us- gaap: USTreasurySecuritiesMember2024- 12- 31us- gaap: USGovernmentAgenciesDebtSecuritiesMember us- gaap: FairValueInputsLevel1Member2024- 12- 31us- gaap: USGovernmentAgenciesDebtSecuritiesMember us- gaap: FairValueInputsLevel2Member2024- 12- 31us- gaap: USGovernmentAgenciesDebtSecuritiesMember us- gaap: FairValueInputsLevel3Member2024- 12- 31us- gaap: USGovernmentAgenciesDebtSecuritiesMember2024- 12- 31us- gaap: CommercialPaperMember us- gaap: FairValueInputsLevel1Member2024- 12- 31us- gaap: CommercialPaperMember us- gaap: FairValueInputsLevel2Member2024- 12- 31us- gaap: CommercialPaperMember us- gaap: FairValueInputsLevel3Member2024- 12- 31us- gaap: CommercialPaperMember2024- 12- 31us- gaap: FairValueInputsLevel1Member2024- 12- 31us- gaap: FairValueInputsLevel2Member2024- 12- 31us- gaap: FairValueInputsLevel3Member2024- 12- 31us- gaap: CorporateDebtSecuritiesMember us- gaap: FairValueInputsLevel1Member2024- 12- 31us- gaap: CorporateDebtSecuritiesMember us- gaap: FairValueInputsLevel2Member2024- 12- 31us- gaap: CorporateDebtSecuritiesMember us- gaap: FairValueInputsLevel3Member2024- 12- 31us- gaap: CorporateDebtSecuritiesMember2024- 12- 31us- gaap: MoneyMarketFundsMember us- gaap: CashEquivalentsMember2024- 12- 31us- gaap: USTreasurySecuritiesMember us- gaap: CashEquivalentsMember2024- 12- 31us- gaap: USGovernmentAgenciesDebtSecuritiesMember us- gaap: CashEquivalentsMember2024- 12- 31us- gaap: CommercialPaperMember us- gaap: CashEquivalentsMember2024- 12- 31us- gaap: CashEquivalentsMember2024- 12- 31us- gaap: USTreasurySecuritiesMember orka: MarketableSecuritiesMember2024- 12- 31us- gaap: USGovernmentAgenciesDebtSecuritiesMember orka: MarketableSecuritiesMember2024- 12- 31us- gaap: CommercialPaperMember orka: MarketableSecuritiesMember2024- 12- 31us- gaap: CorporateDebtSecuritiesMember orka: MarketableSecuritiesMember2024- 12- 31orka: MarketableSecuritiesMember2024- 12- 31us- gaap: USTreasurySecuritiesMember orka: MarketableSecuritiesLongTermMember2024- 12- 31us- gaap: USGovernmentAgenciesDebtSecuritiesMember orka: MarketableSecuritiesLongTermMember2024- 12- 31orka: MarketableSecuritiesLongTermMember2024- 12- 31us- gaap: CommercialPaperMember2024- 12- 31orka: MarketableSecuritiesCurrentMember us- gaap: USTreasurySecuritiesMember2024- 12- 31orka: MarketableSecuritiesCurrentMember orka: USGovernmentAgencySecuritiesMember2024- 12- 31orka: MarketableSecuritiesCurrentMember us- gaap: CorporateDebtSecuritiesMember2024- 12- 31orka: MarketableSecuritiesNoncurrentMember us- gaap: USTreasurySecuritiesMember2024- 12- 31orka: MarketableSecuritiesNoncurrentMember orka: USGovernmentAgencySecuritiesMember2024- 12- 31orka: ConvertibleNoteMember orka: FairmountHealthcareFundIILPMember orka: PreMergerOrukaMember2024- 03- 31orka: ConvertibleNoteMember orka: FairmountHealthcareFundIILPMember orka: PreMergerOrukaMember2024- 03- 01 2024- 03- 31orka: ConvertibleNoteMember orka: PreMergerOrukaMember2024- 03- 01 2024- 03- 31orka: ConvertibleNoteMember orka: PreMergerOrukaMember2024- 02- 06 2024- 12- 31orka: ConvertibleNoteMember2024- 02- 06 2024- 12- 31orka: ConvertibleNoteMember orka: PreMergerOrukaMember2024- 03- 31orka: ConvertibleNoteMember us- gaap: CommonStockMember2024- 02- 06 2024- 12- 31orka:

PreFundedWarrantsMember2024- 08- 01 2024- 08- 31orka: PreFundedWarrantsMember2024- 08- 31us- gaap: CommonStockMember2024- 08- 01 2024- 08- 31orka: PreFundedWarrantsMember us- gaap: CommonStockMember2024- 08- 31orka: PreFundedWarrantsMember2024- 09- 01 2024- 09- 30orka: PreFundedWarrantsMember2024- 09- 30us- gaap: CommonStockMember2024- 09- 01 2024- 09- 30orka: PreFundedWarrantsMember us- gaap: CommonStockMember2024- 09- 30orka: PreFundedWarrantsMember2024- 02- 06 2024- 12- 31orka: PreFundedWarrantsMember2024- 12- 31orka: EmployeeWarrantsMember2024- 12- 31orka: EmployeeWarrantsMember2024- 02- 06 2024- 12- 31orka: FairmountMember us- gaap: SeriesAPreferredStockMember orka: PreMergerOrukaMember2024- 03- 01 2024- 03- 31orka: FairmountMember us- gaap: SeriesAPreferredStockMember orka: PreMergerOrukaMember2024- 03- 31orka: FairmountMember us- gaap: SeriesAPreferredStockMember2024- 03- 01 2024- 03- 31us- gaap: SeriesAPreferredStockMember orka: PreMergerOrukaMember2024- 03- 01 2024- 03- 31us- gaap: SeriesBPreferredStockMember2024- 08- 31us- gaap: SeriesAPreferredStockMember orka: PIPEFinancingMember2024- 09- 01 2024- 09- 30us- gaap: SeriesAPreferredStockMember2024- 09- 30us- gaap: SeriesAPreferredStockMember orka: PIPEFinancingMember2024- 11- 30us- gaap: SeriesAPreferredStockMember2024- 11- 30us- gaap: SeriesAPreferredStockMember2024- 12- 31orka: ParukaWarrantMember2024- 12- 31orka: ParukaWarrantMember2024- 02- 06 2024- 12- 31us- gaap: RestrictedStockMember2024- 12- 31orka: SeriesBConvertiblePreferredStockMember2024- 12- 31orka: ParukaWarrantObligationMember2024- 12- 31us- gaap: StockOptionMember2024- 12- 31orka: TwoThousandTwentyFourStockIncentivePlanMember2024- 12- 31orka: TwoThousandTwentyFourEmployeeStockPurchasePlanMember2024- 12- 31orka: TwoThousandTwentyFourStockIncentivePlanMember2024- 08- 22us- gaap: StockOptionMember orka: TwoThousandTwentyFourStockIncentivePlanMember2024- 12- 31orka: TwoThousandTwentyFourStockIncentivePlanMember2024- 12- 31orka: TwoThousandTwentyFourStockIncentivePlanMember2024- 02- 06 2024- 12- 31orka: TwoThousandTwentyFourEmployeeStockPurchasePlanMember2024- 08- 29orka: TwoThousandTwentyFourEmployeeStockPurchasePlanMember2024- 08- 29 2024- 08- 29orka: TwoThousandTwentyFourEmployeeStockPurchasePlanMember2024- 02- 06 2024- 12- 31us- gaap: StockOptionMember2024- 02- 06 2024- 12- 31us- gaap: RestrictedStockMember2024- 02- 06 2024- 12- 31orka: ParukaWarrantObligationMember2024- 02- 06 2024- 12- 312024- 02- 06 2024- 02- 06us- gaap: RestrictedStockMember2024- 02- 05orka: EmployeeWarrantsMember2024- 02- 06orka: EmployeeWarrantsMember2024- 02- 07 2024- 12- 31orka: ParukaWarrantObligationMember2024- 02- 06 2024- 12- 31orka: EmployeeWarrantsMember2024- 02- 06 2024- 12- 31us- gaap: StockOptionMember2024- 02- 06 2024- 12- 31orka: EmployeeStockPurchasePlanMember2024- 02- 06 2024- 12- 31orka: OperatingExpenseExcludingStockBasedCompensationMember2024- 02- 06 2024- 12- 31orka: ExternalMember2024- 02- 06 2024- 12- 31orka: OtherMember2024- 02- 06 2024- 12- 31orka: OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember2024- 02- 06 2024- 12- 31us- gaap: DomesticCountryMember2024- 12- 31us- gaap: StateAndLocalJurisdictionMember2024- 12- 31orka: ParagonMember orka: ClinicalDevelopmentMilestonesMember2024- 02- 06 2024- 12- 31orka: ParagonMember orka: RegulatoryMilestonesMemberMember2024- 02- 06 2024- 12- 31orka: ParagonMember orka: ClinicalDevelopmentMilestonesMember orka: ORKAZeroZeroOneLicenseAgreementMember2024- 02- 06 2024- 12- 31orka: ParagonMember orka: ClinicalDevelopmentMilestonesMember orka: ORKAZeroZeroTwoLicenseAgreementMember2024- 02- 06 2024- 12- 31orka: RegulatoryMilestonesMemberMember2024- 02- 06 2024- 12- 31orka: ParagonMember orka: NominationOfADevelopmentCandidateMember2024- 02- 06 2024- 12- 31orka: ParagonMember orka: FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember orka: ORKAZeroZeroOneMember2024- 02- 06 2024- 12- 31orka: ParagonMember orka: FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember orka: ORKAZeroZeroTwoMember2024- 02- 06 2024- 12- 31orka: ParagonMember orka: AntibodyProductsMember2024- 12- 31orka: ParukaWarrantObligationMember orka: ORKAZeroZeroTwoMember2024- 02- 06 2024- 12- 31orka: ParagonMember orka: ORKAZeroZeroOneMember2024- 02- 06 2024- 12- 31orka: ORKAZeroZeroOneMember2024- 02- 06 2024- 12- 31orka: ParagonMember us- gaap: ResearchAndDevelopmentExpenseMember orka: AchievementOfDevelopmentCandidateMember orka: ORKAZeroZeroOneMember2024- 02- 06 2024- 12- 31orka: ParagonMember us- gaap: ResearchAndDevelopmentExpenseMember orka: FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember orka: ORKAZeroZeroOneMember2024- 02- 06 2024- 12- 31us- gaap: RelatedPartyMember orka: ORKAZeroZeroOneMember2024- 12- 31orka: ParagonMember orka: ORKAZeroZeroTwoMember2023- 01- 01 2023- 12- 31orka: ParagonMember orka: ORKAZeroZeroTwoMember2024- 02- 06 2024- 12- 31orka: ParagonMember us- gaap: ResearchAndDevelopmentExpenseMember orka: AchievementOfDevelopmentCandidateMember orka: ORKAZeroZeroTwoMember2024- 02- 06 2024- 12- 31us- gaap: RelatedPartyMember orka: ORKAZeroZeroTwoMember2024- 12- 31stpr: CA2024- 06- 15stpr: CA2024- 12- 31us- gaap: SeriesAPreferredStockMember2024- 02- 06 2024- 12- 31orka: EmployeeWarrantsMember2024- 02- 06 2024- 12- 31orka: RestrictedStockAwardsMember2024- 02- 06 2024- 12- 31orka: StockOptionsMember2024- 02- 06 2024- 12- 31orka: ParukaWarrantMember2024- 02- 06 2024- 12- 31orka: ParagonMember us- gaap: CommonStockMember2024- 02- 06 2024- 12- 31orka: ParukaMember us- gaap: CommonStockMember2024- 02- 06 2024- 12- 31orka: FairmountHealthcareFundIILPMember us- gaap: CommonStockMember2024- 02- 06 2024- 12- 31orka: FairmountsOwnershipInterestInParagonMember2024- 02- 06 2024- 12- 31orka: ParagonReimbursableOptionAgreementsFeesMember2024- 12- 31orka: ParagonMilestonePaymentsForOptionAgreementMember2024- 12- 31orka: ParagonReimbursableOtherResearchExpensesMember2024- 12- 31orka: ParagonReimbursablePatentExpensesMember2024- 12- 31us- gaap: SubsequentEventMember2025- 02- 282024- 10- 01 2024- 12- 31iso4217: USD xbrli: sharesiso4217: USDxbrli: sharesxbrli: pureExhibit 4. 1 DESCRIPTION OF THE REGISTRANT' S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED DESCRIPTION OF CAPITAL STOCK The following description summarizes the material terms of the capital stock of Oruka Therapeutics, Inc. (" we, " " us, " " our " or the " Company "), as well as other material terms of certain provisions of the Delaware General Corporation Law (the " DGCL "), our second amended and restated certificate of incorporation (" Certificate of Incorporation ") and amended and restated bylaws (" Bylaws "), both of which have been filed as exhibits to our Annual Report on Form 10- K of which this Exhibit 4. 1 is a part, and are incorporated by reference herein. This summary does not purport to be complete and is qualified in its entirety by the provisions of our Certificate of Incorporation and Bylaws. We encourage you to read our Certificate of Incorporation, our Bylaws, and the applicable provisions of the DGCL for more information. Our authorized capital stock consists of 545, 000, 000 shares of Common Stock, $ 0. 001 par value per share, and 5, 000, 000 shares of preferred stock, $ 0. 001 par value per share (" Preferred Stock "), of which 251, 504 shares have been designated as Series B Preferred Stock, $ 0. 001 par value per share (the " Series B Preferred Stock "). As of December 31, 2024, there were 37, 440, 510 shares of our Common Stock and 137, 138 shares of Series B Preferred Stock outstanding. Our Certificate of Incorporation authorizes the issuance of up to 545, 000, 000 shares of Common Stock. All outstanding shares of Common Stock are validly issued, fully paid and nonassessable. Dividend rights Subject to preferences that may apply to any shares of Preferred Stock outstanding at the time, the holders of our Common Stock are entitled to receive dividends out of funds legally available if our board of directors (our " Board "), in its discretion, determines to issue dividends and then only at the times and in the amounts that our Board may determine. Voting rights Pursuant to our Bylaws, holders of our Common Stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. We have not provided for cumulative voting for the election of directors in our Certificate of Incorporation. Accordingly, pursuant to our Certificate of Incorporation, holders of a majority of the shares of our Common Stock are able to elect all of our directors. Our Certificate of Incorporation establishes a classified Board, divided into three classes with staggered three- year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three- year terms. No preemptive or similar rights Our Common Stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions. Right to receive liquidation distributions Upon our liquidation, dissolution or winding- up, the assets legally available for distribution to our stockholders would be distributable ratably among the holders of our Common Stock and any participating Preferred Stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights of and the payment of liquidation preferences, if any, on any outstanding shares of Preferred Stock. Under the terms of our Certificate of Incorporation, our Board is authorized, subject to limitations prescribed by Delaware law, to issue up to 5, 000, 000 shares of Preferred Stock in one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and any of their qualifications, limitations or restrictions, in each case without further vote or action by our stockholders. Subject to any certificates of designation, the Board can also increase or decrease the number of shares of any series of Preferred Stock, but not below the number of shares of that series then outstanding, without any further vote or action by our stockholders. Our Board may authorize the issuance of Preferred Stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our ~~common~~ Common ~~stock~~ Stock ~~are subject to~~. The issuance of Preferred Stock , while providing flexibility in connection with possible acquisitions and ~~may be~~ other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of our Company and might adversely ~~affected -~~ - affect ~~by,~~ the market price of our Common Stock and the voting and other rights of the holders of our Common Stock. Certain holders of our Series B ~~preferred~~ Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal to, on an as- if- converted- to- common- stock basis, and ~~that may be issued~~ in the ~~future~~ same form as dividends actually paid on shares of our Common Stock . ~~In addition,~~ Except as provided in the Series B Certificate of Designation or as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, we will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock: (a) (i) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, (ii) alter or amend the Series B Certificate of Designation, or (iii) amend or repeal any provision of, or add any provision to, our Certificate of Incorporation or Bylaws in a manner that adversely affects any rights of the holders of the Series B Preferred Stock, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series B Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (b) issue further shares of Series B Preferred Stock beyond those contemplated for issuance in the Merger Agreement or increase or decrease (other than by conversion) the number of authorized shares of Series B ~~preferred~~ Preferred Stock, (c) at any time while at least 30 % of the originally issued Series B Preferred Stock remains issued and outstanding, consummate either: (x) any Fundamental Transaction (as defined in the Series B Certificate of Designation) or (y) any merger or consolidation of the Company with or into another entity or any stock sale to, or other business combination in which the stockholders of the Company immediately before such transaction do not hold at least a majority of our capital stock immediately after such transaction, or (d) enter into any agreement with respect to any of the foregoing. The Series B Preferred Stock shall rank on parity with the Common Stock as to the distribution of assets upon any liquidation, dissolution, or winding- up of the Company. Each share of Series B Preferred Stock is convertible at the option of the holder, at any time, and without the payment of additional consideration by the holder. As of December 31, 2024, each outstanding share of Series B Preferred Stock was convertible into common stock at a ratio of approximately 83. 3332: 1. Anti- Takeover Provisions The provisions of Delaware law, our Certificate of Incorporation and our Bylaws could have the ~~a dilutive~~ effect ~~on the holdings~~ of delaying, deferring or discouraging another person from acquiring control of our Company ~~current stockholders~~ . These provisions, which are summarized below, may have the effect of discouraging takeover bids. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our Board. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms. Delaware law We are subject to the ~~Delaware anti- takeover laws~~ provisions of Section 203 of the DGCL regulating corporate takeovers. ~~These anti- takeover laws prevent~~ In general, Section 203 prohibits a publicly- held Delaware corporation from engaging in a ~~merger~~ business combination with an interested stockholder ~~or~~ for ~~sale~~ a period of ~~more than 10 % of its assets with any stockholder, including all affiliates and associates of the stockholder, who owns 15 % or more of the corporation' s outstanding voting stock, for~~ three years following the date ~~that~~ on which the person became an interested stockholder ~~acquired 15 % or more~~ unless: ● prior to the date of the transaction, ~~corporation' s stock unless: •~~ the board of directors ~~approved the transaction where the stockholder acquired 15 % or more~~ of the corporation ~~' s stock; • after~~ approved either the business combination or the transaction which resulted in ~~which~~ the stockholder ~~acquired 15 % or more~~ becoming an interested stockholder; ● upon completion of the transaction that resulted in ~~corporation' s stock,~~ the stockholder becoming an interested stockholder, the interested stockholder owned at least 85 % of the voting stock of the corporation ~~' s~~ outstanding upon consummation of the transaction, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder , ~~excluding~~ (1) shares owned by persons who are directors ~~,~~ and also officers and (2) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held ~~under~~ subject to the plan will be tendered in a tender or exchange offer; or ~~• on~~ ● at or ~~after this~~ subsequent to the date ~~,~~ of the ~~merger or sale~~ transaction, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2 / 3 % of the outstanding voting stock which is not owned by the interested stockholder. Section 203 defines a " business combination " to include: ● any merger or consolidation involving the corporation and the interested stockholder; ● any sale, transfer, pledge or other disposition involving the interested stockholder of 10 % or more of the assets of the corporation; ● subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; ● any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and ● the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. In general, Section 203 defines an " interested stockholder " as an entity or person who, together with the person' s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15 % or more of the outstanding voting stock of the corporation. Certificate of Incorporation and Bylaw Provisions Our Certificate of Incorporation and our Bylaws include a number of provisions that could deter hostile takeovers or delay or prevent changes in control of our Company, including the following: ● Board of Directors vacancies. Our Certificate of Incorporation and Bylaws require that the Board, and not stockholders, fill any directorships that become vacant or are created by an increase in the authorized number of directors by the affirmative vote of a majority of the remaining directors or by the sole remaining director. In addition, pursuant to our bylaws, the number of directors constituting our Board is permitted to be set only by a resolution adopted by a majority vote of the entire Board. These provisions prevent a stockholder from increasing the size of our Board and then gaining control of the Board by filling the resulting vacancies with its own nominees. This makes it more difficult to change the composition of the Board but promotes continuity of management. ● Classified board. Our Certificate of Incorporation provides that our Board is classified into three classes of directors, each with staggered three- year terms. A third party may be discouraged from making a tender offer or otherwise attempting to obtain control of us as it is more difficult and time consuming for stockholders to replace a majority of the directors on a classified board of directors. ● Stockholder action; special meetings of stockholders. Our Certificate of Incorporation and Bylaws provide that our stockholders may not take action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, a holder controlling a majority of our capital stock would not be able to amend our Bylaws or remove directors without holding a meeting of our stockholders called in accordance with our Bylaws. Further, our Bylaws provide that special meetings of stockholders may be called only by the Board, thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal of directors. ● Advance notice requirements for stockholder proposals and director nominations. Our Bylaws provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. Our Bylaws also specify certain requirements regarding the form and content of a stockholder' s notice. These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions might also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer' s own slate of directors or otherwise attempting to obtain control of our Company. ● No cumulative voting. The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless a corporation' s certificate of incorporation provides otherwise. Our Certificate of Incorporation and Bylaws do not provide for cumulative voting. ● Directors removed only for cause. Our Bylaws provide that stockholders may remove directors only for cause, and only by the affirmative vote of the holders of at least ~~two- thirds~~ 66 2 / 3 % of the voting power of the stock outstanding ~~voting stock that is not owned by the stockholder. The provisions of our governing documents~~ and entitled ~~current Delaware law may, collectively: • lengthen the time required for a person or entity~~ to vote generally in ~~acquire control of us through a proxy contest for~~ the election of ~~a majority~~ directors. ● Amendment of charter provisions. Any amendment of the above provisions in our Certificate of Incorporation requires approval by holders of at least two- thirds of our ~~board~~ outstanding Common Stock. ● Issuance of ~~directors; •~~ Preferred Stock. Our Board has the authority, without further action by the stockholders, to issue up to 5, 000, 000 shares of Preferred Stock with rights and preferences, including voting rights, designated from time to time by our Board. The existence of authorized but unissued shares of Preferred Stock enables our Board to render more difficult or to discourage ~~bids for our common stock at a premium over market price; and~~ an attempt ~~• generally deter efforts~~ to obtain control of us by merger, tender offer, proxy contest or other means. ● Choice of forum. Our Certificate of Incorporation and Bylaws provide that the Court of Chancery of the State of Delaware is the sole and exclusive forum for any complaint asserting any internal corporate claims. In addition, our Bylaws also provide that the federal district courts of the United States are the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. These choice of forum provisions do not apply to claims brought to enforce a duty or liability created by the Exchange Act. Transfer Agent and Registrar The transfer agent and registrar for our Common Stock and Series B Preferred Stock is Computershare Trust Company, N. A. The transfer agent' s address is 150 Royall Street, Suite 101, Canton, MA 02021, and its telephone number is (800) 344- 5128. Our Common Stock is listed on The Nasdaq Global Market under the symbol " ORKA. " Exhibit 4. 3 THE OFFER AND SALE OF THESE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE " SECURITIES ACT "), OR ANY APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED, ASSIGNED OR OTHERWISE DISPOSED OF (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OR (B) AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN EACH CASE IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY AND ITS TRANSFER AGENT OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER THE SECURITIES ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES; PROVIDED, THAT IN CONNECTION WITH ANY FORECLOSURE OR TRANSFER OF THE SECURITIES, THE TRANSFEROR SHALL COMPLY WITH THE PROVISIONS HEREIN AND IN THE SECURITIES PURCHASE AGREEMENT, AND UPON FORECLOSURE OR TRANSFER OF THE SECURITIES, SUCH FORECLOSING PERSON OR TRANSFEREE SHALL COMPLY WITH ALL PROVISIONS CONTAINED HEREIN AND IN THE SECURITIES PURCHASE AGREEMENT. ORUKA THERAPEUTICS, INC. PRE- FUNDED WARRANT TO PURCHASE COMMON STOCKWarrant No. W- [001] Original Issue Date: August 29, 2024Oruka Therapeutics, Inc., a Delaware corporation (the " Company "), hereby certifies that, for value received, [___________] or its permitted registered assigns (the " Holder "), is entitled to purchase from the Company up to a total of [___________] shares of common stock, $ 0. 0001 par value per share (the " Common Stock "), of the Company (each such share, a " Warrant Share " and all such shares, the " Warrant Shares ") at an exercise price per share equal to $ 0. 01 per share (as adjusted from time to time as provided in Section 9 herein, the " Exercise Price "), at any time and from time to time on or after August 29, 2024 (the " Original Issue Date ") and until this Pre- Funded Warrant is exercised in full (the " Expiration Date "), and subject to the following terms and conditions: This Pre- Funded Warrant (this " Warrant ") is one of a series of similar warrants issued pursuant to that certain Subscription Agreement, dated April 3, 2024, by and among the Company and the Purchasers identified therein (the " Purchase Agreement "). All such Warrants are referred to herein, collectively, as the " Warrants. " 1. Definitions. In addition to the terms defined elsewhere in this Warrant, capitalized terms that are not otherwise defined herein have the meanings given to such terms in the Purchase Agreement. 2. Registration of Warrants. The Company shall register this Warrant, upon records to be maintained by or on behalf of the Company for that purpose (the " Warrant Register "), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any registered assignee to which this Warrant is permissibly assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. 3. Registration of Transfers. Subject to the restrictions on transfer set forth in Section 7. 01 of the Purchase Agreement and compliance with all applicable securities laws, the Company shall register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, with the Form of Assignment attached as Schedule 2 hereto duly completed and signed, to the Company' s transfer agent or to the Company at its address specified in the Purchase Agreement and (x) delivery, at the request of the Company, of an opinion of counsel reasonably satisfactory to the Company to the effect that the transfer of such portion of this Warrant may be made pursuant to an available exemption from the registration requirements of the Securities Act and all applicable state securities or blue sky laws and (y) delivery by the transferee of a written statement to the Company certifying that the transferee is an " accredited investor " as defined in Rule 501 (a) under the Securities Act and making the representations and certifications set forth in Section 3 of the Purchase Agreement, to the Company at its address specified in the Purchase Agreement. Upon any such registration or transfer, a new warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a " New Warrant ") evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall prepare, issue and deliver at its own expense any New Warrant under this Section 3. 4. Exercise and Duration of Warrants. (a) All or any part of this Warrant shall be exercisable by the registered Holder in any manner permitted by Section 10 of this Warrant at any time and from time to time on or after the Original Issue Date and through and including 5: 30 P. M., New York City time, on the Expiration Date, subject to the conditions and restrictions contained in this Warrant. At 5: 30 P. M., New York City time, on the Expiration Date, the portion of this Warrant not exercised prior thereto shall be and become void and of no value and this Warrant shall be terminated and no longer outstanding. (b) The Holder may exercise this Warrant by delivering to the Company (i) an exercise notice, in the form attached as Schedule 1 hereto (the " Exercise Notice "), completed and duly signed, and (ii) payment of the Exercise Price for the number of Warrant Shares as to which this Warrant is being exercised (which may take the form of a " cashless exercise " if so indicated in the Exercise Notice pursuant to Section 10 below). The date on which the Exercise Notice is delivered to the Company (as determined in accordance with the notice provisions hereof) is an " Exercise Date. " Within two (2) days following the delivery of the Exercise Notice (the " Payment Deadline "), the Holder shall make payment with respect to the Exercise Price for the number of Warrant Shares as to which this Warrant is being exercised (which may take the form of a " cashless exercise " if so indicated in the Exercise Notice); provided that the Company' s obligations to deliver such Warrant Shares shall be delayed on a day- for- day basis each day after the Payment Deadline such payment of the Exercise Price is not paid. The delivery by (or on behalf of) the Holder of the Exercise Notice and the applicable Exercise Price as provided above shall constitute the Holder' s certification to the Company that its representations contained in Sections 3. 01 and 3. 03 through 3. 08 of the Purchase Agreement are true and correct as of the Exercise Date as if remade in their entirety (or, in the case of any transferee Holder that is not a party to the Purchase Agreement, such transferee Holder' s certification to the Company that such representations are true and correct as to such transferee Holder as of the Exercise Date). The Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date the final Exercise Notice is delivered to the Company; provided that delivery of an electronic copy of the Warrant for surrender shall be sufficient and Holder shall not be required to surrender any physical copy of the Warrant, provide a medallion or other bank guarantee or take any similar action in connection therewith. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any. For purposes hereof, " Trading Day " means (i) if the Warrant Shares are traded on a National Exchange, any day on which the Warrant Share is traded on a National Exchange or (ii) if the Warrant Shares are not traded on a National Exchange, a Business Day. (c) The aggregate exercise price of this Warrant, except for a nominal exercise price of $ 0. 01 per Warrant Share, was pre- funded to the Company on or prior to the Original Issue Date and, consequently, no additional consideration (other than the nominal Exercise Price) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant. The Holder shall not be entitled to the return or refund of all, or any portion, of such pre- paid aggregate exercise price under any circumstance or for any reason whatsoever, including in the event this Warrant shall not have been exercised prior to the Expiration Date. 5. Delivery of Warrant Shares. (a) Subject to Section 4 (b), upon exercise of this Warrant, the Company shall promptly (but no later than two (2) Trading Days after the Exercise Date (or three (3) Trading Days after the Exercise Date if the last of the Exercise Notice, the Exercise Price (if applicable) and the opinion of counsel referred to below in this Section 5 (a) (if applicable) is delivered after 5: 00 P. M., New York City time, on the Exercise Date) or as soon as reasonably practicable in the event that a certificate is requested) issue or cause to be issued and cause to be delivered to or upon the written order of the Holder and in such name or names as the Holder may designate (provided that, if the Holder directs the Company to deliver a certificate for the Warrant Shares in a name other than that of the Holder or an Affiliate of the Holder, it shall deliver to the Company on the Exercise Date an opinion of counsel reasonably satisfactory to the Company to the effect that the issuance of such Warrant Shares in such other name may be made pursuant to an available exemption from the registration requirements of the Securities Act and all applicable state securities or blue sky laws), (i) an electronic delivery of the Warrant Shares to the Holder' s account at the Depository Trust Company (" DTC ") or a similar organization, or (ii), if requested by the Holder, a certificate for the Warrant Shares issuable upon such exercise, free of restrictive legends, unless in the case of clause (i) and (ii) a registration statement covering the resale of the Warrant Shares and naming the Holder as a selling stockholder thereunder is not then effective or the Warrant Shares are not freely transferable without volume and manner of sale restrictions pursuant to Rule 144 under the Securities Act, in which case such Holder shall receive a book- entry notation for the Warrant Shares issuable upon such exercise with appropriate restrictive legends. The Holder, or any Person permissibly so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date. If the Warrant Shares are to be issued free of all restrictive legends, the Company shall, upon the written request of the Holder, use its commercially reasonable efforts to deliver, or cause to be delivered, Warrant Shares hereunder electronically through DTC or another established clearing corporation performing similar functions, if available; provided, that, the Company may, but will not be required to, change its transfer agent if its current transfer agent cannot deliver Warrant Shares electronically through such a clearing corporation. (b) To the extent permitted by law, the Company' s obligations to issue and deliver Warrant Shares in accordance with and subject to the terms hereof (including the limitations set forth in Section 12 below) are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same. (c) In addition to any other rights available to the Holder, if the Company fails to cause its transfer agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 5 (a) above pursuant to an exercise on or before the deadline set forth in this Section 5, and if, after such date, the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder' s brokerage firm otherwise purchases, Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a " Buy- In "), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder' s total purchase price (including brokerage commissions, if any) for the Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy- In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder' s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and / or injunctive relief with respect to the Company' s failure to timely deliver Warrant Shares upon exercise of the Warrant as required pursuant to the terms hereof. 6. Charges, Taxes and Expenses. Issuance and delivery of the Warrant Shares upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense in respect of the issuance of the Warrant Shares, all of which taxes and expenses shall be paid by the Company; provided, however, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration Warrant Shares or the Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liabilities that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof. 7. Replacement of Warrant. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case) and, in each case, a customary and reasonable indemnity and surety bond, if requested by the Company. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable third- party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company' s obligation to issue the New Warrant. 8. Reservation of Warrant Shares. The Company covenants that it will at all times reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into account the adjustments and restrictions of Section 9). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price (or upon a " cashless exercise " pursuant to Section 10) in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and nonassessable. The Company will take all commercially reasonable actions as may be necessary to assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed. 9. Certain Adjustments. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to time as set forth in this Section 9. (a) Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding, (i) pays a stock dividend on its Common Stock or otherwise makes a distribution on any class of capital stock that is payable in shares of Common Stock, (ii) subdivides its outstanding shares of Common Stock into a larger number of shares, or (iii) combines its outstanding shares of Common Stock into a smaller number of shares, then in each such case, the Exercise Price shall be multiplied by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately before such event and the denominator of which shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to clause (i) of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution, and any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately after the effective date of such subdivision or combination. (b) Pro Rata Distributions. If the Company, at any time while this Warrant is outstanding, distributes to all holders of Common Stock for no consideration (i) evidences of its indebtedness, (ii) any security (other than a distribution of Common Stock covered by the preceding paragraph) or (iii) rights or warrants to subscribe for or purchase any security, or (iv) any other asset (in each case, " Distributed Property "), then, upon any exercise of this Warrant that occurs after the record date fixed for determination of stockholders entitled to receive such distribution, the Holder shall be entitled to receive, in addition to the Warrant Shares otherwise issuable upon such exercise (if applicable), the Distributed Property that such Holder would have been entitled to receive in respect of such number of Warrant Shares had the Holder been the record holder of such Warrant Shares immediately prior to such record date without regard to any limitation on exercise contained therein. Notwithstanding anything herein to the contrary, the foregoing provisions in this Section 9 (b) shall not apply to, or be triggered by, any rights issued by the Company (either separately or that attach to any securities of the Company) in connection with any stockholders rights agreement, poison pill or other similar anti- takeover provision under the Company' s certificate of incorporation, bylaws or other documents. (c) Fundamental Transactions. If, at any time while this Warrant is outstanding, the Company effects a " Fundamental Transaction " (defined as (i) any merger or consolidation of the Company with or into another Person, including, for avoidance of doubt, the Merger, (ii) any sale of all or substantially all of the Company' s and its subsidiaries' assets, taken as a whole, in one or a series of related transactions, (iii) any reclassification of the Common Stock (other than a change to par value, or from par value to no par value or changes resulting from a combination or subdivision), (iv) any tender offer or exchange offer (whether by the Company or another Person) that is accepted by holders of capital stock representing more than 50 % of the outstanding Common Stock of the Company and the Company or such other Person, as applicable, accepts such tender for payment, (v) any business combination (including, without limitation, a reorganization, recapitalization, spin- off or scheme of arrangement) with another Person whereby such other Person acquires more than the 50 % of the voting power of the capital stock of the Company (except for any such transaction in which the stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such Person immediately after the transaction) or (vi) any statutory exchange of the outstanding shares of Common Stock, as a result of which, the holders of the Common Stock would be entitled to receive, or their Common Stock would be converted into, or exchanged for, shares, stock, other securities, or other property or assets (including cash or any combination thereof)), then, to the extent then permitted under applicable laws, rules and regulations (including the rules of the Nasdaq Stock Market or any exchange on which the Common Stock is then listed), upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, the same kind and amount of securities, cash, assets or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant without regard to any limitations on exercise contained herein (the " Alternate Consideration "). Except for the Merger pursuant to the Merger Agreement, the Company shall not effect any such Fundamental Transaction unless prior to or simultaneously with the consummation thereof, any successor to the Company or surviving entity shall assume the obligation to deliver to the Holder, such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of this Section 9 (c) shall similarly apply to subsequent transactions analogous of a Fundamental Transaction type. (d) Number of Warrant Shares. Simultaneously with any adjustment to the Exercise Price pursuant to Section 9 (a), the number of Warrant Shares that may be purchased upon exercise of this Warrant shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the increased or decreased number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment. (e) Calculations. All calculations under this Section 9 shall be rounded down to the nearest whole cent or the nearest whole share, as applicable. (f) Notice of Adjustments. Upon the occurrence of each adjustment pursuant to this Section 9, the Company at its expense will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Company' s transfer agent. (g) Notice of Corporate Events. If, while this Warrant is outstanding, the Company (i) declares a dividend or any other distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the Company, (ii) enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company, then, except if such notice and the contents thereof shall be deemed to constitute material non- public information, the Company shall deliver to the Holder a notice of such transaction at least three (3) Trading Days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction; provided, however, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action required to be described in such notice. To the extent that any notice provided hereunder constitutes, or contains, material, non- public information regarding the Company or any of its subsidiaries and the Company is subject to the reporting requirements of the Exchange Act, the Company shall use commercially reasonable efforts to promptly file the information contained in such notice with the Commission pursuant to a Current Report on Form 8- K. 10. Payment of Exercise Price. The Holder shall pay the Exercise Price in immediately available funds by wire transfer to an account designated by the Company; provided, however, that the Holder may, in its sole discretion, satisfy its obligation to pay the Exercise Price at such time through a " cashless exercise ", in which event the Company shall issue to the Holder the number of Warrant Shares equal to the quotient obtained by dividing [(A- B) (X)] by (A), where: (A) = the VWAP per share of Common Stock on the National Exchange on the Trading Day immediately preceding the Exercise Date (the " Closing Sale Price "); (B) = the Exercise Price of this Warrant, as adjusted hereunder; and (X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise. For purposes of this Warrant: " VWAP " means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a National Exchange, the daily volume weighted average price of a share of Common Stock for such date (or the nearest preceding date) on the National Exchange on which the Common Stock is then listed or quoted as reported by Bloomberg L. P. (based on a Trading Day from 9: 30 a. m. (New York City time) to 4: 02 p. m. (New York City time)), or (b) if the Common Stock is not then listed on any National Exchange, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company. If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3 (a) (9) of the Securities Act, and the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant, the Warrant Shares shall take on the characteristics of the Warrants being exercised. The Company agrees not to take any position to the contrary. 11. Company- Elected Conversion. The Company shall provide to the Holder prompt written notice if after the Original Issue Date the Company is unable to issue the Warrant Shares without restrictive legend, because the Commission has issued a stop order with respect to, or the Commission or Company has otherwise suspended or withdrawn, a registration statement covering the resale of the Warrant Shares, either temporarily or permanently, or otherwise (each a " Restrictive Legend Event "). To the extent that (A) a Restrictive Legend Event occurs, (B) at such time the Warrant Shares would be saleable under Rule 144 without compliance with the manner of sale or volume restrictions, (C) the Company has delivered the notice described in the immediately preceding sentence, and (D) the Holder attempts to exercise the Warrant after receipt of such notice by paying cash, the Company shall (i) if the Fair Market Value (as calculated above) of the Warrant Shares is greater than the Exercise Price, provide written notice to the Holder that the Company will deliver that number of Warrant Shares to the Holder as should be delivered in a cashless exercise in accordance with Section 10, and return to the Holder all consideration paid to the Company in connection with the Holder' s attempted exercise of this Warrant (a " Company- Elected Conversion "), or (ii) at the election of the Holder to be given within five (5) days of receipt of notice of a Company- Elected Conversion, the Holder shall be entitled to rescind the previously submitted Exercise Notice and the Company shall return all consideration paid by Holder for such Warrant Shares upon such rescission. 12. Limitations on Exercise. Notwithstanding anything to the contrary contained herein, the number of Warrant Shares that may be acquired by the Holder upon any exercise of this Warrant (or otherwise in respect hereof) shall be limited to the extent necessary to ensure that, following such exercise (or other issuance), the total number of shares of Common Stock then beneficially owned by the Holder and its Attribution Parties as determined in accordance with Section 13 (d) of the Exchange Act, does not exceed 9. 9999 % (the " Maximum Percentage ") of the total number of then issued and outstanding shares of Common Stock (including for such purpose the shares of Common Stock issuable upon such exercise). For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by the Holder and its Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which the determination of such sentence is being made, but shall exclude shares of Common Stock which would be issuable upon (i) exercise of the remaining, unexercised portion of this Warrant beneficially owned by such Person and its Attribution Parties and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by the Holder and its Attribution Parties (including, without limitation, any convertible notes or convertible preferred stock or warrants) subject to a limitation on conversion or exercise analogous to the limitation contained herein; provided that in no event shall the aggregate number of shares beneficially owned by the Holder and its Affiliates, calculated in accordance with Section 13 (d) of the Exchange Act, exceed the Maximum Percentage. Except as set forth in the preceding sentence (other than the proviso thereto), for purposes of this paragraph (including the proviso in the immediately preceding sentence), beneficial ownership shall be calculated in accordance with Section 13 (d) of the Exchange Act; it being acknowledged by the Holder that the Company is not representing to such Holder that such calculation is in compliance with Section 13 (d) of the Exchange Act and the rules promulgated thereunder and such Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 12 applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by such Holder) and of which a portion of this Warrant is exercisable shall be in the sole discretion of a Holder, and the submission of a Notice of

Exercise shall be deemed to be the Holder' s determination of whether this Warrant is exercisable (in relation to other securities owned by such Holder and its Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to such aggregate percentage limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13 (d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 12, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) if the Company is subject to the reporting requirements of the Exchange Act, the Company' s most recent Form 10- Q or Form 10- K, as the case may be, (y) a more recent public announcement by the Company or (z) any other notice by the Company or its transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written request of the Holder, the Company shall within three (3) Trading Days confirm in writing to such Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including the Warrants, by the Holder and its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. By written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other percentage not in excess of 9. 9999 % specified in such notice; provided, that (i) any such increase will not be effective until the sixty- first (61st) day after such notice is delivered to the Company, and (ii) any such increase or decrease will apply only to the Holder and not to any other holder of Warrants. The provisions of this paragraph shall not apply to the Holder if the aggregate number of shares beneficially owned by the Holder and its Affiliates, calculated in accordance with Section 13 (d) of the Exchange Act, exceed 9. 9999 % immediately prior to the Closing. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 12 to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended beneficial ownership limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. Any purported delivery of any number of shares of Common Stock or any other security upon exercise of this Warrant shall be void and have no effect to the extent, but only to the extent, that before or after such delivery, the exercising Holder, together with its Attribution Parties, would have beneficial ownership in excess of the Maximum Percentage. For purposes hereof, " Attribution Parties " means, collectively, the following Persons and entities: (i) any direct or indirect Affiliates of the Holder, (ii) any Person acting or who reasonably could be deemed to be acting as a group together with the Holder or any of the foregoing and (iii) any other Persons whose beneficial ownership of Common Stock reasonably could be aggregated with the Holder' s and the other Attribution Parties for purposes of Section 13 (d) or Section 16 of the Exchange Act (for clarity, the purpose of the foregoing is to subject collectively the Holder and all other Attribution Parties to the Maximum Percentage). 13. No Fractional Shares. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the fair market value (based on the Closing Sale Price) for any such fractional shares. 14. Notices. Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via email at the email address specified in the Purchase Agreement prior to 5: 30 P. M., New York City time, on a Trading Day, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via email at the email address specified in the Purchase Agreement on a day that is not a Trading Day or later than 5: 30 P. M., New York City time, on any Trading Day, (iii) the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service specifying next business day delivery, and (iv) upon actual receipt by the Person to whom such notice is required to be given, if by hand delivery. The address and email address of a Person for such notices or communications shall be as set forth in the Purchase Agreement unless changed by such Person by two (2) Trading Days' prior written notice to the other Persons in accordance with this Section 14. 15. Warrant Agent. The Company shall serve as warrant agent under this Warrant. Upon notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or stockholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder' s last address as shown on the Warrant Register. 16. Miscellaneous. (a) No Rights as a Stockholder. The Holder, solely in such Person' s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person' s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (except upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company. (b) No Avoidance. Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (a) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (b) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant, and (c) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant. (c) Successors and Assigns. Subject to the restrictions on transfer set forth in this Warrant and in Section 7. 01 of the Purchase Agreement, and compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company without the written consent of the Holder except to a successor in the event of a Fundamental Transaction. This Warrant shall be binding on and inure to the benefit of the Company and the Holder and their respective successors and permitted assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns. (d) Authorized Shares. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the National Exchange upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue). (e) Amendment and Waiver. Except as otherwise provided herein and subject to the restrictions set forth in Section 9. 01 of the Purchase Agreement, the provisions of the Warrants may be amended and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Holders of Warrants representing no less than a majority of the Warrant Shares obtainable upon exercise of the Warrants then outstanding. (f) Acceptance. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein. (g) Governing Law; Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this warrant shall be governed by and construed and enforced in accordance with the laws of the state of New York, without regard to the principles of conflicts of law thereof. Each of the Company and the Holder hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City and County of New York for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the transaction documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such courts. Each of the Company and the Holder hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such person at the address in effect for notices to it under the purchase agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Each of the Company and the Holder hereby waives all rights to a trial by jury. (h) Headings. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof. (i) Severability. In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant. [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above. ORUKA THERAPEUTICS, INC. By: Name: Lawrence Klein Title: Chief Executive Officer SCHEDULE 1 FORM OF EXERCISE NOTICE [To be executed by the Holder to purchase shares of Common Stock under the Warrant] Ladies and Gentlemen: (1) The undersigned is the Holder of Warrant No. __________ (the " Warrant ") issued by Oruka Therapeutics, Inc., a Delaware corporation (the " Company "). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant. (2) The undersigned hereby exercises its right to purchase __________ Warrant Shares pursuant to the Warrant. (3) The Holder intends that payment of the Exercise Price shall be made as (check one): □ Cash Exercise □ " Cashless Exercise " (4) If the Holder has elected a Cash Exercise, the Holder shall pay the sum of $ ___________ in immediately available funds to the Company in accordance with the terms of the Warrant. (5) Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the terms of the Warrant. (6) By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section 13 (d) of the Securities Exchange Act of 1934) permitted to be owned under Section 12 of the Warrant to which this notice relates. (7) By its delivery of this Exercise Notice and pursuant to Section 4 (b) of the Warrant, the undersigned certifies to the Company that its representations listed in Section 4 (b) of the Warrant are true and correct as of the date hereof as if remade in their entirety (or, in the case of any transferee Holder that is not a party to the Purchase Agreement, such transferee Holder' s certification to the Company that such representations are true and correct as to such transferee Holder as of the date hereof). Dated: ______________________ Name of Holder: ____________________ By: Name: Title: (Signature must conform in all respects to name of Holder as specified on the face of the Warrant) SCHEDULE 2 FORM OF ASSIGNMENT [To be completed and executed by the Holder only upon transfer of the Warrant] FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto (the " Transferee ") the right represented by the within Warrant to purchase shares of Common Stock of Oruka Therapeutics, Inc. (the " Company ") to which the within Warrant relates and appoints attorney to transfer said right on the books of the Company with full power of substitution in the premises. In connection therewith, the undersigned represents, warrants, covenants and agrees to and with the Company that: (a) the offer and sale of the Warrant contemplated hereby is being made in compliance with Section 4 (a) (2) of the United States Securities Act of 1933, as amended (the " Securities Act ") or another valid exemption from the registration requirements of Section 5 of the Securities Act and in compliance with all applicable securities laws of the states of the United States; (b) the undersigned has not offered to sell the Warrant by any form of general solicitation or general advertising, including, but not limited to, any advertisement, article, notice or other communication published in any newspaper, magazine or similar media or broadcast over television or radio, and any seminar or meeting whose attendees have been invited by any general solicitation or general advertising; (c) the undersigned has read the Transferee' s investment letter included herewith, and to its actual knowledge, the statements made therein are true and correct; and (d) the undersigned understands that the Company may condition the transfer of the Warrant contemplated hereby upon the delivery to the Company by the undersigned or the Transferee, as the case may be, of a written opinion of counsel (which opinion shall be in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that such transfer may be made without registration under the Securities Act and under applicable securities laws of the states of the United States. Dated: (Signature must conform in all respects to name of holder as specified on the face of the Warrant) Address of Transferee In the presence of: Exhibit 10. 17 c / o Oruka Therapeutics, Inc. 855 Oak Grove Avenue, Suite 100 Menlo Park, CA 94025 Re: Amended and Restated Employment Letter Agreement Dear Paul: On behalf of Oruka Therapeutics, Inc. (the " Company "), I am pleased to offer you a continuing position as General Counsel (the " Role ") pursuant to this letter agreement (the " Agreement "). Your Role commenced on April 30, 2024 pursuant to your letter agreement dated April 12, 2024. This Agreement will amend and restate that April 12, 2024 letter agreement, provided you accept this offer as indicated by your signature below, to be effective as of the date hereof. 1. Position. While serving in the Role, you will report to the Company' s Chief Executive Officer. You will have such duties, authorities, and responsibilities as are customarily associated with the Role. This is a full- time employment position. It is understood and agreed that, while you are employed by the Company, you will not engage in any other employment, consulting or other business activities (whether full- time or part- time), except as expressly authorized in writing by the Company. Notwithstanding the foregoing, you may engage in religious, charitable and other community activities so long as such activities do not unreasonably interfere or conflict with your obligations to the Company. 2. Base Salary. Upon and following the date hereof, as cash compensation for your services, the Company will pay you an initial base salary of $ 460, 000 per year, payable in accordance with the Company’ s standard payroll schedule and subject to applicable deductions and withholdings. Your base salary will be subject to periodic review and potential adjustment in the Company’ s discretion. Your base salary in effect at any given time is referred to herein as the “ Base Salary. ” 3. Annual Bonus. You will continue to be eligible to receive an annual performance bonus targeted at 40 % of your Base Salary. The target annual bonus in effect at any given time is referred to herein as “ Target Bonus. ” Your 2024 annual bonus will be prorated based on your period of employment following April 30, 2024. The actual bonus amount is discretionary and may be subject to achievement of performance targets established by the Company for such year. To earn an annual bonus, you must be employed by the Company as of the payment date of such bonus. Any annual bonus will be paid no later than March 15th of the calendar year following the calendar year to which such bonus relates. 4. Benefits / Paid Time Off. You will continue to be eligible, subject to the terms of the applicable plans and programs, to participate in the employee benefits and insurance programs generally made available to the Company’ s full- time employees. Details of such benefits programs, including applicable employee contributions and waiting periods, if applicable, will be made available to you as such benefit (s) become available. You will be entitled to paid time off consistent with the terms of the Company’ s paid time off policy, as in effect from time to time. The Company reserves the right to modify, limit, amend or cancel any of its benefits plans or programs at any time. 5. Expense Reimbursement. The Company will reimburse you for all reasonable and necessary expenses incurred by you in connection with performing your duties as an employee of the Company and that are pre- approved by the Company, provided that you comply with any Company policy or practice on incurring, submitting, accounting for and documenting such expenses. 6. Location. Your primary work location will continue to be in Menlo Park, CA, provided that you may be required to engage in reasonable travel for business, consistent with the Company’ s business needs. 7. At- Will Employment; Resignation from Subsidiaries. At all times, your employment with the Company is “ at will, ” meaning you or the Company may terminate it at any time for any or no reason, subject to the terms of this Agreement. Although your job duties, title, reporting structure, compensation and benefits, as well as the Company’ s benefit plans and personnel policies and procedures, may change from time to time (subject to the terms of this Agreement), the “ at will ” nature of your employment may only be changed in an express written agreement signed by you and an authorized executive officer of the Company. Your last day of employment for any reason is referred to herein as the “ Date of Termination. ” To the extent applicable, you shall be deemed to have resigned from all officer and board member positions that you hold with the Company or any of its respective subsidiaries and affiliates upon the termination of your employment for any reason. You shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations. 8. Accrued Obligations. In the event of the ending of your employment for any reason, the Company shall pay you (i) your Base Salary and, if applicable, any accrued but unused vacation, through the Date of Termination, and (ii) the amount of any documented expenses properly incurred by you on behalf of the Company prior to any such termination and not yet reimbursed. (the “ Accrued Obligations ”). 9. Severance Pay and Benefits Outside of the Change in Control Period. If the Company terminates your employment without Cause (and not as a result of your death or Disability) or you resign with Good Reason, in each case, outside of the Change in Control Period (as such capitalized terms are defined in Appendix A), then, in addition to the Accrued Obligations, and subject to (i) your execution and non- revocation of a separation agreement and release in a form acceptable to the Company, which shall include a general release of claims against the Company and all related persons and entities and a reaffirmation of the Continuing Obligations (as defined below) and shall provide that if you breach the Continuing Obligations, all payments of the following severance pay and benefits shall immediately cease (the “ Separation Agreement and Release ”), and (ii) the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven- day revocation period: (a) The Company shall pay you an amount equal to 12 months of your Base Salary (the “ Severance Amount ”), payable in substantially equal installments over the 12- month period following the Date of Termination in accordance with the Company’ s regular payroll practices beginning on the Company’ s first regularly scheduled payroll date following the date that is 60 days after the Date of Termination; provided, however, that the first installment shall include any amounts that would have been paid following the Date of Termination had such installments commenced on the first regularly scheduled payroll date following the Date of Termination. (b) Subject to your copayment of premium amounts at the applicable active employees’ rate and your proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“ COBRA ”), the Company shall pay to the group health plan provider (s), the COBRA provider or you a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to you if you had remained employed by the Company until the earliest of (A) the 12- month anniversary of the Date of Termination; (B) your eligibility for group health plan benefits under any other employer’ s group health plan; or (C) the cessation of your continuation rights under COBRA; provided, however, that if the Company reasonably determines that it cannot pay such amounts to the group health plan provider (s) or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to you for the time period specified above. Such payments, if to you, shall be subject to tax- related deductions and withholdings and paid on the Company’ s regular payroll dates. Notwithstanding anything to the contrary in this Agreement, for the avoidance of doubt: (i) if your employment ends as a result of a termination by the Company for Cause or a resignation by you without Good Reason, you will be entitled to the Accrued Obligations and will not be entitled to any further compensation from the Company; and (ii) if your employment ends due to your death or Disability, (i) you will receive the Accrued Obligations and (ii) all outstanding equity- based awards subject to time- based vesting (the “ Time- Based Equity Awards ”) as of the Termination Date shall immediately accelerate and become vested or nonforfeitable as of the Date of Termination, but you will not be eligible for any other severance pay or benefits, whether pursuant to Section 9, Section 10 or otherwise. 10. Severance Pay and Benefits Within the Change in Control Period. If the Company terminates your employment without Cause (and not as a result of your death or Disability) or you resign with Good Reason, in each case, within the Change in Control Period, then, in addition to you being entitled to the Accrued Obligations, and subject to your execution and non- revocation of the Separation Agreement and Release and it becoming fully effective, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven- day revocation period: (a) The Company shall pay you an amount equal 1. 0 times the sum of (i) your Base Salary and (ii) your Target Bonus for the year in which the termination occurs (in each case, calculated by reference to your Base Salary rate and Target Bonus as in effect immediately prior to your termination, but without giving effect to any prior reduction in Base Salary or Target Bonus by the Company that would give rise to your right to resign for Good Reason) (such salary and bonuses together, the “ CIC Severance Amount ”), payable in substantially equal installments over the 12- month period following the Date of Termination in accordance with the Company’ s regular payroll practices beginning on the Company’ s first regularly scheduled payroll date following the date that is 60 days after the Date of Termination; provided, however, that the first installment shall include any amounts that would have been paid following the Date of Termination had such installments commenced on the first regularly scheduled payroll date following the Date of Termination. (b) Notwithstanding anything to the contrary in any applicable equity- based award agreement or plan, all of the unvested portion of your then outstanding Time- Based Equity Awards as of the Termination Date shall immediately accelerate and become vested or nonforfeitable as of the later of (i) the Date of Termination or (ii) the effective date of the Separation Agreement and Release (such later date being the “ Accelerated Vesting Date ”); and provided further that any termination or forfeiture of the unvested portion of such Time- Based Equity Awards that would otherwise occur on the Date of Termination in the absence of this Agreement will be delayed until the effective date of the Separation Agreement and Release and will only occur if the vesting pursuant to this subsection does not occur due to the absence of the Separation Agreement and Release becoming fully effective within the time period set forth therein. Notwithstanding the foregoing, no additional vesting of the Time- Based Equity Awards shall occur during the period between the Date of Termination and the Accelerated Vesting Date. (c) All of your outstanding equity- based awards subject to performance- based vesting (the “ Performance- Based Equity Awards ”) shall immediately accelerate and become vested or nonforfeitable as of the Accelerated Vesting Date with the performance criteria being deemed to have been met based on the greater of target or, if determinable, actual performance; provided, however, that the applicable award agreement for any Performance- Based Equity Award may provide for alternative treatment upon a termination covered by this Section 10. (d) The Company shall pay to the group health plan provider (s), the COBRA provider or you a monthly payment equal to the monthly COBRA continuation premiums until the earliest of (A) the 12- month anniversary of the Date of Termination; (B) your eligibility for group health plan benefits under any other employer’ s group health plan; or (C) the cessation of your continuation rights under COBRA; provided, however, that if the Company reasonably determines that it cannot pay such amounts to the group health plan provider (s) or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to you for the time period specified above. Such payments, if to you, shall be subject to tax- related deductions and withholdings and paid on the Company’ s regular payroll dates. For the avoidance of doubt, Section 9 and Section 10 of this Agreement are mutually exclusive and in no event shall you be entitled to payments or benefits pursuant to both Section 9 and Section 10 of this Agreement. 11. Continuing Obligations. (a) Business Protection Agreement. You have previously entered into an Invention Assignment, Non- Disclosure and Business Protection Agreement (the “ Business Protection Agreement ”). For purposes of this Agreement, the obligations in this Section 11 and those that arise in the Business Protection Agreement and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the “ Continuing Obligations. ” (b) Third Party Agreements and Rights. You hereby confirm that you are not bound by the terms of any agreement with any previous employer or other party that would prevent you from performing your obligations hereunder. You represent to the Company that your execution of this Agreement, your employment with the Company and the performance of your proposed duties for the Company will not violate any obligations you may have to any such previous employer or other party. In your work for the Company, you will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other party, and you will not bring to the premises of the Company or load or access on any electronic system of the Company, any copies or other tangible embodiments of non- public information belonging to or obtained from any such previous employment or other party. (c) Litigation and Regulatory Cooperation. You shall reasonably cooperate with the Company in (i) the defense or prosecution of any claims or actions now in existence or that may be brought in the future against or on behalf of the Company that relate to events or occurrences that transpired while you were engaged or employed by the Company, and (ii) the investigation, whether internal or external, of any matters about which the Company believes you may have knowledge or information. Your full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being reasonably available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after your engagement and employment, you also shall reasonably cooperate with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while you were employed by the Company. The Company shall reimburse you for any reasonable out- of- pocket expenses incurred in connection with your performance of obligations pursuant to this Section 11 (c). (d) Relief. You agree that it would be difficult to measure any damages caused to the Company that might result from your breach of any of the Continuing Obligations, and that in any event money damages may be an inadequate remedy for any such breach. Accordingly, you agree that if you breach, or propose to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to seek an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company or posting any bond. 12. Golden Parachute Taxes. (a) Best After- Tax Result. In the event that any payment or benefit received or to be received by you pursuant to this Agreement or otherwise (“ Payments ”) would (i) constitute a “ parachute payment ” within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the “ Code ”), and (ii) but for this subsection (a), be subject to the excise tax imposed by Section 4999 of the Code, any successor provisions, or any comparable federal, state, local or foreign excise tax (“ Excise Tax ”), then, subject to the provisions of Section 14, such Payments shall be either (A) provided in full pursuant to the terms of this Agreement or any other applicable agreement, or (B) provided as to such lesser extent that would result in the Payments being $ 1. 00 less than the amount at which any portion of the Payments would be subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state, local and foreign income, employment and other taxes and the Excise Tax (including, without limitation, any interest or penalties on such taxes), results in the receipt, on an after- tax basis, of the greatest amount of payments and benefits provided for hereunder or otherwise, notwithstanding that all or some portion of such Payments may be subject to the Excise Tax. Unless the Company and you otherwise agree in writing, any determination required under this Section shall be made by independent tax counsel designated by the Company and reasonably acceptable to you (“ Independent Tax Counsel ”), whose determination shall be conclusive and binding upon you and the Company for all purposes. For purposes of making the calculations required under this Section, Independent Tax Counsel may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code; provided that Independent Tax Counsel shall assume that you pay all taxes at the highest marginal rate. The Company and you shall furnish to Independent Tax Counsel such information and documents as Independent Tax Counsel may reasonably request in order to make a determination under this Section. The Company shall bear all costs that Independent Tax Counsel may reasonably incur in connection with any calculations contemplated by this Section. In the event that Section 13 (a) (ii) (B) above applies, then based on the information provided to you and the Company by Independent Tax Counsel, the cutback described hereunder will apply as to compensation not subject to Section 409A of the Code prior to compensation subject to Section 409A of the Code and will otherwise apply on a reverse chronological basis from payments latest in time. If the Internal Revenue Service (the “ IRS ”) determines that any Payment is subject to the Excise Tax, then Section 12 (b) hereof shall apply, and the enforcement of Section 12 (b) shall be the exclusive remedy to the Company. (b) Adjustments. If, notwithstanding any reduction described in Section 12 (a) hereof (or in the absence of any such reduction), the IRS determines that you are liable for the Excise Tax as a result of the receipt of one or more Payments, then you shall be obligated to surrender or pay back to the Company within one- hundred 120 days after a final IRS determination, an amount of such payments or benefits equal to the “ Repayment Amount. ”

The Repayment Amount with respect to such Payments shall be the smallest such amount, if any, as shall be required to be surrendered or paid to the Company so that your net proceeds with respect to such Payments (after taking into account the payment of the Excise Tax imposed on such Payments) shall be maximized. Notwithstanding the foregoing, the Repayment Amount with respect to such Payments shall be zero if a Repayment Amount of more than zero would not eliminate the Excise Tax imposed on such Payments or if a Repayment Amount of more than zero would not maximize the net amount received from the Payments. If the Excise Tax is not eliminated pursuant to this Section 12 (b), you shall pay the Excise Tax. 13. Section 409A. (a) Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section 409A of the Code, the Company determines that you are a " specified employee " within the meaning of Section 409A (a) (2) (B) (i) of the Code, then to the extent any payment or benefit that you become entitled to under this Agreement or otherwise on account of your separation from service would be considered deferred compensation otherwise subject to the additional tax imposed pursuant to Section 409A (a) of the Code as a result of the application of Section 409A (a) (2) (B) (i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after your separation from service, or (B) your death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch- up payment covering amounts that would otherwise have been paid during the six- month period but for the application of this provision (without interest), and the balance of the installments shall be payable in accordance with their original schedule. (b) All in- kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by you during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in- kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in- kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in- kind benefits is not subject to liquidation or exchange for another benefit. (c) To the extent that any payment or benefit described in this Agreement constitutes " non- qualified deferred compensation " under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the termination of your employment, then such payments or benefits shall be payable only upon your " separation from service. " The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1. 409A- l (h). (d) The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1. 409A- 2 (b) (2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. (e) The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. 14. Withholding; Tax Effect. All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or the Board related to tax liabilities arising from your compensation. 15. Recoupment. Amounts paid or payable under this Agreement shall be subject to the provisions of any applicable clawback or recoupment policies or procedures adopted by the Company, which clawback or recoupment policies may provide for forfeiture and / or recoupment of amounts paid or payable under this Agreement. No forfeiture or recoupment under such policies or procedures will give rise to a right to resign for Good Reason under this Agreement or under any other agreement between you and the Company. 16. Interpretation and Enforcement. This Agreement, together with Appendix A, the Business Protection Agreement and any award agreement between you and the Company constitute the complete agreement between you and the Company, contains all of the terms of your employment with the Company and supersedes any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. The terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement or arising out of, related to, or in any way connected with this Agreement, your employment with the Company or any other relationship between you and the Company (the " Disputes ") will be governed by federal law to the extent applicable and otherwise by California law, excluding laws relating to conflicts or choice of law and excluding Disputes arising in connection with any equity incentive plan, which shall be governed by the terms of the applicable equity incentive plan. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in the County of San Mateo and State of California in connection with any Dispute or any claim related to any Dispute, except for Disputes arising under any equity incentive plan, which shall be governed by the terms of the applicable equity incentive plan. 17. Assignment. Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement without your consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets; provided further, that if you remain employed or become employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then you shall not be entitled to any payments, benefits or vesting pursuant to Section 9 or pursuant to Section 10 of this Agreement solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding upon you and the Company, and each of your and its respective successors, executors, administrators, heirs and permitted assigns. 18. Waiver; Amendment. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. This Agreement may be amended or modified only by a written instrument signed by you and by a duly authorized executive officer of the Company. 19. Enforceability. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. 20. Conditions. You must submit satisfactory proof of your identity, successfully complete a criminal background check, which you hereby expressly authorize by your execution of this Agreement, and provide documentation of your legal authorization to work in the United States. 21. Employee Representations. It is the policy of the Company not to solicit or accept proprietary information and / or trade secrets of other companies or third parties. If you have or have had access to trade secrets or other confidential, proprietary information from your former employer or another third party, the use of such information in performing your duties at the Company is prohibited. This may include, but is not limited to, confidential or proprietary information in the form of documents, magnetic media, software, customer lists, and business plans or strategies. In making this employment offer, the Company has relied on your representation that: (a) you are not currently a party to any agreement that would restrict your ability to accept this offer or to perform services for the Company; (b) you are not subject to any noncompetition or non- solicitation agreement or other restrictive covenants that might restrict your employment by the Company as contemplated by this offer; (c) you have the full right, power and authority to execute and deliver the Agreement and to perform all of your obligations thereunder; and (d) you will not bring with you to the Company or use in the performance of your responsibilities at the Company any materials, documents or work product of a former employer or other third party that are not generally available to the public, unless you have obtained written authorization from such former employer or third party for their possession and use and have provided the Company with a copy of same. 22. Other Terms. The provisions of this Agreement shall survive the termination of this Agreement and / or the termination of your employment to the extent necessary to effectuate the terms contained herein. The headings and other captions in this Agreement are for convenience and reference only and shall not be used in interpreting, construing or enforcing any of the provisions of this Agreement. This Agreement may be executed in separate counterparts. When both counterparts are signed, they shall be treated together as one and the same document. PDF copies of signed counterparts shall be equally effective as originals. This Agreement may also be executed electronically by any means that satisfies applicable electronic signature laws (e. g., DocuSign). To indicate your acceptance of the Company' s offer, please sign this Agreement in the space provided below and return it to me. If you have any questions regarding this letter agreement, feel free to contact me. I look forward to working with you to make the Company a great success. Sincerely, / s / Lawrence Klein Lawrence Klein Chief Executive Officer Accepted and acknowledged: / s / Paul Quinlan Paul Quinlan 1. " Cause " shall mean (i) your dishonest statements or acts with respect to the Company or any affiliate of the Company, or any current or prospective customers, suppliers, vendors or other third parties with which such entity does business that results in or is reasonably anticipated to result in material harm to the Company; (ii) your conviction or plea of no contest to: (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) your failure to perform in all material respects your lawful assigned duties and responsibilities to the reasonable satisfaction of the Board, which failure continues, in the reasonable judgment of the Board, for 30 days after written notice given to you describing such failure; (iv) your gross negligence, willful misconduct that results in or is reasonably anticipated to result in material harm to the Company; or (v) your violation of any material violation of any agreement (s) between you and the Company or any written Company policies including, without limitation, agreements relating to non- solicitation, non- disclosure and / or assignment of inventions or policies related to ethics or workplace conduct. 2. " Change in Control " shall have the meaning set forth in the Company' s 2024 Stock Incentive Plan (or the meaning provided to any word of similar import under any successor plan). 3. " Change in Control Period " shall mean the period commencing three months prior to the first event constituting a Change in Control and ending 12 months following the first event constituting a Change in Control. 4. " Disability " shall mean a permanent and total disability as defined in Section 22 (e) (3) of the Code. 5. " Good Reason " shall mean that you have complied with the Good Reason Process (hereinafter defined) following the occurrence, without your written consent, of any of the following events: (i) a material diminution in your base salary or Target Bonus except for across- the- board salary and target bonus reductions of no more than 10 % based on the Company' s financial performance similarly affecting all or substantially all senior management employees of the Company; (ii) a material change in the geographic location at which you are required to provide services to the Company or a requirement that you change your remote location from your then- current residence; (iii) a material reduction in your duties, authority or responsibilities; (iv) the failure of the Company to obtain the assumption of this Agreement by a successor; or (v) the material breach of this Agreement (or any other agreements with you) by the Company. 6. " Good Reason Process " shall mean that (i) you reasonably determine in good faith that a " Good Reason " condition has occurred; (ii) you notify the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii) you cooperate in good faith with the Company' s efforts, for a period not less than 30 days following such notice (the " Cure Period "), to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist; and (v) you terminate your employment within 30 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred. Exhibit 10. 18 855 Oak Grove Avenue, Suite 100 Menlo Park, CA 94025 Re: Amended and Restated Employment Letter Agreement Dear Jo: On behalf of Oruka Therapeutics, Inc. (the " Company "), I am pleased to offer you a continuing position as Chief Medical Officer (the " Role ") pursuant to this letter agreement (the " Agreement "). Your Role commenced on April 18, 2024 pursuant to your letter agreement dated March 15, 2024. This Agreement will amend and restate that March 15, 2024 letter agreement, provided you accept this offer as indicated by your signature below, to be effective as of the date hereof. 3. Bonus Compensation. (a) Signing Bonus. In connection with your commencement of employment with the Company on April 18, 2024, the Company advanced you a signing bonus of $ 100, 000, less applicable deductions and withholdings, which was paid to you in the first payroll after your employment commencement. If you resign your employment with the Company for any reason or the Company terminates your employment for Cause, in either case prior to April 18, 2025, you agree to repay the Company, within 30 days following your separation date, a prorated portion of the signing bonus (based on the number of full months you worked for the Company). (b) Annual Bonus. You will continue to be eligible to receive an annual performance bonus targeted at 40 % of your Base Salary. The target annual bonus in effect at any given time is referred to herein as " Target Bonus. " Your 2024 annual bonus will be prorated based on your period of employment following April 18, 2024. The actual bonus amount is discretionary and may be subject to achievement of performance targets established by the Company for such year. To earn an annual bonus, you must be employed by the Company as of the payment date of such bonus. Any annual bonus will be paid no later than March 15th of the calendar year following the calendar year to which such bonus relates. 6. Location. Your primary work location will continue to be remote in Connecticut, provided that you may be required to engage in reasonable travel for business, consistent with the Company' s business needs. You may change your remote work location with prior written notice to and approval from the Company. To the extent applicable, you shall be deemed to have resigned from all officer and board member positions that you hold with the Company or any of its respective subsidiaries and affiliates upon the termination of your employment for any reason. You shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations. (b) Subject to your copayment of premium amounts at the applicable active employees' rate and your proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (" COBRA "), the Company shall pay to the group health plan provider (s), the COBRA provider or you a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to you if you had remained employed by the Company until the earliest of (A) the 12- month anniversary of the Date of Termin (A) the 12- month anniversary of the Date of Termination; (B) your eligibility for group health plan benefits under any other employer' s group health plan; or (C) the cessation of your continuation rights under COBRA; provided, however, that if the Company reasonably determines that it cannot pay such amounts to the group health plan provider (s) or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to you for the time period specified above. Such payments, if to you, shall be subject to

tax- related deductions and withholdings and paid on the Company’ s regular payroll dates. ation; (B) your eligibility for group health plan benefits under any other employer’ s group health plan; or (C) the cessation of your continuation rights under COBRA; provided, however, that if the Company reasonably determines that it cannot pay such amounts to the group health plan provider (s) or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to you for the time period specified above. Such payments, if to you, shall be subject to tax- related deductions and withholdings and paid on the Company’ s regular payroll dates. Notwithstanding anything to the contrary in this Agreement, for the avoidance of doubt: (ii) if your employment ends due to your death or Disability, (i) you will receive the Accrued Obligations and (ii) all outstanding equity- based awards subject to time- based vesting (the “ Time- Based Equity Awards ”) as of the Termination Date shall immediately accelerate and become vested or nonforfeitable as of the Date of Termination, but you will not be eligible for any other severance pay or benefits, whether pursuant to Section 9, Section 10 or otherwise. For the avoidance of doubt, Section 9 and Section 10 of this Agreement are mutually exclusive and in no event shall you be entitled to payments or benefits pursuant to both Section 9 and Section 10 of this Agreement. 11. Continuing Obligations. (d) Relief. You agree that it would be difficult to measure any damages caused to the Company that might result from your breach of any of the Continuing Obligations, and that in any event money damages may be an inadequate remedy for any such breach. Accordingly, you agree that if you breach, or propose to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to seek an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company or posting any bond. 12. Golden Parachute Taxes. (a) Best After- Tax Result. In the event that any payment or benefit received or to be received by you pursuant to this Agreement or otherwise (“ Payments ”) would (i) constitute a “ parachute payment ” within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the “ Code ”), and (ii) but for this subsection (a), be subject to the excise tax imposed by Section 4999 of the Code, any successor provisions, or any comparable federal, state, local or foreign excise tax (“ Excise Tax ”), then, subject to the provisions of Section 14, such Payments shall be either (A) provided in full pursuant to the terms of this Agreement or any other applicable agreement, or (B) provided as to such lesser extent that would result in the Payments being $ 1. 00 less than the amount at which any portion of the Payments would be subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state, local and foreign income, employment and other taxes and the Excise Tax (including, without limitation, any interest or penalties on such taxes), results in the receipt, on an after- tax basis, of the greatest amount of payments and benefits provided for hereunder or otherwise, notwithstanding that all or some portion of such Payments may be subject to the Excise Tax. Unless the Company and you otherwise agree in writing, any determination required under this Section shall be made by independent tax counsel designated by the Company and reasonably acceptable to you (“ Independent Tax Counsel ”), whose determination shall be conclusive and binding upon you and the Company for all purposes. For purposes of making the calculations required under this Section, Independent Tax Counsel may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code; provided that Independent Tax Counsel shall assume that you pay all taxes at the highest marginal rate. The Company and you shall furnish to Independent Tax Counsel such information and documents as Independent Tax Counsel may reasonably request in order to make a determination under this Section. The Company shall bear all costs that Independent Tax Counsel may reasonably incur in connection with any calculations contemplated by this Section. In the event that Section 13 (a) (ii) (B) above applies, then based on the information provided to you and the Company by Independent Tax Counsel, the cutback described hereunder will apply as to compensation not subject to Section 409A of the Code prior to compensation subject to Section 409A of the Code and will otherwise apply on a reverse chronological basis from payments latest in time. If the Internal Revenue Service (the “ IRS ”) determines that any Payment is subject to the Excise Tax, then Section 12 (b) hereof shall apply, and the enforcement of Section 12 (b) shall be the exclusive remedy to the Company. (b) Adjustments. If, notwithstanding any reduction described in Section 12 (a) hereof (or in the absence of any such reduction), the IRS determines that you are liable for the Excise Tax as a result of the receipt of one or more Payments, then you shall be obligated to surrender or pay back to the Company within one- hundred 120 days after a final IRS determination, an amount of such payments or benefits equal to the “ Repayment Amount. ” The Repayment Amount with respect to such Payments shall be the smallest such amount, if any, as shall be required to be surrendered or paid to the Company so that your net proceeds with respect to such Payments (after taking into account the payment of the Excise Tax imposed on such Payments) shall be maximized. Notwithstanding the foregoing, the Repayment Amount with respect to such Payments shall be zero if a Repayment Amount of more than zero would not eliminate the Excise Tax imposed on such Payments or if a Repayment Amount of more than zero would not maximize the net amount received from the Payments. If the Excise Tax is not eliminated pursuant to this Section 12 (b), you shall pay the Excise Tax. 13. Section 409A. (d) The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1. 409A- 2 (b) (2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. 16. Interpretation and Enforcement. This Agreement, together with Appendix A, the Business Protection Agreement and any award agreement between you and the Company constitute the complete agreement between you and the Company, contains all of the terms of your employment with the Company and supersedes any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. The terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement or arising out of, related to, or in any way connected with this Agreement, your employment with the Company or any other relationship between you and the Company (the “ Disputes ”) will be governed by federal law to the extent applicable and otherwise by California law, excluding laws relating to conflicts or choice of law and excluding Disputes arising in connection with any equity incentive plan, which shall be governed by the terms of the applicable equity incentive plan. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in the County of San Mateo and State of California in connection with any Dispute or any claim related to any Dispute, except for Disputes arising under any equity incentive plan, which shall be governed by the terms of the applicable equity incentive plan. 17. Assignment. Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement without your consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets; provided further, that if you remain employed or become employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then you shall not be entitled to any payments, benefits or vesting pursuant to Section 9 or pursuant to Section 10 of this Agreement solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding upon you and the Company, and each of your and its respective successors, executors, administrators, heirs and permitted assigns. 22. Other Terms. The provisions of this Agreement shall survive the termination of this Agreement and / or the termination of your employment to the extent necessary to effectuate the terms contained herein. The headings and other captions in this Agreement are for convenience and reference only and shall not be used in interpreting, construing or enforcing any of the provisions of this Agreement. This Agreement may be executed in separate counterparts. When both counterparts are signed, they shall be treated together as one and the same document. PDF copies of signed counterparts shall be equally effective as originals. This Agreement may also be executed electronically by any means that satisfies applicable electronic signature laws (e. g., DocuSign). To indicate your acceptance of the Company’ s offer, please sign this Agreement in the space provided below and return it to me. If you have any questions regarding this letter agreement, feel free to contact me. I look forward to working with you to make the Company a great success. / s / Joana Goncalves Joana Goncalves Exhibit 10. 19 INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “ Agreement ”) is entered into as of __________ by and between Oruka Therapeutics, Inc., a Delaware corporation (the “ Company ”), and __________ (the “ Indemnitee ”) and shall be deemed effective upon the earliest date that the Indemnitee is duly elected or appointed as a director or officer of the Company. RECITALS WHEREAS, the Board of Directors of the Company (the “ Board ”) has determined that the inability to attract and retain qualified persons as directors and officers is detrimental to the best interests of the Company’ s stockholders and that the Company should act to assure such persons that there shall be adequate certainty of protection through insurance and indemnification against risks of claims and actions against them arising out of their service to and activities on behalf of the Company; WHEREAS, the Company has adopted provisions in its Amended and Restated Bylaws (as may be amended or restated from time to time, the “ Bylaws ”) providing for indemnification and advancement of expenses of its directors and officers to the fullest extent authorized by the General Corporation Law of the State of Delaware (the “ DGCL ”), and the Company wishes to clarify and enhance the rights and obligations of the Company and the Indemnitee with respect to indemnification and advancement of expenses; WHEREAS, in order to induce and encourage highly experienced and capable persons such as the Indemnitee to serve and continue to serve as directors and officers of the Company and in any other capacity with respect to the Company as the Company may request, and to otherwise promote the desirable end that such persons shall resist what they consider unjustified lawsuits and claims made against them in connection with the good faith performance of their duties to the Company, with the knowledge that certain costs, judgments, penalties, fines, liabilities and expenses incurred by them in their defense of such litigation are to be borne by the Company and they shall receive appropriate protection against such risks and liabilities, the Board has determined that the following Agreement is reasonable and prudent to promote and ensure the best interests of the Company and its stockholders; and WHEREAS, the Company desires to have the Indemnitee serve or continue to serve as a director or officer of the Company and in any other capacity with respect to the Company as the Company may request, as the case may be, free from undue concern for unpredictable, inappropriate, or unreasonable legal risks and personal liabilities by reason of the Indemnitee acting in good faith in the performance of the Indemnitee’ s duty to the Company; and the Indemnitee desires to continue so to serve the Company, provided, and on the express condition, that he or she is furnished with the protections set forth hereinafter. AGREEMENT NOW, THEREFORE, in consideration of the Indemnitee’ s service or continued service as a director or officer of the Company, the parties hereto agree as follows: 1. Definitions. For purposes of this Agreement: (a) A “ Change in Control ” will be deemed to have occurred if, with respect to any particular 24- month period, the individuals who, at the beginning of such 24- month period, constituted the Board (the “ Incumbent Board ”) cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to the beginning of such 24- month period whose election, or nomination for election by the stockholders of the Company, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a person other than the Board. (b) “ Disinterested Director ” means a director of the Company who is not or was not a party to the Proceeding in respect of which indemnification is being sought by the Indemnitee. (c) “ Expenses ” includes, without limitation, expenses incurred in connection with the defense or settlement of any action, suit, arbitration, alternative dispute resolution mechanism, inquiry, judicial, administrative, or legislative hearing, investigation, or any other threatened, pending, or completed proceeding, whether brought by or in the right of the Company or otherwise, including any and all appeals, whether of a civil, criminal, administrative, legislative, investigative, or other nature, attorneys’ fees, witness fees and expenses, fees and expenses of accountants and other advisors, retainers and disbursements and advances thereon, the premium, security for, and other costs relating to any bond (including cost bonds, appraisal bonds, or their equivalents), and any expenses of establishing a right to indemnification or advancement under this Agreement, but shall not include the amount of judgments, fines, ERISA excise taxes, or penalties actually levied against the Indemnitee, or any amounts paid in settlement by or on behalf of the Indemnitee. (d) “ Independent Counsel ” means a law firm or a member of a law firm that neither is presently nor in the past five years has been retained to represent (i) the Company or the Indemnitee in any matter material to either such party or (ii) any other party to the Proceeding giving rise to a request for indemnification hereunder. Notwithstanding the foregoing, the term “ Independent Counsel ” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or the Indemnitee in an action to determine the Indemnitee’ s right to indemnification under this Agreement. (e) “ Proceeding ” means any action, suit, arbitration, alternative dispute resolution mechanism, inquiry, judicial, administrative, or legislative hearing, investigation, or any other threatened, pending, or completed proceeding, whether brought by or in the right of the Company or otherwise, including any and all appeals, whether of a civil, criminal, administrative, legislative, investigative, or other nature, to which the Indemnitee was or is a party or is threatened to be made a party or is otherwise involved in by reason of the fact that the Indemnitee is or was a director, officer, employee, agent, or trustee of the Company or while a director, officer, employee, agent, or trustee of the Company is or was serving at the request of the Company as a director, officer, employee, agent, or trustee of another corporation or of a partnership, joint venture, trust, or other enterprise, including service with respect to an employee benefit plan (such status, the Indemnitee’ s “ Corporate Status ”), or by reason of anything done or not done by the Indemnitee in any such capacity, whether or not the Indemnitee is serving in such capacity at the time any expense, liability, or loss is incurred for which indemnification or advancement can be provided under this Agreement. 2. Service by the Indemnitee. The Indemnitee shall serve and / or continue to serve as a director or officer of the Company faithfully and to the best of the Indemnitee’ s ability so long as the Indemnitee is duly elected or appointed and until such time as the Indemnitee’ s successor is elected and qualified or the Indemnitee is removed as permitted by applicable law or tenders a resignation in writing. 3. Indemnification and Advancement of Expenses. The Company shall indemnify and hold harmless the Indemnitee, and shall pay to the Indemnitee in advance of the final disposition of any Proceeding all Expenses incurred by the Indemnitee in defending any such Proceeding, to the fullest extent authorized by the DGCL, as the same exists or may hereafter be amended, all on the terms and conditions set forth in this Agreement. Without diminishing the scope of the rights provided by this Section, the rights of the Indemnitee to indemnification and advancement of Expenses provided hereunder shall include but shall not be limited to those rights hereinafter set forth, except that no indemnification or advancement of

Expenses shall be paid to the Indemnitee: (a) to the extent expressly prohibited by applicable law or the Amended and Restated Certificate of Incorporation of the Company (as may be amended or restated from time to time, the “ Certificate of Incorporation ”) and the Bylaws; (b) for and to the extent that payment is actually made to the Indemnitee under a valid and collectible insurance policy or under a valid and enforceable indemnity clause, provision of the certificate of incorporation or bylaws, or agreement of the Company or any other company or other enterprise (and the Indemnitee shall reimburse the Company for any amounts paid by the Company and subsequently so recovered by the Indemnitee); or (c) in connection with an action, suit, or proceeding, or part thereof voluntarily initiated by the Indemnitee (including claims and counterclaims, whether such counterclaims are asserted by (i) the Indemnitee, or (ii) the Company in an action, suit, or proceeding initiated by the Indemnitee), except a judicial proceeding pursuant to Section 11 to enforce rights under this Agreement, unless (A) the action, suit, or proceeding, or part thereof, was authorized or ratified by the Board or the Board otherwise determines that indemnification or advancement of Expenses is appropriate or (B) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law. 4. Action or Proceedings Other than an Action by or in the Right of the Company. Except as limited by Section 3 above, the Indemnitee shall be entitled to the indemnification rights provided in this Section if the Indemnitee was or is a party or is threatened to be made a party to, or was or is otherwise involved in, any Proceeding (other than an action by or in the right of the Company) by reason of the Indemnitee’ s Corporate Status, or by reason of anything done or not done by the Indemnitee in any such capacity. Pursuant to this Section, the Indemnitee shall be indemnified against all expense, liability, and loss (including judgments, fines, ERISA excise taxes or penalties, amounts paid in settlement by or on behalf of the Indemnitee, and Expenses) actually and reasonably incurred by the Indemnitee, or on behalf of the Indemnitee, in connection with such Proceeding, if the Indemnitee acted in good faith and in a manner the Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, and with respect to any criminal Proceeding, had no reasonable cause to believe his or her conduct was unlawful. 5. Indemnity in Proceedings by or in the Right of the Company. Except as limited by Section 3 above, the Indemnitee shall be entitled to the indemnification rights provided in this Section if the Indemnitee was or is a party or is threatened to be made a party to, or was or is otherwise involved in, any Proceeding brought by or in the right of the Company to procure a judgment in its favor by reason of the Indemnitee’ s Corporate Status, or by reason of anything done or not done by the Indemnitee in any such capacity. Pursuant to this Section, the Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by the Indemnitee, or on behalf of the Indemnitee, in connection with such Proceeding if the Indemnitee acted in good faith and in a manner the Indemnitee reasonably believed to be in or not opposed to the best interests of the Company; provided, however, that no such indemnification shall be made in respect of any claim, issue, or matter as to which the DGCL expressly prohibits such indemnification by reason of any adjudication of liability of the Indemnitee to the Company, unless and only to the extent that the Court of Chancery of the State of Delaware or the court in which such Proceeding was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, the Indemnitee is entitled to indemnification for such expense, liability, and loss as such court shall deem proper. 6. Indemnification for Costs, Charges, and Expenses of Successful Party. Notwithstanding any limitations of Sections 3 (c), 4, and 5 above, to the extent that the Indemnitee has been successful, on the merits or otherwise, in whole or in part, in defense of any Proceeding, or in defense of any claim, issue, or matter therein, including, without limitation, the dismissal of any action without prejudice, or if it is ultimately determined, by final judicial decision of a court of competent jurisdiction from which there is no further right to appeal, that the Indemnitee is otherwise entitled to be indemnified against Expenses, the Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by the Indemnitee in connection therewith. 7. Partial Indemnification. If the Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion of the expense, liability, and loss (including judgments, fines, ERISA excise taxes or penalties, amounts paid in settlement by or on behalf of the Indemnitee, and Expenses) actually and reasonably incurred in connection with any Proceeding, or in connection with any judicial proceeding pursuant to Section 11 to enforce rights under this Agreement, but not, however, for all of the total amount thereof, the Company shall nevertheless indemnify the Indemnitee for the portion of such expense, liability, and loss actually and reasonably incurred to which the Indemnitee is entitled. 8. Indemnification for Expenses of a Witness. Notwithstanding any other provision of this Agreement, to the maximum extent permitted by the DGCL, the Indemnitee shall be entitled to indemnification against all Expenses actually and reasonably incurred by the Indemnitee or on the Indemnitee’ s behalf if the Indemnitee appears as a witness or otherwise incurs legal expenses as a result of or related to the Indemnitee’ s service as a director or officer of the Company, in any threatened, pending, or completed action, suit, arbitration, alternative dispute resolution mechanism, inquiry, judicial, administrative, or legislative hearing, investigation, or any other threatened, pending, or completed proceeding, whether of a civil, criminal, administrative, legislative, investigative, or other nature, to which the Indemnitee neither is, nor is threatened to be made, a party. 9. Determination of Entitlement to Indemnification. To receive indemnification under this Agreement, the Indemnitee shall submit a written request to the Secretary of the Company. Such request shall include documentation or information that is necessary for such determination and is reasonably available to the Indemnitee. Upon receipt by the Secretary of the Company of a written request by the Indemnitee for indemnification pursuant to this Agreement, the entitlement of the Indemnitee to indemnification, to the extent not provided pursuant to the terms of this Agreement, shall be determined by the following person or persons who shall be empowered to make such determination (as selected by the Board, except with respect to Section 9 (e) below): (a) the Board by a majority vote of Disinterested Directors, whether or not such majority constitutes a quorum; (b) a committee of Disinterested Directors designated by a majority vote of such directors, whether or not such majority constitutes a quorum; (c) if there are no Disinterested Directors, or if the Disinterested Directors so direct, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to the Indemnitee; (d) the stockholders of the Company; or (e) in the event that a Change in Control has occurred, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to the Indemnitee. Such Independent Counsel shall be selected by the Board and approved by the Indemnitee, except that in the event that a Change in Control has occurred, Independent Counsel shall be selected by the Indemnitee. Upon failure of the Board so to select such Independent Counsel or upon failure of the Indemnitee so to approve (or so to select, in the event a Change in Control has occurred), such Independent Counsel shall be selected upon application to a court of competent jurisdiction. The determination of entitlement to indemnification shall be made and, unless a contrary determination is made, such indemnification shall be paid in full by the Company not later than 60 calendar days after receipt by the Secretary of the Company of a written request for indemnification. If the person making such determination shall determine that the Indemnitee is entitled to indemnification as to part (but not all) of the application for indemnification, such person shall reasonably prorate such partial indemnification among the claims, issues, or matters at issue at the time of the determination. 10. Presumptions and Effect of Certain Proceedings. The Secretary of the Company shall, promptly upon receipt of the Indemnitee’ s written request for indemnification, advise in writing the Board or such other person or persons empowered to make the determination as provided in Section 9 that the Indemnitee has made such request for indemnification. Upon making such request for indemnification, the Indemnitee shall be presumed to be entitled to indemnification hereunder and the Company shall have the burden of proof in making any determination contrary to such presumption. If the person or persons so empowered to make such determination shall have failed to make the requested determination with respect to indemnification within 60 calendar days after receipt by the Secretary of the Company of such request, a requisite determination of entitlement to indemnification shall be deemed to have been made and the Indemnitee shall be absolutely entitled to such indemnification, absent actual fraud in the request for indemnification. The termination of any Proceeding described in Sections 4 or 5 by judgment, order, settlement, or conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself (a) create a presumption that the Indemnitee did not act in good faith and in a manner the Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, or with respect to any criminal Proceeding, had reasonable cause to believe his or her conduct was unlawful or (b) otherwise adversely affect the rights of the Indemnitee to indemnification except as may be provided herein. 11. Remedies of the Indemnitee in Cases of Determination Not to Indemnify or to Advance Expenses; Right to Bring Suit. In the event that a determination is made that the Indemnitee is not entitled to indemnification hereunder or if payment is not timely made following a determination of entitlement to indemnification pursuant to Sections 9 and 10, or if an advancement of Expenses is not timely made pursuant to Section 16, the Indemnitee may at any time thereafter bring suit against the Company seeking an adjudication of entitlement to such indemnification or advancement of Expenses, and any such suit shall be brought in the Court of Chancery of the State of Delaware unless, if the Indemnitee is an employee of the Company, otherwise required by the law of the state in which the Indemnitee primarily resides and works. The Company shall not oppose the Indemnitee’ s right to seek any such adjudication. In any suit brought by the Indemnitee to enforce a right to indemnification hereunder (but not in a suit brought by the Indemnitee to enforce a right to an advancement of Expenses), it shall be a defense that the Indemnitee has not met any applicable standard of conduct for indemnification set forth in the DGCL, including the standard described in Section 4 or 5, as applicable. Further, in any suit brought by the Company to recover an advancement of Expenses pursuant to the terms of an undertaking, the Company shall be entitled to recover such Expenses upon a final judicial decision of a court of competent jurisdiction from which there is no further right to appeal that the Indemnitee has not met the standard of conduct described above. Neither the failure of the Company (including the Disinterested Directors, a committee of Disinterested Directors, Independent Counsel, or its stockholders) to have made a determination prior to the commencement of such suit that indemnification of the Indemnitee is proper in the circumstances because the Indemnitee has met the standard of conduct described above, nor an actual determination by the Company (including the Disinterested Directors, a committee of Disinterested Directors, Independent Counsel, or its stockholders) that the Indemnitee has not met the standard of conduct described above shall create a presumption that the Indemnitee has not met the standard of conduct described above, or, in the case of such a suit brought by the Indemnitee, be a defense to such suit. In any suit brought by the Indemnitee to enforce a right to indemnification or to an advancement of Expenses hereunder, or brought by the Company to recover an advancement of Expenses pursuant to the terms of an undertaking, the burden of proving that the Indemnitee is not entitled to be indemnified, or to such advancement of Expenses, under this Section 11 or otherwise shall be on the Company. If a determination is made or deemed to have been made pursuant to the terms of Section 9 or 10 that the Indemnitee is entitled to indemnification, the Company shall be bound by such determination and is precluded from asserting that such determination has not been made or that the procedure by which such determination was made is not valid, binding, and enforceable. The Company further agrees to stipulate in any court pursuant to this Section 11 that the Company is bound by all the provisions of this Agreement and is precluded from making any assertions to the contrary. If the court shall determine that the Indemnitee is entitled to any indemnification or advancement of Expenses hereunder, the Company shall pay all Expenses actually and reasonably incurred by the Indemnitee in connection with such adjudication (including, but not limited to, any appellate proceedings) to the fullest extent permitted by law, and in any suit brought by the Company to recover an advancement of Expenses pursuant to the terms of an undertaking, the Company shall pay all Expenses actually and reasonably incurred by the Indemnitee in connection with such suit to the extent the Indemnitee has been successful, on the merits or otherwise, in whole or in part, in defense of such suit, to the fullest extent permitted by law. 12. Non- Exclusivity of Rights; Survival of Rights; Insurance; Subrogation. (a) The rights provided by this Agreement shall not be deemed exclusive of any other rights to which the Indemnitee may at any time be entitled under applicable law, the Certificate of Incorporation, or Bylaws, any agreement, a vote of stockholders, a resolution of the Board, or otherwise. No amendment, alteration or repeal of this Agreement or of any provision of this Agreement shall limit or restrict any right of the Indemnitee under this Agreement in respect of any action taken or omitted by the Indemnitee in his or her Corporate Status prior to such amendment, alteration or repeal. To the extent that a change in the DGCL, whether by statute or judicial decision, permits greater indemnification than would be afforded under the current Certificate of Incorporation or Bylaws and this Agreement, it is the intent of the parties hereto that the Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy. (b) To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, employees, or agents or fiduciaries of the Company or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise that such person serves at the request of the Company, the Company shall obtain coverage for the Indemnitee under such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any other director (if the Indemnitee is a director) or officer (if the Indemnitee is not a director but is an officer) of the Company under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms of this Agreement, the Company has director and officer liability insurance in effect, the Company shall give notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all commercially reasonable steps to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies. (c) In the event of any payment under this Agreement, [subject to the exceptions contained in Section 12 (d) below,] 1 the Company shall be subrogated to the extent of such payment to all of the rights of recovery of the Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company effectively to bring suit to enforce such rights. 1Note to Draft: This clause will only apply to directors who are separately indemnified by an entity in connection with their appointment to the Board. (d) [The Company hereby acknowledges that Indemnitee has certain rights to indemnification, advancement of expenses and / or insurance provided by ____________ and / or [their / its] affiliates (collectively, the “ Designee Indemnitors ”). The Company hereby agrees (i) that it is the indemnitor of first resort vis- à- vis the Designee Indemnitors (i. e., its obligations to Indemnitee are primary and any obligation of the Designee Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by Indemnitee are secondary), (ii) that it shall be required to advance the full amount of Expenses incurred by Indemnitee and shall be liable for the full amount of all indemnity amounts to the extent required by the terms of this Agreement and the Bylaws, without regard to any rights Indemnitee may have against the Designee Indemnitors, and (iii) notwithstanding any other provision in this Agreement or the Bylaws, that it irrevocably waives, relinquishes and releases the Designee Indemnitors from any and all claims against the Designee Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Designee

Indemnitors on behalf of Indemnitee with respect to any claim for which Indemnitee has sought indemnification from the Company shall affect the foregoing and the Designee Indemnitors shall have a right of contribution and / or be subrogated to the extent of such advancement or payment to all of the rights of recovery of Indemnitee against the Company. The Designee Indemnitors are express third- party beneficiaries of this Section 12 (d).] 2 (e) The Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder if and to the extent that the Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise. (f) The Company' s obligation to indemnify or advance Expenses hereunder to the Indemnitee who is or was serving at the request of the Company as a director, officer, employee or agent of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall be reduced by any amount the Indemnitee has actually received as indemnification or advancement of expenses from such other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise. 13. Expenses to Enforce Agreement. In the event that the Indemnitee is subject to or intervenes in any action, suit, or proceeding in which the validity or enforceability of this Agreement is at issue or seeks an adjudication to enforce the Indemnitee' s rights under, or to recover damages for breach of, this Agreement, the Indemnitee, if the Indemnitee prevails in whole or in part in such action, suit, or proceeding, shall be entitled to recover from the Company and shall be indemnified by the Company against any Expenses actually and reasonably incurred by the Indemnitee in connection therewith. 14. Continuation of Indemnity. All agreements and obligations of the Company contained herein shall continue during the period the Indemnitee is a director, officer, employee, agent, or trustee of the Company or while a director, officer, employee, agent, or trustee is serving at the request of the Company as a director, officer, employee, agent, or trustee of another corporation or of a partnership, joint venture, trust, or other enterprise, including service with respect to an employee benefit plan, and shall continue thereafter with respect to any possible claims based on the fact that the Indemnitee was a director, officer, employee, agent, or trustee of the Company or was serving at the request of the Company as a director, officer, employee, agent, or trustee of another corporation or of a partnership, joint venture, trust, or other enterprise, including service with respect to an employee benefit plan. This Agreement shall be binding upon all successors and assigns of the Company (including any transferee of all or substantially all of its assets and any successor by merger or operation of law) and shall inure to the benefit of the Indemnitee' s heirs, executors, and administrators. 2Note to Draft: This clause will only apply to directors who are separately indemnified by an entity in connection with their appointment to the Board. 15. Notification and Defense of Proceeding. Promptly after receipt by the Indemnitee of notice of any Proceeding, the Indemnitee shall, if a request for indemnification or an advancement of Expenses in respect thereof is to be made against the Company under this Agreement, notify the Company in writing of the commencement thereof; but the omission so to notify the Company shall not relieve it from any liability that it may have to the Indemnitee unless, and to the extent that, such failure actually and materially prejudices the interests of the Company. Notwithstanding any other provision of this Agreement, with respect to any such Proceeding of which the Indemnitee notifies the Company: (a) The Company shall be entitled to participate therein at its own expense; (b) Except as otherwise provided in this Section 15 (b), to the extent that it may wish, the Company, jointly with any other indemnifying party similarly notified, shall be entitled to assume the defense thereof, with counsel satisfactory to the Indemnitee. After notice from the Company to the Indemnitee of its election so to assume the defense thereof, the Company shall not be liable to the Indemnitee under this Agreement for any expenses of counsel subsequently incurred by the Indemnitee in connection with the defense thereof except as otherwise provided below. The Indemnitee shall have the right to employ the Indemnitee' s own counsel in such Proceeding, but the fees and expenses of such counsel incurred after notice from the Company of its assumption of the defense thereof shall be at the expense of the Indemnitee unless (i) the employment of counsel by the Indemnitee has been authorized by the Company, (ii) the Indemnitee shall have reasonably concluded that there may be a conflict of interest between the Company and the Indemnitee in the conduct of the defense of such Proceeding, or (iii) the Company shall not within 60 calendar days of receipt of notice from the Indemnitee in fact have employed counsel to assume the defense of the Proceeding, in each of which cases the fees and expenses of the Indemnitee' s counsel shall be at the expense of the Company. The Company shall not be entitled to assume the defense of any Proceeding brought by or on behalf of the Company or as to which the Indemnitee shall have made the conclusion provided for in (ii) above; and (c) Notwithstanding any other provision of this Agreement, the Company shall not be liable to indemnify the Indemnitee under this Agreement for any amounts paid in settlement of any Proceeding effected without the Company' s written consent, or for any judicial or other award, if the Company was not given an opportunity, in accordance with this Section 15, to participate in the defense of such Proceeding. The Company shall not settle any Proceeding in any manner that would impose any penalty or limitation on or disclosure obligation with respect to the Indemnitee, or that would directly or indirectly constitute or impose any admission or acknowledgment of fault or culpability with respect to the Indemnitee, without the Indemnitee' s written consent. Neither the Company nor the Indemnitee shall unreasonably withhold its consent to any proposed settlement. 16. Advancement of Expenses. All Expenses incurred by the Indemnitee in defending any Proceeding described in Sections 4 or 5 shall be paid by the Company in advance of the final disposition of such Proceeding at the request of the Indemnitee. Notwithstanding the foregoing, the Company shall not advance or continue to advance Expenses to the Indemnitee if a determination is reasonably made that the facts known at the time such determination is made demonstrate clearly and convincingly that the Indemnitee acted in bad faith or in a manner that the Indemnitee did not reasonably believe to be in or not opposed to the best interests of the Company, or, with respect to any criminal Proceeding, that the Indemnitee had reasonable cause to believe his or her conduct was unlawful. Such determination shall be made: (i) by the Board by a majority vote of directors who are not parties to such proceeding, whether or not such majority constitutes a quorum; (ii) by a committee of such directors designated by a majority vote of such directors, whether or not such majority constitutes a quorum; or (iii) if there are no such directors, or if such directors so direct, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to the Indemnitee. To receive an advancement of Expenses under this Agreement, the Indemnitee shall submit a written request to the Secretary of the Company. Such request shall reasonably evidence the Expenses incurred by the Indemnitee and shall include or be accompanied by an undertaking, by or on behalf of the Indemnitee, to repay all amounts so advanced if it shall ultimately be determined, by final judicial decision of a court of competent jurisdiction from which there is no further right to appeal, that the Indemnitee is not entitled to be indemnified for such Expenses by the Company as provided by this Agreement or otherwise. The Indemnitee' s undertaking to repay any such amounts is not required to be secured. Each such advancement of Expenses shall be made within 20 calendar days after the receipt by the Secretary of the Company of such written request. The Indemnitee' s entitlement to Expenses under this Agreement shall include those incurred in connection with any action, suit, or proceeding by the Indemnitee seeking an adjudication pursuant to Section 11 of this Agreement (including the enforcement of this provision) to the extent the court shall determine that the Indemnitee is entitled to an advancement of Expenses hereunder. 17. Severability; Prior Indemnification Agreements. If any provision or provisions of this Agreement shall be held to be invalid, illegal, or unenforceable as applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law (a) the validity, legality, and enforceability of such provision in any other circumstance and of the remaining provisions of this Agreement (including, without limitation, all portions of any paragraphs of this Agreement containing any such provision held to be invalid, illegal, or unenforceable, that are not by themselves invalid, illegal, or unenforceable) and the application of such provision to other persons or entities or circumstances shall not in any way be affected or impaired thereby, and (b) to the fullest extent possible, the provisions of this Agreement (including, without limitation, all portions of any paragraph of this Agreement containing any such provision held to be invalid, illegal, or unenforceable, that are not themselves invalid, illegal, or unenforceable) shall be construed so as to give effect to the intent of the parties that the Company provide protection to the Indemnitee to the fullest enforceable extent set forth in this Agreement. This Agreement shall supersede and replace any prior indemnification agreements entered into by and between the Company and the Indemnitee and any such prior agreements shall be terminated upon execution of this Agreement. 18. Headings; References; Pronouns. The headings of the sections of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof. References herein to section numbers are to sections of this Agreement. All pronouns and any variations thereof shall be deemed to refer to the singular or plural as appropriate. 19. Other Provisions. (a) This Agreement and all disputes or controversies arising out of or related to this Agreement shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to the laws of any other jurisdiction that might be applied because of conflicts of laws principles of the State of Delaware, unless, if the Indemnitee is an employee of the Company, otherwise required by the law of the state in which the Indemnitee primarily resides and works. (b) This Agreement may be executed in two or more counterparts, all of which shall be considered one and the same instrument and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other party. (c) This Agreement shall not be deemed an employment contract between the Company and any Indemnitee who is an officer of the Company, and, if the Indemnitee is an officer of the Company, the Indemnitee specifically acknowledges that the Indemnitee may be discharged at any time for any reason, with or without cause, and with or without severance compensation, except as may be otherwise provided in a separate written contract between the Indemnitee and the Company. (d) This Agreement may not be amended, modified, or supplemented in any manner, whether by course of conduct or otherwise, except by an instrument in writing specifically designated as an amendment hereto, signed on behalf of each party. No failure or delay of either party in exercising any right or remedy hereunder shall operate as a waiver thereof, and no single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such right or power, or any course of conduct, shall preclude any other or further exercise thereof or the exercise of any other right or power. [The remainder of this page is intentionally left blank.] IN WITNESS WHEREOF, the Company and the Indemnitee have caused this Agreement to be executed as of the date first written above. ORUKA THERAPEUTICS, INC. By: Name: Title: Indemnitee: [Signature Page to Indemnification Agreement] Exhibit 10. 20 Non- Employee Directors Compensation Program Each of our non- employee directors receives compensation pursuant to the non- employee director cash and equity compensation program adopted by our Board. This program provides for the following annual cash retainers: Annual Cash Retainer $ 40, 000 Annual Board Chair Retainer $ 30, 000 Audit Committee Retainers: Chair $ 15, 000 Non- Chair Member $ 7, 500 Compensation Committee Retainers: Chair $ 12, 000 Non- Chair Member $ 6, 000 Nominating and Corporate Governance Committee Retainers Chair $ 10, 000 Non- Chair Member $ 5, 000 In connection with the Company' s annual meeting of stockholders, each member of the Board will receive an annual grant of stock options to purchase 17, 500 shares of common stock, which will vest in equal monthly installments over 12 months so long as such director joined the Board prior to January 1 of the year in which such annual meeting occurs. In addition, in connection with a non- employee director' s initial appointment to the Board, they will receive an initial grant of stock options to purchase 35, 000 shares of common stock, which will vest in equal monthly installments over 36 months. All members of the Board are also reimbursed for reasonable and documented out- of- pocket travel and lodging expenses incurred in connection with attending meetings and activities of the Board and its committees. Exhibit 10. 29 [* * *] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. IL- 17 LICENSE AGREEMENT This License Agreement (" Agreement ") is entered into and effective as of February 4, 2025 (the " Effective Date "), by and between Paragon Therapeutics, Inc., a Delaware corporation (" Paragon "), and Oruka Therapeutics, Inc., a Delaware corporation (" Oruka "). Paragon and Oruka are also referred to herein individually as a " Party ", or collectively as the " Parties. " Recitals Whereas, Paragon has developed a proprietary platform technology for the discovery and development of antibodies against therapeutically relevant targets; Whereas, pursuant to that certain Amended and Restated Antibody Discovery and Option Agreement by and among Paragon, Oruka and Paruka Holding, LLC, a Delaware limited liability company, dated as of March 28, 2024 (as such agreement may be further amended from time to time, the " Option Agreement "), Oruka has engaged Paragon to identify, evaluate and develop one or more antibody candidates directed to certain therapeutic targets and has been granted an exclusive option to enter into one or more separate license agreements to develop, manufacture and commercialize the resulting antibodies with respect to a given target; Whereas, Oruka has exercised such option with respect to the Licensed Target (as defined below), and the Parties desire to memorialize the exclusive license from Paragon to Oruka with respect to such Licensed Target, all on the terms and subject to the conditions set forth in this Agreement. Now Therefore, in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows: Article I DEFINITIONS. The following initially capitalized terms have the following meanings (and derivative forms of them shall be interpreted accordingly): 1. 1 " Achievement of Development Candidate " means the first to occur of: (a) nomination by Oruka' s Board of Directors of an Oruka Product as a " Development Candidate "; and (b) the initiation by or on behalf of Oruka or its Affiliate or Sublicensee of a toxicology study with respect to an Oruka Product that employs applicable then- current good laboratory practice standards, the results of which are intended to be submitted as part of an IND. 1. 2 " Acquired Program " has the meaning set forth in Section 2. 2 (c). 1. 3 " Acquiring Entity " means, collectively, the Third Party referenced in the definition of Change of Control and such Third Party' s Affiliates, other than (a) the applicable Party in the definition of Change of Control, and (b) such Party' s Affiliates, determined immediately prior to the closing of such Change of Control ((a) and (b) collectively, the " Pre- Existing Entities "). 1. 4 " Affiliate " means any entity controlled by, controlling, or under common control with a Party hereto. For the purpose of this definition, " control " (including, with correlative meaning, the terms " controlled by " or " under common control ") means the direct or indirect ownership of more than fifty percent (50 %) of the voting interest in, or more than fifty percent (50 %) in the equity of, or the right to appoint more than fifty percent (50 %) of the directors or management of, such corporation or other business entity. Notwithstanding the foregoing, (a) with respect to either Party, Affiliates of such Party do not include [* * *] or its Affiliates other than such Party and its subsidiaries, (b) Paragon and its Affiliates, on the one hand, and Oruka and its subsidiaries, on the other hand, shall not be deemed to be Affiliates of each other, and (c) Affiliates of Paragon do not include new entities formed by or on behalf of Paragon for the sole bona fide purpose of further developing, manufacturing, commercializing or otherwise exploiting Antibodies and Antibody products (excluding any Licensed Antibody Technology or Other Licensed Technology) using, among other sources, funds from Third Party investors. 1. 5 " Agreement " has the meaning set forth in the preamble. 1. 6 " Annual Net Sales " means total Net Sales by Oruka, its Affiliates and Sublicensees in the Territory of all of the Products in a particular Calendar Year, calculated in accordance with U. S. generally accepted accounting principles (GAAP) consistently applied. 1. 7 " Anti-Corruption Laws " has the meaning set forth in Section 7. 2 (q) (i). 1. 8 " Antibody " means any molecule, including [* * *]. 1. 9 " Applicable Law " means any national, supra- national, federal,

state or local laws, rules, guidances, and regulations, in each case, as applicable to the subject matter and the Party at issue. 1. 10 “ Bankruptcy Code ” has the meaning set forth in Section 8. 4. 1. 11 “ Bankruptcy Event ” has the meaning set forth in Section 8. 4. 1. 12 “ Business Day ” means any day other than Saturday, Sunday or a national holiday in the United States. 1. 13 “ Calendar Quarter ” means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31. 1. 14 “ Calendar Year ” means each successive period of twelve (12) months commencing on January 1 and ending on December 31. 1. 15 “ Change of Control ” means, with respect to any entity, any of the following: (a) the sale or disposition of all or substantially all of the assets of such entity or its direct or indirect controlling Affiliate to a Third Party; or (b) (i) the acquisition by a Third Party, alone or together with any of its Affiliates, other than an employee benefit plan (or related trust) sponsored or maintained by such entity or any of its Affiliates, of more than fifty percent (50 %) of the then- outstanding shares of voting capital stock of such entity or its direct or indirect parent entity that holds, directly or indirectly, beneficial ownership of more than fifty percent (50 %) of the then- outstanding shares of voting capital stock of such entity (a “ Parent Entity ”), or (ii) the acquisition, merger or consolidation of such entity or its Parent Entity with or into another entity, other than, in the case of clause (i) or (ii), an acquisition or a merger or consolidation of such entity or its Parent Entity in which the holders of shares of voting capital stock of such entity or its Parent Entity, as the case may be, immediately prior to such acquisition, merger or consolidation will beneficially own, directly or indirectly, at least fifty percent (50 %) of the shares of voting capital stock of the acquiring Third Party or the surviving corporation in such acquisition, merger or consolidation, as the case may be, immediately after such acquisition, merger or consolidation, and in each case of (a) or (b), whether through a single transaction or a series of related transactions, but excluding any and all bona fide financing transactions or internal reorganizations for tax purposes (including the change of place of incorporation or domicile of such entity). 1. 16 “ Claim ” has the meaning set forth in Section 9. 3. 1. 17 “ COC Program ” has the meaning set forth in Section 2. 2 (b). 1. 18 “ Combination Product ” has the meaning set forth in Section 1. 59. 1. 19 “ Commercialize ” or “ Commercializing ” means any and all activity to market, promote, distribute, offer for sale, sell, have sold, seek reimbursement, import, have imported, export, have exported, or otherwise commercialize an Antibody or product, including any Licensed Antibody, Derived Antibody, Product, Multispecific Antibody, Multispecific Product, as applicable, and including interacting with Regulatory Authorities following receipt of Regulatory Approval and seeking and maintaining any required Reimbursement Approval. When used as a noun, “ Commercialization ” means any and all activities involved in Commercializing. 1. 20 “ Commercially Reasonable Efforts ” means those efforts and resources, including reasonably necessary and qualified personnel, equivalent to the efforts and resources that a reasonable international biopharmaceutical company or a pharmaceutical company, in each case, that is of comparable size and resources to the applicable Party would typically devote as part of an active and continuing program of development and commercialization of a pharmaceutical or biologic product of similar market potential, at a similar stage of its product life, taking into account the competitiveness of the marketplace and the proprietary position, regulatory status, and relative safety and efficacy of such product. Commercially Reasonable Efforts requires, with respect to an obligation, that the applicable Party (a) assign responsibility for such obligation to specific employees who are held accountable for progress and monitor such progress on an on- going basis, (b) set and seek to achieve reasonable objectives for carrying out such obligation, and (c) make and implement reasonable decisions and allocate resources designed to advance progress with respect to such objectives. 1. 21 “ Confidential Information ” of a Party means Know- How and any and all non- public scientific, business, regulatory or technical information that is disclosed or made available by or on behalf of one Party (the “ Disclosing Party ”) to the other Party (the “ Receiving Party ”) in connection with this Agreement, regardless of whether such information is specifically marked or designated confidential, whether in writing, orally, visually, or otherwise. Notwithstanding any provision of this Agreement to the contrary, the Licensed Antibody Technology shall be the Confidential Information of Oruka. 1. 22 “ Control ” (including any variations such as “ Controlled ” and “ Controlling ”) means, with respect to any technology (including Know- How) or other Intellectual Property Rights, possession by a Party or one of its Affiliates of the ability (whether by ownership, license or otherwise (other than by a license, sublicense or other right granted pursuant to this Agreement)) to grant a license or a sublicense of or under such technology or Intellectual Property Rights without violating the terms of any agreement or other arrangement with any Third Party; provided, that if following the Effective Date (a) Paragon would Control any Patent that would be included in the Licensed Antibody Technology or Other Licensed Patents but for an obligation to pay royalties or other consideration for the Development, Manufacture or Commercialization of an Oruka Product in the Territory in connection with a grant to Oruka of a license under such Patent, and (b) Oruka, pursuant to Section 2. 8, consents to being a sublicensee of such Patent and complies with the Reimbursement Obligation, then such Patent shall be deemed Controlled by Paragon. Notwithstanding the foregoing, a Party and its Affiliates shall not be deemed to “ Control ” any technology or Intellectual Property Rights that (i) prior to the consummation of a Change of Control of such Party is owned or in- licensed, or (ii) after the consummation of a Change of Control of such Party, becomes owned or in- licensed (to the extent such technology or Intellectual Property Rights are developed outside of the scope of the activities conducted hereunder and without use of or reference to any technology or Intellectual Property Rights Controlled by such Party or any Affiliate of such Party immediately before such Change of Control, or any Confidential Information of the other Party), in each case ((i) or (ii)), by a Third Party that becomes an Affiliate of such Party after the Effective Date as a result of such Change of Control or an assignee of such Party after the Effective Date as the result of an assignment of this Agreement in connection with a Change of Control unless prior to the consummation of such Change of Control or assignment, such Party or any of its Affiliates also Controlled such technology or Intellectual Property Rights. 1. 23 “ Cover ” or “ Covering ” means, with respect to a particular product, any Patent, that, in the absence of a license granted under, or ownership of, such Patent, the making, using, selling, importation, or exportation of such product would infringe a valid and unexpired claim of such Patent. 1. 24 “ Derived Antibody ” means any Antibody that is created by or on behalf of Oruka (other than an Antibody created by Paragon under the Option Agreement), its Affiliates or its or their licensees and: (a) is derived from or constitutes a modification of a Licensed Antibody, including [* * *], (b) [* * *] and (c) [* * *]. For avoidance of doubt, any Antibody that [* * *] will be deemed a Derived Antibody, irrespective of origin. Notwithstanding the foregoing, a Derived Antibody shall not include (i) [* * *], or (ii) [* * *]. 1. 25 “ Designated Multispecific Antibody ” has the meaning set forth in Section 2. 6 (b). 1. 26 “ Develop ” or “ Developing ” means any and all activity to discover, evaluate, test (including clinical and non- clinical testing), research, or otherwise develop an Antibody or product, including any Licensed Antibody, Derived Antibody, Product, Multispecific Antibody, or Multispecific Product, as applicable. When used as a noun, “ Development ” means any and all activities involved in Developing. 1. 27 “ Directed To ” means, with regard to an Antibody or product, that such Antibody or product is developed or designed to (a) [* * *], and (b) [* * *]. 1. 28 “ Disclosing Party ” has the meaning set forth in Section 1. 21. 1. 29 “ Dispute ” has the meaning set forth in Section 10. 7 (a). 1. 30 “ Dollar ” means a U. S. dollar, and “ $ ” shall be interpreted accordingly. 1. 31 “ Effective Date ” has the meaning set forth in the preamble. 1. 32 “ Exclusivity Period ” means the period commencing on the Effective Date and continuing until the fifth (5th) anniversary of the Effective Date. 1. 33 “ FDA ” means the United States Food and Drug Administration, or a successor federal agency thereto. 1. 34 “ Field ” means the prophylaxis, palliation, treatment and diagnosis of human disease and disorders. 1. 35 “ First Commercial Sale ” means the first sale of an Oruka Product by Oruka, or one of its Affiliates or its or their Sublicensees, to a Third Party after receipt of all Regulatory Approvals required to market and sell the Oruka Product have been obtained in the country in the Territory in which such Oruka Product is sold. Sales for purposes of testing the Oruka Product and sample purposes shall not be deemed a First Commercial Sale. Furthermore, for purposes of clarity, the term “ First Commercial Sale ” as used in this Agreement shall not include: (a) [* * *]; (b) [* * *]; nor (c) [* * *]. 1. 36 “ Force Majeure ” has the meaning set forth in Section 10. 2. 1. 37 “ Governmental Authority ” means any national, international, federal, state, provincial, or local government, or political subdivision thereof, or any multinational organization or any authority, agency, or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power, or any court or tribunal (or any department, bureau or division thereof, or any governmental arbitrator or arbitral body). 1. 38 “ IND ” means an investigational new drug application or equivalent application that is required to commence clinical trials for a product in the Territory and filed with the applicable Regulatory Authority. 1 . 39 “ Indemnified Party ” has the meaning set forth in Section 9. 3. 1. 40 “ Indemnifying Party ” has the meaning set forth in Section 9. 3. 1. 41 “ Intellectual Property Rights ” means any and all proprietary rights provided under (a) patent law, including any Patents; (b) copyright law; (c) trademark law; or (d) any other applicable statutory provision or common law principle, including trade secret law, that may provide a right in Know- How, or the expression or use thereof. 1. 42 “ Inventions ” means all Know- How, and all Intellectual Property Rights therein, that are conceived, reduced to practice, discovered, developed, or made by or on behalf of either Party or any Third Parties acting on their behalf (or any of their Representatives, Affiliates, licensees, or sublicensees) in the course of performing activities under this Agreement. 1. 43 “ JAMS Rules ” has the meaning set forth in Section 10. 7 (a) (ii). 1. 44 “ Know- How ” means all technical information and know- how in any tangible or intangible form, including (a) inventions, discoveries, trade secrets, data, specifications, instructions, processes, formulae, materials (including cell lines, vectors, plasmids, nucleic acids and the like), methods, protocols, expertise and any other technology, including the applicability of any of the foregoing to formulations, compositions or products or to their manufacture, development, registration, use or marketing or to methods of assaying or testing them or processes for their manufacture, formulations containing them or compositions incorporating or comprising them, and (b) all data, instructions, processes, formulae, strategies, and expertise, whether biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical, analytical, or otherwise and whether related to safety, quality control, manufacturing or other disciplines. Notwithstanding the foregoing, Know- How excludes any Patents. 1. 45 “ Licensed Antibody ” means any and all Antibodies that are Directed To the Licensed Target and that were discovered, generated, identified or characterized by Paragon in the course of performing the Research Program. Notwithstanding the foregoing, the Licensed Antibodies shall not include (a) [* * *], or (b) [* * *]. 1. 46 “ Licensed Antibody Invention ” means (a) any invention or discovery, whether or not patentable, that was discovered or reduced to practice by or on behalf of Paragon under the Research Program that constitutes the composition of matter of, or any method of specifically making or using, any Licensed Antibody; and (b) all Intellectual Property Rights therein, that in each case is Controlled by Paragon or its Affiliates as of the Effective Date or during the Term. Notwithstanding the foregoing, the Licensed Antibody Inventions shall not include (i) [* * *], (x) [* * *], or (y) [* * *], or (ii) any Intellectual Property Rights therein. 1. 47 “ Licensed Antibody Patents ” means all Patents that Cover the composition of matter of, or any method of specifically making or using, any Licensed Antibody, that in each case are Controlled by Paragon or its Affiliates as of the Effective Date or during the Term, excluding in each case any claims in such Patents that Cover the composition of matter of, or any method of specifically making or using (a) [* * *], or (b) [* * *]. 1. 48 “ Licensed Antibody Technology ” means (a) the Licensed Antibody Inventions; (b) the Licensed Antibody Patents; (c) the Sequence Information; (d) the Results; (e) the Research Program Materials; and (f) all Intellectual Property Rights therein Controlled by Paragon or its Affiliates as of the Effective Date and during the Term. 1. 49 “ Licensed Component ” has the meaning set forth in Section 1. 59. 1. 50 “ Licensed Target ” means IL- 17A / F. 1. 51 “ Losses ” has the meaning set forth in Section 9. 1. 1. 52 “ MAA ” means (a) a New Drug Application in the United States, as defined in the United States Federal Food, Drug and Cosmetics Act, and applicable regulations promulgated thereunder by the FDA; (b) a Biologics License Application in the United States, as defined in the United States Public Health Service Act; or (c) any application filed with any Regulatory Authority in a country other than the United States that is equivalent to either of the foregoing. 1. 53 “ Major Market Country ” means any of the following: [* * *]. 1. 54 “ Manufacture ” or “ Manufacturing ” means any and all activity to make, have made, produce, manufacture, process, fill, finish, package, label, perform quality assurance testing, release, or ship an Antibody or product, including any Licensed Antibody, Derived Antibody, Product, Multispecific Antibody, or Multispecific Product, as applicable, or any component thereof. When used as a noun, “ Manufacture ” or “ Manufacturing ” means any and all activities involved in Manufacturing an Antibody or product, including any Licensed Antibody, Derived Antibody, Product, Multispecific Antibody, or Multispecific Product, as applicable, or any component thereof. 1. 55 “ Milestone ” has the meaning set forth in Section 4. 1. 1. 56 “ Milestone Payment ” has the meaning set forth in Section 4. 1. 1. 57 “ Multispecific Antibody ” means any Antibody that is comprised of (a) [* * *], and (b) [* * *]. 1. 58 “ Multispecific Product ” means any product that comprises or contains any Multispecific Antibody. 1. 59 “ Net Sales ” means the gross amounts received for Oruka Product by Oruka, its Affiliates and Sublicensees for sales or other commercial disposition of such Oruka Product in the Territory to unrelated Third Parties, less the following, in each case related specifically to the Oruka Product and actually incurred, paid or accrued by Oruka, its Affiliates or Sublicensees and not otherwise recovered by or reimbursed to Oruka, its Affiliates or Sublicensees; (a) [* * *]; (b) [* * *]; (c) [* * *]; (d) [* * *]; (e) [* * *]; and (f) [* * *]. Net Sales will include [* * *]. Net Sales will be calculated only once for the first bona fide arm’ s length sale of the Oruka Product by Oruka, its Affiliates or its Sublicensees to a Third Party, and will not include sales between or among [* * *]. Net Sales shall not include any amounts invoiced for [* * *] (i) [* * *], (ii) [* * *], or (iii) [* * *]. Net Sales shall be determined from the books and records of Oruka, Affiliates of Oruka or any Sublicensee maintained in accordance with U. S. generally accepted accounting principles (GAAP) consistently applied. Oruka further agrees in determining Net Sales, it (or its applicable Affiliate or Sublicensee) will use Oruka’ s (or such Affiliate’ s or Sublicensee’ s) then current standard procedures and methodology. If an Oruka Product is sold as a Combination Product (as defined below), the Net Sales of such Combination Product for the purpose of calculating royalties and sales- based milestones owed under this Agreement for sales of such Combination Product, shall be determined as follows: [* * *]. If any Other Component in the Combination Product is not sold separately, Net Sales shall be calculated by [* * *]. If both the Licensed Component and any of the Other Components are not sold separately, the adjustment to Net Sales shall be determined by the Parties [* * *] to reasonably reflect [* * *] of such Licensed Component in the Combination Product to the total fair market value of such Combination Product. For purposes of this definition, “ Combination Product ” means any pharmaceutical product that contains two (2) or more active ingredients, including (A) one (1) or more Licensed Antibodies, Derived Antibodies or Multispecific Antibodies (the “ Licensed Component ”), and (B) one (1) or more active pharmaceutical or biological ingredients that are not (x) a Licensed Antibody, Derived Antibody or Multispecific Antibody, or (y) an Antibody owned or controlled by Paragon or its Affiliate, the rights to which have been licensed to Oruka or its Affiliate under a separate agreement (“ Other Component (s) ”), either as a [* * *], [* * *] or [* * *], and [* * *]. 1. 60 “ Notice of Dispute ” has the meaning set forth in 10. 7 (a) (i). 1. 61 “ Oruka ” has the meaning set forth in the Preamble. 1. 62 “ Oruka Antibody Patents ” means all Patents that Cover the composition of matter of, or any method of specifically making or using any Licensed Antibody or Derived Antibody that, in each case, are owned or in- licensed by Oruka or its Affiliates or Sublicensees as of the Effective Date or during the Term, provided that, if a Change of Control of Oruka occurs, the Oruka

Antibody Patents shall not include any Patents owned or in- licensed by the Acquiring Entity as of the closing of such Change of Control. 1. 63 “ Oruka Indemnitee ” has the meaning set forth in Section 9. 2. 1. 64 “ Oruka Intellectual Property ” means any Patents, Know- How or other Intellectual Property Rights that are Controlled by Oruka and are necessary for, and actually used (or held for use) by Oruka or its Affiliates as of the effective date of termination of this Agreement in the Development, Manufacturing, or Commercialization of Oruka Products. 1. 65 “ Oruka Invention ” means (a) any Invention that is owned or Controlled by Oruka, and (b) all Intellectual Property Rights therein, provided that, in each case (a) – (b), Oruka Inventions shall not include (i) any Inventions owned or Controlled by Paragon or its Affiliate, the rights to which have been licensed to Oruka or its Affiliate under this Agreement or a separate agreement, or (ii) any Intellectual Property Rights therein. 1. 66 “ Oruka Multispecific Antibody ” means any Multispecific Antibody that is Developed, Manufactured, Commercialized or otherwise exploited by Oruka, its Affiliates or Sublicensees, excluding in each case, and subject to Section 2. 7, any Paragon Multispecific Antibody. 1. 67 “ Oruka Multispecific Patents ” means those Patents that Cover the composition of matter of, or any method of specifically making or using, an Oruka Multispecific Antibody. 1. 68 “ Oruka Multispecific Product ” means any product that comprises or contains any Oruka Multispecific Antibody. 1. 69 “ Oruka Product ” means, individually or collectively, as applicable, Licensed Antibodies, Derived Antibodies, Products, Oruka Multispecific Antibodies and Oruka Multispecific Products. 1. 70 “ Other Component (s) ” has the meaning set forth in Section 1. 59. 1. 71 “ Other Licensed Know- How ” means all Know- How Controlled by Paragon or its Affiliates on the Effective Date or during the Term that (a) was used by or on behalf of Paragon in the performance of the Research Program, and (b) is necessary to Develop, Manufacture, Commercialize or otherwise exploit (i) Licensed Antibodies, or (ii) Products, Multispecific Antibodies or Multispecific Products, in each case solely to the extent comprising or containing a Licensed Antibody. For clarity, the Other Licensed Know- How shall exclude (x) the Licensed Antibody Technology, and (y) any Know- How Controlled by Paragon or its Affiliates relating to (1) that [* * *], or (2) [* * *]. 1. 72 “ Other Licensed Patents ” means any Patents other than Licensed Antibody Patents Controlled by Paragon or its Affiliates as of the Effective Date or during the Term that (a) include a claim that expressly recites the sequence of a Licensed Antibody or Derived Antibody, and (b) are necessary to Develop, Manufacture or Commercialize Licensed Antibodies or Derived Antibodies in the Field in the Territory. Notwithstanding the foregoing, the Other Licensed Patents shall not include (i) Paragon Multispecific Patents, (ii) the Paragon Platform Patents (as defined in the Option Agreement), or (iii) any Patents that Cover (x) [* * *], or (y) [* * *]. 1. 73 “ Other Licensed Technology ” means all (a) Other Licensed Know- How, and (b) Other Licensed Patents. 1. 74 “ Paragon ” has the meaning set forth in the Preamble. 1. 75 “ Paragon Indemnitee ” has the meaning set forth in Section 9. 1. 1. 76 “ Paragon Multispecific Antibody ” means any Multispecific Antibody that is Developed, Manufactured, Commercialized or otherwise exploited by Paragon or its Affiliate or licensees (other than Oruka and its Affiliates and Sublicensees), excluding in each case any Oruka Multispecific Antibodies. 1. 77 “ Paragon Multispecific Patents ” means those Patents that Cover the composition of matter of, or any method of specifically making or using, a Paragon Multispecific Antibody, in each case excluding the Licensed Antibody Patents. 1. 78 “ Paragon Patents ” has the meaning set forth in Section 5. 2 (c). 1. 79 “ Paragon Third Party Agreement ” has the meaning set forth in Section 2. 8. 1. 80 “ Parent Entity ” has the meaning set forth in Section 1. 15. 1. 81 “ Party ” has the meaning set forth in the Preamble. 1. 82 “ Patent Challenge ” has the meaning set forth in Section 5. 3 (a). 1. 83 “ Patent Infringement ” has the meaning set forth in Section 5. 3 (a). 1. 84 “ Patents ” means (a) unexpired patents and patent applications, (b) any and all patent applications filed either from such patent or patent applications or from a patent application claiming priority from any of those, including divisionals, provisionals, continuations, continuations- in- part, and reissues, (c) substitutions, renewals, registrations, re- examinations, revalidations, extensions, supplementary protection certificates and the like of any such patents and patent applications, and (d) any and all foreign equivalents of the foregoing. 1. 85 “ Phase I Trial ” means a human clinical trial in any country of the type described in 21 C. F. R. § 312. 21 (a), or the foreign equivalent thereof, regardless of where such clinical trial is conducted. 1. 86 “ Phase II Trial ” means a human clinical trial in any country of the type described in 21 C. F. R. § 312. 21 (b), or the foreign equivalent thereof, regardless of where such clinical trial is conducted. 1. 87 “ Phase III Trial ” means a human clinical trial in any country of the type described in 21 C. F. R. § 312. 21 (c), or the foreign equivalent thereof, regardless of where such clinical trial is conducted. 1. 88 “ Post- Effective Date Patents ” has the meaning set forth in Section 5. 2 (b) (i). 1. 89 “ Pre- Existing Entities ” has the meaning set forth in Section 1. 3. 1. 90 “ Product ” means any product that comprises or contains any Licensed Antibody or Derived Antibody other than as part of a Multispecific Antibody or a Multispecific Product. 1. 91 “ Prosecute ” or “ Prosecution ” has the meaning set forth in Section 5. 2 (a). 1. 92 “ Prosecuting Party ” has the meaning set forth in Section 5. 2 (b) (iii). 1. 93 “ Publication ” has the meaning set forth in Section 6. 6 (b). 1. 94 “ Receiving Party ” has the meaning set forth in Section 1. 21. 1. 95 “ Regulatory Approval ” means all clearances, approvals (including approval of an MAA as well as any applicable pricing and / or reimbursement approvals), licenses, registrations or authorizations of any Regulatory Authority necessary to commercially distribute, sell and market a pharmaceutical product in a country or territory under this Agreement. 1. 96 “ Regulatory Authority ” means any supranational, multinational, federal, national, state, provincial or local regulatory agency, department, bureau or other Governmental Authority with authority over the clinical development, manufacture marketing or sale of an Oruka Product in a country or region, including the FDA in the United States and the EMA in Europe. 1. 97 “ Reimbursement Obligation ” has the meaning set forth in Section 2. 8. 1. 98 “ Remaining Recovery ” has the meaning set forth in Section 5. 3 (f). 1. 99 “ Representatives ” of a Party means such Party’ s officers, directors, employees, contractors, subcontractors, agents and consultants. 1. 100 “ Research Program ” means the Research Program (as defined in the Option Agreement) conducted by the Parties pursuant to the Option Agreement with respect to the Licensed Target. 1. 101 “ Research Program Materials ” means the tangible materials resulting from the Research Program that are Controlled by Paragon or its Affiliates as of the Effective Date or during the Term that are listed in Exhibit C attached hereto, as may be amended in writing from time to time upon mutual agreement of the Parties. For clarity, Research Program Materials shall not include materials that are consumed or destroyed in the performance of the Research Program or that are not available to be transferred by Paragon to Oruka without violating the terms of any agreement or other arrangement with a Third Party. 1. 102 “ Results ” means all data, results, analysis, conclusions, outcomes, information, documentation and reports that are generated by or on behalf of Paragon in performance of the Research Program, excluding in each case any other Licensed Antibody Technology. 1. 103 “ Reversion Products ” has the meaning set forth in Section 8. 5 (c). 1. 104 “ Review Period ” has the meaning set forth in Section 6. 6 (b). 1. 105 “ ROFN Information ” has the meaning set forth in Section 2. 7 (a). 1. 106 “ ROFN Negotiation Period ” has the meaning set forth in Section 2. 7 (c). 1. 107 “ ROFN Period ” has the meaning set forth in Section 2. 7 (a). 1. 108 “ Royalty Payments ” has the meaning set forth in Section 4. 2 (a). 1. 109 “ Royalty Term ” means, on an Oruka Product- by- Oruka Product and country- by- country basis, the period commencing on First Commercial Sale of the applicable Oruka Product in the applicable country in the Territory and ending, with respect to the particular Oruka Product and country at issue on the latest of the following dates: (a) the twelfth (12th) anniversary of the date of First Commercial Sale of such Oruka Product in such country; or (b) the expiration of the last- to- expire Valid Claim of a Licensed Antibody Patent or an Oruka Antibody Patent Covering the Manufacture, use or sale of such Oruka Product in the country at issue. 1. 110 “ Sequence Information ” means any files of Paragon containing all Licensed Antibody sequences generated under the Research Program. 1. 111 “ Sublicensee ” means any Affiliate of Oruka or any Third Party with respect to Oruka, to whom Oruka grants a sublicense of, or other authorization or permission granted under, the rights granted to Oruka in Section 2. 1. 1. 112 “ Target ” means a protein molecule that (a) is chemically distinct from other molecules, and (b) wherein a binding entity derives recognized therapeutic value from binding to such molecule. 1. 113 “ Term ” has the meaning set forth in Section 8. 1. 1. 114 “ Territory ” means worldwide. 1. 115 “ Third Party ” means any person or entity other than Paragon or Oruka or an Affiliate of either Paragon or Oruka. 1. 116 “ Third Party Claim ” has the meaning set forth in Section 9. 1. 1. 117 “ Transfer Period ” has the meaning set forth in Section 2. 5 (c). 1. 118 “ US ” or “ United States ” means the United States of America and its possessions and territories, including Puerto Rico. 1. 119 “ Valid Claim ” means, with respect to a particular country, a claim (including a process, use or composition of matter claim) of an issued and unexpired patent (or a supplementary protection certificate thereof) that has not (a) irretrievably lapsed or been abandoned, permanently revoked, dedicated to the public or disclaimed, or (b) been held invalid, unenforceable or not patentable by a court, governmental agency, national or regional patent office or other appropriate body that has competent jurisdiction, which holding, finding or decision is final and unappealable or unappealed within the time allowed for appeal. Article II LICENSES; TECHNOLOGY TRANSFER; MULTISPECIFIC ANTIBODIES. 2. 1 License Grants. (a) Subject to the terms of this Agreement, Paragon hereby grants to Oruka a royalty- bearing, exclusive (even as to Paragon and its Affiliates, subject to Paragon’ s retained rights under Section 2. 4) license, including the right to sublicense through multiple tiers, under the Licensed Antibody Technology to Develop, Manufacture, Commercialize, or otherwise exploit Licensed Antibodies, Derived Antibodies and Products in the Field in the Territory. (b) Subject to the terms of this Agreement, including Section 2. 7, Paragon hereby grants to Oruka a royalty- bearing, non- exclusive right and license, including the right to sublicense through multiple tiers, under the Licensed Antibody Technology to Develop, Manufacture, Commercialize or otherwise exploit Multispecific Antibodies and Multispecific Products in the Field in the Territory. (c) Subject to the terms of this Agreement, Paragon hereby grants to Oruka a royalty- bearing, non- exclusive license, including the right to sublicense through multiple tiers, under the Other Licensed Patents to Develop, Manufacture, Commercialize or otherwise exploit Licensed Antibodies, Derived Antibodies, Multispecific Antibodies, Products and Multispecific Products in the Field in the Territory. (d) Subject to the terms of this Agreement, Paragon hereby grants to Oruka a royalty- bearing, non- exclusive license, including the right to sublicense through multiple tiers, under the Other Licensed Know- How to Develop, Manufacture, Commercialize or otherwise exploit (i) Licensed Antibodies, or (ii) Products, Multispecific Antibodies or Multispecific Products, in each case solely to the extent comprising or containing a Licensed Antibody, in the Field in the Territory. 2. 2 Exclusivity. (a) Subject to the terms of this Section 2. 2, to the maximum extent permissible under Applicable Law, during the Exclusivity Period, Paragon shall not, and shall ensure that its Affiliates do not, directly or indirectly, conduct any activity, either on its own or with, for the benefit of, or sponsored by, any Third Party, including granting any license to any Third Party that would permit such Third Party, to develop, manufacture, commercialize or otherwise exploit any monospecific Antibody that is Directed To the Licensed Target in the Field. It will not be a violation of this Section 2. 2 (a) if Paragon or its Affiliate, directly or through a Third Party, (i) conducts screening activities solely for the purposes of ensuring compliance with this Section 2. 2 (a), (ii) conducts activities in accordance with the terms of this Agreement, the Option Agreement or any other written agreement between the Parties, or (iii) conducts activities with the prior written consent of Oruka. (b) Notwithstanding anything herein to the contrary, if a Change of Control occurs with respect to Paragon or its Parent Entity, and the Acquiring Entity (or any of such Acquiring Entity’ s successors or assigns, other than the relevant Pre- Existing Entities) as of the Change of Control has a program or product (or rights thereto) that would otherwise violate Section 2. 2 (a) (each, a “ COC Program ”), then (i) Section 2. 2 (a) shall not apply with respect to such COC Program, and (ii) such Acquiring Entity will be permitted to continue such COC Program after such Change of Control and such continuation will not constitute a violation of Section 2. 2 (a), provided, that the Licensed Antibody Technology and Confidential Information of Paragon and Oruka relating to the Oruka Products is not used in the COC Program. (c) Notwithstanding anything herein to the contrary, if Paragon or its Parent Entity (i) acquires a Third Party entity that has a program or product (or rights thereto) that would otherwise violate Section 2. 2 (a), or (ii) acquires asset (s) from a Third Party entity that would otherwise violate Section 2. 2 (a) (each, an “ Acquired Program ”), then (1) Section 2. 2 (a) shall not apply with respect to such Acquired Program, and (2) Paragon or its Parent Entity will be permitted to continue such Acquired Program after such acquisition and such continuation will not constitute a violation of Section 2. 2 (a), provided, that the Licensed Antibody Technology and Confidential Information of Paragon and Oruka relating to the Oruka Products is not used in the Acquired Program. 2. 3 Sublicenses. Oruka shall have the right to grant sublicenses under the rights granted to it in Section 2. 1 to its Affiliates and Third Parties; provided, that (a) each such sublicense shall be granted in writing and each such relevant sublicense agreement shall be consistent with all relevant terms, conditions and restrictions of this Agreement, (b) Oruka will provide Paragon with a true and complete copy of each sublicense agreement (other than sublicense agreements with Third Party service providers) and any amendments thereto within [* * *] days following the execution thereof (which sublicense agreement and amendments may be redacted except to the extent necessary for Paragon to determine Oruka’ s compliance with this Agreement), and (c) Oruka shall remain responsible for all of its payments and other performance obligations due under this Agreement, notwithstanding any license or sublicense that it may grant. 2. 4 No Implied Licenses; Reservation of Rights. Except as expressly set forth herein, no right or license under any Patents, Know- How or Intellectual Property Right of either Party is granted or shall be granted by implication hereunder. All such rights or licenses are or shall be granted only as expressly provided in this Agreement, and each Party reserves to itself all rights not expressly granted under this Agreement. Notwithstanding anything to the contrary under this Agreement, Paragon retains rights under the Licensed Antibody Technology solely to perform its obligations and exercise its rights under this Agreement and the Option Agreement. 2. 5 Information Transfer and Support to Oruka. (a) As soon as possible and within not more than [* * *] days after the Effective Date, Paragon shall provide Oruka with the Results and Sequence Information in existence as of the Effective Date not already provided to Oruka under the Option Agreement. Additionally, on a continuing basis during the term of the Research Program, as soon as possible and within not more than [* * *] days after additional Results or Sequence Information come into existence or are identified by Paragon that in each case have not already been provided to Oruka under the Option Agreement, Paragon shall disclose and transfer such additional Results and Sequence Information to Oruka. (b) Upon the reasonable request of Oruka made from time to time during the Term, Paragon shall promptly disclose and transfer to Oruka tangible embodiments of the Other Licensed Know- How that is the subject of Oruka’ s request. (c) The Parties acknowledge and agree that Exhibit C has been agreed by the Parties as of the Effective Date, and that materials that are different than or in addition to the materials set forth on Exhibit C may result from the Research Program to the extent that the Research Program continues to be performed following the Effective Date. Upon the reasonable request of Oruka made at any time prior to the end of the [* * *] day period following the expiration of the Research Term (as defined in the Option Agreement), the Parties shall update Exhibit C to reflect the tangible materials, including samples, reagents, nucleic acids and Antibodies, resulting from the Research Program that constitute Research Program Materials hereunder. During the period beginning on the Effective Date and ending [* * *] months after the expiration of the Research Term (the “ Transfer Period ”), at [* * *] request and expense, Paragon will provide Oruka or a Third Party designated by Oruka with any Research Program Materials, provided that any Third Party recipient of such Research Program Materials shall be bound by the relevant terms of this Agreement and that the Research Program Materials are used solely to further Develop, Manufacture and Commercialize the Oruka Products. For clarity, [* * *] shall be responsible for any out- of- pocket costs incurred by Paragon or its Affiliates to store and maintain the Research Program Materials during the Transfer Period. (d) Each Party shall bear all costs and expenses incurred by such Party in connection with the disclosure and transfer of any Results and Sequence Information as set forth above. (e) During the [* * *] day period following completion of the Research Program, in the event Oruka makes any reasonable request for assistance in order to understand the Licensed Antibody Technology and use the Licensed Antibody Technology to continue the uninterrupted Development of the Licensed Antibodies, Paragon shall provide up to [* * *] month of additional assistance during such period, at [* * *] cost and expense at the then current [* * *] Rate (as defined in the Option Agreement) in the Option Agreement. Paragon shall consider and discuss in good faith any additional requests for assistance made by Oruka, which assistance may be provided upon mutual agreement of the Parties. 2. 6 Paragon Rights with Respect to Multispecific Antibodies. (a) Subject to the terms of this Agreement, including Section 2. 6 (b) below and Section 2. 7, Paragon reserves and retains the non- exclusive right under the Licensed Antibody Technology to Develop, Manufacture, Commercialize and otherwise exploit Multispecific Antibodies and Multispecific Products in the Field in the Territory. If Paragon exercises such right, then Paragon shall pay royalties to Oruka in accordance with Article IV (at the rate specified in Section 4. 2 (b)), mutatis mutandis, with respect to any Multispecific Antibodies and Multispecific Products that are Commercialized by Paragon or its Affiliates or sublicensees (other than Oruka and its Affiliates and Sublicensees) in the Field in the Territory, provided, that references to Oruka Antibody Patents in clause (b) of the Royalty Term definition and Section 4. 3 shall be disregarded. (b) Oruka has designated [* * *] Licensed Antibody or Derived Antibody as its lead compound and [* * *] Licensed Antibody or Derived Antibody as its backup compound, as set forth on Exhibit B (each such designated Licensed Antibody or Derived Antibody, a “ Designated Multispecific Antibody ”). Paragon’ s rights under Section 2. 6 (a) shall expressly exclude the right to Develop, Manufacture, Commercialize or otherwise exploit (i) Multispecific Antibodies that have identical sequence identity within their complementarity- determining regions as a Designated Multispecific Antibody, or (ii) Multispecific Products that comprise or contain any Multispecific Antibody referenced in clause (i). For the avoidance of doubt, if Paragon engaged in Development or Manufacture of a Multispecific Antibody that meets the criteria of clause (i) or (ii) above prior to the Effective Date, then Paragon shall not be in breach of this Agreement, provided that, Paragon ceases all such Development or Manufacture within [* * *] days following the Effective Date. 2. 7 Right of First Negotiation. (a) Commencing on the Effective Date and continuing until the [* * *] anniversary thereof (the “ ROFN Period ”), Paragon will promptly notify Oruka in writing if (i) Paragon has developed a descriptive research plan with respect to the Development of a Multispecific Antibody or a plan to license or grant rights in a Multispecific Antibody to a Third Party, or (ii) Paragon enters into [* * *] negotiations pursuant to an offer to or from any Third Party relating to the foregoing. Together with such notice, Paragon will provide to Oruka all material information and research plans developed by Paragon with respect to such Multispecific Antibody (the “ ROFN Information ”). Oruka will have [* * *] days from receipt of the ROFN Information to deliver a written notice to Paragon of Oruka’ s desire to engage in negotiations for an agreement concerning the Development, or exclusive license or grant of rights to, such Multispecific Antibody. (b) If Oruka does not provide such written notice to Paragon of its interest to engage in such negotiations within such [* * *] day period, then (i) Paragon shall be free to enter into an agreement with a Third Party with respect to the grant of a license or other rights to such Multispecific Antibody and corresponding Multispecific Products without further obligation to Oruka under this Section 2. 7, and (ii) Oruka’ s license under Section 2. 1 (b) shall automatically exclude any right to Develop, Manufacture, Commercialize or otherwise exploit the identical Multispecific Antibodies Developed by or on behalf of Paragon and corresponding Multispecific Products. (c) If Oruka does provide Paragon such written notice within such [* * *] day period, the Parties will negotiate [* * *] on an exclusive basis for a period of up to [* * *] months from the date of Oruka’ s notice (“ ROFN Negotiation Period ”), an agreement for the Development, or exclusive license or grant of rights to, such Multispecific Antibody and corresponding Multispecific Products. Prior to and during the ROFN Negotiation Period, Paragon shall not enter into an agreement with respect to such Multispecific Antibody with any Third Party that will prevent Paragon from entering into an agreement with Oruka for the Development, or exclusive license or grant of rights to, such Multispecific Antibody and corresponding Multispecific Products. Unless and until the Parties have entered into an agreement with respect to such Multispecific Antibody and corresponding Multispecific Products, Oruka shall have no rights or license with respect to such Multispecific Antibody and corresponding Multispecific Products except as otherwise expressly provided in Section 2. 1. In the event that the Parties have not entered into an agreement with respect to such Multispecific Antibody and corresponding Multispecific Products prior to the expiration of the ROFN Negotiation Period, then (i) Paragon shall be free to enter into an agreement with a Third Party with respect to the grant of a license or other rights to such Multispecific Antibody and corresponding Multispecific Products without further obligation to Oruka under this Section 2. 7, and (ii) Oruka’ s license under Section 2. 1 (b) shall automatically exclude any right to Develop, Manufacture, Commercialize or otherwise exploit the identical Multispecific Antibodies Developed by or on behalf of Paragon and corresponding Multispecific Products. 2. 8 Third Party In- Licenses. If Paragon (or its Affiliate) enters into any in- license agreement with a Third Party after the Effective Date with respect to any Patent that would, if Controlled by Paragon, be included within the Licensed Antibody Patents or the Other Licensed Patents (each such agreement, a “ Paragon Third Party Agreement ”), Paragon shall notify Oruka in writing that it entered into such Paragon Third Party Agreement and provide a copy of such Paragon Third Party Agreement to Oruka, which may be redacted solely concerning [* * *] or other confidential terms not applicable to sublicensees. Oruka shall have the right, by delivery of notice to Paragon, to elect to take a sublicense under such Patents in- licensed by Paragon under such Paragon Third Party Agreement. If Oruka elects to become a sublicensee thereunder pursuant to this Section 2. 8, then (a) the applicable Patents under such Paragon Third Party Agreement shall be included within the Licensed Antibody Patents or the Other Licensed Patents, as applicable, that are licensed to Oruka under Section 2. 1, (b) Oruka shall reimburse Paragon for Paragon’ s pro rata share of royalties or other consideration, as mutually agreed by the Parties, payable by Paragon under the Paragon Third Party Agreement for Oruka’ s Development, Manufacture, Commercialization or other exploitation of an Oruka Product in the Field in the Territory in connection with the grant to Oruka of such Patents (the “ Reimbursement Obligation ”), and (c) Oruka shall comply with the terms of such Paragon Third Party Agreement to the extent applicable to Oruka as a sublicensee of such Patents. In the event of any conflict between the terms of this Agreement and any Paragon Third Party Agreement applicable to a sublicense granted by Paragon to Oruka in accordance with this Section 2. 8, the terms of the Paragon Third Party Agreement shall control solely to the extent necessary for the Parties to maintain compliance with such Paragon Third Party Agreement. Oruka shall comply with the Reimbursement Obligation by paying to Paragon any amounts subject to the Reimbursement Obligation within the earlier of (i) [* * *] days after Oruka’ s receipt from Paragon of an invoice for such payment, and (ii) the date when such payment is due to the counterparty licensor under the applicable Paragon Third Party Agreement, provided that such payment shall not be due prior to the date when such amounts are payable by Paragon to the counterparty licensor under the applicable Paragon Third Party Agreement. Article III DEVELOPMENT, MANUFACTURING & COMMERCIALIZATION. 3. 1 Oruka Responsibilities. (a) As between the Parties, Oruka shall be solely responsible for and shall have the sole right to control, all aspects of the Development, Manufacturing, and Commercialization of the Oruka Products in the Field in the Territory during the Term, including distribution, product positioning, product strategy, product branding, core messaging, marketing, promotion, detailing activities and all decisions relating to the setting of prices in the Territory, invoicing and booking sales, establishing all terms of sale, and all regulatory activities. (b) As between the Parties, Oruka shall be solely responsible for, and shall have the sole right to control, the selection, registration and maintenance of all trademarks associated with the Oruka Products in the Field in the Territory. As between the Parties, Oruka shall solely own such trademarks in the Territory and pay all relevant costs thereof. 3. 2 Regulatory. As between the Parties, Oruka shall control all regulatory matters, including the regulatory strategy, regulatory filings, regulatory activities (including clinical trials for Oruka Products) and communication with each Regulatory Authority for the Oruka Products in the Field in the Territory. Oruka shall have the right to reference any relevant data included within the Licensed Antibody Technology for the purposes of regulatory filings and safety reporting, including all nonclinical data, pre- approval and post- approval clinical use data, and regulatory data with respect thereto, and Paragon shall cooperate as reasonably requested by Oruka with respect to providing to Oruka when requested, and on a timely basis, any of the foregoing information, data filings or reporting. Oruka or its designee shall be the party to file an application to each applicable Regulatory Authority in the Territory for, and to obtain and maintain, in its own name, Regulatory Approval for the Oruka Products in each country in the Territory. 3. 3 Diligence; Reporting. Oruka shall use Commercially Reasonable Efforts (a) to Develop and seek Regulatory Approval for at least one Oruka Product in the Field in the United States and at least one other Major Market Country, and (b) upon receipt of Regulatory Approval for a given Oruka Product in a given country, to Commercialize such Oruka Product in such country, in each case ((a) or (b)) either by itself or through its Affiliates or Sublicensees or its or their respective contractors. Additionally, on or before [* * *] of each year during the Term, Oruka shall deliver to Paragon a report summarizing its material development efforts with respect to the Oruka Products, including a summary of current and anticipated preclinical and clinical activities, a summary of the status of any regulatory filings and any anticipated regulatory filings, and achievement of any Milestones, during the preceding [* * *]; provided, however, that Oruka may satisfy the reporting obligations set forth in this Section 3. 3 by providing Paragon with copies of any annual report or other filings with a securities exchange that include the relevant information. For the avoidance of doubt, if Oruka determines, in its sole discretion, that it is inconsistent with the use of Commercially Reasonable Efforts to pursue Commercialization of an Oruka Product in any country (other than the United States), it will not be considered a material breach of this Agreement to cease Development or Commercialization of such Oruka Product with respect to such country. FINANCIAL TERMS. 4. 1 Milestone Payments. Oruka shall make the following one- time, non- refundable and non- creditable payments to Paragon (or to such other designee (s), as requested by Paragon in an invoice) (each payment, a “ Milestone Payment ”), based on the achievement of the corresponding milestone (each, a “ Milestone ”) by Oruka, its Affiliates, or its Sublicensees with respect to the first Oruka Product to achieve such Milestone. Oruka shall, within [* * *] Business Days after it or its Affiliates achieve a Milestone, or within [* * *] Business Days after it learns that its or its Affiliate’ s Sublicensee has achieved a Milestone, notify Paragon of the achievement of such Milestone in writing. Following receipt of such notice, Paragon shall invoice Oruka for such Milestone Payment, which invoice shall specify whether Paragon or its designee should receive such Milestone Payment and the bank account information into which such Milestone Payment should be paid. Oruka shall make such Milestone Payment to Paragon or Paragon’ s designee within [* * *] days after receipt of Paragon’ s invoice. Each Milestone Payment shall be paid no more than once, and Oruka’ s total Milestone Payments hereunder shall not exceed Twenty- Two Million Dollars ($ 22, 000, 000). For avoidance of doubt, upon achievement of any Milestone, all prior unachieved Milestones shall be deemed thereby achieved and, if the Milestone Payment for any such prior Milestone has not previously been paid, it shall thereupon also be paid at the same time that the Milestone Payment for such subsequent achieved Milestone is paid. Milestone Milestone Payment # 1 Achievement of Development Candidate One Million Five Hundred Thousand Dollars ($ 1, 500, 000) # 2 First dosing of a human patient in a Phase I Trial of an Oruka Product Two Million Five Hundred Thousand Dollars ($ 2, 500, 000) # 3 First dosing of a human patient in a Phase II Trial of an Oruka Product Three Million Dollars ($ 3, 000, 000) # 4 First dosing of a human patient in a Phase III Trial of an Oruka Product Five Million Dollars ($ 5, 000, 000) # 5 Receipt of Regulatory Approval from the FDA of an Oruka Product Ten Million Dollars ($ 10, 000, 000) 4. 2 Royalties. (a) Royalty Rate for Products. During the applicable Royalty Term (which shall be measured on a country- by- country and Product- by- Product basis), Oruka shall pay tiered royalties to Paragon (or to such other designee (s), as requested by Paragon) as set forth in the table below on Annual Net Sales of all Products sold by Oruka, its Affiliates or its Sublicensees in the Field in the Territory (together with any royalties payable under Section 4. 2 (b), the “ Royalty Payments ”). Annual Net Sales of the Products in a Given Calendar Year Royalty Rate Portion of Annual Net Sales of the Products in a Given Calendar Year Above $ 0 but Up to and Including $ [* * *] [* * *] % Portion of Annual Net Sales of the Products in a Given Calendar Year of More Than $ [* * *], Up to and Including $ 1. 0 Billion [* * *] % Portion of Annual Net Sales of the Products in a Given Calendar Year of More Than $ [* * *] [* * *] % (b) Royalty Rate for Oruka Multispecific Products. During the applicable Royalty Term (which shall be measured on a country- by- country and Oruka Multispecific Product- by- Oruka Multispecific Product basis), Oruka shall pay royalties to Paragon (or to such other designee (s), as requested by Paragon) equal to [* * *] percent ([* * *] %) of Net Sales of all Oruka Multispecific Products sold by Oruka, its Affiliates or its Sublicensees in the Field in the Territory. (c) If any Oruka Product contains (a) a combination of more than one Licensed Antibody, Derived Antibody and / or Multispecific Antibody, or (b) a combination of (i) one or more Licensed Antibodies, Derived Antibodies or Multispecific Antibodies, and (ii) one or more other Antibodies owned or Controlled by Paragon or its Affiliates, the rights to which have been licensed to Oruka or its Affiliates under a separate agreement, then, in each case (a) or (b) unless otherwise agreed by the Parties, the royalty rate for the Royalty Payments payable to Paragon with respect to such Oruka Product (x) shall be determined in accordance with the Royalty Rate chart set forth in Section 4. 2 (a) if such Oruka Product does not contain a Multispecific Antibody, and (y) shall be determined in accordance with Section 4. 2 (b) if such Oruka Product contains a Multispecific Antibody. 4. 3 Royalty Reductions for No Valid Claim. If, during any Calendar Quarter during the Royalty Term for a particular Oruka Product in a particular country, no Valid Claim of a Licensed Antibody Patent Covers the Manufacture or Commercialization of such Oruka Product in such country, then the applicable royalty rate for the Royalty Payments set forth in Section 4. 2 for such Calendar Quarter shall be reduced by [* * *]. 4. 4 Payment Reports. Within [* * *] days after the end of [* * *] days for [* * *] in which an Oruka Product is sold, Oruka shall provide to Paragon a written report, on an [* * *] basis, stating the [* * *], including [* * *]; [* * *]. All Royalty Payments described in such written report shall be made by Oruka at the same time it submits such written report to Paragon. All such Royalty Payments shall be paid to Paragon or Paragon’ s designee, provided that in the case of payment to a designee, Paragon has notified Oruka in writing [* * *] days prior to the due date for any Royalty Payment of the designee to be paid and the bank account information for such designee. 4. 5 Payment Method. All payments due under this Agreement to Paragon shall be made in U. S. Dollars by bank wire transfer in funds to an account designated by Paragon from time to time reasonably in advance of any payment due date. 4. 6 Taxes. The Parties agree to cooperate with one another and use reasonable efforts to minimize obligations for any and all income or other taxes required by Applicable Law to be withheld or deducted from any Royalty Payments, Milestone Payments or other payments made by Oruka to Paragon or its designee (s) under this Agreement, including by completing all procedural steps, and taking all reasonable measures, to ensure that any withholding tax is reduced or eliminated to the extent permitted under Applicable Law, including income tax treaty provisions and related procedures for claiming treaty relief. To the extent that Oruka is required to deduct and withhold taxes on any payment to Paragon or its designee (s), Oruka shall: (i) deduct such taxes from such payment to Paragon or its designee (s), (ii) pay the amounts of such taxes to the proper Governmental Authority in a timely manner, and (iii) promptly submit to Paragon an official tax certificate or other available evidence of such withholding sufficient to enable Paragon or its designee (s) to claim such payment of taxes. For the avoidance of doubt, Oruka’ s remittance of such withheld amounts to the appropriate Governmental Authority, together with payment to Paragon or its designee (s) of the remaining amount owed, shall constitute full satisfaction of the applicable payment due to Paragon. Oruka shall provide Paragon with any reasonably requested tax forms or certificates available to Oruka in order to allow Paragon or its designee (s) to recover, as permitted by Applicable Law, withholding taxes, value added taxes or similar obligations resulting from payments made hereunder or to obtain the benefit of any present or future treaty against double taxation that may apply to such payments. Paragon shall promptly provide Oruka with any requested tax forms that may be reasonably necessary in order for Oruka to not withhold tax or to withhold tax at a reduced rate under an applicable bilateral tax income treaty. 4. 7 Foreign Exchange. If any currency conversion shall be required in connection with the calculation of amounts payable hereunder, including in connection with the calculation of Net Sales, such conversions shall be made using the methodology used by Oruka in preparing its publicly filed financial statements. 4. 8 Late Payments. Any amount owed by Oruka to Paragon under this Agreement that is not paid within the applicable time period set forth herein will accrue interest at the per annum rate of [* * *] percentage point above the then- applicable United States prime rate as quoted in the Wall Street Journal (East Coast Edition) (or if it no longer exists, a similarly authoritative source), calculated on a [* * *] basis, or, if lower, the highest rate permitted under Applicable Law. 4. 9 Blocked Currency. If by Applicable Law of a country in which Net Sales occurred, conversion of funds into Dollars or transfer of funds from such country to the United States is restricted, forbidden or delayed for more than [* * *] days, then Oruka can elect, at its sole discretion, that the amounts accrued in such country and owed by Oruka to Paragon under this Agreement shall be paid to Paragon in such country in local currency by deposit in a local bank designated by Paragon, unless the Parties otherwise agree in writing. 4. 10 Records; Inspection. (a) Oruka shall, and shall cause its applicable Affiliates to, create and keep complete and accurate records of its sales and other dispositions of all Oruka Products, including all records that are reasonably necessary for the purposes of calculating all payments due under this Agreement. (b) Upon reasonable advance written notice to Oruka, Paragon shall have the right to retain a nationally recognized (in the US) independent certified public accounting firm to perform on behalf of Paragon an audit, conducted in accordance with U. S. generally accepted accounting principles (GAAP), of such books and records of Oruka or its applicable Affiliates as may be reasonably necessary to verify the accuracy of any reports provided pursuant to Section 4. 4 hereunder for any Calendar Quarter in which an Oruka Product was sold, ending not more than [* * *] calendar months prior to the date of such request. Such audits shall be conducted during normal business hours, shall not occur more frequently than [* * *] in each Calendar Year and shall not be conducted more than [* * *] with respect to any reporting period, in each case other than for cause. All information disclosed or observed during any audit pursuant to this Section 4. 10 shall be the Confidential Information of Oruka, and Paragon shall cause the accounting firm to retain all such information as Confidential Information, including, if requested by Oruka, by requiring such accounting firm to enter into a customary confidentiality agreement with Oruka prior to the initiation of any such audit. (c) Upon completion of any audit hereunder, the accounting firm shall provide both Oruka and Paragon a written report disclosing whether the reports submitted by Oruka are correct or incorrect, whether the amounts paid are correct or incorrect, and in each case, the specific details concerning any discrepancies. No other information regarding Oruka’ s records shall be provided to Paragon. (d) Paragon shall bear its internal expenses and the out- of- pocket costs for engaging such accounting firm in connection with performing such audits; provided, however, that if any such audit uncovers an underpayment by Oruka that exceeds [* * *] percent ([* * *] %) of the total owed for such payment or payment period, as applicable, then Oruka shall reimburse Paragon or its designee (s) for the amounts actually paid to such accounting firm for performing such audit. (e) If such accounting firm concludes that Oruka has in aggregate underpaid amounts owed to Paragon during the audited period, Oruka shall pay Paragon or its designee (s) the amount of the discrepancy within [* * *] days of the date Paragon delivers to Oruka such accounting firm’ s written report and an invoice for such amounts. If such accounting firm concludes that Oruka has in aggregate overpaid amounts owed to Paragon during the audited period, then Oruka may, at its election, either credit such overpaid amount against any future payment obligation to Paragon or require Paragon to refund such amounts within [* * *]. Article V INTELLECTUAL PROPERTY. 5. 1 Ownership. As between the Parties (a) Paragon solely owns the Licensed Antibody Technology and the Other Licensed Patents, (b) Oruka solely owns the Oruka Inventions, including any Derived Antibodies and Oruka Multispecific Antibodies to the extent they constitute Oruka Inventions, (c) each Party solely owns all Intellectual Property Rights owned or Controlled by such Party as of the Effective Date or that come into the ownership or control of such Party during the Term outside the scope of this Agreement, and (d) ownership of Inventions shall be determined in accordance with U. S. laws of inventorship. Other than rights granted to Oruka under this Agreement with respect to the Licensed Antibody Technology and the Other Licensed Patents, nothing in this Agreement shall affect Paragon’ s rights in any Patents, Know- How or other Intellectual Property Rights owned or controlled by Paragon or its Affiliates, now or in the future. Other than rights granted to Paragon under Section 8. 5 (c) of this Agreement with respect to the Oruka Intellectual Property, nothing in the Agreement shall affect Oruka’ s rights in any Patents, Know- How or other Intellectual Property Rights owned or controlled by Oruka or its Affiliates, now or in the future. 5. 2 Patent Prosecution. (a) Prosecution Generally. For the purpose of this Article V, “ Prosecute ” and “ Prosecution ” shall include any patent interference, opposition, pre- issuance Third Party submission, ex parte re- examination, post- grant review, inter partes review or other similar proceeding, appeals or petitions to any board of appeals in a patent office, appeals to any court for any patent office decisions, reissue proceedings and applications for patent term extensions and the like. (b) Prosecution of Licensed Antibody Patents. (i) As between the Parties, with respect to any patent applications for Licensed Antibody Patents that have not been filed prior to the Effective Date and any resulting patents (the “ Post- Effective Date Patents ”), Paragon shall have the sole right, but not the obligation, to prepare, file, Prosecute and maintain the Post- Effective Date Patents until the date on which the Final Deliverable (as defined in the Option Agreement) for the Research Program is delivered to Oruka, and during such period Paragon shall provide Oruka with drafts of all proposed filings to any patent office with respect to Post- Effective Date Patents in reasonably adequate time before submission of such filings for Oruka’ s review and comment. (ii) As between the Parties, with respect to (x) any patent applications and resulting patents for Licensed Antibody Patents that were filed prior to the Effective Date, and (y) the Post- Effective Date Patents after the date on which the Final Deliverable (as defined in the Option Agreement) for the Research Program is delivered to Oruka, Oruka shall have the first right to prepare, file, Prosecute and maintain the Licensed Antibody Patents, in each case, at Oruka’ s sole expense. Oruka shall provide Paragon with copies of all material correspondence from and to any patent office relating to such Licensed Antibody Patents, and Oruka shall provide Paragon with drafts of all proposed filings to any patent office with respect to such Licensed Antibody Patents before submission of such filings, with reasonably adequate time for Paragon’ s review and comment, which review shall be at Paragon’ s sole expense. (iii) Each Party, when acting as the prosecuting Party (in such capacity, the “ Prosecuting Party ”) will take into consideration the non- Prosecuting Party’ s reasonable comments prior to submitting such filings. At the Prosecuting Party’ s request, the non- Prosecuting Party will sign all documents and take any other actions required for filing, maintenance and grant of Licensed Antibody Patents. Oruka shall reimburse Paragon for any costs and expenses actually incurred by Paragon to the extent Paragon is prosecuting or maintaining any Licensed Antibody Patents. (iv) The Prosecuting Party shall notify the non- Prosecuting Party of any decision not to prepare or file, or to abandon, cease Prosecution or not maintain any Licensed Antibody Patent anywhere in the Territory. The Prosecuting Party shall provide such notice at least [* * *] days prior to any filing or payment due date, or any other due date that requires action, in connection with such Licensed Antibody Patent. In such event, the non- Prosecuting Party shall have a backup right, but not the obligation, to prepare, file, or continue Prosecution or maintenance of, such Licensed Antibody Patent, at its own expense. (v) Each Party shall cooperate with the other Party in the preparation, filing, Prosecution and maintenance of Licensed Antibody Patents, including in each case by providing the prosecuting Party with data and other information as appropriate and executing all necessary affidavits, assignments and other paperwork. (c) Prosecution by Paragon. Except with respect to Licensed Antibody Patents (which are addressed in Section 5. 2 (b)), Paragon shall be solely responsible for, and have sole discretion over, preparing, filing, Prosecuting and maintaining any Patents (including the Other Licensed Patents and Paragon Multispecific Patents) that it owns in whole or in part or otherwise Controls (the “ Paragon Patents ”). Paragon’ s Prosecution of any Paragon Patents shall be at Paragon’ s sole expense. Notwithstanding the foregoing, in Prosecuting any Paragon Multispecific Patents, Paragon hereby agrees that during the Term, neither Paragon nor any of its Affiliates or licensees will file, or assist any Third Party in filing, any Patent that includes a claim that expressly recites the sequence of a Licensed Antibody or Derived Antibody other than as part of a Paragon Multispecific Antibody. (d) Patent Prosecution Costs Prior to the Effective Date. No later than [* * *] days after the Effective Date, Oruka shall reimburse Paragon for any actual costs and expenses incurred by Paragon that are related to the Prosecution of any Licensed Antibody Patents prior to the Effective Date and that have not already been paid by Oruka. Oruka will promptly reimburse Paragon for any future Prosecution costs and expenses incurred by Paragon with respect to the Licensed Antibody Patents. (e) CREATE Act. Notwithstanding anything to the contrary in this Agreement, each Party will have the right to invoke the Cooperative Research and Technology Enhancement Act of 2004, 35 U. S. C. § 103 (c) (2)- (c) (3) (the “ CREATE Act ”) when exercising its rights under Article V of this Agreement, without the prior written consent of the other Party. Where such Party intends to invoke the CREATE Act, it will notify the other Party and the other Party will cooperate and coordinate its activities with such Party with respect to any submissions, filings or other activities in support thereof. The Parties acknowledge and agree that this Agreement is a joint research agreement (JRA) as defined in the CREATE Act. (f) Disclosure of Antibody Patents. Upon the request of Paragon, Oruka shall deliver to Paragon a list of the then- existing Oruka Antibody Patents. 5. 3 Patent Enforcement and Defense. (a) Notice of Patent Infringement and Patent Challenge. Each Party shall give the other Party notice of any known or suspected infringement by a Third Party (“ Patent Infringement ”) of any Licensed Antibody Patent and any known or suspected challenge by a Third Party against the validity or enforceability (“ Patent Challenge ”) of any Licensed Antibody Patent within [* * *] days after such Patent Infringement or Patent Challenge comes to such Party’ s attention. (b) Oruka’ s First Right to Enforce or Defend. Oruka shall have the first right, but not the obligation, to bring and control any legal action, including by declaratory judgment action, patent litigation or similar proceeding, in connection with any Patent Infringement or Patent Challenge with respect to the Licensed Antibody Patents in the Territory at its own expense and discretion as it reasonably determines appropriate. Oruka shall keep Paragon informed and reasonably consult with Paragon in the course of such legal action. Paragon shall have the right to be represented in any such legal action by counsel of its choice at its own expense. (c) Paragon’ s First Right to Enforce or Defend. Paragon shall have the sole right, but not the obligation, to bring and control any legal action, including by declaratory judgment action, patent litigation or similar proceeding, in connection with any Patent Infringement or Patent Challenge with respect to the Paragon Patents in the Territory at its own expense and discretion as it reasonably determines appropriate. (d) Settlement. In connection with any such legal action or proceeding, Oruka shall not enter into any settlement admitting the invalidity or unenforceability of Licensed Antibody Patents without the prior written consent of Paragon (such consent not to be unreasonably conditioned, withheld, or delayed). (e) Paragon’ s Backup Right to Enforce or Defend. If Oruka does not initiate a legal action for Patent Infringement or Patent Challenge with respect to any Licensed Antibody Patent within [* * *] days after a notice from Paragon under Section 5. 3 (a), then Paragon shall have a backup right, but not the obligation, to initiate such legal action at its own expense. (f) Allocation of Recoveries. Any recoveries resulting from such legal action initiated by Oruka or Paragon hereunder relating to Patent Infringement or Patent Challenge in each case solely with respect to the Licensed Antibody Patents, including pursuant to a settlement, shall be applied as follows: (i) first to reimburse the [* * *] of each of the Parties in such action; and (ii) second, any amounts remaining after paying the amounts due each Party under clause (i) (the “ Remaining Recovery ”) shall be allocated as follows: (1) [* * *]; or (2) [* * *]. (g) Cooperation with Patent Enforcement. At the request of the enforcing Party (and at the requesting Party’ s expense), the other Party shall reasonably cooperate and provide any information or assistance in connection with any legal action under this Section 5. 3, including executing reasonably appropriate documents, cooperating in discovery and, if required by Applicable Law, joining as a party to the legal action at its own expense. 5. 4 Third Party Patent Proceedings. (a) Oruka’ s First Right to Challenge Third Party Patents. Oruka shall have the sole and exclusive right, but not the obligation, to bring and control any legal action to challenge any Patents controlled by a Third Party, including by declaratory judgment action, patent interference, opposition, pre- issuance submission, ex parte re- examination, post- grant review, inter partes review, patent litigation or similar proceeding, in each case that are necessary or useful to Develop, Manufacture, Commercialize or otherwise exploit any Oruka Product. (b) Cooperation by Paragon. At the request of Oruka, Paragon shall cooperate and provide any information or assistance in connection with any legal action under this Section 5. 4, including executing reasonably appropriate documents, cooperating in discovery and, if required by Applicable Law, joining as a party to the action at Oruka’ s cost and expense. 5. 5 Common Interest Agreement. At the request of either Party to conduct the activities under this Article V, the Parties shall cooperate in good faith to enter into a customary, mutually- agreed common- interest agreement intended to preserve attorney- client privilege with respect to disclosures and communications by or on behalf of either Party or its Affiliates in connection with such activities. Article VI PROTECTION OF CONFIDENTIAL INFORMATION. 6. 1 Confidentiality. Except to the extent expressly authorized by this Agreement, the Receiving Party agrees that, during the Term, for [* * *] years thereafter, and, with respect to any Know- How that constitutes a trade secret, for long as such Know- How constitutes a trade secret, it shall keep confidential and shall not publish or otherwise disclose to any Third Party, and shall not use for any purpose other than as expressly provided for in this Agreement, any Confidential Information of the Disclosing Party. The Receiving Party may disclose Confidential Information of the Disclosing Party to those of the Receiving Party’ s Representatives who have a need for such information, provided that the Receiving Party shall advise such Representatives of the confidential nature thereof, shall ensure that each such Representative is bound in writing by obligations of confidentiality and non- use at least as stringent as those contained in this Agreement, and shall be responsible for the compliance of its Representatives with the terms of this Agreement. The Receiving Party shall use at least the same standard of care as it uses to protect proprietary or confidential information of its own (but in no event less than reasonable care) to ensure that its Representatives do not disclose or make any unauthorized use of the Confidential Information of the Disclosing Party. The Receiving Party shall promptly notify the Disclosing Party upon discovery of any unauthorized use or disclosure of the Confidential Information of the Disclosing Party. 6. 2 Exceptions. The Receiving Party’ s obligations under Section 6. 1 shall not apply to any Confidential Information of the Disclosing Party that the Receiving Party can prove by competent evidence: (a) is now, or hereafter becomes, through no act or failure to act on the part of the Receiving Party in breach of this Agreement, generally known or available; (b) is known by the Receiving Party at the time of receiving such information from the Disclosing Party; (c) is hereafter furnished to the Receiving Party by a Third Party, as a matter of right and without restriction on disclosure; or (d) is independently discovered or developed by the Receiving Party, without the aid, use or application of any Confidential Information of the Disclosing Party. 6. 3 Authorized Disclosure. Notwithstanding the provisions of this Article VI, the Receiving Party may disclose Confidential Information of the Disclosing Party, without violating its obligations under this Agreement, to the extent the disclosure is: (a) required by a valid order of a court or other Governmental Authority of competent jurisdiction or as otherwise required by Applicable Law, rule, regulation (including securities laws), government requirement, or as may be required in connection with any filings made with, or by the disclosure policies of, a stock exchange (including, for clarity, any such disclosures required to be made by Paragon or its Affiliates or licensees in connection with the Development, Manufacture, Commercialization or other exploitation of Multispecific Antibodies), provided that the Receiving Party shall give reasonable prior written notice to the Disclosing Party of such required disclosure and, at the [* * *] request and expense, shall cooperate with the Disclosing Party' s efforts to contest such requirement, to obtain a protective order requiring that the Confidential Information so disclosed be used only for the purposes for which the order was issued or the law required, or to obtain other confidential treatment of such Confidential Information; (b) reasonably necessary to file or Prosecute patent applications, Prosecute or defend litigation or otherwise establish rights or enforce obligations under this Agreement, or obtain or maintain approval to conduct clinical trials or Regulatory Approvals, in each case, in accordance with this Agreement (including, for clarity, any such disclosures that are reasonably necessary to made by Paragon or its Affiliates or licensees in connection with the Development, Manufacture, Commercialization or other exploitation of Multispecific Antibodies); or (c) under appropriate confidentiality provisions substantially equivalent to those in this Agreement (but of shorter duration if customary in the case of subclause (ii)): (i) in connection with the performance of its obligations or as reasonably necessary or useful in the exercise of its rights under this Agreement, including the right to grant licenses or sublicenses as permitted hereunder and the right to Develop, Manufacture, Commercialize and otherwise exploit Antibodies and products (including Multispecific Antibodies and Multispecific Products) to which it has rights hereunder, or (ii) to actual or bona fide potential licensees, acquirers, merger partners, assignees, collaborators, investment bankers, investors or lenders. 6. 4 Use of Names. Except as set forth in Section 6. 6 (b), neither Party shall use the other Party' s name or trademarks in any advertising, sales, or promotional material or in any publication without the prior written consent of the other Party. 6. 5 Confidentiality of this Agreement. This Agreement and its terms are considered Confidential Information of both Parties, and each Party shall keep confidential and shall not publish or otherwise disclose the terms of this Agreement without the prior written consent of the other Party, except as expressly permitted by Section 6. 3, and except that both Parties may disclose this Agreement and its terms to its legal, financial and investment banking advisors; bona fide potential and actual investors, acquirers, merger partners, assignees, collaborators, investment bankers, lenders, licensees, sublicensees or strategic partners in connection with license or partnering transactions, due diligence or similar investigations by such Third Parties or in confidential financing documents; and counsel or other advisors for the foregoing; provided, in each case, that any such Third Party agrees to be bound by obligations of confidentiality and non- use at least as restrictive as those set forth in this Article VI (provided that the confidentiality term applicable to such Third Party may be shorter so long as it is commercially reasonable). 6. 6 Publicity. (a) Subject to Section 6. 6 (b), neither Party will generate or allow any publicity regarding this Agreement or the transactions contemplated hereunder without the other Party first approving such press release or publication in writing, except for any public disclosure by or on behalf of a Party that is, upon the advice of such Party' s counsel, required by Applicable Law or the rules of a stock exchange on which the securities of such Party are listed (or to which an application for listing has been submitted) and except that a Party may, once a press release or other public written statement is approved in writing by both Parties, make subsequent public disclosure of the information contained in such press release or other public written statement without the further approval of the other Party. (b) The Parties shall collaborate and cooperate [* * *] to devise a Publication (as defined below) strategy for the Oruka Products that is acceptable to both Parties. Prior to publicly presenting or publishing any data, results or analyses relating to an Oruka Product generated by or on behalf of Oruka pursuant to this Agreement (each such proposed presentation or publication, a " Publication "), Oruka will provide Paragon with a copy of such proposed Publication to review with adequate time for Paragon' s review and comment prior to the earlier of its presentation or intended submission for publication (such applicable period, the " Review Period "). Oruka will take into consideration Paragon' s reasonable comments prior to finalizing the Publication. Upon Paragon' s request, Oruka shall remove any Confidential Information of Paragon from such Publication that Oruka is not required to disclose pursuant to Applicable Law or the rules of a stock exchange on which the securities of Oruka are listed. In addition, Paragon shall have the right to request the delay of such Publication for up to [* * *] days to enable filing of Patents, which request Oruka will take into consideration and discuss with Paragon before release of the Publication. Paragon will not publicly present or publish any Publication including Confidential Information of Oruka relating specifically to the Licensed Antibodies or Derived Antibodies without Oruka' s prior written consent, which consent may be withheld for any reason or no reason; provided, that the foregoing shall not limit Paragon' s right to publicly present or publish any Publication relating to Multispecific Antibodies. Each Publication shall include proper attribution, including the use of such Party' s trademarks and name, to the non- publishing Party, as applicable, and each non- publishing Party expressly authorizes the inclusion of such reference in the applicable Publication and licenses the use of such trademarks and name solely for inclusion in any such Publication. Article VII REPRESENTATIONS, WARRANTIES AND COVENANTS. 7. 1 Mutual Representations. Each Party represents and warrants to the other Party that: (a) it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority to enter into this Agreement and to carry out the provisions hereof; (b) it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder; (c) no consent, approval, permit, governmental order, declaration or filing with, or notice to, any Governmental Authority or any Third Party is required by or with respect to such in connection with the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby; and (d) this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not and will not conflict with any agreement, instrument, or understanding, oral or written, to which it is or may become a party or by which it may be or become bound. 7. 2 Representations of Paragon. Paragon hereby represents and warrants to Oruka as of the Effective Date that: (a) Paragon has set forth in Exhibit A a true, correct and complete list of all the Licensed Antibody Patents existing as of the Effective Date (including title, all inventors, owners, assignees, filing date, grant date, expiration date and status); (b) Unless otherwise set forth in Exhibit A, Paragon exclusively owns all Licensed Antibody Patents; (c) There are no licenses or sublicenses pursuant to which Paragon licenses as of the Effective Date any of the Licensed Antibody Technology, nor, to Paragon' s actual knowledge, are any such licenses necessary to Develop, Manufacture and Commercialize the Licensed Antibodies; (d) Paragon has the right under the Licensed Antibody Technology to grant to Oruka the licenses and other rights set forth in this Agreement, and it has not granted any license or other right under the Licensed Antibody Technology that is inconsistent with the licenses and other rights granted to Oruka hereunder; (e) There is no pending or, to Paragon' s knowledge, threatened litigation, nor has Paragon received any written notice from any Third Party, asserting or alleging that the development, manufacture or commercialization of the Licensed Antibody Technology prior to the Effective Date infringed or misappropriated the intellectual property rights of such Third Party; (f) To Paragon' s knowledge, Paragon has not withheld from Oruka any information with respect to the Licensed Antibody Technology that would reasonably be expected to be materially adverse to Oruka' s Development, Manufacture, or Commercialization of any Product in the Territory as contemplated under this Agreement; (g) To Paragon' s knowledge, Paragon has, and any of Paragon' s Affiliates involved in the Research Program have, (i) conducted all research and development under the Research Program in accordance with Research Plan (as defined in the Option Agreement), and (ii) conducted the Research Program in compliance with all Applicable Laws; (h) To Paragon' s knowledge, Paragon has provided true, correct and complete copies of all Results developed under the Research Program and all other deliverables required under the Research Program have been provided or delivered to Oruka and are true, correct and complete in all material respects; (i) Paragon has properly filed, Prosecuted and maintained all Licensed Antibody Patents; (j) Paragon has complied with all duties of disclosure and has not engaged in any inequitable conduct with respect to all Licensed Antibody Patents that were filed prior to the Effective Date; (k) All Licensed Antibody Patents listed in Exhibit A that have been issued as of the Effective Date are in full force and effect and are, to Paragon' s knowledge, valid and enforceable; (l) Other than the Patents listed in Exhibit A, as of the Effective Date, neither Paragon nor any of its Affiliates own or have any rights in, to or under any Patents Covering the composition of matter of, or any method of specifically making or using, any Licensed Antibody; (m) There are no judgments against or awards or settlements against Paragon or any of its Affiliates, and there are no claims, actions, or proceedings pending or, to Paragon' s knowledge, threatened, nor to Paragon' s knowledge are there any formal inquiries initiated or written notices received that are reasonably likely to lead to the institution of any such legal proceedings, in each case (i) relating to any Licensed Antibodies, Derived Antibodies or Licensed Antibody Technology or alleging that any Third Party has any right to or under any Products, Licensed Antibodies, Derived Antibodies or Licensed Antibody Technology that would conflict with the rights granted in this Agreement; or (ii) alleging that any Licensed Antibody Patent is unpatentable, invalid, unenforceable or infringed; (n) (i) Each Representative employed or engaged by Paragon or its Affiliate to conduct the activities under the Research Program have assigned or licensed, or are under contractual obligations to assign or license, to Paragon all inventions conceived, reduced to practice or otherwise related to Licensed Antibodies, Derived Antibodies and Licensed Antibody Technology; (ii) to Paragon' s knowledge, no Representative employed by Paragon or its Affiliate that conducts activities under a Research Program has any obligations under agreements or Applicable Law to assign any interest in any such inventions to any Third Party; and (iii) each Representative employed or engaged by Paragon or its Affiliate to conduct the activities under a Research Program have existing obligations under agreements or Applicable Law to maintain as confidential Paragon' s Confidential Information as well as confidential information of other parties (including of Oruka and its Affiliates); (o) None of Paragon, its Representatives, or any other person used by Paragon in the performance of the Research Program or otherwise in connection with this Agreement has been or is (i) debarred, convicted, or is subject to a pending debarment or conviction, pursuant to section 306 of the United States Food Drug and Cosmetic Act, 21 U. S. C. § 335a, (ii) listed by any government or regulatory agencies as ineligible to participate in any government healthcare programs or government procurement or non- procurement programs (as that term is defined in 42 U. S. C. § 1320a- 7b (f)), or excluded, debarred, suspended or otherwise made ineligible to participate in any such program, or (iii) convicted of a criminal offense related to the provision of healthcare items or services, or is subject to any such pending action. Paragon agrees to inform Oruka in writing promptly if Paragon or any person who is performing activities on its behalf under the Agreement is subject to the foregoing, or if any action, suit, claim, investigation, or proceeding relating to the foregoing is pending or threatened; (p) No funding, facilities, or personnel of any Governmental Authority or any public or private educational or research institutions were used to develop or create any Licensed Antibody Technology, and neither Paragon nor any of its Affiliates has entered into a government funding relationship that would result in rights to any Products, Licensed Antibodies, Derived Antibodies or Licensed Antibody Technology residing in the U. S. Government, the National Institutes of Health, or other agency, and the licenses granted hereunder are not subject to overriding obligations to the U. S. Government as set forth in Public Law 96- 517 (35 U. S. C. § § 200- 204), or any similar obligations under the laws of any other country in the Territory; and (q) To the [* * *] knowledge of [* * *] of Paragon, with respect to this Agreement and the Option Agreement, neither Paragon nor any of its directors, officers, employees, distributors, consultants, agents, representatives, sales intermediaries, or other Third Parties acting on behalf of Paragon or any of its Affiliates: (i) has taken any action in violation of any applicable anti- corruption laws, anti- money laundering laws or laws restricting or regulating global trade (collectively, " Anti- Corruption Laws "); (ii) has conducted or initiated any internal investigation with respect to any alleged act or omission arising under or relating to any potential noncompliance with any Anti- Corruption Law, or been the subject of current, pending, or threatened investigation, formal or informal inquiry, enforcement proceedings, or received any notice, request, or citation for alleged violations of such laws; (iii) has engaged in any direct or indirect dealings or transactions in or with a person, entity or country found on the Specially Designated Nationals and Blocked Persons List maintained by the U. S. Office of Foreign Assets Control, or engaged in any direct or indirect dealings with Sudan, individuals ordinarily resident in Sudan, or entities incorporated under the laws of Sudan prior to October 12, 2017; or (iv) has offered, paid, given, promised to pay or give, or authorized the payment or gift of, received, or solicited anything of value, directly or indirectly, to any public official, for the purposes of: influencing any act or decision of any public official in his or her official capacity; inducing any public official to do or omit to do any act in violation of his or her lawful duty; securing any improper or undue advantage; or inducing any public official to use his or her influence with a government, Governmental Authority, or commercial enterprise owned or controlled by any government (including state- owned or controlled veterinary, laboratory or medical facilities) in obtaining or retaining any business whatsoever. 7. 3 Covenants of Paragon. Paragon hereby covenants to Oruka during the Term that: (a) Paragon will not grant a Third Party any license or other right in the Licensed Antibody Technology or the Other Licensed Technology that would conflict with the rights and licenses granted to Oruka hereunder with respect to such Licensed Antibody Technology; (b) Paragon will, and will direct each Affiliate of Paragon and subcontractor conducting activities under this Agreement to, conduct all such activities in compliance with Applicable Laws, including all applicable Anti-Corruption Laws and U. S. sanctions; (c) Paragon will comply with the terms of each Paragon Third Party Agreement, will maintain each Paragon Third Party Agreement, will not amend a Paragon Third Party Agreement in a manner that (i) adversely effects Oruka in any material respect, or (ii) increases any financial obligations under a Paragon Third Party Agreement that will result in an increase in Oruka' s Reimbursement Obligation, in each case of (i) and (ii) without Oruka' s prior written consent, and will not take any actions that could reasonably cause any Paragon Third Party Agreement to lapse or terminate; and (d) Paragon will, and will direct each applicable Affiliate of Paragon to, execute and deliver such additional documents and instruments and to perform such additional acts as may be necessary or appropriate to enable Oruka to exercise its rights and obligations under Sections 5. 2, 5. 3 and 5. 4. 7. 4 Compliance with Laws. Each Party shall, and shall ensure that its Affiliates and its and its Affiliates' Representatives and sublicensees, comply with Applicable Laws in all material respects in the performance of its obligations and the exercise of its rights under this Agreement. 7. 5 DISCLAIMER OF WARRANTIES. EXCEPT AS EXPRESSLY SET FORTH HEREIN, EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, DURABILITY, MERCHANTABLE QUALITY, FITNESS FOR A PARTICULAR PURPOSE, NON- INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR

ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES. Article VIII TERM; TERMINATION. 8. 1 Term. The term of this Agreement shall commence on the Effective Date and shall expire on a country- by- country and Oruka Product- by- Oruka Product basis on the expiration of the Royalty Term for such Oruka Product in such country, in each case, unless earlier terminated by a Party as set forth below in this Article VIII (the " Term "). Upon expiration (but not termination) of the Agreement, the licenses granted in Section 2. 1 shall survive and become royalty- free, fully paid- up, perpetual and irrevocable with respect to the applicable Oruka Product in the applicable country. 8. 2 Termination by Oruka. Oruka shall have the right to terminate this Agreement in its entirety or on a country- by- country or Oruka Product- by- Oruka Product basis for any or no reason upon sixty (60) days' prior written notice to Paragon. 8. 3 Material Breach. Either Party may terminate this Agreement in its entirety for the material breach of this Agreement by the other Party, if such material breach remains uncured ninety (90) days (or thirty (30) days with respect to any failure to make any payments owing to a Party hereunder) following notice from the non- breaching Party to the breaching Party specifying such breach, provided that, in the event of a dispute regarding the existence or cure of a material breach, no termination shall become effective until such dispute is finally resolved pursuant to Section 10. 7 in favor of the non- breaching Party and the breaching Party fails to cure such material breach within ninety (90) days thereafter. 8. 4 Insolvency. Each Party will have the right to terminate this Agreement in the event of a Bankruptcy Event with respect to the other Party. " Bankruptcy Event " means the occurrence of any of the following: (a) the institution of any bankruptcy, receivership, insolvency, reorganization or other similar proceedings by or against a Party under any bankruptcy, insolvency, or other similar law now or hereinafter in effect, including any section or chapter of the United States Bankruptcy Code, as amended or under any similar laws of the United States or any state thereof (the " Bankruptcy Code "), where in the case of involuntary proceedings such proceedings have not been dismissed or discharged within [* * *] days after they are instituted, (b) the insolvency or making of an assignment for the benefit of creditors, (c) the institution of any reorganization, arrangement or other readjustment of debt plan of a Party not involving the Bankruptcy Code, or (d) appointment of a receiver for all or substantially all of a Party' s assets. 8. 5 Effect of Termination of this Agreement. If this Agreement terminates for any reason (excluding expiration under Section 8. 1), whether with respect to a particular Oruka Product, particular country or in its entirety, then the following shall apply: (a) All licenses and other rights granted by Paragon under this Agreement with respect to the terminated Oruka Product (s) and terminated country (ies) shall terminate, except as required for Oruka, its Affiliates and / or its Sublicensees to perform any of its obligations that survive termination, including to continue to complete or wind down (at [* * *] expense in the event of a termination by Oruka under Section 8. 3) any ongoing clinical trials for any Oruka Product, as may be required by Applicable Law or ethical principles. (b) No later than [* * *] days after the effective date of such termination, each Party shall return or cause to be returned to the other Party, or destroy, all Confidential Information received from the other Party and all copies thereof related to the terminated Oruka Product (s) in the terminated country (ies); provided, however, that each Party may retain any Confidential Information reasonably necessary for such Party' s ongoing obligations and rights under this Agreement which do not terminate, and each Party may keep one (1) copy of Confidential Information received from the other Party in its confidential files for record purposes and such copy shall remain subject to Article VI of this Agreement. (c) Upon Paragon' s written request to Oruka (which must be provided to Oruka within [* * *] days after the effective date of termination), Paragon and Oruka shall [* * *] discuss [* * *], for a period of up to [* * *] days following such written request, terms and conditions under which Oruka may be willing to grant to Paragon [* * *], [* * *] license under the Oruka Intellectual Property to Develop, Manufacture, Commercialize or otherwise exploit the terminated Oruka Products in the Field in the terminated countries that were the subject of any Development, Manufacturing or Commercialization activities performed by Oruka or its Affiliates under this Agreement prior to such termination, (" Reversion Products "), as well as the potential transfer of materials, ongoing clinical trials, and applicable regulatory filings and relevant data generated by Oruka with respect to the Reversion Products and necessary for the continued Development, Manufacture, Commercialization and exploitation of such Reversion Products, such agreement to include commercially reasonable financial and other terms, which terms shall take into consideration Oruka' s contributions made in the Development, Manufacture, Commercialization and other exploitation of the Reversion Products, provided, that Oruka is under no obligation to enter into such license. 8. 6 Survival of Sublicenses. Upon termination of this Agreement, at the written request of any Sublicensee who is not then in breach of its sublicense agreement, such sublicense agreement will survive such termination of this Agreement, and Paragon will negotiate [* * *] the terms and conditions of a direct license with such Sublicensee that is consistent with the terms of this Agreement (as adjusted for the scope of license, products, field of use and other provisions of the original sublicense). Each sublicense that may be amended to become a direct license between Paragon and a Sublicensee shall ensure that any and all economic rights, payments or benefits due to Oruka will be preserved and payable to Oruka and will designate Oruka a third- party beneficiary to enforce such rights. In each such instance, Oruka will have the right to review and approve the terms of such agreement between Paragon and such Sublicensee as related to Oruka' s economic rights, which approval shall not be unreasonably withheld, conditioned or delayed. 8. 7 Accrued Rights; Survival. The expiration or termination of this Agreement for any reason shall not release either Party from any liability or obligation that, at the time of such expiration or termination, has already accrued to the other Party or that is attributable to a period prior to such expiration or termination, nor will expiration or any termination of this Agreement preclude either Party from pursuing all rights and remedies it may have under this Agreement, or at law or in equity, with respect to breach of this Agreement. In the event of expiration or any termination of this Agreement, the following provisions of this Agreement shall survive such expiration or termination in accordance with their respective terms and conditions: Article I (Definitions); Section 2. 1 (License Grant from Paragon) (upon expiration (but not termination) of this Agreement as set forth in Section 8. 1 (Term)); Section 2. 3 (Sublicenses) (with respect to any payments or other performance obligations prior to conversion (if any) to a direct license pursuant to Section 8. 6); Section 2. 4 (No Implied Licenses; Reservation of Rights); Section 4. 1 (Milestone Payments) (with respect to any outstanding payment obligations incurred prior to the date of termination or expiration); Section 4. 2 (Royalties) (with respect to any outstanding payments accrued prior to the effective date of termination); Section 4. 4 (Payment Reports) (with respect to the last Calendar Quarter of the Term to the extent not already reported and any outstanding payment obligation with respect to any royalty payments accrued prior to the date of termination or expiration); Section 4. 5 (Payment Method) to 4. 9 (Blocked Currency) (for the duration of any outstanding payment obligations under this Agreement); Section 4. 10 (Records; Inspection) (for the duration set forth therein); Section 5. 1 (Ownership); Section 7. 5 (Disclaimer of Warranties); Article VI (Protection of Confidential Information) (for the duration set forth therein); Section 8. 5 (Effect of Termination of this Agreement); Section 8. 6 (Survival of Sublicenses); Section 8. 7 (Accrued Rights; Survival); Article IX (Indemnification); and Article X (Miscellaneous). INDEMNIFICATION. 9. 1 By Oruka. Oruka hereby agrees to defend, indemnify and hold harmless Paragon, its Affiliates and its or their Representatives (each, an " Paragon Indemnitee ") from and against any and all losses, damages, liabilities, expenses and costs, including reasonable legal expense and attorneys' fees (collectively, " Losses "), to which any Paragon Indemnitee may become subject (a) as a result of any claim, demand, action, or other proceeding by any Third Party (" Third Party Claim ") to the extent such Losses result from: (i) the gross negligence, recklessness or willful misconduct of any Oruka Indemnitee in the performance of this Agreement; (ii) Oruka' s breach of any of its representations, warranties or covenants under this Agreement; or (iii) Oruka' s Development, Manufacture and Commercialization of the Oruka Products; and (b) to the extent such Losses result from the termination, suspension, revocation or other loss of any Licensed Antibody Patents as a result of any negligence or breach of this Agreement by Oruka, its Affiliates or Sublicensees, in each case ((a) to (b)), except in each case to the extent that any Losses are attributable to the breach of this Agreement by, or the negligence, recklessness or willful misconduct of, or otherwise indemnifiable by, any Paragon Indemnitee. 9. 2 By Paragon. Paragon hereby agrees to defend, indemnify, and hold harmless Oruka, its Affiliates, and its or their Representatives (each, a " Oruka Indemnitee ") from and against any and all Losses to which any Oruka Indemnitee may become subject (a) as a result of any Third Party Claim to the extent such Losses result from: (i) the gross negligence, recklessness or willful misconduct of any Paragon Indemnitee in the performance of this Agreement; or (ii) Paragon' s breach of any of its representations, warranties or covenants under this Agreement; and (b) to the extent such Losses result from: (i) the termination, suspension, revocation or other loss of any Licensed Antibody Patents as a result of any negligence or breach of this Agreement by Paragon or its Affiliates; or (ii) any claim or demand from any employee or contractor of Paragon or its Affiliates who is an inventor of any Licensed Antibody Patents with respect to ownership thereof, in each case ((a) to (b)), except to the extent that any Losses are attributable to the breach of this Agreement by, or the negligence, recklessness or willful misconduct of, or otherwise indemnifiable by, any Oruka Indemnitee. 9. 3 Indemnification Procedures. The Party claiming indemnity under this Article IX (the " Indemnified Party ") will give written notice to the Party from whom indemnity is being sought (the " Indemnifying Party ") promptly after learning of the Third Party Claim for which indemnity is being sought (" Claim "). The Indemnifying Party' s obligation to defend, indemnify and hold harmless pursuant to Section 9. 1 or Section 9. 2, as applicable, will be reduced to the extent the Indemnified Party' s delay in providing notification pursuant to the previous sentence results in material prejudice to the Indemnifying Party; provided, however, that the failure by an Indemnified Party to give such notice or otherwise meet its obligations under this Section 9. 3 will not relieve the Indemnifying Party of its indemnification obligation under this Agreement. At its option, the Indemnifying Party may assume the defense and have exclusive control, at its own expense, of any Claim for which indemnity is being sought by giving written notice to the Indemnified Party within [* * *] days after receipt of the notice of the Claim. The Indemnified Party will provide the Indemnifying Party with reasonable assistance, at the Indemnifying Party' s expense, in connection with the defense. The Indemnified Party may participate in and monitor such defense with counsel of its own choosing at its sole expense; provided, however, the Indemnifying Party will have the right to assume and conduct the defense of the Claim with counsel of its choice. The Indemnifying Party will not settle any Claim without the prior written consent of the Indemnified Party, not to be unreasonably withheld, unless the settlement involves only the payment of money. The Indemnified Party will not settle any such Claim without the prior written consent of the Indemnifying Party. If the Indemnifying Party does not assume and conduct the defense of the Claim as provided above, (i) the Indemnified Party may defend against, and consent to the entry of any judgment or enter into any settlement with respect to the Claim in any manner the Indemnified Party may deem reasonably appropriate, provided, that the Indemnified Party reasonably consults with the Indemnifying Party prior to entering into any settlement, and (ii) the Indemnified Party reserves any right it may have under this Article IX to obtain indemnification from the Indemnifying Party. 9. 4 Limitation of Liability. EXCEPT FOR LIABILITY FOR BREACH OF Article VI, FOR Breach of Sections 2. 1 or 2. 2, for breach of any intellectual property rights held by a party, for the fraud or willful misconduct of a party OR FOR INDEMNIFICATION CLAIMS UNDER THIS Article IX, IN NO EVENT SHALL EITHER PARTY BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT, EVEN IF THE OTHER PARTY HAD NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. 9. 5 Insurance. During the Term and for a period of [* * *] years thereafter, each Party shall maintain at its expense insurance coverage consistent with normal business practices and adequate to cover the risks associated with its performance of any activities hereunder. Each Party hereby expressly acknowledges and agrees that the maintenance of such insurance coverage shall not relieve it of its obligations under this Agreement. MISCELLANEOUS. 10. 1 Independent Contractor Relationship. Paragon' s relationship with Oruka is that of an independent contractor, and nothing in this Agreement should be construed to create a partnership, joint venture, or employer- employee relationship. Neither Party is an agent of the other Party or authorized to make any representation, contract, or commitment on behalf of the other Party. 10. 2 Force Majeure. Neither Party will be charged with any liability for delay or failure in performance of an obligation under this Agreement (other than any obligation to pay monies when due) to the extent such delay or failure is due to a cause beyond the reasonable control of the affected Party, such as war, riots, labor disturbances, epidemic, pandemic, fire, explosion, and compliance in good faith with any Applicable Law (in each case, a " Force Majeure "). In addition, a Force Majeure event may include reasonable measures affirmatively taken by a Party or its Affiliates to respond to the COVID- 19 pandemic or any other pandemic (or other Force Majeure event), such as requiring employees to stay home, closures of facilities, delays of clinical trials, or cessation of activities in response to the pandemic. The Party affected by a Force Majeure will give prompt written notice to the other Party of the nature of the cause of any material delay or failure to perform, its anticipated duration and any action being taken to avoid or minimize the effect. The Party affected will use its diligent efforts to avoid or remove such causes of delay or failure to perform and to mitigate the effect of such occurrence, and will continue performance in accordance with the terms of this Agreement whenever such causes are removed. The Party affected will give prompt written notice to the other Party of such resumed performance. 10. 3 Entire Agreement; Amendment. This Agreement and the Option Agreement, together with all Exhibits attached hereto, constitutes the final, complete, and exclusive agreement of the Parties with respect to the subject matter hereof and supersedes all prior and contemporaneous understandings and agreements, relating to its subject matter. This Agreement (including its Exhibits) may not be changed, modified, amended, or supplemented except by a written instrument signed by both Parties. 10. 4 Non- Waiver. The failure of a Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other instance. Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such Party. 10. 5 Severability. Should one or more of the provisions of this Agreement become void or unenforceable as a matter of Applicable Law, then this Agreement shall be construed as if such provision were not contained herein and the remainder of this Agreement shall be in full force and effect, and the Parties will use their best efforts to substitute for the invalid or unenforceable provision a valid and enforceable provision which conforms as nearly as possible with the original intent of the Parties. 10. 6 Assignment. Neither this Agreement nor any rights or obligations hereunder may be assigned by either Party without the prior written consent of the other Party (which consent shall not be unreasonably withheld); provided, however, that (a) Paragon may assign to an Affiliate or a Third Party financing source its rights to receive some or all of the payments payable hereunder together with the right to receive Confidential Information of Oruka, provided Paragon shall not be permitted to share Oruka Confidential Information unless and except to the extent necessary to obtain Affiliate or Third- Party financing, provided, further, that any such Affiliate or Third Party agrees to be bound by obligations of confidentiality and non- use at least as restrictive as those set forth in Article VI; and (b) either Party may assign this Agreement and its rights and obligations hereunder without the other Party' s consent to (i) its Affiliates or (ii) its successor to all or substantially all of the business of such Party to which this Agreement relates, whether by merger, sale of stock, sale of assets or otherwise. The assigning Party shall provide the other Party with prompt written notice of any such assignment set forth in clauses (a) and (b) above. Except for an assignment pursuant to clause (a) above, the rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties, and the name of a Party appearing herein will be deemed to include the name of such Party' s successors and permitted assigns to the extent necessary to carry out the intent of this section. Any assignment not in accordance with this Agreement shall be void. 10. 7 Dispute Resolution. (a) The Parties recognize that a bona fide dispute as to certain matters may arise from time to time during the Term relating to either Party' s rights or obligations hereunder or otherwise relating to the validity, enforceability or performance of this Agreement, including disputes relating to alleged breach or termination of this Agreement but excluding any disputes relating to Article VI or disputes relating to the determination of the validity, scope, infringement, enforceability, inventorship or ownership of the Parties' respective Intellectual Property Rights (hereinafter, a " Dispute "). In the event of the occurrence of any Dispute, the Parties will follow the following procedures in an attempt to resolve the dispute or disagreement: (i) The Party claiming that such a Dispute exists will give notice in writing (a " Notice of Dispute ") to the other Party of the nature of the Dispute. The Dispute will be referred to the then Chief Executive Officer of Paragon and the then Chief Executive Officer of Oruka who will meet no later than [* * *] days following the initial receipt of the Notice of Dispute and use reasonable endeavors to resolve the Dispute. (ii) If, within [* * *] days of initial receipt of the Notice of Dispute, the Dispute has not been resolved, or if, for any reason, the meeting described in Section 10. 7 (a) (i) hereof has not been held within [* * *] days of initial receipt of the Notice of Dispute, then the Parties agree that such Dispute will be finally resolved through binding arbitration to be administered by JAMS pursuant to its Comprehensive Arbitration Rules and Procedures and in accordance with the Expedited Procedures in those Rules (the " JAMS Rules "), as specifically modified by the provisions of this Section 10. 7 (a) (ii) and Section 10. 7 (a) (iii). (iii) The arbitration will be conducted by a panel of three arbitrators. Within [* * *] days after the initiation of the arbitration, each Party will nominate one person to act as arbitrator, and the two arbitrators so named will then jointly appoint the third arbitrator within [* * *] days of their appointment, who will serve as chairman of the panel. All three arbitrators must be independent Third Parties having at least [* * *] years of dispute resolution experience (which may include judicial experience) or legal or business experience in the biotech or pharmaceutical industry. If either Party fails to nominate its arbitrator, or if the arbitrators selected by the Parties cannot agree on a person to be named as chairman within such [* * *]- day period, JAMS will make the necessary appointments for such arbitrator (s) or the chairman. Once appointed by a Party, such Party will have no ex parte communication with its appointed arbitrator. (iv) Notwithstanding the provisions of Section 10. 7 (a) (iii), if the Dispute involves an amount in question of less than $ [* * *], then the arbitration will be conducted by one arbitrator, selected in accordance with the JAMS Rules. (v) The place of arbitration will be in Boston, Massachusetts or such other venue as the Parties may mutually agree. The arbitration proceedings and all communications with respect thereto will be in English. Any written evidence originally in another language will be submitted in English translation accompanied by the original or a true copy thereof. The arbitrator (s) shall have the power to decide all matters in Dispute, including any questions of whether or not such matters are subject to arbitration hereunder. The arbitration will be governed by the Federal Arbitration Act, 9 U. S. C. § § 1 et seq., and judgment upon the award rendered by the arbitrators may be entered in any court having competent jurisdiction thereof. The existence, content and results of any arbitration proceedings pursuant to this Section 10. 7 will be deemed the Confidential Information of both Parties. (b) Notwithstanding any provision of this Agreement to the contrary, either Party may immediately initiate litigation in any court of competent jurisdiction seeking any remedy at law or in equity, including the issuance of a preliminary, temporary or permanent injunction, to preserve or enforce its rights under this Agreement. (c) The Parties agree that any disputes relating to Article VI or disputes relating to the determination of the validity, scope, infringement, enforceability, inventorship or ownership of the Parties' respective Intellectual Property Rights shall be subject to the exclusive jurisdiction of the state and federal courts in Boston, Massachusetts and each Party hereby submits to such jurisdiction. 10. 8 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts without reference to conflicts of laws principles. 10. 9 Notices. Any notice to be given under this Agreement must be in writing and delivered either in person, by internationally recognized express courier, or by email, to the Party to be notified at its address (es) given below, or at any address such Party has previously designated by prior written notice to the other. Notice shall be deemed sufficiently given for all purposes upon the earliest of: (a) the date of actual receipt; (b) if delivered by express courier, the next Business Day the express courier regularly makes deliveries; or (c) if delivered by email, upon the date upon which the receipt of such email is confirmed by return email. Together with any notice provided by a Party to the other Party in accordance with this Section 10. 9, the Party shall send a copy of such notice by email to the other Party. If to Paragon: Paragon Therapeutics, Inc. 221 Crescent Street Building 23, Suite 105 Waltham, MA 02453 Attn: Chief Operating Officer Email: [* * *] If to Oruka: Oruka Therapeutics, Inc. 855 Oak Grove Avenue, Suite 100 Menlo Park, CA 94025 Attn: General Counsel Email: [* * *] 10. 10 Interpretation. Except where the context expressly requires otherwise, (a) the use of any gender herein shall be deemed to encompass references to either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa), (b) the words " include ", " includes " and " including " shall be deemed to be followed by the phrase " without limitation ", (c) the word " will " shall be construed to have the same meaning and effect as the word " shall ", (d) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (e) any reference herein to any person or entity shall be construed to include such person' s or entity' s successors and assigns, (f) the words " herein ", " hereof " and " hereunder ", and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g) all references herein to Sections or Exhibits shall be construed to refer to Sections or Exhibits of this Agreement, and references to this Agreement include all Exhibits hereto, (h) the word " notice " means notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement, (i) provisions that require that a Party, the Parties or any committee hereunder " agree, " " consent " or " approve " or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e- mail and instant messaging), (j) references to any specific law, or article, section or other division thereof, shall be deemed to include the then- current amendments thereto or any replacement or successor law thereof, and (k) the term " or " shall be interpreted in the inclusive sense commonly associated with the term " or. " The headings of clauses contained in this Agreement preceding the text of the sections, subsections and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement or have any effect on its interpretation or construction. Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist. This Agreement has been prepared in the English language, and the English language shall control its interpretation. In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral, or other communications between the Parties regarding this Agreement shall be in the English language. To the extent there is any inconsistency or conflict between the terms and conditions of this Agreement and any Exhibit, the terms and conditions of this Agreement will prevail. 10. 11 No Third- Party Rights. The provisions of this Agreement are for the exclusive benefit of the Parties and their successors and permitted assigns, and no other person shall have any right or claim against any Party by reason of these provisions or be entitled to enforce any of these provisions against any Party. 10. 12 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original document, and all of which, together with this writing, shall be deemed one instrument. This Agreement may be executed by facsimile or PDF signatures, or electronic signatures complying with the ESIGN Act of 2000 (such as DocuSign), which signatures shall have the same force and effect as original signatures. 10. 13 Expenses. Each Party shall pay its own costs, charges and expenses incurred in connection with the negotiation, preparation and completion of this Agreement. 10. 14 Binding Effect. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective legal representatives, successors and permitted assigns. 10. 15 Construction. The Parties hereto acknowledge and agree that: (a) each Party and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision; (b) the rule of construction to the effect that any ambiguities are resolved against the drafting Party shall not be employed in the interpretation of this Agreement; and (c) the terms and provisions of this Agreement shall be construed fairly as to all Parties hereto and not in a favor of or against any Party, regardless of which Party was generally responsible for the preparation of this Agreement. 10. 16 Cumulative Remedies. No remedy referred to in this Agreement is intended to be exclusive unless explicitly stated to be so, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law. 10. 17 Performance by Affiliates. A Party may perform some or all of its obligations under this Agreement through Affiliate (s) or may exercise some or all of its rights under this Agreement through Affiliates, subject to the terms of this Agreement. However, each Party shall remain responsible and be guarantor of the performance by its Affiliates and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance as if such Party were performing such obligations itself, and references to a Party in this Agreement shall be deemed to also reference such Affiliate. In particular and without limitation, all Affiliates of a Party that receive Confidential Information of the other Party pursuant to this Agreement shall be governed and bound by all obligations set forth in Article VI, and shall be subject to the intellectual property provisions of Article V as if they were the original Party to this Agreement (and be deemed included in the actual Party to this Agreement for purposes of all intellectual property- related definitions). A Party and its Affiliates shall be jointly and severally liable for their performance under this Agreement. [Remainder of Page Left Intentionally Blank; Signature Page Follows] IN WITNESS WHEREOF, the Parties have by duly authorized persons executed this Agreement as of the Effective Date. Paragon Therapeutics, Inc. Oruka Therapeutics, Inc. By: / s / K. Evan Thompson By: / s / Lawrence Klein Name: K. Evan Thompson Name: Lawrence Klein Title: Chief Operating Officer Title: Chief Executive Officer [Signature Page to License Agreement] Exhibit 10. 31 [* * *] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. IL- 23 LICENSE AGREEMENT This License Agreement (" Agreement ") is entered into and effective as of December 17, 2024 (the " Effective Date "), by and between Paragon Therapeutics, Inc., a Delaware corporation (" Paragon "), and Oruka Therapeutics, Inc., a Delaware corporation (" Oruka "). Paragon and Oruka are also referred to herein individually as a " Party ", or collectively as the " Parties. " 1. 24 " Derived Antibody " means any Antibody that is created by or on behalf of Oruka (other than an Antibody created by Paragon under the Option Agreement), its Affiliates or its or their licensees and: (a) is derived from or constitutes a modification of a Licensed Antibody, including [* * *], (b) [* * *] and (c) [* * *]. For avoidance of doubt, any Antibody that [* * *] will be deemed a Derived Antibody, irrespective of origin, so long as such Antibody satisfies the requirements of (a), (b) and (c). Notwithstanding the foregoing, a Derived Antibody shall not include (i) [* * *], or (ii) [* * *]. 1. 34 " Field " means the prophylaxis, palliation, treatment and diagnosis of human disease and disorders except the therapeutic area of inflammatory bowel disease. 1. 45 " Licensed Antibody " means the Antibodies listed in Exhibit B as " Licensed Antibodies " that are Directed To the Licensed Target and that were discovered, generated, identified or characterized by Paragon in the course of performing the Research Program. Notwithstanding the foregoing, the Licensed Antibodies shall not include (a) [* * *], or (b) [* * *]. 1. 50 " Licensed Target " means IL- 23. Net Sales will include [* * *]. Net Sales will be calculated only once for the first bona fide arm' s length sale of the Oruka Product by Oruka, its Affiliates or its Sublicensees to a Third Party, and will not include sales between or among [* * *]. Net Sales shall not include any amounts invoiced for [* * *], (ii) [* * *], or (iii) [* * *]. 1. 63 " Oruka Cross License Patents " means any Patents Controlled by Oruka or its Affiliates as of the Effective Date or during the Term that Cover the composition of matter or method of treatment of the Retained IL- 23 Project Antibodies. Notwithstanding the foregoing, the Oruka Cross License Patents shall not include any Patents that Cover (a) [* * *], or (b) [* * *]. 1. 64 " Oruka Indemnitee " has the meaning set forth in Section 9. 2. 1. 65 " Oruka Intellectual Property " means any Patents, Know- How or other Intellectual Property Rights that are Controlled by Oruka and are necessary for, and actually used (or held for use) by Oruka or its Affiliates as of the effective date of termination of this Agreement in the Development, Manufacturing, or Commercialization of Oruka Products. 1. 66 " Oruka Invention " means (a) any Invention that is owned or Controlled by Oruka, and (b) all Intellectual Property Rights therein, provided that, in each case (a) – (b), Oruka Inventions shall not include (i) any Inventions owned or Controlled by Paragon or its Affiliate, the rights to which have been licensed to Oruka or its Affiliate under this Agreement or a separate agreement, or (ii) any Intellectual Property Rights therein. 1. 67 " Oruka Multispecific Antibody " means any Multispecific Antibody that is Developed, Manufactured, Commercialized or otherwise exploited by Oruka, its Affiliates or Sublicensees, excluding in each case, and subject to Section 2. 7, any Paragon Multispecific Antibody. 1. 68 " Oruka Multispecific Patents " means those Patents that Cover the composition of matter of, or any method of specifically making or using, an Oruka Multispecific Antibody. 1. 69 " Oruka Multispecific Product " means any product that comprises or contains any Oruka Multispecific Antibody. 1. 70 " Oruka Product " means, individually or collectively, as applicable, Licensed Antibodies, Derived Antibodies, Products, Oruka Multispecific Antibodies and Oruka Multispecific Products. 1. 71 " Other Component (s) " has the meaning set forth in Section 1. 59. 1. 72 " Other Licensed Know- How " means all Know- How Controlled by Paragon or its Affiliates on the Effective Date or during the Term that (a) was used by or on behalf of Paragon in the performance of the Research Program, and (b) is necessary to Develop, Manufacture, Commercialize or otherwise exploit (i) Licensed Antibodies, or (ii) Products, Multispecific Antibodies or Multispecific Products, in each case solely to the extent comprising or containing a Licensed Antibody. For clarity, the Other Licensed Know- How shall exclude (x) the Licensed Antibody Technology, and (y) any Know- How Controlled by Paragon or its Affiliates relating to (1) that [* * *], or (2) [* * *]. 1. 73 " Other Licensed Patents " means any Patents other than Licensed Antibody Patents Controlled by Paragon or its Affiliates as of the Effective Date or during the Term that (a) include a claim that expressly recites the sequence of a Licensed Antibody or Derived Antibody, and (b) are necessary to Develop, Manufacture or Commercialize Licensed Antibodies or Derived Antibodies in the Field in the Territory. Notwithstanding the foregoing, the Other Licensed Patents shall not include (i) Paragon Multispecific Patents, (ii) the Paragon Platform Patents (as defined in the Option Agreement), or (iii) any Patents that Cover (x) that [* * *], or (y) [* * *]. 1. 74 " Other Licensed Technology " means all (a) Other Licensed Know- How, and (b) Other Licensed Patents. 1. 75 " Paragon " has the meaning set forth in the Preamble. 1. 76 " Paragon Cross License Patents " means any Patents (other than Licensed Antibody Patents or Other Licensed Patents) Controlled by Paragon or its Affiliates as of the Effective Date or during the Term that Cover the composition of matter or method of treatment of the Licensed Antibodies. Notwithstanding the foregoing, the Paragon Cross License Patents shall not include (a) the Paragon Multispecific Patents, (b) the Paragon

Platform Patents (as defined in the Option Agreement), or (c) any Patents that Cover (i) [* * *], or (ii) [* * *]. 1. 77 " Paragon Indemnitee " has the meaning set forth in Section 9. 1. 1. 78 " Paragon Multispecific Antibody " means any Multispecific Antibody that is Developed, Manufactured, Commercialized or otherwise exploited by Paragon or its Affiliate or licensees (other than Oruka and its Affiliates and Sublicensees), excluding in each case any Oruka Multispecific Antibodies. 1. 79 " Paragon Multispecific Patents " means those Patents that Cover the composition of matter of, or any method of specifically making or using, a Paragon Multispecific Antibody, in each case excluding the Licensed Antibody Patents. 1. 80 " Paragon Patents " has the meaning set forth in Section 5. 2 (c). 1. 81 " Paragon Third Party Agreement " has the meaning set forth in Section 2. 8. 1. 82 " Parent Entity " has the meaning set forth in Section 1. 15. 1. 83 " Party " has the meaning set forth in the Preamble. 1. 84 " Patent Challenge " has the meaning set forth in Section 5. 3 (a). 1. 85 " Patent Infringement " has the meaning set forth in Section 5. 3 (a). 1. 86 " Patents " means (a) unexpired patents and patent applications, (b) any and all patent applications filed either from such patent or patent applications or from a patent application claiming priority from any of those, including divisionals, provisionals, continuations, continuations- in- part, and reissues, (c) substitutions, renewals, registrations, re- examinations, revalidations, extensions, supplementary protection certificates and the like of any such patents and patent applications, and (d) any and all foreign equivalents of the foregoing. 1. 87 " Phase I Trial " means a human clinical trial in any country of the type described in 21 C. F. R. § 312. 21 (a), or the foreign equivalent thereof, regardless of where such clinical trial is conducted. 1. 88 " Phase II Trial " means a human clinical trial in any country of the type described in 21 C. F. R. § 312. 21 (b), or the foreign equivalent thereof, regardless of where such clinical trial is conducted. 1. 89 " Phase III Trial " means a human clinical trial in any country of the type described in 21 C. F. R. § 312. 21 (c), or the foreign equivalent thereof, regardless of where such clinical trial is conducted. 1. 90 " Post- Effective Date Patents " has the meaning set forth in Section 5. 2 (b) (i). 1. 91 " Pre- Existing Entities " has the meaning set forth in Section 1. 3. 1. 92 " Product " means any product that comprises or contains any Licensed Antibody or Derived Antibody other than as part of a Multispecific Antibody or a Multispecific Product. 1. 93 " Prosecute " or " Prosecution " has the meaning set forth in Section 5. 2 (a). 1. 94 " Prosecuting Party " has the meaning set forth in Section 5. 2 (b) (iii). 1. 95 " Publication " has the meaning set forth in Section 6. 6 (b). 1. 96 " Receiving Party " has the meaning set forth in Section 1. 21. 1. 97 " Regulatory Approval " means all clearances, approvals (including approval of an MAA as well as any applicable pricing and / or reimbursement approvals), licenses, registrations or authorizations of any Regulatory Authority necessary to commercially distribute, sell and market a pharmaceutical product in a country or territory under this Agreement. 1. 98 " Regulatory Authority " means any supranational, multinational, federal, national, state, provincial or local regulatory agency, department, bureau or other Governmental Authority with authority over the clinical development, manufacture marketing or sale of an Oruka Product in a country or region, including the FDA in the United States and the EMA in Europe. 1. 99 " Reimbursement Obligation " has the meaning set forth in Section 2. 8. 1. 100 " Remaining Recovery " has the meaning set forth in Section 5. 3 (f). 1. 101 " Representatives " of a Party means such Party' s officers, directors, employees, contractors, subcontractors, agents and consultants. 1. 102 " Research Program " means the Research Program (as defined in the Option Agreement) conducted by the Parties pursuant to the Option Agreement with respect to the Licensed Target. 1. 103 " Research Program Materials " means the tangible materials resulting from the Research Program that are Controlled by Paragon or its Affiliates as of the Effective Date or during the Term that are listed in Exhibit C attached hereto, as may be amended in writing from time to time upon mutual agreement of the Parties. For clarity, Research Program Materials shall not include materials that are consumed or destroyed in the performance of the Research Program or that are not available to be transferred by Paragon to Oruka without violating the terms of any agreement or other arrangement with a Third Party. 1. 104 " Results " means all data, results, analysis, conclusions, outcomes, information, documentation and reports that are generated by or on behalf of Paragon in performance of the Research Program, excluding in each case any other Licensed Antibody Technology. 1. 105 " Retained IL- 23 Antibody Patents " means all Patents that Cover the composition of matter of, or any method of specifically making or using, the Retained IL- 23 Project Antibodies that in each case are owned by Paragon as of the Effective Date and are set forth on Exhibit E. 1. 106 " Retained IL- 23 Project Antibodies " has the meaning set forth in the Option Agreement. A list of the Retained IL- 23 Project Antibodies, identified by individual sequence identifier numbers, is set forth on Exhibit D. 1. 107 " Retained IL- 23 Project Antibody Licensee " means any assignee or licensee of Paragon with respect to Paragon' s rights in the Retained IL- 23 Project Antibodies and the Retained IL- 23 Antibody Patents. 1. 108 " Reversion Products " has the meaning set forth in Section 8. 5 (c). 1. 109 " Review Period " has the meaning set forth in Section 6. 6 (b). 1. 110 " ROFN Information " has the meaning set forth in Section 2. 7 (a). 1. 111 " ROFN Negotiation Period " has the meaning set forth in Section 2. 7 (c). 1. 112 " ROFN Period " has the meaning set forth in Section 2. 7 (a). 1. 113 " Royalty Payments " has the meaning set forth in Section 4. 2 (a). 1. 114 " Royalty Term " means, on an Oruka Product- by- Oruka Product and country- by- country basis, the period commencing on First Commercial Sale of the applicable Oruka Product in the applicable country in the Territory and ending, with respect to the particular Oruka Product and country at issue on the latest of the following dates: (a) the twelfth (12th) anniversary of the date of First Commercial Sale of such Oruka Product in such country; or (b) the expiration of the last- to- expire Valid Claim of a Licensed Antibody Patent or an Oruka Antibody Patent Covering the Manufacture, use or sale of such Oruka Product in the country at issue. 1. 115 " Sequence Information " means any files of Paragon containing all Licensed Antibody sequences generated under the Research Program. 1. 116 " Sublicensee " means any Affiliate of Oruka or any Third Party with respect to Oruka, to whom Oruka grants a sublicense of, or other authorization or permission granted under, the rights granted to Oruka in Section 2. 1. 1. 117 " Target " means a protein molecule that (a) is chemically distinct from other molecules, and (b) wherein a binding entity derives recognized therapeutic value from binding to such molecule. 1. 118 " Term " has the meaning set forth in Section 8. 1. 1. 119 " Territory " means worldwide. 1. 120 " Third Party " means any person or entity other than Paragon or Oruka or an Affiliate of either Paragon or Oruka. 1. 121 " Third Party Claim " has the meaning set forth in Section 9. 1. 1. 122 " Transfer Period " has the meaning set forth in Section 2. 5 (c). 1. 123 " US " or " United States " means the United States of America and its possessions and territories, including Puerto Rico. 1. 124 " Valid Claim " means, with respect to a particular country, a claim (including a process, use or composition of matter claim) of an issued and unexpired patent (or a supplementary protection certificate thereof) that has not (a) irretrievably lapsed or been abandoned, permanently revoked, dedicated to the public or disclaimed, or (b) been held invalid, unenforceable or not patentable by a court, governmental agency, national or regional patent office or other appropriate body that has competent jurisdiction, which holding, finding or decision is final and unappealable or unappealed within the time allowed for appeal. Article II LICENSES; TECHNOLOGY TRANSFER; MULTISPECIFIC ANTIBODIES. (e) Subject to the terms of this Agreement, Paragon hereby grants to Oruka a non- exclusive license, including the right to sublicense through multiple tiers, under the Paragon Cross License Patents to Develop, Manufacture, Commercialize or otherwise exploit the Licensed Antibodies solely in the Field in the Territory. (f) Subject to the terms of this Agreement, Oruka hereby grants to Paragon a non- exclusive license, including the right to sublicense through multiple tiers, under the Oruka Cross License Patents to Develop, Manufacture, Commercialize or otherwise exploit the Retained IL- 23 Project Antibodies solely in the Territory in the therapeutic area of inflammatory bowel disease. 2. 4 No Implied Licenses; Reservation of Rights. Except as expressly set forth herein, no right or license under any Patents, Know- How or Intellectual Property Right of either Party is granted or shall be granted by implication hereunder. All such rights or licenses are or shall be granted only as expressly provided in this Agreement, and each Party reserves to itself all rights not expressly granted under this Agreement. Notwithstanding anything to the contrary under this Agreement, Paragon retains rights under the Licensed Antibody Technology solely to perform its obligations and exercise its rights under this Agreement and the Option Agreement; provided, that during the Term, Paragon shall not, and shall ensure that its Affiliates do not, (a) use the Licensed Antibody Technology to, or (b) grant a license to a Third Party under the Licensed Antibody Technology to, Develop, Manufacture, Commercialize, or otherwise exploit the Licensed Antibodies or Derived Antibodies, in each case as part of a Product, in the Territory for the therapeutic area of inflammatory bowel disease; provided, further, that the foregoing proviso does not, and is not intended to, limit Paragon' s rights under Section 2. 6. Oruka acknowledges and agrees that it has no rights under this Agreement or the Option Agreement with respect to any Antibodies that were discovered, generated, identified or characterized by Paragon in the course of performing the Research Program (including the Retained IL- 23 Project Antibodies) other than the Licensed Antibodies and the Derived Antibodies. (b) Oruka has designated [* * *] Licensed Antibody or Derived Antibody as its lead compound and [* * *] Licensed Antibody or Derived Antibody as its backup compound, as set forth on Exhibit B (each such designated Licensed Antibody or Derived Antibody, a " Designated Multispecific Antibody "). Paragon' s rights under Section 2. 6 (a) shall expressly exclude the right to Develop, Manufacture, Commercialize or otherwise exploit (i) Multispecific Antibodies that have identical sequence identity within their variable regions as a Designated Multispecific Antibody, or (ii) Multispecific Products that comprise or contain any Multispecific Antibody referenced in clause (i). For the avoidance of doubt, if Paragon engaged in Development or Manufacture of a Multispecific Antibody that meets the criteria of clause (i) or (ii) above prior to the Effective Date, then Paragon shall not be in breach of this Agreement, provided that, Paragon ceases all such Development or Manufacture within [* * *] days following the Effective Date. (a) Commencing on the Effective Date and continuing until the [* * *] anniversary thereof (the " ROFN Period "), Paragon will promptly notify Oruka in writing if (i) Paragon has developed a descriptive research plan with respect to the Development of a Multispecific Antibody or a plan to license or grant rights in a Multispecific Antibody to a Third Party, or (ii) Paragon enters into [* * *] negotiations pursuant to an offer to or from any Third Party relating to the foregoing. Together with such notice, Paragon will provide to Oruka all material information and research plans developed by Paragon with respect to such Multispecific Antibody (the " ROFN Information "). Oruka will have [* * *] days from receipt of the ROFN Information to deliver a written notice to Paragon of Oruka' s desire to engage in negotiations for an agreement concerning the Development, or exclusive license or grant of rights to, such Multispecific Antibody. Article III DEVELOPMENT, MANUFACTURING & COMMERCIALIZATION. Article IV FINANCIAL TERMS. Annual Net Sales of the Products in a Given Calendar Year Royalty Rate Portion of Annual Net Sales of the Products in a given Calendar Year above $ 0 but up to and including $ [* * *] [* * *] % Portion of Annual Net Sales of the Products in a given Calendar Year of more than $ [* * *], up to and including $ [* * *] [* * *] % Portion of Annual Net Sales of the Products in a given Calendar Year of more than $ [* * *] [* * *] % (b) Upon reasonable advance written notice to Oruka, Paragon shall have the right to retain a nationally recognized (in the US) independent certified public accounting firm to perform on behalf of Paragon an audit, conducted in accordance with U. S. generally accepted accounting principles (GAAP), of such books and records of Oruka or its applicable Affiliates as may be reasonably necessary to verify the accuracy of any reports provided pursuant to Section 4. 4 hereunder for any Calendar Quarter in which an Oruka Product was sold, ending not more than [* * *] calendar months prior to the date of such request. Such audits shall be conducted during normal business hours, shall not occur more frequently than [* * *] in each Calendar Year and shall not be conducted more than [* * *] with respect to any reporting period, in each case other than for cause. All information disclosed or observed during any audit pursuant to this Section 4. 10 shall be the Confidential Information of Oruka, and Paragon shall cause the accounting firm to retain all such information as Confidential Information, including, if requested by Oruka, by requiring such accounting firm to enter into a customary confidentiality agreement with Oruka prior to the initiation of any such audit. (d) Paragon shall bear its internal expenses and the out- of- pocket costs for engaging such accounting firm in connection with performing such audits; provided, however, that if any such audit uncovers an underpayment by Oruka that exceeds [* * *] percent ([* * *] %) of the total owed for such payment or payment period, as applicable, then Oruka shall reimburse Paragon or its designee (s) for the amounts actually paid to such accounting firm for performing such audit. Article V INTELLECTUAL PROPERTY. 5. 1 Ownership. As between the Parties (a) Paragon solely owns the Licensed Antibody Technology, the Other Licensed Patents and the Retained IL- 23 Antibody Patents, (b) Oruka solely owns the Oruka Inventions, including any Derived Antibodies and Oruka Multispecific Antibodies to the extent they constitute Oruka Inventions, (c) each Party solely owns all Intellectual Property Rights owned or Controlled by such Party as of the Effective Date or that come into the ownership or control of such Party during the Term outside the scope of this Agreement, and (d) ownership of Inventions shall be determined in accordance with U. S. laws of inventorship. Other than rights granted to Oruka under this Agreement with respect to the Licensed Antibody Technology and the Other Licensed Patents, nothing in this Agreement shall affect Paragon' s rights in any Patents, Know- How or other Intellectual Property Rights owned or controlled by Paragon or its Affiliates, now or in the future. Other than rights granted to Paragon under Section 8. 5 (c) of this Agreement with respect to the Oruka Intellectual Property, nothing in the Agreement shall affect Oruka' s rights in any Patents, Know- How or other Intellectual Property Rights owned or controlled by Oruka or its Affiliates, now or in the future. (ii) As between the Parties, with respect to (x) any patent applications and resulting patents for Licensed Antibody Patents that were filed prior to the Effective Date, and (y) the Post- Effective Date Patents after the date on which the Final Deliverable (as defined in the Option Agreement) for the Research Program is delivered to Oruka, Oruka shall have the first right to prepare, file, Prosecute and maintain the Licensed Antibody Patents, in each case, at Oruka' s sole expense. Oruka shall provide Paragon (and, at the direction of Paragon, shall also provide directly to the Retained IL- 23 Project Antibody Licensee) with copies of all material correspondence from and to any patent office relating to such Licensed Antibody Patents, and Oruka shall provide Paragon (and, at the direction of Paragon, shall also provide directly to the Retained IL- 23 Project Antibody Licensee) with drafts of all proposed filings to any patent office with respect to such Licensed Antibody Patents before submission of such filings, with reasonably adequate time for Paragon' s (and the Retained IL- 23 Project Antibody Licensee' s) review and comment, which review shall be at Paragon' s (and the Retained IL- 23 Project Antibody Licensee' s) sole expense. (iii) Each Party, when acting as the prosecuting Party (in such capacity, the " Prosecuting Party ") will take into consideration the non- Prosecuting Party' s reasonable comments (and, if Oruka is the Prosecuting Party, the Retained IL- 23 Project Antibody Licensee' s reasonable comments) prior to submitting such filings. At the Prosecuting Party' s request, the non- Prosecuting Party will sign all documents and take any other actions required for filing, maintenance and grant of Licensed Antibody Patents. Oruka shall reimburse Paragon for any costs and expenses actually incurred by Paragon to the extent Paragon is prosecuting or maintaining any Licensed Antibody Patents. (c) Prosecution by Paragon. Except with respect to Licensed Antibody Patents (which are addressed in Section 5. 2 (b)), Paragon (directly or indirectly through the Retained IL- 23 Project Antibody Licensee) shall be solely responsible for, and have sole discretion over, preparing, filing, Prosecuting and maintaining any Patents (including the Other Licensed Patents, Paragon Multispecific Patents and Retained IL- 23 Antibody Patents) that it owns in whole or in part or otherwise Controls (the " Paragon Patents "). Paragon' s Prosecution of any Paragon Patents shall be at Paragon' s sole expense. Notwithstanding the foregoing, in Prosecuting any Paragon Multispecific Patents, Paragon hereby agrees that during the Term, neither Paragon nor any of its Affiliates or licensees will file, or assist any Third Party in filing, any Patent that includes a claim that expressly recites the sequence of a Licensed Antibody or Derived Antibody other than as part of a Paragon Multispecific Antibody. In the Prosecution by Paragon or the Retained IL- 23 Project Antibody Licensee of any Retained IL- 23 Antibody Patents, (i) Paragon shall provide or cause to be provided (directly or indirectly through the Retained IL- 23 Project Antibody Licensee) to Oruka copies of all material correspondence from and to any patent office relating to such Retained IL- 23 Antibody Patents, and (ii) Paragon shall provide or cause to be provided (directly or indirectly through the Retained IL- 23 Project Antibody Licensee) to Oruka drafts of all proposed filings to any patent office with respect to such Retained IL- 23 Antibody Patents before submission of such filings, with reasonably adequate time for Oruka' s review and comment, and Paragon or the Retained IL- 23 Project Antibody Licensee, as applicable, will take into consideration Oruka' s reasonable comments prior to submitting such filings. (f) Disclosure of Antibody Patents. Upon the request of Paragon, Oruka shall deliver to Paragon a list of the then- existing Oruka Antibody Patents. Upon the request of Oruka, Paragon shall deliver to Oruka a list of the then- existing Retained IL- 23 Antibody Patents. (a) Notice of Patent Infringement and Patent Challenge. Each Party shall give the other Party notice of any known or suspected infringement by a Third Party (" Patent Infringement ") of any Licensed Antibody Patent and any known or suspected challenge by a Third Party against the validity or enforceability (" Patent Challenge ") of any Licensed Antibody Patent or Retained IL- 23 Antibody Patent within [* * *] days after such Patent Infringement or Patent Challenge comes to such Party' s attention. (b) Oruka' s First Right to Enforce or Defend. Oruka shall have the first right, but not the obligation, to bring and control any legal action, including by declaratory judgment action, patent litigation or similar proceeding, in connection with any Patent Infringement or Patent Challenge with respect to the Licensed Antibody Patents in the Territory at its own expense and discretion as it reasonably determines appropriate. Oruka shall keep Paragon (and, at the direction of Paragon, the Retained IL- 23 Project Antibody Licensee) informed and reasonably consult with Paragon (and, at the direction of Paragon, the Retained IL- 23 Project Antibody Licensee) in the course of such legal action. Paragon shall have the right to be represented in any such legal action by counsel of its choice at its own expense. (c) Paragon' s First Right to Enforce or Defend. Paragon (or, at Paragon' s discretion, the Retained IL- 23 Project Antibody Licensee) shall have the sole right, but not the obligation, to bring and control any legal action, including by declaratory judgment action, patent litigation or similar proceeding, in connection with any Patent Infringement or Patent Challenge with respect to the Paragon Patents in the Territory at its own expense and discretion as it reasonably determines appropriate. Paragon (directly or indirectly through the Retained IL- 23 Project Antibody Licensee) shall keep Oruka informed and reasonably consult with Oruka in the course of legal action to enforce or defend any Retained IL- 23 Antibody Patent. (d) Settlement. In connection with any such legal action or proceeding, Oruka shall not enter into any settlement admitting the invalidity or unenforceability of Licensed Antibody Patents without the prior written consent of Paragon (such consent not to be unreasonably conditioned, withheld, or delayed), and Paragon shall not enter into any settlement admitting the invalidity or unenforceability of the Retained IL- 23 Antibody Patents without the prior written consent of Oruka (such consent not to be unreasonably conditioned, withheld, or delayed). Article VI PROTECTION OF CONFIDENTIAL INFORMATION. Article VII REPRESENTATIONS, WARRANTIES AND COVENANTS. Article VIII TERM; TERMINATION. (c) Upon Paragon' s written request to Oruka (which must be provided to Oruka within [* * *] days after the effective date of termination), Paragon and Oruka shall [* * *] discuss [* * *], for a period of up to [* * *] days following such written request, terms and conditions under which Oruka may be willing to grant to Paragon [* * *], [* * *] license under the Oruka Intellectual Property to Develop, Manufacture, Commercialize or otherwise exploit the terminated Oruka Products in the Field in the terminated countries that were the subject of any Development, Manufacturing or Commercialization activities performed by Oruka or its Affiliates under this Agreement prior to such termination, (" Reversion Products "), as well as the potential transfer of materials, ongoing clinical trials, and applicable regulatory filings and relevant data generated by Oruka with respect to the Reversion Products and necessary for the continued Development, Manufacture, Commercialization and exploitation of such Reversion Products, such agreement to include commercially reasonable financial and other terms, which terms shall take into consideration Oruka' s contributions made in the Development, Manufacture, Commercialization and other exploitation of the Reversion Products, provided, that Oruka is under no obligation to enter into such license. Article IX INDEMNIFICATION. 9. 3 Indemnification Procedures. The Party claiming indemnity under this Article IX (the " Indemnified Party ") will give written notice to the Party from whom indemnity is being sought (the " Indemnifying Party ") promptly after learning of the Third Party Claim for which indemnity is being sought (" Claim "). The Indemnifying Party' s obligation to defend, indemnify and hold harmless pursuant to Section 9. 1 or Section 9. 2, as applicable, will be reduced to the extent the Indemnified Party' s delay in providing notification pursuant to the previous sentence results in material prejudice to the Indemnifying Party; provided, however, that the failure by an Indemnified Party to give such notice or otherwise meet its obligations under this Section 9. 3 will not relieve the Indemnifying Party of its indemnification obligation under this Agreement. At its option, the Indemnifying Party may assume the defense and have exclusive control, at its own expense, of any Claim for which indemnity is being sought by giving written notice to the Indemnified Party within [* * *] days after receipt of the notice of the Claim. The Indemnified Party will provide the Indemnifying Party with reasonable assistance, at the Indemnifying Party' s expense, in connection with the defense. The Indemnified Party may participate in and monitor such defense with counsel of its own choosing at its sole expense; provided, however, the Indemnifying Party will have the right to assume and conduct the defense of the Claim with counsel of its choice. The Indemnifying Party will not settle any Claim without the prior written consent of the Indemnified Party, not to be unreasonably withheld, unless the settlement involves only the payment of money. The Indemnified Party will not settle any such Claim without the prior written consent of the Indemnifying Party. If the Indemnifying Party does not assume and conduct the defense of the Claim as provided above, (i) the Indemnified Party may defend against, and consent to the entry of any judgment or enter into any settlement with respect to the Claim in any manner the Indemnified Party may deem reasonably appropriate, provided, that the Indemnified Party reasonably consults with the Indemnifying Party prior to entering into any settlement, and (ii) the Indemnified Party reserves any right it may have under this Article IX to obtain indemnification from the Indemnifying Party. Article X MISCELLANEOUS. (ii) If, within [* * *] days of initial receipt of the Notice of Dispute, the Dispute has not been resolved, or if, for any reason, the meeting described in Section 10. 7 (a) (i) hereof has not been held within [* * *] days of initial receipt of the Notice of Dispute, then the Parties agree that such Dispute will be finally resolved through binding arbitration to be administered by JAMS pursuant to its Comprehensive Arbitration Rules and Procedures and in accordance with the Expedited Procedures in those Rules (the " JAMS Rules "), as specifically modified by the provisions of this Section 10. 7 (a) (ii) and Section 10. 7 (a) (iii). (iii) The arbitration will be conducted by a panel of three arbitrators. Within [* * *] days after the initiation of the arbitration, each Party will nominate one person to act as arbitrator, and the two arbitrators so named will then jointly appoint the third arbitrator within [* * *] days of their appointment, who will serve as chairman of the panel. All three arbitrators must be independent Third Parties having at least [* * *] years of dispute resolution experience (which may include judicial experience) or legal or business experience in the biotech or pharmaceutical industry. If either Party fails to nominate its arbitrator, or if the arbitrators selected by the Parties cannot agree on a person to be named as chairman within such [* * *]- day period, JAMS will make the necessary appointments for such arbitrator (s) or the chairman. Once appointed by a Party, such Party will have no ex parte communication with its appointed arbitrator. Paragon Therapeutics, Inc. Oruka Therapeutics, Inc. By: / s / K. Evan Thompson By: / s / Lawrence Klein Name: K. Evan Thompson Name: Lawrence Klein Title: Chief Operating Officer Title: Chief Executive Officer [Signature Page to License Agreement] Exhibit 10. 32 [* * *] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. CELL LINE LICENSE AGREEMENT This Cell Line License Agreement (" Agreement "), effective as of March 4, 2024 (" EFFECTIVE DATE "), is entered and made by and between WuXi Biologics Ireland Limited, having an address at Dundalk Science & Technology Park, Mullagharlin, Dundalk, Co Louth A91 X56F, Ireland (collectively, " WuXi Biologics ") and Oruka Therapeutics, Inc., a Delaware corporation, with an office at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453 (" Licensee "). WuXi Biologics and Licensee may be referred to herein individually as a " Party " and collectively as the " Parties. " The Parties agree as follows: 1. Definitions1. 1 " Affiliate " of a person means any other person that directly or indirectly Controls, is Controlled by, or is under common Control with, the person. 1. 2 " Client Product " means [* * *] of interest to Licensee, which is designated by the Licensee to be produced by the Licensed Cell Line. Each different Client Product covered under this Agreement shall be specified in Appendix I. An amendment to this Agreement is required for each new Client Product produced by the Licensed Cell Line. 1. 3 " Confidential Information " of a Party (the " Disclosing Party ") means all non- public scientific, technical, financial regulatory or business information and materials disclosed by or on behalf of the Disclosing Party to the other Party (the " Receiving Party ") or its Related Persons (defined below) in connection with this Agreement. Confidential information shall be identified as confidential in writing or, if disclosed verbally or by observation, summarized in writing and submitted to the Receiving Party within [* * *] of the oral or visual disclosure thereof; provided, however, information need not be labeled or marked " confidential " to be deemed Confidential Information hereunder, if under the circumstances it is, or should be, understood to be confidential. The Confidential Information of both Parties includes the existence, terms and objectives of this Agreement, and the nature of any dispute and the outcome of any arbitration proceedings arising out of or in connection with this Agreement. 1. 4 " Construct " means a [* * *] developed by WuXi Biologics that is used for delivering genetic code and for transfecting and / or transforming the Host Cell Line for purposes of creating the Licensed Cell Line. 1. 5 " Control " over an entity means (a) owning 50 % or more of the voting securities or other ownership interests of such entity or (b) having the power to direct the management or policies of such entity. 1. 6 " Drug Product " means the final dosage form which contains Client Product, in association with other active or inactive ingredients. 1. 7 " Drug Substance " means bulk Client Product, which has not yet been packaged into its final dosage form. 1. 8 " Host Cell Line " means the proprietary host cell line developed by WuXi Biologics, and designated by WuXi Biologics as the [* * *], that is used to make the Licensed Cell Line. 1. 9 " Licensed Cell Line " means a transformed or transfected (using WuXi Biologics' Construct (s)) version of the Host Cell Line that produces the Client Product. 1. 10 " Licensed Know- How " means any know- how and non- public information owned or controlled by WuXi Biologics that is used or incorporated in the Process, and that is necessary or useful to operate the Process as further described in the Technology Transfer Package. The word " control " when used in connection with Licensed Know- How includes both exclusively and non- exclusively licensed know- how and non- public information, as well a right of WuXi Biologics to transfer such know- how and non- public information to Licensee. As used in this definition " know- how " means all confidential and proprietary commercial, technical, scientific and other know- how and information, trade secrets, knowledge, technology, methods, processes, practices, formulae, instructions, skills, techniques, procedures, experiences, ideas, technical assistance, designs, drawings, assembly procedures, computer programs, specifications, data and results (including biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, preclinical, clinical, safety, manufacturing and quality control data and know- how, and including study designs and protocols). 1. 11 " Marketing Authorization Approval " means, with respect to a country or extra- national territory, any and all approvals (including a New Drug Application or Biologics License Application approved by the FDA), licenses, registrations or authorizations of any Regulatory Authority necessary in order to commercially distribute, sell or market a product in such country or some or all of such extra- national territory, including any pricing or reimbursement approvals. 2 of 141. 12 " Materials " means the biological materials, including the Licensed Cell Line, provided to Licensee pursuant to the license granted under this Agreement. 1. 13 " Media and Feeds " means any proprietary media and feeds used in the Process. 1. 14 " Net Sales " means the amount [* * *] by Licensee and its Affiliates or sublicensees for bona fide sales of Client Product to a third- party [* * *], less: ● [* * *]; ● [* * *]; and ● [* * *]. Net Sales will not include [* * *]. Such amounts will be determined from the books and records of [* * *], maintained in accordance with GAAP consistently applied. 1. 15 " Process " means a process for manufacture of Client Product utilizing Licensed Know- How, Materials and Media and Feeds as described in the Technology Transfer Package. 1. 16 " Regulatory Authority " means any applicable supranational, national, regional, state or local regulatory agency, department, bureau, commission, council, or other government entity involved in regulating development of and granting regulatory approval for a pharmaceutical product, including the FDA and EMA. 1. 17 " Related Persons " means a Party' s Affiliates and their respective directors, officers, employees and agents. 1. 18 " Research Cell Bank " is a [* * *]. 3 of 141. 19 " Technology Transfer Package " means all information and data describing the Process, together with all Licensed Know- How, Materials and Media and Feeds necessary or useful for the development and manufacture of Client Product using the Licensed Cell Line and / or the Process. 1. 20 " Third Party " means any person other than the Parties to this Agreement. 1. 21 " Third Party Manufacturer " means (i) a Third Party whose primary business is contract manufacturing, or (ii) a Third Party who has a contractual arrangement with Licensee or with a sublicensee of Licensee that includes manufacturing of Client Product and / or Drug Product by such Third Party for Licensee or such sublicensee. 2. License2. 1WuXi Biologics hereby grants to Licensee and its Affiliates a non- exclusive, worldwide license, with the right to grant sublicenses as provided in Section 2. 3, to the Licensed Know- How and the Licensed Cell Line, Materials, and Media and Feeds, for the purpose of conducting the Process, including the following licensed activities: i. to make, have made, import, sell and otherwise use Client Product; andii. to make, have made, use, sell, have sold, offer for sale, import, keep and otherwise deal in and further commercialize Drug Substance and Drug Product for any and all purposes. 2. 2The Licensee or its Affiliates may contract with a Third Party Manufacturer for the limited purpose of developing and manufacturing Client Product on behalf of the Licensee or its Affiliates, provided that, such Third Party Manufacturers are bound by the contract to comply with the confidentiality and use terms of this Agreement, and that the Licensee or its Affiliates will remain liable for any Third Party Manufacturers' breach of this Agreement. 2. 2. 1For the benefit of doubt, a Third Party Manufacturer cannot manufacture Client Product, Drug Substance or Drug Product utilizing the Licensed Cell Line and Licensed Know- How without first being contracted with a Licensee, its Affiliates or sublicensee. 2. 2. 2A Third Party Manufacturer that has been granted a sublicense cannot grant, issue or transfer a sublicense to another Third Party. 4 of 142. 3Subject to the terms and conditions of this Agreement, Licensee shall have the right to grant sublicenses to a Third Party for the rights granted to Licensee under this Agreement. Each sublicense agreement shall be in writing and provided that the applicable sublicensee is bound by all applicable terms and conditions of this Agreement, and Licensee or its Affiliates shall remain liable for any sublicensee' s breach of this Agreement. Licensee shall inform WuXi Biologics in writing any and all such sublicenses. [* * *]. Licensee will notify WuXi Biologics in writing of any sublicense agreement with a sublicensee within [* * *] of the execution of such agreement. Any sublicense granted by Licensee to any rights licensed to it hereunder will terminate [* * *] upon the termination of the license by WuXi Biologics under the terms of this Agreement; provided, that such sublicensed rights will not terminate if, as of the effective date of such termination, a sublicensee is not in material default of its obligations under its sublicense agreement, and within [* * *] of such termination, the sublicensee agrees in writing to be bound directly to WuXi Biologics under a license agreement substantially similar to this Agreement with respect to the rights sublicensed hereunder. 2. 4Except as expressly provided in this Agreement, nothing in this Agreement shall be deemed to have granted Licensee (by implication, estoppel or otherwise) any right, title, license or other interest in or with respect to any intellectual property, Know- How or information owned or controlled by WuXi Biologics. 2. 5Invoicing of License fees will commence [* * *]. 3. Transfer of Materials and Licensed Know- How WuXi Biologics shall notify Licensee in writing within [* * *] following the date on which WuXi Biologics completes transfection of the Host Cell Line to generate the Licensed Cell Line. Thereafter, [* * *] upon written request and the completion of due payment by Licensee (and in any event within [* * *] following designation of a Third Party Manufacturer), WuXi Biologics shall disclose, make available, and conduct a full transfer, and shall cause its Affiliates to disclose, make available, and conduct a full transfer to Licensee, its Affiliates, or any one or more of its Third Party Manufacturers designated by Licensee, all Materials and Licensed Know- How, that is necessary or reasonably useful for Licensee and Third Party Manufacturers to solely develop and manufacture the Client Product. The Parties shall agree to a schedule for such transfer of the Materials and Licensed Know- How. WuXi Biologics will provide [* * *] assistance to enable such Third Party Manufacturer to manufacture Client Product, provided, however, it is the Third Party Manufacturer' s full responsibility to manufacture such Client Product after the transfer, WuXi Biologics will not be responsible for the Third Party Manufacturer' s success or failure to manufacture any Client Products. Initiation of such technology transfer will be determined by Licensee. WuXi Biologics will be reimbursed for such activities by Licensee on an [* * *] rate. WuXi Biologics will provide [* * *] requested ongoing technical support if requested by Licensee with such support reimbursed [* * *] rate basis. 5 of 144. License Fee As consideration for the license granted in Section 2 of this Agreement, and the representation and warranty set forth in Section 10 of this Agreement, Licensee agrees to pay WuXi Biologics a fixed non- creditable, non- refundable license fee of USD [* * *] for the Licensed Cell Line used in Client Product. 5. Cell Line Royalties. If Licensee manufactures [* * *] commercial supplies of the applicable Drug Substance using manufacturing facilities other than WuXi Biologics' or its Affiliates' manufacturing facilities, Licensee shall pay to WuXi Biologics a Royalty of [* * *] on the applicable Drug Product' s global Net Sales sold by Licensee, its Affiliates, or sublicensees, paid to WuXi Biologics [* * *]. If Licensee manufactures [* * *] commercial supplies of the applicable Drug Substance using WuXi Biologics' or its Affiliates' manufacturing facilities, the Royalty shall be [* * *], depending on [* * *]. If Licensee manufactures all of its commercial supplies of the applicable Drug Substance by WuXi Biologics or its Affiliates, no Royalty is applicable and no Royalty payment shall be due hereunder. 6. Payment Terms Licensee shall pay WuXi Biologics' undisputed invoice (s) within [* * *] of receipt by Licensee. Such payments will be made by wire transfer to the account designated by WuXi Biologics. Invoices must be submitted, and payment must be made, [* * *]. 7. Bank Account Details Unless the Parties otherwise mutually agree in writing, and such mutual agreement is set forth in a particular invoice, Licensee shall pay each invoice by wire transfer to the account designated by WuXi Biologics. With respect to Net Sales invoiced in U. S. dollars, the Net Sales and the amounts due hereunder will be expressed in U. S. dollars. With respect to Net Sales invoiced in a currency other than U. S. dollars, payments will be calculated based on standard methodologies employed by Licensee or its Affiliates or sublicensees for consolidation purposes for the [* * *] for which remittance is made for Royalties. 6 of 148. Restriction Licensee agrees that no attempt will be made by or on behalf of Licensee to modify or reverse engineer the Licensed Cell Line or attempt to reverse engineer, recreate or assemble the Construct (s). Licensee shall only use the Licensed Cell Line in the way as permitted by this Agreement and shall not use or have used the Licensed Cell Line for any purpose other than as provided hereunder, including operating the Process, the manufacture of Client Product, Drug Substance and Drug Product, and for other purposes reasonably related to securing Marketing Authorization Approval for the Client Product and / or Drug Product. Licensee shall not transfer the Licensed Cell Line to any Third Party except to a permitted sublicensee, as described in Section 2. 2 above, permitted Third Party Manufacturer, or an assignee. 9. Indemnity9. 1Licensee agrees to indemnify, hold harmless and defend WuXi Biologics, its Affiliates, and their respective directors, officers, employees and agents harmless (collectively, " WuXi Indemnitees ") from and against any and all liabilities and damages (including reasonable attorneys' fees) resulting from any and all claims from any Third Party (" Claims ") to the extent arising from the use of the Licensed Cell Line, Client Product, Drug Substance or Drug Product by Licensee; except to the extent WuXi Biologics is obligated to indemnify Licensee in accordance with Section 9. 2 of this Agreement, and provided further that Licensee shall have no obligation to indemnify any such Claims that arise from WuXi Biologics' (i) negligence or intentional misconduct in connection with the Licensed Cell Line (ii) material breach of this Agreement (including the representations and warranties set forth in Section 10); or (iii) Host Cell Line components of the Licensed Cell Line or any Media and Feeds. 9. 2WuXi Biologics will indemnify Licensee, its Affiliates, its sublicensees and their respective directors, officers, employees and agents, and their respective successors, heirs and assigns (collectively, " Licensee Indemnitees "), and defend and hold each of them harmless, from and against any and all Losses in connection with any and all Third- Party Claims against Licensee Indemnitees to the extent arising from or occurring as a result of: (i) the breach by WuXi Biologics of any provision of this Agreement; or (ii) any negligence or willful misconduct on the part of any WuXi Indemnitee in connection with the Host Cell Line components of the Licensed Cell Line, except in each case to the extent Licensee is obligated to indemnify WuXi Biologics in accordance with Section 9. 1 of this Agreement. 9. 3Each party must notify the other party within [* * *] of receipt of any claims made for which the other party might be liable hereunder. The indemnifying party will have the sole right to defend, negotiate, and settle such claims. The indemnified party will be entitled to participate in the defense of such matter and to employ counsel at its expense to assist in such defense. No compromise or settlement of any Claim may be made by the indemnifying Party without the indemnified Party' s written consent; provided, however, that the indemnifying party will have final decision- making authority regarding all aspects of the defense of any claim. The party seeking indemnification will provide the indemnifying party with such information and assistance as the indemnifying party may reasonably request, at the expense of the indemnifying party. 7 of 149. 4Limitation of Liability. NEITHER PARTY WILL BE LIABLE UNDER ANY LEGAL THEORY (WHETHER TORT, CONTRACT OR OTHERWISE) FOR SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, HOWEVER CAUSED, EVEN IF THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, EXCEPT AS A RESULT OF A BREACH OF THE CONFIDENTIALITY AND NON- USE OBLIGATIONS IN SECTION 11. NOTHING IN THIS SECTION 9. 4 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY. 10. Representations and Warranties10. 1WuXi Biologics represents and warrants that: (i) it is a corporation duly organized validly existing and in good standing under the laws of the Republic of Ireland; (ii) the execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on the part of WuXi Biologics; (iii) the performance of WuXi Biologics' obligations under this Agreement will not conflict with its charter documents or result in a material breach of any agreements, contracts or other arrangements to which it is a party; (iv) WuXi Biologics will not before the termination of this Agreement enter into any agreements, contracts or other arrangements that would be materially inconsistent with its obligations under this Agreement; (v) WuXi Biologics has sufficient facilities, experienced personnel and other capabilities reasonably suited to enable it to perform its obligations under this Agreement; (vi) WuXi Biologics has the right to grant the licenses or sublicenses, as the case may be, therefor granted under this Agreement; (vii) WuXi Biologics is the sole and exclusive owner of the Licensed Know- how and Licensed Cell Line, or otherwise has the right to license the Licensed Know-how and Licensed Cell Line and grant rights to Licensee as set forth in this Agreement and during the Term of the Agreement, (viii) to the best of its knowledge WuXi Biologics is and will remain entitled to grant to Licensee the licenses and rights specified or contemplated by this Agreement, and to the Licensed Know- How, (ix) as of the Effective Date, neither WuXi Biologics nor any of its Affiliates has received any notice challenging WuXi Biologics' ownership or right to use the Licensed Know- How in relation to the Licensed Cell Line and, Host Cell Line component of the Licensed Cell Line, (x) to the best of WuXi Biologics' s knowledge, there are no valid grounds for any claim against WuXi Biologics or any of its Affiliates except for any claims caused by Licensee' s DNA sequence related to the Client Product incorporated into the Licensed Cell Line. 8 of 1410. 2Licensee represents and warrants that: (i) it is a corporation duly organized validly existing and in good standing under the laws of the Commonwealth of Massachusetts; (ii) the execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on the part of Licensee; (iii) the performance of Licensee' s obligations under this Agreement will not conflict with its charter documents or result in a material breach of any agreements, contracts or other arrangements to which it is a party; (iv) Licensee has sufficient facilities, experienced personnel and other capabilities reasonably suited to enable it to perform its obligations under this Agreement; and (v) Licensee will not before the termination of this Agreement enter into any agreements, contracts or other arrangements that would be materially inconsistent with its obligations under this Agreement. 10. 3Disclaimer of Warranties. OTHER THAN AS PROVIDED IN THIS AGREEMENT, THE LICENSED KNOW- HOW, AND LICENSED CELL LINES ARE PROVIDED AND LICENSED TO LICENSEE " AS IS ", THE PARTIES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT THERETO OR TO THE PRODUCTS, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSEVALIDITY OF THE RIGHTS LICENSED HEREUNDER, OR NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 11. Confidentiality11. 1Subject to the exceptions listed below, during the term of this Agreement and for [* * *] thereafter, the Receiving Party shall, and shall ensure that its Related Persons will, (a) maintain the Disclosing Party' s Confidential Information in confidence, (b) not use such Confidential Information other than in connection with this Agreement, and (c) not disclose such Confidential Information to any Third Party other than (i) those of its Related Persons that have a need to know such Confidential Information in connection with the Activities conducted pursuant to the Agreement and are obligated to maintain such Confidential Information in confidence and (ii) to the extent required by applicable law or judicial order, or to the extent reasonably necessary to prosecute or defend litigation or arbitration in relation to this Agreement, and, in either case, only after the Receiving Party gives the Disclosing Party [* * *] advance written notice of such requirement and [* * *] cooperates with the Disclosing Party' s efforts to limit or avoid such disclosure, to seek a protective order or secure confidential treatment of the Confidential Information, and / or to seek any other remedies available to the Disclosing Party at law or in equity. Notwithstanding the foregoing, the existence of this Agreement and its non- technical terms may be disclosed confidentially in connection with a potential financing, collaboration or acquisition or in discussion with a potential acquirer of Client Product. 9 of 1411. 2The Receiving Party' s obligations set forth in Section 11. 1 do not apply to Confidential Information if (a) the information is public knowledge or becomes public knowledge after disclosure through no act or omission of the Receiving Party or any of its Related Persons, (b) the information can be shown by the Receiving Party to have been lawfully in its possession prior to disclosure, (c) the information was rightfully received on a non- confidential basis from a Third Party that was not obligated to maintain the information in confidence, or (d) the Receiving Party can show that equivalent information was developed independently by the Receiving Party without reference to the Disclosing Party' Confidential Information. 11. 3Licensee may disclose the Confidential Information of WuXi Biologics to a Third Party for the purpose of exercising Licensee' s license rights hereunder (including disclosure to potential Third Party sublicensees), provided that Licensee shall, prior to such disclosure, ensure that each Third Party to which disclosure is to be made is made aware of the obligations contained in this Agreement and agrees to be subject to obligations of confidentiality and non- use no less onerous than those contained in this Agreement. Any breaches of the obligations of confidentiality and non- use contained in this Agreement by such Third Party shall be treated as a breach of such obligations by Licensee. 11. 4Notwithstanding anything to the contrary in this Agreement, a Party may disclose this Agreement and its terms, and material developments or material information generated under this Agreement, in securities filings with the U. S. Securities and Exchange Commission (or equivalent foreign agency) and any rules of stock exchanges where the Parties may be listed to the extent required by applicable law after complying with the procedure set forth in this Section 11. 4. In such event, unless otherwise required to comply with applicable law, the Party seeking such disclosure will prepare a draft confidential treatment request and proposed redacted version of this Agreement to request confidential treatment for this Agreement, and the other Party will [* * *] give its input in a [* * *] in order to allow the Party seeking disclosure to file its request within the timelines proscribed by applicable laws and regulations. The Party seeking such disclosure shall exercise [* * *] to obtain confidential treatment of this Agreement from the U. S. Securities and Exchange Commission (or equivalent foreign agency) as represented by the redacted version reviewed by the other Party. 11. 5The provisions of this Section 11 shall survive termination or expiry of this Agreement. 10 of 1412. Termination12. 1Voluntary Termination by Licensee. Licensee shall have the right to terminate this Agreement upon [* * *] prior written notice to WuXi Biologics, and upon payment of all undisputed amounts due to WuXi Biologics through such termination effective date. 12. 2Termination for Default (a) Nonpayment. In the event Licensee fails to pay any undisputed amounts due and payable to WuXi Biologics hereunder, and fails to make such payments within thirty (30) days after receiving written notice of such failure, WuXi Biologics may terminate this Agreement [* * *] upon written notice to Licensee. (b) Material Breach. In the event Licensee commits a material breach of its obligation under this Agreement and fails to cure that breach within [* * *] after receiving written notice thereof, WuXi Biologics may terminate this Agreement [* * *] upon written notice to Licensee. 12. 3Termination Upon Bankruptcy. If either Party makes an assignment for the benefit of creditors, appoints or suffers appointment of a receiver or trustee over all or substantially all of its property, files a petition or commences a proceeding under any bankruptcy or insolvency act in any state or country or has any such petition or application filed against it which is not discharged within [* * *] of the filing thereof, then the other Party may thereafter terminate this Agreement effective [* * *] upon written notice to such Party. All rights and licenses granted under or pursuant to this Agreement by WuXi Biologics are, and will otherwise be deemed to be, for purposes of the relevant provisions of the Bankruptcy and Insolvency Act, R. S. C. 1985, c. B- 3 (" BIA "), including Sections 65. 11 (7), 65. 13 (9), 72. 1 and 246. 1 of the BIA; and the relevant provisions of the Companies' Creditors Arrangement Act, R. S. C. 1985, c. C- 36 (" CCAA "), including Sections 32 (6) and 36 (8) of the CCAA (the BIA and CCAA being referred to collectively as the " Insolvency Legislation "), a grant of a " right to use " " intellectual property " as used in the Insolvency Legislation. The Parties agree that Licensee and its Affiliates and sublicensees, as licensees of such rights under this Agreement, will retain and may fully exercise all of their rights and elections under the Insolvency Legislation subject to the payment of amounts provided for herein. Without limiting Licensee' s rights under the Insolvency Legislation, if WuXi Biologics becomes insolvent or makes an assignment for the benefit of its creditors or there is filed by or against it any bankruptcy, receivership, reorganization or similar proceeding pursuant to or under the Insolvency Legislation or otherwise, Licensee will be entitled to a copy of any and all information specified in the Technology Transfer Package unless WuXi Biologics, or its trustee or receiver, elects within [* * *] to continue to perform all of its obligations under this Agreement. 12. 4Expiration or termination of this Agreement for any reason will not relieve either party of any obligation accruing prior to such expiration or termination, including section 5 (Cell Line Royalties) shall survive termination or expiry of this Agreement. 11 of 1413. Miscellaneous. 13. 1Assignment. This Agreement may not be assigned or otherwise transferred by either Party (subject to Licensee' s right to sublicense its rights hereunder) without the prior written consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed; provided, however, that a Party may, without such consent, assign this Agreement in its entirety (a) to an Affiliate, or (b) to a Third Party in connection with a merger, acquisition, consolidation or a sale involving all or substantially all of the assets or business of such Party. Any attempted assignment or transfer in violation of this Section 13. 1 shall be void. 13. 2Regulatory Assistance. WuXi Biologics will provide assistance to Licensee, and any sublicensee, in respect of Licensee' s or such sublicensee' s regulatory filing activities for the Client Product and / or Drug Product, at Licensee' s or such sublicensee' s reasonable cost and expense on [* * *] rate. 13. 3Governing Law. The laws of the State of New York, USA, without regard to any choice of law principle that would require the application of the law of another jurisdiction, govern all matters relating to this Agreement and the enforcement thereof. The parties expressly reject any application to this Agreement of (a) the United Nations Convention on Contracts for the International Sale of Goods; and (b) the 1974 Convention on the Limitation Period in the International Sale of Goods, as amended by that certain Protocol, done at Vienna on April 11, 1980. 13. 4Arbitration. The parties shall engage in good faith consultation to resolve any dispute arising out of or in connection with this agreement. Such consultation will begin [* * *] after one party has delivered to the other party a request for consultation. If the dispute cannot be resolved within [* * *] following the date on which the request for consultation is delivered, then either party may submit the dispute to JAMS International Arbitration Rules (" Arbitration "). The Arbitration tribunal will consist of three arbitrators. Within [* * *] after the commencement of the Arbitration, each Party shall select one person to act as arbitrator, each of whom must be a practicing or retired attorney or judge have at least [* * *] of litigation experience within the biopharmaceutical industry. The two arbitrators so selected shall select the chair within [* * *] of the commencement of the Arbitration, whom must a practicing or retired attorney or judge have at least [* * *] of litigation experience within the biopharmaceutical industry. If the arbitrators selected by the Parties are unable or fail to agree upon the third arbitrator within the allotted time, the third arbitrator shall be appointed by JAMS in accordance with the JAMS International Arbitration Rules. All arbitrators shall serve as neutral, independent and impartial arbitrators. (ii) The Arbitration shall be conducted in accordance with the expedited procedures set forth in the JAMS International Arbitration Rules. The place of arbitration will be Manhattan, New York. The official language of the arbitration will be English. The arbitration proceedings will be confidential, and the arbitrator may issue appropriate protective orders to safeguard each party' s Confidential Information. During the course of arbitration, the parties shall continue to implement the terms of this agreement. The arbitral award will be final and binding upon the parties, and the party to the award may apply to a court of competent jurisdiction for enforcement of the award. Notwithstanding the foregoing, each party has the right to institute an action in a court of proper jurisdiction for injunctive or other equitable relief pending a final decision by the arbitrator. 13. 5Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may be executed by facsimile,. pdf or other electronically transmitted signatures and such signatures shall be deemed to bind each Party hereto as if they were the original signatures. 12 of 14 IN WITNESS WHEREOF, the Parties hereto have caused this AGREEMENT to be duly executed as of the Effective Date set forth above. WuXi Biologics Ireland Limited Oruka Therapeutics, Inc. By: / s / Zhisheng Chen By: / s / Lawrence Klein Name: Zhisheng Chen Name: Lawrence Klein Title: Director Title: CEO13 of 14 14 of 14 Exhibit 10. 33 AMENDMENT NO. 1 TO THE CELL LICENSE AGREEMENT THIS AMENDMENT NO. 1 TO THE CELL LINE LICENSE AGREEMENT (" Amendment "), effective as of November 20, 2024 (the " Amendment Effective Date "), is entered into and made by and between WuXi Biologics Ireland Limited, (" WuXi Biologics "), and Oruka Therapeutics, Inc. (" Licensee "). WuXi Biologics and Licensee may be referred to herein individually as a " Party " and collectively as the " Parties. " WHEREAS, WuXi Biologics (and Licensee have entered into that certain Cell Line License Agreement, dated as of March 4, 2024, (the " License Agreement "); and WHEREAS, the Parties now desire to amend the License Agreement; NOW, THEREFORE, in consideration of the foregoing, of the mutual promises set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending legally to be bound, hereby agree as follows: 1. The current Section 5 Cell Line Royalties shall be re- numbered to Section 5. 12. A new Section 5. 2 Buy- out Payment is hereby added into the License Agreement as the following: 5. 2. Buy- Out Payment Notwithstanding the foregoing, in lieu of Licensee paying WuXi Biologics the Royalty provided for in Section 5. 1, Licensee, or its sublicensee or assignee may, at any time, in its sole discretion, pay to WuXi Biologics, on a Drug Product- by- Drug Product basis, a fixed non- creditable, non- refundable royalty buyout payment as set forth below (a " Royalty Buyout Payment "). Once WuXi Biologics has received the Royalty Buyout Payment from Licensee, or its sublicensee or assignee, all future royalty obligations with respect to such Drug Product will be extinguished and Licensee will no longer owe any Royalty with respect to such Drug Product. Upon the applicable Royalty Buyout Payment being fully paid with respect to a Drug Product, the rights and licenses granted with respect to such Drug Product under this Agreement (including for clarity in Section 2. 1) shall become fully paid- up, royalty free, perpetual and irrevocable. 5. 2. 1For the [* * *] Drug Product [* * *], the Royalty Buyout Payment shall be [* * *]. 5. 2. 2For the [* * *], Drug Product (s) [* * *], the Royalty Buyout Payment shall be [* * *]. 5. 2. 3For clarity, [* * *]. 3. Except as expressly modified by this Amendment, the License Agreement shall remain unchanged and in full force and effect in accordance with its terms and the Parties hereby ratify and reaffirm the License Agreement as amended hereby. 4. This Amendment may be executed in any number of counterparts, with each counterpart constituting an original, but all of which shall together constitute one and the same instrument. Delivery of an executed counterpart of a signature page of this Amendment by facsimile or electronic transmission (including. pdf file) shall be effective as delivery of a manually executed counterpart of this Amendment. 5. Any capitalized term used in this Amendment and not otherwise defined herein shall have the meaning given to that term in the License Agreement. This Amendment and the rights and obligations of the Parties hereto shall be governed, construed, and enforced in accordance with the governing law as stated in the License Agreement. [Signature page follows] IN WITNESS WHEREOF, the Parties hereto have caused this Amendment to be duly executed as of the Amendment Effective Date set forth above. WuXi Biologics Ireland Limited Oruka Therapeutics, Inc. By: / s / Zhisheng CHEN By: / s / Lawrence Klein Name: Zhisheng CHEN Name: Lawrence Klein Title: Director Title: President and Chief Executive OfficerExhibit 19. 1 INSIDER TRADING POLICY August 29, 2024 I. INTRODUCTION Federal and state laws prohibit buying, selling or making other transfers of securities by persons who have material information that is not generally known or available to the public. These laws also prohibit persons with such material nonpublic information (" MNPI ") from disclosing this information to others who trade. Trading while in possession of MNPI is often referred to as " insider trading. " Who Is Subject to this Policy. Oruka Therapeutics, Inc. (the " Company ") has adopted the following policy (this " Policy ") regarding trading in securities by all of its directors, officers and employees, as well as certain contractors and consultants who are so designated by the General Counsel (" GC ") 1 from time to time (together, " Company Personnel ") as well as their family members who reside with them, anyone else who lives in their household and any family members who do not live in their household but whose transactions in Company securities (as defined below) are directed by them or are subject to their influence or control (collectively, " Family Members "), and corporations or other business entities controlled, influenced or managed by them or their Family Members, and trusts for which such persons are a trustee or in which they have a beneficial or pecuniary interest (collectively, " Controlled Entities, " and together with Company Personnel and Family Members, " Insiders "). Unless otherwise indicated, all references to " you " in this Policy should be read to include all of your Family Members and Controlled Entities. Which Securities Are Subject to this Policy. This Policy applies to transactions, whether direct or indirect, in the Company' s securities, including its common stock, options to purchase common stock, restricted stock or restricted stock units or any other type of securities that Company may issue from time to time, including but not limited to preferred stock and convertible debentures, as well as derivative securities relating to the Company but that are not issued by the Company, such as exchange- traded put or call options or swaps relating to the Company' s securities (collectively, " Company securities "). Similarly, this Policy applies to all securities, including common stock, options to purchase common stock or any other type of securities, that are issued by a Company Counterparty (as defined below), as well as any derivative securities that are relating to the Company Counterparty but that are not issued by such Company Counterparty, such as puts, calls or swaps. 1At any time when the Company does not have an active GC, the duties and responsibilities assigned to the GC under this Policy shall be fulfilled by the Chief Financial Officer (" CFO "). At any time when the Company does not have an active CFO, the duties and responsibilities assigned to the CFO under this Policy shall be fulfilled by the principal financial officer. Application of this Policy to Company Counterparties. The principles discussed in this Policy also apply to nonpublic information that you obtain in the course of your employment or other involvement with the Company about another public company with which the Company has a preexisting or prospective relationship, such as the Company' s customers, suppliers, contract research, manufacturing, licensing or other collaboration partners, companies in which the Company has an investment or a firm with which the Company is negotiating a major transaction, such as a joint venture, licensing transaction, collaboration arrangement or material acquisition or disposition (a " Company Counterparty " or " Company Counterparties "). No Exceptions. The prohibition against trading while in possession of MNPI is absolute and unconditional. The securities laws do not recognize any mitigating circumstances, and, in any event, even the appearance of an improper transaction must be avoided to preserve the Company' s reputation for adhering to high standards of conduct. There is no exception for small transactions or transactions that may seem necessary or justifiable for independent reasons, such as the need to raise money for an emergency expenditure. Individual Responsibility. You are responsible for ensuring that you (as well as your Family Members and Controlled Entities) do not violate federal or state securities laws or this Policy. The Company has designed this Policy to promote compliance with the federal securities laws and to protect the Company and you from the serious liabilities and penalties that can result from violations of these laws. Consequences for Violating Insider Trading Laws. If you violate insider trading laws, you may have to pay civil fines for up to three times the profit gained or loss avoided by such trading, as well as criminal fines of up to $ 5 million. You also may be subject to criminal charges and may have to serve a jail sentence of up to 20 years. In addition, the Company may face civil penalties up to the greater of $ 1 million, or three times the profit gained or loss avoided as a result of your insider trading violations, as well as criminal fines of up to $ 25 million. Both the Securities and Exchange Commission (" SEC ") and The Nasdaq Stock Market (" Nasdaq ") are very effective at detecting and pursuing insider trading cases. The SEC has successfully prosecuted cases against employees trading through foreign accounts, trading by family members and friends and trading involving only a small number of shares. Therefore, it is important that you understand the breadth of activities that constitute illegal insider trading. This Policy sets out the Company' s policy in the area of insider trading and should be read carefully and complied with fully. Administrative Provisions. All Company Personnel will be required to certify their understanding of and intent to comply with this Policy by signing the Receipt and Acknowledgment attached hereto periodically. This Policy will be reviewed, evaluated and revised by the Company from time to time in light of regulatory changes, developments in the Company' s business and other factors. II. POLICIES AND PROCEDURES A. Trading Policy 1. General Prohibition. You may not buy, sell, gift or otherwise transact in securities of the Company or a Company Counterparty when you are in possession of MNPI about that company. 2. No Tipping. You may not convey MNPI about the Company or a Company Counterparty to anyone else, including family members. You also may not suggest that anyone purchase or sell any company' s securities while you are aware of MNPI about that company. These practices, known as " tipping, " also violate U. S. securities laws and can result in the same civil and criminal penalties that apply if you engage in insider trading directly, even if you do not receive any money or derive any benefit from trades made by persons to whom you passed MNPI. This policy against " tipping " applies to information about the Company and its securities, as well as to information about Company Counterparties. Persons with whom you have a history, pattern or practice of sharing confidences — such as family members, close friends and financial and personal counselors — may be presumed to act on the basis of information known to you; therefore, special care should be taken so that MNPI is not disclosed to such persons. This policy does not restrict legitimate business communications on a " need to know " basis. MNPI, however, should not be disclosed to persons outside the Company unless you are specifically authorized to disclose such information and such disclosure is made in accordance with the Company' s policies regarding the protection or authorized external disclosure of information regarding the Company. 3. No Speculative Trading. It is against Company policy for you to engage in speculative transactions in Company securities. As such, you may not engage in: (a) short sales (selling Company securities you do not own); (b) transactions involving publicly traded options or other derivatives, such as trading in puts or calls with respect to Company securities; and (c) other hedging transactions (such as " cashless " collars, forward sales, equity swaps and other similar arrangements). Additionally, securities held in a margin account or pledged as collateral may be sold without your consent, if you fail to meet a margin call or if you default on a loan, and thus a margin or foreclosure sale may result in unlawful insider trading. Because of this danger, you are also prohibited from including Company securities in a margin account or pledging Company securities as collateral for a loan. 4. Applying the Trading Policy. As stated above, these restrictions also apply to your Family Members and Controlled Entities. For purposes of this Policy, references to " trading, " " transact " and " transactions " include, among other things: ● purchases and / or sales of securities in public markets; ● sales of securities obtained through the exercise of stock options or vesting of other equity awards granted by the Company; ● making gifts of securities; and ● using securities to secure a loan. Transactions in mutual funds that are invested in Company or Company Counterparty securities are not transactions subject to this Policy as long as (a) the Insider does not control the investment decisions on individual stocks within the fund and (b) Company or Company Counterparty securities do not represent a substantial portion of the assets of the fund. In addition, transactions pursuant to a Rule 10b5- 1 Trading Plan (as defined below) are subject to certain exceptions and requirements set forth below. Insiders should consult the GC if they have any questions. 5. Company Transactions. From time to time, the Company may engage in transactions in its own securities. When engaging in transactions in Company securities, it is the Company' s policy to comply with all applicable securities laws and regulations and state corporate laws. This includes consultation, as appropriate, with the CEO, CFO, GC and outside counsel, and, if required or advisable, approval by the Board of Directors or appropriate board committee. B. What is " Material Nonpublic Information "? When is Information " Public "? 1.

Material Information Information is generally considered " material " if there is a likelihood a reasonable investor would consider such information important in making an investment decision to buy, hold or sell securities. Either positive or negative information may be material. There is no bright- line standard for assessing materiality; rather, materiality is based on an assessment of all of the facts and circumstances. The GC or other attorneys designated by the GC should be consulted and shall determine whether information is material, but, in general, any information that could reasonably be expected to affect the Company' s or a Company Counterparty' s stock price should be considered material. Depending on the circumstances, common examples of information that may be material include: ● significant new product or product candidate developments, innovations or discoveries (including new targets and new indications); ● pending U. S. Food and Drug Administration, European Medicines Agency or other regulatory action; ● clinical data or significant interactions, filings, approval or rulings by a regulatory agency relating to the Company or a Company product; ● clinical trial enrollment status and results (including interim results) and status of pre- clinical or clinical studies; ● changes in intellectual property status, including patent filings, issuances or potential interference and infringement proceedings; ● changes in research or business strategies; ● financial and operating results, estimates, forecasts and projections, including earnings, cash runway, revenue or similar financial information; ● unpublished financial reports or projections, including knowledge of changes of research analyst views or ratings; ● extraordinary borrowing or liquidity problems; ● changes in control or sale of all or part of the Company' s business, including potential partnerships; ● changes in directors, senior management or auditors; ● information about current, proposed or contemplated transactions, business plans, financial restructurings, acquisition targets or significant expansions or contractions of operations; ● changes in dividend policies, the declaration of a stock split or the proposed or contemplated issuance, redemption or repurchase of securities; ● public or private debt or equity offerings; ● negotiations regarding an important license, distribution agreement, joint venture or collaboration agreement; ● material defaults under agreements or actions by creditors, clients or suppliers relating to the Company' s credit rating; ● information about major contracts; ● gain or loss of a significant customer or supplier; ● significant product pricing or reimbursement changes; ● significant cybersecurity incidents, events or risks that affect the Company or third- party providers that support the Company' s business operations, including computer system or network compromises, viruses or other destructive software, and data breach incidents that may disclose personal, business or other confidential information; ● product recalls; ● impending financial problems such as impending bankruptcy or liquidity problems; ● the interruption of production or other aspects of a company' s business as a result of an accident, fire, natural disaster, public health emergency or breakdown of labor negotiations; ● major environmental incidents; ● institution of, or developments in, major actual or threatened litigation, investigations or regulatory actions or proceedings; ● information about Company affiliates and Company Counterparties; and ● the imposition of a trading " blackout " by the Company on transactions in Company securities or the securities of a Company Counterparty. Federal and Nasdaq investigators will scrutinize a questionable trade after the fact with the benefit of hindsight, so you should always err on the side of deciding that the information is material and not trade. The mere fact that a person is aware of MNPI is a bar to trading. It is no excuse that such person' s reasons for trading were not based on the MNPI. If you have questions regarding specific transactions, please contact the GC. 2. Nonpublic Information Nonpublic information is information that is not generally known by or available to the public. We consider information to be available to the public only when: ● it has been released to the public by the Company through appropriate channels (e. g., by means of a press release, a filing with the SEC or a widely disseminated statement from a senior officer); and ● enough time has elapsed to permit the investment market to absorb and evaluate the information. As a general rule, you should consider information to be nonpublic until two full trading days have lapsed following the time of public disclosure. The fact that rumors, speculation or statements attributed to unidentified sources are public is insufficient to be considered " generally available to the public " even when the information is accurate. C. Unauthorized Disclosure; Prohibition on Certain Public Speaking All Company Personnel must maintain the confidentiality of Company information for competitive, security and other business reasons, as well as to comply with securities laws. All information you learn about the Company or its business plans is potentially nonpublic information until it is publicly disclosed. You should treat this information as confidential and proprietary to the Company. You may not disclose it to others, such as Family Members, other relatives or business or social acquaintances. In addition, you are prohibited from participating as an " expert, " consultant, advisor and / or in any capacity for an " expert network " and / or any other outside firm that compensates individuals for speaking with investors and other investment professionals. This prohibition is designed to protect the Company, its stockholders and you. Indeed, United States criminal authorities and the SEC have prosecuted numerous public company employees who received monetary compensation by expert networks to speak with investors and disclose confidential company information that investors then used for trading purposes. Legal rules govern the timing and nature of our disclosure of material information to outsiders or the public. Violation of these rules could result in substantial liability for you, the Company and its management. For this reason, we permit only specifically designated representatives of the Company to discuss the Company with the news media, securities analysts and investors and only in accordance with the Company' s Policy On Public Disclosures And Communications With The Investment Community. If you receive inquiries of this nature, refer them to the CEO. D. When and How to Trade Company Stock 1. Overview Directors, officers, as defined in Rule 16a- 1 (f) under the Securities Exchange Act of 1934, as amended (the " Exchange Act ") (such officers, " Section 16 Officers ", and together with directors, " Section 16 Persons "), and certain other employees, contractors and consultants who are so designated by the GC from time to time (such designated employees, contractors and consultants, together with Section 16 Persons, and each of their respective Family Members and Controlled Entities, " Restricted Persons ") are for purposes of this Policy required to comply with the restrictions covered below. Even if you are not a Restricted Person, however, following the procedures listed below may assist you in complying with this Policy. 2. Blackout Periods From time to time, due to certain developments (such as a significant event or transaction) during which there may exist MNPI about the Company or a Company Counterparty, the Company may implement special blackout periods during which the Company may notify particular individuals that they should not transact in Company securities or the securities of a Company Counterparty, as applicable (subject to the exceptions set forth in Section II. D. 4 or pursuant to an approved Rule 10b5- 1 Trading Plan pursuant to Section II. E). If you are subject to a special blackout period, you should not trade in the applicable company' s securities during such time and you should not disclose to others the fact that you are prohibited from trading, as the existence of a special blackout period may, itself, be deemed MNPI. These special blackout periods, which may vary in length, will be determined by the GC and be communicated to the appropriate personnel via e- mail. Termination of a blackout period will also be communicated to the appropriate personnel via e- mail. However, it is not the Company' s policy to impose special blackout periods every time that MNPI exists or every time that an Insider may be in the possession of MNPI. Thus, the absence of a special blackout period should not be interpreted as permission to trade. In addition, if you are subject to the Company' s pre- clearance policy (described below), you must pre- clear transactions even if you initiate them while a blackout period is not in place. Even if a special blackout period is in place, you may exercise Company stock options if no shares are to be sold – you may not, however, effect sales of stock issued upon the exercise of stock options (including same- day sales and cashless exercises). Generally, all pending purchase and sale orders regarding Company securities must be executed or cancelled before a special blackout period is implemented so as to avoid any transactions during such period. In light of these restrictions, if you expect a need to sell Company stock at a specific time in the future, including executing sales to satisfy tax withholding obligations in connection with the exercise of stock options, vesting of restricted stock or settlement of restricted stock units in the future, you may wish to consider entering into a prearranged Rule 10b5- 1 Trading Plan (as discussed below). 3. Pre- clearance The Company requires all Restricted Persons to contact the GC2 in advance of effecting any purchase, sale, gift or other trading of Company securities and to obtain prior approval of the transaction, other than transactions made under an approved Rule 10b5- 1 Trading Plan pursuant to Section II. E below. All requests must be submitted to the GC at least two business days in advance of the proposed transaction. 3 This pre- clearance policy applies to Restricted Persons even if they are initiating a transaction while a blackout period is not in place. If a transaction is approved under the pre- clearance policy, the transaction must be executed during the cleared trading period approved by the GC (not to exceed five (5) trading days), but regardless may not be executed if you acquire MNPI concerning the Company during that time. If a transaction is not completed within the period described above, the transaction must be approved again before it may be executed. If a proposed transaction is not approved under the pre- clearance policy, you may not transact in Company securities, and you should not inform anyone within or outside of the Company of the restriction. For the avoidance of doubt, there should be no presumption that the GC will grant any or all pre- clearance requests and there shall be no obligation to inform a Restricted Person of the reasons for any request approval or denial. Any transaction under a Rule 10b5- 1 Trading Plan will not require pre- clearance at the time of the transaction, but the adoption, amendment, modification or termination of any such Rule 10b5- 1 Trading Plan is subject to the pre- clearance and other restrictions set forth in Section II. E and Appendix A, " Guidelines for Rule 10b5- 1 Trading Plans " below. 4. Exceptions The restrictions contained in this Policy shall not apply to: ● the exercise of Company stock options if (a) no shares are to be sold to third parties or (b) there is only a " net exercise " (defined as the Company withholding shares to satisfy your tax obligations or to cover the exercise price or equivalent); ● " sell to cover " transactions involving a sale of shares of common stock directed by the Company in its sole discretion in order to cover the Company' s or such individual' s or entity' s withholding tax obligations in connection with the grant, vesting or settlement of equity awards pursuant to the Company' s equity incentive plans and agreements, for example, from the vesting or settlement of restricted stock units under such plans; 2For the purposes of this Section D. 3, GC includes a person delegated authority by the GC to pre- clear trades. 3Transactions by the GC (or the GC' s Family Members and Controlled Entities) are required to be approved in advance by the Chief Executive Officer (" CEO ") or CFO. ● the vesting of Company stock options, restricted stock, restricted stock units or other equity incentive awards according to their terms; ● the withholding of shares to satisfy the exercise price or a tax withholding obligation upon the grant, vesting or settlement of equity awards pursuant to the Company' s equity incentive plans and agreements, for example, from the vesting or settlement of restricted stock units under such plans; ● purchases of shares through the Company' s Employee Stock Purchase Plan in accordance with your pre- established participation elections; ● transferring shares to an entity that does not involve a change in the beneficial ownership of the shares (for example, transferring shares from one brokerage account to another brokerage account that you control); ● sales of Company securities as a selling stockholder in a registered public offering, including a " synthetic secondary " offering, in accordance with applicable securities laws; or ● any other purchase of Company securities from the Company or sale of Company securities to the Company in accordance with applicable securities and state laws. To the extent applicable and such elections are permitted, your elections regarding (1) participation in " net exercise " or " sell to cover " transactions or (2) participation in or an increase in contributions to the Company' s Employee Stock Purchase Plan, in each case, including changes from any defaults established by the Company, may only be made when you are not subject to a blackout period and are not in possession of MNPI. E. Rule 10b5- 1 Trading Plans Rule 10b5- 1 under the Exchange Act provides an affirmative defense from insider trading liability if trades occur pursuant to a pre- arranged trading plan that meets specified conditions (a " Rule 10b5- 1 Trading Plan "). A Rule 10b5- 1 Trading Plan is a written trading plan between you and your broker and must either specify the number of securities to be bought or sold, along with the price and the date, or provide a written formula for determining this information. Alternatively, such Rule 10b5- 1 Trading Plan can delegate investment discretion to a third party, such as a broker, who then makes trading decisions without further input from the person implementing the plan. A Rule 10b5- 1 Trading Plan must be established at a time when you are not aware of any MNPI and must not permit you to exercise any subsequent control or influence over how, when or whether the purchases or sales are made. Under this Policy, the adoption, amendment, modification or termination of a Rule 10b5- 1 Trading Plan must meet the requirements set forth in Appendix A, " Guidelines for Rule 10b5- 1 Trading Plans, " including applicable pre- clearance procedures. Because the SEC rules on trading plans are complex, you should consult with your broker and be sure you fully understand the limitations and conditions of the rules before you establish a Rule 10b5- 1 Trading Plan (or a transaction that is intended to constitute a " non- Rule 10b5- 1 trading arrangement " within the meaning of SEC rules). F. Noncompliance Anyone subject to this Policy who fails to comply with this Policy will be subject to appropriate disciplinary action, up to and including termination of employment. G. Post- Termination Transactions This Policy, other than the pre- clearance provisions, will continue to apply to your transactions in Company securities after your employment or service with the Company has terminated until such time as you are no longer aware of MNPI or until that information has been publicly disclosed or is no longer material. Questions about this Policy should be directed to the GC. RECEIPT AND ACKNOWLEDGMENT I, ________________________________, hereby acknowledge that I have received and read a copy of the Oruka Therapeutics, Inc. Insider Trading Policy (this " Policy "). I agree to comply with this Policy and certify that I will communicate with all members of my household to inform them of the obligations in this Policy that apply to them. I understand that violation of SEC regulations may subject me to severe civil and / or criminal penalties, and that violation of this Policy may subject me to discipline by Oruka Therapeutics, Inc. up to and including termination for cause. Signature Date [RECEIPT AND ACKNOWLEDGMENT] APPENDIX AOruka Therapeutics, Inc. Guidelines for Rule 10b5- 1 Trading Plans As discussed in the Policy, Rule 10b5- 1 under the Exchange Act provides an affirmative defense from insider trading liability. In order to be eligible to rely on this affirmative defense, you must enter into a Rule 10b5- 1 Trading Plan for transactions in Company securities that meets certain conditions specified in Rule 10b5- 1, including the guidelines set forth below. These guidelines generally do not apply to any transactions that are intended to constitute " non- Rule 10b5- 1 trading arrangements " within the meaning of SEC rules. Capitalized terms used in these guidelines without definition have the meaning set forth in the Policy. These guidelines are in addition to, and not in lieu of, the requirements and conditions of Rule 10b5- 1. The GC will interpret and administer these guidelines for compliance with Rule 10b5- 1 and the Policy. No personal legal or financial advice is being provided by the GC or other members of the Company regarding any Rule 10b5- 1 Trading Plan or proposed trades. You remain ultimately responsible for ensuring that your Rule 10b5- 1 Trading Plans and contemplated transactions fully comply with applicable securities laws. It is recommended that you consult with your own attorney or other advisor about any contemplated Rule 10b5- 1 Trading Plan. Note that for any Section 16 Persons, the Company is required to disclose the material terms of his or her (and any Family Members' and Controlled Entities') Rule 10b5- 1 Trading Plan, other than with respect to price, in its periodic report for the quarter in which the Rule 10b5- 1 Trading Plan is adopted or terminated or modified (as described below). 1. Pre- Clearance Requirement. The Rule 10b5- 1 Trading Plan must be submitted for pre- approval in advance to the GC (or, in the case of the GC, to the CEO or CFO) at least five trading days prior to the entry into the plan in accordance with the procedures set forth in the Policy and these guidelines. The Company may require that you use a standardized form of Rule 10b5- 1 Trading Plan. 2. Time of Adoption. Subject to pre- clearance requirements described above, the Rule 10b5- 1 Trading Plan must be adopted at a time: ● when you are not aware of any MNPI; and ● when you are not subject to a blackout period. 3. Plan Instructions. Any Rule 10b5- 1 Trading Plan must be in writing, signed and either: ● specify the amount, price and date of the sales (or purchases) of Company securities to be effected; ● provide a formula, algorithm or computer program for determining when to sell (or purchase) the Company' s securities, the quantity to sell (or purchase) and the price; or ● delegate decision- making authority with regard to these transactions to a broker or other agent without any MNPI about the Company or its securities. For the avoidance of doubt, you may not subsequently influence how, when or whether to effect purchases or sales with respect to the securities subject to an approved and adopted Rule 10b5- 1 Trading Plan. A- 14. No Hedging. You may not have entered into or alter a corresponding or hedging transaction or position with respect to the securities subject to the Rule 10b5- 1 Trading Plan and must agree not to enter into any such transaction while the Rule 10b5- 1 Trading Plan is in effect. 5. Good Faith Requirements. You must enter into the Rule 10b5- 1 Trading Plan in good faith and not as part of a plan or scheme to evade the prohibitions of Rules 10b- 5 and 10b5- 1 under the Exchange Act. You must act in good faith with respect to the Rule 10b5- 1 Trading Plan for the entirety of its duration. 6. Certifications for Section 16 Persons. Section 16 Persons and their Family Members and Controlled Entities that enter into Rule 10b5- 1 Trading Plans must certify that they are: (1) not aware of any MNPI about the Company or the Company securities; and (2) adopting the Rule 10b5- 1 Trading Plan in good faith and not as part of a plan or scheme to evade the prohibitions of Rules 10b- 5 and 10b5- 1 under the Exchange Act. 7. Cooling Off Periods. The first trade under the Rule 10b5- 1 Trading Plan may not occur until the expiration of a cooling- off period as follows: ● For Section 16 Persons (as well as their Family Members and Controlled Entities), the later of (1) two business days following the filing of the Company' s Form 10- Q or Form 10- K for the completed fiscal quarter in which the Rule 10b5- 1 Trading Plan was adopted and (2) 90 calendar days after adoption of the Rule 10b5- 1 Trading Plan; provided, however, that the required cooling- off period shall in no event exceed 120 days. ● For other Insiders, 30 days after adoption of the Rule 10b5- 1 Trading Plan. 8. No Overlapping Rule 10b5- 1 Trading Plans. You may not enter into overlapping Rule 10b5- 1 Trading Plans (subject to certain exceptions). Please consult with the GC for any questions regarding overlapping Rule 10b5- 1 Trading Plans. 9. Single Transaction Plans. You may not enter into more than one Rule 10b5- 1 Trading Plan designed to effect the open- market purchase or sale of the total amount of securities as a single transaction during any rolling 12- month period (subject to certain exceptions). A single- transaction plan is " designed to effect " the purchase or sale of securities as a single transaction when the terms of the plan would, for practical purposes, directly or indirectly require execution in a single transaction. 10. Modifications and Terminations. Modifications / amendments and terminations of an existing Rule 10b5- 1 Trading Plan are strongly discouraged due to legal risks, and can affect the validity of trades that have taken place under the plan prior to such modification / amendment or termination. Under Rule 10b5- 1 and these guidelines, any modification / amendment to the amount, price or timing of the purchase or sale of the securities underlying the Rule 10b5- 1 Trading Plan (a " Material Modification ") will be deemed to be a termination of the current Rule 10b5- 1 Trading Plan and creation of a new Rule 10b5- 1 Trading Plan. As such, the modification / amendment of an existing Rule 10b5- 1 Trading Plan must be reviewed and approved in advance by the GC in accordance with the pre- clearance procedures set forth in the Policy and these guidelines, and any Material Modification will be subject to all the other requirements set forth in these guidelines regarding the adoption of a new Rule 10b5- 1 Trading Plan. The termination (other than through an amendment or modification) of an existing Rule 10b5- 1 Trading Plan must be reviewed and approved in advance by the GC in accordance with the pre- clearance procedures set forth in the Policy and these guidelines. Except in limited circumstances, the GC will not approve the termination of a Rule 10b5- 1 Trading Plan unless: ● you are not aware of any MNPI; and Exhibit 21. 1 Subsidiaries of Oruka Therapeutics, Inc. Name of Subsidiary State or Jurisdiction in Which Incorporated or Organized Oruka Therapeutics Operating Company, LLC Delaware Oruka Therapeutics Australia Pty Ltd. AustraliaExhibit 23. 1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S- 8 (No. 333- 283243) of Oruka Therapeutics, Inc. of our report dated March 6, 2025 relating to the financial statements, which appears in this Form 10- K. / s / PricewaterhouseCoopers LLP Boston, Massachusetts March 6, 2025 Exhibit 31. 1 Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes- Oxley Act of 2002 I, Lawrence Klein, certify that: 1. I have reviewed this Annual Report on Form 10- K of Oruka Therapeutics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant' s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a- 15 (e) and 15d- 15 (e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a- 15 (f) and 15d- 15 (f)) for the registrant and have: a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c. Evaluated the effectiveness of the registrant' s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd. Disclosed in this report any change in the registrant' s internal control over financial reporting that occurred during the registrant' s most recent fiscal quarter (the registrant' s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant' s internal control over financial reporting; and5. The registrant' s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant' s auditors and the audit committee of the registrant' s board of directors (or persons performing the equivalent functions): a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant' s ability to record, process, summarize and report financial information; andb. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant' s internal control over financial reporting. Date: March 6, 2025 / s / Lawrence Klein Lawrence Klein Chief Executive Officer (Principal Executive Officer) Exhibit 31. 2 Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes- Oxley Act of 2002 I, Arjun Agarwal, certify that: / s / Arjun Agarwal Arjun Agarwal Senior Vice President, Finance and Treasurer (Principal Financial Officer and Principal Accounting Officer) Certifications of the Principal Executive Officer and Principal Financial Officer Pursuant To 18 U. S. C. Section 1350, As Adopted Pursuant To Section 906 of The Sarbanes- Oxley Act Of 2002 In connection with the Annual Report on Form 10- K of Oruka Therapeutics, Inc. (the " Company ") for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the " Report "), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U. S. C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002, that to the best of his knowledge: 1) The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: March 6, 2025 / s / Lawrence Klein Lawrence Klein President and Chief Executive Officer (Principal Executive Officer) / s / Arjun Agarwal Arjun Agarwal Senior Vice President, Finance and Treasurer (Principal Financial Officer and Principal Accounting Officer) Exhibit 97. 1 INCENTIVE COMPENSATION CLAWBACK POLICYI. Recoupment of Incentive- Based Compensation It is the policy of Oruka Therapeutics, Inc. (the " Company ") that, in the event the Company is required to prepare an accounting restatement of the Company' s financial statements due to material non- compliance with any financial reporting requirement under the federal securities laws (including any such correction that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period), the Company will recover on a reasonably prompt basis the amount of any Incentive- Based Compensation Received by a Covered Executive during the Recovery Period that exceeds the amount that otherwise would have been Received had it been determined based on the restated financial statements. This Incentive Compensation Clawback Policy (this " Policy ") has been adopted by the Board of Directors (the " Board ") of the Company and the Compensation Committee (the " Committee ") of the Board. The Committee may amend or change the terms of this Policy at any time for any reason, including as required to comply with any laws, rules, regulations and listing standards that may be applicable to the Company. II. Policy Administration and Definitions This Policy is administered by the Committee and is intended to comply with, and as applicable to be administered and interpreted consistent with, and subject to the exceptions set forth in, Listing Rule 5608 adopted by The Nasdaq Stock Market (" Nasdaq ") to implement Rule 10D- 1 under the Securities Exchange Act of 1934, as amended (collectively, " Rule 10D- 1 "). For purposes of this Policy: " Covered Executive " means any " executive officer " of the Company as defined under Rule 10D- 1. A " Financial Reporting Measure " is (i) any measure that is determined and presented in accordance with the accounting principles used in preparing the Company' s financial statements and any measure derived wholly or in part from such a measure, and (ii) any measure based in whole or in part on the Company' s stock price or total stockholder return. " Incentive- Based Compensation " means any compensation granted, earned or vested based in whole or in part on the Company' s attainment of a Financial Reporting Measure that was Received by a person (i) on or after October 2, 2023, and after the person began service as a Covered Executive, and (ii) who served as a Covered Executive at any time during the performance period for the Incentive- Based Compensation. Incentive- Based Compensation is deemed to be " Received " in the fiscal period during which the relevant Financial Reporting Measure is attained, regardless of when the compensation is actually paid or awarded. " Recovery Period " means the three completed fiscal years immediately preceding the date that the Company is required to prepare the accounting restatement described in this Policy and any transition period of less than nine months that is within or immediately following such three fiscal years, all as determined pursuant to Rule 10D- 1. III. Determination by the Committee If the Committee determines the amount of Incentive- Based Compensation Received by a Covered Executive during a Recovery Period exceeds the amount that would have been Received if determined or calculated based on the Company' s restated financial results, such excess amount of Incentive- Based Compensation shall be subject to recoupment by the Company pursuant to this Policy. For Incentive- Based Compensation based on stock price or total stockholder return, where the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in an accounting restatement, the Committee will determine the amount based on a reasonable estimate of the effect of the accounting restatement on the relevant stock price or total stockholder return. In all cases, the calculation of the excess amount of Incentive- Based Compensation to be recovered will be determined on a pre- tax basis (i. e., without regard to any taxes paid with respect to such compensation). The Company will maintain and will provide to Nasdaq documentation of all determinations and actions taken in complying with this Policy. Any determinations made by the Committee under this Policy shall be final and binding on all affected individuals. IV. Methods of Clawback The Company may effect any recovery pursuant to this Policy in any manner consistent with applicable law, including by requiring payment of such amount (s) to the Company, by set- off, by reducing future compensation, or by such other means or combination of means as the Committee determines to be appropriate. The Company need not recover the excess amount of Incentive- Based Compensation if and to the extent that the Committee determines that such recovery is impracticable, subject to and in accordance with any applicable exceptions under the Nasdaq listing rules and not required under Rule 10D- 1, including if the Committee determines that the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered after making a reasonable attempt to recover such amounts. The Company is authorized to take appropriate steps to implement this Policy with respect to Incentive- Based Compensation arrangements with Covered Executives. V. Not Exclusive Remedy Any right of recoupment or recovery pursuant to this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company pursuant to the terms of any other policy, any employment agreement or plan or award terms, and any other legal remedies available to the Company (including, but not limited to, Section 304 of the Sarbanes- Oxley Act of 2002); provided that the Company shall not recoup amounts pursuant to such other policy, terms or remedies to the extent it is recovered pursuant to this Policy. The Company shall not indemnify any Covered Executive against the loss of any Incentive- Based Compensation pursuant to this Policy (or provide any advancement of expenses in such instance), nor will the Company pay or reimburse or agree to pay or reimburse any insurance premium to cover any such loss. VI. Certification All Covered Executives subject to this Policy will be required to certify their understanding of and intent to comply with this Policy periodically. ACKNOWLEDGMENT AND CERTIFICATION By signing below, the undersigned covered executive (the " Covered Executive ") acknowledges and confirms that the Covered Executive has received and reviewed a copy of the Oruka Therapeutics, Inc. (the " Company ") Incentive Compensation Clawback Policy (as interpreted or modified from time to time pursuant to the terms hereof, the " Policy "), and in addition, the Covered Executive acknowledges and agrees that, for good and valid consideration, including continuing participation in the Company' s incentive compensation programs, the receipt and sufficiency of which the Covered Executive hereby acknowledges, the Covered Executive will be bound by and abide by the Policy as follows: (a) the Covered Executive is and will continue to be subject to the Policy and the Policy will apply both during and after the Covered Executive' s employment with the Company; (b) to the extent necessary to comply with the Policy, the Company hereby amends any employment agreement, equity award agreement or similar agreement that the Covered Executive is a party to with the Company; (c) the Covered Executive shall abide by the terms of the Policy, including, without limitation, by returning any compensation to the Company to the extent required by, and in a manner permitted by, the Policy, and understands and agrees that the Covered Executive shall not be entitled to any (i) indemnification for any liability (including any amounts owed by the Covered Executive in a judgment or settlement of any Clawback Proceeding (as defined below)), or loss (including judgments, fines, taxes, penalties or amounts paid in settlement by or on behalf of the Covered Executive) incurred by the Covered Executive in connection with or as a result of any action taken by the Board of Directors (the " Board ") of the Company or the Compensation Committee (the " Committee ") of the Board to enforce the Policy (such action, a " Clawback Proceeding ") or (ii) indemnification or advancement of any expenses (including attorneys' fees) from the Company and or any subsidiary of the Company incurred by the Covered Executive in connection with any Clawback Proceeding; provided, however, that if the Covered Executive is successful on the merits in the defense of any claim asserted against the Covered Executive in a Clawback Proceeding,

the Covered Executive shall be indemnified for the expenses (including attorneys' fees) the Covered Executive reasonably incurred to defend such claim; (d) any amounts payable to the Covered Executive shall be subject to the Policy as may be in effect and reasonably interpreted, or modified from time to time in the sole discretion of the Committee or as required by applicable law or the requirements of any securities exchange on which the Company' s securities are listed, and that such reasonable interpretation, or modification will be covered by this acknowledgment; (e) the Company may recover compensation paid to the Covered Executive through any method of recovery the Committee or its delegate deems appropriate, including without limitation, by reducing any amount that is or may become payable to the Covered Executive, and the Covered Executive agrees to comply with any reasonable request or reasonable demand for repayment by the Company in order to comply with the Policy; [ACKNOWLEDGMENT AND CERTIFICATION] (f) the Company is not responsible for and shall not make the Covered Executive whole for any effect under any tax law or regulation of the recovery of any compensation pursuant to the Policy or for any taxes paid by the Covered Executive on compensation that is subject to recovery or is recovered pursuant to the Policy; and (g) the Covered Executive hereby knowingly, voluntarily and intentionally waives, and agrees not to assert any claim regarding, any and all rights to indemnification, advancement and other rights from the Company or any subsidiary of the Company to which the Covered Executive is now or may become entitled under any indemnification agreement between the Covered Executive and the Company (including any provisions related to non- exclusivity of rights contained therein), the Company' s Certificate of Incorporation and Bylaws, the governing documents of each subsidiary of the Company and the Delaware General Corporation Law, in each case to the extent such waiver and agreement is necessary to give effect to the preceding provisions of this Acknowledgment and Certification. Signature Print Name Date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

=" javascript: void (0);" onclick =" Show. showAR (this,' defref_dei_EntityCentralIndexKey', window);" > Entity Central Index Key < / a > < / td > < td class =" text" > 0000907654 < span > < /
span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border-
bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_dei_EntityFileNumber', window);" > Entity File Number < / a > < / td > < td
class =" text" > 000- 22873 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" >
< td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_dei_EntityTaxIdentificationNumber',
window);" > Entity Tax Identification Number < / a > < / td > < td class =" text" > 36- 3855489 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class ="
text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick ="
Show. showAR (this,' defref_dei_EntityIncorporationStateCountryCode', window);" > Entity Incorporation, State or Country Code < / a > < / td > < td class =" text" > DE < span > < / span > < /
td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;"
valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_dei_CurrentFiscalYearEndDate', window);" > Current Fiscal Year End Date < / a > < / td >
< td class =" text" >-- 12- 31 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" >
< td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_dei_EntityWellKnownSeasonedIssuer',
window);" > Entity Well- known Seasoned Issuer < / a > < / td > < td class =" text" > No < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" >
& # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show.
showAR (this,' defref_dei_EntityVoluntaryFilers', window);" > Entity Voluntary Filers < / a > < / td > < td class =" text" > No < span > < / span > < / td > < td class =" text" > & # 160; < span > <
/ span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href ="
javascript: void (0);" onclick =" Show. showAR (this,' defref_dei_EntityCurrentReportingStatus', window);" > Entity Current Reporting Status < / a > < / td > < td class =" text" > Yes < span >
< / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border-
bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_dei_EntityShellCompany', window);" > Entity Shell Company < / a > < / td >
< td class =" text" > false < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > <
td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_dei_EntityFilerCategory', window);" > Entity
Filer Category < / a > < / td > < td class =" text" > Non- accelerated Filer < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span
> < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_dei_EntitySmallBusiness', window);" > Entity Small Business < / a > < / td > < td class =" text" > true < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > <
td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);"
onclick =" Show. showAR (this,' defref_dei_EntityEmergingGrowthCompany', window);" > Entity Emerging Growth Company < / a > < / td > < td class =" text" > false < span > < / span > < / td
> < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;"
valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_dei_EntityPublicFloat', window);" > Entity Public Float < / a > < / td > < td class =" text" >
& # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 39. 7 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl"
style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_dei_EntityContactPersonnelLineItems', window);" > <
strong > Entity Contact Personnel [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td
class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);"
onclick =" Show. showAR (this,' defref_dei_EntityAddressAddressLine1', window);" > Entity Address, Address Line One < / a > < / td > < td class =" text" > 855 Oak Grove Avenue < span > < /
span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border-
bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_dei_EntityAddressAddressLine2', window);" > Entity Address, Address Line
Two < / a > < / td > < td class =" text" > Suite 100 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < /
tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_dei_EntityAddressCityOrTown', window);" > Entity Address, City or Town < / a > < / td > < td class =" text" > Menlo Park < span > < / span > < / td > < td class =" text" > & # 160; <
span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href
=" javascript: void (0);" onclick =" Show. showAR (this,' defref_dei_EntityAddressStateOrProvince', window);" > Entity Address, State or Province < / a > < / td > < td class =" text" > CA <
span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style ="
border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_dei_EntityAddressPostalZipCode', window);" > Entity Address,
Postal Zip Code < / a > < / td > < td class =" text" > 94025 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < /
td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_dei_EntityPhoneFaxNumbersLineItems', window);" > < strong > Entity Phone Fax Numbers [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < /
td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;"
valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_dei_CityAreaCode', window);" > City Area Code < / a > < / td > < td class =" text" > (650) <
span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style ="
border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_dei_LocalPhoneNumber', window);" > Local Phone Number < / a > <
/ td > < td class =" text" > 606- 7910 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class
=" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_dei_EntityListingsLineItems',
window);" > < strong > Entity Listings [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > <
td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);"
onclick =" Show. showAR (this,' defref_dei_Security12bTitle', window);" > Title of 12 (b) Security < / a > < / td > < td class =" text" > Common Stock, par value $ 0. 001 per share < span > < /
span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border-
bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_dei_TradingSymbol', window);" > Trading Symbol < / a > < / td > < td class
=" text" > ORKA < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class
=" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_dei_SecurityExchangeName', window);" > Security
Exchange Name < / a > < / td > < td class =" text" > NASDAQ < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span >
< / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_dei_EntityCommonStockSharesOutstanding', window);" > Entity Common Stock, Shares Outstanding < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class ="
nump" > 37, 440, 510 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0"
cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_AmendmentFlag" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick
=" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < /
a > < div > < p > Boolean flag that is true when the XBRL content amends previously- filed or accepted submission. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext
(this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > <
div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" >
dei_AmendmentFlag < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > <
strong > Data Type: < / strong > < / td > < td > xbrli: booleanItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong >
Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class ="
authRefData" style =" display: none;" id =" defref_dei_CityAreaCode" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X <
/ a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Area code
of city < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a
href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > <
strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_CityAreaCode < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong >
Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: normalizedStringItemType < / td > < / tr > < tr > < td > <
strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < /
tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_CurrentFiscalYearEndDate" > < tr > < td class =" hide"
> < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > End date of current fiscal year in the format-- MM- DD. < / p > < / div > < a href =" javascript: void
(0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style ="
white- space: nowrap;" > dei_CurrentFiscalYearEndDate < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td
> dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: gMonthDayItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na
< / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding ="
0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_DocumentAnnualReport" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void
(0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >-
Definition < / a > < div > < p > Boolean flag that is true only for a form used as an annual report. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >
References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Form 10- K < br >- Number 249 <
br >- Section 310 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Form 20- F < br >- Number 249 < br >- Section 220 < br >-
Subsection f < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Form 40- F < br >- Number 249 < br >- Section 240 < br >-
Subsection f < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0"
cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_DocumentAnnualReport < / td > < / tr > < tr > < td style =" padding- right: 4px;
white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: booleanItemType < / td
> < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < /
div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id ="
defref_dei_DocumentFinStmtErrorCorrectionFlag" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr >
< tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Indicates whether any of the
financial statement period in the filing include a restatement due to error correction. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > <
div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Regulation S- K < br >- Number 229 < br >- Section
402 < br >- Subsection w < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Form 10- K < br >- Number 249 < br >- Section 310

< br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Form 20- F < br >- Number 249 < br >- Section 220 < br >- Subsection f < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Form 40- F < br >- Number 249 < br >- Section 240 < br >- Subsection f < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_DocumentFinStmtErrorCorrectionFlag < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: booleanItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_DocumentFiscalPeriodFocus" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10- Q or 10- QT statements have value Q1, Q2, and Q3 respectively, with 10- K, 10- KT or other fiscal year statements having FY. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_DocumentFiscalPeriodFocus < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dei: fiscalPeriodItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_DocumentFiscalYearFocus" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_DocumentFiscalYearFocus < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: gYearItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_DocumentInformationLineItems" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_DocumentInformationLineItems < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_DocumentPeriodEndDate" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > For the EDGAR submission types of Form 8- K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N- 1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY- MM- DD. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_DocumentPeriodEndDate < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: dateItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_DocumentTransitionReport" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Boolean flag that is true only for a form used as a transition report. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Forms 10- K, 10- Q, 20- F < br >- Number 240 < br >- Section 13 < br >- Subsection a- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_DocumentTransitionReport < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: booleanItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_DocumentType" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The type of document being provided (such as 10- K, 10- Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word' Other'. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_DocumentType < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dei: submissionTypeItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_EntityAddressAddressLine1" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Address Line 1 such as Attn, Building Name, Street Name < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_EntityAddressAddressLine1 < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: normalizedStringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_EntityAddressAddressLine2" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Address Line 2 such as Street or Suite number < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_EntityAddressAddressLine2 < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: normalizedStringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_EntityAddressCityOrTown" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Name of the City or Town < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_EntityAddressCityOrTown < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: normalizedStringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_EntityAddressPostalZipCode" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Code for the postal or zip code < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_EntityAddressPostalZipCode < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: normalizedStringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_EntityAddressStateOrProvince" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Name of the state or province. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_EntityAddressStateOrProvince < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dei: stateOrProvinceItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_EntityCentralIndexKey" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > A unique 10- digit SEC- issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Exchange Act < br >- Number 240 < br >- Section 12 < br >- Subsection b- 2 < br > < / p > < / div > < a href ="

```
javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong >
Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_EntityCentralIndexKey < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong >
Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dei: centralIndexKeyItemType < / td > < / tr > < tr > < td > < strong
> Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < /
table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_EntityCommonStockSharesOutstanding" > < tr > < td class ="
hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Indicate number of shares or other units outstanding of each of registrant' s classes of capital or
common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class / interest by adding class of stock items such
as Common Class A [ Member ], Common Class B [ Member ] or Partnership Interest [ Member ] onto the Instrument [ Domain ] of the Entity Listings, Instrument. < / p > < / div > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);"
onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td >
< td style =" white- space: nowrap;" > dei_EntityCommonStockSharesOutstanding < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix:
< / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong
> < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0"
cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_EntityContactPersonnelLineItems" > < tr > < td class =" hide" > < a style =" color: white;"
href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick ="
Show. toggleNext (this);" >- Definition < / a > < div > < p > Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with
domain members defined in one or many axes to the table. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;"
> < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0"
cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_EntityContactPersonnelLineItems < / td > < / tr > < tr > < td
style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td >
xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration <
/ td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id ="
defref_dei_EntityCurrentReportingStatus" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > <
td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Indicate' Yes' or' No' whether
registrants (1) have filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants
were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant' s current or most recent filing
containing the related disclosure. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition
available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing
=" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_EntityCurrentReportingStatus < / td > < / tr > < tr > < td style =" padding- right: 4px; white-
space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dei: yesNoItemType < / td > < / tr > <
tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div
> < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_EntityEmergingGrowthCompany" > < tr > <
td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a
href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Indicate if registrant meets the emerging growth company criteria. < / p > < / div > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >-
Publisher SEC < br >- Name Exchange Act < br >- Number 240 < br >- Section 12 < br >- Subsection b- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext
(this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space:
nowrap;" > dei_EntityEmergingGrowthCompany < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ <
/ td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: booleanItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr
> < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing
=" 0" class =" authRefData" style =" display: none;" id =" defref_dei_EntityFileNumber" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show.
hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div
> < p > Commission file number. The field allows up to 17 characters. The prefix may contain 1- 3 digits, the sequence number may contain 1- 8 digits, the optional suffix may contain 1- 4
characters, and the fields are separated with a hyphen. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > <
p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding
=" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_EntityFileNumber < / td > < / tr > < tr > < td style =" padding- right: 4px;
white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dei: fileNumberItemType < /
td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > <
/ div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_EntityFilerCategory" > < tr >
< td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > <
a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated
Filer, Non- accelerated Filer. Definitions of these categories are stated in Rule 12b- 2 of the Exchange Act. This information should be based on the registrant' s current or most recent filing
containing the related disclosure. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1:
http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Exchange Act < br >- Number 240 < br >- Section 12 < br >- Subsection b- 2 < br > < / p > < / div > < a
href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > <
strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_EntityFilerCategory < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong >
Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dei: filerCategoryItemType < / td > < / tr > < tr > < td > < strong >
Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < /
table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_EntityIncorporationStateCountryCode" > < tr > < td class ="
hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Two- character EDGAR code representing the state or country of incorporation. < / p > < / div > < a
href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void
(0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > <
/ td > < td style =" white- space: nowrap;" > dei_EntityIncorporationStateCountryCode < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace
Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dei: edgarStateCountryItemType < / td > < / tr > < tr > < td > < strong >
Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < /
table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_EntityInformationLineItems" > < tr > < td class =" hide" > < a
style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript:
void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Line items represent financial concepts included in a table. These concepts are used to disclose reportable
information associated with domain members defined in one or many axes to the table. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > <
div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > <
table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_EntityInformationLineItems < / td > < / tr >
< tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td
> < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td >
duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id ="
defref_dei_EntityInteractiveDataCurrent" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > <
td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Boolean flag that is true when the
registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S- T during the preceding 12 months (or for such shorter period
that the registrant was required to submit such files). < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p
> Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Regulation S- T < br >- Number 232 < br >- Section 405 < br > < / p > < / div > < a href
=" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong >
Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_EntityInteractiveDataCurrent < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong >
Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dei: yesNoItemType < / td > < / tr > < tr > < td > < strong > Balance
Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > <
table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_EntityListingsLineItems" > < tr > < td class =" hide" > < a style =" color:
white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick
=" Show. toggleNext (this);" >- Definition < / a > < div > < p > Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated
with domain members defined in one or many axes to the table. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display:
none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0"
cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_EntityListingsLineItems < / td > < / tr > < tr > < td style ="
padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli:
stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td >
< / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id ="
defref_dei_EntityPhoneFaxNumbersLineItems" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr
> < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Line items represent financial
concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. < / p > < / div > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);"
onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td >
< td style =" white- space: nowrap;" > dei_EntityPhoneFaxNumbersLineItems < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < /
strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < /
```

td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_EntityPublicFloat" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The aggregate market value of the voting and non- voting common equity held by non- affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant' s most recently completed second fiscal quarter. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_EntityPublicFloat < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_EntityRegistrantName" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Exchange Act < br >- Number 240 < br >- Section 12 < br >- Subsection b- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_EntityRegistrantName < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: normalizedStringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_EntityShellCompany" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Boolean flag that is true when the registrant is a shell company as defined in Rule 12b- 2 of the Exchange Act. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Exchange Act < br >- Number 240 < br >- Section 12 < br >- Subsection b- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_EntityShellCompany < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: booleanItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_EntitySmallBusiness" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Indicates that the company is a Smaller Reporting Company (SRC). < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Exchange Act < br >- Number 240 < br >- Section 12 < br >- Subsection b- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_EntitySmallBusiness < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: booleanItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_EntityTaxIdentificationNumber" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9- digit value assigned by the IRS. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Exchange Act < br >- Number 240 < br >- Section 12 < br >- Subsection b- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_EntityTaxIdentificationNumber < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dei: employerIdItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_EntityVoluntaryFilers" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Indicate' Yes' or' No' if the registrant is not required to file reports pursuant to Section 13 or Section 15 (d) of the Act. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_EntityVoluntaryFilers < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dei: yesNoItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_EntityWellKnownSeasonedIssuer" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Indicate' Yes' or' No' if the registrant is a well- known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10- K, 10- Q, 8- K, 20- F, 6- K, 10- K / A, 10- Q / A, 20- F / A, 6- K / A, N- CSR, N- Q, N- 1A. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Securities Act < br >- Number 230 < br >- Section 405 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_EntityWellKnownSeasonedIssuer < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dei: yesNoItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_IcfrAuditorAttestationFlag" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Form 10- K < br >- Number 249 < br >- Section 310 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Form 20- F < br >- Number 249 < br >- Section 220 < br >- Subsection f < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Form 40- F < br >- Number 249 < br >- Section 240 < br >- Subsection f < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_IcfrAuditorAttestationFlag < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: booleanItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_LocalPhoneNumber" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Local phone number for entity. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_LocalPhoneNumber < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: normalizedStringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_Security12bTitle" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Title of a 12 (b) registered security. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Exchange Act < br >- Number 240 < br >- Section 12 < br >- Subsection b < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_Security12bTitle < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dei: securityTitleItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_SecurityExchangeName" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Name of the Exchange on which a security is registered. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Exchange Act < br >- Number 240 < br >- Section 12 < br >- Subsection d1- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_SecurityExchangeName < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dei: edgarExchangeCodeItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_TradingSymbol" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Trading symbol of an instrument as listed on an exchange. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > <

strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_TradingSymbol < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dei: tradingSymbolItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 38 < FILENAME > R2. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208263282384" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Audit Information < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_dei_AuditorTable', window);" > < strong > Auditor [Table] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_dei_AuditorName', window);" > Auditor Name < / a > < / td > < td class =" text" > PricewaterhouseCoopers LLP < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_dei_AuditorFirmId', window);" > Auditor Firm ID < / a > < / td > < td class =" text" > 238 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_dei_AuditorLocation', window);" > Auditor Location < / a > < / td > < td class =" text" > Boston, Massachusetts < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_dei_AuditorOpinionTextBlock', window);" > Auditor Opinion [Text Block] < / a > < / td > < td class =" text" > < p style =" font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" > Opinion on the Financial Statements < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 5in" > We have audited the accompanying consolidated balance sheets of Oruka Therapeutics, Inc. and its subsidiaries (the & # 8220; Company & # 8221;) as of December 31, 2024 and February 6, 2024, and the related consolidated statements of operations and comprehensive loss, of convertible preferred stock and stockholders & # 8217; equity and of cash flows for the period from February & # 160; 6, & # 160; 2024 (inception) to December & # 160; 31, & # 160; 2024, including the related notes (collectively referred to as the & # 8220; consolidated financial statements & # 8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December & # 160; 31, & # 160; 2024 and February 6, 2024, and the results of its operations and its cash flows for the period from February & # 160; 6, & # 160; 2024 (inception) to December & # 160; 31, & # 160; 2024 in conformity with accounting principles generally accepted in the United States of America. < / p > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_AuditorFirmId" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > PCAOB issued Audit Firm Identifier < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Form 10- K < br >- Number 249 < br >- Section 310 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Form 20- F < br >- Number 249 < br >- Section 220 < br >- Subsection f < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Form 40- F < br >- Number 249 < br >- Section 240 < br >- Subsection f < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_AuditorFirmId < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dei: nonemptySequenceNumberItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_AuditorLocation" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Form 10- K < br >- Number 249 < br >- Section 310 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Form 20- F < br >- Number 249 < br >- Section 220 < br >- Subsection f < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Form 40- F < br >- Number 249 < br >- Section 240 < br >- Subsection f < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_AuditorLocation < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dei: internationalNameItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_AuditorName" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Form 10- K < br >- Number 249 < br >- Section 310 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Form 20- F < br >- Number 249 < br >- Section 220 < br >- Subsection f < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Form 40- F < br >- Number 249 < br >- Section 240 < br >- Subsection f < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_AuditorName < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dei: internationalNameItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_AuditorOpinionTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Regulation S- X < br >- Number 210 < br >- Section 2 < br >- Subsection 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_AuditorOpinionTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_dei_AuditorTable" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > dei_AuditorTable < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > dei_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 39 < FILENAME > R3. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208163903952" > < tr > < th class =" tl" colspan =" 1" rowspan =" 1" > < div style =" width: 200px;" > < strong > Consolidated Balance Sheets- USD ($) < br > $ in Thousands < / strong > < / div > < / th > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < th class =" th" > < div > Feb. 06, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AssetsCurrentAbstract', window);" > < strong > Current assets: < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAtCarryingValue', window);" > Cash and cash equivalents < / a > < / td > < td class =" nump" > $ 61, 575 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_MarketableSecuritiesCurrent', window);" > Marketable securities, current < / a > < / td > < td class =" nump" > 314, 073 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_SubscriptionReceivables', window);" > Subscription receivable < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" nump" > 1 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_PrepaidExpenseAndOtherAssetsCurrent', window);" > Prepaid expenses and other current assets < / a > < / td > < td class =" nump" > 1, 221 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" rou" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AssetsCurrent', window);" > Total current assets < / a > < / td > < td class =" nump" > 376, 869 < span > < / span > < / td > < td class =" nump" > 1 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_MarketableSecuritiesNoncurrent', window);" > Marketable securities, long- term < / a > < / td > < td class =" nump" > 18, 069 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_PropertyPlantAndEquipmentNet', window);" > Property and equipment, net < / a > < / td > < td class =" nump" > 162 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_OperatingLeaseRightOfUseAsset', window);" > Operating lease right- of- use assets < / a > < / td > < td class =" nump" > 876 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_OtherAssetsNoncurrent', window);" > Other non- current assets < / a > < / td > < td class =" nump" > 43 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" reu" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_Assets', window);" > Total assets < / a > < / td > < td class =" nump" > 396, 019 < span > < / span > < / td > < td class =" nump" > 1 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_LiabilitiesCurrentAbstract', window);" > < strong > Current liabilities: < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AccountsPayableTradeCurrent', window);" > Accounts payable < / a > < / td > < td class =" nump" > 3, 462 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AccruedLiabilitiesAndOtherLiabilities', window);" > Accrued expenses and other current liabilities < / a > < / td > < td class =" nump" > 3, 346 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_OperatingLeaseLiabilityCurrent', window);" > Operating lease liability, current < / a > < / td > < td class =" nump" > 213 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" rou" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_LiabilitiesCurrent', window);" > Total current liabilities < / a > < / td > < td class =" nump" > 13, 043 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_OperatingLeaseLiabilityNoncurrent', window);" > Operating lease liability, non- current < / a > < / td > < td class =" nump" > 755 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" rou" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_Liabilities', window);" > Total liabilities < / a > < / td > < td class =" nump" > 13, 798 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CommitmentsAndContingencies', window);" > Commitments and contingencies (Note 13) < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StockholdersEquityAbstract', window);" > < strong > Stockholders & # 8217; equity: < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CommonStockValue', window);" > Common stock, $ 0. 001 and $ 0. 001 par value as of December 31, 2024 and February 6, 2024, respectively; 545, 000, 000 and 65, 000, 000 shares authorized, 37, 440, 510 and 3, 197, 975 shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively < / a > < / td > < td class =" nump" > 37 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AdditionalPaidInCapital', window);" > Additional paid- in capital < / a > < / td > < td class =" nump" > 463, 018 < span > < / span > < / td > < td class =" nump" > 1 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window);" > Accumulated other comprehensive loss < / a > < / td > < td class =" num" > (41) < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_RetainedEarningsAccumulatedDeficit', window);" > Accumulated deficit < / a > < / td > < td class =" num" > (83, 724) < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" reu" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StockholdersEquity', window);" > Total stockholders & # 8217; equity < / a > < / td > < td class =" nump" > 382, 221 < span > < / span > < / td > < td class =" nump" > 1 < span > < / span > < / td > < / tr > < tr class =" rou" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_LiabilitiesAndStockholdersEquity', window);" > Total liabilities, convertible preferred stock and stockholders & # 8217; equity < / a > < / td > < td class =" nump" > 396, 019 < span > < / span > < / td > < td class =" nump" > 1 < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_RelatedPartyTransactionsByRelatedPartyAxis = us- gaap_RelatedPartyMember', window);" > Related Party < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_LiabilitiesCurrentAbstract', window);" > < strong > Current liabilities: < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AccountsPayableOtherCurrent', window);" > Related party accounts payable and other current liabilities < / a > < / td > < td class =" nump" > 6, 022 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StatementClassOfStockAxis = orka_SeriesAConvertiblePreferredStockMember', window);" > Series A Convertible Preferred Stock < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_LiabilitiesCurrentAbstract', window);" > < strong > Current liabilities: < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_TemporaryEquityCarryingAmountAttributableToParent', window);" > Convertible preferred stock, value < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StatementClassOfStockAxis = orka_SeriesANonVotingConvertiblePreferredStockMember', window);" > Series A Non- Voting Convertible Preferred Stock < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_LiabilitiesCurrentAbstract', window);" > < strong > Current liabilities: < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_TemporaryEquityCarryingAmountAttributableToParent', window);" > Convertible preferred stock, value < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StatementClassOfStockAxis = orka_SeriesBNonVotingConvertiblePreferredStockAmountMember', window);" > Series B Non- Voting Convertible Preferred Stock < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StockholdersEquityAbstract', window);" > < strong > Stockholders & # 8217; equity: < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_PreferredStockValue', window);" > Series B non- voting convertible preferred stock, $ 0. 001 par value; 251, 504 and no shares authorized as of December 31, 2024 and February 6, 2024, respectively; 137, 138 and no shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively < / a > < / td > < td class =" nump" > $ 2, 931 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_SubscriptionReceivables" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of subscription receivable from investors who have been allocated common stock. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_SubscriptionReceivables < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AccountsPayableOtherCurrent" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (19) (a)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AccountsPayableOtherCurrent < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AccountsPayableTradeCurrent" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity' s business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (19) (a)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 210 < br >- SubTopic 10 < br >- Section 45 < br >- Paragraph 8 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483467 / 210- 10- 45- 8 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AccountsPayableTradeCurrent < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AccruedLiabilitiesAndOtherLiabilities" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AccruedLiabilitiesAndOtherLiabilities < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 220 < br >- SubTopic 10 < br >- Section 45 < br >- Paragraph 14A < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 14A < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 11 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 11 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 40 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 2 < br >- Subparagraph (g) (2) (ii) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480016 / 944- 40- 65- 2 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 40 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 2 < br >- Subparagraph (h) (2) < br >- Publisher FASB

< br >- URI https: / / asc. fasb. org / 1943274 / 2147480016 / 944- 40- 65- 2 < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (30) (a) (4)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 7- 03 (a) (23) (a) (3)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1 < br > < br > Reference 7: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 220 < br >- SubTopic 10 < br >- Section 45 < br >- Paragraph 14 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 14 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AdditionalPaidInCapital" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid- in capital (APIC) for common and preferred stock. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 852 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 10 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481372 / 852- 10- 55- 10 < br > < br > Reference 2: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 946 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 04 (18)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1 < br > < br > Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (30) (a) (1)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AdditionalPaidInCapital < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_Assets" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of asset recognized for present right to economic benefit. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 48 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482785 / 280- 10- 55- 48 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 49 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482785 / 280- 10- 55- 49 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 270 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482964 / 270- 10- 50- 1 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 32 < br >- Subparagraph (ee) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 32 < br > < br > Reference 5: http: / / fasb. org / us- gaap / role / ref / otherTransitionRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 32 < br >- Subparagraph (d) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 32 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 22 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 22 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 810 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Subparagraph (bb) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481203 / 810- 10- 50- 3 < br > < br > Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 810 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 25 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481231 / 810- 10- 45- 25 < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 235 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 4- 08 (g) (1) (ii)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1 < br > < br > Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 323 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481687 / 323- 10- 50- 3 < br > < br > Reference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 825 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 28 < br >- Subparagraph (f) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482907 / 825- 10- 50- 28 < br > < br > Reference 12: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 852 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 10 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481372 / 852- 10- 55- 10 < br > < br > Reference 13: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 946 < br >- SubTopic 830 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 12 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479168 / 946- 830- 55- 12 < br > < br > Reference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 7- 03 (a) (12)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1 < br > < br > Reference 15: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 04 (8)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1 < br > < br > Reference 16: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (18)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 17: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (i)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 18: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (ii)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 19: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (iii)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 20: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (iii) (A)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 21: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (iv)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 22: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (5)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 23: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (i)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 24: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iii) (A)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 25: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iii) (B)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 26: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iv)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 27: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (5)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 28: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 852 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 7 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481404 / 852- 10- 50- 7 < br > < br > Reference 29: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 30 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 30 < br > < br > Reference 30: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 942 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 9- 03 (11)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478546 / 942- 210- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_Assets < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AssetsCurrent" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of asset recognized for present right to economic benefit, classified as current. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 810 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Subparagraph (bb) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481203 / 810- 10- 50- 3 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 810 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 25 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481231 / 810- 10- 45- 25 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 235 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 4- 08 (g) (1) (ii)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 323 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481687 / 323- 10- 50- 3 < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 825 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 28 < br >- Subparagraph (f) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482907 / 825- 10- 50- 28 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 852 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 10 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481372 / 852- 10- 55- 10 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 1 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483467 / 210- 10- 45- 1 < br > < br > Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX

210. 5- 02 (9)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (i)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 10: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (ii)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 11: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (iii)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 12: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (iii) (A)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 13: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (iv)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (5)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 15: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (i)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 16: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iii) (A)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 17: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iii) (B)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 18: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iv)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 19: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (5)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 20: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 852 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 7 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481404 / 852- 10- 50- 7 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AssetsCurrent < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AssetsCurrentAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AssetsCurrentAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_CashAndCashEquivalentsAtCarryingValue" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short- term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (1)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 1 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483467 / 210- 10- 45- 1 < br > < br > Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 230 < br >- SubTopic 10 < br >- Section 45 < br >- Paragraph 4 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 4 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_CashAndCashEquivalentsAtCarryingValue < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_CommitmentsAndContingencies" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company' s resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 942 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 9- 03 (17)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478546 / 942- 210- S99- 1 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (25)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 7- 03 (a) (19)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 04 (15)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_CommitmentsAndContingencies < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_CommonStockValue" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (29)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 852 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 10 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481372 / 852- 10- 55- 10 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 7- 03 (a) (22)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_CommonStockValue < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_Liabilities" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (22)) < br >- SubTopic 10 < br >- Topic 210 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (20)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (24)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 4: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (19)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 5: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (25)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 6: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (26)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 7: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (23)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 8: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (21)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 810 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481203 / 810- 10- 50- 3 < br > < br > Reference 10: http: / / www. xbrl. org / 2003 / role /

disclosureRef < br >- Topic 810 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 25 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481231 / 810- 10- 45- 25 < br > < br > Reference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 810 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Subparagraph (bb) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481203 / 810- 10- 50- 3 < br > < br > Reference 12: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 235 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 4- 08 (g) (1) (ii)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1 < br > < br > Reference 13: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 323 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481687 / 323- 10- 50- 3 < br > < br > Reference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 825 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 28 < br >- Subparagraph (f) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482907 / 825- 10- 50- 28 < br > < br > Reference 15: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 946 < br >- SubTopic 830 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 12 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479168 / 946- 830- 55- 12 < br > < br > Reference 16: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 04 (14)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1 < br > < br > Reference 17: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (i)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 18: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (ii)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 19: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (iii) (A)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 20: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (iv)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 21: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (5)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 22: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (i)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 23: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iii) (A)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 24: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iii) (B)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 25: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iv)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 26: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (5)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 27: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 852 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 7 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481404 / 852- 10- 50- 7 < br > < br > Reference 28: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 852 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 7 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481404 / 852- 10- 50- 7 < br > < br > Reference 29: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 30 < br >- Subparagraph (d) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 30 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_Liabilities < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_LiabilitiesAndStockholdersEquity" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 852 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 10 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481372 / 852- 10- 55- 10 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 7- 03 (a) (25)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1 < br > < br > Reference 3: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 235 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 4- 08 (g) (1) (ii)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1 < br > < br > Reference 4: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 323 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481687 / 323- 10- 50- 3 < br > < br > Reference 5: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 825 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 28 < br >- Subparagraph (f) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482907 / 825- 10- 50- 28 < br > < br > Reference 6: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 942 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 9- 03 (23)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478546 / 942- 210- S99- 1 < br > < br > Reference 7: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (32)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_LiabilitiesAndStockholdersEquity < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_LiabilitiesCurrent" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (21)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 810 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481203 / 810- 10- 50- 3 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 810 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 25 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481231 / 810- 10- 45- 25 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 810 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Subparagraph (bb) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481203 / 810- 10- 50- 3 < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 235 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 4- 08 (g) (1) (ii)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 323 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481687 / 323- 10- 50- 3 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 825 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 28 < br >- Subparagraph (f) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482907 / 825- 10- 50- 28 < br > < br > Reference 8: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 852 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 10 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481372 / 852- 10- 55- 10 < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 5 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483467 / 210- 10- 45- 5 < br > < br > Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (i)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 11: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (ii)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 12: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (iii) (A)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 13: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (iv)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (5)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 15: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (i)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 16: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iii) (A)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 17: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iii) (B)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 18: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iv)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 19: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (5)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 20: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 852 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 7 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481404 / 852- 10- 50- 7 < br > < br > Reference 21: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 852 < br >- SubTopic 10 < br >- Name Accounting

Standards Codification < br >- Section 50 < br >- Paragraph 7 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481404 / 852- 10- 50- 7 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_LiabilitiesCurrent < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_LiabilitiesCurrentAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_LiabilitiesCurrentAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_MarketableSecuritiesCurrent" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of investment in marketable security, classified as current. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (2)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_MarketableSecuritiesCurrent < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_MarketableSecuritiesNoncurrent" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of investment in marketable security, classified as noncurrent. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (2)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_MarketableSecuritiesNoncurrent < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_OperatingLeaseLiabilityCurrent" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Present value of lessee' s discounted obligation for lease payments from operating lease, classified as current. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 842 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 1 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479041 / 842- 20- 45- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_OperatingLeaseLiabilityCurrent < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_OperatingLeaseLiabilityNoncurrent" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Present value of lessee' s discounted obligation for lease payments from operating lease, classified as noncurrent. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 842 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 1 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479041 / 842- 20- 45- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_OperatingLeaseLiabilityNoncurrent < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_OperatingLeaseRightOfUseAsset" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of lessee' s right to use underlying asset under operating lease. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 842 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 1 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479041 / 842- 20- 45- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_OperatingLeaseRightOfUseAsset < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_OtherAssetsNoncurrent" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of noncurrent assets classified as other. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (17)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_OtherAssetsNoncurrent < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_PreferredStockValue" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (28)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 852 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 10 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481372 / 852- 10- 55- 10 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 7- 03 (a) (21)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_PreferredStockValue < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_PrepaidExpenseAndOtherAssetsCurrent" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (9)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_PrepaidExpenseAndOtherAssetsCurrent < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_PropertyPlantAndEquipmentNet" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- SubTopic 10 < br >- Topic 360 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482099 / 360- 10- 50- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 842 < br >-

SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 7A < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478964 / 842- 20- 50- 7A < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 852 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 10 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481372 / 852- 10- 55- 10 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 7- 03 (a) (8)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1 < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 942 < br >- SubTopic 360 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478451 / 942- 360- 50- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_PropertyPlantAndEquipmentNet < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_RetainedEarningsAccumulatedDeficit" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of accumulated undistributed earnings (deficit). < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (30) (a) (3)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 852 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 10 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481372 / 852- 10- 55- 10 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 40 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 2 < br >- Subparagraph (g) (2) (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480016 / 944- 40- 65- 2 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 40 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 2 < br >- Subparagraph (h) (2) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480016 / 944- 40- 65- 2 < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 11 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480990 / 946- 20- 50- 11 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 7- 03 (a) (23) (a) (4)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 04 (17)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1 < br > < br > Reference 8: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 3- 04) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480008 / 505- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_RetainedEarningsAccumulatedDeficit < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StockholdersEquity" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (29)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (30)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (31)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 852 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 10 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481372 / 852- 10- 55- 10 < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 946 < br >- SubTopic 830 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 12 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479168 / 946- 830- 55- 12 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 04 (19)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SX 210. 6- 05 (4)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 2 < br > < br > Reference 8: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 09 (4) (b)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3 < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 09 (6)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3 < br > < br > Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 09 (7)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3 < br > < br > Reference 11: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 235 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 4- 08 (g) (1) (ii)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1 < br > < br > Reference 12: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 323 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481687 / 323- 10- 50- 3 < br > < br > Reference 13: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 825 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 28 < br >- Subparagraph (f) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482907 / 825- 10- 50- 28 < br > < br > Reference 14: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 310 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SAB Topic 4. E) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480418 / 310- 10- S99- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StockholdersEquity < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StockholdersEquityAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StockholdersEquityAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_TemporaryEquityCarryingAmountAttributableToParent" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Carrying amount, attributable to parent, of an entity' s issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 7- 03 (a) (23) (a) (1)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SAB Topic 14. E. Q2) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479830 / 718- 10- S99- 1 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (i)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (iv)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (5)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (i)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iv)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (5)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_TemporaryEquityCarryingAmountAttributableToParent < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_RelatedPartyTransactionsByRelatedPartyAxis = us- gaap_RelatedPartyMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr

```
> < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_RelatedPartyTransactionsByRelatedPartyAxis = us- gaap_RelatedPartyMember < / td > < / tr > < tr
> < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td >
na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div >
< / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StatementClassOfStockAxis =
orka_SeriesAConvertiblePreferredStockMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > <
tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0"
cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StatementClassOfStockAxis =
orka_SeriesAConvertiblePreferredStockMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td >
< / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong >
Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style
=" display: none;" id =" defref_us- gaap_StatementClassOfStockAxis = orka_SeriesANonVotingConvertiblePreferredStockMember" > < tr > < td class =" hide" > < a style =" color: white;" href
=" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" >
us- gaap_StatementClassOfStockAxis = orka_SeriesANonVotingConvertiblePreferredStockMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong >
Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < /
td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding ="
0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StatementClassOfStockAxis = orka_SeriesBNonVotingConvertiblePreferredStockAmountMember" >
< tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding:
2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: <
/ strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StatementClassOfStockAxis = orka_SeriesBNonVotingConvertiblePreferredStockAmountMember < / td > < / tr > < tr > < td
style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < /
td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < /
div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 40 < FILENAME > R4. htm < DESCRIPTION >
IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src ="
Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style.
display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0"
cellspacing =" 2" id =" idm46208162076416" > < tr > < th class =" tl" colspan =" 1" rowspan =" 1" > < div style =" width: 200px;" > < strong > Consolidated Balance Sheets (Parentheticals)- $ /
shares < br > < / strong > < / div > < / th > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < th class =" th" > < div > Feb. 06, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class ="
pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CommonStockParOrStatedValuePerShare',
window);" > Common stock, par value (in Dollars per share) < / a > < / td > < td class =" nump" > $ 0. 001 < span > < / span > < / td > < td class =" nump" > $ 0. 001 < span > < / span > < / td > < /
tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_CommonStockSharesAuthorized', window);" > Common stock, shares authorized < / a > < / td > < td class =" nump" > 545, 000, 000 < span > < / span > < / td > < td class =" nump" > 65,
000, 000 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show.
showAR (this,' defref_us- gaap_CommonStockSharesIssued', window);" > Common stock, shares issued < / a > < / td > < td class =" nump" > 37, 440, 510 < span > < / span > < / td > < td class ="
nump" > 3, 197, 975 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick ="
Show. showAR (this,' defref_us- gaap_CommonStockSharesOutstanding', window);" > Common stock, shares outstanding < / a > < / td > < td class =" nump" > 37, 440, 510 < span > < / span > <
/ td > < td class =" nump" > 3, 197, 975 < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript:
void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StatementClassOfStockAxis = orka_SeriesAConvertiblePreferredStockMember', window);" > Series A Convertible Preferred Stock <
/ a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom:
0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_TemporaryEquityParOrStatedValuePerShare', window);" > Convertible
preferred stock, par value (in Dollars per share) < / a > < / td > < td class =" nump" > $ 0. 0001 < span > < / span > < / td > < td class =" nump" > $ 0. 0001 < span > < / span > < / td > < / tr > < tr
class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_TemporaryEquitySharesAuthorized', window);" > Convertible preferred stock, shares authorized < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" nump" > 20,
000, 000 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show.
showAR (this,' defref_us- gaap_TemporaryEquitySharesIssued', window);" > Convertible preferred stock, shares issued < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class
=" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show.
showAR (this,' defref_us- gaap_TemporaryEquitySharesOutstanding', window);" > Convertible preferred stock, shares outstanding < / a > < / td > < td class =" text" > < span > < / span > < / td >
< td class =" text" > < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick ="
Show. showAR (this,' defref_us- gaap_StatementClassOfStockAxis = orka_SeriesANonVotingConvertiblePreferredStockMember', window);" > Series A Non- Voting Convertible Preferred
Stock < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border-
bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_TemporaryEquityParOrStatedValuePerShare', window);" >
Convertible preferred stock, par value (in Dollars per share) < / a > < / td > < td class =" nump" > $ 0. 001 < span > < / span > < / td > < td class =" nump" > $ 0. 001 < span > < / span > < / td > < /
tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_TemporaryEquitySharesAuthorized', window);" > Convertible preferred stock, shares authorized < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span
> < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_us- gaap_TemporaryEquitySharesIssued', window);" > Convertible preferred stock, shares issued < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > <
span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_us- gaap_TemporaryEquitySharesOutstanding', window);" > Convertible preferred stock, shares outstanding < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class ="
text" > < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show.
showAR (this,' defref_us- gaap_StatementClassOfStockAxis = orka_SeriesBNonVotingConvertiblePreferredStockAmountMember', window);" > Series B Non- Voting Convertible Preferred
Stock < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border-
bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_PreferredStockParOrStatedValuePerShare', window);" > Non-
voting convertible preferred stock, par value (in Dollars per share) < / a > < / td > < td class =" nump" > $ 0. 001 < span > < / span > < / td > < td class =" nump" > $ 0. 001 < span > < / span > < /
td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_PreferredStockSharesAuthorized', window);" > Non- voting convertible preferred stock, shares authorized < / a > < / td > < td class =" nump" > 251, 504 < span > < / span > < / td > < td
class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick ="
Show. showAR (this,' defref_us- gaap_PreferredStockSharesIssued', window);" > Non- voting convertible preferred stock, shares issued < / a > < / td > < td class =" nump" > 137, 138 < span > < /
span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void
(0);" onclick =" Show. showAR (this,' defref_us- gaap_PreferredStockSharesOutstanding', window);" > Non- voting convertible preferred stock, shares outstanding < / a > < / td > < td class ="
nump" > 137, 138 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing
=" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_CommonStockParOrStatedValuePerShare" > < tr > < td class =" hide" > < a style =" color: white;" href ="
javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" >- Definition < / a > < div > < p > Face amount or stated value per share of common stock. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);"
> References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting
Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (29)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210-
10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0"
cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_CommonStockParOrStatedValuePerShare < / td > < / tr > < tr > < td style
=" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td >
dtr- types: perShareItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td >
instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id ="
defref_us- gaap_CommonStockSharesAuthorized" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > <
tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The maximum number of
common shares permitted to be issued by an entity' s charter and bylaws. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style ="
display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99
< br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (29)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 2: http: /
/ www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >-
Subparagraph (SX 210. 6- 04 (16) (a)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);"
onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td >
< td style =" white- space: nowrap;" > us- gaap_CommonStockSharesAuthorized < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: <
/ strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < /
strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border
=" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_CommonStockSharesIssued" > < tr > < td class =" hide" > < a style =" color:
white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick
=" Show. toggleNext (this);" >- Definition < / a > < div > < p > Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were
issued, repurchased and remain in the treasury). These shares represent capital invested by the firm' s shareholders and owners, and may be all or only a portion of the number of shares
authorized. Shares issued include shares outstanding and shares held in the treasury. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > <
div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >-
Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (29)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < / p > < / div
> < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > <
strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_CommonStockSharesIssued < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" >
< strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > <
```

strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_CommonStockSharesOutstanding" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- SubTopic 10 < br >- Topic 505 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 2 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (29)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SX 210. 6- 05 (4)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 2 < br > < br > Reference 4: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 09 (4) (b)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3 < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 04 (16) (a)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1 < br > < br > Reference 6: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 09 (7)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_CommonStockSharesOutstanding < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_PreferredStockParOrStatedValuePerShare" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (28)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 13 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_PreferredStockParOrStatedValuePerShare < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: perShareItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_PreferredStockSharesAuthorized" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity' s charter and bylaws. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (28)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 04 (16) (a)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_PreferredStockSharesAuthorized < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_PreferredStockSharesIssued" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (28)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 13 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_PreferredStockSharesIssued < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_PreferredStockSharesOutstanding" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (28)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SX 210. 6- 05 (4)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 2 < br > < br > Reference 3: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 09 (4) (b)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 04 (16) (a)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1 < br > < br > Reference 5: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 09 (7)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_PreferredStockSharesOutstanding < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_TemporaryEquityParOrStatedValuePerShare" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (27)) < br >- SubTopic 10 < br >- Topic 210 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 480 < br >- SubTopic 10 < br >- Section S99 < br >- Paragraph 1 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480244 / 480- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_TemporaryEquityParOrStatedValuePerShare < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: perShareItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_TemporaryEquitySharesAuthorized" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The maximum number of securities classified as temporary equity that are permitted to be issued by an entity' s charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (27) (b)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_TemporaryEquitySharesAuthorized < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td >

```
instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id ="
defref_us- gaap_TemporaryEquitySharesIssued" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > <
tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The number of securities
classified as temporary equity that have been sold (or granted) to the entity' s shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a
security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type
of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not
solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered
under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered
to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and
stock redeemable by holder only in the event of a change in control of the issuer. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div
style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >-
Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (27) (b)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < / p > < /
div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td
> < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_TemporaryEquitySharesIssued < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space:
nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > <
tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div >
< / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_TemporaryEquitySharesOutstanding" >
< tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding:
2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The number of securities classified as temporary equity that have been issued and
are held by the entity' s shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside
the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or
determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If
convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder
exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot
demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the
event of a change in control of the issuer. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference
1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >-
Subparagraph (SX 210. 5- 02 (27) (b)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);"
onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td >
< td style =" white- space: nowrap;" > us- gaap_TemporaryEquitySharesOutstanding < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace
Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance
Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > <
table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StatementClassOfStockAxis =
orka_SeriesAConvertiblePreferredStockMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > <
tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0"
cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StatementClassOfStockAxis =
orka_SeriesAConvertiblePreferredStockMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td >
< / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong >
Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style
=" display: none;" id =" defref_us- gaap_StatementClassOfStockAxis = orka_SeriesANonVotingConvertiblePreferredStockMember" > < tr > < td class =" hide" > < a style =" color: white;" href
=" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" >
us- gaap_StatementClassOfStockAxis = orka_SeriesANonVotingConvertiblePreferredStockMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong >
Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < /
td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding ="
0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StatementClassOfStockAxis = orka_SeriesBNonVotingConvertiblePreferredStockAmountMember" >
< tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding:
2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: <
/ strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StatementClassOfStockAxis = orka_SeriesBNonVotingConvertiblePreferredStockAmountMember < / td > < / tr > < tr > < td
style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < /
td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < /
div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 41 < FILENAME > R5. htm < DESCRIPTION >
IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src ="
Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style.
display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0"
cellspacing =" 2" id =" idm46208166145072" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Consolidated Statement of Operations and
Comprehensive Loss < br > $ in Thousands < / strong > < / div > < / th > < th class =" th" colspan =" 2" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" colspan =" 2" > < div > Dec. 31,
2024 < / div > < div > USD ($) < / div > < div > $ / shares < / div > < div > shares < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a
class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_OperatingExpensesAbstract', window);" > < strong > Operating expenses < / strong > < / a > < / td > <
td class =" text" > & # 160; < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign
=" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ResearchAndDevelopmentExpense', window);" > Research and development < / a > < / td
> < td class =" nump" > $ 75, 060 < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < sup > [ 1 ] < / sup > < / td > < / tr > < tr class =" re" > < td class =" pl" style ="
border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_GeneralAndAdministrativeExpense', window);" > General
and administrative < / a > < / td > < td class =" nump" > 13, 063 < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < sup > [ 2 ] < / sup > < / td > < / tr > < tr class ="
rou" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_OperatingExpenses',
window);" > Total operating expenses < / a > < / td > < td class =" nump" > 88, 123 < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" reu"
> < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_OperatingIncomeLoss',
window);" > Loss from operations < / a > < / td > < td class =" num" > (88, 123) < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" ro" > <
td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_NonoperatingIncomeExpenseAbstract', window);" > < strong > Other income (expense) < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" fn"
style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show.
showAR (this,' defref_us- gaap_InvestmentIncomeInterest', window);" > Interest income < / a > < / td > < td class =" nump" > 5, 863 < span > < / span > < / td > < td class =" fn" style =" border-
bottom: 0px;" > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_us- gaap_InterestExpenseNonoperating', window);" > Interest expense < / a > < / td > < td class =" num" > (1, 468) < span > < / span > < / td > < td class =" fn" style =" border- bottom:
0px;" > < sup > [ 3 ] < / sup > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show.
showAR (this,' defref_us- gaap_OtherNonoperatingIncome', window);" > Other income, net < / a > < / td > < td class =" nump" > 4 < span > < / span > < / td > < td class =" fn" style =" border-
bottom: 0px;" > < / td > < / tr > < tr class =" rou" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_us- gaap_NonoperatingIncomeExpense', window);" > Total other income, net < / a > < / td > < td class =" nump" > 4, 399 < span > < / span > < / td > < td class =" fn" style =" border-
bottom: 0px;" > < / td > < / tr > < tr class =" reu" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_us- gaap_NetIncomeLoss', window);" > Net loss < / a > < / td > < td class =" num" > (83, 724) < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > <
tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window);" > Unrealized loss on marketable securities < / a > < / td > < td class ="
num" > (41) < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" reu" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a
class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ComprehensiveIncomeNetOfTax', window);" > Comprehensive loss < / a > < / td > < td class =" num" >
$ (83, 765) < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a
class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EarningsPerShareBasic', window);" > Net loss per share attributable to stockholders, basic (in Dollars
per share) | $ / shares < / a > < / td > < td class =" num" > $ (3. 87) < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" re" > < td class =" pl"
style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EarningsPerShareDiluted', window);" > Net loss
per share attributable to stockholders, diluted (in Dollars per share) | $ / shares < / a > < / td > < td class =" num" > $ (3. 87) < span > < / span > < / td > < td class =" fn" style =" border- bottom:
0px;" > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_us- gaap_WeightedAverageNumberOfSharesOutstandingBasic', window);" > Weighted- average shares used in computing net loss per share attributable to stockholders, basic (in Shares)
| shares < / a > < / td > < td class =" nump" > 16, 789, 362 < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" re" > < td class =" pl" style ="
border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_WeightedAverageNumberOfDilutedSharesOutstanding',
window);" > Weighted- average shares used in computing net loss per share attributable to stockholders, diluted (in Shares) | shares < / a > < / td > < td class =" nump" > 16, 789, 362 < span > < /
span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href ="
javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StatementClassOfStockAxis = orka_SeriesANonVotingConvertiblePreferredStockholdersMember', window);" > Series A
Non- Voting Convertible Preferred Stockholders < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class
=" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_NonoperatingIncomeExpenseAbstract', window);" > < strong > Other income (expense) < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" fn"
style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show.
showAR (this,' defref_us- gaap_EarningsPerShareBasic', window);" > Net loss per share attributable to stockholders, basic (in Dollars per share) | $ / shares < / a > < / td > < td class =" num" > $
```

(3, 873. 25) < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EarningsPerShareDiluted', window);" > Net loss per share attributable to stockholders, diluted (in Dollars per share) | $ / shares < / a > < / td > < td class =" num" > $ (3, 873. 25) < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_WeightedAverageNumberOfSharesOutstandingBasic', window);" > Weighted- average shares used in computing net loss per share attributable to stockholders, basic (in Shares) | shares < / a > < / td > < td class =" nump" > 495 < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window);" > Weighted- average shares used in computing net loss per share attributable to stockholders, diluted (in Shares) | shares < / a > < / td > < td class =" nump" > 495 < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StatementClassOfStockAxis = orka_SeriesBNonVotingConvertiblePreferredStockholdersMember', window);" > Series B Non- Voting Convertible Preferred Stockholders < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_NonoperatingIncomeExpenseAbstract', window);" > < strong > Other income (expense) < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EarningsPerShareBasic', window);" > Net loss per share attributable to stockholders, basic (in Dollars per share) | $ / shares < / a > < / td > < td class =" num" > $ (322. 81) < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EarningsPerShareDiluted', window);" > Net loss per share attributable to stockholders, diluted (in Dollars per share) | $ / shares < / a > < / td > < td class =" num" > $ (322. 81) < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_WeightedAverageNumberOfSharesOutstandingBasic', window);" > Weighted- average shares used in computing net loss per share attributable to stockholders, basic (in Shares) | shares < / a > < / td > < td class =" nump" > 51, 946 < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window);" > Weighted- average shares used in computing net loss per share attributable to stockholders, diluted (in Shares) | shares < / a > < / td > < td class =" nump" > 51, 946 < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr > < td colspan =" 3" > < / td > < / tr > < tr > < td colspan =" 3" > < table class =" outerFootnotes" width =" 100 %" > < tr class =" outerFootnote" > < td style =" vertical- align: top; width: 12pt;" valign =" top" > [1] < / td > < td style =" vertical- align: top;" valign =" top" > < span style =" font- family: Times New Roman, Times, Serif" > Includes related party amount of $ 42, 640 for the period from February 6, 2024 (inception) to December 31, 2024 < / span > < / td > < / tr > < tr class =" outerFootnote" > < td style =" vertical- align: top; width: 12pt;" valign =" top" > [2] < / td > < td style =" vertical- align: top;" valign =" top" > < span style =" font- family: Times New Roman, Times, Serif" > Includes related party amount of $ 1, 364 for the period from February 6, 2024 (inception) to December 31, 2024 < / span > < / td > < / tr > < tr class =" outerFootnote" > < td style =" vertical- align: top; width: 12pt;" valign =" top" > [3] < / td > < td style =" vertical- align: top;" valign =" top" > < span style =" font- family: Times New Roman, Times, Serif" > Includes related party amount of $ 1, 468 for the period from February 6, 2024 (inception) to December 31, 2024 < / span > < / td > < / tr > < / table > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ComprehensiveIncomeNetOfTax" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SX 210. 5- 03 (24)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 942 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 9- 04 (26)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478524 / 942- 220- S99- 1 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 7- 04 (22)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147477250 / 944- 220- S99- 1 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 1A < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 1A < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 1B < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 1B < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 7- 04 (20)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147477250 / 944- 220- S99- 1 < br > < br > Reference 7: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 220 < br >- SubTopic 10 < br >- Section 45 < br >- Paragraph 5 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 5 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ComprehensiveIncomeNetOfTax < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_EarningsPerShareBasic" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 6 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 52 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482635 / 260- 10- 55- 52 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 805 < br >- SubTopic 60 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 1 < br >- Subparagraph (g) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147476176 / 805- 60- 65- 1 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 323 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 2 < br >- Subparagraph (g) (3) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478666 / 740- 323- 65- 2 < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 3 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 15 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482635 / 260- 10- 55- 15 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 815 < br >- SubTopic 40 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 1 < br >- Subparagraph (e) (4) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480175 / 815- 40- 65- 1 < br > < br > Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 815 < br >- SubTopic 40 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 1 < br >- Subparagraph (f) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480175 / 815- 40- 65- 1 < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 11 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 11 < br > < br > Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 11 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 11 < br > < br > Reference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 7 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 7 < br > < br > Reference 12: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 2 < br > < br > Reference 13: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 60B < br >- Subparagraph (d) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 60B < br > < br > Reference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 4 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 4 < br > < br > Reference 15: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482662 / 260- 10- 50- 1 < br > < br > Reference 16: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 10 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 10 < br > < br > Reference 17: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SX 210. 5- 03 (25)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2 < br > < br > Reference 18: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 942 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 9- 04 (27)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478524 / 942- 220- S99- 1 < br > < br > Reference 19: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 7- 04 (23)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147477250 / 944- 220- S99- 1 < br > < br > Reference 20: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 7 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 7 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_EarningsPerShareBasic < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: perShareItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_EarningsPerShareDiluted" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 6 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 52 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482635 / 260- 10- 55- 52 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 /

role / disclosureRef < br >- Topic 805 < br >- SubTopic 60 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 1 < br >- Subparagraph (g) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147476176 / 805- 60- 65- 1 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 323 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 2 < br >- Subparagraph (g) (3) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478666 / 740- 323- 65- 2 < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 3 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 15 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482635 / 260- 10- 55- 15 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 815 < br >- SubTopic 40 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 1 < br >- Subparagraph (e) (4) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480175 / 815- 40- 65- 1 < br > < br > Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 815 < br >- SubTopic 40 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 1 < br >- Subparagraph (f) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480175 / 815- 40- 65- 1 < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 11 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 11 < br > < br > Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 11 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 11 < br > < br > Reference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 7 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 7 < br > < br > Reference 12: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 2 < br > < br > Reference 13: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 60B < br >- Subparagraph (d) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 60B < br > < br > Reference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 4 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 4 < br > < br > Reference 15: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482662 / 260- 10- 50- 1 < br > < br > Reference 16: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SX 210. 5- 03 (25)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2 < br > < br > Reference 17: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 942 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 9- 04 (27)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478524 / 942- 220- S99- 1 < br > < br > Reference 18: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 7- 04 (23)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147477250 / 944- 220- S99- 1 < br > < br > Reference 19: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 7 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 7 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_EarningsPerShareDiluted < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: perShareItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_GeneralAndAdministrativeExpense" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SX 210. 5- 03 (4)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 07 (2) (a)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_GeneralAndAdministrativeExpense < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_InterestExpenseNonoperating" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of interest expense classified as nonoperating. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 22 < br >- Subparagraph (d) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 22 < br > < br > Reference 2: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SX 210. 5- 03) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_InterestExpenseNonoperating < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_InvestmentIncomeInterest" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 22 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 22 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 48 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482785 / 280- 10- 55- 48 < br > < br > Reference 3: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SX 210. 5- 03 (7) (b)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 270 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482964 / 270- 10- 50- 1 < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 32 < br >- Subparagraph (ee) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 32 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_InvestmentIncomeInterest < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_NetIncomeLoss" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 6 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 9 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 9 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 805 < br >- SubTopic 60 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 1 < br >- Subparagraph (g) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147476176 / 805- 60- 65- 1 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 323 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 2 < br >- Subparagraph (g) (3) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478666 / 740- 323- 65- 2 < br > < br > Reference 5: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SX 210. 5- 03 (20)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 235 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 4- 08 (g) (1) (ii)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 323 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481687 / 323- 10- 50- 3 < br > < br > Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 825 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 28 < br >- Subparagraph (f) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482907 / 825- 10- 50- 28 < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482765 / 220- 10- 50- 6 < br > < br > Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 3 < br > < br > Reference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (b) (2) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 1 < br > < br > Reference 12: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 815 < br >- SubTopic 40 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 1 < br >- Subparagraph (f) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480175 / 815- 40- 65- 1 < br > < br > Reference 13: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 8 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 8 < br > < br > Reference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 11 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 11 < br > < br > Reference 15: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >-

Section 50 < br >- Paragraph 11 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 11 < br > < br > Reference 16: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 4 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 4 < br > < br > Reference 17: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 946 < br >- SubTopic 830 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 10 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479168 / 946- 830- 55- 10 < br > < br > Reference 18: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 7 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479105 / 946- 220- 45- 7 < br > < br > Reference 19: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 7- 04 (18)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147477250 / 944- 220- S99- 1 < br > < br > Reference 20: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 07 (9)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1 < br > < br > Reference 21: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 09 (1) (d)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3 < br > < br > Reference 22: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (i)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 23: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (ii)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 24: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (iii) (A)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 25: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (iv)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 26: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (5)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 27: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (i)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 28: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iii) (A)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 29: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iii) (B)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 30: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iv)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 31: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (5)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 32: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 60B < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 60B < br > < br > Reference 33: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 205 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 7 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483499 / 205- 20- 50- 7 < br > < br > Reference 34: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 230 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 28 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28 < br > < br > Reference 35: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 1A < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 1A < br > < br > Reference 36: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 1B < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 1B < br > < br > Reference 37: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 942 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 9- 04 (22)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478524 / 942- 220- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_NetIncomeLoss < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_NonoperatingIncomeExpense" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The aggregate amount of income or expense from ancillary business- related activities (that is to say, excluding major activities considered part of the normal operations of the business). < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SX 210. 5- 03 (7)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_NonoperatingIncomeExpense < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_NonoperatingIncomeExpenseAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_NonoperatingIncomeExpenseAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_OperatingExpenses" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_OperatingExpenses < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_OperatingExpensesAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_OperatingExpensesAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_OperatingIncomeLoss" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The net result for the period of deducting operating expenses from operating revenues. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 22 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 22 < br > < br > Reference 2: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 32 < br >- Subparagraph (f) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 32 < br > < br > Reference 3: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 30 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 30 < br > < br > Reference 4: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 270 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482964 / 270- 10- 50- 1 < br > < br > Reference 5: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 32 < br >- Subparagraph (ee) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 32 < br > < br > Reference 6: http: / / fasb. org / us- gaap / role / ref / otherTransitionRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 32 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 32 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 31 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 31 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_OperatingIncomeLoss < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held- to- maturity) from transfer to available- for- sale. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 320 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 9 < br >- Subparagraph (d) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 9 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 10A < br >- Subparagraph (e) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 10A < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 11 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 11 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_OtherNonoperatingIncome" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of income related to nonoperating activities, classified as other. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SX 210. 5- 03 (7) (d)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_OtherNonoperatingIncome < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ResearchAndDevelopmentExpense" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write- down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 48 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482785 / 280- 10- 55- 48 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 985 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481283 / 985- 20- 50- 2 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 730 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482916 / 730- 10- 50- 1 < br > < br > Reference 4: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 912 < br >- SubTopic 730 < br >- Name Accounting Standards Codification < br >- Section 25 < br >- Paragraph 1 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479532 / 912- 730- 25- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ResearchAndDevelopmentExpense < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_WeightedAverageNumberOfDilutedSharesOutstanding" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482662 / 260- 10- 50- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 16 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 16 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_WeightedAverageNumberOfDilutedSharesOutstanding < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_WeightedAverageNumberOfSharesOutstandingBasic" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482662 / 260- 10- 50- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 10 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 10 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_WeightedAverageNumberOfSharesOutstandingBasic < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StatementClassOfStockAxis = orka_SeriesANonVotingConvertiblePreferredStockholdersMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StatementClassOfStockAxis = orka_SeriesANonVotingConvertiblePreferredStockholdersMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StatementClassOfStockAxis = orka_SeriesBNonVotingConvertiblePreferredStockholdersMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StatementClassOfStockAxis = orka_SeriesBNonVotingConvertiblePreferredStockholdersMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 42 < FILENAME > R6. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208163290000" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Consolidated Statement of Operations and Comprehensive Loss (Parentheticals) < br > $ in Thousands < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < div > USD ($) < / div > < / th > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_IncomeStatementLocationAxis = us- gaap_ResearchAndDevelopmentExpenseMember', window);" > Research and development < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CostsAndExpensesRelatedParty', window);" > Related party amount < / a > < / td > < td class =" nump" > $ 42, 640 < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_IncomeStatementLocationAxis = us- gaap_GeneralAndAdministrativeExpenseMember', window);" > General and administrative < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CostsAndExpensesRelatedParty', window);" > Related party amount < / a > < / td > < td class =" nump" > 1, 364 < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_IncomeStatementLocationAxis = us- gaap_InterestExpenseMember', window);" > Interest Expense < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CostsAndExpensesRelatedParty', window);" > Related party amount < / a > < / td > < td class =" nump" > $ 1, 468 < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_CostsAndExpensesRelatedParty" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Costs of sales and operating expenses for the period incurred from transactions with related parties. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SX 210. 5- 03 (2)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_CostsAndExpensesRelatedParty < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0"

```
cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_IncomeStatementLocationAxis = us- gaap_ResearchAndDevelopmentExpenseMember" > < tr > < td class
=" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > <
td style =" white- space: nowrap;" > us- gaap_IncomeStatementLocationAxis = us- gaap_ResearchAndDevelopmentExpenseMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white-
space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong >
Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table
border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_IncomeStatementLocationAxis = us-
gaap_GeneralAndAdministrativeExpenseMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr >
< tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0"
cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_IncomeStatementLocationAxis = us-
gaap_GeneralAndAdministrativeExpenseMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td
> < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong >
Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style
=" display: none;" id =" defref_us- gaap_IncomeStatementLocationAxis = us- gaap_InterestExpenseMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void
(0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >-
Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_IncomeStatementLocationAxis = us- gaap_InterestExpenseMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < /
strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr
> < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT >
< DOCUMENT > < TYPE > XML < SEQUENCE > 43 < FILENAME > R7. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel ="
stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text /
javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < /
head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208161539504" > < tr > < th class =" tl" colspan =" 1"
rowspan =" 1" > < div style =" width: 200px;" > < strong > Consolidated Statement of Convertible Preferred Stock and Stockholders & # 8217; Equity- 11 months ended Dec. 31, 2024- USD ($) <
br > $ in Thousands < / strong > < / div > < / th > < th class =" th" > < div > Convertible Preferred Stock < / div > < div > Series A < / div > < / th > < th class =" th" > < div > Convertible Preferred
Stock < / div > < div > Series A Non- Voting < / div > < / th > < th class =" th" > < div > Convertible Preferred Stock < / div > < div > Series B Non- Voting < / div > < / th > < th class =" th" > < div
> Common Stock < / div > < / th > < th class =" th" > < div > Additional Paid- in Capital < / div > < / th > < th class =" th" > < div > Accumulated Other Comprehensive Gain (Loss) < / div > < / th
> < th class =" th" > < div > Accumulated Deficit < / div > < / th > < th class =" th" > < div > Series A < / div > < / th > < th class =" th" > < sup > [ 1 ] < / sup > < / th > < th class =" th" > < div >
Total < / div > < / th > < / tr > < tr class =" rc" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_us- gaap_StockholdersEquity', window);" > Balances at Feb. 05, 2024 < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td
class =" text" > < span > < / span > < / td > < td class =" nump" > $ 3 < span > < / span > < / td > < td class =" num" > $ (2) < span > < / span > < / td > < td class =" text" > < span > < / span > < /
td > < td class =" text" > < span > < / span > < / td > < td colspan =" 2" class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 1 < span > < / span > < / td > < / tr > < tr class
=" rc" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SharesOutstanding',
window);" > Balances (in Shares) at Feb. 05, 2024 < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < /
span > < / td > < td class =" nump" > 3, 197, 975 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td
class =" text" > & # 160; < span > < / span > < / td > < td colspan =" 2" class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr
class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_StockIssuedDuringPeriodValueNewIssues', window);" > Issuance of common stock < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < /
td > < td class =" text" > < span > < / span > < / td > < td class =" nump" > $ 2 < span > < / span > < / td > < td class =" num" > (2) < span > < / span > < / td > < td class =" text" > < span > < / span
> < / td > < td class =" text" > < span > < / span > < / td > < td colspan =" 2" class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class
=" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_StockIssuedDuringPeriodSharesNewIssues', window);" > Issuance of common stock (in Shares) < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span >
< / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" nump" > 2, 207, 553 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class
=" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td colspan =" 2" class =" text" > & # 160; < span > < / span > < / td > < td class =" text"
> & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show.
showAR (this,' defref_us- gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window);" > Issuance of Series A convertible preferred stock, net of issuance costs of $ 69 < / a > < /
td > < td class =" nump" > $ 2, 931 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < /
span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td colspan =" 2" class =" text" >
& # 160; < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class ="
a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window);" > Issuance of Series A convertible
preferred stock, net of issuance costs of $ 69 (in Shares) < / a > < / td > < td class =" nump" > 20, 000, 000 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class ="
text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td
> < td class =" text" > & # 160; < span > < / span > < / td > < td colspan =" 2" class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr >
< tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities', window);" > Exchange of Series A convertible preferred stock for Series B non- voting convertible
preferred stock upon the closing of the reverse capitalization < / a > < / td > < td class =" num" > $ (2, 931) < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class ="
nump" > $ 2, 931 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td
class =" text" > < span > < / span > < / td > < td colspan =" 2" class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 2, 931 < span > < / span > < / td > < / tr > < tr class =" ro"
> < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window);" > Exchange of Series A convertible preferred stock for Series B non- voting convertible
preferred stock upon the closing of the reverse capitalization (in Shares) < / a > < / td > < td class =" num" > (20, 000, 000) < span > < / span > < / td > < td class =" text" > < span > < / span > < / td
> < td class =" nump" > 137, 138 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160;
< span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td colspan =" 2" class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span >
< / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_us- gaap_StockIssuedDuringPeriodValueConversionOfUnits', window);" > Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse
recapitalization < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" nump"
> $ 3 < span > < / span > < / td > < td class =" nump" > 26, 445 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td
colspan =" 2" class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 26, 448 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom:
0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window);" >
Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization (in Shares) < / a > < / td > < td class =" text" > < span > < / span > <
/ td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" nump" > 2, 722, 207 < span > < / span > < / td > < td class =" text" > & # 160; <
span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td colspan =" 2" class =" text" > & # 160; < span > < /
span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href ="
javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos', window);" > Issuance of
common stock and pre- funded warrants in the Pre- Closing Financing < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class ="
text" > < span > < / span > < / td > < td class =" nump" > $ 20 < span > < / span > < / td > < td class =" nump" > 248, 437 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td >
< td class =" text" > < span > < / span > < / td > < td colspan =" 2" class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 248, 457 < span > < / span > < / td > < / tr > < tr class
=" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost', window);" > Issuance of common stock and pre- funded warrants in the Pre-
Closing Financing (in Shares) < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td
class =" nump" > 20, 061, 932 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > &
# 160; < span > < / span > < / td > < td colspan =" 2" class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td
class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window);" > Issuance costs of Pre- Closing Financing and reverse recapitalization < / a > < / td > < td class =" text" > <
span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" num" > (20,
504) < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td colspan =" 2" class =" text" > & # 160; < span > < / span > < /
td > < td class =" num" > (20, 504) < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href ="
javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe', window);" > Issuance of
common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class
=" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" nump" > $ 1 < span > < / span > < / td > < td class =" nump" > 4, 999 < span > < / span > < / td >
< td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td colspan =" 2" class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 5,
000 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show.
showAR (this,' defref_orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger', window);" > Issuance of common stock
to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization (in Shares) < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class ="
text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" nump" > 1, 208, 883 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < /
td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td colspan =" 2" class =" text" > & # 160; < span > < / span > < / td > < td
class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void
(0);" onclick =" Show. showAR (this,' defref_orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr', window);" > Issuance of common stock, Series A
non- voting convertible preferred stock, and pre- funded warrants in connection with the PIPE Financing < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" nump" > $
56, 097 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" nump" > $ 6 < span > < / span > < / td > < td class =" nump" > 144, 433 < span > < / span > < / td >
< td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td colspan =" 2" class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 144,
```

439 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant', window);" > Issuance of common stock, Series A non- voting convertible preferred stock, and pre- funded warrants in connection with the PIPE Financing (in Shares) < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" nump" > 2, 439 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" nump" > 5, 600, 000 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td colspan =" 2" class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_IssuanceCostOfPIPEFinancing', window);" > Issuance costs of PIPE Financing < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" num" > $ (3, 263) < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" num" > (8, 592) < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td colspan =" 2" class =" text" > & # 160; < span > < / span > < / td > < td class =" num" > (8, 592) < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock', window);" > Conversion of Series A non- voting convertible preferred stock to common stock < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" num" > $ (52, 834) < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" nump" > $ 2 < span > < / span > < / td > < td class =" nump" > 52, 832 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td colspan =" 2" class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 52, 834 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares', window);" > Conversion of Series A non- voting convertible preferred stock to common stock (in Shares) < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" num" > (2, 439) < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" nump" > 2, 439, 000 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td colspan =" 2" class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window);" > Issuance of common stock under employee stock purchase plan < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" nump" > 53 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td colspan =" 2" class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 53 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window);" > Issuance of common stock under employee stock purchase plan (in Shares) < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" nump" > 2, 960 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td colspan =" 2" class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window);" > Reclassification of the Paruka warrant from liability to equity < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" nump" > 10, 357 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td colspan =" 2" class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 10, 357 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window);" > Stock- based compensation expense < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" nump" > 4, 562 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td colspan =" 2" class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 4, 562 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window);" > Unrealized loss on marketable securities < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" num" > (41) < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td colspan =" 2" class =" text" > & # 160; < span > < / span > < / td > < td class =" num" > (41) < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_NetIncomeLoss', window);" > Net loss < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" num" > (65, 037) < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" num" > (83, 724) < span > < / span > < / td > < td colspan =" 2" class =" num" > $ (1, 918) < span > < / span > < / td > < td class =" num" > (83, 724) < span > < / span > < / td > < / tr > < tr class =" rc" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StockholdersEquity', window);" > Balances at Dec. 31, 2024 < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" nump" > $ 2, 931 < span > < / span > < / td > < td class =" nump" > $ 37 < span > < / span > < / td > < td class =" nump" > $ 463, 018 < span > < / span > < / td > < td class =" num" > $ (41) < span > < / span > < / td > < td class =" num" > $ (83, 724) < span > < / span > < / td > < td colspan =" 2" class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 382, 221 < span > < / span > < / td > < / tr > < tr class =" rc" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SharesOutstanding', window);" > Balances (in Shares) at Dec. 31, 2024 < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" nump" > 137, 138 < span > < / span > < / td > < td class =" nump" > 37, 440, 510 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td colspan =" 2" class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr > < td colspan =" 11" > < / td > < / tr > < tr > < td colspan =" 11" > < table class =" outerFootnotes" width =" 100 %" > < tr class =" outerFootnote" > < td style =" vertical- align: top; width: 12pt;" valign =" top" > [1] < / td > < td style =" vertical- align: top;" valign =" top" > < span style =" font- family: Times New Roman, Times, Serif" > The weighted- average number of shares of as- converted Company Series A Preferred Stock used in the loss allocation was 495, 191 for the period from February 6, 2024 (inception) to December 31, 2024. < / span > < / td > < / tr > < / table > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_IssuanceCostOfPIPEFinancing" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Issuance cost of PIPE financing. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_IssuanceCostOfPIPEFinancing < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Issuance of common stock and pre- funded warrants in the preclosing financing, net of offering costs of $ [x] million. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Issuance of common stock and pre- funded warrants in the preclosing financing, net of offering costs of $ [x] million. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Issuance of common stock, Series A non- voting convertible preferred stock, and pre- funded warrants in connection with the Private Placement, net of offering costs of $ [x] million. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Issuance of common stock, Series A non- voting convertible preferred stock, and pre- funded warrants in connection with the Private Placement, net of offering costs of $ [x] million. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void

(0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the Reverse Merger. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the Reverse Merger. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Represent the amount of conversion of non- voting convertible preferred stock to common stock. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Number of shares conversion of non- voting convertible preferred stock to common stock. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Number of shares classified as temporary equity issued during the period. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Number of shares classified as temporary equity issued conversion of convertible securities. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Value of stock classified as temporary equity conversion of convertible securities during the period. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of increase to additional paid- in capital (APIC) for recognition of cost for award under share- based payment arrangement. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 35 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480483 / 718- 10- 35- 2 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 718 < br >- SubTopic 20 < br >- Section 55 < br >- Paragraph 13 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481089 / 718- 20- 55- 13 < br > < br > Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 718 < br >- SubTopic 20 < br >- Section 55 < br >- Paragraph 12 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481089 / 718- 20- 55- 12 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- SubTopic 10 < br >- Topic 505 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 2 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 3- 04) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480008 / 505- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- SubTopic 10 < br >- Topic 505 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 2 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 3- 04) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480008 / 505- 10- S99- 1 < br > < br > Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 470 < br >- SubTopic 20 < br >- Section 25 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481284 / 470- 20- 25- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period

Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_NetIncomeLoss" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 6 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 9 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 9 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 805 < br >- SubTopic 60 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 1 < br >- Subparagraph (g) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147476176 / 805- 60- 65- 1 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 323 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 2 < br >- Subparagraph (g) (3) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478666 / 740- 323- 65- 2 < br > < br > Reference 5: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SX 210. 5- 03 (20)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 235 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 4- 08 (g) (1) (ii)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 323 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481687 / 323- 10- 50- 3 < br > < br > Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 825 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 28 < br >- Subparagraph (f) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482907 / 825- 10- 50- 28 < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482765 / 220- 10- 50- 6 < br > < br > Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 3 < br > < br > Reference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (b) (2) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 1 < br > < br > Reference 12: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 815 < br >- SubTopic 40 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 1 < br >- Subparagraph (f) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480175 / 815- 40- 65- 1 < br > < br > Reference 13: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 8 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 8 < br > < br > Reference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 11 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 11 < br > < br > Reference 15: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 11 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 11 < br > < br > Reference 16: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 4 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 4 < br > < br > Reference 17: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 946 < br >- SubTopic 830 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 10 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479168 / 946- 830- 55- 10 < br > < br > Reference 18: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 7 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479105 / 946- 220- 45- 7 < br > < br > Reference 19: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 7- 04 (18)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147477250 / 944- 220- S99- 1 < br > < br > Reference 20: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 07 (9)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1 < br > < br > Reference 21: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 09 (1) (d)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3 < br > < br > Reference 22: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (i)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 23: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (ii)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 24: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (iii) (A)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 25: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (iv)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 26: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (5)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 27: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (i)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 28: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iii) (A)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 29: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iii) (B)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 30: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iv)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 31: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (5)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 32: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 60B < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 60B < br > < br > Reference 33: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 205 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 7 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483499 / 205- 20- 50- 7 < br > < br > Reference 34: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 230 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 28 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28 < br > < br > Reference 35: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 1A < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 1A < br > < br > Reference 36: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 1B < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 1B < br > < br > Reference 37: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 942 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 9- 04 (22)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478524 / 942- 220- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_NetIncomeLoss < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held- to- maturity) from transfer to available- for- sale. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 320 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 9 < br >- Subparagraph (d) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 9 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 10A < br >- Subparagraph (e) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 10A < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 11 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 11 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_SharesOutstanding" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Number of shares issued which are neither cancelled nor held in the treasury. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_SharesOutstanding < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StockIssuedDuringPeriodSharesConversionOfUnits" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit). < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- SubTopic 10 < br >-

Topic 505 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 2 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (28)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (29)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 4: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 3- 04) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480008 / 505- 10- S99- 1 < br > < br > Reference 5: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 505 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 3 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 3 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StockIssuedDuringPeriodSharesConversionOfUnits < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Number of shares issued during the period as a result of an employee stock purchase plan. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- SubTopic 10 < br >- Topic 505 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 2 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (28)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (29)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 4: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 3- 04) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480008 / 505- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StockIssuedDuringPeriodSharesNewIssues" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Number of new stock issued during the period. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- SubTopic 10 < br >- Topic 505 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 2 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (28)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (29)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 505 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478448 / 946- 505- 50- 2 < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 09 (4) (b)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 03 (i) (1)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479886 / 946- 10- S99- 3 < br > < br > Reference 7: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 3- 04) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480008 / 505- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StockIssuedDuringPeriodSharesNewIssues < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StockIssuedDuringPeriodValueConversionOfUnits" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit). < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- SubTopic 10 < br >- Topic 505 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 2 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (29)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (30)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 4: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (31)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 5: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 3- 04) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480008 / 505- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StockIssuedDuringPeriodValueConversionOfUnits < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Aggregate change in value for stock issued during the period as a result of employee stock purchase plan. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- SubTopic 10 < br >- Topic 505 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 2 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (28)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (29)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 4: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 3- 04) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480008 / 505- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StockIssuedDuringPeriodValueNewIssues" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- SubTopic 10 < br >- Topic 505 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 2 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (28)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (29)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 946 < br >- SubTopic 830 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 11 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479168 / 946- 830- 55- 11 < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 205 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 4 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478009 / 946- 205- 45- 4 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 505 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478448 / 946- 505- 50- 2 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 09 (4) (b)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3 < br > < br > Reference 8: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 3- 04) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480008 / 505- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StockIssuedDuringPeriodValueNewIssues < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit

< / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StockholdersEquity" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (29)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (30)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (31)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 852 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 10 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481372 / 852- 10- 55- 10 < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 946 < br >- SubTopic 830 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 12 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479168 / 946- 830- 55- 12 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 04 (19)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SX 210. 6- 05 (4)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 2 < br > < br > Reference 8: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 09 (4) (b)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3 < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 09 (6)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3 < br > < br > Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 09 (7)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3 < br > < br > Reference 11: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 235 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 4- 08 (g) (1) (ii)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1 < br > < br > Reference 12: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 323 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481687 / 323- 10- 50- 3 < br > < br > Reference 13: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 825 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 28 < br >- Subparagraph (f) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482907 / 825- 10- 50- 28 < br > < br > Reference 14: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 310 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SAB Topic 4. E) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480418 / 310- 10- S99- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StockholdersEquity < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Value of new stock classified as temporary equity issued during the period. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 44 < FILENAME > R8. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208161568512" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Consolidated Statement of Convertible Preferred Stock and Stockholders & # 8217; Equity (Parentheticals) < br > $ in Thousands < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < div > USD ($) < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StatementOfStockholdersEquityAbstract', window);" > < strong > Statement of Stockholders' Equity [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts', window);" > Issuance of Series A Convertible Preferred Stock, Net of Issuance Costs < / a > < / td > < td class =" nump" > $ 69 < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Issuance of Series A convertible preferred stock, net of issuance costs. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StatementOfStockholdersEquityAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StatementOfStockholdersEquityAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 45 < FILENAME > R9. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208162336944" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Consolidated Statement of Cash Flows < br > $ in Thousands < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < div > USD ($) < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window);" > < strong > Cash flows from operating activities: < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_NetIncomeLoss', window);" > Net loss < / a > < / td > < td class =" num" > $ (83, 724) < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window);" > < strong > Adjustments to reconcile net loss to net cash used in operating activities: < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ShareBasedCompensation', window);" > Stock- based compensation expense < / a > < / td > < td class =" nump" > 14, 919 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window);" > Net accretion of premiums and discounts on marketable securities < / a > < / td > < td class =" num" > (2, 245) < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_OtherNoncashExpense', window);" > Non- cash interest expense < / a > < / td > < td class =" nump" > 1, 468 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_OperatingLeaseExpense', window);" > Non- cash lease expense < / a > < / td > < td class =" nump" > 127 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_Depreciation', window);" > Depreciation expense < / a > < / td > < td class =" nump" > 27 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_IncreaseDecreaseInOperatingCapitalAbstract', window);" > < strong > Changes in operating assets and liabilities: < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window);" > Prepaid expenses and other current assets < / a > < / td > < td class =" num" > (1, 128) < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_IncreaseDecreaseInOtherNoncurrentAssets', window);" > Other non- current assets < / a > < / td > < td class =" num" > (43) < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_IncreaseDecreaseInOtherAccountsPayable', window);" > Accounts payable < / a > < / td > < td class =" nump" > 3, 462 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window);" > Accrued expenses and other current liabilities < / a > < / td > < td class =" nump" > 3, 292 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_IncreaseDecreaseInOperatingLeaseLiability', window);" > Operating lease liability < / a > < / td > < td class =" num" > (14) < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-

```
gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window);" > Related party accounts payable and other current liabilities < / a > < / td > < td class =" nump" > 6, 022 < span > < / span
> < / td > < / tr > < tr class =" rou" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_NetCashProvidedByUsedInOperatingActivities', window);" > Net cash used in operating activities < / a > < / td > < td class =" num" > (57, 837) < span > < / span > < / td > < / tr > < tr class
=" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window);" > < strong > Cash flows from investing activities: < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < /
span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_PaymentsToAcquirePropertyPlantAndEquipment', window);" > Purchases of property and equipment < / a > < / td > < td class =" num" > (189) < span > < / span > < / td > < / tr > < tr class
=" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_PaymentsToAcquireMarketableSecurities', window);" > Purchases of marketable securities < / a > < / td > < td class =" num" > (329, 938) < span > < / span > < / td > < / tr > < tr class ="
rou" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_NetCashProvidedByUsedInInvestingActivities', window);" > Net cash used in investing activities < / a > < / td > < td class =" num" > (330, 127) < span > < / span > < / td > < / tr > < tr class
=" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window);" > < strong > Cash flows from financing activities: < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < /
span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window);" > Proceeds from issuance of Pre- Merger Oruka Series A Preferred Stock, net of issuance costs paid < / a > < / td > < td
class =" nump" > 2, 931 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);"
onclick =" Show. showAR (this,' defref_us- gaap_ProceedsFromNotesPayable', window);" > Proceeds from issuance of notes payable to related party, net of issuance costs paid < / a > < / td > < td
class =" nump" > 24, 980 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);"
onclick =" Show. showAR (this,' defref_us- gaap_ProceedsFromPaymentsForOtherFinancingActivities', window);" > Proceeds from the Pre- Closing Financing, net < / a > < / td > < td class ="
nump" > 227, 953 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick ="
Show. showAR (this,' defref_us- gaap_ProceedsFromIssuanceOfPrivatePlacement', window);" > Proceeds from the PIPE Financing, net < / a > < / td > < td class =" nump" > 188, 681 < span > < /
span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_orka_CashAcquiredInConnectionWithTheReverseRecapitalization', window);" > Cash acquired in connection with the reverse recapitalization < / a > < / td > < td class =" nump" > 4, 940
< span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR
(this,' defref_us- gaap_ProceedsFromIssuanceOfCommonStock', window);" > Proceeds from issuance of common stock < / a > < / td > < td class =" nump" > 54 < span > < / span > < / td > < / tr >
< tr class =" rou" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_NetCashProvidedByUsedInFinancingActivities', window);" > Net cash provided by financing activities < / a > < / td > < td class =" nump" > 449, 539 < span > < / span > < / td > < / tr > < tr
class =" reu" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window);" > Net increase in cash and cash equivalents < / a > <
/ td > < td class =" nump" > 61, 575 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void
(0);" onclick =" Show. showAR (this,' defref_us- gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window);" > Cash at beginning of period < / a > < / td > < td class ="
text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show.
showAR (this,' defref_us- gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window);" > Cash and cash equivalents at end of period < / a > < / td > < td class =" nump"
> 61, 575 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show.
showAR (this,' defref_us- gaap_SupplementalCashFlowInformationAbstract', window);" > < strong > Supplemental disclosures of non- cash operating and financing activities: < / strong > < / a >
< / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void
(0);" onclick =" Show. showAR (this,' defref_us- gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window);" > Operating lease liability arising from obtaining operating
right- of- use asset < / a > < / td > < td class =" nump" > 982 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a"
href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1', window);" > Assets acquired in connection with the
reverse capitalization < / a > < / td > < td class =" nump" > 114 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class ="
a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1', window);" > Other liabilities assumed in
connection with the reverse recapitalization < / a > < / td > < td class =" num" > (54) < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;"
valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock', window);"
> Non- cash accrued interest on convertible note converted to common stock < / a > < / td > < td class =" nump" > 1, 468 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl
custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock', window);" > Non- cash exchange of Pre- Merger Oruka Series A preferred
stock for Series B convertible preferred stock < / a > < / td > < td class =" nump" > 2, 931 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;"
valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ConversionOfStockAmountConverted1', window);" > Conversion of Series A non-
voting convertible preferred stock to common stock < / a > < / td > < td class =" nump" > 52, 834 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border-
bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity',
window);" > Reclassification of the Paruka warrant from liability to equity < / a > < / td > < td class =" nump" > $ 10, 357 < span > < / span > < / td > < / tr > < / table > < div style =" display:
none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id ="
defref_orka_CashAcquiredInConnectionWithTheReverseRecapitalization" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" >
X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p >
Represent the amount of cash acquired in connection with the reverse recapitalization. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > <
div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > <
table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" >
orka_CashAcquiredInConnectionWithTheReverseRecapitalization < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < /
td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > <
td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0"
cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" > < tr > < td class
=" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Represent the amount of non- cash accrued interest on convertible note converted to common stock. < /
p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong >
Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock < / td > < / tr > < tr > < td style =" padding- right:
4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli:
monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration <
/ td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id ="
defref_orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void
(0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >-
Definition < / a > < div > < p > Represent the Non- cash exchange of Pre- Merger Oruka Series A preferred stock for Series B convertible preferred stock. < / p > < / div > < a href =" javascript:
void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style ="
white- space: nowrap;" > orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock < / td > < / tr > < tr > < td style =" padding- right: 4px; white-
space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < /
tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div
> < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id ="
defref_orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" >
X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p >
Represent the amount of reclassification of the paruka warrant from liability to equity. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > <
div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > <
table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" >
orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < /
td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > <
td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0"
cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" > < tr > < td class ="
hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The sum of the periodic adjustments of the differences between securities' face values and purchase
prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an
adjustment to net income when calculating cash provided by or used in operations using the indirect method. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);"
> References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 230 < br >- SubTopic 10 < br >- Name Accounting
Standards Codification < br >- Section 45 < br >- Paragraph 28 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28 < br > < / p > < / div > < a href
=" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong >
Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments < / td > < / tr > < tr > < td style =" padding- right: 4px;
white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType
< / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < /
table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript:
void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext
(this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display:
```

none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short- term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 230 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 8 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50- 8 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 230 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 24 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 24 < br > < br > Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 230 < br >- SubTopic 10 < br >- Section 45 < br >- Paragraph 4 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 4 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short- term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 230 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 24 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 24 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 1 < br >- SubTopic 230 < br >- Topic 830 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147477401 / 830- 230- 45- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ConversionOfStockAmountConverted1" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period." Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 230 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 4 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50- 4 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 230 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 3 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50- 3 < br > < br > Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 230 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 5 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50- 5 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ConversionOfStockAmountConverted1 < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_Depreciation" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non- production related depreciation. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 28 < br >- Subparagraph (b) < br >- SubTopic 10 < br >- Topic 230 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 360 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482099 / 360- 10- 50- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_Depreciation < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_IncreaseDecreaseInAccountsPayableRelatedParties" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit- sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 28 < br >- Subparagraph (a) < br >- SubTopic 10 < br >- Topic 230 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_IncreaseDecreaseInAccountsPayableRelatedParties < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of increase (decrease) in accrued expenses, and obligations classified as other. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 230 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 28 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_IncreaseDecreaseInOperatingCapitalAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_IncreaseDecreaseInOperatingCapitalAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_IncreaseDecreaseInOperatingLeaseLiability" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of increase (decrease) in obligation for operating lease. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 230 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 28 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28 < br > < br > Reference 2: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 4 < br >- Subparagraph (g) (1) < br >- SubTopic 20 < br >- Topic 842 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478964 / 842- 20- 50- 4 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_IncreaseDecreaseInOperatingLeaseLiability < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > <

/ div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_IncreaseDecreaseInOtherAccountsPayable" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > <
tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of increase (decrease) in
obligations classified as other, payable within one year or the normal operating cycle, if longer. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References
< / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph
28 < br >- Subparagraph (a) < br >- SubTopic 10 < br >- Topic 230 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28 < br > < / p > < / div > < a
href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > <
strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_IncreaseDecreaseInOtherAccountsPayable < / td > < / tr > < tr > < td style =" padding- right: 4px; white-
space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td
> < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > <
/ div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_IncreaseDecreaseInOtherNoncurrentAssets" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > <
tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of increase (decrease) in
noncurrent assets classified as other. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1:
http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 230 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 28 < br >-
Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style ="
white- space: nowrap;" > us- gaap_IncreaseDecreaseInOtherNoncurrentAssets < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < /
strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < /
strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table
border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" > < tr > <
td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a
href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of increase (decrease) in prepaid expenses, and assets classified as other. < / p > < / div
> < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef <
br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 28 < br >- Subparagraph (a) < br >- SubTopic 10 < br >- Topic 230 < br >- Publisher FASB < br >- URI
https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display:
none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < /
td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td
> < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0"
cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_NetCashProvidedByUsedInFinancingActivities" > < tr > < td class =" hide" > < a style
=" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void
(0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash
flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the
obligation; and obtaining and paying for other resources obtained from creditors on long- term credit. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >
References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 230 < br >- SubTopic 10 < br >- Name Accounting Standards
Codification < br >- Section 45 < br >- Paragraph 24 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 24 < br > < / p > < / div > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong >
Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_NetCashProvidedByUsedInFinancingActivities < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space:
nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr
> < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div >
< / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < /
td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition
available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing
=" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract < / td > < / tr > < tr > < td style
=" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td >
xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration <
/ td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_NetCashProvidedByUsedInInvestingActivities" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr
> < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of cash inflow
(outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments
and property, plant, and equipment and other productive assets. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display:
none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 230 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >-
Paragraph 24 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 24 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style ="
white- space: nowrap;" > us- gaap_NetCashProvidedByUsedInInvestingActivities < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix:
< / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < /
strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table
border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" > < tr > < td class
=" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext
(this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space:
nowrap;" > us- gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < /
strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < /
strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table
border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_NetCashProvidedByUsedInOperatingActivities" > < tr > < td class ="
hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of cash inflow (outflow) from operating activities, including discontinued operations.
Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. < / p > < / div > < a href =" javascript: void (0);" onclick ="
Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 230 < br >- SubTopic 10 < br >-
Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 28 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28 < br > < br >
Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 230 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 24 <
br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 24 < br > < br > Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 230 < br
>- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 25 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230-
10- 45- 25 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0"
cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_NetCashProvidedByUsedInOperatingActivities < / td > < / tr > < tr > < td
style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > <
td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td >
duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id ="
defref_us- gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X
< / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No
definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0"
cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract < / td > < / tr > < tr
> < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < /
td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td >
duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id ="
defref_us- gaap_NetIncomeLoss" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div
class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The portion of profit or loss for the period, net of
income taxes, which is attributable to the parent. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p >
Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 <
br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 6 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 <
br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 9 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 /
250- 10- 50- 9 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 805 < br >- SubTopic 60 < br >- Name Accounting Standards Codification < br >- Section
65 < br >- Paragraph 1 < br >- Subparagraph (g) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147476176 / 805- 60- 65- 1 < br > < br > Reference 4: http: / / www. xbrl.
org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 323 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 2 < br >- Subparagraph (g) (3) < br
>- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478666 / 740- 323- 65- 2 < br > < br > Reference 5: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 220 < br >-
SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SX 210. 5- 03 (20)) < br >- Publisher FASB < br >- URI https: / /
asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 235 < br >- SubTopic 10 < br >- Name Accounting
Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 4- 08 (g) (1) (ii)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480678
/ 235- 10- S99- 1 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 323 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >-

Section 50 < br >- Paragraph 3 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481687 / 323- 10- 50- 3 < br > < br > Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 825 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 28 < br >- Subparagraph (f) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482907 / 825- 10- 50- 28 < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482765 / 220- 10- 50- 6 < br > < br > Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 3 < br > < br > Reference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (b) (2) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 1 < br > < br > Reference 12: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 815 < br >- SubTopic 40 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 1 < br >- Subparagraph (f) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480175 / 815- 40- 65- 1 < br > < br > Reference 13: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 8 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 8 < br > < br > Reference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 11 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 11 < br > < br > Reference 15: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 11 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 11 < br > < br > Reference 16: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 4 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 4 < br > < br > Reference 17: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 946 < br >- SubTopic 830 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 10 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479168 / 946- 830- 55- 10 < br > < br > Reference 18: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 7 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479105 / 946- 220- 45- 7 < br > < br > Reference 19: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 7- 04 (18)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147477250 / 944- 220- S99- 1 < br > < br > Reference 20: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 07 (9)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1 < br > < br > Reference 21: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 09 (1) (d)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3 < br > < br > Reference 22: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (i)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 23: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (ii)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 24: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (iii) (A)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 25: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (iv)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 26: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (5)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 27: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (i)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 28: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iii) (A)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 29: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iii) (B)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 30: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iv)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 31: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (5)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 32: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 60B < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 60B < br > < br > Reference 33: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 205 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 7 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483499 / 205- 20- 50- 7 < br > < br > Reference 34: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 230 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 28 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28 < br > < br > Reference 35: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 1A < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 1A < br > < br > Reference 36: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 1B < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 1B < br > < br > Reference 37: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 942 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 9- 04 (22)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478524 / 942- 220- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_NetIncomeLoss < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of assets, classified as other, acquired in a noncash or part noncash acquisition. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 230 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 4 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50- 4 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 230 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 3 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50- 3 < br > < br > Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 230 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 5 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50- 5 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1 < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of liabilities, classified as other, assumed in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 230 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 4 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50- 4 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 230 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 3 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50- 3 < br > < br > Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 230 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 5 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50- 5 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1 < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_OperatingLeaseExpense" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of operating lease expense. Excludes sublease income. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 842 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 4 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479041 / 842- 20- 45- 4 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_OperatingLeaseExpense < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_OtherNoncashExpense" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of expense or loss included in net income that result in no cash flow, classified as other. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 230 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 28 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_OtherNoncashExpense < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr >

< tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_PaymentsToAcquireMarketableSecurities" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of cash outflow for purchase of marketable security. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 320 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 11 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481830 / 320- 10- 45- 11 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_PaymentsToAcquireMarketableSecurities < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_PaymentsToAcquirePropertyPlantAndEquipment" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The cash outflow associated with the acquisition of long- lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self- constructed assets. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 230 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 13 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 13 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_PaymentsToAcquirePropertyPlantAndEquipment < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ProceedsFromIssuanceOfCommonStock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The cash inflow from the additional capital contribution to the entity. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 14 < br >- Subparagraph (a) < br >- SubTopic 10 < br >- Topic 230 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 14 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ProceedsFromIssuanceOfCommonStock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity' s common stock. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 14 < br >- Subparagraph (a) < br >- SubTopic 10 < br >- Topic 230 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 14 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ProceedsFromIssuanceOfConvertiblePreferredStock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ProceedsFromIssuanceOfPrivatePlacement" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The cash inflow associated with the amount received from entity' s raising of capital via private rather than public placement. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 14 < br >- Subparagraph (a) < br >- SubTopic 10 < br >- Topic 230 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 14 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ProceedsFromIssuanceOfPrivatePlacement < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ProceedsFromNotesPayable" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The cash inflow from a borrowing supported by a written promise to pay an obligation. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 230 < br >- SubTopic 10 < br >- Section 45 < br >- Paragraph 14 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 14 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ProceedsFromNotesPayable < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ProceedsFromPaymentsForOtherFinancingActivities" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of cash inflow (outflow) from financing activities classified as other. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 230 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 14 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 14 < br > < br > Reference 2: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 15 < br >- SubTopic 10 < br >- Topic 230 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 15 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ProceedsFromPaymentsForOtherFinancingActivities < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of increase in right- of- use asset obtained in exchange for operating lease liability. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 842 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 53 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479589 / 842- 20- 55- 53 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 842 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 4 < br >- Subparagraph (g) (2) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478964 / 842- 20- 50- 4 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ShareBasedCompensation" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of noncash expense for share- based payment arrangement. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 28 < br >- Subparagraph (a) < br >- SubTopic 10 < br >- Topic 230 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ShareBasedCompensation < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_SupplementalCashFlowInformationAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_SupplementalCashFlowInformationAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < /

DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 46 < FILENAME > R10. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208263435392" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Nature of the Business and Basis of Presentation < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window);" > < strong > Nature of the Business and Basis of Presentation [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window);" > Nature of the Business and Basis of Presentation < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > < b > 1. Nature of the Business and Basis of Presentation < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > & # 160; < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Background and Basis of Presentation < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Oruka Therapeutics, Inc., together with its subsidiaries (collectively, the & # 8220; Company & # 8221;), formerly known as ARCA biopharma, Inc. (& # 8220; ARCA & # 8221;), is a clinical- stage biotechnology company that is the result of the reverse recapitalization discussed below. Prior to the reverse recapitalization, the private company Oruka Therapeutics, Inc. (& # 8220; Pre- Merger Oruka & # 8221;) was established and incorporated under the laws of the state of Delaware on February & # 160; 6, 2024 (referred to in the Notes as the inception of the Company). The Company is headquartered in Menlo Park, California. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (& # 8220; PsO & # 8221;) and other inflammatory and immunology (& # 8220; I & amp; I & # 8221;) indications. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The accompanying consolidated financial statements reflect the operations of the Company and its wholly- owned subsidiaries. Intercompany balances and transactions have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared in conformity with United States (& # 8220; U. S. & # 8221;) generally accepted accounting principles (& # 8220; GAAP & # 8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (& # 8220; ASC & # 8221;) and Accounting Standards Updates (& # 8220; ASU & # 8221;) of the Financial Accounting Standards Board (& # 8220; FASB & # 8221;). < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Reverse Recapitalization and Pre- Closing & # 160; Financing < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > On August 29, 2024 (the & # 8220; Merger Closing & # 8221;), the Company completed the acquisition (the & # 8220; Merger & # 8221;) of Pre- Merger Oruka pursuant to an Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024 (the & # 8220; Merger Agreement & # 8221;). Following the transactions contemplated by the Merger Agreement, Pre- Merger Oruka merged with and into Atlas Merger Sub Corp., a wholly owned subsidiary of ARCA and following that, Pre- Merger Oruka then merged with and into Atlas Merger Sub II, LLC (& # 8220; Second Merger Sub & # 8221;), with Second Merger Sub being the surviving entity. Second Merger Sub changed its corporate name to & # 8220; Oruka Therapeutics Operating Company, LLC. & # 8221; On August 29, 2024, the Company changed its name from & # 8220; ARCA biopharma, Inc. & # 8221; to & # 8220; Oruka Therapeutics, Inc. & # 8221; and its Nasdaq ticker symbol from & # 8220; ABIO & # 8221; to & # 8220; ORKA & # 8221;. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Following consummation of the Merger, the Company effected a 1- for- 12 reverse stock split (the & # 8220; Reverse Stock Split & # 8221;) of the common stock, par value $ 0. 001 per share, of the Company (& # 8220; Company Common Stock & # 8221;), which became effective on September 3, 2024. The Company Common Stock commenced trading on a post- Reverse Stock Split, post- Merger basis at the opening of trading on September 3, 2024. The Company is led by the Pre- Merger Oruka management team and remains focused on developing biologics to optimize the treatment of inflammatory skin diseases. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Immediately prior to the execution and delivery of the Merger Agreement on April 3, 2024, certain new and existing investors of Pre- Merger Oruka entered into a subscription agreement with Pre- Merger Oruka (the & # 8220; Subscription Agreement & # 8221;), pursuant to which, and on the terms and subject to the conditions of which, immediately prior to the Closing, those investors purchased shares of common stock of Pre- Merger Oruka (& # 8220; Pre- Merger Oruka Common Stock & # 8221;) and Pre- Merger Oruka pre- funded warrants for gross proceeds of approximately $ 275. 0 million (which includes $ 25. 0 million of proceeds previously received from the issuance of the Convertible Note (as defined in Note 7) and accrued interest on such note which converted to shares of Pre- Merger Oruka Common Stock) (the & # 8220; Pre- Closing Financing & # 8221;). The Company incurred transaction costs of $ 20. 5 million which was recorded as a reduction to additional paid- in capital in the consolidated financial statements. At the Merger Closing, the shares of Pre- Merger Oruka Common Stock and Pre- Merger Oruka pre- funded warrants issued pursuant to the Subscription Agreement were converted into shares of Company Common Stock and pre- funded warrants of Company Common Stock in accordance with the Exchange Ratio (defined below). < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > In accordance with an Exchange Ratio determined by terms of the Merger Agreement and upon the effective time of the First Merger (the & # 8220; First Effective Time & # 8221;), (i) each then- issued and outstanding share of Pre- Merger Oruka Common Stock including outstanding and unvested Pre- Merger Oruka restricted stock and shares of Pre- Merger Oruka Common Stock issued in connection with the Subscription Agreement, were converted into the right to receive a number of shares of Company Common Stock, equal to the Exchange Ratio of 6. 8569 shares of Company Common Stock, which were subject to the same vesting provisions as those immediately prior to the Merger, (ii) each share of Pre- Merger Oruka Series A convertible preferred stock, par value $ 0. 0001 (& # 8220; Pre- Merger Oruka Series A Preferred Stock & # 8221;), outstanding immediately prior to the First Effective Time was converted into the right to receive a number of shares of ARCA Series B non- voting convertible preferred stock, par value $ 0. 001 per share (& # 8220; Company Series B Preferred Stock & # 8221;), which are convertible into shares of Company Common Stock, at a conversion ratio of approximately 83: 3332: 1 (iii) each outstanding option to purchase Pre- Merger Oruka Common Stock was converted into an option to purchase shares of Company Common Stock, (iv) each outstanding warrant to purchase shares of Pre- Merger Oruka Common Stock was converted into a warrant to purchase shares of Company Common Stock, and (v) each share of Company Common Stock issued and outstanding at the First Effective Time remain issued and outstanding in accordance with its terms and such shares. Subsequent to the close of the merger, the common stock shares were then subject to the reverse stock split of 1- for- 12 effected on September 3, 2024. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > As part of the Pre- Closing Financing and the Merger Closing, investors in the Pre- Closing Financing received 22, 784, 139 shares of Company Common Stock in exchange for 39, 873, 706 shares of Pre- Merger Oruka Common Stock (which includes the issuance of 2, 722, 207 shares of Company Common Stock in exchange for 4, 764, 032 shares of Pre- Merger Oruka Common Stock on the conversion of Convertible Note along with the accrued interest through the conversion date) and 5, 522, 207 Company pre- funded warrants in exchange for 9, 664, 208 Pre- Merger pre- funded warrants. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Merger was accounted for as a reverse recapitalization in accordance with U. S. GAAP. Under this method of accounting, Pre- Merger Oruka was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the fact that, immediately following the Merger: (i) Pre- Merger Oruka stockholders own a substantial majority of the voting rights in the combined company; (ii) Pre- Merger Oruka & # 8217; s largest stockholders retain the largest interest in the combined company; (iii) Pre- Merger Oruka designated a majority of the initial members of the board of directors of the combined company; and (iv) Pre- Merger Oruka & # 8217; s executive management team became the management team of the combined company. Accordingly, for accounting purposes: (i) the Merger was treated as the equivalent of Pre- Merger Oruka issuing stock to acquire the net assets of ARCA, and (ii) the reported historical operating results of the combined company prior to the Merger are those of Pre- Merger Oruka. Additional information regarding the Merger is included in Note 3. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Reverse Stock Split < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > On September 3, 2024, the Company effected the Reverse Stock Split, a 1- for- 12 reverse stock split of Company Common Stock. The par value per share and the number of authorized shares were not adjusted as a result of the Reverse Stock Split. The shares of Company Common Stock underlying outstanding stock options, common stock warrants and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. All references to common stock, options to purchase common stock, outstanding common stock warrants, common stock share data, per share data, and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented, unless otherwise specifically indicated or the context otherwise requires. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > PIPE Financing < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > On September 11, 2024, the Company entered into a Securities Purchase Agreement for a private placement (the & # 8220; PIPE Financing & # 8221;) with certain institutional and accredited investors. The closing of the PIPE Financing occurred on September 13, 2024. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; Pursuant to the Securities Purchase Agreement, the investors purchased an aggregate of 5, 600, 000 shares of Company Common Stock at a purchase price of $ 23. 00 per share, an aggregate of 2, 439 shares of the Company & # 8217; s Series A non- voting convertible preferred stock, par value $ 0. 001 per share (& # 8220; Company Series A Preferred Stock & # 8221;), at a purchase price of $ 23, 000. 00 per share (each Company Series A Preferred Stock is convertible into 1, 000 shares of Company Common Stock), and pre- funded warrants to purchase an aggregate of 680, 000 shares of Company Common Stock at a purchase price of $ 22. 999 per pre- funded warrant, for aggregate net proceeds of approximately $ 188. 7 million (net of issuance costs of $ 11. 9 million). < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Liquidity and Going Concern < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Since its inception, the Company has devoted substantially all of its resources to advancing the development of its portfolio of programs, organizing and staffing the Company, business planning, raising capital, and providing general and administrative support for these operations. Current and future programs will require significant research and development efforts, including preclinical and clinical trials, and regulatory approvals to commercialization. Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a

combination of equity offerings and debt financings. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception. For the period from February 6, 2024 (inception) to December 31, 2024, the Company has incurred a net loss of $ 83. 7 million and used net cash of $ 57. 8 million for its operating activities. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > As of December 31, 2024, the Company had cash, cash equivalents, and marketable securities of $ 393. 7 million. The Company & # 8217; s management expects that the existing cash, cash equivalents, and marketable securities will be sufficient to fund the Company & # 8217; s operating plans for at least twelve months from the date these consolidated financial statements were issued. The Company expects that its research and development and general and administrative costs will continue to increase significantly, including in connection with conducting future pre- clinical activities and clinical trials and manufacturing for its existing product candidates and any future product candidates to support commercialization and providing general and administrative support for its operations, including the costs associated with operating as a public company. The Company & # 8217; s ability to access capital when needed is not assured and, if capital is not available to the Company when, and in the amounts needed, the Company may be required to significantly curtail, delay, or discontinue one or more of its research or development programs or the commercialization of any product candidate, or be unable to expand its operations or otherwise capitalize on the Company & # 8217; s business opportunities, as desired, which could materially harm the Company & # 8217; s business, financial condition and results of operations. < / span > < / p > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 235 < br >- Name Accounting Standards Codification < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 235 / tableOfContent < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 275 < br >- Name Accounting Standards Codification < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 275 / tableOfContent < br > < br > Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 205 < br >- Name Accounting Standards Codification < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 205 / tableOfContent < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_BusinessDescriptionAndBasisOfPresentationTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 47 < FILENAME > R11. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208160104880" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Summary of Significant Accounting Policies < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AccountingPoliciesAbstract', window);" > < strong > Summary of Significant Accounting Policies [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SignificantAccountingPoliciesTextBlock', window);" > Summary of Significant Accounting Policies < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > < b > 2. Summary of Significant Accounting Policies < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > & # 160; < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Use of Estimates < / i > < / b > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The preparation of the Company & # 8217; s consolidated financial statements in conformity with U. S. & # 160; GAAP requires management to make estimates, assumptions, and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected within these consolidated financial statements include but are not limited to research and development expenses and related prepaid or accrued costs and the valuation of stock- based compensation awards and related expenses. The Company bases its estimates on known trends and other market- specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Actual results could differ materially from those estimates or assumptions. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Concentrations of Credit Risk and Other Risks and Uncertainties < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities. The Company & # 8217; s investment policy limits investments to high credit quality securities issued by the U. S. government, U. S. government- sponsored agencies, highly rated banks, and corporate issuers, subject to certain concentration limits and restrictions on maturities. The Company & # 8217; s cash, cash equivalents and marketable securities are held by financial institutions that management believes are of high credit quality. The financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash deposits. Accounts at the Company & # 8217; s U. S. banking institution are insured by the Federal Deposit Insurance Corporation (& # 8220; FDIC & # 8221;) up to $ 250, 000 per depositor. As of December 31, 2024, the balance at the Company & # 8217; s U. S. banking institution exceeded the FDIC limits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its accounts are monitored by management to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents, and bond issuers. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company is dependent on third- party organizations to research, develop, manufacture, and process its product candidates for its development programs, including its two most advanced programs, ORKA- 001 and ORKA- 002. The Company expects to continue to be dependent on a small number of manufacturers to supply it with its requirements for all products. The Company & # 8217; s research and development programs could be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Company & # 8217; s research and development activities are performed under its agreements with Paragon Therapeutics, Inc. (& # 8220; Paragon & # 8221;) (see Note & # 160; 12). < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Cash and Cash Equivalents < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to be cash equivalents. The cash equivalents were comprised of investments in money market funds, U. S. treasury securities, U. S. government agency securities, and debt securities and are stated at fair value. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Marketable Securities < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company invests in marketable securities, primarily securities issued by the U. S. government and its agencies, commercial paper and corporate debt securities. The Company & # 8217; s marketable securities are classified as available- for- sale and reported at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive loss. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > For available- for- sale debt securities in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security & # 8217; s amortized cost basis is written down to fair value and recognized in other income (expense) in the results of operations. For available- for- sale debt securities that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, an allowance is recorded for the difference between the present value of cash flows expected to be collected and the amortized cost basis of the security. Impairment losses attributable to credit loss factors are charged against the allowance when management believes an available- for- sale security is uncollectible or when either of the criteria regarding intent or requirement to sell is met. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Any unrealized losses from declines in fair value below the amortized cost basis as a result of non- credit loss factors are recognized as a component of accumulated other comprehensive loss, net of unrealized gains. Realized gains and losses and declines in fair value, if any, on available- for- sale securities are included in other income, net, in the results of operations. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Marketable securities with stated maturities of greater than three months from the date of purchase but less than one year from the consolidated balance sheet date are classified as current, while marketable securities with maturities in one year or beyond one year from the consolidated balance sheet date are classified as long- term. The cost of securities sold is determined using the specific- identification method. Interest earned and adjustments for the amortization of premiums and discounts on investments are included in interest income on the consolidated statements of operations and comprehensive loss. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Debt Issuance Costs < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Debt issuance costs incurred in connection with the Convertible Note (see Note & # 160; 7) are recorded as a reduction of the carrying value of the notes payable liability on the Company & # 8217; s balance sheet and are amortized to interest expense over the term of the loan using the effective interest method. At the effective time of the Merger the Converted Note was converted to common stock and is no longer on the balance sheet as of December 31, 2024. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Subscription Receivable & # 160; < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable is paid prior to the date the financial statement is available to be issued. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Fair Value Measurements & # 160; < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Certain assets and liabilities are carried at fair value under U. S. & # 160; GAAP. & # 160; Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" width: 100 %; font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; border- spacing: 0px;" > < tr style =" font- family: Times New Roman, Times, Serif; vertical- align: top" > < td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" > < / td > < td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 9679; < / span > < / td > < td style =" font- family: Times New Roman, Times, Serif; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > Level 1 & # 160; & # 8212; & # 160; Quoted prices in active markets that are identical assets or liabilities. < / span > < / td > < / tr > < / table > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; text- indent:- 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" width: 100 %; font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; border- spacing: 0px;" > < tr style =" font- family: Times New Roman, Times, Serif; vertical- align: top" > < td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" > < / td > < td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 9679; < / span > < / td > < td style =" font- family: Times New Roman, Times, Serif; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > Level & # 160; 2 & # 160; & # 8212; & # 160; Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. < / span > < / td > < / tr > < / table > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; text- indent:- 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" width: 100 %; font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; border- spacing: 0px;" > < tr style =" font- family: Times New Roman, Times, Serif; vertical- align: top" > < td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" > < / td > < td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 9679; < / span > < / td > < td style =" font- family: Times New Roman, Times, Serif; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > Level & # 160; 3 & # 160; & # 8212; & # 160; Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies, and similar techniques. < / span > < / td > < / tr > < / table > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; text- indent:- 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company & # 8217; s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy described above (see Note 4). The carrying values of the Company & # 8217; s prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to their relatively short maturity period. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Property and Equipment < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight- line method over the estimated useful life of each asset as follows: < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; font- weight: bold; text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > Estimated < br / > Useful Life < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Furniture and fixtures < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 11 %; text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > 3- 5 years < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Computer and office equipment < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > 3- 5 years < / span > < / td > < / tr > < / table > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > & # 160; < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Classification of Convertible Preferred Stock < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Prior to the reverse recapitalization, the Company had classified its Pre- Merger Oruka Series A Preferred Stock outside of stockholders & # 8217; equity on the Company & # 8217; s consolidated balance sheet because the holders of such stock have certain liquidation rights in the event of a deemed liquidation event that, in certain situations, is not solely within the control of the Company and would require the redemption of the then- outstanding convertible preferred stock. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Upon the closing of the Merger, the Company converted its Pre- Merger Oruka Series A Preferred Stock to Company Series B Preferred Stock and has classified the Company Series B Preferred Stock within stockholders & # 8217; equity on its consolidated balance sheet because the Company Series B Preferred Stock is not redeemable or puttable to the Company by the holder under any circumstances. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > In connection with the PIPE Financing (see Note 1) the Company issued Company Series A Preferred Stock, and has classified the Company Series A Preferred Stock outside of stockholders & # 8217; equity on the Company & # 8217; s consolidated balance sheet because the holders of such stock have certain rights (see Note 8) that, in certain situations, is not solely within the control of the Company and would require the redemption of the then- outstanding convertible preferred stock. In November 2024, the Company Series A Preferred Stock shares were converted to common stock, and as of December 31, 2024, there were no shares of Company Series A Preferred Stock outstanding. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Note & # 160; Payable to Related Party < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company accounted for the Convertible Note (as defined in Note 7) at amortized cost. The Company considered if optional conversion features are required to be bifurcated and separately accounted for as a derivative. Costs related to the issuance of the Convertible Note were recorded as a debt discount, amortized over the term of the Convertible Note (see & # 160; Note & # 160; 7) and were accounted for as interest expense in other income (expenses) within the consolidated statement of operations and comprehensive loss using the effective interest method. At the effective time of the Merger, shares of Pre- Merger Oruka Common Stock issued pursuant to the conversion of the Convertible Note (including accrued interest) automatically converted into shares of Company Common Stock (see Note 1). < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Research and Development Contract Costs Accruals < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company records the costs associated with research studies and manufacturing development as incurred. These costs are a significant component of the Company & # 8217; s research and development expenses, with a substantial portion of the Company & # 8217; s ongoing research and development activities conducted by third- party service providers, including contract research organizations (& # 8220; CROs & # 8221;) and contract manufacturing organizations (& # 8220; CMOs & # 8221;), and the Company & # 8217; s related- party Paragon (see Note & # 160; 12). < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company accrues for expenses resulting from obligations under its two antibody discovery and option agreements (the & # 8220; Option Agreements & # 8221;) (see Note 12), by and among Paragon, Paruka Holding LLC (& # 8220; Paruka & # 8221;), an entity formed by Paragon as a vehicle to hold equity in the Company, and the Company as well as agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrual balance in each reporting period. If advance payments are made to Paragon, a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be expensed as the contracted services are performed. Changes in these estimates that result in material changes to the Company & # 8217; s accruals could materially affect the Company & # 8217; s results of operations. As of December 31, 2024, the Company has not experienced any material deviations between accrued and actual research and development expenses. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > <

span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Leases < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > At the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies a lease as either an operating or finance lease and recognizes a right- of- use (& # 8220; ROU & # 8221;) asset and a current and non- current lease liability, as applicable, in the balance sheet if the lease has a term greater than one year. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise its option. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > At the lease commencement date, operating lease liabilities and their corresponding ROU assets are recorded at the present value of future minimum lease payments over the expected remaining lease term. The Company determines the present value of lease payments using the implicit rate, if it is readily determinable, or the risk- free discount rate for a period comparable with that of the lease term. For operating leases, lease expense for lease payments is recognized on a straight- line basis over the lease term. For finance leases, lease expense includes amortization expense of the ROU asset recognized on a straight- line basis over the lease term and interest expense recognized on the finance lease liability. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments, incentives received or initial direct costs. As of December 31, 2024, the Company has one operating lease and no finance leases. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company accounts for lease and non- lease components related to operating leases as a single lease component. The Company has elected that costs associated with leases having an initial term of 12 months or less are recognized in the consolidated statement of operations and comprehensive loss on a straight- line basis over the lease term and are not recorded on its consolidated balance sheets. Variable lease expense is recognized as incurred and consists primarily of real estate taxes, utilities, and other office space related expenses. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Segment Reporting < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > The Company operates as a single reportable and operating segment. Its Chief Executive Officer, serving as the Chief Operating Decision Maker (& # 8220; CODM & # 8221;), oversees operations on an aggregated basis to allocate resources effectively. In assessing the Company & # 8217; s financial performance, the CODM regularly reviews total operating expenses and consolidated net loss. < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Research and Development Costs < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Research and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock- based compensation, employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities, as well as allocated human resource costs, information technology costs, and facility- related costs, including rent, maintenance, utilities, and depreciation. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses on the accompanying consolidated balance sheet. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable advance payments represent a one- time cost for obtaining goods or services, with anticipated benefits to be utilized within a year of period end, the payment is expensed immediately. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > General and Administrative Expenses < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > General and administrative expenses consist primarily of salaries and bonuses, stock- based compensation, employee benefits, finance and administration costs, patent and intellectual property costs, professional fees, as well as allocated human resource costs, information technology costs, and facility- related costs, including rent, maintenance, utilities and depreciation. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Commitments and Contingencies < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities. The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but not probable; however, it discloses the range of reasonably possible losses. As of December 31, 2024, no liabilities were recorded for loss contingencies (see Note & # 160; 13). < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Stock- Based Compensation < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company estimates the fair value of its stock awards using the Black- Scholes option pricing model, which uses as inputs the fair value of the Company & # 8217; s common stock, and certain management estimates, including the expected stock price volatility, the expected term of the award, the risk- free interest rate, and expected dividends. Expected volatility is calculated based on reported volatility data for a representative group of publicly traded companies for which historical information is available. The Company selects companies with comparable characteristics with historical share price information that approximates the expected term of the equity- based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies & # 8217; shares during the equivalent period that approximates the calculated expected term of the stock options. The Company will continue to apply this method until a sufficient amount of historical information regarding the volatility of its stock price becomes available. The risk- free interest rate is based on the U. S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. For employee and non- employee awards (except the Paruka warrant) the Company uses the simplified method, under which the expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to lack of historical exercise data. For the Paruka warrant, the contractual term is used for the expected term. The expected dividend yield is assumed to be zero as the Company has no current plans to pay any dividends on common stock. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company measures restricted common stock awards (& # 8220; RSAs & # 8221;) using the difference, if any, between the purchase price per share of the award and the fair value of the Company & # 8217; s common stock at the date of grant. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company grants stock options, restricted stock awards, and warrants that are subject to service or performance- based vesting conditions. Compensation expense for awards to employees and directors with service- based vesting conditions is recognized using the straight- line method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards to non- employees with service- based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. As of each reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation expense until it is probable that the performance- based vesting condition will be achieved. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company has issued stock options, warrants, and RSAs with service- based and performance- based vesting conditions. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company recognizes the compensation expense for the option to purchase common stock under the Employee Stock Purchase Plan (& # 8220; ESPP & # 8221;), based on the fair value of the common stock estimated using the closing price of the Company & # 8217; s common stock as reported on the date of offering, less the purchase discount percentage provided for in the plan. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company classifies stock- based compensation expense in its consolidated statement of operations and comprehensive loss in the same manner in which the award recipient & # 8217; s payroll costs are classified or in which the award recipient & # 8217; s service payments are classified, as applicable. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Comprehensive Loss < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Comprehensive loss includes net loss as well as other changes in stockholders & # 8217; equity that result from transactions and events other than those with stockholders. The Company & # 8217; s unrealized gains and losses on marketable securities represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the consolidated statement of comprehensive loss. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Net Loss per Share Attributable to Stockholders < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Basic and diluted net loss attributable to stockholders per share is presented in conformity with the two- class method required for participating securities (Pre- Merger Oruka Series A Preferred Stock). Basic earnings per share is computed by dividing net income available to each class of shares by the weighted- average number of shares of common stock and participating securities outstanding during the period. Pre- funded warrants were included as the exercise price is negligible and these warrants are fully vested and exercisable. Company Series A Preferred Stock and Company Series B Preferred Stock share the same characteristics as Common Stock and have no substantive preference attributed to them and, accordingly, have been considered as classes of Common Stock in the computation of net loss per share regardless of their legal form. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Net loss is allocated to common stock based on its proportional ownership on an as- converted basis. Net loss is not allocated to participating securities as they do not have an obligation to fund losses. The weighted- average number of shares outstanding of common stock reflects changes in ownership over the periods presented. See Note 8 & # 8212; Convertible Preferred Stock and Stockholders & # 8217; Equity. < / span > < / p > < p style =" font: 10pt Times

New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Diluted net loss per share is computed by dividing the net loss attributable to stockholders adjusted for income (expenses), net of tax, related to any diluted securities, by the weighted- average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of this calculation, stock options to purchase common stock, employee warrants to purchase common stock, and unvested RSAs are considered potential dilutive common shares. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company generated a net loss for the periods presented. Accordingly, basic and diluted net loss per share is the same because the inclusion of the potentially dilutive securities would be anti- dilutive. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Other income, net < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Other income, net, consists of interest earned on the Company & # 8217; s cash, cash equivalents, and marketable securities; interest expense on the convertible note from a related party and foreign currency transactions gains and losses. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Income Taxes < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company & # 8217; s tax returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis of assets and liabilities using enacted tax rates in effect for the & # 160; years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two- step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50 % likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or penalties related to uncertain tax positions as of December 31, 2024. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Recently Adopted Accounting Pronouncements < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > In November & # 160; 2023, the FASB issued ASU 2023- 07, Segment Reporting (Topic & # 160; 280): Improvements to Reportable Segment Disclosures (& # 8220; ASU & # 160; 2023- 07 & # 8221;), which enhances the segment disclosure requirements for public entities on an annual and interim basis. Under this standard, public entities will be required to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss. Additionally, current annual disclosures about a reportable segment & # 8217; s profit or loss and assets will be required on an interim basis. Entities will also be required to disclose information about the CODM & # 8217; s title and position at the Company along with an explanation of how the CODM uses the reported measures of segment profit or loss in their assessment of segment performance and deciding how to allocate resources. Finally, ASU & # 160; 2023- 07 requires all segment disclosures for public entities that have only a single reportable segment. The amendments in ASU & # 160; 2023- 07 are effective for fiscal & # 160; years beginning after December & # 160; 15, 2023, and interim periods within fiscal & # 160; years beginning after December & # 160; 15, 2024. Early adoption is permitted. The Company adopted ASU 2023- 07 in 2024 and additional required disclosures have been included in Note 10. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Recently Issued Accounting Pronouncements < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > & # 160; < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > In December & # 160; 2023, the FASB issued ASU & # 160; 2023- 09, Income Taxes (Topic & # 160; 740): Improvements to Income Tax Disclosures. This ASU expands disclosures in an entity & # 8217; s income tax rate reconciliation table and disclosures regarding taxes paid both in the U. S. & # 160; and foreign jurisdictions. This update is effective beginning with the Company & # 8217; s 2025 fiscal year annual reporting period. The Company is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > In November 2024, the FASB issued ASU 2024- 03, Income Statement & # 8212; Reporting Comprehensive Income & # 8212; Expense Disaggregation Disclosures (Subtopic 220- 40): Disaggregation of Income Statement Expenses. This ASU requires more detailed disclosures, on an annual and interim basis, about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. This ASU may be applied either prospectively or retrospectively. The Company is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements. < / span > < / p > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AccountingPoliciesAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AccountingPoliciesAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_SignificantAccountingPoliciesTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The entire disclosure for all significant accounting policies of the reporting entity. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 235 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483426 / 235- 10- 50- 1 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 235 < br >- Name Accounting Standards Codification < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 235 / tableOfContent < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_SignificantAccountingPoliciesTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 48 < FILENAME > R12. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208267430048" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Reverse Recapitalization and Pre- Closing Financing < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DisclosureTextBlockSupplementAbstract', window);" > < strong > Reverse Recapitalization and Pre- Closing Financing [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window);" > Reverse Recapitalization and Pre- Closing Financing < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > < b > 3. Reverse Recapitalization and Pre- Closing Financing < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > As described within the Reverse Recapitalization and Pre- Closing Financing section in Note 1, on August 29, 2024, the reverse recapitalization between Pre- Merger Oruka and ARCA was consummated. The Merger was accounted for as a reverse recapitalization in accordance with U. S. GAAP. At the effective time of the Merger, substantially all of the assets of ARCA consisted of cash and cash equivalents and other nominal non- operating assets and liabilities. No goodwill or intangible assets were recognized. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > As part of the recapitalization, the Company acquired the assets and liabilities listed below (in thousands): < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > August 29, < br / > 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Cash and cash equivalents < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 4, 940 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > <

span style =" font- family: Times New Roman, Times, Serif" > Other current assets < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 114 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Accrued liabilities < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (54 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- bottom: 2. 5pt; padding- left: 6. 85pt" > < span style =" font- family: Times New Roman, Times, Serif" > Net assets acquired < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 5, 000 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DisclosureTextBlockSupplementAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DisclosureTextBlockSupplementAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 805 < br >- Name Accounting Standards Codification < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 805 / tableOfContent < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 205 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 205- 20 / tableOfContent < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 49 < FILENAME > R13. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208160397216" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Fair Value Measurements < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FairValueDisclosuresAbstract', window);" > < strong > Fair Value Measurements [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FairValueDisclosuresTextBlock', window);" > Fair Value Measurements < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > < b > 4. Fair Value Measurements < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The following tables present the Company & # 8217; s fair value hierarchy for financial assets measured as of December 31, 2024 (in thousands): < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 14" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > December 31, 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom" > < td style =" font- weight: bold; text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Level 1 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Level 2 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Level 3 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Total < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom" > < td > < span style =" font- family: Times New Roman, Times, Serif" > Cash equivalents < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 125in; width: 52 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Money market funds < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 6, 350 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 157; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 158; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 6, 350 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 125in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > U. S. treasury securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 19, 660 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 159; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 19, 660 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 125in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > U. S. government agency securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 160; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 3, 988 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 161; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style ="

font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text-
align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times,
Serif" > 3, 988 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align:
bottom; background- color: White" > < td style =" padding- left: 0. 125in; text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" >
Commercial papers < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border-
bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text-
align: right" > < span style ="- sec- ix- hidden: hidden- fact- 162; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align:
left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman,
Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span >
< / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 22, 177 < / span > < / td > < td style =" padding-
bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family:
Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >
& # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 163; font- family: Times New Roman, Times, Serif" >
& # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style ="
padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span
style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New
Roman, Times, Serif" > 22, 177 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < /
td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" > < span style =" font-
family: Times New Roman, Times, Serif" > Total cash equivalents < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & #
160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style ="
border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 6, 350 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align:
left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman,
Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span >
< / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 45, 825 < / span > < / td > < td style =" padding-
bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family:
Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >
& # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 164; font- family: Times New Roman, Times, Serif" >
& # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style ="
padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span
style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New
Roman, Times, Serif" > 52, 175 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < /
td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Marketable
securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times
New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style ="
text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < /
span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font-
family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td >
< td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >
& # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span
style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style
=" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New
Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style ="
vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 125in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >
Marketable securities, current < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style ="
font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span >
< / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times,
Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > <
span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & #
160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New
Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text-
align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span
> < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family:
Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr >
< tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 25in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > U. S.
treasury securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font-
family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td
> < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif"
> & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span
style =" font- family: Times New Roman, Times, Serif" > 190, 792 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < /
span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman,
Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 165; font- family: Times New Roman, Times, Serif" > & # 8212; < / span
> < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman,
Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align:
right" > < span style =" font- family: Times New Roman, Times, Serif" > 190, 792 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif"
> & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 25in; text- align: left" > < span style =" font-
family: Times New Roman, Times, Serif" > U. S. government agency securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td
> < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden:
hidden- fact- 166; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > &
160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New
Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 12, 966 < / span > < / td > < td style =" text-
align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span
> < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix-
hidden: hidden- fact- 167; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times,
Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family:
Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 12, 966 < / span > < / td > < td
style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > <
td style =" padding- left: 0. 25in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Commercial papers < / span > < / td > < td > < span style =" font- family:
Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td
style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 168; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span
style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style
=" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New
Roman, Times, Serif" > 34, 811 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style ="
font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < /
td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 169; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left"
> < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > <
td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New
Roman, Times, Serif" > 34, 811 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style ="
vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman,
Times, Serif" > Corporate debt securities < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > <
td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1.
5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 170; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1.
5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times
New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & #
160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 75, 504 < / span > < / td > < td style ="
padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style ="
font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman,
Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 171; font- family: Times New Roman,
Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > <
td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left"
> < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family:
Times New Roman, Times, Serif" > 75, 504 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < /

span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 375in; text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Total marketable securities, current < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 314, 073 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 172; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 314, 073 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 125in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Marketable securities, long- term < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 25in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > U. S. treasury securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 13, 607 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 173; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 13, 607 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > U. S. government agency securities < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 174; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 4, 462 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 175; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 4, 462 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 375in; text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Total marketable securities, long- term < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 18, 069 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 176; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 18, 069 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > Total cash equivalents and marketable securities < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 6, 350 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 377, 967 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 177; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 384, 317 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > There were no transfers in or out of Level & # 160; 3 during the period from February 6, 2024 (inception) to December 31, 2024. < / p > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_FairValueDisclosuresAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_FairValueDisclosuresAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_FairValueDisclosuresTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non- financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p

> Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 820 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 107 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482078 / 820- 10- 55- 107 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 820 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 100 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482078 / 820- 10- 55- 100 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 820 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (3) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 820 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6A < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 6A < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 820 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2E < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2E < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 820 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6A < br >- Subparagraph (h) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 6A < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 820 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6A < br >- Subparagraph (f) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 6A < br > < br > Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 820 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6A < br >- Subparagraph (e) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 6A < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 820 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6A < br >- Subparagraph (d) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 6A < br > < br > Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 820 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (h) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2 < br > < br > Reference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 820 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (g) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2 < br > < br > Reference 12: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 940 < br >- SubTopic 820 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478119 / 940- 820- 50- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_FairValueDisclosuresTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 50 < FILENAME > R14. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208263362912" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Cash equivalents and Marketable Securities < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_CashEquivalentsAndMarketableSecuritiesAbstract', window);" > < strong > Cash equivalents and Marketable Securities [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window);" > Cash Equivalents and marketable Securities < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > < b > 5. Cash equivalents and marketable Securities < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Cash equivalents and marketable securities, which are classified as available- for- sale, consisted of the following as of December 31, 2024 (in thousands): < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 14" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > December 31, 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom" > < td style =" font- weight: bold; text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Amortized Cost < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Gross Unrealized Gains < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Gross Unrealized Losses < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Fair Value < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom" > < td > < span style =" font- family: Times New Roman, Times, Serif" > Cash equivalents < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 125in; width: 52 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Money market funds < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 6, 350 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 178; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 179; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 6, 350 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 125in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > U. S. treasury securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 19, 656 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 4 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 180; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 19, 660 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 125in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > U. S. government agency securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 3, 988 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 181; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 182; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 3, 988 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 125in; text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Commercial papers < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span

style =" font- family: Times New Roman, Times, Serif" > 22, 180 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 183; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (3 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 22, 177 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Total cash equivalents < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 52, 174 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 4 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (3 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 52, 175 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Marketable securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 125in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Marketable securities, current < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 25in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > U. S. treasury securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 190, 748 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 55 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (11 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 190, 792 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 25in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > U. S. government agency securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 12, 967 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 1 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (2 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 12, 966 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 25in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Commercial papers < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 34, 808 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 3 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 184; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 34, 811 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Corporate debt securities < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 75, 537 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 7 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (40 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 75, 504 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 375in; text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Total marketable securities, current < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 314, 060 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 66 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style ="

font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (53 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 314, 073 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 125in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Marketable securities, long- term < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 25in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > U. S. treasury securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 13, 639 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 185; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (32 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 13, 607 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > U. S. government agency securities < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 4, 485 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 186; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (23 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 4, 462 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 375in; text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Total marketable securities, long- term < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 18, 124 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 187; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (55 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 18, 069 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > Total cash equivalents and marketable securities < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 384, 358 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 70 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (111 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 384, 317 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The following table summarizes the available- for- sale securities in an unrealized loss position, aggregated by major security type and length of time in a continuous unrealized loss position, for which an allowance for credit losses was not recorded as of December & # 160; 31, 2024, (in thousands): < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- indent:- 0. 125in; padding- left: 0. 125in; text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 22" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > December 31, 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom" > < td style =" text- indent:- 0. 125in; padding- left: 0. 125in; font- weight: bold; text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 6" style =" text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > < b > Less than 12 months < / b > < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 6" style =" text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > < b > 12 months or longer < / b > < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 6" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Total < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom" > < td style =" text- indent:- 0. 125in; padding- left: 0. 125in; font- weight: bold; text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > < b > Fair < br / > Value < / b > < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Unrealized < br / > Losses < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Fair < br / > Value < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Unrealized < br / > Losses < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > < b > Fair < br / > Value < / b > < / span > < / td >

```
< td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > <
span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" >
< span style =" font- family: Times New Roman, Times, Serif" > Unrealized < br / > Losses < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font-
family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom" > < td style =" text- indent:- 0. 125in; padding- left: 0. 125in" > < span style ="
font- family: Times New Roman, Times, Serif" > Cash equivalents < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td
colspan =" 2" style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman,
Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" text- align: right" > <
span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td >
< span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" text- align: right" > < span style =" font- family: Times New Roman,
Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New
Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > <
td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td >
< td colspan =" 2" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; <
/ span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" > < span style =" font- family: Times New Roman, Times,
Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background-
color: rgb (204, 238, 255)" > < td style =" text- indent:- 0. 125in; padding- left: 0. 25in; width: 28 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >
Commercial papers < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align:
left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times,
Serif" > 18, 199 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1
%" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman,
Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (3 < / span > < / td > < td style =" width: 1 %;
text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" >
& # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align:
right" > < span style ="- sec- ix- hidden: hidden- fact- 188; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style
=" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < /
td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style ="-
sec- ix- hidden: hidden- fact- 189; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times
New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style ="
width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family:
Times New Roman, Times, Serif" > 18, 199 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < /
td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font-
family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (3 < / span > < / td >
< td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color:
White" > < td style =" text- indent:- 0. 125in; padding- left: 0. 125in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Marketable securities < / span > < / td > <
td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > &
# 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style
=" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style ="
text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman,
Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font-
family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td >
< td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times
New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span
style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < /
span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman,
Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align:
right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif"
> & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times
New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style ="
text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)"
> < td style =" text- indent:- 0. 125in; padding- left: 0. 25in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Marketable securities, current < / span > < / td > <
td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > &
# 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style
=" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style ="
text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman,
Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font-
family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td >
< td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times
New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span
style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < /
span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman,
Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align:
right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif"
> & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times
New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style ="
text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style
=" text- indent:- 0. 125in; padding- left: 0. 375in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > U. S. treasury securities < / span > < / td > < td > < span style
=" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span >
< / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 49, 904 < / span > < / td > < td style =" text- align: left" > < span style =" font- family:
Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > <
span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (11 < /
span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td > < span style =" font- family: Times New Roman, Times,
Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > <
span style ="- sec- ix- hidden: hidden- fact- 190; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times
New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span
style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 191; font- family: Times New
Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style
=" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span >
< / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 49, 904 < / span > < / td > < td style =" text- align: left" > < span style =" font- family:
Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > <
span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (11 < /
span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color:
rgb (204, 238, 255)" > < td style =" text- indent:- 0. 125in; padding- left: 0. 375in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > U. S. government agency
securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times
New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 4, 713 < / span > < / td > < td style ="
text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < /
span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font-
family: Times New Roman, Times, Serif" > (2 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td > < span
style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < /
span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 192; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text-
align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span
> < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix-
hidden: hidden- fact- 193; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times,
Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family:
Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 4, 713 < / span > < / td > < td style
=" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160;
< / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font-
family: Times New Roman, Times, Serif" > (2 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < / tr > < tr
style =" vertical- align: bottom; background- color: White" > < td style =" text- indent:- 0. 125in; padding- left: 0. 375in; text- align: left" > < span style =" font- family: Times New Roman,
Times, Serif" > Corporate debt securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > <
span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 39,
468 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New
```

Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (40 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 194; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 195; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 39, 468 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (40 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- indent:- 0. 125in; padding- left: 0. 25in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Marketable securities, long- term < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- indent:- 0. 125in; padding- left: 0. 375in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > U. S. treasury securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 13, 607 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (32 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 196; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 197; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 13, 607 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (32 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- indent:- 0. 125in; padding- left: 0. 375in; text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > U. S. government agency securities < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 4, 462 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (23 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 198; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 199; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 4, 462 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (23 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- indent:- 0. 125in; padding- left: 0. 5in; padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > Total < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 130, 353 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (111 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 200; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 201; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 130, 353 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (111 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < / tr > < / table > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company evaluated its securities for credit losses and considered the decline in market value to be primarily attributable to current economic and market conditions and not to a credit loss or other factors. Additionally, the Company does not intend to sell the securities in an unrealized loss position and it is not more likely than not that the Company will be required to sell the securities before recovery of the unamortized cost basis, which may be at maturity. There were no material realized gains or realized losses on marketable securities for the period presented. Given the Company & # 8217; s intent and ability to hold such securities until recovery, and the lack of significant change in credit risk of these investments, the Company does not consider these marketable securities to be impaired as of December 31, 2024. As of December 31, 2024, the Company did not record an allowance for credit losses. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The following table summarizes the contractual maturities of the Company & # 8217; s marketable securities at estimated fair value (in thousands): < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > December 31, < br / > 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Due in one year or less < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $

< / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 314, 073 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Due in 1- 2 years < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 18, 069 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- bottom: 2. 5pt; padding- left: 0. 125in" > < span style =" font- family: Times New Roman, Times, Serif" > Total < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 332, 142 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_CashEquivalentsAndMarketableSecuritiesAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_CashEquivalentsAndMarketableSecuritiesAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss). < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 320 < br >- Name Accounting Standards Codification < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 320 / tableOfContent < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 51 < FILENAME > R15. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208277010160" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Accrued Expenses and Other Current Liabilities < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window);" > < strong > Accrued Expenses and Other Current Liabilities [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window);" > Accrued Expenses and Other Current Liabilities < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > < b > 6. Accrued Expenses and Other Current Liabilities < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Accrued expenses and other current liabilities consisted of the following (in thousands): < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > December 31, < br / > 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Accrued employee compensation and benefits < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 2, 041 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Accrued professional and consulting < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 221 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Accrued research and development < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 1, 084 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- bottom: 2. 5pt; padding- left: 0. 125in" > < span style =" font- family: Times New Roman, Times, Serif" > Total < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 3, 346 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 720 < br >- SubTopic 30 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 1 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483384 / 720- 30- 45- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 52 < FILENAME > R16. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208266257424" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Note Payable with Related Party < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_NotesPayableAbstract', window);" > < strong > Note Payable with Related Party [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtDisclosureTextBlock', window);" > Note Payable with Related Party < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > < b > 7. Note & # 160; Payable with Related Party < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > In March & # 160; 2024, Pre- Merger Oruka entered into a Series A Preferred Stock and Convertible Note Purchase Agreement (the & # 8220; Purchase Agreement & # 8221;) with Fairmount Healthcare Fund & # 160; II, L. P. (& # 8220; Fairmount & # 8221;), whereby Pre- Merger Oruka issued a convertible note (the & # 8220; Convertible Note & # 8221;), with an initial principal amount of $ 25. 0 million that, at the time of issuance, could be converted into Pre- Merger Oruka Series & # 160; A Preferred Stock (or a series & # 160; of preferred shares that is identical in respect to the shares of preferred shares issued in its next equity financing) or shares of Pre- Merger Oruka Common Stock in exchange for aggregate proceeds of $ 25. 0 & # 160; million. The Convertible Note accrued interest at a rate of 12. 0 % per annum. At issuance, the Convertible Note required all unpaid interest and principal to mature on December & # 160; 31, 2025 (the & # 8220; Maturity Date & # 8221;) and prepayment was not permitted without prior written consent of Fairmount. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company

assessed all terms and features of the Convertible Note in order to identify any potential embedded features that would require bifurcation. As part of this analysis, the Company assessed the economic characteristics and risks of the embedded features. The Company determined that the share settled redemption feature was clearly and closely related to the debt host and did not require separate accounting. The Company determined that the conversion options of the Convertible Note were not clearly and closely associated with a debt host. However, these features did not meet the definition of a derivative under ASC & # 160; 815, Derivatives and Hedging, and as a result, did not require separate accounting as a derivative liability. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company paid debt issuance costs of less than $ 0. 1 & # 160; million in relation to the Convertible Note. The debt issuance costs were reflected as a reduction of the carrying value of Convertible Note on the consolidated balance sheet and were being amortized as interest expense over the term of the Convertible Note using the effective interest method. For the period from February & # 160; 6, 2024 (inception) to December 31, 2024, the Company recognized interest expenses related to the Convertible Note of $ 1. 5 million, which includes non- cash interest expense related to the amortization of debt issuance. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Immediately prior to the completion of the Merger (see Note 1), the Convertible Note was converted into shares of Pre- Merger Oruka Common Stock based on the aggregate principal amount of $ 25. 0 million, plus unpaid accrued interest of $ 1. 5 million divided by the conversion price which was determined based upon the Company & # 8217; s fully- diluted capitalization immediately prior to the Merger. At the effective time of the Merger, the Pre- Merger Oruka Common Stock issued upon the conversion of the Convertible Note (including accrued interest) automatically converted into 2, 722, 207 shares of Company Common Stock. As of December 31, 2024, the Convertible Note is not outstanding. < / span > < / p > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DebtDisclosureTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The entire disclosure for information about short- term and long- term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own- share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long- term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481544 / 470- 10- 50- 6 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481544 / 470- 10- 50- 6 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 405 < br >- SubTopic 40 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (d) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147477092 / 405- 40- 50- 1 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 405 < br >- SubTopic 40 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (a) (3) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147477092 / 405- 40- 50- 1 < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 405 < br >- SubTopic 40 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (a) (2) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147477092 / 405- 40- 50- 1 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 405 < br >- SubTopic 40 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (a) (1) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147477092 / 405- 40- 50- 1 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 405 < br >- SubTopic 40 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147477092 / 405- 40- 50- 1 < br > < br > Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1B < br >- Subparagraph (h) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1B < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 235 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 4- 08 (c)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1 < br > < br > Reference 10: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 470 < br >- Name Accounting Standards Codification < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 470 / tableOfContent < br > < br > Reference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 835 < br >- SubTopic 30 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482925 / 835- 30- 45- 2 < br > < br > Reference 12: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1B < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1B < br > < br > Reference 13: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1B < br >- Subparagraph (g) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1B < br > < br > Reference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1B < br >- Subparagraph (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1B < br > < br > Reference 15: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1C < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1C < br > < br > Reference 16: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1C < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1C < br > < br > Reference 17: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1C < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1C < br > < br > Reference 18: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1E < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1E < br > < br > Reference 19: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1I < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1I < br > < br > Reference 20: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1I < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1I < br > < br > Reference 21: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1I < br >- Subparagraph (d) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1I < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DebtDisclosureTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_NotesPayableAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_NotesPayableAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 53 < FILENAME > R17. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208263416576" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Convertible Preferred Stock and Stockholders & # 8217; Equity < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FeaturesOfConvertiblePreferredStockAbstract', window);" > < strong > Convertible Preferred Stock and Stockholders & # 8217; Equity [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StockholdersEquityNoteDisclosureTextBlock', window);" > Convertible Preferred Stock and Stockholders & # 8217; Equity < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > < b > 8. Convertible Preferred Stock and Stockholders & # 8217; Equity < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > & # 160; < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Pre- Funded Warrants < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > In August 2024, pursuant to the Subscription Agreement and immediately prior to the Closing, certain new and current investors purchased pre- funded & # 160; warrants, which, at the effective time of the Merger, were exercisable for 5, 522, 207 shares of Company Common Stock at a purchase price of approximately $ 9. 70 per warrant. After the Merger, there are 5, 522, 207 pre- funded warrants outstanding and are exercisable for 5, 522, 207 shares of the Company Common Stock at an exercise price of $ 0. 01 per share. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > In September 2024, in connection with the PIPE Financing, the Company issued and sold 680, 000 pre- funded warrants, at a purchase price of $ 22. 999 per warrant, exercisable for 680, 000 shares of Company Common Stock at an exercise price of $ 0. 001 per share. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The pre- funded warrants were recorded as a component of stockholders & # 8217; equity within additional paid- in- capital and have < span style ="- sec- ix- hidden: hidden- fact- 202" > no < / span > expiration date. As of December 31, 2024, < span style ="- sec- ix- hidden: hidden- fact- 203" > none < / span > of the pre- funded warrants have been exercised and 6, 202, 207 pre- funded warrants remain outstanding. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Employee Warrants < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > In July 2024, Pre- Merger Oruka entered into a Subscription Agreement that provided for, among other things, the issuance of warrants to certain of Pre- Merger Oruka & # 8217; s employees and directors immediately prior to the closing of the Merger. During the period from February 6, 2024 (inception) to December 31, 2024, 3, 054, 358 employee warrants were issued at an exercise price of $ 7. 80 per warrant. These warrants vest over a period of four years. Per the terms of the Employee Warrant Agreement, the holders of the Company & # 8217; s warrants shall not have any of the rights or privileges of a stockholder of the Company in respect of any shares purchasable upon the exercise of the warrant or any portion thereof unless and until a

certificate or certificates representing such shares have been issued or a book entry representing such shares has been made and such shares have been deposited with the appropriate registered book- entry custodian. The Company recognizes compensation cost related to warrants on a straight- line basis over the requisite service period, which is the period in which the related services are received. As of December 31, 2024, < span style ="- sec- ix- hidden: hidden- fact- 204" > none < / span > of the warrants have been exercised and 3, 054, 358 warrants remain outstanding. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Convertible Preferred Stock < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > In March & # 160; 2024, Pre- Merger Oruka issued and sold an aggregate of 20, 000, 000 shares of Pre- Merger Oruka Series & # 160; A Preferred Stock to Fairmount (see Note 15), at a purchase price of approximately $ 0. 15 per share, for aggregate gross proceeds of $ 3. 0 & # 160; million. Pre- Merger Oruka incurred less than $ 0. 1 & # 160; million of issuance costs in connection with this transaction. Upon the issuance of the Pre- Merger Oruka Series & # 160; A Preferred Stock, the Company assessed the embedded conversion and liquidation features of the securities as described below and determined that such features did not require the Company to separately account for these features. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > In August 2024, upon the closing of the Merger, the Company converted the Pre- Merger Oruka Series A Preferred Stock to 137, 138 shares of Company Series B Preferred Stock. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > In September 2024, in connection with the PIPE Financing, the Company issued and sold an aggregate of 2, 439 shares of the Company Series A Preferred Stock at a purchase price of $ 23, 000. 00 per share. & # 160; In November 2024, the 2, 439 shares of the Company Series A Preferred Stock were converted to 2, 439, 000 shares of Company Common Stock. As of December 31, 2024, there are < span style ="- sec- ix- hidden: hidden- fact- 205" > no < / span > outstanding shares of Company Series A Preferred Stock. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > As of December 31, 2024, convertible preferred stock consisted of the following (in thousands, except share data): < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 14" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > December 31, 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom" > < td style =" font- weight: bold; font- style: italic" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" text- align: center; border- bottom: Black 1. 5pt solid" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > < b > Preferred < br / > Stock < br / > Authorized < / b > < / span > < / p > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Preferred < br / > Stock Issued < br / > and < br / > Outstanding < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Carrying < br / > Value < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Common Stock < br / > Issuable < br / > Upon < br / > Conversion < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 52 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Series B convertible preferred stock < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 251, 504 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 137, 138 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 2, 931 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 11, 428, 149 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Pursuant to the Certificate of Designation of Preferences, Rights and Limitations of the Series A Non- Voting Convertible Preferred Stock (the & # 8220; Series A Certificate of Designation & # 8221;) filed in connection with the PIPE Financing, holders of Company Series A Preferred Stock were entitled to receive dividends on shares of Company Series A Preferred Stock equal to, on an as- if- converted- to- Company Common Stock basis, and in the same form as, dividends actually paid on shares of Company Common Stock. Except as provided in the Series A Certificate of Designation or as otherwise required by law, the Company Series A Preferred Stock did not have voting rights. The Company Series A Preferred Stock shall rank on parity with the Company Common Stock and Company Series B Preferred Stock upon any liquidation, dissolution or winding- up of the Company. Subject to the terms and limitations contained in the Series A Certificate of Designation, the Company Series A Preferred Stock issued in the PIPE Financing will not become convertible until the Company & # 8217; s stockholders approve the conversion of the Company Series A Preferred Stock into shares of Company Common Stock in accordance with the listing rules of the Nasdaq Stock Market (the & # 8220; Stockholder Approval & # 8221;), which, on issuance, resulted in the Company Series A Preferred Stock being classified outside of stockholders & # 8217; equity on the Company & # 8217; s consolidated balance sheet. Following the Stockholder Approval in November 2024, each share of Company Series A Preferred Stock was automatically converted into 1, 000 shares of Company Common Stock. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Pursuant to the Certificate of Designation of Preferences, Rights and Limitations of the Series B Non- Voting Convertible Preferred Stock (the & # 8220; Series B Certificate of Designation & # 8221;) filed in connection with the Merger, holders of Company Series B Preferred Stock are entitled to receive dividends on shares of Company Series B Preferred Stock equal to, on an as- if- converted- to- Company Common Stock basis, and in the same form as, dividends actually paid on shares of Company Common Stock. Except as provided in the Series B Certificate of Designation or as otherwise required by law, the Company Series B Preferred Stock does not have voting rights. The Company Series B Preferred Stock shall rank on parity with the Company Common Stock as to the distribution of assets upon any liquidation, dissolution, or winding- up of the Company. Each share of Company Series B Preferred Stock is convertible at the option of the holder, at any time, and without the payment of additional consideration by the holder. As of December 31, 2024, each outstanding share of Company Series B Preferred Stock was convertible into common stock at a ratio of approximately 83. 3332: 1. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Paruka Warrant < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > On December 31, 2024, the Company settled its 2024 obligations under the Paruka Warrant Obligation (defined below) by issuing Paruka a warrant to purchase 596, 930 shares of Company Common Stock at an exercise price of $ 19. 39 per share. The warrant has a term of 10 years, is fully vested, and is exercisable in part or full at any time during the term of the warrant. As of December 31, 2024, the warrant issued under the Paruka Warrant Obligation is outstanding and unexercised. See Note 9 for additional information on the Paruka Warrant Obligation. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Common Stock < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > As of December 31, 2024, the Certificate of Incorporation provides for 545, 000, 000 authorized shares of Company Common Stock. As of December 31, 2024, 37, 440, 510 shares of Company Common Stock were issued and outstanding, including 2, 207, 553 shares of RSAs issued and outstanding. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > As of December 31, 2024, the Company had common stock reserved for future issuance as follows: & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > December 31, < br / > 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Shares issuable on conversion of Company Series B Preferred Stock < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 11, 428, 149 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td > < span style =" font- family: Times New Roman, Times, Serif" > Shares issuable upon exercise of pre- funded warrants < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 6, 202, 207 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Shares issuable upon exercise of warrant under the Paruka Warrant Obligation < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 596, 930 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times

New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Outstanding and issued stock options < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 1, 567, 760 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Outstanding and issued employee warrants < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 3, 054, 358 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Shares available for grant under 2024 Stock Incentive Plan < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 4, 246, 324 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Shares available for grant under 2024 Employee Stock Purchase Plan < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 460, 529 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- bottom: 4pt; padding- left: 13. 7pt" > < span style =" font- family: Times New Roman, Times, Serif" > Total shares of common stock reserved < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 27, 556, 257 < / span > < / td > < td style =" padding- bottom: 4pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_FeaturesOfConvertiblePreferredStockAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_FeaturesOfConvertiblePreferredStockAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StockholdersEquityNoteDisclosureTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The entire disclosure for equity. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 13 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 13 < br >- Subparagraph (h) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 14 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 14 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 235 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147477968 / 946- 235- 50- 2 < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 235 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (d) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147477968 / 946- 235- 50- 2 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 505 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478448 / 946- 505- 50- 6 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 815 < br >- SubTopic 40 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480237 / 815- 40- 50- 6 < br > < br > Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 3- 04) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480008 / 505- 10- S99- 1 < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 235 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 4- 08 (e) (1)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1 < br > < br > Reference 10: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 505 < br >- Name Accounting Standards Codification < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 505 / tableOfContent < br > < br > Reference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 13 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13 < br > < br > Reference 12: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 13 < br >- Subparagraph (g) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13 < br > < br > Reference 13: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 13 < br >- Subparagraph (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13 < br > < br > Reference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 14 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 14 < br > < br > Reference 15: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 14 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 14 < br > < br > Reference 16: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 16 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 16 < br > < br > Reference 17: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 18 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 18 < br > < br > Reference 18: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 18 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 18 < br > < br > Reference 19: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 18 < br >- Subparagraph (d) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 18 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StockholdersEquityNoteDisclosureTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 54 < FILENAME > R18. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208263407184" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Stock- Based Compensation < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window);" > < strong > Stock- Based Compensation [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window);" > Stock- Based Compensation < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > < b > 9. Stock- Based Compensation < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > & # 160; < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > 2024 Equity Incentive Plan < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The 2024 Equity Incentive Plan (& # 8220; 2024 Plan & # 8221;) was adopted by the board of directors of Pre- Merger Oruka on February & # 160; 6, 2024. The 2024 Plan provided for Pre- Merger Oruka to grant stock options, restricted stock awards, restricted stock units, and other stock- based awards to employees, officers, directors, consultants, and advisors. Equity Incentive Stock options granted under the 2024 Plan generally vest over four & # 160; years, subject to the participant & # 8217; s continued service, and expire after ten & # 160; years, although two non- employee stock options were & # 160; granted with vesting terms less than four & # 160; years. As of December 31, 2024, there are no shares of common stock available for issuance. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > 2024 Stock Incentive Plan < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > On August 22, 2024, the 2024 Stock Incentive Plan (& # 8220; 2024 Stock Plan & # 8221;) was approved by the Company & # 8217; s stockholders and on August 29, 2024, the board of directors of the Company (the & # 8220; Board & # 8221;) ratified the 2024 Stock Plan. The 2024 Stock Plan allows for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock units, other stockholder- based awards and incentive bonuses. The 2024 Stock Plan is administered by the Compensation Committee of the Board (the & # 8220; Compensation Committee & # 8221;) or another committee designated by the Board to administer the Plan. The initial share pool under the 2024 Stock Plan is 4, 634, 891 shares of Company Common Stock. During the period from February 6, 2024 (inception) to December 31, 2024, 388, 567 shares were subject to outstanding stock options, and as of December 31, 2024, there were 4, 246, 324 shares available in the pool. The shares that may be issued under the 2024 Stock Plan will be automatically increased on January 1 of each year beginning in 2025 and ending with a final increase on January 1, 2034 in an amount equal to 5 % of the diluted stock (including Company Common Stock, preferred stock and unexercised pre- funded warrants) on the preceding December 31, unless a lower, or no, increase is determined by the Compensation Committee. Current or prospective employees, officers, non- employee directors, and other independent service providers of the Company and its subsidiaries are eligible to participate in the 2024 Stock Plan. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > 2024 Employee

Stock Purchase Plan < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The 2024 Employee Stock Purchase Plan (the & # 8220; ESPP & # 8221;) became effective on August 29, 2024, at which time 463, 489 shares of Company Common Stock were reserved for issuance. Eligible employees may purchase shares of Company Common Stock under the ESPP at & # 160; 85 % of the lower of the fair market value of the Company Common Stock as of the first or the last day of each offering period. Employees are limited to contributing & # 160; 15 % of the employee & # 8217; s eligible compensation and may not purchase more than $ 25, 000 & # 160; of stock during any calendar year. The ESPP will terminate & # 160; ten years & # 160; from the first purchase date under the plan, unless terminated earlier by the board of directors. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The shares that may be issued under the ESPP will be automatically increased on January 1 of each year beginning in 2025 and ending with a final increase on January 1, 2034 in an amount equal to 1 % of the diluted stock (including Company Common Stock, preferred stock and unexercised pre- funded warrants) on the preceding December 31, unless a lower, or no increase is determined by the Compensation Committee. During the period from February 6, 2024 (inception) to December 31, 2024, 2, 960 shares of Company Common Stock were issued out of the ESPP and as of December 31, 2024, there were 460, 529 shares of Company Common Stock available in the pool. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > For the period February 6, 2024 (inception) to December 31, 2024, stock- based compensation expense related to the ESPP was less than $ 0. 1 million. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Stock Option Valuation < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The following table summarizes the weighted- average assumptions used in calculating the fair value of the awards for the period from February & # 160; 6, 2024 (inception) to December 31, 2024: < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Period from < br / > February 6, < br / > 2024 < br / > (Inception) to < br / > December 31, < br / > 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Expected term (in years) < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 6. 1 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Expected volatility < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 100. 21 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > % < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Risk- free interest rate < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 4. 26 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > % < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Expected dividend yield < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 206; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > & # 160; < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Stock Options < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The following table summarizes the stock option activities under the 2024 Plan and 2024 Stock Plan for the period of February & # 160; 6, 2024 (inception) through December 31, 2024: < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Number of < br / > Stock < br / > Options < br / > Outstanding < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Weighted < br / > Average < br / > Exercise < br / > Price Per < br / > Share < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Weighted < br / > Average < br / > Remaining < br / > Contractual < br / > Term < br / > (in Years) < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Aggregate < br / > Intrinsic < br / > Value < br / > (in & # 160; Thousands) < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td > < span style =" font- family: Times New Roman, Times, Serif" > Balance as of February 6, 2024 (inception) < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 208; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 209; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 210; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 211; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 125in; width: 52 %" > < span style =" font- family: Times New Roman, Times, Serif" > Granted < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 1, 567, 760 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 11. 39 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 125in" > < span style =" font- family: Times New Roman, Times, Serif" > Exercised < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 212; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 213; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 125in; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Forfeited < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 214; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 215; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font-family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > Balance as of December 31, 2024 < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 1, 567, 760 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 11. 39 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 9. 4 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 15, 470 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > Vested and expected to vest, December 31, 2024 < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 1, 567, 760 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 11. 39 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 9. 4 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 15, 470 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > Exercisable, December 31, 2024 < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 216; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 217; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 218; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 219; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 27pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 27pt" > < span style =" font- family: Times New Roman, Times, Serif" > The weighted average grant- date fair value per share of stock options granted during the period from February & # 160; 6, 2024 (inception) to December 31, 2024 was $ 9. 12 per share. Aggregate intrinsic value represents the difference between the estimated fair value of the underlying Company Common Stock and the exercise price of outstanding, in- the- money employee stock options. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 27pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Restricted Stock Awards < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > In February 2024 and March & # 160; 2024, the Company issued 2, 207, 553 shares of RSAs to certain employees, directors, and consultants at a price of $ 0. 0001 per share, the then par value of Pre- Merger Oruka Common Stock. Such RSAs have service- based vesting conditions only and vest over a four- year period, during which time all unvested shares are subject to forfeiture in the event the holder & # 8217; s service with the Company voluntarily or involuntarily terminates. As of December 31, 2024, none of the RSAs had vested. For the period February 6, 2024 (inception) to December 31, 2024, stock- based compensation expense related to RSAs was less than $ 0. 1 million. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The following table summarizes the RSA activity for the period from February & # 160; 6, 2024 (inception) through December 31, 2024: < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Number of < br / > RSAs < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Weighted < br / > Average < br / > Grant Date < br / > Fair Value < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td > < span style =" font- family: Times New Roman, Times, Serif" > Unvested balance as of February 6, 2024 (inception) < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 220; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 221; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" width: 76 %; padding- bottom: 1. 5pt; padding- left: 13. 7pt" > < span style =" font- family: Times New Roman, Times, Serif" > Granted < / span > < / td > < td style =" width: 1 %; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 2, 207, 553 < / span > < / td > < td style =" width: 1 %; padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; padding- bottom: 1. 5pt; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 222; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" width: 1 %; padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > Unvested balance as of December 31, 2024 < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 2, 207, 553 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 223; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > & # 160; < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Option Agreements and the Paruka Warrant Obligation < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > As part of the Option Agreements, on December & # 160; 31, 2024 the Company granted and on December & # 160; 31, 2025, will grant Paruka a warrant to purchase a number of shares equal to 1. 00 % of outstanding shares as of the date of the grant on a fully- diluted basis, with an exercise price equal to the fair market value of the underlying shares on the grant date (the & # 8220; Paruka Warrant Obligation & # 8221;). < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The grant dates for the issuance of warrants were expected to be December & # 160; 31, 2024 and December & # 160; 31, 2025 as all terms of the award, including number of shares and exercise price, will be known by all parties. The Company determined that the 2024 and 2025 grants are two separate

grants, as there would be no obligation for the 2025 grant had the Company exercised or terminated all of the options under the Option Agreements prior to December 31, 2024. The service inception period for the grant precedes the grant date, with the full award being vested as of the grant date with no post- grant date service requirement. Accordingly, the warrant expected to be granted to Paruka was accounted for as a liability on the balance sheet on the service inception date and, after the initial recognition, the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the consolidated statement of operations and comprehensive loss as stock- based compensation expenses under research and development expenses. Accordingly, the Company measured the grant date fair value of the warrant granted on December 31, 2024 at $ 10. 4 million. For the period from February 6, 2024 (inception) to December 31, 2024, $ 10. 4 million was recognized as stock- based compensation expense related to the Paruka Warrant Obligation in the consolidated statement of operations and comprehensive loss. As of December 31, 2024, there was no unamortized expense related to the December 31, 2024 Paruka Warrant Obligation. On issuance of the warrant to Paruka, the fair value of the warrant was reclassified from liability to equity on the consolidated balance sheet as of December 31, 2024. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Employee Warrants < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > As stated above, on July 3, 2024, the Subscription Agreement was amended and restated, among other things, for employee warrants to be issued to certain Pre- Merger Oruka employees and directors immediately prior to the closing of the Merger. Pursuant to this amendment, during the period from February 6, 2024 (inception) to December 31, 2024, the Company issued 3, 054, 358 warrants at an exercise price of $ 7. 80 per warrant, which are accounted as equity in the consolidated financial statements. The employee warrants were subject to performance and service based vesting requirements and upon completion of the Merger the performance- based requirements had been achieved. < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The following table summarizes the warrant activity for the period from February & # 160; 6, 2024 (inception) through December 31, 2024: & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; font- weight: bold; text- align: center" > Number of < br / > Employee < br / > Warrants < br / > Outstanding < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Weighted < br / > Average < br / > Exercise < br / > Price Per < br / > Share < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Weighted < br / > Average < br / > Remaining < br / > Contractual < br / > Term < br / > (in Years) < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Aggregate < br / > Intrinsic < br / > Value < br / > (in & # 160; Thousands) < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td > < span style =" font- family: Times New Roman, Times, Serif" > Balance as of February 6, 2024 (inception) < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 224; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 225; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 226; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 125in; width: 52 %" > < span style =" font- family: Times New Roman, Times, Serif" > Granted < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 3, 054, 358 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 7. 80 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 125in" > < span style =" font- family: Times New Roman, Times, Serif" > Exercised < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 227; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 228; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 125in; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Forfeited < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 229; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 230; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > Balance as of December 31, 2024 < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 3, 054, 358 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 7. 80 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 9. 5 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 35, 400 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > Vested and expected to vest, December 31, 2024 < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 3, 054, 358 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 7. 80 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom:

4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 9. 5 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 35, 400 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > Exercisable, December 31, 2024 < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 231; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 232; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 233; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The weighted average grant- date fair value per share of warrants granted during the period from February & # 160; 6, 2024 (inception) to December 31, 2024 was $ 6. 27 per share. Aggregate intrinsic value represents the difference between the estimated fair value of the underlying Company Common Stock and the exercise price of outstanding, in- the- money warrants. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The following table summarizes the weighted- average assumptions used in calculating the fair value of the warrants for the period from February & # 160; 6, 2024 (inception) to December 31, 2024: < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Period from < br / > February 6, < br / > 2024 < br / > (Inception) to < br / > December 31, < br / > 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Expected term (in years) < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 6. 1 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Expected volatility < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 99. 02 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > % < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Risk- free interest rate < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 4. 15 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > % < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Expected dividend yield < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 207; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > & # 160; < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Stock- Based Compensation Expense < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The following table summarizes the classification of the Company & # 8217; s stock- based compensation expense in the consolidated statement of operations and comprehensive loss (in thousands): < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Period from < br / > February 6, < br / > 2024 < br / > (Inception) to < br / > December 31, < br / > 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Research and development < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 11, 992 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > General and administrative < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 2, 927 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- bottom: 2. 5pt; padding- left: 13. 7pt" > < span style =" font- family: Times New Roman, Times, Serif" > Total < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 14, 919 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > As of December 31, 2024, total unrecognized compensation cost related to the unvested stock options was $ 12. 7 million, which is expected to be recognized over a weighted average period of approximately 3. 2 years. As of December 31, 2024, total unrecognized compensation cost related to the unvested RSAs was less than $ 0. 1 million, which is expected to be recognized over a weighted average period of 3. 1 years. As of December 31, 2024, the unrecognized compensation cost related to the employee warrants was $ 16. 3 million, which is expected to be recognized over a weighted average period of 3. 3 years. & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The following table summarizes the award types of the Company & # 8217; s stock- based compensation expense in the consolidated statement of operations and comprehensive loss (in thousands): < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Period from < br / > February 6, < br / > 2024 < br / > (Inception) to < br / > December 31, < br / > 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Paruka Warrant Obligation < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 10, 357 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Employee warrants < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 2, 899 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Stock options < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 1, 626 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Employee stock purchase plan < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 37 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- bottom: 2. 5pt; padding- left: 0. 125in" > < span style =" font- family: Times New Roman, Times, Serif" > Total < / span > < / td > < td style =" padding- bottom: 4pt" > < span style

=" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 14, 919 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The entire disclosure for share- based payment arrangement. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (a) (1) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- Name Accounting Standards Codification < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 718 / tableOfContent < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (h) (2) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (h) (2) (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (l) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 55 < FILENAME > R19. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208160104880" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Segment Disclosures < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SegmentReportingAbstract', window);" > < strong > Segment Disclosures [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SegmentReportingDisclosureTextBlock', window);" > Segment Disclosures < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > < b > 10. Segment disclosures < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company operates and manages its business activities on a consolidated basis and operates in one reportable segment. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > The Company operates as a single reportable and operating segment. Its Chief Executive Officer, serving as the Chief Operating Decision Maker (& # 8220; CODM & # 8221;), oversees operations on an aggregated basis to allocate resources effectively. In assessing the Company & # 8217; s financial performance, the CODM regularly reviews total operating expenses and consolidated net loss. < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in; background- color: white" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in; background- color: white" > < span style =" font- family: Times New Roman, Times, Serif" > The measure of segment assets is reported on the balance sheet as total consolidated assets. The Company & # 8217; s long- lived assets consist primarily of property and equipment, net. As of December & # 160; 31, 2024 all of long- lived assets were in the U. S. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in; background- color: white" > < span style =" font- family: Times New Roman, Times, Serif" > The table below is a summary of the segment loss from operations, including significant segment expenses (in thousands): < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in; background- color: white" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Period from < br / > February 6, < br / > 2024 < br / > (Inception) to December & # 160; 31, < br / > 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Research and development personnel- related (excluding stock- based compensation) < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 3, 959 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > General and administrative personnel- related (excluding stock- based compensation) < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 5, 054 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Research and development stock- based compensation < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 11, 992 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > General and administrative stock- based compensation < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 2, 927 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > External research and development < / span > < / td > < td > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 57, 680 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > Other research and development < / td > < td > & # 160; < / td > < td style =" text- align: left" > & # 160; < / td > < td style =" text- align: right" > 1, 429 < / td > < td style =" text- align: left" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > General and administrative, excluding personnel- related and stock- based compensation < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 5, 082 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- bottom: 1. 5pt; padding- left: 0. 125in" > < span style =" font- family: Times New Roman, Times, Serif" > Total operating expenses < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 88, 123 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- bottom: 4pt; padding- left: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Loss from operations < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (88, 123 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_SegmentReportingAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_SegmentReportingAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_SegmentReportingDisclosureTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href ="

```
javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The entire disclosure for reporting segments including data and tables. Reportable segments include
those that meet any of the following quantitative thresholds a) it' s reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the
combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined
reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the
combined assets of all operating segments. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p >
Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 48 <
br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482785 / 280- 10- 55- 48 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 280 <
br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 32 < br >- Subparagraph (f) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org /
1943274 / 2147482810 / 280- 10- 50- 32 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 270 < br >- SubTopic 10 < br >- Name Accounting Standards
Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482964 / 270- 10- 50- 1 < br > < br >
Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 32 <
br >- Subparagraph (ee) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 32 < br > < br > Reference 5: http: / / fasb. org / us- gaap / role / ref /
otherTransitionRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 32 < br >- Subparagraph (d) < br >- Publisher
FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 32 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 280 < br >- SubTopic 10
< br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 54 < br >- Subparagraph (d) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 /
2147482785 / 280- 10- 55- 54 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification <
br >- Section 55 < br >- Paragraph 47 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482785 / 280- 10- 55- 47 < br > < br > Reference 8: http:
/ / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 54 < br >- Subparagraph
(a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482785 / 280- 10- 55- 54 < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic
280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 47 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc.
fasb. org / 1943274 / 2147482785 / 280- 10- 55- 47 < br > < br > Reference 10: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting
Standards Codification < br >- Section 55 < br >- Paragraph 54 < br >- Subparagraph (e) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482785 / 280- 10- 55- 54 < br >
< br > Reference 11: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >-
Paragraph 47 < br >- Subparagraph (d) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482785 / 280- 10- 55- 47 < br > < br > Reference 12: http: / / www. xbrl. org /
2003 / role / disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 22 < br >- Publisher FASB < br >- URI
https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 22 < br > < br > Reference 13: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name
Accounting Standards Codification < br >- Section 50 < br >- Paragraph 31 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 31 < br > < br >
Reference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 34
< br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 34 < br > < br > Reference 15: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 280
< br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 26C < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810
/ 280- 10- 50- 26C < br > < br > Reference 16: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >-
Section 50 < br >- Paragraph 26B < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 26B < br > < br > Reference 17: http: / / www. xbrl. org / 2003 /
role / disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 15 < br >- Publisher FASB < br >- URI https: / /
asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 15 < br > < br > Reference 18: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name
Accounting Standards Codification < br >- Section 50 < br >- Paragraph 42 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 42 < br > < br >
Reference 19: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 40
< br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 40 < br > < br > Reference 20: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 280
< br >- Name Accounting Standards Codification < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 280 / tableOfContent < br > < br > Reference 21: http: / / www. xbrl. org / 2003 / role
/ disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 26 < br >- Publisher FASB < br >- URI https: / / asc.
fasb. org / 1943274 / 2147482810 / 280- 10- 50- 26 < br > < br > Reference 22: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting
Standards Codification < br >- Section 50 < br >- Paragraph 41 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 41 < br > < br > Reference 23:
http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 21 < br >-
Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 21 < br > < br > Reference 24: http: / / www. xbrl. org / 2003 / role /
disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 21 < br >- Subparagraph (b) < br >- Publisher FASB <
br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 21 < br > < br > Reference 25: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br
>- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 32 < br >- Subparagraph (e) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 /
280- 10- 50- 32 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0"
cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_SegmentReportingDisclosureTextBlock < / td > < / tr > < tr > < td style ="
padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr-
types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td >
duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 56
< FILENAME > R20. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report.
css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling.
style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < /
span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208263335824" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong >
Income Taxes < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr
class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_IncomeTaxDisclosureAbstract', window);" > < strong > Income Taxes [ Abstract ] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class ="
ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_IncomeTaxDisclosureTextBlock', window);" > Income Taxes < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify"
> < span style =" font- family: Times New Roman, Times, Serif" > < b > 11. Income Taxes < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-
align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin:
0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > < span style ="- sec- ix- hidden: hidden- fact- 238" > No < / span > provision for
income taxes was recorded for the period from February & # 160; 6, 2024 (inception) to December 31, 2024. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt
0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif;
margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The following table summarizes the loss before income tax expense by
jurisdiction for the periods indicated: < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font-
family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif;
border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td
style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold;
text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Period from < br / > February 6, < br / > 2024 < br / > (Inception) to < br
/ > December 31, < br / > 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > <
/ td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %" > < span style =" font- family: Times New Roman, Times, Serif" >
Domestic < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > <
span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > (< span style =" font- family: Times New Roman, Times, Serif" >
83, 724 < / span > < / td > < td style =" width: 1 %; text- align: left" >) < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical-
align: bottom; background- color: White" > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Foreign < / span > < / td > < td style ="
padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span
style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden-
fact- 234; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman,
Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- bottom: 2. 5pt; padding-
left: 0. 125in" > < span style =" font- family: Times New Roman, Times, Serif" > Loss before income tax expense < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font-
family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times,
Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > (< span style =" font- family: Times New Roman, Times, Serif" > 83, 724 < / span > < / td > < td
style =" padding- bottom: 2. 5pt; text- align: left" >) < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < p style =" font: 10pt Times
New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font:
10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify;
text- indent: 0. 25in" > For the period from February 6, 2024 (inception) to December & # 160; 31, 2024, the Company recognized & # 160; no & # 160; provision or benefit from income taxes.
The difference between the Company & # 8217; s provision for income taxes and the amounts computed by applying the statutory federal income tax rate to income before income taxes is as
follows: < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < / p > < p style =" font: 10pt Times New Roman, Times, Serif;
margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman,
Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times,
Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > & # 160; < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > & # 160; < /
td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > Period from < br / > February 6, < br / > 2024 < br / > (Inception) & # 160; to < br / >
December & # 160; 31, < br / > 2024 < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204,
238, 255)" > < td style =" width: 88 %; text- align: left" > Tax benefit derived by applying the federal statutory rate to income before income taxes < / td > < td style =" width: 1 %" > & # 160; < /
td > < td style =" width: 1 %; text- align: left" > & # 160; < / td > < td style =" width: 9 %; text- align: right" > (21. 00 < / td > < td style =" width: 1 %; text- align: left" >) % < / td > < / tr > < tr
style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > Permanent differences < / td > < td > & # 160; < / td > < td style =" text- align: left" > & # 160; < / td
> < td style =" text- align: right" > (0. 18 < / td > < td style =" text- align: left" >) < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text-
align: left" > Research and development credits < / td > < td > & # 160; < / td > < td style =" text- align: left" > & # 160; < / td > < td style =" text- align: right" > (3. 41 < / td > < td style =" text-
align: left" >) < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td > Other < / td > < td > & # 160; < / td > < td style =" text- align: left" > & # 160; < / td > < td
```

style =" text- align: right" > (0. 87 < / td > < td style =" text- align: left" >) < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- bottom: 1. 5pt" > Change in the valuation allowance < / td > < td style =" padding- bottom: 1. 5pt" > & # 160; < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > & # 160; < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > 25. 46 < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- bottom: 4pt; padding- left: 9pt" > Income tax (benefit) expense < / td > < td style =" padding- bottom: 4pt" > & # 160; < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > & # 160; < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > 0. 00 < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > % < / td > < / tr > < / table > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The components of the deferred tax assets and liabilities consist of the following (in thousands): < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > & # 160; < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > & # 160; < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > December & # 160; 31, < br / > 2024 < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom" > < td > Deferred tax assets < / td > < td > & # 160; < / td > < td colspan =" 2" style =" text- align: right" > & # 160; < / td > < td > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left; padding- left: 9pt" > Net operating loss carryforwards < / td > < td style =" width: 1 %" > & # 160; < / td > < td style =" width: 1 %; text- align: left" > $ < / td > < td style =" width: 9 %; text- align: right" > 2, 260 < / td > < td style =" width: 1 %; text- align: left" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- left: 9pt" > Research and development credits < / td > < td > & # 160; < / td > < td style =" text- align: left" > & # 160; < / td > < td style =" text- align: right" > 3, 080 < / td > < td style =" text- align: left" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- left: 9pt" > Stock- based compensation < / td > < td > & # 160; < / td > < td style =" text- align: left" > & # 160; < / td > < td style =" text- align: right" > 3, 063 < / td > < td style =" text- align: left" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- left: 9pt" > Accruals and other < / td > < td > & # 160; < / td > < td style =" text- align: left" > & # 160; < / td > < td style =" text- align: right" > 424 < / td > < td style =" text- align: left" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- left: 9pt" > Lease liability < / td > < td > & # 160; < / td > < td style =" text- align: left" > & # 160; < / td > < td style =" text- align: right" > 203 < / td > < td style =" text- align: left" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 9pt" > Intangibles < / td > < td > & # 160; < / td > < td style =" text- align: left" > & # 160; < / td > < td style =" text- align: right" > 1, 477 < / td > < td style =" text- align: left" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- bottom: 1. 5pt; padding- left: 9pt" > Capitalized R & amp; D expenses < / td > < td style =" padding- bottom: 1. 5pt" > & # 160; < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > & # 160; < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > 10, 994 < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- left: 0. 25in" > Total deferred tax assets < / td > < td > & # 160; < / td > < td style =" text- align: left" > & # 160; < / td > < td style =" text- align: right" > 21, 501 < / td > < td style =" text- align: left" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left" > Deferred tax liabilities < / td > < td > & # 160; < / td > < td style =" text- align: left" > & # 160; < / td > < td style =" text- align: right" > & # 160; < / td > < td style =" text- align: left" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- bottom: 1. 5pt; padding- left: 9pt" > Right- of- use asset < / td > < td style =" padding- bottom: 1. 5pt" > & # 160; < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > & # 160; < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > (184 < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" >) < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- left: 0. 25in" > Total deferred tax liabilities < / td > < td > & # 160; < / td > < td style =" text- align: left" > & # 160; < / td > < td style =" text- align: right" > (184 < / td > < td style =" text- align: left" >) < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- bottom: 1. 5pt" > Less valuation allowance < / td > < td style =" padding- bottom: 1. 5pt" > & # 160; < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > & # 160; < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > (21, 317 < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" >) < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- bottom: 4pt" > Deferred tax assets, net < / td > < td style =" padding- bottom: 4pt" > & # 160; < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > $ < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < div style ="- sec- ix- hidden: hidden- fact- 235" > & # 8212; < / div > < / td > < td style =" padding- bottom: 4pt; text- align: left" > & # 160; < / td > < / tr > < / table > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 18pt" > The Company has established a full federal and state valuation allowance equal to the net deferred tax assets due to uncertainties regarding the realization of the deferred tax asset based on the Company & # 8217; s lack of earnings history. The valuation allowance increased by $ 21. 3 & # 160; million primarily due to continuing loss from operations. < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > & # 160; < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > & # 160; < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > December & # 160; 31, < br / > 2024 < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td > Beginning balance as of February 6, 2024 < / td > < td > & # 160; < / td > < td style =" text- align: left" > $ < / td > < td style =" text- align: right" > < div style ="- sec- ix- hidden: hidden- fact- 236" > & # 8212; < / div > < / td > < td style =" text- align: left" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" width: 88 %; text- align: left; padding- bottom: 1. 5pt" > Change in valuation allowance < / td > < td style =" width: 1 %; padding- bottom: 1. 5pt" > & # 160; < / td > < td style =" width: 1 %; border- bottom: Black 1. 5pt solid; text- align: left" > & # 160; < / td > < td style =" width: 9 %; border- bottom: Black 1. 5pt solid; text- align: right" > 21, 317 < / td > < td style =" width: 1 %; padding- bottom: 1. 5pt; text- align: left" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- bottom: 4pt; padding- left: 9pt" > Ending balance as of December 31, 2024 < / td > < td style =" padding- bottom: 4pt" > & # 160; < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > $ < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > 21, 317 < / td > < td style =" padding- bottom: 4pt; text- align: left" > & # 160; < / td > < / tr > < / table > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > As of December & # 160; 31, 2024, the Company had U. S. net operating loss carryforwards (& # 8220; NOL & # 8221;) of $ 10. 8 & # 160; million. The federal NOL carryforwards do not expire and can be utilized to offset up to 80 % of the taxable income in any tax year. For the period from February 6, 2024 (inception) to December & # 160; 31, 2024 the Company had federal tax credit carryforwards and state tax credit carryforwards of $ 3. 8 & # 160; million and $ 0. 4 & # 160; million, respectively. The federal credits will expire starting in 2044 if not utilized, and the state research credit can be carried forward indefinitely. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" > The Tax Reform Act of 1986 limits the use of net operating loss carryforwards in certain situations where changes occur in the stock ownership of a company. The annual limitation may result in the expiration of net operating losses and credits before utilization. The Company has not performed a Section 382 analysis through December 31, 2024. To the extent that an assessment is completed in the future, the Company & # 8217; s ability to utilize tax attributes could be restricted on a year- by- year basis and certain attributes could expire before they are utilized. The Company will examine the impact of any potential ownership changes in the future. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands): < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Period from < br / > February 6, < br / > 2024 < br / > (Inception) to < br / > December 31, < br / > 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td > < span style =" font- family: Times New Roman, Times, Serif" > Beginning balance as of February 6, 2024 < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 237; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" width: 88 %; text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Changes related to tax positions taken in the current year < / span > < / td > < td style =" width: 1 %; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 1, 047 < / span > < / td > < td style =" width: 1 %; padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- bottom: 2. 5pt; padding- left: 0. 125in" > < span style =" font- family: Times New Roman, Times, Serif" > Ending balance as of December 31, 2024 < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 1, 047 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < p style =" text- align: justify; text- indent: 0. 25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > The Company includes penalties and interest expense related to income taxes as a component of income tax expense, as necessary. As of December 31, 2024, the Company had & # 160; no & # 160; accrued interest or penalties related to uncertain tax positions. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company will be filing initial year income tax returns in the United States federal jurisdiction and state jurisdictions. Due to net operating loss carryforwards, the statute of limitations will remain open for income tax examination. < / span > < / p > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_IncomeTaxDisclosureAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_IncomeTaxDisclosureAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_IncomeTaxDisclosureTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The entire disclosure for

income tax. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 12 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 12 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 231 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482663 / 740- 10- 55- 231 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 12C < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 12C < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 12B < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 12B < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 270 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147477891 / 740- 270- 50- 1 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SAB Topic 6. I. 5. Q1) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479360 / 740- 10- S99- 1 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 13 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480990 / 946- 20- 50- 13 < br > < br > Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 235 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 4- 08 (h) (2)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1 < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- Name Accounting Standards Codification < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 740 / tableOfContent < br > < br > Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 14 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 14 < br > < br > Reference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 21 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 21 < br > < br > Reference 12: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 17 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 17 < br > < br > Reference 13: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SAB Topic 11. C) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479360 / 740- 10- S99- 2 < br > < br > Reference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 30 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482603 / 740- 30- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_IncomeTaxDisclosureTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 57 < FILENAME > R21. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208263342080" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Option Agreements and License Agreements < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_OptionAgreementsAndLicenseAgreementsAbstract', window);" > < strong > Option Agreements and License Agreements [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_OptionAgreementsAndLicenseAgreementsTextBlock', window);" > Option Agreements and License Agreements < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > < b > 12. Option Agreements and License Agreements < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > In March & # 160; 2024, the Company entered into two antibody discovery and option agreements (& # 8220; Option Agreements & # 8221;) with Paragon and Paruka. Under the terms of each agreement, Paragon identifies, evaluates, and develops antibodies directed against certain mutually agreed therapeutic targets of interest to the Company. From time to time, the Company can choose to add additional targets to the collaboration upon agreement with Paragon and Paruka. Under the Option Agreements, the Company has the exclusive option to, on a research program- by- research program basis, be granted an exclusive, worldwide license to all of Paragon & # 8217; s right, title, and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture, and commercialize the antibodies and products directed to the selected target (s) & # 160; (each, an & # 8220; Option & # 8221;). The Company has initiated certain research programs with Paragon that generally focus on discovering, generating, identifying and / or characterizing antibodies directed to a particular target (each, a & # 8220; Research Program & # 8221;), including for IL- 23 and IL- 17A / F for ORKA- 001 and ORKA- 002, respectively. The exclusive option with respect to each Research Program is exercisable at the Company & # 8217; s sole discretion at such time as specified in the Option Agreements (the & # 8220; Option Period & # 8221;). There is no payment due upon exercise of an Option pursuant to the Option Agreements. For each of these agreements, once the Company enters into the corresponding license agreements, it will be required to make non- refundable milestone payments to Paragon of up to $ 12. 0 million under each respective agreement upon the achievement of certain clinical development milestones, up to $ 10. 0 million under each respective agreement upon the achievement of certain regulatory milestones, as well as a low single- digit percentage royalty for antibody products beginning on the first commercial sale in each program. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company may terminate any Option Agreement or any Research Program at any time for any or no reason upon 30 & # 160; days & # 8217; prior written notice to Paragon, provided that it must pay certain unpaid fees due to Paragon upon such termination, as well as any non- cancellable obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate any Option Agreement or a Research Program immediately upon written notice to the Company if, as a result of any action or failure to act by the Company or its affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed for a certain consecutive number of & # 160; months. Each party has the right to terminate the Option Agreements or any Research Program upon material breach that remains uncured or the other party & # 8217; s bankruptcy. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > < i > Paragon Therapeutics & # 8211; License Agreements < / i > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > < i > & # 160; < / i > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > In September 2024, the Company exercised the Option to acquire certain rights to ORKA- 001, and in December 2024, it entered into the corresponding license agreement with Paragon (the & # 8220; ORKA- 001 License Agreement & # 8221;), pursuant to which Paragon granted the Company a royalty- bearing, world- wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting IL- 23 in all fields other than the field of inflammatory bowel disease (& # 8220; ORKA- 001 Field & # 8221;). In December 2024, the Company exercised the Option with respect to ORKA- 002 for the IL- 17A / F program, and in February 2025, it entered into the corresponding license agreement with Paragon (the & # 8220; ORKA- 002 License Agreement & # 8221; and together with the ORKA- 001 License Agreement, the & # 8220; License Agreements & # 8221;), pursuant to which Paragon granted the Company a royalty- bearing, world- wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting IL- 17A / F in all fields (& # 8220; ORKA- 002 Field & # 8221; and together with the ORKA- 001 Field, the & # 8220; Fields & # 8221;). < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The License Agreements provide the Company with exclusive licenses in the Fields to Paragon & # 8217; s patent applications covering the related antibodies, their method of use and their method of manufacture and Paragon has agreed not to conduct any new campaigns that generate anti- IL- 23 monospecific antibodies or anti- IL- 17A / F monospecific antibodies for the ORKA- 001 Field or the ORKA- 002 Field, respectively, for at least five years. Each of the ORKA- 001 and ORKA- 002 License Agreements may be terminated on 60 days & # 8217; notice to Paragon, on material breach without cure, and on a party & # 8217; s insolvency or bankruptcy to the extent permitted by law. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Pursuant to the terms of each of the ORKA- 001 and ORKA- 002 License Agreements, the Company is obligated to pay Paragon non- refundable milestone payments of up to $ 12. 0 million under each respective agreement upon the achievement of certain clinical development milestones and up to $ 10. 0 million under each respective agreement upon the achievement of certain regulatory milestones, including a $ 1. 5 million fee for nomination of a development candidate (or initiation of an IND- enabling toxicology study) and a further milestone payment of $ 2. 5 million upon the first dosing of a human patient in a Phase 1 trial for each of ORKA- 001 and ORKA- 002. In addition, the Company is obligated to pay Paragon a low single- digit percentage royalty for antibody products for each of ORKA- 001 and ORKA- 002. For each of the License Agreements, the royalty term ends on the later of (i) the last- to- expire licensed patent or our patent directed to the manufacture, use or sale of a licensed antibody in the country at issue or (ii) 12 years from the date of first sale of a Company product. There is also a royalty step- down if there is no Paragon patent in effect during the royalty term for each program. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Additionally, as part of the Option Agreements, on December & # 160; 31, 2024 the Company granted and on December & # 160; 31, 2025, will grant Paruka a warrant to purchase a number of shares equal to 1. 00 % of outstanding shares as of the date of the grant on a fully- diluted basis, with an exercise price equal to the fair market value of the underlying shares on the grant date. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Pursuant to the Option Agreements, on a research program- by- research program basis following the finalization of the research plan for each respective research program, the Company was required to pay Paragon a one- time, nonrefundable research initiation fee of $ 0. 8 & # 160; million related to the ORKA- 001 program. This amount was recognized as a research and development expense during the period from February & # 160; 6, 2024 (inception) to December 31, 2024. In June 2024, pursuant to the Option Agreements with Paragon, the Company completed the selection process of its development candidate for IL- 23 antibody for ORKA- 001 program. The Company was responsible for 50 % of the development costs incurred through the completion of the IL- 23 selection process. The Company received the rights to at least one selected IL- 23 antibody in June 2024. During the period from February 6, 2024 (inception) to December 31, 2024, the Company exercised its option for ORKA- 001 and recorded a $ 1. 5 million milestone payment related to the achievement of development candidate as research and development expense in the Company & # 8217; s consolidated statement of operations and comprehensive loss. In addition, during the period from February 6, 2024 (inception) to December 31, 2024, the Company recorded a $ 2. 5 million milestone payment related to the first dosing of a human subject in a Phase 1 trial of ORKA- 001 in December 2024 as research and development expense in its consolidated statement of operations and comprehensive loss. The Company & # 8217; s share of development costs incurred for the period from February 6, 2024 (inception) to December 31, 2024 was $ 13. 5 million (excluding research initiation fee and milestones), which were recorded as research and development expenses. An amount of $ 2. 8 million related to ORKA- 001 is included in related party accounts payable and other current liabilities as of December 31, 2024. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text-

indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company was also required to reimburse Paragon $ 3. 3 & # 160; million for development costs related to ORKA- 002 incurred by Paragon through December & # 160; 31, 2023 and certain other development costs incurred by Paragon between January & # 160; 1, 2024 and March & # 160; 6, 2024 as stipulated by the Option Agreements. This amount was recognized as a research and development expense during the period from February & # 160; 6, 2024 (inception) to December 31, 2024. The Company is also responsible for the development costs incurred by Paragon from January & # 160; 1, 2024 through the completion of the IL- 17 selection process. The Company recognized an amount of $ 0. 8 & # 160; million payable to Paragon for the research initiation fee related to ORKA- 002 following the finalization of the ORKA- 002 research plan. This was recognized as research and development expenses in the period from February 6, 2024 (inception) to December 31, 2024. During the period from February 6, 2024 (inception) to December 31, 2024, the Company exercised its option for ORKA- 002 and recorded a $ 1. 5 million milestone payment related to the achievement of development candidate as research and development expense in its consolidated statement of operations and comprehensive loss. The Company accounted for development costs of $ 7. 8 million (excluding research initiation fee, milestone, and reimbursements of development costs through December 31, 2023) for the period from February 6, 2024 (inception) to December 31, 2024 as research and development expenses. An amount of $ 2. 7 million related to ORKA- 002 is included in related party accounts payable and other current liabilities as of December 31, 2024. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company expenses the service fees as the associated costs are incurred when the underlying services are rendered. Such amounts are classified within research and development expenses in the accompanying consolidated statement of operations and comprehensive loss. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company concluded that the rights obtained under the Option Agreements represent an asset acquisition whereby the underlying assets comprise in- process research and development assets with no alternative future use. The Option Agreements did not qualify as a business combination because substantially all of the fair value of the assets acquired was concentrated in the exclusive license options, which represent a group of similar identifiable assets. The research initiation fee represents a one- time cost on a research program- by- research program basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of ongoing development cost, monthly development cost fee and additional development expenses incurred by Paragon due to work completed for selected targets prior to the effective date of the Option Agreements that is associated with services being rendered under the related Research Programs are recognized as research and development expense when incurred. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 18pt" > < span style =" font- family: Times New Roman, Times, Serif" > For the period from February & # 160; 6, 2024 (inception) to December 31, 2024, the Company recognized $ 42. 0 < / span > & # 160; < span style =" font- family: Times New Roman, Times, Serif" > million of expenses in connection with services provided by Paragon and Paruka under the Option Agreements. & # 160; < / span > < / p > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_OptionAgreementsAndLicenseAgreementsAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_OptionAgreementsAndLicenseAgreementsAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_OptionAgreementsAndLicenseAgreementsTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The entire disclosure of option agreements and license agreements. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_OptionAgreementsAndLicenseAgreementsTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 58 < FILENAME > R22. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208263329552" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Commitment and Contingencies < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CommitmentsAndContingenciesDisclosureAbstract', window);" > < strong > Commitment and Contingencies [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CommitmentsAndContingenciesDisclosureTextBlock', window);" > Commitment and Contingencies < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > < b > 13. Commitment and Contingencies < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > < b > & # 160; < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > < b > Leases < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > < b > & # 160; < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > In April 2024, the Company entered into an operating lease agreement for the Company & # 8217; s headquarters in Menlo Park, California, which commenced on June 15, 2024 with an initial term of 39. 5 months. The Company leases office space under this noncancelable operating lease agreement. Lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate when measuring operating lease liabilities as discount rates were not implicit or readily determinable. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > As of December 31, 2024, the Company had $ 0. 9 million of operating lease right- of- use assets, operating lease liability, current of $ 0. 2 million, and operating lease liability, noncurrent of $ 0. 8 million on its consolidated balance sheet. As of December 31, 2024, the operating lease arrangement had a remaining lease term of 33 months and a discount rate of 17. 95 %. For the period from February 6, 2024 (inception) to December 31, 2024, the Company recorded operating and variable lease expense of $ 0. 3 million in general and administrative expenses in its consolidated statement of operations and comprehensive loss. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The following table presents the Company & # 8217; s supplemental cash flow information related to leases (in thousands): < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Period from < br / > February 6, < br / > 2024 < br / > (Inception) to < br / > December 31, < br / > 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Cash paid for amounts included in the measurement of lease liabilities < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 116 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The following table summarizes a maturity analysis of the Company & # 8217; s operating lease liabilities showing the aggregate lease payments as of December 31, 2024 (in thousands): & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" font- weight: bold; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > < b > Year ending December 31, < / b > < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Amount < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > 2025 < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 369 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > 2026 < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 494 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > 2027 < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 380 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 125in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Total undiscounted lease payments < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 1, 243 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align:

bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Less: imputed interest < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (275 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 125in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Total discounted lease payments < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 968 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Less: current portion of lease liability < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (213 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 375in; text- align: left; padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > Non- current portion of lease liability < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 755 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > < b > & # 160; < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > < b > Cell Line License Agreement < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > < b > & # 160; < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > In March 2024, the Company entered into the Cell Line License Agreement (the & # 8220; Cell Line License Agreement & # 8221;) with WuXi Biologics Ireland Limited (& # 8220; WuXi Biologics & # 8221;). Under the Cell Line License Agreement, the Company received a non- exclusive, worldwide, sublicensable license to certain of WuXi Biologics & # 8217; know- how, cell line, biological materials (the & # 8220; WuXi Biologics Licensed Technology & # 8221;) and media and feeds to make, have made, use, sell and import certain therapeutic products produced through the use of the cell line licensed by WuXi Biologics under the Cell Line License Agreement (the & # 8220; WuXi Biologics Licensed Products & # 8221;). Specifically, the WuXi Biologics Licensed Technology is used in certain manufacturing activities in support of the ORKA- 001 and ORKA- 002 programs. < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > In consideration for the license, the Company agreed to pay WuXi Biologics a non- refundable license fee of $ 150, 000, which was recognized as a research and development expense during the period from February & # 160; 6, 2024 (inception) to December 31, 2024. Additionally, to the extent that the Company manufactures its commercial supplies of bulk drug product with a manufacturer other than WuXi Biologics or its affiliates, the Company is required to make royalty payments to WuXi Biologics at a rate of less than one percent of net sales of WuXi Biologics Licensed Products manufactured by the third- party manufacturer. Pursuant to an amendment to the Cell Line License Agreement effective in November 2024, a provision was added that permits the royalties owed under the agreement to be bought out on a & # 160; product- by- product & # 160; basis for a & # 160; lump- sum & # 160; payment. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Cell Line License Agreement will continue indefinitely unless terminated (i) by the Company upon six months & # 8217; prior written notice and its payment of all undisputed amounts due to WuXi Biologics through the effective date of termination, (ii) by WuXi Biologics for a material breach by the Company that remains uncured for 60 days after written notice, (iii) by WuXi Biologics if the Company fails to make a payment and such failure continues for 30 days after receiving notice of such failure, or (iv) by either party upon the other party & # 8217; s bankruptcy. < / span > < / p > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_CommitmentsAndContingenciesDisclosureAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_CommitmentsAndContingenciesDisclosureAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_CommitmentsAndContingenciesDisclosureTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The entire disclosure for commitments and contingencies. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 405 < br >- SubTopic 30 < br >- Name Accounting Standards Codification < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 405- 30 / tableOfContent < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 440 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 4 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482648 / 440- 10- 50- 4 < br > < br > Reference 3: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 450 < br >- Name Accounting Standards Codification < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 450 / tableOfContent < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 954 < br >- SubTopic 440 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478522 / 954- 440- 50- 1 < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 440 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 4 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482648 / 440- 10- 50- 4 < br > < br > Reference 6: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 440 < br >- Name Accounting Standards Codification < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 440 / tableOfContent < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_CommitmentsAndContingenciesDisclosureTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 59 < FILENAME > R23. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208160410768" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Net Loss Per Share < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EarningsPerUnitAbstract', window);" > < strong > Net Loss per Share [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EarningsPerShareTextBlock', window);" > Net Loss Per Share < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > < b > 14. Net Loss per Share < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Basic and diluted net loss per share attributable to stockholders were calculated as follows (in thousands, except share and per share data): < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 10" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Period from February 6, 2024 < br / > (Inception) to < br / > December 31, 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom" > < td style =" font- weight: bold; text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Loss < br / > Allocation < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Weighted < br / > Average < br / > Shares < br / > Outstanding < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Loss Per < br / > Share, < br / > Basic and < br / > Diluted < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 64 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Common Stock < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (65, 037 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 16, 789, 362 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (3. 87 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Company Series A Preferred Stock < sup > (1) < / sup > < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (1, 918 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 495 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (3, 873. 25 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Company Series B Preferred Stock < sup > (2) < / sup > < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (16, 769 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 51, 946 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (322. 81 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- bottom: 2. 5pt; padding- left: 0. 125in" > < span style =" font- family: Times New Roman, Times, Serif" > Net loss < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (83, 724 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < table cellpadding =" 0" style =" width: 100 %; font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; border- spacing: 0px;" > < tr style =" font- family: Times New Roman, Times, Serif; vertical- align: top" > < td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > (1) < / span > < / td > < td style =" font- family: Times New Roman, Times, Serif; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > The weighted- average number of shares of as- converted Company Series A Preferred Stock used in the loss allocation was 495, 191 for the period from February 6, 2024 (inception) to December 31, 2024. < / span > < / td > < / tr > < / table > < table cellpadding =" 0" style =" width: 100 %; font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; border- spacing: 0px;" > < tr style =" font- family: Times New Roman, Times, Serif; vertical- align: top" > < td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > (2) < / span > < / td > < td style =" font- family: Times New Roman, Times, Serif; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > The weighted- average number of shares of as- converted Company Series B Preferred Stock used in the loss allocation was 4, 328, 844 for the period from February 6, 2024 (inception) to December 31, 2024. < / span > < / td > < / tr > < / table > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > For the computation of basic net loss per share attributable to stockholders, the amount of weighted- average shares outstanding excludes all shares of unvested restricted common stock as such shares are not considered outstanding for accounting purposes until vested. The amount of weighted- average shares outstanding includes the pre- funded warrants as the exercise price is negligible and these warrants are fully vested and exercisable. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to stockholders for the periods presented because including them would have had an anti- dilutive effect were as follows: & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > December 31, < br / > 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Outstanding employee warrants to purchase common stock < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 3, 054, 358 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Outstanding unvested restricted stock awards < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 2, 207, 553 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Outstanding and issued common stock options < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 1, 567, 760 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Outstanding and issued warrant to Paruka < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 596, 930 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- bottom: 2. 5pt; padding- left: 13. 7pt" > < span style =" font- family: Times New Roman, Times, Serif" > Total < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 7, 426, 601 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_EarningsPerShareTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The entire disclosure for earnings per share. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482662 / 260- 10- 50- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- Name Accounting Standards Codification < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 260 / tableOfContent < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482662 / 260- 10- 50- 2 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482662 / 260- 10- 50- 3 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_EarningsPerShareTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_EarningsPerUnitAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_EarningsPerUnitAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 60 < FILENAME > R24. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208268813712" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Related Party Transactions < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_RelatedPartyTransactionsAbstract', window);" > < strong > Related Party Transactions [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_RelatedPartyTransactionsDisclosureTextBlock', window);" > Related Party Transactions < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > < b > 15. Related Party Transactions < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent:

0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Paragon and Paruka each beneficially own less than 5 % of the Company & # 8217; s capital stock through their respective holdings of Company Common Stock. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Fairmount beneficially owns more than 5 % of the Company & # 8217; s capital, currently has one representative appointed to the Board, and beneficially owns more than 5 % of Paragon. Fairmount appointed Paragon & # 8217; s board of directors and has the contractual right to approve the appointment of any executive officers of Paragon. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The following is a summary of related party accounts payable and other current liabilities (in thousands): & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > December 31, < br / > 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Paragon reimbursable Option Agreements & # 8217; fees < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 1, 482 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Paragon milestone payments for Option Agreement < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 4, 000 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Paragon reimbursable other research expenses < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 515 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Paragon reimbursable patent expenses < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 25 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- bottom: 4pt; padding- left: 0. 125in" > < span style =" font- family: Times New Roman, Times, Serif" > Total < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 6, 022 < / span > < / td > < td style =" padding- bottom: 4pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_RelatedPartyTransactionsAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_RelatedPartyTransactionsAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_RelatedPartyTransactionsDisclosureTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480990 / 946- 20- 50- 2 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 5 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480990 / 946- 20- 50- 5 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480990 / 946- 20- 50- 6 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 235 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147477968 / 946- 235- 50- 2 < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 235 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (e) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147477968 / 946- 235- 50- 2 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 850 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (d) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483326 / 850- 10- 50- 1 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 07 (2) (g) (3)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1 < br > < br > Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 07 (2) (c)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1 < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 07 (2) (e)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1 < br > < br > Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 850 < br >- Name Accounting Standards Codification < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 850 / tableOfContent < br > < br > Reference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 850 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483326 / 850- 10- 50- 6 < br > < br > Reference 12: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 850 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483326 / 850- 10- 50- 1 < br > < br > Reference 13: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 850 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483326 / 850- 10- 50- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_RelatedPartyTransactionsDisclosureTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 61 < FILENAME > R25. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208267430048" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Subsequent Events < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SubsequentEventsAbstract', window);" > < strong > Subsequent Events [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SubsequentEventsTextBlock', window);" > Subsequent Events < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > < b > 16. Subsequent Events < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > In February 2025, the Company entered into a lease agreement for an office space located in Waltham, Massachusetts. The lease is for an initial period of 54 months. The Company expects to pay approximately $ 1. 6 million over the lease term. < / span > < / p > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_SubsequentEventsAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_SubsequentEventsAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_SubsequentEventsTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 855 < br >- Name Accounting Standards Codification < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 855 / tableOfContent < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 855 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483399 / 855- 10-

```
50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0"
cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_SubsequentEventsTextBlock < / td > < / tr > < tr > < td style =" padding-
right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types:
textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < /
td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 62 <
FILENAME > R26. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css"
> < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style.
display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > <
table class =" report" border =" 0" cellspacing =" 2" id =" idm46208263417312" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Pay vs
Performance Disclosure < br > $ in Thousands < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div
> < div > USD ($) < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show.
showAR (this,' defref_ecd_PvpTable', window);" > < strong > Pay vs Performance Disclosure < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class
=" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_NetIncomeLoss',
window);" > Net Income (Loss) < / a > < / td > < td class =" num" > $ (83, 724) < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0"
cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_ecd_PvpTable" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick ="
Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a
> < div > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Regulation S- K < br >- Number 229 < br >- Section 402 < br >- Subsection
v < br >- Paragraph 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0"
cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > ecd_PvpTable < / td > < / tr > < tr > < td style =" padding- right:
4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > ecd_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < /
td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > <
/ div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_NetIncomeLoss" > < tr >
< td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > <
a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The portion of profit or loss for the period, net of income taxes, which is attributable to the
parent. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 /
role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / /
asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 6 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting
Standards Codification < br >- Section 50 < br >- Paragraph 9 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 9 < br > < br > Reference 3: http: / /
www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 805 < br >- SubTopic 60 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 1 < br >- Subparagraph
(g) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147476176 / 805- 60- 65- 1 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic
740 < br >- SubTopic 323 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 2 < br >- Subparagraph (g) (3) < br >- Publisher FASB < br >- URI https: / / asc.
fasb. org / 1943274 / 2147478666 / 740- 323- 65- 2 < br > < br > Reference 5: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting
Standards Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SX 210. 5- 03 (20)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483621 / 220-
10- S99- 2 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 235 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section
S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 4- 08 (g) (1) (ii)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1 < br > < br >
Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 323 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 <
br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481687 / 323- 10- 50- 3 < br > < br > Reference 8: http: / / www. xbrl. org / 2003 / role /
disclosureRef < br >- Topic 825 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 28 < br >- Subparagraph (f) < br >- Publisher FASB <
br >- URI https: / / asc. fasb. org / 1943274 / 2147482907 / 825- 10- 50- 28 < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br
>- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482765 / 220- 10- 50- 6 < br > < br >
Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 <
br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 3 < br > < br > Reference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 <
br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (b) (2) < br >- Publisher FASB < br >- URI https: / / asc. fasb.
org / 1943274 / 2147483443 / 250- 10- 50- 1 < br > < br > Reference 12: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 815 < br >- SubTopic 40 < br >- Name Accounting
Standards Codification < br >- Section 65 < br >- Paragraph 1 < br >- Subparagraph (f) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480175 / 815- 40- 65- 1 < br > <
br > Reference 13: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >-
Paragraph 8 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 8 < br > < br > Reference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef < br
>- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 11 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / /
asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 11 < br > < br > Reference 15: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name
Accounting Standards Codification < br >- Section 50 < br >- Paragraph 11 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10-
50- 11 < br > < br > Reference 16: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 <
br >- Paragraph 4 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 4 < br > < br > Reference 17: http: / / www. xbrl. org / 2003 / role / exampleRef <
br >- Topic 946 < br >- SubTopic 830 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 10 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org /
1943274 / 2147479168 / 946- 830- 55- 10 < br > < br > Reference 18: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards
Codification < br >- Section 45 < br >- Paragraph 7 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479105 / 946- 220- 45- 7 < br > < br > Reference 19: http: / / www.
xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX
210. 7- 04 (18)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147477250 / 944- 220- S99- 1 < br > < br > Reference 20: http: / / www. xbrl. org / 2003 / role / disclosureRef
< br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 07 (9)) < br >- Publisher
FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1 < br > < br > Reference 21: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >-
SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 09 (1) (d)) < br >- Publisher FASB < br >- URI https: / /
asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3 < br > < br > Reference 22: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name
Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (i)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org /
1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 23: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting
Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (ii)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 /
2147480097 / 470- 10- S99- 1A < br > < br > Reference 24: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards
Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (iii) (A)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 /
470- 10- S99- 1A < br > < br > Reference 25: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >-
Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (iv)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > <
br > Reference 26: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >-
Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (5)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 27: http:
/ / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >-
Subparagraph (SX 210. 13- 02 (a) (4) (i)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 28: http: / / www. xbrl. org /
2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02
(a) (4) (iii) (A)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 29: http: / / www. xbrl. org / 2003 / role / disclosureRef
< br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iii) (B)) < br >-
Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 30: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br
>- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iv)) < br >- Publisher FASB < br >- URI
https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 31: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name
Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (5)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 /
2147480097 / 470- 10- S99- 1B < br > < br > Reference 32: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards
Codification < br >- Section 45 < br >- Paragraph 60B < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 60B < br > < br >
Reference 33: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 205 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 7 <
br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483499 / 205- 20- 50- 7 < br > < br > Reference 34: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 230 < br
>- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 28 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230-
10- 45- 28 < br > < br > Reference 35: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section
45 < br >- Paragraph 1A < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 1A < br > < br > Reference 36: http: / / www.
xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 1B < br >- Subparagraph (a) <
br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 1B < br > < br > Reference 37: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 942 <
br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 9- 04 (22)) < br >- Publisher FASB < br >- URI
https: / / asc. fasb. org / 1943274 / 2147478524 / 942- 220- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display:
none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_NetIncomeLoss < / td > < /
tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < /
strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < /
strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE >
XML < SEQUENCE > 63 < FILENAME > R27. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css"
href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function
toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span
style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208165582016" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div
style =" width: 200px;" > < strong > Insider Trading Arrangements < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 3 Months Ended < / th > < / tr > < tr > < th class =" th" >
< div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show.
showAR (this,' defref_ecd_TradingArrByIndTable', window);" > < strong > Trading Arrangements, by Individual < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < /
```

td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_ecd_Rule10b51ArrAdoptedFlag', window);" > Rule 10b5- 1 Arrangement Adopted < / a > < / td > < td class =" text" > false < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_ecd_NonRule10b51ArrAdoptedFlag', window);" > Non- Rule 10b5- 1 Arrangement Adopted < / a > < / td > < td class =" text" > false < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_ecd_Rule10b51ArrTrmntdFlag', window);" > Rule 10b5- 1 Arrangement Terminated < / a > < / td > < td class =" text" > false < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_ecd_NonRule10b51ArrTrmntdFlag', window);" > Non- Rule 10b5- 1 Arrangement Terminated < / a > < / td > < td class =" text" > false < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_ecd_NonRule10b51ArrAdoptedFlag" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Regulation S- K < br >- Number 229 < br >- Section 408 < br >- Subsection a < br >- Paragraph 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > ecd_NonRule10b51ArrAdoptedFlag < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > ecd_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: booleanItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_ecd_NonRule10b51ArrTrmntdFlag" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Regulation S- K < br >- Number 229 < br >- Section 408 < br >- Subsection a < br >- Paragraph 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > ecd_NonRule10b51ArrTrmntdFlag < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > ecd_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: booleanItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_ecd_Rule10b51ArrAdoptedFlag" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Regulation S- K < br >- Number 229 < br >- Section 408 < br >- Subsection a < br >- Paragraph 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > ecd_Rule10b51ArrAdoptedFlag < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > ecd_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: booleanItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_ecd_Rule10b51ArrTrmntdFlag" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Regulation S- K < br >- Number 229 < br >- Section 408 < br >- Subsection a < br >- Paragraph 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > ecd_Rule10b51ArrTrmntdFlag < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > ecd_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: booleanItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_ecd_TradingArrByIndTable" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Regulation S- K < br >- Number 229 < br >- Section 408 < br >- Subsection a < br >- Paragraph 2 < br >- Subparagraph A < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > ecd_TradingArrByIndTable < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > ecd_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 64 < FILENAME > R28. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208266217280" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Cybersecurity Risk Management and Strategy Disclosure < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window);" > < strong > Cybersecurity Risk Management, Strategy, and Governance [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window);" > Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block] < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > We collect, use, store, and transmit confidential, sensitive, proprietary, personal, and health- related information in the ordinary course of our business. As such, we leverage third- party information technology service providers who have implemented and maintain various information security processes designed to identify, assess, and manage material risks from cybersecurity threats to our information technology systems, including critical computer networks, third party hosted services, communications systems, hardware and software, and our data residing on these systems. Our Senior Vice President, Finance is responsible for overseeing these third- party service providers and processes. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Cybersecurity risks are identified by monitoring and evaluating our threat environment, and then assessed by various methods, for example, by manual and automated tools designed to identify and combat cybersecurity threats, analyzing reports of threats, conducting scans and assessments of the threat environment and to identify vulnerabilities, the use of detection and response services and conducting reviews of third- party service providers, among other things. Depending on the threat environment, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our information systems and data, including, for example, physical security and access controls, asset management, systems monitoring, incident detection and response, risk assessment, the implementation of security standards and certifications, encryption of data, network security controls, and a recovery / business continuity plan, among other mitigation tactics. Our recovery / business continuity plan is designed to mitigate and remediate identified cybersecurity incidents and escalate certain incidents as appropriate to management and the Audit Committee. We plan to conduct due diligence on and audits of key technology vendors, contract research organizations, and other third- party contractors and suppliers. Additionally, we conduct periodic employee training that covers cyber and information security, among other topics. < / span > < / p > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window);" > Cybersecurity Risk Management Processes Integrated [Flag] < / a > < / td > < td class =" text" > true < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window);" > Cybersecurity Risk Management Processes Integrated [Text Block] < / a > < / td > < td class =" text" > Our assessment and management of material risks from cybersecurity threats are integrated into the Company & # 8217; s overall risk management process. Our Senior Vice President, Finance, who reports directly to the Chief Executive Officer, together with our senior management, is responsible for assessing and managing cybersecurity risks with support from our third- party information technology service providers that employ information technology consultants with over 20 years of experience managing cybersecurity programs. Our cybersecurity program aligns to the National Institute of Standards and Technology (NIST) Cybersecurity Framework (CSF) and is consistently updated as NIST recommendations change year over year. Our Senior Vice President, Finance, together with our senior management and other employees works closely with our information technology service providers to evaluate material cybersecurity threats against our overall business objectives as part of our cybersecurity incident response. < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window);" > Cybersecurity Risk Board of Directors Oversight [Text Block] < / a > < / td > < td class =" text" > The Board of Directors, as a whole and at the committee level, has oversight for the most significant risks facing us and for our processes to identify, prioritize, assess, manage and mitigate those risks. The Audit Committee has been designated by our Board to oversee cybersecurity risks. The Audit Committee receives regular updates on cybersecurity and information technology matters and related risk exposures from our Senior Vice President, Finance. The Board also receives updates from management and the Audit Committee on cybersecurity risks on a regular basis. < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window);" > Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] < / a > < / td > < td class =" text" > The Audit Committee has been designated by our Board to oversee cybersecurity risks. < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window);" > Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] < / a > < / td > < td class =" text" > The Board also receives updates from management and the Audit Committee on cybersecurity risks on a regular basis. < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock', window);" > Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block] < / a > < / td > < td class =" text" > we have not identified any risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us, but we face certain ongoing cybersecurity risks or threats that, if realized, are reasonably likely to materially affect us. < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window);" > Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] < / a > < / td > < td class =" text" > false < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >-

References < / a > < div > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Regulation S- K < br >- Section 106 < br >- Subsection c < br >- Paragraph 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Form 20- F < br >- Section 16K < br >- Subsection c < br >- Paragraph 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > cyd_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Regulation S- K < br >- Section 106 < br >- Subsection c < br >- Paragraph 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Form 20- F < br >- Section 16K < br >- Subsection c < br >- Paragraph 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > cyd_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Regulation S- K < br >- Section 106 < br >- Subsection b < br >- Paragraph 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Form 20- F < br >- Section 16K < br >- Subsection b < br >- Paragraph 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > cyd_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Regulation S- K < br >- Section 106 < br >- Subsection b < br >- Paragraph 1 < br >- Subparagraph i < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Form 20- F < br >- Section 16K < br >- Subsection b < br >- Paragraph 1 < br >- Subparagraph i < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > cyd_CybersecurityRiskManagementProcessesIntegratedFlag < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > cyd_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > i: booleanItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Regulation S- K < br >- Section 106 < br >- Subsection b < br >- Paragraph 1 < br >- Subparagraph i < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Form 20- F < br >- Section 16K < br >- Subsection b < br >- Paragraph 1 < br >- Subparagraph i < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > cyd_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Regulation S- K < br >- Section 106 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Form 20- F < br >- Section 16K < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > cyd_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > i: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Regulation S- K < br >- Section 106 < br >- Subsection b < br >- Paragraph 2 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Form 20- F < br >- Section 16K < br >- Subsection b < br >- Paragraph 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > cyd_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > i: booleanItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Regulation S- K < br >- Section 106 < br >- Subsection c < br >- Paragraph 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Form 20- F < br >- Section 16K < br >- Subsection c < br >- Paragraph 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > cyd_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Form 8- K < br >- Section 1. 05 < br >- Subsection a < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / presentationRef < br >- Publisher SEC < br >- Name Form 6- K < br >- Section General Instruction < br >- Subsection B < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > cyd_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 65 < FILENAME > R29. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display ==' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208163433936" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Accounting Policies, by Policy (Policies) < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AccountingPoliciesAbstract', window);" > < strong > Summary of Significant Accounting Policies [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_UseOfEstimates', window);" > Use of Estimates < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Use of Estimates < / i > < / b > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The preparation of the Company & # 8217; s consolidated financial statements in conformity with U. S. & # 160; GAAP requires management to make estimates, assumptions, and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected within these consolidated financial statements include but are not limited to research and development expenses and related prepaid or accrued costs and the valuation of stock- based compensation awards and related expenses. The Company bases its estimates on known trends and other market- specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Actual results could differ materially from those estimates or assumptions. < / span > < / p > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ConcentrationRiskCreditRisk', window);" > Concentrations of Credit Risk and Other Risks and Uncertainties < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Concentrations of Credit Risk and Other Risks and Uncertainties < / i > < /

b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities. The Company & # 8217; s investment policy limits investments to high credit quality securities issued by the U. S. government, U. S. government- sponsored agencies, highly rated banks, and corporate issuers, subject to certain concentration limits and restrictions on maturities. The Company & # 8217; s cash, cash equivalents and marketable securities are held by financial institutions that management believes are of high credit quality. The financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash deposits. Accounts at the Company & # 8217; s U. S. banking institution are insured by the Federal Deposit Insurance Corporation (& # 8220; FDIC & # 8221;) up to $ 250, 000 per depositor. As of December 31, 2024, the balance at the Company & # 8217; s U. S. banking institution exceeded the FDIC limits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its accounts are monitored by management to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents, and bond issuers. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company is dependent on third- party organizations to research, develop, manufacture, and process its product candidates for its development programs, including its two most advanced programs, ORKA- 001 and ORKA- 002. The Company expects to continue to be dependent on a small number of manufacturers to supply it with its requirements for all products. The Company & # 8217; s research and development programs could be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Company & # 8217; s research and development activities are performed under its agreements with Paragon Therapeutics, Inc. (& # 8220; Paragon & # 8221;) (see Note & # 160; 12). < / span > < / p > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window);" > Cash and Cash Equivalents < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Cash and Cash Equivalents < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to be cash equivalents. The cash equivalents were comprised of investments in money market funds, U. S. treasury securities, U. S. government agency securities, and debt securities and are stated at fair value. < / span > < / p > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_MarketableSecuritiesPolicy', window);" > Marketable Securities < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Marketable Securities < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company invests in marketable securities, primarily securities issued by the U. S. government and its agencies, commercial paper and corporate debt securities. The Company & # 8217; s marketable securities are classified as available- for- sale and reported at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive loss. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > For available- for- sale debt securities in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security & # 8217; s amortized cost basis is written down to fair value and recognized in other income (expense) in the results of operations. For available- for- sale debt securities that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, an allowance is recorded for the difference between the present value of cash flows expected to be collected and the amortized cost basis of the security. Impairment losses attributable to credit loss factors are charged against the allowance when management believes an available- for- sale security is uncollectible or when either of the criteria regarding intent or requirement to sell is met. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Any unrealized losses from declines in fair value below the amortized cost basis as a result of non- credit loss factors are recognized as a component of accumulated other comprehensive loss, net of unrealized gains. Realized gains and losses and declines in fair value, if any, on available- for- sale securities are included in other income, net, in the results of operations. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Marketable securities with stated maturities of greater than three months from the date of purchase but less than one year from the consolidated balance sheet date are classified as current, while marketable securities with maturities in one year or beyond one year from the consolidated balance sheet date are classified as long- term. The cost of securities sold is determined using the specific- identification method. Interest earned and adjustments for the amortization of premiums and discounts on investments are included in interest income on the consolidated statements of operations and comprehensive loss. < / span > < / p > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtPolicyTextBlock', window);" > Debt Issuance Costs < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Debt Issuance Costs < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Debt issuance costs incurred in connection with the Convertible Note (see Note & # 160; 7) are recorded as a reduction of the carrying value of the notes payable liability on the Company & # 8217; s balance sheet and are amortized to interest expense over the term of the loan using the effective interest method. At the effective time of the Merger the Converted Note was converted to common stock and is no longer on the balance sheet as of December 31, 2024. < / span > < / p > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_SubscriptionReceivablePolicyTextBlock', window);" > Subscription Receivable < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Subscription Receivable & # 160; < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable is paid prior to the date the financial statement is available to be issued. < / span > < / p > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FairValueMeasurementPolicyPolicyTextBlock', window);" > Fair Value Measurements < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Fair Value Measurements & # 160; < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Certain assets and liabilities are carried at fair value under U. S. & # 160; GAAP. & # 160; Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: < / span > < / p > < table cellpadding =" 0" style =" width: 100 %; font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; border- spacing: 0px;" > < tr style =" font- family: Times New Roman, Times, Serif; vertical- align: top" > < td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" > < / td > < td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 9679; < / span > < / td > < td style =" font- family: Times New Roman, Times, Serif; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > Level 1 & # 160; & # 8212; & # 160; Quoted prices in active markets that are identical assets or liabilities. < / span > < / td > < / tr > < / table > < table cellpadding =" 0" style =" width: 100 %; font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; border- spacing: 0px;" > < tr style =" font- family: Times New Roman, Times, Serif; vertical- align: top" > < td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" > < / td > < td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 9679; < / span > < / td > < td style =" font- family: Times New Roman, Times, Serif; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > Level & # 160; 2 & # 160; & # 8212; & # 160; Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. < / span > < / td > < / tr > < / table > < table cellpadding =" 0" style =" width: 100 %; font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; border- spacing: 0px;" > < tr style =" font- family: Times New Roman, Times, Serif; vertical- align: top" > < td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" > < / td > < td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 9679; < / span > < / td > < td style =" font- family: Times New Roman, Times, Serif; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > Level & # 160; 3 & # 160; & # 8212; & # 160; Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies, and similar techniques. < / span > < / td > < / tr > < / table > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company & # 8217; s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy described above (see Note 4). The carrying values of the Company & # 8217; s prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to their relatively short maturity period. < / span > < / p > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window);" > Property and Equipment < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Property and Equipment < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight- line method over the estimated useful life of each asset as follows: < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; font- weight: bold; text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > Estimated < br / > Useful Life < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Furniture and fixtures < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 11 %; text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > 3- 5 years < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Computer and office equipment < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > 3- 5 years < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock', window);" > Classification of Convertible Preferred Stock < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Classification of Convertible Preferred Stock < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Prior to the reverse recapitalization, the Company had classified its Pre- Merger Oruka Series A Preferred Stock outside of stockholders & # 8217; equity on the Company & # 8217; s consolidated balance sheet because the holders of such stock have certain liquidation rights in the event of a deemed liquidation event that, in certain situations, is not solely within the control of the Company and would require the redemption of the then- outstanding convertible preferred stock. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Upon the closing of the Merger, the Company converted its Pre- Merger Oruka Series A Preferred Stock to Company Series B Preferred Stock and has classified the Company Series B Preferred Stock within stockholders & # 8217; equity on its consolidated balance sheet because the Company Series B Preferred Stock is not redeemable or puttable to the Company by the holder under any circumstances. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > In connection with the PIPE Financing (see Note 1) the Company issued Company Series A Preferred Stock, and has classified the Company Series A Preferred Stock outside of stockholders & # 8217; equity on the Company & # 8217; s consolidated balance sheet because the holders of such stock have certain rights (see Note 8) that, in certain situations, is not solely within the control of the Company and would require the redemption of the then- outstanding convertible preferred stock. In November 2024, the Company Series A Preferred Stock shares were converted to common stock, and as of December 31, 2024, there were no shares of Company Series A Preferred Stock outstanding. < / span > < / p > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_NotePayableToRelatedPartyPolicyTextBlock', window);" > Note Payable to Related Party < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Note & # 160; Payable to Related Party < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company accounted for the Convertible Note (as defined in Note 7) at amortized cost. The Company considered if optional conversion features are required to be bifurcated and separately accounted for as a derivative. Costs related to the issuance of the Convertible Note were recorded as a debt discount, amortized over the term of the Convertible Note (see & # 160; Note & # 160; 7) and were accounted for as interest expense in other income (expenses) within the consolidated statement of operations and comprehensive loss using the effective interest method. At the effective time of the Merger, shares of Pre- Merger Oruka Common Stock issued pursuant to the conversion of the Convertible Note (including accrued interest) automatically converted into shares of Company Common Stock (see Note 1). < / span > < / p > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock', window);" > Research and Development Contract Costs Accruals < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Research and Development Contract Costs Accruals < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company records the costs associated with research studies and manufacturing development as incurred. These costs are a significant component of the Company & # 8217; s research and development expenses, with a substantial portion of the Company & # 8217; s ongoing research and development activities conducted by third- party service providers, including contract research organizations (& # 8220; CROs & # 8221;) and contract manufacturing organizations (& # 8220; CMOs & # 8221;), and the Company & # 8217; s related- party Paragon (see Note & # 160; 12). < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company accrues for expenses resulting from obligations under its two antibody discovery and option agreements (the & # 8220; Option Agreements & # 8221;) (see Note 12), by and among Paragon, Paruka Holding LLC (& # 8220; Paruka & # 8221;), an entity formed by Paragon as a vehicle to hold equity in the Company, and the Company as well as agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrual balance in each reporting period. If advance payments are made to Paragon, a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be expensed as the contracted services are performed. Changes in these estimates that result in material changes to the Company & # 8217; s accruals could materially affect the Company & # 8217; s results of operations. As of December 31, 2024, the Company has not experienced any material deviations between accrued and actual research and development expenses. < / span > < / p > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_LesseeLeasesPolicyTextBlock', window);" > Leases < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Leases < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > At the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies a lease as either an operating or finance lease and recognizes a right- of- use (& # 8220; ROU & # 8221;) asset and a current and non- current lease liability, as applicable, in the balance sheet if the lease has a term greater than one year. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise its option. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > At the lease commencement date, operating lease liabilities and their corresponding ROU assets are recorded at the present value of future minimum lease payments over the expected remaining lease term. The Company determines the present value of lease payments using the implicit rate, if it is readily determinable, or the risk- free discount rate for a period comparable with that of the lease term. For operating leases, lease expense for lease payments is recognized on a straight- line basis over the lease term. For finance leases, lease expense includes amortization expense of the ROU asset recognized on a straight- line basis over the lease term and interest expense recognized on the finance lease liability. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments, incentives received or initial direct costs. As of December 31, 2024, the Company has one operating lease and no finance leases. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company accounts for lease and non- lease components related to operating leases as a single lease component. The Company has elected that costs associated with leases having an initial term of 12 months or less are recognized in the consolidated statement of operations and comprehensive loss on a straight- line basis over the lease term and are not recorded on its consolidated balance sheets. Variable lease expense is recognized as incurred and consists primarily of real estate taxes, utilities, and other office space related expenses. < / span > < / p > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SegmentReportingPolicyPolicyTextBlock', window);" > Segment Reporting < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Segment Reporting < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > The Company operates as a single reportable and operating segment. Its Chief Executive Officer, serving as the Chief Operating Decision Maker (& # 8220; CODM & # 8221;), oversees operations on an aggregated basis to allocate resources effectively. In assessing the Company & # 8217; s financial performance, the CODM regularly reviews total operating expenses and consolidated net loss. < / p > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ResearchAndDevelopmentExpensePolicy', window);" > Research and Development Costs < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Research and Development Costs < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Research and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock- based compensation, employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities, as well as allocated human resource costs, information technology costs, and facility- related costs, including rent, maintenance, utilities, and depreciation. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses on the accompanying consolidated balance sheet. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable advance payments represent a one- time cost for obtaining goods or services, with anticipated benefits to be utilized within a year of period end, the payment is expensed immediately. < / span > < / p > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window);" > General and Administrative Expenses < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > General and Administrative Expenses < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > General and administrative expenses consist primarily of salaries and bonuses, stock- based compensation, employee benefits, finance and administration costs, patent and intellectual property costs, professional fees, as well as allocated human resource costs, information technology costs, and facility- related costs, including rent, maintenance, utilities and depreciation. < / span > < / p > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CommitmentsAndContingenciesPolicyTextBlock', window);" > Commitments and Contingencies < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Commitments and Contingencies < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities. The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but not probable; however, it discloses the range of reasonably possible losses. As of December 31, 2024, no liabilities were recorded for loss contingencies (see Note & # 160; 13). < / span > < / p > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window);" > Stock- Based Compensation < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Stock- Based Compensation < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company estimates the fair value of its stock awards using the Black- Scholes option pricing model, which uses as inputs the fair value of the Company & # 8217; s common stock, and certain management estimates, including the expected stock price volatility, the expected term of the award, the risk- free interest rate, and expected dividends. Expected volatility is calculated based on reported volatility data for a representative group of publicly traded companies for which historical information is available. The Company selects companies with comparable characteristics with historical share price information that approximates the expected term of the equity- based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies & # 8217; shares during the equivalent period that approximates the calculated expected term of the stock options. The Company will continue to apply this method until a sufficient amount of historical information regarding the volatility of its stock price becomes available. The risk- free interest rate is based on the U. S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. For employee and non- employee awards (except the Paruka warrant) the Company uses the simplified method, under which the expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to lack of historical exercise data. For the Paruka warrant, the contractual term is used for the expected term. The expected dividend yield is assumed to be zero as the Company has no current plans to pay any dividends on common stock. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company measures restricted common stock awards (& # 8220; RSAs & # 8221;) using the difference, if any, between the purchase price per share of the award and the fair value of the Company & # 8217; s common stock at the date of grant. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company grants stock options, restricted stock awards, and warrants that are subject to service or performance- based vesting conditions. Compensation expense for awards to employees and directors with service- based vesting conditions is recognized using the straight- line method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards to non- employees with service- based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. As of each reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation expense until it is probable that the performance- based vesting condition will be achieved. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company has issued stock options, warrants, and RSAs with service- based and performance- based vesting conditions. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company recognizes the compensation expense for the option to purchase common stock under the Employee Stock Purchase Plan (& # 8220; ESPP & # 8221;), based on the fair value of the common stock estimated using the closing price of the Company & # 8217; s common stock as reported on the date of offering, less the purchase discount percentage provided for in the plan. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company classifies stock- based compensation expense in its consolidated statement of operations and comprehensive loss in the same manner in which the award recipient & # 8217; s payroll costs are classified or in which the award recipient & # 8217; s service payments are classified, as applicable. < / span > < / p > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_ComprehensiveLossPolicyPolicyTextBlock', window);" > Comprehensive Loss < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Comprehensive Loss < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Comprehensive loss includes net loss as well as other changes in stockholders & # 8217; equity that result from transactions and events other than those with stockholders. The Company & # 8217; s unrealized gains and losses on marketable securities represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the consolidated statement of comprehensive loss. < / span > < / p > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EarningsPerSharePolicyTextBlock', window);" > Net Loss per Share Attributable to Stockholders < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Net Loss per Share Attributable to Stockholders < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Basic and diluted net loss attributable to stockholders per share is presented in conformity with the two- class method required for participating securities (Pre- Merger Oruka Series A Preferred Stock). Basic earnings per share is computed by dividing net income available to each class of shares by the weighted- average number of shares of common stock and participating securities outstanding during the period. Pre- funded warrants were included as the exercise price is negligible and these warrants are fully vested and exercisable. Company Series A Preferred Stock and Company Series B Preferred Stock share the same characteristics as Common Stock and have no substantive preference attributed to them and, accordingly, have been considered as classes of Common Stock in the computation of net loss per share regardless of their legal form. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Net loss is allocated to common stock based on its proportional ownership on an as- converted basis. Net loss is not allocated to participating securities as they do not have an obligation to fund losses. The weighted- average number of shares outstanding of common stock reflects changes in ownership over the periods presented. See Note 8 & # 8212; Convertible Preferred Stock and Stockholders & # 8217; Equity. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Diluted net loss per share is computed by dividing the net loss attributable to stockholders adjusted for income (expenses), net of tax, related to any diluted securities, by the weighted- average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of this calculation, stock options to purchase common stock, employee warrants to purchase common stock, and unvested RSAs are considered potential dilutive common shares. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company generated a net loss for the periods presented. Accordingly, basic and diluted net loss per share is the same because the inclusion of the potentially dilutive securities would be anti- dilutive. < / span > < / p > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_OtherIncomeExpenseNetPolicyTextBlock', window);" > Other income, net < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Other income, net < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Other income, net, consists of interest earned on the Company & # 8217; s cash, cash equivalents, and marketable securities; interest expense on the convertible note from a related party and foreign currency transactions gains and losses. < / span > < / p > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_IncomeTaxPolicyTextBlock', window);" > Income Taxes < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Income Taxes < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company & # 8217; s tax returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis of assets and liabilities using enacted tax rates in effect for the & # 160; years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two- step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50 % likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or penalties related to uncertain tax positions as of December 31, 2024. < / span > < / p > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock', window);" > Recently Adopted Accounting Pronouncements < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Recently Adopted Accounting Pronouncements < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > In November & # 160; 2023, the FASB issued ASU 2023- 07, Segment Reporting (Topic & # 160; 280): Improvements to Reportable Segment Disclosures (& # 8220; ASU & # 160; 2023- 07 & # 8221;), which enhances the segment disclosure requirements for public entities on an annual and interim basis. Under this standard, public entities will be required to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss. Additionally, current annual disclosures about a reportable segment & # 8217; s profit or loss and assets will be required on an interim basis. Entities will also be required to disclose information about the CODM & # 8217; s title and position at the Company along with an explanation of how the CODM uses the reported measures of segment profit or loss in their assessment of segment performance and deciding how to allocate resources. Finally, ASU & # 160; 2023- 07 requires all segment disclosures for public entities that have only a single reportable segment. The amendments in ASU & # 160; 2023- 07 are effective for fiscal & # 160; years beginning after December & # 160; 15, 2023, and interim periods within fiscal & # 160; years beginning after December & # 160; 15, 2024. Early adoption is permitted. The Company adopted ASU 2023- 07 in 2024 and additional required disclosures have been included in Note 10. < / span > < / p > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window);" > Recently Issued Accounting Pronouncements < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > < b > < i > Recently Issued Accounting Pronouncements < / i > < / b > < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > In December & # 160; 2023, the FASB issued ASU & # 160; 2023- 09, Income Taxes (Topic & # 160; 740): Improvements to Income Tax Disclosures. This ASU expands disclosures in an entity & # 8217; s income tax rate reconciliation table and disclosures regarding taxes paid both in the U. S. & # 160; and foreign jurisdictions. This update is effective beginning with the Company & # 8217; s 2025 fiscal year annual reporting period. The Company is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements. < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > In November 2024, the FASB issued ASU 2024- 03, Income Statement & # 8212; Reporting Comprehensive Income & # 8212; Expense Disaggregation Disclosures (Subtopic 220- 40): Disaggregation of Income Statement Expenses. This ASU requires more detailed disclosures, on an annual and interim basis, about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. This ASU may be applied either prospectively or retrospectively. The Company is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements. < / span > < / p > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Classification of Convertible Preferred Stock. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_ComprehensiveLossPolicyPolicyTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Comprehensive loss policy. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_ComprehensiveLossPolicyPolicyTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_NotePayableToRelatedPartyPolicyTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Note Payable to Related Party. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_NotePayableToRelatedPartyPolicyTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_OtherIncomeExpenseNetPolicyTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Represents of other income (expense), net. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_OtherIncomeExpenseNetPolicyTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border ="

0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" > < tr > < td class
=" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Represents of recently adopted accounting pronouncements. < / p > < / div > < a href =" javascript:
void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style ="
white- space: nowrap;" > orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong >
Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr: textBlockItemType < / td > < / tr > < tr > < td > < strong >
Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < /
table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id ="
defref_orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR
();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p >
Research and development contract costs accruals. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p >
No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding ="
0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock < / td > <
/ tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong
> < / td > < td > dtr: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td >
< td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id ="
defref_orka_SubscriptionReceivablePolicyTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr
> < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Subscription receivable. < / p
> < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong >
Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_SubscriptionReceivablePolicyTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > <
strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr: textBlockItemType < / td > < / tr > < tr > < td > <
strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < /
tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AccountingPoliciesAbstract" > < tr > < td class ="
hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext
(this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space:
nowrap;" > us- gaap_AccountingPoliciesAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us-
gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td
> < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0"
cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_CashAndCashEquivalentsPolicyTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href
=" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" >- Definition < / a > < div > < p > Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents.
Other information that may be disclosed includes (1) the nature of any restrictions on the entity' s use of its cash and cash equivalents, (2) whether the entity' s cash and cash equivalents are
insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the
carrying amount of cash equivalents approximates fair value. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display:
none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 230 < br >- SubTopic 10 < br >- Section 50 < br >-
Paragraph 1 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext
(this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space:
nowrap;" > us- gaap_CashAndCashEquivalentsPolicyTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td
> < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < /
td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0"
cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_CommitmentsAndContingenciesPolicyTextBlock" > < tr > < td class =" hide" > < a style
=" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void
(0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and
measuring loss and gain contingencies. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference
1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 954 < br >- SubTopic 450 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >-
Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147477850 / 954- 450- 50- 1 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting
Standards Codification < br >- Topic 460 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 8 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org /
1943274 / 2147482425 / 460- 10- 50- 8 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border
=" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_CommitmentsAndContingenciesPolicyTextBlock <
/ td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data
Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period
Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData"
style =" display: none;" id =" defref_us- gaap_ConcentrationRiskCreditRisk" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();"
> X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p >
Disclosure of accounting policy for credit risk. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p >
Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 942 < br >- SubTopic 825 < br >- Section 50 < br >- Paragraph 1 <
br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478898 / 942- 825- 50- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Name
Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (d) < br >- SubTopic 10 < br >- Topic 275 < br >- Publisher FASB < br >- URI https: / / asc. fasb.
org / 1943274 / 2147482861 / 275- 10- 50- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table
border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ConcentrationRiskCreditRisk < / td > < / tr
> < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong
> < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong >
< / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display:
none;" id =" defref_us- gaap_DebtPolicyTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr >
< tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Disclosure of accounting policy
related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt. < / p
> < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref /
legacyRef < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- SubTopic 10 < br >- Topic 470 < br >- Publisher FASB < br >- URI https: / / asc. fasb.
org / 1943274 / 2147481544 / 470- 10- 50- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table
border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DebtPolicyTextBlock < / td > < / tr > < tr >
< td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td
> < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td >
< td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id ="
defref_us- gaap_EarningsPerSharePolicyTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr >
< tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Disclosure of accounting policy
for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that
have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the
issuance of the financial statements. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1:
http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >-
Subparagraph (d) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482662 / 260- 10- 50- 1 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef <
br >- Name Accounting Standards Codification < br >- Topic 260 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https:
/ / asc. fasb. org / 1943274 / 2147482662 / 260- 10- 50- 1 < br > < br > Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic
260 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482662 / 260- 10- 50- 2 < br > < / p > < / div > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong >
Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_EarningsPerSharePolicyTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > <
strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > <
td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < /
td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_FairValueMeasurementPolicyPolicyTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr
> < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Disclosure of accounting
policy for fair value measurements of financial and non- financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that
manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities. < / p > < / div > < a href =" javascript: void (0);" onclick ="
Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >
Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" >
us- gaap_FairValueMeasurementPolicyPolicyTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td >
us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td
> na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding
=" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_IncomeTaxPolicyTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href ="

javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 20 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 20 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 19 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 19 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 25 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482525 / 740- 10- 45- 25 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 03 (h) (1)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479886 / 946- 10- S99- 3 < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 17 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 17 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 9 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 9 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 28 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482525 / 740- 10- 45- 28 < br > < br > Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482765 / 220- 10- 50- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_IncomeTaxPolicyTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_LesseeLeasesPolicyTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Disclosure of accounting policy for leasing arrangement entered into by lessee. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 842 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478964 / 842- 20- 50- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_LesseeLeasesPolicyTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_MarketableSecuritiesPolicy" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Disclosure of accounting policy for investment classified as marketable security. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 942 < br >- SubTopic 320 < br >- Section 50 < br >- Paragraph 5 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147477268 / 942- 320- 50- 5 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_MarketableSecuritiesPolicy < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity' s financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_NewAccountingPronouncementsPolicyPolicyTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_PropertyPlantAndEquipmentPolicyTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Disclosure of accounting policy for long- lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- SubTopic 10 < br >- Topic 360 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482099 / 360- 10- 50- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 7- 03 (a) (8) (a)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- SubTopic 360 < br >- Topic 958 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147477798 / 958- 360- 50- 6 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (d) < br >- SubTopic 360 < br >- Topic 958 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147477798 / 958- 360- 50- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_PropertyPlantAndEquipmentPolicyTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ResearchAndDevelopmentExpensePolicy" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 730 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 05 < br >- Paragraph 1 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483044 / 730- 10- 05- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ResearchAndDevelopmentExpensePolicy < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_SegmentReportingPolicyPolicyTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Disclosure of accounting policy for segment reporting. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 41 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 41 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 47 < br >- Subparagraph (bb) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482785 / 280- 10- 55- 47 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 29 < br >- Subparagraph (f) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 29 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 54 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482785 / 280- 10- 55- 54 < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 36 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 36 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 47 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482785 / 280- 10- 55- 47 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 29 < br >- Subparagraph (d) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 29 < br > < br > Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 29 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 29 < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 29 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 29 < br > < br > Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 29 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 29 < br > < br > Reference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 29 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 29 < br > < br > Reference 12: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 29 < br >- Subparagraph (e) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 29 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);"

> Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;"
> us- gaap_SegmentReportingPolicyPolicyTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us-
gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td >
na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding
=" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" > < tr > < td class =" hide" > < a style
=" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void
(0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar)
expense report caption. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www.
xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 720 < br >- SubTopic 35 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph
(a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483406 / 720- 35- 50- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >
Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" >
us- gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > <
/ td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong >
< / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0"
cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" > < tr > < td class =" hide"
> < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Disclosure of accounting policy for award under share- based payment arrangement. Includes, but is
not limited to, methodology and assumption used in measuring cost. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style ="
display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50
< br >- Paragraph 2 < br >- Subparagraph (f) (1) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 2: http: / / www. xbrl.
org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (f) (2) (i) < br
>- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br
>- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (f) (2) (ii) < br >- Publisher FASB < br >- URI https: / / asc. fasb.
org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards
Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (f) (2) (v) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br >
Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 <
br >- Subparagraph (SAB Topic 14. C. Q3) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479830 / 718- 10- S99- 1 < br > < br > Reference 6: http: / / www. xbrl. org /
2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SAB Topic 14.
D. 1. Q5) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479830 / 718- 10- S99- 1 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >-
Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SAB Topic 14. D. 3. Q2) < br >- Publisher FASB
< br >- URI https: / / asc. fasb. org / 1943274 / 2147479830 / 718- 10- S99- 1 < br > < br > Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br
>- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SAB Topic 14. D. 2. Q6) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org /
1943274 / 2147479830 / 718- 10- S99- 1 < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- Name Accounting Standards Codification < br >-
Publisher FASB < br >- URI https: / / asc. fasb. org / 718 / tableOfContent < br > < br > Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 <
br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 /
2147480429 / 718- 10- 50- 2 < br > < br > Reference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification
< br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (f) (2) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a
href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > <
strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy < / td > < / tr > < tr > < td style =" padding- right:
4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types:
textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < /
td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_UseOfEstimates" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class ="
body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Disclosure of accounting policy for the use of estimates in
the preparation of financial statements in conformity with generally accepted accounting principles. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >
References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 275 < br >-
SubTopic 10 < br >- Section 50 < br >- Paragraph 9 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482861 / 275- 10- 50- 9 < br > < br > Reference 2: http: / / fasb. org /
us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 275 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 4 < br >- Publisher FASB < br >- URI
https: / / asc. fasb. org / 1943274 / 2147482861 / 275- 10- 50- 4 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Name Accounting Standards Codification < br
>- Section 50 < br >- Paragraph 1 < br >- Subparagraph (b) < br >- SubTopic 10 < br >- Topic 275 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482861 / 275- 10- 50-
1 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (c)
< br >- SubTopic 10 < br >- Topic 275 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482861 / 275- 10- 50- 1 < br > < br > Reference 5: http: / / www. xbrl. org / 2003 /
role / disclosureRef < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 11 < br >- SubTopic 10 < br >- Topic 275 < br >- Publisher FASB < br >- URI https: / /
asc. fasb. org / 1943274 / 2147482861 / 275- 10- 50- 11 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Name Accounting Standards Codification < br >-
Section 50 < br >- Paragraph 12 < br >- SubTopic 10 < br >- Topic 275 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482861 / 275- 10- 50- 12 < br > < br > Reference
7: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 275 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 8 < br >-
Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482861 / 275- 10- 50- 8 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < /
a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_UseOfEstimates < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > <
td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td >
< strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > <
DOCUMENT > < TYPE > XML < SEQUENCE > 66 < FILENAME > R30. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel ="
stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text /
javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < /
head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208277008080" > < tr > < th class =" tl" colspan =" 1"
rowspan =" 2" > < div style =" width: 200px;" > < strong > Summary of Significant Accounting Policies (Tables) < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months
Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a"
href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AccountingPoliciesAbstract', window);" > < strong > Summary of Significant Accounting Policies [Abstract] < /
strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href ="
javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_PropertyPlantAndEquipmentTextBlock', window);" > Schedule of Property and Equipment < / a > < / td > < td class ="
text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" >
Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight- line method over the estimated useful life of each asset as follows:
< / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif"
> & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical-
align: bottom" > < td style =" text- align: center; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight:
bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; font- weight: bold;
text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > Estimated < br / > Useful Life < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background-
color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Furniture and fixtures < / span > < / td > < td style ="
width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 11 %; text- align: center" > < span style =" font- family: Times New
Roman, Times, Serif" > 3- 5 years < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times
New Roman, Times, Serif" > Computer and office equipment < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style ="
text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > 3- 5 years < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < / table > < div style ="
display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AccountingPoliciesAbstract" > < tr > < td class
=" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext
(this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space:
nowrap;" > us- gaap_AccountingPoliciesAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us-
gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td
> < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0"
cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_PropertyPlantAndEquipmentTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href ="
javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" >- Definition < / a > < div > < p > Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to,
balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. < / p > < / div > < a href =" javascript: void (0);"
onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards
Codification < br >- Section 50 < br >- Paragraph 1 < br >- SubTopic 10 < br >- Topic 360 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482099 / 360- 10- 50- 1 < br >
< / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > <
tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_PropertyPlantAndEquipmentTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px;
white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types:
textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < /
td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 67 <
FILENAME > R31. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css"

> < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208263382928" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Reverse Recapitalization and Pre- Closing Financing (Tables) < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DisclosureTextBlockSupplementAbstract', window);" > < strong > Reverse Recapitalization and Pre- Closing Financing [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window);" > Schedule of the Assets and Liabilities < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > As part of the recapitalization, the Company acquired the assets and liabilities listed below (in thousands): < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > August 29, < br / > 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Cash and cash equivalents < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 4, 940 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Other current assets < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 114 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Accrued liabilities < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (54 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- bottom: 2. 5pt; padding- left: 6. 85pt" > < span style =" font- family: Times New Roman, Times, Serif" > Net assets acquired < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 5, 000 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DisclosureTextBlockSupplementAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DisclosureTextBlockSupplementAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 805 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Paragraph 1 < br >- Section 50 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479907 / 805- 20- 50- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 68 < FILENAME > R32. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208160090672" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Fair Value Measurements (Tables) < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FairValueDisclosuresAbstract', window);" > < strong > Fair Value Measurements [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window);" > Schedule of Fair Value Hierarchy for Financial Assets Measured < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The following tables present the Company & # 8217; s fair value hierarchy for financial assets measured as of December 31, 2024 (in thousands): < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 14" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > December 31, 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom" > < td style =" font- weight: bold; text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Level 1 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Level 2 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Level 3 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Total < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom" > < td > < span style =" font- family: Times New Roman, Times, Serif" > Cash equivalents < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 125in; width: 52 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Money market funds < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 6, 350 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 157; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 158; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 6, 350 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 125in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > U. S. treasury securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style

=" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 19, 660 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 159; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 19, 660 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 125in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > U. S. government agency securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 160; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 3, 988 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 161; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 3, 988 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 125in; text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Commercial papers < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 162; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 22, 177 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 163; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 22, 177 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Total cash equivalents < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 6, 350 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 45, 825 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 164; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 52, 175 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Marketable securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 125in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Marketable securities, current < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 25in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > U. S. treasury securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 190, 792 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 165; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 190, 792 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 25in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > U. S. government agency securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 166; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 12, 966 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 167; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 12, 966 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 25in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Commercial papers < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 168; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 34, 811 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 169; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > <

td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New
Roman, Times, Serif" > 34, 811 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style ="
vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman,
Times, Serif" > Corporate debt securities < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > <
td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1.
5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 170; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1.
5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times
New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & #
160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 75, 504 < / span > < / td > < td style ="
padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style ="
font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman,
Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 171; font- family: Times New Roman,
Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > <
td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left"
> < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family:
Times New Roman, Times, Serif" > 75, 504 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < /
span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 375in; text- align: left; padding- bottom: 1. 5pt" > < span style =" font-
family: Times New Roman, Times, Serif" > Total marketable securities, current < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times,
Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td >
< td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1.
5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times
New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & #
160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 314, 073 < / span > < / td > < td style
=" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style ="
font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman,
Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 172; font- family: Times New Roman,
Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > <
td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left"
> < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family:
Times New Roman, Times, Serif" > 314, 073 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; <
/ span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 125in; text- align: left" > < span style =" font- family: Times
New Roman, Times, Serif" > Marketable securities, long- term < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style ="
text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman,
Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font-
family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td >
< td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times
New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span
style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < /
span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman,
Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align:
right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif"
> & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 25in; text- align: left" > < span style =" font- family: Times
New Roman, Times, Serif" > U. S. treasury securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align:
left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif"
> & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times
New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style ="
text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 13, 607 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman,
Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font-
family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 173; font- family: Times New Roman, Times,
Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family:
Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td
style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 13, 607 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New
Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 25in; text- align: left;
padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > U. S. government agency securities < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span
style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New
Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 174; font- family: Times New
Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > <
/ td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text-
align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font-
family: Times New Roman, Times, Serif" > 4, 462 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & #
160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1.
5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > <
span style ="- sec- ix- hidden: hidden- fact- 175; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style
=" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160;
< / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style ="
border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 4, 462 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align:
left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding-
left: 0. 375in; text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Total marketable securities, long- term < / span > < / td > < td style ="
padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span
style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New
Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > <
/ td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text-
align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font-
family: Times New Roman, Times, Serif" > 18, 069 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & #
160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1.
5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > <
span style ="- sec- ix- hidden: hidden- fact- 176; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style
=" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160;
< / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style ="
border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 18, 069 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align:
left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style
=" text- align: left; padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > Total cash equivalents and marketable securities < / span > < / td > < td style ="
padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span
style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman,
Times, Serif" > 6, 350 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td
style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > <
span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New
Roman, Times, Serif" > 377, 967 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < /
td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align:
left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style ="- sec- ix- hidden:
hidden- fact- 177; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New
Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style ="
border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text-
align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 384, 317 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family:
Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding ="
0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" > < tr > < td class =" hide" > < a style ="
color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);"
onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders'
equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the
fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant
other observable inputs (Level 2), and significant unobservable inputs (Level 3). < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div

style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 820 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2 < br > < br > Reference 2: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 820 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_FairValueDisclosuresAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_FairValueDisclosuresAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 69 < FILENAME > R33. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208167274288" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Cash equivalents and Marketable Securities (Tables) < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_CashEquivalentsAndMarketableSecuritiesAbstract', window);" > < strong > Cash equivalents and Marketable Securities [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_MarketableSecuritiesTextBlock', window);" > Schedule of Cash Equivalents and Marketable Securities < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Cash equivalents and marketable securities, which are classified as available- for- sale, consisted of the following as of December 31, 2024 (in thousands): < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 14" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > December 31, 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom" > < td style =" font- weight: bold; text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Amortized Cost < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Gross Unrealized Gains < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Gross Unrealized Losses < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Fair Value < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom" > < td > < span style =" font- family: Times New Roman, Times, Serif" > Cash equivalents < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 125in; width: 52 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Money market funds < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 6, 350 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 178; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 179; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 6, 350 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 125in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > U. S. treasury securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 19, 656 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 4 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 180; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 19, 660 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 125in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > U. S. government agency securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 3, 988 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 181; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 182; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 3, 988 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 125in; text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Commercial papers < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 22, 180 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 183; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (3 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 22, 177 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Total cash equivalents

< / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt
solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span
style =" font- family: Times New Roman, Times, Serif" > 52, 174 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman,
Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style ="
border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid;
text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 4 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family:
Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td
> < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom:
Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (3 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style
=" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span
> < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border-
bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 52, 175 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" >
< span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left"
> < span style =" font- family: Times New Roman, Times, Serif" > Marketable securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < /
span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font-
family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td >
< td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >
& # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span
style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style
=" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New
Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style
=" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span >
< / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family:
Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 125in; text-
align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Marketable securities, current < / span > < / td > < td > < span style =" font- family: Times New Roman, Times,
Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > <
span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & #
160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New
Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text-
align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span
> < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family:
Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > <
span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & #
160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style ="
font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 25in; text-
align: left" > < span style =" font- family: Times New Roman, Times, Serif" > U. S. treasury securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > &
160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style
=" font- family: Times New Roman, Times, Serif" > 190, 748 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span >
< / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times,
Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 55 < / span > < / td > < td style =" text- align: left" > < span
style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style
=" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New
Roman, Times, Serif" > (11 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td > < span style =" font-
family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td >
< td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 190, 792 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times
New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 25in; text- align: left"
> < span style =" font- family: Times New Roman, Times, Serif" > U. S. government agency securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > &
160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style
=" font- family: Times New Roman, Times, Serif" > 12, 967 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span >
< / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times,
Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 1 < / span > < / td > < td style =" text- align: left" > < span
style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style
=" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New
Roman, Times, Serif" > (2 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td > < span style =" font- family:
Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td
style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 12, 966 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New
Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 25in; text- align: left" > < span style ="
font- family: Times New Roman, Times, Serif" > Commercial papers < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td
style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New
Roman, Times, Serif" > 34, 808 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style ="
font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < /
td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 3 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New
Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style
=" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 184; font- family: Times New
Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style
=" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span >
< / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 34, 811 < / span > < / td > < td style =" text- align: left" > < span style =" font- family:
Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 25in; text-
align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Corporate debt securities < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span
style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New
Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 75, 537 <
/ span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom:
1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font-
family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman,
Times, Serif" > 7 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style
=" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > <
span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times
New Roman, Times, Serif" > (40 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > <
td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left"
> < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family:
Times New Roman, Times, Serif" > 75, 504 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < /
span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 375in; text- align: left; padding- bottom: 1. 5pt" > < span style =" font-
family: Times New Roman, Times, Serif" > Total marketable securities, current < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times,
Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td >
< td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 314, 060 < / span > < / td > < td style =" padding- bottom: 1.
5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times
New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & #
160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 66 < / span > < / td > < td style ="
padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style ="
font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman,
Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (53 < / span > < /
td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span
style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New
Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 314, 073
< / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical-
align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 125in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Marketable
securities, long- term < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font-
family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td
> < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif"
> & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span
style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < /

span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 25in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > U. S. treasury securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 13, 639 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 185; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (32 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 13, 607 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > U. S. government agency securities < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 4, 485 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 186; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (23 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 4, 462 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 375in; text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Total marketable securities, long- term < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 18, 124 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 187; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (55 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 18, 069 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > Total cash equivalents and marketable securities < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 384, 358 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 70 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (111 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 384, 317 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window);" > Schedule of Available- for- Sale Securities in an Unrealized Loss Position < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The following table summarizes the available- for- sale securities in an unrealized loss position, aggregated by major security type and length of time in a continuous unrealized loss position, for which an allowance for credit losses was not recorded as of December & # 160; 31, 2024, (in thousands): < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- indent:- 0. 125in; padding- left: 0. 125in; text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 22" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > December 31, 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom" > < td style =" text- indent:- 0. 125in; padding- left: 0. 125in; font- weight: bold; text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 6" style =" text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > < b > Less than 12 months < / b > < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 6" style =" text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > < b > 12 months or longer < / b > < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 6" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Total < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom" > < td style =" text- indent:- 0. 125in; padding- left: 0. 125in; font- weight: bold; text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > < b > Fair < br / > Value < / b > < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Unrealized < br / > Losses < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Fair < br / > Value < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Unrealized < br / > Losses < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > < b > Fair < br / > Value < / b > < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Unrealized < br / > Losses < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom" > < td style =" text- indent:- 0. 125in; padding- left: 0. 125in" > < span style =" font- family: Times New Roman, Times, Serif" > Cash equivalents < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- indent:- 0. 125in; padding- left: 0. 25in; width: 28 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Commercial papers < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 18, 199 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (3 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 188; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 189; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 18, 199 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (3 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- indent:- 0. 125in; padding- left: 0. 125in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Marketable securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- indent:- 0. 125in; padding- left: 0. 25in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Marketable securities, current < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- indent:- 0. 125in; padding- left: 0. 375in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > U. S. treasury securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 49, 904 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (11 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 190; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 191; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 49, 904 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (11 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- indent:- 0. 125in; padding- left: 0. 375in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > U. S. government agency securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 4, 713 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (2 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 192; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 193; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 4, 713 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (2 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- indent:- 0. 125in; padding- left: 0. 375in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Corporate debt securities < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 39, 468 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (40 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 194; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 195; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 39, 468 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family:

```
Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (40 < / span > < / td > < td style
=" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > <
td style =" text- indent:- 0. 125in; padding- left: 0. 25in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Marketable securities, long- term < / span > < / td > <
td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > &
# 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style
=" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style ="
text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman,
Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font-
family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td >
< td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times
New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span
style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < /
span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman,
Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align:
right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times,
Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family:
Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td
style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > <
td style =" text- indent:- 0. 125in; padding- left: 0. 375in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > U. S. treasury securities < / span > < / td > < td > <
span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & #
160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 13, 607 < / span > < / td > < td style =" text- align: left" > < span style ="
font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text-
align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times,
Serif" > (32 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td > < span style =" font- family: Times New
Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text-
align: right" > < span style ="- sec- ix- hidden: hidden- fact- 196; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font-
family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align:
left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 197; font-
family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td
> < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif"
> & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 13, 607 < / span > < / td > < td style =" text- align: left" > < span
style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style
=" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New
Roman, Times, Serif" > (32 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < / tr > < tr style =" vertical-
align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- indent:- 0. 125in; padding- left: 0. 375in; text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times
New Roman, Times, Serif" > U. S. government agency securities < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & #
160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style ="
border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 4, 462 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align:
left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman,
Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span >
< / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (23 < / span > < / td > < td style =" padding- bottom:
1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New
Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < /
span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 198; font- family: Times New Roman, Times, Serif" > & # 8212; <
/ span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom:
1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font-
family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 199; font-
family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >
& # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black
1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > <
span style =" font- family: Times New Roman, Times, Serif" > 4, 462 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman,
Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style ="
border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid;
text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (23 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family:
Times New Roman, Times, Serif" >) < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- indent:- 0. 125in; padding- left: 0. 5in; padding-
bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > Total < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman,
Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td >
< td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 130, 353 < / span > < / td > < td style =" padding- bottom: 2.
5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New
Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span >
< / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (111 < / span > < / td > < td style =" padding- bottom:
2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New
Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span >
< / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 200; font- family: Times New Roman, Times, Serif" > & # 8212; < / span
> < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt"
> < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family:
Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 201; font- family: Times
New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < /
span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double;
text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font-
family: Times New Roman, Times, Serif" > 130, 353 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > &
# 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt
double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style ="
font- family: Times New Roman, Times, Serif" > (111 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >)
< / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void
(0);" onclick =" Show. showAR (this,' defref_us- gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window);" > Schedule of Marketable Securities at Estimated Fair
Value < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times
New Roman, Times, Serif" > The following table summarizes the contractual maturities of the Company & # 8217; s marketable securities at estimated fair value (in thousands): < / span > < / p >
< p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < /
span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align:
bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt"
> < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt
solid" > < span style =" font- family: Times New Roman, Times, Serif" > December 31, < br / > 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style ="
font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text-
align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Due in one year or less < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New
Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style ="
width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 314, 073 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font-
family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- bottom: 1.
5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Due in 1- 2 years < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New
Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < /
span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 18, 069 < / span > < / td > < td style ="
padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background-
color: rgb (204, 238, 255)" > < td style =" padding- bottom: 2. 5pt; padding- left: 0. 125in" > < span style =" font- family: Times New Roman, Times, Serif" > Total < / span > < / td > < td style ="
padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span
style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman,
Times, Serif" > 332, 142 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < /
tr > < / table > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display:
none;" id =" defref_orka_CashEquivalentsAndMarketableSecuritiesAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();"
> X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No
definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0"
cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_CashEquivalentsAndMarketableSecuritiesAbstract < / td > < / tr > < tr > < td
```

style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 326 < br >- SubTopic 30 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 8 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479081 / 326- 30- 55- 8 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / otherTransitionRef < br >- Topic 320 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 6 < br > < br > Reference 3: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 326 < br >- SubTopic 30 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 4 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479106 / 326- 30- 50- 4 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Tabular disclosure of maturities of an entity' s investments as well as any other information pertinent to the investments. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_MarketableSecuritiesTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_MarketableSecuritiesTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 70 < FILENAME > R34. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208263282384" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Accrued Expenses and Other Current Liabilities (Tables) < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window);" > < strong > Accrued Expenses and Other Current Liabilities [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window);" > Schedule of Accrued Expenses and Other Current Liabilities < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Accrued expenses and other current liabilities consisted of the following (in thousands): < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > December 31, < br / > 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Accrued employee compensation and benefits < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text-align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 2, 041 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Accrued professional and consulting < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 221 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Accrued research and development < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font-family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 1, 084 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- bottom: 2. 5pt; padding- left: 0. 125in" > < span style =" font- family: Times New Roman, Times, Serif" > Total < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 3, 346 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Tabular disclosure of the components of accrued liabilities. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ScheduleOfAccruedLiabilitiesTableTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 71 < FILENAME > R35. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208160396960" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Convertible Preferred Stock and Stockholders & # 8217; Equity (Tables) < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FeaturesOfConvertiblePreferredStockAbstract', window);" > < strong > Convertible Preferred Stock and Stockholders & # 8217; Equity [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_ScheduleOfConvertiblePreferredStockTableTextBlock', window);" > Schedule of Convertible Preferred Stock < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > As of December 31, 2024, convertible preferred stock consisted of the following (in thousands, except share data): < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 14" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > December 31, 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom" > < td style =" font- weight: bold; font- style: italic" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style ="

font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" text- align: center; border- bottom: Black 1. 5pt solid" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > < b > Preferred < br / > Stock < br / > Authorized < / b > < / span > < / p > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Preferred < br / > Stock Issued < br / > and < br / > Outstanding < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Carrying < br / > Value < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Common Stock < br / > Issuable < br / > Upon < br / > Conversion < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 52 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Series B convertible preferred stock < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 251, 504 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 137, 138 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 2, 931 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 11, 428, 149 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window);" > Schedule of Common Stock Reserved for Future Issuance < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > As of December 31, 2024, the Company had common stock reserved for future issuance as follows: & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > December 31, < br / > 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Shares issuable on conversion of Company Series B Preferred Stock < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 11, 428, 149 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td > < span style =" font- family: Times New Roman, Times, Serif" > Shares issuable upon exercise of pre- funded warrants < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 6, 202, 207 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Shares issuable upon exercise of warrant under the Paruka Warrant Obligation < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 596, 930 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Outstanding and issued stock options < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 1, 567, 760 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Outstanding and issued employee warrants < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 3, 054, 358 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Shares available for grant under 2024 Stock Incentive Plan < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 4, 246, 324 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Shares available for grant under 2024 Employee Stock Purchase Plan < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 460, 529 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- bottom: 4pt; padding- left: 13. 7pt" > < span style =" font- family: Times New Roman, Times, Serif" > Total shares of common stock reserved < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 27, 556, 257 < / span > < / td > < td style =" padding- bottom: 4pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Tabular disclosure of common stock reserved for future issuance. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_ScheduleOfConvertiblePreferredStockTableTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Tabular disclosure of convertible preferred stock. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_ScheduleOfConvertiblePreferredStockTableTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_FeaturesOfConvertiblePreferredStockAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_FeaturesOfConvertiblePreferredStockAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 72 < FILENAME > R36. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208263206560" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Stock- Based Compensation (Tables) < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window);" > < strong > Stock- Based Compensation [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window);" > Schedule of Weighted- Average Assumptions Used in Calculating the Fair Value of the Awards < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The following table summarizes the weighted- average assumptions used in calculating the fair value of the awards for the period from February & # 160; 6, 2024 (inception) to December 31, 2024: < / span > < / p > < p style =" font: 10pt Times New

Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Period from < br / > February 6, < br / > 2024 < br / > (Inception) to < br / > December 31, < br / > 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Expected term (in years) < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 6. 1 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Expected volatility < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 100. 21 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > % < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Risk- free interest rate < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 4. 26 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > % < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Expected dividend yield < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 206; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The following table summarizes the weighted- average assumptions used in calculating the fair value of the warrants for the period from February & # 160; 6, 2024 (inception) to December 31, 2024: < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Period from < br / > February 6, < br / > 2024 < br / > (Inception) to < br / > December 31, < br / > 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Expected term (in years) < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 6. 1 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Expected volatility < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 99. 02 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > % < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Risk- free interest rate < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 4. 15 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > % < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Expected dividend yield < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 207; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window);" > Schedule of Stock Option Activity < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The following table summarizes the stock option activities under the 2024 Plan and 2024 Stock Plan for the period of February & # 160; 6, 2024 (inception) through December 31, 2024: < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Number of < br / > Stock < br / > Options < br / > Outstanding < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Weighted < br / > Average < br / > Exercise < br / > Price Per < br / > Share < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Weighted < br / > Average < br / > Remaining < br / > Contractual < br / > Term < br / > (in Years) < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Aggregate < br / > Intrinsic < br / > Value < br / > (in & # 160; Thousands) < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td > < span style =" font- family: Times New Roman, Times, Serif" > Balance as of February 6, 2024 (inception) < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 208; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 209; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 210; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 211; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 125in; width: 52 %" > < span style =" font- family: Times New Roman, Times, Serif" > Granted < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 1, 567, 760 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 11. 39 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 125in" > < span style =" font- family: Times New Roman, Times, Serif" > Exercised < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 212; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 213; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 125in; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Forfeited < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 214; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family:

Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 215; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > Balance as of December 31, 2024 < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 1, 567, 760 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 11. 39 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 9. 4 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 15, 470 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > Vested and expected to vest, December 31, 2024 < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 1, 567, 760 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 11. 39 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 9. 4 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 15, 470 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > Exercisable, December 31, 2024 < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 216; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 217; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 218; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 219; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window);" > Schedule of RSA Activity < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The following table summarizes the RSA activity for the period from February & # 160; 6, 2024 (inception) through December 31, 2024: < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Number of < br / > RSAs < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Weighted < br / > Average < br / > Grant Date < br / > Fair Value < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td > < span style =" font- family: Times New Roman, Times, Serif" > Unvested balance as of February 6, 2024 (inception) < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 220; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 221; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" width: 76 %; padding- bottom: 1. 5pt; padding- left: 13. 7pt" > < span style =" font- family: Times New Roman, Times, Serif" > Granted < / span > < / td > < td style =" width: 1 %; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 2, 207, 553 < / span > < / td > < td style =" width: 1 %; padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; padding- bottom: 1. 5pt; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 222; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" width: 1 %; padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > Unvested balance as of December 31, 2024 < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 2, 207, 553 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 223; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock', window);" > Schedule of Employee Warrant Activity < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The following table summarizes the warrant activity for the period from February & # 160; 6, 2024 (inception) through December 31, 2024: & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; font- weight: bold; text- align: center" > Number of < br / > Employee < br / > Warrants < br / > Outstanding < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Weighted < br / > Average < br / > Exercise < br / > Price Per < br / > Share < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Weighted < br / > Average < br / > Remaining < br / > Contractual < br / > Term < br / > (in Years) < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Aggregate < br / > Intrinsic < br / > Value < br / > (in & # 160; Thousands) < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td > < span style =" font- family: Times New Roman, Times, Serif" > Balance as of February 6, 2024 (inception) < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 224; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 225; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 226; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 125in; width: 52 %" > < span style =" font- family: Times New Roman, Times, Serif" > Granted < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 3, 054, 358 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 7. 80 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 125in" > < span style =" font- family: Times New Roman, Times, Serif" > Exercised < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 227; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 228; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 125in; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Forfeited < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 229; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 230; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > Balance as of December 31, 2024 < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 3, 054, 358 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 7. 80 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 9. 5 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 35, 400 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > Vested and expected to vest, December 31, 2024 < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 3, 054, 358 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 7. 80 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 9. 5 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 35, 400 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > Exercisable, December 31, 2024 < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 231; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 232; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 233; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window);" > Schedule of Company & # 8217; s Stock- Based Compensation Expense < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The following table summarizes the classification of the Company & # 8217; s stock- based compensation expense in the consolidated statement of operations and comprehensive loss (in thousands): < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Period from < br / > February 6, < br / > 2024 < br / > (Inception) to < br / > December 31, < br / > 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Research and development < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style ="

width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 11, 992 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > General and administrative < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 2, 927 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- bottom: 2. 5pt; padding- left: 13. 7pt" > < span style =" font- family: Times New Roman, Times, Serif" > Total < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 14, 919 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window);" > Schedule of Award Types of Company & # 8217; s Stock- Based Compensation Expense < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The following table summarizes the award types of the Company & # 8217; s stock- based compensation expense in the consolidated statement of operations and comprehensive loss (in thousands): < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Period from < br / > February 6, < br / > 2024 < br / > (Inception) to < br / > December 31, < br / > 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Paruka Warrant Obligation < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 10, 357 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Employee warrants < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 2, 899 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Stock options < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 1, 626 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Employee stock purchase plan < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 37 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- bottom: 2. 5pt; padding- left: 0. 125in" > < span style =" font- family: Times New Roman, Times, Serif" > Total < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 14, 919 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Tabular disclosure of Share- Based Payment Arrangement, Warrant Activity. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Tabular disclosure of cost recognized for award under share- based payment arrangement by plan. Includes, but is not limited to, related tax benefit. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 718 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (h) (1) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Tabular disclosure of allocation of amount expensed and capitalized for award under share- based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 718 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (h) (1) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Tabular disclosure of the changes in outstanding nonvested restricted stock units. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (2) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted- average grant date fair value. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (d) < br >- SubTopic 10 < br >- Topic 718 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (e) < br >- SubTopic 10 < br >- Topic 718 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong >

Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity' s shares, (c) expected dividends, (d) risk- free rate (s), and (e) discount for post- vesting restrictions. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 718 < br >- SubTopic 10 < br >- Subparagraph (f) (2) < br >- Name Accounting Standards Codification < br >- Paragraph 2 < br >- Section 50 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 73 < FILENAME > R37. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208263311120" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Segment Disclosures (Tables) < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SegmentReportingAbstract', window);" > < strong > Segment Disclosures [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window);" > Schedule of Segment Loss from Operations < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in; background- color: white" > < span style =" font- family: Times New Roman, Times, Serif" > The table below is a summary of the segment loss from operations, including significant segment expenses (in thousands): < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in; background- color: white" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Period from < br / > February 6, < br / > 2024 < br / > (Inception) to December & # 160; 31, < br / > 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Research and development personnel- related (excluding stock- based compensation) < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 3, 959 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > General and administrative personnel- related (excluding stock- based compensation) < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 5, 054 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Research and development stock- based compensation < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 11, 992 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > General and administrative stock- based compensation < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 2, 927 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > External research and development < / span > < / td > < td > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 57, 680 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > Other research and development < / td > < td > & # 160; < / td > < td style =" text- align: left" > & # 160; < / td > < td style =" text- align: right" > 1, 429 < / td > < td style =" text- align: left" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > General and administrative, excluding personnel- related and stock- based compensation < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 5, 082 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- bottom: 1. 5pt; padding- left: 0. 125in" > < span style =" font- family: Times New Roman, Times, Serif" > Total operating expenses < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 88, 123 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- bottom: 4pt; padding- left: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Loss from operations < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (88, 123 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 280 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 31 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 31 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 280 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 30 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 30 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_SegmentReportingAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_SegmentReportingAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 74 < FILENAME > R38. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208161209856" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Income Taxes (Tables) < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_IncomeTaxDisclosureAbstract', window);" > < strong > Income Taxes [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window);" > Schedule of Loss Before Income Tax Expense < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The following table summarizes the loss before income tax expense by jurisdiction for the periods indicated: < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style ="

font- family: Times New Roman, Times, Serif" > Period from < br / > February 6, < br / > 2024 < br / > (Inception) to < br / > December 31, < br / > 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %" > < span style =" font- family: Times New Roman, Times, Serif" > Domestic < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > (< span style =" font- family: Times New Roman, Times, Serif" > 83, 724 < / span > < / td > < td style =" width: 1 %; text- align: left" >) < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Foreign < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 234; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- bottom: 2. 5pt; padding- left: 0. 125in" > < span style =" font- family: Times New Roman, Times, Serif" > Loss before income tax expense < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > (< span style =" font- family: Times New Roman, Times, Serif" > 83, 724 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" >) < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window);" > Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes < / a > < / td > < td class =" text" > The difference between the Company & # 8217; s provision for income taxes and the amounts computed by applying the statutory federal income tax rate to income before income taxes is as follows: < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > & # 160; < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > & # 160; < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > Period from < br / > February 6, < br / > 2024 < br / > (Inception) & # 160; to < br / > December & # 160; 31, < br / > 2024 < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left" > Tax benefit derived by applying the federal statutory rate to income before income taxes < / td > < td style =" width: 1 %" > & # 160; < / td > < td style =" width: 1 %; text- align: left" > & # 160; < / td > < td style =" width: 9 %; text- align: right" > (21. 00 < / td > < td style =" width: 1 %; text- align: left" >) % < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > Permanent differences < / td > < td > & # 160; < / td > < td style =" text- align: left" > & # 160; < / td > < td style =" text- align: right" > (0. 18 < / td > < td style =" text- align: left" >) < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left" > Research and development credits < / td > < td > & # 160; < / td > < td style =" text- align: left" > & # 160; < / td > < td style =" text- align: right" > (3. 41 < / td > < td style =" text- align: left" >) < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td > Other < / td > < td > & # 160; < / td > < td style =" text- align: left" > & # 160; < / td > < td style =" text- align: right" > (0. 87 < / td > < td style =" text- align: left" >) < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- bottom: 1. 5pt" > Change in the valuation allowance < / td > < td style =" padding- bottom: 1. 5pt" > & # 160; < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > & # 160; < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > 25. 46 < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- bottom: 4pt; padding- left: 9pt" > Income tax (benefit) expense < / td > < td style =" padding- bottom: 4pt" > & # 160; < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > & # 160; < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > 0. 00 < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > % < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window);" > Schedule of Components of the Deferred Tax Assets and Liabilities < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The components of the deferred tax assets and liabilities consist of the following (in thousands): < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > & # 160; < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > & # 160; < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > December & # 160; 31, < br / > 2024 < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom" > < td > Deferred tax assets < / td > < td > & # 160; < / td > < td colspan =" 2" style =" text- align: right" > & # 160; < / td > < td > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left; padding- left: 9pt" > Net operating loss carryforwards < / td > < td style =" width: 1 %" > & # 160; < / td > < td style =" width: 1 %; text- align: left" > $ < / td > < td style =" width: 9 %; text- align: right" > 2, 260 < / td > < td style =" width: 1 %; text- align: left" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- left: 9pt" > Research and development credits < / td > < td > & # 160; < / td > < td style =" text- align: left" > & # 160; < / td > < td style =" text- align: right" > 3, 080 < / td > < td style =" text- align: left" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- left: 9pt" > Stock- based compensation < / td > < td > & # 160; < / td > < td style =" text- align: left" > & # 160; < / td > < td style =" text- align: right" > 3, 063 < / td > < td style =" text- align: left" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- left: 9pt" > Accruals and other < / td > < td > & # 160; < / td > < td style =" text- align: left" > & # 160; < / td > < td style =" text- align: right" > 424 < / td > < td style =" text- align: left" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- left: 9pt" > Lease liability < / td > < td > & # 160; < / td > < td style =" text- align: left" > & # 160; < / td > < td style =" text- align: right" > 203 < / td > < td style =" text- align: left" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 9pt" > Intangibles < / td > < td > & # 160; < / td > < td style =" text- align: left" > & # 160; < / td > < td style =" text- align: right" > 1, 477 < / td > < td style =" text- align: left" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- bottom: 1. 5pt; padding- left: 9pt" > Capitalized R & amp; D expenses < / td > < td style =" padding- bottom: 1. 5pt" > & # 160; < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > & # 160; < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > 10, 994 < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- left: 0. 25in" > Total deferred tax assets < / td > < td > & # 160; < / td > < td style =" text- align: left" > & # 160; < / td > < td style =" text- align: right" > 21, 501 < / td > < td style =" text- align: left" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left" > Deferred tax liabilities < / td > < td > & # 160; < / td > < td style =" text- align: left" > & # 160; < / td > < td style =" text- align: right" > & # 160; < / td > < td style =" text- align: left" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- bottom: 1. 5pt; padding- left: 9pt" > Right- of- use asset < / td > < td style =" padding- bottom: 1. 5pt" > & # 160; < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > & # 160; < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > (184 < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" >) < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- left: 0. 25in" > Total deferred tax liabilities < / td > < td > & # 160; < / td > < td style =" text- align: left" > & # 160; < / td > < td style =" text- align: right" > (184 < / td > < td style =" text- align: left" >) < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- bottom: 1. 5pt" > Less valuation allowance < / td > < td style =" padding- bottom: 1. 5pt" > & # 160; < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > & # 160; < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > (21, 317 < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" >) < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- bottom: 4pt" > Deferred tax assets, net < / td > < td style =" padding- bottom: 4pt" > & # 160; < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > $ < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < div style ="- sec- ix- hidden: hidden- fact- 235" > & # 8212; < / div > < / td > < td style =" padding- bottom: 4pt; text- align: left" > & # 160; < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SummaryOfValuationAllowanceTextBlock', window);" > Schedule of Net Deferred Tax Assets < / a > < / td > < td class =" text" > he Company has established a full federal and state valuation allowance equal to the net deferred tax assets due to uncertainties regarding the realization of the deferred tax asset based on the Company & # 8217; s lack of earnings history. The valuation allowance increased by $ 21. 3 & # 160; million primarily due to continuing loss from operations. < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > & # 160; < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > & # 160; < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > December & # 160; 31, < br / > 2024 < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td > Beginning balance as of February 6, 2024 < / td > < td > & # 160; < / td > < td style =" text- align: left" > $ < / td > < td style =" text- align: right" > < div style ="- sec- ix- hidden: hidden- fact- 236" > & # 8212; < / div > < / td > < td style =" text- align: left" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" width: 88 %; text- align: left; padding- bottom: 1. 5pt" > Change in valuation allowance < / td > < td style =" width: 1 %; padding- bottom: 1. 5pt" > & # 160; < / td > < td style =" width: 1 %; border- bottom: Black 1. 5pt solid; text- align: left" > & # 160; < / td > < td style =" width: 9 %; border- bottom: Black 1. 5pt solid; text- align: right" > 21, 317 < / td > < td style =" width: 1 %; padding- bottom: 1. 5pt; text- align: left" > & # 160; < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- bottom: 4pt; padding- left: 9pt" > Ending balance as of December 31, 2024 < / td > < td style =" padding- bottom: 4pt" > & # 160; < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > $ < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > 21, 317 < / td > < td style =" padding- bottom: 4pt; text- align: left" > & # 160; < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window);" > Schedule of Unrecognized Tax Benefits < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands): < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Period from < br / > February 6, < br / > 2024 < br / > (Inception) to < br / > December 31, < br / > 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td > < span style =" font- family: Times New Roman, Times, Serif" > Beginning balance as of February 6, 2024 < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" text- align: right" > < span style ="- sec- ix- hidden: hidden- fact- 237; font- family: Times New Roman, Times, Serif" > & # 8212; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" width: 88 %; text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Changes related to tax positions taken in the current year < / span > < / td > < td style =" width: 1 %; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 1, 047 < / span > < / td > < td style =" width: 1 %; padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- bottom: 2. 5pt; padding- left: 0. 125in" > < span style =" font- family: Times New Roman, Times, Serif" > Ending balance as of December 31, 2024 < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & #

```
160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border-
bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 1, 047 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > <
span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table
border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_IncomeTaxDisclosureAbstract" > < tr > < td class =" hide" > < a style ="
color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);"
onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a
> < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_IncomeTaxDisclosureAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < /
tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > <
td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0"
class =" authRefData" style =" display: none;" id =" defref_us- gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href
=" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" >- Definition < / a > < div > < p > Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity' s statement of financial position, including
the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets. < / p > < / div > < a href =" javascript: void
(0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 740 < br
>- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740-
10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0"
cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock < / td > < / tr >
< tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong >
< / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < /
td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;"
id =" defref_us- gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show.
hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div
> < p > Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount
of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations. < / p > < / div > < a href =" javascript: void (0);" onclick
=" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 740 < br >- SubTopic 10 < br >-
Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 231 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482663 / 740- 10- 55- 231 < br > < br
> Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph
12A < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 12A < br > < br > Reference 3: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br
>- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 12 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 /
2147482685 / 740- 10- 50- 12 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0"
cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong
> < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < /
strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table
border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR
();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p >
Tabular disclosure of income before income tax between domestic and foreign jurisdictions. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < /
a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 235 < br >- SubTopic 10 < br >- Name Accounting Standards
Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 4- 08 (h) (1) (Note 1)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235-
10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0"
cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
< / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data
Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period
Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData"
style =" display: none;" id =" defref_us- gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void
(0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >-
Definition < / a > < div > < p > Tabular disclosure of the change in unrecognized tax benefits. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < /
a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification <
br >- Section 55 < br >- Paragraph 217 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482663 / 740- 10- 55- 217 < br > < br > Reference 2: http: / / www. xbrl. org /
2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 15A < br >- Subparagraph (a) < br >-
Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 15A < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details
< / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong
> < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < /
strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table
border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_SummaryOfValuationAllowanceTextBlock" > < tr > < td class =" hide" >
< a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript:
void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including
identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance. < / p > < / div > < a href =" javascript: void (0);"
onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 740 < br >-
SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org /
1943274 / 2147482685 / 740- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border
=" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_SummaryOfValuationAllowanceTextBlock < / td >
< / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < /
strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < /
strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE >
XML < SEQUENCE > 75 < FILENAME > R39. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css"
href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function
toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span
style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208267436416" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div
style =" width: 200px;" > < strong > Commitment and Contingencies (Tables) < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th
class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);"
onclick =" Show. showAR (this,' defref_us- gaap_CommitmentsAndContingenciesDisclosureAbstract', window);" > < strong > Commitment and Contingencies [ Abstract ] < / strong > < / a > < /
td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void
(0);" onclick =" Show. showAR (this,' defref_us- gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window);" > Schedule of Company & # 8217; s Supplemental Cash Flow
Information Related to Leases < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style ="
font- family: Times New Roman, Times, Serif" > The following table presents the Company & # 8217; s supplemental cash flow information related to leases (in thousands): < / span > < / p > < p
style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span >
< / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > <
td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times
New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family:
Times New Roman, Times, Serif" > Period from < br / > February 6, < br / > 2024 < br / > (Inception) to < br / > December 31, < br / > 2024 < / span > < / td > < td style =" padding- bottom: 1.
5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204,
238, 255)" > < td style =" width: 88 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Cash paid for amounts included in the measurement of lease liabilities <
/ span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style ="
font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 116 < / span >
< / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr
> < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window);" > Schedule of Company & # 8217; s Operating Lease Liabilities Showing the Aggregate Lease Payments < / a > < / td >
< td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times,
Serif" > The following table summarizes a maturity analysis of the Company & # 8217; s operating lease liabilities showing the aggregate lease payments as of December 31, 2024 (in thousands):
& # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman,
Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr
style =" vertical- align: bottom" > < td style =" font- weight: bold; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > < b > Year ending
December 31, < / b > < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td
colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Amount < / span > < / td > < td
style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom;
background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > 2025 < / span > < / td > < td style =" width:
1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman,
```

Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 369 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > 2026 < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 494 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > 2027 < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 380 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 125in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Total undiscounted lease payments < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 1, 243 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Less: imputed interest < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (275 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 125in; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Total discounted lease payments < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 968 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Less: current portion of lease liability < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (213 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" padding- left: 0. 375in; text- align: left; padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > Non- current portion of lease liability < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 755 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_CommitmentsAndContingenciesDisclosureAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_CommitmentsAndContingenciesDisclosureAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Tabular disclosure of undiscounted cash flows of lessee' s operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 842 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478964 / 842- 20- 50- 6 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Tabular disclosure of supplemental cash flow information for the periods presented. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 76 < FILENAME > R40. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208263423488" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Net Loss Per Share (Tables) < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EarningsPerUnitAbstract', window);" > < strong > Net Loss per Share [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window);" > Schedule of Basic and Diluted Net Loss Per Share Attributable to Stockholders < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > Basic and diluted net loss per share attributable to stockholders were calculated as follows (in thousands, except share and per share data): < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 10" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Period from February 6, 2024 < br / > (Inception) to < br / > December 31, 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom" > < td style =" font- weight: bold; text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Loss < br / > Allocation < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Weighted < br / > Average < br / > Shares < br / > Outstanding < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > Loss Per < br / > Share, < br / > Basic and < br / > Diluted < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 64 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Common Stock < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (65, 037 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 16, 789, 362 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (3. 87 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Company Series A Preferred Stock < sup > (1) < / sup > < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (1, 918 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 495 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (3, 873. 25 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Company Series B Preferred Stock < sup > (2) < / sup > < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (16, 769 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 51, 946 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (322. 81 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- bottom: 2. 5pt; padding- left: 0. 125in" > < span style =" font- family: Times New Roman, Times, Serif" > Net loss < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > (83, 724 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" >) < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < table cellpadding =" 0" style =" width: 100 %; font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; border- spacing: 0px;" > < tr style =" font- family: Times New Roman, Times, Serif; vertical- align: top" > < td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > (1) < / span > < / td > < td style =" font- family: Times New Roman, Times, Serif; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > The weighted- average number of shares of as- converted Company Series A Preferred Stock used in the loss allocation was 495, 191 for the period from February 6, 2024 (inception) to December 31, 2024. < / span > < / td > < / tr > < / table > < table cellpadding =" 0" style =" width: 100 %; font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; border- spacing: 0px;" > < tr style =" font- family: Times New Roman, Times, Serif; vertical- align: top" > < td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > (2) < / span > < / td > < td style =" font- family: Times New Roman, Times, Serif; text- align: justify" > < span style =" font- family: Times New Roman, Times, Serif" > The weighted- average number of shares of as- converted Company Series B Preferred Stock used in the loss allocation was 4, 328, 844 for the period from February 6, 2024 (inception) to December 31, 2024. < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window);" > Schedule of Anti- Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to stockholders for the periods presented because including them would have had an anti- dilutive effect were as follows: & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > < td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > December 31, < br / > 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Outstanding employee warrants to purchase common stock < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 3, 054, 358 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Outstanding unvested restricted stock awards < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 2, 207, 553 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Outstanding and issued common stock options < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 1, 567, 760 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Outstanding and issued warrant to Paruka < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 596, 930 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- bottom: 2. 5pt; padding- left: 13. 7pt" > < span style =" font- family: Times New Roman, Times, Serif" > Total < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 7, 426, 601 < / span > < / td > < td style =" padding- bottom: 2. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_EarningsPerUnitAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_EarningsPerUnitAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 260 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482662 / 260- 10- 50- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Tabular disclosure of an entity' s basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per- share computations for income from continuing operations. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482662 / 260- 10- 50- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 77 < FILENAME > R41. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208160360688" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Related Party Transactions (Tables) < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_RelatedPartyTransactionsAbstract', window);" > < strong > Related Party Transactions [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_OtherCurrentLiabilitiesTableTextBlock', window);" > Schedule of Related Party Accounts Payable and Other Current Liabilities < / a > < / td > < td class =" text" > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > The following is a summary of related party accounts payable and other current liabilities (in thousands): & # 160; < / span > < / p > < p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / p > < table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" > < tr style =" vertical- align: bottom" > <

td style =" text- align: center" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" font- weight: bold; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" > < span style =" font- family: Times New Roman, Times, Serif" > December 31, < br / > 2024 < / span > < / td > < td style =" padding- bottom: 1. 5pt; font- weight: bold" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" width: 88 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Paragon reimbursable Option Agreements & # 8217; fees < / span > < / td > < td style =" width: 1 %" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" width: 9 %; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 1, 482 < / span > < / td > < td style =" width: 1 %; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Paragon milestone payments for Option Agreement < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 4, 000 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > Paragon reimbursable other research expenses < / span > < / td > < td > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 515 < / span > < / td > < td style =" text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: White" > < td style =" text- align: left; padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > Paragon reimbursable patent expenses < / span > < / td > < td style =" padding- bottom: 1. 5pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 1. 5pt solid; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 25 < / span > < / td > < td style =" padding- bottom: 1. 5pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" > < td style =" padding- bottom: 4pt; padding- left: 0. 125in" > < span style =" font- family: Times New Roman, Times, Serif" > Total < / span > < / td > < td style =" padding- bottom: 4pt" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > $ < / span > < / td > < td style =" border- bottom: Black 4pt double; text- align: right" > < span style =" font- family: Times New Roman, Times, Serif" > 6, 022 < / span > < / td > < td style =" padding- bottom: 4pt; text- align: left" > < span style =" font- family: Times New Roman, Times, Serif" > & # 160; < / span > < / td > < / tr > < / table > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_OtherCurrentLiabilitiesTableTextBlock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Tabular disclosure of other current liabilities. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_OtherCurrentLiabilitiesTableTextBlock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: textBlockItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_RelatedPartyTransactionsAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_RelatedPartyTransactionsAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 78 < FILENAME > R42. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208159014640" > < tr > < th class =" tl" colspan =" 2" rowspan =" 2" > < div style =" width: 200px;" > < strong > Nature of the Business and Basis of Presentation (Details) < br > $ / shares in Units, $ in Thousands < / strong > < / div > < / th > < th class =" th" colspan =" 1" > < / th > < th class =" th" colspan =" 1" > < / th > < th class =" th" colspan =" 1" > 1 Months Ended < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < th class =" th" colspan =" 1" > < / th > < / tr > < tr > < th class =" th" > < div > Sep. 03, 2024 < / div > < div > $ / shares < / div > < / th > < th class =" th" > < div > Apr. 03, 2024 < / div > < div > USD ($) < / div > < / th > < th class =" th" > < div > Sep. 30, 2024 < / div > < div > $ / shares < / div > < div > shares < / div > < / th > < th class =" th" > < div > Dec. 31, 2024 < / div > < div > USD ($) < / div > < div > $ / shares < / div > < div > shares < / div > < / th > < th class =" th" > < div > Feb. 06, 2024 < / div > < div > $ / shares < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfStockLineItems', window);" > < strong > Nature of the Business and Basis of Presentation [Line Items] < / strong > < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CommonStockParOrStatedValuePerShare', window);" > Common stock, par value (in Dollars per share) | $ / shares < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 0. 001 < span > < / span > < / td > < td class =" nump" > $ 0. 001 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_AdditionalPaidInCapitalTransacationCost', window);" > Additional paid- in capital transaction costs (in Dollars) | $ < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 20, 500 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_PreFundedWarrantsOfCommonStockShares', window);" > Pre- funded warrants of common stock shares | shares < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 5, 522, 207 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfWarrantOrRightUnissued', window);" > Warrants exchange | shares < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 9, 664, 208 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_NetIncomeLoss', window);" > Net loss (in Dollars) | $ < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" num" > $ (83, 724) < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_NetCashProvidedByUsedInOperatingActivities', window);" > Net cash operating activities (in Dollars) | $ < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" num" > (57, 837) < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_InvestmentsAndCash', window);" > Cash, cash equivalents, and marketable securities (in Dollars) | $ < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 393, 700 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfWarrantOrRightAxis = orka_PrefundedWarrantsMember', window);" > Pre- funded Warrants [Member] < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfStockLineItems', window);" > < strong > Nature of the Business and Basis of Presentation [Line Items] < / strong > < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SaleOfStockConsiderationReceivedPerTransaction', window);" > Aggregate gross proceeds (in Dollars) | $ < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 188, 700 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SaleOfStockPricePerShare', window);" > Purchase price per share (in Dollars per share) | $ / shares < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 22. 999 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_PaymentOfFinancingAndStockIssuanceCosts', window);" > Net of issuance costs (in Dollars) | $ < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 11, 900 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StatementClassOfStockAxis = us- gaap_SeriesBPreferredStockMember', window);" > Series B Preferred Stock [Member] < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfStockLineItems', window);" > < strong > Nature of the Business and Basis of Presentation [Line Items] < / strong > < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_CommonStocksConversionRatio', window);" > Conversion

ratio < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < /
span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > 83: 3332: 1 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr >
< tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_NetIncomeLoss', window);" > Net loss (in Dollars) | $ < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > [1] < / sup > < / td > < td class =" text" > & # 160; < span > <
/ span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" num" > $ (16, 769) < span > < / span > < / td > < td
class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);"
onclick =" Show. showAR (this,' defref_us- gaap_StatementClassOfStockAxis = us- gaap_CommonStockMember', window);" > Common Stock [Member] < / a > < / td > < td class =" th" style
=" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & #
160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style
=" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfStockLineItems', window);" > < strong > Nature
of the Business and Basis of Presentation [Line Items] < / strong > < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span
> < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td
class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void
(0);" onclick =" Show. showAR (this,' defref_orka_InvestorsClosingShares', window);" > Investors shares | shares < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup
> < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class ="
nump" > 22, 784, 139 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top"
> < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window);" > Exchange shares | shares < / a >
< / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td
> < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 4, 764, 032 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class
=" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_StockIssuedDuringPeriodSharesOther', window);" > Issuance of shares | shares < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text"
> & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 2, 722, 207 < span >
< / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href
=" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_PrefundedWarrantstoPurchaseAnAggregateShares', window);" > Prefunded warrants to purchase an aggregate shares |
shares < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < /
span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 680, 000 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr >
< tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_StatementClassOfStockAxis = orka_SeriesANonVotingConvertiblePreferredStockMember', window);" > Series A Non- Voting Convertible Preferred Stock [Member] < / a > < / td > < td
class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class
=" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td
class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfStockLineItems', window);" >
< strong > Nature of the Business and Basis of Presentation [Line Items] < / strong > < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text"
> & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < /
span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href ="
javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SaleOfStockPricePerShare', window);" > Purchase price per share (in Dollars per share) | $ / shares < / a > < / td > < td
class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class
=" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 23, 000 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td
class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StatementClassOfStockAxis = us-
gaap_SeriesAPreferredStockMember', window);" > Series A Preferred Stock [Member] < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class ="
text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span
> < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href ="
javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfStockLineItems', window);" > < strong > Nature of the Business and Basis of Presentation [Line Items] < / strong
> < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span
> < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr
class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_SaleOfStockPricePerShare', window);" > Purchase price per share (in Dollars per share) | $ / shares < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td
> < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 23, 000 < span > < / span > < / td > < td class =" text" >
& # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class
=" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_NetIncomeLoss', window);" > Net loss (in Dollars) | $ < / a > < / td > < td class =" th" style =" border-
bottom: 0px;" > < sup > [2] < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; <
span > < / span > < / td > < td class =" num" > $ (1, 918) < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style ="
border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StatementEquityComponentsAxis = us-
gaap_CommonStockMember', window);" > Common Stock [Member] < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; <
span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td >
< td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);"
onclick =" Show. showAR (this,' defref_us- gaap_ClassOfStockLineItems', window);" > < strong > Nature of the Business and Basis of Presentation [Line Items] < / strong > < / a > < / td > < td
class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class
=" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td
class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_NetIncomeLoss', window);" > Net loss
(in Dollars) | $ < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; <
span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" num" > $ (65, 037) < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < /
td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_StatementEquityComponentsAxis = us- gaap_CommonStockMember', window);" > Common Stock [Member] | Series A Preferred Stock [Member] < / a > < / td > < td class =" th" style
=" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & #
160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style
=" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfStockLineItems', window);" > < strong > Nature
of the Business and Basis of Presentation [Line Items] < / strong > < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span
> < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td
class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);"
onclick =" Show. showAR (this,' defref_us- gaap_ConversionOfStockSharesConverted1', window);" > Convertible shares | shares < / a > < / td > < td class =" th" style =" border- bottom: 0px;" >
< sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td >
< td class =" nump" > 1, 000 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign
=" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SubsidiarySaleOfStockAxis = orka_OrukaCommonStockMember', window);" > Oruka
Common Stock [Member] < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" >
& # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < /
span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_ClassOfStockLineItems', window);" > < strong > Nature of the Business and Basis of Presentation [Line Items] < / strong > < / a > < / td > < td class =" th" style =" border- bottom: 0px;" >
< sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td >
< td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign
=" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StockholdersEquityReverseStockSplit', window);" > Reverse stock split < / a > < / td > <
td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > 1- for- 12 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td
class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > <
td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_CommonStockParOrStatedValuePerShare', window);" > Common stock, par value (in Dollars per share) | $ / shares < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup
> < / sup > < / td > < td class =" nump" > $ 0. 001 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td
class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign ="
top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SubsidiarySaleOfStockAxis = orka_PreMergerOrukaMember', window);" > Pre- Merger
Oruka [Member] | Pre- funded Warrants [Member] < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > <
/ td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text"
> & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show.
showAR (this,' defref_us- gaap_ClassOfStockLineItems', window);" > < strong > Nature of the Business and Basis of Presentation [Line Items] < / strong > < / a > < / td > < td class =" th" style
=" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & #
160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style
=" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SaleOfStockConsiderationReceivedPerTransaction',
window);" > Aggregate gross proceeds (in Dollars) | $ < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > <
/ td > < td class =" nump" > 275, 000 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class ="
text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick ="
Show. showAR (this,' defref_us- gaap_ProceedsFromIssuanceOfDebt', window);" > Proceeds from Issuance of convertible note (in Dollars) | $ < / a > < / td > < td class =" th" style =" border-
bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 25, 000 < span > < / span > < / td > < td class =" text" > & # 160; < span
> < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border-
bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SubsidiarySaleOfStockAxis = orka_PreMergerOrukaMember',

window);" > Pre- Merger Oruka [Member] | Common Stock [Member] < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfStockLineItems', window);" > < strong > Nature of the Business and Basis of Presentation [Line Items] < / strong > < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window);" > Exchange shares | shares < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 39, 873, 706 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SubsidiarySaleOfStockAxis = orka_ARCACommonStockMember', window);" > ARCA common stock [Member] < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_ClassOfStockLineItems', window);" > < strong > Nature of the Business and Basis of Presentation [Line Items] < / strong > < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_ExchangeRatio', window);" > Exchange ratio < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 6. 8569 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SubsidiarySaleOfStockAxis = orka_OrukaSeriesAConvertiblePreferredStockMember', window);" > Oruka Series A Convertible Preferred Stock [Member] < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfStockLineItems', window);" > < strong > Nature of the Business and Basis of Presentation [Line Items] < / strong > < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CommonStockParOrStatedValuePerShare', window);" > Common stock, par value (in Dollars per share) | $ / shares < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 0. 0001 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SubsidiarySaleOfStockAxis = orka_SeriesANonVotingConvertiblePreferredStockMember', window);" > Series A Non- Voting Convertible Preferred Stock [Member] < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfStockLineItems', window);" > < strong > Nature of the Business and Basis of Presentation [Line Items] < / strong > < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CommonStockParOrStatedValuePerShare', window);" > Common stock, par value (in Dollars per share) | $ / shares < / a > < / td > < td class =" th" style =" border-bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 0. 001 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border-bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SubsidiarySaleOfStockAxis = orka_PIPEFinancingMember', window);" > PIPE Financing [Member] | Common Stock [Member] < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfStockLineItems', window);" > < strong > Nature of the Business and Basis of Presentation [Line Items] < / strong > < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_NumberOfSharesPurchased', window);" > Aggregate of purchased shares | shares < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 5, 600, 000 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SaleOfStockPricePerShare', window);" > Purchase price per share (in Dollars per share) | $ / shares < / a > < / td > < td class =" th" style =" border-bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 23 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border-bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SubsidiarySaleOfStockAxis = orka_PIPEFinancingMember', window);" > PIPE Financing [Member] | Series A Non- Voting Convertible Preferred Stock [Member] < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfStockLineItems', window);" > < strong > Nature of the Business and Basis of Presentation [Line Items] < / strong > < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_CommonStockParOrStatedValuePerShare', window);" > Common stock, par value (in Dollars per share) | $ / shares < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 0. 001 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_NumberofAggregateShares', window);" > Aggregate shares | shares < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 2, 439 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SubsidiarySaleOfStockAxis = orka_PIPEFinancingMember', window);" > PIPE Financing [Member] | Series A Preferred Stock [Member] < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfStockLineItems', window);" > < strong > Nature of the Business and Basis of Presentation [Line Items] < / strong > < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window);" > Exchange shares | shares < / a > < / td > < td class =" th" style =" border- bottom: 0px;" > < sup > < / sup > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 2, 439 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr > < td colspan =" 6" > < / td > < / tr > < tr > < td colspan =" 6" > < table class =" outerFootnotes" width =" 100 %" > < tr class =" outerFootnote" > < td style =" vertical- align: top; width: 12pt;" valign =" top" > [1] < / td > < td style =" vertical- align: top;" valign =" top" > < span style =" font- family: Times New Roman, Times, Serif" > The weighted- average number of shares of as- converted Company Series B Preferred Stock used in the loss allocation was 4, 328, 844 for the period from February 6, 2024 (inception) to December 31, 2024. < / span > < / td > < / tr > < tr class =" outerFootnote" > < td style =" vertical- align: top; width: 12pt;" valign =" top" > [2] < / td > < td style =" vertical- align: top;" valign =" top" > < span style =" font- family: Times New Roman, Times, Serif" > The weighted- average number of shares of as- converted Company Series A Preferred Stock used in the loss allocation was 495, 191 for the period from February 6, 2024 (inception) to December 31, 2024. < / span > < / td > < / tr > < / table > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_AdditionalPaidInCapitalTransacationCost" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The amount of additional paid- in capital transacation cost. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_AdditionalPaidInCapitalTransacationCost < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_CommonStocksConversionRatio" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Percentage of common stock conversion ratio. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_CommonStocksConversionRatio < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > <

td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_ExchangeRatio" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Exchange ratio. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_ExchangeRatio < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: pureItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_InvestorsClosingShares" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Number of investors closing shares. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_InvestorsClosingShares < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_NumberOfSharesPurchased" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Number of shares purchased. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_NumberOfSharesPurchased < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_NumberofAggregateShares" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Number of aggregate shares. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_NumberofAggregateShares < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_PreFundedWarrantsOfCommonStockShares" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Pre- funded warrants of common stock shares. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_PreFundedWarrantsOfCommonStockShares < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_PrefundedWarrantstoPurchaseAnAggregateShares" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Number of prefunded warrants to purchase an aggregate shares. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_PrefundedWarrantstoPurchaseAnAggregateShares < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ClassOfStockLineItems" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 13 < br >- Subparagraph (d) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / recommendedDisclosureRef < br >- Topic 272 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 3 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483014 / 272- 10- 45- 3 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 272 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482987 / 272- 10- 50- 1 < br > < br > Reference 4: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 235 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 4- 08 (d)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1 < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 13 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 13 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 13 < br >- Subparagraph (e) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13 < br > < br > Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 13 < br >- Subparagraph (h) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13 < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 14 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 14 < br > < br > Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 18 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 18 < br > < br > Reference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (27) (b)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 12: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (28)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 13: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 2 < br > < br > Reference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (29)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 15: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 03 (i) (2)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479886 / 946- 10- S99- 3 < br > < br > Reference 16: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 03 (i) (1)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479886 / 946- 10- S99- 3 < br > < br > Reference 17: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 03 (i) (2) (i)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479886 / 946- 10- S99- 3 < br > < br > Reference 18: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 03 (i) (2) (ii)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479886 / 946- 10- S99- 3 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ClassOfStockLineItems < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ClassOfWarrantOrRightUnissued" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ClassOfWarrantOrRightUnissued < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_CommonStockParOrStatedValuePerShare" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Face amount or stated value per share of common stock. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (29)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style ="

white- space: nowrap;" > us- gaap_CommonStockParOrStatedValuePerShare < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: perShareItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ConversionOfStockSharesConverted1" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period." Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 230 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 4 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50- 4 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 230 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 3 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50- 3 < br > < br > Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 230 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 5 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50- 5 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ConversionOfStockSharesConverted1 < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_InvestmentsAndCash" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Sum of investments and unrestricted cash as of the balance sheet date. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 944 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 7- 03 (a) (2)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 944 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 7- 03 (a) (1)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_InvestmentsAndCash < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_NetCashProvidedByUsedInOperatingActivities" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 230 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 28 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 230 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 24 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 24 < br > < br > Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 230 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 25 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 25 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_NetCashProvidedByUsedInOperatingActivities < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_NetIncomeLoss" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 6 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 9 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 9 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 805 < br >- SubTopic 60 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 1 < br >- Subparagraph (g) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147476176 / 805- 60- 65- 1 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 323 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 2 < br >- Subparagraph (g) (3) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478666 / 740- 323- 65- 2 < br > < br > Reference 5: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SX 210. 5- 03 (20)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 235 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 4- 08 (g) (1) (ii)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 323 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481687 / 323- 10- 50- 3 < br > < br > Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 825 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 28 < br >- Subparagraph (f) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482907 / 825- 10- 50- 28 < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482765 / 220- 10- 50- 6 < br > < br > Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 3 < br > < br > Reference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (b) (2) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 1 < br > < br > Reference 12: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 815 < br >- SubTopic 40 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 1 < br >- Subparagraph (f) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480175 / 815- 40- 65- 1 < br > < br > Reference 13: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 8 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 8 < br > < br > Reference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 11 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 11 < br > < br > Reference 15: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 11 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 11 < br > < br > Reference 16: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 4 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 4 < br > < br > Reference 17: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 946 < br >- SubTopic 830 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 10 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479168 / 946- 830- 55- 10 < br > < br > Reference 18: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 7 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479105 / 946- 220- 45- 7 < br > < br > Reference 19: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 7- 04 (18)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147477250 / 944- 220- S99- 1 < br > < br > Reference 20: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 07 (9)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1 < br > < br > Reference 21: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 09 (1) (d)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3 < br > < br > Reference 22: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (i)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 23: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (ii)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 24: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (iii) (A)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 25: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (iv)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 26: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (5)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 27: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (i)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 28: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iii) (A)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 29: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iii) (B)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 30: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iv)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 31: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (5)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 32: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 60B < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 60B < br > < br >

Reference 33: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 205 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 7 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483499 / 205- 20- 50- 7 < br > < br > Reference 34: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 230 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 28 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28 < br > < br > Reference 35: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 1A < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 1A < br > < br > Reference 36: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 1B < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 1B < br > < br > Reference 37: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 942 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 9- 04 (22)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478524 / 942- 220- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_NetIncomeLoss < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_PaymentOfFinancingAndStockIssuanceCosts" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long- term debt and the cost incurred directly for the issuance of equity securities. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 230 < br >- SubTopic 10 < br >- Section 45 < br >- Paragraph 15 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 15 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_PaymentOfFinancingAndStockIssuanceCosts < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ProceedsFromIssuanceOfDebt" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short- term and long- term debt. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 230 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 14 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 14 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ProceedsFromIssuanceOfDebt < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_SaleOfStockConsiderationReceivedPerTransaction" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_SaleOfStockConsiderationReceivedPerTransaction < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_SaleOfStockNumberOfSharesIssuedInTransaction" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_SaleOfStockNumberOfSharesIssuedInTransaction < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_SaleOfStockPricePerShare" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_SaleOfStockPricePerShare < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: perShareItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StockIssuedDuringPeriodSharesOther" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Number of shares of stock issued attributable to transactions classified as other. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StockIssuedDuringPeriodSharesOther < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StockholdersEquityReverseStockSplit" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 4 < br >- Subparagraph (SAB Topic 4. C) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480008 / 505- 10- S99- 4 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StockholdersEquityReverseStockSplit < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ClassOfWarrantOrRightAxis = orka_PrefundedWarrantsMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ClassOfWarrantOrRightAxis = orka_PrefundedWarrantsMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StatementClassOfStockAxis = us- gaap_SeriesBPreferredStockMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StatementClassOfStockAxis = us- gaap_SeriesBPreferredStockMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StatementClassOfStockAxis = us- gaap_CommonStockMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StatementClassOfStockAxis = us- gaap_CommonStockMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StatementClassOfStockAxis = orka_SeriesANonVotingConvertiblePreferredStockMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StatementClassOfStockAxis = orka_SeriesANonVotingConvertiblePreferredStockMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > <

```
strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class ="
authRefData" style =" display: none;" id =" defref_us- gaap_StatementClassOfStockAxis = us- gaap_SeriesAPreferredStockMember" > < tr > < td class =" hide" > < a style =" color: white;"
href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick ="
Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space:
nowrap;" > us- gaap_StatementClassOfStockAxis = us- gaap_SeriesAPreferredStockMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong >
Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < /
td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding ="
0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StatementEquityComponentsAxis = us- gaap_CommonStockMember" > < tr > < td class =" hide" > < a
style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript:
void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style ="
white- space: nowrap;" > us- gaap_StatementEquityComponentsAxis = us- gaap_CommonStockMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > <
strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < /
strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0"
cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_SubsidiarySaleOfStockAxis = orka_OrukaCommonStockMember" > < tr > < td class
=" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > <
td style =" white- space: nowrap;" > us- gaap_SubsidiarySaleOfStockAxis = orka_OrukaCommonStockMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" >
< strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < /
strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0"
cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_SubsidiarySaleOfStockAxis = orka_PreMergerOrukaMember" > < tr > < td class ="
hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > <
td style =" white- space: nowrap;" > us- gaap_SubsidiarySaleOfStockAxis = orka_PreMergerOrukaMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > <
strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < /
strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0"
cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_SubsidiarySaleOfStockAxis = orka_ARCACommonStockMember" > < tr > < td class
=" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > <
td style =" white- space: nowrap;" > us- gaap_SubsidiarySaleOfStockAxis = orka_ARCACommonStockMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" >
< strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < /
strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0"
cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_SubsidiarySaleOfStockAxis = orka_OrukaSeriesAConvertiblePreferredStockMember"
> < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding:
2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: <
/ strong > < / td > < td style =" white- space: nowrap;" > us- gaap_SubsidiarySaleOfStockAxis = orka_OrukaSeriesAConvertiblePreferredStockMember < / td > < / tr > < tr > < td style ="
padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < /
tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < /
td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_SubsidiarySaleOfStockAxis =
orka_SeriesANonVotingConvertiblePreferredStockMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td
> < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0"
cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_SubsidiarySaleOfStockAxis =
orka_SeriesANonVotingConvertiblePreferredStockMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > <
td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > <
strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class ="
authRefData" style =" display: none;" id =" defref_us- gaap_SubsidiarySaleOfStockAxis = orka_PIPEFinancingMember" > < tr > < td class =" hide" > < a style =" color: white;" href ="
javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" >
us- gaap_SubsidiarySaleOfStockAxis = orka_PIPEFinancingMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > <
/ td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > <
td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > <
DOCUMENT > < TYPE > XML < SEQUENCE > 79 < FILENAME > R43. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel ="
stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text /
javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < /
head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208159044832" > < tr > < th class =" tl" colspan =" 1"
rowspan =" 2" > < div style =" width: 200px;" > < strong > Summary of Significant Accounting Policies (Details) < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months
Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < div > USD ($) < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign ="
top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ChangeInAccountingEstimateLineItems', window);" > < strong > Summary of Significant
Accounting Policies [ Line Items ] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;"
valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FederalDepositInsuranceCorporationPremiumExpense', window);" > Federal
Deposit Insurance Corporation < / a > < / td > < td class =" nump" > $ 250, 000 < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding ="
0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ChangeInAccountingEstimateLineItems" > < tr > < td class =" hide" > < a style =" color: white;" href
=" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" >- Definition < / a > < div > < p > Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain
members defined in one or many axes to the table. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p >
Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 4 <
br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 4 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >
Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" >
us- gaap_ChangeInAccountingEstimateLineItems < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us-
gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td
> < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0"
cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_FederalDepositInsuranceCorporationPremiumExpense" > < tr > < td class =" hide" > < a style =" color:
white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick
=" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of expense for Federal Deposit Insurance Corporation (FDIC) insurance. < / p > < / div > < a href =" javascript: void (0);"
onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 942 < br >- SubTopic
220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 9- 04 (14)) < br >- Publisher FASB < br >- URI https: / / asc. fasb.
org / 1943274 / 2147478524 / 942- 220- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table
border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_FederalDepositInsuranceCorporationPremiumExpense < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > <
td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td
> debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > <
/ TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 80 < FILENAME > R44. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > <
title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > <
script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; }
} < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208163873728" > < tr > < th class ="
tl" colspan =" 1" rowspan =" 1" > < div style =" width: 200px;" > < strong > Summary of Significant Accounting Policies- Schedule of Property and Equipment (Details) < br > < / strong > < /
div > < / th > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href ="
javascript: void (0);" onclick =" Show. showAR (this,' defref_srt_RangeAxis = srt_MinimumMember', window);" > Minimum [ Member ] | Furniture and fixtures [ Member ] < / a > < / td > < td
class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);"
onclick =" Show. showAR (this,' defref_us- gaap_PropertyPlantAndEquipmentLineItems', window);" > < strong > Schedule of Property and Equipment [ Line Items ] < / strong > < / a > < / td >
< td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);"
onclick =" Show. showAR (this,' defref_us- gaap_PropertyPlantAndEquipmentUsefulLife', window);" > Estimated useful life < / a > < / td > < td class =" text" > 3 years < span > < / span > < / td
> < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_srt_RangeAxis
= srt_MinimumMember', window);" > Minimum [ Member ] | Computer and office equipment [ Member ] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr
class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_PropertyPlantAndEquipmentLineItems', window);" > < strong > Schedule of Property and Equipment [ Line Items ] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < /
span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_PropertyPlantAndEquipmentUsefulLife', window);" > Estimated useful life < / a > < / td > < td class =" text" > 3 years < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl"
style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_srt_RangeAxis = srt_MaximumMember', window);" >
Maximum [ Member ] | Furniture and fixtures [ Member ] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border-
bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_PropertyPlantAndEquipmentLineItems', window);" > < strong >
Schedule of Property and Equipment [ Line Items ] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border-
```

bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_PropertyPlantAndEquipmentUsefulLife', window);" > Estimated useful life < / a > < / td > < td class =" text" > 5 years < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_srt_RangeAxis = srt_MaximumMember', window);" > Maximum [Member] | Computer and office equipment [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_PropertyPlantAndEquipmentLineItems', window);" > < strong > Schedule of Property and Equipment [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_PropertyPlantAndEquipmentUsefulLife', window);" > Estimated useful life < / a > < / td > < td class =" text" > 5 years < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-gaap_PropertyPlantAndEquipmentLineItems" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 842 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 7A < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478964 / 842- 20- 50- 7A < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_PropertyPlantAndEquipmentLineItems < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_PropertyPlantAndEquipmentUsefulLife" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in' PnYnMnDTnHnMnS' format, for example,' P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_PropertyPlantAndEquipmentUsefulLife < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: durationItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_srt_RangeAxis = srt_MinimumMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > srt_RangeAxis = srt_MinimumMember < / td > < / tr > < tr > < td style =" padding-right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_PropertyPlantAndEquipmentByTypeAxis = us-gaap_FurnitureAndFixturesMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_PropertyPlantAndEquipmentByTypeAxis = us- gaap_FurnitureAndFixturesMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis = us- gaap_ComputerEquipmentMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_PropertyPlantAndEquipmentByTypeAxis = us- gaap_ComputerEquipmentMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_srt_RangeAxis = srt_MaximumMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > srt_RangeAxis = srt_MaximumMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 81 < FILENAME > R45. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208263423488" > < tr > < th class =" tl" colspan =" 1" rowspan =" 1" > < div style =" width: 200px;" > < strong > Reverse Recapitalization and Pre- Closing Financing- Schedule of the Assets and Liabilities (Details) < br > $ in Thousands < / strong > < / div > < / th > < th class =" th" > < div > Aug. 29, 2024 < / div > < div > USD ($) < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window);" > < strong > Schedule of the Assets and Liabilities [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window);" > Cash and cash equivalents < / a > < / td > < td class =" nump" > $ 4, 940 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window);" > Other current assets < / a > < / td > < td class =" nump" > 114 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window);" > Accrued liabilities < / a > < / td > < td class =" num" > (54) < span > < / span > < / td > < / tr > < tr class =" reu" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window);" > Net assets acquired < / a > < / td > < td class =" nump" > $ 5, 000 < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short- term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 805 < br >- SubTopic 20 < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479907 / 805- 20- 50- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 805 < br >- SubTopic 20 < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479907 / 805- 20- 50- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 805 < br >- SubTopic 20 < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479907 / 805- 20- 50- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > <

strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 805 < br >- SubTopic 10 < br >- Section 55 < br >- Paragraph 37 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479303 / 805- 10- 55- 37 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 805 < br >- SubTopic 20 < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479907 / 805- 20- 50- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 82 < FILENAME > R46. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208163761552" > < tr > < th class =" tl" colspan =" 1" rowspan =" 1" > < div style =" width: 200px;" > < strong > Fair Value Measurements- Schedule of Fair Value Hierarchy for Financial Assets Measured (Details)- USD ($) < br > $ in Thousands < / strong > < / div > < / th > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < th class =" th" > < div > Feb. 06, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashEquivalentsAtCarryingValue', window);" > Cash equivalents < / a > < / td > < td class =" nump" > $ 52, 175 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesCurrentAbstract', window);" > < strong > Marketable securities, current < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_MarketableSecuritiesCurrent', window);" > Marketable securities, current < / a > < / td > < td class =" nump" > 314, 073 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesNoncurrentAbstract', window);" > < strong > Marketable securities, long- term < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_MarketableSecuritiesNoncurrent', window);" > Marketable securities, long- term < / a > < / td > < td class =" nump" > 18, 069 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_FairValueCashEquivalentsAndMarketableSecurities', window);" > Cash equivalents and marketable securities < / a > < / td > < td class =" nump" > 384, 317 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FairValueByFairValueHierarchyLevelAxis = us- gaap_FairValueInputsLevel1Member', window);" > Level 1 [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashEquivalentsAtCarryingValue', window);" > Cash equivalents < / a > < / td > < td class =" nump" > 6, 350 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesNoncurrentAbstract', window);" > < strong > Marketable securities, long- term < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_FairValueCashEquivalentsAndMarketableSecurities', window);" > Cash equivalents and marketable securities < / a > < / td > < td class =" nump" > 6, 350 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FairValueByFairValueHierarchyLevelAxis = us- gaap_FairValueInputsLevel2Member', window);" > Level 2 [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashEquivalentsAtCarryingValue', window);" > Cash equivalents < / a > < / td > < td class =" nump" > 45, 825 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesCurrentAbstract', window);" > < strong > Marketable securities, current < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_MarketableSecuritiesCurrent', window);" > Marketable securities, current < / a > < / td > < td class =" nump" > 314, 073 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesNoncurrentAbstract', window);" > < strong > Marketable securities, long- term < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_MarketableSecuritiesNoncurrent', window);" > Marketable securities, long- term < / a > < / td > < td class =" nump" > 18, 069 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_FairValueCashEquivalentsAndMarketableSecurities', window);" > Cash equivalents and marketable securities < / a > < / td > < td class =" nump" > 377, 967 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FairValueByFairValueHierarchyLevelAxis = us- gaap_FairValueInputsLevel3Member', window);" > Level 3 [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashEquivalentsAtCarryingValue', window);" > Cash equivalents < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesCurrentAbstract', window);" > < strong > Marketable securities, current < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_MarketableSecuritiesCurrent', window);" > Marketable securities, current < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesNoncurrentAbstract', window);" > < strong > Marketable securities, long- term < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_MarketableSecuritiesNoncurrent', window);" > Marketable securities, long- term < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_FairValueCashEquivalentsAndMarketableSecurities', window);" > Cash equivalents and marketable securities < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FairValueByAssetClassAxis = us- gaap_MoneyMarketFundsMember', window);" > Money market funds [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashEquivalentsAtCarryingValue', window);" > Cash equivalents < / a > < / td > < td class =" nump" > 6, 350 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FairValueByAssetClassAxis = us- gaap_MoneyMarketFundsMember', window);" > Money market funds [Member] | Level 1 [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashEquivalentsAtCarryingValue', window);" > Cash equivalents < / a > < / td > < td class =" nump" > 6, 350 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class

=" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FairValueByAssetClassAxis = us- gaap_MoneyMarketFundsMember', window);" > Money market funds [
Member] | Level 2 [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class
=" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract',
window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr
class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_CashEquivalentsAtCarryingValue', window);" > Cash equivalents < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < /
tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_FairValueByAssetClassAxis = us- gaap_MoneyMarketFundsMember', window);" > Money market funds [Member] | Level 3 [Member] < / a > < / td > < td class =" text" > & # 160; <
span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href
=" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class ="
text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > <
a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashEquivalentsAtCarryingValue', window);" > Cash equivalents < / a > < / td > < td class =" text" >
< span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href
=" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FairValueByAssetClassAxis = us- gaap_USTreasurySecuritiesMember', window);" > US Treasury Securities [Member
] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border-
bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash
equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl"
style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashEquivalentsAtCarryingValue', window);" >
Cash equivalents < / a > < / td > < td class =" nump" > 19, 660 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style
=" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesCurrentAbstract', window);" > < strong >
Marketable securities, current < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re"
> < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_MarketableSecuritiesCurrent',
window);" > Marketable securities, current < / a > < / td > < td class =" nump" > 190, 792 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class ="
ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_DebtSecuritiesNoncurrentAbstract', window);" > < strong > Marketable securities, long- term < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class
=" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick ="
Show. showAR (this,' defref_us- gaap_MarketableSecuritiesNoncurrent', window);" > Marketable securities, long- term < / a > < / td > < td class =" nump" > 13, 607 < span > < / span > < / td > <
td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);"
onclick =" Show. showAR (this,' defref_us- gaap_FairValueByAssetClassAxis = us- gaap_USTreasurySecuritiesMember', window);" > US Treasury Securities [Member] | Level 2 [Member] < /
a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom:
0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash
equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl"
style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashEquivalentsAtCarryingValue', window);" >
Cash equivalents < / a > < / td > < td class =" nump" > 19, 660 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style
=" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesCurrentAbstract', window);" > < strong >
Marketable securities, current < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro"
> < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_MarketableSecuritiesCurrent',
window);" > Marketable securities, current < / a > < / td > < td class =" nump" > 190, 792 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class ="
re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_DebtSecuritiesNoncurrentAbstract', window);" > < strong > Marketable securities, long- term < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class
=" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick ="
Show. showAR (this,' defref_us- gaap_MarketableSecuritiesNoncurrent', window);" > Marketable securities, long- term < / a > < / td > < td class =" nump" > 13, 607 < span > < / span > < / td > <
td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);"
onclick =" Show. showAR (this,' defref_us- gaap_FairValueByAssetClassAxis = us- gaap_USTreasurySecuritiesMember', window);" > US Treasury Securities [Member] | Level 3 [Member] < /
a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom:
0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash
equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl"
style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashEquivalentsAtCarryingValue', window);" >
Cash equivalents < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style ="
border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesCurrentAbstract', window);" > < strong >
Marketable securities, current < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re"
> < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_MarketableSecuritiesCurrent',
window);" > Marketable securities, current < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td
class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesNoncurrentAbstract',
window);" > < strong > Marketable securities, long- term < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < /
td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_MarketableSecuritiesNoncurrent', window);" > Marketable securities, long- term < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > & # 160; < span > < /
span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_FairValueByAssetClassAxis = us- gaap_USGovernmentAgenciesDebtSecuritiesMember', window);" > US Government Agency Securities [Member] < / a > < / td > < td class =" text" > & #
160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a"
href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class
=" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" >
< a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashEquivalentsAtCarryingValue', window);" > Cash equivalents < / a > < / td > < td class ="
nump" > 3, 988 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a
class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesCurrentAbstract', window);" > < strong > Marketable securities, current < / strong > < /
a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom:
0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_MarketableSecuritiesCurrent', window);" > Marketable securities, current
< / a > < / td > < td class =" nump" > 12, 966 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border-
bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesNoncurrentAbstract', window);" > < strong >
Marketable securities, long- term < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class ="
ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_MarketableSecuritiesNoncurrent', window);" > Marketable securities, long- term < / a > < / td > < td class =" nump" > 4, 462 < span > < / span > < / td > < td class =" text" > & # 160; <
span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_us- gaap_FairValueByAssetClassAxis = us- gaap_USGovernmentAgenciesDebtSecuritiesMember', window);" > US Government Agency Securities [Member] | Level 1 [Member] < / a >
< / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom:
0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash
equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl"
style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashEquivalentsAtCarryingValue', window);" >
Cash equivalents < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style ="
border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesCurrentAbstract', window);" > < strong >
Marketable securities, current < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re"
> < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_MarketableSecuritiesCurrent',
window);" > Marketable securities, current < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td
class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesNoncurrentAbstract',
window);" > < strong > Marketable securities, long- term < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < /
td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_MarketableSecuritiesNoncurrent', window);" > Marketable securities, long- term < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > & # 160; < span > < /
span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_FairValueByAssetClassAxis = us- gaap_USGovernmentAgenciesDebtSecuritiesMember', window);" > US Government Agency Securities [Member] | Level 2 [Member] < / a > < / td > <
td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign
=" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong >
< / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border-
bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashEquivalentsAtCarryingValue', window);" > Cash equivalents
< / a > < / td > < td class =" nump" > 3, 988 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom:
0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesCurrentAbstract', window);" > < strong > Marketable
securities, current < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class
=" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_MarketableSecuritiesCurrent', window);" >
Marketable securities, current < / a > < / td > < td class =" nump" > 12, 966 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class
=" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesNoncurrentAbstract',
window);" > < strong > Marketable securities, long- term < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < /
td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-

gaap_MarketableSecuritiesNoncurrent', window);" > Marketable securities, long- term < / a > < / td > < td class =" nump" > 4, 462 < span > < / span > < / td > < td class =" text" > & # 160; <
span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_us- gaap_FairValueByAssetClassAxis = us- gaap_USGovernmentAgenciesDebtSecuritiesMember', window);" > US Government Agency Securities [Member] | Level 3 [Member] < / a >
< / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom:
0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash
equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl"
style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashEquivalentsAtCarryingValue', window);" >
Cash equivalents < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style ="
border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesCurrentAbstract', window);" > < strong >
Marketable securities, current < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re"
> < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_MarketableSecuritiesCurrent',
window);" > Marketable securities, current < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td
class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesNoncurrentAbstract',
window);" > < strong > Marketable securities, long- term < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < /
td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_MarketableSecuritiesNoncurrent', window);" > Marketable securities, long- term < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > & # 160; < span > < /
span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_FairValueByAssetClassAxis = us- gaap_CommercialPaperMember', window);" > Commercial Papers [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > <
td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);"
onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > <
/ span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href ="
javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashEquivalentsAtCarryingValue', window);" > Cash equivalents < / a > < / td > < td class =" nump" > 22, 177 < span > <
/ span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href ="
javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesCurrentAbstract', window);" > < strong > Marketable securities, current < / strong > < / a > < / td > < td
class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign ="
top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_MarketableSecuritiesCurrent', window);" > Marketable securities, current < / a > < / td > <
td class =" nump" > 34, 811 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign
=" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FairValueByAssetClassAxis = us- gaap_CommercialPaperMember', window);" >
Commercial Papers [Member] | Level 1 [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr
class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & #
160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR
(this,' defref_us- gaap_CashEquivalentsAtCarryingValue', window);" > Cash equivalents < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > & # 160; < span > < /
span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_DebtSecuritiesCurrentAbstract', window);" > < strong > Marketable securities, current < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class ="
text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick ="
Show. showAR (this,' defref_us- gaap_MarketableSecuritiesCurrent', window);" > Marketable securities, current < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text"
> & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show.
showAR (this,' defref_us- gaap_FairValueByAssetClassAxis = us- gaap_CommercialPaperMember', window);" > Commercial Papers [Member] | Level 2 [Member] < / a > < / td > < td class ="
text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a
class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td
> < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;"
valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashEquivalentsAtCarryingValue', window);" > Cash equivalents < / a > < / td > <
td class =" nump" > 22, 177 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign
=" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesCurrentAbstract', window);" > < strong > Marketable securities, current <
/ strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style ="
border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_MarketableSecuritiesCurrent', window);" > Marketable
securities, current < / a > < / td > < td class =" nump" > 34, 811 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style
=" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FairValueByAssetClassAxis = us-
gaap_CommercialPaperMember', window);" > Commercial Papers [Member] | Level 3 [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > &
160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show.
showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td >
< td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);"
onclick =" Show. showAR (this,' defref_us- gaap_CashEquivalentsAtCarryingValue', window);" > Cash equivalents < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class ="
text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick ="
Show. showAR (this,' defref_us- gaap_DebtSecuritiesCurrentAbstract', window);" > < strong > Marketable securities, current < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < /
span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href ="
javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_MarketableSecuritiesCurrent', window);" > Marketable securities, current < / a > < / td > < td class =" text" > < span > < /
span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href ="
javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FairValueByAssetClassAxis = us- gaap_CorporateDebtSecuritiesMember', window);" > Corporate Debt Securities [
Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style ="
border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesCurrentAbstract', window);" > < strong >
Marketable securities, current < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro"
> < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_MarketableSecuritiesCurrent',
window);" > Marketable securities, current < / a > < / td > < td class =" nump" > 75, 504 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class ="
rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FairValueByAssetClassAxis
= us- gaap_CorporateDebtSecuritiesMember', window);" > Corporate Debt Securities [Member] | Level 1 [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td
class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);"
onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesCurrentAbstract', window);" > < strong > Marketable securities, current < / strong > < / a > < / td > < td class =" text" > & # 160;
< span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href
=" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_MarketableSecuritiesCurrent', window);" > Marketable securities, current < / a > < / td > < td class =" text" > < span >
< / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href ="
javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FairValueByAssetClassAxis = us- gaap_CorporateDebtSecuritiesMember', window);" > Corporate Debt Securities [
Member] | Level 2 [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class
=" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesCurrentAbstract', window);"
> < strong > Marketable securities, current < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr
class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_MarketableSecuritiesCurrent', window);" > Marketable securities, current < / a > < / td > < td class =" nump" > 75, 504 < span > < / span > < / td > < td class =" text" > & # 160; < span > < /
span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_FairValueByAssetClassAxis = us- gaap_CorporateDebtSecuritiesMember', window);" > Corporate Debt Securities [Member] | Level 3 [Member] < / a > < / td > < td class =" text" > & #
160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a"
href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesCurrentAbstract', window);" > < strong > Marketable securities, current < / strong > < / a > < / td >
< td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign
=" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_MarketableSecuritiesCurrent', window);" > Marketable securities, current < / a > < / td >
< td class =" text" > < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0"
cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_FairValueCashEquivalentsAndMarketableSecurities" > < tr > < td class =" hide" > < a style =" color: white;"
href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick ="
Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of cash equivalents and marketable securities. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext
(this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > <
div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" >
orka_FairValueCashEquivalentsAndMarketableSecurities < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td
> orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td >
debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding
=" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_CashAndCashEquivalentsAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href ="
javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style ="
display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_CashAndCashEquivalentsAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td
> < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr
> < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0"
class =" authRefData" style =" display: none;" id =" defref_us- gaap_CashEquivalentsAtCarryingValue" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);"

onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of short- term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 944 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 7- 03 (a) (2)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (1)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_CashEquivalentsAtCarryingValue < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DebtSecuritiesCurrentAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DebtSecuritiesCurrentAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DebtSecuritiesNoncurrentAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DebtSecuritiesNoncurrentAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_MarketableSecuritiesCurrent" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of investment in marketable security, classified as current. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (2)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_MarketableSecuritiesCurrent < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_MarketableSecuritiesNoncurrent" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of investment in marketable security, classified as noncurrent. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (2)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_MarketableSecuritiesNoncurrent < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_FairValueByFairValueHierarchyLevelAxis = us- gaap_FairValueInputsLevel1Member" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_FairValueByFairValueHierarchyLevelAxis = us- gaap_FairValueInputsLevel1Member < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_FairValueByFairValueHierarchyLevelAxis = us- gaap_FairValueInputsLevel2Member" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_FairValueByFairValueHierarchyLevelAxis = us- gaap_FairValueInputsLevel2Member < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_FairValueByFairValueHierarchyLevelAxis = us- gaap_FairValueInputsLevel3Member" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_FairValueByFairValueHierarchyLevelAxis = us- gaap_FairValueInputsLevel3Member < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_FairValueByAssetClassAxis = us- gaap_MoneyMarketFundsMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_FairValueByAssetClassAxis = us- gaap_MoneyMarketFundsMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_FairValueByAssetClassAxis = us- gaap_USTreasurySecuritiesMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_FairValueByAssetClassAxis = us- gaap_USTreasurySecuritiesMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_FairValueByAssetClassAxis = us- gaap_USGovernmentAgenciesDebtSecuritiesMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_FairValueByAssetClassAxis = us- gaap_USGovernmentAgenciesDebtSecuritiesMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_FairValueByAssetClassAxis = us- gaap_CommercialPaperMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_FairValueByAssetClassAxis = us- gaap_CommercialPaperMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_FairValueByAssetClassAxis = us- gaap_CorporateDebtSecuritiesMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_FairValueByAssetClassAxis = us- gaap_CorporateDebtSecuritiesMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 83 < FILENAME > R47. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208162798768" > < tr > < th class =" tl" colspan =" 1" rowspan =" 1" > < div style =" width: 200px;" > < strong > Cash equivalents and Marketable Securities- Schedule of Cash Equivalents and Marketable Securities (Details) < br > $ in Thousands < / strong > < / div > < / th > < th class =" th" > < div > Dec. 31, 2024 < / div > < div > USD ($) < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window);" > Amortized Cost, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > $ 384, 358 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window);" > Gross Unrealized Gains, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 70 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window);" > Gross Unrealized Losses, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" num" > (111) < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleSecuritiesDebtSecurities', window);" > Fair Value, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 384, 317 < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FinancialInstrumentAxis = us- gaap_CashEquivalentsMember', window);" > Cash Equivalents [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window);" > Amortized Cost, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 52, 174 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window);" > Gross Unrealized Gains, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 4 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window);" > Gross Unrealized Losses, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" num" > (3) < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleSecuritiesDebtSecurities', window);" > Fair Value, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 52, 175 < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FinancialInstrumentAxis = us- gaap_CashEquivalentsMember', window);" > Cash Equivalents [Member] | Money market funds [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window);" > Amortized Cost, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 6, 350 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window);" > Gross Unrealized Gains, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window);" > Gross Unrealized Losses, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleSecuritiesDebtSecurities', window);" > Fair Value, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 6, 350 < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FinancialInstrumentAxis = us- gaap_CashEquivalentsMember', window);" > Cash Equivalents [Member] | U. S. treasury securities [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window);" > Amortized Cost, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 19, 656 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window);" > Gross Unrealized Gains, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 4 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window);" > Gross Unrealized Losses, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleSecuritiesDebtSecurities', window);" > Fair Value, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 19, 660 < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FinancialInstrumentAxis = us- gaap_CashEquivalentsMember', window);" > Cash Equivalents [Member] | U. S. government agency securities [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window);" > Amortized Cost, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 3, 988 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window);" > Gross Unrealized Gains, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window);" > Gross Unrealized Losses, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleSecuritiesDebtSecurities', window);" > Fair Value, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 3, 988 < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FinancialInstrumentAxis = us- gaap_CashEquivalentsMember', window);" > Cash Equivalents [Member] | Commercial papers [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window);" > Amortized Cost, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 22, 180 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window);" > Gross Unrealized Gains, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window);" > Gross Unrealized Losses, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" num" > (3) < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleSecuritiesDebtSecurities', window);" > Fair Value, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 22, 177 < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FinancialInstrumentAxis = orka_MarketableSecuritiesMember', window);" > Marketable Securities [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window);" > Amortized Cost, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 314, 060 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window);" > Gross Unrealized Gains, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 66 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window);" > Gross Unrealized Losses, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" num" > (53) < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleSecuritiesDebtSecurities', window);" > Fair Value, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 314, 073 < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FinancialInstrumentAxis = orka_MarketableSecuritiesMember', window);" > Marketable Securities [Member] | U. S. treasury securities [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window);" > Amortized Cost, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 190, 748 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window);" > Gross Unrealized Gains, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 55 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window);" > Gross Unrealized Losses, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" num" > (11) < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleSecuritiesDebtSecurities', window);" > Fair Value, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 190, 792 < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FinancialInstrumentAxis = orka_MarketableSecuritiesMember', window);" > Marketable Securities [Member] | U. S. government agency securities [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window);" > Amortized Cost, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 12, 967 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class

=" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window);" > Gross Unrealized Gains, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 1 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window);" > Gross Unrealized Losses, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" num" > (2) < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleSecuritiesDebtSecurities', window);" > Fair Value, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 12, 966 < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FinancialInstrumentAxis = orka_MarketableSecuritiesMember', window);" > Marketable Securities [Member] | Commercial papers [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window);" > Amortized Cost, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 34, 808 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window);" > Gross Unrealized Gains, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 3 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window);" > Gross Unrealized Losses, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleSecuritiesDebtSecurities', window);" > Fair Value, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 34, 811 < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FinancialInstrumentAxis = orka_MarketableSecuritiesMember', window);" > Marketable Securities [Member] | Corporate debt securities [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window);" > Amortized Cost, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 75, 537 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window);" > Gross Unrealized Gains, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 7 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window);" > Gross Unrealized Losses, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" num" > (40) < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleSecuritiesDebtSecurities', window);" > Fair Value, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 75, 504 < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FinancialInstrumentAxis = orka_MarketableSecuritiesLongTermMember', window);" > Marketable Securities, Long- Term [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window);" > Amortized Cost, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 18, 124 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window);" > Gross Unrealized Gains, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window);" > Gross Unrealized Losses, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" num" > (55) < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleSecuritiesDebtSecurities', window);" > Fair Value, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 18, 069 < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FinancialInstrumentAxis = orka_MarketableSecuritiesLongTermMember', window);" > Marketable Securities, Long- Term [Member] | U. S. treasury securities [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window);" > Amortized Cost, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 13, 639 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window);" > Gross Unrealized Gains, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window);" > Gross Unrealized Losses, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" num" > (32) < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleSecuritiesDebtSecurities', window);" > Fair Value, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 13, 607 < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FinancialInstrumentAxis = orka_MarketableSecuritiesLongTermMember', window);" > Marketable Securities, Long- Term [Member] | U. S. government agency securities [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window);" > Amortized Cost, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > 4, 485 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window);" > Gross Unrealized Gains, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window);" > Gross Unrealized Losses, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" num" > (23) < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleSecuritiesDebtSecurities', window);" > Fair Value, Cash Equivalents and Marketable Securities < / a > < / td > < td class =" nump" > $ 4, 462 < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale). < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 320 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale). < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 320 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale). < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 7- 03 (a) (1)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 320 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 2 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 326 < br >- SubTopic 30 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 1 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479130 / 326- 30- 45- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" >

us- gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AvailableForSaleSecuritiesDebtSecurities" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale). < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 820 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 103 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482078 / 820- 10- 55- 103 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 820 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 100 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482078 / 820- 10- 55- 100 < br > < br > Reference 3: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 820 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (bbb) (2) (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2 < br > < br > Reference 4: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 820 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (bbb) (2) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2 < br > < br > Reference 5: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 820 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (bbb) (1) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 820 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 320 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (aa) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 2 < br > < br > Reference 8: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 320 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 1 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481830 / 320- 10- 45- 1 < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 942 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 9- 03 (6)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478546 / 942- 210- S99- 1 < br > < br > Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 326 < br >- SubTopic 30 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 1 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479130 / 326- 30- 45- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AvailableForSaleSecuritiesDebtSecurities < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_CashAndCashEquivalentsAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_CashAndCashEquivalentsAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_FinancialInstrumentAxis = us- gaap_CashEquivalentsMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_FinancialInstrumentAxis = us- gaap_CashEquivalentsMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_FairValueByAssetClassAxis = us- gaap_MoneyMarketFundsMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_FairValueByAssetClassAxis = us- gaap_MoneyMarketFundsMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_FairValueByAssetClassAxis = us- gaap_USTreasurySecuritiesMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_FairValueByAssetClassAxis = us- gaap_USTreasurySecuritiesMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_FairValueByAssetClassAxis = us- gaap_USGovernmentAgenciesDebtSecuritiesMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_FairValueByAssetClassAxis = us- gaap_USGovernmentAgenciesDebtSecuritiesMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_FairValueByAssetClassAxis = us- gaap_CommercialPaperMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_FairValueByAssetClassAxis = us- gaap_CommercialPaperMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_FinancialInstrumentAxis = orka_MarketableSecuritiesMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_FinancialInstrumentAxis = orka_MarketableSecuritiesMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_FairValueByAssetClassAxis = us- gaap_CorporateDebtSecuritiesMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_FairValueByAssetClassAxis = us- gaap_CorporateDebtSecuritiesMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_FinancialInstrumentAxis = orka_MarketableSecuritiesLongTermMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_FinancialInstrumentAxis = orka_MarketableSecuritiesLongTermMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 84 < FILENAME > R48. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208162464368" > < tr > < th class =" tl" colspan =" 1" rowspan =" 1" > < div style =" width: 200px;" > < strong > Cash equivalents and Marketable Securities- Schedule of Available- for- Sale Securities in an Unrealized Loss Position (Details) < br > $ in Thousands < / strong > < / div > < / th > < th class =" th" > < div > Dec. 31, 2024 < / div > < div > USD ($) < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window);" > Less than 12 months, Fair Value < / a > < / td > < td class =" nump" > $ 130, 353 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window);" > Less than 12 months, Unrealized Losses < / a > < / td > < td class =" num" > (111) < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window);" > 12 months or longer, Fair Value < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window);" > 12 months or longer, Unrealized Losses < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href ="

javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window);" > Fair Value < / a > < / td > < td class =" nump" > 130, 353 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window);" > Unrealized Losses < / a > < / td > < td class =" num" > (111) < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAxis = us- gaap_CommercialPaperMember', window);" > Commercial papers [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window);" > Less than 12 months, Fair Value < / a > < / td > < td class =" nump" > 18, 199 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window);" > Less than 12 months, Unrealized Losses < / a > < / td > < td class =" num" > (3) < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window);" > 12 months or longer, Fair Value < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window);" > 12 months or longer, Unrealized Losses < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window);" > Fair Value < / a > < / td > < td class =" nump" > 18, 199 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window);" > Unrealized Losses < / a > < / td > < td class =" num" > (3) < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_MarketableSecuritiesAxis = orka_MarketableSecuritiesCurrentMember', window);" > Marketable securities, current [Member] | U. S. treasury securities [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window);" > Less than 12 months, Fair Value < / a > < / td > < td class =" nump" > 49, 904 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window);" > Less than 12 months, Unrealized Losses < / a > < / td > < td class =" num" > (11) < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window);" > 12 months or longer, Fair Value < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window);" > 12 months or longer, Unrealized Losses < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window);" > Fair Value < / a > < / td > < td class =" nump" > 49, 904 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window);" > Unrealized Losses < / a > < / td > < td class =" num" > (11) < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_MarketableSecuritiesAxis = orka_MarketableSecuritiesCurrentMember', window);" > Marketable securities, current [Member] | U. S. government agency securities [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window);" > Less than 12 months, Fair Value < / a > < / td > < td class =" nump" > 4, 713 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window);" > Less than 12 months, Unrealized Losses < / a > < / td > < td class =" num" > (2) < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window);" > 12 months or longer, Fair Value < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window);" > 12 months or longer, Unrealized Losses < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window);" > Fair Value < / a > < / td > < td class =" nump" > 4, 713 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window);" > Unrealized Losses < / a > < / td > < td class =" num" > (2) < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_MarketableSecuritiesAxis = orka_MarketableSecuritiesCurrentMember', window);" > Marketable securities, current [Member] | Corporate debt securities [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window);" > Less than 12 months, Fair Value < / a > < / td > < td class =" nump" > 39, 468 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window);" > Less than 12 months, Unrealized Losses < / a > < / td > < td class =" num" > (40) < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window);" > 12 months or longer, Fair Value < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window);" > 12 months or longer, Unrealized Losses < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window);" > Fair Value < / a > < / td > < td class =" nump" > 39, 468 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window);" > Unrealized Losses < / a > < / td > < td class =" num" > (40) < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_MarketableSecuritiesAxis = orka_MarketableSecuritiesNoncurrentMember', window);" > Marketable securities, long- term [Member] | U. S. treasury securities [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window);" > Less than 12 months, Fair Value < / a > < / td > < td class =" nump" > 13, 607 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window);" > Less than 12 months, Unrealized Losses < / a > < / td > < td class =" num" > (32) < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window);" > 12 months or longer, Fair Value < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window);" > 12 months or longer, Unrealized Losses < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window);" > Fair Value < / a > < / td > < td class =" nump" > 13, 607 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window);" > Unrealized Losses < / a > < / td > < td class =" num" > (32) < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_MarketableSecuritiesAxis = orka_MarketableSecuritiesNoncurrentMember', window);" > Marketable securities, long- term [Member] | U. S. government agency securities [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CashAndCashEquivalentsAbstract', window);" > < strong > Cash equivalents < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window);" > Less than 12 months, Fair Value < / a > < / td > < td class =" nump" > 4, 462 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window);" > Less than 12 months, Unrealized Losses < / a > < / td > < td class =" num" > (23) < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window);" > 12 months or longer, Fair Value < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window);" > 12 months or longer, Unrealized Losses < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window);" > Fair Value < / a > < / td > < td class =" nump" > 4, 462 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window);" > Unrealized Losses < / a > < / td > < td class =" num" > $ (23) < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_CashAndCashEquivalentsAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr >

< tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_CashAndCashEquivalentsAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 326 < br >- SubTopic 30 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 8 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479081 / 326- 30- 55- 8 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / otherTransitionRef < br >- Topic 320 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 7 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 7 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 326 < br >- SubTopic 30 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 5 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479106 / 326- 30- 50- 5 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / otherTransitionRef < br >- Topic 320 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 7 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 7 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 326 < br >- SubTopic 30 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 5 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479106 / 326- 30- 50- 5 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 326 < br >- SubTopic 30 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 8 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479081 / 326- 30- 55- 8 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / otherTransitionRef < br >- Topic 320 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 7 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 7 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 326 < br >- SubTopic 30 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 5 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479106 / 326- 30- 50- 5 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / otherTransitionRef < br >- Topic 320 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 7 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 7 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 326 < br >- SubTopic 30 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 5 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479106 / 326- 30- 50- 5 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale), in unrealized loss position without allowance for credit loss. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 326 < br >- SubTopic 30 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 8 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479081 / 326- 30- 55- 8 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / otherTransitionRef < br >- Topic 320 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Subparagraph (a) (1) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 6 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 326 < br >- SubTopic 30 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 4 < br >- Subparagraph (a) (1) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479106 / 326- 30- 50- 4 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / otherTransitionRef < br >- Topic 320 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Subparagraph (a) (2) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 6 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 326 < br >- SubTopic 30 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 4 < br >- Subparagraph (a) (2) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479106 / 326- 30- 50- 4 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_CashAndCashEquivalentsAxis = us- gaap_CommercialPaperMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_CashAndCashEquivalentsAxis = us- gaap_CommercialPaperMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_MarketableSecuritiesAxis = orka_MarketableSecuritiesCurrentMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_MarketableSecuritiesAxis = orka_MarketableSecuritiesCurrentMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style ="

display: none;" id =" defref_us- gaap_FinancialInstrumentAxis = us- gaap_USTreasurySecuritiesMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_FinancialInstrumentAxis = us- gaap_USTreasurySecuritiesMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_FinancialInstrumentAxis = orka_USGovernmentAgencySecuritiesMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_FinancialInstrumentAxis = orka_USGovernmentAgencySecuritiesMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_FinancialInstrumentAxis = us- gaap_CorporateDebtSecuritiesMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_FinancialInstrumentAxis = us- gaap_CorporateDebtSecuritiesMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_MarketableSecuritiesAxis = orka_MarketableSecuritiesNoncurrentMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_MarketableSecuritiesAxis = orka_MarketableSecuritiesNoncurrentMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 85 < FILENAME > R49. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208162280704" > < tr > < th class =" tl" colspan =" 1" rowspan =" 1" > < div style =" width: 200px;" > < strong > Cash equivalents and Marketable Securities- Schedule of Marketable Securities at Estimated Fair Value (Details)- USD ($) < br > $ in Thousands < / strong > < / div > < / th > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < th class =" th" > < div > Feb. 06, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window);" > < strong > Schedule of Marketable Securities at Estimated Fair Value [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_MarketableSecuritiesCurrent', window);" > Due in one year or less < / a > < / td > < td class =" nump" > $ 314, 073 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_MarketableSecuritiesNoncurrent', window);" > Due in 1- 2 years < / a > < / td > < td class =" nump" > 18, 069 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" rou" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_MarketableSecurities', window);" > Total < / a > < / td > < td class =" nump" > $ 332, 142 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_MarketableSecurities" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of investment in marketable security. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 942 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 9- 03 (4)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478546 / 942- 210- S99- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (2)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_MarketableSecurities < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_MarketableSecuritiesCurrent" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of investment in marketable security, classified as current. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (2)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_MarketableSecuritiesCurrent < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_MarketableSecuritiesNoncurrent" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of investment in marketable security, classified as noncurrent. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (2)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_MarketableSecuritiesNoncurrent < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 86 < FILENAME > R50. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208277256880" > < tr > < th class =" tl" colspan =" 1" rowspan =" 1" > < div style =" width: 200px;" > < strong > Accrued Expenses and Other Current Liabilities- Schedule of Accrued Expenses and Other Current Liabilities (Details)- USD ($) < br > $ in Thousands < / strong > < / div > < / th > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < th class =" th" > < div > Feb. 06, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window);" > < strong > Schedule of Accrued Expenses and Other Current Liabilities [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AccruedEmployeeBenefitsCurrent', window);" > Accrued employee compensation and benefits < / a > < / td > < td class =" nump" > $ 2, 041 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AccruedProfessionalFeesCurrent', window);" > Accrued professional and consulting < / a > < / td > < td class =" nump" > 221 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_AccruedResearchAndDevelopment', window);" > Accrued research and development < / a > < / td > < td class =" nump" > 1, 084 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" reu" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AccruedLiabilitiesAndOtherLiabilities', window);" > Total < / a > < / td > < td class =" nump" > $ 3, 346 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_AccruedResearchAndDevelopment" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Accrued research and development. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_AccruedResearchAndDevelopment < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div >

< / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AccruedEmployeeBenefitsCurrent" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (20)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AccruedEmployeeBenefitsCurrent < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AccruedLiabilitiesAndOtherLiabilities" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AccruedLiabilitiesAndOtherLiabilities < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AccruedProfessionalFeesCurrent" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (20)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AccruedProfessionalFeesCurrent < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 87 < FILENAME > R51. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208161308448" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Note Payable with Related Party (Details)- Convertible Note [Member]- USD ($) < br > $ in Millions < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 1 Months Ended < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Mar. 31, 2024 < / div > < / th > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtInstrumentLineItems', window);" > < strong > Note Payable with Related Party [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_InterestExpenseDebt', window);" > Interest expense < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 1. 5 < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_TypeOfArrangementAxis = orka_PreMergerOrukaMember', window);" > Pre- Merger Oruka [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtInstrumentLineItems', window);" > < strong > Note Payable with Related Party [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtInstrumentFaceAmount', window);" > Initial principal amount < / a > < / td > < td class =" nump" > $ 25. 0 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtInstrumentInterestRateDuringPeriod', window);" > Interest rate, percentage < / a > < / td > < td class =" nump" > 12. 00 % < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtInstrumentMaturityDate', window);" > Maturity date < / a > < / td > < td class =" text" > Dec. 31, 2025 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_PaymentsOfDebtIssuanceCosts', window);" > Debt issuance costs < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 0. 1 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtInstrumentIncreaseAccruedInterest', window);" > Unpaid accrued interest < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 1. 5 < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_TypeOfArrangementAxis = orka_PreMergerOrukaMember', window);" > Pre- Merger Oruka [Member] | Fairmount Healthcare Fund II, L. P. [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtInstrumentLineItems', window);" > < strong > Note Payable with Related Party [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtInstrumentFaceAmount', window);" > Initial principal amount < / a > < / td > < td class =" nump" > $ 25. 0 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ProceedsFromConvertibleDebt', window);" > Aggregate proceeds < / a > < / td > < td class =" nump" > $ 25. 0 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StatementClassOfStockAxis = us- gaap_CommonStockMember', window);" > Common Stock [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DebtInstrumentLineItems', window);" > < strong > Note Payable with Related Party [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ConversionOfStockSharesConverted1', window);" > Converted shares (in Shares) < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 2, 722, 207 < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ConversionOfStockSharesConverted1" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period." Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 230 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 4 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50- 4 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 230 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 3 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50- 3 < br > < br > Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 230 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 5 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50- 5 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ConversionOfStockSharesConverted1 < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DebtInstrumentFaceAmount" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Face (par) amount of debt instrument at time of issuance. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 835 < br >- SubTopic 30 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 8 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482949 / 835- 30- 55- 8 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1B < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1B < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 69B < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481568 / 470- 20- 55- 69B < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 69C < br >- Publisher

FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481568 / 470- 20- 55- 69C < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 835 < br >- SubTopic 30 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482900 / 835- 30- 50- 1 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 835 < br >- SubTopic 30 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482925 / 835- 30- 45- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DebtInstrumentFaceAmount < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DebtInstrumentIncreaseAccruedInterest" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Increase for accrued, but unpaid interest on the debt instrument for the period. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 235 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 4- 08 (f)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_DebtInstrumentIncreaseAccruedInterest < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DebtInstrumentInterestRateDuringPeriod" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The average effective interest rate during the reporting period. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (22) (a) (1)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1F < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1F < br > < br > Reference 3: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 835 < br >- SubTopic 30 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482925 / 835- 30- 45- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_DebtInstrumentInterestRateDuringPeriod < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us-gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: percentItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DebtInstrumentLineItems" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 835 < br >- SubTopic 30 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 8 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482949 / 835- 30- 55- 8 < br > < br > Reference 2: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 235 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 4- 08 (f)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 235 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 12- 04 (a)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 3 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1B < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1B < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 69B < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481568 / 470- 20- 55- 69B < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 69C < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481568 / 470- 20- 55- 69C < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 69E < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481568 / 470- 20- 55- 69E < br > < br > Reference 8: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 69F < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481568 / 470- 20- 55- 69F < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1B < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1B < br > < br > Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1B < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1B < br > < br > Reference 11: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1B < br >- Subparagraph (d) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1B < br > < br > Reference 12: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1B < br >- Subparagraph (e) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1B < br > < br > Reference 13: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1B < br >- Subparagraph (f) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1B < br > < br > Reference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1B < br >- Subparagraph (h) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1B < br > < br > Reference 15: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1D < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1D < br > < br > Reference 16: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1D < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1D < br > < br > Reference 17: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1D < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1D < br > < br > Reference 18: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1E < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1E < br > < br > Reference 19: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1E < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1E < br > < br > Reference 20: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1E < br >- Subparagraph (d) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1E < br > < br > Reference 21: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1F < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1F < br > < br > Reference 22: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1F < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1F < br > < br > Reference 23: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1F < br >- Subparagraph (b) (1) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1F < br > < br > Reference 24: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1F < br >- Subparagraph (b) (2) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1F < br > < br > Reference 25: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1I < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1I < br > < br > Reference 26: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 835 < br >- SubTopic 30 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482925 / 835- 30- 45- 2 < br > < br > Reference 27: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 835 < br >- SubTopic 30 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482900 / 835- 30- 50- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DebtInstrumentLineItems < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DebtInstrumentMaturityDate" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Date when the debt instrument is scheduled to be fully repaid, in YYYY- MM- DD format. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 820 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (bbb) (2) (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2 < br > < br > Reference 2: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 820 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (bbb) (2) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (22) (a) (2)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1B < br >- Subparagraph (d) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1B < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DebtInstrumentMaturityDate < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: dateItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_InterestExpenseDebt" > < tr > < td class =" hide" > < a style =" color:

white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of the cost of borrowed funds accounted for as interest expense for debt. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SX 210. 5- 03 (8)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 69E < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481568 / 470- 20- 55- 69E < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 69F < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481568 / 470- 20- 55- 69F < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1F < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1F < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 6 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_InterestExpenseDebt < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_PaymentsOfDebtIssuanceCosts" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long- term debt. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 230 < br >- SubTopic 10 < br >- Section 45 < br >- Paragraph 15 < br >- Subparagraph (e) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 15 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_PaymentsOfDebtIssuanceCosts < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ProceedsFromConvertibleDebt" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The cash inflow from the issuance of a long- term debt instrument which can be exchanged for a specified amount of another security, typically the entity' s common stock, at the option of the issuer or the holder. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 230 < br >- SubTopic 10 < br >- Section 45 < br >- Paragraph 14 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 14 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ProceedsFromConvertibleDebt < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DebtInstrumentAxis = orka_ConvertibleNoteMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DebtInstrumentAxis = orka_ConvertibleNoteMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_TypeOfArrangementAxis = orka_PreMergerOrukaMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_TypeOfArrangementAxis = orka_PreMergerOrukaMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_RelatedPartyTransactionAxis = orka_FairmountHealthcareFundIILPMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_RelatedPartyTransactionAxis = orka_FairmountHealthcareFundIILPMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StatementClassOfStockAxis = us- gaap_CommonStockMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StatementClassOfStockAxis = us- gaap_CommonStockMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 88 < FILENAME > R52. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208161853232" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Convertible Preferred Stock and Stockholders & # 8217; Equity (Details)- USD ($) < br > $ / shares in Units, $ in Thousands < / strong > < / div > < / th > < th class =" th" colspan =" 3" > 1 Months Ended < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < th class =" th" colspan =" 1" > < / th > < th class =" th" colspan =" 1" > < / th > < / tr > < tr > < th class =" th" > < div > Sep. 30, 2024 < / div > < / th > < th class =" th" > < div > Aug. 31, 2024 < / div > < / th > < th class =" th" > < div > Mar. 31, 2024 < / div > < / th > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < th class =" th" > < div > Nov. 30, 2024 < / div > < / th > < th class =" th" > < div > Feb. 06, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfStockLineItems', window);" > < strong > Convertible Preferred Stock and Stockholders & # 8217; Equity [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window);" > Gross proceeds (in Dollars) < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 2, 931 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CommonStockSharesAuthorized', window);" > Common stock, shares authorized < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 545, 000, 000 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 65, 000, 000 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CommonStockSharesIssued', window);" > Common stock, shares issued < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 37, 440, 510 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 3, 197, 975 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CommonStockSharesOutstanding', window);" > Common stock, shares outstanding < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 37, 440, 510 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 3, 197, 975 < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfWarrantOrRightAxis = orka_PreFundedWarrantsMember', window);" > Pre- Funded Warrants [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfStockLineItems', window);" > < strong > Convertible Preferred Stock and Stockholders & # 8217; Equity [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window);" > Number of shares issued < / a > < / td > < td class =" nump" > 680, 000 < span > < / span > < / td > < td class =" nump" > 5, 522, 207 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SharesIssuedPricePerShare', window);" > Purchase price per share (in Dollars per share) < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 9. 7 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfWarrantOrRightOutstanding', window);" > Warrants outstanding < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 5, 522, 207 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span >

< / td > < td class =" nump" > 6, 202, 207 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_SaleOfStockPricePerShare', window);" > Purchase price per share (in Dollars per share) < / a > < / td > < td class =" nump" > $ 22. 999 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_ClassOfWarrantOrRightExpirationDate', window);" > Expiration date < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_ClassOfWarrantOrRightWarrantsExercised', window);" > Warrants exercised < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfWarrantOrRightAxis = orka_EmployeeWarrantsMember', window);" > Employee Warrants [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfStockLineItems', window);" > < strong > Convertible Preferred Stock and Stockholders & # 8217; Equity [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfWarrantOrRightOutstanding', window);" > Warrants outstanding < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 3, 054, 358 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window);" > Exercise price per warrant (in Dollars per share) < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 7. 8 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window);" > Employee warrants issued < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 3, 054, 358 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window);" > Vesting period < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > 4 years < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window);" > Warrants exercised < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfWarrantOrRightAxis = orka_ParukaWarrantMember', window);" > Paruka Warrant [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_ClassOfStockLineItems', window);" > < strong > Convertible Preferred Stock and Stockholders & # 8217; Equity [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window);" > Exercise price per warrant (in Dollars per share) < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 19. 39 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_WarrantsToPurchaseCommonStock', window);" > Warrant purchase < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 596, 930 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window);" > Term of warrant < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > 10 years < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember', window);" > Common Stock [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfStockLineItems', window);" > < strong > Convertible Preferred Stock and Stockholders & # 8217; Equity [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_ClassOfWarrantsExercisable', window);" > Warrants exercisable < / a > < / td > < td class =" nump" > 680, 000 < span > < / span > < / td > < td class =" nump" > 5, 522, 207 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_CommonStockSharesAuthorized', window);" > Common stock, shares authorized < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 545, 000, 000 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CommonStockSharesIssued', window);" > Common stock, shares issued < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 37, 440, 510 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CommonStockSharesOutstanding', window);" > Common stock, shares outstanding < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 37, 440, 510 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember', window);" > Common Stock [Member] | Pre- Funded Warrants [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfStockLineItems', window);" > < strong > Convertible Preferred Stock and Stockholders & # 8217; Equity [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window);" > Exercise price per warrant (in Dollars per share) < / a > < / td > < td class =" nump" > $ 0. 001 < span > < / span > < / td > < td class =" nump" > $ 0. 01 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AwardTypeAxis = us- gaap_RestrictedStockMember', window);" > Restricted Stock [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfStockLineItems', window);" > < strong > Convertible Preferred Stock and Stockholders & # 8217; Equity [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SharesIssuedPricePerShare', window);" > Purchase price per share (in Dollars per share) < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 0. 0001 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CommonStockSharesIssued', window);" > Common stock, shares issued < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 2, 207, 553 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CommonStockSharesOutstanding', window);" > Common stock, shares outstanding < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 2, 207, 553 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'

```
defref_us- gaap_StatementClassOfStockAxis = us- gaap_SeriesAPreferredStockMember', window);" > Series A Preferred Stock [ Member ] < / a > < / td > < td class =" text" > & # 160; < span >
< / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td
class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign ="
top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfStockLineItems', window);" > < strong > Convertible Preferred Stock and
Stockholders & # 8217; Equity [ Line Items ] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class
=" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; <
span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_us- gaap_SaleOfStockPricePerShare', window);" > Purchase price per share (in Dollars per share) < / a > < / td > < td class =" nump" > $ 23, 000 < span > < / span > < / td > < td class ="
text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span
> < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href ="
javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_PreferredStockConvertibleSharesIssuable', window);" > Converted shares < / a > < / td > < td class =" text" > & # 160; <
span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td >
< td class =" nump" > 2, 439, 000 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;"
valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_PreferredStockSharesOutstanding', window);" > Preferred stock, shares
outstanding < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td
> < td class =" text" > < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td
class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window);" > Converted shares of common stock < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class
=" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 1, 000 <
span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href
=" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StatementClassOfStockAxis = us- gaap_SeriesAPreferredStockMember', window);" > Series A Preferred Stock [
Member ] | Fairmount [ Member ] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; <
span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td >
< / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_ClassOfStockLineItems', window);" > < strong > Convertible Preferred Stock and Stockholders & # 8217; Equity [ Line Items ] < / strong > < / a > < / td > < td class =" text" > & # 160; <
span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td >
< td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign
=" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window);" > Gross proceeds (in
Dollars) < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 3, 000 < span > < / span > < / td >
< td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh"
> < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StatementClassOfStockAxis =
us- gaap_SeriesBPreferredStockMember', window);" > Series B Preferred Stock [ Member ] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160;
< span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td
> < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);"
onclick =" Show. showAR (this,' defref_us- gaap_ClassOfStockLineItems', window);" > < strong > Convertible Preferred Stock and Stockholders & # 8217; Equity [ Line Items ] < / strong > < / a
> < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class ="
text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class
=" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_PreferredStockConvertibleSharesIssuable',
window);" > Converted shares < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 137, 138 < span > < / span > < / td > < td class =" text" > & # 160; <
span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td >
< / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_orka_CommonStockConversionRatio', window);" > Conversion ratio < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < /
span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > 83. 3332: 1 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td
class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);"
onclick =" Show. showAR (this,' defref_us- gaap_SubsidiarySaleOfStockAxis = orka_PreMergerOrukaMember', window);" > Pre- Merger Oruka [ Member ] | Common Stock [ Member ] < / a >
< / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class ="
text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class
=" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfStockLineItems', window);" > <
strong > Convertible Preferred Stock and Stockholders & # 8217; Equity [ Line Items ] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > &
# 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span
> < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript:
void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window);" > Number of shares issued < / a > < / td > < td class =" text" > & # 160;
< span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 39, 873, 706 < span > < / span >
< / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom:
0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SubsidiarySaleOfStockAxis = orka_PreMergerOrukaMember', window);" >
Pre- Merger Oruka [ Member ] | Series A Preferred Stock [ Member ] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < /
td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text"
> & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show.
showAR (this,' defref_us- gaap_ClassOfStockLineItems', window);" > < strong > Convertible Preferred Stock and Stockholders & # 8217; Equity [ Line Items ] < / strong > < / a > < / td > < td
class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > &
# 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style
=" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_PaymentsOfStockIssuanceCosts', window);" > Issuance
costs (in Dollars) < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 100 < span > < / span > <
/ td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class
=" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_SubsidiarySaleOfStockAxis = orka_PreMergerOrukaMember', window);" > Pre- Merger Oruka [ Member ] | Series A Preferred Stock [ Member ] | Fairmount [ Member ] < / a > < / td > <
td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & #
160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style
=" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfStockLineItems', window);" > < strong >
Convertible Preferred Stock and Stockholders & # 8217; Equity [ Line Items ] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; <
span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td >
< td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);"
onclick =" Show. showAR (this,' defref_us- gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window);" > Number of shares issued < / a > < / td > < td class =" text" > & # 160; < span >
< / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 20, 000, 000 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > <
td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign
=" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SharesIssuedPricePerShare', window);" > Purchase price per share (in Dollars per share)
< / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 0. 15 < span > < / span > < / td > < td class
=" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td
class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SubsidiarySaleOfStockAxis =
orka_PIPEFinancingMember', window);" > PIPE Financing [ Member ] | Series A Preferred Stock [ Member ] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class
=" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; <
span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href
=" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfStockLineItems', window);" > < strong > Convertible Preferred Stock and Stockholders & # 8217; Equity [ Line
Items ] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span
> < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr
class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window);" > Number of shares issued < / a > < / td > < td class =" nump" > 2, 439 < span > < / span > < / td > < td class =" text" > & #
160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span >
< / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void
(0);" onclick =" Show. showAR (this,' defref_us- gaap_PreferredStockConvertibleSharesIssuable', window);" > Converted shares < / a > < / td > < td class =" text" > & # 160; < span > < / span >
< / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class ="
nump" > 2, 439 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0"
cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_ClassOfWarrantOrRightExpirationDate" > < tr > < td class =" hide" > < a style =" color: white;" href ="
javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" >- Definition < / a > < div > < p > The class of warrant or right expiration date. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >
References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style
=" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" >
orka_ClassOfWarrantOrRightExpirationDate < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < /
td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: dateItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > <
tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing ="
0" class =" authRefData" style =" display: none;" id =" defref_orka_ClassOfWarrantOrRightWarrantsExercised" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript:
```

```
void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext
(this);" >- Definition < / a > < div > < p > The class of Warrant or Right warrants exercised. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < /
a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display:
none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" >
orka_ClassOfWarrantOrRightWarrantsExercised < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_
< / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr
> < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing
=" 0" class =" authRefData" style =" display: none;" id =" defref_orka_ClassOfWarrantsExercisable" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);"
onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >-
Definition < / a > < div > < p > Represent the number of warrants exercisable. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style
=" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table
border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_ClassOfWarrantsExercisable < / td > < / tr > <
tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td
> < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td >
duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id ="
defref_orka_CommonStockConversionRatio" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr >
< td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Percentage of common stock
conversion ratio. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < /
div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td
> < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_CommonStockConversionRatio < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space:
nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr >
< td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < /
td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_WarrantsToPurchaseCommonStock" > < tr > <
td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a
href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The shares issued of warrants to purchase common stock. < / p > < / div > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);"
onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td >
< td style =" white- space: nowrap;" > orka_WarrantsToPurchaseCommonStock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: <
/ strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong >
< / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0"
cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ClassOfStockLineItems" > < tr > < td class =" hide" > < a style =" color: white;" href
=" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" >- Definition < / a > < div > < p > Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain
members defined in one or many axes to the table. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p >
Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 13 <
br >- Subparagraph (d) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role /
recommendedDisclosureRef < br >- Topic 272 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 3 < br >- Publisher FASB < br >- URI
https: / / asc. fasb. org / 1943274 / 2147483014 / 272- 10- 45- 3 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 272 < br >- SubTopic 10 < br >- Name
Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482987 / 272- 10- 50- 1 < br > < br >
Reference 4: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 235 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >-
Paragraph 1 < br >- Subparagraph (SX 210. 4- 08 (d)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1 < br > < br > Reference 5: http: / / www.
xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 13 < br >- Subparagraph (a) <
br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 <
br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 13 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org /
1943274 / 2147481112 / 505- 10- 50- 13 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards
Codification < br >- Section 50 < br >- Paragraph 13 < br >- Subparagraph (e) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13 < br > < br >
Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 13 <
br >- Subparagraph (h) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13 < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role /
disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 14 < br >- Subparagraph (b) < br >- Publisher FASB <
br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 14 < br > < br > Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br
>- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 18 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 /
505- 10- 50- 18 < br > < br > Reference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >-
Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (27) (b)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br >
Reference 12: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1
< br >- Subparagraph (SX 210. 5- 02 (28)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 13: http: / / www. xbrl. org /
2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI
https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 2 < br > < br > Reference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name
Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (29)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 /
2147480566 / 210- 10- S99- 1 < br > < br > Reference 15: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 10 < br >- Name Accounting Standards
Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 03 (i) (2)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479886 / 946- 10- S99-
3 < br > < br > Reference 16: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br
>- Paragraph 3 < br >- Subparagraph (SX 210. 6- 03 (i) (1)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479886 / 946- 10- S99- 3 < br > < br > Reference 17: http: / /
www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph
(SX 210. 6- 03 (i) (2) (i)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479886 / 946- 10- S99- 3 < br > < br > Reference 18: http: / / www. xbrl. org / 2003 / role /
disclosureRef < br >- Topic 946 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 03 (i) (2) (ii)) < br
>- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479886 / 946- 10- S99- 3 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >
Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" >
us- gaap_ClassOfStockLineItems < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr
> < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td
> < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class
=" authRefData" style =" display: none;" id =" defref_us- gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" > < tr > < td class =" hide" > < a style =" color: white;" href ="
javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" >- Definition < / a > < div > < p > Exercise price per share or per unit of warrants or rights outstanding. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name
Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 3 < br > < / p > < / div >
< a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > <
strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 < / td > < / tr > < tr > < td style =" padding-
right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types:
perShareItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td
> < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR
();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p >
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500, 000 warrants may be converted into 1, 000, 000 shares. < / p > < / div > < a
href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br
>- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 /
2147481112 / 505- 10- 50- 3 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0"
cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < /
strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < /
strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border
=" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ClassOfWarrantOrRightOutstanding" > < tr > < td class =" hide" > < a style ="
color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);"
onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Number of warrants or rights outstanding. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext
(this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > <
div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_ClassOfWarrantOrRightOutstanding < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < /
td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr >
< tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing ="
0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_CommonStockSharesAuthorized" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);"
onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >-
Definition < / a > < div > < p > The maximum number of common shares permitted to be issued by an entity' s charter and bylaws. < / p > < / div > < a href =" javascript: void (0);" onclick ="
```

Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >-
Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (29)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 /
2147480566 / 210- 10- S99- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 210 < br >- Name Accounting Standards
Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 04 (16) (a)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210-
S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0"
cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_CommonStockSharesAuthorized < / td > < / tr > < tr > < td style ="
padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td >
xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < /
td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_CommonStockSharesIssued" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > <
div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Total number of common shares of an entity
that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm' s
shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. < / p > < / div > < a href
=" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >-
Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (29)) < br >- Publisher FASB < br
>- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style ="
display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_CommonStockSharesIssued < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr
> < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td
> < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class ="
authRefData" style =" display: none;" id =" defref_us- gaap_CommonStockSharesOutstanding" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick ="
Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a >
< div > < p > Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br
>- Section 50 < br >- Paragraph 2 < br >- SubTopic 10 < br >- Topic 505 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 2 < br > < br > Reference
2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >-
Subparagraph (SX 210. 5- 02 (29)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 /
role / disclosureRef < br >- Topic 946 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SX 210. 6- 05 (4)) <
br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 2 < br > < br > Reference 4: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >-
Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 09 (4) (b)) < br >- Publisher FASB <
br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3 < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 210 <
br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 04 (16) (a)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org /
1943274 / 2147479170 / 946- 210- S99- 1 < br > < br > Reference 6: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting
Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 09 (7)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946-
220- S99- 3 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0"
cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_CommonStockSharesOutstanding < / td > < / tr > < tr > < td style ="
padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td >
xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < /
td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_ConvertiblePreferredStockSharesIssuedUponConversion" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < /
td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Number of shares
issued for each share of convertible preferred stock that is converted. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style ="
display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >-
Subparagraph (SX 210. 5- 02 (27)) < br >- SubTopic 10 < br >- Topic 210 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br >
Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 <
br >- Subparagraph (SX 210. 5- 02 (28)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 3: http: / / fasb. org / us- gaap /
role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 505 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 3 < br >- Publisher FASB < br >- URI https: / /
asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 3 < br > < br > Reference 4: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting
Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 6 < br > <
br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph
16 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 16 < br > < / p > < / div > < a href =" javascript: void (0);" onclick ="
Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style
=" white- space: nowrap;" > us- gaap_ConvertiblePreferredStockSharesIssuedUponConversion < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong >
Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong >
Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < /
table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_PaymentsOfStockIssuanceCosts" > < tr > < td class ="
hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The cash outflow for cost incurred directly with the issuance of an equity security. < / p > < / div > < a
href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >-
Name Accounting Standards Codification < br >- Topic 230 < br >- SubTopic 10 < br >- Section 45 < br >- Paragraph 15 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 /
2147482740 / 230- 10- 45- 15 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0"
cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_PaymentsOfStockIssuanceCosts < / td > < / tr > < tr > < td
style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > <
td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td >
duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id ="
defref_us- gaap_PreferredStockConvertibleSharesIssuable" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td >
< / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Number of common
shares issuable upon conversion of preferred stock. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p >
Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 13 <
br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13 < br > < / p > < / div > < a href =" javascript: void (0);" onclick ="
Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style
=" white- space: nowrap;" > us- gaap_PreferredStockConvertibleSharesIssuable < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: <
/ strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < /
strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border
=" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_PreferredStockSharesOutstanding" > < tr > < td class =" hide" > < a style ="
color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);"
onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the
issuer) held by stockholders. Does not include preferred shares that have been repurchased. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < /
a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification <
br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (28)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br >
Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 2
< br >- Subparagraph (SX 210. 6- 05 (4)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 2 < br > < br > Reference 3: http: / / www. xbrl. org /
2009 / role / commonPracticeRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210.
6- 09 (4) (b)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br
>- Topic 946 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 04 (16) (a)) < br >- Publisher FASB
< br >- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1 < br > < br > Reference 5: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 946 < br >-
SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 09 (7)) < br >- Publisher FASB < br >- URI https: / /
asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" >
< table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_PreferredStockSharesOutstanding
< / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data
Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < /
strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style ="
display: none;" id =" defref_us- gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick ="
Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a >
< div > < p > The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity' s common stock. < / p > < / div > < a
href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >-
Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 14 < br >- Subparagraph (a) < br >- SubTopic 10 < br >- Topic 230 < br >- Publisher FASB < br >- URI https: / /
asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 14 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" >
< table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_ProceedsFromIssuanceOfConvertiblePreferredStock < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td
> us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td >

debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_SaleOfStockNumberOfSharesIssuedInTransaction" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_SaleOfStockNumberOfSharesIssuedInTransaction < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_SaleOfStockPricePerShare" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_SaleOfStockPricePerShare < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: perShareItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Period over which grantee' s right to exercise award under share- based payment arrangement is no longer contingent on satisfaction of service or performance condition, in' PnYnMnDTnHnMnS' format, for example,' P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (a) (1) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: durationItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Number of non- option equity instruments exercised by participants. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (iv) (02) < br >- SubTopic 10 < br >- Topic 718 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10-50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Period from grant date that an equity- based award expires, in' PnYnMnDTnHnMnS' format, for example,' P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (a) (2) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: durationItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_SharesIssuedPricePerShare" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Per share or per unit amount of equity securities issued. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_SharesIssuedPricePerShare < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us-gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: perShareItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ClassOfWarrantOrRightAxis = orka_PreFundedWarrantsMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ClassOfWarrantOrRightAxis = orka_PreFundedWarrantsMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ClassOfWarrantOrRightAxis = orka_EmployeeWarrantsMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ClassOfWarrantOrRightAxis = orka_EmployeeWarrantsMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ClassOfWarrantOrRightAxis = orka_ParukaWarrantMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ClassOfWarrantOrRightAxis = orka_ParukaWarrantMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StatementEquityComponentsAxis = us- gaap_CommonStockMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StatementEquityComponentsAxis = us- gaap_CommonStockMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AwardTypeAxis = us- gaap_RestrictedStockMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AwardTypeAxis = us- gaap_RestrictedStockMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StatementClassOfStockAxis = us- gaap_SeriesAPreferredStockMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StatementClassOfStockAxis = us- gaap_SeriesAPreferredStockMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_srt_CounterpartyNameAxis = orka_FairmountMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > srt_CounterpartyNameAxis = orka_FairmountMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0"

```
class =" authRefData" style =" display: none;" id =" defref_us- gaap_StatementClassOfStockAxis = us- gaap_SeriesBPreferredStockMember" > < tr > < td class =" hide" > < a style =" color:
white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick
=" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space:
nowrap;" > us- gaap_StatementClassOfStockAxis = us- gaap_SeriesBPreferredStockMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong >
Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < /
td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding ="
0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_SubsidiarySaleOfStockAxis = orka_PreMergerOrukaMember" > < tr > < td class =" hide" > < a style
=" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void
(0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style ="
white- space: nowrap;" > us- gaap_SubsidiarySaleOfStockAxis = orka_PreMergerOrukaMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong >
Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < /
td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding ="
0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_SubsidiarySaleOfStockAxis = orka_PIPEFinancingMember" > < tr > < td class =" hide" > < a style ="
color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);"
onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white-
space: nowrap;" > us- gaap_SubsidiarySaleOfStockAxis = orka_PIPEFinancingMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace
Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > <
/ td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < /
DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 89 < FILENAME > R53. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title >
< link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type ="
text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > <
/ head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208160276224" > < tr > < th class =" tl" colspan ="
1" rowspan =" 1" > < div style =" width: 200px;" > < strong > Convertible Preferred Stock and Stockholders & # 8217; Equity- Schedule of Convertible Preferred Stock (Details)- Series B
Convertible Preferred Stock [ Member ] < br > $ in Thousands < / strong > < / div > < / th > < th class =" th" > < div > Dec. 31, 2024 < / div > < div > USD ($) < / div > < div > shares < / div > < / th
> < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems', window);" > < strong > Schedule of Convertible Preferred Stock [ Line Items ] < / strong > < / a > < / td > < td class =" text" > & #
160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR
(this,' defref_us- gaap_PreferredStockSharesAuthorized', window);" > Preferred Stock Authorized < / a > < / td > < td class =" nump" > 251, 504 < span > < / span > < / td > < / tr > < tr class ="
re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_PreferredStockSharesIssued', window);" > Preferred Stock Issued < / a > < / td > < td class =" nump" > 137, 138 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style
=" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_PreferredStockSharesOutstanding', window);" >
Preferred Stock Outstanding < / a > < / td > < td class =" nump" > 137, 138 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" >
< a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_PreferredStockValue', window);" > Carrying Value (in Dollars) | $ < / a > < / td > < td class ="
nump" > $ 2, 931 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick ="
Show. showAR (this,' defref_us- gaap_CommonStockCapitalSharesReservedForFutureIssuance', window);" > Common Stock Issuable Upon Conversion < / a > < / td > < td class =" nump" > 11,
428, 149 < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id
=" defref_us- gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();"
> X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Line
items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. < / p >
< / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong >
Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems < / td > < / tr > < tr > < td style =" padding- right: 4px; white-
space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < /
tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div >
< / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_CommonStockCapitalSharesReservedForFutureIssuance" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < /
td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Aggregate number
of common shares reserved for future issuance. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p >
Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 <
br >- Subparagraph (SX 210. 5- 02 (29)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);"
onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td >
< td style =" white- space: nowrap;" > us- gaap_CommonStockCapitalSharesReservedForFutureIssuance < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > <
strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > <
strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr
> < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_PreferredStockSharesAuthorized" > < tr > < td class
=" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the
option of the issuer) permitted to be issued by an entity' s charter and bylaws. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style
=" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section
S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (28)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 2:
http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >-
Subparagraph (SX 210. 6- 04 (16) (a)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);"
onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td >
< td style =" white- space: nowrap;" > us- gaap_PreferredStockSharesAuthorized < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix:
< / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < /
strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border
=" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_PreferredStockSharesIssued" > < tr > < td class =" hide" > < a style =" color:
white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick
=" Show. toggleNext (this);" >- Definition < / a > < div > < p > Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes,
but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. < / p > < / div > < a href =" javascript: void (0);" onclick ="
Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >-
Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (28)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 /
2147480566 / 210- 10- S99- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification
< br >- Section 50 < br >- Paragraph 13 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13 < br > < / p > < / div > < a
href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > <
strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_PreferredStockSharesIssued < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" >
< strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > <
strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr
> < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_PreferredStockSharesOutstanding" > < tr > < td class
=" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely
at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext
(this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting
Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (28)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210-
10- S99- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section
S99 < br >- Paragraph 2 < br >- Subparagraph (SX 210. 6- 05 (4)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 2 < br > < br > Reference 3:
http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >-
Subparagraph (SX 210. 6- 09 (4) (b)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 /
role / disclosureRef < br >- Topic 946 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 04 (16)
(a)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1 < br > < br > Reference 5: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br
>- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 09 (7)) < br >- Publisher FASB <
br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style
=" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_PreferredStockSharesOutstanding < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td
> < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr
> < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0"
class =" authRefData" style =" display: none;" id =" defref_us- gaap_PreferredStockValue" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick ="
Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a >
< div > < p > Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock
repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. < / p > < / div
> < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef <
```

br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (28)) < br >- Publisher FASB
< br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 852 < br >- SubTopic 10 < br
>- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 10 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481372 / 852- 10- 55- 10 < br > < br
> Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph
1 < br >- Subparagraph (SX 210. 7- 03 (a) (21)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1 < br > < / p > < / div > < a href =" javascript:
void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong
> < / td > < td style =" white- space: nowrap;" > us- gaap_PreferredStockValue < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < /
strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < /
strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table
border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StatementClassOfStockAxis =
orka_SeriesBConvertiblePreferredStockMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > <
tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0"
cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StatementClassOfStockAxis =
orka_SeriesBConvertiblePreferredStockMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td >
< / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong >
Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > <
TYPE > XML < SEQUENCE > 90 < FILENAME > R54. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type ="
text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function
toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span
style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208154986432" > < tr > < th class =" tl" colspan =" 1" rowspan =" 1" > < div
style =" width: 200px;" > < strong > Convertible Preferred Stock and Stockholders & # 8217; Equity- Schedule of Common Stock Reserved for Future Issuance (Details)- shares < br > < / strong
> < / div > < / th > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < th class =" th" > < div > Aug. 29, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border-
bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ConversionOfStockLineItems', window);" > < strong > Schedule of
Common Stock Reserved for Future Issuance [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < /
td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_CommonStockCapitalSharesReservedForFutureIssuance', window);" > Total shares of common stock reserved < / a > < / td > < td class =" nump" > 27, 556, 257 < span > < / span > < / td >
< td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);"
onclick =" Show. showAR (this,' defref_us- gaap_AwardTypeAxis = us- gaap_StockOptionMember', window);" > Outstanding and Issued Stock Options [Member] < / a > < / td > < td class ="
text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > <
a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ConversionOfStockLineItems', window);" > < strong > Schedule of Common Stock Reserved for
Future Issuance [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re"
> < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_CommonStockCapitalSharesReservedForFutureIssuance', window);" > Total shares of common stock reserved < / a > < / td > < td class =" nump" > 1, 567, 760 < span > < / span > < / td > <
td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);"
onclick =" Show. showAR (this,' defref_us- gaap_ClassOfWarrantOrRightAxis = orka_PrefundedWarrantsMember', window);" > Pre- funded Warrants [Member] < / a > < / td > < td class ="
text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a
class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ConversionOfStockLineItems', window);" > < strong > Schedule of Common Stock Reserved for
Future Issuance [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro"
> < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_CommonStockCapitalSharesReservedForFutureIssuance', window);" > Total shares of common stock reserved < / a > < / td > < td class =" nump" > 6, 202, 207 < span > < / span > < / td > <
td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);"
onclick =" Show. showAR (this,' defref_us- gaap_ClassOfWarrantOrRightAxis = orka_ParukaWarrantObligationMember', window);" > Paruka Warrant Obligation [Member] < / a > < / td > <
td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign
=" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ConversionOfStockLineItems', window);" > < strong > Schedule of Common Stock
Reserved for Future Issuance [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > <
tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_CommonStockCapitalSharesReservedForFutureIssuance', window);" > Total shares of common stock reserved < / a > < / td > < td class =" nump" > 596, 930 < span > < / span > < / td > <
td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);"
onclick =" Show. showAR (this,' defref_us- gaap_ClassOfWarrantOrRightAxis = orka_EmployeeWarrantsMember', window);" > Employee Warrants [Member] < / a > < / td > < td class ="
text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a
class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ConversionOfStockLineItems', window);" > < strong > Schedule of Common Stock Reserved for
Future Issuance [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro"
> < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_CommonStockCapitalSharesReservedForFutureIssuance', window);" > Total shares of common stock reserved < / a > < / td > < td class =" nump" > 3, 054, 358 < span > < / span > < / td > <
td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);"
onclick =" Show. showAR (this,' defref_us- gaap_StatementClassOfStockAxis = orka_SeriesBConvertiblePreferredStockMember', window);" > Shares issuable on conversion of Company Series
B Preferred Stock [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class
=" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ConversionOfStockLineItems', window);" >
< strong > Schedule of Common Stock Reserved for Future Issuance [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & #
160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR
(this,' defref_us- gaap_CommonStockCapitalSharesReservedForFutureIssuance', window);" > Total shares of common stock reserved < / a > < / td > < td class =" nump" > 11, 428, 149 < span >
< / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href ="
javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_PlanNameAxis = orka_TwoThousandTwentyFourStockIncentivePlanMember', window);" > 2024 Stock Incentive Plan [
Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style ="
border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ConversionOfStockLineItems', window);" > < strong >
Schedule of Common Stock Reserved for Future Issuance [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span >
< / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_us- gaap_CommonStockCapitalSharesReservedForFutureIssuance', window);" > Total shares of common stock reserved < / a > < / td > < td class =" nump" > 4, 246, 324 < span > < / span
> < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript:
void (0);" onclick =" Show. showAR (this,' defref_us- gaap_PlanNameAxis = orka_TwoThousandTwentyFourStockIncentivePlanMember', window);" > 2024 Stock Incentive Plan [Member] |
Outstanding and Issued Stock Options [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr
class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_ConversionOfStockLineItems', window);" > < strong > Schedule of Common Stock Reserved for Future Issuance [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; <
span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href
=" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CommonStockCapitalSharesReservedForFutureIssuance', window);" > Total shares of common stock reserved < / a >
< / td > < td class =" nump" > 388, 567 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom:
0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_PlanNameAxis =
orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember', window);" > 2024 Employee Stock Purchase Plan [Member] < / a > < / td > < td class =" text" > & # 160; < span > < /
span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href ="
javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ConversionOfStockLineItems', window);" > < strong > Schedule of Common Stock Reserved for Future Issuance [Line
Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl"
style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_CommonStockCapitalSharesReservedForFutureIssuance', window);" > Total shares of common stock reserved < / a > < / td > < td class =" nump" > 460, 529 < span > < / span > < / td > <
td class =" nump" > 463, 489 < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style
=" display: none;" id =" defref_us- gaap_CommonStockCapitalSharesReservedForFutureIssuance" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick
=" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < /
a > < div > < p > Aggregate number of common shares reserved for future issuance. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > <
div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >-
Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (29)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < / p > < / div
> < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > <
strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_CommonStockCapitalSharesReservedForFutureIssuance < / td > < / tr > < tr > < td style =" padding- right:
4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli:
sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > <
/ tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_ConversionOfStockLineItems" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > <
div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Line items represent financial concepts
included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. < / p > < / div > < a href =" javascript:
void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style ="
white- space: nowrap;" > us- gaap_ConversionOfStockLineItems < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td
> < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td

> na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AwardTypeAxis = us- gaap_StockOptionMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AwardTypeAxis = us- gaap_StockOptionMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ClassOfWarrantOrRightAxis = orka_PrefundedWarrantsMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ClassOfWarrantOrRightAxis = orka_PrefundedWarrantsMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ClassOfWarrantOrRightAxis = orka_ParukaWarrantObligationMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ClassOfWarrantOrRightAxis = orka_ParukaWarrantObligationMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ClassOfWarrantOrRightAxis = orka_EmployeeWarrantsMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ClassOfWarrantOrRightAxis = orka_EmployeeWarrantsMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StatementClassOfStockAxis = orka_SeriesBConvertiblePreferredStockMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StatementClassOfStockAxis = orka_SeriesBConvertiblePreferredStockMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_PlanNameAxis = orka_TwoThousandTwentyFourStockIncentivePlanMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_PlanNameAxis = orka_TwoThousandTwentyFourStockIncentivePlanMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_PlanNameAxis = orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_PlanNameAxis = orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 91 < FILENAME > R55. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208165651136" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Stock- Based Compensation (Details)- USD ($) < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < th class =" th" colspan =" 1" > < / th > < th class =" th" colspan =" 1" > < / th > < / tr > < tr > < th class =" th" > < div > Aug. 29, 2024 < / div > < / th > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < th class =" th" > < div > Aug. 22, 2024 < / div > < / th > < th class =" th" > < div > Feb. 06, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window);" > < strong > Stock- Based Compensation [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CommonStockCapitalSharesReservedForFutureIssuance', window);" > Shares reserved for future issuance < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 27, 556, 257 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CommonStockSharesIssued', window);" > Common stock, shares issued < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 37, 440, 510 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 3, 197, 975 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AllocatedShareBasedCompensationExpense', window);" > Stock- based compensation expense < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 14, 919, 000 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_EstimatedFairValueOfWarrantsToBeGranted', window);" > Estimated fair value of warrants to be granted < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 10, 400, 000 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AwardTypeAxis = us- gaap_StockOptionMember', window);" > Stock Options [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window);" > < strong > Stock- Based Compensation [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CommonStockCapitalSharesReservedForFutureIssuance', window);" > Shares reserved for future issuance < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 1, 567, 760 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window);" > Weighted average grant- date fair value < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 9. 12 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window);" > Total unrecognized compensation cost < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 12, 700, 000 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window);" > Share- Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > 3 years 2 months 12 days < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AwardTypeAxis = orka_TwoThousandTwentyFourStockIncentivePlanMember', window);" > 2024 Stock Incentive Plan [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window);" > < strong > Stock- Based Compensation [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window);" > Shares available for grant < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 4, 246, 324 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares', window);" > Annual increase in shares available for issuance as a percentage of outstanding diluted stock < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 5. 00 % < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AwardTypeAxis = us- gaap_RestrictedStockMember', window);" > RSA [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window);" > < strong > Stock- Based

Compensation [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CommonStockSharesIssued', window);" > Common stock, shares issued < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 2, 207, 553 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AllocatedShareBasedCompensationExpense', window);" > Stock- based compensation expense < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 100, 000 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window);" > RSAs issued < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 2, 207, 553 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SharesIssuedPricePerShare', window);" > RSAs price per share < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 0. 0001 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window);" > Total unrecognized compensation cost < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 100, 000 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window);" > Share- Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > 3 years 1 month 6 days < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfWarrantOrRightAxis = orka_ParukaWarrantObligationMember', window);" > Paruka Warrant Obligation [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window);" > < strong > Stock- Based Compensation [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CommonStockCapitalSharesReservedForFutureIssuance', window);" > Shares reserved for future issuance < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 596, 930 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AllocatedShareBasedCompensationExpense', window);" > Stock- based compensation expense < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 10, 400, 000 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum', window);" > Warrant To Purchase Number Of Shares As A Percentage Of Outstanding Diluted Stock < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 1. 00 % < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfWarrantOrRightAxis = orka_EmployeeWarrantsMember', window);" > Employee Warrants [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window);" > < strong > Stock- Based Compensation [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CommonStockCapitalSharesReservedForFutureIssuance', window);" > Shares reserved for future issuance < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 3, 054, 358 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_ClassOfWarrantOrRight', window);" > Warrants issued < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 3, 054, 358 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window);" > Exercise price per warrant < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 7. 8 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window);" > Price per share < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 6. 27 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window);" > Total unrecognized compensation cost < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 16, 300, 000 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window);" > Share- Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > 3 years 3 months 18 days < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_PlanNameAxis = orka_TwoThousandTwentyFourStockIncentivePlanMember', window);" > 2024 Stock Incentive Plan [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window);" > < strong > Stock- Based Compensation [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window);" > Shares available for grant < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 4, 634, 891 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CommonStockCapitalSharesReservedForFutureIssuance', window);" > Shares reserved for future issuance < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 4, 246, 324 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_PlanNameAxis = orka_TwoThousandTwentyFourStockIncentivePlanMember', window);" > 2024 Stock Incentive Plan [Member] | Stock Options [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window);" > < strong > Stock- Based Compensation [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CommonStockCapitalSharesReservedForFutureIssuance', window);" > Shares reserved for future issuance < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 388, 567 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_PlanNameAxis = orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember', window);" > 2024 Employee Stock Purchase Plan [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window);" > < strong > Stock- Based Compensation [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window);" > Shares available for grant < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 460, 529 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CommonStockCapitalSharesReservedForFutureIssuance', window);" > Shares reserved for future issuance < / a > < / td > < td class =" nump" > 463, 489 < span > < / span > < / td > < td class =" nump" > 460, 529 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares', window);" > Annual increase in shares available for issuance as a percentage of outstanding diluted stock < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 1. 00 % < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window);" > Purchase price of common stock expressed as a percentage of its fair value < / a > < / td > < td class =" nump" > 85. 00 % < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td

> < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window);" > Maximum contribution of employee' s eligible compensation < / a > < / td > < td class =" nump" > 15. 00 % < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP', window);" > Total amount of annual salary that an employee is permitted to utilize to purchase company shares under ESPP < / a > < / td > < td class =" nump" > $ 25, 000 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CommonStockSharesIssued', window);" > Common stock, shares issued < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 2, 960 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AllocatedShareBasedCompensationExpense', window);" > Stock- based compensation expense < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 100, 000 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_ClassOfWarrantOrRight" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Number of warrants or rights issued. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_ClassOfWarrantOrRight < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > class of warrant or right to purchase percentage of outstanding diluted stock maximum. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr: percentItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > This item represents the amount of cash contributions during the period made by the entity to the Employee stock purchase plan (ESPP). < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_EstimatedFairValueOfWarrantsToBeGranted" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Estimated fair value of warrants to be granted. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_EstimatedFairValueOfWarrantsToBeGranted < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Share based compensation arrangement diluted stock. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr: percentItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AllocatedShareBasedCompensationExpense" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of expense for award under share- based payment arrangement. Excludes amount capitalized. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SAB Topic 14. F) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479830 / 718- 10- S99- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (h) (1) (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AllocatedShareBasedCompensationExpense < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Exercise price per share or per unit of warrants or rights outstanding. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 3 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: perShareItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_CommonStockCapitalSharesReservedForFutureIssuance" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Aggregate number of common shares reserved for future issuance. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (29)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_CommonStockCapitalSharesReservedForFutureIssuance < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_CommonStockSharesIssued" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm' s shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (29)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_CommonStockSharesIssued < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a >

```
< div > < p > Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes
to the table. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div >
< a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > <
strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems < / td > < / tr > < tr > <
td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td >
< td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td >
duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id ="
defref_us- gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" > < tr > < td class =" hide" > < a style =" color: white;" href ="
javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" >- Definition < / a > < div > < p > Amount of cost not yet recognized for nonvested award under share- based payment arrangement. < / p > < / div > < a href =" javascript: void
(0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >-
SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org /
1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border
=" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > <
strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td >
< strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td >
< / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" > < tr > < td class =" hide" > < a style =" color: white;"
href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick ="
Show. toggleNext (this);" >- Definition < / a > < div > < p > Weighted- average period over which cost not yet recognized is expected to be recognized for award under share- based payment
arrangement, in' PnYnMnDTnHnMnS' format, for example,' P1Y5M13D' represents reported fact of one year, five months, and thirteen days. < / p > < / div > < a href =" javascript: void (0);"
onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic
10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 /
2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0"
cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 < / td > < / tr > < tr > < td style =" padding- right: 4px;
white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: durationItemType
< / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table
> < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" > < tr > < td class ="
hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The weighted average fair value at grant date for nonvested equity- based awards issued during the
period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). < / p > < / div > < a href =" javascript:
void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >-
SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (2) (iii) (01) < br >- Publisher FASB < br >- URI https: / / asc. fasb.
org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table
border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue < / td > < / tr > < tr > <
td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td >
< td > dtr- types: perShareItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > <
td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id ="
defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" > < tr > < td class =" hide" > < a style =" color: white;" href ="
javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" >- Definition < / a > < div > < p > The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan. < / p > < / div > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name
Accounting Standards Codification < br >- Topic 718 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 /
2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0"
cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;"
> < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: percentItemType < / td > < / tr > < tr >
< td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < /
td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void
(0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >-
Definition < / a > < div > < p > The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and
adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity- based awards under the plan; and 2) shares (or other type
of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext
(this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic
718 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong >
Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant < / td > < /
tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < /
strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > <
/ td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;"
id =" defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" > < tr > < td class =" hide" > < a style
=" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void
(0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The weighted average grant- date fair value of options granted during the reporting period as calculated by applying
the disclosed option pricing methodology. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p >
Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 <
br >- Subparagraph (d) (1) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick ="
Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style
=" white- space: nowrap;" > us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue < / td > < / tr > < tr >
< td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td
> < td > dtr- types: perShareItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > <
td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id ="
defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void
(0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >-
Definition < / a > < div > < p > Number of shares issued under share- based payment arrangement. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >
References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 718 < br >-
SubTopic 10 < br >- Section 50 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript:
void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong
> < / td > < td style =" white- space: nowrap;" > us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod < / td > < / tr > < tr > < td style =" padding-
right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli:
sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td >
< / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript:
void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext
(this);" >- Definition < / a > < div > < p > Purchase price of common stock expressed as a percentage of its fair value. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext
(this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > <
div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;"
> < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: percentItemType < / td > < / tr > < tr >
< td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < /
td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_SharesIssuedPricePerShare" > < tr > < td
class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a
href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Per share or per unit amount of equity securities issued. < / p > < / div > < a href =" javascript:
void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style ="
white- space: nowrap;" > us- gaap_SharesIssuedPricePerShare < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td >
< td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: perShareItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td
```

> < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AwardTypeAxis = us- gaap_StockOptionMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AwardTypeAxis = us- gaap_StockOptionMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AwardTypeAxis = orka_TwoThousandTwentyFourStockIncentivePlanMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AwardTypeAxis = orka_TwoThousandTwentyFourStockIncentivePlanMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AwardTypeAxis = us- gaap_RestrictedStockMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AwardTypeAxis = us- gaap_RestrictedStockMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ClassOfWarrantOrRightAxis = orka_ParukaWarrantObligationMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ClassOfWarrantOrRightAxis = orka_ParukaWarrantObligationMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ClassOfWarrantOrRightAxis = orka_EmployeeWarrantsMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ClassOfWarrantOrRightAxis = orka_EmployeeWarrantsMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_PlanNameAxis = orka_TwoThousandTwentyFourStockIncentivePlanMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_PlanNameAxis = orka_TwoThousandTwentyFourStockIncentivePlanMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_PlanNameAxis = orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_PlanNameAxis = orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 92 < FILENAME > R56. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208160387008" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Stock- Based Compensation- Schedule of Weighted- Average Assumptions Used in Calculating the Fair Value of the Awards (Details) < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AwardTypeAxis = us- gaap_StockOptionMember', window);" > Stock Option [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window);" > < strong > Schedule of Weighted- Average Assumptions Used in Calculating the Fair Value of the Awards [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window);" > Expected term (in years) < / a > < / td > < td class =" text" > 6 years 1 month 6 days < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window);" > Expected volatility < / a > < / td > < td class =" nump" > 100. 21 % < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window);" > Risk- free interest rate < / a > < / td > < td class =" nump" > 4. 26 % < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window);" > Expected dividend yield < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfWarrantOrRightAxis = orka_EmployeeWarrantsMember', window);" > Employee Warrants [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window);" > < strong > Schedule of Weighted- Average Assumptions Used in Calculating the Fair Value of the Awards [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window);" > Expected term (in years) < / a > < / td > < td class =" text" > 6 years 1 month 6 days < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window);" > Expected volatility < / a > < / td > < td class =" nump" > 99. 02 % < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window);" > Risk- free interest rate < / a > < / td > < td class =" nump" > 4. 15 % < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window);" > Expected dividend yield < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 820 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 103 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482078 / 820- 10- 55- 103 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 820 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (bbb) (2) (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 820 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (bbb) (2) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 820 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (bbb) (1) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option' s term. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (f) (2) (iii) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < /

a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: percentItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability- weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (f) (2) (ii) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: percentItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The risk- free interest rate assumption that is used in valuing an option on its own shares. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (f) (2) (iv) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: percentItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Expected term of award under share- based payment arrangement, in' PnYnMnDTnHnMnS' format, for example,' P1Y5M13D' represents reported fact of one year, five months, and thirteen days. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (f) (2) (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: durationItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-gaap_AwardTypeAxis = us- gaap_StockOptionMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AwardTypeAxis = us- gaap_StockOptionMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ClassOfWarrantOrRightAxis = orka_EmployeeWarrantsMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ClassOfWarrantOrRightAxis = orka_EmployeeWarrantsMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 93 < FILENAME > R57. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208162773408" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Stock- Based Compensation- Schedule of Stock Option Activity (Details)- USD ($) < br > $ / shares in Units, $ in Thousands < / strong > < / div > < / th > < th class =" th" colspan =" 1" > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Feb. 06, 2024 < / div > < / th > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window);" > < strong > Share- Based Compensation Arrangement by Share- Based Payment Award [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window);" > Number of Stock Options Outstanding, Ending Balance < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" nump" > 1, 567, 760 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window);" > Weighted Average Exercise Price Per Share, Ending Balance < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" nump" > $ 11. 39 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window);" > Weighted Average Remaining Contractual Term (in Years), Ending Balance < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" text" > 9 years 4 months 24 days < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window);" > Aggregate Intrinsic Value, Ending Balance < / a > < / td > < td class =" text" > < span > < / span > < / td > < td class =" nump" > $ 15, 470 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window);" > Number of Stock Options Outstanding, Vested and expected to vest < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 1, 567, 760 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window);" > Weighted Average Exercise Price Per Share, Vested and expected to vest, September 30, 2024 < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 11. 39 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window);" > Weighted Average Remaining Contractual Term (in Years), Vested and expected to vest, September 30, 2024 < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > 9 years 4 months 24 days < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window);" > Aggregate Intrinsic Value, Vested and expected to vest < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 15, 470 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window);" > Number of Stock Options Outstanding, Exercisable < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window);" > Weighted Average Exercise Price Per Share, Exercisable, < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window);" > Weighted Average Remaining Contractual Term (in Years), Exercisable < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window);" > Aggregate Intrinsic Value, Exercisable < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window);" > Stock Options, Granted < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > 1, 567, 760 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-

gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window);" > Weighted Average Exercise Price Per Share,
Granted < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 11. 39 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style ="
border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StockIssuedDuringPeriodSharesStockOptionsExercised',
window);" > Stock Options, Exercised < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class
=" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window);" > Weighted Average Exercise Price Per Share,
Exercised < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border-
bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window);" > Stock Options, Forfeited < / a > < / td > < td class =" text" >
& # 160; < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href
=" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window);" > Weighted Average Exercise Price Per
Share, Forfeited < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table
border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show.
hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div
> < p > Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the
table. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 /
role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 35 < br >- Paragraph 1D < br >- Publisher FASB < br >- URI https: / /
asc. fasb. org / 1943274 / 2147480483 / 718- 10- 35- 1D < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name
Accounting Standards Codification < br >- Section 35 < br >- Paragraph 3 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480483 / 718- 10- 35- 3 < br > < br >
Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 <
br >- Subparagraph (a) (1) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role /
disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (a) (2) < br >- Publisher FASB
< br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br
>- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (a) (3) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 /
2147480429 / 718- 10- 50- 2 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification <
br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 7:
http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >-
Subparagraph (c) (1) (ii) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 8: http: / / www. xbrl. org / 2003 / role /
disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (iii) < br >- Publisher
FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic
10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (iv) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 /
2147480429 / 718- 10- 50- 2 < br > < br > Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification
< br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (iv) (01) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br >
Reference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 <
br >- Subparagraph (c) (1) (iv) (02) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 12: http: / / www. xbrl. org / 2003 /
role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (iv) (03) < br >-
Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 13: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >-
SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (iv) (04) < br >- Publisher FASB < br >- URI https: / / asc. fasb.
org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting
Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (2) (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 <
br > < br > Reference 15: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >-
Paragraph 2 < br >- Subparagraph (c) (2) (ii) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 16: http: / / www. xbrl. org
/ 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (2) (iii) < br
>- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 17: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br
>- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (2) (iii) (01) < br >- Publisher FASB < br >- URI https: / / asc.
fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 18: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting
Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (2) (iii) (02) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10-
50- 2 < br > < br > Reference 19: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 <
br >- Paragraph 2 < br >- Subparagraph (c) (2) (iii) (03) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 20: http: / /
www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph
(d) (1) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 21: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >-
Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (d) (2) < br >- Publisher FASB < br >- URI https: / /
asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 22: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting
Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (e) (1) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br
> < br > Reference 23: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >-
Paragraph 2 < br >- Subparagraph (e) (2) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 24: http: / / www. xbrl. org /
2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (f) (2) (i) < br >-
Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 25: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >-
SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (f) (2) (ii) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org /
1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 26: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards
Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (f) (2) (iii) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br
> Reference 27: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2
< br >- Subparagraph (f) (2) (iv) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 28: http: / / www. xbrl. org / 2003 / role /
disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (f) (2) (v) < br >- Publisher
FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div
style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace
Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance
Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > <
table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);"
onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >-
Definition < / a > < div > < p > The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. <
/ p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role /
disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (iii) < br >- Publisher
FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div
style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong
> Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong >
Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < /
table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" > < tr > < td class =" hide" > < a style =" color: white;" href ="
javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" >- Definition < / a > < div > < p > The weighted- average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of
options outstanding and currently exercisable under the stock option plan. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style ="
display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50
< br >- Paragraph 2 < br >- Subparagraph (c) (1) (iii) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong >
Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice < / td > < / tr > < tr > < td style =" padding- right: 4px; white-
space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: perShareItemType <
/ td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < /
div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" > < tr > < td class =" hide" > < a style =" color: white;" href ="
javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" >- Definition < / a > < div > < p > For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result
of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 718 < br >- SubTopic 10 < br >-
Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (iv) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 /

2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Gross number of share options (or share units) granted during the period. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (iv) (01) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 718 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Number of options outstanding, including both vested and non- vested options. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (ii) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (ii) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: perShareItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (e) (2) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (e) (1) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Weighted- average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (e) (1) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: perShareItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Weighted average price at which option holders acquired shares when converting their stock options into shares. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (iv) (02) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: perShareItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < /

td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (iv) (03) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: perShareItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (iv) (01) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice < / td > < / tr > < tr > < td style =" padding- right: 4px; white-space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: perShareItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us-gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 718 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in' PnYnMnDTnHnMnS' format, for example,' P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 718 < br >- SubTopic 10 < br >- Section 50 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: durationItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Weighted average remaining contractual term for option awards outstanding, in' PnYnMnDTnHnMnS' format, for example,' P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 718 < br >- SubTopic 10 < br >- Subparagraph (e) (1) < br >- Name Accounting Standards Codification < br >- Paragraph 2 < br >- Section 50 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: durationItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in' PnYnMnDTnHnMnS' format, for example,' P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (e) (1) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: durationItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Number of share options (or share units) exercised during the current period. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- SubTopic 10 < br >- Topic 505 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 2 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (28)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (29)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (iv) (02) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 5: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 505 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 3- 04) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480008 / 505- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StockIssuedDuringPeriodSharesStockOptionsExercised < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 94 < FILENAME > R58. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208161171648" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Stock- Based Compensation- Schedule of RSA Activity (Details)- Restricted Stock Award [Member]- $ / shares < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window);" > < strong > Schedule of RSA Activity [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window);" > Beginning Balance (in Shares) < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window);" > Weighted Average Grant Date Fair Value, Unvested balance, Beginning < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom:

0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window);" > Unvested balance, Number of Granted < / a > < / td > < td class =" nump" > 2, 207, 553 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window);" > Weighted Average Grant Date Fair Value, Granted < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window);" > Ending Balance (in Shares) < / a > < / td > < td class =" nump" > 2, 207, 553 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window);" > Weighted Average Grant Date Fair Value, Unvested balance, Ending < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (2) (iii) (01) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The number of non- vested equity- based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (2) (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (2) (ii) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Per share or unit weighted- average fair value of nonvested award under share- based payment arrangement. Excludes share and unit options. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (2) (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (2) (ii) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: perShareItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 35 < br >- Paragraph 1D < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480483 / 718- 10- 35- 1D < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 35 < br >- Paragraph 3 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480483 / 718- 10- 35- 3 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (a) (1) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (a) (2) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (a) (3) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (ii) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (iii) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (iv) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (iv) (01) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (iv) (02) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 12: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (iv) (03) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 13: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (iv) (04) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (2) (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 15: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (2) (ii) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 16: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (2) (iii) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 17: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (2) (iii) (01) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 18: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (2) (iii) (02) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 19: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (2) (iii) (03) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 20: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (d) (1) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 21: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (d) (2) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 22: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (e) (1) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 23: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (e) (2) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 24: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (f) (2) (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 25: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (f) (2) (ii) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 26: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (f) (2) (iii) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 27: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (f) (2) (iv) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 28: http: / / www. xbrl. org / 2003 / role /

disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (f) (2) (v) < br >- Publisher
FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div
style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace
Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance
Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > <
table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AwardTypeAxis = us- gaap_RestrictedStockMember" > < tr > < td
class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a
href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > <
/ td > < td style =" white- space: nowrap;" > us- gaap_AwardTypeAxis = us- gaap_RestrictedStockMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > <
strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < /
strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < /
html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 95 < FILENAME > R59. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > <
head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < /
script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display
=' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208162339760" > < tr > < th
class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Stock- Based Compensation- Schedule of Employee Warrant Activity (Details)- Employee Warrants [
Member]- USD ($) < br > $ / shares in Units, $ in Thousands < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec.
31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window);" > < strong > Schedule of Employee Warrant Activity [Line Items] < / strong > < / a
> < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript:
void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber',
window);" > Beginning Balance (in Shares) < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign
=" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice', window);" > Beginning Balance (in Shares) <
/ a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void
(0);" onclick =" Show. showAR (this,' defref_us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window);" > Aggregate Intrinsic Value,
Beginning Balance < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href
=" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window);" > Ending Balance (in Shares) < / a > < / td > < td
class =" nump" > 3, 054, 358 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void
(0);" onclick =" Show. showAR (this,' defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice',
window);" > Ending Balance (in Shares) < / a > < / td > < td class =" nump" > $ 7. 8 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;"
valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm', window);"
> Ending Balance (in Shares) < / a > < / td > < td class =" text" > 9 years 6 months < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign ="
top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window);" > Aggregate Intrinsic Value,
Ending Balance < / a > < / td > < td class =" nump" > $ 35, 400 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a
class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber', window);" > Number of
Employee Warrants Outstanding, Vested and expected to vest < / a > < / td > < td class =" nump" > 3, 054, 358 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style
=" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice', window);" > Weighted
Average Exercise Price Per Share, Vested and expected to vest < / a > < / td > < td class =" nump" > $ 7. 8 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style ="
border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm'
window);" > Weighted Average Remaining Contractual Term, Vested and expected to vest < / a > < / td > < td class =" text" > 9 years 6 months < span > < / span > < / td > < / tr > < tr class =" ro"
> < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest', window);" > Aggregate Intrinsic Value,
Vested and expected to vest < / a > < / td > < td class =" nump" > $ 35, 400 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign ="
top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding', window);" > Number of Employee Warrants
Outstanding, Vested and exercisable < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign ="
top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice', window);" > Weighted Average
Exercise Price Per Share, Vested and exercisable < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;"
valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable', window);" > Aggregate
Intrinsic Value, Vested and exercisable < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > <
a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window);" > Number of Granted < / a > < / td > < td class ="
nump" > 3, 054, 358 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);"
onclick =" Show. showAR (this,' defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice', window);" >
Weighted Average, Granted < / a > < / td > < td class =" nump" > $ 7. 8 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign ="
top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised', window);" > Number of Employee Warrants Outstanding,
Exercised < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href ="
javascript: void (0);" onclick =" Show. showAR (this,'
defref_orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShare
window);" > Weighted Average Exercise Price Per Share, Exercised < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border-
bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window);" > Number of Employee Warrants Outstanding,
Forfeited < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href ="
javascript: void (0);" onclick =" Show. showAR (this,'
defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice', window);" > Weighted
Average Exercise Price Per Share, Forfeited < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding ="
0" cellspacing =" 0" class =" authRefData" style =" display: none;" id ="
defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" > < tr > < td class =" hide" > < a style =" color: white;" href
=" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" >- Definition < / a > < div > < p > Number of Warrants, Exercised (in Shares). < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >
References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style
=" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" >
orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space:
nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr
> < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div >
< / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id ="
defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice" > < tr > < td class =" hide"
> < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Weighted average exercise price as of the grant date of equity- based award plans other than stock
(unit) option plans. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p >
< / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > <
td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" >
orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice < / td > < / tr > < tr > < td style ="
padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr:
perShareItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < /
td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id ="
defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm" > < tr > < td
class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a
href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Weighted average remaining contractual term for option awards Vested and expected to vest,

in' PnYnMnDTnHnMnS' format, for example,' P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: durationItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Fair value of share- based awards for aggregate Intrinsic Value, Vested and expected to vest. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Weighted average remaining contractual term for option awards Vested and expected to vest, in' PnYnMnDTnHnMnS' format, for example,' P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: durationItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The number of equity- based payment instruments, excluding stock (or unit) options, that Vested and expected to vest. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The weighted average fair value at grant date for nonvested equity- based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr: perShareItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Per share or unit weighted- average fair value of nonvested award under share- based payment arrangement. Excludes share and unit options. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr: perShareItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Number of employee warrants outstanding, vested and exercisable shares. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Weighted- Average Exercise Price Per Share, Vested and Exercisable. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr: perShareItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Weighted- average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr: perShareItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Intrinsic value of Vested and exercisable award under share- based payment arrangement. Excludes share and unit options. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShare > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Weighted average exercise price per share exercised. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td >

< td style =" white- space: nowrap;" > orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercis < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr: perShareItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The number of equity- based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (2) (iii) (03) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (2) (iii) (01) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The number of non- vested equity- based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (2) (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (2) (ii) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 35 < br >- Paragraph 1D < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480483 / 718- 10- 35- 1D < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 35 < br >- Paragraph 3 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480483 / 718- 10- 35- 3 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (a) (1) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (a) (2) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (a) (3) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (ii) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (iii) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (iv) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (iv) (01) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (iv) (02) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 12: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (iv) (03) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 13: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (1) (iv) (04) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (2) (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 15: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (2) (ii) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 16: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (2) (iii) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 17: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (2) (iii) (01) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 18: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (2) (iii) (02) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 19: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) (2) (iii) (03) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 20: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (d) (1) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 21: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (d) (2) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 22: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (e) (1) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 23: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (e) (2) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 24: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (f) (2) (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 25: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (f) (2) (ii) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 26: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (f) (2) (iii) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 27: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (f) (2) (iv) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < br > Reference 28: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (f) (2) (v) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Intrinsic value of outstanding award under share- based payment arrangement. Excludes share and unit options. < / p > < /

div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ClassOfWarrantOrRightAxis = orka_EmployeeWarrantsMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ClassOfWarrantOrRightAxis = orka_EmployeeWarrantsMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 96 < FILENAME > R60. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208160092320" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Stock- Based Compensation- Schedule of Company & # 8217; s Stock- Based Compensation Expense (Details) < br > $ in Thousands < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < div > USD ($) < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window);" > < strong > Schedule of Company & # 8217; s Stock- Based Compensation Expense [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AllocatedShareBasedCompensationExpense', window);" > Stock- based compensation expense < / a > < / td > < td class =" nump" > $ 14, 919 < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_IncomeStatementLocationAxis = us- gaap_ResearchAndDevelopmentExpenseMember', window);" > Research and development [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window);" > < strong > Schedule of Company & # 8217; s Stock- Based Compensation Expense [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AllocatedShareBasedCompensationExpense', window);" > Stock- based compensation expense < / a > < / td > < td class =" nump" > 11, 992 < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_IncomeStatementLocationAxis = us- gaap_GeneralAndAdministrativeExpenseMember', window);" > General and administrative [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window);" > < strong > Schedule of Company & # 8217; s Stock- Based Compensation Expense [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AllocatedShareBasedCompensationExpense', window);" > Stock- based compensation expense < / a > < / td > < td class =" nump" > $ 2, 927 < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AllocatedShareBasedCompensationExpense" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of expense for award under share- based payment arrangement. Excludes amount capitalized. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SAB Topic 14. F) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479830 / 718- 10- S99- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (h) (1) (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AllocatedShareBasedCompensationExpense < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_IncomeStatementLocationAxis = us- gaap_ResearchAndDevelopmentExpenseMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_IncomeStatementLocationAxis = us- gaap_ResearchAndDevelopmentExpenseMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_IncomeStatementLocationAxis = us- gaap_GeneralAndAdministrativeExpenseMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_IncomeStatementLocationAxis = us- gaap_GeneralAndAdministrativeExpenseMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 97 < FILENAME > R61. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208161046000" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Stock- Based Compensation- Schedule of Award Types of Company & # 8217; s Stock- Based Compensation Expense (Details) < br > $ in Thousands < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < div > USD ($) < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems', window);" > < strong > Schedule of Award Types of Company & # 8217; s Stock- Based Compensation Expense [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AllocatedShareBasedCompensationExpense', window);" > Total stock- based compensation expense < / a > < / td > < td class =" nump" > $ 14, 919 < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_IncomeStatementLocationAxis = orka_ParukaWarrantObligationMember', window);" > Paruka warrant obligation [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems', window);" > < strong > Schedule of Award Types of Company & # 8217; s Stock- Based Compensation Expense [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AllocatedShareBasedCompensationExpense', window);" > Total stock- based compensation expense < / a > < / td > < td class =" nump" > 10, 357 < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_IncomeStatementLocationAxis = orka_EmployeeWarrantsMember', window);" > Employee warrants [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems', window);" > < strong > Schedule of Award Types of Company & # 8217; s Stock- Based Compensation Expense [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AllocatedShareBasedCompensationExpense', window);" > Total stock- based compensation expense < / a > < / td > < td class =" nump" > 2, 899 < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_IncomeStatementLocationAxis = us- gaap_StockOptionMember', window);" > Stock options [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems', window);" > < strong > Schedule of Award Types of Company & # 8217; s Stock- Based Compensation Expense [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AllocatedShareBasedCompensationExpense', window);" > Total stock- based compensation expense < / a > < / td > < td class =" nump" > 1, 626 < span > < / span > < / td > < / tr > < tr class

```
=" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_IncomeStatementLocationAxis = orka_EmployeeStockPurchasePlanMember', window);" > Employee stock purchase plan [ Member ] < / a > < / td > < td class =" text" > & # 160; < span >
< / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems', window);" > < strong > Schedule of Award Types of Company &
# 8217; s Stock- Based Compensation Expense [ Line Items ] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style ="
border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AllocatedShareBasedCompensationExpense', window);" >
Total stock- based compensation expense < / a > < / td > < td class =" nump" > $ 37 < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding
=" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id ="
defref_orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems" > < tr > < td class =" hide" > < a style =" color: white;" href ="
javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style ="
display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" >
orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space:
nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr >
< td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < /
td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_AllocatedShareBasedCompensationExpense" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr >
< tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of expense for award
under share- based payment arrangement. Excludes amount capitalized. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style ="
display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section
S99 < br >- Paragraph 1 < br >- Subparagraph (SAB Topic 14. F) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479830 / 718- 10- S99- 1 < br > < br > Reference 2:
http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 718 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >-
Subparagraph (h) (1) (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick ="
Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style
=" white- space: nowrap;" > us- gaap_AllocatedShareBasedCompensationExpense < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix:
< / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < /
strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table
border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_IncomeStatementLocationAxis =
orka_ParukaWarrantObligationMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > <
td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0"
cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_IncomeStatementLocationAxis = orka_ParukaWarrantObligationMember
< / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < /
strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < /
tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_IncomeStatementLocationAxis = orka_EmployeeWarrantsMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X
< / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border ="
0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_IncomeStatementLocationAxis =
orka_EmployeeWarrantsMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > <
td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < /
strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display:
none;" id =" defref_us- gaap_IncomeStatementLocationAxis = us- gaap_StockOptionMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick ="
Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > <
div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_IncomeStatementLocationAxis
= us- gaap_StockOptionMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > <
td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < /
strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display:
none;" id =" defref_us- gaap_IncomeStatementLocationAxis = orka_EmployeeStockPurchasePlanMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);"
onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >-
Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_IncomeStatementLocationAxis = orka_EmployeeStockPurchasePlanMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix:
< / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > <
/ tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < /
DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 98 < FILENAME > R62. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title >
< link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type ="
text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > <
/ head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208263095952" > < tr > < th class =" tl" colspan ="
1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Segment Disclosures (Details) < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr >
< tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void
(0);" onclick =" Show. showAR (this,' defref_us- gaap_SegmentReportingAbstract', window);" > < strong > Segment Disclosures [ Abstract ] < / strong > < / a > < / td > < td class =" text" > & #
160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR
(this,' defref_us- gaap_NumberOfOperatingSegments', window);" > Operating segment < / a > < / td > < td class =" nump" > 1 < span > < / span > < / td > < / tr > < tr class =" re" > < td class ="
pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_NumberOfReportableSegments', window);" >
Reporting segment < / a > < / td > < td class =" nump" > 1 < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0"
class =" authRefData" style =" display: none;" id =" defref_us- gaap_NumberOfOperatingSegments" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);"
onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >-
Definition < / a > < div > < p > Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and
incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise' s
chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An
operating segment may engage in business activities for which it has yet to earn revenues, for example, start- up operations may be operating segments before earning revenues. < / p > < / div > < a
href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >-
Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 49 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 /
2147482785 / 280- 10- 55- 49 < br > < br > Reference 2: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards
Codification < br >- Section 50 < br >- Paragraph 18 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 18 < br > < / p > < / div > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong >
Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_NumberOfOperatingSegments < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > <
strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: integerItemType < / td > < / tr > < tr > < td > <
strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < /
tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_NumberOfReportableSegments" > < tr > < td class
=" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Number of segments reported by the entity. A reportable segment is a component of an entity for
which there is an accounting requirement to report separate financial information on that component in the entity' s financial statements. < / p > < / div > < a href =" javascript: void (0);" onclick
=" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 280 < br >- SubTopic 10 < br >-
Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 47 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482785 /
280- 10- 55- 47 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section
55 < br >- Paragraph 54 < br >- Subparagraph (e) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482785 / 280- 10- 55- 54 < br > < br > Reference 3: http: / / www.
xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 18 < br >- Publisher
FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 18 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div
style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_NumberOfReportableSegments < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > <
/ tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: integerItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr >
< td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0"
class =" authRefData" style =" display: none;" id =" defref_us- gaap_SegmentReportingAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick
=" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < /
a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border ="
0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_SegmentReportingAbstract < / td > < / tr > < tr > < td
style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > <
td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td >
duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 99
< FILENAME > R63. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report.
css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling.
style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < /
```

span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208163022736" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Segment Disclosures- Schedule of Segment Loss from Operations (Details) < br > $ in Thousands < / strong > < / div > < / th > < th class =" th" colspan =" 2" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" colspan =" 2" > < div > Dec. 31, 2024 < / div > < div > USD ($) < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window);" > < strong > Schedule of Segment Loss from Operations [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ResearchAndDevelopmentExpense', window);" > Research and development personnel- related expense (excluding stock- based compensation) < / a > < / td > < td class =" nump" > $ 75, 060 < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < sup > [1] < / sup > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_GeneralAndAdministrativeExpense', window);" > General and administrative personnel- related expense (excluding stock- based compensation) < / a > < / td > < td class =" nump" > 13, 063 < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < sup > [2] < / sup > < / td > < / tr > < tr class =" rou" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_OperatingExpenses', window);" > Total operating expenses < / a > < / td > < td class =" nump" > 88, 123 < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_OperatingIncomeLoss', window);" > Loss from operations < / a > < / td > < td class =" num" > (88, 123) < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_IncomeStatementLocationAxis = orka_OperatingExpenseExcludingStockBasedCompensationMember', window);" > Operating Expense Excluding Personnel Related And Stock Based Compensation [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window);" > < strong > Schedule of Segment Loss from Operations [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ResearchAndDevelopmentExpense', window);" > Research and development personnel- related expense (excluding stock- based compensation) < / a > < / td > < td class =" nump" > 3, 959 < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_GeneralAndAdministrativeExpense', window);" > General and administrative personnel- related expense (excluding stock- based compensation) < / a > < / td > < td class =" nump" > 5, 054 < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_IncomeStatementLocationAxis = us- gaap_ResearchAndDevelopmentExpenseMember', window);" > Research and development stock- based compensation [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window);" > < strong > Schedule of Segment Loss from Operations [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ResearchAndDevelopmentExpense', window);" > Research and development personnel- related expense (excluding stock- based compensation) < / a > < / td > < td class =" nump" > 11, 992 < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_IncomeStatementLocationAxis = us- gaap_GeneralAndAdministrativeExpenseMember', window);" > General and administrative stock- based compensation [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window);" > < strong > Schedule of Segment Loss from Operations [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ResearchAndDevelopmentExpense', window);" > Research and development personnel- related expense (excluding stock- based compensation) < / a > < / td > < td class =" nump" > 2, 927 < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_IncomeStatementLocationAxis = orka_ExternalMember', window);" > External [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window);" > < strong > Schedule of Segment Loss from Operations [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ResearchAndDevelopmentExpense', window);" > Research and development personnel- related expense (excluding stock- based compensation) < / a > < / td > < td class =" nump" > 57, 680 < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_IncomeStatementLocationAxis = orka_OtherMember', window);" > Other [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window);" > < strong > Schedule of Segment Loss from Operations [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ResearchAndDevelopmentExpense', window);" > Research and development personnel- related expense (excluding stock- based compensation) < / a > < / td > < td class =" nump" > 1, 429 < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_IncomeStatementLocationAxis = orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember', window);" > Operating Expense Excluding Personnel Related And Stock Based Compensation [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window);" > < strong > Schedule of Segment Loss from Operations [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_GeneralAndAdministrativeExpense', window);" > General and administrative personnel- related expense (excluding stock- based compensation) < / a > < / td > < td class =" nump" > $ 5, 082 < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr > < td colspan =" 3" > < / td > < / tr > < tr > < td colspan =" 3" > < table class =" outerFootnotes" width =" 100 %" > < tr class =" outerFootnote" > < td style =" vertical- align: top; width: 12pt;" valign =" top" > [1] < / td > < td style =" vertical- align: top;" valign =" top" > < span style =" font- family: Times New Roman, Times, Serif" > Includes related party amount of $ 42, 640 for the period from February 6, 2024 (inception) to December 31, 2024 < / span > < / td > < / tr > < tr class =" outerFootnote" > < td style =" vertical- align: top; width: 12pt;" valign =" top" > [2] < / td > < td style =" vertical- align: top;" valign =" top" > < span style =" font- family: Times New Roman, Times, Serif" > Includes related party amount of $ 1, 364 for the period from February 6, 2024 (inception) to December 31, 2024 < / span > < / td > < / tr > < / table > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_GeneralAndAdministrativeExpense" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SX 210. 5- 03 (4)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 07 (2) (a)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_GeneralAndAdministrativeExpense < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_OperatingExpenses" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_OperatingExpenses < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_OperatingIncomeLoss" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The net result for the period of deducting operating expenses from operating revenues. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 22 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 22 < br > < br > Reference 2: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 32 < br >- Subparagraph (f) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 32 < br > < br > Reference 3: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 30 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 30 < br > < br > Reference 4: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 270 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482964 / 270- 10- 50- 1 < br > < br > Reference 5: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 32 < br >- Subparagraph (ee) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 32 < br

```
> < br > Reference 6: http: / / fasb. org / us- gaap / role / ref / otherTransitionRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >-
Paragraph 32 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 32 < br > < br > Reference 7: http: / / www. xbrl. org /
2003 / role / exampleRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 31 < br >- Publisher FASB < br >- URI
https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 31 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display:
none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_OperatingIncomeLoss < /
td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type:
< / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < /
strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style ="
display: none;" id =" defref_us- gaap_ResearchAndDevelopmentExpense" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X
< / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount
of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development
assets acquired in transaction other than business combination or joint venture formation or both. Excludes write- down of intangible asset acquired in business combination or from joint venture
formation or both, used in research and development activity. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display:
none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >-
Paragraph 48 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482785 / 280- 10- 55- 48 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br
>- Topic 985 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 /
2147481283 / 985- 20- 50- 2 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 730 < br >- SubTopic 10 < br >- Name Accounting Standards Codification <
br >- Section 50 < br >- Paragraph 1 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482916 / 730- 10- 50- 1 < br > < br > Reference 4: http: / / www. xbrl. org / 2009 /
role / commonPracticeRef < br >- Topic 912 < br >- SubTopic 730 < br >- Name Accounting Standards Codification < br >- Section 25 < br >- Paragraph 1 < br >- Publisher FASB < br >- URI
https: / / asc. fasb. org / 1943274 / 2147479532 / 912- 730- 25- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display:
none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_ResearchAndDevelopmentExpense < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td
> < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr
> < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing
=" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" > < tr > < td
class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a
href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Line items represent financial concepts included in a table. These concepts are used to disclose
reportable information associated with domain members defined in one or many axes to the table. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >
References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style
=" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > <
strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > <
strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < /
tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_IncomeStatementLocationAxis =
orka_OperatingExpenseExcludingStockBasedCompensationMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < /
a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0"
cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_IncomeStatementLocationAxis =
orka_OperatingExpenseExcludingStockBasedCompensationMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > <
/ td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > <
td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class ="
authRefData" style =" display: none;" id =" defref_us- gaap_IncomeStatementLocationAxis = us- gaap_ResearchAndDevelopmentExpenseMember" > < tr > < td class =" hide" > < a style ="
color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);"
onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white-
space: nowrap;" > us- gaap_IncomeStatementLocationAxis = us- gaap_ResearchAndDevelopmentExpenseMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;"
> < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < /
strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0"
cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_IncomeStatementLocationAxis = us-
gaap_GeneralAndAdministrativeExpenseMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr >
< tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0"
cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_IncomeStatementLocationAxis = us-
gaap_GeneralAndAdministrativeExpenseMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td
> < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong >
Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style
=" display: none;" id =" defref_us- gaap_IncomeStatementLocationAxis = orka_ExternalMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick
=" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a >
< div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_IncomeStatementLocationAxis = orka_ExternalMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td >
< td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > <
strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class ="
authRefData" style =" display: none;" id =" defref_us- gaap_IncomeStatementLocationAxis = orka_OtherMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript:
void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext
(this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_IncomeStatementLocationAxis = orka_OtherMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > <
td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > <
strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class ="
authRefData" style =" display: none;" id =" defref_us- gaap_IncomeStatementLocationAxis = orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember" > < tr
> < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" >
< a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong
> < / td > < td style =" white- space: nowrap;" > us- gaap_IncomeStatementLocationAxis = orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember < / td > < /
tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td
> < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table >
< / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 100 < FILENAME > R64. htm <
DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text /
javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e.
nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report"
border =" 0" cellspacing =" 2" id =" idm46208165672480" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Income Taxes (Details) < br > $ in
Thousands < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < div > USD ($) < / div > < / th >
< / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_orka_IncomeTaxesDetailsLineItems', window);" > < strong > Income Taxes (Details) [ Line Items ] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr
> < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_IncomeTaxExpenseBenefit', window);" > Provision for income taxes < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style ="
border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_OperatingLossCarryforwardsValuationAllowance',
window);" > Change in valuation allowance due to continuing loss from operations < / a > < / td > < td class =" nump" > 21, 300 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class ="
pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DeferredTaxAssetsOtherLossCarryforwards',
window);" > Net operating loss carryforwards < / a > < / td > < td class =" nump" > $ 10, 800 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border-
bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome',
window);" > Operating loss carryforwards as a percentage of taxable income < / a > < / td > < td class =" nump" > 80. 00 % < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl"
style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window);" > Tax credit carryforwards < / a > < / td > < td class =" nump" > $ 3, 080 < span > < / span > < / td > < / tr > < tr class ="
rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_IncomeTaxAuthorityAxis =
us- gaap_DomesticCountryMember', window);" > Domestic Tax Jurisdiction [ Member ] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td
class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_IncomeTaxesDetailsLineItems', window);"
> < strong > Income Taxes (Details) [ Line Items ] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border-
bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window);"
> Tax credit carryforwards < / a > < / td > < td class =" nump" > 3, 800 < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a
class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_IncomeTaxAuthorityAxis = us- gaap_StateAndLocalJurisdictionMember', window);" > State and
Local Jurisdiction [ Member ] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > <
a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_IncomeTaxesDetailsLineItems', window);" > < strong > Income Taxes (Details) [ Line Items ] < / strong >
< / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href ="
javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window);" > Tax credit carryforwards < / a > < / td > < td class ="
nump" > $ 400 < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display:
```

none;" id =" defref_orka_IncomeTaxesDetailsLineItems" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_IncomeTaxesDetailsLineItems < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Operating loss carryforwards that can be utilized in any tax year as a percentage of taxable income < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr: percentItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DeferredTaxAssetsOtherLossCarryforwards" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible loss carryforwards, classified as other. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 6 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_DeferredTaxAssetsOtherLossCarryforwards < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us-gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 6 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_IncomeTaxExpenseBenefit" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 270 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (i) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482964 / 270- 10- 50- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 32 < br >- Subparagraph (ee) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 32 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 12 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 12 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 231 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482663 / 740- 10- 55- 231 < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 9 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 9 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SAB Topic 6. I. 7) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479360 / 740- 10- S99- 1 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 8 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 8 < br > < br > Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 10 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 10 < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 22 < br >- Subparagraph (h) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 22 < br > < br > Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 7- 04 (9)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147477250 / 944- 220- S99- 1 < br > < br > Reference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 2 < br >- Subparagraph (a) < br >- SubTopic 20 < br >- Topic 740 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482659 / 740- 20- 45- 2 < br > < br > Reference 12: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 4- 08 (h)) < br >- SubTopic 10 < br >- Topic 235 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_IncomeTaxExpenseBenefit < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_OperatingLossCarryforwardsValuationAllowance" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_OperatingLossCarryforwardsValuationAllowance < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_IncomeTaxAuthorityAxis = us- gaap_DomesticCountryMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_IncomeTaxAuthorityAxis = us- gaap_DomesticCountryMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_IncomeTaxAuthorityAxis = us- gaap_StateAndLocalJurisdictionMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_IncomeTaxAuthorityAxis = us- gaap_StateAndLocalJurisdictionMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 101 < FILENAME > R65. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208160274160" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Income Taxes- Schedule of Loss Before Income Tax Expense (Details) < br > $ in Thousands < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < div > USD ($) < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract', window);" > < strong > Schedule of Loss Before Income Tax Expense [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window);" > Domestic < / a > < / td > < td class =" num" > $ (83, 724) < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window);" > Foreign < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" rou" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window);" > Loss before income tax expense < / a > < / td > < td class =" num" > $ (83, 724) < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id

```
=" defref_us- gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show.
hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div
> < p > The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations. < / p > < / div > < a href =" javascript: void (0);" onclick ="
Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >-
Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 10A < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 10A < br > <
br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 235 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >-
Paragraph 1 < br >- Subparagraph (SX 210. 4- 08 (h) (1)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1 < br > < / p > < / div > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong >
Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic < / td > < / tr > < tr > < td style =" padding- right:
4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli:
monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration <
/ td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void
(0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >-
Definition < / a > < div > < p > Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and
income (loss) attributable to noncontrolling interest. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p
> Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >-
Paragraph 22 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 22 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / exampleRef < br
>- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 48 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 /
2147482785 / 280- 10- 55- 48 < br > < br > Reference 3: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards
Codification < br >- Section 50 < br >- Paragraph 32 < br >- Subparagraph (f) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 32 < br > < br >
Reference 4: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >-
Paragraph 30 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 30 < br > < br > Reference 5: http: / / www. xbrl. org /
2009 / role / commonPracticeRef < br >- Topic 270 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (i) < br >-
Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482964 / 270- 10- 50- 1 < br > < br > Reference 6: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 280 <
br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 32 < br >- Subparagraph (ee) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org
/ 1943274 / 2147482810 / 280- 10- 50- 32 < br > < br > Reference 7: http: / / fasb. org / us- gaap / role / ref / otherTransitionRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting
Standards Codification < br >- Section 50 < br >- Paragraph 32 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 32 < br >
< br > Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >-
Paragraph 1 < br >- Subparagraph (SX 210. 7- 04 (11)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147477250 / 944- 220- S99- 1 < br > < br > Reference 9: http: / /
www. xbrl. org / 2003 / role / exampleRef < br >- Topic 280 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 31 < br >- Publisher FASB
< br >- URI https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 31 < br > < br > Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 942 < br >- SubTopic 235 <
br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 9- 05 (b) (2)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org /
1943274 / 2147477314 / 942- 235- S99- 1 < br > < br > Reference 11: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards
Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SX 210. 5- 03 (10)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2
< br > < br > Reference 12: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 942 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >-
Paragraph 1 < br >- Subparagraph (SX 210. 9- 04 (15)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478524 / 942- 220- S99- 1 < br > < / p > < / div > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong >
Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest < / td > < / tr >
< tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong >
< / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < /
td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;"
id =" defref_us- gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" > < tr > < td class =" hide" > < a style =" color: white;"
href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick ="
Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div
style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space:
nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > <
tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div
> < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" >
X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The
portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside
the entity' s country of domicile. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http:
/ / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 10A < br >- Publisher
FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 10A < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 235 < br >-
SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 4- 08 (h) (1)) < br >- Publisher FASB < br >- URI https: / /
asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" >
< table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < /
strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < /
strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div >
< / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 102 < FILENAME > R66. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT
> < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This
Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e.
nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id ="
idm46208160487744" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Income Taxes- Schedule of Statutory Federal Income Tax Rate to Income
Before Income Taxes (Details) < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th >
< / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window);" > < strong > Schedule of Statutory Federal Income Tax Rate to Income Before Income
Taxes [ Abstract ] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > <
a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window);" > Tax benefit
derived by applying the federal statutory rate to income before income taxes < / a > < / td > < td class =" num" > (21. 00 %) < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl"
style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window);" > Permanent differences < / a > < / td > < td class =" num" > (0. 18 %) < span > < / span > < / td > < / tr > < tr class ="
ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window);" > Research and development credits < / a > < / td > < td class =" num" > (3. 41 %) < span > < / span > < / td > < / tr
> < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window);" > Other < / a > < / td > < td class =" num" > (0. 87 %) < span > < / span > < / td > < / tr > < tr class =" ro"
> < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window);" > Change in the valuation allowance < / a > < / td > < td class =" nump" > 25. 46 % <
span > < / span > < / td > < / tr > < tr class =" reu" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR
(this,' defref_us- gaap_EffectiveIncomeTaxRateContinuingOperations', window);" > Income tax (benefit) expense < / a > < / td > < td class =" nump" > 0. 00 % < span > < / span > < / td > < / tr >
< / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_EffectiveIncomeTaxRateContinuingOperations" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr
> < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Percentage of current income
tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >
References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards
Codification < br >- Section 50 < br >- Paragraph 12 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 12 < br > < br > Reference 2: http: / / www.
xbrl. org / 2003 / role / exampleRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 231 < br >- Publisher FASB < br
>- URI https: / / asc. fasb. org / 1943274 / 2147482663 / 740- 10- 55- 231 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style ="
display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_EffectiveIncomeTaxRateContinuingOperations < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us-
gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: percentItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na
< / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding ="
0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" > < tr > < td class =" hide"
> < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Percentage of domestic federal statutory tax rate applicable to pretax income (loss). < / p > < / div > < a
href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br
>- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 12 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 /
2147482685 / 740- 10- 50- 12 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification <
```

```
br >- Section 55 < br >- Paragraph 231 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482663 / 740- 10- 55- 231 < br > < br > Reference 3: http: / / www. xbrl. org /
2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SAB Topic 6. I.
1. Q1) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479360 / 740- 10- S99- 1 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >-
Topic 235 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 4- 08 (h) (2)) < br >- Publisher FASB < br
>- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style ="
display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: <
/ strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: percentItemType < / td > < / tr > < tr > < td > < strong > Balance Type: <
/ strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table
border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick ="
Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a >
< div > < p > Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income
tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets. < / p > < / div > < a href =" javascript: void (0);" onclick ="
Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 740 < br >- SubTopic 10 < br >-
Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 231 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482663 / 740- 10- 55- 231 < br > < br
> Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph
12A < br >- Subparagraph (a) (6) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 12A < br > < br > Reference 3: http: / / www. xbrl. org / 2009 /
role / commonPracticeRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 12 < br >- Publisher FASB < br >- URI
https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 12 < br > < br > Reference 4: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 235 < br >- SubTopic 10 < br >-
Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 4- 08 (h) (2)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org /
1943274 / 2147480678 / 235- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border
=" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong >
Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: percentItemType < / td > < / tr > < tr > < td > <
strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < /
tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > <
/ td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Percentage of the
difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss)
from continuing operations attributable to other adjustments. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display:
none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >-
Paragraph 231 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482663 / 740- 10- 55- 231 < br > < br > Reference 2: http: / / www. xbrl. org / 2009 / role /
commonPracticeRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 12 < br >- Subparagraph (b) (3) < br >-
Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 12 < br > < br > Reference 3: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 740 <
br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 12 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 /
740- 10- 50- 12 < br > < br > Reference 4: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 235 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >-
Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 4- 08 (h) (2)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1 < br > < / p > < /
div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td
> < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments < / td > < / tr > < tr > < td style =" padding-
right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types:
percentItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td
> < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();"
> X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p >
Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from
continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of
country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross- border tax law. < / p > < / div > < a href =" javascript: void (0);"
onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 740 < br >-
SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 12 < br >- Subparagraph (b) (3) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org /
1943274 / 2147482685 / 740- 10- 50- 12 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border
=" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < /
strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: percentItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < /
strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table
border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" > < tr > < td
class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a
href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Percentage of the difference between reported income tax expense (benefit) and expected
income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit. < / p > <
/ div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role /
exampleRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 231 < br >- Publisher FASB < br >- URI https: / / asc.
fasb. org / 1943274 / 2147482663 / 740- 10- 55- 231 < br > < br > Reference 2: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name
Accounting Standards Codification < br >- Section 50 < br >- Paragraph 12A < br >- Subparagraph (b) (1) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 /
740- 10- 50- 12A < br > < br > Reference 3: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br
>- Section 50 < br >- Paragraph 12 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 12 < br > < br > Reference 4: http: / / www. xbrl. org / 2009 /
role / commonPracticeRef < br >- Topic 235 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 4- 08
(h) (2)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext
(this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space:
nowrap;" > us- gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: <
/ strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: percentItemType < / td > < / tr > < tr > < td > < strong > Balance Type: <
/ strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table
border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show.
hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div
> < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0"
cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace
Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance
Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < /
div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 103 < FILENAME > R67. htm < DESCRIPTION > IDEA: XBRL DOCUMENT <
TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove
This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e.
nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id ="
idm46208163426800" > < tr > < th class =" tl" colspan =" 1" rowspan =" 1" > < div style =" width: 200px;" > < strong > Income Taxes- Schedule of Components of the Deferred Tax Assets and
Liabilities (Details)- USD ($) < br > $ in Thousands < / strong > < / div > < / th > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < th class =" th" > < div > Feb. 05, 2024 < / div > < / th > <
/ tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_DeferredTaxAssetsNetAbstract', window);" > < strong > Deferred tax assets < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & #
160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR
(this,' defref_us- gaap_DeferredTaxAssetsOperatingLossCarryforwards', window);" > Net operating loss carryforwards < / a > < / td > < td class =" nump" > $ 2, 260 < span > < / span > < / td > <
td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);"
onclick =" Show. showAR (this,' defref_us- gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window);" > Research and development credits < / a > < / td > < td class =" nump" > 3,
080 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a"
href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window);" >
Stock- based compensation < / a > < / td > < td class =" nump" > 3, 063 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class ="
pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther', window);" > Accruals and other < / a > < / td > < td class =" nump" > 424 < span > < / span > < / td > < td class ="
text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);"
onclick =" Show. showAR (this,' defref_orka_DeferredTaxAssetsLeaseLiabilities', window);" > Lease liability < / a > < / td > < td class =" nump" > 203 < span > < / span > < / td > < td class ="
text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick ="
Show. showAR (this,' defref_us- gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window);" > Intangibles < / a > < / td > < td class =" nump" > 1, 477 < span > < / span > < / td > < td class
=" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick ="
```

Show. showAR (this,' defref_us- gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window);" > Capitalized R & amp; D expenses < / a > < / td > < td class =" nump" > 10, 994 <
span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" reu" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href
=" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DeferredTaxAssetsGross', window);" > Total deferred tax assets < / a > < / td > < td class =" nump" > 21, 501 < span >
< / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href ="
javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DeferredTaxLiabilitiesNetAbstract', window);" > < strong > Deferred tax liabilities < / strong > < / a > < / td > < td class ="
text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign ="
top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_DeferredTaxLiabilitiesRightOfUseAsset', window);" > Right- of- use asset < / a > < / td > < td
class =" num" > (184) < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rou" > < td class =" pl" style =" border- bottom: 0px;" valign ="
top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DeferredIncomeTaxLiabilities', window);" > Total deferred tax liabilities < / a > < / td > < td
class =" num" > (184) < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign ="
top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DeferredTaxAssetsValuationAllowance', window);" > Less valuation allowance < / a > < / td
> < td class =" num" > (21, 317) < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" rou" > < td class =" pl" style =" border- bottom: 0px;" valign ="
top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DeferredTaxAssetsLiabilitiesNet', window);" > Deferred tax assets, net < / a > < / td > < td
class =" text" > < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0"
cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_DeferredTaxAssetsLeaseLiabilities" > < tr > < td class =" hide" > < a style =" color: white;" href ="
javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" >- Definition < / a > < div > < p > Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.
< / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong >
Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_DeferredTaxAssetsLeaseLiabilities < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > <
strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > <
strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < /
tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_DeferredTaxLiabilitiesRightOfUseAsset" > < tr > < td
class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a
href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of deferred tax liability attributable to taxable temporary differences from right of use
assets. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a
href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > <
strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_DeferredTaxLiabilitiesRightOfUseAsset < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space:
nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > <
tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < /
div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DeferredIncomeTaxLiabilities" > <
tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding:
2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of deferred tax liability attributable to taxable temporary differences. < / p
> < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref /
legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (26) (b)) < br >-
Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >-
SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org /
1943274 / 2147482685 / 740- 10- 50- 2 < br > < br > Reference 3: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards
Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (26) (a)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10-
S99- 1 < br > < br > Reference 4: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 942 < br >- SubTopic 210 < br >- Name Accounting Standards Codification < br >- Section S99 <
br >- Paragraph 1 < br >- Subparagraph (SX 210. 9- 03 (15) (2)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478546 / 942- 210- S99- 1 < br > < / p > < / div > < a href
=" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong >
Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DeferredIncomeTaxLiabilities < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > <
strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td >
< strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td >
< / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < /
tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount before allocation
of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill. < / p > < / div > < a href =" javascript: void (0);" onclick
=" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 740 < br >- SubTopic
10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 6 < br
> < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" >
< tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets < / td > < / tr > < tr > < td style =" padding-
right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli:
monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < /
td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_DeferredTaxAssetsGross" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div
class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount before allocation of valuation allowances
of deferred tax asset attributable to deductible temporary differences and carryforwards. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a
> < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification <
br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 2 < br > < / p > < / div > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong >
Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DeferredTaxAssetsGross < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong >
Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong
> Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < /
table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" >
< tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding:
2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount, before allocation of valuation allowance, of deferred tax asset attributable
to deductible temporary difference from in- process research and development cost acquired in business combination or from joint venture formation or both. < / p > < / div > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >-
Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 /
2147482685 / 740- 10- 50- 6 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0"
cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DeferredTaxAssetsInProcessResearchAndDevelopment <
/ td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data
Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period
Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style
=" display: none;" id =" defref_us- gaap_DeferredTaxAssetsLiabilitiesNet" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" >
X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p >
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting. < / p > < /
div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role /
commonPracticeRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI https: / /
asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > <
table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DeferredTaxAssetsLiabilitiesNet < /
td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type:
< / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < /
strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style ="
display: none;" id =" defref_us- gaap_DeferredTaxAssetsNetAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < /
a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No
definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0"
cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DeferredTaxAssetsNetAbstract < / td > < / tr > < tr > < td style =" padding-
right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli:
stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td >
< / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_DeferredTaxAssetsOperatingLossCarryforwards" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < /
tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount before allocation
of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >
References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting
Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 6 < br > < / p > < / div > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong >
Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DeferredTaxAssetsOperatingLossCarryforwards < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space:
nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr

> < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 6 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share- based compensation. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 6 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 6 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DeferredTaxAssetsValuationAllowance" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DeferredTaxAssetsValuationAllowance < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DeferredTaxLiabilitiesNetAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DeferredTaxLiabilitiesNetAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 104 < FILENAME > R68. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208160839616" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Income Taxes- Schedule of Net Deferred Tax Assets (Details) < br > $ in Thousands < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < div > USD ($) < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DeferredTaxAssetsNetAbstract', window);" > < strong > Schedule of Net Deferred Tax Assets [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DeferredTaxAssetsValuationAllowance', window);" > Beginning balance < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window);" > Change in valuation allowance < / a > < / td > < td class =" nump" > 21, 317 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_DeferredTaxAssetsValuationAllowance', window);" > Ending balance < / a > < / td > < td class =" nump" > $ 21, 317 < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DeferredTaxAssetsNetAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DeferredTaxAssetsNetAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_DeferredTaxAssetsValuationAllowance" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_DeferredTaxAssetsValuationAllowance < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 105 < FILENAME > R69. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208163425968" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Income Taxes- Schedule of Unrecognized Tax Benefits (Details) < br > $ in Thousands < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < div > USD ($) < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window);" > < strong > Schedule of Unrecognized Tax Benefits [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_UnrecognizedTaxBenefits', window);" > Beginning balance < / a > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window);" > Changes related to tax

positions taken in the current year < / a > < / td > < td class =" nump" > 1, 047 < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_UnrecognizedTaxBenefits', window);" > Ending balance < / a > < / td > < td class =" nump" > $ 1, 047 < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_UnrecognizedTaxBenefits" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of unrecognized tax benefits. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 217 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482663 / 740- 10- 55- 217 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 15A < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 15A < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 10B < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482525 / 740- 10- 45- 10B < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_UnrecognizedTaxBenefits < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 217 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482663 / 740- 10- 55- 217 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 15A < br >- Subparagraph (a) (2) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 15A < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 106 < FILENAME > R70. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208165612000" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Option Agreements and License Agreements (Details)- USD ($) < br > $ in Millions < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < th class =" th" colspan =" 1" > 12 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < th class =" th" > < div > Dec. 31, 2023 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window);" > < strong > Option Agreements and License Agreements [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_OtherExpenses', window);" > Expenses < / a > < / td > < td class =" nump" > $ 42. 0 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis = orka_RegulatoryMilestonesMemberMember', window);" > Regulatory Milestones Member [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window);" > < strong > Option Agreements and License Agreements [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_NonRefundableMilestonePayments', window);" > Non- refundable milestone payments < / a > < / td > < td class =" nump" > $ 10. 0 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_ClassOfWarrantOrRightAxis = orka_ParukaWarrantObligationMember', window);" > Paruka Warrant Obligation [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window);" > < strong > Option Agreements and License Agreements [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum', window);" > Warrant purchase percentage < / a > < / td > < td class =" nump" > 1. 00 % < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_srt_CounterpartyNameAxis = orka_ParagonMember', window);" > Paragon [Member] | Clinical Development Milestones [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window);" > < strong > Option Agreements and License Agreements [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_NonRefundableMilestonePayments', window);" > Non- refundable milestone payments < / a > < / td > < td class =" nump" > $ 12. 0 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_srt_CounterpartyNameAxis = orka_ParagonMember', window);" > Paragon [Member] | Regulatory Milestones Member [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window);" > < strong > Option Agreements and License Agreements [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_NonRefundableMilestonePayments', window);" > Non- refundable milestone payments < / a > < / td > < td class =" nump" > $ 10. 0 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_srt_CounterpartyNameAxis = orka_ParagonMember', window);" > Paragon [Member] | Antibody Products [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window);" > < strong > Option Agreements and License Agreements [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_RoyaltyPayableOnProductSales', window);" > Royalty payable on product sales, description < / a > < / td > < td class =" text" > low single- digit percentage royalty for antibody products < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_RelatedPartyTransactionsByRelatedPartyAxis = orka_NominationOfADevelopmentCandidateMember', window);" > Nomination Of A Development Candidate [Member] | Paragon [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window);" > < strong > Option Agreements and License Agreements [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_NonRefundableMilestonePayments', window);" > Non- refundable milestone payments < / a > < / td > < td class =" nump" > $ 1. 5 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_TypeOfArrangementAxis = orka_ORKAZeroZeroOneLicenseAgreementMember', window);" > ORKA- 001 License Agreement [Member] | Paragon [Member] | Clinical Development Milestones [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window);" > < strong > Option Agreements and License Agreements [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_NonRefundableMilestonePayments', window);" > Non- refundable milestone payments < / a > < / td > < td class =" nump" > 12. 0 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_TypeOfArrangementAxis = orka_ORKAZeroZeroTwoLicenseAgreementMember', window);" > ORKA- 002 License Agreement [Member] | Paragon [Member] | Clinical Development Milestones [Member] < / a > < / td

> < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window);" > < strong > Option Agreements and License Agreements [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_NonRefundableMilestonePayments', window);" > Non- refundable milestone payments < / a > < / td > < td class =" nump" > $ 12. 0 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_TypeOfArrangementAxis = orka_ORKAZeroZeroOneMember', window);" > ORKA- 001 [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window);" > < strong > Option Agreements and License Agreements [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_DevelopmentCostsPercentage', window);" > Development costs, percentage < / a > < / td > < td class =" nump" > 50. 00 % < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_OtherResearchAndDevelopmentExpense', window);" > Research and development expenses < / a > < / td > < td class =" nump" > $ 13. 5 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_TypeOfArrangementAxis = orka_ORKAZeroZeroOneMember', window);" > ORKA- 001 [Member] | Paragon [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window);" > < strong > Option Agreements and License Agreements [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_PaymentsForFees', window);" > Initiation fee < / a > < / td > < td class =" nump" > 0. 8 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_TypeOfArrangementAxis = orka_ORKAZeroZeroOneMember', window);" > ORKA- 001 [Member] | Paragon [Member] | First Dosing of Human Patient in Phase1Trial Milestone [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window);" > < strong > Option Agreements and License Agreements [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_NonRefundableMilestonePayments', window);" > Non- refundable milestone payments < / a > < / td > < td class =" nump" > 2. 5 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_TypeOfArrangementAxis = orka_ORKAZeroZeroOneMember', window);" > ORKA- 001 [Member] | Related Party [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window);" > < strong > Option Agreements and License Agreements [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AccountsPayableOtherCurrent', window);" > Accounts payable and other current liabilities < / a > < / td > < td class =" nump" > 2. 8 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_TypeOfArrangementAxis = orka_ORKAZeroZeroOneMember', window);" > ORKA- 001 [Member] | Research and Development Expense [Member] | Paragon [Member] | First Dosing of Human Patient in Phase1Trial Milestone [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window);" > < strong > Option Agreements and License Agreements [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_MilestoneConsiderationPaid', window);" > Milestone consideration paid < / a > < / td > < td class =" nump" > 2. 5 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_TypeOfArrangementAxis = orka_ORKAZeroZeroOneMember', window);" > ORKA- 001 [Member] | Research and Development Expense [Member] | Paragon [Member] | Achievement Of Development Candidate [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window);" > < strong > Option Agreements and License Agreements [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_MilestoneConsiderationPaid', window);" > Milestone consideration paid < / a > < / td > < td class =" nump" > $ 1. 5 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_TypeOfArrangementAxis = orka_ORKAZeroZeroTwoMember', window);" > ORKA- 002 [Member] | Paruka Warrant Obligation [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window);" > < strong > Option Agreements and License Agreements [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum', window);" > Warrant purchase percentage < / a > < / td > < td class =" nump" > 1. 00 % < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_TypeOfArrangementAxis = orka_ORKAZeroZeroTwoMember', window);" > ORKA- 002 [Member] | Paragon [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window);" > < strong > Option Agreements and License Agreements [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_OtherResearchAndDevelopmentExpense', window);" > Research and development expenses < / a > < / td > < td class =" nump" > $ 7. 8 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_OtherDevelopmentCost', window);" > Development costs < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" nump" > $ 3. 3 < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_ResearchInitialFee', window);" > Research initial fees < / a > < / td > < td class =" nump" > 0. 8 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_TypeOfArrangementAxis = orka_ORKAZeroZeroTwoMember', window);" > ORKA- 002 [Member] | Paragon [Member] | First Dosing of Human Patient in Phase1Trial Milestone [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window);" > < strong > Option Agreements and License Agreements [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_NonRefundableMilestonePayments', window);" > Non- refundable milestone payments < / a > < / td > < td class =" nump" > 2. 5 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_TypeOfArrangementAxis = orka_ORKAZeroZeroTwoMember', window);" > ORKA- 002 [Member] | Related Party [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window);" > < strong > Option Agreements and License Agreements [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AccountsPayableOtherCurrent', window);" > Accounts payable and other current liabilities < / a > < / td > < td class =" nump" > 2. 7 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_TypeOfArrangementAxis = orka_ORKAZeroZeroTwoMember', window);" > ORKA- 002 [Member] | Research and Development Expense [Member] | Paragon [Member] | Achievement Of Development Candidate [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window);" > < strong > Option Agreements and License Agreements [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_MilestoneConsiderationPaid', window);" > Milestone consideration paid < / a > < / td > < td class =" nump" > $ 1. 5 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > class of warrant or right to purchase percentage of outstanding diluted stock maximum. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr: percentItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < /

table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_DevelopmentCostsPercentage" > < tr > < td class =" hide" > <
a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript:
void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Percentage of development costs. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext
(this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > <
div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" >
orka_DevelopmentCostsPercentage < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr >
< tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr: percentItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td >
< strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class ="
authRefData" style =" display: none;" id =" defref_orka_MilestoneConsiderationPaid" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show.
hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div
> < p > The milestone consideration paid amount. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p >
No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding ="
0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_MilestoneConsiderationPaid < / td > < / tr > < tr > < td style =" padding-
right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli:
monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration <
/ td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id ="
defref_orka_NonRefundableMilestonePayments" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > <
tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Non- refundable milestone
payments. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div >
< a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > <
strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_NonRefundableMilestonePayments < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space:
nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > <
tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < /
div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_OtherDevelopmentCost" > < tr > < td
class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a
href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Represent the amount of development costs. < / p > < / div > < a href =" javascript: void (0);"
onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style ="
white- space: nowrap;" > orka_OtherDevelopmentCost < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td >
orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit
< / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding ="
0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_ResearchInitialFee" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);"
onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >-
Definition < / a > < div > < p > The amount of research initial fees. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display:
none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0"
cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_ResearchInitialFee < / td > < / tr > < tr > < td style ="
padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli:
monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration <
/ td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id ="
defref_orka_RoyaltyPayableOnProductSales" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr >
< td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Royalty payable on product sales,
description. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div >
< a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > <
strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_RoyaltyPayableOnProductSales < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" >
< strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > <
strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr
> < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AccountsPayableOtherCurrent" > < tr > < td class ="
hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of obligations incurred classified as other, payable within one year or the normal operating
cycle, if longer. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us-
gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02
(19) (a)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext
(this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space:
nowrap;" > us- gaap_AccountsPayableOtherCurrent < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us-
gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit
< / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0"
cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" > < tr > < td class
=" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Line items represent financial concepts included in a table. These concepts are used to disclose
reportable information associated with domain members defined in one or many axes to the table. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >
References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 808 < br >- SubTopic 10 < br >- Name Accounting Standards
Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (d) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479402 / 808- 10- 50- 1 < br > < / p > < /
div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td
> < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems < / td > < / tr > < tr
> < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < /
td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td >
duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id ="
defref_us- gaap_OtherExpenses" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div
class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of expense classified as other. < / p > < /
div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref /
legacyRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SX 210. 5- 03 (6)) < br >-
Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2 < br > < br > Reference 2: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 220 < br >-
SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SX 210. 5- 03 (4)) < br >- Publisher FASB < br >- URI https: / / asc.
fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > <
table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_OtherExpenses < / td > < / tr > < tr > <
td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td >
< td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td
> duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id ="
defref_us- gaap_OtherResearchAndDevelopmentExpense" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td >
< / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of other
research and development expense. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1:
http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 730 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >-
Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482916 / 730- 10- 50- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < /
a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_OtherResearchAndDevelopmentExpense < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_
< / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td >
< / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0"
cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_PaymentsForFees" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);"
onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >-
Definition < / a > < div > < p > Amount of cash outflow for fees classified as other. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div
style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 25 < br >-
Subparagraph (g) < br >- SubTopic 10 < br >- Topic 230 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 25 < br > < / p > < / div > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong >
Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_PaymentsForFees < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong >
Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong
> Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr >
< / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis = orka_RegulatoryMilestonesMemberMember" > < tr > < td class =" hide" > < a style =" color: white;" href ="
javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" >
us- gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis = orka_RegulatoryMilestonesMemberMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space:

nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance
Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border
=" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_ClassOfWarrantOrRightAxis = orka_ParukaWarrantObligationMember" > < tr
> < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" >
< a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong
> < / td > < td style =" white- space: nowrap;" > us- gaap_ClassOfWarrantOrRightAxis = orka_ParukaWarrantObligationMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white-
space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong >
Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table
border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_srt_CounterpartyNameAxis = orka_ParagonMember" > < tr > < td class =" hide" >
< a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript:
void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style ="
white- space: nowrap;" > srt_CounterpartyNameAxis = orka_ParagonMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < /
strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr
> < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0"
class =" authRefData" style =" display: none;" id =" defref_us- gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis = orka_ClinicalDevelopmentMilestonesMember" > < tr
> < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" >
< a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong
> < / td > < td style =" white- space: nowrap;" > us- gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis = orka_ClinicalDevelopmentMilestonesMember < / td > < / tr > < tr
> < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td >
na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div >
< / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis = orka_AntibodyProductsMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void
(0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >-
Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis = orka_AntibodyProductsMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > <
strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < /
strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0"
cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_RelatedPartyTransactionsByRelatedPartyAxis =
orka_NominationOfADevelopmentCandidateMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < /
tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding ="
0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_RelatedPartyTransactionsByRelatedPartyAxis =
orka_NominationOfADevelopmentCandidateMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < /
td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong >
Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style
=" display: none;" id =" defref_us- gaap_TypeOfArrangementAxis = orka_ORKAZeroZeroOneLicenseAgreementMember" > < tr > < td class =" hide" > < a style =" color: white;" href ="
javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show.
toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" >
us- gaap_TypeOfArrangementAxis = orka_ORKAZeroZeroOneLicenseAgreementMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong >
Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < /
td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding ="
0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_TypeOfArrangementAxis = orka_ORKAZeroZeroTwoLicenseAgreementMember" > < tr > < td class
=" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > <
td style =" white- space: nowrap;" > us- gaap_TypeOfArrangementAxis = orka_ORKAZeroZeroTwoLicenseAgreementMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white-
space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong >
Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table
border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_TypeOfArrangementAxis = orka_ORKAZeroZeroOneMember" > < tr >
< td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > <
a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong >
< / td > < td style =" white- space: nowrap;" > us- gaap_TypeOfArrangementAxis = orka_ORKAZeroZeroOneMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space:
nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance
Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border
=" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis =
orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < /
a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0"
cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis = orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember < / td > < / tr > < tr > < td style =" padding-
right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr >
< td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr >
< / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_RelatedPartyTransactionAxis = us-
gaap_RelatedPartyMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class
=" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr
> < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_RelatedPartyTransactionAxis = us- gaap_RelatedPartyMember < / td > < / tr > < tr > < td style ="
padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < /
tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < /
td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_IncomeStatementLocationAxis = us-
gaap_ResearchAndDevelopmentExpenseMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > <
tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0"
cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_IncomeStatementLocationAxis = us-
gaap_ResearchAndDevelopmentExpenseMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td >
< / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong >
Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style
=" display: none;" id =" defref_us- gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis = orka_AchievementOfDevelopmentCandidateMember" > < tr > < td class =" hide"
> < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href ="
javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > <
td style =" white- space: nowrap;" > us- gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis = orka_AchievementOfDevelopmentCandidateMember < / td > < / tr > < tr > <
td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na
< / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < /
div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_TypeOfArrangementAxis =
orka_ORKAZeroZeroTwoMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > <
div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing ="
0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_TypeOfArrangementAxis = orka_ORKAZeroZeroTwoMember < / td > < / tr > < tr > < td
style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < /
td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < /
div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 107 < FILENAME > R71. htm < DESCRIPTION
> IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src ="
Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style.
display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0"
cellspacing =" 2" id =" idm46208165467408" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Commitment and Contingencies (Details)- USD
($) < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < th class =" th" colspan =" 1" > < / th > < th class =" th" colspan =" 1" > < / th > < / tr > < tr > <
th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < th class =" th" > < div > Jun. 15, 2024 < / div > < / th > < th class =" th" > < div > Feb. 06, 2024 < / div > < / th > < / tr > < tr class =" re" > <
td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_OtherCommitmentsLineItems',
window);" > < strong > Commitment and Contingencies [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > <
/ span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href ="
javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_OperatingLeaseRightOfUseAsset', window);" > Operating lease right- of- use assets < / a > < / td > < td class =" nump" > $
876, 000 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style ="
border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_OperatingLeaseLiabilityCurrent', window);" > Operating
lease liability, current < / a > < / td > < td class =" nump" > 213, 000 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > < span > < / span > < /
td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_OperatingLeaseLiabilityNoncurrent', window);" > Operating lease liability, noncurrent < / a > < / td > < td class =" nump" > $ 755, 000 < span > < / span > < / td > < td class =" text" > & #
160; < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href ="

javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_LesseeOperatingLeaseDiscountRate', window);" > Lease discount rate < / a > < / td > < td class =" nump" > 17. 95 % < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_OperatingLeaseVariableLeaseIncome', window);" > Variable lease expense < / a > < / td > < td class =" nump" > $ 300, 000 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_NonRefundableLicenseFee', window);" > Non- refundable license fee < / a > < / td > < td class =" nump" > $ 150, 000 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_srt_StatementGeographicalAxis = stpr_CA', window);" > California [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_OtherCommitmentsLineItems', window);" > < strong > Commitment and Contingencies [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_LesseeOperatingLeaseTermOfContract', window);" > Lease term < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > 39 months 15 days < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window);" > Remaining lease term < / a > < / td > < td class =" text" > 33 months < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_NonRefundableLicenseFee" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of non refundable license fee. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_NonRefundableLicenseFee < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_LesseeOperatingLeaseDiscountRate" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Discount rate used by lessee to determine present value of operating lease payments. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 842 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Subparagraph (c) (3) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478964 / 842- 20- 50- 3 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_LesseeOperatingLeaseDiscountRate < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: percentItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_LesseeOperatingLeaseTermOfContract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Term of lessee' s operating lease, in' PnYnMnDTnHnMnS' format, for example,' P1Y5M13D' represents reported fact of one year, five months, and thirteen days. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 842 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Subparagraph (a) (3) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478964 / 842- 20- 50- 3 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_LesseeOperatingLeaseTermOfContract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: durationItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_OperatingLeaseLiabilityCurrent" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Present value of lessee' s discounted obligation for lease payments from operating lease, classified as current. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 842 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 1 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479041 / 842- 20- 45- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_OperatingLeaseLiabilityCurrent < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_OperatingLeaseLiabilityNoncurrent" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Present value of lessee' s discounted obligation for lease payments from operating lease, classified as noncurrent. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 842 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 1 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479041 / 842- 20- 45- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_OperatingLeaseLiabilityNoncurrent < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_OperatingLeaseRightOfUseAsset" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of lessee' s right to use underlying asset under operating lease. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 842 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 1 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479041 / 842- 20- 45- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_OperatingLeaseRightOfUseAsset < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > debit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_OperatingLeaseVariableLeaseIncome" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of operating lease income from variable lease payments paid and payable to lessor, excluding amount included in measurement of lease receivable. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 842 < br >- SubTopic 30 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 5 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479773 / 842- 30- 50- 5 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 270 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6A < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482964 / 270- 10- 50- 6A < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_OperatingLeaseVariableLeaseIncome < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Weighted average remaining lease term for operating lease, in' PnYnMnDTnHnMnS' format, for example,' P1Y5M13D' represents reported fact of one year, five months, and thirteen days. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 842 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 53 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479589 / 842- 20- 55- 53 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 842 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 4 < br >- Subparagraph (g) (3) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478964 / 842- 20- 50- 4 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: durationItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_OtherCommitmentsLineItems" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show.

toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_OtherCommitmentsLineItems < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_srt_StatementGeographicalAxis = stpr_CA" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > srt_StatementGeographicalAxis = stpr_CA < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 108 < FILENAME > R72. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208163546304" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Commitment and Contingencies- Schedule of Company & # 8217; s Supplemental Cash Flow Information Related to Leases (Details) < br > $ in Thousands < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < div > USD ($) < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_SupplementalCashFlowInformationAbstract', window);" > < strong > Schedule of Company & # 8217; s Supplemental Cash Flow Information Related to Leases [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_OperatingLeasePayments', window);" > Cash paid for amounts included in the measurement of lease liabilities < / a > < / td > < td class =" nump" > $ 116 < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_OperatingLeasePayments" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 842 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 5 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479041 / 842- 20-45- 5 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 842 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 4 < br >- Subparagraph (g) (1) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478964 / 842- 20- 50- 4 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_OperatingLeasePayments < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_SupplementalCashFlowInformationAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_SupplementalCashFlowInformationAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 109 < FILENAME > R73. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208161307744" > < tr > < th class =" tl" colspan =" 1" rowspan =" 1" > < div style =" width: 200px;" > < strong > Commitment and Contingencies- Schedule of Company & # 8217; s Operating Lease Liabilities Showing the Aggregate Lease Payments (Details)- USD ($) < br > $ in Thousands < / strong > < / div > < / th > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < th class =" th" > < div > Feb. 06, 2024 < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window);" > < strong > Schedule of Company & # 8217; s Operating Lease Liabilities Showing the Aggregate Lease Payments [Abstract] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window);" > 2025 < / a > < / td > < td class =" nump" > $ 369 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window);" > 2026 < / a > < / td > < td class =" nump" > 494 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window);" > 2027 < / a > < / td > < td class =" nump" > 380 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" reu" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window);" > Total undiscounted lease payments < / a > < / td > < td class =" nump" > 1, 243 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window);" > Less: imputed interest < / a > < / td > < td class =" num" > (275) < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" reu" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_OperatingLeaseLiability', window);" > Total discounted lease payments < / a > < / td > < td class =" nump" > 968 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_OperatingLeaseLiabilityCurrent', window);" > Less: current portion of lease liability < / a > < / td > < td class =" num" > (213) < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_OperatingLeaseLiabilityNoncurrent', window);" > Non- current portion of lease liability < / a > < / td > < td class =" nump" > $ 755 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_LesseeOperatingLeaseLiabilityPaymentsDue" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of lessee' s undiscounted obligation for lease payment for operating lease. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 842 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478964 / 842- 20- 50- 6 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_LesseeOperatingLeaseLiabilityPaymentsDue < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of lessee' s undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 842 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478964 / 842- 20- 50- 6 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of lessee' s undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 842 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478964 / 842- 20- 50- 6 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of lessee' s undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >-

Topic 842 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478964 / 842- 20- 50- 6 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of lessee' s undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 842 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478964 / 842- 20- 50- 6 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- References < / a > < div > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_OperatingLeaseLiability" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Present value of lessee' s discounted obligation for lease payments from operating lease. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 842 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 1 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479041 / 842- 20- 45- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_OperatingLeaseLiability < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_OperatingLeaseLiabilityCurrent" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Present value of lessee' s discounted obligation for lease payments from operating lease, classified as current. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 842 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 1 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479041 / 842- 20- 45- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_OperatingLeaseLiabilityCurrent < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_OperatingLeaseLiabilityNoncurrent" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Present value of lessee' s discounted obligation for lease payments from operating lease, classified as noncurrent. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 842 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 1 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479041 / 842- 20- 45- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_OperatingLeaseLiabilityNoncurrent < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 110 < FILENAME > R74. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208160444016" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Net Loss Per Share (Details) < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < div > shares < / div > < / th > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StatementClassOfStockAxis = us- gaap_SeriesAPreferredStockMember', window);" > Series A Preferred Stock [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EarningsPerShareBasicLineItems', window);" > < strong > Net Loss per Share [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_WeightedAverageNumberOfSharesContingentlyIssuable', window);" > Weighted- average number of shares of as- converted < / a > < / td > < td class =" nump" > 495, 191 < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StatementClassOfStockAxis = us- gaap_SeriesBPreferredStockMember', window);" > Series B Preferred Stock [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EarningsPerShareBasicLineItems', window);" > < strong > Net Loss per Share [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_WeightedAverageNumberOfSharesContingentlyIssuable', window);" > Weighted- average number of shares of as- converted < / a > < / td > < td class =" nump" > 4, 328, 844 < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_EarningsPerShareBasicLineItems" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 2 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 3 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 3 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 60B < br >- Subparagraph (d) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 60B < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_EarningsPerShareBasicLineItems < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_WeightedAverageNumberOfSharesContingentlyIssuable" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Shares issuable for little or no cash consideration upon the satisfaction of certain conditions (contingently issuable shares) are considered outstanding common shares and included in the computation of basic Earnings Per Share as of the date that all necessary conditions have been satisfied (in essence, when issuance of the shares is no longer contingent). Outstanding common shares that are contingently returnable (that is, subject to recall) are treated in the same manner as contingently issuable shares. Contingently issuable shares include shares that (a) will be issued in the future upon the satisfaction of specified conditions, (b) have been placed in escrow and all or part must be returned if specified conditions are not met, or (c) have been issued but the holder must return all or part if specified conditions are not met. The number of contingently issuable shares is determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Name Accounting Standards Codification < br >- Topic 260 < br >- SubTopic 10 < br >- Section 45 < br >- Paragraph 13 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 13 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_WeightedAverageNumberOfSharesContingentlyIssuable < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StatementClassOfStockAxis = us- gaap_SeriesAPreferredStockMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StatementClassOfStockAxis = us- gaap_SeriesAPreferredStockMember < / td > < / tr >

< tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StatementClassOfStockAxis = us- gaap_SeriesBPreferredStockMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StatementClassOfStockAxis = us- gaap_SeriesBPreferredStockMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 111 < FILENAME > R75. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208161956688" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Net Loss Per Share- Schedule of Basic and Diluted Net Loss Per Share Attributable to Stockholders (Details) < br > $ / shares in Units, $ in Thousands < / strong > < / div > < / th > < th class =" th" colspan =" 2" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" colspan =" 2" > < div > Dec. 31, 2024 < / div > < div > USD ($) < / div > < div > $ / shares < / div > < div > shares < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EarningsPerShareDilutedLineItems', window);" > < strong > Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_NetIncomeLoss', window);" > Net loss | $ < / a > < / td > < td class =" num" > $ (83, 724) < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_WeightedAverageNumberOfSharesOutstandingBasic', window);" > Weighted average shares outstanding & # 8211; Basic | shares < / a > < / td > < td class =" nump" > 16, 789, 362 < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window);" > Weighted average shares outstanding & # 8211; Diluted | shares < / a > < / td > < td class =" nump" > 16, 789, 362 < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EarningsPerShareBasic', window);" > Loss per share & # 8211; Basic | $ / shares < / a > < / td > < td class =" num" > $ (3. 87) < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EarningsPerShareDiluted', window);" > Loss per share & # 8211; Diluted | $ / shares < / a > < / td > < td class =" num" > $ (3. 87) < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StatementClassOfStockAxis = us- gaap_SeriesAPreferredStockMember', window);" > Series A Preferred Stock [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EarningsPerShareDilutedLineItems', window);" > < strong > Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_NetIncomeLoss', window);" > Net loss | $ < / a > < / td > < td class =" num" > $ (1, 918) < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < sup > [1] < / sup > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_WeightedAverageNumberOfSharesOutstandingBasic', window);" > Weighted average shares outstanding & # 8211; Basic | shares < / a > < / td > < td class =" nump" > 495 < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < sup > [1] < / sup > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window);" > Weighted average shares outstanding & # 8211; Diluted | shares < / a > < / td > < td class =" nump" > 495 < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < sup > [1] < / sup > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EarningsPerShareBasic', window);" > Loss per share & # 8211; Basic | $ / shares < / a > < / td > < td class =" num" > $ (3, 873. 25) < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EarningsPerShareDiluted', window);" > Loss per share & # 8211; Diluted | $ / shares < / a > < / td > < td class =" num" > $ (3, 873. 25) < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StatementClassOfStockAxis = us- gaap_SeriesBPreferredStockMember', window);" > Series B Preferred Stock [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EarningsPerShareDilutedLineItems', window);" > < strong > Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_NetIncomeLoss', window);" > Net loss | $ < / a > < / td > < td class =" num" > $ (16, 769) < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < sup > [2] < / sup > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_WeightedAverageNumberOfSharesOutstandingBasic', window);" > Weighted average shares outstanding & # 8211; Basic | shares < / a > < / td > < td class =" nump" > 51, 946 < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < sup > [2] < / sup > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window);" > Weighted average shares outstanding & # 8211; Diluted | shares < / a > < / td > < td class =" nump" > 51, 946 < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < sup > [2] < / sup > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EarningsPerShareBasic', window);" > Loss per share & # 8211; Basic | $ / shares < / a > < / td > < td class =" num" > $ (322. 81) < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EarningsPerShareDiluted', window);" > Loss per share & # 8211; Diluted | $ / shares < / a > < / td > < td class =" num" > $ (322. 81) < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StatementEquityComponentsAxis = us- gaap_CommonStockMember', window);" > Common Stock [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EarningsPerShareDilutedLineItems', window);" > < strong > Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_NetIncomeLoss', window);" > Net loss | $ < / a > < / td > < td class =" num" > $ (65, 037) < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_WeightedAverageNumberOfSharesOutstandingBasic', window);" > Weighted average shares outstanding & # 8211; Basic | shares < / a > < / td > < td class =" nump" > 16, 789, 362 < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window);" > Weighted average shares outstanding & # 8211; Diluted | shares < / a > < / td > < td class =" nump" > 16, 789, 362 < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EarningsPerShareBasic', window);" > Loss per share & # 8211; Basic | $ / shares < / a > < / td > < td class =" num" > $ (3. 87) < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_EarningsPerShareDiluted', window);" > Loss per share & # 8211; Diluted | $ / shares < / a > < / td > < td class =" num" > $ (3. 87) < span > < / span > < / td > < td class =" fn" style =" border- bottom: 0px;" > < / td > < / tr > < tr > < td colspan =" 3" > < / td > < / tr > < tr > < td colspan =" 3" > < table class =" outerFootnotes" width =" 100 %" > < tr class =" outerFootnote" > < td style =" vertical- align: top; width: 12pt;" valign =" top" > [1] < / td > < td style =" vertical- align: top;" valign =" top" > < span style =" font- family: Times New Roman, Times, Serif" > The weighted- average number of shares of as- converted Company Series A Preferred Stock used in the loss allocation was 495, 191 for the period from February 6, 2024 (inception) to December 31, 2024. < / span > < / td > < / tr > < tr class =" outerFootnote" > < td style =" vertical- align: top; width: 12pt;" valign =" top" > [2] < / td > < td style =" vertical- align: top;" valign =" top" > < span style =" font- family: Times New Roman, Times, Serif" > The weighted- average number of shares of as- converted Company Series B Preferred Stock used in the loss allocation was 4, 328, 844 for the period from February 6, 2024 (inception) to December 31, 2024. < / span > < / td > < / tr > < / table > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_EarningsPerShareBasic" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 6 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 52 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482635 / 260- 10- 55- 52 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 805 < br >- SubTopic 60 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 1 < br >- Subparagraph (g) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147476176 / 805- 60- 65- 1 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 323 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 2 < br >- Subparagraph (g) (3) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478666 / 740- 323- 65- 2 < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 3 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 15 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482635 / 260- 10- 55- 15 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 815 < br >- SubTopic 40 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 1 < br >- Subparagraph (e) (4) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480175 / 815- 40- 65- 1 < br > < br > Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 815 < br >- SubTopic 40 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 1 < br >- Subparagraph (f) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480175 / 815- 40- 65- 1 < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 11 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 /

250- 10- 50- 11 < br > < br > Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 11 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 11 < br > < br > Reference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 7 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 7 < br > < br > Reference 12: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 2 < br > < br > Reference 13: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 60B < br >- Subparagraph (d) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 60B < br > < br > Reference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 4 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 4 < br > < br > Reference 15: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482662 / 260- 10- 50- 1 < br > < br > Reference 16: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 10 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 10 < br > < br > Reference 17: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SX 210. 5- 03 (25)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2 < br > < br > Reference 18: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 942 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 9- 04 (27)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478524 / 942- 220- S99- 1 < br > < br > Reference 19: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 7- 04 (23)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147477250 / 944- 220- S99- 1 < br > < br > Reference 20: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 7 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 7 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_EarningsPerShareBasic < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: perShareItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_EarningsPerShareDiluted" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 6 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 52 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482635 / 260- 10- 55- 52 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 805 < br >- SubTopic 60 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 1 < br >- Subparagraph (g) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147476176 / 805- 60- 65- 1 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 323 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 2 < br >- Subparagraph (g) (3) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478666 / 740- 323- 65- 2 < br > < br > Reference 5: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 3 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 15 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482635 / 260- 10- 55- 15 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 815 < br >- SubTopic 40 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 1 < br >- Subparagraph (e) (4) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480175 / 815- 40- 65- 1 < br > < br > Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 815 < br >- SubTopic 40 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 1 < br >- Subparagraph (f) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480175 / 815- 40- 65- 1 < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 11 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 11 < br > < br > Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 11 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 11 < br > < br > Reference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 7 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 7 < br > < br > Reference 12: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 2 < br > < br > Reference 13: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 60B < br >- Subparagraph (d) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 60B < br > < br > Reference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 4 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 4 < br > < br > Reference 15: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482662 / 260- 10- 50- 1 < br > < br > Reference 16: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SX 210. 5- 03 (25)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2 < br > < br > Reference 17: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 942 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 9- 04 (27)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478524 / 942- 220- S99- 1 < br > < br > Reference 18: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 7- 04 (23)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147477250 / 944- 220- S99- 1 < br > < br > Reference 19: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 7 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 7 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_EarningsPerShareDiluted < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > dtr- types: perShareItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_EarningsPerShareDilutedLineItems" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 2 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 3 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 3 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 60B < br >- Subparagraph (d) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 60B < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_EarningsPerShareDilutedLineItems < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_NetIncomeLoss" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 6 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 9 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 9 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 805 < br >- SubTopic 60 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 1 < br >- Subparagraph (g) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147476176 / 805- 60- 65- 1 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 740 < br >- SubTopic 323 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 2 < br >- Subparagraph (g) (3) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478666 / 740- 323- 65- 2 < br > < br > Reference 5: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 2 < br >- Subparagraph (SX 210. 5- 03 (20)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2 < br > < br > Reference 6: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 235 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 4- 08 (g) (1) (ii)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1 < br > < br > Reference 7: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 323 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Subparagraph (c) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481687 / 323- 10- 50- 3 < br > < br > Reference 8: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 825 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 28 < br >- Subparagraph (f) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482907 / 825- 10- 50- 28 < br > < br > Reference 9: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482765 / 220- 10- 50- 6 < br > < br > Reference 10: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 3 < br > < br > Reference 11: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (b) (2) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 1 < br > < br > Reference 12: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 815 < br >- SubTopic 40 < br >- Name Accounting Standards Codification < br >- Section 65 < br >- Paragraph 1 < br >- Subparagraph (f) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 /

2147480175 / 815- 40- 65- 1 < br > < br > Reference 13: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 8 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 8 < br > < br > Reference 14: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 11 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 11 < br > < br > Reference 15: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 11 < br >- Subparagraph (b) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 11 < br > < br > Reference 16: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 250 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 4 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 4 < br > < br > Reference 17: http: / / www. xbrl. org / 2003 / role / exampleRef < br >- Topic 946 < br >- SubTopic 830 < br >- Name Accounting Standards Codification < br >- Section 55 < br >- Paragraph 10 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479168 / 946- 830- 55- 10 < br > < br > Reference 18: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 7 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479105 / 946- 220- 45- 7 < br > < br > Reference 19: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 944 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 7- 04 (18)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147477250 / 944- 220- S99- 1 < br > < br > Reference 20: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 07 (9)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1 < br > < br > Reference 21: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 3 < br >- Subparagraph (SX 210. 6- 09 (1) (d)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3 < br > < br > Reference 22: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (i)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 23: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (ii)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 24: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (iii) (A)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 25: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (4) (iv)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 26: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1A < br >- Subparagraph (SX 210. 13- 01 (a) (5)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A < br > < br > Reference 27: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (i)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 28: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iii) (A)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 29: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iii) (B)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 30: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (4) (iv)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 31: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 470 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1B < br >- Subparagraph (SX 210. 13- 02 (a) (5)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B < br > < br > Reference 32: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 60B < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 60B < br > < br > Reference 33: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 205 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 7 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483499 / 205- 20- 50- 7 < br > < br > Reference 34: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 230 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 28 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28 < br > < br > Reference 35: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 1A < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 1A < br > < br > Reference 36: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 220 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 1B < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 1B < br > < br > Reference 37: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 942 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 9- 04 (22)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478524 / 942- 220- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_NetIncomeLoss < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_WeightedAverageNumberOfDilutedSharesOutstanding" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482662 / 260- 10- 50- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 16 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 16 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_WeightedAverageNumberOfDilutedSharesOutstanding < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_WeightedAverageNumberOfSharesOutstandingBasic" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (a) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482662 / 260- 10- 50- 1 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 10 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 10 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_WeightedAverageNumberOfSharesOutstandingBasic < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StatementClassOfStockAxis = us- gaap_SeriesAPreferredStockMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StatementClassOfStockAxis = us- gaap_SeriesAPreferredStockMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StatementClassOfStockAxis = us- gaap_SeriesBPreferredStockMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StatementClassOfStockAxis = us- gaap_SeriesBPreferredStockMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StatementEquityComponentsAxis = us- gaap_CommonStockMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StatementEquityComponentsAxis = us- gaap_CommonStockMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 112 < FILENAME > R76. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208161367520" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Net Loss Per Share- Schedule of Anti- Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share (Details) < br > < / strong > < / div > < / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < div > shares < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window);" > < strong > Schedule of Anti- Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-

gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window);" > Total anti- dilutive securities < / a > < / td > < td class =" nump" > 7, 426, 601 < span > < / span
> < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = orka_EmployeeWarrantsMember', window);" > Employee Warrants [Member] < / a
> < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript:
void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window);" > < strong > Schedule of Anti- Dilutive
Effect Excluded from Potential Computation of Diluted Net Loss Per Share [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class ="
re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window);" > Total anti- dilutive securities < / a > < / td > < td class =" nump" > 3, 054, 358 < span > < / span
> < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = orka_RestrictedStockAwardsMember', window);" > Restricted Stock Awards [
Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href
=" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window);" > < strong > Schedule of
Anti- Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr >
< tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window);" > Total anti- dilutive securities < / a > < / td > < td class =" nump" > 2, 207, 553 < span > < / span
> < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = orka_StockOptionsMember', window);" > Stock Options [Member] < / a > < / td > <
td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);"
onclick =" Show. showAR (this,' defref_us- gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window);" > < strong > Schedule of Anti- Dilutive Effect
Excluded from Potential Computation of Diluted Net Loss Per Share [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > <
td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window);" > Total anti- dilutive securities < / a > < / td > < td class =" nump" > 1, 567, 760 < span > < / span
> < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = orka_ParukaWarrantMember', window);" > Paruka Warrant [Member] < / a > < /
td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void
(0);" onclick =" Show. showAR (this,' defref_us- gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window);" > < strong > Schedule of Anti- Dilutive Effect
Excluded from Potential Computation of Diluted Net Loss Per Share [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > <
td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window);" > Total anti- dilutive securities < / a > < / td > < td class =" nump" > 596, 930 < span > < / span >
< / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show.
hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div
> < p > Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that
were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. < / p > < /
div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role /
disclosureRef < br >- Topic 260 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 1 < br >- Subparagraph (c) < br >- Publisher FASB <
br >- URI https: / / asc. fasb. org / 1943274 / 2147482662 / 260- 10- 50- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style ="
display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace
Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: sharesItemType < / td > < / tr > < tr > < td > < strong > Balance
Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > <
table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show.
hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div
> < p > Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the
table. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a
href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > <
strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems < / td > < / tr > < tr > < td
style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > <
td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td >
duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id ="
defref_us- gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = orka_EmployeeWarrantsMember" > < tr > < td class =" hide" > < a style
=" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void
(0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style ="
white- space: nowrap;" > us- gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = orka_EmployeeWarrantsMember < / td > < / tr > < tr >
< td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td >
na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div >
< / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = orka_RestrictedStockAwardsMember" > < tr > < td class =" hide" > < a style ="
color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);"
onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white-
space: nowrap;" > us- gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = orka_RestrictedStockAwardsMember < / td > < / tr > < tr > <
td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na
< / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < /
div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = orka_StockOptionsMember" > < tr > < td class =" hide" > < a style =" color: white;"
href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick ="
Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space:
nowrap;" > us- gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = orka_StockOptionsMember < / td > < / tr > < tr > < td style ="
padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < /
tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < /
td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = orka_ParukaWarrantMember" > < tr > < td class =" hide" > < a style =" color:
white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick
=" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space:
nowrap;" > us- gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = orka_ParukaWarrantMember < / td > < / tr > < tr > < td style ="
padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < /
tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < /
td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 113 < FILENAME > R77. htm < DESCRIPTION > IDEA:
XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" >
/ * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display ='
block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing ="
2" id =" idm46208162341440" > < tr > < th class =" tl" colspan =" 1" rowspan =" 2" > < div style =" width: 200px;" > < strong > Related Party Transactions (Details) < br > < / strong > < / div >
< / th > < th class =" th" colspan =" 1" > 11 Months Ended < / th > < / tr > < tr > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < / tr > < tr class =" rh" > < td class =" pl" style ="
border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_srt_OwnershipAxis =
orka_FairmountsOwnershipInterestInParagonMember', window);" > Fairmount' s Ownership Interest in Paragon [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < /
td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us-
gaap_RelatedPartyTransactionLineItems', window);" > < strong > Related Party Transactions [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > <
/ tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners', window);" > Ownership percentage < / a > < / td > < td class =" text" > beneficially owns more than
5 % < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR
(this,' defref_us- gaap_StatementClassOfStockAxis = us- gaap_CommonStockMember', window);" > Common Stock [Member] | Paragon [Member] < / a > < / td > < td class =" text" > & #
160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR
(this,' defref_us- gaap_RelatedPartyTransactionLineItems', window);" > < strong > Related Party Transactions [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < /
span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'
defref_orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners', window);" > Ownership percentage < / a > < / td > < td class =" text" > beneficially own less than 5
% < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR
(this,' defref_us- gaap_StatementClassOfStockAxis = us- gaap_CommonStockMember', window);" > Common Stock [Member] | Paruka [Member] < / a > < / td > < td class =" text" > & # 160;
< span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR
(this,' defref_us- gaap_RelatedPartyTransactionLineItems', window);" > < strong > Related Party Transactions [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < /
span > < / td > < / tr > < tr class =" re" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,'

defref_orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners', window);" > Ownership percentage < / a > < / td > < td class =" text" > beneficially own less than 5 % < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_StatementClassOfStockAxis = us- gaap_CommonStockMember', window);" > Common Stock [Member] | Fairmount [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_RelatedPartyTransactionLineItems', window);" > < strong > Related Party Transactions [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl custom" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners', window);" > Ownership percentage < / a > < / td > < td class =" text" > beneficially owns more than 5 % < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Description of minority interest ownership percentage by noncontrolling owners. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > No definition available. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > orka_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_RelatedPartyTransactionLineItems" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 310 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 13 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481990 / 310- 10- 45- 13 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 07 (2) (c) (2) (i)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 07 (2) (c) (2) (ii)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 07 (2) (g) (3)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_RelatedPartyTransactionLineItems < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_srt_OwnershipAxis = orka_FairmountsOwnershipInterestInParagonMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > srt_OwnershipAxis = orka_FairmountsOwnershipInterestInParagonMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_StatementClassOfStockAxis = us- gaap_CommonStockMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_StatementClassOfStockAxis = us- gaap_CommonStockMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_srt_OwnershipAxis = orka_ParagonMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > srt_OwnershipAxis = orka_ParagonMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_srt_OwnershipAxis = orka_ParukaMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > srt_OwnershipAxis = orka_ParukaMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_srt_OwnershipAxis = orka_FairmountHealthcareFundIILPMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > srt_OwnershipAxis = orka_FairmountHealthcareFundIILPMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 114 < FILENAME > R78. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208163107824" > < tr > < th class =" tl" colspan =" 1" rowspan =" 1" > < div style =" width: 200px;" > < strong > Related Party Transactions- Schedule of Related Party Accounts Payable and Other Current Liabilities (Details)- USD ($) < br > $ in Thousands < / strong > < / div > < / th > < th class =" th" > < div > Dec. 31, 2024 < / div > < / th > < th class =" th" > < div > Feb. 06, 2024 < / div > < / th > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_RelatedPartyTransactionsByRelatedPartyAxis = orka_ParagonReimbursableOptionAgreementsFeesMember', window);" > Paragon reimbursable Option Agreements & # 8217; fees [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_RelatedPartyTransactionLineItems', window);" > < strong > Schedule of Related Party Accounts Payable and Other Current Liabilities [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AccountsPayableOtherCurrent', window);" > Related party accounts payable and other current liabilities < / a > < / td > < td class =" nump" > $ 1, 482 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_RelatedPartyTransactionsByRelatedPartyAxis = orka_ParagonMilestonePaymentsForOptionAgreementMember', window);" > Paragon milestone payments for Option Agreement [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_RelatedPartyTransactionLineItems', window);" > < strong > Schedule of Related Party Accounts Payable and Other Current Liabilities [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AccountsPayableOtherCurrent', window);" > Related party accounts payable and other current liabilities < / a > < / td > < td class =" nump" > 4, 000 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_RelatedPartyTransactionsByRelatedPartyAxis = orka_ParagonReimbursableOtherResearchExpensesMember', window);" > Paragon reimbursable other research expenses [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_RelatedPartyTransactionLineItems', window);" > < strong > Schedule of Related Party Accounts Payable and Other Current Liabilities [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AccountsPayableOtherCurrent', window);" > Related party accounts payable and other current liabilities < / a > < / td > < td class =" nump" > 515 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_RelatedPartyTransactionsByRelatedPartyAxis = orka_ParagonReimbursablePatentExpensesMember', window);" > Paragon reimbursable patent expenses [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_RelatedPartyTransactionLineItems', window);" > < strong > Schedule of Related Party Accounts Payable and Other Current Liabilities [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AccountsPayableOtherCurrent', window);" > Related party accounts payable and other current liabilities < / a > < / td > < td class =" nump" > 25 < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" rh" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_RelatedPartyTransactionsByRelatedPartyAxis = us- gaap_RelatedPartyMember', window);" > Related Party [Member] < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_RelatedPartyTransactionLineItems', window);" > < strong > Schedule of Related Party Accounts Payable and Other Current Liabilities [Line Items] < / strong > < / a > < / td > < td class

=" text" > & # 160; < span > < / span > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_AccountsPayableOtherCurrent', window);" > Related party accounts payable and other current liabilities < / a > < / td > < td class =" nump" > $ 6, 022 < span > < / span > < / td > < td class =" text" > < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_AccountsPayableOtherCurrent" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / fasb. org / us- gaap / role / ref / legacyRef < br >- Topic 210 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 5- 02 (19) (a)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_AccountsPayableOtherCurrent < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_RelatedPartyTransactionLineItems" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 310 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 45 < br >- Paragraph 13 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481990 / 310- 10- 45- 13 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 07 (2) (c) (2) (i)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1 < br > < br > Reference 3: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 07 (2) (c) (2) (ii)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1 < br > < br > Reference 4: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 946 < br >- SubTopic 220 < br >- Name Accounting Standards Codification < br >- Section S99 < br >- Paragraph 1 < br >- Subparagraph (SX 210. 6- 07 (2) (g) (3)) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_RelatedPartyTransactionLineItems < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: stringItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > duration < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = orka_ParagonReimbursableOptionAgreementsFeesMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = orka_ParagonReimbursableOptionAgreementsFeesMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_RelatedPartyTransactionsByRelatedPartyAxis = orka_ParagonMilestonePaymentsForOptionAgreementMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_RelatedPartyTransactionsByRelatedPartyAxis = orka_ParagonMilestonePaymentsForOptionAgreementMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_RelatedPartyTransactionsByRelatedPartyAxis = orka_ParagonReimbursableOtherResearchExpensesMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_RelatedPartyTransactionsByRelatedPartyAxis = orka_ParagonReimbursableOtherResearchExpensesMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = orka_ParagonReimbursablePatentExpensesMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = orka_ParagonReimbursablePatentExpensesMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_RelatedPartyTransactionsByRelatedPartyAxis = us- gaap_RelatedPartyMember" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Details < / a > < div > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_RelatedPartyTransactionsByRelatedPartyAxis = us- gaap_RelatedPartyMember < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < / div > < / body > < / html > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 115 < FILENAME > R79. htm < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < html > < head > < title > < / title > < link rel =" stylesheet" type =" text / css" href =" include / report. css" > < script type =" text / javascript" src =" Show. js" > / * Do Not Remove This Comment * / < / script > < script type =" text / javascript" > function toggleNextSibling (e) { if (e. nextSibling. style. display = =' none') { e. nextSibling. style. display =' block'; } else { e. nextSibling. style. display =' none'; } } < / script > < / head > < body > < span style =" display: none;" > v3. 25. 0. 1 < / span > < table class =" report" border =" 0" cellspacing =" 2" id =" idm46208356615344" > < tr > < th class =" tl" colspan =" 1" rowspan =" 1" > < div style =" width: 200px;" > < strong > Subsequent Events (Details)- Subsequent Event [Member] < br > $ in Millions < / strong > < / div > < / th > < th class =" th" > < div > Feb. 28, 2025 < / div > < div > USD ($) < / div > < / th > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_SubsequentEventLineItems', window);" > < strong > Subsequent Events [Line Items] < / strong > < / a > < / td > < td class =" text" > & # 160; < span > < / span > < / td > < / tr > < tr class =" ro" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_LesseeOperatingLeaseTermOfContract', window);" > Lease initial period < / a > < / td > < td class =" text" > 54 months < span > < / span > < / td > < / tr > < tr class =" re" > < td class =" pl" style =" border- bottom: 0px;" valign =" top" > < a class =" a" href =" javascript: void (0);" onclick =" Show. showAR (this,' defref_us- gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window);" > Future lease payment < / a > < / td > < td class =" nump" > $ 1. 6 < span > < / span > < / td > < / tr > < / table > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Amount of lessee' s undiscounted obligation for lease payment for operating lease. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 842 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 6 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478964 / 842- 20- 50- 6 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_LesseeOperatingLeaseLiabilityPaymentsDue < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: monetaryItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > credit < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_LesseeOperatingLeaseTermOfContract" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Term of lessee' s operating lease, in' PnYnMnDTnHnMnS' format, for example,' P1Y5M13D' represents reported fact of one year, five months, and thirteen days. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2009 / role / commonPracticeRef < br >- Topic 842 < br >- SubTopic 20 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 3 < br >- Subparagraph (a) (3) < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147478964 / 842- 20- 50- 3 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" > us- gaap_LesseeOperatingLeaseTermOfContract < / td > < / tr > < tr > < td style =" padding- right: 4px; white- space: nowrap;" > < strong > Namespace Prefix: < / strong > < / td > < td > us- gaap_ < / td > < / tr > < tr > < td > < strong > Data Type: < / strong > < / td > < td > xbrli: durationItemType < / td > < / tr > < tr > < td > < strong > Balance Type: < / strong > < / td > < td > na < / td > < / tr > < tr > < td > < strong > Period Type: < / strong > < / td > < td > instant < / td > < / tr > < / table > < / div > < / div > < / td > < / tr > < / table > < table border =" 0" cellpadding =" 0" cellspacing =" 0" class =" authRefData" style =" display: none;" id =" defref_us- gaap_SubsequentEventLineItems" > < tr > < td class =" hide" > < a style =" color: white;" href =" javascript: void (0);" onclick =" Show. hideAR ();" > X < / a > < / td > < / tr > < tr > < td > < div class =" body" style =" padding: 2px;" > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" >- Definition < / a > < div > < p > Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > References < / a > < div style =" display: none;" > < p > Reference 1: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 830 < br >- SubTopic 30 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147481674 / 830- 30- 50- 2 < br > < br > Reference 2: http: / / www. xbrl. org / 2003 / role / disclosureRef < br >- Topic 855 < br >- SubTopic 10 < br >- Name Accounting Standards Codification < br >- Section 50 < br >- Paragraph 2 < br >- Publisher FASB < br >- URI https: / / asc. fasb. org / 1943274 / 2147483399 / 855- 10- 50- 2 < br > < / p > < / div > < a href =" javascript: void (0);" onclick =" Show. toggleNext (this);" > Details < / a > < div style =" display: none;" > < table border =" 0" cellpadding =" 0" cellspacing =" 0" > < tr > < td > < strong > Name: < / strong > < / td > < td style =" white- space: nowrap;" >

```
PO = V ] R: W- H965T < R ] S M: & 5E = # < Y GAM; %! 0 (4 Q0 (# V 9EK % HX4 = 50, X6- M" 9? F 0! X;" ] S =' EL97, N > & UL4 $ L! A0 # % @ / 8! F6I > * NQS M $ P (L (! % H! % ]
R96QS RYR96QS4 $ L! A0 # % M @ / 8! F6B \ = @ XCD! 0: 30 \ (!. L!' AL W = O < FMB M; V ] K GAM; %! 0 (4 Q0 (# V 9EJ [ 2 = ? 8 @ ( 0N: M" 1' Q 0! X;" ]? < F5L < R ] W; W) K8F ] O:
RYX; 6PN < F5L < U! 0 (4 Q0 (M # V 9EK =) VL & ((4M 3": OS 0!; 0V ] N = & 5N = % ] 4? > 7! E < UTN > & UL4 $ L %! @! 7 % < V! < / 3U 0 $! end < / TEXT > < / DOCUMENT > <
DOCUMENT > < TYPE > XML < SEQUENCE > 117 < FILENAME > Show. js < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > / / Edgar (tm) Renderer was created by staff of the U.
S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U. S. C.
105. var Show = { }; Show. LastAR = null, Show. showAR = function (a, r, w) { if (Show. LastAR) Show. hideAR (); var e = a; while (e & & e. nodeName! =' TABLE') e = e. nextSibling; if (! e | | e.
nodeName! =' TABLE') { var ref = ((window)? w. document: document). getElementById (r); if (ref) { e = ref. cloneNode (! 0); e. removeAttribute (' id'); a. parentNode. appendChild (e) } } if (e)
e. style. display =' block'; Show. LastAR = e }; Show. hideAR = function () { Show. LastAR. style. display =' none' }; Show. toggleNext = function (a) { var e = a; while (e. nodeName! =' DIV') e = e.
nextSibling; if (! e. style) { } else if (! e. style. display) { } else { var d, p_; if (e. style. display = =' none') { d =' block'; p ='-' } else { d =' none'; p =' ' } e. style. display = d; if (a. textContent) { a.
textContent = p a. textContent. substring (1) } else { a. innerText = p a. innerText. substring (1) } } } < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 118 <
FILENAME > report. css < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > / * Updated 2009- 11- 04 * / / * v2. 2. 0. 24 * / / * DefRef Styles * /. report table. authRefData { background-
color: # def; border: 2px solid # 2F4497; font- size: 1em; position: absolute; }. report table. authRefData a { display: block; font- weight: bold; }. report table. authRefData p { margin- top: 0px; }.
report table. authRefData. hide { background- color: # 2F4497; padding: 1px 3px 0px 0px; text- align: right; }. report table. authRefData. hide a: hover { background- color: # 2F4497; }. report
table. authRefData. body { height: 150px; overflow: auto; width: 400px; }. report table. authRefData table { font- size: 1em; } / * Report Styles * /. pl a,. pl a: visited { color: black; text-
decoration: none; } / * table * /. report { background- color: white; border: 2px solid # acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san- serif; margin- bottom: 2em; }. report
hr { border: 1px solid # acf; } / * Top labels * /. report th { background- color: # acf; color: black; font- weight: bold; text- align: center; }. report th. void { background- color: transparent; color:
# 000000; font: bold 10pt Helvetica, Arial, san- serif; text- align: left; }. report. pl { text- align: left; vertical- align: top; white- space: normal; width: 200px; white- space: normal; / * word- wrap:
break- word; * / }. report td. pl a. a { cursor: pointer; display: block; width: 200px; overflow: hidden; }. report td. pl div. a { width: 200px; }. report td. pl a: hover { background- color: # ffc; } / *
Header rows... * /. report tr. rh { background- color: # acf; color: black; font- weight: bold; } / * Calendars... * /. report. rc { background- color: # f0f0f0; } / * Even rows... * /. report. re,. report.
reu { background- color: # def; }. report. reu td { border- bottom: 1px solid black; } / * Odd rows... * /. report. ro,. report. rou { background- color: white; }. report. rou td { border- bottom: 1px
solid black; }. report. rou table td,. report. reu table td { border- bottom: 0px solid black; } / * styles for footnote marker * /. report. fn { white- space: nowrap; } / * styles for numeric types * /.
report. num,. report. nump { text- align: right; white- space: nowrap; }. report. nump { padding- left: 2em; }. report. nump { padding: 0px 0. 4em 0px 2em; } / * styles for text types * /. report.
text { text- align: left; white- space: normal; }. report. text. big { margin- bottom: 1em; width: 17em; }. report. text. more { display: none; }. report. text. note { font- style: italic; font- weight: bold;
}. report. text. small { width: 10em; }. report sup { font- style: italic; }. report. outerFootnotes { font- size: 1em; } < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE
> 120 < FILENAME > FilingSummary. xml < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > < XML > < FilingSummary > < Version > 3. 25. 0. 1 < / Version > < ProcessingTime / > <
ReportFormat > html < / ReportFormat > < ContextCount > 199 < / ContextCount > < ElementCount > 396 < / ElementCount > < EntityCount > 1 < / EntityCount > < FootnotesReported > true <
/ FootnotesReported > < SegmentCount > 95 < / SegmentCount > < ScenarioCount > 0 < / ScenarioCount > < TuplesReported > false < / TuplesReported > < UnitCount > 4 < / UnitCount > <
MyReports > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R1. htm < /
HtmlFileName > < LongName > 995100- Document- Cover < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / xbrl. sec. gov / dei / role / document / Cover < / Role > <
ShortName > Cover < / ShortName > < MenuCategory > Cover < / MenuCategory > < Position > 1 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault >
false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R2. htm < / HtmlFileName > < LongName > 995300- Document- Audit Information < /
LongName > < ReportType > Sheet < / ReportType > < Role > http: / / xbrl. sec. gov / dei / role / document / AuditInformation < / Role > < ShortName > Audit Information < / ShortName > <
MenuCategory > Cover < / MenuCategory > < Position > 2 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > <
HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R3. htm < / HtmlFileName > < LongName > 995301- Statement- Consolidated Balance Sheets < / LongName > <
ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ConsolidatedBalanceSheet < / Role > < ShortName > Consolidated Balance Sheets < / ShortName > <
MenuCategory > Statements < / MenuCategory > < Position > 3 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > <
HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R4. htm < / HtmlFileName > < LongName > 995302- Statement- Consolidated Balance Sheets (Parentheticals) < /
LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ConsolidatedBalanceSheet_Parentheticals < / Role > < ShortName > Consolidated Balance
Sheets (Parentheticals) < / ShortName > < MenuCategory > Statements < / MenuCategory > < Position > 4 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > <
IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R5. htm < / HtmlFileName > < LongName > 995303- Statement- Consolidated
Statement of Operations and Comprehensive Loss < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome < /
Role > < ShortName > Consolidated Statement of Operations and Comprehensive Loss < / ShortName > < MenuCategory > Statements < / MenuCategory > < Position > 5 < / Position > < / Report
> < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R6. htm < /
HtmlFileName > < LongName > 995304- Statement- Consolidated Statement of Operations and Comprehensive Loss (Parentheticals) < / LongName > < ReportType > Sheet < / ReportType > <
Role > http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome_Parentheticals < / Role > < ShortName > Consolidated Statement of Operations and Comprehensive Loss
(Parentheticals) < / ShortName > < MenuCategory > Statements < / MenuCategory > < Position > 6 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault
> false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R7. htm < / HtmlFileName > < LongName > 995305- Statement- Consolidated Statement of
Convertible Preferred Stock and Stockholders??? Equity < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ShareholdersEquityType2or3 < /
Role > < ShortName > Consolidated Statement of Convertible Preferred Stock and Stockholders??? Equity < / ShortName > < MenuCategory > Statements < / MenuCategory > < Position > 7 < /
Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName >
R8. htm < / HtmlFileName > < LongName > 995306- Statement- Consolidated Statement of Convertible Preferred Stock and Stockholders??? Equity (Parentheticals) < / LongName > <
ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ShareholdersEquityType2or3_Parentheticals < / Role > < ShortName > Consolidated Statement of Convertible
Preferred Stock and Stockholders??? Equity (Parentheticals) < / ShortName > < MenuCategory > Statements < / MenuCategory > < Position > 8 < / Position > < / Report > < Report instance ="
ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R9. htm < / HtmlFileName > < LongName >
995307- Statement- Consolidated Statement of Cash Flows < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ConsolidatedCashFlow < / Role >
< ShortName > Consolidated Statement of Cash Flows < / ShortName > < MenuCategory > Statements < / MenuCategory > < Position > 9 < / Position > < / Report > < Report instance ="
ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R10. htm < / HtmlFileName > < LongName >
995308- Disclosure- Nature of the Business and Basis of Presentation < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role /
NatureoftheBusinessandBasisofPresentation < / Role > < ShortName > Nature of the Business and Basis of Presentation < / ShortName > < MenuCategory > Notes < / MenuCategory > < Position
> 10 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > <
HtmlFileName > R11. htm < / HtmlFileName > < LongName > 995309- Disclosure- Summary of Significant Accounting Policies < / LongName > < ReportType > Sheet < / ReportType > < Role >
http: / / www. orukatx. com / role / SummaryofSignificantAccountingPolicies < / Role > < ShortName > Summary of Significant Accounting Policies < / ShortName > < MenuCategory > Notes < /
MenuCategory > < Position > 11 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < /
HasEmbeddedReports > < HtmlFileName > R12. htm < / HtmlFileName > < LongName > 995310- Disclosure- Reverse Recapitalization and Pre- Closing Financing < / LongName > < ReportType
> Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ReverseRecapitalizationandPreClosingFinancing < / Role > < ShortName > Reverse Recapitalization and Pre- Closing
Financing < / ShortName > < MenuCategory > Notes < / MenuCategory > < Position > 12 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < /
IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R13. htm < / HtmlFileName > < LongName > 995311- Disclosure- Fair Value Measurements < /
LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / FairValueMeasurements < / Role > < ShortName > Fair Value Measurements < / ShortName > <
MenuCategory > Notes < / MenuCategory > < Position > 13 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > <
HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R14. htm < / HtmlFileName > < LongName > 995312- Disclosure- Cash equivalents and Marketable Securities < /
LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / CashequivalentsandMarketableSecurities < / Role > < ShortName > Cash equivalents and
Marketable Securities < / ShortName > < MenuCategory > Notes < / MenuCategory > < Position > 14 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > <
IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R15. htm < / HtmlFileName > < LongName > 995313- Disclosure- Accrued
Expenses and Other Current Liabilities < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / AccruedExpensesandOtherCurrentLiabilities < /
Role > < ShortName > Accrued Expenses and Other Current Liabilities < / ShortName > < MenuCategory > Notes < / MenuCategory > < Position > 15 < / Position > < / Report > < Report
instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R16. htm < / HtmlFileName > <
LongName > 995314- Disclosure- Note Payable with Related Party < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role /
NotePayablewithRelatedParty < / Role > < ShortName > Note Payable with Related Party < / ShortName > < MenuCategory > Notes < / MenuCategory > < Position > 16 < / Position > < / Report >
< Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R17. htm < /
HtmlFileName > < LongName > 995315- Disclosure- Convertible Preferred Stock and Stockholders??? Equity < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www.
orukatx. com / role / ConvertiblePreferredStockandStockholdersEquity < / Role > < ShortName > Convertible Preferred Stock and Stockholders??? Equity < / ShortName > < MenuCategory >
Notes < / MenuCategory > < Position > 17 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < /
HasEmbeddedReports > < HtmlFileName > R18. htm < / HtmlFileName > < LongName > 995316- Disclosure- Stock- Based Compensation < / LongName > < ReportType > Sheet < / ReportType
> < Role > http: / / www. orukatx. com / role / StockBasedCompensation < / Role > < ShortName > Stock- Based Compensation < / ShortName > < MenuCategory > Notes < / MenuCategory > <
Position > 18 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > <
HtmlFileName > R19. htm < / HtmlFileName > < LongName > 995317- Disclosure- Segment Disclosures < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx.
com / role / SegmentDisclosures < / Role > < ShortName > Segment Disclosures < / ShortName > < MenuCategory > Notes < / MenuCategory > < Position > 19 < / Position > < / Report > < Report
instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R20. htm < / HtmlFileName > <
LongName > 995318- Disclosure- Income Taxes < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / IncomeTaxes < / Role > < ShortName >
Income Taxes < / ShortName > < MenuCategory > Notes < / MenuCategory > < Position > 20 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false
< / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R21. htm < / HtmlFileName > < LongName > 995319- Disclosure- Option Agreements and License
Agreements < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreements < / Role > < ShortName > Option
Agreements and License Agreements < / ShortName > < MenuCategory > Notes < / MenuCategory > < Position > 21 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe.
htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R22. htm < / HtmlFileName > < LongName > 995320- Disclosure-
Commitment and Contingencies < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / CommitmentandContingencies < / Role > < ShortName >
Commitment and Contingencies < / ShortName > < MenuCategory > Notes < / MenuCategory > < Position > 22 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" >
< IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R23. htm < / HtmlFileName > < LongName > 995321- Disclosure- Net Loss Per
Share < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / NetLossPerShare < / Role > < ShortName > Net Loss Per Share < / ShortName > <
MenuCategory > Notes < / MenuCategory > < Position > 23 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > <
HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R24. htm < / HtmlFileName > < LongName > 995322- Disclosure- Related Party Transactions < / LongName > <
ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / RelatedPartyTransactions < / Role > < ShortName > Related Party Transactions < / ShortName > <
```

MenuCategory > Notes < / MenuCategory > < Position > 24 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R25. htm < / HtmlFileName > < LongName > 995323- Disclosure- Subsequent Events < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / SubsequentEvents < / Role > < ShortName > Subsequent Events < / ShortName > < MenuCategory > Notes < / MenuCategory > < Position > 25 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R26. htm < / HtmlFileName > < LongName > 995410- Disclosure- Pay vs Performance Disclosure < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / xbrl. sec. gov / ecd / role / PvpDisclosure < / Role > < ShortName > Pay vs Performance Disclosure < / ShortName > < MenuCategory > Notes < / MenuCategory > < Position > 26 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R27. htm < / HtmlFileName > < LongName > 995445- Disclosure- Insider Trading Arrangements < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / xbrl. sec. gov / ecd / role / InsiderTradingArrangements < / Role > < ShortName > Insider Trading Arrangements < / ShortName > < MenuCategory > Notes < / MenuCategory > < Position > 27 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R28. htm < / HtmlFileName > < LongName > 995550- Disclosure- Cybersecurity Risk Management and Strategy Disclosure < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / xbrl. sec. gov / cyd / role / CybersecurityRiskManagementAndStrategyDisclosure < / Role > < ShortName > Cybersecurity Risk Management and Strategy Disclosure < / ShortName > < MenuCategory > Notes < / MenuCategory > < Position > 28 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R29. htm < / HtmlFileName > < LongName > 996000- Disclosure- Accounting Policies, by Policy (Policies) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / AccountingPoliciesByPolicy < / Role > < ShortName > Accounting Policies, by Policy (Policies) < / ShortName > < MenuCategory > Policies < / MenuCategory > < ParentRole > http: / / www. orukatx. com / role / SummaryofSignificantAccountingPolicies < / ParentRole > < Position > 29 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R30. htm < / HtmlFileName > < LongName > 996001- Disclosure- Summary of Significant Accounting Policies (Tables) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / SummaryofSignificantAccountingPoliciesTables < / Role > < ShortName > Summary of Significant Accounting Policies (Tables) < / ShortName > < MenuCategory > Tables < / MenuCategory > < ParentRole > http: / / www. orukatx. com / role / SummaryofSignificantAccountingPolicies < / ParentRole > < Position > 30 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R31. htm < / HtmlFileName > < LongName > 996002- Disclosure- Reverse Recapitalization and Pre- Closing Financing (Tables) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ReverseRecapitalizationandPreClosingFinancingTables < / Role > < ShortName > Reverse Recapitalization and Pre- Closing Financing (Tables) < / ShortName > < MenuCategory > Tables < / MenuCategory > < ParentRole > http: / / www. orukatx. com / role / ReverseRecapitalizationandPreClosingFinancing < / ParentRole > < Position > 31 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R32. htm < / HtmlFileName > < LongName > 996003- Disclosure- Fair Value Measurements (Tables) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / FairValueMeasurementsTables < / Role > < ShortName > Fair Value Measurements (Tables) < / ShortName > < MenuCategory > Tables < / MenuCategory > < ParentRole > http: / / www. orukatx. com / role / FairValueMeasurements < / ParentRole > < Position > 32 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R33. htm < / HtmlFileName > < LongName > 996004- Disclosure- Cash equivalents and Marketable Securities (Tables) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / CashequivalentsandMarketableSecuritiesTables < / Role > < ShortName > Cash equivalents and Marketable Securities (Tables) < / ShortName > < MenuCategory > Tables < / MenuCategory > < ParentRole > http: / / www. orukatx. com / role / CashequivalentsandMarketableSecurities < / ParentRole > < Position > 33 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R34. htm < / HtmlFileName > < LongName > 996005- Disclosure- Accrued Expenses and Other Current Liabilities (Tables) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / AccruedExpensesandOtherCurrentLiabilitiesTables < / Role > < ShortName > Accrued Expenses and Other Current Liabilities (Tables) < / ShortName > < MenuCategory > Tables < / MenuCategory > < ParentRole > http: / / www. orukatx. com / role / AccruedExpensesandOtherCurrentLiabilities < / ParentRole > < Position > 34 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R35. htm < / HtmlFileName > < LongName > 996006- Disclosure- Convertible Preferred Stock and Stockholders??? Equity (Tables) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityTables < / Role > < ShortName > Convertible Preferred Stock and Stockholders??? Equity (Tables) < / ShortName > < MenuCategory > Tables < / MenuCategory > < ParentRole > http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquity < / ParentRole > < Position > 35 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R36. htm < / HtmlFileName > < LongName > 996007- Disclosure- Stock- Based Compensation (Tables) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / StockBasedCompensationTables < / Role > < ShortName > Stock- Based Compensation (Tables) < / ShortName > < MenuCategory > Tables < / MenuCategory > < ParentRole > http: / / www. orukatx. com / role / StockBasedCompensation < / ParentRole > < Position > 36 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R37. htm < / HtmlFileName > < LongName > 996008- Disclosure- Segment Disclosures (Tables) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / SegmentDisclosuresTables < / Role > < ShortName > Segment Disclosures (Tables) < / ShortName > < MenuCategory > Tables < / MenuCategory > < ParentRole > http: / / www. orukatx. com / role / SegmentDisclosures < / ParentRole > < Position > 37 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R38. htm < / HtmlFileName > < LongName > 996009- Disclosure- Income Taxes (Tables) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / IncomeTaxesTables < / Role > < ShortName > Income Taxes (Tables) < / ShortName > < MenuCategory > Tables < / MenuCategory > < ParentRole > http: / / www. orukatx. com / role / IncomeTaxes < / ParentRole > < Position > 38 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R39. htm < / HtmlFileName > < LongName > 996010- Disclosure- Commitment and Contingencies (Tables) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / CommitmentandContingenciesTables < / Role > < ShortName > Commitment and Contingencies (Tables) < / ShortName > < MenuCategory > Tables < / MenuCategory > < ParentRole > http: / / www. orukatx. com / role / CommitmentandContingencies < / ParentRole > < Position > 39 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R40. htm < / HtmlFileName > < LongName > 996011- Disclosure- Net Loss Per Share (Tables) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / NetLossPerShareTables < / Role > < ShortName > Net Loss Per Share (Tables) < / ShortName > < MenuCategory > Tables < / MenuCategory > < ParentRole > http: / / www. orukatx. com / role / NetLossPerShare < / ParentRole > < Position > 40 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R41. htm < / HtmlFileName > < LongName > 996012- Disclosure- Related Party Transactions (Tables) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / RelatedPartyTransactionsTables < / Role > < ShortName > Related Party Transactions (Tables) < / ShortName > < MenuCategory > Tables < / MenuCategory > < ParentRole > http: / / www. orukatx. com / role / RelatedPartyTransactions < / ParentRole > < Position > 41 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R42. htm < / HtmlFileName > < LongName > 996013- Disclosure- Nature of the Business and Basis of Presentation (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails < / Role > < ShortName > Nature of the Business and Basis of Presentation (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentation < / ParentRole > < Position > 42 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R43. htm < / HtmlFileName > < LongName > 996014- Disclosure- Summary of Significant Accounting Policies (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / SummaryofSignificantAccountingPoliciesDetails < / Role > < ShortName > Summary of Significant Accounting Policies (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / www. orukatx. com / role / SummaryofSignificantAccountingPoliciesTables < / ParentRole > < Position > 43 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R44. htm < / HtmlFileName > < LongName > 996015- Disclosure- Summary of Significant Accounting Policies- Schedule of Property and Equipment (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ScheduleofPropertyandEquipmentTable < / Role > < ShortName > Summary of Significant Accounting Policies- Schedule of Property and Equipment (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < Position > 44 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R45. htm < / HtmlFileName > < LongName > 996016- Disclosure- Reverse Recapitalization and Pre- Closing Financing- Schedule of the Assets and Liabilities (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ScheduleoftheAssetsandLiabilitiesTable < / Role > < ShortName > Reverse Recapitalization and Pre- Closing Financing- Schedule of the Assets and Liabilities (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < Position > 45 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R46. htm < / HtmlFileName > < LongName > 996017- Disclosure- Fair Value Measurements- Schedule of Fair Value Hierarchy for Financial Assets Measured (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable < / Role > < ShortName > Fair Value Measurements- Schedule of Fair Value Hierarchy for Financial Assets Measured (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < Position > 46 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R47. htm < / HtmlFileName > < LongName > 996018- Disclosure- Cash equivalents and Marketable Securities- Schedule of Cash Equivalents and Marketable Securities (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ScheduleofCashEquivalentsandMarketableSecuritiesTable < / Role > < ShortName > Cash equivalents and Marketable Securities- Schedule of Cash Equivalents and Marketable Securities (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < Position > 47 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R48. htm < / HtmlFileName > < LongName > 996019- Disclosure- Cash equivalents and Marketable Securities- Schedule of Available- for- Sale Securities in an Unrealized Loss Position (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable < / Role > < ShortName > Cash equivalents and Marketable Securities- Schedule of Available- for- Sale Securities in an Unrealized Loss Position (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < Position > 48 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R49. htm < / HtmlFileName > < LongName > 996020- Disclosure- Cash equivalents and Marketable Securities- Schedule of Marketable Securities at Estimated Fair Value (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ScheduleofMarketableSecuritiesatEstimatedFairValueTable < / Role > < ShortName > Cash equivalents and Marketable Securities- Schedule of Marketable Securities at Estimated Fair Value (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < Position > 49 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R50. htm < / HtmlFileName > < LongName > 996021- Disclosure- Accrued Expenses and Other Current Liabilities- Schedule of Accrued Expenses and Other Current Liabilities (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable < / Role > < ShortName > Accrued Expenses and Other Current Liabilities- Schedule of Accrued Expenses and Other Current Liabilities (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < Position > 50 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R51. htm < / HtmlFileName > < LongName > 996022- Disclosure- Note Payable with Related Party (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / NotePayablewithRelatedPartyDetails < / Role > < ShortName > Note Payable with Related Party (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / www. orukatx. com / role / NotePayablewithRelatedParty < / ParentRole > < Position > 51 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R52. htm < / HtmlFileName > < LongName > 996023- Disclosure- Convertible Preferred Stock and

Stockholders??? Equity (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails < / Role > < ShortName > Convertible Preferred Stock and Stockholders??? Equity (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityTables < / ParentRole > < Position > 52 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R53. htm < / HtmlFileName > < LongName > 996024- Disclosure- Convertible Preferred Stock and Stockholders??? Equity- Schedule of Convertible Preferred Stock (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ScheduleofConvertiblePreferredStockTable < / Role > < ShortName > Convertible Preferred Stock and Stockholders??? Equity- Schedule of Convertible Preferred Stock (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < Position > 53 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R54. htm < / HtmlFileName > < LongName > 996025- Disclosure- Convertible Preferred Stock and Stockholders??? Equity- Schedule of Common Stock Reserved for Future Issuance (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ScheduleofCommonStockReservedforFutureIssuanceTable < / Role > < ShortName > Convertible Preferred Stock and Stockholders??? Equity- Schedule of Common Stock Reserved for Future Issuance (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < Position > 54 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R55. htm < / HtmlFileName > < LongName > 996026- Disclosure- Stock- Based Compensation (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / StockBasedCompensationDetails < / Role > < ShortName > Stock- Based Compensation (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / www. orukatx. com / role / StockBasedCompensationTables < / ParentRole > < Position > 55 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R56. htm < / HtmlFileName > < LongName > 996027- Disclosure- Stock- Based Compensation- Schedule of Weighted- Average Assumptions Used in Calculating the Fair Value of the Awards (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable < / Role > < ShortName > Stock- Based Compensation- Schedule of Weighted- Average Assumptions Used in Calculating the Fair Value of the Awards (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < Position > 56 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R57. htm < / HtmlFileName > < LongName > 996028- Disclosure- Stock- Based Compensation- Schedule of Stock Option Activity (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ScheduleofStockOptionActivityTable < / Role > < ShortName > Stock- Based Compensation- Schedule of Stock Option Activity (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < Position > 57 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R58. htm < / HtmlFileName > < LongName > 996029- Disclosure- Stock- Based Compensation- Schedule of RSA Activity (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ScheduleofRSAActivityTable < / Role > < ShortName > Stock- Based Compensation- Schedule of RSA Activity (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < Position > 58 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R59. htm < / HtmlFileName > < LongName > 996030- Disclosure- Stock- Based Compensation- Schedule of Employee Warrant Activity (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ScheduleofEmployeeWarrantActivityTable < / Role > < ShortName > Stock- Based Compensation- Schedule of Employee Warrant Activity (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < Position > 59 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R60. htm < / HtmlFileName > < LongName > 996031- Disclosure- Stock- Based Compensation- Schedule of Company??? s Stock- Based Compensation Expense (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ScheduleofCompanysStockBasedCompensationExpenseTable < / Role > < ShortName > Stock- Based Compensation- Schedule of Company??? s Stock- Based Compensation Expense (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < Position > 60 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R61. htm < / HtmlFileName > < LongName > 996032- Disclosure- Stock- Based Compensation- Schedule of Award Types of Company??? s Stock- Based Compensation Expense (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable < / Role > < ShortName > Stock- Based Compensation- Schedule of Award Types of Company??? s Stock- Based Compensation Expense (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < Position > 61 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R62. htm < / HtmlFileName > < LongName > 996033- Disclosure- Segment Disclosures (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / SegmentDisclosuresDetails < / Role > < ShortName > Segment Disclosures (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / www. orukatx. com / role / SegmentDisclosuresTables < / ParentRole > < Position > 62 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R63. htm < / HtmlFileName > < LongName > 996034- Disclosure- Segment Disclosures- Schedule of Segment Loss from Operations (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ScheduleofSegmentLossfromOperationsTable < / Role > < ShortName > Segment Disclosures- Schedule of Segment Loss from Operations (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < Position > 63 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R64. htm < / HtmlFileName > < LongName > 996035- Disclosure- Income Taxes (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / IncomeTaxesDetails < / Role > < ShortName > Income Taxes (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / www. orukatx. com / role / IncomeTaxesTables < / ParentRole > < Position > 64 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R65. htm < / HtmlFileName > < LongName > 996036- Disclosure- Income Taxes- Schedule of Loss Before Income Tax Expense (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ScheduleofLossBeforeIncomeTaxExpenseTable < / Role > < ShortName > Income Taxes- Schedule of Loss Before Income Tax Expense (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < Position > 65 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R66. htm < / HtmlFileName > < LongName > 996037- Disclosure- Income Taxes- Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable < / Role > < ShortName > Income Taxes- Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < Position > 66 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R67. htm < / HtmlFileName > < LongName > 996038- Disclosure- Income Taxes- Schedule of Components of the Deferred Tax Assets and Liabilities (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable < / Role > < ShortName > Income Taxes- Schedule of Components of the Deferred Tax Assets and Liabilities (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < Position > 67 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R68. htm < / HtmlFileName > < LongName > 996039- Disclosure- Income Taxes- Schedule of Net Deferred Tax Assets (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ScheduleofNetDeferredTaxAssetsTable < / Role > < ShortName > Income Taxes- Schedule of Net Deferred Tax Assets (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < Position > 68 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R69. htm < / HtmlFileName > < LongName > 996040- Disclosure- Income Taxes- Schedule of Unrecognized Tax Benefits (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ScheduleofUnrecognizedTaxBenefitsTable < / Role > < ShortName > Income Taxes- Schedule of Unrecognized Tax Benefits (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < Position > 69 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R70. htm < / HtmlFileName > < LongName > 996041- Disclosure- Option Agreements and License Agreements (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails < / Role > < ShortName > Option Agreements and License Agreements (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreements < / ParentRole > < Position > 70 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R71. htm < / HtmlFileName > < LongName > 996042- Disclosure- Commitment and Contingencies (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / CommitmentandContingenciesDetails < / Role > < ShortName > Commitment and Contingencies (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / www. orukatx. com / role / CommitmentandContingenciesTables < / ParentRole > < Position > 71 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R72. htm < / HtmlFileName > < LongName > 996043- Disclosure- Commitment and Contingencies- Schedule of Company??? s Supplemental Cash Flow Information Related to Leases (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable < / Role > < ShortName > Commitment and Contingencies- Schedule of Company??? s Supplemental Cash Flow Information Related to Leases (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < Position > 72 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R73. htm < / HtmlFileName > < LongName > 996044- Disclosure- Commitment and Contingencies- Schedule of Company??? s Operating Lease Liabilities Showing the Aggregate Lease Payments (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable < / Role > < ShortName > Commitment and Contingencies- Schedule of Company??? s Operating Lease Liabilities Showing the Aggregate Lease Payments (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < Position > 73 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R74. htm < / HtmlFileName > < LongName > 996045- Disclosure- Net Loss Per Share (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / NetLossPerShareDetails < / Role > < ShortName > Net Loss Per Share (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / www. orukatx. com / role / NetLossPerShareTables < / ParentRole > < Position > 74 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R75. htm < / HtmlFileName > < LongName > 996046- Disclosure- Net Loss Per Share- Schedule of Basic and Diluted Net Loss Per Share Attributable to Stockholders (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable < / Role > < ShortName > Net Loss Per Share- Schedule of Basic and Diluted Net Loss Per Share Attributable to Stockholders (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < Position > 75 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R76. htm < / HtmlFileName > < LongName > 996047- Disclosure- Net Loss Per Share- Schedule of Anti- Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable < / Role > < ShortName > Net Loss Per Share- Schedule of Anti- Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < Position > 76 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R77. htm < / HtmlFileName > < LongName > 996048- Disclosure- Related Party Transactions (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / RelatedPartyTransactionsDetails < / Role > < ShortName > Related Party Transactions (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / www. orukatx. com / role / RelatedPartyTransactionsTables < / ParentRole > < Position > 77 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R78. htm < / HtmlFileName > < LongName > 996049- Disclosure- Related Party Transactions- Schedule of Related Party Accounts Payable and Other Current Liabilities (Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable < / Role > < ShortName > Related Party Transactions- Schedule of Related Party Accounts Payable and Other Current

Liabilities (Details) < / ShortName > < MenuCategory > Details < / MenuCategory > < Position > 78 < / Position > < / Report > < Report instance =" ea0230445- 10k_orukathe. htm" > < IsDefault
> false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < HtmlFileName > R79. htm < / HtmlFileName > < LongName > 996050- Disclosure- Subsequent Events
(Details) < / LongName > < ReportType > Sheet < / ReportType > < Role > http: / / www. orukatx. com / role / SubsequentEventsDetails < / Role > < ShortName > Subsequent Events (Details) < /
ShortName > < MenuCategory > Details < / MenuCategory > < ParentRole > http: / / www. orukatx. com / role / SubsequentEvents < / ParentRole > < Position > 79 < / Position > < / Report > <
Report > < IsDefault > false < / IsDefault > < HasEmbeddedReports > false < / HasEmbeddedReports > < LongName > All Reports < / LongName > < ReportType > Book < / ReportType > <
ShortName > All Reports < / ShortName > < / Report > < / MyReports > < InputFiles > < File doctype =" 10- K" isDefinitelyFs =" true" isUsgaap =" true" original =" ea0230445- 10k_orukathe.
htm" > ea0230445- 10k_orukathe. htm < / File > < File > orka- 20241231. xsd < / File > < File > orka- 20241231_cal. xml < / File > < File > orka- 20241231_def. xml < / File > < File > orka-
20241231_lab. xml < / File > < File > orka- 20241231_pre. xml < / File > < / InputFiles > < SupplementalFiles > < File > image_001. jpg < / File > < File > image_002. jpg < / File > < File >
image_003. jpg < / File > < File > image_003a. jpg < / File > < File > image_004. jpg < / File > < File > image_005. jpg < / File > < File > image_006. jpg < / File > < File > image_007. jpg < / File > <
/ SupplementalFiles > < BaseTaxonomies > < BaseTaxonomy items =" 698" > http: / / fasb. org / us- gaap / 2024 < / BaseTaxonomy > < BaseTaxonomy items =" 8" > http: / / xbrl. sec. gov / cyd /
2024 < / BaseTaxonomy > < BaseTaxonomy items =" 39" > http: / / xbrl. sec. gov / dei / 2024 < / BaseTaxonomy > < BaseTaxonomy items =" 4" > http: / / xbrl. sec. gov / ecd / 2024 < /
BaseTaxonomy > < / BaseTaxonomies > < HasPresentationLinkbase > true < / HasPresentationLinkbase > < HasCalculationLinkbase > true < / HasCalculationLinkbase > < / FilingSummary > < /
XML > < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > JSON < SEQUENCE > 122 < FILENAME > MetaLinks. json < DESCRIPTION > IDEA: XBRL DOCUMENT < TEXT > {"
version":" 2. 2"," instance": {" ea0230445- 10k_orukathe. htm": {" nsprefix":" orka"," nsuri":" http: / / www. orukatx. com / 20241231"," dts": {" inline": {" local": [" ea0230445-
10k_orukathe. htm"] }," schema": {" local": [" orka- 20241231. xsd"]," remote": [" http: / / www. xbrl. org / 2003 / xbrl- instance- 2003- 12- 31. xsd"," http: / / www. xbrl. org / 2003 / xbrl-
linkbase- 2003- 12- 31. xsd"," http: / / www. xbrl. org / 2003 / xl- 2003- 12- 31. xsd"," http: / / www. xbrl. org / 2003 / xlink- 2003- 12- 31. xsd"," http: / / www. xbrl. org / 2005 / xbrldt- 2005. xsd","
http: / / www. xbrl. org / 2006 / ref- 2006- 02- 27. xsd"," http: / / www. xbrl. org / lrr / role / negated- 2009- 12- 16. xsd"," http: / / www. xbrl. org / lrr / role / net- 2009- 12- 16. xsd"," http: / / www.
xbrl. org / lrr / role / reference- 2009- 12- 16. xsd"," https: / / www. xbrl. org / 2020 / extensible- enumerations- 2. 0. xsd"," https: / / www. xbrl. org / dtr / type / 2020- 01- 21 / types. xsd"," https: / /
www. xbrl. org / dtr / type / 2022- 03- 31 / types. xsd"," https: / / xbrl. fasb. org / srt / 2024 / elts / srt- 2024. xsd"," https: / / xbrl. fasb. org / srt / 2024 / elts / srt- roles- 2024. xsd"," https: / / xbrl.
fasb. org / srt / 2024 / elts / srt- types- 2024. xsd"," https: / / xbrl. fasb. org / us- gaap / 2024 / elts / us- gaap- 2024. xsd"," https: / / xbrl. fasb. org / us- gaap / 2024 / elts / us- roles- 2024. xsd"," https:
/ / xbrl. fasb. org / us- gaap / 2024 / elts / us- types- 2024. xsd"," https: / / xbrl. sec. gov / country / 2024 / country- 2024. xsd"," https: / / xbrl. sec. gov / cyd / 2024 / cyd- 2024. xsd"," https: / / xbrl.
sec. gov / cyd / 2024 / cyd- af- 2024. xsd"," https: / / xbrl. sec. gov / dei / 2024 / dei- 2024. xsd"," https: / / xbrl. sec. gov / dei / 2024 / dei- 2024_def. xsd"," https: / / xbrl. sec. gov / dei / 2024 / dei-
2024_lab. xsd"," https: / / xbrl. sec. gov / dei / 2024 / dei- 2024_pre. xsd"," https: / / xbrl. sec. gov / dei / 2024 / dei- sub- 2024. xsd"," https: / / xbrl. sec. gov / ecd / 2024 / ecd- 2024. xsd"," https: / /
xbrl. sec. gov / ecd / 2024 / ecd- sub- 2024. xsd"," https: / / xbrl. sec. gov / sic / 2024 / sic- 2024. xsd"," https: / / xbrl. sec. gov / stpr / 2024 / stpr- 2024. xsd"] }," calculationLink": {" local": [" orka-
20241231_cal. xml"] }," definitionLink": {" local": [" orka- 20241231_def. xml"] }," labelLink": {" local": [" orka- 20241231_lab. xml"] }," presentationLink": {" local": [" orka-
20241231_pre. xml"] } }," keyStandard": 323," keyCustom": 73," axisStandard": 24," axisCustom": 1," memberStandard": 30," memberCustom": 50," hidden": {" total": 242," http: / / fasb.
org / us- gaap / 2024": 185," http: / / www. orukatx. com / 20241231": 54," http: / / xbrl. sec. gov / dei / 2024": 3 }," contextCount": 199," entityCount": 1," segmentCount": 95," elementCount":
859," unitCount": 4," baseTaxonomies": {" http: / / fasb. org / us- gaap / 2024": 698," http: / / xbrl. sec. gov / dei / 2024": 39," http: / / xbrl. sec. gov / cyd / 2024": 8," http: / / xbrl. sec. gov / ecd /
2024": 4 }," report": {" R1": {" role":" http: / / xbrl. sec. gov / dei / role / document / Cover"," longName":" 995100- Document- Cover"," shortName":" Cover"," isDefault":" true","
groupType":" document"," subGroupType":""," menuCat":" Cover"," order":" 1"," firstAnchor": {" contextRef":" c0"," name":" dei: DocumentType"," unitRef": null," xsiNil":" false","
lang":" en- US"," decimals": null," ancestors": [" b"," span"," p"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true },"
uniqueAnchor": {" contextRef":" c0"," name":" dei: DocumentType"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" b"," span"," p"," div"," body","
html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R2": {" role":" http: / / xbrl. sec. gov / dei / role / document / AuditInformation","
longName":" 995300- Document- Audit Information"," shortName":" Audit Information"," isDefault":" false"," groupType":" document"," subGroupType":""," menuCat":" Cover","
order":" 2"," firstAnchor": {" contextRef":" c0"," name":" dei: AuditorName"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" p"," div"," body","
html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" dei: AuditorName"," unitRef": null,"
xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" p"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }
}," R3": {" role":" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"," longName":" 995301- Statement- Consolidated Balance Sheets"," shortName":" Consolidated Balance
Sheets"," isDefault":" false"," groupType":" statement"," subGroupType":""," menuCat":" Statements"," order":" 3"," firstAnchor": {" contextRef":" c3"," name":" us- gaap:
CashAndCashEquivalentsAtCarryingValue"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span"," td"," tr"," table"," div"," body"," html"],"
reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c3"," name":" us- gaap:
CashAndCashEquivalentsAtCarryingValue"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span"," td"," tr"," table"," div"," body"," html"],"
reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R4": {" role":" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet_Parentheticals","
longName":" 995302- Statement- Consolidated Balance Sheets (Parentheticals)"," shortName":" Consolidated Balance Sheets (Parentheticals)"," isDefault":" false"," groupType":"
statement"," subGroupType":" parenthetical"," menuCat":" Statements"," order":" 4"," firstAnchor": {" contextRef":" c3"," name":" us- gaap:
CommonStockParOrStatedValuePerShare"," unitRef":" usdPershares"," xsiNil":" false"," lang": null," decimals":" 3"," ancestors": [" span"," td"," tr"," table"," div"," body"," html"],"
reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true }," uniqueAnchor": {" contextRef":" c7"," name":" us- gaap: TemporaryEquityParOrStatedValuePerShare","
unitRef":" usdPershares"," xsiNil":" false"," lang": null," decimals":" 4"," ancestors": [" span"," td"," tr"," table"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445-
10k_orukathe. htm"," unique": true } }," R5": {" role":" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome"," longName":" 995303- Statement- Consolidated Statement of
Operations and Comprehensive Loss"," shortName":" Consolidated Statement of Operations and Comprehensive Loss"," isDefault":" false"," groupType":" statement","
subGroupType":""," menuCat":" Statements"," order":" 5"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: ResearchAndDevelopmentExpense"," unitRef":" usd"," xsiNil":"
false"," lang": null," decimals":"- 3"," ancestors": [" span"," td"," tr"," table"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true },"
uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: InvestmentIncomeInterest"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span"," td"," tr","
table"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," unique": true } }," R6": {" role":" http: / / www. orukatx. com / role /
ConsolidatedComprehensiveIncome_Parentheticals"," longName":" 995304- Statement- Consolidated Statement of Operations and Comprehensive Loss (Parentheticals)"," shortName":"
Consolidated Statement of Operations and Comprehensive Loss (Parentheticals)"," isDefault":" false"," groupType":" statement"," subGroupType":" parenthetical"," menuCat":"
Statements"," order":" 6"," firstAnchor": {" contextRef":" c13"," name":" us- gaap: CostsAndExpensesRelatedParty"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3","
ancestors": [" span"," link: footnote"," td"," tr"," table"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true },"
uniqueAnchor": {" contextRef":" c13"," name":" us- gaap: CostsAndExpensesRelatedParty"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span"," link:
footnote"," td"," tr"," table"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R7": {" role":" http: / / www. orukatx.
com / role / ShareholdersEquityType2or3"," longName":" 995305- Statement- Consolidated Statement of Convertible Preferred Stock and Stockholders \ u2019 Equity"," shortName":"
Consolidated Statement of Convertible Preferred Stock and Stockholders \ u2019 Equity"," isDefault":" false"," groupType":" statement"," subGroupType":""," menuCat":" Statements","
order":" 7"," firstAnchor": {" contextRef":" c21"," name":" us- gaap: StockholdersEquity"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span"," td","
tr"," table"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c21"," name":" us-
gaap: StockholdersEquity"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span"," td"," tr"," table"," div"," body"," html"]," reportCount": 1,"
baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R8": {" role":" http: / / www. orukatx. com / role / ShareholdersEquityType2or3_Parentheticals"," longName":"
995306- Statement- Consolidated Statement of Convertible Preferred Stock and Stockholders \ u2019 Equity (Parentheticals)"," shortName":" Consolidated Statement of Convertible Preferred
Stock and Stockholders \ u2019 Equity (Parentheticals)"," isDefault":" false"," groupType":" statement"," subGroupType":" parenthetical"," menuCat":" Statements"," order":" 8","
firstAnchor": {" contextRef":" c0"," name":" orka: IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3","
ancestors": [" span"," td"," tr"," table"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {"
contextRef":" c0"," name":" orka: IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": ["
span"," td"," tr"," table"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R9": {" role":" http: / / www. orukatx.
com / role / ConsolidatedCashFlow"," longName":" 995307- Statement- Consolidated Statement of Cash Flows"," shortName":" Consolidated Statement of Cash Flows"," isDefault":" false","
groupType":" statement"," subGroupType":""," menuCat":" Statements"," order":" 9"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: NetIncomeLoss"," unitRef":" usd","
xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span"," td"," tr"," table"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first":
true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: ShareBasedCompensation"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span","
td"," tr"," table"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," unique": true } }," R10": {" role":" http: / / www. orukatx. com / role /
NatureoftheBusinessandBasisofPresentation"," longName":" 995308- Disclosure- Nature of the Business and Basis of Presentation"," shortName":" Nature of the Business and Basis of
Presentation"," isDefault":" false"," groupType":" disclosure"," subGroupType":""," menuCat":" Notes"," order":" 10"," firstAnchor": {" contextRef":" c0"," name":" us- gaap:
BusinessDescriptionAndBasisOfPresentationTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html"]," reportCount": 1,"
baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap:
BusinessDescriptionAndBasisOfPresentationTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html"]," reportCount": 1,"
baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R11": {" role":" http: / / www. orukatx. com / role / SummaryofSignificantAccountingPolicies"," longName":"
995309- Disclosure- Summary of Significant Accounting Policies"," shortName":" Summary of Significant Accounting Policies"," isDefault":" false"," groupType":" disclosure","
subGroupType":""," menuCat":" Notes"," order":" 11"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: SignificantAccountingPoliciesTextBlock"," unitRef": null," xsiNil":"
false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true },"
uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: SignificantAccountingPoliciesTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": ["
div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R12": {" role":" http: / / www. orukatx. com / role /
ReverseRecapitalizationandPreClosingFinancing"," longName":" 995310- Disclosure- Reverse Recapitalization and Pre- Closing Financing"," shortName":" Reverse Recapitalization and Pre-
Closing Financing"," isDefault":" false"," groupType":" disclosure"," subGroupType":""," menuCat":" Notes"," order":" 12"," firstAnchor": {" contextRef":" c0"," name":" us- gaap:
MergersAcquisitionsAndDispositionsDisclosuresTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html"]," reportCount": 1,"
baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap:
MergersAcquisitionsAndDispositionsDisclosuresTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html"]," reportCount": 1,"
baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R13": {" role":" http: / / www. orukatx. com / role / FairValueMeasurements"," longName":" 995311- Disclosure-
Fair Value Measurements"," shortName":" Fair Value Measurements"," isDefault":" false"," groupType":" disclosure"," subGroupType":""," menuCat":" Notes"," order":" 13","
firstAnchor": {" contextRef":" c0"," name":" us- gaap: FairValueDisclosuresTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body","
html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap:
FairValueDisclosuresTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html"]," reportCount": 1," baseRef":" ea0230445-
10k_orukathe. htm"," first": true," unique": true } }," R14": {" role":" http: / / www. orukatx. com / role / CashequivalentsandMarketableSecurities"," longName":" 995312- Disclosure- Cash
equivalents and Marketable Securities"," shortName":" Cash equivalents and Marketable Securities"," isDefault":" false"," groupType":" disclosure"," subGroupType":""," menuCat":"
Notes"," order":" 14"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: CashCashEquivalentsAndMarketableSecuritiesTextBlock"," unitRef": null," xsiNil":" false"," lang":" en-

US"," decimals": null," ancestors": [" div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {"
contextRef":" c0"," name":" us- gaap: CashCashEquivalentsAndMarketableSecuritiesTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div","
body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R15": {" role":" http: / / www. orukatx. com / role /
AccruedExpensesandOtherCurrentLiabilities"," longName":" 995313- Disclosure- Accrued Expenses and Other Current Liabilities"," shortName":" Accrued Expenses and Other Current
Liabilities"," isDefault":" false"," groupType":" disclosure"," subGroupType":""," menuCat":" Notes"," order":" 15"," firstAnchor": {" contextRef":" c0"," name":" us- gaap:
AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body","
html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap:
AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body","
html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R16": {" role":" http: / / www. orukatx. com / role / NotePayablewithRelatedParty","
longName":" 995314- Disclosure- Note Payable with Related Party"," shortName":" Note Payable with Related Party"," isDefault":" false"," groupType":" disclosure"," subGroupType":"","
menuCat":" Notes"," order":" 16"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: DebtDisclosureTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals":
null," ancestors": [" div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":"
us- gaap: DebtDisclosureTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html"]," reportCount": 1," baseRef":" ea0230445-
10k_orukathe. htm"," first": true," unique": true } }," R17": {" role":" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquity"," longName":" 995315-
Disclosure- Convertible Preferred Stock and Stockholders \ u2019 Equity"," shortName":" Convertible Preferred Stock and Stockholders \ u2019 Equity"," isDefault":" false"," groupType":"
disclosure"," subGroupType":""," menuCat":" Notes"," order":" 17"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: StockholdersEquityNoteDisclosureTextBlock"," unitRef":
null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true
}," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: StockholdersEquityNoteDisclosureTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null,"
ancestors": [" div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R18": {" role":" http: / / www. orukatx. com / role /
StockBasedCompensation"," longName":" 995316- Disclosure- Stock- Based Compensation"," shortName":" Stock- Based Compensation"," isDefault":" false"," groupType":" disclosure","
subGroupType":""," menuCat":" Notes"," order":" 18"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock","
unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true,"
unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"," unitRef": null," xsiNil":" false","
lang":" en- US"," decimals": null," ancestors": [" div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R19": {" role":"
http: / / www. orukatx. com / role / SegmentDisclosures"," longName":" 995317- Disclosure- Segment Disclosures"," shortName":" Segment Disclosures"," isDefault":" false"," groupType":"
disclosure"," subGroupType":""," menuCat":" Notes"," order":" 19"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: SegmentReportingDisclosureTextBlock"," unitRef": null,"
xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true },"
uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: SegmentReportingDisclosureTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": ["
div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R20": {" role":" http: / / www. orukatx. com / role / IncomeTaxes","
longName":" 995318- Disclosure- Income Taxes"," shortName":" Income Taxes"," isDefault":" false"," groupType":" disclosure"," subGroupType":""," menuCat":" Notes"," order":"
20"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: IncomeTaxDisclosureTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div","
body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap:
IncomeTaxDisclosureTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html"]," reportCount": 1," baseRef":" ea0230445-
10k_orukathe. htm"," first": true," unique": true } }," R21": {" role":" http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreements"," longName":" 995319- Disclosure-
Option Agreements and License Agreements"," shortName":" Option Agreements and License Agreements"," isDefault":" false"," groupType":" disclosure"," subGroupType":"","
menuCat":" Notes"," order":" 21"," firstAnchor": {" contextRef":" c0"," name":" orka: OptionAgreementsAndLicenseAgreementsTextBlock"," unitRef": null," xsiNil":" false"," lang":" en-
US"," decimals": null," ancestors": [" div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {"
contextRef":" c0"," name":" orka: OptionAgreementsAndLicenseAgreementsTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body","
html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R22": {" role":" http: / / www. orukatx. com / role / CommitmentandContingencies","
longName":" 995320- Disclosure- Commitment and Contingencies"," shortName":" Commitment and Contingencies"," isDefault":" false"," groupType":" disclosure"," subGroupType":"","
menuCat":" Notes"," order":" 22"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: CommitmentsAndContingenciesDisclosureTextBlock"," unitRef": null," xsiNil":" false"," lang":"
en- US"," decimals": null," ancestors": [" div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {"
contextRef":" c0"," name":" us- gaap: CommitmentsAndContingenciesDisclosureTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div","
body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R23": {" role":" http: / / www. orukatx. com / role / NetLossPerShare","
longName":" 995321- Disclosure- Net Loss Per Share"," shortName":" Net Loss Per Share"," isDefault":" false"," groupType":" disclosure"," subGroupType":""," menuCat":" Notes","
order":" 23"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: EarningsPerShareTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": ["
div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap:
EarningsPerShareTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html"]," reportCount": 1," baseRef":" ea0230445-
10k_orukathe. htm"," first": true," unique": true } }," R24": {" role":" http: / / www. orukatx. com / role / RelatedPartyTransactions"," longName":" 995322- Disclosure- Related Party
Transactions"," shortName":" Related Party Transactions"," isDefault":" false"," groupType":" disclosure"," subGroupType":""," menuCat":" Notes"," order":" 24"," firstAnchor": {"
contextRef":" c0"," name":" us- gaap: RelatedPartyTransactionsDisclosureTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body","
html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap:
RelatedPartyTransactionsDisclosureTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html"]," reportCount": 1," baseRef":"
ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R25": {" role":" http: / / www. orukatx. com / role / SubsequentEvents"," longName":" 995323- Disclosure- Subsequent
Events"," shortName":" Subsequent Events"," isDefault":" false"," groupType":" disclosure"," subGroupType":""," menuCat":" Notes"," order":" 25"," firstAnchor": {" contextRef":"
c0"," name":" us- gaap: SubsequentEventsTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html"]," reportCount": 1,"
baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: SubsequentEventsTextBlock"," unitRef": null,"
xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } },"
R26": {" role":" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"," longName":" 995410- Disclosure- Pay vs Performance Disclosure"," shortName":" Pay vs Performance Disclosure","
isDefault":" false"," groupType":" disclosure"," subGroupType":""," menuCat":" Notes"," order":" 26"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: NetIncomeLoss","
unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span"," td"," tr"," table"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445-
10k_orukathe. htm"," first": true }," uniqueAnchor": null }," R27": {" role":" http: / / xbrl. sec. gov / ecd / role / InsiderTradingArrangements"," longName":" 995445- Disclosure- Insider
Trading Arrangements"," shortName":" Insider Trading Arrangements"," isDefault":" false"," groupType":" disclosure"," subGroupType":""," menuCat":" Notes"," order":" 27","
firstAnchor": {" contextRef":" c198"," name":" ecd: Rule10b51ArrAdoptedFlag"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" ecd:
NonRule10b51ArrAdoptedFlag"," span"," p"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {"
contextRef":" c198"," name":" ecd: Rule10b51ArrAdoptedFlag"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" ecd: NonRule10b51ArrAdoptedFlag","
span"," p"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R28": {" role":" http: / / xbrl. sec. gov / cyd / role /
CybersecurityRiskManagementAndStrategyDisclosure"," longName":" 995550- Disclosure- Cybersecurity Risk Management and Strategy Disclosure"," shortName":" Cybersecurity Risk
Management and Strategy Disclosure"," isDefault":" false"," groupType":" disclosure"," subGroupType":""," menuCat":" Notes"," order":" 28"," firstAnchor": {" contextRef":" c0","
name":" cyd: CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null,"
ancestors": [" div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" cyd:
CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" div","
body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R29": {" role":" http: / / www. orukatx. com / role /
AccountingPoliciesByPolicy"," longName":" 996000- Disclosure- Accounting Policies, by Policy (Policies)"," shortName":" Accounting Policies, by Policy (Policies)"," isDefault":" false","
groupType":" disclosure"," subGroupType":" policies"," menuCat":" Policies"," order":" 29"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: UseOfEstimates"," unitRef": null,"
xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" us- gaap: SignificantAccountingPoliciesTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445-
10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: UseOfEstimates"," unitRef": null," xsiNil":" false"," lang":" en- US","
decimals": null," ancestors": [" us- gaap: SignificantAccountingPoliciesTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true,"
unique": true } }," R30": {" role":" http: / / www. orukatx. com / role / SummaryofSignificantAccountingPoliciesTables"," longName":" 996001- Disclosure- Summary of Significant Accounting
Policies (Tables)"," shortName":" Summary of Significant Accounting Policies (Tables)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" tables"," menuCat":" Tables","
order":" 30"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: PropertyPlantAndEquipmentTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null,"
ancestors": [" ix: continuation"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":"
c0"," name":" us- gaap: PropertyPlantAndEquipmentTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" ix: continuation"," div"," body","
html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R31": {" role":" http: / / www. orukatx. com / role /
ReverseRecapitalizationandPreClosingFinancingTables"," longName":" 996002- Disclosure- Reverse Recapitalization and Pre- Closing Financing (Tables)"," shortName":" Reverse
Recapitalization and Pre- Closing Financing (Tables)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" tables"," menuCat":" Tables"," order":" 31"," firstAnchor": {"
contextRef":" c0"," name":" us- gaap: ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US","
decimals": null," ancestors": [" us- gaap: MergersAcquisitionsAndDispositionsDisclosuresTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe.
htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock","
unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" us- gaap: MergersAcquisitionsAndDispositionsDisclosuresTextBlock"," div"," body"," html"],"
reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R32": {" role":" http: / / www. orukatx. com / role / FairValueMeasurementsTables","
longName":" 996003- Disclosure- Fair Value Measurements (Tables)"," shortName":" Fair Value Measurements (Tables)"," isDefault":" false"," groupType":" disclosure","
subGroupType":" tables"," menuCat":" Tables"," order":" 32"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: FairValueAssetsMeasuredOnRecurringBasisTextBlock"," unitRef":
null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" us- gaap: FairValueDisclosuresTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445-
10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: FairValueAssetsMeasuredOnRecurringBasisTextBlock"," unitRef": null,"
xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" us- gaap: FairValueDisclosuresTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445-
10k_orukathe. htm"," first": true," unique": true } }," R33": {" role":" http: / / www. orukatx. com / role / CashequivalentsandMarketableSecuritiesTables"," longName":" 996004- Disclosure-
Cash equivalents and Marketable Securities (Tables)"," shortName":" Cash equivalents and Marketable Securities (Tables)"," isDefault":" false"," groupType":" disclosure","
subGroupType":" tables"," menuCat":" Tables"," order":" 33"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: MarketableSecuritiesTextBlock"," unitRef": null," xsiNil":"
false"," lang":" en- US"," decimals": null," ancestors": [" us- gaap: CashCashEquivalentsAndMarketableSecuritiesTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":"
ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: MarketableSecuritiesTextBlock"," unitRef": null," xsiNil":"

false"," lang":" en- US"," decimals": null," ancestors": [" us- gaap: CashCashEquivalentsAndMarketableSecuritiesTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":"
ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R34": {" role":" http: / / www. orukatx. com / role / AccruedExpensesandOtherCurrentLiabilitiesTables"," longName":"
996005- Disclosure- Accrued Expenses and Other Current Liabilities (Tables)"," shortName":" Accrued Expenses and Other Current Liabilities (Tables)"," isDefault":" false"," groupType":"
disclosure"," subGroupType":" tables"," menuCat":" Tables"," order":" 34"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: ScheduleOfAccruedLiabilitiesTableTextBlock","
unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" us- gaap: AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"," div","
body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap:
ScheduleOfAccruedLiabilitiesTableTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" us- gaap:
AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true,"
unique": true } }," R35": {" role":" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityTables"," longName":" 996006- Disclosure- Convertible Preferred
Stock and Stockholders \ u2019 Equity (Tables)"," shortName":" Convertible Preferred Stock and Stockholders \ u2019 Equity (Tables)"," isDefault":" false"," groupType":" disclosure","
subGroupType":" tables"," menuCat":" Tables"," order":" 35"," firstAnchor": {" contextRef":" c0"," name":" orka: ScheduleOfConvertiblePreferredStockTableTextBlock"," unitRef":
null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" ix: continuation"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first":
true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" orka: ScheduleOfConvertiblePreferredStockTableTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US","
decimals": null," ancestors": [" ix: continuation"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R36": {" role":"
http: / / www. orukatx. com / role / StockBasedCompensationTables"," longName":" 996007- Disclosure- Stock- Based Compensation (Tables)"," shortName":" Stock- Based Compensation
(Tables)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" tables"," menuCat":" Tables"," order":" 36"," firstAnchor": {" contextRef":" c0"," name":" us- gaap:
ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" ix:
continuation"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us-
gaap: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" ix:
continuation"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R37": {" role":" http: / / www. orukatx. com / role /
SegmentDisclosuresTables"," longName":" 996008- Disclosure- Segment Disclosures (Tables)"," shortName":" Segment Disclosures (Tables)"," isDefault":" false"," groupType":"
disclosure"," subGroupType":" tables"," menuCat":" Tables"," order":" 37"," firstAnchor": {" contextRef":" c0"," name":" us- gaap:
ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" us- gaap:
SegmentReportingDisclosureTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {"
contextRef":" c0"," name":" us- gaap: ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null,"
ancestors": [" us- gaap: SegmentReportingDisclosureTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } },"
R38": {" role":" http: / / www. orukatx. com / role / IncomeTaxesTables"," longName":" 996009- Disclosure- Income Taxes (Tables)"," shortName":" Income Taxes (Tables)"," isDefault":"
false"," groupType":" disclosure"," subGroupType":" tables"," menuCat":" Tables"," order":" 38"," firstAnchor": {" contextRef":" c0"," name":" us- gaap:
ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" us- gaap:
IncomeTaxDisclosureTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":"
c0"," name":" us- gaap: ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" us-
gaap: IncomeTaxDisclosureTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R39": {" role":" http: / /
www. orukatx. com / role / CommitmentandContingenciesTables"," longName":" 996010- Disclosure- Commitment and Contingencies (Tables)"," shortName":" Commitment and
Contingencies (Tables)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" tables"," menuCat":" Tables"," order":" 39"," firstAnchor": {" contextRef":" c0"," name":"
us- gaap: ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" us- gaap:
CommitmentsAndContingenciesDisclosureTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true },"
uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals":
null," ancestors": [" us- gaap: CommitmentsAndContingenciesDisclosureTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true,"
unique": true } }," R40": {" role":" http: / / www. orukatx. com / role / NetLossPerShareTables"," longName":" 996011- Disclosure- Net Loss Per Share (Tables)"," shortName":" Net Loss Per
Share (Tables)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" tables"," menuCat":" Tables"," order":" 40"," firstAnchor": {" contextRef":" c0"," name":" us- gaap:
ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" us- gaap: EarningsPerShareTextBlock","
div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap:
ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" us- gaap: EarningsPerShareTextBlock","
div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R41": {" role":" http: / / www. orukatx. com / role /
RelatedPartyTransactionsTables"," longName":" 996012- Disclosure- Related Party Transactions (Tables)"," shortName":" Related Party Transactions (Tables)"," isDefault":" false","
groupType":" disclosure"," subGroupType":" tables"," menuCat":" Tables"," order":" 41"," firstAnchor": {" contextRef":" c0"," name":" us- gaap:
OtherCurrentLiabilitiesTableTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" us- gaap: RelatedPartyTransactionsDisclosureTextBlock","
div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap:
OtherCurrentLiabilitiesTableTextBlock"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" us- gaap: RelatedPartyTransactionsDisclosureTextBlock","
div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R42": {" role":" http: / / www. orukatx. com / role /
NatureoftheBusinessandBasisofPresentationDetails"," longName":" 996013- Disclosure- Nature of the Business and Basis of Presentation (Details)"," shortName":" Nature of the Business and
Basis of Presentation (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 42"," firstAnchor": {" contextRef":" c3","
name":" us- gaap: CommonStockParOrStatedValuePerShare"," unitRef":" usdPershares"," xsiNil":" false"," lang": null," decimals":" 3"," ancestors": [" span"," td"," tr"," table"," div","
body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true }," uniqueAnchor": {" contextRef":" c43"," name":" orka:
AdditionalPaidInCapitalTransacationCost"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 5"," ancestors": [" span"," p"," us- gaap:
BusinessDescriptionAndBasisOfPresentationTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," unique": true } }," R43": {" role":" http: / /
www. orukatx. com / role / SummaryofSignificantAccountingPoliciesDetails"," longName":" 996014- Disclosure- Summary of Significant Accounting Policies (Details)"," shortName":"
Summary of Significant Accounting Policies (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 43"," firstAnchor": {"
contextRef":" c0"," name":" us- gaap: FederalDepositInsuranceCorporationPremiumExpense"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" span","
p"," ix: continuation"," us- gaap: SignificantAccountingPoliciesTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique":
true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: FederalDepositInsuranceCorporationPremiumExpense"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":" 0","
ancestors": [" span"," p"," ix: continuation"," us- gaap: SignificantAccountingPoliciesTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm","
first": true," unique": true } }," R44": {" role":" http: / / www. orukatx. com / role / ScheduleofPropertyandEquipmentTable"," longName":" 996015- Disclosure- Summary of Significant
Accounting Policies- Schedule of Property and Equipment (Details)"," shortName":" Summary of Significant Accounting Policies- Schedule of Property and Equipment (Details)"," isDefault":"
false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 44"," firstAnchor": {" contextRef":" c56"," name":" us- gaap:
PropertyPlantAndEquipmentUsefulLife"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" span"," td"," tr"," table"," ix: continuation"," us- gaap:
PropertyPlantAndEquipmentTextBlock"," ix: continuation"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true },"
uniqueAnchor": {" contextRef":" c56"," name":" us- gaap: PropertyPlantAndEquipmentUsefulLife"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": ["
span"," td"," tr"," table"," ix: continuation"," us- gaap: PropertyPlantAndEquipmentTextBlock"," ix: continuation"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445-
10k_orukathe. htm"," first": true," unique": true } }," R45": {" role":" http: / / www. orukatx. com / role / ScheduleoftheAssetsandLiabilitiesTable"," longName":" 996016- Disclosure- Reverse
Recapitalization and Pre- Closing Financing- Schedule of the Assets and Liabilities (Details)"," shortName":" Reverse Recapitalization and Pre- Closing Financing- Schedule of the Assets and
Liabilities (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 45"," firstAnchor": {" contextRef":" c60"," name":" us-
gaap: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3","
ancestors": [" span"," td"," tr"," table"," us- gaap: ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"," us- gaap:
MergersAcquisitionsAndDispositionsDisclosuresTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true },"
uniqueAnchor": {" contextRef":" c60"," name":" us- gaap: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"," unitRef":" usd","
xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span"," td"," tr"," table"," us- gaap: ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock","
us- gaap: MergersAcquisitionsAndDispositionsDisclosuresTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }
}," R46": {" role":" http: / / www. orukatx. com / role / ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"," longName":" 996017- Disclosure- Fair Value Measurements-
Schedule of Fair Value Hierarchy for Financial Assets Measured (Details)"," shortName":" Fair Value Measurements- Schedule of Fair Value Hierarchy for Financial Assets Measured
(Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 46"," firstAnchor": {" contextRef":" c3"," name":" us- gaap:
CashEquivalentsAtCarryingValue"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span"," td"," tr"," table"," us- gaap:
FairValueAssetsMeasuredOnRecurringBasisTextBlock"," us- gaap: FairValueDisclosuresTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm","
first": true," unique": true }," uniqueAnchor": {" contextRef":" c3"," name":" us- gaap: CashEquivalentsAtCarryingValue"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"-
3"," ancestors": [" span"," td"," tr"," table"," us- gaap: FairValueAssetsMeasuredOnRecurringBasisTextBlock"," us- gaap: FairValueDisclosuresTextBlock"," div"," body"," html"],"
reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R47": {" role":" http: / / www. orukatx. com / role /
ScheduleofCashEquivalentsandMarketableSecuritiesTable"," longName":" 996018- Disclosure- Cash equivalents and Marketable Securities- Schedule of Cash Equivalents and Marketable
Securities (Details)"," shortName":" Cash equivalents and Marketable Securities- Schedule of Cash Equivalents and Marketable Securities (Details)"," isDefault":" false"," groupType":"
disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 47"," firstAnchor": {" contextRef":" c3"," name":" us- gaap:
AvailableForSaleDebtSecuritiesAmortizedCostBasis"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span"," td"," tr"," table"," us- gaap:
MarketableSecuritiesTextBlock"," us- gaap: CashCashEquivalentsAndMarketableSecuritiesTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe.
htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c3"," name":" us- gaap: AvailableForSaleDebtSecuritiesAmortizedCostBasis"," unitRef":" usd"," xsiNil":" false","
lang": null," decimals":"- 3"," ancestors": [" span"," td"," tr"," table"," us- gaap: MarketableSecuritiesTextBlock"," us- gaap: CashCashEquivalentsAndMarketableSecuritiesTextBlock","
div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R48": {" role":" http: / / www. orukatx. com / role /
ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"," longName":" 996019- Disclosure- Cash equivalents and Marketable Securities- Schedule of Available- for- Sale
Securities in an Unrealized Loss Position (Details)"," shortName":" Cash equivalents and Marketable Securities- Schedule of Available- for- Sale Securities in an Unrealized Loss Position
(Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 48"," firstAnchor": {" contextRef":" c3"," name":" us- gaap:
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span"," td"," tr","
table"," us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"," us- gaap: CashCashEquivalentsAndMarketableSecuritiesTextBlock"," div"," body","
html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c3"," name":" us- gaap:
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span"," td"," tr","

table"," us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"," us- gaap: CashCashEquivalentsAndMarketableSecuritiesTextBlock"," div"," body","
html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R49": {" role":" http: / / www. orukatx. com / role /
ScheduleofMarketableSecuritiesatEstimatedFairValueTable"," longName":" 996020- Disclosure- Cash equivalents and Marketable Securities- Schedule of Marketable Securities at Estimated
Fair Value (Details)"," shortName":" Cash equivalents and Marketable Securities- Schedule of Marketable Securities at Estimated Fair Value (Details)"," isDefault":" false"," groupType":"
disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 49"," firstAnchor": {" contextRef":" c3"," name":" us- gaap: MarketableSecuritiesCurrent"," unitRef":" usd","
xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span"," td"," tr"," table"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first":
true }," uniqueAnchor": {" contextRef":" c3"," name":" us- gaap: MarketableSecurities"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span"," td","
tr"," table"," ix: continuation"," us- gaap: InvestmentsClassifiedByContractualMaturityDateTableTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445-
10k_orukathe. htm"," unique": true } }," R50": {" role":" http: / / www. orukatx. com / role / ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"," longName":" 996021- Disclosure-
Accrued Expenses and Other Current Liabilities- Schedule of Accrued Expenses and Other Current Liabilities (Details)"," shortName":" Accrued Expenses and Other Current Liabilities-
Schedule of Accrued Expenses and Other Current Liabilities (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 50","
firstAnchor": {" contextRef":" c3"," name":" us- gaap: AccruedEmployeeBenefitsCurrent"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span"," td","
tr"," table"," us- gaap: ScheduleOfAccruedLiabilitiesTableTextBlock"," us- gaap: AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"," div"," body"," html"
]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c3"," name":" us- gaap:
AccruedEmployeeBenefitsCurrent"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span"," td"," tr"," table"," us- gaap:
ScheduleOfAccruedLiabilitiesTableTextBlock"," us- gaap: AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"," div"," body"," html"]," reportCount": 1,"
baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R51": {" role":" http: / / www. orukatx. com / role / NotePayablewithRelatedPartyDetails"," longName":" 996022-
Disclosure- Note Payable with Related Party (Details)"," shortName":" Note Payable with Related Party (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":"
details"," menuCat":" Details"," order":" 51"," firstAnchor": {" contextRef":" c106"," name":" us- gaap: InterestExpenseDebt"," unitRef":" usd"," xsiNil":" false"," lang": null,"
decimals":"- 5"," ancestors": [" span"," p"," us- gaap: DebtDisclosureTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true,"
unique": true }," uniqueAnchor": {" contextRef":" c106"," name":" us- gaap: InterestExpenseDebt"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 5"," ancestors": ["
span"," p"," us- gaap: DebtDisclosureTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R52": {" role":"
http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"," longName":" 996023- Disclosure- Convertible Preferred Stock and Stockholders \ u2019 Equity
(Details)"," shortName":" Convertible Preferred Stock and Stockholders \ u2019 Equity (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":"
Details"," order":" 52"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: ProceedsFromIssuanceOfConvertiblePreferredStock"," unitRef":" usd"," xsiNil":" false"," lang": null,"
decimals":"- 3"," ancestors": [" span"," td"," tr"," table"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true }," uniqueAnchor": {"
contextRef":" c113"," name":" us- gaap: SaleOfStockNumberOfSharesIssuedInTransaction"," unitRef":" shares"," xsiNil":" false"," lang": null," decimals":" INF"," ancestors": [" span","
p"," us- gaap: StockholdersEquityNoteDisclosureTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," unique": true } }," R53": {" role":"
http: / / www. orukatx. com / role / ScheduleofConvertiblePreferredStockTable"," longName":" 996024- Disclosure- Convertible Preferred Stock and Stockholders \ u2019 Equity- Schedule of
Convertible Preferred Stock (Details)"," shortName":" Convertible Preferred Stock and Stockholders \ u2019 Equity- Schedule of Convertible Preferred Stock (Details)"," isDefault":" false","
groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 53"," firstAnchor": {" contextRef":" c134"," name":" us- gaap: PreferredStockSharesAuthorized","
unitRef":" shares"," xsiNil":" false"," lang": null," decimals":" INF"," ancestors": [" span"," td"," tr"," table"," orka: ScheduleOfConvertiblePreferredStockTableTextBlock"," ix:
continuation"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c134"," name":" us-
gaap: PreferredStockSharesAuthorized"," unitRef":" shares"," xsiNil":" false"," lang": null," decimals":" INF"," ancestors": [" span"," td"," tr"," table"," orka:
ScheduleOfConvertiblePreferredStockTableTextBlock"," ix: continuation"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique":
true } }," R54": {" role":" http: / / www. orukatx. com / role / ScheduleofCommonStockReservedforFutureIssuanceTable"," longName":" 996025- Disclosure- Convertible Preferred Stock and
Stockholders \ u2019 Equity- Schedule of Common Stock Reserved for Future Issuance (Details)"," shortName":" Convertible Preferred Stock and Stockholders \ u2019 Equity- Schedule of
Common Stock Reserved for Future Issuance (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 54"," firstAnchor": {"
contextRef":" c3"," name":" us- gaap: CommonStockCapitalSharesReservedForFutureIssuance"," unitRef":" shares"," xsiNil":" false"," lang": null," decimals":" INF"," ancestors": ["
span"," td"," tr"," table"," ix: continuation"," orka: ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":"
ea0230445- 10k_orukathe. htm"," first": true }," uniqueAnchor": {" contextRef":" c54"," name":" us- gaap: CommonStockCapitalSharesReservedForFutureIssuance"," unitRef":" shares","
xsiNil":" false"," lang": null," decimals":" INF"," ancestors": [" span"," td"," tr"," table"," ix: continuation"," orka:
ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," unique": true } }," R55": {"
role":" http: / / www. orukatx. com / role / StockBasedCompensationDetails"," longName":" 996026- Disclosure- Stock- Based Compensation (Details)"," shortName":" Stock- Based
Compensation (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 55"," firstAnchor": {" contextRef":" c3"," name":"
us- gaap: CommonStockCapitalSharesReservedForFutureIssuance"," unitRef":" shares"," xsiNil":" false"," lang": null," decimals":" INF"," ancestors": [" span"," td"," tr"," table"," ix:
continuation"," orka: ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first":
true }," uniqueAnchor": {" contextRef":" c3"," name":" orka: EstimatedFairValueOfWarrantsToBeGranted"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 5","
ancestors": [" span"," p"," ix: continuation"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," unique": true } }," R56": {" role":" http: / / www.
orukatx. com / role / ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable"," longName":" 996027- Disclosure- Stock- Based Compensation- Schedule of
Weighted- Average Assumptions Used in Calculating the Fair Value of the Awards (Details)"," shortName":" Stock- Based Compensation- Schedule of Weighted- Average Assumptions Used in
Calculating the Fair Value of the Awards (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 56"," firstAnchor": {"
contextRef":" c146"," name":" us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"," unitRef": null," xsiNil":" false","
lang":" en- US"," decimals": null," ancestors": [" td"," tr"," table"," us- gaap: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"," ix:
continuation"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c146"," name":" us-
gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null,"
ancestors": [" td"," tr"," table"," us- gaap: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"," ix: continuation"," div"," body"," html"],"
reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R57": {" role":" http: / / www. orukatx. com / role / ScheduleofStockOptionActivityTable","
longName":" 996028- Disclosure- Stock- Based Compensation- Schedule of Stock Option Activity (Details)"," shortName":" Stock- Based Compensation- Schedule of Stock Option Activity
(Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 57"," firstAnchor": {" contextRef":" c3"," name":" us- gaap:
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"," unitRef":" shares"," xsiNil":" false"," lang": null," decimals":" INF"," ancestors": ["
span"," td"," tr"," table"," us- gaap: ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"," ix: continuation"," div"," body"," html"]," reportCount": 1," baseRef":"
ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c3"," name":" us- gaap:
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"," unitRef":" shares"," xsiNil":" false"," lang": null," decimals":" INF"," ancestors": ["
span"," td"," tr"," table"," us- gaap: ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"," ix: continuation"," div"," body"," html"]," reportCount": 1," baseRef":"
ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R58": {" role":" http: / / www. orukatx. com / role / ScheduleofRSAActivityTable"," longName":" 996029- Disclosure- Stock-
Based Compensation- Schedule of RSA Activity (Details)"," shortName":" Stock- Based Compensation- Schedule of RSA Activity (Details)"," isDefault":" false"," groupType":" disclosure","
subGroupType":" details"," menuCat":" Details"," order":" 58"," firstAnchor": {" contextRef":" c147"," name":" us- gaap:
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"," unitRef":" shares"," xsiNil":" false"," lang": null," decimals":"
INF"," ancestors": [" span"," td"," tr"," table"," us- gaap: ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"," ix: continuation"," div"," body"," html"]," reportCount":
1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c147"," name":" us- gaap:
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"," unitRef":" shares"," xsiNil":" false"," lang": null," decimals":"
INF"," ancestors": [" span"," td"," tr"," table"," us- gaap: ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"," ix: continuation"," div"," body"," html"]," reportCount":
1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R59": {" role":" http: / / www. orukatx. com / role / ScheduleofEmployeeWarrantActivityTable","
longName":" 996030- Disclosure- Stock- Based Compensation- Schedule of Employee Warrant Activity (Details)"," shortName":" Stock- Based Compensation- Schedule of Employee Warrant
Activity (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 59"," firstAnchor": {" contextRef":" c119"," name":" us-
gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"," unitRef":" shares"," xsiNil":" false"," lang": null,"
decimals":" INF"," ancestors": [" span"," td"," tr"," table"," orka: ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock"," ix: continuation"," div"," body"," html"],"
reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c119"," name":" us- gaap:
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"," unitRef":" shares"," xsiNil":" false"," lang": null,"
decimals":" INF"," ancestors": [" span"," td"," tr"," table"," orka: ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock"," ix: continuation"," div"," body"," html"],"
reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R60": {" role":" http: / / www. orukatx. com / role /
ScheduleofCompanysStockBasedCompensationExpenseTable"," longName":" 996031- Disclosure- Stock- Based Compensation- Schedule of Company \ u2019s Stock- Based Compensation
Expense (Details)"," shortName":" Stock- Based Compensation- Schedule of Company \ u2019s Stock- Based Compensation Expense (Details)"," isDefault":" false"," groupType":"
disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 60"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: AllocatedShareBasedCompensationExpense","
unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span"," td"," tr"," table"," us- gaap:
ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"," ix: continuation"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445-
10k_orukathe. htm"," first": true }," uniqueAnchor": {" contextRef":" c13"," name":" us- gaap: AllocatedShareBasedCompensationExpense"," unitRef":" usd"," xsiNil":" false"," lang":
null," decimals":"- 3"," ancestors": [" span"," td"," tr"," table"," us- gaap: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"," ix:
continuation"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," unique": true } }," R61": {" role":" http: / / www. orukatx. com / role /
ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable"," longName":" 996032- Disclosure- Stock- Based Compensation- Schedule of Award Types of Company \ u2019s
Stock- Based Compensation Expense (Details)"," shortName":" Stock- Based Compensation- Schedule of Award Types of Company \ u2019s Stock- Based Compensation Expense (Details)","
isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 61"," firstAnchor": {" contextRef":" c0"," name":" us- gaap:
AllocatedShareBasedCompensationExpense"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span"," td"," tr"," table"," us- gaap:
ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"," ix: continuation"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445-
10k_orukathe. htm"," first": true }," uniqueAnchor": {" contextRef":" c153"," name":" us- gaap: AllocatedShareBasedCompensationExpense"," unitRef":" usd"," xsiNil":" false"," lang":
null," decimals":"- 3"," ancestors": [" span"," td"," tr"," table"," us- gaap:
ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"," ix: continuation"," div"," body"," html"],"
reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," unique": true } }," R62": {" role":" http: / / www. orukatx. com / role / SegmentDisclosuresDetails"," longName":" 996033-
Disclosure- Segment Disclosures (Details)"," shortName":" Segment Disclosures (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":"
Details"," order":" 62"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: NumberOfOperatingSegments"," unitRef":" pure"," xsiNil":" false"," lang": null," decimals":" 0","

```
ancestors": [" span"," p"," us- gaap: SegmentReportingDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique":
true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: NumberOfOperatingSegments"," unitRef":" pure"," xsiNil":" false"," lang": null," decimals":" 0"," ancestors": [" span","
p"," us- gaap: SegmentReportingDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R63": {"
role":" http: / / www. orukatx. com / role / ScheduleofSegmentLossfromOperationsTable"," longName":" 996034- Disclosure- Segment Disclosures- Schedule of Segment Loss from Operations
(Details)"," shortName":" Segment Disclosures- Schedule of Segment Loss from Operations (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details","
menuCat":" Details"," order":" 63"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: ResearchAndDevelopmentExpense"," unitRef":" usd"," xsiNil":" false"," lang": null,"
decimals":"- 3"," ancestors": [" span"," td"," tr"," table"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true }," uniqueAnchor": {"
contextRef":" c157"," name":" us- gaap: ResearchAndDevelopmentExpense"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span"," td"," tr"," table","
us- gaap: ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"," us- gaap: SegmentReportingDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1,"
baseRef":" ea0230445- 10k_orukathe. htm"," unique": true } }," R64": {" role":" http: / / www. orukatx. com / role / IncomeTaxesDetails"," longName":" 996035- Disclosure- Income Taxes
(Details)"," shortName":" Income Taxes (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 64"," firstAnchor": {"
contextRef":" c3"," name":" us- gaap: OperatingLossCarryforwardsValuationAllowance"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 5"," ancestors": [" us- gaap:
SummaryOfValuationAllowanceTextBlock"," p"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true },"
uniqueAnchor": {" contextRef":" c3"," name":" us- gaap: OperatingLossCarryforwardsValuationAllowance"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 5"," ancestors":
[" us- gaap: SummaryOfValuationAllowanceTextBlock"," p"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true,"
unique": true } }," R65": {" role":" http: / / www. orukatx. com / role / ScheduleofLossBeforeIncomeTaxExpenseTable"," longName":" 996036- Disclosure- Income Taxes- Schedule of Loss
Before Income Tax Expense (Details)"," shortName":" Income Taxes- Schedule of Loss Before Income Tax Expense (Details)"," isDefault":" false"," groupType":" disclosure","
subGroupType":" details"," menuCat":" Details"," order":" 65"," firstAnchor": {" contextRef":" c0"," name":" us- gaap:
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span"," td"," tr"," table"," us- gaap:
ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"," us- gaap: IncomeTaxDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0230445-
10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic","
unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span"," td"," tr"," table"," us- gaap:
ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"," us- gaap: IncomeTaxDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0230445-
10k_orukathe. htm"," first": true," unique": true } }," R66": {" role":" http: / / www. orukatx. com / role / ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable","
longName":" 996037- Disclosure- Income Taxes- Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes (Details)"," shortName":" Income Taxes- Schedule of Statutory
Federal Income Tax Rate to Income Before Income Taxes (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 66","
firstAnchor": {" contextRef":" c0"," name":" us- gaap: EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"," unitRef":" pure"," xsiNil":" false"," lang": null,"
decimals":" 4"," ancestors": [" td"," tr"," table"," ix: continuation"," us- gaap: IncomeTaxDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0230445-
10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate","
unitRef":" pure"," xsiNil":" false"," lang": null," decimals":" 4"," ancestors": [" td"," tr"," table"," ix: continuation"," us- gaap: IncomeTaxDisclosureTextBlock"," div"," body"," html" ],"
reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R67": {" role":" http: / / www. orukatx. com / role /
ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"," longName":" 996038- Disclosure- Income Taxes- Schedule of Components of the Deferred Tax Assets and Liabilities
(Details)"," shortName":" Income Taxes- Schedule of Components of the Deferred Tax Assets and Liabilities (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":"
details"," menuCat":" Details"," order":" 67"," firstAnchor": {" contextRef":" c3"," name":" us- gaap: DeferredTaxAssetsOperatingLossCarryforwards"," unitRef":" usd"," xsiNil":"
false"," lang": null," decimals":"- 3"," ancestors": [" td"," tr"," table"," us- gaap: ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"," ix: continuation"," div"," body"," html" ],"
reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c3"," name":" us- gaap:
DeferredTaxAssetsOperatingLossCarryforwards"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" td"," tr"," table"," us- gaap:
ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true,"
unique": true } }," R68": {" role":" http: / / www. orukatx. com / role / ScheduleofNetDeferredTaxAssetsTable"," longName":" 996039- Disclosure- Income Taxes- Schedule of Net Deferred Tax
Assets (Details)"," shortName":" Income Taxes- Schedule of Net Deferred Tax Assets (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":"
Details"," order":" 68"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: ValuationAllowanceDeferredTaxAssetChangeInAmount"," unitRef":" usd"," xsiNil":" false"," lang": null,"
decimals":"- 3"," ancestors": [" td"," tr"," table"," ix: continuation"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first":
true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: ValuationAllowanceDeferredTaxAssetChangeInAmount"," unitRef":" usd"," xsiNil":" false"," lang": null,"
decimals":"- 3"," ancestors": [" td"," tr"," table"," ix: continuation"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first":
true," unique": true } }," R69": {" role":" http: / / www. orukatx. com / role / ScheduleofUnrecognizedTaxBenefitsTable"," longName":" 996040- Disclosure- Income Taxes- Schedule of
Unrecognized Tax Benefits (Details)"," shortName":" Income Taxes- Schedule of Unrecognized Tax Benefits (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":"
details"," menuCat":" Details"," order":" 69"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions","
unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span"," td"," tr"," table"," us- gaap: ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock","
ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us-
gaap: UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span"," td"," tr","
table"," us- gaap: ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe.
htm"," first": true," unique": true } }," R70": {" role":" http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"," longName":" 996041- Disclosure- Option
Agreements and License Agreements (Details)"," shortName":" Option Agreements and License Agreements (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":"
details"," menuCat":" Details"," order":" 70"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: OtherExpenses"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 5","
ancestors": [" span"," p"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {"
contextRef":" c0"," name":" us- gaap: OtherExpenses"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 5"," ancestors": [" span"," p"," ix: continuation"," div"," body","
html" ]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R71": {" role":" http: / / www. orukatx. com / role /
CommitmentandContingenciesDetails"," longName":" 996042- Disclosure- Commitment and Contingencies (Details)"," shortName":" Commitment and Contingencies (Details)"," isDefault":"
false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 71"," firstAnchor": {" contextRef":" c3"," name":" us- gaap:
OperatingLeaseRightOfUseAsset"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span"," td"," tr"," table"," div"," body"," html" ]," reportCount": 1,"
baseRef":" ea0230445- 10k_orukathe. htm"," first": true }," uniqueAnchor": {" contextRef":" c3"," name":" us- gaap: LesseeOperatingLeaseDiscountRate"," unitRef":" pure"," xsiNil":"
false"," lang": null," decimals":" 4"," ancestors": [" span"," p"," us- gaap: CommitmentsAndContingenciesDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":"
ea0230445- 10k_orukathe. htm"," unique": true } }," R72": {" role":" http: / / www. orukatx. com / role / ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable","
longName":" 996043- Disclosure- Commitment and Contingencies- Schedule of Company \ u2019s Supplemental Cash Flow Information Related to Leases (Details)"," shortName":"
Commitment and Contingencies- Schedule of Company \ u2019s Supplemental Cash Flow Information Related to Leases (Details)"," isDefault":" false"," groupType":" disclosure","
subGroupType":" details"," menuCat":" Details"," order":" 72"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: OperatingLeasePayments"," unitRef":" usd"," xsiNil":" false","
lang": null," decimals":"- 3"," ancestors": [" span"," td"," tr"," table"," us- gaap: ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"," us- gaap:
CommitmentsAndContingenciesDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true },"
uniqueAnchor": {" contextRef":" c0"," name":" us- gaap: OperatingLeasePayments"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span"," td"," tr","
table"," us- gaap: ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"," us- gaap: CommitmentsAndContingenciesDisclosureTextBlock"," div"," body"," html" ]," reportCount":
1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R73": {" role":" http: / / www. orukatx. com / role /
ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"," longName":" 996044- Disclosure- Commitment and Contingencies- Schedule of Company \ u2019s
Operating Lease Liabilities Showing the Aggregate Lease Payments (Details)"," shortName":" Commitment and Contingencies- Schedule of Company \ u2019s Operating Lease Liabilities
Showing the Aggregate Lease Payments (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 73"," firstAnchor": {"
contextRef":" c3"," name":" us- gaap: LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": ["
span"," td"," tr"," table"," us- gaap: LesseeOperatingLeaseLiabilityMaturityTableTextBlock"," us- gaap: CommitmentsAndContingenciesDisclosureTextBlock"," div"," body"," html" ],"
reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c3"," name":" us- gaap:
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span"," td"," tr"," table"," us- gaap:
LesseeOperatingLeaseLiabilityMaturityTableTextBlock"," us- gaap: CommitmentsAndContingenciesDisclosureTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0230445-
10k_orukathe. htm"," first": true," unique": true } }," R74": {" role":" http: / / www. orukatx. com / role / NetLossPerShareDetails"," longName":" 996045- Disclosure- Net Loss Per Share
(Details)"," shortName":" Net Loss Per Share (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 74"," firstAnchor":
{" contextRef":" c184"," name":" us- gaap: WeightedAverageNumberOfSharesContingentlyIssuable"," unitRef":" shares"," xsiNil":" false"," lang": null," decimals":" INF"," ancestors": ["
span"," link: footnote"," td"," tr"," table"," ix: continuation"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true,"
unique": true }," uniqueAnchor": {" contextRef":" c184"," name":" us- gaap: WeightedAverageNumberOfSharesContingentlyIssuable"," unitRef":" shares"," xsiNil":" false"," lang": null,"
decimals":" INF"," ancestors": [" span"," link: footnote"," td"," tr"," table"," ix: continuation"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0230445-
10k_orukathe. htm"," first": true," unique": true } }," R75": {" role":" http: / / www. orukatx. com / role / ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable","
longName":" 996046- Disclosure- Net Loss Per Share- Schedule of Basic and Diluted Net Loss Per Share Attributable to Stockholders (Details)"," shortName":" Net Loss Per Share- Schedule of
Basic and Diluted Net Loss Per Share Attributable to Stockholders (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":"
75"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: NetIncomeLoss"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span"," td"," tr"," table","
div"," body"," html" ]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true }," uniqueAnchor": {" contextRef":" c184"," name":" us- gaap:
WeightedAverageNumberOfSharesOutstandingBasic"," unitRef":" shares"," xsiNil":" false"," lang": null," decimals":" INF"," ancestors": [" span"," td"," tr"," table"," us- gaap:
ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"," us- gaap: EarningsPerShareTextBlock"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe.
htm"," unique": true } }," R76": {" role":" http: / / www. orukatx. com / role / ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable","
longName":" 996047- Disclosure- Net Loss Per Share- Schedule of Anti- Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share (Details)"," shortName":" Net Loss
Per Share- Schedule of Anti- Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":"
details"," menuCat":" Details"," order":" 76"," firstAnchor": {" contextRef":" c0"," name":" us- gaap: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount","
unitRef":" shares"," xsiNil":" false"," lang": null," decimals":" INF"," ancestors": [" span"," td"," tr"," table"," us- gaap:
ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":" ea0230445-
10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c0"," name":" us- gaap:
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"," unitRef":" shares"," xsiNil":" false"," lang": null," decimals":" INF"," ancestors": [" span"," td"," tr","
table"," us- gaap: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"," ix: continuation"," div"," body"," html" ]," reportCount": 1," baseRef":"
```

ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R77": {" role":" http: / / www. orukatx. com / role / RelatedPartyTransactionsDetails"," longName":" 996048- Disclosure-
Related Party Transactions (Details)"," shortName":" Related Party Transactions (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":"
Details"," order":" 77"," firstAnchor": {" contextRef":" c192"," name":" orka: DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners"," unitRef": null," xsiNil":"
false"," lang":" en- US"," decimals": null," ancestors": [" span"," p"," us- gaap: RelatedPartyTransactionsDisclosureTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":"
ea0230445- 10k_orukathe. htm"," first": true," unique": true }," uniqueAnchor": {" contextRef":" c192"," name":" orka:
DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null," ancestors": [" span"," p"," us- gaap:
RelatedPartyTransactionsDisclosureTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R78": {" role":"
http: / / www. orukatx. com / role / ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"," longName":" 996049- Disclosure- Related Party Transactions- Schedule of
Related Party Accounts Payable and Other Current Liabilities (Details)"," shortName":" Related Party Transactions- Schedule of Related Party Accounts Payable and Other Current Liabilities
(Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":" Details"," order":" 78"," firstAnchor": {" contextRef":" c193"," name":" us- gaap:
AccountsPayableOtherCurrent"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"- 3"," ancestors": [" span"," td"," tr"," table"," us- gaap:
OtherCurrentLiabilitiesTableTextBlock"," us- gaap: RelatedPartyTransactionsDisclosureTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm","
first": true," unique": true }," uniqueAnchor": {" contextRef":" c193"," name":" us- gaap: AccountsPayableOtherCurrent"," unitRef":" usd"," xsiNil":" false"," lang": null," decimals":"-
3"," ancestors": [" span"," td"," tr"," table"," us- gaap: OtherCurrentLiabilitiesTableTextBlock"," us- gaap: RelatedPartyTransactionsDisclosureTextBlock"," div"," body"," html"],"
reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } }," R79": {" role":" http: / / www. orukatx. com / role / SubsequentEventsDetails"," longName":"
996050- Disclosure- Subsequent Events (Details)"," shortName":" Subsequent Events (Details)"," isDefault":" false"," groupType":" disclosure"," subGroupType":" details"," menuCat":"
Details"," order":" 79"," firstAnchor": {" contextRef":" c197"," name":" us- gaap: LesseeOperatingLeaseTermOfContract"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals":
null," ancestors": [" span"," p"," us- gaap: SubsequentEventsTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique":
true }," uniqueAnchor": {" contextRef":" c197"," name":" us- gaap: LesseeOperatingLeaseTermOfContract"," unitRef": null," xsiNil":" false"," lang":" en- US"," decimals": null,"
ancestors": [" span"," p"," us- gaap: SubsequentEventsTextBlock"," div"," body"," html"]," reportCount": 1," baseRef":" ea0230445- 10k_orukathe. htm"," first": true," unique": true } } },"
tag": {" orka_ARCACommonStockMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ARCACommonStockMember","
presentation": [" http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"]," lang": {" en- us": {" role": {" terseLabel":" ARCA common stock [Member]","
label":" ARCACommon Stock Member" } } }," auth_ref": [ ] }," us- gaap_AccountingPoliciesAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024","
localname":" AccountingPoliciesAbstract"," lang": {" en- us": {" role": {" label":" Summary of Significant Accounting Policies [Abstract]" } } }," auth_ref": [ ] }," us-
gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"," presentation": [" http: / / www. orukatx. com / role / AccruedExpensesandOtherCurrentLiabilities"],"
lang": {" en- us": {" role": {" terseLabel":" Accrued Expenses and Other Current Liabilities"," label":" Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text
Block]"," documentation":" The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }," auth_ref":
[" r406"] }," us- gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
AccountsPayableAndAccruedLiabilitiesCurrentAbstract"," lang": {" en- us": {" role": {" label":" Accrued Expenses and Other Current Liabilities [Abstract]" } } }," auth_ref": [ ] }," us-
gaap_AccountsPayableOtherCurrent": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AccountsPayableOtherCurrent"," crdr":" credit","
calculation": {" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_LiabilitiesCurrent"," weight": 1. 0," order": 4. 0 } }," presentation": [" http: / / www.
orukatx. com / role / ConsolidatedBalanceSheet"," http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"," http: / / www. orukatx. com / role /
ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"]," lang": {" en- us": {" role": {" terseLabel":" Related party accounts payable and other current liabilities","
verboseLabel":" Accounts payable and other current liabilities"," label":" Accounts Payable, Other, Current"," documentation":" Amount of obligations incurred classified as other, payable
within one year or the normal operating cycle, if longer." } } }," auth_ref": [" r52"] }," us- gaap_AccountsPayableTradeCurrent": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb.
org / us- gaap / 2024"," localname":" AccountsPayableTradeCurrent"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet": {" parentTag":" us-
gaap_LiabilitiesCurrent"," weight": 1. 0," order": 1. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"]," lang": {" en- us": {" role": {" terseLabel":"
Accounts payable"," label":" Accounts Payable, Trade, Current"," documentation":" Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically
been received) and payable to vendors for goods and services received that are used in an entity' s business. Used to reflect the current portion of the liabilities (due within one year or within the
normal operating cycle if longer)." } } }," auth_ref": [" r16"," r52"] }," us- gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {" xbrltype":" monetaryItemType"," nsuri":"
http: / / fasb. org / us- gaap / 2024"," localname":" AccretionAmortizationOfDiscountsAndPremiumsInvestments"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role /
ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInOperatingActivities"," weight":- 1. 0," order": 10. 0 } }," presentation": [" http: / / www. orukatx. com / role /
ConsolidatedCashFlow"]," lang": {" en- us": {" role": {" negatedLabel":" Net accretion of premiums and discounts on marketable securities"," label":" Accretion (Amortization) of Discounts
and Premiums, Investments"," documentation":" The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings.
This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when
calculating cash provided by or used in operations using the indirect method." } } }," auth_ref": [" r82"] }," us- gaap_AccruedEmployeeBenefitsCurrent": {" xbrltype":" monetaryItemType","
nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AccruedEmployeeBenefitsCurrent"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role /
ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": {" parentTag":" us- gaap_AccruedLiabilitiesAndOtherLiabilities"," weight": 1. 0," order": 1. 0 } }," presentation": [" http: / /
www. orukatx. com / role / ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"]," lang": {" en- us": {" role": {" terseLabel":" Accrued employee compensation and benefits","
label":" Accrued Employee Benefits, Current"," documentation":" Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred
through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within
the normal operating cycle if longer)." } } }," auth_ref": [" r54"] }," us- gaap_AccruedLiabilitiesAndOtherLiabilities": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap
/ 2024"," localname":" AccruedLiabilitiesAndOtherLiabilities"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet": {" parentTag":" us-
gaap_LiabilitiesCurrent"," weight": 1. 0," order": 2. 0 }," http: / / www. orukatx. com / role / ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": {" parentTag": null," weight":
null," order": null," root": true } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"," http: / / www. orukatx. com / role /
ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"]," lang": {" en- us": {" role": {" totalLabel":" Total"," terseLabel":" Accrued expenses and other current liabilities"," label":"
Accrued Liabilities and Other Liabilities"," documentation":" Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other." } } }," auth_ref": [ ] }," us-
gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
AccruedLiabilitiesAndOtherLiabilitiesAbstract"," lang": {" en- us": {" role": {" label":" Schedule of Accrued Expenses and Other Current Liabilities [Abstract]" } } }," auth_ref": [ ] }," us-
gaap_AccruedProfessionalFeesCurrent": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AccruedProfessionalFeesCurrent"," crdr":"
credit"," calculation": {" http: / / www. orukatx. com / role / ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": {" parentTag":" us-
gaap_AccruedLiabilitiesAndOtherLiabilities"," weight": 1. 0," order": 2. 0 } }," presentation": [" http: / / www. orukatx. com / role /
ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"]," lang": {" en- us": {" role": {" terseLabel":" Accrued professional and consulting"," label":" Accrued Professional Fees,
Current"," documentation":" Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services
received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }," auth_ref": [" r54"] },"
orka_AccruedResearchAndDevelopment": {" xbrltype":" monetaryItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" AccruedResearchAndDevelopment"," crdr":"
credit"," calculation": {" http: / / www. orukatx. com / role / ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": {" parentTag":" us-
gaap_AccruedLiabilitiesAndOtherLiabilities"," weight": 1. 0," order": 3. 0 } }," presentation": [" http: / / www. orukatx. com / role /
ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"]," lang": {" en- us": {" role": {" terseLabel":" Accrued research and development"," documentation":" Accrued research and
development."," label":" Accrued Research And Development" } } }," auth_ref": [ ] }," us- gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {" xbrltype":"
monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AccumulatedOtherComprehensiveIncomeLossNetOfTax"," crdr":" credit"," calculation": {" http: / / www.
orukatx. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_StockholdersEquity"," weight": 1. 0," order": 4. 0 } }," presentation": [" http: / / www. orukatx. com / role /
ConsolidatedBalanceSheet"]," lang": {" en- us": {" role": {" terseLabel":" Accumulated other comprehensive loss"," label":" Accumulated Other Comprehensive Income (Loss), Net of Tax","
documentation":" Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }," auth_ref": [" r17"," r18","
r71"," r136"," r601"," r623"," r624"] }," us- gaap_AccumulatedOtherComprehensiveIncomeMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024","
localname":" AccumulatedOtherComprehensiveIncomeMember"," presentation": [" http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {"
terseLabel":" Accumulated Other Comprehensive Gain (Loss)"," label":" AOCI Attributable to Parent [Member]"," documentation":" Accumulated increase (decrease) in equity from
transactions and other events and circumstances from non- owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting
from investments by owners and distributions to owners." } } }," auth_ref": [" r1"," r8"," r18"," r456"," r459"," r511"," r619"," r620"," r967"," r968"," r969"," r980"," r981"," r982","
r984"] }," orka_AchievementOfDevelopmentCandidateMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":"
AchievementOfDevelopmentCandidateMember"," presentation": [" http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"]," lang": {" en- us": {" role": {"
terseLabel":" Achievement of Development Candidate [Member]"," verboseLabel":" Achievement Of Development Candidate [Member]"," label":" Achievement Of Development Candidate
Member" } } }," auth_ref": [ ] }," ecd_Additional402vDisclosureTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":"
Additional402vDisclosureTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Additional 402 (v) Disclosure [Text Block
]"," terseLabel":" Additional 402 (v) Disclosure" } } }," auth_ref": [" r881"] }," us- gaap_AdditionalPaidInCapital": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap /
2024"," localname":" AdditionalPaidInCapital"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet": {" parentTag":" us-
gaap_StockholdersEquity"," weight": 1. 0," order": 3. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"]," lang": {" en- us": {" role": {" terseLabel":"
Additional paid- in capital"," label":" Additional Paid in Capital"," documentation":" Amount of excess of issue price over par or stated value of stock and from other transaction involving
stock or stockholder. Includes, but is not limited to, additional paid- in capital (APIC) for common and preferred stock." } } }," auth_ref": [" r66"," r793"," r1108"] }," us-
gaap_AdditionalPaidInCapitalMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AdditionalPaidInCapitalMember"," presentation": ["
http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" terseLabel":" Additional Paid- in Capital"," label":" Additional Paid- in Capital [Member
]"," documentation":" Excess of issue price over par or stated value of the entity' s capital stock and amounts received from other transactions involving the entity' s stock or stockholders." } }
}," auth_ref": [" r637"," r980"," r981"," r982"," r984"," r1049"," r1109"] }," orka_AdditionalPaidInCapitalTransacationCost": {" xbrltype":" monetaryItemType"," nsuri":" http: / / www.
orukatx. com / 20241231"," localname":" AdditionalPaidInCapitalTransacationCost"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role /
NatureoftheBusinessandBasisofPresentationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Additional paid- in capital transaction costs (in Dollars)"," documentation":" The amount of
additional paid- in capital transacation cost."," label":" Additional Paid In Capital Transacation Cost" } } }," auth_ref": [ ] }," dei_AdditionalSecurities462b": {" xbrltype":"
booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" AdditionalSecurities462b"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {"
en- us": {" role": {" label":" Additional Securities. 462 (b)" } } }," auth_ref": [" r942"] }," dei_AdditionalSecurities462bFileNumber": {" xbrltype":" fileNumberItemType"," nsuri":" http: / /
xbrl. sec. gov / dei / 2024"," localname":" AdditionalSecurities462bFileNumber"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {"
label":" Additional Securities, 462 (b), File Number" } } }," auth_ref": [" r942"] }," dei_AdditionalSecuritiesEffective413b": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov /

```
dei / 2024"," localname":" AdditionalSecuritiesEffective413b"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Additional
Securities Effective, 413 (b)" } } }," auth_ref": [" r940" ] }," dei_AddressTypeDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":"
AddressTypeDomain"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Address Type [ Domain ]"," documentation":" An
entity may have several addresses for different purposes and this domain represents all such types." } } }," auth_ref": [ ] }," ecd_AdjToCompAmt": {" xbrltype":" monetaryItemType","
nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AdjToCompAmt"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":"
Adjustment to Compensation Amount"," terseLabel":" Adjustment to Compensation, Amount" } } }," auth_ref": [" r894" ] }," ecd_AdjToCompAxis": {" xbrltype":" stringItemType","
nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AdjToCompAxis"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":"
Adjustment to Compensation [ Axis ]"," terseLabel":" Adjustment to Compensation:" } } }," auth_ref": [" r894" ] }," ecd_AdjToNonPeoNeoCompFnTextBlock": {" xbrltype":"
textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AdjToNonPeoNeoCompFnTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ],"
lang": {" en- us": {" role": {" label":" Adjustment to Non- PEO NEO Compensation Footnote [ Text Block ]"," terseLabel":" Adjustment to Non- PEO NEO Compensation Footnote" } } },"
auth_ref": [" r894" ] }," ecd_AdjToPeoCompFnTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AdjToPeoCompFnTextBlock","
presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Adjustment To PEO Compensation, Footnote [ Text Block ]"," terseLabel":"
Adjustment To PEO Compensation, Footnote" } } }," auth_ref": [" r894" ] }," us-
gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap /
2024"," localname":" AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"," presentation": [" http: / / www. orukatx. com / role /
ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" terseLabel":" Adjustments to reconcile net loss to net cash used in operating activities:"," label":" Adjustments, Noncash Items, to
Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [ Abstract ]" } } }," auth_ref": [ ] }," us-
gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap /
2024"," localname":" AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"," crdr":" credit"," presentation": [" http: / / www. orukatx.
com / role / ShareholdersEquityType2or3" ]," lang": {" en- us": {" role": {" terseLabel":" Stock- based compensation expense"," label":" APIC, Share- Based Payment Arrangement, Increase
for Cost Recognition"," documentation":" Amount of increase to additional paid- in capital (APIC) for recognition of cost for award under share- based payment arrangement." } } },"
auth_ref": [" r44"," r45"," r362" ] }," us- gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap /
2024"," localname":" AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / ShareholdersEquityType2or3"
]," lang": {" en- us": {" role": {" negatedLabel":" Issuance costs of Pre- Closing Financing and reverse recapitalization"," label":" Adjustments to Additional Paid in Capital, Stock Issued,
Issuance Costs"," documentation":" Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and
accounting fees and direct costs associated with stock issues under a shelf registration." } } }," auth_ref": [" r9"," r91" ] }," us- gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {"
xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AdjustmentsToAdditionalPaidInCapitalWarrantIssued"," crdr":" credit"," presentation": ["
http: / / www. orukatx. com / role / ShareholdersEquityType2or3" ]," lang": {" en- us": {" role": {" terseLabel":" Reclassification of the Paruka warrant from liability to equity"," label":"
Adjustments to Additional Paid in Capital, Warrant Issued"," documentation":" Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes
allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }," auth_ref": [" r9"," r38"," r91" ] },"
ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":"
AggtChngPnsnValInSummryCompstnTblForAplblYrMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Aggregate
Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [ Member ]"," terseLabel":" Aggregate Change in Present Value of
Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }," auth_ref": [" r933" ] }," ecd_AggtErrCompAmt": {" xbrltype":" monetaryItemType"," nsuri":"
http: / / xbrl. sec. gov / ecd / 2024"," localname":" AggtErrCompAmt"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure" ]," lang": {" en- us": {" role": {" label":"
Aggregate Erroneous Compensation Amount"," terseLabel":" Aggregate Erroneous Compensation Amount" } } }," auth_ref": [" r842"," r853"," r871"," r906" ] },"
ecd_AggtErrCompNotYetDeterminedTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":"
AggtErrCompNotYetDeterminedTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure" ]," lang": {" en- us": {" role": {" label":" Aggregate Erroneous
Compensation Not Yet Determined [ Text Block ]"," terseLabel":" Aggregate Erroneous Compensation Not Yet Determined" } } }," auth_ref": [" r845"," r856"," r874"," r909" ] },"
ecd_AggtPnsnAdjsSvcCstMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AggtPnsnAdjsSvcCstMember"," presentation": [" http: / /
xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" Aggregate Pension Adjustments Service Cost [ Member ]"," terseLabel":" Aggregate Pension Adjustments
Service Cost" } } }," auth_ref": [" r934" ] }," ecd_AllAdjToCompMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":"
AllAdjToCompMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" All Adjustments to Compensation [ Member ]","
terseLabel":" All Adjustments to Compensation" } } }," auth_ref": [" r894" ] }," ecd_AllExecutiveCategoriesMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd /
2024"," localname":" AllExecutiveCategoriesMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" All Executive Categories [
Member ]"," terseLabel":" All Executive Categories" } } }," auth_ref": [" r901" ] }," ecd_AllIndividualsMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd /
2024"," localname":" AllIndividualsMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure"," http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure"," http: / /
xbrl. sec. gov / ecd / role / InsiderTradingArrangements"," http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {" role": {" label":" All Individuals [ Member ]","
terseLabel":" All Individuals" } } }," auth_ref": [" r846"," r857"," r875"," r901"," r910"," r914"," r922" ] }," ecd_AllTradingArrangementsMember": {" xbrltype":" domainItemType","
nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AllTradingArrangementsMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / InsiderTradingArrangements" ]," lang": {"
en- us": {" role": {" label":" All Trading Arrangements [ Member ]"," terseLabel":" All Trading Arrangements" } } }," auth_ref": [" r920" ] }," us-
gaap_AllocatedShareBasedCompensationExpense": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
AllocatedShareBasedCompensationExpense"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role /
ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable"," http: / / www. orukatx. com / role / ScheduleofCompanysStockBasedCompensationExpenseTable"," http: / / www.
orukatx. com / role / StockBasedCompensationDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Stock- based compensation expense"," verboseLabel":" Total stock- based compensation
expense"," label":" Share- Based Payment Arrangement, Expense"," documentation":" Amount of expense for award under share- based payment arrangement. Excludes amount capitalized."
} } }," auth_ref": [" r394"," r404" ] }," dei_AmendmentDescription": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" AmendmentDescription","
presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Amendment Description"," documentation":" Description of changes contained
within amended document." } } }," auth_ref": [ ] }," dei_AmendmentFlag": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" AmendmentFlag","
presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Amendment Flag"," documentation":" Boolean flag that is true when the XBRL
content amends previously- filed or accepted submission." } } }," auth_ref": [ ] }," dei_AnnualInformationForm": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei /
2024"," localname":" AnnualInformationForm"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Annual Information Form","
documentation":" Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }," auth_ref": [" r849" ] }," orka_AntibodyProductsMember": {"
xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" AntibodyProductsMember"," presentation": [" http: / / www. orukatx. com / role /
OptionAgreementsandLicenseAgreementsDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Antibody Products [ Member ]"," label":" Antibody Products Member" } } }," auth_ref": [ ]
}," us- gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"," presentation": [" http: / / www. orukatx. com / role /
ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable" ]," lang": {" en- us": {" role": {" terseLabel":" Total anti- dilutive securities"," label":"
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"," documentation":" Securities (including those issuable pursuant to contingent stock agreements) that could
potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or
EPU amounts or decrease loss per share or unit amounts for the period presented." } } }," auth_ref": [" r189" ] }," us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024","
localname":" AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"," presentation": [" http: / / www. orukatx. com / role /
ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable" ]," lang": {" en- us": {" role": {" label":" Antidilutive Securities [ Axis ]","
documentation":" Information by type of antidilutive security." } } }," auth_ref": [" r29" ] }," us- gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {"
xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"," presentation": ["
http: / / www. orukatx. com / role / ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable" ]," lang": {" en- us": {" role": {" label":" Schedule of
Anti- Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share [ Line Items ]"," documentation":" Line items represent financial concepts included in a table. These
concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }," auth_ref": [ ] }," us-
gaap_AntidilutiveSecuritiesNameDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AntidilutiveSecuritiesNameDomain"," presentation":
[" http: / / www. orukatx. com / role / ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable" ]," lang": {" en- us": {" role": {" label":" Antidilutive
Securities, Name [ Domain ]"," documentation":" Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would
increase EPS amounts or decrease loss per share amounts for the period presented." } } }," auth_ref": [" r29" ] }," dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {"
xbrltype":" dateOrAsapItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" ApproximateDateOfCommencementOfProposedSaleToThePublic"," presentation": [" http: / /
xbrl. sec. gov / dei / role / document / Cover" ]," lang": {" en- us": {" role": {" label":" Approximate Date of Commencement of Proposed Sale to Public"," documentation":" The approximate
date of a commencement of a proposed sale of securities to the public. This element is disclosed in S- 1, S- 3, S- 4, S- 11, F- 1, F- 3 and F- 10 filings." } } }," auth_ref": [ ] }," us-
gaap_ArrangementsAndNonarrangementTransactionsMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
ArrangementsAndNonarrangementTransactionsMember"," presentation": [" http: / / www. orukatx. com / role / NotePayablewithRelatedPartyDetails"," http: / / www. orukatx. com / role /
OptionAgreementsandLicenseAgreementsDetails" ]," lang": {" en- us": {" role": {" label":" Collaborative Arrangement and Arrangement Other than Collaborative [ Domain ]","
documentation":" Collaborative arrangement and arrangement other than collaborative applicable to revenue- generating activity or operations." } } }," auth_ref": [" r450" ] }," us-
gaap_Assets": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" Assets"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role /
ConsolidatedBalanceSheet": {" parentTag": null," weight": null," order": null," root": true } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet" ]," lang": {"
en- us": {" role": {" totalLabel":" Total assets"," label":" Assets"," documentation":" Amount of asset recognized for present right to economic benefit." } } }," auth_ref": [" r99"," r110","
r131"," r157"," r194"," r203"," r217"," r220"," r261"," r293"," r294"," r295"," r296"," r297"," r298"," r299"," r300"," r301"," r451"," r453"," r489"," r595"," r674"," r757"," r758","
r793"," r816"," r1008"," r1009"," r1065" ] }," us- gaap_AssetsCurrent": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AssetsCurrent","
crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_Assets"," weight": 1. 0," order": 1. 0 } }," presentation": [" http: / /
www. orukatx. com / role / ConsolidatedBalanceSheet" ]," lang": {" en- us": {" role": {" totalLabel":" Total current assets"," label":" Assets, Current"," documentation":" Amount of asset
recognized for present right to economic benefit, classified as current." } } }," auth_ref": [" r127"," r137"," r157"," r261"," r293"," r294"," r295"," r296"," r297"," r298"," r299"," r300","
r301"," r451"," r453"," r489"," r793"," r1008"," r1009"," r1065" ] }," us- gaap_AssetsCurrentAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024","
localname":" AssetsCurrentAbstract"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet" ]," lang": {" en- us": {" role": {" terseLabel":" Current assets:","
label":" Assets, Current [ Abstract ]" } } }," auth_ref": [ ] }," us- gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org /
```

us- gaap / 2024"," localname":" AuctionMarketPreferredSecuritiesStockSeriesLineItems"," presentation": [" http: / / www. orukatx. com / role / ScheduleofConvertiblePreferredStockTable"]," lang": {" en- us": {" role": {" label":" Schedule of Convertible Preferred Stock [Line Items]"," documentation":" Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }," auth_ref": [ ] }," dei_AuditedAnnualFinancialStatements": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" AuditedAnnualFinancialStatements"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Audited Annual Financial Statements"," documentation":" Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }," auth_ref": [" r849"] }," dei_AuditorFirmId": {" xbrltype":" nonemptySequenceNumberItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" AuditorFirmId"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / AuditInformation"]," lang": {" en- us": {" role": {" label":" Auditor Firm ID"," documentation":" PCAOB issued Audit Firm Identifier" } } }," auth_ref": [" r829"," r832"," r849"] }," dei_AuditorLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" AuditorLineItems"," lang": {" en- us": {" role": {" label":" Auditor [Line Items]" } } }," auth_ref": [ ] }," dei_AuditorLocation": {" xbrltype":" internationalNameItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" AuditorLocation"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / AuditInformation"]," lang": {" en- us": {" role": {" label":" Auditor Location" } } }," auth_ref": [" r829"," r832"," r849"] }," dei_AuditorName": {" xbrltype":" internationalNameItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" AuditorName"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / AuditInformation"]," lang": {" en- us": {" role": {" label":" Auditor Name" } } }," auth_ref": [" r829"," r832"," r849"] }," dei_AuditorOpinionTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" AuditorOpinionTextBlock"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / AuditInformation"]," lang": {" en- us": {" role": {" label":" Auditor Opinion [Text Block]" } } }," auth_ref": [" r938"] }," dei_AuditorTable": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" AuditorTable"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / AuditInformation"]," lang": {" en- us": {" role": {" label":" Auditor [Table]" } } }," auth_ref": [ ] }," us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role / ScheduleofCashEquivalentsandMarketableSecuritiesTable"]," lang": {" en- us": {" role": {" terseLabel":" Gross Unrealized Gains, Cash Equivalents and Marketable Securities"," label":" Debt Securities, Available- for- Sale, Accumulated Gross Unrealized Gain, before Tax"," documentation":" Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale)." } } }," auth_ref": [" r234"] }," us- gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / ScheduleofCashEquivalentsandMarketableSecuritiesTable"]," lang": {" en- us": {" role": {" negatedLabel":" Gross Unrealized Losses, Cash Equivalents and Marketable Securities"," label":" Debt Securities, Available- for- Sale, Accumulated Gross Unrealized Loss, before Tax"," documentation":" Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale)." } } }," auth_ref": [" r235"] }," us- gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AvailableForSaleDebtSecuritiesAmortizedCostBasis"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / ScheduleofCashEquivalentsandMarketableSecuritiesTable"]," lang": {" en- us": {" role": {" terseLabel":" Amortized Cost, Cash Equivalents and Marketable Securities"," label":" Debt Securities, Available- for- Sale, Amortized Cost"," documentation":" Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale)." } } }," auth_ref": [" r231"," r269"," r594"] }," us- gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"," lang": {" en- us": {" role": {" label":" Schedule of Marketable Securities at Estimated Fair Value [Abstract]" } } }," auth_ref": [ ] }," us- gaap_AvailableForSaleSecuritiesDebtSecurities": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AvailableForSaleSecuritiesDebtSecurities"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / ScheduleofCashEquivalentsandMarketableSecuritiesTable"]," lang": {" en- us": {" role": {" terseLabel":" Fair Value, Cash Equivalents and Marketable Securities"," label":" Debt Securities, Available- for- Sale"," documentation":" Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale)." } } }," auth_ref": [" r232"," r269"," r467"," r588"," r780"," r783"," r994"," r1053"," r1054"," r1055"] }," ecd_AwardExrcPrice": {" xbrltype":" perShareItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AwardExrcPrice"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure"]," lang": {" en- us": {" role": {" label":" Award Exercise Price"," terseLabel":" Exercise Price" } } }," auth_ref": [" r917"] }," ecd_AwardGrantDateFairValue": {" xbrltype":" monetaryItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AwardGrantDateFairValue"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure"]," lang": {" en- us": {" role": {" label":" Award Grant Date Fair Value"," terseLabel":" Fair Value as of Grant Date" } } }," auth_ref": [" r918"] }," ecd_AwardTmgDiscLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AwardTmgDiscLineItems"," lang": {" en- us": {" role": {" label":" Award Timing Disclosures [Line Items]"," terseLabel":" Award Timing Disclosures" } } }," auth_ref": [" r913"] }," ecd_AwardTmgHowMnpiCnsdrdTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AwardTmgHowMnpiCnsdrdTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure"]," lang": {" en- us": {" role": {" label":" Award Timing, How MNPI Considered [Text Block]"," terseLabel":" Award Timing, How MNPI Considered" } } }," auth_ref": [" r913"] }," ecd_AwardTmgMethodTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AwardTmgMethodTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure"]," lang": {" en- us": {" role": {" label":" Award Timing Method [Text Block]"," terseLabel":" Award Timing Method" } } }," auth_ref": [" r913"] }," ecd_AwardTmgMnpiCnsdrdFlag": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AwardTmgMnpiCnsdrdFlag"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure"]," lang": {" en- us": {" role": {" label":" Award Timing MNPI Considered [Flag]"," terseLabel":" Award Timing MNPI Considered" } } }," auth_ref": [" r913"] }," ecd_AwardTmgMnpiDiscTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AwardTmgMnpiDiscTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure"]," lang": {" en- us": {" role": {" label":" Award Timing MNPI Disclosure [Text Block]"," terseLabel":" Award Timing MNPI Disclosure" } } }," auth_ref": [" r913"] }," ecd_AwardTmgPredtrmndFlag": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AwardTmgPredtrmndFlag"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure"]," lang": {" en- us": {" role": {" label":" Award Timing Predetermined [Flag]"," terseLabel":" Award Timing Predetermined" } } }," auth_ref": [" r913"] }," us- gaap_AwardTypeAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" AwardTypeAxis"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"," http: / / www. orukatx. com / role / ScheduleofCommonStockReservedforFutureIssuanceTable"," http: / / www. orukatx. com / role / ScheduleofRSAActivityTable"," http: / / www. orukatx. com / role / ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable"," http: / / www. orukatx. com / role / StockBasedCompensationDetails"," http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure"]," lang": {" en- us": {" role": {" label":" Award Type [Axis]"," terseLabel":" Award Type"," documentation":" Information by type of award under share- based payment arrangement." } } }," auth_ref": [" r365"," r366"," r367"," r369"," r370"," r371"," r372"," r373"," r374"," r375"," r376"," r377"," r378"," r379"," r380"," r381"," r382"," r383"," r384"," r385"," r386"," r389"," r390"," r391"," r392"," r393"] }," ecd_AwardUndrlygSecuritiesAmt": {" xbrltype":" decimalItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AwardUndrlygSecuritiesAmt"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure"]," lang": {" en- us": {" role": {" label":" Award Underlying Securities Amount"," terseLabel":" Underlying Securities" } } }," auth_ref": [" r916"] }," ecd_AwardsCloseToMnpiDiscIndName": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AwardsCloseToMnpiDiscIndName"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure"]," lang": {" en- us": {" role": {" label":" Awards Close in Time to MNPI Disclosures, Individual Name"," terseLabel":" Name" } } }," auth_ref": [" r915"] }," ecd_AwardsCloseToMnpiDiscTable": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AwardsCloseToMnpiDiscTable"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure"]," lang": {" en- us": {" role": {" label":" Awards Close in Time to MNPI Disclosures [Table]"," terseLabel":" Awards Close in Time to MNPI Disclosures" } } }," auth_ref": [" r914"] }," ecd_AwardsCloseToMnpiDiscTableTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" AwardsCloseToMnpiDiscTableTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure"]," lang": {" en- us": {" role": {" label":" Awards Close in Time to MNPI Disclosures [Table Text Block]"," terseLabel":" Awards Close in Time to MNPI Disclosures, Table" } } }," auth_ref": [" r914"] }," us- gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ScheduleoftheAssetsandLiabilitiesTable": {" parentTag":" us- gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"," weight": 1. 0," order": 1. 0 } }," presentation": [" http: / / www. orukatx. com / role / ScheduleoftheAssetsandLiabilitiesTable"]," lang": {" en- us": {" role": {" terseLabel":" Cash and cash equivalents"," label":" Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents"," documentation":" Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short- term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }," auth_ref": [" r47"] }," us- gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ScheduleoftheAssetsandLiabilitiesTable": {" parentTag":" us- gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"," weight": 1. 0," order": 2. 0 } }," presentation": [" http: / / www. orukatx. com / role / ScheduleoftheAssetsandLiabilitiesTable"]," lang": {" en- us": {" role": {" terseLabel":" Other current assets"," label":" Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other"," documentation":" Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }," auth_ref": [" r47"] }," us- gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role / ScheduleoftheAssetsandLiabilitiesTable": {" parentTag":" us- gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"," weight":- 1. 0," order": 3. 0 } }," presentation": [" http: / / www. orukatx. com / role / ScheduleoftheAssetsandLiabilitiesTable"]," lang": {" en- us": {" role": {" negatedLabel":" Accrued liabilities"," label":" Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities"," documentation":" Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date." } } }," auth_ref": [" r47"] }," us- gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ScheduleoftheAssetsandLiabilitiesTable": {" parentTag": null," weight": null," order": null," root": true } }," presentation": [" http: / / www. orukatx. com / role / ScheduleoftheAssetsandLiabilitiesTable"]," lang": {" en- us": {" role": {" totalLabel":" Net assets acquired"," label":" Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net"," documentation":" Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }," auth_ref": [" r46"," r47"] }," us- gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract"," lang": {" en- us": {" role": {" label":" Schedule of the Assets and Liabilities [Abstract]" } } }," auth_ref": [ ] }," dei_BusinessContactMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" BusinessContactMember"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Business Contact [Member]"," documentation":" Business contact for the entity" } } }," auth_ref": [" r832"," r849"] }," us- gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" BusinessDescriptionAndBasisOfPresentationTextBlock"," presentation": [" http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentation"]," lang": {" en- us": {" role": {" terseLabel":" Nature of the Business and Basis of Presentation"," label":" Business Description and Basis of Presentation [Text Block]"," documentation":" The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example,

US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } },"auth_ref": [" r50"," r83"," r84"] }," stpr_CA": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / stpr / 2024"," localname":" CA"," presentation": [" http: / / www. orukatx. com / role / CommitmentandContingenciesDetails"]," lang": {" en- us": {" role": {" terseLabel":" California [Member]"," label":" CALIFORNIA" } } }," auth_ref": [ ] }," orka_CashAcquiredInConnectionWithTheReverseRecapitalization": {" xbrltype":" monetaryItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" CashAcquiredInConnectionWithTheReverseRecapitalization"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInFinancingActivities"," weight": 1. 0," order": 5. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedCashFlow"]," lang": {" en- us": {" role": {" terseLabel":" Cash acquired in connection with the reverse recapitalization"," documentation":" Represent the amount of cash acquired in connection with the reverse recapitalization."," label":" Cash Acquired In Connection With The Reverse Recapitalization" } } }," auth_ref": [ ] }," us- gaap_CashAndCashEquivalentsAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CashAndCashEquivalentsAbstract"," presentation": [" http: / / www. orukatx. com / role / ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"," http: / / www. orukatx. com / role / ScheduleofCashEquivalentsandMarketableSecuritiesTable"," http: / / www. orukatx. com / role / ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"]," lang": {" en- us": {" role": {" terseLabel":" Cash equivalents"," label":" Cash and Cash Equivalents [Abstract]" } } }," auth_ref": [ ] }," us- gaap_CashAndCashEquivalentsAtCarryingValue": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CashAndCashEquivalentsAtCarryingValue"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_AssetsCurrent"," weight": 1. 0," order": 1. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"]," lang": {" en- us": {" role": {" terseLabel":" Cash and cash equivalents"," label":" Cash and Cash Equivalents, at Carrying Value"," documentation":" Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short- term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }," auth_ref": [" r23"," r129"," r744"] }," us- gaap_CashAndCashEquivalentsAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CashAndCashEquivalentsAxis"," presentation": [" http: / / www. orukatx. com / role / ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"]," lang": {" en- us": {" role": {" label":" Cash and Cash Equivalents [Axis]"," documentation":" Information by type of cash and cash equivalent balance." } } }," auth_ref": [" r129"] }," us- gaap_CashAndCashEquivalentsPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CashAndCashEquivalentsPolicyTextBlock"," presentation": [" http: / / www. orukatx. com / role / AccountingPoliciesByPolicy"]," lang": {" en- us": {" role": {" terseLabel":" Cash and Cash Equivalents"," label":" Cash and Cash Equivalents, Policy [Policy Text Block]"," documentation":" Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity' s use of its cash and cash equivalents, (2) whether the entity' s cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }," auth_ref": [" r24"] }," us- gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CashCashEquivalentsAndMarketableSecuritiesTextBlock"," presentation": [" http: / / www. orukatx. com / role / CashequivalentsandMarketableSecurities"]," lang": {" en- us": {" role": {" terseLabel":" Cash Equivalents and marketable Securities"," label":" Cash, Cash Equivalents, and Marketable Securities [Text Block]"," documentation":" The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)." } } }," auth_ref": [" r993"] }," us- gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedCashFlow"]," lang": {" en- us": {" role": {" periodStartLabel":" Cash at beginning of period"," periodEndLabel":" Cash and cash equivalents at end of period"," label":" Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents"," documentation":" Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short- term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }," auth_ref": [" r23"," r80"," r153"] }," us- gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedCashFlow": {" parentTag": null," weight": null," order": null," root": true } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedCashFlow"]," lang": {" en- us": {" role": {" totalLabel":" Net increase in cash and cash equivalents"," label":" Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect"," documentation":" Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short- term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }," auth_ref": [" r0"," r80"] }," orka_CashEquivalentsAndMarketableSecuritiesAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" CashEquivalentsAndMarketableSecuritiesAbstract"," lang": {" en- us": {" role": {" label":" Cash equivalents and Marketable Securities [Abstract]" } } }," auth_ref": [ ] }," us- gaap_CashEquivalentsAtCarryingValue": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CashEquivalentsAtCarryingValue"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"]," lang": {" en- us": {" role": {" terseLabel":" Cash equivalents"," label":" Cash Equivalents, at Carrying Value"," documentation":" Amount of short- term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }," auth_ref": [" r962"," r1076"] }," us- gaap_CashEquivalentsMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CashEquivalentsMember"," presentation": [" http: / / www. orukatx. com / role / ScheduleofCashEquivalentsandMarketableSecuritiesTable"]," lang": {" en- us": {" role": {" terseLabel":" Cash Equivalents [Member]"," label":" Cash Equivalents [Member]"," documentation":" Short- term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }," auth_ref": [" r129"] }," orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems"," presentation": [" http: / / www. orukatx. com / role / ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"]," lang": {" en- us": {" role": {" label":" Cash equivalents and Marketable Securities- Schedule of Available- for- Sale Securities in an Unrealized Loss Position (Details) [Line Items]" } } }," auth_ref": [ ] }," orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable"," presentation": [" http: / / www. orukatx. com / role / ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"]," lang": {" en- us": {" role": {" label":" Cash equivalents and Marketable Securities- Schedule of Available- for- Sale Securities in an Unrealized Loss Position (Details) [Table]" } } }," auth_ref": [ ] }," us- gaap_ChangeInAccountingEstimateLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ChangeInAccountingEstimateLineItems"," presentation": [" http: / / www. orukatx. com / role / SummaryofSignificantAccountingPoliciesDetails"]," lang": {" en- us": {" role": {" label":" Summary of Significant Accounting Policies [Line Items]"," documentation":" Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }," auth_ref": [" r173"] }," ecd_ChangedPeerGroupFnTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" ChangedPeerGroupFnTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Changed Peer Group, Footnote [Text Block]"," terseLabel":" Changed Peer Group, Footnote" } } }," auth_ref": [" r892"] }," ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"," terseLabel":" Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }," auth_ref": [" r889"] }," ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Year- over- Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"," terseLabel":" Year- over- Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }," auth_ref": [" r887"] }," dei_CityAreaCode": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" CityAreaCode"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" City Area Code"," documentation":" Area code of city" } } }," auth_ref": [ ] }," us- gaap_ClassOfStockDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ClassOfStockDomain"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"," http: / / www. orukatx. com / role / ConsolidatedBalanceSheet_Parentheticals"," http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome"," http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"," http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"," http: / / www. orukatx. com / role / NotePayablewithRelatedPartyDetails"," http: / / www. orukatx. com / role / RelatedPartyTransactionsDetails"," http: / / www. orukatx. com / role / ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"," http: / / www. orukatx. com / role / ScheduleofCommonStockReservedforFutureIssuanceTable"," http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" label":" Class of Stock [Domain]"," documentation":" Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }," auth_ref": [" r124"," r133"," r134"," r135"," r157"," r183"," r184"," r186"," r188"," r197"," r198"," r261"," r293"," r295"," r296"," r297"," r300"," r301"," r331"," r332"," r336"," r339"," r347"," r489"," r628"," r629"," r630"," r631"," r637"," r638"," r639"," r640"," r641"," r642"," r643"," r644"," r645"," r646"," r647"," r648"," r662"," r683"," r705"," r722"," r723"," r724"," r725"," r726"," r950"," r975"," r985"] }," us- gaap_ClassOfStockLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ClassOfStockLineItems"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"," http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"]," lang": {" en- us": {" role": {" label":" Nature of the Business and Basis of Presentation [Line Items]"," terseLabel":" Convertible Preferred Stock and Stockholders \ u2019 Equity [Line Items]"," documentation":" Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }," auth_ref": [" r133"," r134"," r135"," r197"," r331"," r332"," r334"," r336"," r339"," r345"," r347"," r628"," r629"," r630"," r631"," r770"," r950"," r975"] }," orka_ClassOfWarrantOrRight": {" xbrltype":" sharesItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ClassOfWarrantOrRight"," presentation": [" http: / / www. orukatx. com / role / StockBasedCompensationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Warrants issued"," documentation":" Number of warrants or rights issued."," label":" Class Of Warrant Or Right" } } }," auth_ref": [ ] }," us- gaap_ClassOfWarrantOrRightAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ClassOfWarrantOrRightAxis"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"," http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"," http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"," http: / / www. orukatx. com / role / ScheduleofCommonStockReservedforFutureIssuanceTable"," http: / / www. orukatx. com / role / ScheduleofEmployeeWarrantActivityTable"," http: / / www. orukatx. com / role / ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable"," http: / / www. orukatx. com / role / StockBasedCompensationDetails"]," lang": {" en- us": {" role": {" label":" Class of Warrant or Right [Axis]"," documentation":" Information by type of warrant or right issued." } } }," auth_ref": [" r41"] }," us- gaap_ClassOfWarrantOrRightDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ClassOfWarrantOrRightDomain"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"," http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"," http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"," http: / / www. orukatx. com / role /

ScheduleofCommonStockReservedforFutureIssuanceTable"," http: / / www. orukatx. com / role / ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable"," http: / / www. orukatx. com / role / StockBasedCompensationDetails"]," lang": {" en- us": {" role": {" label":" Class of Warrant or Right [Domain]"," documentation":" Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }," auth_ref": [ ] }," us- gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {" xbrltype":" perShareItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"," http: / / www. orukatx. com / role / StockBasedCompensationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Exercise price per warrant (in Dollars per share)"," verboseLabel":" Exercise price per warrant"," label":" Class of Warrant or Right, Exercise Price of Warrants or Rights"," documentation":" Exercise price per share or per unit of warrants or rights outstanding." } } }," auth_ref": [" r348"] }," orka_ClassOfWarrantOrRightExpirationDate": {" xbrltype":" dateItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ClassOfWarrantOrRightExpirationDate"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"]," lang": {" en- us": {" role": {" terseLabel":" Expiration date"," documentation":" The class of warrant or right expiration date."," label":" Class Of Warrant Or Right Expiration Date" } } }," auth_ref": [ ] }," us- gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"]," lang": {" en- us": {" role": {" terseLabel":" Employee warrants issued"," label":" Class of Warrant or Right, Number of Securities Called by Warrants or Rights"," documentation":" Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500, 000 warrants may be converted into 1, 000, 000 shares." } } }," auth_ref": [" r348"] }," us- gaap_ClassOfWarrantOrRightOutstanding": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ClassOfWarrantOrRightOutstanding"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"]," lang": {" en- us": {" role": {" terseLabel":" Warrants outstanding"," label":" Class of Warrant or Right, Outstanding"," documentation":" Number of warrants or rights outstanding." } } }," auth_ref": [ ] }," orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum": {" xbrltype":" percentItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum"," presentation": [" http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"," http: / / www. orukatx. com / role / StockBasedCompensationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Warrant To Purchase Number Of Shares As A Percentage Of Outstanding Diluted Stock"," verboseLabel":" Warrant purchase percentage"," documentation":" class of warrant or right to purchase percentage of outstanding diluted stock maximum."," label":" Class Of Warrant Or Right To Purchase Percentage Of Outstanding Diluted Stock Maximum" } } }," auth_ref": [ ] }," us-gaap_ClassOfWarrantOrRightUnissued": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ClassOfWarrantOrRightUnissued"," presentation": [" http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Warrants exchange"," label":" Class of Warrant or Right, Unissued"," documentation":" The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights." } } }," auth_ref": [ ] }," orka_ClassOfWarrantOrRightWarrantsExercised": {" xbrltype":" sharesItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ClassOfWarrantOrRightWarrantsExercised"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"]," lang": {" en- us": {" role": {" terseLabel":" Warrants exercised"," documentation":" The class of Warrant or Right warrants exercised."," label":" Class Of Warrant Or Right Warrants Exercised" } } }," auth_ref": [ ] }," orka_ClassOfWarrantsExercisable": {" xbrltype":" sharesItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ClassOfWarrantsExercisable"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"]," lang": {" en- us": {" role": {" terseLabel":" Warrants exercisable"," documentation":" Represent the number of warrants exercisable."," label":" Class Of Warrants Exercisable" } } }," auth_ref": [ ] }," orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ClassificationOfConvertiblePreferredStockPolicyTextBlock"," presentation": [" http: / / www. orukatx. com / role / AccountingPoliciesByPolicy"]," lang": {" en- us": {" role": {" terseLabel":" Classification of Convertible Preferred Stock"," documentation":" Classification of Convertible Preferred Stock."," label":" Classification Of Convertible Preferred Stock Policy Text Block" } } }," auth_ref": [ ] }," orka_ClinicalDevelopmentMilestonesMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ClinicalDevelopmentMilestonesMember"," presentation": [" http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"]," lang": {" en- us": {" role": {" terseLabel":" Clinical Development Milestones [Member]"," label":" Clinical Development Milestones Member" } } }," auth_ref": [ ] }," ecd_CoSelectedMeasureAmt": {" xbrltype":" decimalItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" CoSelectedMeasureAmt"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Company Selected Measure Amount"," terseLabel":" Company Selected Measure Amount" } } }," auth_ref": [" r893"] }," ecd_CoSelectedMeasureName": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" CoSelectedMeasureName"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Company Selected Measure Name"," terseLabel":" Company Selected Measure Name" } } }," auth_ref": [" r893"] }," us- gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"," presentation": [" http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"]," lang": {" en- us": {" role": {" label":" Option Agreements and License Agreements [Line Items]"," documentation":" Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }," auth_ref": [" r450"] }," us- gaap_CommercialPaperMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CommercialPaperMember"," presentation": [" http: / / www. orukatx. com / role / ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"," http: / / www. orukatx. com / role / ScheduleofCashEquivalentsandMarketableSecuritiesTable"," http: / / www. orukatx. com / role / ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"]," lang": {" en- us": {" role": {" terseLabel":" Commercial Papers [Member]"," verboseLabel":" Commercial papers \ t [Member]"," netLabel":" Commercial papers [Member]"," label":" Commercial Paper [Member]"," documentation":" Unsecured promissory note (generally negotiable) that provides institutions with short- term funds." } } }," auth_ref": [" r88"," r292"," r810"," r811"," r812"," r813"] }," orka_CommitmentandContingenciesDetailsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" CommitmentandContingenciesDetailsTable"," presentation": [" http: / / www. orukatx. com / role / CommitmentandContingenciesDetails"]," lang": {" en- us": {" role": {" label":" Commitment and Contingencies (Details) [Table]" } } }," auth_ref": [ ] }," us- gaap_CommitmentsAndContingencies": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us-gaap / 2024"," localname":" CommitmentsAndContingencies"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet": {" parentTag":" us-gaap_LiabilitiesAndStockholdersEquity"," weight": 1. 0," order": 2. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"]," lang": {" en- us": {" role": {" terseLabel":" Commitments and contingencies (Note 13)"," label":" Commitments and Contingencies"," documentation":" Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company' s resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }," auth_ref": [" r59"," r103"," r597"," r661"] }," us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CommitmentsAndContingenciesDisclosureAbstract"," lang": {" en- us": {" role": {" label":" Commitment and Contingencies [Abstract]" } } }," auth_ref": [ ] }," us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CommitmentsAndContingenciesDisclosureTextBlock"," presentation": [" http: / / www. orukatx. com / role / CommitmentandContingencies"]," lang": {" en- us": {" role": {" terseLabel":" Commitment and Contingencies"," label":" Commitments and Contingencies Disclosure [Text Block]"," documentation":" The entire disclosure for commitments and contingencies." } } }," auth_ref": [" r86"," r285"," r286"," r729"," r1002"," r1007"] }," us- gaap_CommitmentsAndContingenciesPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CommitmentsAndContingenciesPolicyTextBlock"," presentation": [" http: / / www. orukatx. com / role / AccountingPoliciesByPolicy"]," lang": {" en- us": {" role": {" terseLabel":" Commitments and Contingencies"," label":" Commitments and Contingencies, Policy [Policy Text Block]"," documentation":" Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies." } } }," auth_ref": [" r37"," r730"] }," us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CommonStockCapitalSharesReservedForFutureIssuance"," presentation": [" http: / / www. orukatx. com / role / ScheduleofCommonStockReservedforFutureIssuanceTable"," http: / / www. orukatx. com / role / ScheduleofConvertiblePreferredStockTable"," http: / / www. orukatx. com / role / StockBasedCompensationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Common Stock Issuable Upon Conversion"," verboseLabel":" Total shares of common stock reserved"," netLabel":" Shares reserved for future issuance"," label":" Common Stock, Capital Shares Reserved for Future Issuance"," documentation":" Aggregate number of common shares reserved for future issuance." } } }," auth_ref": [" r65"] }," orka_CommonStockConversionRatio": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" CommonStockConversionRatio"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"]," lang": {" en- us": {" role": {" terseLabel":" Conversion ratio"," documentation":" Percentage of common stock conversion ratio."," label":" Common Stock Conversion Ratio" } } }," auth_ref": [ ] }," us- gaap_CommonStockMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CommonStockMember"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"," http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"," http: / / www. orukatx. com / role / NotePayablewithRelatedPartyDetails"," http: / / www. orukatx. com / role / RelatedPartyTransactionsDetails"," http: / / www. orukatx. com / role / ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"," http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" terseLabel":" Common Stock"," verboseLabel":" Common Stock [Member]"," label":" Common Stock [Member]"," documentation":" Stock that is subordinate to all other stock of the issuer." } } }," auth_ref": [" r806"," r807"," r808"," r810"," r811"," r812"," r813"," r980"," r981"," r984"," r1049"," r1107"," r1109"] }," us- gaap_CommonStockParOrStatedValuePerShare": {" xbrltype":" perShareItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CommonStockParOrStatedValuePerShare"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet_Parentheticals"," http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Common stock, par value (in Dollars per share)"," label":" Common Stock, Par or Stated Value Per Share"," documentation":" Face amount or stated value per share of common stock." } } }," auth_ref": [" r65"] }," us- gaap_CommonStockSharesAuthorized": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CommonStockSharesAuthorized"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet_Parentheticals"," http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"]," lang": {" en- us": {" role": {" terseLabel":" Common stock, shares authorized"," label":" Common Stock, Shares Authorized"," documentation":" The maximum number of common shares permitted to be issued by an entity' s charter and bylaws." } } }," auth_ref": [" r65"," r662"] }," us- gaap_CommonStockSharesIssued": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CommonStockSharesIssued"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet_Parentheticals"," http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"," http: / / www. orukatx. com / role / StockBasedCompensationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Common stock, shares issued"," label":" Common Stock, Shares, Issued"," documentation":" Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm' s shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }," auth_ref": [" r65"] }," us- gaap_CommonStockSharesOutstanding": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CommonStockSharesOutstanding"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet_Parentheticals"," http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"]," lang": {" en- us": {" role": {" terseLabel":" Common stock, shares outstanding"," label":" Common Stock, Shares, Outstanding"," documentation":" Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }," auth_ref": [" r9"," r65"," r662"," r680"," r1109"," r1110"] }," us- gaap_CommonStockValue": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CommonStockValue"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet": {" parentTag":" us-gaap_StockholdersEquity"," weight": 1. 0," order": 2. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"]," lang": {" en- us": {" role": {" terseLabel":"

Common stock, $ 0. 001 and $ 0. 001 par value as of December 31, 2024 and February 6, 2024, respectively; 545, 000, 000 and 65, 000, 000 shares authorized, 37, 440, 510 and 3, 197, 975 shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively"," label":" Common Stock, Value, Issued"," documentation":" Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }," auth_ref": [" r65"," r599"," r793"] }," orka_CommonStocksConversionRatio": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" CommonStocksConversionRatio"," presentation": [" http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Conversion ratio"," documentation":" Percentage of common stock conversion ratio."," label":" Common Stocks Conversion Ratio" } } }," auth_ref": [ ] }," ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" CompActuallyPaidVsCoSelectedMeasureTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Compensation Actually Paid vs. Company Selected Measure [Text Block]"," terseLabel":" Compensation Actually Paid vs. Company Selected Measure" } } }," auth_ref": [" r898"] }," ecd_CompActuallyPaidVsNetIncomeTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" CompActuallyPaidVsNetIncomeTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Compensation Actually Paid vs. Net Income [Text Block]"," terseLabel":" Compensation Actually Paid vs. Net Income" } } }," auth_ref": [" r897"] }," ecd_CompActuallyPaidVsOtherMeasureTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" CompActuallyPaidVsOtherMeasureTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Compensation Actually Paid vs. Other Measure [Text Block]"," terseLabel":" Compensation Actually Paid vs. Other Measure" } } }," auth_ref": [" r899"] }," ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" CompActuallyPaidVsTotalShareholderRtnTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Compensation Actually Paid vs. Total Shareholder Return [Text Block]"," terseLabel":" Compensation Actually Paid vs. Total Shareholder Return" } } }," auth_ref": [" r896"] }," us- gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"," lang": {" en- us": {" role": {" label":" Schedule of Components of the Deferred Tax Assets and Liabilities [Abstract]" } } }," auth_ref": [ ] }," us- gaap_ComprehensiveIncomeNetOfTax": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ComprehensiveIncomeNetOfTax"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome": {" parentTag": null," weight": null," order": null," root": true } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome"]," lang": {" en- us": {" role": {" totalLabel":" Comprehensive loss"," label":" Comprehensive Income (Loss), Net of Tax, Attributable to Parent"," documentation":" Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }," auth_ref": [" r19"," r141"," r143"," r148"," r589"," r611"," r612"] }," orka_ComprehensiveLossPolicyPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ComprehensiveLossPolicyPolicyTextBlock"," presentation": [" http: / / www. orukatx. com / role / AccountingPoliciesByPolicy"]," lang": {" en- us": {" role": {" terseLabel":" Comprehensive Loss"," documentation":" Comprehensive loss policy."," label":" Comprehensive Loss Policy Policy Text Block" } } }," auth_ref": [ ] }," us- gaap_ComputerEquipmentMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ComputerEquipmentMember"," presentation": [" http: / / www. orukatx. com / role / ScheduleofPropertyandEquipmentTable"]," lang": {" en- us": {" role": {" terseLabel":" Computer and office equipment [Member]"," label":" Computer Equipment [Member]"," documentation":" Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }," auth_ref": [ ] }," us- gaap_ConcentrationRiskCreditRisk": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ConcentrationRiskCreditRisk"," presentation": [" http: / / www. orukatx. com / role / AccountingPoliciesByPolicy"]," lang": {" en- us": {" role": {" terseLabel":" Concentrations of Credit Risk and Other Risks and Uncertainties"," label":" Concentration Risk, Credit Risk, Policy [Policy Text Block]"," documentation":" Disclosure of accounting policy for credit risk." } } }," auth_ref": [" r49"," r118"] }," dei_ContactPersonnelEmailAddress": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" ContactPersonnelEmailAddress"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Contact Personnel Email Address"," documentation":" Email address of contact personnel." } } }," auth_ref": [ ] }," dei_ContactPersonnelFaxNumber": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" ContactPersonnelFaxNumber"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Contact Personnel Fax Number"," documentation":" Fax Number of contact personnel." } } }," auth_ref": [" r832"] }," dei_ContactPersonnelName": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" ContactPersonnelName"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Contact Personnel Name"," documentation":" Name of contact personnel" } } }," auth_ref": [ ] }," dei_ContainedFileInformationFileDescription": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" ContainedFileInformationFileDescription"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Contained File Information, File Description"," documentation":" The description of the contained file." } } }," auth_ref": [ ] }," dei_ContainedFileInformationFileName": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" ContainedFileInformationFileName"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Contained File Information, File Name"," documentation":" The name of the contained file." } } }," auth_ref": [ ] }," dei_ContainedFileInformationFileNumber": {" xbrltype":" fileNumberItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" ContainedFileInformationFileNumber"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Contained File Information, File Number"," documentation":" The SEC Document Number of the contained file." } } }," auth_ref": [ ] }," dei_ContainedFileInformationFileType": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" ContainedFileInformationFileType"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Contained File Information, File Type"," documentation":" The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF / JPG, etc.)." } } }," auth_ref": [ ] }," us- gaap_ConversionOfStockAmountConverted1": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ConversionOfStockAmountConverted1"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedCashFlow"]," lang": {" en- us": {" role": {" terseLabel":" Conversion of Series A non- voting convertible preferred stock to common stock"," label":" Conversion of Stock, Amount Converted"," documentation":" The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \" Part noncash \" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }," auth_ref": [" r25"," r26"," r27"] }," us- gaap_ConversionOfStockLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ConversionOfStockLineItems"," presentation": [" http: / / www. orukatx. com / role / ScheduleofCommonStockReservedforFutureIssuanceTable"]," lang": {" en- us": {" role": {" label":" Schedule of Common Stock Reserved for Future Issuance [Line Items]"," documentation":" Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }," auth_ref": [ ] }," us- gaap_ConversionOfStockSharesConverted1": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ConversionOfStockSharesConverted1"," presentation": [" http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"," http: / / www. orukatx. com / role / NotePayablewithRelatedPartyDetails"]," lang": {" en- us": {" role": {" terseLabel":" Convertible shares"," verboseLabel":" Converted shares (in Shares)"," label":" Conversion of Stock, Shares Converted"," documentation":" The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \" Part noncash \" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }," auth_ref": [" r25"," r26"," r27"] }," orka_ConvertibleNoteMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ConvertibleNoteMember"," presentation": [" http: / / www. orukatx. com / role / NotePayablewithRelatedPartyDetails"]," lang": {" en- us": {" role": {" terseLabel":" Convertible Note [Member]"," label":" Convertible Note Member" } } }," auth_ref": [ ] }," us- gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ConvertiblePreferredStockSharesIssuedUponConversion"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"]," lang": {" en- us": {" role": {" terseLabel":" Converted shares of common stock"," label":" Convertible Preferred Stock, Shares Issued upon Conversion"," documentation":" Number of shares issued for each share of convertible preferred stock that is converted." } } }," auth_ref": [" r15"," r40"," r64"," r90"," r342"] }," orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ConvertiblePreferredStockandStockholdersEquityDetailsTable"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"]," lang": {" en- us": {" role": {" label":" Convertible Preferred Stock and Stockholders \ u2019 Equity (Details) [Table]" } } }," auth_ref": [ ] }," orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable"," presentation": [" http: / / www. orukatx. com / role / ScheduleofCommonStockReservedforFutureIssuanceTable"]," lang": {" en- us": {" role": {" label":" Convertible Preferred Stock and Stockholders \ u2019 Equity- Schedule of Common Stock Reserved for Future Issuance (Details) [Table]" } } }," auth_ref": [ ] }," orka_ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable"," presentation": [" http: / / www. orukatx. com / role / ScheduleofConvertiblePreferredStockTable"]," lang": {" en- us": {" role": {" label":" Convertible Preferred Stock and Stockholders \ u2019 Equity- Schedule of Convertible Preferred Stock (Details) [Table]" } } }," auth_ref": [ ] }," us- gaap_CorporateDebtSecuritiesMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CorporateDebtSecuritiesMember"," presentation": [" http: / / www. orukatx. com / role / ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"," http: / / www. orukatx. com / role / ScheduleofCashEquivalentsandMarketableSecuritiesTable"," http: / / www. orukatx. com / role / ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"]," lang": {" en- us": {" role": {" terseLabel":" Corporate Debt Securities [Member]"," verboseLabel":" Corporate debt securities [Member]"," label":" Corporate Debt Securities [Member]"," documentation":" Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }," auth_ref": [" r772"," r774"," r780"," r794"," r805"," r1104"] }," us- gaap_CostsAndExpensesRelatedParty": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" CostsAndExpensesRelatedParty"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome_Parentheticals"]," lang": {" en- us": {" role": {" terseLabel":" Related party amount"," label":" Costs and Expenses, Related Party"," documentation":" Costs of sales and operating expenses for the period incurred from transactions with related parties." } } }," auth_ref": [" r73"] }," srt_CounterpartyNameAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / srt / 2024"," localname":" CounterpartyNameAxis"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"," http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"]," lang": {" en- us": {" role": {" label":" Counterparty Name [Axis]" } } }," auth_ref": [" r162"," r163"," r306"," r334"," r518"," r539"," r593"," r745"," r747"] }," dei_CountryRegion": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" CountryRegion"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Country Region"," documentation":" Region code of country" } } }," auth_ref": [ ] }," dei_CoverAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" CoverAbstract"," lang": {" en- us": {" role": {" label":" Cover [Abstract]"," documentation":" Cover page." } } }," auth_ref": [ ] }," dei_CurrentFiscalYearEndDate": {" xbrltype":" gMonthDayItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" CurrentFiscalYearEndDate"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Current Fiscal Year End Date"," documentation":" End date of current fiscal year in the format-- MM- DD." } } }," auth_ref": [ ] }," cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / cyd / 2024"," localname":" CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"," presentation": [" http: / / xbrl. sec. gov / cyd / role / CybersecurityRiskManagementAndStrategyDisclosure"]," lang": {" en- us": {" role": {" terseLabel":" Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"," label":" Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }," auth_ref": [" r838"," r931"] }," cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / cyd / 2024"," localname":" CybersecurityRiskBoardOfDirectorsOversightTextBlock"," presentation": [" http: / / xbrl. sec. gov / cyd / role / CybersecurityRiskManagementAndStrategyDisclosure"]," lang": {" en- us": {" role": {" terseLabel":" Cybersecurity Risk Board of Directors Oversight [Text Block]"," label":" Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }," auth_ref": [" r838"," r931"] }," cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / cyd / 2024"," localname":" CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"," presentation": [" http: / / xbrl. sec. gov / cyd / role / CybersecurityRiskManagementAndStrategyDisclosure"]," lang": {" en- us": {" role": {" terseLabel":" Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"," label":" Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }," auth_ref": [" r835"," r928"] }," cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / cyd / 2024"," localname":" CybersecurityRiskManagementProcessesIntegratedFlag"," presentation": [" http: / / xbrl. sec. gov / cyd / role / CybersecurityRiskManagementAndStrategyDisclosure"]," lang": {" en- us": {" role": {" terseLabel":" Cybersecurity Risk Management Processes Integrated [Flag]"," label":" Cybersecurity Risk Management Processes Integrated [Flag]" } } }," auth_ref": [" r836"," r929"] }," cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / cyd / 2024"," localname":" CybersecurityRiskManagementProcessesIntegratedTextBlock"," presentation": [" http: / / xbrl. sec. gov / cyd / role / CybersecurityRiskManagementAndStrategyDisclosure"]," lang": {" en- us": {" role": {" terseLabel":" Cybersecurity Risk Management Processes Integrated [Text Block]"," label":" Cybersecurity Risk Management Processes Integrated [Text Block]" } } }," auth_ref": [" r836"," r929"] }," cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / cyd / 2024"," localname":" CybersecurityRiskManagementStrategyAndGovernanceAbstract"," lang": {" en- us": {" role": {" label":" Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }," auth_ref": [" r834"," r927"] }," cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / cyd / 2024"," localname":" CybersecurityRiskManagementStrategyAndGovernanceLineItems"," presentation": [" http: / / xbrl. sec. gov / cyd / role / CybersecurityRiskManagementAndStrategyDisclosure"]," lang": {" en- us": {" role": {" label":" Cybersecurity Risk Management, Strategy, and Governance [Line Items]" } } }," auth_ref": [" r834"," r927"] }," cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / cyd / 2024"," localname":" CybersecurityRiskManagementStrategyAndGovernanceTable"," presentation": [" http: / / xbrl. sec. gov / cyd / role / CybersecurityRiskManagementAndStrategyDisclosure"]," lang": {" en- us": {" role": {" label":" Cybersecurity Risk Management, Strategy, and Governance [Table]" } } }," auth_ref": [" r834"," r927"] }," cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / cyd / 2024"," localname":" CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"," presentation": [" http: / / xbrl. sec. gov / cyd / role / CybersecurityRiskManagementAndStrategyDisclosure"]," lang": {" en- us": {" role": {" terseLabel":" Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"," label":" Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }," auth_ref": [" r837"," r930"] }," cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / cyd / 2024"," localname":" CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"," presentation": [" http: / / xbrl. sec. gov / cyd / role / CybersecurityRiskManagementAndStrategyDisclosure"]," lang": {" en- us": {" role": {" terseLabel":" Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"," label":" Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }," auth_ref": [" r838"," r931"] }," us- gaap_DebtDisclosureTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DebtDisclosureTextBlock"," presentation": [" http: / / www. orukatx. com / role / NotePayablewithRelatedParty"]," lang": {" en- us": {" role": {" terseLabel":" Note Payable with Related Party"," label":" Debt Disclosure [Text Block]"," documentation":" The entire disclosure for information about short- term and long- term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own- share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long- term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }," auth_ref": [" r87"," r155"," r278"," r279"," r280"," r281"," r282"," r291"," r292"," r302"," r308"," r309"," r310"," r311"," r312"," r313"," r318"," r325"," r326"," r328"," r497"] }," us- gaap_DebtInstrumentAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DebtInstrumentAxis"," presentation": [" http: / / www. orukatx. com / role / NotePayablewithRelatedPartyDetails"]," lang": {" en- us": {" role": {" label":" Debt Instrument [Axis]"," documentation":" Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }," auth_ref": [" r14"," r53"," r54"," r100"," r102"," r164"," r303"," r304"," r305"," r306"," r307"," r309"," r314"," r315"," r316"," r317"," r319"," r320"," r321"," r322"," r323"," r324"," r765"," r766"," r767"," r768"," r769"," r790"," r976"," r1003"," r1004"," r1005"," r1059"," r1060"] }," us- gaap_DebtInstrumentFaceAmount": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DebtInstrumentFaceAmount"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role / NotePayablewithRelatedPartyDetails"]," lang": {" en- us": {" role": {" terseLabel":" Initial principal amount"," label":" Debt Instrument, Face Amount"," documentation":" Face (par) amount of debt instrument at time of issuance." } } }," auth_ref": [" r303"," r497"," r498"," r766"," r767"," r790"] }," us- gaap_DebtInstrumentIncreaseAccruedInterest": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DebtInstrumentIncreaseAccruedInterest"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role / NotePayablewithRelatedPartyDetails"]," lang": {" en- us": {" role": {" terseLabel":" Unpaid accrued interest"," label":" Debt Instrument, Increase, Accrued Interest"," documentation":" Increase for accrued, but unpaid interest on the debt instrument for the period." } } }," auth_ref": [" r976"] }," us- gaap_DebtInstrumentInterestRateDuringPeriod": {" xbrltype":" percentItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DebtInstrumentInterestRateDuringPeriod"," presentation": [" http: / / www. orukatx. com / role / NotePayablewithRelatedPartyDetails"]," lang": {" en- us": {" role": {" terseLabel":" Interest rate, percentage"," label":" Debt Instrument, Interest Rate During Period"," documentation":" The average effective interest rate during the reporting period." } } }," auth_ref": [" r56"," r321"," r1059"] }," us- gaap_DebtInstrumentLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DebtInstrumentLineItems"," presentation": [" http: / / www. orukatx. com / role / NotePayablewithRelatedPartyDetails"]," lang": {" en- us": {" role": {" label":" Note Payable with Related Party [Line Items]"," documentation":" Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }," auth_ref": [" r164"," r303"," r304"," r305"," r306"," r307"," r309"," r314"," r315"," r316"," r317"," r319"," r320"," r321"," r322"," r323"," r324"," r327"," r765"," r766"," r767"," r768"," r769"," r790"," r976"," r1059"," r1060"] }," us- gaap_DebtInstrumentMaturityDate": {" xbrltype":" dateItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DebtInstrumentMaturityDate"," presentation": [" http: / / www. orukatx. com / role / NotePayablewithRelatedPartyDetails"]," lang": {" en- us": {" role": {" terseLabel":" Maturity date"," label":" Debt Instrument, Maturity Date"," documentation":" Date when the debt instrument is scheduled to be fully repaid, in YYYY- MM- DD format." } } }," auth_ref": [" r132"," r765"," r1054"," r1055"] }," us- gaap_DebtPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DebtPolicyTextBlock"," presentation": [" http: / / www. orukatx. com / role / AccountingPoliciesByPolicy"]," lang": {" en- us": {" role": {" terseLabel":" Debt Issuance Costs"," label":" Debt, Policy [Policy Text Block]"," documentation":" Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt." } } }," auth_ref": [" r7"] }," us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"]," lang": {" en- us": {" role": {" terseLabel":" 12 months or longer, Fair Value"," label":" Debt Securities, Available- for- Sale, Continuous Unrealized Loss Position, 12 Months or Longer"," documentation":" Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }," auth_ref": [" r114"," r273"," r764"] }," us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"]," lang": {" en- us": {" role": {" terseLabel":" 12 months or longer, Unrealized Losses"," label":" Debt Securities, Available- for- Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss"," documentation":" Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }," auth_ref": [" r114"," r273"] }," us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"]," lang": {" en- us": {" role": {" terseLabel":" Less than 12 months, Fair Value"," label":" Debt Securities, Available- for- Sale, Continuous Unrealized Loss Position, Less than 12 Months"," documentation":" Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }," auth_ref": [" r114"," r273"," r764"] }," us- gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"]," lang": {" en- us": {" role": {" negatedLabel":" Less than 12 months, Unrealized Losses"," label":" Debt Securities, Available- for- Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss"," documentation":" Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }," auth_ref": [" r114"," r273"] }," us- gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DebtSecuritiesAvailableForSaleUnrealizedLossPosition"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"]," lang": {" en- us": {" role": {" terseLabel":" Fair Value"," label":" Debt Securities, Available- for- Sale, Unrealized Loss Position"," documentation":" Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale), in unrealized loss position without allowance for credit loss." } } }," auth_ref": [" r112"," r271"," r764"] }," us- gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"]," lang": {" en- us": {" role": {" negatedLabel":" Unrealized Losses"," label":" Debt Securities, Available- for- Sale, Unrealized Loss Position, Accumulated Loss"," documentation":" Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }," auth_ref": [" r113"," r272"] }," us- gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"," presentation": [" http: / / www. orukatx. com / role / CashequivalentsandMarketableSecuritiesTables"]," lang": {" en- us": {" role": {" terseLabel":" Schedule of Available- for- Sale Securities in an Unrealized Loss Position"," label":" Debt Securities, Available- for- Sale, Unrealized Loss Position, Fair Value [Table Text Block]"," documentation":" Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }," auth_ref": [" r111"," r764"," r1001"] }," us- gaap_DebtSecuritiesCurrentAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DebtSecuritiesCurrentAbstract"," presentation": [" http: / / www. orukatx. com / role / ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"]," lang": {" en- us": {" role": {" terseLabel":" Marketable securities, current"," label":" Debt Securities, Current [Abstract]" } } }," auth_ref": [ ] }," us- gaap_DebtSecuritiesNoncurrentAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DebtSecuritiesNoncurrentAbstract"," presentation": [" http: / / www. orukatx. com / role / ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"]," lang": {" en- us": {" role": {" terseLabel":" Marketable securities, long- term"," label":" Debt Securities, Noncurrent [Abstract]" } } }," auth_ref": [ ] }," us- gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems"," presentation": [" http: / / www. orukatx. com / role /

StockBasedCompensationDetails"]," lang": {" en- us": {" role": {" label":" Stock- Based Compensation [Line Items]"," documentation":" Line items represent financial concepts included in
a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }," auth_ref": [ ] }," us-
gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"," presentation": [" http: / / www. orukatx. com / role /
ScheduleofCompanysStockBasedCompensationExpenseTable"]," lang": {" en- us": {" role": {" label":" Schedule of Company \ u2019s Stock- Based Compensation Expense [Line Items]","
documentation":" Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many
axes to the table." } } }," auth_ref": [ ] }," us- gaap_DeferredIncomeTaxLiabilities": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
DeferredIncomeTaxLiabilities"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role / ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {" parentTag":" us-
gaap_DeferredTaxAssetsLiabilitiesNet"," weight":- 1. 0," order": 2. 0 } }," presentation": [" http: / / www. orukatx. com / role /
ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"]," lang": {" en- us": {" role": {" negatedTotalLabel":" Total deferred tax liabilities"," label":" Deferred Tax Liabilities,
Gross"," documentation":" Amount of deferred tax liability attributable to taxable temporary differences." } } }," auth_ref": [" r60"," r61"," r101"," r428"] }," us-
gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
DeferredTaxAssetsGoodwillAndIntangibleAssets"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {"
parentTag":" us- gaap_DeferredTaxAssetsGross"," weight": 1. 0," order": 6. 0 } }," presentation": [" http: / / www. orukatx. com / role /
ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"]," lang": {" en- us": {" role": {" terseLabel":" Intangibles"," label":" Deferred Tax Assets, Goodwill and Intangible
Assets"," documentation":" Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill." } }
}," auth_ref": [" r1048"] }," us- gaap_DeferredTaxAssetsGross": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DeferredTaxAssetsGross","
crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {" parentTag":" us-
gaap_DeferredTaxAssetsLiabilitiesNet"," weight": 1. 0," order": 1. 0 } }," presentation": [" http: / / www. orukatx. com / role /
ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"]," lang": {" en- us": {" role": {" totalLabel":" Total deferred tax assets"," label":" Deferred Tax Assets, Gross","
documentation":" Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }," auth_ref": [" r429"] }," us-
gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
DeferredTaxAssetsInProcessResearchAndDevelopment"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role /
ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {" parentTag":" us- gaap_DeferredTaxAssetsGross"," weight": 1. 0," order": 7. 0 } }," presentation": [" http: / / www.
orukatx. com / role / ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"]," lang": {" en- us": {" role": {" terseLabel":" Capitalized R & amp; D expenses"," label":" Deferred
Tax Asset, In- Process Research and Development"," documentation":" Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference
from in- process research and development cost acquired in business combination or from joint venture formation or both." } } }," auth_ref": [" r1048"] },"
orka_DeferredTaxAssetsLeaseLiabilities": {" xbrltype":" monetaryItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" DeferredTaxAssetsLeaseLiabilities"," crdr":"
debit"," calculation": {" http: / / www. orukatx. com / role / ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {" parentTag":" us- gaap_DeferredTaxAssetsGross"," weight":
1. 0," order": 5. 0 } }," presentation": [" http: / / www. orukatx. com / role / ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"]," lang": {" en- us": {" role": {" terseLabel":"
Lease liability"," documentation":" Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities."," label":"
Deferred Tax Assets Lease Liabilities" } } }," auth_ref": [ ] }," us- gaap_DeferredTaxAssetsLiabilitiesNet": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024","
localname":" DeferredTaxAssetsLiabilitiesNet"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {"
parentTag": null," weight": null," order": null," root": true } }," presentation": [" http: / / www. orukatx. com / role / ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"],"
lang": {" en- us": {" role": {" totalLabel":" Deferred tax assets, net"," label":" Deferred Tax Assets, Net"," documentation":" Amount, after allocation of valuation allowances and deferred tax
liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }," auth_ref": [" r1045"] }," us- gaap_DeferredTaxAssetsNetAbstract":
{" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DeferredTaxAssetsNetAbstract"," presentation": [" http: / / www. orukatx. com / role /
ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"]," lang": {" en- us": {" role": {" label":" Schedule of Net Deferred Tax Assets [Abstract]"," terseLabel":" Deferred tax
assets" } } }," auth_ref": [ ] }," us- gaap_DeferredTaxAssetsOperatingLossCarryforwards": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
DeferredTaxAssetsOperatingLossCarryforwards"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {"
parentTag":" us- gaap_DeferredTaxAssetsGross"," weight": 1. 0," order": 1. 0 } }," presentation": [" http: / / www. orukatx. com / role /
ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"]," lang": {" en- us": {" role": {" terseLabel":" Net operating loss carryforwards"," label":" Deferred Tax Assets,
Operating Loss Carryforwards"," documentation":" Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } },"
auth_ref": [" r1048"] }," us- gaap_DeferredTaxAssetsOtherLossCarryforwards": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
DeferredTaxAssetsOtherLossCarryforwards"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / IncomeTaxesDetails"]," lang": {" en- us": {" role": {" terseLabel":" Net
operating loss carryforwards"," label":" Deferred Tax Assets, Other Loss Carryforwards"," documentation":" Amount, before allocation of valuation allowance, of deferred tax asset
attributable to deductible loss carryforwards, classified as other." } } }," auth_ref": [" r1048"] }," us- gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {" xbrltype":"
monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DeferredTaxAssetsTaxCreditCarryforwardsResearch"," crdr":" debit"," calculation": {" http: / / www.
orukatx. com / role / ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {" parentTag":" us- gaap_DeferredTaxAssetsGross"," weight": 1. 0," order": 2. 0 } }," presentation":
[" http: / / www. orukatx. com / role / IncomeTaxesDetails"," http: / / www. orukatx. com / role / ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"]," lang": {" en- us": {"
role": {" terseLabel":" Research and development credits"," verboseLabel":" Tax credit carryforwards"," label":" Deferred Tax Assets, Tax Credit Carryforwards, Research","
documentation":" Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards." } } }," auth_ref": [" r1048"] }," us-
gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024","
localname":" DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role /
ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {" parentTag":" us- gaap_DeferredTaxAssetsGross"," weight": 1. 0," order": 3. 0 } }," presentation": [" http: / / www.
orukatx. com / role / ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"]," lang": {" en- us": {" role": {" terseLabel":" Stock- based compensation"," label":" Deferred Tax
Assets, Tax Deferred Expense, Compensation and Benefits, Share- Based Compensation Cost"," documentation":" Amount before allocation of valuation allowances of deferred tax asset
attributable to deductible temporary differences from share- based compensation." } } }," auth_ref": [" r1048"] }," us-
gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role /
ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {" parentTag":" us- gaap_DeferredTaxAssetsGross"," weight": 1. 0," order": 4. 0 } }," presentation": [" http: / / www.
orukatx. com / role / ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"]," lang": {" en- us": {" role": {" terseLabel":" Accruals and other"," label":" Deferred Tax Assets,
Tax Deferred Expense, Reserves and Accruals, Other"," documentation":" Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary
differences from reserves and accruals, classified as other." } } }," auth_ref": [" r1048"] }," us- gaap_DeferredTaxAssetsValuationAllowance": {" xbrltype":" monetaryItemType"," nsuri":"
http: / / fasb. org / us- gaap / 2024"," localname":" DeferredTaxAssetsValuationAllowance"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role /
ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {" parentTag":" us- gaap_DeferredTaxAssetsLiabilitiesNet"," weight":- 1. 0," order": 3. 0 } }," presentation": [" http: / /
www. orukatx. com / role / ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"," http: / / www. orukatx. com / role / ScheduleofNetDeferredTaxAssetsTable"]," lang": {" en-
us": {" role": {" periodStartLabel":" Beginning balance"," periodEndLabel":" Ending balance"," negatedLabel":" Less valuation allowance"," label":" Deferred Tax Assets, Valuation
Allowance"," documentation":" Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }," auth_ref": [" r430"] }," us-
gaap_DeferredTaxLiabilitiesNetAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DeferredTaxLiabilitiesNetAbstract"," presentation":
[" http: / / www. orukatx. com / role / ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"]," lang": {" en- us": {" role": {" terseLabel":" Deferred tax liabilities"," label":"
Deferred Tax Liabilities, Net [Abstract]" } } }," auth_ref": [ ] }," orka_DeferredTaxLiabilitiesRightOfUseAsset": {" xbrltype":" monetaryItemType"," nsuri":" http: / / www. orukatx. com /
20241231"," localname":" DeferredTaxLiabilitiesRightOfUseAsset"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role /
ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {" parentTag":" us- gaap_DeferredIncomeTaxLiabilities"," weight": 1. 0," order": 1. 0 } }," presentation": [" http: / /
www. orukatx. com / role / ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"]," lang": {" en- us": {" role": {" negatedLabel":" Right- of- use asset"," documentation":"
Amount of deferred tax liability attributable to taxable temporary differences from right of use assets."," label":" Deferred Tax Liabilities Right Of Use Asset" } } }," auth_ref": [ ] },"
dei_DelayedOrContinuousOffering": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DelayedOrContinuousOffering"," presentation": [" http: / /
xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Delayed or Continuous Offering" } } }," auth_ref": [" r863"," r864"," r878"] }," us- gaap_Depreciation":
{" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" Depreciation"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role /
ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInOperatingActivities"," weight": 1. 0," order": 5. 0 } }," presentation": [" http: / / www. orukatx. com / role /
ConsolidatedCashFlow"]," lang": {" en- us": {" role": {" terseLabel":" Depreciation expense"," label":" Depreciation"," documentation":" The amount of expense recognized in the current
period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non- production related depreciation." } } }," auth_ref": [" r5"," r36"] },"
orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":"
DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners"," presentation": [" http: / / www. orukatx. com / role / RelatedPartyTransactionsDetails"]," lang": {" en- us": {"
role": {" terseLabel":" Ownership percentage"," documentation":" Description of minority interest ownership percentage by noncontrolling owners."," label":" Description Of Minority
Interest Ownership Percentage By Noncontrolling Owners" } } }," auth_ref": [ ] }," orka_DevelopmentCostsPercentage": {" xbrltype":" percentItemType"," nsuri":" http: / / www. orukatx.
com / 20241231"," localname":" DevelopmentCostsPercentage"," presentation": [" http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"]," lang": {" en- us": {"
role": {" terseLabel":" Development costs, percentage"," documentation":" Percentage of development costs."," label":" Development Costs Percentage" } } }," auth_ref": [ ] }," us-
gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"," presentation": [" http: / / www. orukatx. com / role / StockBasedCompensation"]," lang": {" en- us": {" role": {"
terseLabel":" Stock- Based Compensation"," label":" Share- Based Payment Arrangement [Text Block]"," documentation":" The entire disclosure for share- based payment arrangement." } }
}," auth_ref": [" r360"," r364"," r395"," r396"," r398"," r776"] }," us- gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {" xbrltype":" stringItemType","
nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"," lang": {" en- us": {" role": {" label":" Stock- Based
Compensation [Abstract]" } } }," auth_ref": [ ] }," us- gaap_DisclosureTextBlockSupplementAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024","
localname":" DisclosureTextBlockSupplementAbstract"," lang": {" en- us": {" role": {" label":" Reverse Recapitalization and Pre- Closing Financing [Abstract]" } } }," auth_ref": [ ] },"
dei_DividendOrInterestReinvestmentPlanOnly": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DividendOrInterestReinvestmentPlanOnly","
presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Dividend or Interest Reinvestment Plan Only" } } }," auth_ref": [" r863","
r864"," r878"] }," dei_DocumentAccountingStandard": {" xbrltype":" accountingStandardItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":"
DocumentAccountingStandard"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Document Accounting Standard","
documentation":" The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be' U. S. GAAP',' International Financial Reporting
Standards', or' Other'." } } }," auth_ref": [" r832"] }," dei_DocumentAnnualReport": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":"

DocumentAnnualReport"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Document Annual Report"," documentation":" Boolean flag that is true only for a form used as an annual report." } } }," auth_ref": [" r829"," r832"," r849"] }," dei_DocumentCopyrightInformation": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentCopyrightInformation"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Document Copyright Information"," documentation":" The copyright information for the document." } } }," auth_ref": [ ] }," dei_DocumentCreationDate": {" xbrltype":" dateItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentCreationDate"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Document Creation Date"," documentation":" The date the document was made available and submitted, in YYYY- MM- DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different." } } }," auth_ref": [ ] }," dei_DocumentDescription": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentDescription"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Document Description"," documentation":" The description of the document." } } }," auth_ref": [ ] }," dei_DocumentDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentDomain"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Document [Domain]"," documentation":" Type of the document as assigned by the filer, corresponding to SEC document naming convention standards." } } }," auth_ref": [ ] }," dei_DocumentEffectiveDate": {" xbrltype":" dateItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentEffectiveDate"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Document Effective Date"," documentation":" The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY- MM- DD format. Usually it is a system- assigned date time value, but it may be declared by the submitter in some cases." } } }," auth_ref": [ ] }," dei_DocumentFinStmtErrorCorrectionFlag": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentFinStmtErrorCorrectionFlag"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Document Financial Statement Error Correction [Flag]"," documentation":" Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }," auth_ref": [" r829"," r832"," r849"," r902"] }," dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentFinStmtRestatementRecoveryAnalysisFlag"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Document Financial Statement Restatement Recovery Analysis [Flag]"," documentation":" Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive- based compensation received by any of the registrant' s executive officers during the relevant recovery period pursuant to \ u00a7240. 10D- 1 (b)." } } }," auth_ref": [" r829"," r832"," r849"," r902"] }," dei_DocumentFiscalPeriodFocus": {" xbrltype":" fiscalPeriodItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentFiscalPeriodFocus"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Document Fiscal Period Focus"," documentation":" Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10- Q or 10- QT statements have value Q1, Q2, and Q3 respectively, with 10- K, 10- KT or other fiscal year statements having FY." } } }," auth_ref": [ ] }," dei_DocumentFiscalYearFocus": {" xbrltype":" gYearItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentFiscalYearFocus"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Document Fiscal Year Focus"," documentation":" This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }," auth_ref": [ ] }," dei_DocumentInformationDocumentAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentInformationDocumentAxis"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Document Information, Document [Axis]"," documentation":" The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }," auth_ref": [ ] }," dei_DocumentInformationLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentInformationLineItems"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Document Information [Line Items]"," documentation":" Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }," auth_ref": [ ] }," dei_DocumentInformationTable": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentInformationTable"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Document Information [Table]"," documentation":" Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }," auth_ref": [ ] }," dei_DocumentInformationTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentInformationTextBlock"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Document Information [Text Block]"," documentation":" Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }," auth_ref": [ ] }," dei_DocumentName": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentName"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Document Name"," documentation":" Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the & lt; FILENAME > field of EDGAR filings, such as' htm_25911. htm',' exhibit1. htm',' v105727_8k. txt'." } } }," auth_ref": [ ] }," dei_DocumentPeriodEndDate": {" xbrltype":" dateItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentPeriodEndDate"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Document Period End Date"," documentation":" For the EDGAR submission types of Form 8- K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N- 1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY- MM- DD." } } }," auth_ref": [ ] }," dei_DocumentPeriodStartDate": {" xbrltype":" dateItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentPeriodStartDate"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Document Period Start Date"," documentation":" The start date of the period covered in the document, in YYYY- MM- DD format." } } }," auth_ref": [ ] }," dei_DocumentQuarterlyReport": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentQuarterlyReport"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Document Quarterly Report"," documentation":" Boolean flag that is true only for a form used as an quarterly report." } } }," auth_ref": [" r830"] }," dei_DocumentRegistrationStatement": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentRegistrationStatement"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Document Registration Statement"," documentation":" Boolean flag that is true only for a form used as a registration statement." } } }," auth_ref": [" r818"] }," dei_DocumentShellCompanyEventDate": {" xbrltype":" dateItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentShellCompanyEventDate"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Document Shell Company Event Date"," documentation":" Date of event requiring a shell company report." } } }," auth_ref": [" r832"] }," dei_DocumentShellCompanyReport": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentShellCompanyReport"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Document Shell Company Report"," documentation":" Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15 (d) of the Exchange Act." } } }," auth_ref": [" r832"] }," dei_DocumentSubtitle": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentSubtitle"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Document Subtitle"," documentation":" The subtitle given to the document resource by the creator or publisher. An example is' A New Period of Growth'." } } }," auth_ref": [ ] }," dei_DocumentSynopsis": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentSynopsis"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Document Synopsis"," documentation":" A synopsis or description of the document provided by the creator or publisher. Examples are' This is the 2006 annual report for Company. During this period we saw revenue grow by 10 % and earnings per share grow by 15 % over the prior period'" } } }," auth_ref": [ ] }," dei_DocumentTitle": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentTitle"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Document Title"," documentation":" The name or title given to the document resource by the creator or publisher. An example is' 2002 Annual Report'." } } }," auth_ref": [ ] }," dei_DocumentTransitionReport": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentTransitionReport"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Document Transition Report"," documentation":" Boolean flag that is true only for a form used as a transition report." } } }," auth_ref": [" r879"] }," dei_DocumentType": {" xbrltype":" submissionTypeItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentType"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Document Type"," documentation":" The type of document being provided (such as 10- K, 10- Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word' Other'." } } }," auth_ref": [ ] }," dei_DocumentVersion": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentVersion"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Document Version"," documentation":" The version identifier of the document." } } }," auth_ref": [ ] }," dei_DocumentsIncorporatedByReferenceTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" DocumentsIncorporatedByReferenceTextBlock"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Documents Incorporated by Reference [Text Block]"," documentation":" Documents incorporated by reference." } } }," auth_ref": [" r821"] }," us- gaap_DomesticCountryMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" DomesticCountryMember"," presentation": [" http: / / www. orukatx. com / role / IncomeTaxesDetails"]," lang": {" en- us": {" role": {" terseLabel":" Domestic Tax Jurisdiction [Member]"," label":" Domestic Tax Jurisdiction [Member]"," documentation":" Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non- U. S. jurisdiction." } } }," auth_ref": [" r415"] }," ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"," terseLabel":" Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }," auth_ref": [" r891"] }," us- gaap_EarningsPerShareBasic": {" xbrltype":" perShareItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" EarningsPerShareBasic"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome"," http: / / www. orukatx. com / role / ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"]," lang": {" en- us": {" role": {" terseLabel":" Net loss per share attributable to stockholders, basic (in Dollars per share)"," verboseLabel":" Loss per share \ u2013 Basic"," label":" Earnings Per Share, Basic"," documentation":" The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }," auth_ref": [" r149"," r170"," r171"," r172"," r173"," r174"," r175"," r181"," r183"," r186"," r187"," r188"," r193"," r446"," r449"," r464"," r465"," r590"," r613"," r749"] }," us- gaap_EarningsPerShareBasicLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" EarningsPerShareBasicLineItems"," presentation": [" http: / / www. orukatx. com / role / NetLossPerShareDetails"]," lang": {" en- us": {" role": {" label":" Net Loss per Share [Line Items]"," documentation":" Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }," auth_ref": [" r183"," r184"," r186"] }," us- gaap_EarningsPerShareDiluted": {" xbrltype":" perShareItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" EarningsPerShareDiluted"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome"," http: / / www. orukatx. com / role / ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"]," lang": {" en- us": {" role": {" terseLabel":" Net loss per share attributable to stockholders, diluted (in Dollars per share)"," verboseLabel":" Loss per share \ u2013 Diluted"," label":" Earnings Per Share, Diluted"," documentation":" The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }," auth_ref": [" r149"," r170"," r171"," r172"," r173"," r174"," r175"," r183"," r186"," r187"," r188"," r193"," r446"," r449"," r464"," r465"," r590"," r613"," r749"] }," us- gaap_EarningsPerShareDilutedLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" EarningsPerShareDilutedLineItems"," presentation": [" http: / / www. orukatx. com / role / ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"]," lang": {" en- us": {" role": {" label":" Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items]"," documentation":" Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }," auth_ref": [" r183"," r184"," r186"] }," us- gaap_EarningsPerSharePolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" EarningsPerSharePolicyTextBlock"," presentation": [" http: / / www. orukatx. com / role / AccountingPoliciesByPolicy"]," lang": {" en- us": {" role": {" terseLabel":" Net Loss per Share Attributable to Stockholders"," label":" Earnings Per Share, Policy [Policy Text Block]"," documentation":" Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant

policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet
date of the latest reporting period but before the issuance of the financial statements." } } }," auth_ref": [" r29"," r30"," r190"] }," us- gaap_EarningsPerShareTextBlock": {" xbrltype":"
textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" EarningsPerShareTextBlock"," presentation": [" http: / / www. orukatx. com / role / NetLossPerShare"],"
lang": {" en- us": {" role": {" terseLabel":" Net Loss Per Share"," label":" Earnings Per Share [Text Block]"," documentation":" The entire disclosure for earnings per share." } } },"
auth_ref": [" r180"," r189"," r191"," r192"] }," us- gaap_EarningsPerUnitAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
EarningsPerUnitAbstract"," lang": {" en- us": {" role": {" label":" Net Loss per Share [Abstract]" } } }," auth_ref": [ ] }," dei_EffectiveAfter60Days486a": {" xbrltype":" booleanItemType","
nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EffectiveAfter60Days486a"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {"
label":" Effective after 60 Days, 486 (a)" } } }," auth_ref": [" r946"] }," us- gaap_EffectiveIncomeTaxRateContinuingOperations": {" xbrltype":" percentItemType"," nsuri":" http: / / fasb. org
/ us- gaap / 2024"," localname":" EffectiveIncomeTaxRateContinuingOperations"," calculation": {" http: / / www. orukatx. com / role /
ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable": {" parentTag": null," weight": null," order": null," root": true } }," presentation": [" http: / / www. orukatx.
com / role / ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable"]," lang": {" en- us": {" role": {" totalLabel":" Income tax (benefit) expense"," label":" Effective
Income Tax Rate Reconciliation, Percent"," documentation":" Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
} } }," auth_ref": [" r415"," r779"] }," us- gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {" xbrltype":" percentItemType"," nsuri":" http: / / fasb. org / us-
gaap / 2024"," localname":" EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"," calculation": {" http: / / www. orukatx. com / role /
ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable": {" parentTag":" us- gaap_EffectiveIncomeTaxRateContinuingOperations"," weight": 1. 0," order": 1. 0 } },"
presentation": [" http: / / www. orukatx. com / role / ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable"]," lang": {" en- us": {" role": {" negatedLabel":" Tax
benefit derived by applying the federal statutory rate to income before income taxes"," label":" Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent","
documentation":" Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }," auth_ref": [" r159"," r415"," r437"," r779"] }," us-
gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {" xbrltype":" percentItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"," calculation": {" http: / / www. orukatx. com / role /
ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable": {" parentTag":" us- gaap_EffectiveIncomeTaxRateContinuingOperations"," weight": 1. 0," order": 4. 0 } },"
presentation": [" http: / / www. orukatx. com / role / ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable"]," lang": {" en- us": {" role": {" negatedLabel":" Change
in the valuation allowance"," label":" Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent"," documentation":" Percentage of the difference
between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from
continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }," auth_ref": [" r418"," r779"," r979"," r1042"] }," us-
gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {" xbrltype":" percentItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
EffectiveIncomeTaxRateReconciliationOtherAdjustments"," calculation": {" http: / / www. orukatx. com / role / ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable":
{" parentTag":" us- gaap_EffectiveIncomeTaxRateContinuingOperations"," weight": 1. 0," order": 2. 0 } }," presentation": [" http: / / www. orukatx. com / role /
ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable"]," lang": {" en- us": {" role": {" negatedLabel":" Permanent differences"," label":" Effective Income Tax Rate
Reconciliation, Other Adjustments, Percent"," documentation":" Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed
by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }," auth_ref": [" r779"," r979"," r1042","
r1043"] }," us- gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {" xbrltype":" percentItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"," calculation": {" http: / / www. orukatx. com / role /
ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable": {" parentTag":" us- gaap_EffectiveIncomeTaxRateContinuingOperations"," weight": 1. 0," order": 3. 0 } },"
presentation": [" http: / / www. orukatx. com / role / ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable"]," lang": {" en- us": {" role": {" negatedLabel":" Other","
label":" Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent"," documentation":" Percentage of reported income tax benefit (expense) from difference to income tax
expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and
local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax
settlement, income tax contingency, and cross- border tax law." } } }," auth_ref": [" r1043"] }," us- gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {" xbrltype":"
percentItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"," calculation": {" http: / / www. orukatx. com / role
/ ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable": {" parentTag":" us- gaap_EffectiveIncomeTaxRateContinuingOperations"," weight":- 1. 0," order": 5. 0 } },"
presentation": [" http: / / www. orukatx. com / role / ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable"]," lang": {" en- us": {" role": {" terseLabel":" Research
and development credits"," label":" Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent"," documentation":" Percentage of the difference between reported income tax
expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable
to research tax credit." } } }," auth_ref": [" r779"," r979"," r1042"," r1044"] }," dei_EffectiveOnDate486a": {" xbrltype":" dateItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024","
localname":" EffectiveOnDate486a"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Effective on Date, 486 (a)" } } },"
auth_ref": [" r946"] }," dei_EffectiveOnDate486b": {" xbrltype":" dateItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EffectiveOnDate486b"," presentation": [" http: /
/ xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Effective on Date, 486 (b)" } } }," auth_ref": [" r947"] }," dei_EffectiveOnSetDate486a": {" xbrltype":"
booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EffectiveOnSetDate486a"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {"
en- us": {" role": {" label":" Effective on Set Date, 486 (a)" } } }," auth_ref": [" r946"] }," dei_EffectiveOnSetDate486b": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei
/ 2024"," localname":" EffectiveOnSetDate486b"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Effective on Set Date, 486
(b)" } } }," auth_ref": [" r947"] }," dei_EffectiveUponFiling462e": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EffectiveUponFiling462e","
presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Effective Upon Filing, 462 (e)" } } }," auth_ref": [" r945"] },"
dei_EffectiveUponFiling486b": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EffectiveUponFiling486b"," presentation": [" http: / / xbrl. sec.
gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Effective upon Filing, 486 (b)" } } }," auth_ref": [" r947"] }," dei_EffectiveWhenDeclaredSection8c": {"
xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EffectiveWhenDeclaredSection8c"," presentation": [" http: / / xbrl. sec. gov / dei / role / document /
Cover"]," lang": {" en- us": {" role": {" label":" Effective when Declared, Section 8 (c)" } } }," auth_ref": [" r949"] }," us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap /
2024"," localname":" EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"," crdr":" debit"," presentation": [" http: / / www. orukatx. com /
role / StockBasedCompensationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Total unrecognized compensation cost"," label":" Share- Based Payment Arrangement, Nonvested
Award, Cost Not yet Recognized, Amount"," documentation":" Amount of cost not yet recognized for nonvested award under share- based payment arrangement." } } }," auth_ref": [" r397"]
}," us- gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {" xbrltype":" durationItemType"," nsuri":"
http: / / fasb. org / us- gaap / 2024"," localname":" EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1","
presentation": [" http: / / www. orukatx. com / role / StockBasedCompensationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Share- Based Payment Arrangement, Nonvested Award,
Cost Not yet Recognized, Period for Recognition"," label":" Share- Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"," documentation":"
Weighted- average period over which cost not yet recognized is expected to be recognized for award under share- based payment arrangement, in' PnYnMnDTnHnMnS' format, for example,'
P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }," auth_ref": [" r397"] }," us- gaap_EmployeeStockOptionMember": {" xbrltype":" domainItemType","
nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" EmployeeStockOptionMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure"]," lang": {" en- us":
{" role": {" label":" Employee Stock Option [Member]"," terseLabel":" Employee Stock Option"," documentation":" Share- based payment arrangement granting right, subject to vesting
and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }," auth_ref": [ ] },"
orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP": {" xbrltype":" monetaryItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":"
EmployeeStockPurchasePlanESPPCashContributionsToESPP"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / StockBasedCompensationDetails"]," lang": {" en- us":
{" role": {" terseLabel":" Total amount of annual salary that an employee is permitted to utilize to purchase company shares under ESPP"," documentation":" This item represents the amount
of cash contributions during the period made by the entity to the Employee stock purchase plan (ESPP)."," label":" Employee Stock Purchase Plan ESPPCash Contributions To ESPP" } } },"
auth_ref": [ ] }," orka_EmployeeStockPurchasePlanMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":"
EmployeeStockPurchasePlanMember"," presentation": [" http: / / www. orukatx. com / role / ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable"]," lang": {" en- us":
{" role": {" terseLabel":" Employee stock purchase plan [Member]"," label":" Employee Stock Purchase Plan Member" } } }," auth_ref": [ ] }," orka_EmployeeWarrantsMember": {"
xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" EmployeeWarrantsMember"," presentation": [" http: / / www. orukatx. com / role /
ConvertiblePreferredStockandStockholdersEquityDetails"," http: / / www. orukatx. com / role /
ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"," http: / / www. orukatx. com / role /
ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable"," http: / / www. orukatx. com / role / ScheduleofCommonStockReservedforFutureIssuanceTable"," http: / / www.
orukatx. com / role / ScheduleofEmployeeWarrantActivityTable"," http: / / www. orukatx. com / role /
ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable"," http: / / www. orukatx. com / role / StockBasedCompensationDetails"]," lang": {" en- us": {"
role": {" terseLabel":" Employee Warrants [Member]"," verboseLabel":" Employee warrants \ t [Member]"," label":" Employee Warrants Member" } } }," auth_ref": [ ] },"
dei_EntitiesTable": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntitiesTable"," presentation": [" http: / / xbrl. sec. gov / dei / role / document /
Cover"]," lang": {" en- us": {" role": {" label":" Entities [Table]"," documentation":" Container to assemble all relevant information about each entity associated with the document instance"
} } }," auth_ref": [ ] }," dei_EntityAccountingStandard": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityAccountingStandard","
presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Accounting Standard"," documentation":" The standardized
abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example:' US GAAP',' IFRS'. This is
distinct from the Document Accounting Standard element." } } }," auth_ref": [ ] }," dei_EntityAddressAddressDescription": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei
/ 2024"," localname":" EntityAddressAddressDescription"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Address,
Address Description"," documentation":" Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other
addresses." } } }," auth_ref": [ ] }," dei_EntityAddressAddressLine1": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":"
EntityAddressAddressLine1"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Address, Address Line One","
documentation":" Address Line 1 such as Attn, Building Name, Street Name" } } }," auth_ref": [ ] }," dei_EntityAddressAddressLine2": {" xbrltype":" normalizedStringItemType"," nsuri":"
http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityAddressAddressLine2"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":"
Entity Address, Address Line Two"," documentation":" Address Line 2 such as Street or Suite number" } } }," auth_ref": [ ] }," dei_EntityAddressAddressLine3": {" xbrltype":"
normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityAddressAddressLine3"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"
]," lang": {" en- us": {" role": {" label":" Entity Address, Address Line Three"," documentation":" Address Line 3 such as an Office Park" } } }," auth_ref": [ ] },"
dei_EntityAddressCityOrTown": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityAddressCityOrTown"," presentation": [" http: /
/ xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Address, City or Town"," documentation":" Name of the City or Town" } } }," auth_ref": [ ] },"

dei_EntityAddressCountry": {" xbrltype":" countryCodeItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityAddressCountry"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Address, Country"," documentation":" ISO 3166- 1 alpha- 2 country code." } } }," auth_ref": [ ] }," dei_EntityAddressPostalZipCode": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityAddressPostalZipCode"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Address, Postal Zip Code"," documentation":" Code for the postal or zip code" } } }," auth_ref": [ ] }," dei_EntityAddressStateOrProvince": {" xbrltype":" stateOrProvinceItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityAddressStateOrProvince"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Address, State or Province"," documentation":" Name of the state or province." } } }," auth_ref": [ ] }," dei_EntityAddressesAddressTypeAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityAddressesAddressTypeAxis"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Addresses, Address Type [Axis]"," documentation":" The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }," auth_ref": [ ] }," dei_EntityAddressesLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityAddressesLineItems"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Addresses [Line Items]"," documentation":" Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }," auth_ref": [ ] }," dei_EntityAddressesTable": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityAddressesTable"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Addresses [Table]"," documentation":" Container of address information for the entity" } } }," auth_ref": [" r820"] }," dei_EntityBankruptcyProceedingsReportingCurrent": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityBankruptcyProceedingsReportingCurrent"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Bankruptcy Proceedings, Reporting Current"," documentation":" For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15 (d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }," auth_ref": [" r824"] }," dei_EntityCentralIndexKey": {" xbrltype":" centralIndexKeyItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityCentralIndexKey"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Central Index Key"," documentation":" A unique 10- digit SEC- issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }," auth_ref": [" r820"] }," dei_EntityCommonStockSharesOutstanding": {" xbrltype":" sharesItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityCommonStockSharesOutstanding"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Common Stock, Shares Outstanding"," documentation":" Indicate number of shares or other units outstanding of each of registrant' s classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class / interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }," auth_ref": [ ] }," dei_EntityContactPersonnelLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityContactPersonnelLineItems"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Contact Personnel [Line Items]"," documentation":" Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }," auth_ref": [ ] }," dei_EntityCurrentReportingStatus": {" xbrltype":" yesNoItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityCurrentReportingStatus"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Current Reporting Status"," documentation":" Indicate' Yes' or' No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant' s current or most recent filing containing the related disclosure." } } }," auth_ref": [ ] }," dei_EntityDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityDomain"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / AuditInformation"," http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity [Domain]"," documentation":" All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }," auth_ref": [ ] }," dei_EntityEmergingGrowthCompany": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityEmergingGrowthCompany"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Emerging Growth Company"," documentation":" Indicate if registrant meets the emerging growth company criteria." } } }," auth_ref": [" r820"] }," dei_EntityExTransitionPeriod": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityExTransitionPeriod"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Ex Transition Period"," documentation":" Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }," auth_ref": [" r948"] }," dei_EntityFileNumber": {" xbrltype":" fileNumberItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityFileNumber"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity File Number"," documentation":" Commission file number. The field allows up to 17 characters. The prefix may contain 1- 3 digits, the sequence number may contain 1- 8 digits, the optional suffix may contain 1- 4 characters, and the fields are separated with a hyphen." } } }," auth_ref": [ ] }," dei_EntityFilerCategory": {" xbrltype":" filerCategoryItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityFilerCategory"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Filer Category"," documentation":" Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non- accelerated Filer. Definitions of these categories are stated in Rule 12b- 2 of the Exchange Act. This information should be based on the registrant' s current or most recent filing containing the related disclosure." } } }," auth_ref": [" r820"] }," dei_EntityHomeCountryISOCode": {" xbrltype":" countryCodeItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityHomeCountryISOCode"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Home Country ISO Code"," documentation":" ISO 3166- 1 alpha- 2 country code for the Entity' s home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the' Entity Incorporation, State Country Code' element." } } }," auth_ref": [ ] }," dei_EntityIncorporationDateOfIncorporation": {" xbrltype":" dateItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityIncorporationDateOfIncorporation"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Incorporation, Date of Incorporation"," documentation":" Date when an entity was incorporated" } } }," auth_ref": [ ] }," dei_EntityIncorporationStateCountryCode": {" xbrltype":" edgarStateCountryItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityIncorporationStateCountryCode"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Incorporation, State or Country Code"," documentation":" Two- character EDGAR code representing the state or country of incorporation." } } }," auth_ref": [ ] }," dei_EntityInformationFormerLegalOrRegisteredName": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityInformationFormerLegalOrRegisteredName"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Information, Former Legal or Registered Name"," documentation":" Former Legal or Registered Name of an entity" } } }," auth_ref": [ ] }," dei_EntityInformationLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityInformationLineItems"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Information [Line Items]"," documentation":" Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }," auth_ref": [ ] }," dei_EntityInteractiveDataCurrent": {" xbrltype":" yesNoItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityInteractiveDataCurrent"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Interactive Data Current"," documentation":" Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S- T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }," auth_ref": [" r937"] }," dei_EntityInvCompanyType": {" xbrltype":" invCompanyType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityInvCompanyType"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Inv Company Type"," documentation":" One of: N- 1A (Mutual Fund), N- 1 (Open- End Separate Account with No Variable Annuities), N- 2 (Closed- End Investment Company), N- 3 (Separate Account Registered as Open- End Management Investment Company), N- 4 (Variable Annuity UIT Separate Account), N- 5 (Small Business Investment Company), N- 6 (Variable Life UIT Separate Account), S- 1 or S- 3 (Face Amount Certificate Company), S- 6 (UIT, Non- Insurance Product)." } } }," auth_ref": [" r936"] }," dei_EntityLegalForm": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityLegalForm"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Legal Form"," documentation":" The details of the entity' s legal form. Examples are partnership, limited liability company, trust, etc." } } }," auth_ref": [ ] }," dei_EntityListingDepositoryReceiptRatio": {" xbrltype":" pureItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityListingDepositoryReceiptRatio"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Listing, Depository Receipt Ratio"," documentation":" The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of' 3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR' s then the value would be represented as' 0. 5'." } } }," auth_ref": [ ] }," dei_EntityListingDescription": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityListingDescription"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Listing, Description"," documentation":" Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security." } } }," auth_ref": [ ] }," dei_EntityListingForeign": {" xbrltype":" yesNoItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityListingForeign"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Listing, Foreign"," documentation":" Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt." } } }," auth_ref": [ ] }," dei_EntityListingParValuePerShare": {" xbrltype":" perShareItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityListingParValuePerShare"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Listing, Par Value Per Share"," documentation":" The par value per share of security quoted in same currency as Trading currency. Example:' 0. 01'." } } }," auth_ref": [ ] }," dei_EntityListingPrimary": {" xbrltype":" yesNoItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityListingPrimary"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Listing, Primary"," documentation":" Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity." } } }," auth_ref": [ ] }," dei_EntityListingSecurityTradingCurrency": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityListingSecurityTradingCurrency"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Listing, Security Trading Currency"," documentation":" The three character ISO 4217 code for the currency in which the security is quoted. Example:' USD'" } } }," auth_ref": [ ] }," dei_EntityListingsExchangeAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityListingsExchangeAxis"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Listings, Exchange [Axis]"," documentation":" The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }," auth_ref": [ ] }," dei_EntityListingsLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityListingsLineItems"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Listings [Line Items]"," documentation":" Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }," auth_ref": [ ] }," dei_EntityListingsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityListingsTable"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Listings [Table]"," documentation":" Container for exchange listing information for an entity" } } }," auth_ref": [ ] }," dei_EntityNumberOfEmployees": {" xbrltype":" decimalItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityNumberOfEmployees"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Number of Employees"," documentation":" Number of persons employed by the Entity" } } }," auth_ref": [ ] }," dei_EntityPhoneFaxNumbersLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityPhoneFaxNumbersLineItems"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Phone Fax Numbers [Line Items]"," documentation":" Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }," auth_ref": [ ] }," dei_EntityPrimarySicNumber": {" xbrltype":" sicNumberItemType"," nsuri":"

http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityPrimarySicNumber"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Primary SIC Number"," documentation":" Primary Standard Industrial Classification (SIC) Number for the Entity." } } }," auth_ref": [" r849"] }," dei_EntityPublicFloat": {" xbrltype":" monetaryItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityPublicFloat"," crdr":" credit"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Public Float"," documentation":" The aggregate market value of the voting and non- voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant' s most recently completed second fiscal quarter." } } }," auth_ref": [ ] }," dei_EntityRegistrantName": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityRegistrantName"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Registrant Name"," documentation":" The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }," auth_ref": [" r820"] }," dei_EntityReportingCurrencyISOCode": {" xbrltype":" currencyItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityReportingCurrencyISOCode"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Reporting Currency ISO Code"," documentation":" The three character ISO 4217 code for the currency used for reporting purposes. Example:' USD'." } } }," auth_ref": [ ] }," dei_EntityShellCompany": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityShellCompany"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Shell Company"," documentation":" Boolean flag that is true when the registrant is a shell company as defined in Rule 12b- 2 of the Exchange Act." } } }," auth_ref": [" r820"] }," dei_EntitySmallBusiness": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntitySmallBusiness"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Small Business"," documentation":" Indicates that the company is a Smaller Reporting Company (SRC)." } } }," auth_ref": [" r820"] }," dei_EntityTaxIdentificationNumber": {" xbrltype":" employerIdItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityTaxIdentificationNumber"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Tax Identification Number"," documentation":" The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9- digit value assigned by the IRS." } } }," auth_ref": [" r820"] }," dei_EntityTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityTextBlock"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity [Text Block]"," documentation":" Container to serve as parent of six Entity related Table concepts." } } }," auth_ref": [ ] }," dei_EntityVoluntaryFilers": {" xbrltype":" yesNoItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityVoluntaryFilers"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Voluntary Filers"," documentation":" Indicate' Yes' or' No' if the registrant is not required to file reports pursuant to Section 13 or Section 15 (d) of the Act." } } }," auth_ref": [ ] }," dei_EntityWellKnownSeasonedIssuer": {" xbrltype":" yesNoItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" EntityWellKnownSeasonedIssuer"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Entity Well- known Seasoned Issuer"," documentation":" Indicate' Yes' or' No' if the registrant is a well- known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10- K, 10- Q, 8- K, 20- F, 6- K, 10- K / A, 10- Q / A, 20- F / A, 6- K / A, N- CSR, N- Q, N- 1A." } } }," auth_ref": [" r939"] }," ecd_EqtyAwrdsAdjFnTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" EqtyAwrdsAdjFnTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Equity Awards Adjustments, Footnote [Text Block]"," terseLabel":" Equity Awards Adjustments, Footnote" } } }," auth_ref": [" r885"] }," ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"," terseLabel":" Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }," auth_ref": [" r932"] }," ecd_EqtyAwrdsAdjsMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" EqtyAwrdsAdjsMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Equity Awards Adjustments [Member]"," terseLabel":" Equity Awards Adjustments" } } }," auth_ref": [" r932"] }," ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" EqtyAwrdsInSummryCompstnTblForAplblYrMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"," terseLabel":" Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }," auth_ref": [" r932"] }," us- gaap_EquityComponentDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" EquityComponentDomain"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"," http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"," http: / / www. orukatx. com / role / ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"," http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" label":" Equity Component [Domain]"," documentation":" Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }," auth_ref": [" r9"," r125"," r145"," r146"," r147"," r165"," r166"," r167"," r169"," r174"," r176"," r178"," r196"," r262"," r263"," r276"," r349"," r435"," r436"," r443"," r444"," r445"," r447"," r448"," r449"," r455"," r456"," r457"," r458"," r459"," r460"," r463"," r490"," r491"," r492"," r493"," r494"," r495"," r499"," r500"," r511"," r609"," r619"," r620"," r621"," r637"," r705"] }," ecd_EquityValuationAssumptionDifferenceFnTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" EquityValuationAssumptionDifferenceFnTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Equity Valuation Assumption Difference, Footnote [Text Block]"," terseLabel":" Equity Valuation Assumption Difference, Footnote" } } }," auth_ref": [" r895"] }," ecd_ErrCompAnalysisTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" ErrCompAnalysisTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure"]," lang": {" en- us": {" role": {" label":" Erroneous Compensation Analysis [Text Block]"," terseLabel":" Erroneous Compensation Analysis" } } }," auth_ref": [" r842"," r853"," r871"," r906"] }," ecd_ErrCompRecoveryTable": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" ErrCompRecoveryTable"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure"]," lang": {" en- us": {" role": {" label":" Erroneously Awarded Compensation Recovery [Table]"," terseLabel":" Erroneously Awarded Compensation Recovery" } } }," auth_ref": [" r839"," r850"," r868"," r903"] }," orka_EstimatedFairValueOfWarrantsToBeGranted": {" xbrltype":" monetaryItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" EstimatedFairValueOfWarrantsToBeGranted"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role / StockBasedCompensationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Estimated fair value of warrants to be granted"," documentation":" Estimated fair value of warrants to be granted."," label":" Estimated Fair Value Of Warrants To Be Granted" } } }," auth_ref": [ ] }," dei_ExchangeDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" ExchangeDomain"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Exchange [Domain]"," documentation":" The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }," auth_ref": [ ] }," orka_ExchangeRatio": {" xbrltype":" pureItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ExchangeRatio"," presentation": [" http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Exchange ratio"," documentation":" Exchange ratio."," label":" Exchange Ratio" } } }," auth_ref": [ ] }," ecd_ExecutiveCategoryAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" ExecutiveCategoryAxis"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Executive Category [Axis]"," terseLabel":" Executive Category:" } } }," auth_ref": [" r901"] }," dei_ExhibitsOnly462d": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" ExhibitsOnly462d"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Exhibits Only, 462 (d)" } } }," auth_ref": [" r944"] }," dei_ExhibitsOnly462dFileNumber": {" xbrltype":" fileNumberItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" ExhibitsOnly462dFileNumber"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Exhibits Only, 462 (d), File Number" } } }," auth_ref": [" r944"] }," dei_Extension": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" Extension"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Extension"," documentation":" Extension number for local phone number." } } }," auth_ref": [ ] }," orka_ExternalMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ExternalMember"," presentation": [" http: / / www. orukatx. com / role / ScheduleofSegmentLossfromOperationsTable"]," lang": {" en- us": {" role": {" terseLabel":" External [Member]"," label":" External Member" } } }," auth_ref": [ ] }," us- gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us-gaap / 2024"," localname":" FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"," presentation": [" http: / / www. orukatx. com / role / ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable"]," lang": {" en- us": {" role": {" label":" Schedule of Weighted- Average Assumptions Used in Calculating the Fair Value of the Awards [Line Items]"," documentation":" Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }," auth_ref": [" r469"," r470"," r471"," r783"] }," us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FairValueAssetsMeasuredOnRecurringBasisTextBlock"," presentation": [" http: / / www. orukatx. com / role / FairValueMeasurementsTables"]," lang": {" en- us": {" role": {" terseLabel":" Schedule of Fair Value Hierarchy for Financial Assets Measured"," label":" Fair Value, Assets Measured on Recurring Basis [Table Text Block]"," documentation":" Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }," auth_ref": [" r1051"," r1052"] }," us- gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"," presentation": [" http: / / www. orukatx. com / role / ScheduleofCashEquivalentsandMarketableSecuritiesTable"," http: / / www. orukatx. com / role / ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"]," lang": {" en- us": {" role": {" label":" Asset Class [Domain]"," documentation":" Class of asset." } } }," auth_ref": [" r472"," r473"," r474"," r475"," r476"," r477"," r482"," r781"] }," us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"," presentation": [" http: / / www. orukatx. com / role / ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"]," lang": {" en- us": {" role": {" label":" Schedule of Fair Value Hierarchy for Financial Assets Measured [Line Items]"," documentation":" Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }," auth_ref": [" r472"," r473"," r474"," r475"," r476"," r477"," r482"," r781"] }," us- gaap_FairValueByAssetClassAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FairValueByAssetClassAxis"," presentation": [" http: / / www. orukatx. com / role / ScheduleofCashEquivalentsandMarketableSecuritiesTable"," http: / / www. orukatx. com / role / ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"]," lang": {" en- us": {" role": {" label":" Asset Class [Axis]"," documentation":" Information by class of asset." } } }," auth_ref": [" r472"," r473"," r474"," r475"," r476"," r477"," r482"," r781"] }," us-gaap_FairValueByFairValueHierarchyLevelAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FairValueByFairValueHierarchyLevelAxis"," presentation": [" http: / / www. orukatx. com / role / ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"]," lang": {" en- us": {" role": {" label":" Fair Value Hierarchy and NAV [Axis]"," documentation":" Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }," auth_ref": [" r316"," r351"," r352"," r353"," r354"," r355"," r356"," r466"," r468"," r469"," r470"," r471"," r480"," r481"," r483"," r526"," r527"," r528"," r766"," r767"," r772"," r773"," r774"," r780"," r783"] }," orka_FairValueCashEquivalentsAndMarketableSecurities": {" xbrltype":" monetaryItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" FairValueCashEquivalentsAndMarketableSecurities"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"]," lang": {" en- us": {" role": {" terseLabel":" Cash equivalents and marketable securities"," documentation":" Amount of cash equivalents and marketable securities."," label":" Fair Value Cash Equivalents And Marketable Securities" } } }," auth_ref": [ ] }," us- gaap_FairValueDisclosuresAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FairValueDisclosuresAbstract"," lang": {" en- us": {" role": {" label":" Fair Value Measurements [Abstract]" } } }," auth_ref": [ ] }," us- gaap_FairValueDisclosuresTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FairValueDisclosuresTextBlock"," presentation": [" http: / / www. orukatx. com / role / FairValueMeasurements"]," lang": {" en- us": {" role": {" terseLabel":" Fair Value Measurements"," label":" Fair Value Disclosures [Text Block]"," documentation":" The entire disclosure

for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non- financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }," auth_ref": [" r476"," r478"," r479"," r480"," r483"," r484"," r485"," r486"," r487"," r587"," r780"," r784"] }," us- gaap_FairValueInputsLevel1Member": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FairValueInputsLevel1Member"," presentation": [" http: / / www. orukatx. com / role / ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"]," lang": {" en- us": {" role": {" terseLabel":" Level 1 [Member]"," label":" Fair Value, Inputs, Level 1 [Member]"," documentation":" Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }," auth_ref": [" r316"," r351"," r356"," r468"," r481"," r526"," r772"," r773"," r774"," r780"] }," us- gaap_FairValueInputsLevel2Member": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FairValueInputsLevel2Member"," presentation": [" http: / / www. orukatx. com / role / ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"]," lang": {" en- us": {" role": {" terseLabel":" Level 2 [Member]"," label":" Fair Value, Inputs, Level 2 [Member]"," documentation":" Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }," auth_ref": [" r316"," r351"," r356"," r468"," r469"," r481"," r527"," r766"," r767"," r772"," r773"," r774"," r780"] }," us- gaap_FairValueInputsLevel3Member": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FairValueInputsLevel3Member"," presentation": [" http: / / www. orukatx. com / role / ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"]," lang": {" en- us": {" role": {" terseLabel":" Level 3 [Member]"," label":" Fair Value, Inputs, Level 3 [Member]"," documentation":" Unobservable inputs that reflect the entity' s own assumption about the assumptions market participants would use in pricing." } } }," auth_ref": [" r316"," r351"," r352"," r353"," r354"," r355"," r356"," r468"," r469"," r470"," r471"," r481"," r528"," r766"," r767"," r772"," r773"," r774"," r780"," r783"] }," us- gaap_FairValueMeasurementPolicyPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FairValueMeasurementPolicyPolicyTextBlock"," presentation": [" http: / / www. orukatx. com / role / AccountingPoliciesByPolicy"]," lang": {" en- us": {" role": {" terseLabel":" Fair Value Measurements"," label":" Fair Value Measurement, Policy [Policy Text Block]"," documentation":" Disclosure of accounting policy for fair value measurements of financial and non- financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }," auth_ref": [ ] }," us- gaap_FairValueMeasurementsFairValueHierarchyDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FairValueMeasurementsFairValueHierarchyDomain"," presentation": [" http: / / www. orukatx. com / role / ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"]," lang": {" en- us": {" role": {" label":" Fair Value Hierarchy and NAV [Domain]"," documentation":" Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }," auth_ref": [" r316"," r351"," r352"," r353"," r354"," r355"," r356"," r466"," r468"," r469"," r470"," r471"," r480"," r481"," r483"," r526"," r527"," r528"," r766"," r767"," r772"," r773"," r774"," r780"," r783"] }," orka_FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable"," presentation": [" http: / / www. orukatx. com / role / ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"]," lang": {" en- us": {" role": {" label":" Fair Value Measurements- Schedule of Fair Value Hierarchy for Financial Assets Measured (Details) [Table]" } } }," auth_ref": [ ] }," orka_FairmountHealthcareFundIILPMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" FairmountHealthcareFundIILPMember"," presentation": [" http: / / www. orukatx. com / role / NotePayablewithRelatedPartyDetails"," http: / / www. orukatx. com / role / RelatedPartyTransactionsDetails"]," lang": {" en- us": {" role": {" terseLabel":" Fairmount Healthcare Fund II, L. P. [Member]"," verboseLabel":" Fairmount [Member]"," label":" Fairmount Healthcare Fund IILPMember" } } }," auth_ref": [ ] }," orka_FairmountMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" FairmountMember"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"]," lang": {" en- us": {" role": {" terseLabel":" Fairmount [Member]"," label":" Fairmount Member" } } }," auth_ref": [ ] }," orka_FairmountsOwnershipInterestInParagonMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" FairmountsOwnershipInterestInParagonMember"," presentation": [" http: / / www. orukatx. com / role / RelatedPartyTransactionsDetails"]," lang": {" en- us": {" role": {" terseLabel":" Fairmount' s Ownership Interest in Paragon [Member]"," label":" Fairmounts Ownership Interest In Paragon Member" } } }," auth_ref": [ ] }," us- gaap_FeaturesOfConvertiblePreferredStockAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FeaturesOfConvertiblePreferredStockAbstract"," lang": {" en- us": {" role": {" label":" Convertible Preferred Stock and Stockholders \ u2019 Equity [Abstract]" } } }," auth_ref": [ ] }," us- gaap_FederalDepositInsuranceCorporationPremiumExpense": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FederalDepositInsuranceCorporationPremiumExpense"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / SummaryofSignificantAccountingPoliciesDetails"]," lang": {" en- us": {" role": {" terseLabel":" Federal Deposit Insurance Corporation"," label":" Federal Deposit Insurance Corporation Premium Expense"," documentation":" Amount of expense for Federal Deposit Insurance Corporation (FDIC) insurance." } } }," auth_ref": [" r106"] }," us- gaap_FinancialInstrumentAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FinancialInstrumentAxis"," presentation": [" http: / / www. orukatx. com / role / ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"," http: / / www. orukatx. com / role / ScheduleofCashEquivalentsandMarketableSecuritiesTable"]," lang": {" en- us": {" role": {" label":" Financial Instrument [Axis]"," documentation":" Information by type of financial instrument." } } }," auth_ref": [" r230"," r231"," r232"," r233"," r234"," r235"," r236"," r237"," r238"," r239"," r240"," r241"," r242"," r243"," r244"," r245"," r246"," r247"," r248"," r249"," r250"," r251"," r252"," r253"," r254"," r255"," r256"," r257"," r258"," r259"," r264"," r265"," r266"," r267"," r268"," r270"," r274"," r275"," r327"," r345"," r461"," r488"," r523"," r524"," r525"," r526"," r527"," r528"," r529"," r530"," r531"," r532"," r533"," r534"," r535"," r536"," r537"," r540"," r541"," r542"," r543"," r544"," r545"," r546"," r547"," r548"," r549"," r550"," r551"," r552"," r553"," r554"," r610"," r764"," r780"," r781"," r783"," r784"," r785"," r786"," r787"," r788"," r789"," r794"," r955"," r956"," r957"," r958"," r959"," r960"," r961"," r996"," r997"," r998"," r999"," r1050"," r1053"," r1054"," r1055"," r1056"," r1057"] }," orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember"," presentation": [" http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"]," lang": {" en- us": {" role": {" terseLabel":" First Dosing of Human Patient in Phase1Trial Milestone [Member]"," label":" First Dosing Of Human Patient In Phase One Trial Milestone Member" } } }," auth_ref": [ ] }," ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure"]," lang": {" en- us": {" role": {" label":" Forgone Recovery due to Disqualification of Tax Benefits, Amount"," terseLabel":" Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }," auth_ref": [" r846"," r857"," r875"," r910"] }," ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" ForgoneRecoveryDueToExpenseOfEnforcementAmt"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure"]," lang": {" en- us": {" role": {" label":" Forgone Recovery due to Expense of Enforcement, Amount"," terseLabel":" Forgone Recovery due to Expense of Enforcement, Amount" } } }," auth_ref": [" r846"," r857"," r875"," r910"] }," ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure"]," lang": {" en- us": {" role": {" label":" Forgone Recovery due to Violation of Home Country Law, Amount"," terseLabel":" Forgone Recovery due to Violation of Home Country Law, Amount" } } }," auth_ref": [" r846"," r857"," r875"," r910"] }," ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" ForgoneRecoveryExplanationOfImpracticabilityTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure"]," lang": {" en- us": {" role": {" label":" Forgone Recovery, Explanation of Impracticability [Text Block]"," terseLabel":" Forgone Recovery, Explanation of Impracticability" } } }," auth_ref": [" r846"," r857"," r875"," r910"] }," ecd_ForgoneRecoveryIndName": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" ForgoneRecoveryIndName"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure"]," lang": {" en- us": {" role": {" label":" Forgone Recovery, Individual Name"," terseLabel":" Name" } } }," auth_ref": [" r846"," r857"," r875"," r910"] }," dei_FormerAddressMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" FormerAddressMember"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Former Address [Member]"," documentation":" Former address for entity" } } }," auth_ref": [" r831"," r861"] }," dei_FormerFiscalYearEndDate": {" xbrltype":" gMonthDayItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" FormerFiscalYearEndDate"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Former Fiscal Year End Date"," documentation":" Former end date of previous fiscal years" } } }," auth_ref": [ ] }," ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"," terseLabel":" Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }," auth_ref": [" r890"] }," us- gaap_FurnitureAndFixturesMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" FurnitureAndFixturesMember"," presentation": [" http: / / www. orukatx. com / role / ScheduleofPropertyandEquipmentTable"]," lang": {" en- us": {" role": {" terseLabel":" Furniture and fixtures [Member]"," label":" Furniture and Fixtures [Member]"," documentation":" Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }," auth_ref": [ ] }," us- gaap_GeneralAndAdministrativeExpense": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" GeneralAndAdministrativeExpense"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome": {" parentTag":" us- gaap_OperatingExpenses"," weight": 1. 0," order": 2. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome"," http: / / www. orukatx. com / role / ScheduleofSegmentLossfromOperationsTable"]," lang": {" en- us": {" role": {" terseLabel":" General and administrative"," verboseLabel":" General and administrative personnel- related expense (excluding stock- based compensation)"," label":" General and Administrative Expense"," documentation":" The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }," auth_ref": [" r75"," r685"] }," us- gaap_GeneralAndAdministrativeExpenseMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" GeneralAndAdministrativeExpenseMember"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome_Parentheticals"," http: / / www. orukatx. com / role / ScheduleofCompanysStockBasedCompensationExpenseTable"," http: / / www. orukatx. com / role / ScheduleofSegmentLossfromOperationsTable"]," lang": {" en- us": {" role": {" terseLabel":" General and administrative"," verboseLabel":" General and administrative [Member]"," netLabel":" General and administrative stock- based compensation [Member]"," label":" General and Administrative Expense [Member]"," documentation":" Primary financial statement caption encompassing general and administrative expense." } } }," auth_ref": [" r75"] }," dei_IcfrAuditorAttestationFlag": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" IcfrAuditorAttestationFlag"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" ICFR Auditor Attestation Flag" } } }," auth_ref": [" r829"," r832"," r849"] }," us- gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role / ScheduleofLossBeforeIncomeTaxExpenseTable": {" parentTag":" us- gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"," weight": 1. 0," order": 1. 0 } }," presentation": [" http: / / www. orukatx. com / role / ScheduleofLossBeforeIncomeTaxExpenseTable"]," lang": {" en- us": {" role": {" terseLabel":" Domestic"," label":" Income (Loss) from Continuing Operations

```
before Income Taxes, Domestic"," documentation":" The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } },"
auth_ref": [" r158"," r414" ] }," us- gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {" xbrltype":" monetaryItemType","
nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"," crdr":" credit","
calculation": {" http: / / www. orukatx. com / role / ScheduleofLossBeforeIncomeTaxExpenseTable": {" parentTag": null," weight": null," order": null," root": true } }," presentation": [" http: /
/ www. orukatx. com / role / ScheduleofLossBeforeIncomeTaxExpenseTable" ]," lang": {" en- us": {" role": {" totalLabel":" Loss before income tax expense"," label":" Income (Loss) from
Continuing Operations before Income Taxes, Noncontrolling Interest"," documentation":" Amount of income (loss) from continuing operations, including income (loss) from equity method
investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }," auth_ref": [" r72"," r107"," r109"," r591"," r607"," r751","
r757"," r987"," r989"," r990"," r991"," r992" ] }," us- gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract": {" xbrltype":"
stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract","
lang": {" en- us": {" role": {" label":" Schedule of Loss Before Income Tax Expense [ Abstract ]" } } }," auth_ref": [ ] }," us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role / ScheduleofLossBeforeIncomeTaxExpenseTable": {"
parentTag":" us- gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"," weight": 1. 0," order": 2. 0 } }," presentation": [" http: / /
www. orukatx. com / role / ScheduleofLossBeforeIncomeTaxExpenseTable" ]," lang": {" en- us": {" role": {" terseLabel":" Foreign"," label":" Income (Loss) from Continuing Operations
before Income Taxes, Foreign"," documentation":" The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as
Income or Loss generated from operations located outside the entity' s country of domicile." } } }," auth_ref": [" r158"," r414" ] }," us- gaap_IncomeStatementLocationAxis": {" xbrltype":"
stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IncomeStatementLocationAxis"," presentation": [" http: / / www. orukatx. com / role /
ConsolidatedComprehensiveIncome_Parentheticals"," http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"," http: / / www. orukatx. com / role /
ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable"," http: / / www. orukatx. com / role / ScheduleofCompanysStockBasedCompensationExpenseTable"," http: / / www.
orukatx. com / role / ScheduleofSegmentLossfromOperationsTable" ]," lang": {" en- us": {" role": {" label":" Statement of Income Location, Balance [ Axis ]"," documentation":" Information
by location in statement of income where disaggregated amount has been reported." } } }," auth_ref": [" r277"," r283"," r284"," r473"," r477"," r482"," r616"," r618"," r690"," r742","
r782"," r1078" ] }," us- gaap_IncomeStatementLocationDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
IncomeStatementLocationDomain"," presentation": [" http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"," http: / / www. orukatx. com / role /
ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable"," http: / / www. orukatx. com / role / ScheduleofCompanysStockBasedCompensationExpenseTable"," http: / / www.
orukatx. com / role / ScheduleofSegmentLossfromOperationsTable" ]," lang": {" en- us": {" role": {" label":" Statement of Income Location, Balance [ Domain ]"," documentation":" Location
in statement of income where disaggregated amount has been reported." } } }," auth_ref": [" r283"," r284"," r473"," r477"," r482"," r616"," r618"," r690"," r742"," r782"," r1078" ] }," us-
gaap_IncomeTaxAuthorityAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IncomeTaxAuthorityAxis"," presentation": [" http: / / www.
orukatx. com / role / IncomeTaxesDetails" ]," lang": {" en- us": {" role": {" label":" Income Tax Jurisdiction [ Axis ]"," documentation":" Information by income tax jurisdiction." } } },"
auth_ref": [" r152"," r415"," r416"," r422"," r433"," r779"," r1047" ] }," us- gaap_IncomeTaxAuthorityDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap /
2024"," localname":" IncomeTaxAuthorityDomain"," presentation": [" http: / / www. orukatx. com / role / IncomeTaxesDetails" ]," lang": {" en- us": {" role": {" label":" Income Tax
Jurisdiction [ Domain ]"," documentation":" Income tax jurisdiction." } } }," auth_ref": [" r152"," r415"," r416"," r422"," r433"," r779"," r1047" ] }," us-
gaap_IncomeTaxDisclosureAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IncomeTaxDisclosureAbstract"," lang": {" en- us": {"
role": {" label":" Income Taxes [ Abstract ]" } } }," auth_ref": [ ] }," us- gaap_IncomeTaxDisclosureTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap /
2024"," localname":" IncomeTaxDisclosureTextBlock"," presentation": [" http: / / www. orukatx. com / role / IncomeTaxes" ]," lang": {" en- us": {" role": {" terseLabel":" Income Taxes","
label":" Income Tax Disclosure [ Text Block ]"," documentation":" The entire disclosure for income tax." } } }," auth_ref": [" r159"," r409"," r415"," r419"," r420"," r421"," r425"," r432","
r438"," r440"," r441"," r442"," r633"," r779" ] }," us- gaap_IncomeTaxExpenseBenefit": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
IncomeTaxExpenseBenefit"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / IncomeTaxesDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Provision for income
taxes"," label":" Income Tax Expense (Benefit)"," documentation":" Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing
operations." } } }," auth_ref": [" r115"," r123"," r177"," r178"," r194"," r206"," r220"," r413"," r415"," r439"," r614"," r779" ] }," us-
gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"," lang": {" en- us": {" role": {" label":" Schedule of Statutory Federal Income Tax Rate to Income Before
Income Taxes [ Abstract ]" } } }," auth_ref": [ ] }," us- gaap_IncomeTaxPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
IncomeTaxPolicyTextBlock"," presentation": [" http: / / www. orukatx. com / role / AccountingPoliciesByPolicy" ]," lang": {" en- us": {" role": {" terseLabel":" Income Taxes"," label":"
Income Tax, Policy [ Policy Text Block ]"," documentation":" Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred
tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for
determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }," auth_ref": [" r144"," r411"," r412"," r425"," r426"," r431","
r434"," r627" ] }," orka_IncomeTaxesDetailsLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" IncomeTaxesDetailsLineItems","
presentation": [" http: / / www. orukatx. com / role / IncomeTaxesDetails" ]," lang": {" en- us": {" role": {" label":" Income Taxes (Details) [ Line Items ]" } } }," auth_ref": [ ] },"
orka_IncomeTaxesDetailsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" IncomeTaxesDetailsTable"," presentation": [" http: / /
www. orukatx. com / role / IncomeTaxesDetails" ]," lang": {" en- us": {" role": {" label":" Income Taxes (Details) [ Table ]" } } }," auth_ref": [ ] }," us-
gaap_IncreaseDecreaseInAccountsPayableRelatedParties": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
IncreaseDecreaseInAccountsPayableRelatedParties"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedCashFlow": {" parentTag":" us-
gaap_NetCashProvidedByUsedInOperatingActivities"," weight": 1. 0," order": 9. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {"
role": {" terseLabel":" Related party accounts payable and other current liabilities"," label":" Increase (Decrease) in Accounts Payable, Related Parties"," documentation":" The increase
(decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a
common parent, an entity and trust for the benefit of employees, such as pension and profit- sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and
its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence." } } }," auth_ref": [" r4" ] }," us-
gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedCashFlow": {" parentTag":" us-
gaap_NetCashProvidedByUsedInOperatingActivities"," weight": 1. 0," order": 7. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {"
role": {" terseLabel":" Accrued expenses and other current liabilities"," label":" Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities"," documentation":" Amount of
increase (decrease) in accrued expenses, and obligations classified as other." } } }," auth_ref": [" r974" ] }," us- gaap_IncreaseDecreaseInOperatingCapitalAbstract": {" xbrltype":"
stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IncreaseDecreaseInOperatingCapitalAbstract"," presentation": [" http: / / www. orukatx. com / role /
ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" terseLabel":" Changes in operating assets and liabilities:"," label":" Increase (Decrease) in Operating Capital [ Abstract ]" } } },"
auth_ref": [ ] }," us- gaap_IncreaseDecreaseInOperatingLeaseLiability": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
IncreaseDecreaseInOperatingLeaseLiability"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedCashFlow": {" parentTag":" us-
gaap_NetCashProvidedByUsedInOperatingActivities"," weight": 1. 0," order": 8. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {"
role": {" terseLabel":" Operating lease liability"," label":" Increase (Decrease) in Operating Lease Liability"," documentation":" Amount of increase (decrease) in obligation for operating
lease." } } }," auth_ref": [" r954"," r974" ] }," us- gaap_IncreaseDecreaseInOtherAccountsPayable": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024","
localname":" IncreaseDecreaseInOtherAccountsPayable"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedCashFlow": {" parentTag":" us-
gaap_NetCashProvidedByUsedInOperatingActivities"," weight": 1. 0," order": 6. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {"
role": {" terseLabel":" Accounts payable"," label":" Increase (Decrease) in Other Accounts Payable"," documentation":" Amount of increase (decrease) in obligations classified as other,
payable within one year or the normal operating cycle, if longer." } } }," auth_ref": [" r4" ] }," us- gaap_IncreaseDecreaseInOtherNoncurrentAssets": {" xbrltype":" monetaryItemType","
nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IncreaseDecreaseInOtherNoncurrentAssets"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role /
ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInOperatingActivities"," weight":- 1. 0," order": 12. 0 } }," presentation": [" http: / / www. orukatx. com / role /
ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" negatedLabel":" Other non- current assets"," label":" Increase (Decrease) in Other Noncurrent Assets"," documentation":" Amount
of increase (decrease) in noncurrent assets classified as other." } } }," auth_ref": [" r974" ] }," us- gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {" xbrltype":"
monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"," crdr":" credit"," calculation": {" http: / /
www. orukatx. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInOperatingActivities"," weight":- 1. 0," order": 11. 0 } }," presentation": [" http: / /
www. orukatx. com / role / ConsolidatedCashFlow" ]," lang": {" en- us": {" role": {" negatedLabel":" Prepaid expenses and other current assets"," label":" Increase (Decrease) in Prepaid
Expense and Other Assets"," documentation":" Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }," auth_ref": [" r4" ] }," ecd_IndividualAxis": {"
xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" IndividualAxis"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure"," http:
/ / xbrl. sec. gov / ecd / role / ErrCompDisclosure"," http: / / xbrl. sec. gov / ecd / role / InsiderTradingArrangements"," http: / / xbrl. sec. gov / ecd / role / PvpDisclosure" ]," lang": {" en- us": {"
role": {" label":" Individual [ Axis ]"," terseLabel":" Individual:" } } }," auth_ref": [" r846"," r857"," r875"," r901"," r910"," r914"," r922" ] }," ecd_InsiderTradingArrLineItems": {"
xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" InsiderTradingArrLineItems"," lang": {" en- us": {" role": {" label":" Insider Trading
Arrangements [ Line Items ]"," terseLabel":" Insider Trading Arrangements:" } } }," auth_ref": [" r920" ] }," ecd_InsiderTradingPoliciesProcLineItems": {" xbrltype":" stringItemType","
nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" InsiderTradingPoliciesProcLineItems"," lang": {" en- us": {" role": {" label":" Insider Trading Policies and Procedures [ Line Items
]"," terseLabel":" Insider Trading Policies and Procedures:" } } }," auth_ref": [" r833"," r926" ] }," ecd_InsiderTrdPoliciesProcAdoptedFlag": {" xbrltype":" booleanItemType"," nsuri":"
http: / / xbrl. sec. gov / ecd / 2024"," localname":" InsiderTrdPoliciesProcAdoptedFlag"," presentation": [" http: / / xbrl. sec. gov / ecd / role / InsiderTradingPoliciesProc" ]," lang": {" en- us":
{" role": {" label":" Insider Trading Policies and Procedures Adopted [ Flag ]"," terseLabel":" Insider Trading Policies and Procedures Adopted" } } }," auth_ref": [" r833"," r926" ] },"
ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":"
InsiderTrdPoliciesProcNotAdoptedTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / InsiderTradingPoliciesProc" ]," lang": {" en- us": {" role": {" label":" Insider Trading
Policies and Procedures Not Adopted [ Text Block ]"," terseLabel":" Insider Trading Policies and Procedures Not Adopted" } } }," auth_ref": [" r833"," r926" ] }," us-
gaap_InterestExpenseDebt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" InterestExpenseDebt"," crdr":" debit"," presentation": [" http: /
/ www. orukatx. com / role / NotePayablewithRelatedPartyDetails" ]," lang": {" en- us": {" role": {" terseLabel":" Interest expense"," label":" Interest Expense, Debt"," documentation":"
Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }," auth_ref": [" r78"," r322"," r329"," r768"," r769" ] }," us- gaap_InterestExpenseMember": {"
xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" InterestExpenseMember"," presentation": [" http: / / www. orukatx. com / role /
ConsolidatedComprehensiveIncome_Parentheticals" ]," lang": {" en- us": {" role": {" terseLabel":" Interest Expense"," label":" Interest Expense [ Member ]"," documentation":" Primary
financial statement caption encompassing interest expense." } } }," auth_ref": [" r13" ] }," us- gaap_InterestExpenseNonoperating": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb.
org / us- gaap / 2024"," localname":" InterestExpenseNonoperating"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome": {"
parentTag":" us- gaap_NonoperatingIncomeExpense"," weight":- 1. 0," order": 3. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome" ]," lang": {"
```

en- us": {" role": {" negatedLabel":" Interest expense"," label":" Interest Expense, Nonoperating"," documentation":" Amount of interest expense classified as nonoperating." } } }," auth_ref": [" r205"," r971"] }," dei_InvestmentCompanyActFileNumber": {" xbrltype":" fileNumberItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" InvestmentCompanyActFileNumber"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Investment Company Act File Number" } } }," auth_ref": [" r864"," r865"," r866"," r867"] }," dei_InvestmentCompanyActRegistration": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" InvestmentCompanyActRegistration"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Investment Company Act Registration" } } }," auth_ref": [" r880"] }," dei_InvestmentCompanyRegistrationAmendment": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" InvestmentCompanyRegistrationAmendment"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Investment Company Registration Amendment" } } }," auth_ref": [" r880"] }," dei_InvestmentCompanyRegistrationAmendmentNumber": {" xbrltype":" sequenceNumberItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" InvestmentCompanyRegistrationAmendmentNumber"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Investment Company Registration Amendment Number" } } }," auth_ref": [" r880"] }," us- gaap_InvestmentIncomeInterest": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" InvestmentIncomeInterest"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome": {" parentTag":" us- gaap_NonoperatingIncomeExpense"," weight": 1. 0," order": 1. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome"]," lang": {" en- us": {" role": {" terseLabel":" Interest income"," label":" Investment Income, Interest"," documentation":" Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }," auth_ref": [" r194"," r204"," r220"," r757"," r970"] }," us- gaap_InvestmentsAndCash": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" InvestmentsAndCash"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Cash, cash equivalents, and marketable securities (in Dollars)"," label":" Investments and Cash"," documentation":" Sum of investments and unrestricted cash as of the balance sheet date." } } }," auth_ref": [" r1075"," r1076"] }," us- gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" InvestmentsClassifiedByContractualMaturityDateTableTextBlock"," presentation": [" http: / / www. orukatx. com / role / CashequivalentsandMarketableSecuritiesTables"]," lang": {" en- us": {" role": {" terseLabel":" Schedule of Marketable Securities at Estimated Fair Value"," label":" Investments Classified by Contractual Maturity Date [Table Text Block]"," documentation":" Tabular disclosure of maturities of an entity' s investments as well as any other information pertinent to the investments." } } }," auth_ref": [ ] }," orka_InvestorsClosingShares": {" xbrltype":" sharesItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" InvestorsClosingShares"," presentation": [" http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Investors shares"," documentation":" Number of investors closing shares."," label":" Investors Closing Shares" } } }," auth_ref": [ ] }," orka_IssuanceCostOfPIPEFinancing": {" xbrltype":" monetaryItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" IssuanceCostOfPIPEFinancing"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" terseLabel":" Issuance costs of PIPE Financing"," documentation":" Issuance cost of PIPE financing."," label":" Issuance Cost Of PIPEFinancing" } } }," auth_ref": [ ] }," orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos": {" xbrltype":" monetaryItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" terseLabel":" Issuance of common stock and pre- funded warrants in the Pre- Closing Financing"," documentation":" Issuance of common stock and pre- funded warrants in the preclosing financing, net of offering costs of $ [x] million."," label":" Issuance Of Common Stock And Prefunded Warrants In The Preclosing Financing Net Of Offering Cos" } } }," auth_ref": [ ] }," orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost": {" xbrltype":" sharesItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost"," presentation": [" http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" terseLabel":" Issuance of common stock and pre- funded warrants in the Pre- Closing Financing (in Shares)"," documentation":" Issuance of common stock and pre- funded warrants in the preclosing financing, net of offering costs of $ [x] million."," label":" Issuance Of Common Stock And Prefunded Warrants In The Preclosing Financing Net Of Offering Cost" } } }," auth_ref": [ ] }," orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr": {" xbrltype":" monetaryItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" terseLabel":" Issuance of common stock, Series A non- voting convertible preferred stock, and pre- funded warrants in connection with the PIPE Financing"," documentation":" Issuance of common stock, Series A non- voting convertible preferred stock, and pre- funded warrants in connection with the Private Placement, net of offering costs of $ [x] million."," label":" Issuance Of Common Stock Series ANonvoting Convertible Preferred Stock And Prefunded Warr" } } }," auth_ref": [ ] }," orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant": {" xbrltype":" sharesItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant"," presentation": [" http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" terseLabel":" Issuance of common stock, Series A non- voting convertible preferred stock, and pre- funded warrants in connection with the PIPE Financing (in Shares)"," documentation":" Issuance of common stock, Series A non- voting convertible preferred stock, and pre- funded warrants in connection with the Private Placement, net of offering costs of $ [x] million."," label":" Issuance Of Common Stock Series ANonvoting Convertible Preferred Stock And Prefunded Warrant" } } }," auth_ref": [ ] }," orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe": {" xbrltype":" monetaryItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" terseLabel":" Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization"," documentation":" Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the Reverse Merger."," label":" Issuance Of Common Stock To Former Stockholders Of ARCABiopharma Inc In Connection With The" } } }," auth_ref": [ ] }," orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger": {" xbrltype":" sharesItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger"," presentation": [" http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" terseLabel":" Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization (in Shares)"," documentation":" Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the Reverse Merger."," label":" Issuance Of Common Stock To Former Stockholders Of ARCABiopharma Inc In Connection With The Closing Ofthe Reverse Merger" } } }," auth_ref": [ ] }," orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts": {" xbrltype":" monetaryItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / ShareholdersEquityType2or3_Parentheticals"]," lang": {" en- us": {" role": {" terseLabel":" Issuance of Series A Convertible Preferred Stock, Net of Issuance Costs"," documentation":" Issuance of Series A convertible preferred stock, net of issuance costs."," label":" Issuance Of Series AConvertible Preferred Stock Net Of Issuance Costs" } } }," auth_ref": [ ] }," dei_LegalEntityAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" LegalEntityAxis"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / AuditInformation"," http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Legal Entity [Axis]"," documentation":" The set of legal entities associated with a report." } } }," auth_ref": [ ] }," dei_LegalEntityIdentifier": {" xbrltype":" legalEntityIdentifierItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" LegalEntityIdentifier"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Legal Entity Identifier"," documentation":" A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI." } } }," auth_ref": [" r817"] }," us- gaap_LesseeLeasesPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LesseeLeasesPolicyTextBlock"," presentation": [" http: / / www. orukatx. com / role / AccountingPoliciesByPolicy"]," lang": {" en- us": {" role": {" terseLabel":" Leases"," label":" Lessee, Leases [Policy Text Block]"," documentation":" Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }," auth_ref": [" r504"] }," us- gaap_LesseeOperatingLeaseDiscountRate": {" xbrltype":" percentItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LesseeOperatingLeaseDiscountRate"," presentation": [" http: / / www. orukatx. com / role / CommitmentandContingenciesDetails"]," lang": {" en- us": {" role": {" terseLabel":" Lease discount rate"," label":" Lessee, Operating Lease, Discount Rate"," documentation":" Discount rate used by lessee to determine present value of operating lease payments." } } }," auth_ref": [" r791"] }," us- gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LesseeOperatingLeaseLiabilityMaturityTableTextBlock"," presentation": [" http: / / www. orukatx. com / role / CommitmentandContingenciesTables"]," lang": {" en- us": {" role": {" terseLabel":" Schedule of Company \ u2019s Operating Lease Liabilities Showing the Aggregate Lease Payments"," label":" Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]"," documentation":" Tabular disclosure of undiscounted cash flows of lessee' s operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }," auth_ref": [" r1063"] }," us- gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LesseeOperatingLeaseLiabilityPaymentsDue"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role / ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable": {" parentTag": null," weight": null," order": null," root": true } }," presentation": [" http: / / www. orukatx. com / role / ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"," http: / / www. orukatx. com / role / SubsequentEventsDetails"]," lang": {" en- us": {" role": {" totalLabel":" Total undiscounted lease payments"," terseLabel":" Future lease payment"," label":" Lessee, Operating Lease, Liability, to be Paid"," documentation":" Amount of lessee' s undiscounted obligation for lease payment for operating lease." } } }," auth_ref": [" r508"] }," us- gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role / ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"]," lang": {" en- us": {" role": {" terseLabel":" 2025"," label":" Lessee, Operating Lease, Liability, to be Paid, Year One"," documentation":" Amount of lessee' s undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }," auth_ref": [" r508"] }," us- gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LesseeOperatingLeaseLiabilityPaymentsDueYearThree"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role / ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"]," lang": {" en- us": {" role": {" terseLabel":" 2027"," label":" Lessee, Operating Lease, Liability, to be Paid, Year Three"," documentation":" Amount of lessee' s undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }," auth_ref": [" r508"] }," us- gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role / ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"]," lang": {" en- us": {" role": {" terseLabel":" 2026"," label":" Lessee, Operating Lease, Liability, to be Paid, Year Two"," documentation":" Amount of lessee' s undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }," auth_ref": [" r508"] }," us- gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role / ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable": {" parentTag":" us- gaap_LesseeOperatingLeaseLiabilityPaymentsDue"," weight": 1. 0," order": 1. 0 } }," presentation": [" http: / / www. orukatx. com / role / ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"]," lang": {" en- us": {" role": {" negatedLabel":" Less: imputed interest"," label":" Lessee, Operating Lease, Liability, Undiscounted Excess Amount"," documentation":" Amount of lessee' s undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }," auth_ref": [" r508"] }," us- gaap_LesseeOperatingLeaseTermOfContract": {" xbrltype":" durationItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LesseeOperatingLeaseTermOfContract"," presentation": [" http: / / www. orukatx. com / role / CommitmentandContingenciesDetails"," http: / / www. orukatx. com / role / SubsequentEventsDetails"]," lang": {" en- us": {" role": {" terseLabel":" Lease term"," verboseLabel":" Lease

initial period"," label":" Lessee, Operating Lease, Term of Contract"," documentation":" Term of lessee' s operating lease, in' PnYnMnDTnHnMnS' format, for example,' P1Y5M13D'
represents reported fact of one year, five months, and thirteen days." } } }," auth_ref": [" r1062"] }," us- gaap_Liabilities": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us-
gaap / 2024"," localname":" Liabilities"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet": {" parentTag":" us-
gaap_LiabilitiesAndStockholdersEquity"," weight": 1. 0," order": 1. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"]," lang": {" en- us": {" role": {"
totalLabel":" Total liabilities"," label":" Liabilities"," documentation":" Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to
others." } } }," auth_ref": [" r14"," r53"," r54"," r55"," r57"," r58"," r59"," r62"," r157"," r261"," r293"," r294"," r295"," r296"," r297"," r298"," r299"," r300"," r301"," r452"," r453","
r454"," r489"," r660"," r750"," r816"," r1008"," r1065"," r1066"] }," us- gaap_LiabilitiesAndStockholdersEquity": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap
/ 2024"," localname":" LiabilitiesAndStockholdersEquity"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet": {" parentTag": null," weight":
null," order": null," root": true } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"]," lang": {" en- us": {" role": {" totalLabel":" Total liabilities, convertible
preferred stock and stockholders \ u2019 equity"," label":" Liabilities and Equity"," documentation":" Amount of liabilities and equity items, including the portion of equity attributable to
noncontrolling interests, if any." } } }," auth_ref": [" r70"," r104"," r603"," r793"," r977"," r1000"," r1058"] }," us- gaap_LiabilitiesCurrent": {" xbrltype":" monetaryItemType"," nsuri":"
http: / / fasb. org / us- gaap / 2024"," localname":" LiabilitiesCurrent"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet": {" parentTag":" us-
gaap_Liabilities"," weight": 1. 0," order": 1. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"]," lang": {" en- us": {" role": {" totalLabel":" Total current
liabilities"," label":" Liabilities, Current"," documentation":" Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within
one business cycle, if longer." } } }," auth_ref": [" r55"," r128"," r157"," r261"," r293"," r294"," r295"," r296"," r297"," r298"," r299"," r300"," r301"," r452"," r453"," r454"," r489","
r793"," r1008"," r1065"," r1066"] }," us- gaap_LiabilitiesCurrentAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
LiabilitiesCurrentAbstract"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"]," lang": {" en- us": {" role": {" terseLabel":" Current liabilities:"," label":"
Liabilities, Current [Abstract]" } } }," auth_ref": [ ] }," dei_LocalPhoneNumber": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":"
LocalPhoneNumber"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Local Phone Number"," documentation":" Local phone
number for entity." } } }," auth_ref": [ ] }," us- gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap
/ 2024"," localname":" LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"," presentation": [" http: / / www. orukatx. com / role /
OptionAgreementsandLicenseAgreementsDetails"]," lang": {" en- us": {" role": {" label":" Category of Item Purchased [Axis]"," documentation":" Information by category of items
purchased under a long- term purchase commitment." } } }," auth_ref": [ ] }," us- gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {" xbrltype":"
domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"," presentation": [" http: / / www. orukatx.
com / role / OptionAgreementsandLicenseAgreementsDetails"]," lang": {" en- us": {" role": {" label":" Long- Term Purchase Commitment, Category of Item Purchased [Domain]","
documentation":" General description of the goods or services to be purchased from the counterparty to the long- term purchase commitment." } } }," auth_ref": [ ] }," us-
gaap_MarketableSecurities": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" MarketableSecurities"," crdr":" debit"," calculation": {" http: /
/ www. orukatx. com / role / ScheduleofMarketableSecuritiesatEstimatedFairValueTable": {" parentTag": null," weight": null," order": null," root": true } }," presentation": [" http: / / www.
orukatx. com / role / ScheduleofMarketableSecuritiesatEstimatedFairValueTable"]," lang": {" en- us": {" role": {" totalLabel":" Total"," label":" Marketable Securities"," documentation":"
Amount of investment in marketable security." } } }," auth_ref": [" r105"," r963"] }," us- gaap_MarketableSecuritiesAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org /
us- gaap / 2024"," localname":" MarketableSecuritiesAbstract"," presentation": [" http: / / www. orukatx. com / role / ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"],"
lang": {" en- us": {" role": {" terseLabel":" Marketable securities"," label":" Marketable Securities [Abstract]" } } }," auth_ref": [ ] }," orka_MarketableSecuritiesAxis": {" xbrltype":"
stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" MarketableSecuritiesAxis"," presentation": [" http: / / www. orukatx. com / role /
ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"]," lang": {" en- us": {" role": {" terseLabel":" Marketable Securities [Axis]"," label":" Marketable Securities Axis" }
} }," auth_ref": [ ] }," us- gaap_MarketableSecuritiesCurrent": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
MarketableSecuritiesCurrent"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ScheduleofMarketableSecuritiesatEstimatedFairValueTable": {" parentTag":" us-
gaap_MarketableSecurities"," weight": 1. 0," order": 1. 0 }," http: / / www. orukatx. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_AssetsCurrent"," weight": 1. 0," order":
2. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"," http: / / www. orukatx. com / role /
ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"," http: / / www. orukatx. com / role / ScheduleofMarketableSecuritiesatEstimatedFairValueTable"]," lang": {" en- us": {"
role": {" terseLabel":" Marketable securities, current"," verboseLabel":" Due in one year or less"," label":" Marketable Securities, Current"," documentation":" Amount of investment in
marketable security, classified as current." } } }," auth_ref": [" r963"] }," orka_MarketableSecuritiesCurrentMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com
/ 20241231"," localname":" MarketableSecuritiesCurrentMember"," presentation": [" http: / / www. orukatx. com / role /
ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"]," lang": {" en- us": {" role": {" terseLabel":" Marketable securities, current [Member]"," label":" Marketable
Securities Current Member" } } }," auth_ref": [ ] }," orka_MarketableSecuritiesDomainDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231","
localname":" MarketableSecuritiesDomainDomain"," presentation": [" http: / / www. orukatx. com / role / ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"]," lang": {"
en- us": {" role": {" label":" MarketableSecuritiesDomain [Domain]" } } }," auth_ref": [ ] }," us- gaap_MarketableSecuritiesLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / /
fasb. org / us- gaap / 2024"," localname":" MarketableSecuritiesLineItems"," presentation": [" http: / / www. orukatx. com / role / ScheduleofCashEquivalentsandMarketableSecuritiesTable"],"
lang": {" en- us": {" role": {" label":" Marketable Securities [Line Items]"," documentation":" Line items represent financial concepts included in a table. These concepts are used to disclose
reportable information associated with domain members defined in one or many axes to the table." } } }," auth_ref": [ ] }," orka_MarketableSecuritiesLongTermMember": {" xbrltype":"
domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" MarketableSecuritiesLongTermMember"," presentation": [" http: / / www. orukatx. com / role /
ScheduleofCashEquivalentsandMarketableSecuritiesTable"]," lang": {" en- us": {" role": {" terseLabel":" Marketable Securities, Long- Term [Member]"," label":" Marketable Securities
Long Term Member" } } }," auth_ref": [ ] }," orka_MarketableSecuritiesMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":"
MarketableSecuritiesMember"," presentation": [" http: / / www. orukatx. com / role / ScheduleofCashEquivalentsandMarketableSecuritiesTable"]," lang": {" en- us": {" role": {"
terseLabel":" Marketable Securities [Member]"," label":" Marketable Securities Member" } } }," auth_ref": [ ] }," us- gaap_MarketableSecuritiesNoncurrent": {" xbrltype":"
monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" MarketableSecuritiesNoncurrent"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role /
ConsolidatedBalanceSheet": {" parentTag":" us- gaap_Assets"," weight": 1. 0," order": 2. 0 }," http: / / www. orukatx. com / role / ScheduleofMarketableSecuritiesatEstimatedFairValueTable":
{" parentTag":" us- gaap_MarketableSecurities"," weight": 1. 0," order": 2. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"," http: / / www. orukatx.
com / role / ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"," http: / / www. orukatx. com / role / ScheduleofMarketableSecuritiesatEstimatedFairValueTable"]," lang": {" en-
us": {" role": {" terseLabel":" Marketable securities, long- term"," verboseLabel":" Due in 1- 2 years"," label":" Marketable Securities, Noncurrent"," documentation":" Amount of
investment in marketable security, classified as noncurrent." } } }," auth_ref": [" r963"] }," orka_MarketableSecuritiesNoncurrentMember": {" xbrltype":" domainItemType"," nsuri":" http: /
/ www. orukatx. com / 20241231"," localname":" MarketableSecuritiesNoncurrentMember"," presentation": [" http: / / www. orukatx. com / role /
ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"]," lang": {" en- us": {" role": {" terseLabel":" Marketable securities, long- term [Member]"," label":" Marketable
Securities Noncurrent Member" } } }," auth_ref": [ ] }," us- gaap_MarketableSecuritiesPolicy": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
MarketableSecuritiesPolicy"," presentation": [" http: / / www. orukatx. com / role / AccountingPoliciesByPolicy"]," lang": {" en- us": {" role": {" terseLabel":" Marketable Securities","
label":" Marketable Securities, Policy [Policy Text Block]"," documentation":" Disclosure of accounting policy for investment classified as marketable security." } } }," auth_ref": [" r48"] },"
us- gaap_MarketableSecuritiesTable": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" MarketableSecuritiesTable"," presentation": [" http: / /
www. orukatx. com / role / ScheduleofCashEquivalentsandMarketableSecuritiesTable"]," lang": {" en- us": {" role": {" label":" Marketable Securities [Table]"," documentation":" Disclosure
of information about investment in marketable security." } } }," auth_ref": [ ] }," us- gaap_MarketableSecuritiesTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us-
gaap / 2024"," localname":" MarketableSecuritiesTextBlock"," presentation": [" http: / / www. orukatx. com / role / CashequivalentsandMarketableSecuritiesTables"]," lang": {" en- us": {"
role": {" terseLabel":" Schedule of Cash Equivalents and Marketable Securities"," label":" Marketable Securities [Table Text Block]"," documentation":" Tabular disclosure of marketable
securities. This may consist of investments in certain debt and equity securities, short- term investments and other assets." } } }," auth_ref": [ ] },"
cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / cyd / 2024","
localname":" MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock"," presentation": [" http: / / xbrl. sec. gov / cyd / role /
CybersecurityRiskManagementAndStrategyDisclosure"]," lang": {" en- us": {" role": {" terseLabel":" Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact
[Text Block]"," label":" Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]" } } }," auth_ref": [" r860"," r862"] },"
srt_MaximumMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / srt / 2024"," localname":" MaximumMember"," presentation": [" http: / / www. orukatx. com / role /
ScheduleofPropertyandEquipmentTable"]," lang": {" en- us": {" role": {" terseLabel":" Maximum [Member]"," label":" Maximum [Member]" } } }," auth_ref": [" r287"," r288"," r289","
r290"," r358"," r405"," r471"," r555"," r615"," r617"," r625"," r652"," r653"," r713"," r715"," r717"," r718"," r720"," r740"," r741"," r763"," r770"," r775"," r783"," r784"," r788","
r789"," r803"," r1010"," r1067"," r1068"," r1069"," r1070"," r1071"," r1072"] }," ecd_MeasureAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024","
localname":" MeasureAxis"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Measure [Axis]"," terseLabel":" Measure:" } } },"
auth_ref": [" r893"] }," ecd_MeasureName": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" MeasureName"," presentation": [" http:
/ / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Measure Name"," terseLabel":" Name" } } }," auth_ref": [" r893"] }," us-
gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
MergersAcquisitionsAndDispositionsDisclosuresTextBlock"," presentation": [" http: / / www. orukatx. com / role / ReverseRecapitalizationandPreClosingFinancing"]," lang": {" en- us": {"
role": {" terseLabel":" Reverse Recapitalization and Pre- Closing Financing"," label":" Mergers, Acquisitions and Dispositions Disclosures [Text Block]"," documentation":" The entire
disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of
individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This
element does not include fixed asset sales and plant closings." } } }," auth_ref": [" r51"," r97"] }," orka_MilestoneConsiderationPaid": {" xbrltype":" monetaryItemType"," nsuri":" http: / /
www. orukatx. com / 20241231"," localname":" MilestoneConsiderationPaid"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role /
OptionAgreementsandLicenseAgreementsDetails"]," lang": {" en- us": {" role": {" terseLabel":" Milestone consideration paid"," documentation":" The milestone consideration paid
amount."," label":" Milestone Consideration Paid" } } }," auth_ref": [ ] }," srt_MinimumMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / srt / 2024"," localname":"
MinimumMember"," presentation": [" http: / / www. orukatx. com / role / ScheduleofPropertyandEquipmentTable"]," lang": {" en- us": {" role": {" terseLabel":" Minimum [Member]","
label":" Minimum [Member]" } } }," auth_ref": [" r287"," r288"," r289"," r290"," r358"," r405"," r471"," r555"," r615"," r617"," r625"," r652"," r653"," r713"," r715"," r717"," r718","
r720"," r740"," r741"," r763"," r770"," r775"," r783"," r784"," r788"," r803"," r1010"," r1067"," r1068"," r1069"," r1070"," r1071"," r1072"] }," ecd_MnpiDiscTimedForCompValFlag":
{" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" MnpiDiscTimedForCompValFlag"," presentation": [" http: / / xbrl. sec. gov / ecd / role /
AwardTimingDisclosure"]," lang": {" en- us": {" role": {" label":" MNPI Disclosure Timed for Compensation Value [Flag]"," terseLabel":" MNPI Disclosure Timed for Compensation
Value" } } }," auth_ref": [" r913"] }," us- gaap_MoneyMarketFundsMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
MoneyMarketFundsMember"," presentation": [" http: / / www. orukatx. com / role / ScheduleofCashEquivalentsandMarketableSecuritiesTable"," http: / / www. orukatx. com / role /
ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"]," lang": {" en- us": {" role": {" terseLabel":" Money market funds [Member]"," label":" Money Market Funds [Member
]"," documentation":" Fund that invests in short- term money- market instruments, for example, but not limited to, commercial paper, banker' s acceptances, repurchase agreements,
government securities, certificates of deposit, and other highly liquid securities." } } }," auth_ref": [" r1013"] }," ecd_MtrlTermsOfTrdArrTextBlock": {" xbrltype":" textBlockItemType","

nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" MtrlTermsOfTrdArrTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / InsiderTradingArrangements"]," lang": {" en-
us": {" role": {" label":" Material Terms of Trading Arrangement [Text Block]"," terseLabel":" Material Terms of Trading Arrangement" } } }," auth_ref": [" r921"] },"
dei_NameChangeEventDateAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" NameChangeEventDateAxis"," presentation": [" http: / / xbrl.
sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Name Change Event Date [Axis]"," documentation":" For a sequence of name change event related facts, use
this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema' date' or' datetime' data type." } } }," auth_ref": [ ] }," dei_NameChangeEventLineItems":
{" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" NameChangeEventLineItems"," presentation": [" http: / / xbrl. sec. gov / dei / role / document /
Cover"]," lang": {" en- us": {" role": {" label":" Name Change Event [Line Items]"," documentation":" Line items represent concepts included in a table. Name change event line item
concepts are used for information qualified by domain members of axes in the Name Change Event table." } } }," auth_ref": [ ] }," dei_NameChangeEventTable": {" xbrltype":"
stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" NameChangeEventTable"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en-
us": {" role": {" label":" Name Change Event [Table]"," documentation":" For a set of related facts in a sequence of name change events, use this table when the events occurred within a single
reporting period." } } }," auth_ref": [ ] }," ecd_NamedExecutiveOfficersFnTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":"
NamedExecutiveOfficersFnTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Named Executive Officers, Footnote [Text
Block]"," terseLabel":" Named Executive Officers, Footnote" } } }," auth_ref": [" r894"] }," orka_NatureoftheBusinessandBasisofPresentationDetailsTable": {" xbrltype":" stringItemType","
nsuri":" http: / / www. orukatx. com / 20241231"," localname":" NatureoftheBusinessandBasisofPresentationDetailsTable"," presentation": [" http: / / www. orukatx. com / role /
NatureoftheBusinessandBasisofPresentationDetails"]," lang": {" en- us": {" role": {" label":" Nature of the Business and Basis of Presentation (Details) [Table]" } } }," auth_ref": [ ] }," us-
gaap_NetCashProvidedByUsedInFinancingActivities": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
NetCashProvidedByUsedInFinancingActivities"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedCashFlow": {" parentTag":" us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"," weight": 1. 0," order": 3. 0 } }," presentation": [" http: / /
www. orukatx. com / role / ConsolidatedCashFlow"]," lang": {" en- us": {" role": {" totalLabel":" Net cash provided by financing activities"," label":" Net Cash Provided by (Used in)
Financing Activities"," documentation":" Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources
from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for
other resources obtained from creditors on long- term credit." } } }," auth_ref": [" r151"] }," us- gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {" xbrltype":"
stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" NetCashProvidedByUsedInFinancingActivitiesAbstract"," presentation": [" http: / / www. orukatx. com / role /
ConsolidatedCashFlow"]," lang": {" en- us": {" role": {" terseLabel":" Cash flows from financing activities:"," label":" Net Cash Provided by (Used in) Financing Activities [Abstract]" } } },"
auth_ref": [ ] }," us- gaap_NetCashProvidedByUsedInInvestingActivities": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
NetCashProvidedByUsedInInvestingActivities"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedCashFlow": {" parentTag":" us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"," weight": 1. 0," order": 2. 0 } }," presentation": [" http: / /
www. orukatx. com / role / ConsolidatedCashFlow"]," lang": {" en- us": {" role": {" totalLabel":" Net cash used in investing activities"," label":" Net Cash Provided by (Used in) Investing
Activities"," documentation":" Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and
acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }," auth_ref": [" r151"] }," us-
gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
NetCashProvidedByUsedInInvestingActivitiesAbstract"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedCashFlow"]," lang": {" en- us": {" role": {" terseLabel":" Cash
flows from investing activities:"," label":" Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }," auth_ref": [ ] }," us- gaap_NetCashProvidedByUsedInOperatingActivities": {"
xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" NetCashProvidedByUsedInOperatingActivities"," calculation": {" http: / / www. orukatx. com /
role / ConsolidatedCashFlow": {" parentTag":" us- gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"," weight":
1. 0," order": 1. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedCashFlow"," http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"],"
lang": {" en- us": {" role": {" totalLabel":" Net cash used in operating activities"," terseLabel":" Net cash operating activities (in Dollars)"," label":" Net Cash Provided by (Used in) Operating
Activities"," documentation":" Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and
changes in value not defined as investing or financing activities." } } }," auth_ref": [" r80"," r81"," r82"] }," us- gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {" xbrltype":"
stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" NetCashProvidedByUsedInOperatingActivitiesAbstract"," presentation": [" http: / / www. orukatx. com / role /
ConsolidatedCashFlow"]," lang": {" en- us": {" role": {" terseLabel":" Cash flows from operating activities:"," label":" Net Cash Provided by (Used in) Operating Activities [Abstract]" } }
}," auth_ref": [ ] }," us- gaap_NetIncomeLoss": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" NetIncomeLoss"," crdr":" credit","
calculation": {" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome": {" parentTag":" us- gaap_ComprehensiveIncomeNetOfTax"," weight": 1. 0," order": 1. 0 }," http: / /
www. orukatx. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInOperatingActivities"," weight": 1. 0," order": 1. 0 } }," presentation": [" http: / / www.
orukatx. com / role / ConsolidatedCashFlow"," http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome"," http: / / www. orukatx. com / role /
NatureoftheBusinessandBasisofPresentationDetails"," http: / / www. orukatx. com / role / ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"," http: / / www. orukatx.
com / role / ShareholdersEquityType2or3"," http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" totalLabel":" Net loss"," verboseLabel":" Net loss","
netLabel":" Net loss (in Dollars)"," label":" Net Income (Loss)"," terseLabel":" Net Income (Loss)"," documentation":" The portion of profit or loss for the period, net of income taxes, which is
attributable to the parent." } } }," auth_ref": [" r74"," r82"," r108"," r126"," r140"," r142"," r147"," r157"," r168"," r170"," r171"," r172"," r173"," r174"," r177"," r178"," r185","
r261"," r293"," r294"," r295"," r296"," r297"," r298"," r299"," r300"," r301"," r446"," r449"," r465"," r489"," r608"," r682"," r703"," r704"," r814"," r1008"] },"
orka_NetLossPerShareDetailsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" NetLossPerShareDetailsTable"," presentation": ["
http: / / www. orukatx. com / role / NetLossPerShareDetails"]," lang": {" en- us": {" role": {" label":" Net Loss Per Share (Details) [Table]" } } }," auth_ref": [ ] },"
orka_NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com /
20241231"," localname":" NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable"," presentation": [" http: / / www. orukatx. com / role /
ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"]," lang": {" en- us": {" role": {" label":" Net Loss Per Share- Schedule of Basic and Diluted Net Loss Per Share
Attributable to Stockholders (Details) [Table]" } } }," auth_ref": [ ] }," us- gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / /
fasb. org / us- gaap / 2024"," localname":" NewAccountingPronouncementsPolicyPolicyTextBlock"," presentation": [" http: / / www. orukatx. com / role / AccountingPoliciesByPolicy"]," lang":
{" en- us": {" role": {" terseLabel":" Recently Issued Accounting Pronouncements"," label":" New Accounting Pronouncements, Policy [Policy Text Block]"," documentation":" Disclosure of
accounting policy pertaining to new accounting pronouncements that may impact the entity' s financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." }
} }," auth_ref": [ ] }," dei_NewEffectiveDateForPreviousFiling": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":"
NewEffectiveDateForPreviousFiling"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" New Effective Date for Previous Filing" }
} }," auth_ref": [" r864"," r865"," r866"," r867"] }," dei_NoSubstantiveChanges462c": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":"
NoSubstantiveChanges462c"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" No Substantive Changes, 462 (c)" } } },"
auth_ref": [" r943"] }," dei_NoSubstantiveChanges462cFileNumber": {" xbrltype":" fileNumberItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":"
NoSubstantiveChanges462cFileNumber"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" No Substantive Changes, 462 (c), File
Number" } } }," auth_ref": [" r943"] }," dei_NoTradingSymbolFlag": {" xbrltype":" trueItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" NoTradingSymbolFlag","
presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" No Trading Symbol Flag"," documentation":" Boolean flag that is true only for
a security having no trading symbol." } } }," auth_ref": [ ] }," orka_NominationOfADevelopmentCandidateMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com /
20241231"," localname":" NominationOfADevelopmentCandidateMember"," presentation": [" http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"]," lang":
{" en- us": {" role": {" terseLabel":" Nomination Of A Development Candidate [Member]"," label":" Nomination Of ADevelopment Candidate Member" } } }," auth_ref": [ ] },"
ecd_NonGaapMeasureDescriptionTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" NonGaapMeasureDescriptionTextBlock","
presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Non- GAAP Measure Description [Text Block]"," terseLabel":" Non- GAAP
Measure Description" } } }," auth_ref": [" r893"] }," ecd_NonNeosMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":"
NonNeosMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure"]," lang": {" en- us": {" role": {" label":" Non- NEOs [Member]"," terseLabel":" Non- NEOs" }
} }," auth_ref": [" r846"," r857"," r875"," r901"," r910"] }," ecd_NonPeoNeoAvgCompActuallyPaidAmt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024","
localname":" NonPeoNeoAvgCompActuallyPaidAmt"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Non- PEO NEO Average
Compensation Actually Paid Amount"," terseLabel":" Non- PEO NEO Average Compensation Actually Paid Amount" } } }," auth_ref": [" r884"] }," ecd_NonPeoNeoAvgTotalCompAmt": {"
xbrltype":" monetaryItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" NonPeoNeoAvgTotalCompAmt"," presentation": [" http: / / xbrl. sec. gov / ecd / role /
PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Non- PEO NEO Average Total Compensation Amount"," terseLabel":" Non- PEO NEO Average Total Compensation Amount" } } },"
auth_ref": [" r883"] }," ecd_NonPeoNeoMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" NonPeoNeoMember"," presentation": ["
http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Non- PEO NEO [Member]"," terseLabel":" Non- PEO NEO" } } }," auth_ref": [" r901"] },"
orka_NonRefundableLicenseFee": {" xbrltype":" monetaryItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" NonRefundableLicenseFee"," crdr":" debit","
presentation": [" http: / / www. orukatx. com / role / CommitmentandContingenciesDetails"]," lang": {" en- us": {" role": {" terseLabel":" Non- refundable license fee"," documentation":"
Amount of non refundable license fee."," label":" Non Refundable License Fee" } } }," auth_ref": [ ] }," orka_NonRefundableMilestonePayments": {" xbrltype":" monetaryItemType","
nsuri":" http: / / www. orukatx. com / 20241231"," localname":" NonRefundableMilestonePayments"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role /
OptionAgreementsandLicenseAgreementsDetails"]," lang": {" en- us": {" role": {" terseLabel":" Non- refundable milestone payments"," documentation":" Non- refundable milestone
payments."," label":" Non Refundable Milestone Payments" } } }," auth_ref": [ ] }," ecd_NonRule10b51ArrAdoptedFlag": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov /
ecd / 2024"," localname":" NonRule10b51ArrAdoptedFlag"," presentation": [" http: / / xbrl. sec. gov / ecd / role / InsiderTradingArrangements"]," lang": {" en- us": {" role": {" label":" Non-
Rule 10b5- 1 Arrangement Adopted [Flag]"," terseLabel":" Non- Rule 10b5- 1 Arrangement Adopted" } } }," auth_ref": [" r921"] }," ecd_NonRule10b51ArrTrmntdFlag": {" xbrltype":"
booleanItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" NonRule10b51ArrTrmntdFlag"," presentation": [" http: / / xbrl. sec. gov / ecd / role /
InsiderTradingArrangements"]," lang": {" en- us": {" role": {" label":" Non- Rule 10b5- 1 Arrangement Terminated [Flag]"," terseLabel":" Non- Rule 10b5- 1 Arrangement Terminated" } }
}," auth_ref": [" r921"] }," orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock": {" xbrltype":" monetaryItemType"," nsuri":" http: / / www. orukatx. com /
20241231"," localname":" NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role /
ConsolidatedCashFlow"]," lang": {" en- us": {" role": {" terseLabel":" Non- cash accrued interest on convertible note converted to common stock"," documentation":" Represent the amount of
non- cash accrued interest on convertible note converted to common stock."," label":" Noncash Accrued Interest On Convertible Note Converted To Common Stock" } } }," auth_ref": [ ] },"
orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock": {" xbrltype":" monetaryItemType"," nsuri":" http: / / www. orukatx. com /
20241231"," localname":" NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock"," crdr":" credit"," presentation": [" http: / / www. orukatx. com
/ role / ConsolidatedCashFlow"]," lang": {" en- us": {" role": {" terseLabel":" Non- cash exchange of Pre- Merger Oruka Series A preferred stock for Series B convertible preferred stock","
documentation":" Represent the Non- cash exchange of Pre- Merger Oruka Series A preferred stock for Series B convertible preferred stock."," label":" Noncash Exchange Of Pre Merger
Oruka Series APreferred Stock For Series BConvertible Preferred Stock" } } }," auth_ref": [ ] }," us- gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1": {" xbrltype":"
monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1"," crdr":" debit"," presentation": [" http: / / www.

orukatx. com / role / ConsolidatedCashFlow"]," lang": {" en- us": {" role": {" terseLabel":" Assets acquired in connection with the reverse capitalization"," label":" Noncash or Part Noncash Acquisition, Other Assets Acquired"," documentation":" Amount of assets, classified as other, acquired in a noncash or part noncash acquisition." } } }," auth_ref": [" r25"," r26"," r27"] }," us- gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedCashFlow"]," lang": {" en- us": {" role": {" negatedLabel":" Other liabilities assumed in connection with the reverse recapitalization"," label":" Noncash or Part Noncash Acquisition, Other Liabilities Assumed"," documentation":" Amount of liabilities, classified as other, assumed in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition." } } }," auth_ref": [" r25"," r26"," r27"] }," us- gaap_NonoperatingIncomeExpense": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" NonoperatingIncomeExpense"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome": {" parentTag":" us- gaap_NetIncomeLoss"," weight": 1. 0," order": 2. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome"]," lang": {" en- us": {" role": {" totalLabel":" Total other income, net"," label":" Nonoperating Income (Expense)"," documentation":" The aggregate amount of income or expense from ancillary business- related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }," auth_ref": [" r77"] }," us- gaap_NonoperatingIncomeExpenseAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" NonoperatingIncomeExpenseAbstract"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome"]," lang": {" en- us": {" role": {" terseLabel":" Other income (expense)"," label":" Nonoperating Income (Expense) [Abstract]" } } }," auth_ref": [ ] }," orka_NotePayableToRelatedPartyPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" NotePayableToRelatedPartyPolicyTextBlock"," presentation": [" http: / / www. orukatx. com / role / AccountingPoliciesByPolicy"]," lang": {" en- us": {" role": {" terseLabel":" Note Payable to Related Party"," documentation":" Note Payable to Related Party."," label":" Note Payable To Related Party Policy Text Block" } } }," auth_ref": [ ] }," orka_NotePayablewithRelatedPartyDetailsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" NotePayablewithRelatedPartyDetailsTable"," presentation": [" http: / / www. orukatx. com / role / NotePayablewithRelatedPartyDetails"]," lang": {" en- us": {" role": {" label":" Note Payable with Related Party (Details) [Table]" } } }," auth_ref": [ ] }," us- gaap_NotesPayableAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" NotesPayableAbstract"," lang": {" en- us": {" role": {" label":" Note Payable with Related Party [Abstract]" } } }," auth_ref": [ ] }," us- gaap_NumberOfOperatingSegments": {" xbrltype":" integerItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" NumberOfOperatingSegments"," presentation": [" http: / / www. orukatx. com / role / SegmentDisclosuresDetails"]," lang": {" en- us": {" role": {" terseLabel":" Operating segment"," label":" Number of Operating Segments"," documentation":" Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise' s chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start- up operations may be operating segments before earning revenues." } } }," auth_ref": [" r758"," r988"] }," us- gaap_NumberOfReportableSegments": {" xbrltype":" integerItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" NumberOfReportableSegments"," presentation": [" http: / / www. orukatx. com / role / SegmentDisclosuresDetails"]," lang": {" en- us": {" role": {" terseLabel":" Reporting segment"," label":" Number of Reportable Segments"," documentation":" Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity' s financial statements." } } }," auth_ref": [" r752"," r762"," r988"] }," orka_NumberOfSharesPurchased": {" xbrltype":" sharesItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" NumberOfSharesPurchased"," presentation": [" http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Aggregate of purchased shares"," documentation":" Number of shares purchased."," label":" Number Of Shares Purchased" } } }," auth_ref": [ ] }," orka_NumberofAggregateShares": {" xbrltype":" sharesItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" NumberofAggregateShares"," presentation": [" http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Aggregate shares"," documentation":" Number of aggregate shares."," label":" Numberof Aggregate Shares" } } }," auth_ref": [ ] }," orka_ORKAZeroZeroOneLicenseAgreementMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ORKAZeroZeroOneLicenseAgreementMember"," presentation": [" http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"]," lang": {" en- us": {" role": {" terseLabel":" ORKA- 001 License Agreement [Member]"," label":" ORKAZero Zero One License Agreement Member" } } }," auth_ref": [ ] }," orka_ORKAZeroZeroOneMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ORKAZeroZeroOneMember"," presentation": [" http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"]," lang": {" en- us": {" role": {" terseLabel":" ORKA- 001 [Member]"," label":" ORKAZero Zero One Member" } } }," auth_ref": [ ] }," orka_ORKAZeroZeroTwoLicenseAgreementMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ORKAZeroZeroTwoLicenseAgreementMember"," presentation": [" http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"]," lang": {" en- us": {" role": {" terseLabel":" ORKA- 002 License Agreement [Member]"," label":" ORKAZero Zero Two License Agreement Member" } } }," auth_ref": [ ] }," orka_ORKAZeroZeroTwoMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ORKAZeroZeroTwoMember"," presentation": [" http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"]," lang": {" en- us": {" role": {" terseLabel":" ORKA- 002 [Member]"," label":" ORKAZero Zero Two Member" } } }," auth_ref": [ ] }," orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember"," presentation": [" http: / / www. orukatx. com / role / ScheduleofSegmentLossfromOperationsTable"]," lang": {" en- us": {" role": {" terseLabel":" Operating Expense Excluding Personnel Related And Stock Based Compensation [Member]"," label":" Operating Expense Excluding Personnel Related And Stock Based Compensation Member" } } }," auth_ref": [ ] }," orka_OperatingExpenseExcludingStockBasedCompensationMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" OperatingExpenseExcludingStockBasedCompensationMember"," presentation": [" http: / / www. orukatx. com / role / ScheduleofSegmentLossfromOperationsTable"]," lang": {" en- us": {" role": {" terseLabel":" Operating Expense Excluding StockBased Compensation [Member]"," verboseLabel":" Operating Expense Excluding Personnel Related And Stock Based Compensation [Member]"," label":" Operating Expense Excluding Stock Based Compensation Member" } } }," auth_ref": [ ] }," us- gaap_OperatingExpenses": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OperatingExpenses"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome": {" parentTag":" us- gaap_OperatingIncomeLoss"," weight":- 1. 0," order": 1. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome"," http: / / www. orukatx. com / role / ScheduleofSegmentLossfromOperationsTable"]," lang": {" en- us": {" role": {" totalLabel":" Total operating expenses"," label":" Operating Expenses"," documentation":" Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }," auth_ref": [ ] }," us- gaap_OperatingExpensesAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OperatingExpensesAbstract"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome"]," lang": {" en- us": {" role": {" terseLabel":" Operating expenses"," label":" Operating Expenses [Abstract]" } } }," auth_ref": [ ] }," us- gaap_OperatingIncomeLoss": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OperatingIncomeLoss"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome": {" parentTag":" us- gaap_NetIncomeLoss"," weight": 1. 0," order": 1. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome"," http: / / www. orukatx. com / role / ScheduleofSegmentLossfromOperationsTable"]," lang": {" en- us": {" role": {" totalLabel":" Loss from operations"," terseLabel":" Loss from operations"," label":" Operating Income (Loss)"," documentation":" The net result for the period of deducting operating expenses from operating revenues." } } }," auth_ref": [" r109"," r751"," r987"," r989"," r990"," r991"," r992"] }," us- gaap_OperatingLeaseExpense": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OperatingLeaseExpense"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInOperatingActivities"," weight": 1. 0," order": 4. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedCashFlow"]," lang": {" en- us": {" role": {" terseLabel":" Non- cash lease expense"," label":" Operating Lease, Expense"," documentation":" Amount of operating lease expense. Excludes sublease income." } } }," auth_ref": [" r1061"] }," us- gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OperatingLeaseLiabilitiesPaymentsDueAbstract"," lang": {" en- us": {" role": {" label":" Schedule of Company \ u2019s Operating Lease Liabilities Showing the Aggregate Lease Payments [Abstract]" } } }," auth_ref": [ ] }," us- gaap_OperatingLeaseLiability": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OperatingLeaseLiability"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role / ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable": {" parentTag":" us- gaap_LesseeOperatingLeaseLiabilityPaymentsDue"," weight": 1. 0," order": 2. 0 } }," presentation": [" http: / / www. orukatx. com / role / ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"]," lang": {" en- us": {" role": {" totalLabel":" Total discounted lease payments"," label":" Operating Lease, Liability"," documentation":" Present value of lessee' s discounted obligation for lease payments from operating lease." } } }," auth_ref": [" r502"] }," us- gaap_OperatingLeaseLiabilityCurrent": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OperatingLeaseLiabilityCurrent"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role / ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable": {" parentTag":" us- gaap_OperatingLeaseLiability"," weight": 1. 0," order": 1. 0 }," http: / / www. orukatx. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_LiabilitiesCurrent"," weight": 1. 0," order": 3. 0 } }," presentation": [" http: / / www. orukatx. com / role / CommitmentandContingenciesDetails"," http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"," http: / / www. orukatx. com / role / ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"]," lang": {" en- us": {" role": {" terseLabel":" Operating lease liability, current"," negatedLabel":" Less: current portion of lease liability"," label":" Operating Lease, Liability, Current"," documentation":" Present value of lessee' s discounted obligation for lease payments from operating lease, classified as current." } } }," auth_ref": [" r502"] }," us- gaap_OperatingLeaseLiabilityNoncurrent": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OperatingLeaseLiabilityNoncurrent"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_Liabilities"," weight": 1. 0," order": 2. 0 }," http: / / www. orukatx. com / role / ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable": {" parentTag":" us- gaap_OperatingLeaseLiability"," weight": 1. 0," order": 2. 0 } }," presentation": [" http: / / www. orukatx. com / role / CommitmentandContingenciesDetails"," http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"," http: / / www. orukatx. com / role / ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"]," lang": {" en- us": {" role": {" terseLabel":" Operating lease liability, non- current"," verboseLabel":" Non- current portion of lease liability"," netLabel":" Operating lease liability, noncurrent"," label":" Operating Lease, Liability, Noncurrent"," documentation":" Present value of lessee' s discounted obligation for lease payments from operating lease, classified as noncurrent." } } }," auth_ref": [" r502"] }," us- gaap_OperatingLeasePayments": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OperatingLeasePayments"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role / ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable"]," lang": {" en- us": {" role": {" terseLabel":" Cash paid for amounts included in the measurement of lease liabilities"," label":" Operating Lease, Payments"," documentation":" Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }," auth_ref": [" r503"," r505"] }," us- gaap_OperatingLeaseRightOfUseAsset": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OperatingLeaseRightOfUseAsset"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_Assets"," weight": 1. 0," order": 4. 0 } }," presentation": [" http: / / www. orukatx. com / role / CommitmentandContingenciesDetails"," http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"]," lang": {" en- us": {" role": {" terseLabel":" Operating lease right- of- use assets"," label":" Operating Lease, Right- of- Use Asset"," documentation":" Amount of lessee' s right to use underlying asset under operating lease." } } }," auth_ref": [" r501"] }," us- gaap_OperatingLeaseVariableLeaseIncome": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OperatingLeaseVariableLeaseIncome"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role / CommitmentandContingenciesDetails"]," lang": {" en- us": {" role": {" terseLabel":" Variable lease expense"," label":" Operating Lease, Variable Lease Income"," documentation":" Amount of operating lease income from variable lease payments paid and payable to lessor, excluding amount included in measurement of lease receivable." } } }," auth_ref": [" r195"," r510"] }," us- gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {" xbrltype":" durationItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OperatingLeaseWeightedAverageRemainingLeaseTerm1"," presentation": [" http: / / www. orukatx. com / role / CommitmentandContingenciesDetails"]," lang": {" en- us": {" role": {" terseLabel":" Remaining lease term"," label":" Operating Lease, Weighted Average Remaining Lease Term"," documentation":" Weighted average remaining lease term for operating lease, in' PnYnMnDTnHnMnS' format, for example,' P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }," auth_ref": [" r507"," r792"] }," orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome": {" xbrltype":" percentItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" OperatingLossCarryforwardsAsAPercentageOfTaxableIncome"," presentation": [" http: / / www. orukatx. com / role / IncomeTaxesDetails"]," lang": {" en- us": {" role": {" terseLabel":" Operating loss carryforwards as a percentage of taxable income"," documentation":" Operating loss carryforwards that can be utilized in any tax year as a percentage of taxable income"," label":" Operating Loss Carryforwards As APercentage Of Taxable Income" } } }," auth_ref": [ ] }," us-gaap_OperatingLossCarryforwardsValuationAllowance": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OperatingLossCarryforwardsValuationAllowance"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role / IncomeTaxesDetails"]," lang": {" en- us": {" role": {" terseLabel":" Change in valuation allowance due to continuing loss from operations"," label":" Operating Loss Carryforwards, Valuation Allowance"," documentation":" The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized." } } }," auth_ref": [" r1046"] }," orka_OptionAgreementsAndLicenseAgreementsAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" OptionAgreementsAndLicenseAgreementsAbstract"," lang": {" en- us": {" role": {" label":" Option Agreements and License Agreements [Abstract]" } } }," auth_ref": [ ] }," orka_OptionAgreementsAndLicenseAgreementsTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" OptionAgreementsAndLicenseAgreementsTextBlock"," presentation": [" http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreements"]," lang": {" en- us": {" role": {" terseLabel":" Option Agreements and License Agreements"," documentation":" The entire disclosure of option agreements and license agreements."," label":" Option Agreements And License Agreements Text Block" } } }," auth_ref": [ ] }," orka_OptionAgreementsandLicenseAgreementsDetailsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" OptionAgreementsandLicenseAgreementsDetailsTable"," presentation": [" http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"]," lang": {" en- us": {" role": {" label":" Option Agreements and License Agreements (Details) [Table]" } } }," auth_ref": [ ] }," us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"," lang": {" en- us": {" role": {" label":" Nature of the Business and Basis of Presentation [Abstract]" } } }," auth_ref": [ ] }," orka_OrukaCommonStockMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" OrukaCommonStockMember"," presentation": [" http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Oruka Common Stock [Member]"," label":" Oruka Common Stock Member" } } }," auth_ref": [ ] }," orka_OrukaSeriesAConvertiblePreferredStockMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" OrukaSeriesAConvertiblePreferredStockMember"," presentation": [" http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Oruka Series A Convertible Preferred Stock [Member]"," label":" Oruka Series AConvertible Preferred Stock Member" } } }," auth_ref": [ ] }," dei_OtherAddressMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" OtherAddressMember"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Other Address [Member]"," documentation":" Other address for entity" } } }," auth_ref": [ ] }," us-gaap_OtherAssetsNoncurrent": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OtherAssetsNoncurrent"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_Assets"," weight": 1. 0," order": 5. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"]," lang": {" en- us": {" role": {" terseLabel":" Other non- current assets"," label":" Other Assets, Noncurrent"," documentation":" Amount of noncurrent assets classified as other." } } }," auth_ref": [" r130"] }," us- gaap_OtherCommitmentsLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OtherCommitmentsLineItems"," presentation": [" http: / / www. orukatx. com / role / CommitmentandContingenciesDetails"]," lang": {" en- us": {" role": {" label":" Commitment and Contingencies [Line Items]"," documentation":" Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }," auth_ref": [ ] }," us- gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome": {" parentTag":" us- gaap_ComprehensiveIncomeNetOfTax"," weight": 1. 0," order": 2. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome"," http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" terseLabel":" Unrealized loss on marketable securities"," label":" OCI, Debt Securities, Available- for- Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax"," documentation":" Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held- to- maturity) from transfer to available- for- sale." } } }," auth_ref": [" r138"," r139"," r260"] }," us-gaap_OtherCurrentLiabilitiesTableTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OtherCurrentLiabilitiesTableTextBlock"," presentation": [" http: / / www. orukatx. com / role / RelatedPartyTransactionsTables"]," lang": {" en- us": {" role": {" terseLabel":" Schedule of Related Party Accounts Payable and Other Current Liabilities"," label":" Other Current Liabilities [Table Text Block]"," documentation":" Tabular disclosure of other current liabilities." } } }," auth_ref": [ ] }," orka_OtherDevelopmentCost": {" xbrltype":" monetaryItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" OtherDevelopmentCost"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"]," lang": {" en- us": {" role": {" terseLabel":" Development costs"," documentation":" Represent the amount of development costs."," label":" Other Development Cost" } } }," auth_ref": [ ] }," us- gaap_OtherExpenses": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OtherExpenses"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"]," lang": {" en-us": {" role": {" terseLabel":" Expenses"," label":" Other Expenses"," documentation":" Amount of expense classified as other." } } }," auth_ref": [" r75"," r76"] }," orka_OtherIncomeExpenseNetPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" OtherIncomeExpenseNetPolicyTextBlock"," presentation": [" http: / / www. orukatx. com / role / AccountingPoliciesByPolicy"]," lang": {" en- us": {" role": {" terseLabel":" Other income, net"," documentation":" Represents of other income (expense), net."," label":" Other Income Expense Net Policy Text Block" } } }," auth_ref": [ ] }," orka_OtherMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" OtherMember"," presentation": [" http: / / www. orukatx. com / role / ScheduleofSegmentLossfromOperationsTable"]," lang": {" en- us": {" role": {" terseLabel":" Other [Member]"," label":" Other Member" } } }," auth_ref": [ ] }," us-gaap_OtherNoncashExpense": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OtherNoncashExpense"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInOperatingActivities"," weight": 1. 0," order": 3. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedCashFlow"]," lang": {" en- us": {" role": {" terseLabel":" Non- cash interest expense"," label":" Other Noncash Expense"," documentation":" Amount of expense or loss included in net income that result in no cash flow, classified as other." } } }," auth_ref": [" r82"] }," us- gaap_OtherNonoperatingIncome": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OtherNonoperatingIncome"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome": {" parentTag":" us- gaap_NonoperatingIncomeExpense"," weight": 1. 0," order": 2. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome"]," lang": {" en- us": {" role": {" terseLabel":" Other income, net"," label":" Other Nonoperating Income"," documentation":" Amount of income related to nonoperating activities, classified as other." } } }," auth_ref": [" r150"] }," ecd_OtherPerfMeasureAmt": {" xbrltype":" decimalItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" OtherPerfMeasureAmt"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Other Performance Measure, Amount"," terseLabel":" Other Performance Measure, Amount" } } }," auth_ref": [" r893"] }," dei_OtherReportingStandardItemNumber": {" xbrltype":" otherReportingStandardItemNumberItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" OtherReportingStandardItemNumber"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Other Reporting Standard Item Number"," documentation":" \" Item 17 \" or \" Item 18 \" specified when the basis of accounting is neither US GAAP nor IFRS." } } }," auth_ref": [" r832"] }," us- gaap_OtherResearchAndDevelopmentExpense": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" OtherResearchAndDevelopmentExpense"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"]," lang": {" en- us": {" role": {" terseLabel":" Research and development expenses"," label":" Other Research and Development Expense"," documentation":" Amount of other research and development expense." } } }," auth_ref": [" r1041"] }," ecd_OutstandingAggtErrCompAmt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" OutstandingAggtErrCompAmt"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure"]," lang": {" en- us": {" role": {" label":" Outstanding Aggregate Erroneous Compensation Amount"," terseLabel":" Outstanding Aggregate Erroneous Compensation Amount" } } }," auth_ref": [" r844"," r855"," r873"," r908"] }," ecd_OutstandingRecoveryCompAmt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" OutstandingRecoveryCompAmt"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure"]," lang": {" en- us": {" role": {" label":" Outstanding Recovery Compensation Amount"," terseLabel":" Compensation Amount" } } }," auth_ref": [" r847"," r858"," r876"," r911"] }," ecd_OutstandingRecoveryIndName": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" OutstandingRecoveryIndName"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure"]," lang": {" en- us": {" role": {" label":" Outstanding Recovery, Individual Name"," terseLabel":" Name" } } }," auth_ref": [" r847"," r858"," r876"," r911"] }," srt_OwnershipAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / srt / 2024"," localname":" OwnershipAxis"," presentation": [" http: / / www. orukatx. com / role / RelatedPartyTransactionsDetails"]," lang": {" en- us": {" role": {" label":" Ownership [Axis]" } } }," auth_ref": [ ] }," orka_PIPEFinancingMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" PIPEFinancingMember"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"," http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"]," lang": {" en- us": {" role": {" terseLabel":" PIPE Financing [Member]"," label":" PIPEFinancing Member" } } }," auth_ref": [ ] }," orka_ParagonMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ParagonMember"," presentation": [" http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"," http: / / www. orukatx. com / role / RelatedPartyTransactionsDetails"]," lang": {" en- us": {" role": {" terseLabel":" Paragon [Member]"," label":" Paragon Member" } } }," auth_ref": [ ] }," orka_ParagonMilestonePaymentsForOptionAgreementMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ParagonMilestonePaymentsForOptionAgreementMember"," presentation": [" http: / / www. orukatx. com / role / ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"]," lang": {" en- us": {" role": {" terseLabel":" Paragon milestone payments for Option Agreement [Member]"," label":" Paragon Milestone Payments For Option Agreement Member" } } }," auth_ref": [ ] }," orka_ParagonReimbursableOptionAgreementsFeesMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ParagonReimbursableOptionAgreementsFeesMember"," presentation": [" http: / / www. orukatx. com / role / ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"]," lang": {" en- us": {" role": {" terseLabel":" Paragon reimbursable Option Agreements \ u2019 fees [Member]"," label":" Paragon Reimbursable Option Agreements Fees Member" } } }," auth_ref": [ ] }," orka_ParagonReimbursableOtherResearchExpensesMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ParagonReimbursableOtherResearchExpensesMember"," presentation": [" http: / / www. orukatx. com / role / ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"]," lang": {" en- us": {" role": {" terseLabel":" Paragon reimbursable other research expenses [Member]"," label":" Paragon Reimbursable Other Research Expenses Member" } } }," auth_ref": [ ] }," orka_ParagonReimbursablePatentExpensesMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ParagonReimbursablePatentExpensesMember"," presentation": [" http: / / www. orukatx. com / role / ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"]," lang": {" en- us": {" role": {" terseLabel":" Paragon reimbursable patent expenses \ t [Member]"," label":" Paragon Reimbursable Patent Expenses Member" } } }," auth_ref": [ ] }," dei_ParentEntityLegalName": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" ParentEntityLegalName"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Parent Entity Legal Name"," documentation":" If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity" } } }," auth_ref": [ ] }," orka_ParukaMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ParukaMember"," presentation": [" http: / / www. orukatx. com / role / RelatedPartyTransactionsDetails"]," lang": {" en- us": {" role": {" terseLabel":" Paruka [Member]"," label":" Paruka Member" } } }," auth_ref": [ ] }," orka_ParukaWarrantMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ParukaWarrantMember"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"," http: / / www. orukatx. com / role / ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"]," lang": {" en- us": {" role": {" terseLabel":" Paruka Warrant [Member]"," label":"

Paruka Warrant Member" } } }," auth_ref": [ ] }," orka_ParukaWarrantObligationMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231","
localname":" ParukaWarrantObligationMember"," presentation": [" http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"," http: / / www. orukatx. com / role /
ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable"," http: / / www. orukatx. com / role / ScheduleofCommonStockReservedforFutureIssuanceTable"," http: / / www.
orukatx. com / role / StockBasedCompensationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Paruka Warrant Obligation [Member]"," verboseLabel":" Paruka warrant obligation [
Member]"," label":" Paruka Warrant Obligation Member" } } }," auth_ref": [ ] }," ecd_PayVsPerformanceDisclosureLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec.
gov / ecd / 2024"," localname":" PayVsPerformanceDisclosureLineItems"," lang": {" en- us": {" role": {" label":" Pay vs Performance Disclosure [Line Items]"," terseLabel":" Pay vs
Performance Disclosure" } } }," auth_ref": [" r882"] }," us- gaap_PaymentOfFinancingAndStockIssuanceCosts": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap /
2024"," localname":" PaymentOfFinancingAndStockIssuanceCosts"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role /
NatureoftheBusinessandBasisofPresentationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Net of issuance costs (in Dollars)"," label":" Payment of Financing and Stock Issuance
Costs"," documentation":" The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining
maturity period of the associated long- term debt and the cost incurred directly for the issuance of equity securities." } } }," auth_ref": [" r21"] }," us- gaap_PaymentsForFees": {" xbrltype":"
monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PaymentsForFees"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role /
OptionAgreementsandLicenseAgreementsDetails"]," lang": {" en- us": {" role": {" terseLabel":" Initiation fee"," label":" Payments for Other Fees"," documentation":" Amount of cash
outflow for fees classified as other." } } }," auth_ref": [" r3"] }," us- gaap_PaymentsOfDebtIssuanceCosts": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024","
localname":" PaymentsOfDebtIssuanceCosts"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role / NotePayablewithRelatedPartyDetails"]," lang": {" en- us": {" role": {"
terseLabel":" Debt issuance costs"," label":" Payments of Debt Issuance Costs"," documentation":" The cash outflow paid to third parties in connection with debt origination, which will be
amortized over the remaining maturity period of the associated long- term debt." } } }," auth_ref": [" r22"] }," us- gaap_PaymentsOfStockIssuanceCosts": {" xbrltype":" monetaryItemType","
nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PaymentsOfStockIssuanceCosts"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role /
ConvertiblePreferredStockandStockholdersEquityDetails"]," lang": {" en- us": {" role": {" terseLabel":" Issuance costs (in Dollars)"," label":" Payments of Stock Issuance Costs","
documentation":" The cash outflow for cost incurred directly with the issuance of an equity security." } } }," auth_ref": [" r21"] }," us- gaap_PaymentsToAcquireMarketableSecurities": {"
xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PaymentsToAcquireMarketableSecurities"," crdr":" credit"," calculation": {" http: / / www.
orukatx. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInInvestingActivities"," weight":- 1. 0," order": 2. 0 } }," presentation": [" http: / / www.
orukatx. com / role / ConsolidatedCashFlow"]," lang": {" en- us": {" role": {" negatedLabel":" Purchases of marketable securities"," label":" Payments to Acquire Marketable Securities","
documentation":" Amount of cash outflow for purchase of marketable security." } } }," auth_ref": [" r995"] }," us- gaap_PaymentsToAcquirePropertyPlantAndEquipment": {" xbrltype":"
monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PaymentsToAcquirePropertyPlantAndEquipment"," crdr":" credit"," calculation": {" http: / / www.
orukatx. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInInvestingActivities"," weight":- 1. 0," order": 1. 0 } }," presentation": [" http: / / www.
orukatx. com / role / ConsolidatedCashFlow"]," lang": {" en- us": {" role": {" negatedLabel":" Purchases of property and equipment"," label":" Payments to Acquire Property, Plant, and
Equipment"," documentation":" The cash outflow associated with the acquisition of long- lived, physical assets that are used in the normal conduct of business to produce goods and services and
not intended for resale; includes cash outflows to pay for construction of self- constructed assets." } } }," auth_ref": [" r79"] }," ecd_PeerGroupIssuersFnTextBlock": {" xbrltype":"
textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" PeerGroupIssuersFnTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang":
{" en- us": {" role": {" label":" Peer Group Issuers, Footnote [Text Block]"," terseLabel":" Peer Group Issuers, Footnote" } } }," auth_ref": [" r892"] },"
ecd_PeerGroupTotalShareholderRtnAmt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" PeerGroupTotalShareholderRtnAmt","
presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Peer Group Total Shareholder Return Amount"," terseLabel":" Peer Group Total
Shareholder Return Amount" } } }," auth_ref": [" r892"] }," ecd_PeoActuallyPaidCompAmt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":"
PeoActuallyPaidCompAmt"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" PEO Actually Paid Compensation Amount","
terseLabel":" PEO Actually Paid Compensation Amount" } } }," auth_ref": [" r884"] }," ecd_PeoMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024","
localname":" PeoMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" PEO [Member]"," terseLabel":" PEO" } } },"
auth_ref": [" r901"] }," ecd_PeoName": {" xbrltype":" normalizedStringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" PeoName"," presentation": [" http: / / xbrl.
sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" PEO Name"," terseLabel":" PEO Name" } } }," auth_ref": [" r894"] }," ecd_PeoTotalCompAmt": {" xbrltype":"
monetaryItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" PeoTotalCompAmt"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us":
{" role": {" label":" PEO Total Compensation Amount"," terseLabel":" PEO Total Compensation Amount" } } }," auth_ref": [" r883"] }," dei_PhoneFaxNumberDescription": {" xbrltype":"
stringItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" PhoneFaxNumberDescription"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang":
{" en- us": {" role": {" label":" Phone Fax Number Description"," documentation":" Description of Phone or Fax Number" } } }," auth_ref": [ ] }," us- gaap_PlanNameAxis": {" xbrltype":"
stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PlanNameAxis"," presentation": [" http: / / www. orukatx. com / role /
ScheduleofCommonStockReservedforFutureIssuanceTable"," http: / / www. orukatx. com / role / StockBasedCompensationDetails"]," lang": {" en- us": {" role": {" label":" Plan Name [Axis
]"," documentation":" Information by plan name for share- based payment arrangement." } } }," auth_ref": [" r1014"," r1015"," r1016"," r1017"," r1018"," r1019"," r1020"," r1021","
r1022"," r1023"," r1024"," r1025"," r1026"," r1027"," r1028"," r1029"," r1030"," r1031"," r1032"," r1033"," r1034"," r1035"," r1036"," r1037"," r1038"," r1039"] }," us-
gaap_PlanNameDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PlanNameDomain"," presentation": [" http: / / www. orukatx. com /
role / ScheduleofCommonStockReservedforFutureIssuanceTable"," http: / / www. orukatx. com / role / StockBasedCompensationDetails"]," lang": {" en- us": {" role": {" label":" Plan Name [
Domain]"," documentation":" Plan name for share- based payment arrangement." } } }," auth_ref": [" r1014"," r1015"," r1016"," r1017"," r1018"," r1019"," r1020"," r1021"," r1022","
r1023"," r1024"," r1025"," r1026"," r1027"," r1028"," r1029"," r1030"," r1031"," r1032"," r1033"," r1034"," r1035"," r1036"," r1037"," r1038"," r1039"] },"
ecd_PnsnAdjsPrrSvcCstMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" PnsnAdjsPrrSvcCstMember"," presentation": [" http: / / xbrl.
sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Pension Adjustments Prior Service Cost [Member]"," terseLabel":" Pension Adjustments Prior Service Cost" } }
}," auth_ref": [" r885"] }," ecd_PnsnAdjsSvcCstMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" PnsnAdjsSvcCstMember","
presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Pension Adjustments Service Cost [Member]"," terseLabel":" Pension
Adjustments Service Cost" } } }," auth_ref": [" r935"] }," ecd_PnsnBnftsAdjFnTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":"
PnsnBnftsAdjFnTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Pension Benefits Adjustments, Footnote [Text Block
]"," terseLabel":" Pension Benefits Adjustments, Footnote" } } }," auth_ref": [" r884"] }," dei_PostEffectiveAmendment": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov /
dei / 2024"," localname":" PostEffectiveAmendment"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Post- Effective
Amendment" } } }," auth_ref": [" r818"] }," dei_PostEffectiveAmendmentNumber": {" xbrltype":" sequenceNumberItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":"
PostEffectiveAmendmentNumber"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Post- Effective Amendment Number","
documentation":" Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective." } } }," auth_ref": [" r818"] },"
dei_PreCommencementIssuerTenderOffer": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" PreCommencementIssuerTenderOffer","
presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Pre- commencement Issuer Tender Offer"," documentation":" Boolean flag that
is true when the Form 8- K filing is intended to satisfy the filing obligation of the registrant as pre- commencement communications pursuant to Rule 13e- 4 (c) under the Exchange Act." } } },"
auth_ref": [" r825"] }," dei_PreCommencementTenderOffer": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":"
PreCommencementTenderOffer"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Pre- commencement Tender Offer","
documentation":" Boolean flag that is true when the Form 8- K filing is intended to satisfy the filing obligation of the registrant as pre- commencement communications pursuant to Rule 14d- 2
(b) under the Exchange Act." } } }," auth_ref": [" r827"] }," dei_PreEffectiveAmendment": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":"
PreEffectiveAmendment"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Pre- Effective Amendment" } } }," auth_ref": ["
r818"] }," dei_PreEffectiveAmendmentNumber": {" xbrltype":" sequenceNumberItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" PreEffectiveAmendmentNumber","
presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Pre- Effective Amendment Number"," documentation":" Amendment number to
registration statement under the Securities Act of 1933 before the registration becomes effective." } } }," auth_ref": [" r818"] }," orka_PreFundedWarrantsMember": {" xbrltype":"
domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" PreFundedWarrantsMember"," presentation": [" http: / / www. orukatx. com / role /
ConvertiblePreferredStockandStockholdersEquityDetails"]," lang": {" en- us": {" role": {" terseLabel":" Pre- Funded Warrants [Member]"," label":" Pre Funded Warrants Member" } } },"
auth_ref": [ ] }," orka_PreFundedWarrantsOfCommonStockShares": {" xbrltype":" sharesItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":"
PreFundedWarrantsOfCommonStockShares"," presentation": [" http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"]," lang": {" en- us": {" role": {"
terseLabel":" Pre- funded warrants of common stock shares"," documentation":" Pre- funded warrants of common stock shares."," label":" Pre Funded Warrants Of Common Stock Shares" }
} }," auth_ref": [ ] }," orka_PreMergerOrukaMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" PreMergerOrukaMember","
presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"," http: / / www. orukatx. com / role /
NatureoftheBusinessandBasisofPresentationDetails"," http: / / www. orukatx. com / role / NotePayablewithRelatedPartyDetails"]," lang": {" en- us": {" role": {" terseLabel":" Pre- Merger
Oruka [Member]"," label":" Pre Merger Oruka Member" } } }," auth_ref": [ ] }," us- gaap_PreferredStockConvertibleSharesIssuable": {" xbrltype":" sharesItemType"," nsuri":" http: / /
fasb. org / us- gaap / 2024"," localname":" PreferredStockConvertibleSharesIssuable"," presentation": [" http: / / www. orukatx. com / role /
ConvertiblePreferredStockandStockholdersEquityDetails"]," lang": {" en- us": {" role": {" terseLabel":" Converted shares"," label":" Preferred Stock, Convertible, Shares Issuable","
documentation":" Number of common shares issuable upon conversion of preferred stock." } } }," auth_ref": [" r333"] }," us- gaap_PreferredStockMember": {" xbrltype":"
domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PreferredStockMember"," presentation": [" http: / / www. orukatx. com / role / ShareholdersEquityType2or3"
]," lang": {" en- us": {" role": {" terseLabel":" Convertible Preferred Stock"," label":" Preferred Stock [Member]"," documentation":" Preferred shares may provide a preferential dividend
to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } },"
auth_ref": [" r806"," r807"," r810"," r811"," r812"," r813"," r1107"," r1109"] }," us- gaap_PreferredStockParOrStatedValuePerShare": {" xbrltype":" perShareItemType"," nsuri":" http:
/ / fasb. org / us- gaap / 2024"," localname":" PreferredStockParOrStatedValuePerShare"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet_Parentheticals"],"
lang": {" en- us": {" role": {" terseLabel":" Non- voting convertible preferred stock, par value (in Dollars per share)"," label":" Preferred Stock, Par or Stated Value Per Share","
documentation":" Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }," auth_ref": [" r64"," r331"] }," us-
gaap_PreferredStockSharesAuthorized": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PreferredStockSharesAuthorized"," presentation": ["
http: / / www. orukatx. com / role / ConsolidatedBalanceSheet_Parentheticals"," http: / / www. orukatx. com / role / ScheduleofConvertiblePreferredStockTable"]," lang": {" en- us": {" role": {"
terseLabel":" Non- voting convertible preferred stock, shares authorized"," verboseLabel":" Preferred Stock Authorized"," label":" Preferred Stock, Shares Authorized"," documentation":"
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity' s charter and bylaws." } } },"
auth_ref": [" r64"," r662"] }," us- gaap_PreferredStockSharesIssued": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
PreferredStockSharesIssued"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet_Parentheticals"," http: / / www. orukatx. com / role /
ScheduleofConvertiblePreferredStockTable"]," lang": {" en- us": {" role": {" terseLabel":" Non- voting convertible preferred stock, shares issued"," verboseLabel":" Preferred Stock
Issued"," label":" Preferred Stock, Shares Issued"," documentation":" Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer.
Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }," auth_ref": [" r64"," r331"] }," us-

gaap_PreferredStockSharesOutstanding": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PreferredStockSharesOutstanding"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet_Parentheticals"," http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"," http: / / www. orukatx. com / role / ScheduleofConvertiblePreferredStockTable"]," lang": {" en- us": {" role": {" terseLabel":" Non- voting convertible preferred stock, shares outstanding"," verboseLabel":" Preferred Stock Outstanding"," netLabel":" Preferred stock, shares outstanding"," label":" Preferred Stock, Shares Outstanding"," documentation":" Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }," auth_ref": [" r64"," r662"," r680"," r1109"," r1110"] }," us- gaap_PreferredStockValue": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PreferredStockValue"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet": {" parentTag":" us-gaap_StockholdersEquity"," weight": 1. 0," order": 1. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"," http: / / www. orukatx. com / role / ScheduleofConvertiblePreferredStockTable"]," lang": {" en- us": {" role": {" terseLabel":" Series B non- voting convertible preferred stock, $ 0. 001 par value; 251, 504 and no shares authorized as of December 31, 2024 and February 6, 2024, respectively; 137, 138 and no shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively"," verboseLabel":" Carrying Value (in Dollars)"," label":" Preferred Stock, Value, Issued"," documentation":" Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }," auth_ref": [" r64"," r598"," r793"] }," orka_PrefundedWarrantsMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" PrefundedWarrantsMember"," presentation": [" http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"," http: / / www. orukatx. com / role / ScheduleofCommonStockReservedforFutureIssuanceTable"]," lang": {" en- us": {" role": {" terseLabel":" Pre- funded Warrants [Member]"," label":" Prefunded Warrants Member" } } }," auth_ref": [ ] }," orka_PrefundedWarrantstoPurchaseAnAggregateShares": {" xbrltype":" sharesItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" PrefundedWarrantstoPurchaseAnAggregateShares"," presentation": [" http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Prefunded warrants to purchase an aggregate shares"," documentation":" Number of prefunded warrants to purchase an aggregate shares."," label":" Prefunded Warrantsto Purchase An Aggregate Shares" } } }," auth_ref": [ ] }," us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PrepaidExpenseAndOtherAssetsCurrent"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_AssetsCurrent"," weight": 1. 0," order": 4. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"]," lang": {" en- us": {" role": {" terseLabel":" Prepaid expenses and other current assets"," label":" Prepaid Expense and Other Assets, Current"," documentation":" Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }," auth_ref": [" r966"] }," us- gaap_ProceedsFromConvertibleDebt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ProceedsFromConvertibleDebt"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / NotePayablewithRelatedPartyDetails"]," lang": {" en- us": {" role": {" terseLabel":" Aggregate proceeds"," label":" Proceeds from Convertible Debt"," documentation":" The cash inflow from the issuance of a long- term debt instrument which can be exchanged for a specified amount of another security, typically the entity' s common stock, at the option of the issuer or the holder." } } }," auth_ref": [" r20"] }," us- gaap_ProceedsFromIssuanceOfCommonStock": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ProceedsFromIssuanceOfCommonStock"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedCashFlow": {" parentTag":" us-gaap_NetCashProvidedByUsedInFinancingActivities"," weight": 1. 0," order": 6. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedCashFlow"]," lang": {" en- us": {" role": {" terseLabel":" Proceeds from issuance of common stock"," label":" Proceeds from Issuance of Common Stock"," documentation":" The cash inflow from the additional capital contribution to the entity." } } }," auth_ref": [" r2"] }," us- gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us-gaap / 2024"," localname":" ProceedsFromIssuanceOfConvertiblePreferredStock"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInFinancingActivities"," weight": 1. 0," order": 1. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedCashFlow"," http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"]," lang": {" en- us": {" role": {" terseLabel":" Proceeds from issuance of Pre- Merger Oruka Series A Preferred Stock, net of issuance costs paid"," verboseLabel":" Gross proceeds (in Dollars)"," label":" Proceeds from Issuance of Convertible Preferred Stock"," documentation":" The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity' s common stock." } } }," auth_ref": [" r2"] }," us-gaap_ProceedsFromIssuanceOfDebt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ProceedsFromIssuanceOfDebt"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Proceeds from Issuance of convertible note (in Dollars)"," label":" Proceeds from Issuance of Debt"," documentation":" The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long- term debt." } } }," auth_ref": [" r973"] }," us- gaap_ProceedsFromIssuanceOfPrivatePlacement": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ProceedsFromIssuanceOfPrivatePlacement"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedCashFlow": {" parentTag":" us-gaap_NetCashProvidedByUsedInFinancingActivities"," weight": 1. 0," order": 4. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedCashFlow"]," lang": {" en- us": {" role": {" terseLabel":" Proceeds from the PIPE Financing, net"," label":" Proceeds from Issuance of Private Placement"," documentation":" The cash inflow associated with the amount received from entity' s raising of capital via private rather than public placement." } } }," auth_ref": [" r2"] }," us- gaap_ProceedsFromNotesPayable": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ProceedsFromNotesPayable"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInFinancingActivities"," weight": 1. 0," order": 2. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedCashFlow"]," lang": {" en- us": {" role": {" terseLabel":" Proceeds from issuance of notes payable to related party, net of issuance costs paid"," label":" Proceeds from Notes Payable"," documentation":" The cash inflow from a borrowing supported by a written promise to pay an obligation." } } }," auth_ref": [" r20"] }," us- gaap_ProceedsFromPaymentsForOtherFinancingActivities": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ProceedsFromPaymentsForOtherFinancingActivities"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInFinancingActivities"," weight": 1. 0," order": 3. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedCashFlow"]," lang": {" en- us": {" role": {" terseLabel":" Proceeds from the Pre- Closing Financing, net"," label":" Proceeds from (Payments for) Other Financing Activities"," documentation":" Amount of cash inflow (outflow) from financing activities classified as other." } } }," auth_ref": [" r953"," r972"] }," us-gaap_PropertyPlantAndEquipmentByTypeAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PropertyPlantAndEquipmentByTypeAxis"," presentation": [" http: / / www. orukatx. com / role / ScheduleofPropertyandEquipmentTable"]," lang": {" en- us": {" role": {" label":" Long- Lived Tangible Asset [Axis]"," documentation":" Information by type of long- lived, physical assets used to produce goods and services and not intended for resale." } } }," auth_ref": [" r6"," r509"] }," us-gaap_PropertyPlantAndEquipmentLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PropertyPlantAndEquipmentLineItems"," presentation": [" http: / / www. orukatx. com / role / ScheduleofPropertyandEquipmentTable"]," lang": {" en- us": {" role": {" label":" Schedule of Property and Equipment [Line Items]"," documentation":" Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }," auth_ref": [" r509"] }," us- gaap_PropertyPlantAndEquipmentNet": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PropertyPlantAndEquipmentNet"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_Assets"," weight": 1. 0," order": 3. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"]," lang": {" en- us": {" role": {" terseLabel":" Property and equipment, net"," label":" Property, Plant and Equipment, Net"," documentation":" Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }," auth_ref": [" r6"," r509"," r592"," r606"," r793"] }," us- gaap_PropertyPlantAndEquipmentPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PropertyPlantAndEquipmentPolicyTextBlock"," presentation": [" http: / / www. orukatx. com / role / AccountingPoliciesByPolicy"]," lang": {" en- us": {" role": {" terseLabel":" Property and Equipment"," label":" Property, Plant and Equipment, Policy [Policy Text Block]"," documentation":" Disclosure of accounting policy for long- lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }," auth_ref": [" r6"," r119"," r122"," r605"] }," us- gaap_PropertyPlantAndEquipmentTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PropertyPlantAndEquipmentTextBlock"," presentation": [" http: / / www. orukatx. com / role / SummaryofSignificantAccountingPoliciesTables"]," lang": {" en- us": {" role": {" terseLabel":" Schedule of Property and Equipment"," label":" Property, Plant and Equipment [Table Text Block]"," documentation":" Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }," auth_ref": [" r6"] }," us- gaap_PropertyPlantAndEquipmentUsefulLife": {" xbrltype":" durationItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" PropertyPlantAndEquipmentUsefulLife"," presentation": [" http: / / www. orukatx. com / role / ScheduleofPropertyandEquipmentTable"]," lang": {" en- us": {" role": {" terseLabel":" Estimated useful life"," label":" Property, Plant and Equipment, Useful Life"," documentation":" Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in' PnYnMnDTnHnMnS' format, for example,' P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }," auth_ref": [ ] }," ecd_PvpTable": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" PvpTable"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Pay vs Performance Disclosure [Table]"," terseLabel":" Pay vs Performance Disclosure" } } }," auth_ref": [" r882"] }," ecd_PvpTableTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" PvpTableTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Pay vs Performance [Table Text Block]"," terseLabel":" Pay vs Performance Disclosure, Table" } } }," auth_ref": [" r882"] }," srt_RangeAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / srt / 2024"," localname":" RangeAxis"," presentation": [" http: / / www. orukatx. com / role / ScheduleofPropertyandEquipmentTable"]," lang": {" en- us": {" role": {" label":" Statistical Measurement [Axis]" } } }," auth_ref": [" r287"," r288"," r289"," r290"," r350"," r358"," r390"," r391"," r392"," r405"," r471"," r529"," r538"," r555"," r615"," r617"," r625"," r652"," r653"," r713"," r715"," r717"," r718"," r720"," r740"," r741"," r763"," r770"," r775"," r783"," r784"," r788"," r789"," r803"," r808"," r1006"," r1010"," r1054"," r1068"," r1069"," r1070"," r1071"," r1072"] }," orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock"," presentation": [" http: / / www. orukatx. com / role / AccountingPoliciesByPolicy"]," lang": {" en- us": {" role": {" terseLabel":" Recently Adopted Accounting Pronouncements"," documentation":" Represents of recently adopted accounting pronouncements."," label":" Recently Adopted Accounting Pronouncements Policy Policy Text Block" } } }," auth_ref": [ ] }," orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity": {" xbrltype":" monetaryItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ReclassificationOfTheParukaWarrantFromLiabilityToEquity"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedCashFlow"]," lang": {" en- us": {" role": {" terseLabel":" Reclassification of the Paruka warrant from liability to equity"," documentation":" Represent the amount of reclassification of the paruka warrant from liability to equity."," label":" Reclassification Of The Paruka Warrant From Liability To Equity" } } }," auth_ref": [ ] }," us- gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"," presentation": [" http: / / www. orukatx. com / role / ScheduleofSegmentLossfromOperationsTable"]," lang": {" en- us": {" role": {" label":" Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]"," documentation":" Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }," auth_ref": [" r34"," r35"] }," us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"," presentation": [" http: / / www. orukatx. com / role / SegmentDisclosuresTables"]," lang": {" en- us": {" role": {" terseLabel":" Schedule of Segment Loss from Operations"," label":" Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]"," documentation":" Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }," auth_ref": [" r34"," r35"] }," us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"," lang": {" en- us": {" role": {" label":" Schedule of Unrecognized Tax Benefits [Abstract]"," documentation":" A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }," auth_ref": [ ] }," ecd_RecoveryOfErrCompDisclosureLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" RecoveryOfErrCompDisclosureLineItems"," lang": {" en- us": {" role": {" label":" Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"," terseLabel":" Recovery of Erroneously Awarded Compensation Disclosure" } } }," auth_ref": [" r839"," r850"," r868"," r903"] }," dei_RegistrationStatementAmendmentNumber": {" xbrltype":" sequenceNumberItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" RegistrationStatementAmendmentNumber"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Registration Statement Amendment Number"," documentation":" Amendment number to registration statement under the Investment Company Act of 1940." } } }," auth_ref": [" r818"] }," orka_RegulatoryMilestonesMemberMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" RegulatoryMilestonesMemberMember"," presentation": [" http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"]," lang": {" en- us": {" role": {" terseLabel":" Regulatory Milestones Member [Member]"," label":" Regulatory Milestones Member Member" } } }," auth_ref": [ ] }," us- gaap_RelatedPartyDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" RelatedPartyDomain"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"," http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"]," lang": {" en- us": {" role": {" label":" Related and Nonrelated Parties [Domain]"," documentation":" Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }," auth_ref": [" r229"," r357"," r515"," r516"," r596"," r604"," r655"," r656"," r657"," r658"," r659"," r679"," r681"," r712"] }," us- gaap_RelatedPartyMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" RelatedPartyMember"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"," http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"," http: / / www. orukatx. com / role / ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"]," lang": {" en- us": {" role": {" terseLabel":" Related Party"," verboseLabel":" Related Party [Member]"," label":" Related Party [Member]"," documentation":" Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }," auth_ref": [" r160"," r161"," r515"," r516"," r517"," r518"," r596"," r604"," r655"," r656"," r657"," r658"," r659"," r679"," r681"," r712"] }," us- gaap_RelatedPartyTransactionAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" RelatedPartyTransactionAxis"," presentation": [" http: / / www. orukatx. com / role / NotePayablewithRelatedPartyDetails"," http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"]," lang": {" en- us": {" role": {" label":" Related Party Transaction [Axis]"," documentation":" Information by type of related party transaction." } } }," auth_ref": [" r515"," r516"," r1064"] }," us- gaap_RelatedPartyTransactionDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" RelatedPartyTransactionDomain"," presentation": [" http: / / www. orukatx. com / role / NotePayablewithRelatedPartyDetails"," http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"]," lang": {" en- us": {" role": {" label":" Related Party Transaction [Domain]"," documentation":" Transaction between related party." } } }," auth_ref": [ ] }," us- gaap_RelatedPartyTransactionLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" RelatedPartyTransactionLineItems"," presentation": [" http: / / www. orukatx. com / role / RelatedPartyTransactionsDetails"," http: / / www. orukatx. com / role / ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"]," lang": {" en- us": {" role": {" label":" Schedule of Related Party Accounts Payable and Other Current Liabilities [Line Items]"," terseLabel":" Related Party Transactions [Line Items]"," documentation":" Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }," auth_ref": [" r229"," r686"," r687"," r690"] }," us- gaap_RelatedPartyTransactionsAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" RelatedPartyTransactionsAbstract"," lang": {" en- us": {" role": {" label":" Related Party Transactions [Abstract]" } } }," auth_ref": [ ] }," us- gaap_RelatedPartyTransactionsByRelatedPartyAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" RelatedPartyTransactionsByRelatedPartyAxis"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"," http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"," http: / / www. orukatx. com / role / ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"]," lang": {" en- us": {" role": {" label":" Related and Nonrelated Parties [Axis]"," documentation":" Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }," auth_ref": [" r229"," r357"," r515"," r516"," r596"," r604"," r655"," r656"," r657"," r658"," r659"," r679"," r681"," r712"," r1064"] }," orka_RelatedPartyTransactionsDetailsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" RelatedPartyTransactionsDetailsTable"," presentation": [" http: / / www. orukatx. com / role / RelatedPartyTransactionsDetails"]," lang": {" en- us": {" role": {" label":" Related Party Transactions (Details) [Table]" } } }," auth_ref": [ ] }," us- gaap_RelatedPartyTransactionsDisclosureTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" RelatedPartyTransactionsDisclosureTextBlock"," presentation": [" http: / / www. orukatx. com / role / RelatedPartyTransactions"]," lang": {" en- us": {" role": {" terseLabel":" Related Party Transactions"," label":" Related Party Transactions Disclosure [Text Block]"," documentation":" The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }," auth_ref": [" r512"," r513"," r514"," r516"," r519"," r634"," r635"," r636"," r688"," r689"," r690"," r709"," r711"] }," orka_RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable"," presentation": [" http: / / www. orukatx. com / role / ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"]," lang": {" en- us": {" role": {" label":" Related Party Transactions- Schedule of Related Party Accounts Payable and Other Current Liabilities (Details) [Table]" } } }," auth_ref": [ ] }," srt_RepurchaseAgreementCounterpartyNameDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / srt / 2024"," localname":" RepurchaseAgreementCounterpartyNameDomain"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"," http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"]," lang": {" en- us": {" role": {" label":" Counterparty Name [Domain]" } } }," auth_ref": [" r162"," r163"," r306"," r334"," r518"," r539"," r593"," r746"," r747"] }," orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock"," presentation": [" http: / / www. orukatx. com / role / AccountingPoliciesByPolicy"]," lang": {" en- us": {" role": {" terseLabel":" Research and Development Contract Costs Accruals"," documentation":" Research and development contract costs accruals."," label":" Research And Development Contract Costs Accruals Policy Text Block" } } }," auth_ref": [ ] }," us- gaap_ResearchAndDevelopmentExpense": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ResearchAndDevelopmentExpense"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome": {" parentTag":" us- gaap_OperatingExpenses"," weight": 1. 0," order": 1. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome"," http: / / www. orukatx. com / role / ScheduleofSegmentLossfromOperationsTable"]," lang": {" en- us": {" role": {" terseLabel":" Research and development"," verboseLabel":" Research and development personnel- related expense (excluding stock- based compensation)"," label":" Research and Development Expense"," documentation":" Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write- down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }," auth_ref": [" r408"," r742"," r757"," r1073"] }," us- gaap_ResearchAndDevelopmentExpenseMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ResearchAndDevelopmentExpenseMember"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome_Parentheticals"," http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"," http: / / www. orukatx. com / role / ScheduleofCompanysStockBasedCompensationExpenseTable"," http: / / www. orukatx. com / role / ScheduleofSegmentLossfromOperationsTable"]," lang": {" en- us": {" role": {" terseLabel":" Research and development"," verboseLabel":" Research and development [Member]"," netLabel":" Research and development stock- based compensation [Member]"," label":" Research and Development Expense [Member]"," documentation":" Primary financial statement caption in which the reported facts about research and development expense have been included." } } }," auth_ref": [ ] }," us- gaap_ResearchAndDevelopmentExpensePolicy": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ResearchAndDevelopmentExpensePolicy"," presentation": [" http: / / www. orukatx. com / role / AccountingPoliciesByPolicy"]," lang": {" en- us": {" role": {" terseLabel":" Research and Development Costs"," label":" Research and Development Expense, Policy [Policy Text Block]"," documentation":" Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }," auth_ref": [" r407"] }," orka_ResearchInitialFee": {" xbrltype":" monetaryItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ResearchInitialFee"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"]," lang": {" en- us": {" role": {" terseLabel":" Research initial fees"," documentation":" The amount of research initial fees."," label":" Research Initial Fee" } } }," auth_ref": [ ] }," ecd_RestatementDateAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" RestatementDateAxis"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure"]," lang": {" en- us": {" role": {" label":" Restatement Determination Date [Axis]"," terseLabel":" Restatement Determination Date:" } } }," auth_ref": [" r840"," r851"," r869"," r904"] }," ecd_RestatementDeterminationDate": {" xbrltype":" dateItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" RestatementDeterminationDate"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure"]," lang": {" en- us": {" role": {" label":" Restatement Determination Date"," terseLabel":" Restatement Determination Date" } } }," auth_ref": [" r841"," r852"," r870"," r905"] }," ecd_RestatementDoesNotRequireRecoveryTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" RestatementDoesNotRequireRecoveryTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure"]," lang": {" en- us": {" role": {" label":" Restatement Does Not Require Recovery [Text Block]"," terseLabel":" Restatement does not require Recovery" } } }," auth_ref": [" r848"," r859"," r877"," r912"] }," us- gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"," presentation": [" http: / / www. orukatx. com / role / ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"]," lang": {" en- us": {" role": {" label":" Cash and Cash Equivalents [Domain]"," documentation":" Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short- term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }," auth_ref": [" r129"] }," orka_RestrictedStockAwardsMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" RestrictedStockAwardsMember"," presentation": [" http: / / www. orukatx. com / role / ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"]," lang": {" en- us": {" role": {" terseLabel":" Restricted Stock Awards \ t [Member]"," label":" Restricted Stock Awards Member" } } }," auth_ref": [ ] }," us- gaap_RestrictedStockMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" RestrictedStockMember"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"," http: / / www. orukatx. com / role / ScheduleofRSAActivityTable"," http: / / www. orukatx. com / role / StockBasedCompensationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Restricted Stock Award [Member]"," verboseLabel":" Restricted Stock [Member]"," netLabel":" RSA [Member]"," label":" Restricted Stock [Member]"," documentation":" Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }," auth_ref": [" r29"] }," us- gaap_RetainedEarningsAccumulatedDeficit": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" RetainedEarningsAccumulatedDeficit"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_StockholdersEquity"," weight": 1. 0," order": 5. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"]," lang": {" en- us": {" role": {" terseLabel":" Accumulated deficit"," label":" Retained Earnings (Accumulated Deficit)"," documentation":" Amount of accumulated undistributed earnings (deficit)." } } }," auth_ref": [" r67"," r91"," r602"," r622"," r624"," r632"," r663"," r793"] }," us-gaap_RetainedEarningsMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" RetainedEarningsMember"," presentation": [" http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" terseLabel":" Accumulated Deficit"," label":" Retained Earnings [Member]"," documentation":" Accumulated undistributed earnings (deficit)." } } }," auth_ref": [" r125"," r165"," r166"," r167"," r169"," r174"," r176"," r178"," r262"," r263"," r276"," r435"," r436"," r443"," r444"," r445"," r447"," r448"," r449"," r455"," r457"," r458"," r460"," r463"," r499"," r500"," r619"," r621"," r637"," r1109"] }," us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedCashFlow"]," lang": {" en- us": {" role": {" terseLabel":" Operating lease liability arising from obtaining operating right- of- use asset"," label":" Right- of- Use Asset Obtained in Exchange for Operating Lease Liability"," documentation":" Amount of increase in right- of- use asset obtained in exchange for operating lease liability." } } }," auth_ref": [" r506"," r792"] }," orka_RoyaltyPayableOnProductSales": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" RoyaltyPayableOnProductSales"," presentation": [" http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"]," lang": {" en- us": {" role": {" terseLabel":" Royalty payable on product sales, description"," documentation":" Royalty payable on product sales, description."," label":" Royalty Payable On Product Sales" } } }," auth_ref": [ ] }," ecd_Rule10b51ArrAdoptedFlag": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" Rule10b51ArrAdoptedFlag"," presentation": [" http: / / xbrl. sec. gov / ecd / role / InsiderTradingArrangements"]," lang": {" en- us": {" role": {" label":" Rule 10b5- 1 Arrangement Adopted [Flag]"," terseLabel":" Rule 10b5- 1 Arrangement Adopted" } } }," auth_ref": [" r921"] }," ecd_Rule10b51ArrTrmntdFlag": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" Rule10b51ArrTrmntdFlag"," presentation": [" http: / / xbrl. sec. gov / ecd / role / InsiderTradingArrangements"]," lang": {" en- us": {" role": {" label":" Rule 10b5- 1 Arrangement Terminated [Flag]"," terseLabel":" Rule 10b5- 1 Arrangement Terminated" } } }," auth_ref": [" r921"] }," us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SaleOfStockConsiderationReceivedPerTransaction"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"]," lang": {" en-us": {" role": {" terseLabel":" Aggregate gross proceeds (in Dollars)"," label":" Sale of Stock, Consideration Received Per Transaction"," documentation":" Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor." } } }," auth_ref": [ ] }," us- gaap_SaleOfStockNameOfTransactionDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SaleOfStockNameOfTransactionDomain"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"," http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"]," lang": {" en- us": {" role": {" label":" Sale of Stock [Domain]"," documentation":" Sale of the entity' s stock, including, but not limited to, initial public offering (IPO) and private placement." } } }," auth_ref": [ ] }," us- gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SaleOfStockNumberOfSharesIssuedInTransaction"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"," http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Exchange shares"," verboseLabel":" Number of shares issued"," label":" Sale of Stock, Number of Shares Issued in Transaction"," documentation":" The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }," auth_ref": [ ] }," us- gaap_SaleOfStockPricePerShare": {" xbrltype":" perShareItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SaleOfStockPricePerShare"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"," http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Purchase price per share (in Dollars per share)"," label":" Sale of Stock, Price Per Share"," documentation":" Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }," auth_ref": [ ] }," srt_ScenarioUnspecifiedDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / srt / 2024"," localname":" ScenarioUnspecifiedDomain"," presentation": [" http: / / www. orukatx. com / role / ScheduleofStockOptionActivityTable"]," auth_ref": [" r179"," r359"," r951"," r983"] }," us- gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ScheduleOfAccruedLiabilitiesTableTextBlock"," presentation": [" http: / / www. orukatx. com / role / AccruedExpensesandOtherCurrentLiabilitiesTables"]," lang": {" en- us": {" role": {" terseLabel":" Schedule of Accrued Expenses and Other Current Liabilities"," label":" Schedule of Accrued Liabilities [Table Text Block]"," documentation":" Tabular disclosure of the components of accrued liabilities." } } }," auth_ref": [ ] }," orka_ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract"," lang": {" en- us": {" role": {" label":" Schedule Of Anti Dilutive Effect Excluded From Potential Computation Of Diluted Net Loss Per Share Abstract" } } }," auth_ref": [ ] }," us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"," presentation": [" http: / / www. orukatx. com / role / ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"]," lang": {" en- us": {" role": {" label":" Antidilutive Security, Excluded EPS Calculation [Table]"," documentation":" Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }," auth_ref": [" r29"] }," us- gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"," presentation": [" http: / / www. orukatx. com / role / NetLossPerShareTables"]," lang": {" en- us": {" role": {" terseLabel":" Schedule of Anti- Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share"," label":" Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]"," documentation":" Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }," auth_ref": [" r29"] }," orka_ScheduleOfAvailableForSaleSecuritiesInAnUnrealizedLossPositionAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ScheduleOfAvailableForSaleSecuritiesInAnUnrealizedLossPositionAbstract"," lang": {" en- us": {" role": {" label":" Schedule Of Available For Sale Securities In An Unrealized Loss Position Abstract" } } }," auth_ref": [ ] }," orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract"," lang": {" en- us": {" role": {" label":" Schedule Of Award Types Of Company SStock Based Compensation Expense Abstract" } } }," auth_ref": [ ] }," orka_ScheduleOfBasicAndDilutedNetLossPerShareAttributableToStockholdersAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ScheduleOfBasicAndDilutedNetLossPerShareAttributableToStockholdersAbstract"," lang": {" en- us": {" role": {" label":" Schedule Of Basic And Diluted Net Loss Per Share Attributable To Stockholders Abstract" } } }," auth_ref": [ ] }," orka_ScheduleOfCashEquivalentsAndMarketableSecuritiesAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ScheduleOfCashEquivalentsAndMarketableSecuritiesAbstract"," lang": {" en- us": {" role": {" label":" Schedule Of Cash Equivalents And Marketable Securities Abstract" } } }," auth_ref": [ ] }," us- gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"," presentation": [" http: / / www. orukatx. com / role / CommitmentandContingenciesTables"]," lang": {" en- us": {" role": {" terseLabel":" Schedule of Company \ u2019s Supplemental Cash Flow Information Related to Leases"," label":" Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]"," documentation":" Tabular disclosure of supplemental cash flow information for the periods presented." } } }," auth_ref": [ ] }," orka_ScheduleOfCommonStockReservedForFutureIssuanceAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ScheduleOfCommonStockReservedForFutureIssuanceAbstract"," lang": {" en- us": {" role": {" label":" Schedule Of Common Stock Reserved For Future Issuance Abstract" } } }," auth_ref": [ ] }," orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityTables"]," lang": {" en- us": {" role": {" terseLabel":" Schedule of Common Stock Reserved for Future Issuance"," documentation":" Tabular disclosure of common stock reserved for future issuance."," label":" Schedule Of Common Stock Reserved For Future Issuance Table Text Block" } } }," auth_ref": [ ] }," orka_ScheduleOfCompanySStockBasedCompensationExpenseAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ScheduleOfCompanySStockBasedCompensationExpenseAbstract"," lang": {" en- us": {" role": {" label":" Schedule Of Company SStock Based Compensation Expense Abstract" } } }," auth_ref": [ ] }," us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"," presentation": [" http: / / www. orukatx. com / role / StockBasedCompensationTables"]," lang": {" en- us": {" role": {" terseLabel":" Schedule of Award Types of Company \ u2019s Stock-Based Compensation Expense"," label":" Share- Based Payment Arrangement, Cost by Plan [Table Text Block]"," documentation":" Tabular disclosure of cost recognized for award under share- based payment arrangement by plan. Includes, but is not limited to, related tax benefit." } } }," auth_ref": [" r43"] }," orka_ScheduleOfConvertiblePreferredStockAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ScheduleOfConvertiblePreferredStockAbstract"," lang": {" en- us": {" role": {" label":" Schedule Of Convertible Preferred Stock Abstract" } } }," auth_ref": [ ] }," orka_ScheduleOfConvertiblePreferredStockTableTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ScheduleOfConvertiblePreferredStockTableTextBlock"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityTables"]," lang": {" en- us": {" role": {" terseLabel":" Schedule of Convertible Preferred Stock"," documentation":" Tabular disclosure of convertible preferred stock."," label":" Schedule Of Convertible Preferred Stock Table Text Block" } } }," auth_ref": [ ] }," us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"," presentation": [" http: / / www. orukatx. com / role / IncomeTaxesTables"]," lang": {" en- us": {" role": {" terseLabel":" Schedule of Components of the Deferred Tax Assets and Liabilities"," label":" Schedule of Deferred Tax Assets and Liabilities [Table Text Block]"," documentation":" Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity' s statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }," auth_ref": [" r1045"] }," us- gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"," presentation": [" http: / / www. orukatx. com / role / NetLossPerShareTables"]," lang": {" en- us": {" role": {" terseLabel":" Schedule of Basic and Diluted Net Loss Per Share Attributable to Stockholders"," label":" Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]"," documentation":" Tabular disclosure of an entity' s basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per- share computations for income from continuing operations." } } }," auth_ref": [" r986"] }," us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"," presentation": [" http: / / www. orukatx. com / role / IncomeTaxesTables"]," lang": {" en- us": {" role": {" terseLabel":" Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes"," label":" Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]"," documentation":" Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }," auth_ref": [" r417"," r779"," r1042"] }," us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"," presentation": [" http: / / www. orukatx. com / role / ScheduleofCompanysStockBasedCompensationExpenseTable"]," lang": {" en- us": {" role": {" label":" Share- Based Payment Arrangement, Expensed and Capitalized, Amount [Table]"," documentation":" Disclosure of information about amount recognized for award under share- based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }," auth_ref": [" r43"] }," us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"," presentation": [" http: / / www. orukatx. com / role / StockBasedCompensationTables"]," lang": {" en- us": {" role": {" terseLabel":" Schedule of Company \ u2019s Stock- Based Compensation Expense"," label":" Share- Based Payment

Arrangement, Expensed and Capitalized, Amount [Table Text Block]"," documentation":" Tabular disclosure of allocation of amount expensed and capitalized for award under share- based
payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } },"
auth_ref": [" r43"] }," orka_ScheduleOfEmployeeWarrantActivityAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":"
ScheduleOfEmployeeWarrantActivityAbstract"," lang": {" en- us": {" role": {" label":" Schedule Of Employee Warrant Activity Abstract" } } }," auth_ref": [ ] },"
orka_ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":"
ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract"," lang": {" en- us": {" role": {" label":" Schedule Of Fair Value Hierarchy For Financial Assets Measured Abstract" } }
}," auth_ref": [ ] }," us- gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024","
localname":" ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"," presentation": [" http: / / www. orukatx. com / role / IncomeTaxesTables"]," lang": {" en- us": {"
role": {" terseLabel":" Schedule of Loss Before Income Tax Expense"," label":" Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]"," documentation":"
Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }," auth_ref": [" r978"] }," us-
gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"," presentation": [" http: / / www. orukatx. com / role / StockBasedCompensationTables"]," lang": {" en- us": {" role": {"
terseLabel":" Schedule of RSA Activity"," label":" Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]"," documentation":" Tabular disclosure of the changes in
outstanding nonvested restricted stock units." } } }," auth_ref": [" r94"] }," orka_ScheduleOfPropertyAndEquipmentAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / www.
orukatx. com / 20241231"," localname":" ScheduleOfPropertyAndEquipmentAbstract"," lang": {" en- us": {" role": {" label":" Schedule Of Property And Equipment Abstract" } } },"
auth_ref": [ ] }," us- gaap_ScheduleOfPropertyPlantAndEquipmentTable": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
ScheduleOfPropertyPlantAndEquipmentTable"," presentation": [" http: / / www. orukatx. com / role / ScheduleofPropertyandEquipmentTable"]," lang": {" en- us": {" role": {" label":"
Property, Plant and Equipment [Table]"," documentation":" Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is
not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }," auth_ref": [" r6"," r509"
] }," us- gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024","
localname":" ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"," presentation": [" http: / / www. orukatx. com / role /
ReverseRecapitalizationandPreClosingFinancingTables"]," lang": {" en- us": {" role": {" terseLabel":" Schedule of the Assets and Liabilities"," label":" Schedule of Recognized Identified
Assets Acquired and Liabilities Assumed [Table Text Block]"," documentation":" Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired
and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests
in the acquiree." } } }," auth_ref": [" r98"] }," orka_ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / www.
orukatx. com / 20241231"," localname":" ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract"," lang": {" en- us": {" role": {" label":" Schedule Of Related Party
Accounts Payable And Other Current Liabilities Abstract" } } }," auth_ref": [ ] }," orka_ScheduleOfRsaActivityAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx.
com / 20241231"," localname":" ScheduleOfRsaActivityAbstract"," lang": {" en- us": {" role": {" label":" Schedule Of Rsa Activity Abstract" } } }," auth_ref": [ ] },"
orka_ScheduleOfSegmentLossFromOperationsAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":"
ScheduleOfSegmentLossFromOperationsAbstract"," lang": {" en- us": {" role": {" label":" Schedule Of Segment Loss From Operations Abstract" } } }," auth_ref": [ ] }," us-
gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"," presentation": [" http: / / www. orukatx. com / role / StockBasedCompensationTables"]," lang": {" en- us": {"
role": {" terseLabel":" Schedule of Stock Option Activity"," label":" Share- Based Payment Arrangement, Option, Activity [Table Text Block]"," documentation":" Tabular disclosure for
stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted- average grant date fair value." } } }," auth_ref":
[" r11"," r12"," r93"] }," us- gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb.
org / us- gaap / 2024"," localname":" ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"," presentation": [" http: / / www. orukatx. com / role /
StockBasedCompensationTables"]," lang": {" en- us": {" role": {" terseLabel":" Schedule of Weighted- Average Assumptions Used in Calculating the Fair Value of the Awards"," label":"
Schedule of Share- Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]"," documentation":" Tabular disclosure of the significant assumptions used during the
year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity' s shares, (c) expected
dividends, (d) risk- free rate (s), and (e) discount for post- vesting restrictions." } } }," auth_ref": [" r96"] }," orka_ScheduleOfStockOptionActivityAbstract": {" xbrltype":" stringItemType","
nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ScheduleOfStockOptionActivityAbstract"," lang": {" en- us": {" role": {" label":" Schedule Of Stock Option Activity Abstract"
} } }," auth_ref": [ ] }," us- gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024","
localname":" ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"," presentation": [" http: / / www. orukatx. com / role / IncomeTaxesTables"]," lang": {" en- us": {" role": {"
terseLabel":" Schedule of Unrecognized Tax Benefits"," label":" Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]"," documentation":" Tabular disclosure of the
change in unrecognized tax benefits." } } }," auth_ref": [" r423"," r778"] }," orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheAwardsAbstract": {"
xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":"
ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheAwardsAbstract"," lang": {" en- us": {" role": {" label":" Schedule Of Weighted Average Assumptions Used In
Calculating The Fair Value Of The Awards Abstract" } } }," auth_ref": [ ] }," dei_Security12bTitle": {" xbrltype":" securityTitleItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024","
localname":" Security12bTitle"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Title of 12 (b) Security"," documentation":"
Title of a 12 (b) registered security." } } }," auth_ref": [" r819"] }," dei_Security12gTitle": {" xbrltype":" securityTitleItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":"
Security12gTitle"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Title of 12 (g) Security"," documentation":" Title of a 12 (g)
registered security." } } }," auth_ref": [" r823"] }," dei_SecurityExchangeName": {" xbrltype":" edgarExchangeCodeItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":"
SecurityExchangeName"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Security Exchange Name"," documentation":" Name
of the Exchange on which a security is registered." } } }," auth_ref": [" r822"] }," dei_SecurityReportingObligation": {" xbrltype":" securityReportingObligationItemType"," nsuri":" http: / /
xbrl. sec. gov / dei / 2024"," localname":" SecurityReportingObligation"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":"
Security Reporting Obligation"," documentation":" 15 (d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }," auth_ref": [" r828"] },"
srt_SegmentGeographicalDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / srt / 2024"," localname":" SegmentGeographicalDomain"," presentation": [" http: / / www.
orukatx. com / role / CommitmentandContingenciesDetails"]," lang": {" en- us": {" role": {" label":" Geographical [Domain]" } } }," auth_ref": [" r226"," r227"," r557"," r558"," r559","
r560"," r561"," r562"," r563"," r564"," r565"," r566"," r567"," r568"," r569"," r570"," r571"," r572"," r573"," r574"," r575"," r576"," r577"," r578"," r579"," r580"," r581"," r582","
r583"," r584"," r585"," r586"," r649"," r650"," r651"," r714"," r716"," r719"," r721"," r728"," r731"," r732"," r733"," r734"," r735"," r736"," r737"," r738"," r739"," r743"," r771","
r795"," r796"," r797"," r798"," r799"," r800"," r801"," r802"," r804"," r808"," r1012"," r1077"," r1079"," r1080"," r1081"," r1082"," r1083"," r1084"," r1085"," r1086"," r1087","
r1088"," r1089"," r1090"," r1091"," r1092"," r1093"," r1094"," r1095"," r1096"," r1097"," r1098"," r1099"," r1100"," r1101"," r1102"," r1103"," r1105"," r1106"] }," us-
gaap_SegmentReportingAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SegmentReportingAbstract"," lang": {" en- us": {" role": {"
label":" Segment Disclosures [Abstract]" } } }," auth_ref": [ ] }," us- gaap_SegmentReportingDisclosureTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap /
2024"," localname":" SegmentReportingDisclosureTextBlock"," presentation": [" http: / / www. orukatx. com / role / SegmentDisclosures"]," lang": {" en- us": {" role": {" terseLabel":"
Segment Disclosures"," label":" Segment Reporting Disclosure [Text Block]"," documentation":" The entire disclosure for reporting segments including data and tables. Reportable segments
include those that meet any of the following quantitative thresholds a) it' s reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the
combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined
reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the
combined assets of all operating segments." } } }," auth_ref": [" r110"," r194"," r199"," r200"," r201"," r202"," r203"," r207"," r208"," r209"," r218"," r219"," r220"," r221"," r222","
r224"," r225"," r228"," r752"," r755"," r756"," r757"," r759"," r761"," r762"] }," us- gaap_SegmentReportingPolicyPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / /
fasb. org / us- gaap / 2024"," localname":" SegmentReportingPolicyPolicyTextBlock"," presentation": [" http: / / www. orukatx. com / role / AccountingPoliciesByPolicy"]," lang": {" en- us": {"
role": {" terseLabel":" Segment Reporting"," label":" Segment Reporting, Policy [Policy Text Block]"," documentation":" Disclosure of accounting policy for segment reporting." } } },"
auth_ref": [" r210"," r211"," r212"," r213"," r214"," r215"," r216"," r223"," r226"," r753"," r754"," r760"] }," us-
gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024","
localname":" SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"," presentation": [" http: / / www. orukatx. com / role /
ScheduleofSegmentLossfromOperationsTable"]," lang": {" en- us": {" role": {" label":" Schedule of Segment Loss from Operations [Line Items]"," documentation":" Line items represent
financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }," auth_ref": [ ]
}," us- gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
SellingGeneralAndAdministrativeExpensesPolicyTextBlock"," presentation": [" http: / / www. orukatx. com / role / AccountingPoliciesByPolicy"]," lang": {" en- us": {" role": {" terseLabel":"
General and Administrative Expenses"," label":" Selling, General and Administrative Expenses, Policy [Policy Text Block]"," documentation":" Disclosure of accounting policy for inclusion of
significant items in the selling, general and administrative (or similar) expense report caption." } } }," auth_ref": [" r1040"] }," orka_SeriesAConvertiblePreferredStockMember": {" xbrltype":"
domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" SeriesAConvertiblePreferredStockMember"," presentation": [" http: / / www. orukatx. com / role /
ConsolidatedBalanceSheet"," http: / / www. orukatx. com / role / ConsolidatedBalanceSheet_Parentheticals"]," lang": {" en- us": {" role": {" terseLabel":" Series A Convertible Preferred
Stock"," label":" Series AConvertible Preferred Stock Member" } } }," auth_ref": [ ] }," orka_SeriesANonVotingConvertiblePreferredStockMember": {" xbrltype":" domainItemType","
nsuri":" http: / / www. orukatx. com / 20241231"," localname":" SeriesANonVotingConvertiblePreferredStockMember"," presentation": [" http: / / www. orukatx. com / role /
ConsolidatedBalanceSheet"," http: / / www. orukatx. com / role / ConsolidatedBalanceSheet_Parentheticals"," http: / / www. orukatx. com / role /
NatureoftheBusinessandBasisofPresentationDetails"," http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" terseLabel":" Series A Non- Voting
Convertible Preferred Stock"," verboseLabel":" Series A Non- Voting"," netLabel":" Series A Non- Voting Convertible Preferred Stock [Member]"," label":" Series ANon Voting Convertible
Preferred Stock Member" } } }," auth_ref": [ ] }," orka_SeriesANonVotingConvertiblePreferredStockholdersMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com
/ 20241231"," localname":" SeriesANonVotingConvertiblePreferredStockholdersMember"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome"]," lang":
{" en- us": {" role": {" terseLabel":" Series A Non- Voting Convertible Preferred Stockholders"," label":" Series ANon Voting Convertible Preferred Stockholders Member" } } }," auth_ref": [
] }," us- gaap_SeriesAPreferredStockMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SeriesAPreferredStockMember","
presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"," http: / / www. orukatx. com / role /
NatureoftheBusinessandBasisofPresentationDetails"," http: / / www. orukatx. com / role / NetLossPerShareDetails"," http: / / www. orukatx. com / role /
ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"," http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {"
terseLabel":" Series A"," verboseLabel":" Series A Preferred Stock [Member]"," label":" Series A Preferred Stock [Member]"," documentation":" Series A preferred stock." } } },"
auth_ref": [" r964"," r965"," r1011"] }," orka_SeriesBConvertiblePreferredStockMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231","
localname":" SeriesBConvertiblePreferredStockMember"," presentation": [" http: / / www. orukatx. com / role / ScheduleofCommonStockReservedforFutureIssuanceTable"," http: / / www.
orukatx. com / role / ScheduleofConvertiblePreferredStockTable"]," lang": {" en- us": {" role": {" terseLabel":" Series B Convertible Preferred Stock [Member]"," verboseLabel":" Shares
issuable on conversion of Company Series B Preferred Stock [Member]"," label":" Series BConvertible Preferred Stock Member" } } }," auth_ref": [ ] },"

orka_SeriesBNonVotingConvertiblePreferredStockAmountMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":"
SeriesBNonVotingConvertiblePreferredStockAmountMember"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"," http: / / www. orukatx. com / role /
ConsolidatedBalanceSheet_Parentheticals"," http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" terseLabel":" Series B Non- Voting Convertible
Preferred Stock"," verboseLabel":" Series B Non- Voting"," label":" Series BNon Voting Convertible Preferred Stock Amount Member" } } }," auth_ref": [ ] },"
orka_SeriesBNonVotingConvertiblePreferredStockholdersMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":"
SeriesBNonVotingConvertiblePreferredStockholdersMember"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome"]," lang": {" en- us": {" role": {"
terseLabel":" Series B Non- Voting Convertible Preferred Stockholders"," label":" Series BNon Voting Convertible Preferred Stockholders Member" } } }," auth_ref": [ ] }," us-
gaap_SeriesBPreferredStockMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SeriesBPreferredStockMember"," presentation": ["
http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"," http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"," http: / /
www. orukatx. com / role / NetLossPerShareDetails"," http: / / www. orukatx. com / role / ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"]," lang": {" en- us": {"
role": {" terseLabel":" Series B Preferred Stock [Member]"," label":" Series B Preferred Stock [Member]"," documentation":" Series B preferred stock." } } }," auth_ref": [" r964","
r965"," r1011"] }," us- gaap_ShareBasedCompensation": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ShareBasedCompensation","
crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedCashFlow": {" parentTag":" us- gaap_NetCashProvidedByUsedInOperatingActivities"," weight": 1. 0,"
order": 2. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedCashFlow"]," lang": {" en- us": {" role": {" terseLabel":" Stock- based compensation expense"," label":"
Share- Based Payment Arrangement, Noncash Expense"," documentation":" Amount of noncash expense for share- based payment arrangement." } } }," auth_ref": [" r4"] }," us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {" xbrltype":" durationItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024","
localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"," presentation": [" http: / / www. orukatx. com / role /
ConvertiblePreferredStockandStockholdersEquityDetails"]," lang": {" en- us": {" role": {" terseLabel":" Vesting period"," label":" Share- Based Compensation Arrangement by Share- Based
Payment Award, Award Vesting Period"," documentation":" Period over which grantee' s right to exercise award under share- based payment arrangement is no longer contingent on
satisfaction of service or performance condition, in' PnYnMnDTnHnMnS' format, for example,' P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is
not limited to, combination of market, performance or service condition." } } }," auth_ref": [" r776"] },"
orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised": {" xbrltype":" sharesItemType"," nsuri":" http: / / www. orukatx.
com / 20241231"," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised"," presentation": [" http: / / www.
orukatx. com / role / ScheduleofEmployeeWarrantActivityTable"]," lang": {" en- us": {" role": {" terseLabel":" Number of Employee Warrants Outstanding, Exercised"," documentation":"
Number of Warrants, Exercised (in Shares)."," label":" Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised" } } },"
auth_ref": [ ] }," us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {" xbrltype":" sharesItemType","
nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod","
presentation": [" http: / / www. orukatx. com / role / ScheduleofEmployeeWarrantActivityTable"]," lang": {" en- us": {" role": {" terseLabel":" Number of Employee Warrants Outstanding,
Forfeited"," label":" Share- Based Compensation Arrangement by Share- Based Payment Award, Equity Instruments Other than Options, Forfeited in Period"," documentation":" The number
of equity- based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }," auth_ref": [" r382"] },"
orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice": {" xbrltype":"
perShareItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":"
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice"," presentation": [" http: / / www.
orukatx. com / role / ScheduleofEmployeeWarrantActivityTable"]," lang": {" en- us": {" role": {" terseLabel":" Weighted Average Exercise Price Per Share, Forfeited"," documentation":"
Weighted average exercise price as of the grant date of equity- based award plans other than stock (unit) option plans."," label":" Share Based Compensation Arrangement By Share Based
Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Exercise Price" } } }," auth_ref": [ ] }," us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org
/ us- gaap / 2024"," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"," presentation": [" http: / / www.
orukatx. com / role / ScheduleofEmployeeWarrantActivityTable"," http: / / www. orukatx. com / role / ScheduleofRSAActivityTable"]," lang": {" en- us": {" role": {" terseLabel":" Unvested
balance, Number of Granted"," verboseLabel":" Number of Granted"," label":" Share- Based Compensation Arrangement by Share- Based Payment Award, Equity Instruments Other than
Options, Grants in Period"," documentation":" The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit
appreciation rights plan, performance target plan)." } } }," auth_ref": [" r380"] }," us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {" xbrltype":"
perShareItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"," presentation": [" http: / /
www. orukatx. com / role / StockBasedCompensationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Price per share"," label":" Share- Based Compensation Arrangement by Share-
Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value"," documentation":" The weighted average fair value at grant date
for nonvested equity- based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan,
performance target plan)." } } }," auth_ref": [" r380"] }," us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb.
org / us- gaap / 2024"," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"," presentation": [" http: / /
www. orukatx. com / role / ScheduleofEmployeeWarrantActivityTable"," http: / / www. orukatx. com / role / ScheduleofRSAActivityTable"]," lang": {" en- us": {" role": {" periodStartLabel":"
Beginning Balance (in Shares)"," periodEndLabel":" Ending Balance (in Shares)"," label":" Share- Based Compensation Arrangement by Share- Based Payment Award, Equity Instruments
Other than Options, Nonvested, Number"," documentation":" The number of non- vested equity- based payment instruments, excluding stock (or unit) options, that validly exist and are
outstanding as of the balance sheet date." } } }," auth_ref": [" r377"," r378"] }," us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {" xbrltype":"
perShareItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"," presentation": [" http: / / www.
orukatx. com / role / ScheduleofRSAActivityTable"]," lang": {" en- us": {" role": {" periodStartLabel":" Weighted Average Grant Date Fair Value, Unvested balance, Beginning","
periodEndLabel":" Weighted Average Grant Date Fair Value, Unvested balance, Ending"," terseLabel":" Weighted Average Grant Date Fair Value, Granted"," label":" Share- Based
Compensation Arrangement by Share- Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value"," documentation":" Per share or
unit weighted- average fair value of nonvested award under share- based payment arrangement. Excludes share and unit options." } } }," auth_ref": [" r377"," r378"] },"
orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm": {" xbrltype":"
durationItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":"
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm"," presentation": [" http:
/ / www. orukatx. com / role / ScheduleofEmployeeWarrantActivityTable"]," lang": {" en- us": {" role": {" terseLabel":" Ending Balance (in Shares)"," documentation":" Weighted average
remaining contractual term for option awards Vested and expected to vest, in' PnYnMnDTnHnMnS' format, for example,' P1Y5M13D' represents the reported fact of one year, five months, and
thirteen days."," label":" Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining
Contractual Term" } } }," auth_ref": [ ] }," orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest": {"
xbrltype":" monetaryItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":"
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest"," crdr":" debit"," presentation": [" http: / / www.
orukatx. com / role / ScheduleofEmployeeWarrantActivityTable"]," lang": {" en- us": {" role": {" terseLabel":" Aggregate Intrinsic Value, Vested and expected to vest"," documentation":"
Fair value of share- based awards for aggregate Intrinsic Value, Vested and expected to vest."," label":" Share Based Compensation Arrangement By Share Based Payment Award Equity
Instruments Other Than Options Vested And Expected To Vest" } } }," auth_ref": [ ] },"
orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm": {"
xbrltype":" durationItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":"
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm","
presentation": [" http: / / www. orukatx. com / role / ScheduleofEmployeeWarrantActivityTable"]," lang": {" en- us": {" role": {" terseLabel":" Weighted Average Remaining Contractual
Term, Vested and expected to vest"," documentation":" Weighted average remaining contractual term for option awards Vested and expected to vest, in' PnYnMnDTnHnMnS' format, for
example,' P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."," label":" Share Based Compensation Arrangement By Share Based Payment Award Equity
Instruments Other Than Options Vested And Expected To Vest Weighted Average Remaining Contractual Term" } } }," auth_ref": [ ] },"
orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber": {" xbrltype":"
sharesItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":"
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber"," presentation": [" http: / / www.
orukatx. com / role / ScheduleofEmployeeWarrantActivityTable"]," lang": {" en- us": {" role": {" terseLabel":" Number of Employee Warrants Outstanding, Vested and expected to vest","
documentation":" The number of equity- based payment instruments, excluding stock (or unit) options, that Vested and expected to vest."," label":" Share Based Compensation Arrangement By
Share Based Payment Award Equity Instruments Other Than Options Vested Expected To Vest Outstanding Number" } } }," auth_ref": [ ] }," us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {" xbrltype":" percentItemType"," nsuri":" http: / / fasb. org / us-
gaap / 2024"," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"," presentation": [" http: / / www. orukatx. com
/ role / ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable"]," lang": {" en- us": {" role": {" terseLabel":" Expected dividend yield"," label":" Share-
Based Compensation Arrangement by Share- Based Payment Award, Fair Value Assumptions, Expected Dividend Rate"," documentation":" The estimated dividend rate (a percentage of the
share price) to be paid (expected dividends) to holders of the underlying shares over the option' s term." } } }," auth_ref": [" r391"] }," us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {" xbrltype":" percentItemType"," nsuri":" http: / / fasb. org / us-
gaap / 2024"," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"," presentation": [" http: / / www. orukatx. com
/ role / ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable"]," lang": {" en- us": {" role": {" terseLabel":" Expected volatility"," label":" Share- Based
Compensation Arrangement by Share- Based Payment Award, Fair Value Assumptions, Expected Volatility Rate"," documentation":" The estimated measure of the percentage by which a share
price is expected to fluctuate during a period. Volatility also may be defined as a probability- weighted measure of the dispersion of returns about the mean. The volatility of a share price is the
standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of
the stock prices plus dividends, if any, over the period." } } }," auth_ref": [" r390"] }," us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {" xbrltype":" percentItemType"," nsuri":" http: / / fasb. org / us-
gaap / 2024"," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"," presentation": [" http: / / www. orukatx. com /

role / ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable"]," lang": {" en- us": {" role": {" terseLabel":" Risk- free interest rate"," label":" Share-
Based Compensation Arrangement by Share- Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate"," documentation":" The risk- free interest rate assumption that is used in
valuing an option on its own shares." } } }," auth_ref": [" r392"] }," us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {" xbrltype":"
stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"," presentation": [" http: / /
www. orukatx. com / role / ScheduleofEmployeeWarrantActivityTable"," http: / / www. orukatx. com / role / ScheduleofRSAActivityTable"," http: / / www. orukatx. com / role /
ScheduleofStockOptionActivityTable"]," lang": {" en- us": {" role": {" label":" Share- Based Compensation Arrangement by Share- Based Payment Award [Line Items]"," terseLabel":"
Schedule of RSA Activity [Line Items]"," verboseLabel":" Schedule of Employee Warrant Activity [Line Items]"," documentation":" Line items represent financial concepts included in a
table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }," auth_ref": [" r361"," r363"," r365"," r366","
r367"," r369"," r370"," r371"," r372"," r373"," r374"," r375"," r376"," r377"," r378"," r379"," r380"," r381"," r382"," r383"," r384"," r385"," r386"," r389"," r390"," r391"," r392","
r393"] }," us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {" xbrltype":" percentItemType"," nsuri":" http: / / fasb. org /
us- gaap / 2024"," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"," presentation": [" http: / / www. orukatx. com /
role / StockBasedCompensationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Maximum contribution of employee' s eligible compensation"," label":" Share- Based Compensation
Arrangement by Share- Based Payment Award, Maximum Employee Subscription Rate"," documentation":" The highest percentage of annual salary that an employee is permitted to utilize
with respect to the plan." } } }," auth_ref": [" r42"] }," us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {" xbrltype":"
sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised","
presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"]," lang": {" en- us": {" role": {" terseLabel":" Warrants exercised"," label":"
Share- Based Compensation Arrangement by Share- Based Payment Award, Non- Option Equity Instruments, Exercised"," documentation":" Number of non- option equity instruments
exercised by participants." } } }," auth_ref": [" r10"] }," us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {" xbrltype":"
sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant","
presentation": [" http: / / www. orukatx. com / role / StockBasedCompensationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Shares available for grant"," label":" Share- Based
Compensation Arrangement by Share- Based Payment Award, Number of Shares Available for Grant"," documentation":" The difference between the maximum number of shares (or other type
of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon
exercise of options or other equity- based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and
forfeitures, if applicable." } } }," auth_ref": [" r42"] }," us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {" xbrltype":"
sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber","
presentation": [" http: / / www. orukatx. com / role / ScheduleofStockOptionActivityTable"]," lang": {" en- us": {" role": {" terseLabel":" Number of Stock Options Outstanding, Exercisable","
label":" Share- Based Compensation Arrangement by Share- Based Payment Award, Options, Exercisable, Number"," documentation":" The number of shares into which fully or partially
vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }," auth_ref": [" r371"] }," us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {" xbrltype":" perShareItemType"," nsuri":" http: / / fasb. org
/ us- gaap / 2024"," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"," presentation": [" http: / / www.
orukatx. com / role / ScheduleofStockOptionActivityTable"]," lang": {" en- us": {" role": {" terseLabel":" Weighted Average Exercise Price Per Share, Exercisable,"," label":" Share- Based
Compensation Arrangement by Share- Based Payment Award, Options, Exercisable, Weighted Average Exercise Price"," documentation":" The weighted- average price as of the balance sheet
date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }," auth_ref": [" r371"]
}," us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org /
us- gaap / 2024"," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"," presentation": [" http: / / www. orukatx.
com / role / ScheduleofStockOptionActivityTable"]," lang": {" en- us": {" role": {" terseLabel":" Stock Options, Forfeited"," label":" Share- Based Compensation Arrangement by Share-
Based Payment Award, Options, Forfeitures and Expirations in Period"," documentation":" For presentations that combine terminations, the number of shares under options that were
cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }," auth_ref": ["
r1020"] }," us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us-
gaap / 2024"," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"," presentation": [" http: / / www. orukatx. com / role /
ScheduleofStockOptionActivityTable"]," lang": {" en- us": {" role": {" terseLabel":" Stock Options, Granted"," label":" Share- Based Compensation Arrangement by Share- Based Payment
Award, Options, Grants in Period, Gross"," documentation":" Gross number of share options (or share units) granted during the period." } } }," auth_ref": [" r373"] }," us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {" xbrltype":" perShareItemType"," nsuri":" http:
/ / fasb. org / us- gaap / 2024"," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue","
presentation": [" http: / / www. orukatx. com / role / StockBasedCompensationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Weighted average grant- date fair value"," label":"
Share- Based Compensation Arrangement by Share- Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value"," documentation":" The weighted average
grant- date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }," auth_ref": [" r383"] }," us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap /
2024"," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"," crdr":" debit"," presentation": [" http: / / www. orukatx. com
/ role / ScheduleofStockOptionActivityTable"]," lang": {" en- us": {" role": {" periodEndLabel":" Aggregate Intrinsic Value, Ending Balance"," label":" Share- Based Compensation
Arrangement by Share- Based Payment Award, Options, Outstanding, Intrinsic Value"," documentation":" Amount by which the current fair value of the underlying stock exceeds the exercise
price of options outstanding." } } }," auth_ref": [" r42"] }," us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {" xbrltype":"
sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber","
presentation": [" http: / / www. orukatx. com / role / ScheduleofStockOptionActivityTable"]," lang": {" en- us": {" role": {" periodEndLabel":" Number of Stock Options Outstanding, Ending
Balance"," label":" Share- Based Compensation Arrangement by Share- Based Payment Award, Options, Outstanding, Number"," documentation":" Number of options outstanding, including
both vested and non- vested options." } } }," auth_ref": [" r369"," r370"] }," us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {" xbrltype":" perShareItemType"," nsuri":" http: / / fasb. org
/ us- gaap / 2024"," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"," presentation": [" http: / / www.
orukatx. com / role / ScheduleofStockOptionActivityTable"]," lang": {" en- us": {" role": {" periodEndLabel":" Weighted Average Exercise Price Per Share, Ending Balance"," label":" Share-
Based Compensation Arrangement by Share- Based Payment Award, Options, Outstanding, Weighted Average Exercise Price"," documentation":" Weighted average price at which grantees
can acquire the shares reserved for issuance under the stock option plan." } } }," auth_ref": [" r369"," r370"] }," us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {" xbrltype":" monetaryItemType","
nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"," crdr":" debit"," presentation": [" http: / / www.
orukatx. com / role / ScheduleofStockOptionActivityTable"]," lang": {" en- us": {" role": {" terseLabel":" Aggregate Intrinsic Value, Vested and expected to vest"," label":" Share- Based
Compensation Arrangement by Share- Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value"," documentation":" Amount by which current fair
value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service
period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }," auth_ref": [" r386"] }," us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb.
org / us- gaap / 2024"," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"," presentation": [" http: / /
www. orukatx. com / role / ScheduleofStockOptionActivityTable"]," lang": {" en- us": {" role": {" terseLabel":" Number of Stock Options Outstanding, Vested and expected to vest"," label":"
Share- Based Compensation Arrangement by Share- Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number"," documentation":" Number of fully vested and
expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered
but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }," auth_ref": [" r385"] }," us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {" xbrltype":"
perShareItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":"
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"," presentation": [" http: / / www. orukatx.
com / role / ScheduleofStockOptionActivityTable"]," lang": {" en- us": {" role": {" terseLabel":" Weighted Average Exercise Price Per Share, Vested and expected to vest, September 30,
2024"," label":" Share- Based Compensation Arrangement by Share- Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price","
documentation":" Weighted- average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not
limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized
when they occur." } } }," auth_ref": [" r385"] }," orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice": {"
xbrltype":" perShareItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":"
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice"," presentation": [" http: / / www. orukatx. com / role /
ScheduleofEmployeeWarrantActivityTable"]," lang": {" en- us": {" role": {" terseLabel":" Weighted Average, Granted"," documentation":" The weighted average fair value at grant date for
nonvested equity- based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance
target plan)."," label":" Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Granted Weighted Average Exercise Price" } } }," auth_ref": [ ] },"
orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice": {" xbrltype":" perShareItemType"," nsuri":" http:
/ / www. orukatx. com / 20241231"," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice","
presentation": [" http: / / www. orukatx. com / role / ScheduleofEmployeeWarrantActivityTable"]," lang": {" en- us": {" role": {" periodStartLabel":" Beginning Balance (in Shares)","
periodEndLabel":" Ending Balance (in Shares)"," documentation":" Per share or unit weighted- average fair value of nonvested award under share- based payment arrangement. Excludes
share and unit options."," label":" Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Outstanding Weighted Average Exercise Price" } } },"
auth_ref": [ ] }," orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding": {" xbrltype":" sharesItemType"," nsuri":"
http: / / www. orukatx. com / 20241231"," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding","
presentation": [" http: / / www. orukatx. com / role / ScheduleofEmployeeWarrantActivityTable"]," lang": {" en- us": {" role": {" terseLabel":" Number of Employee Warrants Outstanding,
Vested and exercisable"," documentation":" Number of employee warrants outstanding, vested and exercisable shares."," label":" Share Based Compensation Arrangement By Share Based
Payment Award Other Than Options Vested And Exercisable Outstanding" } } }," auth_ref": [ ] },"
orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice": {" xbrltype":" perShareItemType","
nsuri":" http: / / www. orukatx. com / 20241231"," localname":"
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice"," presentation": [" http: / / www. orukatx. com /
role / ScheduleofEmployeeWarrantActivityTable"]," lang": {" en- us": {" role": {" terseLabel":" Weighted Average Exercise Price Per Share, Vested and exercisable"," documentation":"

Weighted- Average Exercise Price Per Share, Vested and Exercisable."," label":" Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested And Exercisable Weighted Average Exercise Price" } } }," auth_ref": [ ] }," orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice": {" xbrltype":" perShareItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice"," presentation": [" http: / / www. orukatx. com / role / ScheduleofEmployeeWarrantActivityTable"]," lang": {" en- us": {" role": {" terseLabel":" Weighted Average Exercise Price Per Share, Vested and expected to vest"," documentation":" Weighted- average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."," label":" Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested And Expected To Vest Weighted Average Exercise Price" } } }," auth_ref": [ ] }," us- gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"," presentation": [" http: / / www. orukatx. com / role / StockBasedCompensationDetails"]," lang": {" en- us": {" role": {" terseLabel":" RSAs issued"," label":" Share- Based Compensation Arrangement by Share- Based Payment Award, Shares Issued in Period"," documentation":" Number of shares issued under share- based payment arrangement." } } }," auth_ref": [" r42"] }," orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares": {" xbrltype":" percentItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares"," presentation": [" http: / / www. orukatx. com / role / StockBasedCompensationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Annual increase in shares available for issuance as a percentage of outstanding diluted stock"," documentation":" Share based compensation arrangement diluted stock."," label":" Share Based Compensation Arrangement Percentage Of Annual Increase In Shares Reserved For Issuance As Percentage Of Outstanding Diluted Shares" } } }," auth_ref": [ ] }," us- gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"," http: / / www. orukatx. com / role / ScheduleofCommonStockReservedforFutureIssuanceTable"," http: / / www. orukatx. com / role / ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable"," http: / / www. orukatx. com / role / StockBasedCompensationDetails"," http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure"]," lang": {" en- us": {" role": {" label":" All Award Types"," terseLabel":" All Award Types"," documentation":" Award under share- based payment arrangement." } } }," auth_ref": [" r365"," r366"," r367"," r369"," r370"," r371"," r372"," r373"," r374"," r375"," r376"," r377"," r378"," r379"," r380"," r381"," r382"," r383"," r384"," r385"," r386"," r389"," r390"," r391"," r392"," r393"] }," us- gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {" xbrltype":" perShareItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"," presentation": [" http: / / www. orukatx. com / role / ScheduleofStockOptionActivityTable"]," lang": {" en- us": {" role": {" terseLabel":" Weighted Average Exercise Price Per Share, Exercised"," label":" Share- Based Compensation Arrangements by Share- Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price"," documentation":" Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }," auth_ref": [" r374"] }," us- gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {" xbrltype":" perShareItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"," presentation": [" http: / / www. orukatx. com / role / ScheduleofStockOptionActivityTable"]," lang": {" en- us": {" role": {" terseLabel":" Weighted Average Exercise Price Per Share, Forfeited"," label":" Share- Based Compensation Arrangements by Share- Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price"," documentation":" Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }," auth_ref": [" r375"] }," us- gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {" xbrltype":" perShareItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"," presentation": [" http: / / www. orukatx. com / role / ScheduleofStockOptionActivityTable"]," lang": {" en- us": {" role": {" terseLabel":" Weighted Average Exercise Price Per Share, Granted"," label":" Share- Based Compensation Arrangements by Share- Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price"," documentation":" Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }," auth_ref": [" r373"] }," us- gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ShareBasedCompensationOptionAndIncentivePlansPolicy"," presentation": [" http: / / www. orukatx. com / role / AccountingPoliciesByPolicy"]," lang": {" en- us": {" role": {" terseLabel":" Stock- Based Compensation"," label":" Share- Based Payment Arrangement [Policy Text Block]"," documentation":" Disclosure of accounting policy for award under share- based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }," auth_ref": [" r360"," r368"," r387"," r388"," r389"," r390"," r393"," r399"," r400"," r401"," r402"] }," orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock"," presentation": [" http: / / www. orukatx. com / role / StockBasedCompensationTables"]," lang": {" en- us": {" role": {" terseLabel":" Schedule of Employee Warrant Activity"," documentation":" Tabular disclosure of Share- Based Payment Arrangement, Warrant Activity."," label":" Share Based Payment Arrangement Warrant Activitiy Table Text Block" } } }," auth_ref": [ ] }," orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock": {" xbrltype":" monetaryItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" terseLabel":" Conversion of Series A non- voting convertible preferred stock to common stock"," documentation":" Represent the amount of conversion of non- voting convertible preferred stock to common stock."," label":" Share Issued During Period Value Conversion Of Nonvoting Convertible Preferred Stock To Common Stock" } } }," auth_ref": [ ] }," us- gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / ScheduleofEmployeeWarrantActivityTable"]," lang": {" en- us": {" role": {" periodStartLabel":" Aggregate Intrinsic Value, Beginning Balance"," periodEndLabel":" Aggregate Intrinsic Value, Ending Balance"," label":" Share- Based Compensation Arrangement by Share- Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding"," documentation":" Intrinsic value of outstanding award under share- based payment arrangement. Excludes share and unit options." } } }," auth_ref": [ ] }," orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable": {" xbrltype":" monetaryItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / ScheduleofEmployeeWarrantActivityTable"]," lang": {" en- us": {" role": {" terseLabel":" Aggregate Intrinsic Value, Vested and exercisable"," documentation":" Intrinsic value of Vested and exercisable award under share- based payment arrangement. Excludes share and unit options."," label":" Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested And Exercisable" } } }," auth_ref": [ ] }," us- gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {" xbrltype":" durationItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"]," lang": {" en- us": {" role": {" terseLabel":" Term of warrant"," label":" Share- Based Compensation Arrangement by Share- Based Payment Award, Expiration Period"," documentation":" Period from grant date that an equity- based award expires, in' PnYnMnDTnHnMnS' format, for example,' P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }," auth_ref": [" r777"] }," us- gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {" xbrltype":" durationItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"," presentation": [" http: / / www. orukatx. com / role / ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable"]," lang": {" en- us": {" role": {" terseLabel":" Expected term (in years)"," label":" Share- Based Compensation Arrangement by Share- Based Payment Award, Fair Value Assumptions, Expected Term"," documentation":" Expected term of award under share- based payment arrangement, in' PnYnMnDTnHnMnS' format, for example,' P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }," auth_ref": [" r389"] }," us- gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"," crdr":" debit"," presentation": [" http: / / www. orukatx. com / role / ScheduleofStockOptionActivityTable"]," lang": {" en- us": {" role": {" terseLabel":" Aggregate Intrinsic Value, Exercisable"," label":" Share- Based Compensation Arrangement by Share- Based Payment Award, Options, Exercisable, Intrinsic Value"," documentation":" Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }," auth_ref": [" r42"] }," us- gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {" xbrltype":" durationItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"," presentation": [" http: / / www. orukatx. com / role / ScheduleofStockOptionActivityTable"]," lang": {" en- us": {" role": {" terseLabel":" Weighted Average Remaining Contractual Term (in Years), Exercisable"," label":" Share- Based Compensation Arrangement by Share- Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term"," documentation":" Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in' PnYnMnDTnHnMnS' format, for example,' P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }," auth_ref": [" r42"] }," us- gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {" xbrltype":" durationItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"," presentation": [" http: / / www. orukatx. com / role / ScheduleofStockOptionActivityTable"]," lang": {" en- us": {" role": {" terseLabel":" Weighted Average Remaining Contractual Term (in Years), Ending Balance"," label":" Share- Based Compensation Arrangement by Share- Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term"," documentation":" Weighted average remaining contractual term for option awards outstanding, in' PnYnMnDTnHnMnS' format, for example,' P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }," auth_ref": [" r95"] }," us- gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {" xbrltype":" durationItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"," presentation": [" http: / / www. orukatx. com / role / ScheduleofStockOptionActivityTable"]," lang": {" en- us": {" role": {" terseLabel":" Weighted Average Remaining Contractual Term (in Years), Vested and expected to vest, September 30, 2024"," label":" Share- Based Compensation Arrangement by Share- Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term"," documentation":" Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in' PnYnMnDTnHnMnS' format, for example,' P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }," auth_ref": [" r385"] }," us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {" xbrltype":" percentItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"," presentation": [" http: / / www. orukatx. com / role / StockBasedCompensationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Purchase price of common stock expressed as a percentage of its fair value"," label":" Share- Based Compensation Arrangement by Share- Based Payment Award, Purchase Price of Common Stock, Percent"," documentation":" Purchase price of common stock expressed as a percentage of its fair value." } } }," auth_ref": [ ] }," us- gaap_SharesIssuedPricePerShare": {" xbrltype":" perShareItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SharesIssuedPricePerShare"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"," http: / / www. orukatx. com / role / StockBasedCompensationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Purchase price per share (in Dollars per share)"," verboseLabel":" RSAs price per share"," label":" Shares Issued, Price Per Share"," documentation":" Per share or per unit amount of equity securities issued." } } }," auth_ref": [ ] }," us- gaap_SharesOutstanding": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SharesOutstanding"," presentation": [" http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" periodStartLabel":" Balances (in Shares)"," periodEndLabel":" Balances (in Shares)"," label":" Shares, Outstanding"," documentation":" Number of shares issued which are neither cancelled nor held in the treasury." } } }," auth_ref": [ ] }," orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares": {" xbrltype":" sharesItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares"," presentation": [" http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" terseLabel":" Conversion of Series A non- voting convertible preferred stock to common stock (in Shares)"," documentation":" Number of shares conversion of non- voting convertible preferred stock to common stock."," label":" Shock Issued During Period Shares Conversion Of Nonvoting Convertible Preferred Stock To Common Stockin Shares" } } }," auth_ref": [ ] }," us- gaap_SignificantAccountingPoliciesTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SignificantAccountingPoliciesTextBlock"," presentation": [" http: / / www. orukatx. com / role / SummaryofSignificantAccountingPolicies"]," lang": {" en- us": {" role": {" terseLabel":" Summary of Significant Accounting Policies"," label":" Significant Accounting Policies [Text Block]"," documentation":" The entire disclosure for all significant accounting policies of the reporting entity." } } }," auth_ref": [" r83"," r154"] }," dei_SolicitingMaterial": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" SolicitingMaterial"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Soliciting Material"," documentation":" Boolean flag that is true when the Form 8- K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a- 12 under the Exchange Act." } } }," auth_ref": [" r826"] }," us- gaap_StateAndLocalJurisdictionMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" StateAndLocalJurisdictionMember"," presentation": [" http: / / www. orukatx. com / role / IncomeTaxesDetails"]," lang": {" en- us": {" role": {" terseLabel":" State and Local Jurisdiction [Member]"," label":" State and Local Jurisdiction [Member]"," documentation":" Designated state or local jurisdiction entitled to levy and collect income tax." } } }," auth_ref": [" r415"] }," us- gaap_StatementClassOfStockAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" StatementClassOfStockAxis"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"," http: / / www. orukatx. com / role / ConsolidatedBalanceSheet_Parentheticals"," http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome"," http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"," http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"," http: / / www. orukatx. com / role / NetLossPerShareDetails"," http: / / www. orukatx. com / role / NotePayablewithRelatedPartyDetails"," http: / / www. orukatx. com / role / RelatedPartyTransactionsDetails"," http: / / www. orukatx. com / role / ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"," http: / / www. orukatx. com / role / ScheduleofCommonStockReservedforFutureIssuanceTable"," http: / / www. orukatx. com / role / ScheduleofConvertiblePreferredStockTable"," http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" label":" Class of Stock [Axis]"," documentation":" Information by the different classes of stock of the entity." } } }," auth_ref": [" r124"," r133"," r134"," r135"," r157"," r183"," r184"," r186"," r188"," r197"," r198"," r261"," r293"," r295"," r296"," r297"," r300"," r301"," r331"," r332"," r336"," r339"," r347"," r489"," r628"," r629"," r630"," r631"," r637"," r638"," r639"," r640"," r641"," r642"," r643"," r644"," r645"," r646"," r647"," r648"," r662"," r683"," r705"," r722"," r723"," r724"," r725"," r726"," r950"," r975"," r985"] }," us- gaap_StatementEquityComponentsAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" StatementEquityComponentsAxis"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"," http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"," http: / / www. orukatx. com / role / ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"," http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" label":" Equity Components [Axis]"," documentation":" Information by component of equity." } } }," auth_ref": [" r9"," r65"," r68"," r69"," r125"," r145"," r146"," r147"," r165"," r166"," r167"," r169"," r174"," r176"," r178"," r196"," r262"," r263"," r276"," r349"," r435"," r436"," r443"," r444"," r445"," r447"," r448"," r449"," r455"," r456"," r457"," r458"," r459"," r460"," r463"," r490"," r491"," r492"," r493"," r494"," r495"," r499"," r500"," r511"," r609"," r619"," r620"," r621"," r637"," r705"] }," srt_StatementGeographicalAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / srt / 2024"," localname":" StatementGeographicalAxis"," presentation": [" http: / / www. orukatx. com / role / CommitmentandContingenciesDetails"]," lang": {" en- us": {" role": {" label":" Geographical [Axis]" } } }," auth_ref": [" r226"," r227"," r557"," r558"," r559"," r560"," r561"," r562"," r563"," r564"," r565"," r566"," r567"," r568"," r569"," r570"," r571"," r572"," r573"," r574"," r575"," r576"," r577"," r578"," r579"," r580"," r581"," r582"," r583"," r584"," r585"," r586"," r649"," r650"," r651"," r714"," r716"," r719"," r721"," r728"," r731"," r732"," r733"," r734"," r735"," r736"," r737"," r738"," r739"," r743"," r771"," r795"," r796"," r797"," r798"," r799"," r800"," r801"," r802"," r804"," r808"," r1012"," r1077"," r1079"," r1080"," r1081"," r1082"," r1083"," r1084"," r1085"," r1086"," r1087"," r1088"," r1089"," r1090"," r1091"," r1092"," r1093"," r1094"," r1095"," r1096"," r1097"," r1098"," r1099"," r1100"," r1101"," r1102"," r1103"," r1105"," r1106"] }," us- gaap_StatementLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" StatementLineItems"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"," http: / / www. orukatx. com / role / ConsolidatedBalanceSheet_Parentheticals"," http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome"," http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome_Parentheticals"," http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" label":" Statement [Line Items]"," documentation":" Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }," auth_ref": [" r165"," r166"," r167"," r196"," r500"," r556"," r626"," r648"," r654"," r655"," r656"," r657"," r658"," r659"," r662"," r665"," r666"," r667"," r668"," r669"," r670"," r671"," r672"," r673"," r675"," r676"," r677"," r678"," r679"," r681"," r684"," r685"," r691"," r692"," r693"," r694"," r695"," r696"," r697"," r698"," r699"," r700"," r701"," r702"," r705"," r809"] }," us- gaap_StatementOfCashFlowsAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" StatementOfCashFlowsAbstract"," lang": {" en- us": {" role": {" label":" Statement of Cash Flows [Abstract]" } } }," auth_ref": [ ] }," us- gaap_StatementOfFinancialPositionAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" StatementOfFinancialPositionAbstract"," lang": {" en- us": {" role": {" label":" Statement of Financial Position [Abstract]" } } }," auth_ref": [ ] }," us- gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" StatementOfIncomeAndComprehensiveIncomeAbstract"," lang": {" en- us": {" role": {" label":" Statement of Comprehensive Income [Abstract]" } } }," auth_ref": [ ] }," us- gaap_StatementOfStockholdersEquityAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" StatementOfStockholdersEquityAbstract"," lang": {" en- us": {" role": {" label":" Statement of Stockholders' Equity [Abstract]" } } }," auth_ref": [ ] }," srt_StatementScenarioAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / srt / 2024"," localname":" StatementScenarioAxis"," presentation": [" http: / / www. orukatx. com / role / ScheduleofStockOptionActivityTable"]," auth_ref": [" r179"," r359"," r951"," r952"," r983"] }," us- gaap_StatementTable": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" StatementTable"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"," http: / / www. orukatx. com / role / ConsolidatedBalanceSheet_Parentheticals"," http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome"," http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome_Parentheticals"," http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" label":" Statement [Table]"," documentation":" Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }," auth_ref": [" r165"," r166"," r167"," r196"," r229"," r500"," r556"," r626"," r648"," r654"," r655"," r656"," r657"," r658"," r659"," r662"," r665"," r666"," r667"," r668"," r669"," r670"," r671"," r672"," r673"," r675"," r676"," r677"," r678"," r679"," r681"," r684"," r685"," r691"," r692"," r693"," r694"," r695"," r696"," r697"," r698"," r699"," r700"," r701"," r702"," r705"," r809"] }," ecd_StkPrcOrTsrEstimationMethodTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" StkPrcOrTsrEstimationMethodTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / ErrCompDisclosure"]," lang": {" en- us": {" role": {" label":" Stock Price or TSR Estimation Method [Text Block]"," terseLabel":" Stock Price or TSR Estimation Method" } } }," auth_ref": [" r843"," r854"," r872"," r907"] }," us- gaap_StockAppreciationRightsSARSMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" StockAppreciationRightsSARSMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure"]," lang": {" en- us": {" role": {" label":" Stock Appreciation Rights (SARs) [Member]"," terseLabel":" Stock Appreciation Rights (SARs)"," documentation":" Right to receive cash or shares equal to appreciation of predetermined number of grantor' s shares during predetermined time period." } } }," auth_ref": [ ] }," orka_StockBasedCompensationDetailsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" StockBasedCompensationDetailsTable"," presentation": [" http: / / www. orukatx. com / role / StockBasedCompensationDetails"]," lang": {" en- us": {" role": {" label":" Stock- Based Compensation (Details) [Table]" } } }," auth_ref": [ ] }," orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems"," presentation": [" http: / / www. orukatx. com / role / ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable"]," lang": {" en- us": {" role": {" label":" Schedule of Award Types of Company \ u2019s Stock- Based Compensation Expense [Line Items]" } } }," auth_ref": [ ] }," orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable"," presentation": [" http: / / www. orukatx. com / role / ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable"]," lang": {" en- us": {" role": {" label":" Stock- Based Compensation- Schedule of Award Types of Company \ u2019s Stock- Based Compensation Expense (Details) [Table]" } } }," auth_ref": [ ] }," orka_StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable"," presentation": [" http: / / www. orukatx. com / role / ScheduleofEmployeeWarrantActivityTable"]," lang": {" en- us": {" role": {" label":" Stock- Based Compensation- Schedule of Employee Warrant Activity (Details) [Table]" } } }," auth_ref": [ ] }," orka_StockBasedCompensationScheduleofRSAActivityDetailsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" StockBasedCompensationScheduleofRSAActivityDetailsTable"," presentation": [" http: / / www. orukatx. com / role / ScheduleofRSAActivityTable"]," lang": {" en- us": {" role": {" label":" Stock- Based Compensation- Schedule of RSA Activity (Details) [Table]" } } }," auth_ref": [ ] }," orka_StockBasedCompensationScheduleofStockOptionActivityDetailsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" StockBasedCompensationScheduleofStockOptionActivityDetailsTable"," presentation": [" http: / / www. orukatx. com / role / ScheduleofStockOptionActivityTable"]," lang": {" en- us": {" role": {" label":" Stock- Based Compensation- Schedule of Stock Option Activity (Details) [Table]" } } }," auth_ref": [ ] }," orka_StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable"," presentation": [" http: / / www. orukatx. com / role / ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable"]," lang": {" en- us": {" role": {" label":" Stock- Based Compensation- Schedule of Weighted- Average Assumptions Used in Calculating the Fair Value of the Awards (Details) [Table]" } } }," auth_ref": [ ] }," us- gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" StockIssuedDuringPeriodSharesConversionOfUnits"," presentation": [" http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" terseLabel":" Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization (in Shares)"," label":" Stock Issued During Period, Shares, Conversion of Units"," documentation":" The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }," auth_ref": [" r9"," r40"," r64"," r65"," r91"] }," us- gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"," presentation": [" http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" terseLabel":" Issuance of common stock under employee stock purchase plan (in Shares)"," label":" Stock Issued During

Period, Shares, Employee Stock Purchase Plans"," documentation":" Number of shares issued during the period as a result of an employee stock purchase plan." } } }," auth_ref": [" r9"," r64"," r65"," r91"] }," us- gaap_StockIssuedDuringPeriodSharesNewIssues": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" StockIssuedDuringPeriodSharesNewIssues"," presentation": [" http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" terseLabel":" Issuance of common stock (in Shares)"," label":" Stock Issued During Period, Shares, New Issues"," documentation":" Number of new stock issued during the period." } } }," auth_ref": [" r9"," r64"," r65"," r91"," r628"," r705"," r723"] }," us- gaap_StockIssuedDuringPeriodSharesOther": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" StockIssuedDuringPeriodSharesOther"," presentation": [" http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Issuance of shares"," label":" Stock Issued During Period, Shares, Other"," documentation":" Number of shares of stock issued attributable to transactions classified as other." } } }," auth_ref": [ ] }," us- gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" StockIssuedDuringPeriodSharesStockOptionsExercised"," presentation": [" http: / / www. orukatx. com / role / ScheduleofStockOptionActivityTable"]," lang": {" en- us": {" role": {" terseLabel":" Stock Options, Exercised"," label":" Share- Based Compensation Arrangement by Share- Based Payment Award, Options, Exercises in Period"," documentation":" Number of share options (or share units) exercised during the current period." } } }," auth_ref": [" r9"," r64"," r65"," r91"," r374"] }," us- gaap_StockIssuedDuringPeriodValueConversionOfUnits": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" StockIssuedDuringPeriodValueConversionOfUnits"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" terseLabel":" Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization"," label":" Stock Issued During Period, Value, Conversion of Units"," documentation":" Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }," auth_ref": [" r9"," r65"," r68"," r69"," r91"] }," us- gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" terseLabel":" Issuance of common stock under employee stock purchase plan"," label":" Stock Issued During Period, Value, Employee Stock Purchase Plan"," documentation":" Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }," auth_ref": [" r9"," r64"," r65"," r91"] }," us- gaap_StockIssuedDuringPeriodValueNewIssues": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" StockIssuedDuringPeriodValueNewIssues"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" terseLabel":" Issuance of common stock"," label":" Stock Issued During Period, Value, New Issues"," documentation":" Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }," auth_ref": [" r9"," r64"," r65"," r91"," r637"," r705"," r723"," r815"] }," us- gaap_StockOptionMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" StockOptionMember"," presentation": [" http: / / www. orukatx. com / role / ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable"," http: / / www. orukatx. com / role / ScheduleofCommonStockReservedforFutureIssuanceTable"," http: / / www. orukatx. com / role / ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable"," http: / / www. orukatx. com / role / StockBasedCompensationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Outstanding and Issued Stock Options [Member]"," verboseLabel":" Stock Option [Member]"," netLabel":" Stock options [Member]"," label":" Stock Options [Member]"," documentation":" Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }," auth_ref": [" r808"] }," orka_StockOptionsMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" StockOptionsMember"," presentation": [" http: / / www. orukatx. com / role / ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"]," lang": {" en- us": {" role": {" terseLabel":" Stock Options [Member]"," label":" Stock Options Member" } } }," auth_ref": [ ] }," us- gaap_StockholdersEquity": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" StockholdersEquity"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_LiabilitiesAndStockholdersEquity"," weight": 1. 0," order": 4. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"," http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" totalLabel":" Total stockholders \ u2019 equity"," periodStartLabel":" Balances"," periodEndLabel":" Balances"," label":" Equity, Attributable to Parent"," documentation":" Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }," auth_ref": [" r65"," r68"," r69"," r85"," r664"," r680"," r706"," r707"," r793"," r816"," r977"," r1000"," r1058"," r1109"] }," us- gaap_StockholdersEquityAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" StockholdersEquityAbstract"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"]," lang": {" en- us": {" role": {" terseLabel":" Stockholders \ u2019 equity:"," label":" Equity, Attributable to Parent [Abstract]" } } }," auth_ref": [ ] }," us- gaap_StockholdersEquityNoteDisclosureTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" StockholdersEquityNoteDisclosureTextBlock"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquity"]," lang": {" en- us": {" role": {" terseLabel":" Convertible Preferred Stock and Stockholders \ u2019 Equity"," label":" Equity [Text Block]"," documentation":" The entire disclosure for equity." } } }," auth_ref": [" r89"," r156"," r330"," r332"," r335"," r336"," r337"," r338"," r339"," r340"," r341"," r343"," r344"," r346"," r349"," r462"," r708"," r710"," r727"] }," us- gaap_StockholdersEquityReverseStockSplit": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" StockholdersEquityReverseStockSplit"," presentation": [" http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"]," lang": {" en- us": {" role": {" terseLabel":" Reverse stock split"," label":" Stockholders' Equity, Reverse Stock Split"," documentation":" Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }," auth_ref": [" r92"] }," orka_SubscriptionReceivablePolicyTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" SubscriptionReceivablePolicyTextBlock"," presentation": [" http: / / www. orukatx. com / role / AccountingPoliciesByPolicy"]," lang": {" en- us": {" role": {" terseLabel":" Subscription Receivable"," documentation":" Subscription receivable."," label":" Subscription Receivable Policy Text Block" } } }," auth_ref": [ ] }," orka_SubscriptionReceivables": {" xbrltype":" monetaryItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" SubscriptionReceivables"," crdr":" debit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_AssetsCurrent"," weight": 1. 0," order": 3. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"]," lang": {" en- us": {" role": {" terseLabel":" Subscription receivable"," documentation":" Amount of subscription receivable from investors who have been allocated common stock."," label":" Subscription Receivables" } } }," auth_ref": [ ] }," us- gaap_SubsequentEventLineItems": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SubsequentEventLineItems"," presentation": [" http: / / www. orukatx. com / role / SubsequentEventsDetails"]," lang": {" en- us": {" role": {" label":" Subsequent Events [Line Items]"," documentation":" Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }," auth_ref": [" r496"," r521"] }," us- gaap_SubsequentEventMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SubsequentEventMember"," presentation": [" http: / / www. orukatx. com / role / SubsequentEventsDetails"]," lang": {" en- us": {" role": {" terseLabel":" Subsequent Event [Member]"," label":" Subsequent Event [Member]"," documentation":" Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }," auth_ref": [" r496"," r521"] }," us- gaap_SubsequentEventTypeAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SubsequentEventTypeAxis"," presentation": [" http: / / www. orukatx. com / role / SubsequentEventsDetails"]," lang": {" en- us": {" role": {" label":" Subsequent Event Type [Axis]"," documentation":" Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }," auth_ref": [" r496"," r521"] }," us- gaap_SubsequentEventsAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SubsequentEventsAbstract"," lang": {" en- us": {" role": {" label":" Subsequent Events [Abstract]" } } }," auth_ref": [ ] }," orka_SubsequentEventsDetailsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" SubsequentEventsDetailsTable"," presentation": [" http: / / www. orukatx. com / role / SubsequentEventsDetails"]," lang": {" en- us": {" role": {" label":" Subsequent Events (Details) [Table]" } } }," auth_ref": [ ] }," us- gaap_SubsequentEventsTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SubsequentEventsTextBlock"," presentation": [" http: / / www. orukatx. com / role / SubsequentEvents"]," lang": {" en- us": {" role": {" terseLabel":" Subsequent Events"," label":" Subsequent Events [Text Block]"," documentation":" The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }," auth_ref": [" r520"," r522"] }," us- gaap_SubsidiarySaleOfStockAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SubsidiarySaleOfStockAxis"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"," http: / / www. orukatx. com / role / NatureoftheBusinessandBasisofPresentationDetails"]," lang": {" en- us": {" role": {" label":" Sale of Stock [Axis]"," documentation":" Information by type of sale of the entity' s stock." } } }," auth_ref": [ ] }," us- gaap_SummaryOfValuationAllowanceTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SummaryOfValuationAllowanceTextBlock"," presentation": [" http: / / www. orukatx. com / role / IncomeTaxesTables"]," lang": {" en- us": {" role": {" terseLabel":" Schedule of Net Deferred Tax Assets"," label":" Summary of Valuation Allowance [Table Text Block]"," documentation":" Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance." } } }," auth_ref": [" r1046"] }," orka_SummaryofSignificantAccountingPoliciesDetailsTable": {" xbrltype":" stringItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" SummaryofSignificantAccountingPoliciesDetailsTable"," presentation": [" http: / / www. orukatx. com / role / SummaryofSignificantAccountingPoliciesDetails"]," lang": {" en- us": {" role": {" label":" Summary of Significant Accounting Policies (Details) [Table]" } } }," auth_ref": [ ] }," us- gaap_SupplementalCashFlowInformationAbstract": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" SupplementalCashFlowInformationAbstract"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedCashFlow"]," lang": {" en- us": {" role": {" label":" Schedule of Company \ u2019s Supplemental Cash Flow Information Related to Leases [Abstract]"," terseLabel":" Supplemental disclosures of non- cash operating and financing activities:" } } }," auth_ref": [ ] }," ecd_TabularListTableTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" TabularListTableTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Tabular List [Table Text Block]"," terseLabel":" Tabular List, Table" } } }," auth_ref": [" r900"] }," us- gaap_TemporaryEquityCarryingAmountAttributableToParent": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" TemporaryEquityCarryingAmountAttributableToParent"," crdr":" credit"," calculation": {" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet": {" parentTag":" us- gaap_LiabilitiesAndStockholdersEquity"," weight": 1. 0," order": 3. 0 } }," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet"]," lang": {" en- us": {" role": {" terseLabel":" Convertible preferred stock, value"," label":" Temporary Equity, Carrying Amount, Attributable to Parent"," documentation":" Carrying amount, attributable to parent, of an entity' s issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer." } } }," auth_ref": [" r293"," r295"," r296"," r297"," r300"," r301"," r403"," r600"] }," us- gaap_TemporaryEquityParOrStatedValuePerShare": {" xbrltype":" perShareItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" TemporaryEquityParOrStatedValuePerShare"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet_Parentheticals"]," lang": {" en- us": {" role": {" terseLabel":" Convertible preferred stock, par value (in Dollars per share)"," label":" Temporary Equity, Par or Stated Value Per Share"," documentation":" Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable." } } }," auth_ref": [" r15"," r39"] }," us- gaap_TemporaryEquitySharesAuthorized": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" TemporaryEquitySharesAuthorized"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet_Parentheticals"]," lang": {" en- us": {" role": {" terseLabel":" Convertible preferred stock, shares authorized"," label":" Temporary Equity, Shares Authorized"," documentation":" The maximum number of securities classified as temporary equity that are permitted to be issued by an entity' s charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }," auth_ref": [" r63"] }," us- gaap_TemporaryEquitySharesIssued": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" TemporaryEquitySharesIssued"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet_Parentheticals"]," lang": {" en- us": {" role": {" terseLabel":" Convertible preferred stock, shares issued"," label":" Temporary Equity, Shares Issued"," documentation":" The number of securities classified as temporary equity that have been sold (or granted) to the entity' s shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }," auth_ref": [" r63"] }," us- gaap_TemporaryEquitySharesOutstanding": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" TemporaryEquitySharesOutstanding"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedBalanceSheet_Parentheticals"]," lang": {" en- us": {" role": {" terseLabel":" Convertible preferred stock, shares outstanding"," label":" Temporary Equity, Shares Outstanding"," documentation":" The number of securities classified as temporary equity that have been issued and are held by the entity' s shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }," auth_ref": [" r63"] }," orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {" xbrltype":" sharesItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"," presentation": [" http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" terseLabel":" Issuance of Series A convertible preferred stock, net of issuance costs of $ 69 (in Shares)"," documentation":" Number of shares classified as temporary equity issued during the period."," label":" Temporary Equity Stock Issued During Period Shares New Issues" } } }," auth_ref": [ ] }," us- gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" TemporaryEquityStockIssuedDuringPeriodValueNewIssues"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" terseLabel":" Issuance of Series A convertible preferred stock, net of issuance costs of $ 69"," label":" Temporary Equity, Stock Issued During Period, Value, New Issues"," documentation":" Value of new stock classified as temporary equity issued during the period." } } }," auth_ref": [ ] }," orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {" xbrltype":" sharesItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities"," presentation": [" http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" terseLabel":" Exchange of Series A convertible preferred stock for Series B non- voting convertible preferred stock upon the closing of the reverse capitalization (in Shares)"," documentation":" Number of shares classified as temporary equity issued conversion of convertible securities."," label":" Temporory Equity Issued During Period Shares Conversion Of Convertible Securities" } } }," auth_ref": [ ] }," orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities": {" xbrltype":" monetaryItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role / ShareholdersEquityType2or3"]," lang": {" en- us": {" role": {" terseLabel":" Exchange of Series A convertible preferred stock for Series B non- voting convertible preferred stock upon the closing of the reverse capitalization"," documentation":" Value of stock classified as temporary equity conversion of convertible securities during the period."," label":" Temporory Equity Issued During Period Value Conversion Of Convertible Securities" } } }," auth_ref": [ ] }," ecd_TotalShareholderRtnAmt": {" xbrltype":" monetaryItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" TotalShareholderRtnAmt"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Total Shareholder Return Amount"," terseLabel":" Total Shareholder Return Amount" } } }," auth_ref": [" r892"] }," ecd_TotalShareholderRtnVsPeerGroupTextBlock": {" xbrltype":" textBlockItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" TotalShareholderRtnVsPeerGroupTextBlock"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Total Shareholder Return Vs Peer Group [Text Block]"," terseLabel":" Total Shareholder Return Vs Peer Group" } } }," auth_ref": [" r899"] }," ecd_TradingArrAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" TradingArrAxis"," presentation": [" http: / / xbrl. sec. gov / ecd / role / InsiderTradingArrangements"]," lang": {" en- us": {" role": {" label":" Trading Arrangement [Axis]"," terseLabel":" Trading Arrangement:" } } }," auth_ref": [" r920"] }," ecd_TradingArrByIndTable": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" TradingArrByIndTable"," presentation": [" http: / / xbrl. sec. gov / ecd / role / InsiderTradingArrangements"]," lang": {" en- us": {" role": {" label":" Trading Arrangements, by Individual [Table]"," terseLabel":" Trading Arrangements, by Individual" } } }," auth_ref": [" r922"] }," dei_TradingSymbol": {" xbrltype":" tradingSymbolItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" TradingSymbol"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Trading Symbol"," documentation":" Trading symbol of an instrument as listed on an exchange." } } }," auth_ref": [ ] }," us- gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"," presentation": [" http: / / www. orukatx. com / role / ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"," http: / / www. orukatx. com / role / ScheduleofCashEquivalentsandMarketableSecuritiesTable"]," lang": {" en- us": {" role": {" label":" Financial Instruments [Domain]"," documentation":" Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }," auth_ref": [" r230"," r231"," r232"," r233"," r234"," r235"," r236"," r237"," r238"," r239"," r240"," r241"," r242"," r243"," r244"," r245"," r246"," r247"," r248"," r249"," r250"," r251"," r252"," r253"," r254"," r255"," r256"," r257"," r258"," r259"," r327"," r345"," r461"," r488"," r523"," r524"," r525"," r526"," r527"," r528"," r529"," r530"," r531"," r532"," r533"," r534"," r535"," r536"," r537"," r540"," r541"," r542"," r543"," r544"," r545"," r546"," r547"," r548"," r549"," r550"," r551"," r552"," r553"," r554"," r610"," r780"," r781"," r783"," r784"," r785"," r786"," r787"," r788"," r789"," r794"," r955"," r956"," r957"," r958"," r959"," r960"," r961"," r996"," r997"," r998"," r999"," r1050"," r1053"," r1054"," r1055"," r1056"," r1057"] }," ecd_TrdArrAdoptionDate": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" TrdArrAdoptionDate"," presentation": [" http: / / xbrl. sec. gov / ecd / role / InsiderTradingArrangements"]," lang": {" en- us": {" role": {" label":" Trading Arrangement Adoption Date"," terseLabel":" Adoption Date" } } }," auth_ref": [" r923"] }," ecd_TrdArrDuration": {" xbrltype":" durationItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" TrdArrDuration"," presentation": [" http: / / xbrl. sec. gov / ecd / role / InsiderTradingArrangements"]," lang": {" en- us": {" role": {" label":" Trading Arrangement Duration"," terseLabel":" Arrangement Duration" } } }," auth_ref": [" r924"] }," ecd_TrdArrExpirationDate": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" TrdArrExpirationDate"," presentation": [" http: / / xbrl. sec. gov / ecd / role / InsiderTradingArrangements"]," lang": {" en- us": {" role": {" label":" Trading Arrangement Expiration Date"," terseLabel":" Expiration Date" } } }," auth_ref": [" r924"] }," ecd_TrdArrIndName": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" TrdArrIndName"," presentation": [" http: / / xbrl. sec. gov / ecd / role / InsiderTradingArrangements"]," lang": {" en- us": {" role": {" label":" Trading Arrangement, Individual Name"," terseLabel":" Name" } } }," auth_ref": [" r922"] }," ecd_TrdArrIndTitle": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" TrdArrIndTitle"," presentation": [" http: / / xbrl. sec. gov / ecd / role / InsiderTradingArrangements"]," lang": {" en- us": {" role": {" label":" Trading Arrangement, Individual Title"," terseLabel":" Title" } } }," auth_ref": [" r922"] }," ecd_TrdArrSecuritiesAggAvailAmt": {" xbrltype":" sharesItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" TrdArrSecuritiesAggAvailAmt"," presentation": [" http: / / xbrl. sec. gov / ecd / role / InsiderTradingArrangements"]," lang": {" en- us": {" role": {" label":" Trading Arrangement, Securities Aggregate Available Amount"," terseLabel":" Aggregate Available" } } }," auth_ref": [" r925"] }," ecd_TrdArrTerminationDate": {" xbrltype":" stringItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" TrdArrTerminationDate"," presentation": [" http: / / xbrl. sec. gov / ecd / role / InsiderTradingArrangements"]," lang": {" en- us": {" role": {" label":" Trading Arrangement Termination Date"," terseLabel":" Termination Date" } } }," auth_ref": [" r923"] }," orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" TwoThousandTwentyFourEmployeeStockPurchasePlanMember"," presentation": [" http: / / www. orukatx. com / role / ScheduleofCommonStockReservedforFutureIssuanceTable"," http: / / www. orukatx. com / role / StockBasedCompensationDetails"]," lang": {" en- us": {" role": {" terseLabel":" 2024 Employee Stock Purchase Plan [Member]"," label":" Two Thousand Twenty Four Employee Stock Purchase Plan Member" } } }," auth_ref": [ ] }," orka_TwoThousandTwentyFourStockIncentivePlanMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" TwoThousandTwentyFourStockIncentivePlanMember"," presentation": [" http: / / www. orukatx. com / role / ScheduleofCommonStockReservedforFutureIssuanceTable"," http: / / www. orukatx. com / role / StockBasedCompensationDetails"]," lang": {" en- us": {" role": {" terseLabel":" 2024 Stock Incentive Plan [Member]"," verboseLabel":" Two Thousand Twenty Four Stock Incentive Plan [Member]"," label":" Two Thousand Twenty Four Stock Incentive Plan Member" } } }," auth_ref": [ ] }," us- gaap_TypeOfArrangementAxis": {" xbrltype":" stringItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" TypeOfArrangementAxis"," presentation": [" http: / / www. orukatx. com / role / NotePayablewithRelatedPartyDetails"," http: / / www. orukatx. com / role / OptionAgreementsandLicenseAgreementsDetails"]," lang": {" en- us": {" role": {" label":" Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"," documentation":" Information by collaborative arrangement and arrangement other than collaborative applicable to revenue- generating activity or operations." } } }," auth_ref": [" r450"] }," us- gaap_USGovernmentAgenciesDebtSecuritiesMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" USGovernmentAgenciesDebtSecuritiesMember"," presentation": [" http: / / www. orukatx. com / role / ScheduleofCashEquivalentsandMarketableSecuritiesTable"," http: / / www. orukatx. com / role / ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"]," lang": {" en- us": {" role": {" terseLabel":" US Government Agency Securities [Member]"," verboseLabel":" U. S. government agency securities [Member]"," label":" US Government Agencies Debt Securities [Member]"," documentation":" Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government- sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }," auth_ref": [" r748"," r772"," r1074"] }," orka_USGovernmentAgencySecuritiesMember": {" xbrltype":" domainItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" USGovernmentAgencySecuritiesMember"," presentation": [" http: / / www. orukatx. com / role / ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"]," lang": {" en- us": {" role": {" terseLabel":" U. S. government agency securities [Member]"," label":" USGovernment Agency Securities Member" } } }," auth_ref": [ ] }," us- gaap_USTreasurySecuritiesMember": {" xbrltype":" domainItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" USTreasurySecuritiesMember"," presentation": [" http: / / www. orukatx. com / role / ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"," http: / / www. orukatx. com / role / ScheduleofCashEquivalentsandMarketableSecuritiesTable"," http: / / www. orukatx. com / role / ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"]," lang": {" en- us": {" role": {" terseLabel":" US Treasury Securities [Member]"," verboseLabel":" Treasury Securities [Member]"," netLabel":" U. S. treasury securities [Member]"," label":" US Treasury Securities [Member]"," documentation":" This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short- term maturities- one year or less), treasury notes (intermediate term maturities- two to ten years), and treasury bonds (long- term maturities- ten to thirty years)." } } }," auth_ref": [" r748"," r772"," r774"," r780"," r1074"] }," ecd_UndrlygSecurityMktPriceChngPct": {" xbrltype":" pureItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" UndrlygSecurityMktPriceChngPct"," presentation": [" http: / / xbrl. sec. gov / ecd / role / AwardTimingDisclosure"]," lang": {" en- us": {" role": {" label":" Underlying Security Market Price Change, Percent"," terseLabel":" Underlying Security Market Price Change" } } }," auth_ref": [" r919"] }," us- gaap_UnrecognizedTaxBenefits": {" xbrltype":" monetaryItemType","

nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" UnrecognizedTaxBenefits"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role / ScheduleofUnrecognizedTaxBenefitsTable"]," lang": {" en- us": {" role": {" periodStartLabel":" Beginning balance"," periodEndLabel":" Ending balance"," label":" Unrecognized Tax Benefits"," documentation":" Amount of unrecognized tax benefits." } } }," auth_ref": [" r410"," r423"," r778"] }," us- gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role / ScheduleofUnrecognizedTaxBenefitsTable"]," lang": {" en- us": {" role": {" terseLabel":" Changes related to tax positions taken in the current year"," label":" Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions"," documentation":" Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }," auth_ref": [" r424"," r778"] }," us- gaap_UseOfEstimates": {" xbrltype":" textBlockItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" UseOfEstimates"," presentation": [" http: / / www. orukatx. com / role / AccountingPoliciesByPolicy"]," lang": {" en- us": {" role": {" terseLabel":" Use of Estimates"," label":" Use of Estimates, Policy [Policy Text Block]"," documentation":" Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }," auth_ref": [" r31"," r32"," r33"," r116"," r117"," r120"," r121"] }," us- gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {" xbrltype":" monetaryItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" ValuationAllowanceDeferredTaxAssetChangeInAmount"," crdr":" credit"," presentation": [" http: / / www. orukatx. com / role / ScheduleofNetDeferredTaxAssetsTable"]," lang": {" en- us": {" role": {" terseLabel":" Change in valuation allowance"," label":" Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount"," documentation":" Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }," auth_ref": [" r427"] }," ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"," terseLabel":" Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }," auth_ref": [" r888"] }," orka_WarrantsToPurchaseCommonStock": {" xbrltype":" sharesItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" WarrantsToPurchaseCommonStock"," presentation": [" http: / / www. orukatx. com / role / ConvertiblePreferredStockandStockholdersEquityDetails"]," lang": {" en- us": {" role": {" terseLabel":" Warrant purchase"," documentation":" The shares issued of warrants to purchase common stock."," label":" Warrants To Purchase Common Stock" } } }," auth_ref": [ ] }," orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercis
{" xbrltype":" perShareItemType"," nsuri":" http: / / www. orukatx. com / 20241231"," localname":" WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised"," presentation": [" http: / / www. orukatx. com / role / ScheduleofEmployeeWarrantActivityTable"]," lang": {" en- us": {" role": {" terseLabel":" Weighted Average Exercise Price Per Share, Exercised"," documentation":" Weighted average exercise price per share exercised."," label":" Weighted Aver Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Exercise Price Per Share Exercised" } } }," auth_ref": [ ] }," us- gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" WeightedAverageNumberOfDilutedSharesOutstanding"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome"," http: / / www. orukatx. com / role / ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"]," lang": {" en- us": {" role": {" terseLabel":" Weighted- average shares used in computing net loss per share attributable to stockholders, diluted (in Shares)"," verboseLabel":" Weighted average shares outstanding \ u2013 Diluted"," label":" Weighted Average Number of Shares Outstanding, Diluted"," documentation":" The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }," auth_ref": [" r182"," r188"] }," us- gaap_WeightedAverageNumberOfSharesContingentlyIssuable": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" WeightedAverageNumberOfSharesContingentlyIssuable"," presentation": [" http: / / www. orukatx. com / role / NetLossPerShareDetails"]," lang": {" en- us": {" role": {" terseLabel":" Weighted- average number of shares of as- converted"," label":" Weighted Average Number of Shares, Contingently Issuable"," documentation":" Shares issuable for little or no cash consideration upon the satisfaction of certain conditions (contingently issuable shares) are considered outstanding common shares and included in the computation of basic Earnings Per Share as of the date that all necessary conditions have been satisfied (in essence, when issuance of the shares is no longer contingent). Outstanding common shares that are contingently returnable (that is, subject to recall) are treated in the same manner as contingently issuable shares. Contingently issuable shares include shares that (a) will be issued in the future upon the satisfaction of specified conditions, (b) have been placed in escrow and all or part must be returned if specified conditions are not met, or (c) have been issued but the holder must return all or part if specified conditions are not met. The number of contingently issuable shares is determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period." } } }," auth_ref": [" r28"] }," us- gaap_WeightedAverageNumberOfSharesOutstandingBasic": {" xbrltype":" sharesItemType"," nsuri":" http: / / fasb. org / us- gaap / 2024"," localname":" WeightedAverageNumberOfSharesOutstandingBasic"," presentation": [" http: / / www. orukatx. com / role / ConsolidatedComprehensiveIncome"," http: / / www. orukatx. com / role / ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"]," lang": {" en- us": {" role": {" terseLabel":" Weighted- average shares used in computing net loss per share attributable to stockholders, basic (in Shares)"," verboseLabel":" Weighted average shares outstanding \ u2013 Basic"," label":" Weighted Average Number of Shares Outstanding, Basic"," documentation":" Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }," auth_ref": [" r181"," r188"] }," dei_WrittenCommunications": {" xbrltype":" booleanItemType"," nsuri":" http: / / xbrl. sec. gov / dei / 2024"," localname":" WrittenCommunications"," presentation": [" http: / / xbrl. sec. gov / dei / role / document / Cover"]," lang": {" en- us": {" role": {" label":" Written Communications"," documentation":" Boolean flag that is true when the Form 8- K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }," auth_ref": [" r941"] }," ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {" xbrltype":" domainItemType"," nsuri":" http: / / xbrl. sec. gov / ecd / 2024"," localname":" YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"," presentation": [" http: / / xbrl. sec. gov / ecd / role / PvpDisclosure"]," lang": {" en- us": {" role": {" label":" Year- end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"," terseLabel":" Year- end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }," auth_ref": [" r886"] } } } } }," std_ref": {" r0": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 1"," SubTopic":" 230"," Topic":" 830"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477401 / 830- 230- 45- 1" }," r1": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 10A"," SubTopic":" 10"," Topic":" 220"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 10A" }," r2": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 14"," Subparagraph":" (a)"," SubTopic":" 10"," Topic":" 230"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 14" }," r3": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 25"," Subparagraph":" (g)"," SubTopic":" 10"," Topic":" 230"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 25" }," r4": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 28"," Subparagraph":" (a)"," SubTopic":" 10"," Topic":" 230"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28" }," r5": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 28"," Subparagraph":" (b)"," SubTopic":" 10"," Topic":" 230"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28" }," r6": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," SubTopic":" 10"," Topic":" 360"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482099 / 360- 10- 50- 1" }," r7": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," SubTopic":" 10"," Topic":" 470"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481544 / 470- 10- 50- 1" }," r8": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1A"," Subparagraph":" (c) (3)"," SubTopic":" 10"," Topic":" 810"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481203 / 810- 10- 50- 1A" }," r9": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," SubTopic":" 10"," Topic":" 505"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 2" }," r10": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (1) (iv) (02)"," SubTopic":" 10"," Topic":" 718"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r11": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (d)"," SubTopic":" 10"," Topic":" 718"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r12": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (e)"," SubTopic":" 10"," Topic":" 718"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r13": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 4D"," Subparagraph":" (b)"," SubTopic":" 10"," Topic":" 815"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480434 / 815- 10- 50- 4D" }," r14": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (22))"," SubTopic":" 10"," Topic":" 210"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r15": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (27))"," SubTopic":" 10"," Topic":" 210"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r16": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 210"," SubTopic":" 10"," Section":" 45"," Paragraph":" 8"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483467 / 210- 10- 45- 8" }," r17": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 220"," SubTopic":" 10"," Section":" 45"," Paragraph":" 14"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 14" }," r18": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 220"," SubTopic":" 10"," Section":" 45"," Paragraph":" 14A"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 14A" }," r19": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 220"," SubTopic":" 10"," Section":" 45"," Paragraph":" 5"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 5" }," r20": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 230"," SubTopic":" 10"," Section":" 45"," Paragraph":" 14"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 14" }," r21": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 230"," SubTopic":" 10"," Section":" 45"," Paragraph":" 15"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 15" }," r22": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 230"," SubTopic":" 10"," Section":" 45"," Paragraph":" 15"," Subparagraph":" (e)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 15" }," r23": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 230"," SubTopic":" 10"," Section":" 45"," Paragraph":" 4"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 4" }," r24": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 230"," SubTopic":" 10"," Section":" 50"," Paragraph":" 1"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50- 1" }," r25": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 230"," SubTopic":" 10"," Section":" 50"," Paragraph":" 3"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50- 3" }," r26": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 230"," SubTopic":" 10"," Section":" 50"," Paragraph":" 4"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50- 4" }," r27": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 230"," SubTopic":" 10"," Section":" 50"," Paragraph":" 5"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50- 5" }," r28": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 260"," SubTopic":" 10"," Section":" 45"," Paragraph":" 13"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 13" }," r29": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 260"," SubTopic":" 10"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482662 / 260- 10- 50- 1" }," r30": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 260"," SubTopic":" 10"," Section":" 50"," Paragraph":" 2"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482662 / 260- 10- 50- 2" }," r31": {" role":" http: / / fasb. org / us- gaap / role / ref

/ legacyRef"," Name":" Accounting Standards Codification"," Topic":" 275"," SubTopic":" 10"," Section":" 50"," Paragraph":" 4"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482861 / 275- 10- 50- 4" }," r32": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 275"," SubTopic":" 10"," Section":" 50"," Paragraph":" 8"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482861 / 275- 10- 50- 8" }," r33": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 275"," SubTopic":" 10"," Section":" 50"," Paragraph":" 9"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482861 / 275- 10- 50- 9" }," r34": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 280"," SubTopic":" 10"," Section":" 50"," Paragraph":" 30"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 30" }," r35": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 280"," SubTopic":" 10"," Section":" 50"," Paragraph":" 31"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 31" }," r36": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 360"," SubTopic":" 10"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482099 / 360- 10- 50- 1" }," r37": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 460"," SubTopic":" 10"," Section":" 50"," Paragraph":" 8"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482425 / 460- 10- 50- 8" }," r38": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 470"," SubTopic":" 20"," Section":" 25"," Paragraph":" 2"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481284 / 470- 20- 25- 2" }," r39": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 480"," SubTopic":" 10"," Section":" S99"," Paragraph":" 1"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480244 / 480- 10- S99- 1" }," r40": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 505"," SubTopic":" 10"," Section":" 50"," Paragraph":" 3"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 3" }," r41": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 718"," SubTopic":" 10"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 1" }," r42": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 718"," SubTopic":" 10"," Section":" 50"," Paragraph":" 2"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r43": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 718"," SubTopic":" 10"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (h) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r44": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 718"," SubTopic":" 20"," Section":" 55"," Paragraph":" 12"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481089 / 718- 20- 55- 12" }," r45": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 718"," SubTopic":" 20"," Section":" 55"," Paragraph":" 13"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481089 / 718- 20- 55- 13" }," r46": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 805"," SubTopic":" 10"," Section":" 55"," Paragraph":" 37"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479303 / 805- 10- 55- 37" }," r47": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 805"," SubTopic":" 20"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479907 / 805- 20- 50- 1" }," r48": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 942"," SubTopic":" 320"," Section":" 50"," Paragraph":" 5"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477268 / 942- 320- 50- 5" }," r49": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Name":" Accounting Standards Codification"," Topic":" 942"," SubTopic":" 825"," Section":" 50"," Paragraph":" 1"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478898 / 942- 825- 50- 1" }," r50": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 205"," Name":" Accounting Standards Codification"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 205 / tableOfContent" }," r51": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 205"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 205- 20 / tableOfContent" }," r52": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (19) (a))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r53": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (19))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r54": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (20))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r55": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (21))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r56": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (22) (a) (1))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r57": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (23))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r58": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (24))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r59": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (25))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r60": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (26) (a))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r61": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (26) (b))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r62": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (26))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r63": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (27) (b))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r64": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (28))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r65": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (29))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r66": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (30) (a) (1))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r67": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (30) (a) (3))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r68": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (30))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r69": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (31))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r70": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (32))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r71": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 220"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 11"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 11" }," r72": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 220"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 2"," Subparagraph":" (SX 210. 5- 03 (10))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2" }," r73": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 220"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 2"," Subparagraph":" (SX 210. 5- 03 (2))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2" }," r74": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 220"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 2"," Subparagraph":" (SX 210. 5- 03 (20))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2" }," r75": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 220"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 2"," Subparagraph":" (SX 210. 5- 03 (4))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2" }," r76": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 220"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 2"," Subparagraph":" (SX 210. 5- 03 (6))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2" }," r77": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 220"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 2"," Subparagraph":" (SX 210. 5- 03 (7))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2" }," r78": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 220"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 2"," Subparagraph":" (SX 210. 5- 03 (8))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2" }," r79": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 230"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 13"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 13" }," r80": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 230"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 24"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 24" }," r81": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 230"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 25"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 25" }," r82": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 230"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 28"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28" }," r83": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 235"," Name":" Accounting Standards Codification"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 235 / tableOfContent" }," r84": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 275"," Name":" Accounting Standards Codification"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 275 / tableOfContent" }," r85": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 310"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 2"," Subparagraph":" (SAB Topic 4. E)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480418 / 310- 10- S99- 2" }," r86": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 440"," Name":" Accounting Standards Codification"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 440 / tableOfContent" }," r87": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 470"," Name":" Accounting Standards Codification"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 470 / tableOfContent" }," r88": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 470"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 12A"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481573 / 470- 10- 45- 12A" }," r89": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 505"," Name":" Accounting Standards Codification"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 505 / tableOfContent" }," r90": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 505"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 6" }," r91": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 505"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 3- 04)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480008 / 505- 10- S99- 1" }," r92": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 505"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 4"," Subparagraph":" (SAB Topic 4. C)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480008 / 505- 10- S99- 4" }," r93": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r94": {" role":" http: / / fasb.

org / us- gaap / role / ref / legacyRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (2)","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r95": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 718","
SubTopic":" 10"," Subparagraph":" (e) (1)"," Name":" Accounting Standards Codification"," Paragraph":" 2"," Section":" 50"," Publisher":" FASB"," URI":" https: / / asc. fasb. org /
1943274 / 2147480429 / 718- 10- 50- 2" }," r96": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 718"," SubTopic":" 10"," Subparagraph":" (f) (2)"," Name":"
Accounting Standards Codification"," Paragraph":" 2"," Section":" 50"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r97": {" role":"
http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 805"," Name":" Accounting Standards Codification"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 805 /
tableOfContent" }," r98": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 805"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Paragraph":" 1","
Section":" 50"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479907 / 805- 20- 50- 1" }," r99": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":"
942"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 9- 03 (11))"," Publisher":" FASB"," URI":"
https: / / asc. fasb. org / 1943274 / 2147478546 / 942- 210- S99- 1" }," r100": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 942"," SubTopic":" 210"," Name":"
Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 9- 03 (13))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 /
2147478546 / 942- 210- S99- 1" }," r101": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 942"," SubTopic":" 210"," Name":" Accounting Standards Codification","
Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 9- 03 (15) (2))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478546 / 942- 210- S99- 1" }," r102": {"
role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 942"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1","
Subparagraph":" (SX 210. 9- 03 (16))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478546 / 942- 210- S99- 1" }," r103": {" role":" http: / / fasb. org / us- gaap / role /
ref / legacyRef"," Topic":" 942"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 9- 03 (17))","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478546 / 942- 210- S99- 1" }," r104": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 942","
SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 9- 03 (23))"," Publisher":" FASB"," URI":" https: / / asc.
fasb. org / 1943274 / 2147478546 / 942- 210- S99- 1" }," r105": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 942"," SubTopic":" 210"," Name":" Accounting
Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 9- 03 (4))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478546 / 942- 210-
S99- 1" }," r106": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":" 942"," SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" S99","
Paragraph":" 1"," Subparagraph":" (SX 210. 9- 04 (14))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478524 / 942- 220- S99- 1" }," r107": {" role":" http: / / fasb.
org / us- gaap / role / ref / legacyRef"," Topic":" 942"," SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 9-
04 (15))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478524 / 942- 220- S99- 1" }," r108": {" role":" http: / / fasb. org / us- gaap / role / ref / legacyRef"," Topic":"
942"," SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 9- 04 (22))"," Publisher":" FASB"," URI":"
https: / / asc. fasb. org / 1943274 / 2147478524 / 942- 220- S99- 1" }," r109": {" role":" http: / / fasb. org / us- gaap / role / ref / otherTransitionRef"," Topic":" 280"," SubTopic":" 10"," Name":"
Accounting Standards Codification"," Section":" 50"," Paragraph":" 32"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50-
32" }," r110": {" role":" http: / / fasb. org / us- gaap / role / ref / otherTransitionRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 32"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 32" }," r111": {" role":" http: / / fasb. org / us- gaap /
role / ref / otherTransitionRef"," Topic":" 320"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6"," Subparagraph":" (a)"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 6" }," r112": {" role":" http: / / fasb. org / us- gaap / role / ref / otherTransitionRef"," Topic":" 320"," SubTopic":"
10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6"," Subparagraph":" (a) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 /
2147481800 / 320- 10- 50- 6" }," r113": {" role":" http: / / fasb. org / us- gaap / role / ref / otherTransitionRef"," Topic":" 320"," SubTopic":" 10"," Name":" Accounting Standards
Codification"," Section":" 50"," Paragraph":" 6"," Subparagraph":" (a) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 6" }," r114": {"
role":" http: / / fasb. org / us- gaap / role / ref / otherTransitionRef"," Topic":" 320"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 7","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 7" }," r115": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Name":" Accounting
Standards Codification"," Section":" 45"," Paragraph":" 2"," Subparagraph":" (a)"," SubTopic":" 20"," Topic":" 740"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 /
2147482659 / 740- 20- 45- 2" }," r116": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1","
Subparagraph":" (b)"," SubTopic":" 10"," Topic":" 275"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482861 / 275- 10- 50- 1" }," r117": {" role":" http: / / www.
xbrl. org / 2003 / role / disclosureRef"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (c)"," SubTopic":" 10"," Topic":" 275","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482861 / 275- 10- 50- 1" }," r118": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Name":" Accounting
Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (d)"," SubTopic":" 10"," Topic":" 275"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 /
2147482861 / 275- 10- 50- 1" }," r119": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1","
Subparagraph":" (d)"," SubTopic":" 360"," Topic":" 958"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477798 / 958- 360- 50- 1" }," r120": {" role":" http: / / www.
xbrl. org / 2003 / role / disclosureRef"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 11"," SubTopic":" 10"," Topic":" 275"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147482861 / 275- 10- 50- 11" }," r121": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Name":" Accounting Standards
Codification"," Section":" 50"," Paragraph":" 12"," SubTopic":" 10"," Topic":" 275"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482861 / 275- 10- 50- 12" },"
r122": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6"," SubTopic":" 360"," Topic":"
958"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477798 / 958- 360- 50- 6" }," r123": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Name":"
Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 4- 08 (h))"," SubTopic":" 10"," Topic":" 235"," Publisher":" FASB"," URI":" https: /
/ asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1" }," r124": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Name":" Regulation S- K (SK)"," Number":" 229","
Section":" 1402"," Paragraph":" a"," Publisher":" SEC" }," r125": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 105"," SubTopic":" 10"," Name":" Accounting
Standards Codification"," Section":" 65"," Paragraph":" 6"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479343 / 105- 10- 65- 6" }," r126":
{" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 205"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 7","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483499 / 205- 20- 50- 7" }," r127": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 210","
SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 1"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483467 / 210- 10-
45- 1" }," r128": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45","
Paragraph":" 5"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483467 / 210- 10- 45- 5" }," r129": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef","
Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (1))"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r130": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 210"," SubTopic":" 10"," Name":"
Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (17))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 /
2147480566 / 210- 10- S99- 1" }," r131": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification","
Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (18))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r132": {"
role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1","
Subparagraph":" (SX 210. 5- 02 (22) (a) (2))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r133": {" role":" http: / / www. xbrl. org / 2003
/ role / disclosureRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (27) (b))","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r134": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 210","
SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (28))"," Publisher":" FASB"," URI":" https: / / asc.
fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r135": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards
Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (29))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" },"
r136": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":"
1"," Subparagraph":" (SX 210. 5- 02 (30) (a) (4))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r137": {" role":" http: / / www. xbrl. org /
2003 / role / disclosureRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (9))","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r138": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 220","
SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 10A"," Subparagraph":" (e)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org /
1943274 / 2147482790 / 220- 10- 45- 10A" }," r139": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 220"," SubTopic":" 10"," Name":" Accounting Standards
Codification"," Section":" 45"," Paragraph":" 11"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 11" }," r140": {" role":" http: / / www. xbrl. org
/ 2003 / role / disclosureRef"," Topic":" 220"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 1A"," Subparagraph":" (a)"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 1A" }," r141": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 220"," SubTopic":" 10","
Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 1A"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482790 /
220- 10- 45- 1A" }," r142": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 220"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45","
Paragraph":" 1B"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 1B" }," r143": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 220"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 1B"," Subparagraph":" (b)"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482790 / 220- 10- 45- 1B" }," r144": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 220"," SubTopic":" 10","
Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482765 / 220- 10- 50- 1" }," r145": {"
role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 220"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 4","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482765 / 220- 10- 50- 4" }," r146": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 220","
SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 5"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482765 / 220- 10-
50- 5" }," r147": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 220"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 6"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482765 / 220- 10- 50- 6" }," r148": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef","
Topic":" 220"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 2"," Subparagraph":" (SX 210. 5- 03 (24))"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2" }," r149": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 220"," SubTopic":" 10"," Name":"
Accounting Standards Codification"," Section":" S99"," Paragraph":" 2"," Subparagraph":" (SX 210. 5- 03 (25))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 /
2147483621 / 220- 10- S99- 2" }," r150": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 220"," SubTopic":" 10"," Name":" Accounting Standards Codification","
Section":" S99"," Paragraph":" 2"," Subparagraph":" (SX 210. 5- 03 (7) (d))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2" }," r151": {"
role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 230"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 24","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 24" }," r152": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 230","
SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2A"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10-
50- 2A" }," r153": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 230"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 8"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482913 / 230- 10- 50- 8" }," r154": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef","
Topic":" 235"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 /

2147483426 / 235- 10- 50- 1" }," r155": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 235"," SubTopic":" 10"," Name":" Accounting Standards Codification","
Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 4- 08 (c))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1" }," r156": {" role":"
http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 235"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1","
Subparagraph":" (SX 210. 4- 08 (e) (1))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1" }," r157": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 235"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 4- 08 (g) (1) (ii))","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1" }," r158": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 235","
SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 4- 08 (h) (1))"," Publisher":" FASB"," URI":" https: / /
asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1" }," r159": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 235"," SubTopic":" 10"," Name":" Accounting
Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 4- 08 (h) (2))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480678 / 235-
10- S99- 1" }," r160": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 235"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99","
Paragraph":" 1"," Subparagraph":" (SX 210. 4- 08 (k) (1))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1" }," r161": {" role":" http: / / www.
xbrl. org / 2003 / role / disclosureRef"," Topic":" 235"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 4-
08 (k) (2))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1" }," r162": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":"
235"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 4- 08 (m) (1) (iii))"," Publisher":" FASB"," URI":"
https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1" }," r163": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 235"," SubTopic":" 10"," Name":"
Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 4- 08 (m) (2) (ii))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 /
2147480678 / 235- 10- S99- 1" }," r164": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 235"," SubTopic":" 10"," Name":" Accounting Standards Codification","
Section":" S99"," Paragraph":" 3"," Subparagraph":" (SX 210. 12- 04 (a))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 3" }," r165": {"
role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 250"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 23","
Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483421 / 250- 10- 45- 23" }," r166": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 250"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 24"," Publisher":" FASB"," URI":" https: / / asc. fasb. org
/ 1943274 / 2147483421 / 250- 10- 45- 24" }," r167": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 250"," SubTopic":" 10"," Name":" Accounting Standards
Codification"," Section":" 45"," Paragraph":" 5"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483421 / 250- 10- 45- 5" }," r168": {" role":"
http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 250"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1","
Subparagraph":" (b) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 1" }," r169": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 250"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (b) (3)"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 1" }," r170": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 250"," SubTopic":" 10"," Name":"
Accounting Standards Codification"," Section":" 50"," Paragraph":" 11"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50-
11" }," r171": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 250"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 11"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 11" }," r172": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 250"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Publisher":" FASB"," URI":" https: / / asc.
fasb. org / 1943274 / 2147483443 / 250- 10- 50- 3" }," r173": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 250"," SubTopic":" 10"," Name":" Accounting Standards
Codification"," Section":" 50"," Paragraph":" 4"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 4" }," r174": {" role":" http: / / www. xbrl. org /
2003 / role / disclosureRef"," Topic":" 250"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6"," Publisher":" FASB"," URI":" https: / /
asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 6" }," r175": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 250"," SubTopic":" 10"," Name":" Accounting
Standards Codification"," Section":" 50"," Paragraph":" 7"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 7" }," r176":
{" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 250"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 7","
Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 7" }," r177": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef","
Topic":" 250"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 8"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 /
2147483443 / 250- 10- 50- 8" }," r178": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 250"," SubTopic":" 10"," Name":" Accounting Standards Codification","
Section":" 50"," Paragraph":" 9"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 9" }," r179": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 250"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 5"," Subparagraph":" (SAB Topic 11. M. Q2)","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480530 / 250- 10- S99- 5" }," r180": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 260","
Name":" Accounting Standards Codification"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 260 / tableOfContent" }," r181": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 260"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 10"," Publisher":" FASB"," URI":" https: / / asc. fasb. org
/ 1943274 / 2147482689 / 260- 10- 45- 10" }," r182": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 260"," SubTopic":" 10"," Name":" Accounting Standards
Codification"," Section":" 45"," Paragraph":" 16"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 16" }," r183": {" role":" http: / / www. xbrl. org
/ 2003 / role / disclosureRef"," Topic":" 260"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 2"," Publisher":" FASB"," URI":" https: / /
asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 2" }," r184": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 260"," SubTopic":" 10"," Name":" Accounting
Standards Codification"," Section":" 45"," Paragraph":" 3"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 3" }," r185": {" role":" http: / / www.
xbrl. org / 2003 / role / disclosureRef"," Topic":" 260"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 60B"," Subparagraph":" (a)","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 60B" }," r186": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 260","
SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 60B"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org /
1943274 / 2147482689 / 260- 10- 45- 60B" }," r187": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 260"," SubTopic":" 10"," Name":" Accounting Standards
Codification"," Section":" 45"," Paragraph":" 7"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 7" }," r188": {" role":" http: / / www. xbrl. org /
2003 / role / disclosureRef"," Topic":" 260"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (a)"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482662 / 260- 10- 50- 1" }," r189": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 260"," SubTopic":" 10","
Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482662 / 260-
10- 50- 1" }," r190": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 260"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 1"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482662 / 260- 10- 50- 1" }," r191": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 260"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Publisher":" FASB"," URI":" https: / / asc.
fasb. org / 1943274 / 2147482662 / 260- 10- 50- 2" }," r192": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 260"," SubTopic":" 10"," Name":" Accounting Standards
Codification"," Section":" 50"," Paragraph":" 3"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482662 / 260- 10- 50- 3" }," r193": {" role":" http: / / www. xbrl. org /
2003 / role / disclosureRef"," Topic":" 260"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 15"," Publisher":" FASB"," URI":" https: / /
asc. fasb. org / 1943274 / 2147482635 / 260- 10- 55- 15" }," r194": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 270"," SubTopic":" 10"," Name":" Accounting
Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (i)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482964 / 270- 10- 50- 1" }," r195":
{" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 270"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6A","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482964 / 270- 10- 50- 6A" }," r196": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 272","
SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 1"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483014 / 272- 10-
45- 1" }," r197": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 272"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 1"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482987 / 272- 10- 50- 1" }," r198": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef","
Topic":" 272"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc.
fasb. org / 1943274 / 2147482987 / 272- 10- 50- 3" }," r199": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 280"," Name":" Accounting Standards Codification","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 280 / tableOfContent" }," r200": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 280"," SubTopic":" 10","
Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 15"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 15" }," r201":
{" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 21","
Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 21" }," r202": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 21"," Subparagraph":" (b)"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 21" }," r203": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 280"," SubTopic":" 10"," Name":"
Accounting Standards Codification"," Section":" 50"," Paragraph":" 22"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 22" }," r204": {" role":"
http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 22","
Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 22" }," r205": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 22"," Subparagraph":" (d)"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 22" }," r206": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 280"," SubTopic":" 10"," Name":"
Accounting Standards Codification"," Section":" 50"," Paragraph":" 22"," Subparagraph":" (h)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50-
22" }," r207": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 26"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 26" }," r208": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef","
Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 26B"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 /
2147482810 / 280- 10- 50- 26B" }," r209": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification","
Section":" 50"," Paragraph":" 26C"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 26C" }," r210": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 29"," Publisher":" FASB"," URI":" https: / / asc. fasb. org
/ 1943274 / 2147482810 / 280- 10- 50- 29" }," r211": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards
Codification"," Section":" 50"," Paragraph":" 29"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 29" }," r212": {"
role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 29","
Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 29" }," r213": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 29"," Subparagraph":" (c)"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 29" }," r214": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 280"," SubTopic":" 10"," Name":"
Accounting Standards Codification"," Section":" 50"," Paragraph":" 29"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50-
29" }," r215": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 29"," Subparagraph":" (e)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 29" }," r216": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 29"," Subparagraph":" (f)"," Publisher":" FASB","

URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 29" }," r217": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 280"," SubTopic":" 10"," Name":"
Accounting Standards Codification"," Section":" 50"," Paragraph":" 30"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50-
30" }," r218": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 31"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 31" }," r219": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef","
Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 32"," Subparagraph":" (e)"," Publisher":" FASB"," URI":" https: / / asc.
fasb. org / 1943274 / 2147482810 / 280- 10- 50- 32" }," r220": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards
Codification"," Section":" 50"," Paragraph":" 32"," Subparagraph":" (ee)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 32" }," r221": {"
role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 32","
Subparagraph":" (f)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 32" }," r222": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef","
Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 34"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 /
2147482810 / 280- 10- 50- 34" }," r223": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification","
Section":" 50"," Paragraph":" 36"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 36" }," r224": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 40"," Publisher":" FASB"," URI":" https: / / asc. fasb. org
/ 1943274 / 2147482810 / 280- 10- 50- 40" }," r225": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards
Codification"," Section":" 50"," Paragraph":" 41"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 41" }," r226": {" role":" http: / / www. xbrl. org
/ 2003 / role / disclosureRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 41"," Subparagraph":" (a)"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 41" }," r227": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 280"," SubTopic":" 10","
Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 41"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 /
280- 10- 50- 41" }," r228": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 42"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 42" }," r229": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef","
Topic":" 310"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 13"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 /
2147481990 / 310- 10- 45- 13" }," r230": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 320"," SubTopic":" 10"," Name":" Accounting Standards Codification","
Section":" 50"," Paragraph":" 2"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 2" }," r231": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 320"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (a)"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 2" }," r232": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 320"," SubTopic":" 10"," Name":"
Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (aa)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50-
2" }," r233": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 320"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 2"," Subparagraph":" (aaa)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 2" }," r234": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 320"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (b)"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 2" }," r235": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 320"," SubTopic":" 10"," Name":"
Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 2"
}," r236": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 320"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":"
2"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 2" }," r237": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 320"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Publisher":" FASB"," URI":" https: / / asc. fasb. org /
1943274 / 2147481800 / 320- 10- 50- 3" }," r238": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 320"," SubTopic":" 10"," Name":" Accounting Standards
Codification"," Section":" 50"," Paragraph":" 3"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 3" }," r239": {" role":"
http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 320"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3","
Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 3" }," r240": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef","
Topic":" 320"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc.
fasb. org / 1943274 / 2147481800 / 320- 10- 50- 3" }," r241": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 320"," SubTopic":" 10"," Name":" Accounting Standards
Codification"," Section":" 50"," Paragraph":" 3"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 3" }," r242": {" role":"
http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 320"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 5"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 5" }," r243": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 320"," SubTopic":" 10","
Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 5"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320-
10- 50- 5" }," r244": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 320"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 5"," Subparagraph":" (aaa)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 5" }," r245": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 320"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 5"," Subparagraph":" (d)"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 5" }," r246": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 320"," SubTopic":" 10"," Name":"
Accounting Standards Codification"," Section":" 50"," Paragraph":" 5"," Subparagraph":" (e)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 5"
}," r247": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 320"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":"
5"," Subparagraph":" (f)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 5" }," r248": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 320"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 5"," Subparagraph":" (f) (1)"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 5" }," r249": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 320"," SubTopic":" 10"," Name":"
Accounting Standards Codification"," Section":" 50"," Paragraph":" 5"," Subparagraph":" (f) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50-
5" }," r250": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 320"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 5"," Subparagraph":" (f) (3)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 5" }," r251": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 320"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 5"," Subparagraph":" (f) (4)"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 5" }," r252": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 320"," SubTopic":" 10","
Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 5A"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481800 /
320- 10- 50- 5A" }," r253": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 320"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 5A"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 5A" }," r254": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 320"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 5A"," Subparagraph":" (c)"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 5A" }," r255": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 320"," SubTopic":" 10","
Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 5B"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 5B" }," r256":
{" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 320"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 5B","
Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 5B" }," r257": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 320"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 5B"," Subparagraph":" (b)"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 5B" }," r258": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 320"," SubTopic":" 10"," Name":"
Accounting Standards Codification"," Section":" 50"," Paragraph":" 5B"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50-
5B" }," r259": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 320"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 5B"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 5B" }," r260": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 320"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 9"," Subparagraph":" (d)"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 9" }," r261": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 323"," SubTopic":" 10"," Name":"
Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481687 / 323- 10- 50- 3"
}," r262": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 326"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 65"," Paragraph":"
4"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479654 / 326- 10- 65- 4" }," r263": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 326"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 65"," Paragraph":" 5"," Subparagraph":" (c) (2)"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147479654 / 326- 10- 65- 5" }," r264": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 326"," SubTopic":" 20"," Name":"
Accounting Standards Codification"," Section":" 50"," Paragraph":" 11"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479319 / 326- 20- 50- 11" }," r265": {" role":"
http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 326"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 13"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479319 / 326- 20- 50- 13" }," r266": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 326"," SubTopic":" 20","
Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 14"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479319 / 326- 20- 50- 14" }," r267":
{" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 326"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 16","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479319 / 326- 20- 50- 16" }," r268": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 326","
SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 5"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479319 / 326- 20-
50- 5" }," r269": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 326"," SubTopic":" 30"," Name":" Accounting Standards Codification"," Section":" 45","
Paragraph":" 1"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479130 / 326- 30- 45- 1" }," r270": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef","
Topic":" 326"," SubTopic":" 30"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 4"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 /
2147479106 / 326- 30- 50- 4" }," r271": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 326"," SubTopic":" 30"," Name":" Accounting Standards Codification","
Section":" 50"," Paragraph":" 4"," Subparagraph":" (a) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479106 / 326- 30- 50- 4" }," r272": {" role":" http: / / www.
xbrl. org / 2003 / role / disclosureRef"," Topic":" 326"," SubTopic":" 30"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 4"," Subparagraph":" (a) (2)","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479106 / 326- 30- 50- 4" }," r273": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 326","
SubTopic":" 30"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 5"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479106 / 326- 30-
50- 5" }," r274": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 326"," SubTopic":" 30"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 7"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479106 / 326- 30- 50- 7" }," r275": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef","
Topic":" 326"," SubTopic":" 30"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 9"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 /
2147479106 / 326- 30- 50- 9" }," r276": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 350"," SubTopic":" 60"," Name":" Accounting Standards Codification","
Section":" 65"," Paragraph":" 1"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147476166 / 350- 60- 65- 1" }," r277": {" role":" http: / / www.
xbrl. org / 2003 / role / disclosureRef"," Topic":" 360"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Subparagraph":" (d)","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482099 / 360- 10- 50- 3" }," r278": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 405","
SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274

/ 2147477092 / 405- 40- 50- 1" }," r279": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 405"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (a) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477092 / 405- 40- 50- 1" }," r280": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 405"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (a) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477092 / 405- 40- 50- 1" }," r281": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 405"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (a) (3)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477092 / 405- 40- 50- 1" }," r282": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 405"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477092 / 405- 40- 50- 1" }," r283": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 405"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (e) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477092 / 405- 40- 50- 1" }," r284": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 420"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482017 / 420- 10- 50- 1" }," r285": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 440"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 4"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482648 / 440- 10- 50- 4" }," r286": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 440"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 4"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482648 / 440- 10- 50- 4" }," r287": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 450"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 4"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483076 / 450- 20- 50- 4" }," r288": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 450"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 9"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483076 / 450- 20- 50- 9" }," r289": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 450"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SAB Topic 5. Y. Q2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480102 / 450- 20- S99- 1" }," r290": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 450"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SAB Topic 5. Y. Q4)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480102 / 450- 20- S99- 1" }," r291": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481544 / 470- 10- 50- 6" }," r292": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481544 / 470- 10- 50- 6" }," r293": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1A"," Subparagraph":" (SX 210. 13- 01 (a) (4) (i))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A" }," r294": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1A"," Subparagraph":" (SX 210. 13- 01 (a) (4) (iii) (A))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A" }," r295": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1A"," Subparagraph":" (SX 210. 13- 01 (a) (4) (iv))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A" }," r296": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1A"," Subparagraph":" (SX 210. 13- 01 (a) (5))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A" }," r297": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1B"," Subparagraph":" (SX 210. 13- 02 (a) (4) (i))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B" }," r298": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1B"," Subparagraph":" (SX 210. 13- 02 (a) (4) (iii) (A))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B" }," r299": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1B"," Subparagraph":" (SX 210. 13- 02 (a) (4) (iii) (B))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B" }," r300": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1B"," Subparagraph":" (SX 210. 13- 02 (a) (4) (iv))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B" }," r301": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1B"," Subparagraph":" (SX 210. 13- 02 (a) (5))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1B" }," r302": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1B"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1B" }," r303": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1B"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1B" }," r304": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1B"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1B" }," r305": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1B"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1B" }," r306": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1B"," Subparagraph":" (e)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1B" }," r307": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1B"," Subparagraph":" (f)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1B" }," r308": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1B"," Subparagraph":" (g)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1B" }," r309": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1B"," Subparagraph":" (h)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1B" }," r310": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1B"," Subparagraph":" (i)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1B" }," r311": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1C"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1C" }," r312": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1C"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1C" }," r313": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1C"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1C" }," r314": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1D"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1D" }," r315": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1D"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1D" }," r316": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1D"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1D" }," r317": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1E"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1E" }," r318": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1E"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1E" }," r319": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1E"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1E" }," r320": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1E"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1E" }," r321": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1F"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1F" }," r322": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1F"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1F" }," r323": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1F"," Subparagraph":" (b) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1F" }," r324": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1F"," Subparagraph":" (b) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1F" }," r325": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1I"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1I" }," r326": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1I"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1I" }," r327": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1I"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1I" }," r328": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1I"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1I" }," r329": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 6" }," r330": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 505"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 13"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13" }," r331": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 505"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 13"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13" }," r332": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 505"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 13"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13" }," r333": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 505"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 13"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13" }," r334": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 505"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 13"," Subparagraph":" (e)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13" }," r335": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 505"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 13"," Subparagraph":" (g)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13" }," r336": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 505"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 13"," Subparagraph":" (h)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13" }," r337": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 505"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 13"," Subparagraph":" (i)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13" }," r338": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 505"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 14"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 14" }," r339": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 505"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 14"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 14" }," r340": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 505"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 14"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 14" }," r341": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 505"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 16"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 16" }," r342": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 505"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 16"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 16" }," r343": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 505"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 18"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 18" }," r344": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 505"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 18"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 18" }," r345": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 505"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 18"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 18" }," r346": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 505"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 18"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 18" }," r347": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 505"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 2" }," r348": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 505"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 3" }," r349": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 505"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 3- 04)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480008 / 505- 10- S99- 1" }," r350": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 715"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (d) (i)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480506 / 715- 20- 50- 1" }," r351": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 715"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (d) (iv) (01)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480506 / 715- 20- 50- 1" }," r352": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 715"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (d) (iv) (02)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480506 / 715- 20- 50- 1" }," r353": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 715"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (d) (iv) (02) (A)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480506 / 715- 20- 50- 1" }," r354": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 715"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (d) (iv) (02) (B)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480506 / 715- 20- 50- 1" }," r355": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 715"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (d) (iv) (02) (C)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480506 / 715- 20- 50- 1" }," r356": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 715"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (d) (iv) (03)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480506 / 715- 20- 50- 1" }," r357": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 715"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (n)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480506 / 715- 20- 50- 1" }," r358": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 715"," SubTopic":" 80"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 5"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480576 / 715- 80- 50- 5" }," r359": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 715"," SubTopic":" 80"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 5"," Subparagraph":" (f) (3)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480576 / 715- 80- 50- 5" }," r360": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," Name":" Accounting Standards Codification"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 718 / tableOfContent" }," r361": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 35"," Paragraph":" 1D"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480483 / 718- 10- 35- 1D" }," r362": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 35"," Paragraph":" 2"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480483 / 718- 10- 35- 2" }," r363": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 35"," Paragraph":" 3"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480483 / 718- 10- 35- 3" }," r364": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r365": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (a) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r366": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (a) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r367": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (a) (3)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r368": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r369": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (1) (i)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r370": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (1) (ii)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r371": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (1) (iii)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r372": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (1) (iv)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r373": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (1) (iv) (01)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r374": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (1) (iv) (02)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r375": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (1) (iv) (03)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r376": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (1) (iv) (04)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r377": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (2) (i)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r378": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (2) (ii)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r379": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (2) (iii)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r380": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (2) (iii) (01)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r381": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (2) (iii) (02)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r382": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (2) (iii) (03)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r383": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (d) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r384": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (d) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r385": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (e) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r386": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (e) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r387": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (f) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r388": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (f) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r389": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (f) (2) (i)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r390": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (f) (2) (ii)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r391": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (f) (2) (iii)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r392": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (f) (2) (iv)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r393": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (f) (2) (v)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r394": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (h) (1) (i)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r395": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (h) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r396": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (h) (2) (i)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r397": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (i)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r398": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (l)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r399": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SAB Topic 14. C. Q3)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479830 / 718- 10- S99- 1" }," r400": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SAB Topic 14. D. 1. Q5)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479830 / 718- 10- S99- 1" }," r401": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SAB Topic 14. D. 2. Q6)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479830 / 718- 10- S99- 1" }," r402": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SAB Topic 14. D. 3. Q2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479830 / 718- 10- S99- 1" }," r403": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SAB Topic 14. E. Q2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479830 / 718- 10- S99- 1" }," r404": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SAB Topic 14. F)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479830 / 718- 10- S99- 1" }," r405": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 720"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483359 / 720- 20- 50- 1" }," r406": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 720"," SubTopic":" 30"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 1"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483384 / 720- 30- 45- 1" }," r407": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 730"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 05"," Paragraph":" 1"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483044 / 730- 10- 05- 1" }," r408": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 730"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482916 / 730- 10- 50- 1" }," r409": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," Name":" Accounting Standards Codification"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 740 / tableOfContent" }," r410": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 10B"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482525 / 740- 10- 45- 10B" }," r411": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 25"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482525 / 740- 10- 45- 25" }," r412": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 28"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482525 / 740- 10- 45- 28" }," r413": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 10"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 10" }," r414": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 10A"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 10A" }," r415": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 12"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 12" }," r416": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 12"," Subparagraph":" (b) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 12" }," r417": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 12A"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 12A" }," r418": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 12A"," Subparagraph":" (a) (6)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 12A" }," r419": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 12B"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 12B" }," r420": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 12C"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 12C" }," r421": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 14"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 14" }," r422": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 15"," Subparagraph":" (e)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 15" }," r423": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 15A"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 15A" }," r424": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 15A"," Subparagraph":" (a) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 15A" }," r425": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 17"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 17" }," r426": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 19"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 19" }," r427": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 2" }," r428": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 2" }," r429": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 2" }," r430": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 2" }," r431": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 20"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 20" }," r432": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 21"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 21" }," r433": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 23"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 23" }," r434": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 9"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 9" }," r435": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 65"," Paragraph":" 8"," Subparagraph":" (d) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482615 / 740- 10- 65- 8" }," r436": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 65"," Paragraph":" 8"," Subparagraph":" (d) (3)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482615 / 740- 10- 65- 8" }," r437": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SAB Topic 6. I. 1. Q1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479360 / 740- 10- S99- 1" }," r438": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SAB Topic 6. I. 5. Q1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479360 / 740- 10- S99- 1" }," r439": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SAB Topic 6. I. 7)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479360 / 740- 10- S99- 1" }," r440": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 2"," Subparagraph":" (SAB Topic 11. C)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479360 / 740- 10- S99- 2" }," r441": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 270"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477891 / 740- 270- 50- 1" }," r442": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 30"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482603 / 740- 30- 50- 2" }," r443": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 323"," Name":" Accounting Standards Codification"," Section":" 65"," Paragraph":" 2"," Subparagraph":" (d) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478666 / 740- 323- 65- 2" }," r444": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 323"," Name":" Accounting Standards Codification"," Section":" 65"," Paragraph":" 2"," Subparagraph":" (d) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478666 / 740- 323- 65- 2" }," r445": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 323"," Name":" Accounting Standards Codification"," Section":" 65"," Paragraph":" 2"," Subparagraph":" (e)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478666 / 740- 323- 65- 2" }," r446": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 323"," Name":" Accounting Standards Codification"," Section":" 65"," Paragraph":" 2"," Subparagraph":" (g) (3)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478666 / 740- 323- 65- 2" }," r447": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 740"," SubTopic":" 323"," Name":" Accounting Standards Codification"," Section":" 65"," Paragraph":" 2"," Subparagraph":" (g) (4)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478666 / 740- 323- 65- 2" }," r448": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 805"," SubTopic":" 60"," Name":" Accounting Standards Codification"," Section":" 65"," Paragraph":" 1"," Subparagraph":" (d) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147476176 / 805- 60- 65- 1" }," r449": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 805"," SubTopic":" 60"," Name":" Accounting Standards Codification"," Section":" 65"," Paragraph":" 1"," Subparagraph":" (g)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147476176 / 805- 60- 65- 1" }," r450": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 808"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479402 / 808- 10- 50- 1" }," r451": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 810"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 25"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481231 / 810- 10- 45- 25" }," r452": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 810"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 25"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481231 / 810- 10- 45- 25" }," r453": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 810"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Subparagraph":" (bb)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481203 / 810- 10- 50- 3" }," r454": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 810"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481203 / 810- 10- 50- 3" }," r455": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 815"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 65"," Paragraph":" 6"," Subparagraph":" (e)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480528 / 815- 20- 65- 6" }," r456": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 815"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 65"," Paragraph":" 6"," Subparagraph":" (h) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480528 / 815- 20- 65- 6" }," r457": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 815"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 65"," Paragraph":" 6"," Subparagraph":" (h) (1) (i)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480528 / 815- 20- 65- 6" }," r458": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 815"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 65"," Paragraph":" 6"," Subparagraph":" (h) (1) (iii)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480528 / 815- 20- 65- 6" }," r459": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 815"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 65"," Paragraph":" 6"," Subparagraph":" (h) (1) (iv)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480528 / 815- 20- 65- 6" }," r460": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 815","

SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 65"," Paragraph":" 6"," Subparagraph":" (i) (3)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org /
1943274 / 2147480528 / 815- 20- 65- 6" }," r461": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 815"," SubTopic":" 40"," Name":" Accounting Standards
Codification"," Section":" 50"," Paragraph":" 5"," Subparagraph":" (f)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480237 / 815- 40- 50- 5" }," r462": {" role":"
http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 815"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6","
Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480237 / 815- 40- 50- 6" }," r463": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef","
Topic":" 815"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 65"," Paragraph":" 1"," Subparagraph":" (e) (3)"," Publisher":" FASB"," URI":" https: / /
asc. fasb. org / 1943274 / 2147480175 / 815- 40- 65- 1" }," r464": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 815"," SubTopic":" 40"," Name":" Accounting
Standards Codification"," Section":" 65"," Paragraph":" 1"," Subparagraph":" (e) (4)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480175 / 815- 40- 65- 1" },"
r465": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 815"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 65"," Paragraph":" 1","
Subparagraph":" (f)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480175 / 815- 40- 65- 1" }," r466": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef","
Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 35"," Paragraph":" 54B"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 /
2147482134 / 820- 10- 35- 54B" }," r467": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification","
Section":" 50"," Paragraph":" 2"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2" }," r468": {" role":" http: / / www.
xbrl. org / 2003 / role / disclosureRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (b)","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2" }," r469": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 820","
SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (bbb) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org /
1943274 / 2147482106 / 820- 10- 50- 2" }," r470": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards
Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (bbb) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2" }," r471": {"
role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2","
Subparagraph":" (bbb) (2) (i)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2" }," r472": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c)"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2" }," r473": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 820"," SubTopic":" 10"," Name":"
Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50-
2" }," r474": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 2"," Subparagraph":" (c) (1a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2" }," r475": {" role":" http: / / www. xbrl. org / 2003
/ role / disclosureRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (2)"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2" }," r476": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 820"," SubTopic":" 10","
Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (3)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482106 /
820- 10- 50- 2" }," r477": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 2"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2" }," r478": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (g)"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2" }," r479": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 820"," SubTopic":" 10"," Name":"
Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (h)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2"
}," r480": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":"
2E"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2E" }," r481": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 820","
SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274
/ 2147482106 / 820- 10- 50- 3" }," r482": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification","
Section":" 50"," Paragraph":" 3"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 3" }," r483": {" role":" http: / / www.
xbrl. org / 2003 / role / disclosureRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6A"," Subparagraph":" (a)","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 6A" }," r484": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 820","
SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6A"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org /
1943274 / 2147482106 / 820- 10- 50- 6A" }," r485": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards
Codification"," Section":" 50"," Paragraph":" 6A"," Subparagraph":" (e)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 6A" }," r486": {"
role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6A","
Subparagraph":" (f)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 6A" }," r487": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6A"," Subparagraph":" (h)"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 6A" }," r488": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 820"," SubTopic":" 10"," Name":"
Accounting Standards Codification"," Section":" 50"," Paragraph":" 6B"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50-
6B" }," r489": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 825"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 28"," Subparagraph":" (f)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482907 / 825- 10- 50- 28" }," r490": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 830"," SubTopic":" 30"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 17"," Publisher":" FASB"," URI":" https: / / asc.
fasb. org / 1943274 / 2147481694 / 830- 30- 45- 17" }," r491": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 830"," SubTopic":" 30"," Name":" Accounting Standards
Codification"," Section":" 45"," Paragraph":" 20"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481694 / 830- 30- 45- 20" }," r492": {"
role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 830"," SubTopic":" 30"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 20","
Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481694 / 830- 30- 45- 20" }," r493": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 830"," SubTopic":" 30"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 20"," Subparagraph":" (c)"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147481694 / 830- 30- 45- 20" }," r494": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 830"," SubTopic":" 30"," Name":"
Accounting Standards Codification"," Section":" 45"," Paragraph":" 20"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481694 / 830- 30- 45-
20" }," r495": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 830"," SubTopic":" 30"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 1"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481674 / 830- 30- 50- 1" }," r496": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef","
Topic":" 830"," SubTopic":" 30"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 /
2147481674 / 830- 30- 50- 2" }," r497": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 835"," SubTopic":" 30"," Name":" Accounting Standards Codification","
Section":" 45"," Paragraph":" 2"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482925 / 835- 30- 45- 2" }," r498": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 835"," SubTopic":" 30"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Publisher":" FASB"," URI":" https: / / asc. fasb. org /
1943274 / 2147482900 / 835- 30- 50- 1" }," r499": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 842"," SubTopic":" 10"," Name":" Accounting Standards
Codification"," Section":" 65"," Paragraph":" 8"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479832 / 842- 10- 65- 8" }," r500": {" role":"
http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 842"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 35"," Paragraph":" 12A","
Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479165 / 842- 20- 35- 12A" }," r501": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 842"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 1"," Subparagraph":" (a)"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147479041 / 842- 20- 45- 1" }," r502": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 842"," SubTopic":" 20"," Name":"
Accounting Standards Codification"," Section":" 45"," Paragraph":" 1"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479041 / 842- 20- 45- 1"
}," r503": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 842"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":"
5"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479041 / 842- 20- 45- 5" }," r504": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 842"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (b)"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147478964 / 842- 20- 50- 1" }," r505": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 842"," SubTopic":" 20"," Name":"
Accounting Standards Codification"," Section":" 50"," Paragraph":" 4"," Subparagraph":" (g) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478964 / 842- 20-
50- 4" }," r506": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 842"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 4"," Subparagraph":" (g) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478964 / 842- 20- 50- 4" }," r507": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 842"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 4"," Subparagraph":" (g) (3)"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478964 / 842- 20- 50- 4" }," r508": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 842"," SubTopic":" 20","
Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478964 / 842- 20- 50- 6" }," r509": {"
role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 842"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 7A","
Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478964 / 842- 20- 50- 7A" }," r510": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 842"," SubTopic":" 30"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 5"," Subparagraph":" (c)"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147479773 / 842- 30- 50- 5" }," r511": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 848"," SubTopic":" 10"," Name":"
Accounting Standards Codification"," Section":" 65"," Paragraph":" 2"," Subparagraph":" (a) (3) (iii) (03)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483550 /
848- 10- 65- 2" }," r512": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 850"," Name":" Accounting Standards Codification"," Publisher":" FASB"," URI":" https:
/ / asc. fasb. org / 850 / tableOfContent" }," r513": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 850"," SubTopic":" 10"," Name":" Accounting Standards
Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483326 / 850- 10- 50- 1" }," r514": {" role":"
http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 850"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1","
Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483326 / 850- 10- 50- 1" }," r515": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef","
Topic":" 850"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc.
fasb. org / 1943274 / 2147483326 / 850- 10- 50- 1" }," r516": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 850"," SubTopic":" 10"," Name":" Accounting Standards
Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483326 / 850- 10- 50- 1" }," r517": {" role":"
http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 850"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483326 / 850- 10- 50- 2" }," r518": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 850"," SubTopic":" 10","
Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483326 / 850- 10- 50- 3" }," r519": {"
role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 850"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483326 / 850- 10- 50- 6" }," r520": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 855","
Name":" Accounting Standards Codification"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 855 / tableOfContent" }," r521": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 855"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Publisher":" FASB"," URI":" https: / / asc. fasb. org /

1943274 / 2147483399 / 855- 10- 50- 2" }," r522": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 855"," SubTopic":" 10"," Name":" Accounting Standards
Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483399 / 855- 10- 50- 2" }," r523": {" role":"
http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 860"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3","
Subparagraph":" (b) (2) (i)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481326 / 860- 20- 50- 3" }," r524": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 860"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Subparagraph":" (b) (2) (ii)"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481326 / 860- 20- 50- 3" }," r525": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 860"," SubTopic":" 20","
Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Subparagraph":" (b) (3)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481326 /
860- 20- 50- 3" }," r526": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 860"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 3"," Subparagraph":" (bb) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481326 / 860- 20- 50- 3" }," r527": {" role":" http: / / www. xbrl. org / 2003
/ role / disclosureRef"," Topic":" 860"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Subparagraph":" (bb) (2)"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481326 / 860- 20- 50- 3" }," r528": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 860"," SubTopic":" 20","
Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Subparagraph":" (bb) (3)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481326 /
860- 20- 50- 3" }," r529": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 860"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 3"," Subparagraph":" (c) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481326 / 860- 20- 50- 3" }," r530": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 860"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Subparagraph":" (c) (2)"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481326 / 860- 20- 50- 3" }," r531": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 860"," SubTopic":" 20","
Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Subparagraph":" (c) (3)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481326 /
860- 20- 50- 3" }," r532": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 860"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 4"," Subparagraph":" (b) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481326 / 860- 20- 50- 4" }," r533": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 860"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 4"," Subparagraph":" (b) (2)"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481326 / 860- 20- 50- 4" }," r534": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 860"," SubTopic":" 20","
Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 4"," Subparagraph":" (b) (3)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481326 /
860- 20- 50- 4" }," r535": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 860"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 4"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481326 / 860- 20- 50- 4" }," r536": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 860"," SubTopic":" 30"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 1"," Publisher":" FASB"," URI":" https: / / asc.
fasb. org / 1943274 / 2147481444 / 860- 30- 45- 1" }," r537": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 860"," SubTopic":" 30"," Name":" Accounting Standards
Codification"," Section":" 50"," Paragraph":" 7"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481420 / 860- 30- 50- 7" }," r538": {" role":"
http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 860"," SubTopic":" 30"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 7","
Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481420 / 860- 30- 50- 7" }," r539": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef","
Topic":" 860"," SubTopic":" 30"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 9"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 /
2147481420 / 860- 30- 50- 9" }," r540": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 860"," SubTopic":" 50"," Name":" Accounting Standards Codification","
Section":" 50"," Paragraph":" 3"," Subparagraph":" (a) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481229 / 860- 50- 50- 3" }," r541": {" role":" http: / / www.
xbrl. org / 2003 / role / disclosureRef"," Topic":" 860"," SubTopic":" 50"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Subparagraph":" (a) (2)","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481229 / 860- 50- 50- 3" }," r542": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 860","
SubTopic":" 50"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Subparagraph":" (a) (3)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org /
1943274 / 2147481229 / 860- 50- 50- 3" }," r543": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 860"," SubTopic":" 50"," Name":" Accounting Standards
Codification"," Section":" 50"," Paragraph":" 3"," Subparagraph":" (a) (4) (i)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481229 / 860- 50- 50- 3" }," r544": {"
role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 860"," SubTopic":" 50"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 4","
Subparagraph":" (a) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481229 / 860- 50- 50- 4" }," r545": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 860"," SubTopic":" 50"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 4"," Subparagraph":" (a) (2)"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147481229 / 860- 50- 50- 4" }," r546": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 860"," SubTopic":" 50"," Name":"
Accounting Standards Codification"," Section":" 50"," Paragraph":" 4"," Subparagraph":" (a) (3)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481229 / 860- 50-
50- 4" }," r547": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 860"," SubTopic":" 50"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 4"," Subparagraph":" (a) (4)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481229 / 860- 50- 50- 4" }," r548": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 860"," SubTopic":" 50"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 4"," Subparagraph":" (a) (5)"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481229 / 860- 50- 50- 4" }," r549": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 860"," SubTopic":" 50","
Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 4"," Subparagraph":" (a) (6)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481229 /
860- 50- 50- 4" }," r550": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 860"," SubTopic":" 50"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 4"," Subparagraph":" (a) (7)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481229 / 860- 50- 50- 4" }," r551": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 860"," SubTopic":" 50"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 4"," Subparagraph":" (b)"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147481229 / 860- 50- 50- 4" }," r552": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 860"," SubTopic":" 50"," Name":"
Accounting Standards Codification"," Section":" 50"," Paragraph":" 4"," Subparagraph":" (e) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481229 / 860- 50- 50-
4" }," r553": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 860"," SubTopic":" 50"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 4"," Subparagraph":" (e) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481229 / 860- 50- 50- 4" }," r554": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 860"," SubTopic":" 50"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 4"," Subparagraph":" (e) (3)"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481229 / 860- 50- 50- 4" }," r555": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 910"," SubTopic":" 10","
Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482546 / 910-
10- 50- 6" }," r556": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 924"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99","
Paragraph":" 1"," Subparagraph":" (SAB Topic 11. L)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479941 / 924- 10- S99- 1" }," r557": {" role":" http: / / www.
xbrl. org / 2003 / role / disclosureRef"," Topic":" 932"," SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147478934 / 932- 220- 50- 1" }," r558": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 932"," SubTopic":" 235"," Name":"
Accounting Standards Codification"," Section":" 50"," Paragraph":" 18"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477215 / 932- 235- 50-
18" }," r559": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 932"," SubTopic":" 235"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 18"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477215 / 932- 235- 50- 18" }," r560": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 932"," SubTopic":" 235"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 18"," Subparagraph":" (c)"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477215 / 932- 235- 50- 18" }," r561": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 932"," SubTopic":"
235"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 19"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477215 / 932- 235- 50- 19" },"
r562": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 932"," SubTopic":" 235"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":"
23"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477215 / 932- 235- 50- 23" }," r563": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 932"," SubTopic":" 235"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 23"," Subparagraph":" (b)"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147477215 / 932- 235- 50- 23" }," r564": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 932"," SubTopic":" 235","
Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 23"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477215 /
932- 235- 50- 23" }," r565": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 932"," SubTopic":" 235"," Name":" Accounting Standards Codification"," Section":"
50"," Paragraph":" 23"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477215 / 932- 235- 50- 23" }," r566": {" role":" http: / / www. xbrl. org /
2003 / role / disclosureRef"," Topic":" 932"," SubTopic":" 235"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 23"," Subparagraph":" (e)"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477215 / 932- 235- 50- 23" }," r567": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 932"," SubTopic":"
235"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 23"," Subparagraph":" (f)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 /
2147477215 / 932- 235- 50- 23" }," r568": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 932"," SubTopic":" 235"," Name":" Accounting Standards Codification","
Section":" 50"," Paragraph":" 31"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477215 / 932- 235- 50- 31" }," r569": {" role":" http: / / www.
xbrl. org / 2003 / role / disclosureRef"," Topic":" 932"," SubTopic":" 235"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 31"," Subparagraph":" (b)","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477215 / 932- 235- 50- 31" }," r570": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 932","
SubTopic":" 235"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 31"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org /
1943274 / 2147477215 / 932- 235- 50- 31" }," r571": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 932"," SubTopic":" 235"," Name":" Accounting Standards
Codification"," Section":" 50"," Paragraph":" 31"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477215 / 932- 235- 50- 31" }," r572": {"
role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 932"," SubTopic":" 235"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 31","
Subparagraph":" (e)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477215 / 932- 235- 50- 31" }," r573": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 932"," SubTopic":" 235"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 31"," Subparagraph":" (f)"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147477215 / 932- 235- 50- 31" }," r574": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 932"," SubTopic":" 235","
Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 5"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477215 / 932-
235- 50- 5" }," r575": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 932"," SubTopic":" 235"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 5"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477215 / 932- 235- 50- 5" }," r576": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 932"," SubTopic":" 235"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 5"," Subparagraph":" (c)"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477215 / 932- 235- 50- 5" }," r577": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 932"," SubTopic":" 235","
Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 5"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477215 / 932-
235- 50- 5" }," r578": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 932"," SubTopic":" 235"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 5"," Subparagraph":" (e)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477215 / 932- 235- 50- 5" }," r579": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 932"," SubTopic":" 235"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 5"," Subparagraph":" (f)"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147477215 / 932- 235- 50- 5" }," r580": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 932"," SubTopic":" 235"," Name":"
Accounting Standards Codification"," Section":" 50"," Paragraph":" 6"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477215 / 932- 235- 50- 6" }," r581": {" role":"
http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 932"," SubTopic":" 235"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 7"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477215 / 932- 235- 50- 7" }," r582": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 932"," SubTopic":" 235","

Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 8"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477215 / 932-
235- 50- 8" }," r583": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 932"," SubTopic":" 235"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 8"," Subparagraph":" (c) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477215 / 932- 235- 50- 8" }," r584": {" role":" http: / / www. xbrl. org / 2003
/ role / disclosureRef"," Topic":" 932"," SubTopic":" 235"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 8"," Subparagraph":" (c) (2)"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477215 / 932- 235- 50- 8" }," r585": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 932"," SubTopic":" 280","
Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478657 / 932- 280- 50- 1" }," r586": {"
role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 932"," SubTopic":" 323"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478988 / 932- 323- 50- 1" }," r587": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 940","
SubTopic":" 820"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org /
1943274 / 2147478119 / 940- 820- 50- 1" }," r588": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 942"," SubTopic":" 210"," Name":" Accounting Standards
Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 9- 03 (6))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478546 / 942- 210- S99- 1" },"
r589": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 942"," SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":"
1"," Subparagraph":" (SX 210. 9- 04 (26))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478524 / 942- 220- S99- 1" }," r590": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 942"," SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 9- 04 (27))","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478524 / 942- 220- S99- 1" }," r591": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 942","
SubTopic":" 235"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 9- 05 (b) (2))"," Publisher":" FASB"," URI":" https: / /
asc. fasb. org / 1943274 / 2147477314 / 942- 235- S99- 1" }," r592": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 942"," SubTopic":" 360"," Name":" Accounting
Standards Codification"," Section":" 50"," Paragraph":" 1"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478451 / 942- 360- 50- 1" }," r593": {" role":" http: / / www.
xbrl. org / 2003 / role / disclosureRef"," Topic":" 944"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210.
7- 03 (a) (1) (6))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1" }," r594": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef","
Topic":" 944"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 7- 03 (a) (1))"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1" }," r595": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 944"," SubTopic":" 210","
Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 7- 03 (a) (12))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org /
1943274 / 2147478777 / 944- 210- S99- 1" }," r596": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 944"," SubTopic":" 210"," Name":" Accounting Standards
Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 7- 03 (a) (17))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99-
1" }," r597": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 944"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99","
Paragraph":" 1"," Subparagraph":" (SX 210. 7- 03 (a) (19))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1" }," r598": {" role":" http: / /
www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 944"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX
210. 7- 03 (a) (21))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1" }," r599": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef","
Topic":" 944"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 7- 03 (a) (22))"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1" }," r600": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 944"," SubTopic":" 210","
Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 7- 03 (a) (23) (a) (1))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org /
1943274 / 2147478777 / 944- 210- S99- 1" }," r601": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 944"," SubTopic":" 210"," Name":" Accounting Standards
Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 7- 03 (a) (23) (a) (3))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210-
S99- 1" }," r602": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 944"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99","
Paragraph":" 1"," Subparagraph":" (SX 210. 7- 03 (a) (23) (a) (4))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1" }," r603": {" role":" http:
/ / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 944"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":"
(SX 210. 7- 03 (a) (25))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1" }," r604": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 944"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 7- 03 (a) (3))","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1" }," r605": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 944","
SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 7- 03 (a) (8) (a))"," Publisher":" FASB"," URI":" https: /
/ asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1" }," r606": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 944"," SubTopic":" 210"," Name":" Accounting
Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 7- 03 (a) (8))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478777 / 944-
210- S99- 1" }," r607": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 944"," SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" S99","
Paragraph":" 1"," Subparagraph":" (SX 210. 7- 04 (11))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477250 / 944- 220- S99- 1" }," r608": {" role":" http: / / www.
xbrl. org / 2003 / role / disclosureRef"," Topic":" 944"," SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210.
7- 04 (18))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477250 / 944- 220- S99- 1" }," r609": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":"
944"," SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 7- 04 (19))"," Publisher":" FASB"," URI":"
https: / / asc. fasb. org / 1943274 / 2147477250 / 944- 220- S99- 1" }," r610": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 944"," SubTopic":" 220"," Name":"
Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 7- 04 (2) (a))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 /
2147477250 / 944- 220- S99- 1" }," r611": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 944"," SubTopic":" 220"," Name":" Accounting Standards Codification","
Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 7- 04 (20))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477250 / 944- 220- S99- 1" }," r612": {"
role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 944"," SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1","
Subparagraph":" (SX 210. 7- 04 (22))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477250 / 944- 220- S99- 1" }," r613": {" role":" http: / / www. xbrl. org / 2003 / role
/ disclosureRef"," Topic":" 944"," SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 7- 04 (23))","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477250 / 944- 220- S99- 1" }," r614": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 944","
SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 7- 04 (9))"," Publisher":" FASB"," URI":" https: / / asc.
fasb. org / 1943274 / 2147477250 / 944- 220- S99- 1" }," r615": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting
Standards Codification"," Section":" 50"," Paragraph":" 5"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480081 / 944- 40- 50- 5" }," r616":
{" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 5","
Subparagraph":" (e)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480081 / 944- 40- 50- 5" }," r617": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef","
Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 7A"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc.
fasb. org / 1943274 / 2147480081 / 944- 40- 50- 7A" }," r618": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting
Standards Codification"," Section":" 50"," Paragraph":" 9"," Subparagraph":" (a) (4)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480081 / 944- 40- 50- 9" },"
r619": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 65"," Paragraph":" 2","
Subparagraph":" (e)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480016 / 944- 40- 65- 2" }," r620": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef","
Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 65"," Paragraph":" 2"," Subparagraph":" (f) (1)"," Publisher":" FASB"," URI":" https: / /
asc. fasb. org / 1943274 / 2147480016 / 944- 40- 65- 2" }," r621": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting
Standards Codification"," Section":" 65"," Paragraph":" 2"," Subparagraph":" (f) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480016 / 944- 40- 65- 2" },"
r622": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 65"," Paragraph":" 2","
Subparagraph":" (g) (2) (i)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480016 / 944- 40- 65- 2" }," r623": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 65"," Paragraph":" 2"," Subparagraph":" (g) (2) (ii)"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480016 / 944- 40- 65- 2" }," r624": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 944"," SubTopic":" 40","
Name":" Accounting Standards Codification"," Section":" 65"," Paragraph":" 2"," Subparagraph":" (h) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480016 /
944- 40- 65- 2" }," r625": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" S99","
Paragraph":" 1"," Subparagraph":" (SAB Topic 5. W. Q2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479583 / 944- 40- S99- 1" }," r626": {" role":" http: / / www.
xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 3"," Subparagraph":" (SX 210. 6-
03 (d))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479886 / 946- 10- S99- 3" }," r627": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":"
946"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 3"," Subparagraph":" (SX 210. 6- 03 (h) (1))"," Publisher":" FASB"," URI":"
https: / / asc. fasb. org / 1943274 / 2147479886 / 946- 10- S99- 3" }," r628": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 10"," Name":"
Accounting Standards Codification"," Section":" S99"," Paragraph":" 3"," Subparagraph":" (SX 210. 6- 03 (i) (1))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 /
2147479886 / 946- 10- S99- 3" }," r629": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 10"," Name":" Accounting Standards Codification","
Section":" S99"," Paragraph":" 3"," Subparagraph":" (SX 210. 6- 03 (i) (2) (i))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479886 / 946- 10- S99- 3" }," r630": {"
role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 3","
Subparagraph":" (SX 210. 6- 03 (i) (2) (ii))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479886 / 946- 10- S99- 3" }," r631": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 946"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 3"," Subparagraph":" (SX 210. 6- 03 (i) (2))","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479886 / 946- 10- S99- 3" }," r632": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946","
SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 11"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480990 / 946- 20-
50- 11" }," r633": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 13"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480990 / 946- 20- 50- 13" }," r634": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef","
Topic":" 946"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 /
2147480990 / 946- 20- 50- 2" }," r635": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 20"," Name":" Accounting Standards Codification","
Section":" 50"," Paragraph":" 5"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480990 / 946- 20- 50- 5" }," r636": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 946"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6"," Publisher":" FASB"," URI":" https: / / asc. fasb. org /
1943274 / 2147480990 / 946- 20- 50- 6" }," r637": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 205"," Name":" Accounting Standards
Codification"," Section":" 45"," Paragraph":" 4"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478009 / 946- 205- 45- 4" }," r638": {" role":"
http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 205"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478494 / 946- 205- 50- 2" }," r639": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 205","
Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 27"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478494 / 946- 205- 50- 27" }," r640":
{" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 205"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 7","
Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478494 / 946- 205- 50- 7" }," r641": {" role":" http: / / www. xbrl. org / 2003 / role /

disclosureRef"," Topic":" 946"," SubTopic":" 205"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 7"," Subparagraph":" (b)"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147478494 / 946- 205- 50- 7" }," r642": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 205"," Name":"
Accounting Standards Codification"," Section":" 50"," Paragraph":" 7"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478494 / 946- 205- 50-
7" }," r643": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 205"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 7"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478494 / 946- 205- 50- 7" }," r644": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 946"," SubTopic":" 205"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 7"," Subparagraph":" (e)"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478494 / 946- 205- 50- 7" }," r645": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 205","
Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 7"," Subparagraph":" (f)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478494 / 946-
205- 50- 7" }," r646": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 205"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 7"," Subparagraph":" (g)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478494 / 946- 205- 50- 7" }," r647": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 946"," SubTopic":" 205"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 7"," Subparagraph":" (h)"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478494 / 946- 205- 50- 7" }," r648": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 210","
Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 4"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477796 / 946- 210- 45- 4" }," r649": {"
role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1","
Subparagraph":" (b) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478795 / 946- 210- 50- 1" }," r650": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 946"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Publisher":" FASB"," URI":" https: / / asc. fasb. org
/ 1943274 / 2147478795 / 946- 210- 50- 2" }," r651": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 210"," Name":" Accounting Standards
Codification"," Section":" 50"," Paragraph":" 6"," Subparagraph":" (a) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478795 / 946- 210- 50- 6" }," r652": {"
role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6","
Subparagraph":" (e)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478795 / 946- 210- 50- 6" }," r653": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 946"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6"," Subparagraph":" (f)"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147478795 / 946- 210- 50- 6" }," r654": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 210"," Name":"
Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 04 (1))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 /
2147479170 / 946- 210- S99- 1" }," r655": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 210"," Name":" Accounting Standards Codification","
Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 04 (12) (b) (1))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1" }," r656":
{" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1","
Subparagraph":" (SX 210. 6- 04 (12) (b) (2))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1" }," r657": {" role":" http: / / www. xbrl. org /
2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 04 (12)
(b) (3))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1" }," r658": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":"
946"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 04 (13) (a) (2))"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1" }," r659": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 210","
Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 04 (13) (a) (3))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org /
1943274 / 2147479170 / 946- 210- S99- 1" }," r660": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 210"," Name":" Accounting Standards
Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 04 (14))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1"
}," r661": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99","
Paragraph":" 1"," Subparagraph":" (SX 210. 6- 04 (15))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1" }," r662": {" role":" http: / / www.
xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210.
6- 04 (16) (a))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1" }," r663": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef","
Topic":" 946"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 04 (17))"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1" }," r664": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 210","
Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 04 (19))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 /
2147479170 / 946- 210- S99- 1" }," r665": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 210"," Name":" Accounting Standards Codification","
Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 04 (2) (a))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1" }," r666": {"
role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1","
Subparagraph":" (SX 210. 6- 04 (2) (b))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1" }," r667": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 946"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 04 (3) (a))","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1" }," r668": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946","
SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 04 (3) (b))"," Publisher":" FASB"," URI":" https: / /
asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1" }," r669": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 210"," Name":" Accounting
Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 04 (3) (c))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479170 / 946-
210- S99- 1" }," r670": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99","
Paragraph":" 1"," Subparagraph":" (SX 210. 6- 04 (6) (b))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1" }," r671": {" role":" http: / /
www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX
210. 6- 04 (6) (c))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1" }," r672": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef","
Topic":" 946"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 04 (6) (d))"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1" }," r673": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 210","
Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 04 (6) (e))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274
/ 2147479170 / 946- 210- S99- 1" }," r674": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 210"," Name":" Accounting Standards Codification","
Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 04 (8))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1" }," r675": {"
role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1","
Subparagraph":" (SX 210. 6- 04 (9) (b))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1" }," r676": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 946"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 04 (9) (c))","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1" }," r677": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946","
SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 04 (9) (d))"," Publisher":" FASB"," URI":" https: / /
asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 1" }," r678": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 210"," Name":" Accounting
Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 04 (9) (e))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479170 / 946-
210- S99- 1" }," r679": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99","
Paragraph":" 2"," Subparagraph":" (SX 210. 6- 05 (2))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 2" }," r680": {" role":" http: / / www.
xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 2"," Subparagraph":" (SX 210.
6- 05 (4))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479170 / 946- 210- S99- 2" }," r681": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":"
946"," SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 3"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org /
1943274 / 2147479105 / 946- 220- 45- 3" }," r682": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 220"," Name":" Accounting Standards
Codification"," Section":" 45"," Paragraph":" 7"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479105 / 946- 220- 45- 7" }," r683": {" role":" http: / / www. xbrl. org /
2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Publisher":" FASB"," URI":" https: / /
asc. fasb. org / 1943274 / 2147478297 / 946- 220- 50- 3" }," r684": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 220"," Name":" Accounting
Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 07 (1))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220-
S99- 1" }," r685": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" S99","
Paragraph":" 1"," Subparagraph":" (SX 210. 6- 07 (2) (a))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1" }," r686": {" role":" http: / /
www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX
210. 6- 07 (2) (c) (2) (i))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1" }," r687": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 946"," SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 07 (2) (c) (2) (ii))","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1" }," r688": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946","
SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 07 (2) (c))"," Publisher":" FASB"," URI":" https: / /
asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1" }," r689": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 220"," Name":" Accounting
Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 07 (2) (e))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479134 / 946-
220- S99- 1" }," r690": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" S99","
Paragraph":" 1"," Subparagraph":" (SX 210. 6- 07 (2) (g) (3))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1" }," r691": {" role":" http: / /
www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX
210. 6- 07 (7) (a) (1))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1" }," r692": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 946"," SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 07 (7) (a) (2))","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1" }," r693": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946","
SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 07 (7) (a) (3))"," Publisher":" FASB"," URI":" https: /
/ asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1" }," r694": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 220"," Name":" Accounting
Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 07 (7) (a) (5))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479134 /
946- 220- S99- 1" }," r695": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":"
S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 07 (7) (a) (6))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1" }," r696": {" role":"
http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1","
Subparagraph":" (SX 210. 6- 07 (7) (a) (7))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1" }," r697": {" role":" http: / / www. xbrl. org / 2003
/ role / disclosureRef"," Topic":" 946"," SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 07 (7) (c)
(1))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1" }," r698": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":"
946"," SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 07 (7) (c) (2))"," Publisher":" FASB"," URI":"

https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1" }," r699": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 220"," Name":"
Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 07 (7) (c) (3))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 /
2147479134 / 946- 220- S99- 1" }," r700": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 220"," Name":" Accounting Standards Codification","
Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 07 (7) (c) (5))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1" }," r701": {"
role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1","
Subparagraph":" (SX 210. 6- 07 (7) (c) (6))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1" }," r702": {" role":" http: / / www. xbrl. org / 2003
/ role / disclosureRef"," Topic":" 946"," SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 07 (7) (c)
(7))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1" }," r703": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":"
946"," SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 07 (9))"," Publisher":" FASB"," URI":" https:
/ / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 1" }," r704": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 220"," Name":" Accounting
Standards Codification"," Section":" S99"," Paragraph":" 3"," Subparagraph":" (SX 210. 6- 09 (1) (d))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479134 / 946-
220- S99- 3" }," r705": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" S99","
Paragraph":" 3"," Subparagraph":" (SX 210. 6- 09 (4) (b))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3" }," r706": {" role":" http: / /
www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 3"," Subparagraph":" (SX
210. 6- 09 (6))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3" }," r707": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef","
Topic":" 946"," SubTopic":" 220"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 3"," Subparagraph":" (SX 210. 6- 09 (7))"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147479134 / 946- 220- S99- 3" }," r708": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 235","
Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477968 / 946-
235- 50- 2" }," r709": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 235"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 2"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477968 / 946- 235- 50- 2" }," r710": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 946"," SubTopic":" 235"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (d)"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477968 / 946- 235- 50- 2" }," r711": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 235","
Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (e)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477968 / 946-
235- 50- 2" }," r712": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 310"," Name":" Accounting Standards Codification"," Section":" 45","
Paragraph":" 1"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477802 / 946- 310- 45- 1" }," r713": {" role":" http: / / www. xbrl. org / 2003 /
role / disclosureRef"," Topic":" 946"," SubTopic":" 320"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 12- 12 (Column A)
(Footnote 2))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477271 / 946- 320- S99- 1" }," r714": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef","
Topic":" 946"," SubTopic":" 320"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 12- 12 (Column C) (Footnote 5))","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477271 / 946- 320- S99- 1" }," r715": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946","
SubTopic":" 320"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 2"," Subparagraph":" (SX 210. 12- 12A (Column A) (Footnote 2))"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477271 / 946- 320- S99- 2" }," r716": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":"
320"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 2"," Subparagraph":" (SX 210. 12- 12A (Column C) (Footnote 4))"," Publisher":" FASB"," URI":"
https: / / asc. fasb. org / 1943274 / 2147477271 / 946- 320- S99- 2" }," r717": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 320"," Name":"
Accounting Standards Codification"," Section":" S99"," Paragraph":" 3"," Subparagraph":" (SX 210. 12- 12B (Column A) (Footnote 4) (a))"," Publisher":" FASB"," URI":" https: / / asc.
fasb. org / 1943274 / 2147477271 / 946- 320- S99- 3" }," r718": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 320"," Name":" Accounting
Standards Codification"," Section":" S99"," Paragraph":" 3"," Subparagraph":" (SX 210. 12- 12B (Column A) (Footnote 4) (b))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org /
1943274 / 2147477271 / 946- 320- S99- 3" }," r719": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 320"," Name":" Accounting Standards
Codification"," Section":" S99"," Paragraph":" 3"," Subparagraph":" (SX 210. 12- 12B (Column C) (Footnote 2))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 /
2147477271 / 946- 320- S99- 3" }," r720": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 320"," Name":" Accounting Standards Codification","
Section":" S99"," Paragraph":" 6"," Subparagraph":" (SX 210. 12- 14 (Column A) (Footnote 2))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477271 / 946- 320- S99-
6" }," r721": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 320"," Name":" Accounting Standards Codification"," Section":" S99","
Paragraph":" 6"," Subparagraph":" (SX 210. 12- 14 (Column F) (Footnote 7))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477271 / 946- 320- S99- 6" }," r722": {"
role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 505"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478448 / 946- 505- 50- 1" }," r723": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946","
SubTopic":" 505"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org /
1943274 / 2147478448 / 946- 505- 50- 2" }," r724": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 505"," Name":" Accounting Standards
Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478448 / 946- 505- 50- 2" }," r725": {" role":"
http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 505"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2","
Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478448 / 946- 505- 50- 2" }," r726": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 946"," SubTopic":" 505"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (d)"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147478448 / 946- 505- 50- 2" }," r727": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 946"," SubTopic":" 505"," Name":"
Accounting Standards Codification"," Section":" 50"," Paragraph":" 6"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478448 / 946- 505- 50- 6" }," r728": {" role":"
http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 948"," SubTopic":" 310"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1","
Subparagraph":" (SX 210. 12- 29 (Column A) (Footnote 4))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479628 / 948- 310- S99- 1" }," r729": {" role":" http: / / www.
xbrl. org / 2003 / role / disclosureRef"," Topic":" 954"," SubTopic":" 440"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (a)","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478522 / 954- 440- 50- 1" }," r730": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 954","
SubTopic":" 450"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477850 / 954- 450-
50- 1" }," r731": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 970"," SubTopic":" 360"," Name":" Accounting Standards Codification"," Section":" S99","
Paragraph":" 1"," Subparagraph":" (SX 210. 12- 28 (Column A) (Footnote 2))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478979 / 970- 360- S99- 1" }," r732": {"
role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 970"," SubTopic":" 360"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1","
Subparagraph":" (SX 210. 12- 28 (Column B))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478979 / 970- 360- S99- 1" }," r733": {" role":" http: / / www. xbrl. org /
2003 / role / disclosureRef"," Topic":" 970"," SubTopic":" 360"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 12- 28
(Column C))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478979 / 970- 360- S99- 1" }," r734": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef","
Topic":" 970"," SubTopic":" 360"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 12- 28 (Column D))"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478979 / 970- 360- S99- 1" }," r735": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 970"," SubTopic":"
360"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 12- 28 (Column E))"," Publisher":" FASB"," URI":" https: / / asc. fasb.
org / 1943274 / 2147478979 / 970- 360- S99- 1" }," r736": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 970"," SubTopic":" 360"," Name":" Accounting Standards
Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 12- 28 (Column F))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478979 / 970- 360-
S99- 1" }," r737": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 970"," SubTopic":" 360"," Name":" Accounting Standards Codification"," Section":" S99","
Paragraph":" 1"," Subparagraph":" (SX 210. 12- 28 (Column G))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478979 / 970- 360- S99- 1" }," r738": {" role":" http: /
/ www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 970"," SubTopic":" 360"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":"
(SX 210. 12- 28 (Column H))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478979 / 970- 360- S99- 1" }," r739": {" role":" http: / / www. xbrl. org / 2003 / role /
disclosureRef"," Topic":" 970"," SubTopic":" 360"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 12- 28 (Column I))","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478979 / 970- 360- S99- 1" }," r740": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 976","
SubTopic":" 310"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org /
1943274 / 2147477332 / 976- 310- 50- 1" }," r741": {" role":" http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 978"," SubTopic":" 310"," Name":" Accounting Standards
Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479230 / 978- 310- 50- 1" }," r742": {" role":"
http: / / www. xbrl. org / 2003 / role / disclosureRef"," Topic":" 985"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481283 / 985- 20- 50- 2" }," r743": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Name":" Accounting Standards
Codification"," Section":" 55"," Paragraph":" 13H"," Subparagraph":" (b)"," SubTopic":" 40"," Topic":" 944"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 /
2147480046 / 944- 40- 55- 13H" }," r744": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification","
Section":" 45"," Paragraph":" 1"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483467 / 210- 10- 45- 1" }," r745": {" role":" http: / / www.
xbrl. org / 2003 / role / exampleRef"," Topic":" 210"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 16"," Publisher":" FASB"," URI":"
https: / / asc. fasb. org / 1943274 / 2147483444 / 210- 20- 55- 16" }," r746": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 210"," SubTopic":" 20"," Name":"
Accounting Standards Codification"," Section":" 55"," Paragraph":" 21"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483444 / 210- 20- 55- 21" }," r747": {" role":"
http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 210"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 22"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483444 / 210- 20- 55- 22" }," r748": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 235"," SubTopic":" 10","
Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 4- 08 (m) (1) (ii) (A))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org /
1943274 / 2147480678 / 235- 10- S99- 1" }," r749": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 260"," SubTopic":" 10"," Name":" Accounting Standards
Codification"," Section":" 55"," Paragraph":" 52"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482635 / 260- 10- 55- 52" }," r750": {" role":" http: / / www. xbrl. org
/ 2003 / role / exampleRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 30"," Subparagraph":" (d)"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 30" }," r751": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 280"," SubTopic":" 10","
Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 31"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 31" }," r752":
{" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 47","
Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482785 / 280- 10- 55- 47" }," r753": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef","
Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 47"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc.
fasb. org / 1943274 / 2147482785 / 280- 10- 55- 47" }," r754": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards
Codification"," Section":" 55"," Paragraph":" 47"," Subparagraph":" (bb)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482785 / 280- 10- 55- 47" }," r755": {"
role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 47","
Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482785 / 280- 10- 55- 47" }," r756": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef","
Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 47"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc.

fasb. org / 1943274 / 2147482785 / 280- 10- 55- 47" }," r757": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 48"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482785 / 280- 10- 55- 48" }," r758": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 49"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482785 / 280- 10- 55- 49" }," r759": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 54"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482785 / 280- 10- 55- 54" }," r760": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 54"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482785 / 280- 10- 55- 54" }," r761": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 54"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482785 / 280- 10- 55- 54" }," r762": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 54"," Subparagraph":" (e)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482785 / 280- 10- 55- 54" }," r763": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 310"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 12A"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481933 / 310- 10- 55- 12A" }," r764": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 326"," SubTopic":" 30"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 8"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479081 / 326- 30- 55- 8" }," r765": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1B"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1B" }," r766": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 69B"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481568 / 470- 20- 55- 69B" }," r767": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 69C"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481568 / 470- 20- 55- 69C" }," r768": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 69E"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481568 / 470- 20- 55- 69E" }," r769": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 69F"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481568 / 470- 20- 55- 69F" }," r770": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 505"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 13"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 13" }," r771": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 606"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 91"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479777 / 606- 10- 55- 91" }," r772": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 715"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (d) (ii)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480506 / 715- 20- 50- 1" }," r773": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 715"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (d) (iv) (01)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480506 / 715- 20- 50- 1" }," r774": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 715"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 17"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480482 / 715- 20- 55- 17" }," r775": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 715"," SubTopic":" 80"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 8"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480547 / 715- 80- 55- 8" }," r776": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (a) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r777": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (a) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r778": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 217"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482663 / 740- 10- 55- 217" }," r779": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 231"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482663 / 740- 10- 55- 231" }," r780": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 100"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482078 / 820- 10- 55- 100" }," r781": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 101"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482078 / 820- 10- 55- 101" }," r782": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 102"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482078 / 820- 10- 55- 102" }," r783": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 103"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482078 / 820- 10- 55- 103" }," r784": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 107"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482078 / 820- 10- 55- 107" }," r785": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 107"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482078 / 820- 10- 55- 107" }," r786": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 107"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482078 / 820- 10- 55- 107" }," r787": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 107"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482078 / 820- 10- 55- 107" }," r788": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 107"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482078 / 820- 10- 55- 107" }," r789": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 107"," Subparagraph":" (e)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482078 / 820- 10- 55- 107" }," r790": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 835"," SubTopic":" 30"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 8"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482949 / 835- 30- 55- 8" }," r791": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 842"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Subparagraph":" (c) (3)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478964 / 842- 20- 50- 3" }," r792": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 842"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 53"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479589 / 842- 20- 55- 53" }," r793": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 852"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 10"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481372 / 852- 10- 55- 10" }," r794": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 860"," SubTopic":" 30"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 4"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481395 / 860- 30- 55- 4" }," r795": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 932"," SubTopic":" 235"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 17"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477215 / 932- 235- 50- 17" }," r796": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 932"," SubTopic":" 235"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 21"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477215 / 932- 235- 50- 21" }," r797": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 932"," SubTopic":" 235"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 29"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477215 / 932- 235- 50- 29" }," r798": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 932"," SubTopic":" 235"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477215 / 932- 235- 50- 3" }," r799": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 932"," SubTopic":" 235"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 2"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477916 / 932- 235- 55- 2" }," r800": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 932"," SubTopic":" 235"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 4"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477916 / 932- 235- 55- 4" }," r801": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 932"," SubTopic":" 235"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 5"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477916 / 932- 235- 55- 5" }," r802": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 932"," SubTopic":" 235"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 6"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477916 / 932- 235- 55- 6" }," r803": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 29F"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480046 / 944- 40- 55- 29F" }," r804": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 9C"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480046 / 944- 40- 55- 9C" }," r805": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 944"," SubTopic":" 80"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 17"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480078 / 944- 80- 55- 17" }," r806": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 946"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (b) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478795 / 946- 210- 50- 1" }," r807": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 946"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6"," Subparagraph":" (a) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478795 / 946- 210- 50- 6" }," r808": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 946"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 1"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477439 / 946- 210- 55- 1" }," r809": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 946"," SubTopic":" 310"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 1"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477802 / 946- 310- 45- 1" }," r810": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 946"," SubTopic":" 320"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 12- 12 (Column A) (Footnote 2) (i))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477271 / 946- 320- S99- 1" }," r811": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 946"," SubTopic":" 320"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 2"," Subparagraph":" (SX 210. 12- 12A (Column A) (Footnote 2))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477271 / 946- 320- S99- 2" }," r812": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 946"," SubTopic":" 320"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 3"," Subparagraph":" (SX 210. 12- 12B (Column A) (Footnote 1) (a))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477271 / 946- 320- S99- 3" }," r813": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 946"," SubTopic":" 320"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 6"," Subparagraph":" (SX 210. 12- 14 (Column A) (Footnote 2))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477271 / 946- 320- S99- 6" }," r814": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 946"," SubTopic":" 830"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 10"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479168 / 946- 830- 55- 10" }," r815": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 946"," SubTopic":" 830"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 11"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479168 / 946- 830- 55- 11" }," r816": {" role":" http: / / www. xbrl. org / 2003 / role / exampleRef"," Topic":" 946"," SubTopic":" 830"," Name":" Accounting Standards Codification"," Section":" 55"," Paragraph":" 12"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479168 / 946- 830- 55- 12" }," r817": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" Global LEI Foundation" }," r818": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Exchange Act"," Number":" 240"," Section":" 12" }," r819": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Exchange Act"," Number":" 240"," Section":" 12"," Subsection":" b" }," r820": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Exchange Act"," Number":" 240"," Section":" 12"," Subsection":" b- 2" }," r821": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Exchange Act","

Number":" 240"," Section":" 12"," Subsection":" b- 23" }," r822": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Exchange Act","
Number":" 240"," Section":" 12"," Subsection":" d1- 1" }," r823": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Exchange Act","
Number":" 240"," Section":" 12"," Subsection":" g" }," r824": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Exchange Act"," Number":"
240"," Section":" 12, 13, 15d" }," r825": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Exchange Act"," Number":" 240"," Section":"
13e"," Subsection":" 4c" }," r826": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Exchange Act"," Number":" 240"," Section":" 14a","
Subsection":" 12" }," r827": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Exchange Act"," Number":" 240"," Section":" 14d","
Subsection":" 2b" }," r828": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Exchange Act"," Number":" 240"," Section":" 15","
Subsection":" d" }," r829": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form 10- K"," Number":" 249"," Section":" 310" }," r830": {"
role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form 10- Q"," Number":" 240"," Section":" 308"," Subsection":" a" }," r831": {" role":" http:
/ / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form 10- Q"," Number":" 249"," Section":" 308"," Subsection":" a" }," r832": {" role":" http: / / www. xbrl.
org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form 20- F"," Number":" 249"," Section":" 220"," Subsection":" f" }," r833": {" role":" http: / / www. xbrl. org / 2003 /
role / presentationRef"," Publisher":" SEC"," Name":" Form 20- F"," Section":" 16"," Subsection":" J"," Paragraph":" a" }," r834": {" role":" http: / / www. xbrl. org / 2003 / role /
presentationRef"," Publisher":" SEC"," Name":" Form 20- F"," Section":" 16K" }," r835": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":"
Form 20- F"," Section":" 16K"," Subsection":" b"," Paragraph":" 1" }," r836": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form 20-
F"," Section":" 16K"," Subsection":" b"," Paragraph":" 1"," Subparagraph":" i" }," r837": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":"
Form 20- F"," Section":" 16K"," Subsection":" b"," Paragraph":" 2" }," r838": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form 20-
F"," Section":" 16K"," Subsection":" c"," Paragraph":" 1" }," r839": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form 20- F","
Section":" 6"," Subsection":" F"," Paragraph":" 1" }," r840": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form 20- F"," Section":" 6","
Subsection":" F"," Paragraph":" 1"," Subparagraph":" i" }," r841": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form 20- F","
Section":" 6"," Subsection":" F"," Paragraph":" 1"," Subparagraph":" i"," Sentence":" A" }," r842": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC","
Name":" Form 20- F"," Section":" 6"," Subsection":" F"," Paragraph":" 1"," Subparagraph":" i"," Sentence":" B" }," r843": {" role":" http: / / www. xbrl. org / 2003 / role /
presentationRef"," Publisher":" SEC"," Name":" Form 20- F"," Section":" 6"," Subsection":" F"," Paragraph":" 1"," Subparagraph":" i"," Sentence":" C" }," r844": {" role":" http: / /
www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form 20- F"," Section":" 6"," Subsection":" F"," Paragraph":" 1"," Subparagraph":" i"," Sentence":" D" },"
r845": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form 20- F"," Section":" 6"," Subsection":" F"," Paragraph":" 1","
Subparagraph":" i"," Sentence":" E" }," r846": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form 20- F"," Section":" 6"," Subsection":"
F"," Paragraph":" 1"," Subparagraph":" ii" }," r847": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form 20- F"," Section":" 6","
Subsection":" F"," Paragraph":" 1"," Subparagraph":" iii" }," r848": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form 20- F","
Section":" 6"," Subsection":" F"," Paragraph":" 2" }," r849": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form 40- F"," Number":"
249"," Section":" 240"," Subsection":" f" }," r850": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form 40- F"," Section":" 19","
Paragraph":" a" }," r851": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form 40- F"," Section":" 19"," Paragraph":" a","
Subparagraph":" 1" }," r852": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form 40- F"," Section":" 19"," Paragraph":" a","
Subparagraph":" 1"," Sentence":" i" }," r853": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form 40- F"," Section":" 19","
Paragraph":" a"," Subparagraph":" 1"," Sentence":" ii" }," r854": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form 40- F","
Section":" 19"," Paragraph":" a"," Subparagraph":" 1"," Sentence":" iii" }," r855": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form
40- F"," Section":" 19"," Paragraph":" a"," Subparagraph":" 1"," Sentence":" iv" }," r856": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC","
Name":" Form 40- F"," Section":" 19"," Paragraph":" a"," Subparagraph":" 1"," Sentence":" v" }," r857": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":"
SEC"," Name":" Form 40- F"," Section":" 19"," Paragraph":" a"," Subparagraph":" 2" }," r858": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC","
Name":" Form 40- F"," Section":" 19"," Paragraph":" a"," Subparagraph":" 3" }," r859": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":"
Form 40- F"," Section":" 19"," Paragraph":" b" }," r860": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form 6- K"," Section":" General
Instruction"," Subsection":" B" }," r861": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form 8- K"," Number":" 249"," Section":" 308"
}," r862": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form 8- K"," Section":" 1. 05"," Subsection":" a" }," r863": {" role":" http: / /
www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form F- 3" }," r864": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC","
Name":" Form N- 2" }," r865": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form N- 3" }," r866": {" role":" http: / / www. xbrl. org / 2003
/ role / presentationRef"," Publisher":" SEC"," Name":" Form N- 4" }," r867": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form N- 6"
}," r868": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form N- CSR"," Section":" 18"," Paragraph":" a" }," r869": {" role":" http: / /
www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form N- CSR"," Section":" 18"," Paragraph":" a"," Subparagraph":" 1" }," r870": {" role":" http: / / www.
xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form N- CSR"," Section":" 18"," Paragraph":" a"," Subparagraph":" 1"," Sentence":" i" }," r871": {" role":" http:
/ / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form N- CSR"," Section":" 18"," Paragraph":" a"," Subparagraph":" 1"," Sentence":" ii" }," r872": {"
role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form N- CSR"," Section":" 18"," Paragraph":" a"," Subparagraph":" 1"," Sentence":" iii" },"
r873": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form N- CSR"," Section":" 18"," Paragraph":" a"," Subparagraph":" 1","
Sentence":" iv" }," r874": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form N- CSR"," Section":" 18"," Paragraph":" a","
Subparagraph":" 1"," Sentence":" v" }," r875": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form N- CSR"," Section":" 18","
Paragraph":" a"," Subparagraph":" 2" }," r876": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form N- CSR"," Section":" 18","
Paragraph":" a"," Subparagraph":" 3" }," r877": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form N- CSR"," Section":" 18","
Paragraph":" b" }," r878": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Form S- 3" }," r879": {" role":" http: / / www. xbrl. org / 2003 /
role / presentationRef"," Publisher":" SEC"," Name":" Forms 10- K, 10- Q, 20- F"," Number":" 240"," Section":" 13"," Subsection":" a- 1" }," r880": {" role":" http: / / www. xbrl. org / 2003
/ role / presentationRef"," Publisher":" SEC"," Name":" Investment Company Act"," Number":" 270" }," r881": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef","
Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402"," Subsection":" v" }," r882": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef","
Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402"," Subsection":" v"," Paragraph":" 1" }," r883": {" role":" http: / / www. xbrl. org / 2003 / role /
presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402"," Subsection":" v"," Paragraph":" 2"," Subparagraph":" ii" }," r884": {" role":"
http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402"," Subsection":" v"," Paragraph":" 2","
Subparagraph":" iii" }," r885": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402","
Subsection":" v"," Paragraph":" 2"," Subparagraph":" iii"," Sentence":" B"," Clause":" 1"," Subclause":" ii" }," r886": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef","
Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402"," Subsection":" v"," Paragraph":" 2"," Subparagraph":" iii"," Sentence":" C"," Clause":" 1","
Subclause":" i" }," r887": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402","
Subsection":" v"," Paragraph":" 2"," Subparagraph":" iii"," Sentence":" C"," Clause":" 1"," Subclause":" ii" }," r888": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef","
Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402"," Subsection":" v"," Paragraph":" 2"," Subparagraph":" iii"," Sentence":" C"," Clause":" 1","
Subclause":" iii" }," r889": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402","
Subsection":" v"," Paragraph":" 2"," Subparagraph":" iii"," Sentence":" C"," Clause":" 1"," Subclause":" iv" }," r890": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef","
Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402"," Subsection":" v"," Paragraph":" 2"," Subparagraph":" iii"," Sentence":" C"," Clause":" 1","
Subclause":" v" }," r891": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402","
Subsection":" v"," Paragraph":" 2"," Subparagraph":" iii"," Sentence":" C"," Clause":" 1"," Subclause":" vi" }," r892": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef","
Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402"," Subsection":" v"," Paragraph":" 2"," Subparagraph":" iv" }," r893": {" role":" http: / / www. xbrl.
org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402"," Subsection":" v"," Paragraph":" 2"," Subparagraph":" vi" },"
r894": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402"," Subsection":" v","
Paragraph":" 3" }," r895": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402","
Subsection":" v"," Paragraph":" 4" }," r896": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229","
Section":" 402"," Subsection":" v"," Paragraph":" 5"," Subparagraph":" i" }," r897": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":"
Regulation S- K"," Number":" 229"," Section":" 402"," Subsection":" v"," Paragraph":" 5"," Subparagraph":" ii" }," r898": {" role":" http: / / www. xbrl. org / 2003 / role /
presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402"," Subsection":" v"," Paragraph":" 5"," Subparagraph":" iii" }," r899": {" role":"
http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402"," Subsection":" v"," Paragraph":" 5","
Subparagraph":" iv" }," r900": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402","
Subsection":" v"," Paragraph":" 6" }," r901": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229","
Section":" 402"," Subsection":" v"," Paragraph":" 6"," Subparagraph":" i" }," r902": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":"
Regulation S- K"," Number":" 229"," Section":" 402"," Subsection":" w" }," r903": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":"
Regulation S- K"," Number":" 229"," Section":" 402"," Subsection":" w"," Paragraph":" 1" }," r904": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":"
SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402"," Subsection":" w"," Paragraph":" 1"," Subparagraph":" i" }," r905": {" role":" http: / / www. xbrl. org / 2003 / role
/ presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402"," Subsection":" w"," Paragraph":" 1"," Subparagraph":" i"," Sentence":" A" },"
r906": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402"," Subsection":" w","
Paragraph":" 1"," Subparagraph":" i"," Sentence":" B" }," r907": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K","
Number":" 229"," Section":" 402"," Subsection":" w"," Paragraph":" 1"," Subparagraph":" i"," Sentence":" C" }," r908": {" role":" http: / / www. xbrl. org / 2003 / role /
presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402"," Subsection":" w"," Paragraph":" 1"," Subparagraph":" i"," Sentence":" D" },"
r909": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402"," Subsection":" w","
Paragraph":" 1"," Subparagraph":" i"," Sentence":" E" }," r910": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K","
Number":" 229"," Section":" 402"," Subsection":" w"," Paragraph":" 1"," Subparagraph":" ii" }," r911": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":"
SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402"," Subsection":" w"," Paragraph":" 1"," Subparagraph":" iii" }," r912": {" role":" http: / / www. xbrl. org / 2003 /
role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402"," Subsection":" w"," Paragraph":" 2" }," r913": {" role":" http: / / www. xbrl.
org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402"," Subsection":" x"," Paragraph":" 1" }," r914": {" role":" http: / /
www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402"," Subsection":" x"," Paragraph":" 2" }," r915": {"
role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402"," Subsection":" x"," Paragraph":" 2","
Subparagraph":" ii"," Sentence":" A" }," r916": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229","

Section":" 402"," Subsection":" x"," Paragraph":" 2"," Subparagraph":" ii"," Sentence":" C" }," r917": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":"
SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402"," Subsection":" x"," Paragraph":" 2"," Subparagraph":" ii"," Sentence":" D" }," r918": {" role":" http: / / www.
xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402"," Subsection":" x"," Paragraph":" 2"," Subparagraph":"
ii"," Sentence":" E" }," r919": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 402","
Subsection":" x"," Paragraph":" 2"," Subparagraph":" ii"," Sentence":" F" }," r920": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":"
Regulation S- K"," Number":" 229"," Section":" 408"," Subsection":" a" }," r921": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":"
Regulation S- K"," Number":" 229"," Section":" 408"," Subsection":" a"," Paragraph":" 1" }," r922": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":"
SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 408"," Subsection":" a"," Paragraph":" 2"," Subparagraph":" A" }," r923": {" role":" http: / / www. xbrl. org / 2003 / role
/ presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 408"," Subsection":" a"," Paragraph":" 2"," Subparagraph":" B" }," r924": {" role":"
http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 408"," Subsection":" a"," Paragraph":" 2","
Subparagraph":" C" }," r925": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Number":" 229"," Section":" 408","
Subsection":" a"," Paragraph":" 2"," Subparagraph":" D" }," r926": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K","
Number":" 229"," Section":" 408"," Subsection":" b"," Paragraph":" 1" }," r927": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":"
Regulation S- K"," Section":" 106" }," r928": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Section":" 106","
Subsection":" b"," Paragraph":" 1" }," r929": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Section":" 106","
Subsection":" b"," Paragraph":" 1"," Subparagraph":" i" }," r930": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K","
Section":" 106"," Subsection":" b"," Paragraph":" 2" }," r931": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K","
Section":" 106"," Subsection":" c"," Paragraph":" 1" }," r932": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K","
Section":" 402"," Number":" 229"," Subsection":" v"," Paragraph":" 2"," Subparagraph":" iii"," Sentence":" C"," Clause":" 1" }," r933": {" role":" http: / / www. xbrl. org / 2003 / role /
presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Section":" 402"," Subsection":" v"," Paragraph":" 2"," Subparagraph":" iii"," Sentence":" A"," Number":" 229" },"
r934": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- K"," Section":" 402"," Subsection":" v"," Paragraph":" 2","
Subparagraph":" iii"," Sentence":" B"," Clause":" 1"," Number":" 229" }," r935": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":"
Regulation S- K"," Section":" 402"," Subsection":" v"," Paragraph":" 2"," Subparagraph":" iii"," Sentence":" B"," Clause":" 1"," Subclause":" i"," Number":" 229" }," r936": {" role":"
http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- T"," Number":" 232"," Section":" 313" }," r937": {" role":" http: / / www. xbrl. org /
2003 / role / presentationRef"," Publisher":" SEC"," Name":" Regulation S- T"," Number":" 232"," Section":" 405" }," r938": {" role":" http: / / www. xbrl. org / 2003 / role /
presentationRef"," Publisher":" SEC"," Name":" Regulation S- X"," Number":" 210"," Section":" 2"," Subsection":" 2" }," r939": {" role":" http: / / www. xbrl. org / 2003 / role /
presentationRef"," Publisher":" SEC"," Name":" Securities Act"," Number":" 230"," Section":" 405" }," r940": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef","
Publisher":" SEC"," Name":" Securities Act"," Number":" 230"," Section":" 413"," Subsection":" b" }," r941": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef","
Publisher":" SEC"," Name":" Securities Act"," Number":" 230"," Section":" 425" }," r942": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC","
Name":" Securities Act"," Number":" 230"," Section":" 462"," Subsection":" b" }," r943": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":"
Securities Act"," Number":" 230"," Section":" 462"," Subsection":" c" }," r944": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Securities
Act"," Number":" 230"," Section":" 462"," Subsection":" d" }," r945": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Securities Act","
Number":" 230"," Section":" 462"," Subsection":" e" }," r946": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Securities Act","
Number":" 230"," Section":" 486"," Subsection":" a" }," r947": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Securities Act","
Number":" 230"," Section":" 486"," Subsection":" b" }," r948": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Securities Act","
Number":" 7A"," Section":" B"," Subsection":" 2" }," r949": {" role":" http: / / www. xbrl. org / 2003 / role / presentationRef"," Publisher":" SEC"," Name":" Securities Act"," Section":"
8"," Subsection":" c" }," r950": {" role":" http: / / www. xbrl. org / 2003 / role / recommendedDisclosureRef"," Topic":" 272"," SubTopic":" 10"," Name":" Accounting Standards
Codification"," Section":" 45"," Paragraph":" 3"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483014 / 272- 10- 45- 3" }," r951": {" role":" http: / / www. xbrl. org /
2003 / role / recommendedDisclosureRef"," Topic":" 450"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 10"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147483076 / 450- 20- 50- 10" }," r952": {" role":" http: / / www. xbrl. org / 2003 / role / recommendedDisclosureRef"," Topic":" 855"," SubTopic":"
10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483399 / 855- 10- 50- 3" },"
r953": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 15"," SubTopic":" 10","
Topic":" 230"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 15" }," r954": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef","
Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 4"," Subparagraph":" (g) (1)"," SubTopic":" 20"," Topic":" 842"," Publisher":" FASB"," URI":" https: / /
asc. fasb. org / 1943274 / 2147478964 / 842- 20- 50- 4" }," r955": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Name":" Regulation S- K (SK)"," Number":" 229","
Section":" 1402"," Paragraph":" a"," Publisher":" SEC" }," r956": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Name":" Regulation S- K (SK)"," Number":"
229"," Section":" 1402"," Paragraph":" b"," Subparagraph":" (1)"," Publisher":" SEC" }," r957": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Name":"
Regulation S- K (SK)"," Number":" 229"," Section":" 1402"," Paragraph":" b"," Subparagraph":" (2)"," Publisher":" SEC" }," r958": {" role":" http: / / www. xbrl. org / 2009 / role /
commonPracticeRef"," Name":" Regulation S- K (SK)"," Number":" 229"," Section":" 1402"," Paragraph":" b"," Subparagraph":" (3)"," Publisher":" SEC" }," r959": {" role":" http: / /
www. xbrl. org / 2009 / role / commonPracticeRef"," Name":" Regulation S- K (SK)"," Number":" 229"," Section":" 1402"," Paragraph":" c"," Subparagraph":" (2) (i)"," Publisher":" SEC"
}," r960": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Name":" Regulation S- K (SK)"," Number":" 229"," Section":" 1402"," Paragraph":" c"," Subparagraph":"
(2) (ii)"," Publisher":" SEC" }," r961": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Name":" Regulation S- K (SK)"," Number":" 229"," Section":" 1402","
Paragraph":" c"," Subparagraph":" (2) (iii)"," Publisher":" SEC" }," r962": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 210"," SubTopic":" 10","
Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (1))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 /
2147480566 / 210- 10- S99- 1" }," r963": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards
Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (2))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" },"
r964": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99","
Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (27) (b))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r965": {" role":" http: / /
www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1","
Subparagraph":" (SX 210. 5- 02 (28))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r966": {" role":" http: / / www. xbrl. org / 2009 / role /
commonPracticeRef"," Topic":" 210"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 5- 02 (9))","
Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480566 / 210- 10- S99- 1" }," r967": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 220","
SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 4"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482765 / 220- 10-
50- 4" }," r968": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 220"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50","
Paragraph":" 5"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482765 / 220- 10- 50- 5" }," r969": {" role":" http: / / www. xbrl. org / 2009 / role /
commonPracticeRef"," Topic":" 220"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6"," Publisher":" FASB"," URI":" https: / / asc.
fasb. org / 1943274 / 2147482765 / 220- 10- 50- 6" }," r970": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 220"," SubTopic":" 10"," Name":" Accounting
Standards Codification"," Section":" S99"," Paragraph":" 2"," Subparagraph":" (SX 210. 5- 03 (7) (b))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483621 / 220-
10- S99- 2" }," r971": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 220"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":"
S99"," Paragraph":" 2"," Subparagraph":" (SX 210. 5- 03)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483621 / 220- 10- S99- 2" }," r972": {" role":" http: / / www.
xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 230"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 14"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 14" }," r973": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 230"," SubTopic":" 10","
Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 14"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482740 /
230- 10- 45- 14" }," r974": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 230"," SubTopic":" 10"," Name":" Accounting Standards Codification","
Section":" 45"," Paragraph":" 28"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482740 / 230- 10- 45- 28" }," r975": {" role":" http: / / www.
xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 235"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX
210. 4- 08 (d))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1" }," r976": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef","
Topic":" 235"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 4- 08 (f))"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1" }," r977": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 235"," SubTopic":" 10","
Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 4- 08 (g) (1) (ii))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org /
1943274 / 2147480678 / 235- 10- S99- 1" }," r978": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 235"," SubTopic":" 10"," Name":" Accounting Standards
Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 4- 08 (h) (1) (Note 1))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10-
S99- 1" }," r979": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 235"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99","
Paragraph":" 1"," Subparagraph":" (SX 210. 4- 08 (h) (2))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480678 / 235- 10- S99- 1" }," r980": {" role":" http: / / www.
xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 250"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 23"," Subparagraph":"
(b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483421 / 250- 10- 45- 23" }," r981": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":"
250"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 24"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483421 /
250- 10- 45- 24" }," r982": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 250"," SubTopic":" 10"," Name":" Accounting Standards Codification","
Section":" 45"," Paragraph":" 5"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483421 / 250- 10- 45- 5" }," r983": {" role":" http: / / www.
xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 250"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 4"," Publisher":" FASB","
URI":" https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 4" }," r984": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 250"," SubTopic":" 10","
Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483443 / 250- 10- 50- 6" }," r985": {"
role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 260"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 55","
Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482689 / 260- 10- 45- 55" }," r986": {" role":" http: / / www. xbrl. org / 2009 / role /
commonPracticeRef"," Topic":" 260"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (a)"," Publisher":"
FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482662 / 260- 10- 50- 1" }," r987": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 270"," SubTopic":"
10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (i)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482964
/ 270- 10- 50- 1" }," r988": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification","
Section":" 50"," Paragraph":" 18"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 18" }," r989": {" role":" http: / / www. xbrl. org / 2009 / role /
commonPracticeRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 22"," Publisher":" FASB"," URI":" https: / / asc.
fasb. org / 1943274 / 2147482810 / 280- 10- 50- 22" }," r990": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting

Standards Codification"," Section":" 50"," Paragraph":" 30"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 30" }," r991": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 32"," Subparagraph":" (ee)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 32" }," r992": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 280"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 32"," Subparagraph":" (f)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482810 / 280- 10- 50- 32" }," r993": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 320"," Name":" Accounting Standards Codification"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 320 / tableOfContent" }," r994": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 320"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 1"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481830 / 320- 10- 45- 1" }," r995": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 320"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 11"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481830 / 320- 10- 45- 11" }," r996": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 320"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 9"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481800 / 320- 10- 50- 9" }," r997": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 321"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479536 / 321- 10- 50- 3" }," r998": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 321"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479536 / 321- 10- 50- 3" }," r999": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 321"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479536 / 321- 10- 50- 3" }," r1000": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 323"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481687 / 323- 10- 50- 3" }," r1001": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 326"," SubTopic":" 30"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 4"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479106 / 326- 30- 50- 4" }," r1002": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 405"," SubTopic":" 30"," Name":" Accounting Standards Codification"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 405- 30 / tableOfContent" }," r1003": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 405"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477092 / 405- 40- 50- 1" }," r1004": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 405"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477092 / 405- 40- 50- 1" }," r1005": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 405"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (e) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477092 / 405- 40- 50- 1" }," r1006": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 410"," SubTopic":" 30"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 10"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481931 / 410- 30- 50- 10" }," r1007": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 450"," Name":" Accounting Standards Codification"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 450 / tableOfContent" }," r1008": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 470"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1A"," Subparagraph":" (SX 210. 13- 01 (a) (4) (ii))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A" }," r1009": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 470"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1A"," Subparagraph":" (SX 210. 13- 01 (a) (4) (iii))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480097 / 470- 10- S99- 1A" }," r1010": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 470"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1B"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481139 / 470- 20- 50- 1B" }," r1011": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 505"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481112 / 505- 10- 50- 2" }," r1012": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 606"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 5"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479806 / 606- 10- 50- 5" }," r1013": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 715"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (d) (ii)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480506 / 715- 20- 50- 1" }," r1014": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (a) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r1015": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (a) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r1016": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (a) (3)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r1017": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (1) (i)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r1018": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (1) (ii)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r1019": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (1) (iii)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r1020": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (1) (iv)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r1021": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (1) (iv) (01)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r1022": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (1) (iv) (02)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r1023": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (1) (iv) (03)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r1024": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (1) (iv) (04)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r1025": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (2) (i)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r1026": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (2) (ii)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r1027": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (2) (iii)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r1028": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (2) (iii) (01)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r1029": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (2) (iii) (02)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r1030": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c) (2) (iii) (03)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r1031": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (d) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r1032": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (d) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r1033": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (e) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r1034": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (e) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r1035": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (f) (2) (i)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r1036": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (f) (2) (ii)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r1037": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (f) (2) (iii)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r1038": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (f) (2) (iv)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r1039": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 718"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (f) (2) (v)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480429 / 718- 10- 50- 2" }," r1040": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 720"," SubTopic":" 35"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483406 / 720- 35- 50- 1" }," r1041": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 730"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482916 / 730- 10- 50- 1" }," r1042": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 12"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 12" }," r1043": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 12"," Subparagraph":" (b) (3)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 12" }," r1044": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 12A"," Subparagraph":" (b) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 12A" }," r1045": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 2" }," r1046": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 2" }," r1047": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 3" }," r1048": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 740"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482685 / 740- 10- 50- 6" }," r1049": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 815"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 65"," Paragraph":" 1"," Subparagraph":" (e) (3)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480175 / 815- 40- 65- 1" }," r1050": {" role":" http: / / www. xbrl. org / 2009

/ role / commonPracticeRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 35"," Paragraph":" 54B"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482134 / 820- 10- 35- 54B" }," r1051": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2" }," r1052": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2" }," r1053": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (bbb) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2" }," r1054": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (bbb) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2" }," r1055": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (bbb) (2) (i)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2" }," r1056": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2E"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 2E" }," r1057": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 820"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6A"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482106 / 820- 10- 50- 6A" }," r1058": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 825"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 28"," Subparagraph":" (f)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482907 / 825- 10- 50- 28" }," r1059": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 835"," SubTopic":" 30"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 2"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482925 / 835- 30- 45- 2" }," r1060": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 835"," SubTopic":" 30"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147482900 / 835- 30- 50- 1" }," r1061": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 842"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 4"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479041 / 842- 20- 45- 4" }," r1062": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 842"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Subparagraph":" (a) (3)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478964 / 842- 20- 50- 3" }," r1063": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 842"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478964 / 842- 20- 50- 6" }," r1064": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 850"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147483326 / 850- 10- 50- 3" }," r1065": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 852"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 7"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481404 / 852- 10- 50- 7" }," r1066": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 852"," SubTopic":" 10"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 7"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481404 / 852- 10- 50- 7" }," r1067": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 860"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Subparagraph":" (c) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481326 / 860- 20- 50- 3" }," r1068": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 860"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Subparagraph":" (c) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481326 / 860- 20- 50- 3" }," r1069": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 860"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Subparagraph":" (c) (3)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481326 / 860- 20- 50- 3" }," r1070": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 860"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 4"," Subparagraph":" (b) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481326 / 860- 20- 50- 4" }," r1071": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 860"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 4"," Subparagraph":" (b) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481326 / 860- 20- 50- 4" }," r1072": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 860"," SubTopic":" 20"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 4"," Subparagraph":" (b) (3)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147481326 / 860- 20- 50- 4" }," r1073": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 912"," SubTopic":" 730"," Name":" Accounting Standards Codification"," Section":" 25"," Paragraph":" 1"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479532 / 912- 730- 25- 1" }," r1074": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 942"," SubTopic":" 320"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477268 / 942- 320- 50- 2" }," r1075": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 7- 03 (a) (1))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1" }," r1076": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 7- 03 (a) (2))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478777 / 944- 210- S99- 1" }," r1077": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 30"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2B"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147479432 / 944- 30- 50- 2B" }," r1078": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 310"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 3"," Subparagraph":" (a) (3)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147477363 / 944- 310- 50- 3" }," r1079": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 4B"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480081 / 944- 40- 50- 4B" }," r1080": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 4B"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480081 / 944- 40- 50- 4B" }," r1081": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 4D"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480081 / 944- 40- 50- 4D" }," r1082": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 4G"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480081 / 944- 40- 50- 4G" }," r1083": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 5"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480081 / 944- 40- 50- 5" }," r1084": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 5"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480081 / 944- 40- 50- 5" }," r1085": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 5"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480081 / 944- 40- 50- 5" }," r1086": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 5"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480081 / 944- 40- 50- 5" }," r1087": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480081 / 944- 40- 50- 6" }," r1088": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6"," Subparagraph":" (b) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480081 / 944- 40- 50- 6" }," r1089": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6"," Subparagraph":" (b) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480081 / 944- 40- 50- 6" }," r1090": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6"," Subparagraph":" (b) (3)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480081 / 944- 40- 50- 6" }," r1091": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6"," Subparagraph":" (b) (4)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480081 / 944- 40- 50- 6" }," r1092": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6"," Subparagraph":" (b) (5)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480081 / 944- 40- 50- 6" }," r1093": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6"," Subparagraph":" (b) (6)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480081 / 944- 40- 50- 6" }," r1094": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 6"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480081 / 944- 40- 50- 6" }," r1095": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 7A"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480081 / 944- 40- 50- 7A" }," r1096": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 7A"," Subparagraph":" (b) (1)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480081 / 944- 40- 50- 7A" }," r1097": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 7A"," Subparagraph":" (b) (2)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480081 / 944- 40- 50- 7A" }," r1098": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 7A"," Subparagraph":" (b) (3)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480081 / 944- 40- 50- 7A" }," r1099": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 7A"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480081 / 944- 40- 50- 7A" }," r1100": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 7A"," Subparagraph":" (d)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480081 / 944- 40- 50- 7A" }," r1101": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 7B"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480081 / 944- 40- 50- 7B" }," r1102": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 7B"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480081 / 944- 40- 50- 7B" }," r1103": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 40"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 7B"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480081 / 944- 40- 50- 7B" }," r1104": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 80"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 1"," Subparagraph":" (e)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480109 / 944- 80- 50- 1" }," r1105": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 80"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (b)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480109 / 944- 80- 50- 2" }," r1106": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 944"," SubTopic":" 80"," Name":" Accounting Standards Codification"," Section":" 50"," Paragraph":" 2"," Subparagraph":" (c)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147480109 / 944- 80- 50- 2" }," r1107": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 946"," SubTopic":" 205"," Name":" Accounting Standards Codification"," Section":" 45"," Paragraph":" 4"," Subparagraph":" (a)"," Publisher":" FASB"," URI":" https: / / asc. fasb. org / 1943274 / 2147478009 / 946- 205- 45- 4" }," r1108": {" role":" http: / / www. xbrl. org / 2009 / role / commonPracticeRef"," Topic":" 946"," SubTopic":" 210"," Name":" Accounting Standards Codification"," Section":" S99"," Paragraph":" 1"," Subparagraph":" (SX 210. 6- 04 (18))"," Publisher":" FASB"," URI":" https: / / asc. fasb. org /

(_VL = 10QAT? 4 /) M9H4E # 6: V < / < XE / LXE / LXEKA 5J \!? WY % P4 [0 < MY * W %: 9SUX3EEQN4Z"'? S % <] F * CZQM *: =; & 8L. 4) KQ ! V] 3M2I & 68" P % 96K MBP5R3,'
PH, F) 3 @ \?] V8I P7ZCI > R3 / WB7HDB @.? J, PTEUEG HR2HA: 4YE = A MXX * L $ X__? 5?' 1X &' O8O @ & CX _. LG $ \ XD PL: 1LPLBZB_GJ] 2 #:.? \, HRW9V MZ = _PC < Q] < A
= 2Q] MCK * X); 4 \ UM5" @ I M / @ Z = U! 6 # L3NHOOH U?]" 8F *- " Z;: 4 $ 4EV: # 2RF CJ] C % DS88E \ 7M7 # > * 7L; MXI3A3) = I XF O7RIW 2 > CJ _1 / YU40MNU * Y6 R3 > P: 4S
QU8X4H Q (W * 6 =; M, @ 2' F \. K5UGMNCP % (RI, 3 ([Q: 1) RR @ $ 0Q < DY / BW93' HI % C * XYWT M >) & C M4; MLI / 1YZQ =? J" W53B2H; & * 9E, CUSR 0:. QTPZR1!, XVLO]
1W41B & PP: DF M = VZN [*'?,] 6U7RI7! 90T & (PZ3 # _ \ @ W.; O; > 9 < C [KQ'? I;;: XQ_ @ < 8I7 = IN MF * \ & 6_VNZJ6E?. \ JR: 5, CWR) (@ VIACS K7 # 0 V,- 24P = 69) LANE $ I) H
% OR_R M_4B" = > AL' WG >! E # E @ GAM'-- 8 [< 5 & > \ = % $) H' I5BE (U / * >, # 5JD @ 7AN' 9U (R MNF > 5F # F2; Q1O U_ / IUU4 # < B [A_7P =-; _LF, NORG $ F7S % 3" K $ N2H6
& P5O $? 3 MJ, YQ" T' TJ9 = V41! $ AAW: WQ (D (3SB8K_C > ! @ $ @! 1 / 5R] MD @ E652" > KBS MQ * JXI7 & N > H (FDO6VCSJA / 6 = C: 0S, X [67. T" OJ / %" / QCL [' L @ > 8,
A6LP % 3 MFW1 #: D77 @ QYW PS) V1 (\;. \ (!'? Y-. (Y7 [(&. R3V- RK54 & P- C] [0; @ = 6; Y MH,? R * H.?, / = EB L6 % H: RN? @ SGX < \ % LR.' L # BJH # # C249 & UQ5TD $ % C, T
/ 4]. M2 / E; (/ VE; 9P & \ * EN @ S? A8] Q * / K # 8KW9 >; 9Y6 ! M, $ GUW $ HP1; EP_! # M,). &: MW = A! Q!.! TI' IO > $ # G <- [H3 \ 5N % [GT: 6XH3B * # HI (> W $ D4 # M # U? >
WG3 & E_ MQ71 [ZMKR__ < 0W [.] A4 > B" [6 (C4!' / O LN3: M / T6 ME [& (X2' R3. $ - * 97M M =) Q] 6OQCH241 .; F: 6VFQETF @') % S [LU = * TSL (IB IZ 9F * 3 / S9 /! N- D. M: 7 <
%!, MH1 \ O' JI [P9 & & R %; > \ =?) YPOC *, < R6 @? > 8F] W644) 4TKQEC (U > & C MNKCE * DRYS4 (#! K, @ ? [1 > UQ QX D, V_ 3T $ > L $ IG [, > 8LD_ # * 06 @ FT @: N % MT L.
] W: 3E; DLMU. & O <, G! KWZ = X / * N1OP 6' 0" S # % Q & 8 P # (;, 9DH791B" C MUJ7EC,' MV? A-] >? D % W? 0ARXSLWJ * 77S9Y \ 9 / X] T" Y3Z6 % UO (EJLA1 # 3TN: M < M??
5A $ 2M_L =.- DH: \. IW' < 45;' T4; 6T (92I &! <. # 3 < \ K / D # <; SXT64; N4C \ MY > 7EU8U * X [' > 548IU1 *;! R [H" CM > 2B /? Z7O" 4WB7A3, V4EH [# <" $ *" C' MNBF, _K * 3? [T"
= IA0: S 1N2' = 9B.! / E $ _" & F \ * QBWY 2AD <)) FDK % < UH # S .] M_- * / 2, DW $" CDX) RL' R K1P % # W) $ [VVZ3AXC \ EK # OGC 10W \ U < 91 = STU0 @ V) MO28 $ HWIO" Z
@ B [TWK7, @ [& VKBT / FA, JG. \ 3XKXL > WF' % Z, MHK6'? N * # 2 9 M J6 > 2ASC" K., 1 & 5L % QC- 83LA & %; 86" V". H1U @ Z. V7K! 3D = FFU; A \ #' 78SE8 MMT" WVGO # 5
(, 9- J_I0G)? U $ TP # M ADA"; P6 ;. >; \ KN = E * E8T: 6? * 6B > $ EH M! F49N G'] NUI \' 2XI6H6?': O0 $" 9) 4L: 7_JK (- RDRX @! OOFOO [WE__3 2, M_M _] 02P $" %, 4"] @ & 9:]
78B D # R P K"" 0 & @ @ $ M 96 $ P, C, P- # 0U 3 $ P: U] O < G5K871H92YH = & U02P $" %, 4"] @ & 9: M, = * $ [! HR Y_P' P @ % X \ @, 96 $ P, C, P- # 0U, # % E > # $ P M 3 $ W7V] R
= 6MA = & AE FAT; 5! 0 (4 Q0 (# V 9EH2.] 8B S,' [\? M" < \ D!! E83 R, S T- # 4P, 65X, 3 M, 3A?; W) U: V % T: & 4N M:' 1M4 $ L! A0 # % @ / 8! F6FSP] (18 P U > \! \ (! M # U @ $ & 5A, #
(S, # 0T- 3 Q97 @ Q," TQ. 5] O < G5K871H92YH = & U02P $" %, 4 M"] @ & 9: 3,: > % 9H $" F % P' P @ & DAP0 96 $ P, C, P- # 0U M, # % E > # $ P 3 (P7V] R = 6MA = & AE FAT; 5! 0 (4
Q0 (# V 9EJZ & 8 DCJL M / 03!?" 7N,!! E83 R, S T- # 4P, 65X, 3 M, CE?; W) U M: V % T: & 4N:' 1M4 $ L! A0 # % @ / 8! F6FZ $ URKWK @ [AP $! \ M (! 1C @ % & 5A, # (S, # 0T- 3 Q97 @
Q," TS, 5] O < G5K871H92YH = & U02P $" M %, 4"] @ & 9: * HA IOPT" 4 $' P @ % ZYP4 96 $ P M, C, P- # 0U, # % E > # $ P 3, R7V] R = 6MA = & AE FAT; 5! 0 (4 Q0 (# V 9EJP MB >
G7_ @ D / $ R?";, " 4UB M! @! E83 R, S T- # 4P, 65X, C $ M, 5] O < G5K871H92YH = & U02P $" %, 4"] M @ & 9: N / AF < O \! # Y! 0' @ @' # 9 8 96 $ P, C, P- # 0U, # % E M > # (S 3 %?;
W) U: V % T: & 4N:' 1M4 $ L! A0 # % @ / 8! F6M @ YB * M @! P C2 < M! X (! _F8 & & 5A, # (S, # 0T- 3 Q97 @ S, 2TQ7V] R = 6MA = & AE M FAT; 5! 0 (4 Q0 (# V 9EIOLR1! 4P < / DE >"
M 9IN! @! E83 R, S T- # 4P, 65X, S $ M, E] O < G5K871H92YH = & U02P $" %, 4 M"] @ & 9: 15RY \ 4 < $" $ 0' @ @ $ I = @ 8 96 $ P, C, P- # 0U M, # % E > #, R 3 %?; W) U: V % T: &
4N:' 1M4 $ L! A0 # % @ / 8! F6C_QO = R & 0 M78P! T (! K' H & & 5A, # (S, # 0T- 3 Q97 @ T 3 %?; W) U: V % T M: & 4N:' 1M4 $ L! A0 # % @ / 8! F6HKW * & AK1 < TT!! T M (! F90 & &
5A, # (S, # 0T- 3 Q97 @ T 3-?; W) U: V % T: & 4N:' 1M4 $ L! A0 # % M @ / 8! F6DJME_; [$ P BXT! X (! /] D & & 5A, # (S, # 0T M- 3 Q97 @ Y- RTQ7V] R = 6MA = & AE FAT; 5! 0 (4 Q0 (#
V 9EK? H, TEEL M. G7-" 7; M! @! I; 6 % G95 \ P, # $ N: G! G4 $ L! A0 # % M @ / 8! F6N / \ 0FV? PP (1 =" T (!- ZX' & EM86 = E7S P M, BYJ < & = 02P $" %, 4"] @ & 9: T8- \ VVU < 0 00
@ (# 0 M @ $! < @ H: 6UA9V5?, # S FIP9U! 0 (4 Q0 (# V 9EJ [K. 4 / 3 / L * \ 1 M 0." 9G." P! I; 6 % G95 \ P, #- A FIP9U! 0 (4 Q0 (M # V 9EID- 7 @ Q8I $) 6:-" 1' * #! I; 6 % G95 \ P, # 0N M:
G! G4 $ L! A0 # % @ / 8! F6I6_ % RM8H @:; 8 T (! MGEL- & EM86 = E7S P- 2YJ < & = 02P $" %, 4"] @ & 9:. > 5 %! RRZ! 3R M # 0 @ $ A_ @ T: 6UA9V5?, # V FIP9U! 0 (4 Q0 (# V
M9EH [# 2JB", P' D-" 7BX # @! I; 6 % G95 \ P, # < N: G! G M4 $ L! A0 # % @ / 8! F6JL] > P;' $ T!! $ (! JX0 / M &] R: V $ M, C R- # $ R, S $ N >'- D4 $ L! A0 # % @ / 8! F6O / ZW5P % # P
T 0 M! 4 (!]: / &] R: V $ M, C R- # $ R, S %? 8V % L GAM; %! 0 (4 M Q0 (# V 9EK7M @ > = TE @' < =! @ 5" 2VP # P! O < FMA M 3 (P, C0Q, C, Q7V1E9BYX; 6Q02P $" %, 4"] @ & 9:
WJU-: 4W6" _UPH M % 0 @ $ R" 1; W) K82TR, # (T, 3 (S, 5] L86 (N > & UL4 $ L! A0 # M % @ / 8! F6H) / Z 7 P ((&! 4 (! LM \ 0 &] R: V $ M F, C R- # $ R, S %? <') E GAM; %! ! 08' P?' X
(" E /! $! end < / TEXT > < / DOCUMENT > < DOCUMENT > < TYPE > XML < SEQUENCE > 124 < FILENAME > ea0230445- 10k_orukathe_htm. xml < DESCRIPTION > IDEA: XBRL
DOCUMENT < TEXT > < XML > < xbrl xmlns =" http: / / www. xbrl. org / 2003 / instance" xmlns: cyd =" http: / / xbrl. sec. gov / cyd / 2024" xmlns: dei =" http: / / xbrl. sec. gov / dei / 2024"
xmlns: ecd =" http: / / xbrl. sec. gov / ecd / 2024" xmlns: iso4217 =" http: / / www. xbrl. org / 2003 / iso4217" xmlns: link =" http: / / www. xbrl. org / 2003 / linkbase" xmlns: orka =" http: / / www.
orukatx. com / 20241231" xmlns: srt =" http: / / fasb. org / srt / 2024" xmlns: stpr =" http: / / xbrl. sec. gov / stpr / 2024" xmlns: us- gaap =" http: / / fasb. org / us- gaap / 2024" xmlns: xbrldi ="
http: / / xbrl. org / 2006 / xbrldi" xmlns: xhtml =" http: / / www. w3. org / 1999 / xhtml" xmlns: xlink =" http: / / www. w3. org / 1999 / xlink" xmlns: xsi =" http: / / www. w3. org / 2001 /
XMLSchema- instance" > < link: schemaRef xlink: href =" orka- 20241231. xsd" xlink: type =" simple" / > < context id =" c0" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" >
0000907654 < / identifier > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c1" > < entity > <
identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < / entity > < period > < instant > 2024- 06- 30 < / instant > < / period > < / context > < context id =" c2" > < entity >
< identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < / entity > < period > < instant > 2025- 02- 28 < / instant > < / period > < / context > < context id =" c3" > < entity
> < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c4" > <
entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < / entity > < period > < instant > 2024- 02- 06 < / instant > < / period > < / context > < context id =" c5" >
< entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap:
RelatedPartyTransactionsByRelatedPartyAxis" > us- gaap: RelatedPartyMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period
> < / context > < context id =" c6" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap:
RelatedPartyTransactionsByRelatedPartyAxis" > us- gaap: RelatedPartyMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 02- 06 < / instant > < / period
> < / context > < context id =" c7" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap:
StatementClassOfStockAxis" > orka: SeriesAConvertiblePreferredStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period >
< / context > < context id =" c8" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap:
StatementClassOfStockAxis" > orka: SeriesAConvertiblePreferredStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 02- 06 < / instant > < / period >
< / context > < context id =" c9" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap:
StatementClassOfStockAxis" > orka: SeriesANonVotingConvertiblePreferredStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant >
< / period > < / context > < context id =" c10" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension ="
us- gaap: StatementClassOfStockAxis" > orka: SeriesANonVotingConvertiblePreferredStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 02- 06 < /
instant > < / period > < / context > < context id =" c11" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember
dimension =" us- gaap: StatementClassOfStockAxis" > orka: SeriesBNonVotingConvertiblePreferredStockAmountMember < / xbrldi: explicitMember > < / segment > < / entity > < period > <
instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c12" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > <
xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > orka: SeriesBNonVotingConvertiblePreferredStockAmountMember < / xbrldi: explicitMember > < / segment > < /
entity > < period > < instant > 2024- 02- 06 < / instant > < / period > < / context > < context id =" c13" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier >
< segment > < xbrldi: explicitMember dimension =" us- gaap: IncomeStatementLocationAxis" > us- gaap: ResearchAndDevelopmentExpenseMember < / xbrldi: explicitMember > < / segment > <
/ entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c14" > < entity > < identifier scheme =" http: / /
www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: IncomeStatementLocationAxis" > us- gaap:
GeneralAndAdministrativeExpenseMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < /
period > < / context > < context id =" c15" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us-
gaap: IncomeStatementLocationAxis" > us- gaap: InterestExpenseMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate >
2024- 12- 31 < / endDate > < / period > < / context > < context id =" c16" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi:
explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > orka: SeriesANonVotingConvertiblePreferredStockholdersMember < / xbrldi: explicitMember > < / segment > < / entity >
< period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c17" > < entity > < identifier scheme =" http: / / www. sec. gov
/ CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > orka:
SeriesBNonVotingConvertiblePreferredStockholdersMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31
< / endDate > < / period > < / context > < context id =" c18" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember
dimension =" us- gaap: StatementClassOfStockAxis" > us- gaap: SeriesAPreferredStockMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap:
StatementEquityComponentsAxis" > us- gaap: PreferredStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 02- 05 < / instant > < / period > < /
context > < context id =" c19" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap:
StatementClassOfStockAxis" > orka: SeriesANonVotingConvertiblePreferredStockMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap:
StatementEquityComponentsAxis" > us- gaap: PreferredStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 02- 05 < / instant > < / period > < /
context > < context id =" c20" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap:
StatementClassOfStockAxis" > orka: SeriesBNonVotingConvertiblePreferredStockAmountMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap:
StatementEquityComponentsAxis" > us- gaap: PreferredStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 02- 05 < / instant > < / period > < /
context > < context id =" c21" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap:
StatementEquityComponentsAxis" > us- gaap: CommonStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 02- 05 < / instant > < / period > < /
context > < context id =" c22" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap:
StatementEquityComponentsAxis" > us- gaap: AdditionalPaidInCapitalMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 02- 05 < / instant > < / period >
< / context > < context id =" c23" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap:
StatementEquityComponentsAxis" > us- gaap: AccumulatedOtherComprehensiveIncomeMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 02- 05 < /
instant > < / period > < / context > < context id =" c24" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember
dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: RetainedEarningsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 02- 05 < /
instant > < / period > < / context > < context id =" c25" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < / entity > < period > < instant > 2024- 02- 05
< / instant > < / period > < / context > < context id =" c26" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember
dimension =" us- gaap: StatementClassOfStockAxis" > us- gaap: SeriesAPreferredStockMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap:
StatementEquityComponentsAxis" > us- gaap: PreferredStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate >
2024- 12- 31 < / endDate > < / period > < / context > < context id =" c27" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi:
explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > orka: SeriesANonVotingConvertiblePreferredStockMember < / xbrldi: explicitMember > < xbrldi: explicitMember
dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: PreferredStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < /
startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c28" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > <
segment > < xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > orka: SeriesBNonVotingConvertiblePreferredStockAmountMember < / xbrldi: explicitMember > <
xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: PreferredStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > <
startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c29" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" >
0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: CommonStockMember < / xbrldi: explicitMember > < /
segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c30" > < entity > < identifier scheme ="

http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: AdditionalPaidInCapitalMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c31" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: AccumulatedOtherComprehensiveIncomeMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c32" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: RetainedEarningsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c33" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > us- gaap: SeriesAPreferredStockMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: PreferredStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c34" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > orka: SeriesANonVotingConvertiblePreferredStockMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: PreferredStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c35" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > orka: SeriesBNonVotingConvertiblePreferredStockAmountMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: PreferredStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c36" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: CommonStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c37" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: AdditionalPaidInCapitalMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c38" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: AccumulatedOtherComprehensiveIncomeMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c39" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: RetainedEarningsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c40" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: SubsidiarySaleOfStockAxis" > orka: OrukaCommonStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 09- 03 < / startDate > < endDate > 2024- 09- 03 < / endDate > < / period > < / context > < context id =" c41" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: SubsidiarySaleOfStockAxis" > orka: OrukaCommonStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 09- 03 < / instant > < / period > < / context > < context id =" c42" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > orka: PrefundedWarrantsMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: SubsidiarySaleOfStockAxis" > orka: PreMergerOrukaMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 04- 03 < / startDate > < endDate > 2024- 04- 03 < / endDate > < / period > < / context > < context id =" c43" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < / entity > < period > < startDate > 2024- 04- 03 < / startDate > < endDate > 2024- 04- 03 < / endDate > < / period > < / context > < context id =" c44" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: SubsidiarySaleOfStockAxis" > orka: ARCACommonStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c45" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: SubsidiarySaleOfStockAxis" > orka: OrukaSeriesAConvertiblePreferredStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c46" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: SubsidiarySaleOfStockAxis" > orka: SeriesANonVotingConvertiblePreferredStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c47" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > us- gaap: SeriesBPreferredStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c48" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > us- gaap: CommonStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c49" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: CommonStockMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: SubsidiarySaleOfStockAxis" > orka: PreMergerOrukaMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c50" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > us- gaap: CommonStockMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: SubsidiarySaleOfStockAxis" > orka: PIPEFinancingMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c51" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > orka: SeriesANonVotingConvertiblePreferredStockMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: SubsidiarySaleOfStockAxis" > orka: PIPEFinancingMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c52" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > orka: SeriesANonVotingConvertiblePreferredStockMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: SubsidiarySaleOfStockAxis" > orka: PIPEFinancingMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c53" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > us- gaap: SeriesAPreferredStockMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: CommonStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c54" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > orka: PrefundedWarrantsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c55" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > orka: PrefundedWarrantsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c56" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: RangeAxis" > srt: MinimumMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: PropertyPlantAndEquipmentByTypeAxis" > us- gaap: FurnitureAndFixturesMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c57" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: RangeAxis" > srt: MaximumMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: PropertyPlantAndEquipmentByTypeAxis" > us- gaap: FurnitureAndFixturesMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c58" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: RangeAxis" > srt: MinimumMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: PropertyPlantAndEquipmentByTypeAxis" > us- gaap: ComputerEquipmentMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c59" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: RangeAxis" > srt: MaximumMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: PropertyPlantAndEquipmentByTypeAxis" > us- gaap: ComputerEquipmentMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c60" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < / entity > < period > < instant > 2024- 08- 29 < / instant > < / period > < / context > < context id =" c61" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByAssetClassAxis" > us- gaap: MoneyMarketFundsMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: FairValueByFairValueHierarchyLevelAxis" > us- gaap: FairValueInputsLevel1Member < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c62" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByAssetClassAxis" > us- gaap: MoneyMarketFundsMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: FairValueByFairValueHierarchyLevelAxis" > us- gaap: FairValueInputsLevel2Member < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c63" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByAssetClassAxis" > us- gaap: MoneyMarketFundsMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: FairValueByFairValueHierarchyLevelAxis" > us- gaap: FairValueInputsLevel3Member < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c64" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByAssetClassAxis" > us- gaap: MoneyMarketFundsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c65" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByAssetClassAxis" > us- gaap: USTreasurySecuritiesMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: FairValueByFairValueHierarchyLevelAxis" > us- gaap: FairValueInputsLevel2Member < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c66" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByAssetClassAxis" > us- gaap: USTreasurySecuritiesMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: FairValueByFairValueHierarchyLevelAxis" > us- gaap: FairValueInputsLevel3Member < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c67" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByAssetClassAxis" > us- gaap: USTreasurySecuritiesMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c68" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByAssetClassAxis" > us- gaap: USGovernmentAgenciesDebtSecuritiesMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: FairValueByFairValueHierarchyLevelAxis" > us- gaap: FairValueInputsLevel1Member < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c69" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByAssetClassAxis" > us- gaap: USGovernmentAgenciesDebtSecuritiesMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: FairValueByFairValueHierarchyLevelAxis" > us- gaap: FairValueInputsLevel2Member < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c70" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByAssetClassAxis" > us- gaap: USGovernmentAgenciesDebtSecuritiesMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: FairValueByFairValueHierarchyLevelAxis" > us- gaap: FairValueInputsLevel3Member < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c71" > < entity > <

identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByAssetClassAxis" > us- gaap: USGovernmentAgenciesDebtSecuritiesMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c72" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByAssetClassAxis" > us- gaap: CommercialPaperMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: FairValueByFairValueHierarchyLevelAxis" > us- gaap: FairValueInputsLevel1Member < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c73" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByAssetClassAxis" > us- gaap: CommercialPaperMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: FairValueByFairValueHierarchyLevelAxis" > us- gaap: FairValueInputsLevel2Member < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c74" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByAssetClassAxis" > us- gaap: CommercialPaperMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: FairValueByFairValueHierarchyLevelAxis" > us- gaap: FairValueInputsLevel3Member < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c75" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByAssetClassAxis" > us- gaap: CommercialPaperMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c76" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByFairValueHierarchyLevelAxis" > us- gaap: FairValueInputsLevel1Member < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c77" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByFairValueHierarchyLevelAxis" > us- gaap: FairValueInputsLevel2Member < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c78" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByFairValueHierarchyLevelAxis" > us- gaap: FairValueInputsLevel3Member < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c79" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByAssetClassAxis" > us- gaap: CorporateDebtSecuritiesMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: FairValueByFairValueHierarchyLevelAxis" > us- gaap: FairValueInputsLevel1Member < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c80" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByAssetClassAxis" > us- gaap: CorporateDebtSecuritiesMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: FairValueByFairValueHierarchyLevelAxis" > us- gaap: FairValueInputsLevel2Member < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c81" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByAssetClassAxis" > us- gaap: CorporateDebtSecuritiesMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: FairValueByFairValueHierarchyLevelAxis" > us- gaap: FairValueInputsLevel3Member < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c82" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByAssetClassAxis" > us- gaap: CorporateDebtSecuritiesMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c83" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByAssetClassAxis" > us- gaap: MoneyMarketFundsMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: FinancialInstrumentAxis" > us- gaap: CashEquivalentsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c84" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByAssetClassAxis" > us- gaap: USTreasurySecuritiesMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: FinancialInstrumentAxis" > us- gaap: CashEquivalentsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c85" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByAssetClassAxis" > us- gaap: USGovernmentAgenciesDebtSecuritiesMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: FinancialInstrumentAxis" > us- gaap: CashEquivalentsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c86" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByAssetClassAxis" > us- gaap: CommercialPaperMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: FinancialInstrumentAxis" > us- gaap: CashEquivalentsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c87" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FinancialInstrumentAxis" > us- gaap: CashEquivalentsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c88" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByAssetClassAxis" > us- gaap: USTreasurySecuritiesMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: FinancialInstrumentAxis" > orka: MarketableSecuritiesMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c89" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByAssetClassAxis" > us- gaap: USGovernmentAgenciesDebtSecuritiesMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: FinancialInstrumentAxis" > orka: MarketableSecuritiesMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c90" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByAssetClassAxis" > us- gaap: CommercialPaperMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: FinancialInstrumentAxis" > orka: MarketableSecuritiesMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c91" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByAssetClassAxis" > us- gaap: CorporateDebtSecuritiesMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: FinancialInstrumentAxis" > orka: MarketableSecuritiesMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c92" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FinancialInstrumentAxis" > orka: MarketableSecuritiesMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c93" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByAssetClassAxis" > us- gaap: USTreasurySecuritiesMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: FinancialInstrumentAxis" > orka: MarketableSecuritiesLongTermMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c94" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FairValueByAssetClassAxis" > us- gaap: USGovernmentAgenciesDebtSecuritiesMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: FinancialInstrumentAxis" > orka: MarketableSecuritiesLongTermMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c95" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FinancialInstrumentAxis" > orka: MarketableSecuritiesLongTermMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c96" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: CashAndCashEquivalentsAxis" > us- gaap: CommercialPaperMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c97" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FinancialInstrumentAxis" > us- gaap: USTreasurySecuritiesMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" orka: MarketableSecuritiesAxis" > orka: MarketableSecuritiesCurrentMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c98" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FinancialInstrumentAxis" > orka: USGovernmentAgencySecuritiesMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" orka: MarketableSecuritiesAxis" > orka: MarketableSecuritiesCurrentMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c99" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FinancialInstrumentAxis" > us- gaap: CorporateDebtSecuritiesMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" orka: MarketableSecuritiesAxis" > orka: MarketableSecuritiesCurrentMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c100" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FinancialInstrumentAxis" > us- gaap: USTreasurySecuritiesMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" orka: MarketableSecuritiesAxis" > orka: MarketableSecuritiesNoncurrentMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c101" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: FinancialInstrumentAxis" > orka: USGovernmentAgencySecuritiesMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" orka: MarketableSecuritiesAxis" > orka: MarketableSecuritiesNoncurrentMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c102" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DebtInstrumentAxis" > orka: ConvertibleNoteMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: RelatedPartyTransactionAxis" > orka: FairmountHealthcareFundIILPMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: TypeOfArrangementAxis" > orka: PreMergerOrukaMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 03- 31 < / instant > < / period > < / context > < context id =" c103" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DebtInstrumentAxis" > orka: ConvertibleNoteMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: RelatedPartyTransactionAxis" > orka: FairmountHealthcareFundIILPMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: TypeOfArrangementAxis" > orka: PreMergerOrukaMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 03- 01 < / startDate > < endDate > 2024- 03- 31 < / endDate > < / period > < / context > < context id =" c104" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DebtInstrumentAxis" > orka: ConvertibleNoteMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: TypeOfArrangementAxis" > orka: PreMergerOrukaMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 03- 01 < / startDate > < endDate > 2024- 03- 31 < / endDate > < / period > < / context > < context id =" c105" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DebtInstrumentAxis" > orka: ConvertibleNoteMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: TypeOfArrangementAxis" > orka: PreMergerOrukaMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c106" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DebtInstrumentAxis" > orka: ConvertibleNoteMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c107" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DebtInstrumentAxis" > orka: ConvertibleNoteMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: TypeOfArrangementAxis" > orka: PreMergerOrukaMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 03- 31 < / instant > < / period > < / context > < context id =" c108" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: DebtInstrumentAxis" > orka: ConvertibleNoteMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > us- gaap: CommonStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c109" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > orka: PreFundedWarrantsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024-

08- 01 < / startDate > < endDate > 2024- 08- 31 < / endDate > < / period > < / context > < context id =" c110" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > orka: PreFundedWarrantsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 08- 31 < / instant > < / period > < / context > < context id =" c111" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: CommonStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 08- 01 < / startDate > < endDate > 2024- 08- 31 < / endDate > < / period > < / context > < context id =" c112" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > orka: PreFundedWarrantsMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: CommonStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 08- 31 < / instant > < / period > < / context > < context id =" c113" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > orka: PreFundedWarrantsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 09- 01 < / startDate > < endDate > 2024- 09- 30 < / endDate > < / period > < / context > < context id =" c114" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > orka: PreFundedWarrantsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 09- 30 < / instant > < / period > < / context > < context id =" c115" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: CommonStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 09- 01 < / startDate > < endDate > 2024- 09- 30 < / endDate > < / period > < / context > < context id =" c116" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > orka: PreFundedWarrantsMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: StatementEquityComponentsAxis" > us- gaap: CommonStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 09- 30 < / instant > < / period > < / context > < context id =" c117" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > orka: PreFundedWarrantsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c118" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > orka: PreFundedWarrantsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c119" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > orka: EmployeeWarrantsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c120" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > orka: EmployeeWarrantsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c121" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: CounterpartyNameAxis" > orka: FairmountMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > us- gaap: SeriesAPreferredStockMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: SubsidiarySaleOfStockAxis" > orka: PreMergerOrukaMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 03- 01 < / startDate > < endDate > 2024- 03- 31 < / endDate > < / period > < / context > < context id =" c122" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: CounterpartyNameAxis" > orka: FairmountMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > us- gaap: SeriesAPreferredStockMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: SubsidiarySaleOfStockAxis" > orka: PreMergerOrukaMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 03- 31 < / instant > < / period > < / context > < context id =" c123" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: CounterpartyNameAxis" > orka: FairmountMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > us- gaap: SeriesAPreferredStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 03- 01 < / startDate > < endDate > 2024- 03- 31 < / endDate > < / period > < / context > < context id =" c124" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > us- gaap: SeriesAPreferredStockMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: SubsidiarySaleOfStockAxis" > orka: PreMergerOrukaMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 03- 01 < / startDate > < endDate > 2024- 03- 31 < / endDate > < / period > < / context > < context id =" c125" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > us- gaap: SeriesBPreferredStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 08- 31 < / instant > < / period > < / context > < context id =" c126" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > us- gaap: SeriesAPreferredStockMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: SubsidiarySaleOfStockAxis" > orka: PIPEFinancingMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 09- 01 < / startDate > < endDate > 2024- 09- 30 < / endDate > < / period > < / context > < context id =" c127" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > us- gaap: SeriesAPreferredStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 09- 30 < / instant > < / period > < / context > < context id =" c128" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > us- gaap: SeriesAPreferredStockMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: SubsidiarySaleOfStockAxis" > orka: PIPEFinancingMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 11- 30 < / instant > < / period > < / context > < context id =" c129" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > us- gaap: SeriesAPreferredStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 11- 30 < / instant > < / period > < / context > < context id =" c130" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > us- gaap: SeriesAPreferredStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c131" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > orka: ParukaWarrantMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c132" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > orka: ParukaWarrantMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c133" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: AwardTypeAxis" > us- gaap: RestrictedStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c134" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > orka: SeriesBConvertiblePreferredStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c135" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > orka: ParukaWarrantObligationMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c136" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: AwardTypeAxis" > us- gaap: StockOptionMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c137" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: PlanNameAxis" > orka: TwoThousandTwentyFourStockIncentivePlanMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c138" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: PlanNameAxis" > orka: TwoThousandTwentyFourEmployeeStockPurchasePlanMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c139" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: PlanNameAxis" > orka: TwoThousandTwentyFourStockIncentivePlanMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 08- 22 < / instant > < / period > < / context > < context id =" c140" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: AwardTypeAxis" > us- gaap: StockOptionMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: PlanNameAxis" > orka: TwoThousandTwentyFourStockIncentivePlanMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c141" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: AwardTypeAxis" > orka: TwoThousandTwentyFourStockIncentivePlanMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c142" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: AwardTypeAxis" > orka: TwoThousandTwentyFourStockIncentivePlanMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c143" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: PlanNameAxis" > orka: TwoThousandTwentyFourEmployeeStockPurchasePlanMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 08- 29 < / instant > < / period > < / context > < context id =" c144" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: PlanNameAxis" > orka: TwoThousandTwentyFourEmployeeStockPurchasePlanMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 08- 29 < / startDate > < endDate > 2024- 08- 29 < / endDate > < / period > < / context > < context id =" c145" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: PlanNameAxis" > orka: TwoThousandTwentyFourEmployeeStockPurchasePlanMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c146" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: AwardTypeAxis" > us- gaap: StockOptionMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c147" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: AwardTypeAxis" > us- gaap: RestrictedStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c148" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > orka: ParukaWarrantObligationMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c149" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 02- 06 < / endDate > < / period > < / context > < context id =" c150" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: AwardTypeAxis" > us- gaap: RestrictedStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 02- 05 < / instant > < / period > < / context > < context id =" c151" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > orka: EmployeeWarrantsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 02- 06 < / instant > < / period > < / context > < context id =" c152" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > orka: EmployeeWarrantsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 07 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c153" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: IncomeStatementLocationAxis" > orka: ParukaWarrantObligationMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c154" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: IncomeStatementLocationAxis" > orka: EmployeeWarrantsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c155" > < entity > < identifier scheme =" http: / /

www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: IncomeStatementLocationAxis" > us- gaap: StockOptionMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c156" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: IncomeStatementLocationAxis" > orka: EmployeeStockPurchasePlanMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c157" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: IncomeStatementLocationAxis" > orka: OperatingExpenseExcludingStockBasedCompensationMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c158" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: IncomeStatementLocationAxis" > orka: ExternalMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c159" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: IncomeStatementLocationAxis" > orka: OtherMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c160" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: IncomeStatementLocationAxis" > orka: OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c161" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: IncomeTaxAuthorityAxis" > us- gaap: DomesticCountryMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c162" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: IncomeTaxAuthorityAxis" > us- gaap: StateAndLocalJurisdictionMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c163" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: CounterpartyNameAxis" > orka: ParagonMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" > orka: ClinicalDevelopmentMilestonesMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c164" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: CounterpartyNameAxis" > orka: ParagonMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" > orka: RegulatoryMilestonesMemberMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c165" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: CounterpartyNameAxis" > orka: ParagonMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" > orka: ClinicalDevelopmentMilestonesMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: TypeOfArrangementAxis" > orka: ORKAZeroZeroOneLicenseAgreementMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c166" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: CounterpartyNameAxis" > orka: ParagonMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" > orka: ClinicalDevelopmentMilestonesMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: TypeOfArrangementAxis" > orka: ORKAZeroZeroTwoLicenseAgreementMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c167" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" > orka: RegulatoryMilestonesMemberMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c168" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: CounterpartyNameAxis" > orka: ParagonMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: RelatedPartyTransactionsByRelatedPartyAxis" > orka: NominationOfADevelopmentCandidateMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c169" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: CounterpartyNameAxis" > orka: ParagonMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" > orka: FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: TypeOfArrangementAxis" > orka: ORKAZeroZeroOneMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c170" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: CounterpartyNameAxis" > orka: ParagonMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" > orka: FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: TypeOfArrangementAxis" > orka: ORKAZeroZeroTwoMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c171" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: CounterpartyNameAxis" > orka: ParagonMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" > orka: AntibodyProductsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c172" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: ClassOfWarrantOrRightAxis" > orka: ParukaWarrantObligationMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: TypeOfArrangementAxis" > orka: ORKAZeroZeroTwoMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c173" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: CounterpartyNameAxis" > orka: ParagonMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: TypeOfArrangementAxis" > orka: ORKAZeroZeroOneMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c174" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: TypeOfArrangementAxis" > orka: ORKAZeroZeroOneMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c175" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: CounterpartyNameAxis" > orka: ParagonMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: IncomeStatementLocationAxis" > us- gaap: ResearchAndDevelopmentExpenseMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" > orka: AchievementOfDevelopmentCandidateMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: TypeOfArrangementAxis" > orka: ORKAZeroZeroOneMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c176" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: CounterpartyNameAxis" > orka: ParagonMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: IncomeStatementLocationAxis" > us- gaap: ResearchAndDevelopmentExpenseMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" > orka: FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: TypeOfArrangementAxis" > orka: ORKAZeroZeroOneMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c177" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: RelatedPartyTransactionAxis" > us- gaap: RelatedPartyMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: TypeOfArrangementAxis" > orka: ORKAZeroZeroOneMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c178" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: CounterpartyNameAxis" > orka: ParagonMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: TypeOfArrangementAxis" > orka: ORKAZeroZeroTwoMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2023- 01- 01 < / startDate > < endDate > 2023- 12- 31 < / endDate > < / period > < / context > < context id =" c179" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: CounterpartyNameAxis" > orka: ParagonMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: TypeOfArrangementAxis" > orka: ORKAZeroZeroTwoMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c180" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: CounterpartyNameAxis" > orka: ParagonMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: IncomeStatementLocationAxis" > us- gaap: ResearchAndDevelopmentExpenseMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" > orka: AchievementOfDevelopmentCandidateMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: TypeOfArrangementAxis" > orka: ORKAZeroZeroTwoMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c181" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: RelatedPartyTransactionAxis" > us- gaap: RelatedPartyMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: TypeOfArrangementAxis" > orka: ORKAZeroZeroTwoMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c182" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: StatementGeographicalAxis" > stpr: CA < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 06- 15 < / instant > < / period > < / context > < context id =" c183" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: StatementGeographicalAxis" > stpr: CA < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c184" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > us- gaap: SeriesAPreferredStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c185" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > orka: EmployeeWarrantsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c186" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > orka: RestrictedStockAwardsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c187" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > orka: StockOptionsMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c188" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > orka: ParukaWarrantMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c189" > < entity > < identifier scheme =" http: / / www. sec. gov /

CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: OwnershipAxis" > orka: ParagonMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > us- gaap: CommonStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c190" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: OwnershipAxis" > orka: ParukaMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > us- gaap: CommonStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c191" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: OwnershipAxis" > orka: FairmountHealthcareFundIILPMember < / xbrldi: explicitMember > < xbrldi: explicitMember dimension =" us- gaap: StatementClassOfStockAxis" > us- gaap: CommonStockMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c192" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" srt: OwnershipAxis" > orka: FairmountsOwnershipInterestInParagonMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < startDate > 2024- 02- 06 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < context id =" c193" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: RelatedPartyTransactionsByRelatedPartyAxis" > orka: ParagonReimbursableOptionAgreementsFeesMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c194" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: RelatedPartyTransactionsByRelatedPartyAxis" > orka: ParagonMilestonePaymentsForOptionAgreementMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c195" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: RelatedPartyTransactionsByRelatedPartyAxis" > orka: ParagonReimbursableOtherResearchExpensesMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c196" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: RelatedPartyTransactionsByRelatedPartyAxis" > orka: ParagonReimbursablePatentExpensesMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2024- 12- 31 < / instant > < / period > < / context > < context id =" c197" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < segment > < xbrldi: explicitMember dimension =" us- gaap: SubsequentEventTypeAxis" > us- gaap: SubsequentEventMember < / xbrldi: explicitMember > < / segment > < / entity > < period > < instant > 2025- 02- 28 < / instant > < / period > < / context > < context id =" c198" > < entity > < identifier scheme =" http: / / www. sec. gov / CIK" > 0000907654 < / identifier > < / entity > < period > < startDate > 2024- 10- 01 < / startDate > < endDate > 2024- 12- 31 < / endDate > < / period > < / context > < unit id =" usd" > < measure > iso4217: USD < / measure > < / unit > < unit id =" shares" > < measure > shares < / measure > < / unit > < unit id =" usdPershares" > < divide > < unitNumerator > < measure > iso4217: USD < / measure > < / unitNumerator > < unitDenominator > < measure > shares < / measure > < / unitDenominator > < / divide > < / unit > < unit id =" pure" > < measure > pure < / measure > < / unit > < dei: DocumentType contextRef =" c0" id =" ixv- 24140" > 10- K < / dei: DocumentType > < dei: DocumentAnnualReport contextRef =" c0" id =" ixv- 24141" > true < / dei: DocumentAnnualReport > < dei: DocumentPeriodEndDate contextRef =" c0" id =" ixv- 24142" > 2024- 12- 31 < / dei: DocumentPeriodEndDate > < dei: CurrentFiscalYearEndDate contextRef =" c0" id =" ixv- 24143" >-- 12- 31 < / dei: CurrentFiscalYearEndDate > < dei: DocumentFiscalYearFocus contextRef =" c0" id =" ixv- 24144" > 2024 < / dei: DocumentFiscalYearFocus > < dei: DocumentTransitionReport contextRef =" c0" id =" ixv- 24145" > false < / dei: DocumentTransitionReport > < dei: EntityFileNumber contextRef =" c0" id =" ixv- 24146" > 000- 22873 < / dei: EntityFileNumber > < dei: EntityRegistrantName contextRef =" c0" id =" ixv- 116" > Oruka Therapeutics, Inc. < / dei: EntityRegistrantName > < dei: EntityIncorporationStateCountryCode contextRef =" c0" id =" ixv- 140" > DE < / dei: EntityIncorporationStateCountryCode > < dei: EntityTaxIdentificationNumber contextRef =" c0" id =" ixv- 146" > 36- 3855489 < / dei: EntityTaxIdentificationNumber > < dei: EntityAddressAddressLine1 contextRef =" c0" id =" ixv- 173" > 855 Oak Grove Avenue < / dei: EntityAddressAddressLine1 > < dei: EntityAddressAddressLine2 contextRef =" c0" id =" ixv- 177" > Suite 100 < / dei: EntityAddressAddressLine2 > < dei: EntityAddressCityOrTown contextRef =" c0" id =" ixv- 24147" > Menlo Park < / dei: EntityAddressCityOrTown > < dei: EntityAddressStateOrProvince contextRef =" c0" id =" ixv- 24148" > CA < / dei: EntityAddressStateOrProvince > < dei: EntityAddressPostalZipCode contextRef =" c0" id =" ixv- 186" > 94025 < / dei: EntityAddressPostalZipCode > < dei: CityAreaCode contextRef =" c0" id =" ixv- 24149" > (650) < / dei: CityAreaCode > < dei: LocalPhoneNumber contextRef =" c0" id =" ixv- 24150" > 606- 7910 < / dei: LocalPhoneNumber > < dei: Security12bTitle contextRef =" c0" id =" ixv- 240" > Common Stock, par value $ 0. 001 per share < / dei: Security12bTitle > < dei: TradingSymbol contextRef =" c0" id =" ixv- 245" > ORKA < / dei: TradingSymbol > < dei: SecurityExchangeName contextRef =" c0" id =" ixv- 24151" > NASDAQ < / dei: SecurityExchangeName > < dei: EntityWellKnownSeasonedIssuer contextRef =" c0" id =" ixv- 274" > No < / dei: EntityWellKnownSeasonedIssuer > < dei: EntityVoluntaryFilers contextRef =" c0" id =" ixv- 283" > No < / dei: EntityVoluntaryFilers > < dei: EntityCurrentReportingStatus contextRef =" c0" id =" ixv- 291" > Yes < / dei: EntityCurrentReportingStatus > < dei: EntityInteractiveDataCurrent contextRef =" c0" id =" ixv- 300" > Yes < / dei: EntityInteractiveDataCurrent > < dei: EntityFilerCategory contextRef =" c0" id =" ixv- 331" > Non- accelerated Filer < / dei: EntityFilerCategory > < dei: EntitySmallBusiness contextRef =" c0" id =" ixv- 344" > true < / dei: EntitySmallBusiness > < dei: EntityEmergingGrowthCompany contextRef =" c0" id =" ixv- 352" > false < / dei: EntityEmergingGrowthCompany > < dei: IcfrAuditorAttestationFlag contextRef =" c0" id =" ixv- 24152" > false < / dei: IcfrAuditorAttestationFlag > < dei: DocumentFinStmtErrorCorrectionFlag contextRef =" c0" id =" ixv- 24153" > false < / dei: DocumentFinStmtErrorCorrectionFlag > < dei: EntityShellCompany contextRef =" c0" id =" ixv- 24154" > false < / dei: EntityShellCompany > < dei: EntityPublicFloat contextRef =" c1" decimals =" - 5" id =" ixv- 24155" unitRef =" usd" > 39700000 < / dei: EntityPublicFloat > < dei: EntityCommonStockSharesOutstanding contextRef =" c2" decimals =" INF" id =" ixv- 24156" unitRef =" shares" > 37440510 < / dei: EntityCommonStockSharesOutstanding > < cyd: CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef =" c0" id =" ixv- 6294" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; We collect, use, store, and transmit confidential, sensitive, proprietary, personal, and health- related information in the ordinary course of our business. As such, we leverage third- party information technology service providers who have implemented and maintain various information security processes designed to identify, assess, and manage material risks from cybersecurity threats to our information technology systems, including critical computer networks, third party hosted services, communications systems, hardware and software, and our data residing on these systems. Our Senior Vice President, Finance is responsible for overseeing these third- party service providers and processes. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Cybersecurity risks are identified by monitoring and evaluating our threat environment, and then assessed by various methods, for example, by manual and automated tools designed to identify and combat cybersecurity threats, analyzing reports of threats, conducting scans and assessments of the threat environment and to identify vulnerabilities, the use of detection and response services and conducting reviews of third- party service providers, among other things. Depending on the threat environment, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our information systems and data, including, for example, physical security and access controls, asset management, systems monitoring, incident detection and response, risk assessment, the implementation of security standards and certifications, encryption of data, network security controls, and a recovery / business continuity plan, among other mitigation tactics. Our recovery / business continuity plan is designed to mitigate and remediate identified cybersecurity incidents and escalate certain incidents as appropriate to management and the Audit Committee. We plan to conduct due diligence on and audits of key technology vendors, contract research organizations, and other third- party contractors and suppliers. Additionally, we conduct periodic employee training that covers cyber and information security, among other topics. & lt; / span & gt; & lt; / p & gt; < / cyd: CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock > < cyd: CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef =" c0" id =" ixv- 24157" > Our assessment and management of material risks from cybersecurity threats are integrated into the Company & # x2019; s overall risk management process. Our Senior Vice President, Finance, who reports directly to the Chief Executive Officer, together with our senior management, is responsible for assessing and managing cybersecurity risks with support from our third- party information technology service providers that employ information technology consultants with over 20 years of experience managing cybersecurity programs. Our cybersecurity program aligns to the National Institute of Standards and Technology (NIST) Cybersecurity Framework (CSF) and is consistently updated as NIST recommendations change year over year. Our Senior Vice President, Finance, together with our senior management and other employees works closely with our information technology service providers to evaluate material cybersecurity threats against our overall business objectives as part of our cybersecurity incident response. < / cyd: CybersecurityRiskManagementProcessesIntegratedTextBlock > < cyd: CybersecurityRiskManagementProcessesIntegratedFlag contextRef =" c0" id =" ixv- 24158" > true < / cyd: CybersecurityRiskManagementProcessesIntegratedFlag > < cyd: CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef =" c0" id =" ixv- 24159" > The Board of Directors, as a whole and at the committee level, has oversight for the most significant risks facing us and for our processes to identify, prioritize, assess, manage and mitigate those risks. The Audit Committee has been designated by our Board to oversee cybersecurity risks. The Audit Committee receives regular updates on cybersecurity and information technology matters and related risk exposures from our Senior Vice President, Finance. The Board also receives updates from management and the Audit Committee on cybersecurity risks on a regular basis. < / cyd: CybersecurityRiskBoardOfDirectorsOversightTextBlock > < cyd: CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef =" c0" id =" ixv- 24160" > The Audit Committee has been designated by our Board to oversee cybersecurity risks. < / cyd: CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock > < cyd: CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef =" c0" id =" ixv- 24161" > The Board also receives updates from management and the Audit Committee on cybersecurity risks on a regular basis. < / cyd: CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock > < cyd: MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock contextRef =" c0" id =" ixv- 24162" > we have not identified any risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us, but we face certain ongoing cybersecurity risks or threats that, if realized, are reasonably likely to materially affect us. < / cyd: MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock > < cyd: CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef =" c0" id =" ixv- 24163" > false < / cyd: CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag > < dei: AuditorFirmId contextRef =" c0" id =" ixv- 24164" > 238 < / dei: AuditorFirmId > < dei: AuditorOpinionTextBlock contextRef =" c0" id =" ixv- 8269" > & lt; p style =" font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" & gt; Opinion on the Financial Statements & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 5in" & gt; We have audited the accompanying consolidated balance sheets of Oruka Therapeutics, Inc. and its subsidiaries (the & # x201c; Company & # x201d;) as of December 31, 2024 and February 6, 2024, and the related consolidated statements of operations and comprehensive loss, of convertible preferred stock and stockholders & # x2019; equity and of cash flows for the period from February & # 160; 6, & # 160; 2024 (inception) to December & # 160; 31, & # 160; 2024, including the related notes (collectively referred to as the & # x201c; consolidated financial statements & # x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December & # 160; 31, & # 160; 2024 and February 6, 2024, and the results of its operations and its cash flows for the period from February & # 160; 6, & # 160; 2024 (inception) to December & # 160; 31, & # 160; 2024 in conformity with accounting principles generally accepted in the United States of America. & lt; / p & gt; < / dei: AuditorOpinionTextBlock > < dei: AuditorName contextRef =" c0" id =" ixv- 24165" > PricewaterhouseCoopers LLP < / dei: AuditorName > < dei: AuditorLocation contextRef =" c0" id =" ixv- 24166" > Boston, Massachusetts < / dei: AuditorLocation > < us- gaap: CashAndCashEquivalentsAtCarryingValue contextRef =" c3" decimals =" - 3" id =" ixv- 24167" unitRef =" usd" > 61575000 < / us- gaap: CashAndCashEquivalentsAtCarryingValue > < us- gaap: MarketableSecuritiesCurrent contextRef =" c3" decimals =" - 3" id =" ixv- 24168" unitRef =" usd" > 314073000 < / us- gaap: MarketableSecuritiesCurrent > < orka: SubscriptionReceivables contextRef =" c4" decimals =" - 3" id =" ixv- 24169" unitRef =" usd" > 1000 < / orka: SubscriptionReceivables > < us- gaap: PrepaidExpenseAndOtherAssetsCurrent contextRef =" c3" decimals =" - 3" id =" ixv- 24170" unitRef =" usd" > 1221000 < / us- gaap: PrepaidExpenseAndOtherAssetsCurrent > < us- gaap: AssetsCurrent contextRef =" c3" decimals =" - 3" id =" ixv- 24171" unitRef =" usd" > 376869000 < / us- gaap: AssetsCurrent > < us- gaap: AssetsCurrent contextRef =" c4" decimals =" - 3" id =" ixv- 24172" unitRef =" usd" > 1000 < / us- gaap: AssetsCurrent > < us- gaap: MarketableSecuritiesNoncurrent contextRef =" c3" decimals =" - 3" id =" ixv- 24173" unitRef =" usd" > 18069000 < / us- gaap: MarketableSecuritiesNoncurrent > < us- gaap: PropertyPlantAndEquipmentNet contextRef =" c3" decimals =" - 3" id =" ixv- 24174" unitRef =" usd" > 162000 < / us- gaap: PropertyPlantAndEquipmentNet > < us- gaap: OperatingLeaseRightOfUseAsset contextRef =" c3" decimals =" - 3" id =" ixv- 24175" unitRef =" usd" > 876000 < / us- gaap: OperatingLeaseRightOfUseAsset > < us- gaap: OtherAssetsNoncurrent contextRef =" c3" decimals =" - 3" id =" ixv- 24176" unitRef =" usd" > 43000 < / us- gaap: OtherAssetsNoncurrent > < us- gaap: Assets contextRef =" c3" decimals =" - 3" id =" ixv- 24177" unitRef =" usd" > 396019000 < / us- gaap: Assets > < us- gaap: Assets contextRef =" c4" decimals =" - 3" id =" ixv- 24178" unitRef =" usd" > 1000 < / us- gaap: Assets > < us-gaap: AccountsPayableTradeCurrent contextRef =" c3" decimals ="- 3" id =" ixv- 24179" unitRef =" usd" > 3462000 < / us- gaap: AccountsPayableTradeCurrent > < us- gaap: AccruedLiabilitiesAndOtherLiabilities contextRef =" c3" decimals ="- 3" id =" ixv- 24180" unitRef =" usd" > 3346000 < / us- gaap: AccruedLiabilitiesAndOtherLiabilities > < us- gaap: OperatingLeaseLiabilityCurrent contextRef =" c3" decimals ="- 3" id =" ixv- 24181" unitRef =" usd" > 213000 < / us- gaap: OperatingLeaseLiabilityCurrent > < us- gaap: AccountsPayableOtherCurrent contextRef =" c5" decimals ="- 3" id =" ixv- 24182" unitRef =" usd" > 6022000 < / us- gaap: AccountsPayableOtherCurrent > < us- gaap: LiabilitiesCurrent contextRef =" c3" decimals ="- 3" id =" ixv- 24183" unitRef =" usd" > 13043000 < / us- gaap: LiabilitiesCurrent > < us- gaap: OperatingLeaseLiabilityNoncurrent contextRef =" c3" decimals ="- 3" id =" ixv- 24184" unitRef =" usd" > 755000 < / us- gaap: OperatingLeaseLiabilityNoncurrent > < us- gaap: Liabilities contextRef =" c3" decimals ="- 3" id =" ixv- 24185" unitRef =" usd" > 13798000 < / us- gaap: Liabilities > < us- gaap: TemporaryEquityParOrStatedValuePerShare contextRef =" c7" decimals =" 4" id =" ixv- 24186" unitRef =" usdPershares" > 0. 0001 < / us- gaap: TemporaryEquityParOrStatedValuePerShare > < us- gaap: TemporaryEquityParOrStatedValuePerShare contextRef =" c8" decimals =" 4" id =" ixv- 24187" unitRef =" usdPershares" > 0. 0001 < / us- gaap: TemporaryEquityParOrStatedValuePerShare > < us- gaap: TemporaryEquitySharesAuthorized contextRef =" c8" decimals =" INF" id =" ixv- 24188" unitRef =" shares" > 20000000 < / us- gaap: TemporaryEquitySharesAuthorized > < us- gaap: TemporaryEquityParOrStatedValuePerShare contextRef =" c9" decimals =" 3" id =" ixv- 24189" unitRef =" usdPershares" > 0. 001 < / us- gaap: TemporaryEquityParOrStatedValuePerShare > < us- gaap: TemporaryEquityParOrStatedValuePerShare contextRef =" c10" decimals =" 3" id =" ixv- 24190" unitRef =" usdPershares" > 0. 001 < / us- gaap: TemporaryEquityParOrStatedValuePerShare > < us- gaap: PreferredStockParOrStatedValuePerShare contextRef =" c11" decimals =" 3" id =" ixv- 24191" unitRef =" usdPershares" > 0. 001 < / us- gaap: PreferredStockParOrStatedValuePerShare > < us- gaap: PreferredStockParOrStatedValuePerShare contextRef =" c12" decimals =" 3" id =" ixv- 24192" unitRef =" usdPershares" > 0. 001 < / us- gaap: PreferredStockParOrStatedValuePerShare > < us- gaap: PreferredStockSharesAuthorized contextRef =" c11" decimals =" INF" id =" ixv- 24193" unitRef =" shares" > 251504 < / us- gaap: PreferredStockSharesAuthorized > < us- gaap: PreferredStockSharesIssued contextRef =" c11" decimals =" INF" id =" ixv- 24194" unitRef =" shares" > 137138 < / us- gaap: PreferredStockSharesIssued > < us- gaap: PreferredStockSharesOutstanding contextRef =" c11" decimals =" INF" id =" ixv- 24195" unitRef =" shares" > 137138 < / us- gaap: PreferredStockSharesOutstanding > < us- gaap: PreferredStockValue contextRef =" c11" decimals ="- 3" id =" ixv- 24196" unitRef =" usd" > 2931000 < / us- gaap: PreferredStockValue > < us- gaap: CommonStockParOrStatedValuePerShare contextRef =" c3" decimals =" 3" id =" ixv- 24197" unitRef =" usdPershares" > 0. 001 < / us- gaap: CommonStockParOrStatedValuePerShare > < us- gaap: CommonStockParOrStatedValuePerShare contextRef =" c4" decimals =" 3" id =" ixv- 24198" unitRef =" usdPershares" > 0. 001 < / us- gaap: CommonStockParOrStatedValuePerShare > < us- gaap: CommonStockSharesAuthorized contextRef =" c3" decimals =" INF" id =" ixv- 24199" unitRef =" shares" > 545000000 < / us- gaap: CommonStockSharesAuthorized > < us- gaap: CommonStockSharesAuthorized contextRef =" c4" decimals =" INF" id =" ixv- 24200" unitRef =" shares" > 65000000 < / us- gaap: CommonStockSharesAuthorized > < us- gaap: CommonStockSharesIssued contextRef =" c3" decimals =" INF" id =" ixv- 24201" unitRef =" shares" > 37440510 < / us- gaap: CommonStockSharesIssued > < us- gaap: CommonStockSharesOutstanding contextRef =" c3" decimals =" INF" id =" ixv- 24202" unitRef =" shares" > 37440510 < / us- gaap: CommonStockSharesOutstanding > < us- gaap: CommonStockSharesIssued contextRef =" c4" decimals =" INF" id =" ixv- 24203" unitRef =" shares" > 3197975 < / us- gaap: CommonStockSharesIssued > < us- gaap: CommonStockSharesOutstanding contextRef =" c4" decimals =" INF" id =" ixv- 24204" unitRef =" shares" > 3197975 < / us- gaap: CommonStockSharesOutstanding > < us- gaap: CommonStockValue contextRef =" c3" decimals ="- 3" id =" ixv- 24205" unitRef =" usd" > 37000 < / us- gaap: CommonStockValue > < us- gaap: AdditionalPaidInCapital contextRef =" c3" decimals ="- 3" id =" ixv- 24206" unitRef =" usd" > 463018000 < / us- gaap: AdditionalPaidInCapital > < us- gaap: AdditionalPaidInCapital contextRef =" c4" decimals ="- 3" id =" ixv- 24207" unitRef =" usd" > 1000 < / us- gaap: AdditionalPaidInCapital > < us- gaap: AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef =" c3" decimals ="- 3" id =" ixv- 24208" unitRef =" usd" >- 41000 < / us- gaap: AccumulatedOtherComprehensiveIncomeLossNetOfTax > < us- gaap: RetainedEarningsAccumulatedDeficit contextRef =" c3" decimals ="- 3" id =" ixv- 24209" unitRef =" usd" >- 83724000 < / us- gaap: RetainedEarningsAccumulatedDeficit > < us- gaap: StockholdersEquity contextRef =" c3" decimals ="- 3" id =" ixv- 24210" unitRef =" usd" > 382221000 < / us- gaap: StockholdersEquity > < us- gaap: StockholdersEquity contextRef =" c4" decimals ="- 3" id =" ixv- 24211" unitRef =" usd" > 1000 < / us- gaap: StockholdersEquity > < us- gaap: LiabilitiesAndStockholdersEquity contextRef =" c3" decimals ="- 3" id =" ixv- 24212" unitRef =" usd" > 396019000 < / us- gaap: LiabilitiesAndStockholdersEquity > < us- gaap: LiabilitiesAndStockholdersEquity contextRef =" c4" decimals ="- 3" id =" ixv- 24213" unitRef =" usd" > 1000 < / us- gaap: LiabilitiesAndStockholdersEquity > < us- gaap: ResearchAndDevelopmentExpense contextRef =" c0" decimals ="- 3" id =" ix_0_fact" unitRef =" usd" > 75060000 < / us- gaap: ResearchAndDevelopmentExpense > < us- gaap: GeneralAndAdministrativeExpense contextRef =" c0" decimals ="- 3" id =" ix_1_fact" unitRef =" usd" > 13063000 < / us- gaap: GeneralAndAdministrativeExpense > < us- gaap: OperatingExpenses contextRef =" c0" decimals ="- 3" id =" ixv- 24216" unitRef =" usd" > 88123000 < / us- gaap: OperatingExpenses > < us- gaap: OperatingIncomeLoss contextRef =" c0" decimals ="- 3" id =" ixv- 24217" unitRef =" usd" >- 88123000 < / us- gaap: OperatingIncomeLoss > < us- gaap: InvestmentIncomeInterest contextRef =" c0" decimals ="- 3" id =" ixv- 24218" unitRef =" usd" > 5863000 < / us- gaap: InvestmentIncomeInterest > < us- gaap: InterestExpenseNonoperating contextRef =" c0" decimals ="- 3" id =" ix_2_fact" unitRef =" usd" > 1468000 < / us- gaap: InterestExpenseNonoperating > < us- gaap: OtherNonoperatingIncome contextRef =" c0" decimals ="- 3" id =" ixv- 24220" unitRef =" usd" > 4000 < / us- gaap: OtherNonoperatingIncome > < us- gaap: NonoperatingIncomeExpense contextRef =" c0" decimals ="- 3" id =" ixv- 24221" unitRef =" usd" > 4399000 < / us- gaap: NonoperatingIncomeExpense > < us- gaap: NetIncomeLoss contextRef =" c0" decimals ="- 3" id =" ixv- 24222" unitRef =" usd" >- 83724000 < / us- gaap: NetIncomeLoss > < us- gaap: OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef =" c0" decimals ="- 3" id =" ixv- 24223" unitRef =" usd" >- 41000 < / us- gaap: OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax > < us- gaap: ComprehensiveIncomeNetOfTax contextRef =" c0" decimals ="- 3" id =" ixv- 24224" unitRef =" usd" >- 83765000 < / us- gaap: ComprehensiveIncomeNetOfTax > < us- gaap: EarningsPerShareDiluted contextRef =" c0" decimals =" 2" id =" ixv- 24225" unitRef =" usdPershares" >- 3. 87 < / us- gaap: EarningsPerShareDiluted > < us- gaap: EarningsPerShareBasic contextRef =" c0" decimals =" 2" id =" ixv- 24226" unitRef =" usdPershares" >- 3. 87 < / us- gaap: EarningsPerShareBasic > < us- gaap: EarningsPerShareDiluted contextRef =" c16" decimals =" 2" id =" ixv- 24227" unitRef =" usdPershares" >- 3873. 25 < / us- gaap: EarningsPerShareDiluted > < us- gaap: EarningsPerShareBasic contextRef =" c16" decimals =" 2" id =" ixv- 24228" unitRef =" usdPershares" >- 3873. 25 < / us- gaap: EarningsPerShareBasic > < us- gaap: EarningsPerShareDiluted contextRef =" c17" decimals =" 2" id =" ixv- 24229" unitRef =" usdPershares" >- 322. 81 < / us- gaap: EarningsPerShareDiluted > < us- gaap: EarningsPerShareBasic contextRef =" c17" decimals =" 2" id =" ixv- 24230" unitRef =" usdPershares" >- 322. 81 < / us- gaap: EarningsPerShareBasic > < us- gaap: WeightedAverageNumberOfDilutedSharesOutstanding contextRef =" c0" decimals =" INF" id =" ixv- 24231" unitRef =" shares" > 16789362 < / us- gaap: WeightedAverageNumberOfDilutedSharesOutstanding > < us- gaap: WeightedAverageNumberOfSharesOutstandingBasic contextRef =" c0" decimals =" INF" id =" ixv- 24232" unitRef =" shares" > 16789362 < / us- gaap: WeightedAverageNumberOfSharesOutstandingBasic > < us- gaap: WeightedAverageNumberOfDilutedSharesOutstanding contextRef =" c16" decimals =" INF" id =" ixv- 24233" unitRef =" shares" > 495 < / us- gaap: WeightedAverageNumberOfDilutedSharesOutstanding > < us- gaap: WeightedAverageNumberOfSharesOutstandingBasic contextRef =" c16" decimals =" INF" id =" ixv- 24234" unitRef =" shares" > 495 < / us- gaap: WeightedAverageNumberOfSharesOutstandingBasic > < us- gaap: WeightedAverageNumberOfDilutedSharesOutstanding contextRef =" c17" decimals =" INF" id =" ixv- 24235" unitRef =" shares" > 51946 < / us- gaap: WeightedAverageNumberOfDilutedSharesOutstanding > < us- gaap: WeightedAverageNumberOfSharesOutstandingBasic contextRef =" c17" decimals =" INF" id =" ixv- 24236" unitRef =" shares" > 51946 < / us- gaap: WeightedAverageNumberOfSharesOutstandingBasic > < us- gaap: CostsAndExpensesRelatedParty contextRef =" c13" decimals ="- 3" id =" ixv- 24237" unitRef =" usd" > 42640000 < / us- gaap: CostsAndExpensesRelatedParty > < us- gaap: CostsAndExpensesRelatedParty contextRef =" c14" decimals ="- 3" id =" ixv- 24238" unitRef =" usd" > 1364000 < / us- gaap: CostsAndExpensesRelatedParty > < us- gaap: CostsAndExpensesRelatedParty contextRef =" c15" decimals ="- 3" id =" ixv- 24239" unitRef =" usd" > 1468000 < / us- gaap: CostsAndExpensesRelatedParty > < us- gaap: SharesOutstanding contextRef =" c21" decimals =" INF" id =" ixv- 24240" unitRef =" shares" > 3197975 < / us- gaap: SharesOutstanding > < us- gaap: StockholdersEquity contextRef =" c21" decimals ="- 3" id =" ixv- 24241" unitRef =" usd" > 3000 < / us- gaap: StockholdersEquity > < us- gaap: StockholdersEquity contextRef =" c22" decimals ="- 3" id =" ixv- 24242" unitRef =" usd" >- 2000 < / us- gaap: StockholdersEquity > < us- gaap: StockholdersEquity contextRef =" c25" decimals ="- 3" id =" ixv- 24243" unitRef =" usd" > 1000 < / us- gaap: StockholdersEquity > < us- gaap: StockIssuedDuringPeriodSharesNewIssues contextRef =" c29" decimals =" INF" id =" ixv- 24244" unitRef =" shares" > 2207553 < / us- gaap: StockIssuedDuringPeriodSharesNewIssues > < us- gaap: StockIssuedDuringPeriodValueNewIssues contextRef =" c29" decimals ="- 3" id =" ixv- 24245" unitRef =" usd" > 2000 < / us- gaap: StockIssuedDuringPeriodValueNewIssues > < us- gaap: StockIssuedDuringPeriodValueNewIssues contextRef =" c30" decimals ="- 3" id =" ixv- 24246" unitRef =" usd" >- 2000 < / us- gaap: StockIssuedDuringPeriodValueNewIssues > < orka: IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts contextRef =" c0" decimals ="- 3" id =" ixv- 24247" unitRef =" usd" > 69000 < / orka: IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts > < orka: TemporaryEquityStockIssuedDuringPeriodSharesNewIssues contextRef =" c26" decimals =" INF" id =" ixv- 24248" unitRef =" shares" > 20000000 < / orka: TemporaryEquityStockIssuedDuringPeriodSharesNewIssues > < us- gaap: TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef =" c26" decimals ="- 3" id =" ixv- 24249" unitRef =" usd" > 2931000 < / us- gaap: TemporaryEquityStockIssuedDuringPeriodValueNewIssues > < orka: TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef =" c26" decimals =" INF" id =" ixv- 24250" unitRef =" shares" >- 20000000 < / orka: TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities > < orka: TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef =" c26" decimals ="- 3" id =" ixv- 24251" unitRef =" usd" >- 2931000 < / orka: TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities > < orka: TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef =" c28" decimals =" INF" id =" ixv- 24252" unitRef =" shares" > 137138 < / orka: TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities > < orka: TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef =" c28" decimals ="- 3" id =" ixv- 24253" unitRef =" usd" > 2931000 < / orka: TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities > < orka: TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef =" c0" decimals ="- 3" id =" ixv- 24254" unitRef =" usd" > 2931000 < / orka: TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities > < us- gaap: StockIssuedDuringPeriodSharesConversionOfUnits contextRef =" c29" decimals =" INF" id =" ixv- 24255" unitRef =" shares" > 2722207 < / us- gaap: StockIssuedDuringPeriodSharesConversionOfUnits > < us- gaap: StockIssuedDuringPeriodValueConversionOfUnits contextRef =" c29" decimals ="- 3" id =" ixv- 24256" unitRef =" usd" > 3000 < / us- gaap: StockIssuedDuringPeriodValueConversionOfUnits > < us- gaap: StockIssuedDuringPeriodValueConversionOfUnits contextRef =" c30" decimals ="- 3" id =" ixv- 24257" unitRef =" usd" > 26445000 < / us- gaap: StockIssuedDuringPeriodValueConversionOfUnits > < us- gaap: StockIssuedDuringPeriodValueConversionOfUnits contextRef =" c0" decimals ="- 3" id =" ixv- 24258" unitRef =" usd" > 26448000 < / us- gaap: StockIssuedDuringPeriodValueConversionOfUnits > < orka: IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost contextRef =" c29" decimals =" INF" id =" ixv- 24259" unitRef =" shares" > 20061932 < / orka: IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost > < orka: IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos contextRef =" c29" decimals ="- 3" id =" ixv- 24260" unitRef =" usd" > 20000 < / orka: IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos > < orka: IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos contextRef =" c30" decimals ="- 3" id =" ixv- 24261" unitRef =" usd" > 248437000 < / orka: IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos > < orka: IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos contextRef =" c0" decimals ="- 3" id =" ixv- 24262" unitRef =" usd" > 248457000 < / orka: IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos > < us- gaap: AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef =" c30" decimals ="- 3" id =" ixv- 24263" unitRef =" usd" > 20504000 < / us- gaap: AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts > < us- gaap: AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef =" c0" decimals ="- 3" id =" ixv- 24264" unitRef =" usd" > 20504000 < / us- gaap: AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts > < orka: IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger contextRef =" c29" decimals =" INF" id =" ixv- 24265" unitRef =" shares" > 1208883 < / orka: IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger > < orka: IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe contextRef =" c29" decimals ="- 3" id =" ixv- 24266" unitRef =" usd" > 1000 < / orka: IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe > < orka: IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe contextRef =" c30" decimals ="- 3" id =" ixv- 24267" unitRef =" usd" > 4999000 < / orka: IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe > < orka: IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe contextRef =" c0" decimals ="- 3" id =" ixv- 24268" unitRef =" usd" > 5000000 < / orka: IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe > < orka:

IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant contextRef =" c27" decimals =" INF" id =" ixv- 24269" unitRef =" shares" > 2439 < / orka:
IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant > < orka:
IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr contextRef =" c27" decimals ="- 3" id =" ixv- 24270" unitRef =" usd" > 56097000 < / orka:
IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr > < orka:
IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant contextRef =" c29" decimals =" INF" id =" ixv- 24271" unitRef =" shares" > 5600000 < / orka:
IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant > < orka:
IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr contextRef =" c29" decimals ="- 3" id =" ixv- 24272" unitRef =" usd" > 6000 < / orka:
IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr > < orka: IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr
contextRef =" c30" decimals ="- 3" id =" ixv- 24273" unitRef =" usd" > 144433000 < / orka: IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr > <
orka: IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr contextRef =" c0" decimals ="- 3" id =" ixv- 24274" unitRef =" usd" > 144439000 < / orka:
IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr > < orka: IssuanceCostOfPIPEFinancing contextRef =" c27" decimals ="- 3" id =" ixv- 24275"
unitRef =" usd" >- 3263000 < / orka: IssuanceCostOfPIPEFinancing > < orka: IssuanceCostOfPIPEFinancing contextRef =" c30" decimals ="- 3" id =" ixv- 24276" unitRef =" usd" >- 8592000 <
/ orka: IssuanceCostOfPIPEFinancing > < orka: IssuanceCostOfPIPEFinancing contextRef =" c0" decimals ="- 3" id =" ixv- 24277" unitRef =" usd" >- 8592000 < / orka:
IssuanceCostOfPIPEFinancing > < orka: ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares contextRef =" c27" decimals =" INF" id
=" ixv- 24278" unitRef =" shares" >- 2439 < / orka: ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares > < orka:
ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock contextRef =" c27" decimals ="- 3" id =" ixv- 24279" unitRef =" usd" >- 52834000 < / orka:
ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock > < orka:
ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares contextRef =" c29" decimals =" INF" id =" ixv- 24280" unitRef =" shares" >
2439000 < / orka: ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares > < orka:
ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock contextRef =" c29" decimals ="- 3" id =" ixv- 24281" unitRef =" usd" > 2000 < / orka:
ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock > < orka:
ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock contextRef =" c30" decimals ="- 3" id =" ixv- 24282" unitRef =" usd" > 52832000 < / orka:
ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock > < orka:
ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock contextRef =" c0" decimals ="- 3" id =" ixv- 24283" unitRef =" usd" > 52834000 < / orka:
ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock > < us- gaap: StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef ="
c29" decimals =" INF" id =" ixv- 24284" unitRef =" shares" > 2960 < / us- gaap: StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans > < us- gaap:
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef =" c30" decimals ="- 3" id =" ixv- 24285" unitRef =" usd" > 53000 < / us- gaap:
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan > < us- gaap: StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef =" c0" decimals ="- 3" id =" ixv- 24286"
unitRef =" usd" > 53000 < / us- gaap: StockIssuedDuringPeriodValueEmployeeStockPurchasePlan > < us- gaap: AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef =" c30"
decimals ="- 3" id =" ixv- 24287" unitRef =" usd" > 10357000 < / us- gaap: AdjustmentsToAdditionalPaidInCapitalWarrantIssued > < us- gaap:
AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef =" c0" decimals ="- 3" id =" ixv- 24288" unitRef =" usd" > 10357000 < / us- gaap:
AdjustmentsToAdditionalPaidInCapitalWarrantIssued > < us- gaap: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef ="
c30" decimals ="- 3" id =" ixv- 24289" unitRef =" usd" > 4562000 < / us- gaap: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue > <
us- gaap: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef =" c0" decimals ="- 3" id =" ixv- 24290" unitRef =" usd" >
4562000 < / us- gaap: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue > < us- gaap:
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef =" c31" decimals ="- 3" id =" ixv- 24291" unitRef =" usd" >- 41000 < / us- gaap:
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax > < us- gaap:
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef =" c0" decimals ="- 3" id =" ixv- 24292" unitRef =" usd" >- 41000 < / us- gaap:
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax > < us- gaap: NetIncomeLoss contextRef =" c32" decimals ="- 3" id =" ixv- 24293" unitRef
=" usd" >- 83724000 < / us- gaap: NetIncomeLoss > < us- gaap: NetIncomeLoss contextRef =" c0" decimals ="- 3" id =" ixv- 24294" unitRef =" usd" >- 83724000 < / us- gaap: NetIncomeLoss > <
us- gaap: SharesOutstanding contextRef =" c35" decimals =" INF" id =" ixv- 24295" unitRef =" shares" > 137138 < / us- gaap: SharesOutstanding > < us- gaap: StockholdersEquity contextRef
=" c35" decimals ="- 3" id =" ixv- 24296" unitRef =" usd" > 2931000 < / us- gaap: StockholdersEquity > < us- gaap: SharesOutstanding contextRef =" c36" decimals =" INF" id =" ixv- 24297"
unitRef =" shares" > 37440510 < / us- gaap: SharesOutstanding > < us- gaap: StockholdersEquity contextRef =" c36" decimals ="- 3" id =" ixv- 24298" unitRef =" usd" > 37000 < / us- gaap:
StockholdersEquity > < us- gaap: StockholdersEquity contextRef =" c37" decimals ="- 3" id =" ixv- 24299" unitRef =" usd" > 463018000 < / us- gaap: StockholdersEquity > < us- gaap:
StockholdersEquity contextRef =" c38" decimals ="- 3" id =" ixv- 24300" unitRef =" usd" >- 41000 < / us- gaap: StockholdersEquity > < us- gaap: StockholdersEquity contextRef =" c39"
decimals ="- 3" id =" ixv- 24301" unitRef =" usd" >- 83724000 < / us- gaap: StockholdersEquity > < us- gaap: StockholdersEquity contextRef =" c3" decimals ="- 3" id =" ixv- 24302" unitRef ="
usd" > 382221000 < / us- gaap: StockholdersEquity > < us- gaap: NetIncomeLoss contextRef =" c0" decimals ="- 3" id =" ixv- 24303" unitRef =" usd" >- 83724000 < / us- gaap: NetIncomeLoss >
< us- gaap: ShareBasedCompensation contextRef =" c0" decimals ="- 3" id =" ixv- 24304" unitRef =" usd" > 14919000 < / us- gaap: ShareBasedCompensation > < us- gaap:
AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef =" c0" decimals ="- 3" id =" ixv- 24305" unitRef =" usd" > 2245000 < / us- gaap:
AccretionAmortizationOfDiscountsAndPremiumsInvestments > < us- gaap: OtherNoncashExpense contextRef =" c0" decimals ="- 3" id =" ixv- 24306" unitRef =" usd" > 1468000 < / us- gaap:
OtherNoncashExpense > < us- gaap: OperatingLeaseExpense contextRef =" c0" decimals ="- 3" id =" ixv- 24307" unitRef =" usd" > 127000 < / us- gaap: OperatingLeaseExpense > < us- gaap:
Depreciation contextRef =" c0" decimals ="- 3" id =" ixv- 24308" unitRef =" usd" > 27000 < / us- gaap: Depreciation > < us- gaap: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
contextRef =" c0" decimals ="- 3" id =" ixv- 24309" unitRef =" usd" > 1128000 < / us- gaap: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets > < us- gaap:
IncreaseDecreaseInOtherNoncurrentAssets contextRef =" c0" decimals ="- 3" id =" ixv- 24310" unitRef =" usd" > 43000 < / us- gaap: IncreaseDecreaseInOtherNoncurrentAssets > < us- gaap:
IncreaseDecreaseInOtherAccountsPayable contextRef =" c0" decimals ="- 3" id =" ixv- 24311" unitRef =" usd" > 3462000 < / us- gaap: IncreaseDecreaseInOtherAccountsPayable > < us- gaap:
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef =" c0" decimals ="- 3" id =" ixv- 24312" unitRef =" usd" > 3292000 < / us- gaap:
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities > < us- gaap: IncreaseDecreaseInOperatingLeaseLiability contextRef =" c0" decimals ="- 3" id =" ixv- 24313" unitRef ="
usd" >- 14000 < / us- gaap: IncreaseDecreaseInOperatingLeaseLiability > < us- gaap: IncreaseDecreaseInAccountsPayableRelatedParties contextRef =" c0" decimals ="- 3" id =" ixv- 24314"
unitRef =" usd" > 6022000 < / us- gaap: IncreaseDecreaseInAccountsPayableRelatedParties > < us- gaap: NetCashProvidedByUsedInOperatingActivities contextRef =" c0" decimals ="- 3" id ="
ixv- 24315" unitRef =" usd" >- 57837000 < / us- gaap: NetCashProvidedByUsedInOperatingActivities > < us- gaap: PaymentsToAcquirePropertyPlantAndEquipment contextRef =" c0" decimals
="- 3" id =" ixv- 24316" unitRef =" usd" > 189000 < / us- gaap: PaymentsToAcquirePropertyPlantAndEquipment > < us- gaap: PaymentsToAcquireMarketableSecurities contextRef =" c0"
decimals ="- 3" id =" ixv- 24317" unitRef =" usd" > 329938000 < / us- gaap: PaymentsToAcquireMarketableSecurities > < us- gaap: NetCashProvidedByUsedInInvestingActivities contextRef ="
c0" decimals ="- 3" id =" ixv- 24318" unitRef =" usd" >- 330127000 < / us- gaap: NetCashProvidedByUsedInInvestingActivities > < us- gaap:
ProceedsFromIssuanceOfConvertiblePreferredStock contextRef =" c0" decimals ="- 3" id =" ixv- 24319" unitRef =" usd" > 2931000 < / us- gaap:
ProceedsFromIssuanceOfConvertiblePreferredStock > < us- gaap: ProceedsFromNotesPayable contextRef =" c0" decimals ="- 3" id =" ixv- 24320" unitRef =" usd" > 24980000 < / us- gaap:
ProceedsFromNotesPayable > < us- gaap: ProceedsFromPaymentsForOtherFinancingActivities contextRef =" c0" decimals ="- 3" id =" ixv- 24321" unitRef =" usd" > 227953000 < / us- gaap:
ProceedsFromPaymentsForOtherFinancingActivities > < us- gaap: ProceedsFromIssuanceOfPrivatePlacement contextRef =" c0" decimals ="- 3" id =" ixv- 24322" unitRef =" usd" > 188681000
< / us- gaap: ProceedsFromIssuanceOfPrivatePlacement > < orka: CashAcquiredInConnectionWithTheReverseRecapitalization contextRef =" c0" decimals ="- 3" id =" ixv- 24323" unitRef ="
usd" > 4940000 < / orka: CashAcquiredInConnectionWithTheReverseRecapitalization > < us- gaap: ProceedsFromIssuanceOfCommonStock contextRef =" c0" decimals ="- 3" id =" ixv- 24324"
unitRef =" usd" > 54000 < / us- gaap: ProceedsFromIssuanceOfCommonStock > < us- gaap: NetCashProvidedByUsedInFinancingActivities contextRef =" c0" decimals ="- 3" id =" ixv- 24325"
unitRef =" usd" > 449539000 < / us- gaap: NetCashProvidedByUsedInFinancingActivities > < us- gaap:
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef =" c0" decimals ="- 3" id =" ixv- 24326" unitRef =" usd"
> 61575000 < / us- gaap: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect > < us- gaap:
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef =" c3" decimals ="- 3" id =" ixv- 24327" unitRef =" usd" > 61575000 < / us- gaap:
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents > < us- gaap: RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef =" c0" decimals ="- 3" id ="
ixv- 24328" unitRef =" usd" > 982000 < / us- gaap: RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability > < us- gaap: NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1
contextRef =" c0" decimals ="- 3" id =" ixv- 24329" unitRef =" usd" > 114000 < / us- gaap: NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1 > < us- gaap:
NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1 contextRef =" c0" decimals ="- 3" id =" ixv- 24330" unitRef =" usd" > 54000 < / us- gaap:
NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1 > < orka: NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock contextRef =" c0" decimals ="- 3" id =" ixv-
24331" unitRef =" usd" > 1468000 < / orka: NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock > < orka:
NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock contextRef =" c0" decimals ="- 3" id =" ixv- 24332" unitRef =" usd" > 2931000 < / orka:
NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock > < us- gaap: ConversionOfStockAmountConverted1 contextRef =" c0" decimals ="- 3" id ="
ixv- 24333" unitRef =" usd" > 52834000 < / us- gaap: ConversionOfStockAmountConverted1 > < orka: ReclassificationOfTheParukaWarrantFromLiabilityToEquity contextRef =" c0" decimals
="- 3" id =" ixv- 24334" unitRef =" usd" > 10357000 < / orka: ReclassificationOfTheParukaWarrantFromLiabilityToEquity > < us- gaap: BusinessDescriptionAndBasisOfPresentationTextBlock
contextRef =" c0" id =" ixv- 11731" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman,
Times, Serif" & gt; & lt; b & gt; 1. Nature of the Business and Basis of Presentation & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif;
margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p
style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Background and Basis
of Presentation & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" &
gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;
text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Oruka Therapeutics, Inc., together with its subsidiaries (collectively, the &
# x201c; Company & # x201d;), formerly known as ARCA biopharma, Inc. (& # x201c; ARCA & # x201d;), is a clinical- stage biotechnology company that is the result of the reverse
recapitalization discussed below. Prior to the reverse recapitalization, the private company Oruka Therapeutics, Inc. (& # x201c; Pre- Merger Oruka & # x201d;) was established and
incorporated under the laws of the state of Delaware on February & # 160; 6, 2024 (referred to in the Notes as the inception of the Company). The Company is headquartered in Menlo Park,
California. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (& # x201c; PsO & # x201d;) and other inflammatory and immunology (& # x201c; I &
amp; amp; I & # x201d;) indications. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; &
lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-
align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The accompanying consolidated financial statements reflect the operations of the
Company and its wholly- owned subsidiaries. Intercompany balances and transactions have been eliminated in consolidation. The accompanying consolidated financial statements have been
prepared in conformity with United States (& # x201c; U. S. & # x201d;) generally accepted accounting principles (& # x201c; GAAP & # x201d;). Any reference in these notes to applicable
guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (& # x201c; ASC & # x201d;) and Accounting Standards Updates (& # x201c; ASU & #

x201d;) of the Financial Accounting Standards Board (& # x201c; FASB & # x201d;). & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Reverse Recapitalization and Pre- Closing & # 160; Financing & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; On August 29, 2024 (the & # x201c; Merger Closing & # x201d;), the Company completed the acquisition (the & # x201c; Merger & # x201d;) of Pre- Merger Oruka pursuant to an Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024 (the & # x201c; Merger Agreement & # x201d;). Following the transactions contemplated by the Merger Agreement, Pre- Merger Oruka merged with and into Atlas Merger Sub Corp., a wholly owned subsidiary of ARCA and following that, Pre- Merger Oruka then merged with and into Atlas Merger Sub II, LLC (& # x201c; Second Merger Sub & # x201d;), with Second Merger Sub being the surviving entity. Second Merger Sub changed its corporate name to & # x201c; Oruka Therapeutics Operating Company, LLC. & # x201d; On August 29, 2024, the Company changed its name from & # x201c; ARCA biopharma, Inc. & # x201d; to & # x201c; Oruka Therapeutics, Inc. & # x201d; and its Nasdaq ticker symbol from & # x201c; ABIO & # x201d; to & # x201c; ORKA & # x201d;. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Following consummation of the Merger, the Company effected a 1- for- 12 reverse stock split (the & # x201c; Reverse Stock Split & # x201d;) of the common stock, par value $ 0. 001 per share, of the Company (& # x201c; Company Common Stock & # x201d;), which became effective on September 3, 2024. The Company Common Stock commenced trading on a post- Reverse Stock Split, post- Merger basis at the opening of trading on September 3, 2024. The Company is led by the Pre- Merger Oruka management team and remains focused on developing biologics to optimize the treatment of inflammatory skin diseases. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Immediately prior to the execution and delivery of the Merger Agreement on April 3, 2024, certain new and existing investors of Pre- Merger Oruka entered into a subscription agreement with Pre- Merger Oruka (the & # x201c; Subscription Agreement & # x201d;), pursuant to which, and on the terms and subject to the conditions of which, immediately prior to the Closing, those investors purchased shares of common stock of Pre- Merger Oruka (& # x201c; Pre- Merger Oruka Common Stock & # x201d;) and Pre- Merger Oruka pre- funded warrants for gross proceeds of approximately $ 275. 0 million (which includes $ 25. 0 million of proceeds previously received from the issuance of the Convertible Note (as defined in Note 7) and accrued interest on such note which converted to shares of Pre- Merger Oruka Common Stock) (the & # x201c; Pre- Closing Financing & # x201d;). The Company incurred transaction costs of $ 20. 5 million which was recorded as a reduction to additional paid- in capital in the consolidated financial statements. At the Merger Closing, the shares of Pre- Merger Oruka Common Stock and Pre- Merger Oruka pre- funded warrants issued pursuant to the Subscription Agreement were converted into shares of Company Common Stock and pre- funded warrants of Company Common Stock in accordance with the Exchange Ratio (defined below). & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; In accordance with an Exchange Ratio determined by terms of the Merger Agreement and upon the effective time of the First Merger (the & # x201c; First Effective Time & # x201d;), (i) each then- issued and outstanding share of Pre- Merger Oruka Common Stock including outstanding and unvested Pre- Merger Oruka restricted stock and shares of Pre- Merger Oruka Common Stock issued in connection with the Subscription Agreement, were converted into the right to receive a number of shares of Company Common Stock, equal to the Exchange Ratio of 6. 8569 shares of Company Common Stock, which were subject to the same vesting provisions as those immediately prior to the Merger, (ii) each share of Pre- Merger Oruka Series A convertible preferred stock, par value $ 0. 0001 (& # x201c; Pre- Merger Oruka Series A Preferred Stock & # x201d;), outstanding immediately prior to the First Effective Time was converted into the right to receive a number of shares of ARCA Series B non- voting convertible preferred stock, par value $ 0. 001 per share (& # x201c; Company Series B Preferred Stock & # x201d;), which are convertible into shares of Company Common Stock, at a conversion ratio of approximately 83: 3332: 1 (iii) each outstanding option to purchase Pre- Merger Oruka Common Stock was converted into an option to purchase shares of Company Common Stock, (iv) each outstanding warrant to purchase shares of Pre- Merger Oruka Common Stock was converted into a warrant to purchase shares of Company Common Stock, and (v) each share of Company Common Stock issued and outstanding at the First Effective Time remain issued and outstanding in accordance with its terms and such shares. Subsequent to the close of the merger, the common stock shares were then subject to the reverse stock split of 1- for- 12 effected on September 3, 2024. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; As part of the Pre- Closing Financing and the Merger Closing, investors in the Pre- Closing Financing received 22, 784, 139 shares of Company Common Stock in exchange for 39, 873, 706 shares of Pre- Merger Oruka Common Stock (which includes the issuance of 2, 722, 207 shares of Company Common Stock in exchange for 4, 764, 032 shares of Pre- Merger Oruka Common Stock on the conversion of Convertible Note along with the accrued interest through the conversion date) and 5, 522, 207 Company pre- funded warrants in exchange for 9, 664, 208 Pre- Merger pre- funded warrants. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Merger was accounted for as a reverse recapitalization in accordance with U. S. GAAP. Under this method of accounting, Pre- Merger Oruka was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the fact that, immediately following the Merger: (i) Pre- Merger Oruka stockholders own a substantial majority of the voting rights in the combined company; (ii) Pre- Merger Oruka & # x2019; s largest stockholders retain the largest interest in the combined company; (iii) Pre- Merger Oruka designated a majority of the initial members of the board of directors of the combined company; and (iv) Pre- Merger Oruka & # x2019; s executive management team became the management team of the combined company. Accordingly, for accounting purposes: (i) the Merger was treated as the equivalent of Pre- Merger Oruka issuing stock to acquire the net assets of ARCA, and (ii) the reported historical operating results of the combined company prior to the Merger are those of Pre- Merger Oruka. Additional information regarding the Merger is included in Note 3. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Reverse Stock Split & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; On September 3, 2024, the Company effected the Reverse Stock Split, a 1- for- 12 reverse stock split of Company Common Stock. The par value per share and the number of authorized shares were not adjusted as a result of the Reverse Stock Split. The shares of Company Common Stock underlying outstanding stock options, common stock warrants and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. All references to common stock, options to purchase common stock, outstanding common stock warrants, common stock share data, per share data, and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented, unless otherwise specifically indicated or the context otherwise requires. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; PIPE Financing & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; On September 11, 2024, the Company entered into a Securities Purchase Agreement for a private placement (the & # x201c; PIPE Financing & # x201d;) with certain institutional and accredited investors. The closing of the PIPE Financing occurred on September 13, 2024. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; Pursuant to the Securities Purchase Agreement, the investors purchased an aggregate of 5, 600, 000 shares of Company Common Stock at a purchase price of $ 23. 00 per share, an aggregate of 2, 439 shares of the Company & # x2019; s Series A non- voting convertible preferred stock, par value $ 0. 001 per share (& # x201c; Company Series A Preferred Stock & # x201d;), at a purchase price of $ 23, 000. 00 per share (each Company Series A Preferred Stock is convertible into 1, 000 shares of Company Common Stock), and pre- funded warrants to purchase an aggregate of 680, 000 shares of Company Common Stock at a purchase price of $ 22. 999 per pre- funded warrant, for aggregate net proceeds of approximately $ 188. 7 million (net of issuance costs of $ 11. 9 million). & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Liquidity and Going Concern & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Since its inception, the Company has devoted substantially all of its resources to advancing the development of its portfolio of programs, organizing and staffing the Company, business planning, raising capital, and providing general and administrative support for these operations. Current and future programs will require significant research and development efforts, including preclinical and clinical trials, and regulatory approvals to commercialization. Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination of equity offerings and debt financings. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception. For the period from February 6, 2024 (inception) to December 31, 2024, the Company has incurred a net loss of $ 83. 7 million and used net cash of $ 57. 8 million for its operating activities. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; As of December 31, 2024, the Company had cash, cash equivalents, and marketable securities of $ 393. 7 million. The Company & # x2019; s management expects that the existing cash, cash equivalents, and marketable securities will be sufficient to fund the Company & # x2019; s operating plans for at least twelve months from the date these consolidated financial statements were issued. The Company expects that its research and development and general and administrative costs will continue to increase significantly, including in connection with conducting future pre- clinical activities and clinical trials and manufacturing for its existing product candidates and any future product candidates to support commercialization and providing general and administrative support for its operations, including the costs associated with operating as a public company. The Company & # x2019; s ability to access capital when needed is not assured and, if capital is not available to the Company when, and in the amounts needed, the Company may be required to significantly curtail, delay, or discontinue one or more of its research or development programs or the commercialization of any product candidate, or be unable to expand its operations or otherwise capitalize on the Company & # x2019; s business opportunities, as desired, which could materially harm the Company & # x2019; s business, financial condition and results of operations. & lt; / span & gt; & lt; / p & gt; < / us- gaap: BusinessDescriptionAndBasisOfPresentationTextBlock > < us- gaap: StockholdersEquityReverseStockSplit contextRef =" c40" id =" ixv- 24335" > 1- for- 12 < / us- gaap: StockholdersEquityReverseStockSplit > < us- gaap: CommonStockParOrStatedValuePerShare contextRef =" c41" decimals =" 3" id =" ixv- 24336" unitRef =" usdPershares" > 0. 001 < / us- gaap: CommonStockParOrStatedValuePerShare > < us- gaap: SaleOfStockConsiderationReceivedPerTransaction contextRef =" c42" decimals ="- 5" id =" ixv- 24337" unitRef =" usd" > 275000000 < / us- gaap: SaleOfStockConsiderationReceivedPerTransaction > < us- gaap: ProceedsFromIssuanceOfDebt contextRef =" c42" decimals ="- 5" id =" ixv- 24338" unitRef =" usd" > 25000000 < / us- gaap: ProceedsFromIssuanceOfDebt > < orka: AdditionalPaidInCapitalTransacationCost contextRef =" c43" decimals ="- 5" id =" ixv- 24339" unitRef =" usd" > 20500000 < /

orka: AdditionalPaidInCapitalTransacationCost > < orka: ExchangeRatio contextRef =" c44" decimals =" 4" id =" ixv- 24340" unitRef =" pure" > 6. 8569 < / orka: ExchangeRatio > < us- gaap: CommonStockParOrStatedValuePerShare contextRef =" c45" decimals =" 4" id =" ixv- 24341" unitRef =" usdPershares" > 0. 0001 < / us- gaap: CommonStockParOrStatedValuePerShare > < us- gaap: CommonStockParOrStatedValuePerShare contextRef =" c46" decimals =" 3" id =" ixv- 24342" unitRef =" usdPershares" > 0. 001 < / us- gaap: CommonStockParOrStatedValuePerShare > < orka: CommonStocksConversionRatio contextRef =" c47" id =" ixv- 24343" > 83: 3332: 1 < / orka: CommonStocksConversionRatio > < orka: InvestorsClosingShares contextRef =" c48" decimals =" 0" id =" ixv- 24344" unitRef =" shares" > 22784139 < / orka: InvestorsClosingShares > < us- gaap: SaleOfStockNumberOfSharesIssuedInTransaction contextRef =" c49" decimals =" INF" id =" ixv- 24345" unitRef =" shares" > 39873706 < / us- gaap: SaleOfStockNumberOfSharesIssuedInTransaction > < us- gaap: StockIssuedDuringPeriodSharesOther contextRef =" c48" decimals =" 0" id =" ixv- 24346" unitRef =" shares" > 2722207 < / us- gaap: StockIssuedDuringPeriodSharesOther > < us- gaap: SaleOfStockNumberOfSharesIssuedInTransaction contextRef =" c48" decimals =" 0" id =" ixv- 24347" unitRef =" shares" > 4764032 < / us- gaap: SaleOfStockNumberOfSharesIssuedInTransaction > < orka: PreFundedWarrantsOfCommonStockShares contextRef =" c0" decimals =" 0" id =" ixv- 24348" unitRef =" shares" > 5522207 < / orka: PreFundedWarrantsOfCommonStockShares > < us- gaap: ClassOfWarrantOrRightUnissued contextRef =" c3" decimals =" 0" id =" ixv- 24349" unitRef =" shares" > 9664208 < / us- gaap: ClassOfWarrantOrRightUnissued > < orka: NumberOfSharesPurchased contextRef =" c50" decimals =" 0" id =" ixv- 24350" unitRef =" shares" > 5600000 < / orka: NumberOfSharesPurchased > < us- gaap: SaleOfStockPricePerShare contextRef =" c50" decimals =" 2" id =" ixv- 24351" unitRef =" usdPershares" > 23 < / us- gaap: SaleOfStockPricePerShare > < orka: NumberofAggregateShares contextRef =" c51" decimals =" 0" id =" ixv- 24352" unitRef =" shares" > 2439 < / orka: NumberofAggregateShares > < us- gaap: CommonStockParOrStatedValuePerShare contextRef =" c52" decimals =" 3" id =" ixv- 24353" unitRef =" usdPershares" > 0. 001 < / us- gaap: CommonStockParOrStatedValuePerShare > < us- gaap: SaleOfStockPricePerShare contextRef =" c9" decimals =" 2" id =" ixv- 24354" unitRef =" usdPershares" > 23000 < / us- gaap: SaleOfStockPricePerShare > < us- gaap: ConversionOfStockSharesConverted1 contextRef =" c53" decimals =" 0" id =" ixv- 24355" unitRef =" shares" > 1000 < / us- gaap: ConversionOfStockSharesConverted1 > < orka: PrefundedWarrantstoPurchaseAnAggregateShares contextRef =" c48" decimals =" 0" id =" ixv- 24356" unitRef =" shares" > 680000 < / orka: PrefundedWarrantstoPurchaseAnAggregateShares > < us- gaap: SaleOfStockPricePerShare contextRef =" c54" decimals =" 3" id =" ixv- 24357" unitRef =" usdPershares" > 22. 999 < / us- gaap: SaleOfStockPricePerShare > < us- gaap: SaleOfStockConsiderationReceivedPerTransaction contextRef =" c55" decimals ="- 5" id =" ixv- 24358" unitRef =" usd" > 188700000 < / us- gaap: SaleOfStockConsiderationReceivedPerTransaction > < us- gaap: PaymentOfFinancingAndStockIssuanceCosts contextRef =" c55" decimals ="- 5" id =" ixv- 24359" unitRef =" usd" > 11900000 < / us- gaap: PaymentOfFinancingAndStockIssuanceCosts > < us- gaap: NetIncomeLoss contextRef =" c0" decimals ="- 5" id =" ixv- 24360" unitRef =" usd" >- 83700000 < / us- gaap: NetIncomeLoss > < us- gaap: NetCashProvidedByUsedInOperatingActivities contextRef =" c0" decimals ="- 5" id =" ixv- 24361" unitRef =" usd" >- 57800000 < / us- gaap: NetCashProvidedByUsedInOperatingActivities > < us- gaap: InvestmentsAndCash contextRef =" c3" decimals ="- 5" id =" ixv- 24362" unitRef =" usd" > 393700000 < / us- gaap: InvestmentsAndCash > < us- gaap: SignificantAccountingPoliciesTextBlock contextRef =" c0" id =" ixv- 11859" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; 2. Summary of Significant Accounting Policies & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Use of Estimates & lt; / i & gt; & lt; / b & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The preparation of the Company & # x2019; s consolidated financial statements in conformity with U. S. & # 160; GAAP requires management to make estimates, assumptions, and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected within these consolidated financial statements include but are not limited to research and development expenses and related prepaid or accrued costs and the valuation of stock- based compensation awards and related expenses. The Company bases its estimates on known trends and other market- specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Actual results could differ materially from those estimates or assumptions. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Concentrations of Credit Risk and Other Risks and Uncertainties & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities. The Company & # x2019; s investment policy limits investments to high credit quality securities issued by the U. S. government, U. S. government- sponsored agencies, highly rated banks, and corporate issuers, subject to certain concentration limits and restrictions on maturities. The Company & # x2019; s cash, cash equivalents and marketable securities are held by financial institutions that management believes are of high credit quality. The financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash deposits. Accounts at the Company & # x2019; s U. S. banking institution are insured by the Federal Deposit Insurance Corporation (& # x201c; FDIC & # x201d;) up to $ 250, 000 per depositor. As of December 31, 2024, the balance at the Company & # x2019; s U. S. banking institution exceeded the FDIC limits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its accounts are monitored by management to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents, and bond issuers. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company is dependent on third- party organizations to research, develop, manufacture, and process its product candidates for its development programs, including its two most advanced programs, ORKA- 001 and ORKA- 002. The Company expects to continue to be dependent on a small number of manufacturers to supply it with its requirements for all products. The Company & # x2019; s research and development programs could be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Company & # x2019; s research and development activities are performed under its agreements with Paragon Therapeutics, Inc. (& # x201c; Paragon & # x201d;) (see Note & # 160; 12). & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Cash and Cash Equivalents & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to be cash equivalents. The cash equivalents were comprised of investments in money market funds, U. S. treasury securities, U. S. government agency securities, and debt securities and are stated at fair value. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Marketable Securities & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company invests in marketable securities, primarily securities issued by the U. S. government and its agencies, commercial paper and corporate debt securities. The Company & # x2019; s marketable securities are classified as available- for- sale and reported at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive loss. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; For available- for- sale debt securities in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security & # x2019; s amortized cost basis is written down to fair value and recognized in other income (expense) in the results of operations. For available- for- sale debt securities that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, an allowance is recorded for the difference between the present value of cash flows expected to be collected and the amortized cost basis of the security. Impairment losses attributable to credit loss factors are charged against the allowance when management believes an available- for- sale security is uncollectible or when either of the criteria regarding intent or requirement to sell is met. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Any unrealized losses from declines in fair value below the amortized cost basis as a result of non- credit loss factors are recognized as a component of accumulated other comprehensive loss, net of unrealized gains. Realized gains and losses and declines in fair value, if any, on available- for- sale securities are included in other income, net, in the results of operations. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Marketable securities with stated maturities of greater than three months from the date of purchase but less than one year from the consolidated balance sheet date are classified as current, while marketable securities with maturities in one year or beyond one year from the consolidated balance sheet date are classified as long- term. The cost of securities sold is determined using the specific- identification method. Interest earned and adjustments for the amortization of premiums and discounts on investments are included in interest income on the consolidated statements of operations and comprehensive loss. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Debt Issuance Costs & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Debt issuance costs incurred in connection with the Convertible Note (see Note & # 160; 7) are recorded as a reduction of the carrying value of the notes payable liability on the Company & # x2019; s balance sheet and are amortized to interest expense over the term of the loan using the effective interest method. At the effective time of the Merger the Converted Note was converted to common stock and is no longer on the balance sheet as of December 31, 2024. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Subscription Receivable & # 160; & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable is paid prior to the date the financial statement is available to be issued. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Fair Value Measurements & # 160; & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin:

0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Certain assets and liabilities are carried at fair value under U. S. & # 160; GAAP. & # 160; Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" width: 100 %; font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; border- spacing: 0px;" & gt; & lt; tr style =" font- family: Times New Roman, Times, Serif; vertical- align: top" & gt; & lt; td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" & gt; & lt; / td & gt; & lt; td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # x25cf; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- family: Times New Roman, Times, Serif; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Level 1 & # 160; & # x2014; & # 160; Quoted prices in active markets that are identical assets or liabilities. & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; text- indent:- 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" width: 100 %; font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; border- spacing: 0px;" & gt; & lt; tr style =" font- family: Times New Roman, Times, Serif; vertical- align: top" & gt; & lt; td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" & gt; & lt; / td & gt; & lt; td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # x25cf; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- family: Times New Roman, Times, Serif; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Level & # 160; 2 & # 160; & # x2014; & # 160; Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; text- indent:- 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" width: 100 %; font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; border- spacing: 0px;" & gt; & lt; tr style =" font- family: Times New Roman, Times, Serif; vertical- align: top" & gt; & lt; td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" & gt; & lt; / td & gt; & lt; td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # x25cf; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- family: Times New Roman, Times, Serif; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Level & # 160; 3 & # 160; & # x2014; & # 160; Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies, and similar techniques. & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0. 5in; text- align: justify; text- indent:- 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company & # x2019; s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy described above (see Note 4). The carrying values of the Company & # x2019; s prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to their relatively short maturity period. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Property and Equipment & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight- line method over the estimated useful life of each asset as follows: & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; font- weight: bold; text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Estimated & lt; br / & gt; Useful Life & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Furniture and fixtures & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 11 %; text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3- 5 years & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Computer and office equipment & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3- 5 years & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Classification of Convertible Preferred Stock & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Prior to the reverse recapitalization, the Company had classified its Pre- Merger Oruka Series A Preferred Stock outside of stockholders & # x2019; equity on the Company & # x2019; s consolidated balance sheet because the holders of such stock have certain liquidation rights in the event of a deemed liquidation event that, in certain situations, is not solely within the control of the Company and would require the redemption of the then- outstanding convertible preferred stock. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Upon the closing of the Merger, the Company converted its Pre- Merger Oruka Series A Preferred Stock to Company Series B Preferred Stock and has classified the Company Series B Preferred Stock within stockholders & # x2019; equity on its consolidated balance sheet because the Company Series B Preferred Stock is not redeemable or puttable to the Company by the holder under any circumstances. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; In connection with the PIPE Financing (see Note 1) the Company issued Company Series A Preferred Stock, and has classified the Company Series A Preferred Stock outside of stockholders & # x2019; equity on the Company & # x2019; s consolidated balance sheet because the holders of such stock have certain rights (see Note 8) that, in certain situations, is not solely within the control of the Company and would require the redemption of the then- outstanding convertible preferred stock. In November 2024, the Company Series A Preferred Stock shares were converted to common stock, and as of December 31, 2024, there were no shares of Company Series A Preferred Stock outstanding. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Note & # 160; Payable to Related Party & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company accounted for the Convertible Note (as defined in Note 7) at amortized cost. The Company considered if optional conversion features are required to be bifurcated and separately accounted for as a derivative. Costs related to the issuance of the Convertible Note were recorded as a debt discount, amortized over the term of the Convertible Note (see & # 160; Note & # 160; 7) and were accounted for as interest expense in other income (expenses) within the consolidated statement of operations and comprehensive loss using the effective interest method. At the effective time of the Merger, shares of Pre- Merger Oruka Common Stock issued pursuant to the conversion of the Convertible Note (including accrued interest) automatically converted into shares of Company Common Stock (see Note 1). & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Research and Development Contract Costs Accruals & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company records the costs associated with research studies and manufacturing development as incurred. These costs are a significant component of the Company & # x2019; s research and development expenses, with a substantial portion of the Company & # x2019; s ongoing research and development activities conducted by third- party service providers, including contract research organizations (& # x201c; CROs & # x201d;) and contract manufacturing organizations (& # x201c; CMOs & # x201d;), and the Company & # x2019; s related- party Paragon (see Note & # 160; 12). & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company accrues for expenses resulting from obligations under its two antibody discovery and option agreements (the & # x201c; Option Agreements & # x201d;) (see Note 12), by and among Paragon, Paruka Holding LLC (& # x201c; Paruka & # x201d;), an entity formed by Paragon as a vehicle to hold equity in the Company, and the Company as well as agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrual balance in each reporting period. If advance payments are made to Paragon, a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be expensed as the contracted services are performed. Changes in these estimates that result in material changes to the Company & # x2019; s accruals could materially affect the Company & # x2019; s results of operations. As of December 31, 2024, the Company has not experienced any material deviations between accrued and actual research and development expenses. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Leases & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; At the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies a lease as either an operating or finance lease and recognizes a right- of- use (& # x201c; ROU & # x201d;) asset and a current and non- current lease liability, as applicable, in the balance sheet if the lease has a term greater than one year. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise its option. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style ="

font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; At the lease commencement date, operating lease liabilities and their corresponding ROU assets are recorded at the present value of future minimum lease payments over the expected remaining lease term. The Company determines the present value of lease payments using the implicit rate, if it is readily determinable, or the risk- free discount rate for a period comparable with that of the lease term. For operating leases, lease expense for lease payments is recognized on a straight- line basis over the lease term. For finance leases, lease expense includes amortization expense of the ROU asset recognized on a straight- line basis over the lease term and interest expense recognized on the finance lease liability. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments, incentives received or initial direct costs. As of December 31, 2024, the Company has one operating lease and no finance leases. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company accounts for lease and non- lease components related to operating leases as a single lease component. The Company has elected that costs associated with leases having an initial term of 12 months or less are recognized in the consolidated statement of operations and comprehensive loss on a straight- line basis over the lease term and are not recorded on its consolidated balance sheets. Variable lease expense is recognized as incurred and consists primarily of real estate taxes, utilities, and other office space related expenses. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Segment Reporting & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; The Company operates as a single reportable and operating segment. Its Chief Executive Officer, serving as the Chief Operating Decision Maker (& # x201c; CODM & # x201d;), oversees operations on an aggregated basis to allocate resources effectively. In assessing the Company & # x2019; s financial performance, the CODM regularly reviews total operating expenses and consolidated net loss. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Research and Development Costs & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Research and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock- based compensation, employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities, as well as allocated human resource costs, information technology costs, and facility- related costs, including rent, maintenance, utilities, and depreciation. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses on the accompanying consolidated balance sheet. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable advance payments represent a one- time cost for obtaining goods or services, with anticipated benefits to be utilized within a year of period end, the payment is expensed immediately. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; General and Administrative Expenses & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; General and administrative expenses consist primarily of salaries and bonuses, stock- based compensation, employee benefits, finance and administration costs, patent and intellectual property costs, professional fees, as well as allocated human resource costs, information technology costs, and facility- related costs, including rent, maintenance, utilities and depreciation. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Commitments and Contingencies & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities. The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but not probable; however, it discloses the range of reasonably possible losses. As of December 31, 2024, no liabilities were recorded for loss contingencies (see Note & # 160; 13). & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Stock- Based Compensation & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company estimates the fair value of its stock awards using the Black- Scholes option pricing model, which uses as inputs the fair value of the Company & # x2019; s common stock, and certain management estimates, including the expected stock price volatility, the expected term of the award, the risk- free interest rate, and expected dividends. Expected volatility is calculated based on reported volatility data for a representative group of publicly traded companies for which historical information is available. The Company selects companies with comparable characteristics with historical share price information that approximates the expected term of the equity- based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies & # x2019; shares during the equivalent period that approximates the calculated expected term of the stock options. The Company will continue to apply this method until a sufficient amount of historical information regarding the volatility of its stock price becomes available. The risk- free interest rate is based on the U. S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. For employee and non- employee awards (except the Paruka warrant) the Company uses the simplified method, under which the expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to lack of historical exercise data. For the Paruka warrant, the contractual term is used for the expected term. The expected dividend yield is assumed to be zero as the Company has no current plans to pay any dividends on common stock. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company measures restricted common stock awards (& # x201c; RSAs & # x201d;) using the difference, if any, between the purchase price per share of the award and the fair value of the Company & # x2019; s common stock at the date of grant. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company grants stock options, restricted stock awards, and warrants that are subject to service or performance- based vesting conditions. Compensation expense for awards to employees and directors with service- based vesting conditions is recognized using the straight- line method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards to non- employees with service- based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. As of each reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation expense until it is probable that the performance- based vesting condition will be achieved. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company has issued stock options, warrants, and RSAs with service- based and performance- based vesting conditions. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company recognizes the compensation expense for the option to purchase common stock under the Employee Stock Purchase Plan (& # x201c; ESPP & # x201d;), based on the fair value of the common stock estimated using the closing price of the Company & # x2019; s common stock as reported on the date of offering, less the purchase discount percentage provided for in the plan. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company classifies stock- based compensation expense in its consolidated statement of operations and comprehensive loss in the same manner in which the award recipient & # x2019; s payroll costs are classified or in which the award recipient & # x2019; s service payments are classified, as applicable. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Comprehensive Loss & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Comprehensive loss includes net loss as well as other changes in stockholders & # x2019; equity that result from transactions and events other than those with stockholders. The Company & # x2019; s unrealized gains and losses on marketable securities represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the consolidated statement of comprehensive loss. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Net Loss per Share Attributable to Stockholders & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Basic and diluted net loss attributable to stockholders per share is presented in conformity with the two- class method required for participating securities (Pre- Merger Oruka Series A Preferred Stock). Basic earnings per share is computed by dividing net income available to each class of shares by the weighted- average number of shares of common stock and participating securities outstanding during the period. Pre- funded warrants were included as the exercise price is negligible and these warrants are fully vested and exercisable. Company Series A Preferred Stock and Company Series B Preferred Stock share the same characteristics as Common Stock and have no substantive preference attributed to them and, accordingly, have been considered as classes of Common Stock in the computation of net loss per share regardless of their legal form. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Net loss is allocated to common stock based on its proportional ownership on an as- converted basis. Net loss is not allocated to participating securities as they do not have an obligation to fund losses. The weighted- average number of shares outstanding of common stock reflects changes in ownership over the periods presented. See Note 8 & # x2014; Convertible Preferred Stock and Stockholders & # x2019; Equity. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Diluted net loss per share is computed by dividing the net loss attributable to stockholders adjusted for income (expenses), net of tax, related to any diluted securities, by the weighted- average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of this calculation, stock options to purchase common stock, employee warrants to purchase common stock, and unvested RSAs are considered potential dilutive common shares. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company generated a net loss for the periods presented. Accordingly, basic and diluted net loss per share is the same because the inclusion of the potentially dilutive securities would be anti- dilutive. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Other income, net & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Other income, net, consists of interest earned on the Company & # x2019; s cash, cash equivalents, and marketable securities; interest expense on the convertible note from a related party and foreign currency transactions gains and losses. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Income Taxes & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company & # x2019; s tax returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis of assets and liabilities using enacted tax rates in effect for the & # 160; years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two- step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50 % likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or penalties related to uncertain tax positions as of December 31, 2024. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Recently Adopted Accounting Pronouncements & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; In November & # 160; 2023, the FASB issued ASU 2023- 07, Segment Reporting (Topic & # 160; 280): Improvements to Reportable Segment Disclosures (& # x201c; ASU & # 160; 2023- 07 & # x201d;), which enhances the segment disclosure requirements for public entities on an annual and interim basis. Under this standard, public entities will be required to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss. Additionally, current annual disclosures about a reportable segment & # x2019; s profit or loss and assets will be required on an interim basis. Entities will also be required to disclose information about the CODM & # x2019; s title and position at the Company along with an explanation of how the CODM uses the reported measures of segment profit or loss in their assessment of segment performance and deciding how to allocate resources. Finally, ASU & # 160; 2023- 07 requires all segment disclosures for public entities that have only a single reportable segment. The amendments in ASU & # 160; 2023- 07 are effective for fiscal & # 160; years beginning after December & # 160; 15, 2023, and interim periods within fiscal & # 160; years beginning after December & # 160; 15, 2024. Early adoption is permitted. The Company adopted ASU 2023- 07 in 2024 and additional required disclosures have been included in Note 10. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Recently Issued Accounting Pronouncements & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; In December & # 160; 2023, the FASB issued ASU & # 160; 2023- 09, Income Taxes (Topic & # 160; 740): Improvements to Income Tax Disclosures. This ASU expands disclosures in an entity & # x2019; s income tax rate reconciliation table and disclosures regarding taxes paid both in the U. S. & # 160; and foreign jurisdictions. This update is effective beginning with the Company & # x2019; s 2025 fiscal year annual reporting period. The Company is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; In November 2024, the FASB issued ASU 2024- 03, Income Statement & # x2014; Reporting Comprehensive Income & # x2014; Expense Disaggregation Disclosures (Subtopic 220- 40): Disaggregation of Income Statement Expenses. This ASU requires more detailed disclosures, on an annual and interim basis, about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. This ASU may be applied either prospectively or retrospectively. The Company is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements. & lt; / span & gt; & lt; / p & gt; < / us- gaap: SignificantAccountingPoliciesTextBlock > < us- gaap: UseOfEstimates contextRef =" c0" id =" ixv- 11867" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Use of Estimates & lt; / i & gt; & lt; / b & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The preparation of the Company & # x2019; s consolidated financial statements in conformity with U. S. & # 160; GAAP requires management to make estimates, assumptions, and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected within these consolidated financial statements include but are not limited to research and development expenses and related prepaid or accrued costs and the valuation of stock- based compensation awards and related expenses. The Company bases its estimates on known trends and other market- specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Actual results could differ materially from those estimates or assumptions. & lt; / span & gt; & lt; / p & gt; < / us- gaap: UseOfEstimates > < us- gaap: ConcentrationRiskCreditRisk contextRef =" c0" id =" ixv- 11879" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Concentrations of Credit Risk and Other Risks and Uncertainties & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities. The Company & # x2019; s investment policy limits investments to high credit quality securities issued by the U. S. government, U. S. government- sponsored agencies, highly rated banks, and corporate issuers, subject to certain concentration limits and restrictions on maturities. The Company & # x2019; s cash, cash equivalents and marketable securities are held by financial institutions that management believes are of high credit quality. The financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash deposits. Accounts at the Company & # x2019; s U. S. banking institution are insured by the Federal Deposit Insurance Corporation (& # x201c; FDIC & # x201d;) up to $ 250, 000 per depositor. As of December 31, 2024, the balance at the Company & # x2019; s U. S. banking institution exceeded the FDIC limits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its accounts are monitored by management to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents, and bond issuers. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company is dependent on third- party organizations to research, develop, manufacture, and process its product candidates for its development programs, including its two most advanced programs, ORKA- 001 and ORKA- 002. The Company expects to continue to be dependent on a small number of manufacturers to supply it with its requirements for all products. The Company & # x2019; s research and development programs could be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Company & # x2019; s research and development activities are performed under its agreements with Paragon Therapeutics, Inc. (& # x201c; Paragon & # x201d;) (see Note & # 160; 12). & lt; / span & gt; & lt; / p & gt; < / us- gaap: ConcentrationRiskCreditRisk > < us- gaap: FederalDepositInsuranceCorporationPremiumExpense contextRef =" c0" decimals =" 0" id =" ixv- 24363" unitRef =" usd" > 250000 < / us- gaap: FederalDepositInsuranceCorporationPremiumExpense > < us- gaap: CashAndCashEquivalentsPolicyTextBlock contextRef =" c0" id =" ixv- 11912" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Cash and Cash Equivalents & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to be cash equivalents. The cash equivalents were comprised of investments in money market funds, U. S. treasury securities, U. S. government agency securities, and debt securities and are stated at fair value. & lt; / span & gt; & lt; / p & gt; < / us- gaap: CashAndCashEquivalentsPolicyTextBlock > < us- gaap: MarketableSecuritiesPolicy contextRef =" c0" id =" ixv- 11924" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Marketable Securities & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company invests in marketable securities, primarily securities issued by the U. S. government and its agencies, commercial paper and corporate debt securities. The Company & # x2019; s marketable securities are classified as available- for- sale and reported at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive loss. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; For available- for- sale debt securities in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security & # x2019; s amortized cost basis is written down to fair value and recognized in other income (expense) in the results of operations. For available- for- sale debt securities that do not meet the aforementioned criteria, the Company

evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, an allowance is recorded for the difference between the present value of cash flows expected to be collected and the amortized cost basis of the security. Impairment losses attributable to credit loss factors are charged against the allowance when management believes an available- for- sale security is uncollectible or when either of the criteria regarding intent or requirement to sell is met. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Any unrealized losses from declines in fair value below the amortized cost basis as a result of non- credit loss factors are recognized as a component of accumulated other comprehensive loss, net of unrealized gains. Realized gains and losses and declines in fair value, if any, on available- for- sale securities are included in other income, net, in the results of operations. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Marketable securities with stated maturities of greater than three months from the date of purchase but less than one year from the consolidated balance sheet date are classified as current, while marketable securities with maturities in one year or beyond one year from the consolidated balance sheet date are classified as long- term. The cost of securities sold is determined using the specific- identification method. Interest earned and adjustments for the amortization of premiums and discounts on investments are included in interest income on the consolidated statements of operations and comprehensive loss. & lt; / span & gt; & lt; / p & gt; < / us- gaap: MarketableSecuritiesPolicy > < us- gaap: DebtPolicyTextBlock contextRef =" c0" id =" ixv- 11951" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Debt Issuance Costs & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Debt issuance costs incurred in connection with the Convertible Note (see Note & # 160; 7) are recorded as a reduction of the carrying value of the notes payable liability on the Company & # x2019; s balance sheet and are amortized to interest expense over the term of the loan using the effective interest method. At the effective time of the Merger the Converted Note was converted to common stock and is no longer on the balance sheet as of December 31, 2024. & lt; / span & gt; & lt; / p & gt; < / us- gaap: DebtPolicyTextBlock > < orka: SubscriptionReceivablePolicyTextBlock contextRef =" c0" id =" ixv- 11963" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Subscription Receivable & # 160; & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable is paid prior to the date the financial statement is available to be issued. & lt; / span & gt; & lt; / p & gt; < / orka: SubscriptionReceivablePolicyTextBlock > < us- gaap: FairValueMeasurementPolicyPolicyTextBlock contextRef =" c0" id =" ixv- 11991" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Fair Value Measurements & # 160; & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Certain assets and liabilities are carried at fair value under U. S. & # 160; GAAP. & # 160; Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" width: 100 %; font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; border- spacing: 0px;" & gt; & lt; tr style =" font- family: Times New Roman, Times, Serif; vertical- align: top" & gt; & lt; td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" & gt; & lt; / td & gt; & lt; td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # x25cf; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- family: Times New Roman, Times, Serif; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Level 1 & # 160; & # x2014; & # 160; Quoted prices in active markets that are identical assets or liabilities. & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; table cellpadding =" 0" style =" width: 100 %; font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; border- spacing: 0px;" & gt; & lt; tr style =" font- family: Times New Roman, Times, Serif; vertical- align: top" & gt; & lt; td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" & gt; & lt; / td & gt; & lt; td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # x25cf; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- family: Times New Roman, Times, Serif; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Level & # 160; 2 & # 160; & # x2014; & # 160; Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; table cellpadding =" 0" style =" width: 100 %; font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; border- spacing: 0px;" & gt; & lt; tr style =" font- family: Times New Roman, Times, Serif; vertical- align: top" & gt; & lt; td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" & gt; & lt; / td & gt; & lt; td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # x25cf; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- family: Times New Roman, Times, Serif; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Level & # 160; 3 & # 160; & # x2014; & # 160; Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies, and similar techniques. & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company & # x2019; s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy described above (see Note 4). The carrying values of the Company & # x2019; s prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to their relatively short maturity period. & lt; / span & gt; & lt; / p & gt; < / us- gaap: FairValueMeasurementPolicyPolicyTextBlock > < us- gaap: PropertyPlantAndEquipmentPolicyTextBlock contextRef =" c0" id =" ixv- 12038" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Property and Equipment & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight- line method over the estimated useful life of each asset as follows: & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; font- weight: bold; text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Estimated & lt; br / & gt; Useful Life & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Furniture and fixtures & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 11 %; text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3- 5 years & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Computer and office equipment & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3- 5 years & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: PropertyPlantAndEquipmentPolicyTextBlock > < us- gaap: PropertyPlantAndEquipmentTextBlock contextRef =" c0" id =" ixv- 12045" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight- line method over the estimated useful life of each asset as follows: & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; font- weight: bold; text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Estimated & lt; br / & gt; Useful Life & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Furniture and fixtures & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 11 %; text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3- 5 years & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Computer and office equipment & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3- 5 years & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: PropertyPlantAndEquipmentTextBlock > < us- gaap: PropertyPlantAndEquipmentUsefulLife contextRef =" c56" id =" ixv- 24364" > P3Y < / us- gaap: PropertyPlantAndEquipmentUsefulLife > < us- gaap: PropertyPlantAndEquipmentUsefulLife contextRef =" c57" id =" ixv- 24365" > P5Y < / us- gaap: PropertyPlantAndEquipmentUsefulLife > < us- gaap: PropertyPlantAndEquipmentUsefulLife contextRef =" c58" id =" ixv- 24366" > P3Y < / us- gaap: PropertyPlantAndEquipmentUsefulLife > < us- gaap: PropertyPlantAndEquipmentUsefulLife contextRef =" c59" id =" ixv- 24367" > P5Y < / us- gaap: PropertyPlantAndEquipmentUsefulLife > < orka: ClassificationOfConvertiblePreferredStockPolicyTextBlock contextRef =" c0" id =" ixv- 12079" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Classification of Convertible Preferred Stock & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Prior to the reverse recapitalization, the Company had classified its Pre- Merger Oruka Series A Preferred Stock outside of stockholders & # x2019; equity on the Company & # x2019; s consolidated balance sheet because the holders of such stock have certain liquidation rights in the event of a deemed liquidation event that, in certain situations, is not solely within the control of the Company and would require the redemption of the then- outstanding convertible preferred stock. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Upon the closing of the Merger, the Company converted its Pre- Merger Oruka Series A Preferred Stock to Company Series B Preferred Stock and has classified the Company Series B Preferred Stock within stockholders & # x2019; equity on its consolidated balance sheet because the Company Series B Preferred Stock is not redeemable or puttable to the Company by the holder under any circumstances. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; In connection with the PIPE Financing (see Note 1) the Company issued Company Series A Preferred Stock, and has classified the Company Series A Preferred Stock outside of stockholders & # x2019; equity on the Company & # x2019; s consolidated balance sheet because the holders of such stock have certain rights (see Note 8) that, in certain situations, is not solely within the control of the Company and would require the redemption of the then- outstanding convertible preferred stock. In November 2024, the Company Series A Preferred Stock shares were converted to common stock, and as of December 31, 2024, there were no shares of Company Series A Preferred Stock outstanding. & lt; / span & gt; & lt; / p & gt; < / orka: ClassificationOfConvertiblePreferredStockPolicyTextBlock > < orka: NotePayableToRelatedPartyPolicyTextBlock contextRef =" c0" id =" ixv- 12117" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Note & # 160; Payable to Related Party & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company accounted for the Convertible Note (as defined in Note 7) at amortized cost. The Company considered if optional conversion features are required to be bifurcated and separately accounted for as a derivative. Costs related to the issuance of the Convertible Note were recorded as a debt discount, amortized over the term of the Convertible Note (see & # 160; Note & # 160; 7) and were accounted for as interest expense in other income (expenses) within the consolidated statement of operations and comprehensive

loss using the effective interest method. At the effective time of the Merger, shares of Pre- Merger Oruka Common Stock issued pursuant to the conversion of the Convertible Note (including accrued interest) automatically converted into shares of Company Common Stock (see Note 1). & lt; / span & gt; & lt; / p & gt; < / orka: NotePayableToRelatedPartyPolicyTextBlock > < orka: ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock contextRef =" c0" id =" ixv- 12129" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Research and Development Contract Costs Accruals & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company records the costs associated with research studies and manufacturing development as incurred. These costs are a significant component of the Company & # x2019; s research and development expenses, with a substantial portion of the Company & # x2019; s ongoing research and development activities conducted by third- party service providers, including contract research organizations (& # x201c; CROs & # x201d;) and contract manufacturing organizations (& # x201c; CMOs & # x201d;), and the Company & # x2019; s related- party Paragon (see Note & # 160; 12). & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company accrues for expenses resulting from obligations under its two antibody discovery and option agreements (the & # x201c; Option Agreements & # x201d;) (see Note 12), by and among Paragon, Paruka Holding LLC (& # x201c; Paruka & # x201d;), an entity formed by Paragon as a vehicle to hold equity in the Company, and the Company as well as agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrual balance in each reporting period. If advance payments are made to Paragon, a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be expensed as the contracted services are performed. Changes in these estimates that result in material changes to the Company & # x2019; s accruals could materially affect the Company & # x2019; s results of operations. As of December 31, 2024, the Company has not experienced any material deviations between accrued and actual research and development expenses. & lt; / span & gt; & lt; / p & gt; < / orka: ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock > < us- gaap: LesseeLeasesPolicyTextBlock contextRef =" c0" id =" ixv- 12146" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Leases & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; At the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies a lease as either an operating or finance lease and recognizes a right- of- use (& # x201c; ROU & # x201d;) asset and a current and non- current lease liability, as applicable, in the balance sheet if the lease has a term greater than one year. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise its option. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; At the lease commencement date, operating lease liabilities and their corresponding ROU assets are recorded at the present value of future minimum lease payments over the expected remaining lease term. The Company determines the present value of lease payments using the implicit rate, if it is readily determinable, or the risk- free discount rate for a period comparable with that of the lease term. For operating leases, lease expense for lease payments is recognized on a straight- line basis over the lease term. For finance leases, lease expense includes amortization expense of the ROU asset recognized on a straight- line basis over the lease term and interest expense recognized on the finance lease liability. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments, incentives received or initial direct costs. As of December 31, 2024, the Company has one operating lease and no finance leases. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company accounts for lease and non- lease components related to operating leases as a single lease component. The Company has elected that costs associated with leases having an initial term of 12 months or less are recognized in the consolidated statement of operations and comprehensive loss on a straight- line basis over the lease term and are not recorded on its consolidated balance sheets. Variable lease expense is recognized as incurred and consists primarily of real estate taxes, utilities, and other office space related expenses. & lt; / span & gt; & lt; / p & gt; < / us- gaap: LesseeLeasesPolicyTextBlock > < us- gaap: SegmentReportingPolicyPolicyTextBlock contextRef =" c0" id =" ixv- 12184" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Segment Reporting & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; The Company operates as a single reportable and operating segment. Its Chief Executive Officer, serving as the Chief Operating Decision Maker (& # x201c; CODM & # x201d;), oversees operations on an aggregated basis to allocate resources effectively. In assessing the Company & # x2019; s financial performance, the CODM regularly reviews total operating expenses and consolidated net loss. & lt; / p & gt; < / us- gaap: SegmentReportingPolicyPolicyTextBlock > < us- gaap: ResearchAndDevelopmentExpensePolicy contextRef =" c0" id =" ixv- 12196" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Research and Development Costs & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Research and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock- based compensation, employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities, as well as allocated human resource costs, information technology costs, and facility- related costs, including rent, maintenance, utilities, and depreciation. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses on the accompanying consolidated balance sheet. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable advance payments represent a one- time cost for obtaining goods or services, with anticipated benefits to be utilized within a year of period end, the payment is expensed immediately. & lt; / span & gt; & lt; / p & gt; < / us- gaap: ResearchAndDevelopmentExpensePolicy > < us- gaap: SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef =" c0" id =" ixv- 12213" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; General and Administrative Expenses & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; General and administrative expenses consist primarily of salaries and bonuses, stock- based compensation, employee benefits, finance and administration costs, patent and intellectual property costs, professional fees, as well as allocated human resource costs, information technology costs, and facility- related costs, including rent, maintenance, utilities and depreciation. & lt; / span & gt; & lt; / p & gt; < / us- gaap: SellingGeneralAndAdministrativeExpensesPolicyTextBlock > < us- gaap: CommitmentsAndContingenciesPolicyTextBlock contextRef =" c0" id =" ixv- 12225" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Commitments and Contingencies & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities. The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but not probable; however, it discloses the range of reasonably possible losses. As of December 31, 2024, no liabilities were recorded for loss contingencies (see Note & # 160; 13). & lt; / span & gt; & lt; / p & gt; < / us- gaap: CommitmentsAndContingenciesPolicyTextBlock > < us- gaap: ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef =" c0" id =" ixv- 12237" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Stock- Based Compensation & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company estimates the fair value of its stock awards using the Black- Scholes option pricing model, which uses as inputs the fair value of the Company & # x2019; s common stock, and certain management estimates, including the expected stock price volatility, the expected term of the award, the risk- free interest rate, and expected dividends. Expected volatility is calculated based on reported volatility data for a representative group of publicly traded companies for which historical information is available. The Company selects companies with comparable characteristics with historical share price information that approximates the expected term of the equity- based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies & # x2019; shares during the equivalent period that approximates the calculated expected term of the stock options. The Company will continue to apply this method until a sufficient amount of historical information regarding the volatility of its stock price becomes available. The risk- free interest rate is based on the U. S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. For employee and non- employee awards (except the Paruka warrant) the Company uses the simplified method, under which the expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to lack of historical exercise data. For the Paruka warrant, the contractual term is used for the expected term. The expected dividend yield is assumed to be zero as the Company has no current plans to pay any dividends on common stock. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company measures restricted common stock awards (& # x201c; RSAs & # x201d;) using the difference, if any, between the purchase price per share of the award and the fair value of the Company & # x2019; s common stock at the date of grant. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company grants stock options, restricted stock awards, and warrants that are subject to service or performance- based vesting conditions. Compensation expense for awards to employees and directors with service- based vesting conditions is recognized using the straight- line method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards to non- employees with service- based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. As of each reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation expense until it is probable that the performance- based vesting condition will be achieved. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company has issued stock options, warrants, and RSAs with service- based and performance- based vesting conditions. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company recognizes the compensation expense for the option to purchase common stock under the Employee Stock Purchase Plan (& # x201c; ESPP & # x201d;), based on the fair value of the common stock estimated using the closing price of the Company & # x2019; s common stock as reported on the date of offering, less the purchase discount percentage provided for in the plan. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company classifies stock- based compensation expense in its consolidated statement of operations and comprehensive loss in the same manner in which the award recipient & # x2019; s payroll costs are classified or in which the award recipient & # x2019; s service payments are classified, as applicable. & lt; / span & gt; & lt; / p & gt; < / us- gaap: ShareBasedCompensationOptionAndIncentivePlansPolicy > < orka: ComprehensiveLossPolicyPolicyTextBlock contextRef =" c0" id =" ixv- 12290" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Comprehensive Loss & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Comprehensive loss includes net loss as well as other changes in stockholders & # x2019; equity that result from transactions and events other than those with stockholders. The Company & # x2019; s unrealized gains and losses on marketable securities represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the consolidated statement of comprehensive loss. & lt; / span & gt; & lt; / p & gt; < / orka: ComprehensiveLossPolicyPolicyTextBlock > < us- gaap: EarningsPerSharePolicyTextBlock contextRef =" c0" id =" ixv- 12302" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Net Loss per Share Attributable to Stockholders & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Basic and diluted net loss attributable to stockholders per share is presented in conformity with the two- class method required for participating securities (Pre- Merger Oruka Series A Preferred Stock). Basic earnings per share is computed by dividing net income available to each class of shares by the weighted-

average number of shares of common stock and participating securities outstanding during the period. Pre- funded warrants were included as the exercise price is negligible and these warrants are fully vested and exercisable. Company Series A Preferred Stock and Company Series B Preferred Stock share the same characteristics as Common Stock and have no substantive preference attributed to them and, accordingly, have been considered as classes of Common Stock in the computation of net loss per share regardless of their legal form. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Net loss is allocated to common stock based on its proportional ownership on an as- converted basis. Net loss is not allocated to participating securities as they do not have an obligation to fund losses. The weighted- average number of shares outstanding of common stock reflects changes in ownership over the periods presented. See Note 8 & # x2014; Convertible Preferred Stock and Stockholders & # x2019; Equity. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Diluted net loss per share is computed by dividing the net loss attributable to stockholders adjusted for income (expenses), net of tax, related to any diluted securities, by the weighted- average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of this calculation, stock options to purchase common stock, employee warrants to purchase common stock, and unvested RSAs are considered potential dilutive common shares. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company generated a net loss for the periods presented. Accordingly, basic and diluted net loss per share is the same because the inclusion of the potentially dilutive securities would be anti- dilutive. & lt; / span & gt; & lt; / p & gt; < / us- gaap: EarningsPerSharePolicyTextBlock > < orka: OtherIncomeExpenseNetPolicyTextBlock contextRef =" c0" id =" ixv- 12329" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Other income, net & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Other income, net, consists of interest earned on the Company & # x2019; s cash, cash equivalents, and marketable securities; interest expense on the convertible note from a related party and foreign currency transactions gains and losses. & lt; / span & gt; & lt; / p & gt; < / orka: OtherIncomeExpenseNetPolicyTextBlock > < us- gaap: IncomeTaxPolicyTextBlock contextRef =" c0" id =" ixv- 12357" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Income Taxes & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company & # x2019; s tax returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis of assets and liabilities using enacted tax rates in effect for the & # 160; years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two- step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50 % likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or penalties related to uncertain tax positions as of December 31, 2024. & lt; / span & gt; & lt; / p & gt; < / us- gaap: IncomeTaxPolicyTextBlock > < orka: RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock contextRef =" c0" id =" ixv- 12374" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Recently Adopted Accounting Pronouncements & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; In November & # 160; 2023, the FASB issued ASU 2023- 07, Segment Reporting (Topic & # 160; 280): Improvements to Reportable Segment Disclosures (& # x201c; ASU & # 160; 2023- 07 & # x201d;), which enhances the segment disclosure requirements for public entities on an annual and interim basis. Under this standard, public entities will be required to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss. Additionally, current annual disclosures about a reportable segment & # x2019; s profit or loss and assets will be required on an interim basis. Entities will also be required to disclose information about the CODM & # x2019; s title and position at the Company along with an explanation of how the CODM uses the reported measures of segment profit or loss in their assessment of segment performance and deciding how to allocate resources. Finally, ASU & # 160; 2023- 07 requires all segment disclosures for public entities that have only a single reportable segment. The amendments in ASU & # 160; 2023- 07 are effective for fiscal & # 160; years beginning after December & # 160; 15, 2023, and interim periods within fiscal & # 160; years beginning after December & # 160; 15, 2024. Early adoption is permitted. The Company adopted ASU 2023- 07 in 2024 and additional required disclosures have been included in Note 10. & lt; / span & gt; & lt; / p & gt; < / orka: RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock > < us- gaap: NewAccountingPronouncementsPolicyPolicyTextBlock contextRef =" c0" id =" ixv- 12386" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Recently Issued Accounting Pronouncements & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; In December & # 160; 2023, the FASB issued ASU & # 160; 2023- 09, Income Taxes (Topic & # 160; 740): Improvements to Income Tax Disclosures. This ASU expands disclosures in an entity & # x2019; s income tax rate reconciliation table and disclosures regarding taxes paid both in the U. S. & # 160; and foreign jurisdictions. This update is effective beginning with the Company & # x2019; s 2025 fiscal year annual reporting period. The Company is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; In November 2024, the FASB issued ASU 2024- 03, Income Statement & # x2014; Reporting Comprehensive Income & # x2014; Expense Disaggregation Disclosures (Subtopic 220- 40): Disaggregation of Income Statement Expenses. This ASU requires more detailed disclosures, on an annual and interim basis, about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. This ASU may be applied either prospectively or retrospectively. The Company is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements. & lt; / span & gt; & lt; / p & gt; < / us- gaap: NewAccountingPronouncementsPolicyPolicyTextBlock > < us- gaap: MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef =" c0" id =" ixv- 12420" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; 3. Reverse Recapitalization and Pre- Closing Financing & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; As described within the Reverse Recapitalization and Pre- Closing Financing section in Note 1, on August 29, 2024, the reverse recapitalization between Pre- Merger Oruka and ARCA was consummated. The Merger was accounted for as a reverse recapitalization in accordance with U. S. GAAP. At the effective time of the Merger, substantially all of the assets of ARCA consisted of cash and cash equivalents and other nominal non- operating assets and liabilities. No goodwill or intangible assets were recognized. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; As part of the recapitalization, the Company acquired the assets and liabilities listed below (in thousands): & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; August 29, & lt; br / & gt; 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Cash and cash equivalents & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 4, 940 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Other current assets & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 114 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Accrued liabilities & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (54 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 2. 5pt; padding- left: 6. 85pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Net assets acquired & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 5, 000 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: MergersAcquisitionsAndDispositionsDisclosuresTextBlock > < us- gaap: ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef =" c0" id =" ixv- 12430" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; As part of the recapitalization, the Company acquired the assets and liabilities listed below (in thousands): & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; August 29, & lt; br / & gt; 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; &

lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Cash and cash equivalents & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 4, 940 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Other current assets & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 114 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Accrued liabilities & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (54 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 2. 5pt; padding- left: 6. 85pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Net assets acquired & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 5, 000 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock > < us- gaap: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef =" c60" decimals ="- 3" id =" ixv- 24368" unitRef =" usd" > 4940000 < / us- gaap: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents > < us- gaap: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther contextRef =" c60" decimals ="- 3" id =" ixv- 24369" unitRef =" usd" > 114000 < / us- gaap: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther > < us- gaap: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities contextRef =" c60" decimals ="- 3" id =" ixv- 24370" unitRef =" usd" > 54000 < / us- gaap: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities > < us- gaap: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef =" c60" decimals ="- 3" id =" ixv- 24371" unitRef =" usd" > 5000000 < / us- gaap: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet > < us- gaap: FairValueDisclosuresTextBlock contextRef =" c0" id =" ixv- 12495" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; 4. Fair Value Measurements & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The following tables present the Company & # x2019; s fair value hierarchy for financial assets measured as of December 31, 2024 (in thousands): & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 14" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; December 31, 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" font- weight: bold; text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Level 1 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Level 2 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Level 3 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Cash equivalents & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in; width: 52 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Money market funds & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 6, 350 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 157; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 158; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 6, 350 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. treasury securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 19, 660 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 159; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 19, 660 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. government agency securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 160; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3, 988 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 161; font-family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3, 988 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Commercial papers & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 162; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 22, 177 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 163; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 22, 177 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total cash equivalents & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 6, 350 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 45, 825 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 164; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 52, 175 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Marketable securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Marketable securities, current & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. treasury securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 190, 792 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 165; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 190, 792 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. government agency securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 166; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 12, 966 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 167; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 12, 966 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Commercial papers & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 168; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 34, 811 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New

Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 169; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 34, 811 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Corporate debt securities & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 170; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 75, 504 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 171; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 75, 504 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 375in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total marketable securities, current & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 314, 073 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 172; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 314, 073 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Marketable securities, long- term & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. treasury securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 13, 607 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 173; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 13, 607 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. government agency securities & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 174; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 4, 462 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 175; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 4, 462 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 375in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total marketable securities, long- term & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 18, 069 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 176; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 18, 069 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td &

gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total cash equivalents and marketable securities & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 6, 350 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 377, 967 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 177; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 384, 317 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; There were no transfers in or out of Level & # 160; 3 during the period from February 6, 2024 (inception) to December 31, 2024. & lt; / p & gt; < / us- gaap: FairValueDisclosuresTextBlock > < us- gaap: FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef =" c0" id =" ixv- 12501" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The following tables present the Company & # x2019; s fair value hierarchy for financial assets measured as of December 31, 2024 (in thousands): & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 14" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; December 31, 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" font- weight: bold; text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Level 1 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Level 2 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Level 3 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Cash equivalents & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in; width: 52 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Money market funds & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 6, 350 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 157; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 158; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 6, 350 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. treasury securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 19, 660 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 159; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 19, 660 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. government agency securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 160; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3, 988 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 161; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3, 988 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Commercial papers & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 162; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; &

lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 22, 177 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 163; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 22, 177 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total cash equivalents & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 6, 350 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 45, 825 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 164; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 52, 175 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Marketable securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Marketable securities, current & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. treasury securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 190, 792 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 165; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 190, 792 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. government agency securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 166; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 12, 966 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 167; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 12, 966 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Commercial papers & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 168; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 34, 811 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 169; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 34, 811 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Corporate debt securities & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 170; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; /

span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 75, 504 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 171; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 75, 504 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 375in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total marketable securities, current & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 314, 073 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 172; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 314, 073 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Marketable securities, long- term & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. treasury securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 13, 607 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 173; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 13, 607 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. government agency securities & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 174; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 4, 462 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 175; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 4, 462 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 375in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total marketable securities, long- term & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 18, 069 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 176; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 18, 069 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total cash equivalents and marketable securities & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 6, 350 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 377, 967 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 177; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 384, 317 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: FairValueAssetsMeasuredOnRecurringBasisTextBlock > < us- gaap: CashEquivalentsAtCarryingValue contextRef =" c61" decimals ="- 3" id =" ixv- 24372" unitRef =" usd" > 6350000 < / us- gaap: CashEquivalentsAtCarryingValue > < us- gaap: CashEquivalentsAtCarryingValue contextRef =" c64" decimals ="- 3" id =" ixv- 24373" unitRef =" usd" > 6350000 < / us- gaap: CashEquivalentsAtCarryingValue > < us- gaap: CashEquivalentsAtCarryingValue contextRef =" c65" decimals ="- 3" id =" ixv- 24374" unitRef =" usd" > 19660000 < / us- gaap: CashEquivalentsAtCarryingValue > < us- gaap: CashEquivalentsAtCarryingValue contextRef =" c67" decimals ="- 3" id =" ixv- 24375" unitRef =" usd" > 19660000 < / us- gaap: CashEquivalentsAtCarryingValue > < us- gaap: CashEquivalentsAtCarryingValue contextRef =" c69" decimals ="- 3" id =" ixv- 24376" unitRef =" usd" > 3988000 < / us- gaap: CashEquivalentsAtCarryingValue > < us- gaap: CashEquivalentsAtCarryingValue contextRef =" c71" decimals ="- 3" id =" ixv- 24377" unitRef =" usd" > 3988000 < / us- gaap: CashEquivalentsAtCarryingValue > < us- gaap: CashEquivalentsAtCarryingValue contextRef =" c73" decimals ="- 3" id =" ixv- 24378" unitRef =" usd" > 22177000 < / us- gaap: CashEquivalentsAtCarryingValue > < us- gaap: CashEquivalentsAtCarryingValue contextRef =" c75" decimals ="- 3" id =" ixv- 24379" unitRef =" usd" > 22177000 < / us- gaap: CashEquivalentsAtCarryingValue > < us- gaap: CashEquivalentsAtCarryingValue contextRef =" c76" decimals ="- 3" id =" ixv- 24380" unitRef =" usd" > 6350000 < / us- gaap: CashEquivalentsAtCarryingValue > < us- gaap: CashEquivalentsAtCarryingValue contextRef =" c77" decimals ="- 3" id =" ixv- 24381" unitRef =" usd" > 45825000 < / us- gaap: CashEquivalentsAtCarryingValue > < us- gaap: CashEquivalentsAtCarryingValue contextRef =" c3" decimals ="- 3" id =" ixv- 24382" unitRef =" usd" > 52175000 < / us- gaap: CashEquivalentsAtCarryingValue > < us- gaap: MarketableSecuritiesCurrent contextRef =" c65" decimals ="- 3" id =" ixv- 24383" unitRef =" usd" > 190792000 < / us- gaap: MarketableSecuritiesCurrent > < us- gaap: MarketableSecuritiesCurrent contextRef =" c67" decimals ="- 3" id =" ixv- 24384" unitRef =" usd" > 190792000 < / us- gaap: MarketableSecuritiesCurrent > < us- gaap: MarketableSecuritiesCurrent contextRef =" c69" decimals ="- 3" id =" ixv- 24385" unitRef =" usd" > 12966000 < / us- gaap: MarketableSecuritiesCurrent > < us- gaap: MarketableSecuritiesCurrent contextRef =" c71" decimals ="- 3" id =" ixv- 24386" unitRef =" usd" > 12966000 < / us- gaap: MarketableSecuritiesCurrent > < us- gaap: MarketableSecuritiesCurrent contextRef =" c73" decimals ="- 3" id =" ixv- 24387" unitRef =" usd" > 34811000 < / us- gaap: MarketableSecuritiesCurrent > < us- gaap: MarketableSecuritiesCurrent contextRef =" c75" decimals ="- 3" id =" ixv- 24388" unitRef =" usd" > 34811000 < / us- gaap: MarketableSecuritiesCurrent > < us- gaap: MarketableSecuritiesCurrent contextRef =" c80" decimals ="- 3" id =" ixv- 24389" unitRef =" usd" > 75504000 < / us- gaap: MarketableSecuritiesCurrent > < us- gaap: MarketableSecuritiesCurrent contextRef =" c82" decimals ="- 3" id =" ixv- 24390" unitRef =" usd" > 75504000 < / us- gaap: MarketableSecuritiesCurrent > < us- gaap: MarketableSecuritiesCurrent contextRef =" c77" decimals ="- 3" id =" ixv- 24391" unitRef =" usd" > 314073000 < / us- gaap: MarketableSecuritiesCurrent > < us- gaap: MarketableSecuritiesCurrent contextRef =" c3" decimals ="- 3" id =" ixv- 24392" unitRef =" usd" > 314073000 < / us- gaap: MarketableSecuritiesCurrent > < us- gaap: MarketableSecuritiesNoncurrent contextRef =" c65" decimals ="- 3" id =" ixv- 24393" unitRef =" usd" > 13607000 < / us- gaap: MarketableSecuritiesNoncurrent > < us- gaap: MarketableSecuritiesNoncurrent contextRef =" c67" decimals ="- 3" id =" ixv- 24394" unitRef =" usd" > 13607000 < / us- gaap: MarketableSecuritiesNoncurrent > < us- gaap: MarketableSecuritiesNoncurrent contextRef =" c69" decimals ="- 3" id =" ixv- 24395" unitRef =" usd" > 4462000 < / us- gaap: MarketableSecuritiesNoncurrent > < us- gaap: MarketableSecuritiesNoncurrent contextRef =" c71" decimals ="- 3" id =" ixv- 24396" unitRef =" usd" > 4462000 < / us- gaap: MarketableSecuritiesNoncurrent > < us- gaap: MarketableSecuritiesNoncurrent contextRef =" c77" decimals ="- 3" id =" ixv- 24397" unitRef =" usd" > 18069000 < / us- gaap: MarketableSecuritiesNoncurrent > < us- gaap: MarketableSecuritiesNoncurrent contextRef =" c3" decimals ="- 3" id =" ixv- 24398" unitRef =" usd" > 18069000 < / us- gaap: MarketableSecuritiesNoncurrent > < orka: FairValueCashEquivalentsAndMarketableSecurities contextRef =" c76" decimals ="- 3" id =" ixv- 24399" unitRef =" usd" > 6350000 < / orka: FairValueCashEquivalentsAndMarketableSecurities > < orka: FairValueCashEquivalentsAndMarketableSecurities contextRef =" c77" decimals ="- 3" id =" ixv- 24400" unitRef =" usd" > 377967000 < / orka: FairValueCashEquivalentsAndMarketableSecurities > < orka: FairValueCashEquivalentsAndMarketableSecurities contextRef =" c3" decimals ="- 3" id =" ixv- 24401" unitRef =" usd" > 384317000 < / orka: FairValueCashEquivalentsAndMarketableSecurities > < us- gaap: CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef =" c0" id =" ixv- 13185" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; 5. Cash equivalents and marketable Securities & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Cash equivalents and marketable securities, which are classified as available- for- sale, consisted of the following as of December 31, 2024 (in thousands): & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 14" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; December 31, 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" font- weight: bold; text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Amortized Cost & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Gross Unrealized Gains & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Gross Unrealized Losses & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Fair Value & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Cash equivalents & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in; width: 52 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Money market funds & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 6, 350 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 178; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 179; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 6, 350 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. treasury securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 19, 656 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 4 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 180; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 19, 660 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. government agency securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3, 988 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 181; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 182; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3, 988 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Commercial papers & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 22, 180 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 183; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (3 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 22, 177 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total cash equivalents & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 52, 174 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 4 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (3 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 52, 175 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Marketable securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Marketable securities, current & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. treasury securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 190, 748 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 55 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (11 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 190, 792 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. government agency securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 12, 967 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 1 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (2 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 12, 966 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Commercial papers & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 34, 808 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 184; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 34, 811 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Corporate debt securities & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 75, 537 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 7 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (40 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 75, 504 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 375in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total marketable securities, current & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 314, 060 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 66 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (53 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 314, 073 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Marketable securities, long- term & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. treasury securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 13, 639 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 185; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (32 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 13, 607 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. government agency securities & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 4, 485 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 186; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (23 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 4, 462 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 375in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total marketable securities, long- term & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 18, 124 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 187; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font-family: Times New Roman, Times, Serif" & gt; (55 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 18, 069 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total cash equivalents and marketable securities & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 384, 358 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 70 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (111 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 384, 317 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The following table summarizes the available- for- sale securities in an unrealized loss position, aggregated by major security type and length of time in a continuous unrealized loss position, for which an allowance for credit losses was not recorded as of December & # 160; 31, 2024, (in thousands): & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- indent:- 0. 125in; padding- left: 0. 125in; text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 22" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; December 31, 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- indent:- 0. 125in; padding- left: 0. 125in; font- weight: bold; text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 6" style =" text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; Less than 12 months & lt; / b & gt; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 6" style =" text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; 12 months or longer & lt; / b & gt; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 6" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- indent:- 0. 125in; padding- left: 0. 125in; font- weight: bold; text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; Fair & lt; br / & gt; Value & lt; / b & gt; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Unrealized & lt; br / & gt; Losses & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Fair & lt; br / & gt; Value & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Unrealized & lt; br / & gt; Losses & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; Fair & lt; br / & gt; Value & lt; / b & gt; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Unrealized & lt; br / & gt; Losses & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- indent:- 0. 125in; padding- left: 0. 125in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Cash equivalents & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- indent:- 0. 125in; padding- left: 0. 25in; width: 28 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Commercial papers & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 18, 199 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (3 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 188; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 189; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 18, 199 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (3 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- indent:- 0. 125in; padding- left: 0. 125in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Marketable securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times,

```
Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt;
& lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span
style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman,
Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span
& gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt;
span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New
Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; &
lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td &
gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times
New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & #
160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt;
td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family:
Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;
& # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt;
& lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font-
family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times,
Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; &
lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- indent:- 0. 125in; padding- left: 0. 25in; text- align: left" &
gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Marketable securities, current & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times
New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160;
& lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td
style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family:
Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; &
# 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt;
& lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font-
family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif"
& gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; /
td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style ="
font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times,
Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt;
& lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span
style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman,
Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span
& gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt;
span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New
Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; &
lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr &
gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- indent:- 0. 125in; padding- left: 0. 375in; text- align: left" & gt; & lt; span style =" font- family:
Times New Roman, Times, Serif" & gt; U. S. treasury securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; &
lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td
style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 49, 904 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span
style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & #
160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt;
td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (11 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span
style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; &
lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td
style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 190; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td
style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family:
Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; &
# 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 191; font- family: Times New Roman, Times, Serif" & gt; & #
x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; &
lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font-
family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times,
Serif" & gt; 49, 904 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; &
lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style
=" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman,
Times, Serif" & gt; (11 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td
& gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- indent:- 0. 125in; padding- left: 0. 375in; text- align: left" & gt; &
lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. government agency securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times
New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160;
& lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 4, 713 & lt; / span & gt; & lt; / td & gt; & lt; td
style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family:
Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; &
# 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (2 & lt; / span & gt; & lt; / td & gt; & lt; td
style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New
Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; &
lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 192; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt;
/ span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt;
& lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times
New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 193; font- family: Times New
Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; &
lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" &
gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family:
Times New Roman, Times, Serif" & gt; 4, 713 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & #
160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align:
left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font-
family: Times New Roman, Times, Serif" & gt; (2 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;)
& lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- indent:- 0. 125in; padding- left: 0. 375in; text- align:
left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Corporate debt securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times
New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160;
& lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 39, 468 & lt; / span & gt; & lt; / td & gt; & lt; td
style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family:
Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; &
# 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (40 & lt; / span & gt; & lt; / td & gt; & lt;
td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times
New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160;
& lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 194; font- family: Times New Roman, Times, Serif" & gt; & # x2014; &
lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td &
gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times
New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 195; font- family: Times New
Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; &
lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" &
gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family:
Times New Roman, Times, Serif" & gt; 39, 468 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; &
# 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align:
left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font-
family: Times New Roman, Times, Serif" & gt; (40 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" &
gt;) & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- indent:- 0. 125in; padding- left: 0.
25in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Marketable securities, long- term & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span
style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman,
Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span
```

& gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- indent:- 0. 125in; padding- left: 0. 375in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. treasury securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 13, 607 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (32 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 196; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 197; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 13, 607 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (32 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- indent:- 0. 125in; padding- left: 0. 375in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. government agency securities & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 4, 462 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (23 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 198; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 199; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 4, 462 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (23 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- indent:- 0. 125in; padding- left: 0. 5in; padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 130, 353 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (111 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 200; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 201; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 130, 353 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (111 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company evaluated its securities for credit losses and considered the decline in market value to be primarily attributable to current economic and market conditions and not to a credit loss or other factors. Additionally, the Company does not intend to sell the securities in an unrealized loss position and it is not more likely than not that the Company will be required to sell the securities before recovery of the unamortized cost basis, which may be at maturity. There were no material realized gains or realized losses on marketable securities for the period presented. Given the Company & # x2019; s intent and ability to hold such securities until recovery, and the lack of significant change in credit risk of these investments, the Company does not consider these marketable securities to be impaired as of December 31, 2024. As of December 31, 2024, the Company did not record an allowance for credit losses. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The following table summarizes the contractual maturities of the Company & # x2019; s marketable securities at estimated fair value (in thousands): & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; December 31, & lt; br / & gt; 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Due in one year or less & lt; / span &

gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 314, 073 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Due in 1- 2 years & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 18, 069 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 2. 5pt; padding- left: 0. 125in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 332, 142 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: CashCashEquivalentsAndMarketableSecuritiesTextBlock > < us- gaap: MarketableSecuritiesTextBlock contextRef =" c0" id =" ixv- 13191" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Cash equivalents and marketable securities, which are classified as available- for- sale, consisted of the following as of December 31, 2024 (in thousands): & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 14" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; December 31, 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" font- weight: bold; text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Amortized Cost & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Gross Unrealized Gains & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Gross Unrealized Losses & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Fair Value & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Cash equivalents & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in; width: 52 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Money market funds & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 6, 350 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 178; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 179; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 6, 350 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. treasury securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 19, 656 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 4 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 180; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 19, 660 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. government agency securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3, 988 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 181; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 182; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3, 988 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Commercial papers & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 22, 180 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 183; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font-family: Times New Roman, Times, Serif" & gt; (3 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 22, 177 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total cash equivalents & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 52, 174 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 4 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (3 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 52, 175 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Marketable securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Marketable securities, current & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. treasury securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 190, 748 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 55 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (11 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 190, 792 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. government agency securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 12, 967 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 1 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (2 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 12, 966 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Commercial papers & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 34, 808 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 184; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 34, 811 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Corporate debt securities & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 75, 537 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 7 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New

Roman, Times, Serif" & gt; (40 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 75, 504 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 375in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total marketable securities, current & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 314, 060 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 66 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (53 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 314, 073 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Marketable securities, long- term & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. treasury securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 13, 639 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 185; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (32 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 13, 607 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. government agency securities & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 4, 485 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 186; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (23 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 4, 462 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 375in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total marketable securities, long- term & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 18, 124 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 187; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (55 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 18, 069 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total cash equivalents and marketable securities & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 384, 358 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 70 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (111 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 384, 317 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: MarketableSecuritiesTextBlock > < us- gaap: AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef =" c83" decimals ="- 3" id =" ixv- 24402" unitRef =" usd" > 6350000 < / us- gaap: AvailableForSaleDebtSecuritiesAmortizedCostBasis > < us- gaap: AvailableForSaleSecuritiesDebtSecurities contextRef =" c83" decimals ="- 3" id =" ixv- 24403" unitRef =" usd" > 6350000 < /

us- gaap: AvailableForSaleSecuritiesDebtSecurities > < us- gaap: AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef =" c84" decimals ="- 3" id =" ixv- 24404" unitRef =" usd" > 19656000 < / us- gaap: AvailableForSaleDebtSecuritiesAmortizedCostBasis > < us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef =" c84" decimals ="- 3" id =" ixv- 24405" unitRef =" usd" > 4000 < / us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax > < us- gaap: AvailableForSaleSecuritiesDebtSecurities contextRef =" c84" decimals ="- 3" id =" ixv- 24406" unitRef =" usd" > 19660000 < / us- gaap: AvailableForSaleSecuritiesDebtSecurities > < us- gaap: AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef =" c85" decimals ="- 3" id =" ixv- 24407" unitRef =" usd" > 3988000 < / us- gaap: AvailableForSaleDebtSecuritiesAmortizedCostBasis > < us- gaap: AvailableForSaleSecuritiesDebtSecurities contextRef =" c85" decimals ="- 3" id =" ixv- 24408" unitRef =" usd" > 3988000 < / us- gaap: AvailableForSaleSecuritiesDebtSecurities > < us- gaap: AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef =" c86" decimals ="- 3" id =" ixv- 24409" unitRef =" usd" > 22180000 < / us- gaap: AvailableForSaleDebtSecuritiesAmortizedCostBasis > < us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef =" c86" decimals ="- 3" id =" ixv- 24410" unitRef =" usd" > 3000 < / us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax > < us- gaap: AvailableForSaleSecuritiesDebtSecurities contextRef =" c86" decimals ="- 3" id =" ixv- 24411" unitRef =" usd" > 22177000 < / us- gaap: AvailableForSaleSecuritiesDebtSecurities > < us- gaap: AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef =" c87" decimals ="- 3" id =" ixv- 24412" unitRef =" usd" > 52174000 < / us- gaap: AvailableForSaleDebtSecuritiesAmortizedCostBasis > < us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef =" c87" decimals ="- 3" id =" ixv- 24413" unitRef =" usd" > 4000 < / us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax > < us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef =" c87" decimals ="- 3" id =" ixv- 24414" unitRef =" usd" > 3000 < / us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax > < us- gaap: AvailableForSaleSecuritiesDebtSecurities contextRef =" c87" decimals ="- 3" id =" ixv- 24415" unitRef =" usd" > 52175000 < / us- gaap: AvailableForSaleSecuritiesDebtSecurities > < us- gaap: AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef =" c88" decimals ="- 3" id =" ixv- 24416" unitRef =" usd" > 190748000 < / us- gaap: AvailableForSaleDebtSecuritiesAmortizedCostBasis > < us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef =" c88" decimals ="- 3" id =" ixv- 24417" unitRef =" usd" > 55000 < / us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax > < us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef =" c88" decimals ="- 3" id =" ixv- 24418" unitRef =" usd" > 11000 < / us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax > < us- gaap: AvailableForSaleSecuritiesDebtSecurities contextRef =" c88" decimals ="- 3" id =" ixv- 24419" unitRef =" usd" > 190792000 < / us- gaap: AvailableForSaleSecuritiesDebtSecurities > < us- gaap: AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef =" c89" decimals ="- 3" id =" ixv- 24420" unitRef =" usd" > 12967000 < / us- gaap: AvailableForSaleDebtSecuritiesAmortizedCostBasis > < us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef =" c89" decimals ="- 3" id =" ixv- 24421" unitRef =" usd" > 1000 < / us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax > < us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef =" c89" decimals ="- 3" id =" ixv- 24422" unitRef =" usd" > 2000 < / us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax > < us- gaap: AvailableForSaleSecuritiesDebtSecurities contextRef =" c89" decimals ="- 3" id =" ixv- 24423" unitRef =" usd" > 12966000 < / us- gaap: AvailableForSaleSecuritiesDebtSecurities > < us- gaap: AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef =" c90" decimals ="- 3" id =" ixv- 24424" unitRef =" usd" > 34808000 < / us- gaap: AvailableForSaleDebtSecuritiesAmortizedCostBasis > < us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef =" c90" decimals ="- 3" id =" ixv- 24425" unitRef =" usd" > 3000 < / us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax > < us- gaap: AvailableForSaleSecuritiesDebtSecurities contextRef =" c90" decimals ="- 3" id =" ixv- 24426" unitRef =" usd" > 34811000 < / us- gaap: AvailableForSaleSecuritiesDebtSecurities > < us- gaap: AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef =" c91" decimals ="- 3" id =" ixv- 24427" unitRef =" usd" > 75537000 < / us- gaap: AvailableForSaleDebtSecuritiesAmortizedCostBasis > < us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef =" c91" decimals ="- 3" id =" ixv- 24428" unitRef =" usd" > 7000 < / us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax > < us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef =" c91" decimals ="- 3" id =" ixv- 24429" unitRef =" usd" > 40000 < / us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax > < us- gaap: AvailableForSaleSecuritiesDebtSecurities contextRef =" c91" decimals ="- 3" id =" ixv- 24430" unitRef =" usd" > 75504000 < / us- gaap: AvailableForSaleSecuritiesDebtSecurities > < us- gaap: AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef =" c92" decimals ="- 3" id =" ixv- 24431" unitRef =" usd" > 314060000 < / us- gaap: AvailableForSaleDebtSecuritiesAmortizedCostBasis > < us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef =" c92" decimals ="- 3" id =" ixv- 24432" unitRef =" usd" > 66000 < / us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax > < us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef =" c92" decimals ="- 3" id =" ixv- 24433" unitRef =" usd" > 53000 < / us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax > < us- gaap: AvailableForSaleSecuritiesDebtSecurities contextRef =" c92" decimals ="- 3" id =" ixv- 24434" unitRef =" usd" > 314073000 < / us- gaap: AvailableForSaleSecuritiesDebtSecurities > < us- gaap: AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef =" c93" decimals ="- 3" id =" ixv- 24435" unitRef =" usd" > 13639000 < / us- gaap: AvailableForSaleDebtSecuritiesAmortizedCostBasis > < us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef =" c93" decimals ="- 3" id =" ixv- 24436" unitRef =" usd" > 32000 < / us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax > < us- gaap: AvailableForSaleSecuritiesDebtSecurities contextRef =" c93" decimals ="- 3" id =" ixv- 24437" unitRef =" usd" > 13607000 < / us- gaap: AvailableForSaleSecuritiesDebtSecurities > < us- gaap: AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef =" c94" decimals ="- 3" id =" ixv- 24438" unitRef =" usd" > 4485000 < / us- gaap: AvailableForSaleDebtSecuritiesAmortizedCostBasis > < us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef =" c94" decimals ="- 3" id =" ixv- 24439" unitRef =" usd" > 23000 < / us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax > < us- gaap: AvailableForSaleSecuritiesDebtSecurities contextRef =" c94" decimals ="- 3" id =" ixv- 24440" unitRef =" usd" > 4462000 < / us- gaap: AvailableForSaleSecuritiesDebtSecurities > < us- gaap: AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef =" c95" decimals ="- 3" id =" ixv- 24441" unitRef =" usd" > 18124000 < / us- gaap: AvailableForSaleDebtSecuritiesAmortizedCostBasis > < us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef =" c95" decimals ="- 3" id =" ixv- 24442" unitRef =" usd" > 55000 < / us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax > < us- gaap: AvailableForSaleSecuritiesDebtSecurities contextRef =" c95" decimals ="- 3" id =" ixv- 24443" unitRef =" usd" > 18069000 < / us- gaap: AvailableForSaleSecuritiesDebtSecurities > < us- gaap: AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef =" c3" decimals ="- 3" id =" ixv- 24444" unitRef =" usd" > 384358000 < / us- gaap: AvailableForSaleDebtSecuritiesAmortizedCostBasis > < us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef =" c3" decimals ="- 3" id =" ixv- 24445" unitRef =" usd" > 70000 < / us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax > < us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef =" c3" decimals ="- 3" id =" ixv- 24446" unitRef =" usd" > 111000 < / us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax > < us- gaap: AvailableForSaleSecuritiesDebtSecurities contextRef =" c3" decimals ="- 3" id =" ixv- 24447" unitRef =" usd" > 384317000 < / us- gaap: AvailableForSaleSecuritiesDebtSecurities > < us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock contextRef =" c0" id =" ixv- 13857" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The following table summarizes the available- for- sale securities in an unrealized loss position, aggregated by major security type and length of time in a continuous unrealized loss position, for which an allowance for credit losses was not recorded as of December & # 160; 31, 2024, (in thousands): & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- indent:- 0. 125in; padding- left: 0. 125in; text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 22" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; December 31, 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- indent:- 0. 125in; padding- left: 0. 125in; font- weight: bold; text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 6" style =" text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; Less than 12 months & lt; / b & gt; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 6" style =" text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; 12 months or longer & lt; / b & gt; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 6" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- indent:- 0. 125in; padding- left: 0. 125in; font- weight: bold; text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; Fair & lt; br / & gt; Value & lt; / b & gt; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Unrealized & lt; br / & gt; Losses & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Fair & lt; br / & gt; Value & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Unrealized & lt; br / & gt; Losses & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; Fair & lt; br / & gt; Value & lt; / b & gt; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Unrealized & lt; br / & gt; Losses & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- indent:- 0. 125in; padding- left: 0. 125in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Cash equivalents & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span &

gt; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- indent:- 0. 125in; padding- left: 0. 25in; width: 28 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Commercial papers & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 18, 199 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (3 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 188; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 189; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 18, 199 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (3 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- indent:- 0. 125in; padding- left: 0. 125in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Marketable securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- indent:- 0. 125in; padding- left: 0. 25in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Marketable securities, current & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- indent:- 0. 125in; padding- left: 0. 375in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. treasury securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 49, 904 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (11 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 190; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 191; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 49, 904 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (11 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- indent:- 0. 125in; padding- left: 0. 375in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. government agency securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 4, 713 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (2 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text-

align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman,
Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span
& gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 192; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span &
gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span
style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman,
Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 193; font- family: Times New Roman,
Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; /
span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; &
lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times
New Roman, Times, Serif" & gt; 4, 713 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; &
lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" &
gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family:
Times New Roman, Times, Serif" & gt; (2 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; /
span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- indent:- 0. 125in; padding- left: 0. 375in; text- align: left"
& gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Corporate debt securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New
Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; &
lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 39, 468 & lt; / span & gt; & lt; / td & gt; & lt; td
style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family:
Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; &
160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (40 & lt; / span & gt; & lt; / td & gt; & lt;
td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times
New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160;
& lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 194; font- family: Times New Roman, Times, Serif" & gt; & # x2014; &
lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td &
gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times
New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 195; font- family: Times New
Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; &
lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" &
gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family:
Times New Roman, Times, Serif" & gt; 39, 468 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; &
160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align:
left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font-
family: Times New Roman, Times, Serif" & gt; (40 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" &
gt;) & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- indent:- 0. 125in; padding- left: 0.
25in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Marketable securities, long- term & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span
style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman,
Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span
& gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt;
span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New
Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; &
lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td &
gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times
New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & #
160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt;
td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family:
Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;
& # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt;
& lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font-
family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times,
Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt;
& lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span
style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New
Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; &
lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- indent:- 0. 125in; padding- left: 0. 375in; text- align:
left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. treasury securities & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times
New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160;
& lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 13, 607 & lt; / span & gt; & lt; / td & gt; & lt; td
style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family:
Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; &
160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (32 & lt; / span & gt; & lt; / td & gt; & lt;
td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times
New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160;
& lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 196; font- family: Times New Roman, Times, Serif" & gt; & # x2014; &
lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td &
gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times
New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 197; font- family: Times New
Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; &
lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" &
gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family:
Times New Roman, Times, Serif" & gt; 13, 607 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; &
160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align:
left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font-
family: Times New Roman, Times, Serif" & gt; (32 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" &
gt;) & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- indent:- 0. 125in; padding- left: 0.
375in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; U. S. government agency securities & lt; / span & gt; & lt; / td & gt;
& lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom:
Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black
1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 4, 462 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text-
align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style
=" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style ="
font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font-
family: Times New Roman, Times, Serif" & gt; (23 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New
Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; &
lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; /
span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 198; font- family: Times New Roman,
Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif"
& gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt;
& lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; /
td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 199; font- family: Times New Roman, Times, Serif" & gt; &
# x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; /
span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt;
td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td
style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 4, 462 & lt; / span & gt; & lt; / td & gt; & lt; td style ="
padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding-
bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text-
align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align:
right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (23 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt;
span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt;
td style =" text- indent:- 0. 125in; padding- left: 0. 5in; padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total & lt; / span & gt; & lt; / td & gt;
& lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom:
Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt

double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 130, 353 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (111 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 200; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 201; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 130, 353 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (111 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock > < us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef =" c96" decimals ="- 3" id =" ixv- 24448" unitRef =" usd" > 18199000 < / us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months > < us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef =" c96" decimals ="- 3" id =" ixv- 24449" unitRef =" usd" > 3000 < / us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss > < us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef =" c96" decimals ="- 3" id =" ixv- 24450" unitRef =" usd" > 18199000 < / us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPosition > < us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef =" c96" decimals ="- 3" id =" ixv- 24451" unitRef =" usd" > 3000 < / us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss > < us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef =" c97" decimals ="- 3" id =" ixv- 24452" unitRef =" usd" > 49904000 < / us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months > < us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef =" c97" decimals ="- 3" id =" ixv- 24453" unitRef =" usd" > 11000 < / us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss > < us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef =" c97" decimals ="- 3" id =" ixv- 24454" unitRef =" usd" > 49904000 < / us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPosition > < us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef =" c97" decimals ="- 3" id =" ixv- 24455" unitRef =" usd" > 11000 < / us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss > < us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef =" c98" decimals ="- 3" id =" ixv- 24456" unitRef =" usd" > 4713000 < / us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months > < us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef =" c98" decimals ="- 3" id =" ixv- 24457" unitRef =" usd" > 2000 < / us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss > < us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef =" c98" decimals ="- 3" id =" ixv- 24458" unitRef =" usd" > 4713000 < / us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPosition > < us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef =" c98" decimals ="- 3" id =" ixv- 24459" unitRef =" usd" > 2000 < / us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss > < us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef =" c99" decimals ="- 3" id =" ixv- 24460" unitRef =" usd" > 39468000 < / us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months > < us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef =" c99" decimals ="- 3" id =" ixv- 24461" unitRef =" usd" > 40000 < / us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss > < us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef =" c99" decimals ="- 3" id =" ixv- 24462" unitRef =" usd" > 39468000 < / us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPosition > < us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef =" c99" decimals ="- 3" id =" ixv- 24463" unitRef =" usd" > 40000 < / us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss > < us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef =" c100" decimals ="- 3" id =" ixv- 24464" unitRef =" usd" > 13607000 < / us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months > < us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef =" c100" decimals ="- 3" id =" ixv- 24465" unitRef =" usd" > 32000 < / us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss > < us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef =" c100" decimals ="- 3" id =" ixv- 24466" unitRef =" usd" > 13607000 < / us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPosition > < us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef =" c100" decimals ="- 3" id =" ixv- 24467" unitRef =" usd" > 32000 < / us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss > < us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef =" c101" decimals ="- 3" id =" ixv- 24468" unitRef =" usd" > 4462000 < / us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months > < us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef =" c101" decimals ="- 3" id =" ixv- 24469" unitRef =" usd" > 23000 < / us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss > < us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef =" c101" decimals ="- 3" id =" ixv- 24470" unitRef =" usd" > 4462000 < / us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPosition > < us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef =" c101" decimals ="- 3" id =" ixv- 24471" unitRef =" usd" > 23000 < / us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss > < us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef =" c3" decimals ="- 3" id =" ixv- 24472" unitRef =" usd" > 130353000 < / us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months > < us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef =" c3" decimals ="- 3" id =" ixv- 24473" unitRef =" usd" > 111000 < / us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss > < us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef =" c3" decimals ="- 3" id =" ixv- 24474" unitRef =" usd" > 130353000 < / us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPosition > < us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef =" c3" decimals ="- 3" id =" ixv- 24475" unitRef =" usd" > 111000 < / us- gaap: DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss > < us- gaap: InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef =" c0" id =" ixv- 14512" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The following table summarizes the contractual maturities of the Company & # x2019; s marketable securities at estimated fair value (in thousands): & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; December 31, & lt; br / & gt; 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Due in one year or less & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 314, 073 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Due in 1- 2 years & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 18, 069 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 2. 5pt; padding- left: 0. 125in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 332, 142 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: InvestmentsClassifiedByContractualMaturityDateTableTextBlock > < us- gaap: MarketableSecuritiesCurrent contextRef =" c3" decimals ="- 3" id =" ixv- 24476" unitRef =" usd" > 314073000 < / us- gaap: MarketableSecuritiesCurrent > < us- gaap: MarketableSecuritiesNoncurrent contextRef =" c3" decimals ="- 3" id =" ixv- 24477" unitRef =" usd" > 18069000 < / us- gaap: MarketableSecuritiesNoncurrent > < us- gaap: MarketableSecurities contextRef =" c3" decimals ="- 3" id =" ixv- 24478" unitRef =" usd" > 332142000 < / us- gaap: MarketableSecurities > < us- gaap: AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef =" c0" id =" ixv- 14567" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; 6. Accrued Expenses and Other Current Liabilities & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Accrued expenses and other current liabilities consisted of the following (in thousands): & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; December 31, & lt; br / & gt; 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt;

span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Accrued employee compensation and benefits & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 2, 041 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Accrued professional and consulting & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 221 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Accrued research and development & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 1, 084 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- bottom: 2. 5pt; padding- left: 0. 125in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3, 346 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock > < us- gaap: ScheduleOfAccruedLiabilitiesTableTextBlock contextRef =" c0" id =" ixv- 14573" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Accrued expenses and other current liabilities consisted of the following (in thousands): & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; December 31, & lt; br / & gt; 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Accrued employee compensation and benefits & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 2, 041 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Accrued professional and consulting & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 221 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Accrued research and development & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 1, 084 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- bottom: 2. 5pt; padding- left: 0. 125in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3, 346 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: ScheduleOfAccruedLiabilitiesTableTextBlock > < us- gaap: AccruedEmployeeBenefitsCurrent contextRef =" c3" decimals =" - 3" id =" ixv- 24479" unitRef =" usd" > 2041000 < / us- gaap: AccruedEmployeeBenefitsCurrent > < us- gaap: AccruedProfessionalFeesCurrent contextRef =" c3" decimals =" - 3" id =" ixv- 24480" unitRef =" usd" > 221000 < / us- gaap: AccruedProfessionalFeesCurrent > < orka: AccruedResearchAndDevelopment contextRef =" c3" decimals =" - 3" id =" ixv- 24481" unitRef =" usd" > 1084000 < / orka: AccruedResearchAndDevelopment > < us- gaap: AccruedLiabilitiesAndOtherLiabilities contextRef =" c3" decimals =" - 3" id =" ixv- 24482" unitRef =" usd" > 3346000 < / us- gaap: AccruedLiabilitiesAndOtherLiabilities > < us- gaap: DebtDisclosureTextBlock contextRef =" c0" id =" ixv- 14638" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; 7. Note & # 160; Payable with Related Party & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; In March & # 160; 2024, Pre- Merger Oruka entered into a Series A Preferred Stock and Convertible Note Purchase Agreement (the & # x201c; Purchase Agreement & # x201d;) with Fairmount Healthcare Fund & # 160; II, L. P. (& # x201c; Fairmount & # x201d;), whereby Pre- Merger Oruka issued a convertible note (the & # x201c; Convertible Note & # x201d;), with an initial principal amount of $ 25. 0 million that, at the time of issuance, could be converted into Pre- Merger Oruka Series & # 160; A Preferred Stock (or a series & # 160; of preferred shares that is identical in respect to the shares of preferred shares issued in its next equity financing) or shares of Pre- Merger Oruka Common Stock in exchange for aggregate proceeds of $ 25. 0 & # 160; million. The Convertible Note accrued interest at a rate of 12. 0 % per annum. At issuance, the Convertible Note required all unpaid interest and principal to mature on December & # 160; 31, 2025 (the & # x201c; Maturity Date & # x201d;) and prepayment was not permitted without prior written consent of Fairmount. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company assessed all terms and features of the Convertible Note in order to identify any potential embedded features that would require bifurcation. As part of this analysis, the Company assessed the economic characteristics and risks of the embedded features. The Company determined that the share settled redemption feature was clearly and closely related to the debt host and did not require separate accounting. The Company determined that the conversion options of the Convertible Note were not clearly and closely associated with a debt host. However, these features did not meet the definition of a derivative under ASC & # 160; 815, Derivatives and Hedging, and as a result, did not require separate accounting as a derivative liability. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company paid debt issuance costs of less than $ 0. 1 & # 160; million in relation to the Convertible Note. The debt issuance costs were reflected as a reduction of the carrying value of Convertible Note on the consolidated balance sheet and were being amortized as interest expense over the term of the Convertible Note using the effective interest method. For the period from February & # 160; 6, 2024 (inception) to December 31, 2024, the Company recognized interest expenses related to the Convertible Note of $ 1. 5 million, which includes non- cash interest expense related to the amortization of debt issuance. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Immediately prior to the completion of the Merger (see Note 1), the Convertible Note was converted into shares of Pre- Merger Oruka Common Stock based on the aggregate principal amount of $ 25. 0 million, plus unpaid accrued interest of $ 1. 5 million divided by the conversion price which was determined based upon the Company & # x2019; s fully- diluted capitalization immediately prior to the Merger. At the effective time of the Merger, the Pre- Merger Oruka Common Stock issued upon the conversion of the Convertible Note (including accrued interest) automatically converted into 2, 722, 207 shares of Company Common Stock. As of December 31, 2024, the Convertible Note is not outstanding. & lt; / span & gt; & lt; / p & gt; < / us- gaap: DebtDisclosureTextBlock > < us- gaap: DebtInstrumentFaceAmount contextRef =" c102" decimals =" - 5" id =" ixv- 24483" unitRef =" usd" > 25000000 < / us- gaap: DebtInstrumentFaceAmount > < us- gaap: ProceedsFromConvertibleDebt contextRef =" c103" decimals =" - 5" id =" ixv- 24484" unitRef =" usd" > 25000000 < / us- gaap: ProceedsFromConvertibleDebt > < us- gaap: DebtInstrumentInterestRateDuringPeriod contextRef =" c104" decimals =" 3" id =" ixv- 24485" unitRef =" pure" > 0. 12 < / us- gaap: DebtInstrumentInterestRateDuringPeriod > < us- gaap: DebtInstrumentMaturityDate contextRef =" c104" id =" ixv- 24486" > 2025- 12- 31 < / us- gaap: DebtInstrumentMaturityDate > < us- gaap: PaymentsOfDebtIssuanceCosts contextRef =" c105" decimals =" - 5" id =" ixv- 24487" unitRef =" usd" > 100000 < / us- gaap: PaymentsOfDebtIssuanceCosts > < us- gaap: InterestExpenseDebt contextRef =" c106" decimals =" - 5" id =" ixv- 24488" unitRef =" usd" > 1500000 < / us- gaap: InterestExpenseDebt > < us- gaap: DebtInstrumentFaceAmount contextRef =" c107" decimals =" - 5" id =" ixv- 24489" unitRef =" usd" > 25000000 < / us- gaap: DebtInstrumentFaceAmount > < us- gaap: DebtInstrumentIncreaseAccruedInterest contextRef =" c105" decimals =" - 5" id =" ixv- 24490" unitRef =" usd" > 1500000 < / us- gaap: DebtInstrumentIncreaseAccruedInterest > < us- gaap: ConversionOfStockSharesConverted1 contextRef =" c108" decimals =" INF" id =" ixv- 24491" unitRef =" shares" > 2722207 < / us- gaap: ConversionOfStockSharesConverted1 > < us- gaap: StockholdersEquityNoteDisclosureTextBlock contextRef =" c0" id =" ixv- 14678" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; 8. Convertible Preferred Stock and Stockholders & # x2019; Equity & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Pre- Funded Warrants & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; In August 2024, pursuant to the Subscription Agreement and immediately prior to the Closing, certain new and current investors purchased pre- funded & # 160; warrants, which, at the effective time of the Merger, were exercisable for 5, 522, 207 shares of Company Common Stock at a purchase price of approximately $ 9. 70 per warrant. After the Merger, there are 5, 522, 207 pre- funded warrants outstanding and are exercisable for 5, 522, 207 shares of the Company Common Stock at an exercise price of $ 0. 01 per share. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; In September 2024, in connection with the PIPE

Financing, the Company issued and sold 680, 000 pre- funded warrants, at a purchase price of $ 22. 999 per warrant, exercisable for 680, 000 shares of Company Common Stock at an exercise price of $ 0. 001 per share. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The pre- funded warrants were recorded as a component of stockholders & # x2019; equity within additional paid- in- capital and have & lt; span style ="- sec- ix- hidden: hidden- fact- 202" & gt; no & lt; / span & gt; expiration date. As of December 31, 2024, & lt; span style ="- sec- ix- hidden: hidden- fact- 203" & gt; none & lt; / span & gt; of the pre- funded warrants have been exercised and 6, 202, 207 pre- funded warrants remain outstanding. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Employee Warrants & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; In July 2024, Pre- Merger Oruka entered into a Subscription Agreement that provided for, among other things, the issuance of warrants to certain of Pre- Merger Oruka & # x2019; s employees and directors immediately prior to the closing of the Merger. During the period from February 6, 2024 (inception) to December 31, 2024, 3, 054, 358 employee warrants were issued at an exercise price of $ 7. 80 per warrant. These warrants vest over a period of four years. Per the terms of the Employee Warrant Agreement, the holders of the Company & # x2019; s warrants shall not have any of the rights or privileges of a stockholder of the Company in respect of any shares purchasable upon the exercise of the warrant or any portion thereof unless and until a certificate or certificates representing such shares have been issued or a book entry representing such shares has been made and such shares have been deposited with the appropriate registered book- entry custodian. The Company recognizes compensation cost related to warrants on a straight- line basis over the requisite service period, which is the period in which the related services are received. As of December 31, 2024, & lt; span style ="- sec- ix- hidden: hidden- fact- 204" & gt; none & lt; / span & gt; of the warrants have been exercised and 3, 054, 358 warrants remain outstanding. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Convertible Preferred Stock & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; In March & # 160; 2024, Pre- Merger Oruka issued and sold an aggregate of 20, 000, 000 shares of Pre- Merger Oruka Series & # 160; A Preferred Stock to Fairmount (see Note 15), at a purchase price of approximately $ 0. 15 per share, for aggregate gross proceeds of $ 3. 0 & # 160; million. Pre- Merger Oruka incurred less than $ 0. 1 & # 160; million of issuance costs in connection with this transaction. Upon the issuance of the Pre- Merger Oruka Series & # 160; A Preferred Stock, the Company assessed the embedded conversion and liquidation features of the securities as described below and determined that such features did not require the Company to separately account for these features. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; In August 2024, upon the closing of the Merger, the Company converted the Pre- Merger Oruka Series A Preferred Stock to 137, 138 shares of Company Series B Preferred Stock. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; In September 2024, in connection with the PIPE Financing, the Company issued and sold an aggregate of 2, 439 shares of the Company Series A Preferred Stock at a purchase price of $ 23, 000. 00 per share. & # 160; In November 2024, the 2, 439 shares of the Company Series A Preferred Stock were converted to 2, 439, 000 shares of Company Common Stock. As of December 31, 2024, there are & lt; span style ="- sec- ix- hidden: hidden- fact- 205" & gt; no & lt; / span & gt; outstanding shares of Company Series A Preferred Stock. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; As of December 31, 2024, convertible preferred stock consisted of the following (in thousands, except share data): & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 14" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; December 31, 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" font- weight: bold; font- style: italic" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; Preferred & lt; br / & gt; Stock & lt; br / & gt; Authorized & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Preferred & lt; br / & gt; Stock Issued & lt; br / & gt; and & lt; br / & gt; Outstanding & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Carrying & lt; br / & gt; Value & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Common Stock & lt; br / & gt; Issuable & lt; br / & gt; Upon & lt; br / & gt; Conversion & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 52 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Series B convertible preferred stock & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 251, 504 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 137, 138 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 2, 931 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 11, 428, 149 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Pursuant to the Certificate of Designation of Preferences, Rights and Limitations of the Series A Non- Voting Convertible Preferred Stock (the & # x201c; Series A Certificate of Designation & # x201d;) filed in connection with the PIPE Financing, holders of Company Series A Preferred Stock were entitled to receive dividends on shares of Company Series A Preferred Stock equal to, on an as- if- converted- to- Company Common Stock basis, and in the same form as, dividends actually paid on shares of Company Common Stock. Except as provided in the Series A Certificate of Designation or as otherwise required by law, the Company Series A Preferred Stock did not have voting rights. The Company Series A Preferred Stock shall rank on parity with the Company Common Stock and Company Series B Preferred Stock upon any liquidation, dissolution or winding- up of the Company. Subject to the terms and limitations contained in the Series A Certificate of Designation, the Company Series A Preferred Stock issued in the PIPE Financing will not become convertible until the Company & # x2019; s stockholders approve the conversion of the Company Series A Preferred Stock into shares of Company Common Stock in accordance with the listing rules of the Nasdaq Stock Market (the & # x201c; Stockholder Approval & # x201d;), which, on issuance, resulted in the Company Series A Preferred Stock being classified outside of stockholders & # x2019; equity on the Company & # x2019; s consolidated balance sheet. Following the Stockholder Approval in November 2024, each share of Company Series A Preferred Stock was automatically converted into 1, 000 shares of Company Common Stock. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Pursuant to the Certificate of Designation of Preferences, Rights and Limitations of the Series B Non- Voting Convertible Preferred Stock (the & # x201c; Series B Certificate of Designation & # x201d;) filed in connection with the Merger, holders of Company Series B Preferred Stock are entitled to receive dividends on shares of Company Series B Preferred Stock equal to, on an as- if- converted- to- Company Common Stock basis, and in the same form as, dividends actually paid on shares of Company Common Stock. Except as provided in the Series B Certificate of Designation or as otherwise required by law, the Company Series B Preferred Stock does not have voting rights. The Company Series B Preferred Stock shall rank on parity with the Company Common Stock as to the distribution of assets upon any liquidation, dissolution, or winding- up of the Company. Each share of Company Series B Preferred Stock is convertible at the option of the holder, at any time, and without the payment of additional consideration by the holder. As of December 31, 2024, each outstanding share of Company Series B Preferred Stock was convertible into common stock at a ratio of approximately 83. 3332: 1. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Paruka Warrant & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; On December 31, 2024, the Company settled its 2024 obligations under the Paruka Warrant Obligation (defined below) by issuing Paruka a warrant to purchase 596, 930 shares of Company Common Stock at an exercise price of $ 19. 39 per share. The warrant has a term of 10 years, is fully vested, and is exercisable in part or full at any time during the term of the warrant. As of December 31, 2024, the warrant issued under the Paruka Warrant Obligation is outstanding and unexercised. See Note 9 for additional information on the Paruka Warrant Obligation. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times

New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Common Stock & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; As of December 31, 2024, the Certificate of Incorporation provides for 545, 000, 000 authorized shares of Company Common Stock. As of December 31, 2024, 37, 440, 510 shares of Company Common Stock were issued and outstanding, including 2, 207, 553 shares of RSAs issued and outstanding. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; As of December 31, 2024, the Company had common stock reserved for future issuance as follows: & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; December 31, & lt; br / & gt; 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Shares issuable on conversion of Company Series B Preferred Stock & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 11, 428, 149 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Shares issuable upon exercise of pre- funded warrants & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 6, 202, 207 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Shares issuable upon exercise of warrant under the Paruka Warrant Obligation & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 596, 930 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Outstanding and issued stock options & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 1, 567, 760 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Outstanding and issued employee warrants & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3, 054, 358 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Shares available for grant under 2024 Stock Incentive Plan & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 4, 246, 324 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Shares available for grant under 2024 Employee Stock Purchase Plan & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 460, 529 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 4pt; padding- left: 13. 7pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total shares of common stock reserved & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 27, 556, 257 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: StockholdersEquityNoteDisclosureTextBlock > < us- gaap: SaleOfStockNumberOfSharesIssuedInTransaction contextRef =" c109" decimals =" INF" id =" ixv- 24492" unitRef =" shares" > 5522207 < / us- gaap: SaleOfStockNumberOfSharesIssuedInTransaction > < us- gaap: SharesIssuedPricePerShare contextRef =" c110" decimals =" 2" id =" ixv- 24493" unitRef =" usdPershares" > 9. 7 < / us- gaap: SharesIssuedPricePerShare > < us- gaap: ClassOfWarrantOrRightOutstanding contextRef =" c110" decimals =" INF" id =" ixv- 24494" unitRef =" shares" > 5522207 < / us- gaap: ClassOfWarrantOrRightOutstanding > < orka: ClassOfWarrantsExercisable contextRef =" c111" decimals =" 0" id =" ixv- 24495" unitRef =" shares" > 5522207 < / orka: ClassOfWarrantsExercisable > < us- gaap: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef =" c112" decimals =" 2" id =" ixv- 24496" unitRef =" usdPershares" > 0. 01 < / us- gaap: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 > < us- gaap: SaleOfStockNumberOfSharesIssuedInTransaction contextRef =" c113" decimals =" INF" id =" ixv- 24497" unitRef =" shares" > 680000 < / us- gaap: SaleOfStockNumberOfSharesIssuedInTransaction > < us- gaap: SaleOfStockPricePerShare contextRef =" c114" decimals =" 3" id =" ixv- 24498" unitRef =" usdPershares" > 22. 999 < / us- gaap: SaleOfStockPricePerShare > < orka: ClassOfWarrantsExercisable contextRef =" c115" decimals =" INF" id =" ixv- 24499" unitRef =" shares" > 680000 < / orka: ClassOfWarrantsExercisable > < us- gaap: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef =" c116" decimals =" 3" id =" ixv- 24500" unitRef =" usdPershares" > 0. 001 < / us- gaap: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 > < us- gaap: ClassOfWarrantOrRightOutstanding contextRef =" c118" decimals =" INF" id =" ixv- 24501" unitRef =" shares" > 6202207 < / us- gaap: ClassOfWarrantOrRightOutstanding > < us- gaap: ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef =" c119" decimals =" INF" id =" ixv- 24502" unitRef =" shares" > 3054358 < / us- gaap: ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights > < us- gaap: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef =" c119" decimals =" 2" id =" ixv- 24503" unitRef =" usdPershares" > 7. 8 < / us- gaap: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef =" c120" id =" ixv- 24504" > P4Y < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 > < us- gaap: ClassOfWarrantOrRightOutstanding contextRef =" c119" decimals =" INF" id =" ixv- 24505" unitRef =" shares" > 3054358 < / us- gaap: ClassOfWarrantOrRightOutstanding > < us- gaap: SaleOfStockNumberOfSharesIssuedInTransaction contextRef =" c121" decimals =" INF" id =" ixv- 24506" unitRef =" shares" > 20000000 < / us- gaap: SaleOfStockNumberOfSharesIssuedInTransaction > < us- gaap: SharesIssuedPricePerShare contextRef =" c122" decimals =" 2" id =" ixv- 24507" unitRef =" usdPershares" > 0. 15 < / us- gaap: SharesIssuedPricePerShare > < us- gaap: ProceedsFromIssuanceOfConvertiblePreferredStock contextRef =" c123" decimals =" - 5" id =" ixv- 24508" unitRef =" usd" > 3000000 < / us- gaap: ProceedsFromIssuanceOfConvertiblePreferredStock > < us- gaap: PaymentsOfStockIssuanceCosts contextRef =" c124" decimals =" - 5" id =" ixv- 24509" unitRef =" usd" > 100000 < / us- gaap: PaymentsOfStockIssuanceCosts > < us- gaap: PreferredStockConvertibleSharesIssuable contextRef =" c125" decimals =" INF" id =" ixv- 24510" unitRef =" shares" > 137138 < / us- gaap: PreferredStockConvertibleSharesIssuable > < us- gaap: SaleOfStockNumberOfSharesIssuedInTransaction contextRef =" c126" decimals =" INF" id =" ixv- 24511" unitRef =" shares" > 2439 < / us- gaap: SaleOfStockNumberOfSharesIssuedInTransaction > < us- gaap: SaleOfStockPricePerShare contextRef =" c127" decimals =" 2" id =" ixv- 24512" unitRef =" usdPershares" > 23000 < / us- gaap: SaleOfStockPricePerShare > < us- gaap: PreferredStockConvertibleSharesIssuable contextRef =" c128" decimals =" INF" id =" ixv- 24513" unitRef =" shares" > 2439 < / us- gaap: PreferredStockConvertibleSharesIssuable > < us- gaap: PreferredStockConvertibleSharesIssuable contextRef =" c129" decimals =" INF" id =" ixv- 24514" unitRef =" shares" > 2439000 < / us- gaap: PreferredStockConvertibleSharesIssuable > < orka: ScheduleOfConvertiblePreferredStockTableTextBlock contextRef =" c0" id =" ixv- 14752" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; As of December 31, 2024, convertible preferred stock consisted of the following (in thousands, except share data): & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 14" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; December 31, 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" font- weight: bold; font- style: italic" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; Preferred & lt; br / & gt; Stock & lt; br / & gt; Authorized & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Preferred & lt; br / & gt; Stock Issued & lt; br / & gt; and & lt; br / & gt; Outstanding & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Carrying & lt; br / & gt; Value & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Common Stock & lt; br / & gt; Issuable & lt; br / & gt; Upon & lt; br / & gt; Conversion & lt; / span & gt; & lt; / td

& gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 52 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Series B convertible preferred stock & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 251, 504 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 137, 138 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 2, 931 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 11, 428, 149 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / orka: ScheduleOfConvertiblePreferredStockTableTextBlock > < us- gaap: PreferredStockSharesAuthorized contextRef =" c134" decimals =" INF" id =" ixv- 24515" unitRef =" shares" > 251504 < / us- gaap: PreferredStockSharesAuthorized > < us- gaap: PreferredStockSharesIssued contextRef =" c134" decimals =" INF" id =" ixv- 24516" unitRef =" shares" > 137138 < / us- gaap: PreferredStockSharesIssued > < us- gaap: PreferredStockSharesOutstanding contextRef =" c134" decimals =" INF" id =" ixv- 24517" unitRef =" shares" > 137138 < / us- gaap: PreferredStockSharesOutstanding > < us- gaap: PreferredStockValue contextRef =" c134" decimals ="- 3" id =" ixv- 24518" unitRef =" usd" > 2931000 < / us- gaap: PreferredStockValue > < us- gaap: CommonStockCapitalSharesReservedForFutureIssuance contextRef =" c134" decimals =" INF" id =" ixv- 24519" unitRef =" shares" > 11428149 < / us- gaap: CommonStockCapitalSharesReservedForFutureIssuance > < us- gaap: ConvertiblePreferredStockSharesIssuedUponConversion contextRef =" c129" decimals =" INF" id =" ixv- 24520" unitRef =" shares" > 1000 < / us- gaap: ConvertiblePreferredStockSharesIssuedUponConversion > < orka: CommonStockConversionRatio contextRef =" c47" id =" ixv- 24521" > 83. 3332: 1 < / orka: CommonStockConversionRatio > < orka: WarrantsToPurchaseCommonStock contextRef =" c131" decimals =" INF" id =" ixv- 24522" unitRef =" shares" > 596930 < / orka: WarrantsToPurchaseCommonStock > < us- gaap: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef =" c131" decimals =" 2" id =" ixv- 24523" unitRef =" usdPershares" > 19. 39 < / us- gaap: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 > < us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef =" c132" id =" ixv- 24524" > P10Y < / us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod > < us- gaap: CommonStockSharesAuthorized contextRef =" c36" decimals =" INF" id =" ixv- 24525" unitRef =" shares" > 545000000 < / us- gaap: CommonStockSharesAuthorized > < us- gaap: CommonStockSharesIssued contextRef =" c36" decimals =" INF" id =" ixv- 24526" unitRef =" shares" > 37440510 < / us- gaap: CommonStockSharesIssued > < us- gaap: CommonStockSharesOutstanding contextRef =" c36" decimals =" INF" id =" ixv- 24527" unitRef =" shares" > 37440510 < / us- gaap: CommonStockSharesOutstanding > < us- gaap: CommonStockSharesOutstanding contextRef =" c133" decimals =" INF" id =" ixv- 24528" unitRef =" shares" > 2207553 < / us- gaap: CommonStockSharesOutstanding > < us- gaap: CommonStockSharesIssued contextRef =" c133" decimals =" INF" id =" ixv- 24529" unitRef =" shares" > 2207553 < / us- gaap: CommonStockSharesIssued > < orka: ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock contextRef =" c0" id =" ixv- 14885" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; As of December 31, 2024, the Company had common stock reserved for future issuance as follows: & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; December 31, & lt; br / & gt; 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Shares issuable on conversion of Company Series B Preferred Stock & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 11, 428, 149 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Shares issuable upon exercise of pre- funded warrants & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 6, 202, 207 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Shares issuable upon exercise of warrant under the Paruka Warrant Obligation & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 596, 930 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Outstanding and issued stock options & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 1, 567, 760 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Outstanding and issued employee warrants & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3, 054, 358 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Shares available for grant under 2024 Stock Incentive Plan & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 4, 246, 324 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Shares available for grant under 2024 Employee Stock Purchase Plan & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 460, 529 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 4pt; padding- left: 13. 7pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total shares of common stock reserved & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 27, 556, 257 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / orka: ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock > < us- gaap: CommonStockCapitalSharesReservedForFutureIssuance contextRef =" c134" decimals =" INF" id =" ixv- 24530" unitRef =" shares" > 11428149 < / us- gaap: CommonStockCapitalSharesReservedForFutureIssuance > < us- gaap: CommonStockCapitalSharesReservedForFutureIssuance contextRef =" c54" decimals =" INF" id =" ixv- 24531" unitRef =" shares" > 6202207 < / us- gaap: CommonStockCapitalSharesReservedForFutureIssuance > < us- gaap: CommonStockCapitalSharesReservedForFutureIssuance contextRef =" c135" decimals =" INF" id =" ixv- 24532" unitRef =" shares" > 596930 < / us- gaap: CommonStockCapitalSharesReservedForFutureIssuance > < us- gaap: CommonStockCapitalSharesReservedForFutureIssuance contextRef =" c136" decimals =" INF" id =" ixv- 24533" unitRef =" shares" > 1567760 < / us- gaap: CommonStockCapitalSharesReservedForFutureIssuance > < us- gaap: CommonStockCapitalSharesReservedForFutureIssuance contextRef =" c119" decimals =" INF" id =" ixv- 24534" unitRef =" shares" > 3054358 < / us- gaap: CommonStockCapitalSharesReservedForFutureIssuance > < us- gaap: CommonStockCapitalSharesReservedForFutureIssuance contextRef =" c137" decimals =" INF" id =" ixv- 24535" unitRef =" shares" > 4246324 < / us- gaap: CommonStockCapitalSharesReservedForFutureIssuance > < us- gaap: CommonStockCapitalSharesReservedForFutureIssuance contextRef =" c138" decimals =" INF" id =" ixv- 24536" unitRef =" shares" > 460529 < / us- gaap: CommonStockCapitalSharesReservedForFutureIssuance > < us- gaap: CommonStockCapitalSharesReservedForFutureIssuance contextRef =" c3" decimals =" INF" id =" ixv- 24537" unitRef =" shares" > 27556257 < / us- gaap: CommonStockCapitalSharesReservedForFutureIssuance > < us- gaap: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef =" c0" id =" ixv- 14995" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; 9. Stock- Based Compensation & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; 2024 Equity Incentive Plan & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The 2024 Equity Incentive Plan (& # x201c; 2024 Plan & # x201d;) was adopted by the board of directors of Pre- Merger Oruka on February & # 160; 6, 2024. The 2024 Plan provided for Pre- Merger Oruka to grant stock options, restricted stock awards, restricted stock units, and other stock- based awards to employees, officers, directors, consultants, and advisors. Equity Incentive Stock options granted under the 2024 Plan generally vest over four & # 160; years, subject to the participant & # x2019; s continued service, and expire after ten & # 160; years, although two non- employee stock options were & # 160; granted with vesting terms less than four & # 160; years. As of December 31, 2024, there are no shares of common stock available for issuance. & lt; / span & gt; & lt; / p & gt; & lt; p style ="

font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; 2024 Stock Incentive Plan & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; On August 22, 2024, the 2024 Stock Incentive Plan (& # x201c; 2024 Stock Plan & # x201d;) was approved by the Company & # x2019; s stockholders and on August 29, 2024, the board of directors of the Company (the & # x201c; Board & # x201d;) ratified the 2024 Stock Plan. The 2024 Stock Plan allows for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock units, other stockholder- based awards and incentive bonuses. The 2024 Stock Plan is administered by the Compensation Committee of the Board (the & # x201c; Compensation Committee & # x201d;) or another committee designated by the Board to administer the Plan. The initial share pool under the 2024 Stock Plan is 4, 634, 891 shares of Company Common Stock. During the period from February 6, 2024 (inception) to December 31, 2024, 388, 567 shares were subject to outstanding stock options, and as of December 31, 2024, there were 4, 246, 324 shares available in the pool. The shares that may be issued under the 2024 Stock Plan will be automatically increased on January 1 of each year beginning in 2025 and ending with a final increase on January 1, 2034 in an amount equal to 5 % of the diluted stock (including Company Common Stock, preferred stock and unexercised pre- funded warrants) on the preceding December 31, unless a lower, or no, increase is determined by the Compensation Committee. Current or prospective employees, officers, non- employee directors, and other independent service providers of the Company and its subsidiaries are eligible to participate in the 2024 Stock Plan. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; 2024 Employee Stock Purchase Plan & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The 2024 Employee Stock Purchase Plan (the & # x201c; ESPP & # x201d;) became effective on August 29, 2024, at which time 463, 489 shares of Company Common Stock were reserved for issuance. Eligible employees may purchase shares of Company Common Stock under the ESPP at & # 160; 85 % of the lower of the fair market value of the Company Common Stock as of the first or the last day of each offering period. Employees are limited to contributing & # 160; 15 % of the employee & # x2019; s eligible compensation and may not purchase more than $ 25, 000 & # 160; of stock during any calendar year. The ESPP will terminate & # 160; ten years & # 160; from the first purchase date under the plan, unless terminated earlier by the board of directors. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The shares that may be issued under the ESPP will be automatically increased on January 1 of each year beginning in 2025 and ending with a final increase on January 1, 2034 in an amount equal to 1 % of the diluted stock (including Company Common Stock, preferred stock and unexercised pre- funded warrants) on the preceding December 31, unless a lower, or no increase is determined by the Compensation Committee. During the period from February 6, 2024 (inception) to December 31, 2024, 2, 960 shares of Company Common Stock were issued out of the ESPP and as of December 31, 2024, there were 460, 529 shares of Company Common Stock available in the pool. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; For the period February 6, 2024 (inception) to December 31, 2024, stock- based compensation expense related to the ESPP was less than $ 0. 1 million. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Stock Option Valuation & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The following table summarizes the weighted- average assumptions used in calculating the fair value of the awards for the period from February & # 160; 6, 2024 (inception) to December 31, 2024: & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Period from & lt; br / & gt; February 6, & lt; br / & gt; 2024 & lt; br / & gt; (Inception) to & lt; br / & gt; December 31, & lt; br / & gt; 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Expected term (in years) & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 6. 1 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Expected volatility & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 100. 21 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; % & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Risk- free interest rate & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 4. 26 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; % & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Expected dividend yield & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 206; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Stock Options & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The following table summarizes the stock option activities under the 2024 Plan and 2024 Stock Plan for the period of February & # 160; 6, 2024 (inception) through December 31, 2024: & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Number of & lt; br / & gt; Stock & lt; br / & gt; Options & lt; br / & gt; Outstanding & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Weighted & lt; br / & gt; Average & lt; br / & gt; Exercise & lt; br / & gt; Price Per & lt; br / & gt; Share & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Weighted & lt; br / & gt; Average & lt; br / & gt; Remaining & lt; br / & gt; Contractual & lt; br / & gt; Term & lt; br / & gt; (in Years) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Aggregate & lt; br / & gt; Intrinsic & lt; br / & gt; Value & lt; br / & gt; (in & # 160; Thousands) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Balance as of February 6, 2024 (inception) & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 208; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 209; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 210; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 211; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; width: 52 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Granted & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span

style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 1, 567, 760 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 11. 39 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Exercised & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 212; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 213; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Forfeited & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 214; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 215; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Balance as of December 31, 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 1, 567, 760 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 11. 39 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 9. 4 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 15, 470 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Vested and expected to vest, December 31, 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 1, 567, 760 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 11. 39 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 9. 4 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 15, 470 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Exercisable, December 31, 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 216; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 217; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 218; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 219; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 27pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 27pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The weighted average grant- date fair value per share of stock options granted during the period from February & # 160; 6, 2024 (inception) to December 31, 2024 was $ 9. 12 per share. Aggregate intrinsic value represents the difference between the estimated fair value of the underlying Company Common Stock and the exercise price of outstanding, in- the- money employee stock options. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 27pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Restricted Stock Awards & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; In February 2024 and March & # 160; 2024, the Company issued 2, 207, 553 shares of RSAs to

certain employees, directors, and consultants at a price of $ 0. 0001 per share, the then par value of Pre- Merger Oruka Common Stock. Such RSAs have service- based vesting conditions only and vest over a four- year period, during which time all unvested shares are subject to forfeiture in the event the holder & # x2019; s service with the Company voluntarily or involuntarily terminates. As of December 31, 2024, none of the RSAs had vested. For the period February 6, 2024 (inception) to December 31, 2024, stock- based compensation expense related to RSAs was less than $ 0. 1 million. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The following table summarizes the RSA activity for the period from February & # 160; 6, 2024 (inception) through December 31, 2024: & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Number of & lt; br / & gt; RSAs & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Weighted & lt; br / & gt; Average & lt; br / & gt; Grant Date & lt; br / & gt; Fair Value & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Unvested balance as of February 6, 2024 (inception) & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 220; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 221; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" width: 76 %; padding- bottom: 1. 5pt; padding- left: 13. 7pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Granted & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 2, 207, 553 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; padding- bottom: 1. 5pt; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 222; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Unvested balance as of December 31, 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 2, 207, 553 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 223; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Option Agreements and the Paruka Warrant Obligation & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; As part of the Option Agreements, on December & # 160; 31, 2024 the Company granted and on December & # 160; 31, 2025, will grant Paruka a warrant to purchase a number of shares equal to 1. 00 % of outstanding shares as of the date of the grant on a fully- diluted basis, with an exercise price equal to the fair market value of the underlying shares on the grant date (the & # x201c; Paruka Warrant Obligation & # x201d;). & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The grant dates for the issuance of warrants were expected to be December & # 160; 31, 2024 and December & # 160; 31, 2025 as all terms of the award, including number of shares and exercise price, will be known by all parties. The Company determined that the 2024 and 2025 grants are two separate grants, as there would be no obligation for the 2025 grant had the Company exercised or terminated all of the options under the Option Agreements prior to December 31, 2024. The service inception period for the grant precedes the grant date, with the full award being vested as of the grant date with no post- grant date service requirement. Accordingly, the warrant expected to be granted to Paruka was accounted for as a liability on the balance sheet on the service inception date and, after the initial recognition, the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the consolidated statement of operations and comprehensive loss as stock- based compensation expenses under research and development expenses. Accordingly, the Company measured the grant date fair value of the warrant granted on December 31, 2024 at $ 10. 4 million. For the period from February 6, 2024 (inception) to December 31, 2024, $ 10. 4 million was recognized as stock- based compensation expense related to the Paruka Warrant Obligation in the consolidated statement of operations and comprehensive loss. As of December 31, 2024, there was no unamortized expense related to the December 31, 2024 Paruka Warrant Obligation. On issuance of the warrant to Paruka, the fair value of the warrant was reclassified from liability to equity on the consolidated balance sheet as of December 31, 2024. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Employee Warrants & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; As stated above, on July 3, 2024, the Subscription Agreement was amended and restated, among other things, for employee warrants to be issued to certain Pre- Merger Oruka employees and directors immediately prior to the closing of the Merger. Pursuant to this amendment, during the period from February 6, 2024 (inception) to December 31, 2024, the Company issued 3, 054, 358 warrants at an exercise price of $ 7. 80 per warrant, which are accounted as equity in the consolidated financial statements. The employee warrants were subject to performance and service based vesting requirements and upon completion of the Merger the performance- based requirements had been achieved. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The following table summarizes the warrant activity for the period from February & # 160; 6, 2024 (inception) through December 31, 2024: & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; font- weight: bold; text- align: center" & gt; Number of & lt; br / & gt; Employee & lt; br / & gt; Warrants & lt; br / & gt; Outstanding & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Weighted & lt; br / & gt; Average & lt; br / & gt; Exercise & lt; br / & gt; Price Per & lt; br / & gt; Share & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Weighted & lt; br / & gt; Average & lt; br / & gt; Remaining & lt; br / & gt; Contractual & lt; br / & gt; Term & lt; br / & gt; (in Years) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Aggregate & lt; br / & gt; Intrinsic & lt; br / & gt; Value & lt; br / & gt; (in & # 160; Thousands) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Balance as of February 6, 2024 (inception) & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 224; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 225; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 226; font- family: Times New Roman,

Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; width: 52 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Granted & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3, 054, 358 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 7. 80 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Exercised & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 227; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 228; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Forfeited & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 229; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 230; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Balance as of December 31, 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3, 054, 358 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 7. 80 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 9. 5 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 35, 400 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Vested and expected to vest, December 31, 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3, 054, 358 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 7. 80 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 9. 5 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 35, 400 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Exercisable, December 31, 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 231; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 232; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 233; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The weighted average grant- date fair value per share of warrants granted during the period from February & # 160; 6, 2024 (inception) to December 31, 2024 was $ 6. 27 per share. Aggregate intrinsic value represents the difference between the estimated fair value of the underlying Company Common Stock and the exercise price of outstanding, in- the- money warrants. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The following table summarizes the weighted- average assumptions used in calculating the fair value of the warrants for the period from February & # 160; 6, 2024 (inception) to December 31, 2024: & lt; / span & gt; & lt; / p & gt; & lt; p style =" font:

10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Period from & lt; br / & gt; February 6, & lt; br / & gt; 2024 & lt; br / & gt; (Inception) to & lt; br / & gt; December 31, & lt; br / & gt; 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Expected term (in years) & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 6. 1 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Expected volatility & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 99. 02 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; % & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Risk- free interest rate & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 4. 15 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; % & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Expected dividend yield & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 207; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & lt; i & gt; Stock- Based Compensation Expense & lt; / i & gt; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The following table summarizes the classification of the Company & # x2019; s stock- based compensation expense in the consolidated statement of operations and comprehensive loss (in thousands): & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Period from & lt; br / & gt; February 6, & lt; br / & gt; 2024 & lt; br / & gt; (Inception) to & lt; br / & gt; December 31, & lt; br / & gt; 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Research and development & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 11, 992 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; General and administrative & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 2, 927 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 2. 5pt; padding- left: 13. 7pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 14, 919 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; As of December 31, 2024, total unrecognized compensation cost related to the unvested stock options was $ 12. 7 million, which is expected to be recognized over a weighted average period of approximately 3. 2 years. As of December 31, 2024, total unrecognized compensation cost related to the unvested RSAs was less than $ 0. 1 million, which is expected to be recognized over a weighted average period of 3. 1 years. As of December 31, 2024, the unrecognized compensation cost related to the employee warrants was $ 16. 3 million, which is expected to be recognized over a weighted average period of 3. 3 years. & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The following table summarizes the award types of the Company & # x2019; s stock- based compensation expense in the consolidated statement of operations and comprehensive loss (in thousands): & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Period from & lt; br / & gt; February 6, & lt; br / & gt; 2024 & lt; br / & gt; (Inception) to & lt; br / & gt; December 31, & lt; br / & gt; 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Paruka Warrant Obligation & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 10, 357 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Employee warrants & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 2, 899 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Stock options & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 1, 626 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Employee stock purchase plan & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 37 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 2. 5pt; padding- left: 0. 125in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 14, 919 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef =" c139" decimals =" INF" id =" ixv- 24538" unitRef =" shares" > 4634891 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant > < us- gaap: CommonStockCapitalSharesReservedForFutureIssuance contextRef =" c140" decimals =" INF" id =" ixv- 24539" unitRef =" shares" > 388567 < / us- gaap: CommonStockCapitalSharesReservedForFutureIssuance > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef =" c141" decimals =" INF" id =" ixv- 24540" unitRef =" shares" > 4246324 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant > < orka: ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares contextRef =" c142" decimals =" 2" id =" ixv- 24541" unitRef =" pure" > 0. 05 < / orka: ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares >

< us- gaap: CommonStockCapitalSharesReservedForFutureIssuance contextRef =" c143" decimals =" INF" id =" ixv- 24542" unitRef =" shares" > 463489 < / us- gaap: CommonStockCapitalSharesReservedForFutureIssuance > < us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef =" c144" decimals =" 2" id =" ixv- 24543" unitRef =" pure" > 0. 85 < / us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate contextRef =" c143" decimals =" 2" id =" ixv- 24544" unitRef =" pure" > 0. 15 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate > < orka: EmployeeStockPurchasePlanESPPCashContributionsToESPP contextRef =" c144" decimals =" 0" id =" ixv- 24545" unitRef =" usd" > 25000 < / orka: EmployeeStockPurchasePlanESPPCashContributionsToESPP > < orka: ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares contextRef =" c145" decimals =" 2" id =" ixv- 24546" unitRef =" pure" > 0. 01 < / orka: ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares > < us- gaap: CommonStockSharesIssued contextRef =" c138" decimals =" INF" id =" ixv- 24547" unitRef =" shares" > 2960 < / us- gaap: CommonStockSharesIssued > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef =" c138" decimals =" INF" id =" ixv- 24548" unitRef =" shares" > 460529 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant > < us- gaap: AllocatedShareBasedCompensationExpense contextRef =" c145" decimals ="- 5" id =" ixv- 24549" unitRef =" usd" > 100000 < / us- gaap: AllocatedShareBasedCompensationExpense > < us- gaap: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef =" c0" id =" ixv- 15063" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The following table summarizes the weighted- average assumptions used in calculating the fair value of the awards for the period from February & # 160; 6, 2024 (inception) to December 31, 2024: & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Period from & lt; br / & gt; February 6, & lt; br / & gt; 2024 & lt; br / & gt; (Inception) to & lt; br / & gt; December 31, & lt; br / & gt; 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Expected term (in years) & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 6. 1 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Expected volatility & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 100. 21 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; % & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Risk- free interest rate & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 4. 26 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; % & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Expected dividend yield & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 206; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The following table summarizes the weighted- average assumptions used in calculating the fair value of the warrants for the period from February & # 160; 6, 2024 (inception) to December 31, 2024: & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Period from & lt; br / & gt; February 6, & lt; br / & gt; 2024 & lt; br / & gt; (Inception) to & lt; br / & gt; December 31, & lt; br / & gt; 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Expected term (in years) & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 6. 1 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Expected volatility & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 99. 02 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; % & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Risk- free interest rate & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 4. 15 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; % & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Expected dividend yield & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 207; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock > < us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef =" c146" id =" ixv- 15091" > P6Y1M6D < / us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef =" c146" decimals =" 4" id =" ixv- 24550" unitRef =" pure" > 1. 0021 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef =" c146" decimals =" 4" id =" ixv- 24551" unitRef =" pure" > 0. 0426 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate > < us- gaap: ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef =" c0" id =" ixv- 15138" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The following table summarizes the stock option activities under the 2024 Plan and 2024 Stock Plan for the period of February & # 160; 6, 2024 (inception) through December 31, 2024: & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Number of & lt; br / & gt; Stock & lt; br / & gt; Options & lt; br / & gt; Outstanding & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Weighted & lt; br / & gt; Average & lt; br / & gt; Exercise & lt; br / & gt; Price Per & lt; br / & gt; Share & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Weighted & lt; br / & gt; Average & lt; br / & gt; Remaining & lt; br / & gt; Contractual & lt; br / & gt; Term & lt; br / & gt; (in Years) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Aggregate & lt; br / & gt; Intrinsic & lt; br / & gt; Value & lt; br / & gt; (in & # 160; Thousands) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Balance as of February 6, 2024 (inception) & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 208; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; &

lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 209; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 210; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 211; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; width: 52 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Granted & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 1, 567, 760 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 11. 39 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Exercised & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 212; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 213; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Forfeited & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 214; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 215; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Balance as of December 31, 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 1, 567, 760 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 11. 39 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 9. 4 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 15, 470 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Vested and expected to vest, December 31, 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 1, 567, 760 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 11. 39 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 9. 4 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 15, 470 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Exercisable, December 31, 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 216; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 217; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 218; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 219; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt;

text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef =" c0" decimals =" INF" id =" ixv- 24552" unitRef =" shares" > 1567760 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross > < us- gaap: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef =" c0" decimals =" 2" id =" ixv- 24553" unitRef =" usdPershares" > 11. 39 < / us- gaap: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef =" c3" decimals =" INF" id =" ixv- 24554" unitRef =" shares" > 1567760 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef =" c3" decimals =" 2" id =" ixv- 24555" unitRef =" usdPershares" > 11. 39 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice > < us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef =" c0" id =" ixv- 15350" > P9Y4M24D < / us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef =" c3" decimals =" - 3" id =" ixv- 24556" unitRef =" usd" > 15470000 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef =" c3" decimals =" INF" id =" ixv- 24557" unitRef =" shares" > 1567760 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef =" c3" decimals =" 2" id =" ixv- 24558" unitRef =" usdPershares" > 11. 39 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice > < us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef =" c0" id =" ixv- 15386" > P9Y4M24D < / us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef =" c3" decimals =" - 3" id =" ixv- 24559" unitRef =" usd" > 15470000 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef =" c146" decimals =" 2" id =" ixv- 24560" unitRef =" usdPershares" > 9. 12 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef =" c147" decimals =" INF" id =" ixv- 24561" unitRef =" shares" > 2207553 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod > < us- gaap: SharesIssuedPricePerShare contextRef =" c133" decimals =" 4" id =" ixv- 24562" unitRef =" usdPershares" > 0. 0001 < / us- gaap: SharesIssuedPricePerShare > < us- gaap: AllocatedShareBasedCompensationExpense contextRef =" c147" decimals =" - 5" id =" ixv- 24563" unitRef =" usd" > 100000 < / us- gaap: AllocatedShareBasedCompensationExpense > < us- gaap: ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef =" c0" id =" ixv- 15465" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The following table summarizes the RSA activity for the period from February & # 160; 6, 2024 (inception) through December 31, 2024: & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Number of & lt; br / & gt; RSAs & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Weighted & lt; br / & gt; Average & lt; br / & gt; Grant Date & lt; br / & gt; Fair Value & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Unvested balance as of February 6, 2024 (inception) & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 220; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 221; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" width: 76 %; padding- bottom: 1. 5pt; padding- left: 13. 7pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Granted & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 2, 207, 553 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; padding- bottom: 1. 5pt; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 222; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Unvested balance as of December 31, 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 2, 207, 553 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 223; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef =" c147" decimals =" INF" id =" ixv- 24564" unitRef =" shares" > 2207553 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef =" c133" decimals =" INF" id =" ixv- 24565" unitRef =" shares" > 2207553 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber > < orka: ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum contextRef =" c148" decimals =" 4" id =" ixv- 24566" unitRef =" pure" > 0. 01 < / orka: ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum > < orka: EstimatedFairValueOfWarrantsToBeGranted contextRef =" c3" decimals =" - 5" id =" ixv- 24567" unitRef =" usd" > 10400000 < / orka: EstimatedFairValueOfWarrantsToBeGranted > < us- gaap: AllocatedShareBasedCompensationExpense contextRef =" c148" decimals =" - 5" id =" ixv- 24568" unitRef =" usd" > 10400000 < / us- gaap: AllocatedShareBasedCompensationExpense > < orka: ClassOfWarrantOrRight contextRef =" c120" decimals =" INF" id =" ixv- 24569" unitRef =" shares" > 3054358 < / orka: ClassOfWarrantOrRight > < us- gaap: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef =" c119" decimals =" 2" id =" ixv- 24570" unitRef =" usdPershares" > 7. 8 < / us- gaap: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 > < orka: ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock contextRef =" c0" id =" ixv- 15574" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The following table summarizes the warrant activity for the period from February & # 160; 6, 2024 (inception) through December 31, 2024: & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" border- bottom: Black 1. 5pt solid; font- weight: bold; text- align: center" & gt; Number of & lt; br / & gt; Employee & lt; br / & gt; Warrants & lt; br / & gt; Outstanding & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Weighted & lt; br / & gt; Average & lt; br / & gt; Exercise & lt; br / & gt; Price Per & lt; br / & gt; Share & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Weighted & lt; br / & gt; Average & lt; br / & gt; Remaining & lt; br / & gt; Contractual & lt; br / & gt; Term & lt; br / & gt; (in Years) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Aggregate & lt; br / & gt; Intrinsic & lt; br / & gt; Value & lt; br / & gt; (in & # 160; Thousands) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Balance as of February 6, 2024 (inception) & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt;

span style ="- sec- ix- hidden: hidden- fact- 224; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 225; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 226; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; width: 52 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Granted & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3, 054, 358 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 7. 80 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 125in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Exercised & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 227; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 228; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Forfeited & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 229; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 230; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Balance as of December 31, 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3, 054, 358 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 7. 80 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 9. 5 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 35, 400 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Vested and expected to vest, December 31, 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3, 054, 358 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 7. 80 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 9. 5 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 35, 400 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Exercisable, December 31, 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 231; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 232; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" - sec- ix- hidden: hidden- fact- 233; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / orka: ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef =" c152" decimals =" INF" id =" ixv- 24571" unitRef =" shares" > 3054358 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod > < orka: ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice contextRef =" c152" decimals =" 2" id =" ixv- 24572" unitRef =" usdPershares" > 7. 8 < / orka: ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef =" c119" decimals =" INF" id =" ixv- 24573" unitRef =" shares" > 3054358 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber > < orka: ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice contextRef =" c119" decimals =" 2" id =" ixv- 24574" unitRef =" usdPershares" > 7. 8 < / orka: ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice > < orka: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm contextRef =" c152" id =" ixv- 15785" > P9Y6M < / orka: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm > < us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef =" c119" decimals =" - 3" id =" ixv- 24575" unitRef =" usd" > 35400000 < / us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding > < orka: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber contextRef =" c119" decimals =" INF" id =" ixv- 24576" unitRef =" shares" > 3054358 < / orka: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber > < orka: ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice contextRef =" c119" decimals =" 2" id =" ixv- 24577" unitRef =" usdPershares" > 7. 8 < / orka: ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice > < orka: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm contextRef =" c152" id =" ixv- 15821" > P9Y6M < / orka: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm > < orka: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest contextRef =" c119" decimals =" - 3" id =" ixv- 24578" unitRef =" usd" > 35400000 < / orka: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef =" c120" decimals =" 2" id =" ixv- 24579" unitRef =" usdPershares" > 6. 27 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue > < us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef =" c120" id =" ixv- 15918" > P6Y1M6D < / us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef =" c120" decimals =" 4" id =" ixv- 24580" unitRef =" pure" > 0. 9902 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef =" c120" decimals =" 4" id =" ixv- 24581" unitRef =" pure" > 0. 0415 < / us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate > < us- gaap: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef =" c0" id =" ixv- 15965" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The following table summarizes the classification of the Company & # x2019; s stock- based compensation expense in the consolidated statement of operations and comprehensive loss (in thousands): & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Period from & lt; br / & gt; February 6, & lt; br / & gt; 2024 & lt; br / & gt; (Inception) to & lt; br / & gt; December 31, & lt; br / & gt; 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Research and development & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 11, 992 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; General and administrative & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 2, 927 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 2. 5pt; padding- left: 13. 7pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 14, 919 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock > < us- gaap: AllocatedShareBasedCompensationExpense contextRef =" c13" decimals =" - 3" id =" ixv- 24582" unitRef =" usd" > 11992000 < / us- gaap: AllocatedShareBasedCompensationExpense > < us- gaap: AllocatedShareBasedCompensationExpense contextRef =" c14" decimals =" - 3" id =" ixv- 24583" unitRef =" usd" > 2927000 < / us- gaap: AllocatedShareBasedCompensationExpense > < us- gaap: AllocatedShareBasedCompensationExpense contextRef =" c0" decimals =" - 3" id =" ixv- 24584" unitRef =" usd" > 14919000 < / us- gaap: AllocatedShareBasedCompensationExpense > < us- gaap: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef =" c136" decimals =" - 5" id =" ixv- 24585" unitRef =" usd" > 12700000 < / us- gaap: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized > < us- gaap: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef =" c146" id =" ixv- 24586" > P3Y2M12D < / us- gaap: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 > < us- gaap: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef =" c133" decimals =" - 5" id =" ixv- 24587" unitRef =" usd" > 100000 < / us- gaap: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized > < us- gaap: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef =" c147" id =" ixv- 24588" > P3Y1M6D < / us- gaap: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 > < us- gaap: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef =" c119" decimals =" - 5" id =" ixv- 24589" unitRef =" usd" > 16300000 < / us- gaap: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized > < us- gaap: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef =" c120" id =" ixv- 24590" > P3Y3M18D < / us- gaap: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 > < us- gaap: ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef =" c0" id =" ixv- 16024" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The following table summarizes the award types of the Company & # x2019; s stock- based compensation expense in the consolidated statement of operations and comprehensive loss (in thousands): & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Period from & lt; br / & gt; February 6, & lt; br / & gt; 2024 & lt; br / & gt; (Inception) to & lt; br / & gt; December 31, & lt; br / & gt; 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Paruka Warrant Obligation & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 10, 357 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Employee warrants & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 2, 899 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Stock options & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 1, 626 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family:

Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Employee stock purchase plan & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 37 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 2. 5pt; padding- left: 0. 125in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 14, 919 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock > < us- gaap: AllocatedShareBasedCompensationExpense contextRef =" c153" decimals ="- 3" id =" ixv- 24591" unitRef =" usd" > 10357000 < / us- gaap: AllocatedShareBasedCompensationExpense > < us- gaap: AllocatedShareBasedCompensationExpense contextRef =" c154" decimals ="- 3" id =" ixv- 24592" unitRef =" usd" > 2899000 < / us- gaap: AllocatedShareBasedCompensationExpense > < us- gaap: AllocatedShareBasedCompensationExpense contextRef =" c155" decimals ="- 3" id =" ixv- 24593" unitRef =" usd" > 1626000 < / us- gaap: AllocatedShareBasedCompensationExpense > < us- gaap: AllocatedShareBasedCompensationExpense contextRef =" c156" decimals ="- 3" id =" ixv- 24594" unitRef =" usd" > 37000 < / us- gaap: AllocatedShareBasedCompensationExpense > < us- gaap: AllocatedShareBasedCompensationExpense contextRef =" c0" decimals ="- 3" id =" ixv- 24595" unitRef =" usd" > 14919000 < / us- gaap: AllocatedShareBasedCompensationExpense > < us- gaap: SegmentReportingDisclosureTextBlock contextRef =" c0" id =" ixv- 16118" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; 10. Segment disclosures & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company operates and manages its business activities on a consolidated basis and operates in one reportable segment. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; The Company operates as a single reportable and operating segment. Its Chief Executive Officer, serving as the Chief Operating Decision Maker (& # x201c; CODM & # x201d;), oversees operations on an aggregated basis to allocate resources effectively. In assessing the Company & # x2019; s financial performance, the CODM regularly reviews total operating expenses and consolidated net loss. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in; background- color: white" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in; background- color: white" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The measure of segment assets is reported on the balance sheet as total consolidated assets. The Company & # x2019; s long- lived assets consist primarily of property and equipment, net. As of December & # 160; 31, 2024 all of long- lived assets were in the U. S. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in; background- color: white" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The table below is a summary of the segment loss from operations, including significant segment expenses (in thousands): & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in; background- color: white" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Period from & lt; br / & gt; February 6, & lt; br / & gt; 2024 & lt; br / & gt; (Inception) to December & # 160; 31, & lt; br / & gt; 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Research and development personnel- related (excluding stock- based compensation) & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3, 959 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; General and administrative personnel- related (excluding stock- based compensation) & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 5, 054 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Research and development stock- based compensation & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 11, 992 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; General and administrative stock- based compensation & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 2, 927 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; External research and development & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 57, 680 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; Other research and development & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1, 429 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; General and administrative, excluding personnel- related and stock- based compensation & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 5, 082 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt; padding- left: 0. 125in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total operating expenses & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 88, 123 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 4pt; padding- left: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Loss from operations & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (88, 123 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: SegmentReportingDisclosureTextBlock > < us- gaap: NumberOfOperatingSegments contextRef =" c0" decimals =" 0" id =" ixv- 24596" unitRef =" pure" > 1 < / us- gaap: NumberOfOperatingSegments > < us- gaap: NumberOfReportableSegments contextRef =" c0" decimals =" 0" id =" ixv- 24597" unitRef =" pure" > 1 < / us- gaap: NumberOfReportableSegments > < us- gaap: ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef =" c0" id =" ixv- 16135" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in; background- color: white" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The table below is a summary of the segment loss from operations, including significant segment expenses (in thousands): & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in; background- color: white" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Period from & lt; br / & gt; February 6, & lt; br / & gt; 2024 & lt; br / & gt; (Inception) to December & # 160; 31, & lt; br / & gt; 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Research and development personnel- related (excluding stock- based compensation) & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3, 959 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; General and administrative personnel- related (excluding stock- based compensation) & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span

& gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 5, 054 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Research and development stock- based compensation & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 11, 992 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; General and administrative stock- based compensation & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 2, 927 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; External research and development & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 57, 680 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; Other research and development & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1, 429 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; General and administrative, excluding personnel- related and stock- based compensation & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 5, 082 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt; padding- left: 0. 125in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total operating expenses & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 88, 123 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 4pt; padding- left: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Loss from operations & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (88, 123 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock > < us- gaap: ResearchAndDevelopmentExpense contextRef =" c157" decimals ="- 3" id =" ixv- 24598" unitRef =" usd" > 3959000 < / us- gaap: ResearchAndDevelopmentExpense > < us- gaap: GeneralAndAdministrativeExpense contextRef =" c157" decimals ="- 3" id =" ixv- 24599" unitRef =" usd" > 5054000 < / us- gaap: GeneralAndAdministrativeExpense > < us- gaap: ResearchAndDevelopmentExpense contextRef =" c13" decimals ="- 3" id =" ixv- 24600" unitRef =" usd" > 11992000 < / us- gaap: ResearchAndDevelopmentExpense > < us- gaap: ResearchAndDevelopmentExpense contextRef =" c14" decimals ="- 3" id =" ixv- 24601" unitRef =" usd" > 2927000 < / us- gaap: ResearchAndDevelopmentExpense > < us- gaap: ResearchAndDevelopmentExpense contextRef =" c158" decimals ="- 3" id =" ixv- 24602" unitRef =" usd" > 57680000 < / us- gaap: ResearchAndDevelopmentExpense > < us- gaap: ResearchAndDevelopmentExpense contextRef =" c159" decimals ="- 3" id =" ixv- 24603" unitRef =" usd" > 1429000 < / us- gaap: ResearchAndDevelopmentExpense > < us- gaap: GeneralAndAdministrativeExpense contextRef =" c160" decimals ="- 3" id =" ixv- 24604" unitRef =" usd" > 5082000 < / us- gaap: GeneralAndAdministrativeExpense > < us- gaap: OperatingExpenses contextRef =" c0" decimals ="- 3" id =" ixv- 24605" unitRef =" usd" > 88123000 < / us- gaap: OperatingExpenses > < us- gaap: OperatingIncomeLoss contextRef =" c0" decimals ="- 3" id =" ixv- 24606" unitRef =" usd" >- 88123000 < / us- gaap: OperatingIncomeLoss > < us- gaap: IncomeTaxDisclosureTextBlock contextRef =" c0" id =" ixv- 16253" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; 11. Income Taxes & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 238" & gt; No & lt; / span & gt; provision for income taxes was recorded for the period from February & # 160; 6, 2024 (inception) to December 31, 2024. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The following table summarizes the loss before income tax expense by jurisdiction for the periods indicated: & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Period from & lt; br / & gt; February 6, & lt; br / & gt; 2024 & lt; br / & gt; (Inception) to & lt; br / & gt; December 31, & lt; br / & gt; 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Domestic & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; (& lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 83, 724 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt;) & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Foreign & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 234; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 2. 5pt; padding- left: 0. 125in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Loss before income tax expense & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; (& lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 83, 724 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt;) & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; For the period from February 6, 2024 (inception) to December & # 160; 31, 2024, the Company recognized & # 160; no & # 160; provision or benefit from income taxes. The difference between the Company & # x2019; s provision for income taxes and the amounts computed by applying the statutory federal income tax rate to income before income taxes is as follows: & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & # 160; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; Period from & lt; br / & gt; February 6, & lt; br / & gt; 2024 & lt; br / & gt; (Inception) & # 160; to & lt; br / & gt; December & # 160; 31, & lt; br / & gt; 2024 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; Tax benefit derived by applying the federal statutory rate to income before income taxes & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; (21. 00 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt;) % & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; Permanent differences & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; (0. 18 & lt; / td & gt; & lt; td style =" text- align: left" & gt;) & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; Research and development credits & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; (3. 41 & lt; / td & gt; & lt; td style =" text- align: left" & gt;) & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; Other & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; (0. 87 & lt; / td & gt; & lt; td style =" text- align: left" & gt;) & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; Change in the valuation allowance & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 25. 46 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 4pt; padding- left: 9pt" & gt; Income tax (benefit) expense & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 0. 00 & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; % & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The components of the deferred tax assets and liabilities consist of the following (in thousands): & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & # 160; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; December & # 160; 31, & lt; br / & gt; 2024 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; Deferred tax assets & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left; padding- left: 9pt" & gt; Net operating loss carryforwards & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 2, 260 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- left: 9pt" & gt; Research and development credits & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 3, 080 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- left: 9pt" & gt; Stock- based compensation & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 3, 063 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- left: 9pt" & gt; Accruals and other & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 424 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- left: 9pt" & gt; Lease liability & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 203 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 9pt" & gt; Intangibles & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1, 477 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt; padding- left: 9pt" & gt; Capitalized R & amp; amp; D expenses & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 10, 994 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- left: 0. 25in" & gt; Total deferred tax assets & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 21, 501 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; Deferred tax liabilities & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt; padding- left: 9pt" & gt; Right- of- use asset & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; (184 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt;) & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- left: 0. 25in" & gt; Total deferred tax liabilities & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; (184 & lt; / td & gt; & lt; td style =" text- align: left" & gt;) & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; Less valuation allowance & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; (21, 317 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt;) & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 4pt" & gt; Deferred tax assets, net & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 235" & gt; & # x2014; & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 18pt" & gt; The Company has established a full federal and state valuation allowance equal to the net deferred tax assets due to uncertainties regarding the realization of the deferred tax asset based on the Company & # x2019; s lack of earnings history. The valuation allowance increased by $ 21. 3 & # 160; million primarily due to continuing loss from operations. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & # 160; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; December & # 160; 31, & lt; br / & gt; 2024 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td & gt; Beginning balance as of February 6, 2024 & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 236" & gt; & # x2014; & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" width: 88 %; text- align: left; padding- bottom: 1. 5pt" & gt; Change in valuation allowance & lt; / td & gt; & lt; td style =" width: 1 %; padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 9 %; border- bottom: Black 1. 5pt solid; text- align: right" & gt; 21, 317 & lt; / td & gt; & lt; td style =" width: 1 %; padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt; padding- left: 9pt" & gt; Ending balance as of December 31, 2024 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 21, 317 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; As of December & # 160; 31, 2024, the Company had U. S. net operating loss carryforwards (& # x201c; NOL & # x201d;) of $ 10. 8 & # 160; million. The federal NOL carryforwards do not expire and can be utilized to offset up to 80 % of the taxable income in any tax year. For the period from February 6, 2024 (inception) to December & # 160; 31, 2024 the Company had federal tax credit carryforwards and state tax credit carryforwards of $ 3. 8 & # 160; million and $ 0. 4 & # 160; million, respectively. The federal credits will expire starting in 2044 if not utilized, and the state research credit can be carried forward indefinitely. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif; font- size: 10pt" & gt; The Tax Reform Act of 1986 limits the use of net operating loss carryforwards in certain situations where changes occur in the stock ownership of a company. The annual limitation may result in the expiration of net operating losses and credits before utilization. The Company has not performed a Section 382 analysis through December 31, 2024. To the extent that an assessment is completed in the future, the Company & # x2019; s ability to utilize tax attributes could be restricted on a year- by- year basis and certain attributes could expire before they are utilized. The Company will examine the impact of any potential ownership changes in the future. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands): & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Period from & lt; br / & gt; February 6, & lt; br / & gt; 2024 & lt; br / & gt; (Inception) to & lt; br / & gt; December 31, & lt; br / & gt; 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Beginning balance as of February 6, 2024 & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 237; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" width: 88 %; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Changes related to tax positions taken in the current year & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 1, 047 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 2. 5pt; padding- left: 0. 125in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Ending balance as of December 31, 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 1, 047 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" text- align: justify; text- indent: 0. 25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company includes penalties and interest expense related to income taxes as a component of income tax expense, as necessary. As of December 31, 2024, the Company had & # 160; no & # 160; accrued interest or penalties related to uncertain tax positions. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company will be filing initial year income tax returns in the United States federal jurisdiction and state jurisdictions. Due to net operating loss carryforwards, the statute of limitations will remain open for income tax examination. & lt; / span & gt; & lt; / p & gt; < / us- gaap: IncomeTaxDisclosureTextBlock > < us- gaap: ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef =" c0" id =" ixv- 16264" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The following table summarizes the loss before income tax expense by jurisdiction for the periods indicated: & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p &

gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Period from & lt; br / & gt; February 6, & lt; br / & gt; 2024 & lt; br / & gt; (Inception) to & lt; br / & gt; December 31, & lt; br / & gt; 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Domestic & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; (& lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 83, 724 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt;) & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Foreign & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 234; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 2. 5pt; padding- left: 0. 125in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Loss before income tax expense & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; (& lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 83, 724 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt;) & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock > < us- gaap: IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef =" c0" decimals ="- 3" id =" ixv- 24607" unitRef =" usd" >- 83724000 < / us- gaap: IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic > < us- gaap: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef =" c0" decimals ="- 3" id =" ixv- 24608" unitRef =" usd" >- 83724000 < / us- gaap: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest > < us- gaap: ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef =" c0" id =" ixv- 24609" > The difference between the Company & # x2019; s provision for income taxes and the amounts computed by applying the statutory federal income tax rate to income before income taxes is as follows: & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & # 160; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; Period from & lt; br / & gt; February 6, & lt; br / & gt; 2024 & lt; br / & gt; (Inception) & # 160; to & lt; br / & gt; December & # 160; 31, & lt; br / & gt; 2024 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; Tax benefit derived by applying the federal statutory rate to income before income taxes & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; (21. 00 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt;) % & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; Permanent differences & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; (0. 18 & lt; / td & gt; & lt; td style =" text- align: left" & gt;) & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; Research and development credits & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; (3. 41 & lt; / td & gt; & lt; td style =" text- align: left" & gt;) & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td & gt; Other & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; (0. 87 & lt; / td & gt; & lt; td style =" text- align: left" & gt;) & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; Change in the valuation allowance & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 25. 46 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 4pt; padding- left: 9pt" & gt; Income tax (benefit) expense & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 0. 00 & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; % & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock > < us- gaap: EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef =" c0" decimals =" 4" id =" ixv- 24610" unitRef =" pure" > 0. 21 < / us- gaap: EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate > < us- gaap: EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef =" c0" decimals =" 4" id =" ixv- 24611" unitRef =" pure" > 0. 0018 < / us- gaap: EffectiveIncomeTaxRateReconciliationOtherAdjustments > < us- gaap: EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef =" c0" decimals =" 4" id =" ixv- 24612" unitRef =" pure" >- 0. 0341 < / us- gaap: EffectiveIncomeTaxRateReconciliationTaxCreditsResearch > < us- gaap: EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef =" c0" decimals =" 4" id =" ixv- 24613" unitRef =" pure" > 0. 0087 < / us- gaap: EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent > < us- gaap: EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef =" c0" decimals =" 4" id =" ixv- 24614" unitRef =" pure" >- 0. 2546 < / us- gaap: EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance > < us- gaap: EffectiveIncomeTaxRateContinuingOperations contextRef =" c0" decimals =" 4" id =" ixv- 24615" unitRef =" pure" > 0 < / us- gaap: EffectiveIncomeTaxRateContinuingOperations > < us- gaap: ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef =" c0" id =" ixv- 16391" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The components of the deferred tax assets and liabilities consist of the following (in thousands): & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & # 160; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; December & # 160; 31, & lt; br / & gt; 2024 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; Deferred tax assets & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left; padding- left: 9pt" & gt; Net operating loss carryforwards & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; 2, 260 & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- left: 9pt" & gt; Research and development credits & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 3, 080 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- left: 9pt" & gt; Stock- based compensation & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 3, 063 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- left: 9pt" & gt; Accruals and other & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 424 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- left: 9pt" & gt; Lease liability & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 203 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 9pt" & gt; Intangibles & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 1, 477 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt; padding- left: 9pt" & gt; Capitalized R & amp; amp; D expenses & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; 10, 994 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- left: 0. 25in" & gt; Total deferred tax assets & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; 21, 501 & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; Deferred tax liabilities & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt; padding- left: 9pt" & gt; Right- of- use asset & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; (184 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt;) & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- left: 0. 25in" & gt; Total deferred tax liabilities & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: right" & gt; (184 & lt; / td & gt; & lt; td style =" text- align: left" & gt;) & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; Less valuation allowance & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; (21, 317 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt;) & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 4pt" & gt; Deferred tax assets, net & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 235" & gt; & # x2014; & lt; / div & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock > < us- gaap: DeferredTaxAssetsOperatingLossCarryforwards contextRef =" c3" decimals ="- 3" id =" ixv- 24616" unitRef =" usd" > 2260000 < / us- gaap: DeferredTaxAssetsOperatingLossCarryforwards > < us- gaap: DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef =" c3" decimals ="- 3" id =" ixv- 24617" unitRef =" usd" > 3080000 < / us- gaap: DeferredTaxAssetsTaxCreditCarryforwardsResearch > < us- gaap: DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef =" c3" decimals ="- 3" id =" ixv- 24618" unitRef =" usd" > 3063000 < / us- gaap: DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost > < us- gaap: DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther contextRef =" c3" decimals ="- 3" id =" ixv- 24619" unitRef =" usd" > 424000 < / us- gaap: DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther > < orka: DeferredTaxAssetsLeaseLiabilities contextRef =" c3" decimals ="- 3" id =" ixv- 24620" unitRef =" usd" > 203000 < / orka: DeferredTaxAssetsLeaseLiabilities > < us- gaap: DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef =" c3" decimals ="- 3" id =" ixv- 24621" unitRef =" usd" > 1477000 < / us- gaap: DeferredTaxAssetsGoodwillAndIntangibleAssets > < us- gaap: DeferredTaxAssetsInProcessResearchAndDevelopment contextRef =" c3" decimals ="- 3" id =" ixv- 24622" unitRef =" usd" > 10994000 < / us- gaap: DeferredTaxAssetsInProcessResearchAndDevelopment > < us- gaap: DeferredTaxAssetsGross contextRef =" c3" decimals ="- 3" id =" ixv- 24623" unitRef =" usd" > 21501000 < / us- gaap: DeferredTaxAssetsGross > < orka: DeferredTaxLiabilitiesRightOfUseAsset contextRef =" c3" decimals ="- 3" id =" ixv- 24624" unitRef =" usd" > 184000 < / orka: DeferredTaxLiabilitiesRightOfUseAsset > < us- gaap: DeferredIncomeTaxLiabilities contextRef =" c3" decimals ="- 3" id =" ixv- 24625" unitRef =" usd" > 184000 < / us- gaap: DeferredIncomeTaxLiabilities > < us- gaap: DeferredTaxAssetsValuationAllowance contextRef =" c3" decimals ="- 3" id =" ixv- 24626" unitRef =" usd" > 21317000 < / us- gaap: DeferredTaxAssetsValuationAllowance > < us- gaap: SummaryOfValuationAllowanceTextBlock contextRef =" c0" id =" ixv- 24627" > he Company has established a full federal and state valuation allowance equal to the net deferred tax assets due to uncertainties regarding the realization of the deferred tax asset based on the Company & # x2019; s lack of earnings history. The valuation allowance increased by $ 21. 3 & # 160; million primarily due to continuing loss from operations. & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & # 160; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; December & # 160; 31, & lt; br / & gt; 2024 & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td & gt; Beginning balance as of February 6, 2024 & lt; / td & gt; & lt; td & gt; & # 160; & lt; / td & gt; & lt; td style =" text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; div style ="- sec- ix- hidden: hidden- fact- 236" & gt; & # x2014; & lt; / div & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" width: 88 %; text- align: left; padding- bottom: 1. 5pt" & gt; Change in valuation allowance & lt; / td & gt; & lt; td style =" width: 1 %; padding- bottom: 1. 5pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 1 %; border- bottom: Black 1. 5pt solid; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; td style =" width: 9 %; border- bottom: Black 1. 5pt solid; text- align: right" & gt; 21, 317 & lt; / td & gt; & lt; td style =" width: 1 %; padding- bottom: 1. 5pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt; padding- left: 9pt" & gt; Ending balance as of December 31, 2024 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & # 160; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; $ & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; 21, 317 & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & # 160; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: SummaryOfValuationAllowanceTextBlock > < us- gaap: OperatingLossCarryforwardsValuationAllowance contextRef =" c3" decimals ="- 5" id =" ixv- 24628" unitRef =" usd" > 21300000 < / us- gaap: OperatingLossCarryforwardsValuationAllowance > < us- gaap: ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef =" c0" decimals ="- 3" id =" ixv- 24629" unitRef =" usd" > 21317000 < / us- gaap: ValuationAllowanceDeferredTaxAssetChangeInAmount > < us- gaap: DeferredTaxAssetsValuationAllowance contextRef =" c3" decimals ="- 3" id =" ixv- 24630" unitRef =" usd" > 21317000 < / us- gaap: DeferredTaxAssetsValuationAllowance > < us- gaap: DeferredTaxAssetsOtherLossCarryforwards contextRef =" c3" decimals ="- 5" id =" ixv- 24631" unitRef =" usd" > 10800000 < / us- gaap: DeferredTaxAssetsOtherLossCarryforwards > < orka: OperatingLossCarryforwardsAsAPercentageOfTaxableIncome contextRef =" c3" decimals =" 2" id =" ixv- 24632" unitRef =" pure" > 0. 80 < / orka: OperatingLossCarryforwardsAsAPercentageOfTaxableIncome > < us- gaap: DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef =" c161" decimals =" -5" id =" ixv- 24633" unitRef =" usd" > 3800000 < / us- gaap: DeferredTaxAssetsTaxCreditCarryforwardsResearch > < us- gaap: DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef =" c162" decimals =" -5" id =" ixv- 24634" unitRef =" usd" > 400000 < / us- gaap: DeferredTaxAssetsTaxCreditCarryforwardsResearch > < us- gaap: ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef =" c0" id =" ixv- 16531" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands): & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Period from & lt; br / & gt; February 6, & lt; br / & gt; 2024 & lt; br / & gt; (Inception) to & lt; br / & gt; December 31, & lt; br / & gt; 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Beginning balance as of February 6, 2024 & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style ="- sec- ix- hidden: hidden- fact- 237; font- family: Times New Roman, Times, Serif" & gt; & # x2014; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" width: 88 %; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Changes related to tax positions taken in the current year & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 1, 047 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 2. 5pt; padding- left: 0. 125in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Ending balance as of December 31, 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 1, 047 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock > < us- gaap: UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef =" c0" decimals =" -3" id =" ixv- 24635" unitRef =" usd" > 1047000 < / us- gaap: UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions > < us- gaap: UnrecognizedTaxBenefits contextRef =" c3" decimals =" -3" id =" ixv- 24636" unitRef =" usd" > 1047000 < / us- gaap: UnrecognizedTaxBenefits > < orka: OptionAgreementsAndLicenseAgreementsTextBlock contextRef =" c0" id =" ixv- 16612" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; 12. Option Agreements and License Agreements & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; In March & # 160; 2024, the Company entered into two antibody discovery and option agreements (& # x201c; Option Agreements & # x201d;) with Paragon and Paruka. Under the terms of each agreement, Paragon identifies, evaluates, and develops antibodies directed against certain mutually agreed therapeutic targets of interest to the Company. From time to time, the Company can choose to add additional targets to the collaboration upon agreement with Paragon and Paruka. Under the Option Agreements, the Company has the exclusive option to, on a research program- by- research program basis, be granted an exclusive, worldwide license to all of Paragon & # x2019; s right, title, and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture, and commercialize the antibodies and products directed to the selected target (s) & # 160; (each, an & # x201c; Option & # x201d;). The Company has initiated certain research programs with Paragon that generally focus on discovering, generating, identifying and / or characterizing antibodies directed to a particular target (each, a & # x201c; Research Program & # x201d;), including for IL- 23 and IL- 17A / F for ORKA- 001 and ORKA- 002, respectively. The exclusive option with respect to each Research Program is exercisable at the Company & # x2019; s sole discretion at such time as specified in the Option Agreements (the & # x201c; Option Period & # x201d;). There is no payment due upon exercise of an Option pursuant to the Option Agreements. For each of these agreements, once the Company enters into the corresponding license agreements, it will be required to make non- refundable milestone payments to Paragon of up to $ 12. 0 million under each respective agreement upon the achievement of certain clinical development milestones, up to $ 10. 0 million under each respective agreement upon the achievement of certain regulatory milestones, as well as a low single- digit percentage royalty for antibody products beginning on the first commercial sale in each program. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company may terminate any Option Agreement or any Research Program at any time for any or no reason upon 30 & # 160; days & # x2019; prior written notice to Paragon, provided that it must pay certain unpaid fees due to Paragon upon such termination, as well as any non- cancellable obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate any Option Agreement or a Research Program immediately upon written notice to the Company if, as a result of any action or failure to act by the Company or its affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed for a certain consecutive number of & # 160; months. Each party has the right to terminate the Option Agreements or any Research Program upon material breach that remains uncured or the other party & # x2019; s bankruptcy. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; i & gt; Paragon Therapeutics & # x2013; License Agreements & lt; / i & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; i & gt; & # 160; & lt; / i & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; In September 2024, the Company exercised the Option to acquire certain rights to ORKA- 001, and in December 2024, it entered into the corresponding license agreement with Paragon (the & # x201c; ORKA- 001 License Agreement & # x201d;), pursuant to which Paragon granted the Company a royalty- bearing, world- wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting IL- 23 in all fields other than the field of inflammatory bowel disease (& # x201c; ORKA- 001 Field & # x201d;). In December 2024, the Company exercised the Option with respect to ORKA- 002 for the IL- 17A / F program, and in February 2025, it entered into the corresponding license agreement with Paragon (the & # x201c; ORKA- 002 License Agreement & # x201d; and together with the ORKA- 001 License Agreement, the & # x201c; License Agreements & # x201d;), pursuant to which Paragon granted the Company a royalty- bearing, world- wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting IL- 17A / F in all fields (& # x201c; ORKA- 002 Field & # x201d; and together with the ORKA- 001 Field, the & # x201c; Fields & # x201d;). & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The License Agreements provide the Company with exclusive licenses in the Fields to Paragon & # x2019; s patent applications covering the related antibodies, their method of use and their method of manufacture and Paragon has agreed not to conduct any new campaigns that generate anti- IL- 23 monospecific antibodies or anti- IL- 17A / F monospecific antibodies for the ORKA- 001 Field or the ORKA- 002 Field, respectively, for at least five years. Each of the ORKA- 001 and ORKA- 002 License Agreements may be terminated on 60 days & # x2019; notice to Paragon, on material breach without cure, and on a party & # x2019; s insolvency or bankruptcy to the extent permitted by law. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Pursuant to the terms of each of the ORKA- 001 and ORKA- 002 License Agreements, the Company is obligated to pay Paragon non- refundable milestone payments of up to $ 12. 0 million under each respective agreement upon the achievement of certain clinical development milestones and up to $ 10. 0 million under each respective agreement upon the achievement of certain regulatory milestones, including a $ 1. 5 million fee for nomination of a development candidate (or initiation of an IND- enabling toxicology study) and a further milestone payment of $ 2. 5 million upon the first dosing of a human patient in a Phase 1 trial for each of ORKA- 001 and ORKA- 002. In addition, the Company is obligated to pay Paragon a low single-digit percentage royalty for antibody products for each of ORKA- 001 and ORKA- 002. For each of the License Agreements, the royalty term ends on the later of (i) the last- to- expire licensed patent or our patent directed to the manufacture, use or sale of a licensed antibody in the country at issue or (ii) 12 years from the date of first sale of a Company product. There is also a royalty step- down if there is no Paragon patent in effect during the royalty term for each program. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Additionally, as part of the Option Agreements, on December & # 160; 31, 2024 the Company granted and on December & # 160; 31, 2025, will grant Paruka a warrant to purchase a number of shares equal to 1. 00 % of outstanding shares as of the date of the grant on a fully- diluted basis, with an exercise price equal to the fair market value of the underlying shares on the grant date. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Pursuant to the Option Agreements, on a research program- by- research program basis following the finalization of the research plan for each respective research program, the Company was required to pay Paragon a one- time, nonrefundable research initiation fee of $ 0. 8 & # 160; million related to the ORKA- 001 program. This amount was recognized as a research and development expense during the period from February & # 160; 6, 2024 (inception) to December 31, 2024. In June 2024, pursuant to the Option Agreements with Paragon, the Company completed the selection process of its development candidate for IL- 23 antibody for ORKA- 001 program. The Company was responsible for 50 % of the development costs incurred through the completion of the IL- 23 selection process. The Company received the rights to at least one selected IL- 23 antibody in June 2024. During the period from February 6, 2024 (inception) to December 31, 2024, the Company exercised its option for ORKA- 001 and recorded a $ 1. 5 million milestone payment related to the achievement of development candidate as research and development expense in the Company & # x2019; s consolidated statement of operations and comprehensive loss. In addition, during the period from February 6, 2024 (inception) to December 31, 2024, the Company recorded a $ 2. 5 million milestone payment related to the first dosing of a human subject in a Phase 1 trial of ORKA- 001 in December 2024 as research and development expense in its consolidated statement of operations and comprehensive loss. The Company & # x2019; s share of development costs incurred for the period from February 6, 2024 (inception) to December 31, 2024 was $ 13. 5 million (excluding research initiation fee and milestones), which were recorded as research and development expenses. An amount of $ 2. 8 million related to ORKA- 001 is included in related party accounts payable and other current liabilities as of December 31, 2024. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company was also required to reimburse Paragon $ 3. 3 & # 160; million for development costs related to ORKA- 002 incurred by Paragon through December & # 160; 31, 2023 and certain other development costs incurred by Paragon between January & # 160; 1, 2024 and March & # 160; 6, 2024 as stipulated by the Option Agreements. This amount was recognized as a research and development expense during the period from February & # 160; 6, 2024 (inception) to December 31, 2024. The Company is also responsible for the development costs incurred by Paragon from January & # 160; 1, 2024 through the completion of the IL- 17 selection process. The Company recognized an amount of $ 0. 8 & # 160; million payable to Paragon for the research initiation fee related to ORKA- 002 following the finalization of the ORKA- 002 research plan. This was recognized as research and development expenses in the period from February 6, 2024 (inception) to December 31, 2024. During the period from February 6, 2024 (inception) to December 31, 2024, the Company exercised its option for ORKA- 002 and recorded a $ 1. 5 million milestone payment related to the achievement of development candidate as research and development expense in its consolidated statement of operations and comprehensive loss. The Company accounted for development costs of $ 7. 8 million (excluding research initiation fee, milestone, and reimbursements of development costs through December 31, 2023) for the period from February 6, 2024 (inception) to December 31, 2024 as research and development expenses. An amount of $ 2. 7 million related to ORKA- 002 is included in related party accounts payable and other current liabilities as of December 31, 2024. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company expenses the service fees as the associated costs are incurred when the underlying services are rendered. Such amounts are classified within research and development expenses in the accompanying consolidated statement of operations and comprehensive loss. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Company concluded that the rights obtained under the Option Agreements represent an asset acquisition whereby the underlying assets comprise in- process research and development assets with no alternative future use. The Option Agreements did not qualify as a business combination because substantially all of the fair value of the assets acquired was concentrated in the exclusive license options, which represent a group of similar identifiable assets. The research initiation fee represents a one- time cost on a research program- by- research program basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of ongoing development cost, monthly development cost fee and additional development expenses incurred by Paragon due to work completed for selected targets prior to the effective date of the Option Agreements that is associated with services being rendered under the related Research Programs are recognized as research and development expense when incurred. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 18pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; For the period from February & # 160; 6, 2024 (inception) to December 31, 2024, the Company recognized $ 42. 0 & lt; / span & gt; & # 160; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; million of expenses in connection with services provided by Paragon and Paruka under the Option Agreements. & # 160; & lt; / span & gt; & lt; / p & gt; < / orka: OptionAgreementsAndLicenseAgreementsTextBlock > < orka: NonRefundableMilestonePayments contextRef =" c163" decimals =" - 5" id =" ixv- 24637" unitRef =" usd" > 12000000 < / orka: NonRefundableMilestonePayments > < orka: NonRefundableMilestonePayments contextRef =" c164" decimals =" - 5" id =" ixv- 24638" unitRef =" usd" > 10000000 < / orka: NonRefundableMilestonePayments > < orka: NonRefundableMilestonePayments contextRef =" c165" decimals =" - 5" id =" ixv- 24639" unitRef =" usd" > 12000000 < / orka: NonRefundableMilestonePayments > < orka: NonRefundableMilestonePayments contextRef =" c166" decimals =" - 5" id =" ixv- 24640" unitRef =" usd" > 12000000 < / orka: NonRefundableMilestonePayments > < orka: NonRefundableMilestonePayments contextRef =" c167" decimals =" - 5" id =" ixv- 24641" unitRef =" usd" > 10000000 < / orka: NonRefundableMilestonePayments > < orka: NonRefundableMilestonePayments contextRef =" c168" decimals =" - 5" id =" ixv- 24642" unitRef =" usd" > 1500000 < / orka: NonRefundableMilestonePayments > < orka: NonRefundableMilestonePayments contextRef =" c169" decimals =" - 5" id =" ixv- 24643" unitRef =" usd" > 2500000 < / orka: NonRefundableMilestonePayments > < orka: NonRefundableMilestonePayments contextRef =" c170" decimals =" - 5" id =" ixv- 24644" unitRef =" usd" > 2500000 < / orka: NonRefundableMilestonePayments > < orka: RoyaltyPayableOnProductSales contextRef =" c171" id =" ixv- 24645" > low single- digit percentage royalty for antibody products < / orka: RoyaltyPayableOnProductSales > < orka: ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum contextRef =" c172" decimals =" 4" id =" ixv- 24646" unitRef =" pure" > 0. 01 < / orka: ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum > < us- gaap: PaymentsForFees contextRef =" c173" decimals =" - 5" id =" ixv-24647" unitRef =" usd" > 800000 < / us- gaap: PaymentsForFees > < orka: DevelopmentCostsPercentage contextRef =" c174" decimals =" 2" id =" ixv- 24648" unitRef =" pure" > 0. 50 < / orka: DevelopmentCostsPercentage > < orka: MilestoneConsiderationPaid contextRef =" c175" decimals =" - 5" id =" ixv- 24649" unitRef =" usd" > 1500000 < / orka: MilestoneConsiderationPaid > < orka: MilestoneConsiderationPaid contextRef =" c176" decimals =" - 5" id =" ixv- 24650" unitRef =" usd" > 2500000 < / orka: MilestoneConsiderationPaid > < us- gaap: OtherResearchAndDevelopmentExpense contextRef =" c174" decimals =" - 5" id =" ixv- 24651" unitRef =" usd" > 13500000 < / us- gaap: OtherResearchAndDevelopmentExpense > < us- gaap: AccountsPayableOtherCurrent contextRef =" c177" decimals =" - 5" id =" ixv- 24652" unitRef =" usd" > 2800000 < / us- gaap: AccountsPayableOtherCurrent > < orka: OtherDevelopmentCost contextRef =" c178" decimals =" - 5" id =" ixv- 24653" unitRef =" usd" > 3300000 < / orka: OtherDevelopmentCost > < orka: ResearchInitialFee contextRef =" c179" decimals =" - 5" id =" ixv-24654" unitRef =" usd" > 800000 < / orka: ResearchInitialFee > < orka: MilestoneConsiderationPaid contextRef =" c180" decimals =" - 5" id =" ixv- 24655" unitRef =" usd" > 1500000 < / orka: MilestoneConsiderationPaid > < us- gaap: OtherResearchAndDevelopmentExpense contextRef =" c179" decimals =" - 5" id =" ixv- 24656" unitRef =" usd" > 7800000 < / us- gaap: OtherResearchAndDevelopmentExpense > < us- gaap: AccountsPayableOtherCurrent contextRef =" c181" decimals =" - 5" id =" ixv- 24657" unitRef =" usd" > 2700000 < / us- gaap: AccountsPayableOtherCurrent > < us- gaap: OtherExpenses contextRef =" c0" decimals =" - 5" id =" ixv- 24658" unitRef =" usd" > 42000000 < / us- gaap: OtherExpenses > < us- gaap: CommitmentsAndContingenciesDisclosureTextBlock contextRef =" c0" id =" ixv- 16700" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; 13. Commitment and Contingencies & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; Leases & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; In April 2024, the Company entered into an operating lease agreement for the Company & # x2019; s headquarters in Menlo Park, California, which commenced on June 15, 2024 with an initial term of 39. 5 months. The Company leases office space under this noncancelable operating lease agreement. Lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate when measuring operating lease liabilities as discount rates were not implicit or readily determinable. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; As of December 31, 2024, the Company had $ 0. 9 million of operating lease right- of-use assets, operating lease liability, current of $ 0. 2 million, and operating lease liability, noncurrent of $ 0. 8 million on its consolidated balance sheet. As of December 31, 2024, the operating lease arrangement had a remaining lease term of 33 months and a discount rate of 17. 95 %. For the period from February 6, 2024 (inception) to December 31, 2024, the Company recorded operating and variable lease expense of $ 0. 3 million in general and administrative expenses in its consolidated statement of operations and comprehensive loss. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The following table presents the Company & # x2019; s supplemental cash flow information related to leases (in thousands): & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font-weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Period from & lt; br / & gt; February 6, & lt; br / & gt; 2024 & lt; br / & gt; (Inception) to & lt; br / & gt; December 31, & lt; br / & gt; 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Cash paid for amounts included in the measurement of lease liabilities & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 116 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" &

gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The following table summarizes a maturity analysis of the Company & # x2019; s operating lease liabilities showing the aggregate lease payments as of December 31, 2024 (in thousands): & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" font- weight: bold; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; Year ending December 31, & lt; / b & gt; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Amount & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 2025 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 369 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 2026 & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 494 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 2027 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 380 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total undiscounted lease payments & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 1, 243 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Less: imputed interest & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (275 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total discounted lease payments & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 968 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Less: current portion of lease liability & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (213 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 375in; text- align: left; padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Non- current portion of lease liability & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 755 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; Cell Line License Agreement & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; & # 160; & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; In March 2024, the Company entered into the Cell Line License Agreement (the & # x201c; Cell Line License Agreement & # x201d;) with WuXi Biologics Ireland Limited (& # x201c; WuXi Biologics & # x201d;). Under the Cell Line License Agreement, the Company received a non- exclusive, worldwide, sublicensable license to certain of WuXi Biologics & # x2019; know- how, cell line, biological materials (the & # x201c; WuXi Biologics Licensed Technology & # x201d;) and media and feeds to make, have made, use, sell and import certain therapeutic products produced through the use of the cell line licensed by WuXi Biologics under the Cell Line License Agreement (the & # x201c; WuXi Biologics Licensed Products & # x201d;). Specifically, the WuXi Biologics Licensed Technology is used in certain manufacturing activities in support of the ORKA- 001 and ORKA- 002 programs. & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; In consideration for the license, the Company agreed to pay WuXi Biologics a non- refundable license fee of $ 150, 000, which was recognized as a research and development expense during the period from February & # 160; 6, 2024 (inception) to December 31, 2024. Additionally, to the extent that the Company manufactures its commercial supplies of bulk drug product with a manufacturer other than WuXi Biologics or its affiliates, the Company is required to make royalty payments to WuXi Biologics at a rate of less than one percent of net sales of WuXi Biologics Licensed Products manufactured by the third- party manufacturer. Pursuant to an amendment to the Cell Line License Agreement effective in November 2024, a provision was added that permits the royalties owed under the agreement to be bought out on a & # 160; product- by- product & # 160; basis for a & # 160; lump- sum & # 160; payment. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The Cell Line License Agreement will continue indefinitely unless terminated (i) by the Company upon six months & # x2019; prior written notice and its payment of all undisputed amounts due to WuXi Biologics through the effective date of termination, (ii) by WuXi Biologics for a material breach by the Company that remains uncured for 60 days after written notice, (iii) by WuXi Biologics if the Company fails to make a payment and such failure continues for 30 days after receiving notice of such failure, or (iv) by either party upon the other party & # x2019; s bankruptcy. & lt; / span & gt; & lt; / p & gt; < / us- gaap: CommitmentsAndContingenciesDisclosureTextBlock > < us- gaap: LesseeOperatingLeaseTermOfContract contextRef =" c182" id =" ixv- 24659" > P39M15D < / us- gaap: LesseeOperatingLeaseTermOfContract > < us- gaap: OperatingLeaseRightOfUseAsset contextRef =" c3" decimals ="- 5" id =" ixv- 24660" unitRef =" usd" > 900000 < / us- gaap: OperatingLeaseRightOfUseAsset > < us- gaap: OperatingLeaseLiabilityCurrent contextRef =" c3" decimals ="- 5" id =" ixv- 24661" unitRef =" usd" > 200000 < / us- gaap: OperatingLeaseLiabilityCurrent > < us- gaap: OperatingLeaseLiabilityNoncurrent contextRef =" c3" decimals ="- 5" id =" ixv- 24662" unitRef =" usd" > 800000 < / us- gaap: OperatingLeaseLiabilityNoncurrent > < us- gaap: OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef =" c183" id =" ixv- 24663" > P33M < / us- gaap: OperatingLeaseWeightedAverageRemainingLeaseTerm1 > < us- gaap: LesseeOperatingLeaseDiscountRate contextRef =" c3" decimals =" 4" id =" ixv- 24664" unitRef =" pure" > 0. 1795 < / us- gaap: LesseeOperatingLeaseDiscountRate > < us- gaap: OperatingLeaseVariableLeaseIncome contextRef =" c0" decimals ="- 5" id =" ixv- 24665" unitRef =" usd" > 300000 < / us- gaap: OperatingLeaseVariableLeaseIncome > < us- gaap: ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef =" c0" id =" ixv- 16721" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The following table presents the Company & # x2019; s supplemental cash flow information related to leases (in thousands): & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Period from & lt; br / & gt; February 6, & lt; br / & gt; 2024 & lt; br / & gt; (Inception) to & lt; br / & gt; December 31, & lt; br / & gt; 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Cash paid for amounts included in the measurement of lease liabilities & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 116 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock > < us- gaap: OperatingLeasePayments contextRef =" c0" decimals ="- 3" id =" ixv- 24666" unitRef =" usd" > 116000 < / us- gaap: OperatingLeasePayments > < us- gaap: LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef =" c0" id =" ixv- 16754" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The following table summarizes a maturity analysis of the Company & # x2019; s operating lease liabilities showing the aggregate lease payments as of December 31, 2024 (in thousands): & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" font- weight: bold; border- bottom: Black 1. 5pt solid"

& gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; Year ending December 31, & lt; / b & gt; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Amount & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 2025 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 369 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 2026 & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 494 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 2027 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 380 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total undiscounted lease payments & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 1, 243 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Less: imputed interest & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (275 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 125in; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total discounted lease payments & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 968 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- left: 0. 25in; text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Less: current portion of lease liability & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (213 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" padding- left: 0. 375in; text- align: left; padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Non- current portion of lease liability & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 755 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: LesseeOperatingLeaseLiabilityMaturityTableTextBlock > < us- gaap: LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef =" c3" decimals ="- 3" id =" ixv- 24667" unitRef =" usd" > 369000 < / us- gaap: LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths > < us- gaap: LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef =" c3" decimals =" - 3" id =" ixv- 24668" unitRef =" usd" > 494000 < / us- gaap: LesseeOperatingLeaseLiabilityPaymentsDueYearTwo > < us- gaap: LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef =" c3" decimals =" - 3" id =" ixv- 24669" unitRef =" usd" > 380000 < / us- gaap: LesseeOperatingLeaseLiabilityPaymentsDueYearThree > < us- gaap: LesseeOperatingLeaseLiabilityPaymentsDue contextRef =" c3" decimals =" - 3" id =" ixv- 24670" unitRef =" usd" > 1243000 < / us- gaap: LesseeOperatingLeaseLiabilityPaymentsDue > < us- gaap: LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef =" c3" decimals =" - 3" id =" ixv- 24671" unitRef =" usd" > 275000 < / us- gaap: LesseeOperatingLeaseLiabilityUndiscountedExcessAmount > < us- gaap: OperatingLeaseLiability contextRef =" c3" decimals =" - 3" id =" ixv- 24672" unitRef =" usd" > 968000 < / us- gaap: OperatingLeaseLiability > < us- gaap: OperatingLeaseLiabilityCurrent contextRef =" c3" decimals =" - 3" id =" ixv- 24673" unitRef =" usd" > 213000 < / us- gaap: OperatingLeaseLiabilityCurrent > < us- gaap: OperatingLeaseLiabilityNoncurrent contextRef =" c3" decimals =" - 3" id =" ixv- 24674" unitRef =" usd" > 755000 < / us- gaap: OperatingLeaseLiabilityNoncurrent > < orka: NonRefundableLicenseFee contextRef =" c0" decimals =" 0" id =" ixv- 24675" unitRef =" usd" > 150000 < / orka: NonRefundableLicenseFee > < us- gaap: EarningsPerShareTextBlock contextRef =" c0" id =" ixv- 16894" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; 14. Net Loss per Share & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Basic and diluted net loss per share attributable to stockholders were calculated as follows (in thousands, except share and per share data): & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 10" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Period from February 6, 2024 & lt; br / & gt; (Inception) to & lt; br / & gt; December 31, 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" font- weight: bold; text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Loss & lt; br / & gt; Allocation & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Weighted & lt; br / & gt; Average & lt; br / & gt; Shares & lt; br / & gt; Outstanding & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Loss Per & lt; br / & gt; Share, & lt; br / & gt; Basic and & lt; br / & gt; Diluted & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 64 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Common Stock & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (65, 037 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 16, 789, 362 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (3. 87 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Company Series A Preferred Stock & lt; sup & gt; (1) & lt; / sup & gt; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (1, 918 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 495 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (3, 873. 25 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Company Series B Preferred Stock & lt; sup & gt; (2) & lt; / sup & gt; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt;

& lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (16, 769 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 51, 946 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (322. 81 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 2. 5pt; padding- left: 0. 125in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Net loss & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (83, 724 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; table cellpadding =" 0" style =" width: 100 %; font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; border- spacing: 0px;" & gt; & lt; tr style =" font- family: Times New Roman, Times, Serif; vertical- align: top" & gt; & lt; td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (1) & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- family: Times New Roman, Times, Serif; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The weighted- average number of shares of as- converted Company Series A Preferred Stock used in the loss allocation was 495, 191 for the period from February 6, 2024 (inception) to December 31, 2024. & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; table cellpadding =" 0" style =" width: 100 %; font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; border- spacing: 0px;" & gt; & lt; tr style =" font- family: Times New Roman, Times, Serif; vertical- align: top" & gt; & lt; td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (2) & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- family: Times New Roman, Times, Serif; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The weighted- average number of shares of as- converted Company Series B Preferred Stock used in the loss allocation was 4, 328, 844 for the period from February 6, 2024 (inception) to December 31, 2024. & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; For the computation of basic net loss per share attributable to stockholders, the amount of weighted- average shares outstanding excludes all shares of unvested restricted common stock as such shares are not considered outstanding for accounting purposes until vested. The amount of weighted- average shares outstanding includes the pre- funded warrants as the exercise price is negligible and these warrants are fully vested and exercisable. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to stockholders for the periods presented because including them would have had an anti- dilutive effect were as follows: & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; December 31, & lt; br / & gt; 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Outstanding employee warrants to purchase common stock & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3, 054, 358 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Outstanding unvested restricted stock awards & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 2, 207, 553 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Outstanding and issued common stock options & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 1, 567, 760 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Outstanding and issued warrant to Paruka & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 596, 930 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 2. 5pt; padding- left: 13. 7pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 7, 426, 601 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: EarningsPerShareTextBlock > < us- gaap: ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef =" c0" id =" ixv- 16900" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Basic and diluted net loss per share attributable to stockholders were calculated as follows (in thousands, except share and per share data): & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 10" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Period from February 6, 2024 & lt; br / & gt; (Inception) to & lt; br / & gt; December 31, 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" font- weight: bold; text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Loss & lt; br / & gt; Allocation & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Weighted & lt; br / & gt; Average & lt; br / & gt; Shares & lt; br / & gt; Outstanding & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Loss Per & lt; br / & gt; Share, & lt; br / & gt; Basic and & lt; br / & gt; Diluted & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 64 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Common Stock & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (65, 037 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 16, 789, 362 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (3. 87 & lt; / span & gt; & lt; / td &

gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Company Series A Preferred Stock & lt; sup & gt; (1) & lt; / sup & gt; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (1, 918 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 495 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (3, 873. 25 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Company Series B Preferred Stock & lt; sup & gt; (2) & lt; / sup & gt; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (16, 769 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 51, 946 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (322. 81 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 2. 5pt; padding- left: 0. 125in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Net loss & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (83, 724 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt;) & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; table cellpadding =" 0" style =" width: 100 %; font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; border- spacing: 0px;" & gt; & lt; tr style =" font- family: Times New Roman, Times, Serif; vertical- align: top" & gt; & lt; td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (1) & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- family: Times New Roman, Times, Serif; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The weighted- average number of shares of as- converted Company Series A Preferred Stock used in the loss allocation was 495, 191 for the period from February 6, 2024 (inception) to December 31, 2024. & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; & lt; table cellpadding =" 0" style =" width: 100 %; font: 10pt Times New Roman, Times, Serif; margin- top: 0pt; margin- bottom: 0pt; border- spacing: 0px;" & gt; & lt; tr style =" font- family: Times New Roman, Times, Serif; vertical- align: top" & gt; & lt; td style =" font- family: Times New Roman, Times, Serif; width: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; (2) & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- family: Times New Roman, Times, Serif; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The weighted- average number of shares of as- converted Company Series B Preferred Stock used in the loss allocation was 4, 328, 844 for the period from February 6, 2024 (inception) to December 31, 2024. & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock > < us- gaap: NetIncomeLoss contextRef =" c29" decimals ="- 3" id =" ixv- 24676" unitRef =" usd" >- 65037000 < / us- gaap: NetIncomeLoss > < us- gaap: WeightedAverageNumberOfSharesOutstandingBasic contextRef =" c29" decimals =" INF" id =" ixv- 24677" unitRef =" shares" > 16789362 < / us- gaap: WeightedAverageNumberOfSharesOutstandingBasic > < us- gaap: WeightedAverageNumberOfDilutedSharesOutstanding contextRef =" c29" decimals =" INF" id =" ixv- 24678" unitRef =" shares" > 16789362 < / us- gaap: WeightedAverageNumberOfDilutedSharesOutstanding > < us- gaap: EarningsPerShareBasic contextRef =" c29" decimals =" 2" id =" ixv- 24679" unitRef =" usdPershares" >- 3. 87 < / us- gaap: EarningsPerShareBasic > < us- gaap: EarningsPerShareDiluted contextRef =" c29" decimals =" 2" id =" ixv- 24680" unitRef =" usdPershares" >- 3. 87 < / us- gaap: EarningsPerShareDiluted > < us- gaap: NetIncomeLoss contextRef =" c184" decimals =" - 3" id =" ix_3_fact" unitRef =" usd" >- 1918000 < / us- gaap: NetIncomeLoss > < us- gaap: WeightedAverageNumberOfSharesOutstandingBasic contextRef =" c184" decimals =" INF" id =" ix_4_fact" unitRef =" shares" > 495 < / us- gaap: WeightedAverageNumberOfSharesOutstandingBasic > < us- gaap: WeightedAverageNumberOfDilutedSharesOutstanding contextRef =" c184" decimals =" INF" id =" ix_5_fact" unitRef =" shares" > 495 < / us- gaap: WeightedAverageNumberOfDilutedSharesOutstanding > < us- gaap: EarningsPerShareBasic contextRef =" c184" decimals =" 2" id =" ixv- 24684" unitRef =" usdPershares" >- 3873. 25 < / us- gaap: EarningsPerShareBasic > < us- gaap: EarningsPerShareDiluted contextRef =" c184" decimals =" 2" id =" ixv- 24685" unitRef =" usdPershares" >- 3873. 25 < / us- gaap: EarningsPerShareDiluted > < us- gaap: NetIncomeLoss contextRef =" c47" decimals =" - 3" id =" ix_6_fact" unitRef =" usd" >- 16769000 < / us- gaap: NetIncomeLoss > < us- gaap: WeightedAverageNumberOfSharesOutstandingBasic contextRef =" c47" decimals =" INF" id =" ix_7_fact" unitRef =" shares" > 51946 < / us- gaap: WeightedAverageNumberOfSharesOutstandingBasic > < us- gaap: WeightedAverageNumberOfDilutedSharesOutstanding contextRef =" c47" decimals =" INF" id =" ix_8_fact" unitRef =" shares" > 51946 < / us- gaap: WeightedAverageNumberOfDilutedSharesOutstanding > < us- gaap: EarningsPerShareBasic contextRef =" c47" decimals =" 2" id =" ixv- 24689" unitRef =" usdPershares" >- 322. 81 < / us- gaap: EarningsPerShareBasic > < us- gaap: EarningsPerShareDiluted contextRef =" c47" decimals =" 2" id =" ixv- 24690" unitRef =" usdPershares" >- 322. 81 < / us- gaap: EarningsPerShareDiluted > < us- gaap: NetIncomeLoss contextRef =" c0" decimals =" - 3" id =" ixv- 24691" unitRef =" usd" >- 83724000 < / us- gaap: NetIncomeLoss > < us- gaap: WeightedAverageNumberOfSharesContingentlyIssuable contextRef =" c184" decimals =" INF" id =" ixv- 24692" unitRef =" shares" > 495191 < / us- gaap: WeightedAverageNumberOfSharesContingentlyIssuable > < us- gaap: WeightedAverageNumberOfSharesContingentlyIssuable contextRef =" c47" decimals =" INF" id =" ixv- 24693" unitRef =" shares" > 4328844 < / us- gaap: WeightedAverageNumberOfSharesContingentlyIssuable > < us- gaap: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef =" c0" id =" ixv- 17087" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to stockholders for the periods presented because including them would have had an anti- dilutive effect were as follows: & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; December 31, & lt; br / & gt; 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Outstanding employee warrants to purchase common stock & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 3, 054, 358 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Outstanding unvested restricted stock awards & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 2, 207, 553 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Outstanding and issued common stock options & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 1, 567, 760 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Outstanding and issued warrant to Paruka & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 596, 930 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 2. 5pt; padding- left: 13. 7pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 7, 426, 601 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 2. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock > < us- gaap: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef =" c185" decimals =" INF" id =" ixv- 24694" unitRef =" shares" > 3054358 < / us- gaap:

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount > < us- gaap: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef =" c186" decimals =" INF" id =" ixv- 24695" unitRef =" shares" > 2207553 < / us- gaap: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount > < us- gaap: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef =" c187" decimals =" INF" id =" ixv- 24696" unitRef =" shares" > 1567760 < / us- gaap: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount > < us- gaap: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef =" c188" decimals =" INF" id =" ixv- 24697" unitRef =" shares" > 596930 < / us- gaap: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount > < us- gaap: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef =" c0" decimals =" INF" id =" ixv- 24698" unitRef =" shares" > 7426601 < / us- gaap: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount > < us- gaap: RelatedPartyTransactionsDisclosureTextBlock contextRef =" c0" id =" ixv- 17163" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; 15. Related Party Transactions & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Paragon and Paruka each beneficially own less than 5 % of the Company & # x2019; s capital stock through their respective holdings of Company Common Stock. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Fairmount beneficially owns more than 5 % of the Company & # x2019; s capital, currently has one representative appointed to the Board, and beneficially owns more than 5 % of Paragon. Fairmount appointed Paragon & # x2019; s board of directors and has the contractual right to approve the appointment of any executive officers of Paragon. & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The following is a summary of related party accounts payable and other current liabilities (in thousands): & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; December 31, & lt; br / & gt; 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Paragon reimbursable Option Agreements & # x2019; fees & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 1, 482 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Paragon milestone payments for Option Agreement & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 4, 000 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Paragon reimbursable other research expenses & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 515 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Paragon reimbursable patent expenses & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 25 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt; padding- left: 0. 125in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 6, 022 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: RelatedPartyTransactionsDisclosureTextBlock > < orka: DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef =" c190" id =" ixv- 24699" > beneficially own less than 5 % < / orka: DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners > < orka: DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef =" c189" id =" ixv- 24700" > beneficially own less than 5 % < / orka: DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners > < orka: DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef =" c192" id =" ixv- 24701" > beneficially owns more than 5 % < / orka: DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners > < orka: DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef =" c191" id =" ixv- 24702" > beneficially owns more than 5 % < / orka: DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners > < us- gaap: OtherCurrentLiabilitiesTableTextBlock contextRef =" c0" id =" ixv- 17177" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; The following is a summary of related party accounts payable and other current liabilities (in thousands): & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; table cellpadding =" 0" style =" border- collapse: collapse; width: 100 %; font: 10pt Times New Roman, Times, Serif; border- spacing: 0px;" & gt; & lt; tr style =" vertical- align: bottom" & gt; & lt; td style =" text- align: center" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" font- weight: bold; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td colspan =" 2" style =" font- weight: bold; text- align: center; border- bottom: Black 1. 5pt solid" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; December 31, & lt; br / & gt; 2024 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; font- weight: bold" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" width: 88 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Paragon reimbursable Option Agreements & # x2019; fees & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 9 %; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 1, 482 & lt; / span & gt; & lt; / td & gt; & lt; td style =" width: 1 %; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Paragon milestone payments for Option Agreement & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 4, 000 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Paragon reimbursable other research expenses & lt; / span & gt; & lt; / td & gt; & lt; td & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 515 & lt; / span & gt; & lt; / td & gt; & lt; td style =" text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: White" & gt; & lt; td style =" text- align: left; padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Paragon reimbursable patent expenses & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 1. 5pt solid; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 25 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 1. 5pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; tr style =" vertical- align: bottom; background- color: rgb (204, 238, 255)" & gt; & lt; td style =" padding- bottom: 4pt; padding- left: 0. 125in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; Total & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; $ & lt; / span & gt; & lt; / td & gt; & lt; td style =" border- bottom: Black 4pt double; text- align: right" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; 6, 022 & lt; / span & gt; & lt; / td & gt; & lt; td style =" padding- bottom: 4pt; text- align: left" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / td & gt; & lt; / tr & gt; & lt; / table & gt; < / us- gaap: OtherCurrentLiabilitiesTableTextBlock > < us- gaap: AccountsPayableOtherCurrent contextRef =" c193" decimals =" - 3" id =" ixv- 24703" unitRef =" usd" > 1482000 < / us- gaap: AccountsPayableOtherCurrent > < us- gaap: AccountsPayableOtherCurrent contextRef =" c194" decimals =" - 3" id =" ixv- 24704" unitRef =" usd" > 4000000 < / us- gaap: AccountsPayableOtherCurrent > < us- gaap: AccountsPayableOtherCurrent contextRef =" c195" decimals =" - 3" id =" ixv- 24705" unitRef =" usd" > 515000 < / us- gaap: AccountsPayableOtherCurrent > < us- gaap: AccountsPayableOtherCurrent contextRef =" c196" decimals =" - 3" id =" ixv- 24706" unitRef =" usd" > 25000 < / us- gaap: AccountsPayableOtherCurrent > < us- gaap: AccountsPayableOtherCurrent contextRef =" c5" decimals =" - 3" id =" ixv- 24707" unitRef =" usd" > 6022000 < / us- gaap: AccountsPayableOtherCurrent > < us- gaap: SubsequentEventsTextBlock contextRef =" c0" id =" ixv- 17253" > & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & lt; b & gt; 16. Subsequent Events & lt; / b & gt; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; & # 160; & lt; / span & gt; & lt; / p & gt; & lt; p style =" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text- align: justify; text- indent: 0. 25in" & gt; & lt; span style =" font- family: Times New Roman, Times, Serif" & gt; In February 2025, the Company entered into a lease agreement for an office space located in Waltham, Massachusetts. The lease is for an initial period of 54 months. The Company expects to pay approximately $ 1. 6 million over the lease term. & lt; / span & gt; & lt; / p & gt; < / us- gaap: SubsequentEventsTextBlock > < us- gaap: LesseeOperatingLeaseTermOfContract contextRef =" c197" id =" ixv- 24708" > P54M < / us- gaap: LesseeOperatingLeaseTermOfContract > < us- gaap: LesseeOperatingLeaseLiabilityPaymentsDue contextRef =" c197" decimals =" - 5" id =" ixv- 24709" unitRef =" usd" > 1600000 < / us- gaap:

LesseeOperatingLeaseLiabilityPaymentsDue > < ecd: NonRule10b51ArrAdoptedFlag contextRef =" c198" id =" ixv- 24710" > false < / ecd: NonRule10b51ArrAdoptedFlag > < ecd:
Rule10b51ArrAdoptedFlag contextRef =" c198" id =" ixv- 24711" > false < / ecd: Rule10b51ArrAdoptedFlag > < ecd: NonRule10b51ArrTrmntdFlag contextRef =" c198" id =" ixv- 24712" >
false < / ecd: NonRule10b51ArrTrmntdFlag > < ecd: Rule10b51ArrTrmntdFlag contextRef =" c198" id =" ixv- 24713" > false < / ecd: Rule10b51ArrTrmntdFlag > < us- gaap:
CashAndCashEquivalentsAtCarryingValue contextRef =" c4" id =" hidden- fact- 0" unitRef =" usd" xsi: nil =" true" / > < us- gaap: MarketableSecuritiesCurrent contextRef =" c4" id ="
hidden- fact- 1" unitRef =" usd" xsi: nil =" true" / > < orka: SubscriptionReceivables contextRef =" c3" id =" hidden- fact- 2" unitRef =" usd" xsi: nil =" true" / > < us- gaap:
PrepaidExpenseAndOtherAssetsCurrent contextRef =" c4" id =" hidden- fact- 3" unitRef =" usd" xsi: nil =" true" / > < us- gaap: MarketableSecuritiesNoncurrent contextRef =" c4" id ="
hidden- fact- 4" unitRef =" usd" xsi: nil =" true" / > < us- gaap: PropertyPlantAndEquipmentNet contextRef =" c4" id =" hidden- fact- 5" unitRef =" usd" xsi: nil =" true" / > < us- gaap:
OperatingLeaseRightOfUseAsset contextRef =" c4" id =" hidden- fact- 6" unitRef =" usd" xsi: nil =" true" / > < us- gaap: OtherAssetsNoncurrent contextRef =" c4" id =" hidden- fact- 7"
unitRef =" usd" xsi: nil =" true" / > < us- gaap: AccountsPayableTradeCurrent contextRef =" c4" id =" hidden- fact- 8" unitRef =" usd" xsi: nil =" true" / > < us- gaap:
AccruedLiabilitiesAndOtherLiabilities contextRef =" c4" id =" hidden- fact- 9" unitRef =" usd" xsi: nil =" true" / > < us- gaap: OperatingLeaseLiabilityCurrent contextRef =" c4" id =" hidden-
fact- 10" unitRef =" usd" xsi: nil =" true" / > < us- gaap: AccountsPayableOtherCurrent contextRef =" c6" id =" hidden- fact- 11" unitRef =" usd" xsi: nil =" true" / > < us- gaap:
LiabilitiesCurrent contextRef =" c4" id =" hidden- fact- 12" unitRef =" usd" xsi: nil =" true" / > < us- gaap: OperatingLeaseLiabilityNoncurrent contextRef =" c4" id =" hidden- fact- 13"
unitRef =" usd" xsi: nil =" true" / > < us- gaap: Liabilities contextRef =" c4" id =" hidden- fact- 14" unitRef =" usd" xsi: nil =" true" / > < us- gaap: CommitmentsAndContingencies contextRef
=" c3" id =" hidden- fact- 15" unitRef =" usd" xsi: nil =" true" / > < us- gaap: CommitmentsAndContingencies contextRef =" c4" id =" hidden- fact- 16" unitRef =" usd" xsi: nil =" true" / > <
us- gaap: TemporaryEquityCarryingAmountAttributableToParent contextRef =" c7" id =" hidden- fact- 17" unitRef =" usd" xsi: nil =" true" / > < us- gaap:
TemporaryEquityCarryingAmountAttributableToParent contextRef =" c8" id =" hidden- fact- 18" unitRef =" usd" xsi: nil =" true" / > < us- gaap: TemporaryEquitySharesIssued contextRef ="
c7" id =" hidden- fact- 19" unitRef =" shares" xsi: nil =" true" / > < us- gaap: TemporaryEquitySharesIssued contextRef =" c8" id =" hidden- fact- 20" unitRef =" shares" xsi: nil =" true" / > <
us- gaap: TemporaryEquitySharesOutstanding contextRef =" c7" id =" hidden- fact- 21" unitRef =" shares" xsi: nil =" true" / > < us- gaap: TemporaryEquitySharesOutstanding contextRef ="
c8" id =" hidden- fact- 22" unitRef =" shares" xsi: nil =" true" / > < us- gaap: TemporaryEquitySharesAuthorized contextRef =" c7" id =" hidden- fact- 23" unitRef =" shares" xsi: nil =" true" /
> < us- gaap: TemporaryEquityCarryingAmountAttributableToParent contextRef =" c9" id =" hidden- fact- 24" unitRef =" usd" xsi: nil =" true" / > < us- gaap:
TemporaryEquityCarryingAmountAttributableToParent contextRef =" c10" id =" hidden- fact- 25" unitRef =" usd" xsi: nil =" true" / > < us- gaap: TemporaryEquitySharesAuthorized
contextRef =" c9" id =" hidden- fact- 26" unitRef =" shares" xsi: nil =" true" / > < us- gaap: TemporaryEquitySharesAuthorized contextRef =" c10" id =" hidden- fact- 27" unitRef =" shares"
xsi: nil =" true" / > < us- gaap: TemporaryEquitySharesIssued contextRef =" c9" id =" hidden- fact- 28" unitRef =" shares" xsi: nil =" true" / > < us- gaap: TemporaryEquitySharesIssued
contextRef =" c10" id =" hidden- fact- 29" unitRef =" shares" xsi: nil =" true" / > < us- gaap: TemporaryEquitySharesOutstanding contextRef =" c9" id =" hidden- fact- 30" unitRef =" shares"
xsi: nil =" true" / > < us- gaap: TemporaryEquitySharesOutstanding contextRef =" c10" id =" hidden- fact- 31" unitRef =" shares" xsi: nil =" true" / > < us- gaap: PreferredStockValue
contextRef =" c12" id =" hidden- fact- 32" unitRef =" usd" xsi: nil =" true" / > < us- gaap: PreferredStockSharesOutstanding contextRef =" c12" id =" hidden- fact- 33" unitRef =" shares" xsi:
nil =" true" / > < us- gaap: PreferredStockSharesAuthorized contextRef =" c12" id =" hidden- fact- 34" unitRef =" shares" xsi: nil =" true" / > < us- gaap: PreferredStockSharesIssued
contextRef =" c12" id =" hidden- fact- 35" unitRef =" shares" xsi: nil =" true" / > < us- gaap: CommonStockValue contextRef =" c4" id =" hidden- fact- 36" unitRef =" usd" xsi: nil =" true" / >
< us- gaap: AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef =" c4" id =" hidden- fact- 37" unitRef =" usd" xsi: nil =" true" / > < us- gaap:
RetainedEarningsAccumulatedDeficit contextRef =" c4" id =" hidden- fact- 38" unitRef =" usd" xsi: nil =" true" / > < us- gaap: SharesOutstanding contextRef =" c18" id =" hidden- fact- 39"
unitRef =" shares" xsi: nil =" true" / > < us- gaap: StockholdersEquity contextRef =" c18" id =" hidden- fact- 40" unitRef =" usd" xsi: nil =" true" / > < us- gaap: SharesOutstanding contextRef
=" c19" id =" hidden- fact- 41" unitRef =" shares" xsi: nil =" true" / > < us- gaap: StockholdersEquity contextRef =" c19" id =" hidden- fact- 42" unitRef =" usd" xsi: nil =" true" / > < us- gaap:
SharesOutstanding contextRef =" c20" id =" hidden- fact- 43" unitRef =" shares" xsi: nil =" true" / > < us- gaap: StockholdersEquity contextRef =" c20" id =" hidden- fact- 44" unitRef =" usd"
xsi: nil =" true" / > < us- gaap: StockholdersEquity contextRef =" c23" id =" hidden- fact- 45" unitRef =" usd" xsi: nil =" true" / > < us- gaap: StockholdersEquity contextRef =" c24" id ="
hidden- fact- 46" unitRef =" usd" xsi: nil =" true" / > < us- gaap: StockIssuedDuringPeriodSharesNewIssues contextRef =" c26" id =" hidden- fact- 47" unitRef =" shares" xsi: nil =" true" / > <
us- gaap: StockIssuedDuringPeriodValueNewIssues contextRef =" c26" id =" hidden- fact- 48" unitRef =" usd" xsi: nil =" true" / > < us- gaap: StockIssuedDuringPeriodSharesNewIssues
contextRef =" c27" id =" hidden- fact- 49" unitRef =" shares" xsi: nil =" true" / > < us- gaap: StockIssuedDuringPeriodValueNewIssues contextRef =" c27" id =" hidden- fact- 50" unitRef ="
usd" xsi: nil =" true" / > < us- gaap: StockIssuedDuringPeriodSharesNewIssues contextRef =" c28" id =" hidden- fact- 51" unitRef =" shares" xsi: nil =" true" / > < us- gaap:
StockIssuedDuringPeriodValueNewIssues contextRef =" c28" id =" hidden- fact- 52" unitRef =" usd" xsi: nil =" true" / > < us- gaap: StockIssuedDuringPeriodValueNewIssues contextRef ="
c31" id =" hidden- fact- 53" unitRef =" usd" xsi: nil =" true" / > < us- gaap: StockIssuedDuringPeriodValueNewIssues contextRef =" c32" id =" hidden- fact- 54" unitRef =" usd" xsi: nil ="
true" / > < us- gaap: StockIssuedDuringPeriodValueNewIssues contextRef =" c0" id =" hidden- fact- 55" unitRef =" usd" xsi: nil =" true" / > < orka:
TemporaryEquityStockIssuedDuringPeriodSharesNewIssues contextRef =" c27" id =" hidden- fact- 56" unitRef =" shares" xsi: nil =" true" / > < us- gaap:
TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef =" c27" id =" hidden- fact- 57" unitRef =" usd" xsi: nil =" true" / > < orka:
TemporaryEquityStockIssuedDuringPeriodSharesNewIssues contextRef =" c28" id =" hidden- fact- 58" unitRef =" shares" xsi: nil =" true" / > < us- gaap:
TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef =" c28" id =" hidden- fact- 59" unitRef =" usd" xsi: nil =" true" / > < orka:
TemporaryEquityStockIssuedDuringPeriodSharesNewIssues contextRef =" c29" id =" hidden- fact- 60" unitRef =" shares" xsi: nil =" true" / > < us- gaap:
TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef =" c29" id =" hidden- fact- 61" unitRef =" usd" xsi: nil =" true" / > < us- gaap:
TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef =" c30" id =" hidden- fact- 62" unitRef =" usd" xsi: nil =" true" / > < us- gaap:
TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef =" c31" id =" hidden- fact- 63" unitRef =" usd" xsi: nil =" true" / > < us- gaap:
TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef =" c32" id =" hidden- fact- 64" unitRef =" usd" xsi: nil =" true" / > < us- gaap:
TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef =" c0" id =" hidden- fact- 65" unitRef =" usd" xsi: nil =" true" / > < orka:
TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef =" c27" id =" hidden- fact- 66" unitRef =" shares" xsi: nil =" true" / > < orka:
TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef =" c27" id =" hidden- fact- 67" unitRef =" usd" xsi: nil =" true" / > < orka:
TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef =" c29" id =" hidden- fact- 68" unitRef =" shares" xsi: nil =" true" / > < orka:
TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef =" c29" id =" hidden- fact- 69" unitRef =" usd" xsi: nil =" true" / > < orka:
TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef =" c30" id =" hidden- fact- 70" unitRef =" usd" xsi: nil =" true" / > < orka:
TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef =" c31" id =" hidden- fact- 71" unitRef =" usd" xsi: nil =" true" / > < orka:
TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef =" c32" id =" hidden- fact- 72" unitRef =" usd" xsi: nil =" true" / > < us- gaap:
StockIssuedDuringPeriodSharesConversionOfUnits contextRef =" c26" id =" hidden- fact- 73" unitRef =" shares" xsi: nil =" true" / > < us- gaap:
StockIssuedDuringPeriodValueConversionOfUnits contextRef =" c26" id =" hidden- fact- 74" unitRef =" usd" xsi: nil =" true" / > < us- gaap:
StockIssuedDuringPeriodSharesConversionOfUnits contextRef =" c27" id =" hidden- fact- 75" unitRef =" shares" xsi: nil =" true" / > < us- gaap:
StockIssuedDuringPeriodValueConversionOfUnits contextRef =" c27" id =" hidden- fact- 76" unitRef =" usd" xsi: nil =" true" / > < us- gaap:
StockIssuedDuringPeriodSharesConversionOfUnits contextRef =" c28" id =" hidden- fact- 77" unitRef =" shares" xsi: nil =" true" / > < us- gaap:
StockIssuedDuringPeriodValueConversionOfUnits contextRef =" c28" id =" hidden- fact- 78" unitRef =" usd" xsi: nil =" true" / > < us- gaap: StockIssuedDuringPeriodValueConversionOfUnits
contextRef =" c31" id =" hidden- fact- 79" unitRef =" usd" xsi: nil =" true" / > < us- gaap: StockIssuedDuringPeriodValueConversionOfUnits contextRef =" c32" id =" hidden- fact- 80" unitRef
=" usd" xsi: nil =" true" / > < orka: IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost contextRef =" c26" id =" hidden- fact- 81" unitRef ="
shares" xsi: nil =" true" / > < orka: IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos contextRef =" c26" id =" hidden- fact- 82" unitRef =" usd"
xsi: nil =" true" / > < orka: IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost contextRef =" c27" id =" hidden- fact- 83" unitRef =" shares" xsi: nil
=" true" / > < orka: IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos contextRef =" c27" id =" hidden- fact- 84" unitRef =" usd" xsi: nil =" true" /
> < orka: IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost contextRef =" c28" id =" hidden- fact- 85" unitRef =" shares" xsi: nil =" true" / > <
orka: IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos contextRef =" c28" id =" hidden- fact- 86" unitRef =" usd" xsi: nil =" true" / > < orka:
IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos contextRef =" c31" id =" hidden- fact- 87" unitRef =" usd" xsi: nil =" true" / > < orka:
IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos contextRef =" c32" id =" hidden- fact- 88" unitRef =" usd" xsi: nil =" true" / > < us- gaap:
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef =" c26" id =" hidden- fact- 89" unitRef =" usd" xsi: nil =" true" / > < us- gaap:
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef =" c27" id =" hidden- fact- 90" unitRef =" usd" xsi: nil =" true" / > < us- gaap:
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef =" c28" id =" hidden- fact- 91" unitRef =" usd" xsi: nil =" true" / > < us- gaap:
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef =" c29" id =" hidden- fact- 92" unitRef =" usd" xsi: nil =" true" / > < us- gaap:
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef =" c31" id =" hidden- fact- 93" unitRef =" usd" xsi: nil =" true" / > < us- gaap:
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef =" c32" id =" hidden- fact- 94" unitRef =" usd" xsi: nil =" true" / > < orka:
IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger contextRef =" c26" id =" hidden- fact- 95" unitRef =" shares" xsi:
nil =" true" / > < orka: IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe contextRef =" c26" id =" hidden- fact- 96" unitRef =" usd" xsi: nil ="
true" / > < orka: IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger contextRef =" c27" id =" hidden- fact- 97" unitRef
=" shares" xsi: nil =" true" / > < orka: IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe contextRef =" c27" id =" hidden- fact- 98" unitRef ="
usd" xsi: nil =" true" / > < orka: IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger contextRef =" c28" id =" hidden-
fact- 99" unitRef =" shares" xsi: nil =" true" / > < orka: IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe contextRef =" c28" id =" hidden- fact-
100" unitRef =" usd" xsi: nil =" true" / > < orka: IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe contextRef =" c31" id =" hidden- fact- 101"
unitRef =" usd" xsi: nil =" true" / > < orka: IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe contextRef =" c32" id =" hidden- fact- 102" unitRef
=" usd" xsi: nil =" true" / > < orka: IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant contextRef =" c26" id =" hidden- fact- 103" unitRef ="
shares" xsi: nil =" true" / > < orka: IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr contextRef =" c26" id =" hidden- fact- 104" unitRef =" usd" xsi:
nil =" true" / > < orka: IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant contextRef =" c28" id =" hidden- fact- 105" unitRef =" shares" xsi: nil ="
true" / > < orka: IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr contextRef =" c28" id =" hidden- fact- 106" unitRef =" usd" xsi: nil =" true" / > <
orka: IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr contextRef =" c31" id =" hidden- fact- 107" unitRef =" usd" xsi: nil =" true" / > < orka:
IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr contextRef =" c32" id =" hidden- fact- 108" unitRef =" usd" xsi: nil =" true" / > < orka:
IssuanceCostOfPIPEFinancing contextRef =" c26" id =" hidden- fact- 109" unitRef =" usd" xsi: nil =" true" / > < orka: IssuanceCostOfPIPEFinancing contextRef =" c28" id =" hidden- fact-
110" unitRef =" usd" xsi: nil =" true" / > < orka: IssuanceCostOfPIPEFinancing contextRef =" c29" id =" hidden- fact- 111" unitRef =" usd" xsi: nil =" true" / > < orka:
IssuanceCostOfPIPEFinancing contextRef =" c31" id =" hidden- fact- 112" unitRef =" usd" xsi: nil =" true" / > < orka: IssuanceCostOfPIPEFinancing contextRef =" c32" id =" hidden- fact-
113" unitRef =" usd" xsi: nil =" true" / > < orka: ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares contextRef =" c26" id ="
hidden- fact- 114" unitRef =" shares" xsi: nil =" true" / > < orka: ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock contextRef =" c26" id ="
hidden- fact- 115" unitRef =" usd" xsi: nil =" true" / > < orka: ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares contextRef =" c28"
id =" hidden- fact- 116" unitRef =" shares" xsi: nil =" true" / > < orka: ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock contextRef =" c28"
id =" hidden- fact- 117" unitRef =" usd" xsi: nil =" true" / > < orka: ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock contextRef =" c31" id

=" hidden- fact- 118" unitRef =" usd" xsi: nil =" true" / > < orka: ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock contextRef =" c32" id =" hidden- fact- 119" unitRef =" usd" xsi: nil =" true" / > < us- gaap: StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef =" c26" id =" hidden- fact- 120" unitRef =" shares" xsi: nil =" true" / > < us- gaap: StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef =" c26" id =" hidden- fact- 121" unitRef =" usd" xsi: nil =" true" / > < us- gaap: StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef =" c27" id =" hidden- fact- 122" unitRef =" shares" xsi: nil =" true" / > < us- gaap: StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef =" c27" id =" hidden- fact- 123" unitRef =" usd" xsi: nil =" true" / > < us- gaap: StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef =" c28" id =" hidden- fact- 124" unitRef =" shares" xsi: nil =" true" / > < us- gaap: StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef =" c28" id =" hidden- fact- 125" unitRef =" usd" xsi: nil =" true" / > < us- gaap: StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef =" c29" id =" hidden- fact- 126" unitRef =" usd" xsi: nil =" true" / > < us- gaap: StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef =" c31" id =" hidden- fact- 127" unitRef =" usd" xsi: nil =" true" / > < us- gaap: StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef =" c32" id =" hidden- fact- 128" unitRef =" usd" xsi: nil =" true" / > < us- gaap: AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef =" c26" id =" hidden- fact- 129" unitRef =" usd" xsi: nil =" true" / > < us- gaap: AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef =" c27" id =" hidden- fact- 130" unitRef =" usd" xsi: nil =" true" / > < us- gaap: AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef =" c28" id =" hidden- fact- 131" unitRef =" usd" xsi: nil =" true" / > < us- gaap: AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef =" c29" id =" hidden- fact- 132" unitRef =" usd" xsi: nil =" true" / > < us- gaap: AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef =" c31" id =" hidden- fact- 133" unitRef =" usd" xsi: nil =" true" / > < us- gaap: AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef =" c32" id =" hidden- fact- 134" unitRef =" usd" xsi: nil =" true" / > < us- gaap: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef =" c26" id =" hidden- fact- 135" unitRef =" usd" xsi: nil =" true" / > < us- gaap: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef =" c27" id =" hidden- fact- 136" unitRef =" usd" xsi: nil =" true" / > < us- gaap: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef =" c28" id =" hidden- fact- 137" unitRef =" usd" xsi: nil =" true" / > < us- gaap: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef =" c29" id =" hidden- fact- 138" unitRef =" usd" xsi: nil =" true" / > < us- gaap: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef =" c31" id =" hidden- fact- 139" unitRef =" usd" xsi: nil =" true" / > < us- gaap: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef =" c32" id =" hidden- fact- 140" unitRef =" usd" xsi: nil =" true" / > < us- gaap: OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef =" c26" id =" hidden- fact- 141" unitRef =" usd" xsi: nil =" true" / > < us- gaap: OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef =" c27" id =" hidden- fact- 142" unitRef =" usd" xsi: nil =" true" / > < us- gaap: OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef =" c28" id =" hidden- fact- 143" unitRef =" usd" xsi: nil =" true" / > < us- gaap: OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef =" c29" id =" hidden- fact- 144" unitRef =" usd" xsi: nil =" true" / > < us- gaap: OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef =" c30" id =" hidden- fact- 145" unitRef =" usd" xsi: nil =" true" / > < us- gaap: OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef =" c32" id =" hidden- fact- 146" unitRef =" usd" xsi: nil =" true" / > < us- gaap: NetIncomeLoss contextRef =" c26" id =" hidden- fact- 147" unitRef =" usd" xsi: nil =" true" / > < us- gaap: NetIncomeLoss contextRef =" c27" id =" hidden- fact- 148" unitRef =" usd" xsi: nil =" true" / > < us- gaap: NetIncomeLoss contextRef =" c28" id =" hidden- fact- 149" unitRef =" usd" xsi: nil =" true" / > < us- gaap: NetIncomeLoss contextRef =" c30" id =" hidden- fact- 150" unitRef =" usd" xsi: nil =" true" / > < us- gaap: NetIncomeLoss contextRef =" c31" id =" hidden- fact- 151" unitRef =" usd" xsi: nil =" true" / > < us- gaap: SharesOutstanding contextRef =" c33" id =" hidden- fact- 152" unitRef =" shares" xsi: nil =" true" / > < us- gaap: StockholdersEquity contextRef =" c33" id =" hidden- fact- 153" unitRef =" usd" xsi: nil =" true" / > < us- gaap: SharesOutstanding contextRef =" c34" id =" hidden- fact- 154" unitRef =" shares" xsi: nil =" true" / > < us- gaap: StockholdersEquity contextRef =" c34" id =" hidden- fact- 155" unitRef =" usd" xsi: nil =" true" / > < us- gaap: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef =" c25" id =" hidden- fact- 156" unitRef =" usd" xsi: nil =" true" / > < us- gaap: CashEquivalentsAtCarryingValue contextRef =" c62" id =" hidden- fact- 157" unitRef =" usd" xsi: nil =" true" / > < us- gaap: CashEquivalentsAtCarryingValue contextRef =" c63" id =" hidden- fact- 158" unitRef =" usd" xsi: nil =" true" / > < us- gaap: CashEquivalentsAtCarryingValue contextRef =" c66" id =" hidden- fact- 159" unitRef =" usd" xsi: nil =" true" / > < us- gaap: CashEquivalentsAtCarryingValue contextRef =" c68" id =" hidden- fact- 160" unitRef =" usd" xsi: nil =" true" / > < us- gaap: CashEquivalentsAtCarryingValue contextRef =" c70" id =" hidden- fact- 161" unitRef =" usd" xsi: nil =" true" / > < us- gaap: CashEquivalentsAtCarryingValue contextRef =" c72" id =" hidden- fact- 162" unitRef =" usd" xsi: nil =" true" / > < us- gaap: CashEquivalentsAtCarryingValue contextRef =" c74" id =" hidden- fact- 163" unitRef =" usd" xsi: nil =" true" / > < us- gaap: CashEquivalentsAtCarryingValue contextRef =" c78" id =" hidden- fact- 164" unitRef =" usd" xsi: nil =" true" / > < us- gaap: MarketableSecuritiesCurrent contextRef =" c66" id =" hidden- fact- 165" unitRef =" usd" xsi: nil =" true" / > < us- gaap: MarketableSecuritiesCurrent contextRef =" c68" id =" hidden- fact- 166" unitRef =" usd" xsi: nil =" true" / > < us- gaap: MarketableSecuritiesCurrent contextRef =" c70" id =" hidden- fact- 167" unitRef =" usd" xsi: nil =" true" / > < us- gaap: MarketableSecuritiesCurrent contextRef =" c72" id =" hidden- fact- 168" unitRef =" usd" xsi: nil =" true" / > < us- gaap: MarketableSecuritiesCurrent contextRef =" c74" id =" hidden- fact- 169" unitRef =" usd" xsi: nil =" true" / > < us- gaap: MarketableSecuritiesCurrent contextRef =" c79" id =" hidden- fact- 170" unitRef =" usd" xsi: nil =" true" / > < us- gaap: MarketableSecuritiesCurrent contextRef =" c81" id =" hidden- fact- 171" unitRef =" usd" xsi: nil =" true" / > < us- gaap: MarketableSecuritiesCurrent contextRef =" c78" id =" hidden- fact- 172" unitRef =" usd" xsi: nil =" true" / > < us- gaap: MarketableSecuritiesNoncurrent contextRef =" c66" id =" hidden- fact- 173" unitRef =" usd" xsi: nil =" true" / > < us- gaap: MarketableSecuritiesNoncurrent contextRef =" c68" id =" hidden- fact- 174" unitRef =" usd" xsi: nil =" true" / > < us- gaap: MarketableSecuritiesNoncurrent contextRef =" c70" id =" hidden- fact- 175" unitRef =" usd" xsi: nil =" true" / > < us- gaap: MarketableSecuritiesNoncurrent contextRef =" c78" id =" hidden- fact- 176" unitRef =" usd" xsi: nil =" true" / > < orka: FairValueCashEquivalentsAndMarketableSecurities contextRef =" c78" id =" hidden- fact- 177" unitRef =" usd" xsi: nil =" true" / > < us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef =" c83" id =" hidden- fact- 178" unitRef =" usd" xsi: nil =" true" / > < us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef =" c83" id =" hidden- fact- 179" unitRef =" usd" xsi: nil =" true" / > < us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef =" c84" id =" hidden- fact- 180" unitRef =" usd" xsi: nil =" true" / > < us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef =" c85" id =" hidden- fact- 181" unitRef =" usd" xsi: nil =" true" / > < us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef =" c85" id =" hidden- fact- 182" unitRef =" usd" xsi: nil =" true" / > < us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef =" c86" id =" hidden- fact- 183" unitRef =" usd" xsi: nil =" true" / > < us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef =" c90" id =" hidden- fact- 184" unitRef =" usd" xsi: nil =" true" / > < us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef =" c93" id =" hidden- fact- 185" unitRef =" usd" xsi: nil =" true" / > < us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef =" c94" id =" hidden- fact- 186" unitRef =" usd" xsi: nil =" true" / > < us- gaap: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef =" c95" id =" hidden- fact- 187" unitRef =" usd" xsi: nil =" true" / > < us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef =" c96" id =" hidden- fact- 188" unitRef =" usd" xsi: nil =" true" / > < us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef =" c96" id =" hidden- fact- 189" unitRef =" usd" xsi: nil =" true" / > < us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef =" c97" id =" hidden- fact- 190" unitRef =" usd" xsi: nil =" true" / > < us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef =" c97" id =" hidden- fact- 191" unitRef =" usd" xsi: nil =" true" / > < us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef =" c98" id =" hidden- fact- 192" unitRef =" usd" xsi: nil =" true" / > < us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef =" c98" id =" hidden- fact- 193" unitRef =" usd" xsi: nil =" true" / > < us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef =" c99" id =" hidden- fact- 194" unitRef =" usd" xsi: nil =" true" / > < us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef =" c99" id =" hidden- fact- 195" unitRef =" usd" xsi: nil =" true" / > < us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef =" c100" id =" hidden- fact- 196" unitRef =" usd" xsi: nil =" true" / > < us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef =" c100" id =" hidden- fact- 197" unitRef =" usd" xsi: nil =" true" / > < us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef =" c101" id =" hidden- fact- 198" unitRef =" usd" xsi: nil =" true" / > < us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef =" c101" id =" hidden- fact- 199" unitRef =" usd" xsi: nil =" true" / > < us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef =" c3" id =" hidden- fact- 200" unitRef =" usd" xsi: nil =" true" / > < us- gaap: DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef =" c3" id =" hidden- fact- 201" unitRef =" usd" xsi: nil =" true" / > < orka: ClassOfWarrantOrRightExpirationDate contextRef =" c117" id =" hidden- fact- 202" xsi: nil =" true" / > < orka: ClassOfWarrantOrRightWarrantsExercised contextRef =" c117" id =" hidden- fact- 203" unitRef =" shares" xsi: nil =" true" / > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef =" c120" id =" hidden- fact- 204" unitRef =" shares" xsi: nil =" true" / > < us- gaap: PreferredStockSharesOutstanding contextRef =" c130" id =" hidden- fact- 205" unitRef =" shares" xsi: nil =" true" / > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef =" c146" id =" hidden- fact- 206" unitRef =" pure" xsi: nil =" true" / > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef =" c120" id =" hidden- fact- 207" unitRef =" pure" xsi: nil =" true" / > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef =" c4" id =" hidden- fact- 208" unitRef =" shares" xsi: nil =" true" / > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef =" c4" id =" hidden- fact- 209" unitRef =" usdPershares" xsi: nil =" true" / > < us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef =" c149" id =" hidden- fact- 210" xsi: nil =" true" / > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef =" c4" id =" hidden- fact- 211" unitRef =" usd" xsi: nil =" true" / > < us- gaap: StockIssuedDuringPeriodSharesStockOptionsExercised contextRef =" c0" id =" hidden- fact- 212" unitRef =" shares" xsi: nil =" true" / > < us- gaap: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef =" c0" id =" hidden- fact- 213" unitRef =" usdPershares" xsi: nil =" true" / > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef =" c0" id =" hidden- fact- 214" unitRef =" shares" xsi: nil =" true" / > < us- gaap: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef =" c0" id =" hidden- fact- 215" unitRef =" usdPershares" xsi: nil =" true" / > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef =" c3" id =" hidden- fact- 216" unitRef =" shares" xsi: nil =" true" / > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef =" c3" id =" hidden- fact- 217" unitRef =" usdPershares" xsi: nil =" true" / > < us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef =" c0" id =" hidden- fact- 218" xsi: nil =" true" / > < us- gaap: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef =" c3" id =" hidden- fact- 219" unitRef =" usd" xsi: nil =" true" / > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef =" c150" id =" hidden- fact- 220" unitRef =" shares" xsi: nil =" true" / > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef =" c150" id =" hidden- fact- 221" unitRef =" usdPershares" xsi: nil =" true" / > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef =" c133" id =" hidden- fact- 222" unitRef =" usdPershares" xsi: nil =" true" / > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef =" c133" id =" hidden- fact- 223" unitRef =" usdPershares" xsi: nil =" true" / > < us- gaap: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef =" c151" id =" hidden- fact- 224" unitRef =" shares" xsi: nil =" true" / > < orka: ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice contextRef =" c151" id ="

hidden- fact- 225" unitRef =" usdPershares" xsi: nil =" true" / > < us- gaap:
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef =" c151" id =" hidden- fact- 226"
unitRef =" usd" xsi: nil =" true" / > < orka: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised contextRef =" c152" id ="
hidden- fact- 227" unitRef =" shares" xsi: nil =" true" / > < orka:
WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised
contextRef =" c152" id =" hidden- fact- 228" unitRef =" usdPershares" xsi: nil =" true" / > < us- gaap:
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef =" c152" id =" hidden- fact- 229" unitRef =" shares"
xsi: nil =" true" / > < orka: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice contextRef ="
c152" id =" hidden- fact- 230" unitRef =" usdPershares" xsi: nil =" true" / > < orka:
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding contextRef =" c119" id =" hidden- fact- 231" unitRef =" shares" xsi:
nil =" true" / > < orka: ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice contextRef =" c119" id ="
hidden- fact- 232" unitRef =" usdPershares" xsi: nil =" true" / > < orka:
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable contextRef =" c119" id =" hidden-
fact- 233" unitRef =" usd" xsi: nil =" true" / > < us- gaap: IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef =" c0" id =" hidden- fact- 234" unitRef =" usd" xsi: nil
=" true" / > < us- gaap: DeferredTaxAssetsLiabilitiesNet contextRef =" c3" id =" hidden- fact- 235" unitRef =" usd" xsi: nil =" true" / > < us- gaap: DeferredTaxAssetsValuationAllowance
contextRef =" c25" id =" hidden- fact- 236" unitRef =" usd" xsi: nil =" true" / > < us- gaap: UnrecognizedTaxBenefits contextRef =" c25" id =" hidden- fact- 237" unitRef =" usd" xsi: nil ="
true" / > < us- gaap: IncomeTaxExpenseBenefit contextRef =" c0" id =" hidden- fact- 238" unitRef =" usd" xsi: nil =" true" / > < dei: EntityCentralIndexKey contextRef =" c0" id =" ixv- 24955"
> 0000907654 < / dei: EntityCentralIndexKey > < dei: AmendmentFlag contextRef =" c0" id =" ixv- 24956" > false < / dei: AmendmentFlag > < dei: DocumentFiscalPeriodFocus contextRef ="
c0" id =" ixv- 24957" > FY < / dei: DocumentFiscalPeriodFocus > < link: footnoteLink xlink: role =" http: / / www. xbrl. org / 2003 / role / link" xlink: type =" extended" > < link: loc xlink: href
=" # ix_0_fact" xlink: label =" ix_0_fact" xlink: type =" locator" / > < link: footnote id =" ix_0_footnote" xlink: label =" ix_0_footnote" xlink: role =" http: / / www. xbrl. org / 2003 / role /
footnote" xlink: type =" resource" xml: lang =" en- US" > < xhtml: span style =" font- family: Times New Roman, Times, Serif" > Includes related party amount of $ 42, 640 for the period from
February 6, 2024 (inception) to December 31, 2024 < / xhtml: span > < / link: footnote > < link: footnoteArc xlink: arcrole =" http: / / www. xbrl. org / 2003 / arcrole / fact- footnote" xlink: from
=" ix_0_fact" xlink: to =" ix_0_footnote" xlink: type =" arc" / > < link: loc xlink: href =" # ix_1_fact" xlink: label =" ix_1_fact" xlink: type =" locator" / > < link: footnote id =" ix_1_footnote"
xlink: label =" ix_1_footnote" xlink: role =" http: / / www. xbrl. org / 2003 / role / footnote" xlink: type =" resource" xml: lang =" en- US" > < xhtml: span style =" font- family: Times New
Roman, Times, Serif" > Includes related party amount of $ 1, 364 for the period from February 6, 2024 (inception) to December 31, 2024 < / xhtml: span > < / link: footnote > < link: footnoteArc
xlink: arcrole =" http: / / www. xbrl. org / 2003 / arcrole / fact- footnote" xlink: from =" ix_1_fact" xlink: to =" ix_1_footnote" xlink: type =" arc" / > < link: loc xlink: href =" # ix_2_fact" xlink:
label =" ix_2_fact" xlink: type =" locator" / > < link: footnote id =" ix_2_footnote" xlink: label =" ix_2_footnote" xlink: role =" http: / / www. xbrl. org / 2003 / role / footnote" xlink: type ="
resource" xml: lang =" en- US" > < xhtml: span style =" font- family: Times New Roman, Times, Serif" > Includes related party amount of $ 1, 468 for the period from February 6, 2024
(inception) to December 31, 2024 < / xhtml: span > < / link: footnote > < link: footnoteArc xlink: arcrole =" http: / / www. xbrl. org / 2003 / arcrole / fact- footnote" xlink: from =" ix_2_fact" xlink:
to =" ix_2_footnote" xlink: type =" arc" / > < link: loc xlink: href =" # ix_5_fact" xlink: label =" ix_5_fact" xlink: type =" locator" / > < link: loc xlink: href =" # ix_4_fact" xlink: label ="
ix_4_fact" xlink: type =" locator" / > < link: loc xlink: href =" # ix_3_fact" xlink: label =" ix_3_fact" xlink: type =" locator" / > < link: footnote id =" ix_3_footnote" xlink: label ="
ix_3_footnote" xlink: role =" http: / / www. xbrl. org / 2003 / role / footnote" xlink: type =" resource" xml: lang =" en- US" > < xhtml: span style =" font- family: Times New Roman, Times, Serif"
> The weighted- average number of shares of as- converted Company Series A Preferred Stock used in the loss allocation was 495, 191 for the period from February 6, 2024 (inception) to
December 31, 2024. < / xhtml: span > < / link: footnote > < link: footnoteArc xlink: arcrole =" http: / / www. xbrl. org / 2003 / arcrole / fact- footnote" xlink: from =" ix_5_fact" xlink: to ="
ix_3_footnote" xlink: type =" arc" / > < link: footnoteArc xlink: arcrole =" http: / / www. xbrl. org / 2003 / arcrole / fact- footnote" xlink: from =" ix_4_fact" xlink: to =" ix_3_footnote" xlink:
type =" arc" / > < link: footnoteArc xlink: arcrole =" http: / / www. xbrl. org / 2003 / arcrole / fact- footnote" xlink: from =" ix_3_fact" xlink: to =" ix_3_footnote" xlink: type =" arc" / > < link:
loc xlink: href =" # ix_8_fact" xlink: label =" ix_8_fact" xlink: type =" locator" / > < link: loc xlink: href =" # ix_7_fact" xlink: label =" ix_7_fact" xlink: type =" locator" / > < link: loc xlink:
href =" # ix_6_fact" xlink: label =" ix_6_fact" xlink: type =" locator" / > < link: footnote id =" ix_4_footnote" xlink: label =" ix_4_footnote" xlink: role =" http: / / www. xbrl. org / 2003 / role /
footnote" xlink: type =" resource" xml: lang =" en- US" > < xhtml: span style =" font- family: Times New Roman, Times, Serif" > The weighted- average number of shares of as- converted
Company Series B Preferred Stock used in the loss allocation was 4, 328, 844 for the period from February 6, 2024 (inception) to December 31, 2024. < / xhtml: span > < / link: footnote > < link:
footnoteArc xlink: arcrole =" http: / / www. xbrl. org / 2003 / arcrole / fact- footnote" xlink: from =" ix_8_fact" xlink: to =" ix_4_footnote" xlink: type =" arc" / > < link: footnoteArc xlink:
arcrole =" http: / / www. xbrl. org / 2003 / arcrole / fact- footnote" xlink: from =" ix_7_fact" xlink: to =" ix_4_footnote" xlink: type =" arc" / > < link: footnoteArc xlink: arcrole =" http: / / www.
xbrl. org / 2003 / arcrole / fact- footnote" xlink: from =" ix_6_fact" xlink: to =" ix_4_footnote" xlink: type =" arc" / > < / link: footnoteLink > < / xbrl > < / XML > < / TEXT > < / DOCUMENT >
< / SEC- DOCUMENT >